-DOCSTART- -X- -X- O
   
22 NN NN O
- NN NN O
oxacalcitriol NN NN O
suppresses NN NN O
secondary NN NN B-Disease
hyperparathyroidism NN NN I-Disease
without NN NN O
inducing NN NN O
low NN NN B-Disease
bone NN NN I-Disease
turnover NN NN I-Disease
in NN NN O
dogs NN NN O
with NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Calcitriol NN NN O
therapy NN NN O
suppresses NN NN O
serum NN NN O
levels NN NN O
of NN NN O
parathyroid NN NN O
hormone NN NN O
( NN NN O
PTH NN NN O
) NN NN O
in NN NN O
patients NN NN O
with NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
but NN NN O
has NN NN O
several NN NN O
drawbacks NN NN O
, NN NN O
including NN NN O
hypercalcemia NN NN B-Disease
and NN NN O
/ NN NN O
or NN NN O
marked NN NN O
suppression NN NN B-Disease
of NN NN I-Disease
bone NN NN I-Disease
turnover NN NN I-Disease
, NN NN O
which NN NN O
may NN NN O
lead NN NN O
to NN NN O
adynamic NN NN B-Disease
bone NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
A NN NN O
new NN NN O
vitamin NN NN O
D NN NN O
analogue NN NN O
, NN NN O
22 NN NN O
- NN NN O
oxacalcitriol NN NN O
( NN NN O
OCT NN NN O
) NN NN O
, NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
have NN NN O
promising NN NN O
characteristics NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
undertaken NN NN O
to NN NN O
determine NN NN O
the NN NN O
effects NN NN O
of NN NN O
OCT NN NN O
on NN NN O
serum NN NN O
PTH NN NN O
levels NN NN O
and NN NN O
bone NN NN O
turnover NN NN O
in NN NN O
states NN NN O
of NN NN O
normal NN NN O
or NN NN O
impaired NN NN B-Disease
renal NN NN I-Disease
function NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Sixty NN NN O
dogs NN NN O
were NN NN O
either NN NN O
nephrectomized NN NN O
( NN NN O
Nx NN NN O
, NN NN O
N NN NN O
= NN NN O
38 NN NN O
) NN NN O
or NN NN O
sham NN NN O
- NN NN O
operated NN NN O
( NN NN O
Sham NN NN O
, NN NN O
N NN NN O
= NN NN O
22 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
animals NN NN O
received NN NN O
supplemental NN NN O
phosphate NN NN O
to NN NN O
enhance NN NN O
PTH NN NN O
secretion NN NN O
. NN NN O
   
Fourteen NN NN O
weeks NN NN O
after NN NN O
the NN NN O
start NN NN O
of NN NN O
phosphate NN NN O
supplementation NN NN O
, NN NN O
half NN NN O
of NN NN O
the NN NN O
Nx NN NN O
and NN NN O
Sham NN NN O
dogs NN NN O
received NN NN O
doses NN NN O
of NN NN O
OCT NN NN O
( NN NN O
three NN NN O
times NN NN O
per NN NN O
week NN NN O
) NN NN O
; NN NN O
the NN NN O
other NN NN O
half NN NN O
were NN NN O
given NN NN O
vehicle NN NN O
for NN NN O
60 NN NN O
weeks NN NN O
. NN NN O
   
Thereafter NN NN O
, NN NN O
the NN NN O
treatment NN NN O
modalities NN NN O
for NN NN O
a NN NN O
subset NN NN O
of NN NN O
animals NN NN O
were NN NN O
crossed NN NN O
over NN NN O
for NN NN O
an NN NN O
additional NN NN O
eight NN NN O
months NN NN O
. NN NN O
   
Biochemical NN NN O
and NN NN O
hormonal NN NN O
indices NN NN O
of NN NN O
calcium NN NN O
and NN NN O
bone NN NN O
metabolism NN NN O
were NN NN O
measured NN NN O
throughout NN NN O
the NN NN O
study NN NN O
, NN NN O
and NN NN O
bone NN NN O
biopsies NN NN O
were NN NN O
done NN NN O
at NN NN O
baseline NN NN O
, NN NN O
60 NN NN O
weeks NN NN O
after NN NN O
OCT NN NN O
or NN NN O
vehicle NN NN O
treatment NN NN O
, NN NN O
and NN NN O
at NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
crossover NN NN O
period NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
In NN NN O
Nx NN NN O
dogs NN NN O
, NN NN O
OCT NN NN O
significantly NN NN O
decreased NN NN O
serum NN NN O
PTH NN NN O
levels NN NN O
soon NN NN O
after NN NN O
the NN NN O
induction NN NN O
of NN NN O
renal NN NN B-Disease
insufficiency NN NN I-Disease
. NN NN O
   
In NN NN O
long NN NN O
- NN NN O
standing NN NN O
secondary NN NN B-Disease
hyperparathyroidism NN NN I-Disease
, NN NN O
OCT NN NN O
( NN NN O
0 NN NN O
. NN NN O
03 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
stabilized NN NN O
serum NN NN O
PTH NN NN O
levels NN NN O
during NN NN O
the NN NN O
first NN NN O
months NN NN O
. NN NN O
   
Serum NN NN O
PTH NN NN O
levels NN NN O
rose NN NN O
thereafter NN NN O
, NN NN O
but NN NN O
the NN NN O
rise NN NN O
was NN NN O
less NN NN O
pronounced NN NN O
compared NN NN O
with NN NN O
baseline NN NN O
than NN NN O
the NN NN O
rise NN NN O
seen NN NN O
in NN NN O
Nx NN NN O
control NN NN O
. NN NN O
   
These NN NN O
effects NN NN O
were NN NN O
accompanied NN NN O
by NN NN O
episodes NN NN O
of NN NN O
hypercalcemia NN NN B-Disease
and NN NN O
hyperphosphatemia NN NN B-Disease
. NN NN O
   
In NN NN O
animals NN NN O
with NN NN O
normal NN NN O
renal NN NN O
function NN NN O
, NN NN O
OCT NN NN O
induced NN NN O
a NN NN O
transient NN NN O
decrease NN NN O
in NN NN O
serum NN NN O
PTH NN NN O
levels NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
0 NN NN O
. NN NN O
1 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
which NN NN O
was NN NN O
not NN NN O
sustained NN NN O
with NN NN O
lowering NN NN O
of NN NN O
the NN NN O
doses NN NN O
. NN NN O
   
In NN NN O
Nx NN NN O
dogs NN NN O
, NN NN O
OCT NN NN O
reversed NN NN O
abnormal NN NN O
bone NN NN O
formation NN NN O
, NN NN O
such NN NN O
as NN NN O
woven NN NN B-Disease
osteoid NN NN I-Disease
and NN NN O
fibrosis NN NN B-Disease
, NN NN O
but NN NN O
did NN NN O
not NN NN O
significantly NN NN O
alter NN NN O
the NN NN O
level NN NN O
of NN NN O
bone NN NN O
turnover NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
OCT NN NN O
improved NN NN O
mineralization NN NN O
lag NN NN O
time NN NN O
, NN NN O
( NN NN O
that NN NN O
is NN NN O
, NN NN O
the NN NN O
rate NN NN O
at NN NN O
which NN NN O
osteoid NN NN O
mineralizes NN NN O
) NN NN O
in NN NN O
both NN NN O
Nx NN NN O
and NN NN O
Sham NN NN O
dogs NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
even NN NN O
though NN NN O
OCT NN NN O
does NN NN O
not NN NN O
completely NN NN O
prevent NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
hypercalcemia NN NN B-Disease
in NN NN O
experimental NN NN O
dogs NN NN O
with NN NN O
renal NN NN B-Disease
insufficiency NN NN I-Disease
, NN NN O
it NN NN O
may NN NN O
be NN NN O
of NN NN O
use NN NN O
in NN NN O
the NN NN O
management NN NN O
of NN NN O
secondary NN NN B-Disease
hyperparathyroidism NN NN I-Disease
because NN NN O
it NN NN O
does NN NN O
not NN NN O
induce NN NN O
low NN NN B-Disease
bone NN NN I-Disease
turnover NN NN I-Disease
and NN NN O
, NN NN O
therefore NN NN O
, NN NN O
does NN NN O
not NN NN O
increase NN NN O
the NN NN O
risk NN NN O
of NN NN O
adynamic NN NN B-Disease
bone NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Hypotension NN NN B-Disease
, NN NN O
bradycardia NN NN B-Disease
, NN NN O
and NN NN O
asystole NN NN B-Disease
after NN NN O
high NN NN O
- NN NN O
dose NN NN O
intravenous NN NN O
methylprednisolone NN NN O
in NN NN O
a NN NN O
monitored NN NN O
patient NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
hypotension NN NN B-Disease
, NN NN O
bradycardia NN NN B-Disease
, NN NN O
and NN NN O
asystole NN NN B-Disease
after NN NN O
intravenous NN NN O
administration NN NN O
of NN NN O
high NN NN O
- NN NN O
dose NN NN O
methylprednisolone NN NN O
in NN NN O
a NN NN O
73 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
patient NN NN O
who NN NN O
underwent NN NN O
electrocardiographic NN NN O
( NN NN O
ECG NN NN O
) NN NN O
monitoring NN NN O
throughout NN NN O
the NN NN O
episode NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
history NN NN O
of NN NN O
ischemic NN NN B-Disease
cardiac NN NN B-Disease
disease NN NN I-Disease
9 NN NN O
years NN NN O
earlier NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
was NN NN O
admitted NN NN O
with NN NN O
a NN NN O
pulmonary NN NN B-Disease
- NN NN I-Disease
renal NN NN I-Disease
syndrome NN NN I-Disease
with NN NN O
hemoptysis NN NN B-Disease
, NN NN O
rapidly NN NN O
progressive NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
, NN NN O
and NN NN O
hypoxemia NN NN B-Disease
that NN NN O
required NN NN O
mechanical NN NN O
ventilation NN NN O
in NN NN O
the NN NN O
intensive NN NN O
care NN NN O
unit NN NN O
. NN NN O
   
After NN NN O
receiving NN NN O
advanced NN NN O
cardiopulmonary NN NN O
resuscitation NN NN O
, NN NN O
the NN NN O
patient NN NN O
recovered NN NN O
cardiac NN NN O
rhythm NN NN O
. NN NN O
   
The NN NN O
ECG NN NN O
showed NN NN O
a NN NN O
junctional NN NN O
rhythm NN NN O
without NN NN O
ventricular NN NN B-Disease
arrhythmia NN NN I-Disease
. NN NN O
   
This NN NN O
study NN NN O
reviews NN NN O
the NN NN O
current NN NN O
proposed NN NN O
mechanisms NN NN O
of NN NN O
sudden NN NN B-Disease
death NN NN I-Disease
after NN NN O
a NN NN O
high NN NN O
dose NN NN O
of NN NN O
intravenous NN NN O
methylprednisolone NN NN O
( NN NN O
IVMP NN NN O
) NN NN O
. NN NN O
   
These NN NN O
mechanisms NN NN O
are NN NN O
not NN NN O
well NN NN O
understood NN NN O
because NN NN O
, NN NN O
in NN NN O
most NN NN O
cases NN NN O
, NN NN O
the NN NN O
patients NN NN O
were NN NN O
not NN NN O
monitored NN NN O
at NN NN O
the NN NN O
moment NN NN O
of NN NN O
the NN NN O
event NN NN O
. NN NN O
   
Rapid NN NN O
infusion NN NN O
and NN NN O
underlying NN NN O
cardiac NN NN B-Disease
disease NN NN I-Disease
were NN NN O
important NN NN O
risk NN NN O
factors NN NN O
in NN NN O
the NN NN O
case NN NN O
reported NN NN O
here NN NN O
, NN NN O
and NN NN O
the NN NN O
authors NN NN O
discount NN NN O
ventricular NN NN B-Disease
arrhythmia NN NN I-Disease
as NN NN O
the NN NN O
main NN NN O
mechanism NN NN O
. NN NN O
   
Worsening NN NN O
of NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
by NN NN O
motor NN NN O
and NN NN O
mental NN NN O
tasks NN NN O
. NN NN O
   
Ten NN NN O
patients NN NN O
who NN NN O
had NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
with NN NN O
disabling NN NN O
dyskinesia NN NN B-Disease
were NN NN O
included NN NN O
in NN NN O
this NN NN O
study NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
role NN NN O
of NN NN O
mental NN NN O
( NN NN O
mental NN NN O
calculation NN NN O
) NN NN O
and NN NN O
motor NN NN O
( NN NN O
flexion NN NN O
/ NN NN O
extension NN NN O
of NN NN O
right NN NN O
fingers NN NN O
, NN NN O
flexion NN NN O
/ NN NN O
extension NN NN O
of NN NN O
left NN NN O
fingers NN NN O
, NN NN O
flexion NN NN O
/ NN NN O
extension NN NN O
of NN NN O
the NN NN O
neck NN NN O
, NN NN O
speaking NN NN O
aloud NN NN O
) NN NN O
tasks NN NN O
on NN NN O
the NN NN O
worsening NN NN O
of NN NN O
peak NN NN O
- NN NN O
dose NN NN O
dyskinesia NN NN B-Disease
following NN NN O
administration NN NN O
of NN NN O
an NN NN O
effective NN NN O
single NN NN O
dose NN NN O
of NN NN O
apomorphine NN NN O
. NN NN O
   
Compared NN NN O
with NN NN O
the NN NN O
score NN NN O
at NN NN O
rest NN NN O
( NN NN O
1 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
3 NN NN O
) NN NN O
, NN NN O
a NN NN O
significant NN NN O
aggravation NN NN O
of NN NN O
the NN NN O
dyskinesia NN NN B-Disease
score NN NN O
was NN NN O
observed NN NN O
during NN NN O
speaking NN NN O
aloud NN NN O
( NN NN O
5 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
1 NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
movements NN NN O
of NN NN O
right NN NN O
( NN NN O
4 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
0 NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
and NN NN O
left NN NN O
( NN NN O
3 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
8 NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
fingers NN NN O
, NN NN O
movements NN NN O
of NN NN O
the NN NN O
neck NN NN O
( NN NN O
5 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
0 NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
and NN NN O
mental NN NN O
calculation NN NN O
( NN NN O
3 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
0 NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
activation NN NN O
tasks NN NN O
such NN NN O
as NN NN O
"""""""" NN NN O
speaking NN NN O
aloud NN NN O
"""""""" NN NN O
could NN NN O
be NN NN O
used NN NN O
for NN NN O
objective NN NN O
assessment NN NN O
of NN NN O
dyskinesia NN NN B-Disease
severity NN NN O
. NN NN O
   
Urine NN NN O
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
beta NN NN O
- NN NN O
D NN NN O
- NN NN O
glucosaminidase NN NN O
- NN NN O
- NN NN O
a NN NN O
marker NN NN O
of NN NN O
tubular NN NN O
damage NN NN O
? NN NN O
   
BACKGROUND NN NN O
: NN NN O
Although NN NN O
an NN NN O
indicator NN NN O
of NN NN O
renal NN NN B-Disease
tubular NN NN I-Disease
dysfunction NN NN I-Disease
, NN NN O
an NN NN O
increased NN NN O
urinary NN NN O
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
beta NN NN O
- NN NN O
D NN NN O
- NN NN O
glucosaminidase NN NN O
( NN NN O
NAG NN NN O
) NN NN O
activity NN NN O
might NN NN O
reflect NN NN O
increased NN NN O
lysosomal NN NN O
activity NN NN O
in NN NN O
renal NN NN O
tubular NN NN O
cells NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Puromycin NN NN O
aminonucleoside NN NN O
( NN NN O
PAN NN NN O
) NN NN O
was NN NN O
administered NN NN O
to NN NN O
Sprague NN NN O
Dawley NN NN O
rats NN NN O
to NN NN O
induce NN NN O
proteinuria NN NN B-Disease
. NN NN O
   
Total NN NN O
protein NN NN O
, NN NN O
albumin NN NN O
, NN NN O
NAG NN NN O
activity NN NN O
and NN NN O
protein NN NN O
electrophoretic NN NN O
pattern NN NN O
were NN NN O
assessed NN NN O
in NN NN O
daily NN NN O
urine NN NN O
samples NN NN O
for NN NN O
33 NN NN O
days NN NN O
. NN NN O
   
The NN NN O
morphological NN NN O
appearance NN NN O
of NN NN O
the NN NN O
kidneys NN NN O
was NN NN O
examined NN NN O
on NN NN O
days NN NN O
three NN NN O
, NN NN O
four NN NN O
, NN NN O
six NN NN O
, NN NN O
eight NN NN O
and NN NN O
thirty NN NN O
three NN NN O
and NN NN O
the NN NN O
NAG NN NN O
isoenzyme NN NN O
patterns NN NN O
on NN NN O
days NN NN O
zero NN NN O
, NN NN O
four NN NN O
, NN NN O
eight NN NN O
and NN NN O
thirty NN NN O
three NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Following NN NN O
intravenous NN NN O
PAN NN NN O
urine NN NN O
volume NN NN O
and NN NN O
urine NN NN O
NAG NN NN O
activity NN NN O
increased NN NN O
significantly NN NN O
by NN NN O
day NN NN O
two NN NN O
, NN NN O
but NN NN O
returned NN NN O
to NN NN O
normal NN NN O
by NN NN O
day NN NN O
four NN NN O
. NN NN O
   
After NN NN O
day NN NN O
four NN NN O
all NN NN O
treated NN NN O
animals NN NN O
exhibited NN NN O
a NN NN O
marked NN NN O
rise NN NN O
in NN NN O
urine NN NN O
albumin NN NN O
, NN NN O
total NN NN O
protein NN NN O
excretion NN NN O
and NN NN O
NAG NN NN O
activity NN NN O
. NN NN O
   
Electrophoresis NN NN O
showed NN NN O
a NN NN O
generalised NN NN O
increase NN NN O
in NN NN O
middle NN NN O
and NN NN O
high NN NN O
molecular NN NN O
weight NN NN O
urine NN NN O
proteins NN NN O
from NN NN O
day NN NN O
four NN NN O
onwards NN NN O
. NN NN O
   
Protein NN NN O
droplets NN NN O
first NN NN O
appeared NN NN O
prominent NN NN O
in NN NN O
tubular NN NN O
cells NN NN O
on NN NN O
day NN NN O
four NN NN O
. NN NN O
   
Peak NN NN O
urine NN NN O
NAG NN NN O
activity NN NN O
and NN NN O
a NN NN O
change NN NN O
in NN NN O
NAG NN NN O
isoenzyme NN NN O
pattern NN NN O
coincided NN NN O
with NN NN O
both NN NN O
the NN NN O
peak NN NN O
proteinuria NN NN B-Disease
and NN NN O
the NN NN O
reduction NN NN O
in NN NN O
intracellular NN NN O
protein NN NN O
and NN NN O
NAG NN NN O
droplets NN NN O
( NN NN O
day NN NN O
six NN NN O
onwards NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
This NN NN O
animal NN NN O
model NN NN O
demonstrates NN NN O
that NN NN O
an NN NN O
increase NN NN O
in NN NN O
lysosomal NN NN O
turnover NN NN O
and NN NN O
hence NN NN O
urine NN NN O
NAG NN NN O
activity NN NN O
, NN NN O
occurs NN NN O
when NN NN O
increased NN NN O
protein NN NN O
is NN NN O
presented NN NN O
to NN NN O
the NN NN O
tubular NN NN O
cells NN NN O
. NN NN O
   
Urine NN NN O
NAG NN NN O
activity NN NN O
is NN NN O
thus NN NN O
a NN NN O
measure NN NN O
of NN NN O
altered NN NN O
function NN NN O
in NN NN O
the NN NN O
renal NN NN O
tubules NN NN O
and NN NN O
not NN NN O
simply NN NN O
an NN NN O
indicator NN NN O
of NN NN O
damage NN NN O
. NN NN O
   
Cauda NN NN B-Disease
equina NN NN I-Disease
syndrome NN NN I-Disease
after NN NN O
spinal NN NN O
anaesthesia NN NN O
with NN NN O
hyperbaric NN NN O
5 NN NN O
% NN NN O
lignocaine NN NN O
: NN NN O
a NN NN O
review NN NN O
of NN NN O
six NN NN O
cases NN NN O
of NN NN O
cauda NN NN B-Disease
equina NN NN I-Disease
syndrome NN NN I-Disease
reported NN NN O
to NN NN O
the NN NN O
Swedish NN NN O
Pharmaceutical NN NN O
Insurance NN NN O
1993 NN NN O
- NN NN O
1997 NN NN O
. NN NN O
   
Six NN NN O
cases NN NN O
of NN NN O
cauda NN NN B-Disease
equina NN NN I-Disease
syndrome NN NN I-Disease
with NN NN O
varying NN NN O
severity NN NN O
were NN NN O
reported NN NN O
to NN NN O
the NN NN O
Swedish NN NN O
Pharmaceutical NN NN O
Insurance NN NN O
during NN NN O
the NN NN O
period NN NN O
1993 NN NN O
- NN NN O
1997 NN NN O
. NN NN O
   
All NN NN O
were NN NN O
associated NN NN O
with NN NN O
spinal NN NN O
anaesthesia NN NN O
using NN NN O
hyperbaric NN NN O
5 NN NN O
% NN NN O
lignocaine NN NN O
. NN NN O
   
Five NN NN O
cases NN NN O
had NN NN O
single NN NN O
- NN NN O
shot NN NN O
spinal NN NN O
anaesthesia NN NN O
and NN NN O
one NN NN O
had NN NN O
a NN NN O
repeat NN NN O
spinal NN NN O
anaesthetic NN NN O
due NN NN O
to NN NN O
inadequate NN NN O
block NN NN O
. NN NN O
   
The NN NN O
dose NN NN O
of NN NN O
hyperbaric NN NN O
5 NN NN O
% NN NN O
lignocaine NN NN O
administered NN NN O
ranged NN NN O
from NN NN O
60 NN NN O
to NN NN O
120 NN NN O
mg NN NN O
. NN NN O
   
Three NN NN O
of NN NN O
the NN NN O
cases NN NN O
were NN NN O
most NN NN O
likely NN NN O
caused NN NN O
by NN NN O
direct NN NN O
neurotoxicity NN NN B-Disease
of NN NN O
hyperbaric NN NN O
5 NN NN O
% NN NN O
lignocaine NN NN O
. NN NN O
   
In NN NN O
the NN NN O
other NN NN O
3 NN NN O
cases NN NN O
, NN NN O
direct NN NN O
neurotoxicity NN NN B-Disease
was NN NN O
also NN NN O
probable NN NN O
, NN NN O
but NN NN O
unfortunately NN NN O
radiological NN NN O
investigations NN NN O
were NN NN O
not NN NN O
done NN NN O
to NN NN O
definitely NN NN O
exclude NN NN O
a NN NN O
compressive NN NN O
aetiology NN NN O
. NN NN O
   
All NN NN O
cases NN NN O
sustained NN NN O
permanent NN NN O
neurological NN NN B-Disease
deficits NN NN I-Disease
. NN NN O
   
We NN NN O
recommend NN NN O
that NN NN O
hyperbaric NN NN O
lignocaine NN NN O
should NN NN O
be NN NN O
administered NN NN O
in NN NN O
concentrations NN NN O
not NN NN O
greater NN NN O
than NN NN O
2 NN NN O
% NN NN O
and NN NN O
at NN NN O
a NN NN O
total NN NN O
dose NN NN O
preferably NN NN O
not NN NN O
exceeding NN NN O
60 NN NN O
mg NN NN O
. NN NN O
   
Systemic NN NN O
toxicity NN NN B-Disease
following NN NN O
administration NN NN O
of NN NN O
sirolimus NN NN O
( NN NN O
formerly NN NN O
rapamycin NN NN O
) NN NN O
for NN NN O
psoriasis NN NN B-Disease
: NN NN O
association NN NN O
of NN NN O
capillary NN NN B-Disease
leak NN NN I-Disease
syndrome NN NN I-Disease
with NN NN O
apoptosis NN NN O
of NN NN O
lesional NN NN O
lymphocytes NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Sirolimus NN NN O
( NN NN O
formerly NN NN O
rapamycin NN NN O
) NN NN O
is NN NN O
an NN NN O
immunosuppressive NN NN O
agent NN NN O
that NN NN O
interferes NN NN O
with NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
After NN NN O
2 NN NN O
individuals NN NN O
with NN NN O
psoriasis NN NN B-Disease
developed NN NN O
a NN NN O
capillary NN NN B-Disease
leak NN NN I-Disease
syndrome NN NN I-Disease
following NN NN O
treatment NN NN O
with NN NN O
oral NN NN O
sirolimus NN NN O
lesional NN NN O
skin NN NN O
cells NN NN O
and NN NN O
activated NN NN O
peripheral NN NN O
blood NN NN O
cells NN NN O
were NN NN O
analyzed NN NN O
for NN NN O
induction NN NN O
of NN NN O
apoptosis NN NN O
. NN NN O
   
OBSERVATIONS NN NN O
: NN NN O
A NN NN O
keratome NN NN O
skin NN NN O
specimen NN NN O
from NN NN O
1 NN NN O
patient NN NN O
with NN NN O
sirolimus NN NN O
- NN NN O
induced NN NN O
capillary NN NN B-Disease
leak NN NN I-Disease
syndrome NN NN I-Disease
had NN NN O
a NN NN O
2 NN NN O
. NN NN O
3 NN NN O
- NN NN O
fold NN NN O
increase NN NN O
in NN NN O
percentage NN NN O
of NN NN O
apoptotic NN NN O
cells NN NN O
( NN NN O
to NN NN O
48 NN NN O
% NN NN O
) NN NN O
compared NN NN O
with NN NN O
an NN NN O
unaffected NN NN O
sirolimus NN NN O
- NN NN O
treated NN NN O
patient NN NN O
with NN NN O
psoriasis NN NN B-Disease
( NN NN O
21 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Activated NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
cells NN NN O
from NN NN O
patients NN NN O
with NN NN O
psoriasis NN NN B-Disease
tended NN NN O
to NN NN O
exhibit NN NN O
greater NN NN O
spontaneous NN NN O
or NN NN O
dexamethasone NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
than NN NN O
did NN NN O
normal NN NN O
T NN NN O
cells NN NN O
, NN NN O
particularly NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
sirolimus NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Severe NN NN O
adverse NN NN O
effects NN NN O
of NN NN O
sirolimus NN NN O
include NN NN O
fever NN NN B-Disease
, NN NN O
anemia NN NN B-Disease
, NN NN O
and NN NN O
capillary NN NN B-Disease
leak NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
These NN NN O
symptoms NN NN O
may NN NN O
be NN NN O
the NN NN O
result NN NN O
of NN NN O
drug NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
of NN NN O
lesional NN NN O
leukocytes NN NN O
, NN NN O
especially NN NN O
activated NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
and NN NN O
possibly NN NN O
release NN NN O
of NN NN O
inflammatory NN NN O
mediators NN NN O
. NN NN O
   
Because NN NN O
patients NN NN O
with NN NN O
severe NN NN O
psoriasis NN NN B-Disease
may NN NN O
develop NN NN O
capillary NN NN B-Disease
leak NN NN I-Disease
from NN NN O
various NN NN O
systemic NN NN O
therapies NN NN O
, NN NN O
clinical NN NN O
monitoring NN NN O
is NN NN O
advisable NN NN O
for NN NN O
patients NN NN O
with NN NN O
inflammatory NN NN B-Disease
diseases NN NN I-Disease
who NN NN O
are NN NN O
treated NN NN O
with NN NN O
immune NN NN O
modulators NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
lithium NN NN O
maintenance NN NN O
therapy NN NN O
on NN NN O
thyroid NN NN O
and NN NN O
parathyroid NN NN O
function NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
To NN NN O
assess NN NN O
changes NN NN O
induced NN NN O
by NN NN O
lithium NN NN O
maintenance NN NN O
therapy NN NN O
on NN NN O
the NN NN O
incidence NN NN O
of NN NN O
thyroid NN NN O
, NN NN O
parathyroid NN NN O
and NN NN O
ion NN NN O
alterations NN NN O
. NN NN O
   
These NN NN O
were NN NN O
evaluated NN NN O
with NN NN O
respect NN NN O
to NN NN O
the NN NN O
duration NN NN O
of NN NN O
lithium NN NN O
therapy NN NN O
, NN NN O
age NN NN O
, NN NN O
sex NN NN O
, NN NN O
and NN NN O
family NN NN O
history NN NN O
( NN NN O
whether NN NN O
or NN NN O
not NN NN O
the NN NN O
patient NN NN O
had NN NN O
a NN NN O
first NN NN O
- NN NN O
degree NN NN O
relative NN NN O
with NN NN O
thyroid NN NN B-Disease
disease NN NN I-Disease
) NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
Prospective NN NN O
study NN NN O
. NN NN O
   
SETTING NN NN O
: NN NN O
Affective NN NN O
Disorders NN NN O
Clinic NN NN O
at NN NN O
St NN NN O
. NN NN O
   
Mary NN NN O
' NN NN O
s NN NN O
Hospital NN NN O
, NN NN O
Montreal NN NN O
. NN NN O
   
PATIENTS NN NN O
: NN NN O
One NN NN O
hundred NN NN O
and NN NN O
one NN NN O
patients NN NN O
( NN NN O
28 NN NN O
men NN NN O
and NN NN O
73 NN NN O
women NN NN O
) NN NN O
with NN NN O
bipolar NN NN B-Disease
disorder NN NN I-Disease
receiving NN NN O
lithium NN NN O
maintenance NN NN O
therapy NN NN O
ranging NN NN O
from NN NN O
1 NN NN O
year NN NN O
' NN NN O
s NN NN O
to NN NN O
32 NN NN O
years NN NN O
' NN NN O
duration NN NN O
. NN NN O
   
The NN NN O
control NN NN O
group NN NN O
consisted NN NN O
of NN NN O
82 NN NN O
patients NN NN O
with NN NN O
no NN NN O
psychiatric NN NN B-Disease
or NN NN O
endocrinological NN NN O
diagnoses NN NN O
from NN NN O
the NN NN O
hospital NN NN O
' NN NN O
s NN NN O
out NN NN O
- NN NN O
patient NN NN O
clinics NN NN O
. NN NN O
   
OUTCOME NN NN O
MEASURES NN NN O
: NN NN O
Laboratory NN NN O
analyses NN NN O
of NN NN O
calcium NN NN O
, NN NN O
magnesium NN NN O
and NN NN O
thyroid NN NN O
- NN NN O
stimulating NN NN O
hormone NN NN O
levels NN NN O
performed NN NN O
before NN NN O
beginning NN NN O
lithium NN NN O
therapy NN NN O
and NN NN O
at NN NN O
biannual NN NN O
follow NN NN O
- NN NN O
up NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Hypothyroidism NN NN B-Disease
developed NN NN O
in NN NN O
40 NN NN O
patients NN NN O
, NN NN O
excluding NN NN O
8 NN NN O
patients NN NN O
who NN NN O
were NN NN O
hypothyroid NN NN B-Disease
at NN NN O
baseline NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
having NN NN O
first NN NN O
- NN NN O
degree NN NN O
relatives NN NN O
affected NN NN O
by NN NN O
thyroid NN NN B-Disease
illness NN NN I-Disease
had NN NN O
accelerated NN NN O
onset NN NN O
of NN NN O
hypothyroidism NN NN B-Disease
( NN NN O
3 NN NN O
. NN NN O
7 NN NN O
years NN NN O
after NN NN O
onset NN NN O
of NN NN O
lithium NN NN O
therapy NN NN O
) NN NN O
compared NN NN O
with NN NN O
patients NN NN O
without NN NN O
a NN NN O
family NN NN O
history NN NN O
( NN NN O
8 NN NN O
. NN NN O
6 NN NN O
years NN NN O
after NN NN O
onset NN NN O
of NN NN O
lithium NN NN O
therapy NN NN O
) NN NN O
. NN NN O
   
Women NN NN O
over NN NN O
60 NN NN O
years NN NN O
of NN NN O
age NN NN O
were NN NN O
more NN NN O
often NN NN O
affected NN NN O
by NN NN O
hypothyroidism NN NN B-Disease
than NN NN O
women NN NN O
under NN NN O
60 NN NN O
years NN NN O
of NN NN O
age NN NN O
( NN NN O
34 NN NN O
. NN NN O
6 NN NN O
% NN NN O
versus NN NN O
31 NN NN O
. NN NN O
9 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Magnesium NN NN O
levels NN NN O
in NN NN O
patients NN NN O
on NN NN O
lithium NN NN O
treatment NN NN O
were NN NN O
unchanged NN NN O
from NN NN O
baseline NN NN O
levels NN NN O
. NN NN O
   
After NN NN O
lithium NN NN O
treatment NN NN O
, NN NN O
calcium NN NN O
levels NN NN O
were NN NN O
higher NN NN O
than NN NN O
either NN NN O
baseline NN NN O
levels NN NN O
or NN NN O
control NN NN O
levels NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
lithium NN NN O
treatment NN NN O
counteracted NN NN O
the NN NN O
decrease NN NN O
in NN NN O
plasma NN NN O
calcium NN NN O
levels NN NN O
associated NN NN O
with NN NN O
aging NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Familial NN NN O
thyroid NN NN B-Disease
illness NN NN I-Disease
is NN NN O
a NN NN O
risk NN NN O
factor NN NN O
for NN NN O
hypothyroidism NN NN B-Disease
and NN NN O
hypercalcemia NN NN B-Disease
during NN NN O
lithium NN NN O
therapy NN NN O
. NN NN O
   
Severe NN NN O
immune NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
associated NN NN O
with NN NN O
prophylactic NN NN O
use NN NN O
of NN NN O
cefotetan NN NN O
in NN NN O
obstetric NN NN O
and NN NN O
gynecologic NN NN O
procedures NN NN O
. NN NN O
   
Second NN NN O
- NN NN O
and NN NN O
third NN NN O
- NN NN O
generation NN NN O
cephalosporins NN NN O
, NN NN O
especially NN NN O
cefotetan NN NN O
, NN NN O
are NN NN O
increasingly NN NN O
associated NN NN O
with NN NN O
severe NN NN O
, NN NN O
sometimes NN NN O
fatal NN NN O
immune NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
. NN NN O
   
We NN NN O
noticed NN NN O
that NN NN O
10 NN NN O
of NN NN O
our NN NN O
35 NN NN O
cases NN NN O
of NN NN O
cefotetan NN NN O
- NN NN O
induced NN NN O
hemolytic NN NN B-Disease
anemias NN NN I-Disease
were NN NN O
in NN NN O
patients NN NN O
who NN NN O
had NN NN O
received NN NN O
cefotetan NN NN O
prophylactically NN NN O
for NN NN O
obstetric NN NN O
and NN NN O
gynecologic NN NN O
procedures NN NN O
. NN NN O
   
Eight NN NN O
of NN NN O
these NN NN O
cases NN NN O
of NN NN O
severe NN NN O
immune NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
are NN NN O
described NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
nonsteroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
on NN NN O
hemostasis NN NN O
in NN NN O
patients NN NN O
with NN NN O
aneurysmal NN NN B-Disease
subarachnoid NN NN I-Disease
hemorrhage NN NN I-Disease
. NN NN O
   
Platelet NN NN O
function NN NN O
is NN NN O
impaired NN NN O
by NN NN O
nonsteroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
( NN NN O
NSAIDs NN NN O
) NN NN O
with NN NN O
prominent NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
properties NN NN O
. NN NN O
   
Their NN NN O
safety NN NN O
in NN NN O
patients NN NN O
undergoing NN NN O
intracranial NN NN O
surgery NN NN O
is NN NN O
under NN NN O
debate NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
aneurysmal NN NN B-Disease
subarachnoid NN NN I-Disease
hemorrhage NN NN I-Disease
( NN NN O
SAH NN NN B-Disease
) NN NN O
were NN NN O
randomized NN NN O
to NN NN O
receive NN NN O
either NN NN O
ketoprofen NN NN O
, NN NN O
100 NN NN O
mg NN NN O
, NN NN O
three NN NN O
times NN NN O
a NN NN O
day NN NN O
( NN NN O
ketoprofen NN NN O
group NN NN O
, NN NN O
n NN NN O
= NN NN O
9 NN NN O
) NN NN O
or NN NN O
a NN NN O
weak NN NN O
NSAID NN NN O
, NN NN O
acetaminophen NN NN O
, NN NN O
1 NN NN O
g NN NN O
, NN NN O
three NN NN O
times NN NN O
a NN NN O
day NN NN O
( NN NN O
acetaminophen NN NN O
group NN NN O
, NN NN O
n NN NN O
= NN NN O
9 NN NN O
) NN NN O
starting NN NN O
immediately NN NN O
after NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
aneurysmal NN NN B-Disease
SAH NN NN B-Disease
. NN NN O
   
Treatment NN NN O
was NN NN O
continued NN NN O
for NN NN O
3 NN NN O
days NN NN O
postoperatively NN NN O
. NN NN O
   
Test NN NN O
blood NN NN O
samples NN NN O
were NN NN O
taken NN NN O
before NN NN O
treatment NN NN O
and NN NN O
surgery NN NN O
as NN NN O
well NN NN O
as NN NN O
on NN NN O
the NN NN O
first NN NN O
, NN NN O
third NN NN O
, NN NN O
and NN NN O
fifth NN NN O
postoperative NN NN O
mornings NN NN O
. NN NN O
   
Maximal NN NN O
platelet NN NN B-Disease
aggregation NN NN I-Disease
induced NN NN O
by NN NN O
6 NN NN O
microM NN NN O
of NN NN O
adenosine NN NN O
diphosphate NN NN O
decreased NN NN O
after NN NN O
administration NN NN O
of NN NN O
ketoprofen NN NN O
. NN NN O
   
Aggregation NN NN O
was NN NN O
lower NN NN O
( NN NN O
P NN NN O
< NN NN O
. NN NN O
05 NN NN O
) NN NN O
in NN NN O
the NN NN O
ketoprofen NN NN O
group NN NN O
than NN NN O
in NN NN O
the NN NN O
acetaminophen NN NN O
group NN NN O
just NN NN O
before NN NN O
surgery NN NN O
and NN NN O
on NN NN O
the NN NN O
third NN NN O
postoperative NN NN O
day NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
maximal NN NN O
platelet NN NN B-Disease
aggregation NN NN I-Disease
increased NN NN O
in NN NN O
the NN NN O
acetaminophen NN NN O
group NN NN O
on NN NN O
the NN NN O
third NN NN O
postoperative NN NN O
day NN NN O
as NN NN O
compared NN NN O
with NN NN O
the NN NN O
pretreatment NN NN O
platelet NN NN B-Disease
aggregation NN NN I-Disease
results NN NN O
( NN NN O
P NN NN O
< NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
One NN NN O
patient NN NN O
in NN NN O
the NN NN O
ketoprofen NN NN O
group NN NN O
developed NN NN O
a NN NN O
postoperative NN NN O
intracranial NN NN O
hematoma NN NN B-Disease
. NN NN O
   
Coagulation NN NN O
( NN NN O
prothrombin NN NN O
time NN NN O
[ NN NN O
PT NN NN O
] NN NN O
, NN NN O
activated NN NN O
partial NN NN O
thromboplastin NN NN O
time NN NN O
[ NN NN O
APPT NN NN O
] NN NN O
, NN NN O
fibrinogen NN NN O
concentration NN NN O
, NN NN O
and NN NN O
antithrombin NN NN O
III NN NN O
[ NN NN O
AT NN NN O
III NN NN O
] NN NN O
) NN NN O
was NN NN O
comparable NN NN O
between NN NN O
the NN NN O
two NN NN O
groups NN NN O
. NN NN O
   
Ketoprofen NN NN O
but NN NN O
not NN NN O
acetaminophen NN NN O
impaired NN NN O
platelet NN NN O
function NN NN O
in NN NN O
patients NN NN O
with NN NN O
SAH NN NN B-Disease
. NN NN O
   
If NN NN O
ketoprofen NN NN O
is NN NN O
used NN NN O
before NN NN O
surgery NN NN O
on NN NN O
cerebral NN NN O
artery NN NN B-Disease
aneurysms NN NN I-Disease
, NN NN O
it NN NN O
may NN NN O
pose NN NN O
an NN NN O
additional NN NN O
risk NN NN O
factor NN NN O
for NN NN O
hemorrhage NN NN B-Disease
. NN NN O
   
Nitric NN NN O
oxide NN NN O
synthase NN NN O
expression NN NN O
in NN NN O
the NN NN O
course NN NN O
of NN NN O
lead NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
. NN NN O
   
We NN NN O
recently NN NN O
showed NN NN O
elevated NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
( NN NN O
ROS NN NN O
) NN NN O
, NN NN O
reduced NN NN O
urinary NN NN O
excretion NN NN O
of NN NN O
NO NN NN O
metabolites NN NN O
( NN NN O
NOx NN NN O
) NN NN O
, NN NN O
and NN NN O
increased NN NN O
NO NN NN O
sequestration NN NN O
as NN NN O
nitrotyrosine NN NN O
in NN NN O
various NN NN O
tissues NN NN O
in NN NN O
rats NN NN O
with NN NN O
lead NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
discern NN NN O
whether NN NN O
the NN NN O
reduction NN NN O
in NN NN O
urinary NN NN O
NOx NN NN O
in NN NN O
lead NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
is NN NN O
, NN NN O
in NN NN O
part NN NN O
, NN NN O
due NN NN O
to NN NN O
depressed NN NN O
NO NN NN O
synthase NN NN O
( NN NN O
NOS NN NN O
) NN NN O
expression NN NN O
. NN NN O
   
Male NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
were NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
a NN NN O
lead NN NN O
- NN NN O
treated NN NN O
group NN NN O
( NN NN O
given NN NN O
lead NN NN O
acetate NN NN O
, NN NN O
100 NN NN O
ppm NN NN O
, NN NN O
in NN NN O
drinking NN NN O
water NN NN O
and NN NN O
regular NN NN O
rat NN NN O
chow NN NN O
) NN NN O
, NN NN O
a NN NN O
group NN NN O
given NN NN O
lead NN NN O
and NN NN O
vitamin NN NN O
E NN NN O
- NN NN O
fortified NN NN O
chow NN NN O
, NN NN O
or NN NN O
a NN NN O
normal NN NN O
control NN NN O
group NN NN O
given NN NN O
either NN NN O
regular NN NN O
food NN NN O
and NN NN O
water NN NN O
or NN NN O
vitamin NN NN O
E NN NN O
- NN NN O
fortified NN NN O
food NN NN O
for NN NN O
12 NN NN O
weeks NN NN O
. NN NN O
   
Tail NN NN O
blood NN NN O
pressure NN NN O
, NN NN O
urinary NN NN O
NOx NN NN O
excretion NN NN O
, NN NN O
plasma NN NN O
malondialdehyde NN NN O
( NN NN O
MDA NN NN O
) NN NN O
, NN NN O
and NN NN O
endothelial NN NN O
and NN NN O
inducible NN NN O
NOS NN NN O
( NN NN O
eNOS NN NN O
and NN NN O
iNOS NN NN O
) NN NN O
isotypes NN NN O
in NN NN O
the NN NN O
aorta NN NN O
and NN NN O
kidney NN NN O
were NN NN O
measured NN NN O
. NN NN O
   
The NN NN O
lead NN NN O
- NN NN O
treated NN NN O
group NN NN O
exhibited NN NN O
a NN NN O
rise NN NN O
in NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
plasma NN NN O
MDA NN NN O
concentration NN NN O
, NN NN O
a NN NN O
fall NN NN O
in NN NN O
urinary NN NN O
NOx NN NN O
excretion NN NN O
, NN NN O
and NN NN O
a NN NN O
paradoxical NN NN O
rise NN NN O
in NN NN O
vascular NN NN O
and NN NN O
renal NN NN O
tissue NN NN O
eNOS NN NN O
and NN NN O
iNOS NN NN O
expression NN NN O
. NN NN O
   
Vitamin NN NN O
E NN NN O
supplementation NN NN O
ameliorated NN NN O
hypertension NN NN B-Disease
, NN NN O
lowered NN NN O
plasma NN NN O
MDA NN NN O
concentration NN NN O
, NN NN O
and NN NN O
raised NN NN O
urinary NN NN O
NOx NN NN O
excretion NN NN O
while NN NN O
significantly NN NN O
lowering NN NN O
vascular NN NN O
, NN NN O
but NN NN O
not NN NN O
renal NN NN O
, NN NN O
tissue NN NN O
eNOS NN NN O
and NN NN O
iNOS NN NN O
expression NN NN O
. NN NN O
   
Vitamin NN NN O
E NN NN O
supplementation NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
either NN NN O
blood NN NN O
pressure NN NN O
, NN NN O
plasma NN NN O
MDA NN NN O
, NN NN O
or NN NN O
NOS NN NN O
expression NN NN O
in NN NN O
the NN NN O
control NN NN O
group NN NN O
. NN NN O
   
The NN NN O
study NN NN O
also NN NN O
revealed NN NN O
significant NN NN O
inhibition NN NN O
of NN NN O
NOS NN NN O
enzymatic NN NN O
activity NN NN O
by NN NN O
lead NN NN O
in NN NN O
cell NN NN O
- NN NN O
free NN NN O
preparations NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
lead NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
in NN NN O
this NN NN O
model NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
compensatory NN NN O
upregulation NN NN O
of NN NN O
renal NN NN O
and NN NN O
vascular NN NN O
eNOS NN NN O
and NN NN O
iNOS NN NN O
expression NN NN O
. NN NN O
   
This NN NN O
is NN NN O
, NN NN O
in NN NN O
part NN NN O
, NN NN O
due NN NN O
to NN NN O
ROS NN NN O
- NN NN O
mediated NN NN O
NO NN NN O
inactivation NN NN O
, NN NN O
lead NN NN O
- NN NN O
associated NN NN O
inhibition NN NN O
of NN NN O
NOS NN NN O
activity NN NN O
, NN NN O
and NN NN O
perhaps NN NN O
stimulatory NN NN O
actions NN NN O
of NN NN O
increased NN NN O
shear NN NN O
stress NN NN O
associated NN NN O
with NN NN O
hypertension NN NN B-Disease
. NN NN O
   
Glyceryl NN NN O
trinitrate NN NN O
induces NN NN O
attacks NN NN O
of NN NN O
migraine NN NN B-Disease
without NN NN I-Disease
aura NN NN I-Disease
in NN NN O
sufferers NN NN O
of NN NN O
migraine NN NN B-Disease
with NN NN I-Disease
aura NN NN I-Disease
. NN NN O
   
Migraine NN NN B-Disease
with NN NN I-Disease
aura NN NN I-Disease
and NN NN O
migraine NN NN B-Disease
without NN NN I-Disease
aura NN NN I-Disease
have NN NN O
the NN NN O
same NN NN O
pain NN NN B-Disease
phase NN NN O
, NN NN O
thus NN NN O
indicating NN NN O
that NN NN O
migraine NN NN B-Disease
with NN NN I-Disease
aura NN NN I-Disease
and NN NN O
migraine NN NN B-Disease
without NN NN I-Disease
aura NN NN I-Disease
share NN NN O
a NN NN O
common NN NN O
pathway NN NN O
of NN NN O
nociception NN NN O
. NN NN O
   
In NN NN O
recent NN NN O
years NN NN O
, NN NN O
increasing NN NN O
evidence NN NN O
has NN NN O
suggested NN NN O
that NN NN O
the NN NN O
messenger NN NN O
molecule NN NN O
nitric NN NN O
oxide NN NN O
( NN NN O
NO NN NN O
) NN NN O
is NN NN O
involved NN NN O
in NN NN O
pain NN NN B-Disease
mechanisms NN NN O
of NN NN O
migraine NN NN B-Disease
without NN NN I-Disease
aura NN NN I-Disease
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
clarify NN NN O
whether NN NN O
the NN NN O
same NN NN O
is NN NN O
true NN NN O
for NN NN O
migraine NN NN B-Disease
with NN NN I-Disease
aura NN NN I-Disease
, NN NN O
in NN NN O
the NN NN O
present NN NN O
study NN NN O
we NN NN O
examined NN NN O
the NN NN O
headache NN NN B-Disease
response NN NN O
to NN NN O
intravenous NN NN O
infusion NN NN O
of NN NN O
glyceryl NN NN O
trinitrate NN NN O
( NN NN O
GTN NN NN O
) NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
for NN NN O
20 NN NN O
min NN NN O
) NN NN O
in NN NN O
12 NN NN O
sufferers NN NN O
of NN NN O
migraine NN NN B-Disease
with NN NN I-Disease
aura NN NN I-Disease
. NN NN O
   
The NN NN O
specific NN NN O
aim NN NN O
was NN NN O
to NN NN O
elucidate NN NN O
whether NN NN O
an NN NN O
aura NN NN O
and NN NN O
/ NN NN O
or NN NN O
an NN NN O
attack NN NN O
of NN NN O
migraine NN NN B-Disease
without NN NN I-Disease
aura NN NN I-Disease
could NN NN O
be NN NN O
induced NN NN O
. NN NN O
   
Fourteen NN NN O
healthy NN NN O
subjects NN NN O
served NN NN O
as NN NN O
controls NN NN O
. NN NN O
   
Aura NN NN O
symptoms NN NN O
were NN NN O
not NN NN O
elicited NN NN O
in NN NN O
any NN NN O
subject NN NN O
. NN NN O
   
Headache NN NN B-Disease
was NN NN O
more NN NN O
severe NN NN O
in NN NN O
migraineurs NN NN B-Disease
than NN NN O
in NN NN O
the NN NN O
controls NN NN O
during NN NN O
and NN NN O
immediately NN NN O
after NN NN O
GTN NN NN O
infusion NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
037 NN NN O
) NN NN O
as NN NN O
well NN NN O
as NN NN O
during NN NN O
the NN NN O
following NN NN O
11 NN NN O
h NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
008 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
controls NN NN O
, NN NN O
the NN NN O
GTN NN NN O
- NN NN O
induced NN NN O
headache NN NN B-Disease
gradually NN NN O
disappeared NN NN O
, NN NN O
whereas NN NN O
in NN NN O
migraineurs NN NN B-Disease
peak NN NN O
headache NN NN B-Disease
intensity NN NN O
occurred NN NN O
at NN NN O
a NN NN O
mean NN NN O
time NN NN O
of NN NN O
240 NN NN O
min NN NN O
post NN NN O
- NN NN O
infusion NN NN O
. NN NN O
   
At NN NN O
this NN NN O
time NN NN O
the NN NN O
induced NN NN O
headache NN NN B-Disease
in NN NN O
6 NN NN O
of NN NN O
12 NN NN O
migraineurs NN NN B-Disease
fulfilled NN NN O
the NN NN O
diagnostic NN NN O
criteria NN NN O
for NN NN O
migraine NN NN B-Disease
without NN NN I-Disease
aura NN NN I-Disease
of NN NN O
the NN NN O
International NN NN O
Headache NN NN B-Disease
Society NN NN O
. NN NN O
   
The NN NN O
results NN NN O
therefore NN NN O
suggest NN NN O
that NN NN O
NO NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
pain NN NN B-Disease
mechanisms NN NN O
of NN NN O
migraine NN NN B-Disease
with NN NN I-Disease
aura NN NN I-Disease
. NN NN O
   
Since NN NN O
cortical NN NN O
spreading NN NN O
depression NN NN B-Disease
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
liberate NN NN O
NO NN NN O
in NN NN O
animals NN NN O
, NN NN O
this NN NN O
finding NN NN O
may NN NN O
help NN NN O
our NN NN O
understanding NN NN O
of NN NN O
the NN NN O
coupling NN NN O
between NN NN O
cortical NN NN O
spreading NN NN O
depression NN NN B-Disease
and NN NN O
headache NN NN B-Disease
in NN NN O
migraine NN NN B-Disease
with NN NN I-Disease
aura NN NN I-Disease
. NN NN O
   
Rapid NN NN O
reversal NN NN O
of NN NN O
life NN NN O
- NN NN O
threatening NN NN O
diltiazem NN NN O
- NN NN O
induced NN NN O
tetany NN NN B-Disease
with NN NN O
calcium NN NN O
chloride NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
patient NN NN O
who NN NN O
developed NN NN O
tetany NN NN B-Disease
with NN NN O
sudden NN NN O
respiratory NN NN B-Disease
arrest NN NN I-Disease
after NN NN O
the NN NN O
infusion NN NN O
of NN NN O
intravenous NN NN O
diltiazem NN NN O
. NN NN O
   
The NN NN O
administration NN NN O
of NN NN O
calcium NN NN O
chloride NN NN O
rapidly NN NN O
resolved NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
tetany NN NN B-Disease
with NN NN O
prompt NN NN O
recovery NN NN O
of NN NN O
respiratory NN NN O
function NN NN O
, NN NN O
averting NN NN O
the NN NN O
need NN NN O
for NN NN O
more NN NN O
aggressive NN NN O
airway NN NN O
management NN NN O
and NN NN O
ventilatory NN NN O
support NN NN O
. NN NN O
   
The NN NN O
emergency NN NN O
physician NN NN O
should NN NN O
be NN NN O
aware NN NN O
that NN NN O
life NN NN O
- NN NN O
threatening NN NN O
tetany NN NN B-Disease
may NN NN O
accompany NN NN O
the NN NN O
administration NN NN O
of NN NN O
intravenous NN NN O
diltiazem NN NN O
and NN NN O
that NN NN O
calcium NN NN O
chloride NN NN O
may NN NN O
be NN NN O
a NN NN O
rapid NN NN O
and NN NN O
effective NN NN O
remedy NN NN O
. NN NN O
   
Predictors NN NN O
of NN NN O
decreased NN NN B-Disease
renal NN NN I-Disease
function NN NN I-Disease
in NN NN O
patients NN NN O
with NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
during NN NN O
angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
inhibitor NN NN O
therapy NN NN O
: NN NN O
results NN NN O
from NN NN O
the NN NN O
studies NN NN O
of NN NN O
left NN NN B-Disease
ventricular NN NN I-Disease
dysfunction NN NN I-Disease
( NN NN O
SOLVD NN NN O
) NN NN O
   
BACKGROUND NN NN O
: NN NN O
Although NN NN O
angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
inhibitor NN NN O
therapy NN NN O
reduces NN NN O
mortality NN NN O
rates NN NN O
in NN NN O
patients NN NN O
with NN NN O
congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
( NN NN O
CHF NN NN B-Disease
) NN NN O
, NN NN O
it NN NN O
may NN NN O
also NN NN O
cause NN NN O
decreased NN NN B-Disease
renal NN NN I-Disease
function NN NN I-Disease
. NN NN O
   
Little NN NN O
information NN NN O
is NN NN O
available NN NN O
to NN NN O
predict NN NN O
which NN NN O
patients NN NN O
are NN NN O
at NN NN O
highest NN NN O
risk NN NN O
for NN NN O
this NN NN O
complication NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
quantify NN NN O
specific NN NN O
clinical NN NN O
predictors NN NN O
of NN NN O
reduction NN NN B-Disease
in NN NN I-Disease
renal NN NN I-Disease
function NN NN I-Disease
in NN NN O
patients NN NN O
with NN NN O
CHF NN NN B-Disease
who NN NN O
are NN NN O
prescribed NN NN O
angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
inhibitor NN NN O
therapy NN NN O
. NN NN O
   
METHOD NN NN O
: NN NN O
We NN NN O
analyzed NN NN O
data NN NN O
from NN NN O
the NN NN O
Studies NN NN O
of NN NN O
Left NN NN B-Disease
Ventricular NN NN I-Disease
Dysfunction NN NN I-Disease
( NN NN O
SOLVD NN NN O
) NN NN O
, NN NN O
a NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
trial NN NN O
of NN NN O
enalapril NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
CHF NN NN B-Disease
. NN NN O
   
There NN NN O
were NN NN O
3379 NN NN O
patients NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
enalapril NN NN O
with NN NN O
a NN NN O
median NN NN O
follow NN NN O
- NN NN O
up NN NN O
of NN NN O
974 NN NN O
days NN NN O
and NN NN O
3379 NN NN O
patients NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
placebo NN NN O
with NN NN O
a NN NN O
mean NN NN O
follow NN NN O
- NN NN O
up NN NN O
of NN NN O
967 NN NN O
days NN NN O
. NN NN O
   
Decreased NN NN B-Disease
renal NN NN I-Disease
function NN NN I-Disease
was NN NN O
defined NN NN O
as NN NN O
a NN NN O
rise NN NN O
in NN NN O
serum NN NN O
creatinine NN NN O
> NN NN O
/ NN NN O
= NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
( NN NN O
44 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
) NN NN O
from NN NN O
baseline NN NN O
. NN NN O
   
We NN NN O
used NN NN O
time NN NN O
- NN NN O
to NN NN O
- NN NN O
event NN NN O
analysis NN NN O
to NN NN O
identify NN NN O
potential NN NN O
predictors NN NN O
of NN NN O
decrease NN NN O
in NN NN O
renal NN NN O
function NN NN O
including NN NN O
age NN NN O
, NN NN O
baseline NN NN O
ejection NN NN O
fraction NN NN O
, NN NN O
baseline NN NN O
creatinine NN NN O
, NN NN O
low NN NN O
systolic NN NN O
blood NN NN O
pressure NN NN O
( NN NN O
< NN NN O
100 NN NN O
mm NN NN O
Hg NN NN O
) NN NN O
, NN NN O
history NN NN O
of NN NN O
hypertension NN NN B-Disease
, NN NN O
diabetes NN NN B-Disease
, NN NN O
and NN NN O
use NN NN O
of NN NN O
antiplatelet NN NN O
, NN NN O
diuretic NN NN O
, NN NN O
and NN NN O
beta NN NN O
- NN NN O
blocker NN NN O
therapy NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Patients NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
enalapril NN NN O
had NN NN O
a NN NN O
33 NN NN O
% NN NN O
greater NN NN O
likelihood NN NN O
of NN NN O
decreased NN NN B-Disease
renal NN NN I-Disease
function NN NN I-Disease
than NN NN O
controls NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O
003 NN NN O
) NN NN O
. NN NN O
   
By NN NN O
multivariate NN NN O
analysis NN NN O
, NN NN O
in NN NN O
both NN NN O
the NN NN O
placebo NN NN O
and NN NN O
enalapril NN NN O
groups NN NN O
older NN NN O
age NN NN O
, NN NN O
diuretic NN NN O
therapy NN NN O
, NN NN O
and NN NN O
diabetes NN NN B-Disease
were NN NN O
associated NN NN O
with NN NN O
decreased NN NN B-Disease
renal NN NN I-Disease
function NN NN I-Disease
, NN NN O
whereas NN NN O
beta NN NN O
- NN NN O
blocker NN NN O
therapy NN NN O
and NN NN O
higher NN NN O
ejection NN NN O
fraction NN NN O
were NN NN O
renoprotective NN NN O
. NN NN O
   
Older NN NN O
age NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
greater NN NN O
risk NN NN O
of NN NN O
developing NN NN O
decreased NN NN B-Disease
renal NN NN I-Disease
function NN NN I-Disease
in NN NN O
both NN NN O
groups NN NN O
, NN NN O
but NN NN O
significantly NN NN O
more NN NN O
so NN NN O
in NN NN O
the NN NN O
enalapril NN NN O
group NN NN O
( NN NN O
enalapril NN NN O
: NN NN O
risk NN NN O
ratio NN NN O
[ NN NN O
RR NN NN O
] NN NN O
1 NN NN O
. NN NN O
42 NN NN O
per NN NN O
10 NN NN O
years NN NN O
, NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
[ NN NN O
CI NN NN O
] NN NN O
1 NN NN O
. NN NN O
32 NN NN O
- NN NN O
1 NN NN O
. NN NN O
52 NN NN O
with NN NN O
enalapril NN NN O
; NN NN O
placebo NN NN O
: NN NN O
RR NN NN O
1 NN NN O
. NN NN O
18 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
1 NN NN O
. NN NN O
12 NN NN O
- NN NN O
1 NN NN O
. NN NN O
25 NN NN O
) NN NN O
. NN NN O
   
Diuretic NN NN O
therapy NN NN O
was NN NN O
likewise NN NN O
associated NN NN O
with NN NN O
a NN NN O
greater NN NN O
risk NN NN O
of NN NN O
decreased NN NN B-Disease
renal NN NN I-Disease
function NN NN I-Disease
in NN NN O
the NN NN O
enalapril NN NN O
group NN NN O
( NN NN O
RR NN NN O
1 NN NN O
. NN NN O
89 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
1 NN NN O
. NN NN O
70 NN NN O
- NN NN O
2 NN NN O
. NN NN O
08 NN NN O
) NN NN O
than NN NN O
in NN NN O
the NN NN O
placebo NN NN O
group NN NN O
( NN NN O
RR NN NN O
1 NN NN O
. NN NN O
35 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
1 NN NN O
. NN NN O
09 NN NN O
- NN NN O
1 NN NN O
. NN NN O
66 NN NN O
) NN NN O
. NN NN O
   
Conversely NN NN O
, NN NN O
enalapril NN NN O
had NN NN O
a NN NN O
relative NN NN O
renoprotective NN NN O
effect NN NN O
( NN NN O
RR NN NN O
1 NN NN O
. NN NN O
33 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
1 NN NN O
. NN NN O
13 NN NN O
- NN NN O
1 NN NN O
. NN NN O
53 NN NN O
) NN NN O
compared NN NN O
with NN NN O
placebo NN NN O
( NN NN O
RR NN NN O
1 NN NN O
. NN NN O
96 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
1 NN NN O
. NN NN O
57 NN NN O
- NN NN O
2 NN NN O
. NN NN O
44 NN NN O
) NN NN O
in NN NN O
patients NN NN O
with NN NN O
diabetes NN NN B-Disease
. NN NN O
   
A NN NN O
lower NN NN O
risk NN NN O
of NN NN O
renal NN NN B-Disease
impairment NN NN I-Disease
was NN NN O
seen NN NN O
in NN NN O
both NN NN O
groups NN NN O
with NN NN O
beta NN NN O
- NN NN O
blocker NN NN O
therapy NN NN O
( NN NN O
RR NN NN O
0 NN NN O
. NN NN O
70 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
0 NN NN O
. NN NN O
57 NN NN O
- NN NN O
0 NN NN O
. NN NN O
85 NN NN O
) NN NN O
and NN NN O
higher NN NN O
baseline NN NN O
ejection NN NN O
fraction NN NN O
( NN NN O
RR NN NN O
0 NN NN O
. NN NN O
93 NN NN O
per NN NN O
5 NN NN O
% NN NN O
increment NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
0 NN NN O
. NN NN O
91 NN NN O
- NN NN O
0 NN NN O
. NN NN O
96 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Enalapril NN NN O
use NN NN O
caused NN NN O
a NN NN O
33 NN NN O
% NN NN O
increase NN NN O
in NN NN O
the NN NN O
risk NN NN O
of NN NN O
decreased NN NN B-Disease
renal NN NN I-Disease
function NN NN I-Disease
in NN NN O
patients NN NN O
with NN NN O
CHF NN NN B-Disease
. NN NN O
   
Diuretic NN NN O
use NN NN O
and NN NN O
advanced NN NN O
age NN NN O
increased NN NN O
this NN NN O
risk NN NN O
. NN NN O
   
Diabetes NN NN B-Disease
was NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
renal NN NN B-Disease
impairment NN NN I-Disease
in NN NN O
all NN NN O
patients NN NN O
with NN NN O
CHF NN NN B-Disease
, NN NN O
but NN NN O
this NN NN O
risk NN NN O
was NN NN O
reduced NN NN O
in NN NN O
the NN NN O
enalapril NN NN O
group NN NN O
compared NN NN O
with NN NN O
the NN NN O
placebo NN NN O
group NN NN O
. NN NN O
   
beta NN NN O
- NN NN O
Blocker NN NN O
therapy NN NN O
and NN NN O
higher NN NN O
ejection NN NN O
fraction NN NN O
were NN NN O
renoprotective NN NN O
in NN NN O
all NN NN O
patients NN NN O
regardless NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
Hypomania NN NN B-Disease
- NN NN O
like NN NN O
syndrome NN NN O
induced NN NN O
by NN NN O
olanzapine NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
female NN NN O
patient NN NN O
with NN NN O
a NN NN O
diagnosis NN NN O
of NN NN O
a NN NN O
not NN NN O
otherwise NN NN O
specified NN NN O
psychotic NN NN B-Disease
disorder NN NN I-Disease
( NN NN O
DSM NN NN O
- NN NN O
IV NN NN O
) NN NN O
who NN NN O
developed NN NN O
hypomania NN NN B-Disease
shortly NN NN O
after NN NN O
the NN NN O
introduction NN NN O
of NN NN O
olanzapine NN NN O
treatment NN NN O
. NN NN O
   
Acetazolamide NN NN O
- NN NN O
induced NN NN O
Gerstmann NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
Acute NN NN O
confusion NN NN B-Disease
induced NN NN O
by NN NN O
acetazolamide NN NN O
is NN NN O
a NN NN O
well NN NN O
known NN NN O
adverse NN NN O
drug NN NN O
reaction NN NN O
in NN NN O
patients NN NN O
with NN NN O
renal NN NN B-Disease
impairment NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
acetazolamide NN NN O
- NN NN O
induced NN NN O
Gerstmann NN NN B-Disease
syndrome NN NN I-Disease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
normal NN NN O
renal NN NN O
function NN NN O
, NN NN O
to NN NN O
highlight NN NN O
predisposing NN NN O
factors NN NN O
that NN NN O
are NN NN O
frequently NN NN O
overlooked NN NN O
. NN NN O
   
Vasopressin NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
milrinone NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
in NN NN O
severe NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
The NN NN O
use NN NN O
of NN NN O
phosphodiesterase NN NN O
inhibitors NN NN O
such NN NN O
as NN NN O
milrinone NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
severe NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
is NN NN O
frequently NN NN O
restricted NN NN O
because NN NN O
they NN NN O
cause NN NN O
vasodilation NN NN O
and NN NN O
hypotension NN NN B-Disease
. NN NN O
   
In NN NN O
patients NN NN O
with NN NN O
decompensated NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
with NN NN O
hypotension NN NN B-Disease
after NN NN O
treatment NN NN O
with NN NN O
milrinone NN NN O
, NN NN O
low NN NN O
doses NN NN O
of NN NN O
vasopressin NN NN O
restored NN NN O
blood NN NN O
pressure NN NN O
without NN NN O
inhibiting NN NN O
the NN NN O
inotropic NN NN O
effect NN NN O
of NN NN O
milrinone NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
tacrolimus NN NN O
- NN NN O
related NN NN O
adverse NN NN O
effects NN NN O
by NN NN O
conversion NN NN O
to NN NN O
cyclosporine NN NN O
in NN NN O
liver NN NN O
transplant NN NN O
recipients NN NN O
. NN NN O
   
When NN NN O
tacrolimus NN NN O
side NN NN O
effects NN NN O
persist NN NN O
despite NN NN O
dose NN NN O
reduction NN NN O
, NN NN O
conversion NN NN O
to NN NN O
cyclosporine NN NN O
- NN NN O
based NN NN O
immunosuppression NN NN O
( NN NN O
CyA NN NN O
) NN NN O
is NN NN O
necessary NN NN O
. NN NN O
   
We NN NN O
characterized NN NN O
tacrolimus NN NN O
side NN NN O
effects NN NN O
that NN NN O
warranted NN NN O
discontinuation NN NN O
of NN NN O
the NN NN O
drug NN NN O
, NN NN O
and NN NN O
outcomes NN NN O
after NN NN O
conversion NN NN O
. NN NN O
   
Of NN NN O
388 NN NN O
liver NN NN O
recipients NN NN O
who NN NN O
received NN NN O
tacrolimus NN NN O
as NN NN O
primary NN NN O
immunosuppression NN NN O
, NN NN O
70 NN NN O
required NN NN O
conversion NN NN O
to NN NN O
CyA NN NN O
. NN NN O
   
We NN NN O
recorded NN NN O
indication NN NN O
for NN NN O
conversion NN NN O
, NN NN O
whether NN NN O
conversion NN NN O
was NN NN O
early NN NN O
or NN NN O
late NN NN O
after NN NN O
transplantation NN NN O
, NN NN O
tacrolimus NN NN O
dose NN NN O
and NN NN O
trough NN NN O
blood NN NN O
level NN NN O
at NN NN O
conversion NN NN O
, NN NN O
and NN NN O
incidence NN NN O
of NN NN O
rejection NN NN O
after NN NN O
conversion NN NN O
. NN NN O
   
Conversion NN NN O
was NN NN O
early NN NN O
in NN NN O
29 NN NN O
patients NN NN O
( NN NN O
41 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
and NN NN O
late NN NN O
in NN NN O
41 NN NN O
( NN NN O
58 NN NN O
. NN NN O
6 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Indications NN NN O
for NN NN O
early NN NN O
conversion NN NN O
were NN NN O
neurotoxicity NN NN B-Disease
( NN NN O
20 NN NN O
) NN NN O
, NN NN O
( NN NN B-Disease
insulin NN NN I-Disease
- NN NN I-Disease
dependent NN NN I-Disease
) NN NN I-Disease
diabetes NN NN I-Disease
mellitus NN NN I-Disease
( NN NN O
IDDM NN NN B-Disease
) NN NN O
( NN NN O
5 NN NN O
) NN NN O
, NN NN O
nephrotoxicity NN NN B-Disease
( NN NN O
3 NN NN O
) NN NN O
, NN NN O
gastrointestinal NN NN B-Disease
( NN NN I-Disease
GI NN NN I-Disease
) NN NN I-Disease
toxicity NN NN I-Disease
( NN NN O
6 NN NN O
) NN NN O
, NN NN O
and NN NN O
cardiomyopathy NN NN B-Disease
( NN NN O
1 NN NN O
) NN NN O
, NN NN O
and NN NN O
for NN NN O
late NN NN O
conversion NN NN O
were NN NN O
neurotoxicity NN NN B-Disease
( NN NN O
15 NN NN O
) NN NN O
, NN NN O
IDDM NN NN B-Disease
( NN NN O
12 NN NN O
) NN NN O
, NN NN O
nephrotoxicity NN NN B-Disease
( NN NN O
3 NN NN O
) NN NN O
, NN NN O
GI NN NN B-Disease
toxicity NN NN I-Disease
( NN NN O
5 NN NN O
) NN NN O
, NN NN O
hepatotoxicity NN NN B-Disease
( NN NN O
6 NN NN O
) NN NN O
, NN NN O
post NN NN B-Disease
- NN NN I-Disease
transplant NN NN I-Disease
lmphoproliferate NN NN I-Disease
disease NN NN I-Disease
( NN NN O
PTLD NN NN B-Disease
) NN NN O
( NN NN O
2 NN NN O
) NN NN O
, NN NN O
cardiomyopathy NN NN B-Disease
( NN NN O
1 NN NN O
) NN NN O
, NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
( NN NN O
1 NN NN O
) NN NN O
, NN NN O
and NN NN O
pruritus NN NN B-Disease
( NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
All NN NN O
early NN NN O
- NN NN O
conversion NN NN O
patients NN NN O
showed NN NN O
improvement NN NN O
/ NN NN O
resolution NN NN O
of NN NN O
symptoms NN NN O
. NN NN O
   
Among NN NN O
late NN NN O
- NN NN O
conversion NN NN O
patients NN NN O
, NN NN O
37 NN NN O
( NN NN O
90 NN NN O
. NN NN O
2 NN NN O
% NN NN O
) NN NN O
had NN NN O
improvement NN NN O
/ NN NN O
resolution NN NN O
; NN NN O
in NN NN O
4 NN NN O
( NN NN O
9 NN NN O
. NN NN O
8 NN NN O
% NN NN O
) NN NN O
, NN NN O
adverse NN NN O
effects NN NN O
persisted NN NN O
. NN NN O
   
The NN NN O
overall NN NN O
rejection NN NN O
rate NN NN O
was NN NN O
30 NN NN O
% NN NN O
. NN NN O
   
Sixty NN NN O
- NN NN O
two NN NN O
patients NN NN O
( NN NN O
88 NN NN O
. NN NN O
6 NN NN O
% NN NN O
) NN NN O
are NN NN O
alive NN NN O
with NN NN O
functioning NN NN O
grafts NN NN O
686 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
362 NN NN O
days NN NN O
( NN NN O
range NN NN O
, NN NN O
154 NN NN O
- NN NN O
1433 NN NN O
days NN NN O
) NN NN O
after NN NN O
conversion NN NN O
. NN NN O
   
When NN NN O
tacrolimus NN NN O
side NN NN O
effects NN NN O
are NN NN O
unresponsive NN NN O
to NN NN O
dose NN NN O
reduction NN NN O
, NN NN O
conversion NN NN O
to NN NN O
CyA NN NN O
can NN NN O
be NN NN O
accomplished NN NN O
safely NN NN O
, NN NN O
with NN NN O
no NN NN O
increased NN NN O
risk NN NN O
of NN NN O
rejection NN NN O
and NN NN O
excellent NN NN O
long NN NN O
- NN NN O
term NN NN O
outcome NN NN O
. NN NN O
   
Ocular NN NN O
manifestations NN NN O
of NN NN O
juvenile NN NN B-Disease
rheumatoid NN NN I-Disease
arthritis NN NN I-Disease
. NN NN O
   
We NN NN O
followed NN NN O
210 NN NN O
cases NN NN O
of NN NN O
juvenile NN NN B-Disease
rheumatoid NN NN I-Disease
arthritis NN NN I-Disease
closely NN NN O
for NN NN O
eleven NN NN O
years NN NN O
. NN NN O
   
Thirty NN NN O
- NN NN O
six NN NN O
of NN NN O
the NN NN O
210 NN NN O
patients NN NN O
( NN NN O
17 NN NN O
. NN NN O
2 NN NN O
% NN NN O
) NN NN O
developed NN NN O
iridocyclitis NN NN B-Disease
. NN NN O
   
Iridocyclitis NN NN B-Disease
was NN NN O
seen NN NN O
most NN NN O
frequently NN NN O
in NN NN O
young NN NN O
female NN NN O
patients NN NN O
( NN NN O
0 NN NN O
to NN NN O
4 NN NN O
years NN NN O
) NN NN O
with NN NN O
the NN NN O
monoarticular NN NN O
or NN NN O
pauciatricular NN NN O
form NN NN O
of NN NN O
the NN NN O
arthritis NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
30 NN NN O
% NN NN O
of NN NN O
the NN NN O
patients NN NN O
developed NN NN O
uveitis NN NN B-Disease
after NN NN O
16 NN NN O
years NN NN O
of NN NN O
age NN NN O
. NN NN O
   
Although NN NN O
61 NN NN O
% NN NN O
of NN NN O
patients NN NN O
had NN NN O
a NN NN O
noncontributory NN NN O
ocular NN NN O
history NN NN O
on NN NN O
entry NN NN O
, NN NN O
42 NN NN O
% NN NN O
had NN NN O
active NN NN O
uveitis NN NN B-Disease
on NN NN O
entry NN NN O
. NN NN O
   
Our NN NN O
approach NN NN O
was NN NN O
effective NN NN O
in NN NN O
detecting NN NN O
uveitis NN NN B-Disease
in NN NN O
new NN NN O
cases NN NN O
and NN NN O
exacerbations NN NN O
of NN NN O
uveitis NN NN B-Disease
in NN NN O
established NN NN O
cases NN NN O
. NN NN O
   
Forty NN NN O
- NN NN O
four NN NN O
percent NN NN O
of NN NN O
patients NN NN O
with NN NN O
uveitis NN NN B-Disease
had NN NN O
one NN NN O
or NN NN O
more NN NN O
identifiable NN NN O
signs NN NN O
or NN NN O
symptoms NN NN O
, NN NN O
such NN NN O
as NN NN O
red NN NN O
eye NN NN O
, NN NN O
ocular NN NN B-Disease
pain NN NN I-Disease
, NN NN O
decreased NN NN B-Disease
visual NN NN I-Disease
acuity NN NN I-Disease
, NN NN O
or NN NN O
photophobia NN NN B-Disease
, NN NN O
in NN NN O
order NN NN O
of NN NN O
decreasing NN NN O
frequency NN NN O
. NN NN O
   
Even NN NN O
after NN NN O
early NN NN O
detection NN NN O
and NN NN O
prompt NN NN O
treatment NN NN O
, NN NN O
41 NN NN O
% NN NN O
of NN NN O
cases NN NN O
of NN NN O
uveitis NN NN B-Disease
did NN NN O
not NN NN O
respond NN NN O
to NN NN O
more NN NN O
than NN NN O
six NN NN O
months NN NN O
of NN NN O
intensive NN NN O
topical NN NN O
treatment NN NN O
with NN NN O
corticosteroids NN NN O
and NN NN O
mydriatics NN NN O
. NN NN O
   
Despite NN NN O
this NN NN O
, NN NN O
there NN NN O
was NN NN O
a NN NN O
dramatic NN NN O
decrease NN NN O
in NN NN O
the NN NN O
50 NN NN O
% NN NN O
incidence NN NN O
of NN NN O
blinding NN NN O
complications NN NN O
of NN NN O
uveitis NN NN B-Disease
cited NN NN O
in NN NN O
earlier NN NN O
studies NN NN O
. NN NN O
   
Cataract NN NN B-Disease
and NN NN O
band NN NN B-Disease
keratopathy NN NN I-Disease
occurred NN NN O
in NN NN O
only NN NN O
22 NN NN O
and NN NN O
13 NN NN O
% NN NN O
of NN NN O
our NN NN O
group NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
We NN NN O
used NN NN O
chloroquine NN NN O
or NN NN O
hydroxychloroquine NN NN O
in NN NN O
173 NN NN O
of NN NN O
210 NN NN O
cases NN NN O
and NN NN O
found NN NN O
only NN NN O
one NN NN O
case NN NN O
of NN NN O
chorioretinopathy NN NN B-Disease
attributable NN NN O
to NN NN O
these NN NN O
drugs NN NN O
. NN NN O
   
Systemically NN NN O
administered NN NN O
corticosteroids NN NN O
were NN NN O
used NN NN O
in NN NN O
75 NN NN O
of NN NN O
210 NN NN O
cases NN NN O
; NN NN O
a NN NN O
significant NN NN O
number NN NN O
of NN NN O
posterior NN NN O
subcapsular NN NN O
cataracts NN NN B-Disease
was NN NN O
found NN NN O
. NN NN O
   
Typical NN NN O
keratoconjunctivitis NN NN B-Disease
sicca NN NN O
developed NN NN O
in NN NN O
three NN NN O
of NN NN O
the NN NN O
uveitis NN NN B-Disease
cases NN NN O
. NN NN O
   
This NN NN O
association NN NN O
with NN NN O
uveitis NN NN B-Disease
and NN NN O
JRA NN NN O
was NN NN O
not NN NN O
noted NN NN O
previously NN NN O
. NN NN O
   
Surgical NN NN O
treatment NN NN O
of NN NN O
cataracts NN NN B-Disease
, NN NN O
band NN NN B-Disease
keratopathy NN NN I-Disease
, NN NN O
and NN NN O
glaucoma NN NN B-Disease
achieved NN NN O
uniformly NN NN O
discouraging NN NN O
results NN NN O
. NN NN O
   
Cyclophosphamide NN NN O
- NN NN O
induced NN NN O
cystitis NN NN B-Disease
in NN NN O
freely NN NN O
- NN NN O
moving NN NN O
conscious NN NN O
rats NN NN O
: NN NN O
behavioral NN NN O
approach NN NN O
to NN NN O
a NN NN O
new NN NN O
model NN NN O
of NN NN O
visceral NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
PURPOSE NN NN O
: NN NN O
To NN NN O
develop NN NN O
a NN NN O
model NN NN O
of NN NN O
visceral NN NN B-Disease
pain NN NN I-Disease
in NN NN O
rats NN NN O
using NN NN O
a NN NN O
behavioral NN NN O
approach NN NN O
. NN NN O
   
Cyclophosphamide NN NN O
( NN NN O
CP NN NN O
) NN NN O
, NN NN O
an NN NN O
antitumoral NN NN O
agent NN NN O
known NN NN O
to NN NN O
produce NN NN O
toxic NN NN O
effects NN NN O
on NN NN O
the NN NN O
bladder NN NN O
wall NN NN O
through NN NN O
its NN NN O
main NN NN O
toxic NN NN O
metabolite NN NN O
acrolein NN NN O
, NN NN O
was NN NN O
used NN NN O
to NN NN O
induce NN NN O
cystitis NN NN B-Disease
. NN NN O
   
MATERIALS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
CP NN NN O
was NN NN O
administered NN NN O
at NN NN O
doses NN NN O
of NN NN O
50 NN NN O
, NN NN O
100 NN NN O
and NN NN O
200 NN NN O
mg NN NN O
. NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
i NN NN O
. NN NN O
p NN NN O
. NN NN O
to NN NN O
male NN NN O
rats NN NN O
, NN NN O
and NN NN O
their NN NN O
behavior NN NN O
observed NN NN O
and NN NN O
scored NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
morphine NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
to NN NN O
4 NN NN O
mg NN NN O
. NN NN O
/ NN NN O
kg NN NN O
. NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
on NN NN O
CP NN NN O
- NN NN O
induced NN NN O
behavioral NN NN O
modifications NN NN O
were NN NN O
tested NN NN O
administered NN NN O
alone NN NN O
and NN NN O
after NN NN O
naloxone NN NN O
( NN NN O
1 NN NN O
mg NN NN O
. NN NN O
/ NN NN O
kg NN NN O
. NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
90 NN NN O
minutes NN NN O
after NN NN O
CP NN NN O
injection NN NN O
, NN NN O
that NN NN O
is NN NN O
, NN NN O
at NN NN O
the NN NN O
time NN NN O
of NN NN O
administration NN NN O
of NN NN O
morphine NN NN O
, NN NN O
the NN NN O
bladder NN NN O
was NN NN O
removed NN NN O
in NN NN O
some NN NN O
rats NN NN O
for NN NN O
histological NN NN O
examination NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
to NN NN O
show NN NN O
that NN NN O
the NN NN O
bladder NN NN O
is NN NN O
essential NN NN O
for NN NN O
the NN NN O
CP NN NN O
- NN NN O
induced NN NN O
behavioral NN NN O
modifications NN NN O
, NN NN O
female NN NN O
rats NN NN O
also NN NN O
received NN NN O
CP NN NN O
at NN NN O
doses NN NN O
of NN NN O
200 NN NN O
mg NN NN O
. NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
i NN NN O
. NN NN O
p NN NN O
. NN NN O
and NN NN O
of NN NN O
20 NN NN O
mg NN NN O
. NN NN O
by NN NN O
the NN NN O
intravesical NN NN O
route NN NN O
, NN NN O
and NN NN O
acrolein NN NN O
at NN NN O
doses NN NN O
of NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
. NN NN O
by NN NN O
the NN NN O
intravesical NN NN O
route NN NN O
and NN NN O
of NN NN O
5 NN NN O
mg NN NN O
. NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
i NN NN O
. NN NN O
v NN NN O
. NN NN O
RESULTS NN NN O
: NN NN O
CP NN NN O
dose NN NN O
- NN NN O
relatedly NN NN O
induced NN NN O
marked NN NN O
behavioral NN NN O
modifications NN NN O
in NN NN O
male NN NN O
rats NN NN O
: NN NN O
breathing NN NN O
rate NN NN O
decrease NN NN O
, NN NN O
closing NN NN O
of NN NN O
the NN NN O
eyes NN NN O
and NN NN O
occurrence NN NN O
of NN NN O
specific NN NN O
postures NN NN O
. NN NN O
   
Morphine NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
reversed NN NN O
these NN NN O
behavioral NN NN B-Disease
disorders NN NN I-Disease
. NN NN O
   
A NN NN O
dose NN NN O
of NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
. NN NN O
/ NN NN O
kg NN NN O
. NN NN O
produced NN NN O
a NN NN O
reduction NN NN O
of NN NN O
almost NN NN O
50 NN NN O
% NN NN O
of NN NN O
the NN NN O
behavioral NN NN O
score NN NN O
induced NN NN O
by NN NN O
CP NN NN O
200 NN NN O
mg NN NN O
. NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
was NN NN O
completely NN NN O
prevented NN NN O
by NN NN O
pretreatment NN NN O
with NN NN O
naloxone NN NN O
. NN NN O
   
At NN NN O
the NN NN O
time NN NN O
of NN NN O
administration NN NN O
of NN NN O
morphine NN NN O
, NN NN O
histological NN NN O
modifications NN NN O
of NN NN O
the NN NN O
bladder NN NN O
wall NN NN O
, NN NN O
such NN NN O
as NN NN O
chorionic NN NN O
and NN NN O
muscle NN NN O
layer NN NN O
edema NN NN B-Disease
, NN NN O
were NN NN O
observed NN NN O
. NN NN O
   
In NN NN O
female NN NN O
rats NN NN O
, NN NN O
CP NN NN O
200 NN NN O
mg NN NN O
. NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
i NN NN O
. NN NN O
p NN NN O
. NN NN O
produced NN NN O
the NN NN O
same NN NN O
marked NN NN O
behavioral NN NN O
modifications NN NN O
as NN NN O
those NN NN O
observed NN NN O
in NN NN O
male NN NN O
rats NN NN O
. NN NN O
   
Administered NN NN O
at NN NN O
the NN NN O
dose NN NN O
of NN NN O
20 NN NN O
mg NN NN O
. NN NN O
intravesically NN NN O
, NN NN O
CP NN NN O
did NN NN O
not NN NN O
produce NN NN O
any NN NN O
behavioral NN NN O
effects NN NN O
, NN NN O
whereas NN NN O
acrolein NN NN O
at NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
. NN NN O
intravesically NN NN O
induced NN NN O
behavioral NN NN O
modifications NN NN O
identical NN NN O
to NN NN O
those NN NN O
under NN NN O
CP NN NN O
200 NN NN O
mg NN NN O
. NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
i NN NN O
. NN NN O
p NN NN O
. NN NN O
, NN NN O
with NN NN O
the NN NN O
same NN NN O
maximal NN NN O
levels NN NN O
. NN NN O
   
Conversely NN NN O
, NN NN O
acrolein NN NN O
5 NN NN O
mg NN NN O
. NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
i NN NN O
. NN NN O
v NN NN O
. NN NN O
did NN NN O
not NN NN O
produce NN NN O
any NN NN O
behavioral NN NN O
effects NN NN O
at NN NN O
all NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Overall NN NN O
, NN NN O
these NN NN O
results NN NN O
indicate NN NN O
that NN NN O
this NN NN O
experimental NN NN O
model NN NN O
of NN NN O
CP NN NN O
- NN NN O
induced NN NN O
cystitis NN NN B-Disease
may NN NN O
be NN NN O
an NN NN O
interesting NN NN O
new NN NN O
behavioral NN NN O
model NN NN O
of NN NN O
inflammatory NN NN O
visceral NN NN B-Disease
pain NN NN I-Disease
, NN NN O
allowing NN NN O
a NN NN O
better NN NN O
understanding NN NN O
of NN NN O
these NN NN O
painful NN NN B-Disease
syndromes NN NN I-Disease
and NN NN O
thus NN NN O
a NN NN O
better NN NN O
therapeutic NN NN O
approach NN NN O
to NN NN O
them NN NN O
. NN NN O
   
Prednisolone NN NN O
- NN NN O
induced NN NN O
muscle NN NN B-Disease
dysfunction NN NN I-Disease
is NN NN O
caused NN NN O
more NN NN O
by NN NN O
atrophy NN NN B-Disease
than NN NN O
by NN NN O
altered NN NN O
acetylcholine NN NN O
receptor NN NN O
expression NN NN O
. NN NN O
   
Large NN NN O
doses NN NN O
of NN NN O
glucocorticoids NN NN O
can NN NN O
alter NN NN O
muscle NN NN O
physiology NN NN O
and NN NN O
susceptibility NN NN O
to NN NN O
neuromuscular NN NN O
blocking NN NN O
drugs NN NN O
by NN NN O
mechanisms NN NN O
not NN NN O
clearly NN NN O
understood NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
moderate NN NN O
and NN NN O
large NN NN O
doses NN NN O
of NN NN O
prednisolone NN NN O
on NN NN O
muscle NN NN O
function NN NN O
and NN NN O
pharmacology NN NN O
, NN NN O
and NN NN O
their NN NN O
relationship NN NN O
to NN NN O
changes NN NN O
in NN NN O
muscle NN NN O
size NN NN O
and NN NN O
acetylcholine NN NN O
receptor NN NN O
( NN NN O
AChR NN NN O
) NN NN O
expression NN NN O
. NN NN O
   
With NN NN O
institutional NN NN O
approval NN NN O
, NN NN O
35 NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
were NN NN O
randomly NN NN O
allocated NN NN O
to NN NN O
receive NN NN O
daily NN NN O
subcutaneous NN NN O
doses NN NN O
of NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
prednisolone NN NN O
( NN NN O
P10 NN NN O
group NN NN O
) NN NN O
, NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
prednisolone NN NN O
( NN NN O
P100 NN NN O
group NN NN O
) NN NN O
, NN NN O
or NN NN O
an NN NN O
equal NN NN O
volume NN NN O
of NN NN O
saline NN NN O
( NN NN O
S NN NN O
group NN NN O
) NN NN O
for NN NN O
7 NN NN O
days NN NN O
. NN NN O
   
A NN NN O
fourth NN NN O
group NN NN O
of NN NN O
rats NN NN O
was NN NN O
pair NN NN O
fed NN NN O
( NN NN O
food NN NN O
restricted NN NN O
) NN NN O
with NN NN O
the NN NN O
P100 NN NN O
rats NN NN O
for NN NN O
7 NN NN O
days NN NN O
( NN NN O
FR NN NN O
group NN NN O
) NN NN O
. NN NN O
   
On NN NN O
Day NN NN O
8 NN NN O
, NN NN O
the NN NN O
nerve NN NN O
- NN NN O
evoked NN NN O
peak NN NN O
twitch NN NN O
tensions NN NN O
, NN NN O
tetanic NN NN B-Disease
tensions NN NN O
, NN NN O
and NN NN O
fatigability NN NN O
, NN NN O
and NN NN O
the NN NN O
dose NN NN O
- NN NN O
response NN NN O
curves NN NN O
of NN NN O
d NN NN O
- NN NN O
tubocurarine NN NN O
in NN NN O
the NN NN O
tibialis NN NN O
cranialis NN NN O
muscle NN NN O
were NN NN O
measured NN NN O
in NN NN O
vivo NN NN O
and NN NN O
related NN NN O
to NN NN O
muscle NN NN O
mass NN NN O
or NN NN O
expression NN NN O
of NN NN O
AChRs NN NN O
. NN NN O
   
Rate NN NN O
of NN NN O
body NN NN O
weight NN NN O
gain NN NN O
was NN NN O
depressed NN NN O
in NN NN O
the NN NN O
P100 NN NN O
, NN NN O
FR NN NN O
, NN NN O
and NN NN O
P10 NN NN O
groups NN NN O
compared NN NN O
with NN NN O
the NN NN O
S NN NN O
group NN NN O
. NN NN O
   
Tibialis NN NN O
muscle NN NN O
mass NN NN O
was NN NN O
smaller NN NN O
in NN NN O
the NN NN O
P100 NN NN O
group NN NN O
than NN NN O
in NN NN O
the NN NN O
P10 NN NN O
or NN NN O
S NN NN O
groups NN NN O
. NN NN O
   
The NN NN O
evoked NN NN O
peak NN NN O
twitch NN NN O
and NN NN O
tetanic NN NN B-Disease
tensions NN NN O
were NN NN O
less NN NN O
in NN NN O
the NN NN O
P100 NN NN O
group NN NN O
than NN NN O
in NN NN O
the NN NN O
P10 NN NN O
or NN NN O
S NN NN O
groups NN NN O
, NN NN O
however NN NN O
, NN NN O
tension NN NN O
per NN NN O
milligram NN NN O
of NN NN O
muscle NN NN O
mass NN NN O
was NN NN O
greater NN NN O
in NN NN O
the NN NN O
P100 NN NN O
group NN NN O
than NN NN O
in NN NN O
the NN NN O
S NN NN O
group NN NN O
. NN NN O
   
The NN NN O
50 NN NN O
% NN NN O
effective NN NN O
dose NN NN O
of NN NN O
d NN NN O
- NN NN O
tubocurarine NN NN O
( NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
in NN NN O
the NN NN O
tibialis NN NN O
muscle NN NN O
was NN NN O
smaller NN NN O
in NN NN O
the NN NN O
P10 NN NN O
( NN NN O
33 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
. NN NN O
4 NN NN O
) NN NN O
than NN NN O
in NN NN O
the NN NN O
S NN NN O
( NN NN O
61 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
. NN NN O
0 NN NN O
) NN NN O
or NN NN O
the NN NN O
P100 NN NN O
( NN NN O
71 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
9 NN NN O
. NN NN O
6 NN NN O
) NN NN O
groups NN NN O
. NN NN O
   
AChR NN NN O
expression NN NN O
was NN NN O
less NN NN O
in NN NN O
the NN NN O
P10 NN NN O
group NN NN O
than NN NN O
in NN NN O
the NN NN O
S NN NN O
group NN NN O
. NN NN O
   
The NN NN O
evoked NN NN O
tensions NN NN O
correlated NN NN O
with NN NN O
muscle NN NN O
mass NN NN O
( NN NN O
r NN NN O
( NN NN O
2 NN NN O
) NN NN O
= NN NN O
0 NN NN O
. NN NN O
32 NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
however NN NN O
, NN NN O
not NN NN O
with NN NN O
expression NN NN O
of NN NN O
AChR NN NN O
. NN NN O
   
The NN NN O
50 NN NN O
% NN NN O
effective NN NN O
dose NN NN O
of NN NN O
d NN NN O
- NN NN O
tubocurarine NN NN O
did NN NN O
not NN NN O
correlate NN NN O
with NN NN O
muscle NN NN O
mass NN NN O
or NN NN O
AChR NN NN O
expression NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
neuromuscular NN NN B-Disease
dysfunction NN NN I-Disease
after NN NN O
prednisolone NN NN O
is NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
, NN NN O
and NN NN O
derives NN NN O
primarily NN NN O
from NN NN O
muscle NN NN B-Disease
atrophy NN NN I-Disease
and NN NN O
derives NN NN O
less NN NN O
so NN NN O
from NN NN O
changes NN NN O
in NN NN O
AChR NN NN O
expression NN NN O
. NN NN O
   
IMPLICATIONS NN NN O
: NN NN O
The NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
chronic NN NN O
glucocorticoid NN NN O
therapy NN NN O
alters NN NN O
neuromuscular NN NN O
physiology NN NN O
and NN NN O
pharmacology NN NN O
are NN NN O
unclear NN NN O
. NN NN O
   
We NN NN O
suggest NN NN O
that NN NN O
the NN NN O
observed NN NN O
effects NN NN O
are NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
and NN NN O
derive NN NN O
primarily NN NN O
from NN NN O
muscle NN NN B-Disease
atrophy NN NN I-Disease
and NN NN O
derive NN NN O
less NN NN O
from NN NN O
changes NN NN O
in NN NN O
acetylcholine NN NN O
receptor NN NN O
expression NN NN O
. NN NN O
   
Apomorphine NN NN O
: NN NN O
an NN NN O
underutilized NN NN O
therapy NN NN O
for NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Apomorphine NN NN O
was NN NN O
the NN NN O
first NN NN O
dopaminergic NN NN O
drug NN NN O
ever NN NN O
used NN NN O
to NN NN O
treat NN NN O
symptoms NN NN O
of NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
While NN NN O
powerful NN NN O
antiparkinsonian NN NN O
effects NN NN O
had NN NN O
been NN NN O
observed NN NN O
as NN NN O
early NN NN O
as NN NN O
1951 NN NN O
, NN NN O
the NN NN O
potential NN NN O
of NN NN O
treating NN NN O
fluctuating NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
by NN NN O
subcutaneous NN NN O
administration NN NN O
of NN NN O
apomorphine NN NN O
has NN NN O
only NN NN O
recently NN NN O
become NN NN O
the NN NN O
subject NN NN O
of NN NN O
systematic NN NN O
study NN NN O
. NN NN O
   
A NN NN O
number NN NN O
of NN NN O
small NN NN O
scale NN NN O
clinical NN NN O
trials NN NN O
have NN NN O
unequivocally NN NN O
shown NN NN O
that NN NN O
intermittent NN NN O
subcutaneous NN NN O
apomorphine NN NN O
injections NN NN O
produce NN NN O
antiparkinsonian NN NN O
benefit NN NN O
close NN NN O
if NN NN O
not NN NN O
identical NN NN O
to NN NN O
that NN NN O
seen NN NN O
with NN NN O
levodopa NN NN O
and NN NN O
that NN NN O
apomorphine NN NN O
rescue NN NN O
injections NN NN O
can NN NN O
reliably NN NN O
revert NN NN O
off NN NN O
- NN NN O
periods NN NN O
even NN NN O
in NN NN O
patients NN NN O
with NN NN O
complex NN NN O
on NN NN O
- NN NN O
off NN NN O
motor NN NN O
swings NN NN O
. NN NN O
   
Continuous NN NN O
subcutaneous NN NN O
apomorphine NN NN O
infusions NN NN O
can NN NN O
reduce NN NN O
daily NN NN O
off NN NN O
- NN NN O
time NN NN O
by NN NN O
more NN NN O
than NN NN O
50 NN NN O
% NN NN O
in NN NN O
this NN NN O
group NN NN O
of NN NN O
patients NN NN O
, NN NN O
which NN NN O
appears NN NN O
to NN NN O
be NN NN O
a NN NN O
stronger NN NN O
effect NN NN O
than NN NN O
that NN NN O
generally NN NN O
seen NN NN O
with NN NN O
add NN NN O
- NN NN O
on NN NN O
therapy NN NN O
with NN NN O
oral NN NN O
dopamine NN NN O
agonists NN NN O
or NN NN O
COMT NN NN O
inhibitors NN NN O
. NN NN O
   
Extended NN NN O
follow NN NN O
- NN NN O
up NN NN O
studies NN NN O
of NN NN O
up NN NN O
to NN NN O
8 NN NN O
years NN NN O
have NN NN O
demonstrated NN NN O
long NN NN O
- NN NN O
term NN NN O
persistence NN NN O
of NN NN O
apomorphine NN NN O
efficacy NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
there NN NN O
is NN NN O
convincing NN NN O
clinical NN NN O
evidence NN NN O
that NN NN O
monotherapy NN NN O
with NN NN O
continuous NN NN O
subcutaneous NN NN O
apomorphine NN NN O
infusions NN NN O
is NN NN O
associated NN NN O
with NN NN O
marked NN NN O
reductions NN NN O
of NN NN O
preexisting NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
. NN NN O
   
The NN NN O
main NN NN O
side NN NN O
effects NN NN O
of NN NN O
subcutaneous NN NN O
apomorphine NN NN O
treatment NN NN O
are NN NN O
related NN NN O
to NN NN O
cutaneous NN NN O
tolerability NN NN O
problems NN NN O
, NN NN O
whereas NN NN O
sedation NN NN O
and NN NN O
psychiatric NN NN B-Disease
complications NN NN O
play NN NN O
a NN NN O
lesser NN NN O
role NN NN O
. NN NN O
   
Given NN NN O
the NN NN O
marked NN NN O
degree NN NN O
of NN NN O
efficacy NN NN O
of NN NN O
subcutaneous NN NN O
apomorphine NN NN O
treatment NN NN O
in NN NN O
fluctuating NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
, NN NN O
this NN NN O
approach NN NN O
seems NN NN O
to NN NN O
deserve NN NN O
more NN NN O
widespread NN NN O
clinical NN NN O
use NN NN O
. NN NN O
   
Probing NN NN O
peripheral NN NN O
and NN NN O
central NN NN O
cholinergic NN NN O
system NN NN O
responses NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
The NN NN O
pharmacological NN NN O
response NN NN O
to NN NN O
drugs NN NN O
that NN NN O
act NN NN O
on NN NN O
the NN NN O
cholinergic NN NN O
system NN NN O
of NN NN O
the NN NN O
iris NN NN O
has NN NN O
been NN NN O
used NN NN O
to NN NN O
predict NN NN O
deficits NN NN O
in NN NN O
central NN NN O
cholinergic NN NN O
functioning NN NN O
due NN NN O
to NN NN O
diseases NN NN O
such NN NN O
as NN NN O
Alzheimer NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
, NN NN O
yet NN NN O
correlations NN NN O
between NN NN O
central NN NN O
and NN NN O
peripheral NN NN O
responses NN NN O
have NN NN O
not NN NN O
been NN NN O
properly NN NN O
studied NN NN O
. NN NN O
   
This NN NN O
study NN NN O
assessed NN NN O
the NN NN O
effect NN NN O
of NN NN O
normal NN NN O
aging NN NN O
on NN NN O
( NN NN O
1 NN NN O
) NN NN O
the NN NN O
tropicamide NN NN O
- NN NN O
induced NN NN O
increase NN NN O
in NN NN O
pupil NN NN O
diameter NN NN O
, NN NN O
and NN NN O
( NN NN O
2 NN NN O
) NN NN O
the NN NN O
reversal NN NN O
of NN NN O
this NN NN O
effect NN NN O
with NN NN O
pilocarpine NN NN O
. NN NN O
   
Scopolamine NN NN O
was NN NN O
used NN NN O
as NN NN O
a NN NN O
positive NN NN O
control NN NN O
to NN NN O
detect NN NN O
age NN NN O
- NN NN O
dependent NN NN O
changes NN NN O
in NN NN O
central NN NN O
cholinergic NN NN O
functioning NN NN O
in NN NN O
the NN NN O
elderly NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
Randomized NN NN O
double NN NN O
- NN NN O
blind NN NN O
controlled NN NN O
trial NN NN O
. NN NN O
   
PARTICIPANTS NN NN O
: NN NN O
Ten NN NN O
healthy NN NN O
elderly NN NN O
( NN NN O
mean NN NN O
age NN NN O
70 NN NN O
) NN NN O
and NN NN O
9 NN NN O
young NN NN O
( NN NN O
mean NN NN O
age NN NN O
33 NN NN O
) NN NN O
volunteers NN NN O
. NN NN O
   
INTERVENTIONS NN NN O
: NN NN O
Pupil NN NN O
diameter NN NN O
was NN NN O
monitored NN NN O
using NN NN O
a NN NN O
computerized NN NN O
infrared NN NN O
pupillometer NN NN O
over NN NN O
4 NN NN O
hours NN NN O
. NN NN O
   
The NN NN O
study NN NN O
involved NN NN O
4 NN NN O
sessions NN NN O
. NN NN O
   
In NN NN O
1 NN NN O
session NN NN O
, NN NN O
tropicamide NN NN O
( NN NN O
20 NN NN O
microL NN NN O
, NN NN O
0 NN NN O
. NN NN O
01 NN NN O
% NN NN O
) NN NN O
was NN NN O
administered NN NN O
to NN NN O
one NN NN O
eye NN NN O
and NN NN O
placebo NN NN O
to NN NN O
the NN NN O
other NN NN O
. NN NN O
   
In NN NN O
another NN NN O
session NN NN O
, NN NN O
tropicamide NN NN O
( NN NN O
20 NN NN O
microL NN NN O
, NN NN O
0 NN NN O
. NN NN O
01 NN NN O
% NN NN O
) NN NN O
was NN NN O
administered NN NN O
to NN NN O
both NN NN O
eyes NN NN O
, NN NN O
followed NN NN O
23 NN NN O
minutes NN NN O
later NN NN O
by NN NN O
the NN NN O
application NN NN O
of NN NN O
pilocarpine NN NN O
( NN NN O
20 NN NN O
microL NN NN O
, NN NN O
0 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
to NN NN O
one NN NN O
eye NN NN O
and NN NN O
placebo NN NN O
to NN NN O
the NN NN O
other NN NN O
. NN NN O
   
All NN NN O
eye NN NN O
drops NN NN O
were NN NN O
given NN NN O
in NN NN O
a NN NN O
randomized NN NN O
order NN NN O
. NN NN O
   
In NN NN O
2 NN NN O
separate NN NN O
sessions NN NN O
, NN NN O
a NN NN O
single NN NN O
dose NN NN O
of NN NN O
scopolamine NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
, NN NN O
intravenously NN NN O
) NN NN O
or NN NN O
placebo NN NN O
was NN NN O
administered NN NN O
, NN NN O
and NN NN O
the NN NN O
effects NN NN O
on NN NN O
word NN NN O
recall NN NN O
were NN NN O
measured NN NN O
using NN NN O
the NN NN O
Buschke NN NN O
Selective NN NN O
Reminding NN NN O
Test NN NN O
over NN NN O
2 NN NN O
hours NN NN O
. NN NN O
   
OUTCOME NN NN O
MEASURES NN NN O
: NN NN O
Pupil NN NN O
size NN NN O
at NN NN O
time NN NN O
points NN NN O
after NN NN O
administration NN NN O
of NN NN O
tropicamide NN NN O
and NN NN O
pilocarpine NN NN O
; NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
impairment NN NN B-Disease
in NN NN I-Disease
word NN NN I-Disease
recall NN NN I-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
There NN NN O
was NN NN O
no NN NN O
significant NN NN O
difference NN NN O
between NN NN O
elderly NN NN O
and NN NN O
young NN NN O
volunteers NN NN O
in NN NN O
pupillary NN NN O
response NN NN O
to NN NN O
tropicamide NN NN O
at NN NN O
any NN NN O
time NN NN O
point NN NN O
( NN NN O
p NN NN O
> NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
elderly NN NN O
group NN NN O
had NN NN O
a NN NN O
significantly NN NN O
greater NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
net NN NN O
decrease NN NN O
in NN NN O
pupil NN NN O
size NN NN O
85 NN NN O
, NN NN O
125 NN NN O
, NN NN O
165 NN NN O
and NN NN O
215 NN NN O
minutes NN NN O
after NN NN O
administration NN NN O
, NN NN O
compared NN NN O
with NN NN O
the NN NN O
young NN NN O
group NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Compared NN NN O
with NN NN O
the NN NN O
young NN NN O
group NN NN O
, NN NN O
the NN NN O
elderly NN NN O
group NN NN O
had NN NN O
greater NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
impairment NN NN B-Disease
in NN NN I-Disease
word NN NN I-Disease
recall NN NN I-Disease
60 NN NN O
, NN NN O
90 NN NN O
and NN NN O
120 NN NN O
minutes NN NN O
after NN NN O
administration NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
There NN NN O
is NN NN O
an NN NN O
age NN NN O
- NN NN O
related NN NN O
pupillary NN NN O
response NN NN O
to NN NN O
pilocarpine NN NN O
that NN NN O
is NN NN O
not NN NN O
found NN NN O
with NN NN O
tropicamide NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
pilocarpine NN NN O
may NN NN O
be NN NN O
useful NN NN O
to NN NN O
assess NN NN O
variations NN NN O
in NN NN O
central NN NN O
cholinergic NN NN O
function NN NN O
in NN NN O
elderly NN NN O
patients NN NN O
. NN NN O
   
Pain NN NN B-Disease
responses NN NN O
in NN NN O
methadone NN NN O
- NN NN O
maintained NN NN O
opioid NN NN O
abusers NN NN O
. NN NN O
   
Providing NN NN O
pain NN NN B-Disease
management NN NN O
for NN NN O
known NN NN O
opioid NN NN O
abusers NN NN O
is NN NN O
a NN NN O
challenging NN NN O
clinical NN NN O
task NN NN O
, NN NN O
in NN NN O
part NN NN O
because NN NN O
little NN NN O
is NN NN O
known NN NN O
about NN NN O
their NN NN O
pain NN NN B-Disease
experience NN NN O
and NN NN O
analgesic NN NN O
requirements NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
describe NN NN O
pain NN NN B-Disease
tolerance NN NN O
and NN NN O
analgesic NN NN O
response NN NN O
in NN NN O
a NN NN O
sample NN NN O
of NN NN O
opioid NN NN B-Disease
addicts NN NN I-Disease
stabilized NN NN O
in NN NN O
methadone NN NN O
- NN NN O
maintenance NN NN O
( NN NN O
MM NN NN O
) NN NN O
treatment NN NN O
( NN NN O
n NN NN O
= NN NN O
60 NN NN O
) NN NN O
in NN NN O
comparison NN NN O
to NN NN O
matched NN NN O
nondependent NN NN O
control NN NN O
subjects NN NN O
( NN NN O
n NN NN O
= NN NN O
60 NN NN O
) NN NN O
. NN NN O
   
By NN NN O
using NN NN O
a NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
, NN NN O
two NN NN O
- NN NN O
way NN NN O
factorial NN NN O
design NN NN O
, NN NN O
tolerance NN NN O
to NN NN O
cold NN NN O
- NN NN O
pressor NN NN O
( NN NN O
CP NN NN O
) NN NN O
pain NN NN B-Disease
was NN NN O
examined NN NN O
, NN NN O
both NN NN O
before NN NN O
and NN NN O
after NN NN O
oral NN NN O
administration NN NN O
of NN NN O
therapeutic NN NN O
doses NN NN O
of NN NN O
common NN NN O
opioid NN NN O
( NN NN O
hydromorphone NN NN O
2 NN NN O
mg NN NN O
) NN NN O
and NN NN O
nonsteroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
( NN NN O
ketorolac NN NN O
10 NN NN O
mg NN NN O
) NN NN O
analgesic NN NN O
agents NN NN O
. NN NN O
   
Results NN NN O
showed NN NN O
that NN NN O
MM NN NN O
individuals NN NN O
were NN NN O
significantly NN NN O
less NN NN O
tolerant NN NN O
of NN NN O
CP NN NN O
pain NN NN B-Disease
than NN NN O
control NN NN O
subjects NN NN O
, NN NN O
replicating NN NN O
previous NN NN O
work NN NN O
. NN NN O
   
Analgesic NN NN O
effects NN NN O
were NN NN O
significant NN NN O
neither NN NN O
for NN NN O
medication NN NN O
nor NN NN O
group NN NN O
. NN NN O
   
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
MM NN NN O
opioid NN NN O
abusers NN NN O
represent NN NN O
a NN NN O
pain NN NN B-Disease
- NN NN I-Disease
intolerant NN NN I-Disease
subset NN NN O
of NN NN O
clinical NN NN O
patients NN NN O
. NN NN O
   
Their NN NN O
complaints NN NN O
of NN NN O
pain NN NN B-Disease
should NN NN O
be NN NN O
evaluated NN NN O
seriously NN NN O
and NN NN O
managed NN NN O
aggressively NN NN O
. NN NN O
   
High NN NN O
- NN NN O
dose NN NN O
methylprednisolone NN NN O
may NN NN O
do NN NN O
more NN NN O
harm NN NN O
for NN NN O
spinal NN NN B-Disease
cord NN NN I-Disease
injury NN NN I-Disease
. NN NN O
   
Because NN NN O
of NN NN O
the NN NN O
National NN NN O
Acute NN NN O
Spinal NN NN B-Disease
Cord NN NN I-Disease
Injury NN NN I-Disease
Studies NN NN O
( NN NN O
NASCIS NN NN O
) NN NN O
, NN NN O
high NN NN O
- NN NN O
dose NN NN O
methylprednisolone NN NN O
became NN NN O
the NN NN O
standard NN NN O
of NN NN O
care NN NN O
for NN NN O
the NN NN O
acute NN NN O
spinal NN NN B-Disease
cord NN NN I-Disease
injury NN NN I-Disease
. NN NN O
   
In NN NN O
the NN NN O
NASCIS NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
mention NN NN O
regarding NN NN O
the NN NN O
possibility NN NN O
of NN NN O
acute NN NN O
corticosteroid NN NN O
myopathy NN NN B-Disease
that NN NN O
high NN NN O
- NN NN O
dose NN NN O
methylprednisolone NN NN O
may NN NN O
cause NN NN O
. NN NN O
   
The NN NN O
dosage NN NN O
of NN NN O
methylprednisolone NN NN O
recommended NN NN O
by NN NN O
the NN NN O
NASCIS NN NN O
3 NN NN O
is NN NN O
the NN NN O
highest NN NN O
dose NN NN O
of NN NN O
steroids NN NN O
ever NN NN O
being NN NN O
used NN NN O
during NN NN O
a NN NN O
2 NN NN O
- NN NN O
day NN NN O
period NN NN O
for NN NN O
any NN NN O
clinical NN NN O
condition NN NN O
. NN NN O
   
We NN NN O
hypothesize NN NN O
that NN NN O
it NN NN O
may NN NN O
cause NN NN O
some NN NN O
damage NN NN B-Disease
to NN NN I-Disease
the NN NN I-Disease
muscle NN NN I-Disease
of NN NN O
spinal NN NN B-Disease
cord NN NN I-Disease
injury NN NN I-Disease
patients NN NN O
. NN NN O
   
Further NN NN O
, NN NN O
steroid NN NN O
myopathy NN NN B-Disease
recovers NN NN O
naturally NN NN O
and NN NN O
the NN NN O
neurological NN NN O
improvement NN NN O
shown NN NN O
in NN NN O
the NN NN O
NASCIS NN NN O
may NN NN O
be NN NN O
just NN NN O
a NN NN O
recording NN NN O
of NN NN O
this NN NN O
natural NN NN O
motor NN NN O
recovery NN NN O
from NN NN O
the NN NN O
steroid NN NN O
myopathy NN NN B-Disease
, NN NN O
instead NN NN O
of NN NN O
any NN NN O
protection NN NN O
that NN NN O
methylprednisolone NN NN O
offers NN NN O
to NN NN O
the NN NN O
spinal NN NN B-Disease
cord NN NN I-Disease
injury NN NN I-Disease
. NN NN O
   
To NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
this NN NN O
is NN NN O
the NN NN O
first NN NN O
discussion NN NN O
considering NN NN O
the NN NN O
possibility NN NN O
that NN NN O
the NN NN O
methylprednisolone NN NN O
recommended NN NN O
by NN NN O
NASCIS NN NN O
may NN NN O
cause NN NN O
acute NN NN O
corticosteroid NN NN O
myopathy NN NN B-Disease
. NN NN O
   
Conversion NN NN O
to NN NN O
rapamycin NN NN O
immunosuppression NN NN O
in NN NN O
renal NN NN O
transplant NN NN O
recipients NN NN O
: NN NN O
report NN NN O
of NN NN O
an NN NN O
initial NN NN O
experience NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
is NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
effects NN NN O
of NN NN O
RAPA NN NN O
conversion NN NN O
in NN NN O
patients NN NN O
undergoing NN NN O
cyclosporine NN NN O
( NN NN O
CsA NN NN O
) NN NN O
or NN NN O
tacrolimus NN NN O
( NN NN O
Tac NN NN O
) NN NN O
toxicity NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Twenty NN NN O
renal NN NN O
transplant NN NN O
recipients NN NN O
were NN NN O
switched NN NN O
to NN NN O
fixed NN NN O
dose NN NN O
rapamycin NN NN O
( NN NN O
RAPA NN NN O
) NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
0 NN NN O
to NN NN O
204 NN NN O
months NN NN O
posttransplant NN NN O
. NN NN O
   
Drug NN NN O
monitoring NN NN O
was NN NN O
not NN NN O
initially NN NN O
used NN NN O
to NN NN O
adjust NN NN O
doses NN NN O
. NN NN O
   
The NN NN O
indications NN NN O
for NN NN O
switch NN NN O
were NN NN O
chronic NN NN O
CsA NN NN O
or NN NN O
Tac NN NN O
nephrotoxicity NN NN B-Disease
( NN NN O
12 NN NN O
) NN NN O
, NN NN O
acute NN NN O
CsA NN NN O
or NN NN O
Tac NN NN O
toxicity NN NN B-Disease
( NN NN O
3 NN NN O
) NN NN O
, NN NN O
severe NN NN O
facial NN NN B-Disease
dysmorphism NN NN I-Disease
( NN NN O
2 NN NN O
) NN NN O
, NN NN O
posttransplant NN NN B-Disease
lymphoproliferative NN NN I-Disease
disorder NN NN I-Disease
( NN NN O
PTLD NN NN B-Disease
) NN NN O
in NN NN O
remission NN NN O
( NN NN O
2 NN NN O
) NN NN O
, NN NN O
and NN NN O
hepatotoxicity NN NN B-Disease
in NN NN O
1 NN NN O
. NN NN O
   
Follow NN NN O
- NN NN O
up NN NN O
is NN NN O
7 NN NN O
to NN NN O
24 NN NN O
months NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
In NN NN O
the NN NN O
12 NN NN O
patients NN NN O
switched NN NN O
because NN NN O
of NN NN O
chronic NN NN O
nephrotoxicity NN NN B-Disease
there NN NN O
was NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
serum NN NN O
creatinine NN NN O
[ NN NN O
233 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
34 NN NN O
to NN NN O
210 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
56 NN NN O
micromol NN NN O
/ NN NN O
liter NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
at NN NN O
6 NN NN O
months NN NN O
] NN NN O
. NN NN O
   
Facial NN NN B-Disease
dysmorphism NN NN I-Disease
improved NN NN O
in NN NN O
two NN NN O
patients NN NN O
. NN NN O
   
No NN NN O
relapse NN NN O
of NN NN O
PTLD NN NN B-Disease
was NN NN O
observed NN NN O
. NN NN O
   
Five NN NN O
patients NN NN O
developed NN NN O
pneumonia NN NN B-Disease
( NN NN O
two NN NN O
Pneumocystis NN NN B-Disease
carinii NN NN I-Disease
pneumonia NN NN I-Disease
, NN NN O
one NN NN O
infectious NN NN B-Disease
mononucleosis NN NN I-Disease
with NN NN O
polyclonal NN NN O
PTLD NN NN B-Disease
lung NN NN O
infiltrate NN NN O
) NN NN O
and NN NN O
two NN NN O
had NN NN O
bronchiolitis NN NN B-Disease
obliterans NN NN I-Disease
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
deaths NN NN O
. NN NN O
   
RAPA NN NN O
was NN NN O
discontinued NN NN O
in NN NN O
four NN NN O
patients NN NN O
, NN NN O
because NN NN O
of NN NN O
pneumonia NN NN B-Disease
in NN NN O
two NN NN O
, NN NN O
PTLD NN NN B-Disease
in NN NN O
one NN NN O
, NN NN O
and NN NN O
oral NN NN O
aphtous NN NN B-Disease
ulcers NN NN I-Disease
in NN NN O
one NN NN O
. NN NN O
   
RAPA NN NN O
levels NN NN O
were NN NN O
high NN NN O
( NN NN O
> NN NN O
15 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
) NN NN O
in NN NN O
7 NN NN O
of NN NN O
13 NN NN O
( NN NN O
54 NN NN O
% NN NN O
) NN NN O
patients NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
RAPA NN NN O
conversion NN NN O
provides NN NN O
adequate NN NN O
immunosuppression NN NN O
to NN NN O
enable NN NN O
CsA NN NN O
withdrawal NN NN O
. NN NN O
   
However NN NN O
, NN NN O
when NN NN O
converting NN NN O
patients NN NN O
to NN NN O
RAPA NN NN O
drug NN NN O
levels NN NN O
should NN NN O
be NN NN O
monitored NN NN O
to NN NN O
avoid NN NN O
over NN NN O
- NN NN O
immunosuppression NN NN O
and NN NN O
adequate NN NN O
antiviral NN NN O
and NN NN O
Pneumocystis NN NN B-Disease
carinii NN NN I-Disease
pneumonia NN NN I-Disease
prophylaxis NN NN O
should NN NN O
be NN NN O
given NN NN O
. NN NN O
   
Electro NN NN O
- NN NN O
oculography NN NN O
, NN NN O
electroretinography NN NN O
, NN NN O
visual NN NN O
evoked NN NN O
potentials NN NN O
, NN NN O
and NN NN O
multifocal NN NN O
electroretinography NN NN O
in NN NN O
patients NN NN O
with NN NN O
vigabatrin NN NN O
- NN NN O
attributed NN NN O
visual NN NN B-Disease
field NN NN I-Disease
constriction NN NN I-Disease
. NN NN O
   
PURPOSE NN NN O
: NN NN O
Symptomatic NN NN O
visual NN NN B-Disease
field NN NN I-Disease
constriction NN NN I-Disease
thought NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
vigabatrin NN NN O
has NN NN O
been NN NN O
reported NN NN O
. NN NN O
   
The NN NN O
current NN NN O
study NN NN O
investigated NN NN O
the NN NN O
visual NN NN O
fields NN NN O
and NN NN O
visual NN NN O
electrophysiology NN NN O
of NN NN O
eight NN NN O
patients NN NN O
with NN NN O
known NN NN O
vigabatrin NN NN O
- NN NN O
attributed NN NN O
visual NN NN B-Disease
field NN NN I-Disease
loss NN NN I-Disease
, NN NN O
three NN NN O
of NN NN O
whom NN NN O
were NN NN O
reported NN NN O
previously NN NN O
. NN NN O
   
Six NN NN O
of NN NN O
the NN NN O
patients NN NN O
were NN NN O
no NN NN O
longer NN NN O
receiving NN NN O
vigabatrin NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
central NN NN O
and NN NN O
peripheral NN NN O
fields NN NN O
were NN NN O
examined NN NN O
with NN NN O
the NN NN O
Humphrey NN NN O
Visual NN NN O
Field NN NN O
Analyzer NN NN O
. NN NN O
   
Full NN NN O
visual NN NN O
electrophysiology NN NN O
, NN NN O
including NN NN O
flash NN NN O
electroretinography NN NN O
( NN NN O
ERG NN NN O
) NN NN O
, NN NN O
pattern NN NN O
electroretinography NN NN O
, NN NN O
multifocal NN NN O
ERG NN NN O
using NN NN O
the NN NN O
VERIS NN NN O
system NN NN O
, NN NN O
electro NN NN O
- NN NN O
oculography NN NN O
, NN NN O
and NN NN O
flash NN NN O
and NN NN O
pattern NN NN O
visual NN NN O
evoked NN NN O
potentials NN NN O
, NN NN O
was NN NN O
undertaken NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Seven NN NN O
patients NN NN O
showed NN NN O
marked NN NN O
visual NN NN B-Disease
field NN NN I-Disease
constriction NN NN I-Disease
with NN NN O
some NN NN O
sparing NN NN O
of NN NN O
the NN NN O
temporal NN NN O
visual NN NN O
field NN NN O
. NN NN O
   
The NN NN O
eighth NN NN O
exhibited NN NN O
concentric NN NN O
constriction NN NN O
. NN NN O
   
Most NN NN O
electrophysiological NN NN O
responses NN NN O
were NN NN O
usually NN NN O
just NN NN O
within NN NN O
normal NN NN O
limits NN NN O
; NN NN O
two NN NN O
patients NN NN O
had NN NN O
subnormal NN NN O
Arden NN NN O
electro NN NN O
- NN NN O
oculography NN NN O
indices NN NN O
; NN NN O
and NN NN O
one NN NN O
patient NN NN O
showed NN NN O
an NN NN O
abnormally NN NN O
delayed NN NN O
photopic NN NN O
b NN NN O
wave NN NN O
. NN NN O
   
However NN NN O
, NN NN O
five NN NN O
patients NN NN O
showed NN NN O
delayed NN NN O
30 NN NN O
- NN NN O
Hz NN NN O
flicker NN NN O
b NN NN O
waves NN NN O
, NN NN O
and NN NN O
seven NN NN O
patients NN NN O
showed NN NN O
delayed NN NN O
oscillatory NN NN O
potentials NN NN O
. NN NN O
   
Multifocal NN NN O
ERG NN NN O
showed NN NN O
abnormalities NN NN O
that NN NN O
sometimes NN NN O
correlated NN NN O
with NN NN O
the NN NN O
visual NN NN O
field NN NN O
appearance NN NN O
and NN NN O
confirmed NN NN O
that NN NN O
the NN NN O
deficit NN NN O
occurs NN NN O
at NN NN O
the NN NN O
retinal NN NN O
level NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Marked NN NN O
visual NN NN B-Disease
field NN NN I-Disease
constriction NN NN I-Disease
appears NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
vigabatrin NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
field NN NN O
defects NN NN O
and NN NN O
some NN NN O
electrophysiological NN NN O
abnormalities NN NN O
persist NN NN O
when NN NN O
vigabatrin NN NN O
therapy NN NN O
is NN NN O
withdrawn NN NN O
. NN NN O
   
Myocardial NN NN B-Disease
ischemia NN NN I-Disease
due NN NN O
to NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
spasm NN NN I-Disease
during NN NN O
dobutamine NN NN O
stress NN NN O
echocardiography NN NN O
. NN NN O
   
Dobutamine NN NN O
stress NN NN O
echocardiography NN NN O
( NN NN O
DSE NN NN O
) NN NN O
is NN NN O
a NN NN O
useful NN NN O
and NN NN O
safe NN NN O
provocation NN NN O
test NN NN O
for NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
. NN NN O
   
Until NN NN O
now NN NN O
, NN NN O
the NN NN O
test NN NN O
has NN NN O
been NN NN O
focused NN NN O
only NN NN O
on NN NN O
the NN NN O
organic NN NN O
lesion NN NN O
in NN NN O
the NN NN O
coronary NN NN O
artery NN NN O
, NN NN O
and NN NN O
positive NN NN O
DSE NN NN O
has NN NN O
indicated NN NN O
the NN NN O
presence NN NN O
of NN NN O
significant NN NN O
fixed NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
stenosis NN NN I-Disease
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
is NN NN O
to NN NN O
examine NN NN O
whether NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
due NN NN O
to NN NN O
coronary NN NN B-Disease
spasm NN NN I-Disease
is NN NN O
induced NN NN O
by NN NN O
dobutamine NN NN O
. NN NN O
   
We NN NN O
performed NN NN O
DSE NN NN O
on NN NN O
51 NN NN O
patients NN NN O
with NN NN O
coronary NN NN B-Disease
spastic NN NN I-Disease
angina NN NN I-Disease
but NN NN O
without NN NN O
significant NN NN O
fixed NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
stenosis NN NN I-Disease
. NN NN O
   
All NN NN O
patients NN NN O
had NN NN O
anginal NN NN B-Disease
attacks NN NN O
at NN NN O
rest NN NN O
with NN NN O
ST NN NN O
elevation NN NN O
on NN NN O
the NN NN O
electrocardiogram NN NN O
( NN NN O
variant NN NN B-Disease
angina NN NN I-Disease
) NN NN O
. NN NN O
   
Coronary NN NN O
spasm NN NN O
was NN NN O
induced NN NN O
by NN NN O
intracoronary NN NN O
injection NN NN O
of NN NN O
acetylcholine NN NN O
, NN NN O
and NN NN O
no NN NN O
fixed NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
stenosis NN NN I-Disease
was NN NN O
documented NN NN O
on NN NN O
angiograms NN NN O
in NN NN O
all NN NN O
patients NN NN O
. NN NN O
   
DSE NN NN O
was NN NN O
performed NN NN O
with NN NN O
intravenous NN NN O
dobutamine NN NN O
infusion NN NN O
with NN NN O
an NN NN O
incremental NN NN O
doses NN NN O
of NN NN O
5 NN NN O
, NN NN O
10 NN NN O
, NN NN O
20 NN NN O
, NN NN O
30 NN NN O
, NN NN O
and NN NN O
40 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
every NN NN O
5 NN NN O
minutes NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
51 NN NN O
patients NN NN O
, NN NN O
7 NN NN O
patients NN NN O
showed NN NN O
asynergy NN NN O
with NN NN O
ST NN NN O
elevation NN NN O
. NN NN O
   
All NN NN O
7 NN NN O
patients NN NN O
( NN NN O
13 NN NN O
. NN NN O
7 NN NN O
% NN NN O
) NN NN O
had NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
during NN NN O
asynergy NN NN O
, NN NN O
and NN NN O
both NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
and NN NN O
electrocardiographic NN NN O
changes NN NN O
were NN NN O
preceded NN NN O
by NN NN O
asynergy NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
dobutamine NN NN O
can NN NN O
provoke NN NN O
coronary NN NN B-Disease
spasm NN NN I-Disease
in NN NN O
some NN NN O
patients NN NN O
with NN NN O
coronary NN NN B-Disease
spastic NN NN I-Disease
angina NN NN I-Disease
. NN NN O
   
When NN NN O
DSE NN NN O
is NN NN O
performed NN NN O
to NN NN O
evaluate NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
, NN NN O
not NN NN O
only NN NN O
fixed NN NN O
coronary NN NN B-Disease
stenosis NN NN I-Disease
, NN NN O
but NN NN O
also NN NN O
coronary NN NN B-Disease
spasm NN NN I-Disease
should NN NN O
be NN NN O
considered NN NN O
as NN NN O
a NN NN O
genesis NN NN O
of NN NN O
asynergy NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
intravenous NN NN O
metoprolol NN NN O
or NN NN O
intravenous NN NN O
metoprolol NN NN O
plus NN NN O
glucagon NN NN O
on NN NN O
dobutamine NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
. NN NN O
   
STUDY NN NN O
OBJECTIVE NN NN O
: NN NN O
To NN NN O
determine NN NN O
the NN NN O
effect NN NN O
of NN NN O
metoprolol NN NN O
on NN NN O
dobutamine NN NN O
stress NN NN O
testing NN NN O
with NN NN O
technetium NN NN O
- NN NN O
99m NN NN O
sestamibi NN NN O
single NN NN O
- NN NN O
photon NN NN O
emission NN NN O
computed NN NN O
tomography NN NN O
imaging NN NN O
and NN NN O
ST NN NN O
- NN NN O
segment NN NN O
monitoring NN NN O
, NN NN O
and NN NN O
to NN NN O
assess NN NN O
the NN NN O
impact NN NN O
of NN NN O
intravenous NN NN O
glucagon NN NN O
on NN NN O
metoprolol NN NN O
' NN NN O
s NN NN O
effects NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
Randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
trial NN NN O
. NN NN O
   
SETTING NN NN O
: NN NN O
Community NN NN O
hospital NN NN O
. NN NN O
   
PATIENTS NN NN O
: NN NN O
Twenty NN NN O
- NN NN O
two NN NN O
patients NN NN O
with NN NN O
known NN NN O
reversible NN NN O
perfusion NN NN O
defects NN NN O
. NN NN O
   
INTERVENTION NN NN O
: NN NN O
Patients NN NN O
underwent NN NN O
dobutamine NN NN O
stress NN NN O
tests NN NN O
per NN NN O
standard NN NN O
protocol NN NN O
. NN NN O
   
Before NN NN O
dobutamine NN NN O
was NN NN O
begun NN NN O
, NN NN O
no NN NN O
therapy NN NN O
was NN NN O
given NN NN O
during NN NN O
the NN NN O
first NN NN O
visit NN NN O
, NN NN O
and NN NN O
patients NN NN O
were NN NN O
randomized NN NN O
on NN NN O
subsequent NN NN O
visits NN NN O
to NN NN O
receive NN NN O
metoprolol NN NN O
or NN NN O
metoprolol NN NN O
plus NN NN O
glucagon NN NN O
1 NN NN O
mg NN NN O
. NN NN O
   
Metoprolol NN NN O
was NN NN O
dosed NN NN O
to NN NN O
achieve NN NN O
a NN NN O
resting NN NN O
predobutamine NN NN O
heart NN NN O
rate NN NN O
below NN NN O
65 NN NN O
beats NN NN O
/ NN NN O
minute NN NN O
or NN NN O
a NN NN O
total NN NN O
intravenous NN NN O
dose NN NN O
of NN NN O
20 NN NN O
mg NN NN O
. NN NN O
   
MEASUREMENTS NN NN O
AND NN NN O
MAIN NN NN O
RESULTS NN NN O
: NN NN O
Metoprolol NN NN O
reduced NN NN O
maximum NN NN O
heart NN NN O
rate NN NN O
31 NN NN O
% NN NN O
, NN NN O
summed NN NN O
stress NN NN O
scores NN NN O
29 NN NN O
% NN NN O
, NN NN O
and NN NN O
summed NN NN O
difference NN NN O
scores NN NN O
43 NN NN O
% NN NN O
versus NN NN O
control NN NN O
. NN NN O
   
Metoprolol NN NN O
plus NN NN O
glucagon NN NN O
also NN NN O
reduced NN NN O
the NN NN O
maximum NN NN O
heart NN NN O
rate NN NN O
29 NN NN O
% NN NN O
versus NN NN O
control NN NN O
. NN NN O
   
Summed NN NN O
stress NN NN O
and NN NN O
summed NN NN O
difference NN NN O
scores NN NN O
were NN NN O
not NN NN O
significantly NN NN O
reduced NN NN O
, NN NN O
although NN NN O
they NN NN O
were NN NN O
18 NN NN O
% NN NN O
and NN NN O
30 NN NN O
% NN NN O
lower NN NN O
, NN NN O
respectively NN NN O
, NN NN O
than NN NN O
control NN NN O
. NN NN O
   
No NN NN O
significant NN NN O
differences NN NN O
were NN NN O
found NN NN O
in NN NN O
any NN NN O
parameter NN NN O
between NN NN O
metoprolol NN NN O
and NN NN O
metoprolol NN NN O
- NN NN O
glucagon NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
During NN NN O
dobutamine NN NN O
stress NN NN O
testing NN NN O
, NN NN O
metoprolol NN NN O
attenuates NN NN O
or NN NN O
eliminates NN NN O
evidence NN NN O
of NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
. NN NN O
   
Glucagon NN NN O
1 NN NN O
mg NN NN O
, NN NN O
although NN NN O
somewhat NN NN O
effective NN NN O
, NN NN O
does NN NN O
not NN NN O
correct NN NN O
this NN NN O
effect NN NN O
to NN NN O
the NN NN O
extent NN NN O
that NN NN O
it NN NN O
can NN NN O
be NN NN O
administered NN NN O
clinically NN NN O
. NN NN O
   
Evidence NN NN O
of NN NN O
functional NN NN O
somatotopy NN NN O
in NN NN O
GPi NN NN O
from NN NN O
results NN NN O
of NN NN O
pallidotomy NN NN O
. NN NN O
   
The NN NN O
objective NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
explore NN NN O
the NN NN O
functional NN NN O
anatomy NN NN O
of NN NN O
the NN NN O
globus NN NN O
pallidus NN NN O
internus NN NN O
( NN NN O
GPi NN NN O
) NN NN O
by NN NN O
studying NN NN O
the NN NN O
effects NN NN O
of NN NN O
unilateral NN NN O
pallidotomy NN NN O
on NN NN O
parkinsonian NN NN B-Disease
' NN NN O
off NN NN O
' NN NN O
signs NN NN O
and NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
( NN NN O
LID NN NN B-Disease
) NN NN O
. NN NN O
   
We NN NN O
found NN NN O
significant NN NN O
positive NN NN O
correlations NN NN O
between NN NN O
the NN NN O
preoperative NN NN O
levodopa NN NN O
responsiveness NN NN O
of NN NN O
motor NN NN O
signs NN NN O
and NN NN O
the NN NN O
levodopa NN NN O
responsiveness NN NN O
of NN NN O
scores NN NN O
in NN NN O
timed NN NN O
tests NN NN O
( NN NN O
Core NN NN O
Assessment NN NN O
Program NN NN O
for NN NN O
Intracerebral NN NN O
Transplantations NN NN O
) NN NN O
in NN NN O
the NN NN O
contralateral NN NN O
limbs NN NN O
and NN NN O
the NN NN O
improvement NN NN O
in NN NN O
these NN NN O
scores NN NN O
after NN NN O
surgery NN NN O
, NN NN O
whereas NN NN O
there NN NN O
was NN NN O
no NN NN O
correlation NN NN O
with NN NN O
the NN NN O
improvement NN NN O
in NN NN O
LID NN NN B-Disease
. NN NN O
   
We NN NN O
also NN NN O
found NN NN O
a NN NN O
highly NN NN O
significant NN NN O
correlation NN NN O
( NN NN O
P NN NN O
: NN NN O
< NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
, NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
8 NN NN O
) NN NN O
between NN NN O
the NN NN O
volume NN NN O
of NN NN O
the NN NN O
ventral NN NN O
lesion NN NN O
in NN NN O
the NN NN O
GPi NN NN O
and NN NN O
the NN NN O
improvement NN NN O
in NN NN O
LID NN NN B-Disease
in NN NN O
the NN NN O
contralateral NN NN O
limbs NN NN O
, NN NN O
whereas NN NN O
there NN NN O
was NN NN O
no NN NN O
correlation NN NN O
between NN NN O
the NN NN O
ventral NN NN O
volume NN NN O
and NN NN O
the NN NN O
improvement NN NN O
in NN NN O
parkinsonian NN NN B-Disease
' NN NN O
off NN NN O
' NN NN O
signs NN NN O
. NN NN O
   
The NN NN O
volumes NN NN O
of NN NN O
the NN NN O
total NN NN O
lesion NN NN O
cylinder NN NN O
and NN NN O
the NN NN O
dorsal NN NN O
lesion NN NN O
did NN NN O
not NN NN O
correlate NN NN O
with NN NN O
the NN NN O
outcome NN NN O
of NN NN O
either NN NN O
dyskinesias NN NN B-Disease
or NN NN O
parkinsonian NN NN B-Disease
' NN NN O
off NN NN O
' NN NN O
signs NN NN O
. NN NN O
   
The NN NN O
differential NN NN O
predictive NN NN O
value NN NN O
of NN NN O
levodopa NN NN O
responsiveness NN NN O
for NN NN O
the NN NN O
outcome NN NN O
of NN NN O
parkinsonian NN NN B-Disease
' NN NN O
off NN NN O
' NN NN O
signs NN NN O
and NN NN O
LID NN NN B-Disease
and NN NN O
the NN NN O
different NN NN O
correlations NN NN O
of NN NN O
ventral NN NN O
lesion NN NN O
volume NN NN O
with NN NN O
dyskinesias NN NN B-Disease
and NN NN O
parkinsonian NN NN B-Disease
' NN NN O
off NN NN O
' NN NN O
signs NN NN O
indicate NN NN O
that NN NN O
different NN NN O
anatomical NN NN O
or NN NN O
pathophysiological NN NN O
substrates NN NN O
may NN NN O
be NN NN O
responsible NN NN O
for NN NN O
the NN NN O
generation NN NN O
of NN NN O
parkinsonian NN NN B-Disease
' NN NN O
off NN NN O
' NN NN O
signs NN NN O
and NN NN O
dyskinesias NN NN B-Disease
. NN NN O
   
Whereas NN NN O
cells NN NN O
in NN NN O
a NN NN O
wider NN NN O
area NN NN O
of NN NN O
the NN NN O
GPi NN NN O
may NN NN O
be NN NN O
implicated NN NN O
in NN NN O
parkinsonism NN NN B-Disease
, NN NN O
the NN NN O
ventral NN NN O
GPi NN NN O
seems NN NN O
to NN NN O
be NN NN O
crucial NN NN O
for NN NN O
the NN NN O
manifestation NN NN O
of NN NN O
LID NN NN B-Disease
. NN NN O
   
We NN NN O
suggest NN NN O
that NN NN O
our NN NN O
observations NN NN O
are NN NN O
additional NN NN O
proof NN NN O
of NN NN O
the NN NN O
functional NN NN O
somatotopy NN NN O
of NN NN O
the NN NN O
systems NN NN O
within NN NN O
the NN NN O
GPi NN NN O
that NN NN O
mediate NN NN O
parkinsonism NN NN B-Disease
and NN NN O
dyskinesias NN NN B-Disease
, NN NN O
especially NN NN O
along NN NN O
the NN NN O
dorsoventral NN NN O
trajectory NN NN O
used NN NN O
in NN NN O
pallidotomy NN NN O
. NN NN O
   
The NN NN O
outcome NN NN O
of NN NN O
pallidotomy NN NN O
in NN NN O
which NN NN O
the NN NN O
lesion NN NN O
involves NN NN O
the NN NN O
ventral NN NN O
and NN NN O
dorsal NN NN O
GPi NN NN O
could NN NN O
be NN NN O
the NN NN O
net NN NN O
effect NN NN O
of NN NN O
alteration NN NN O
in NN NN O
the NN NN O
activity NN NN O
of NN NN O
pathways NN NN O
which NN NN O
mediate NN NN O
different NN NN O
symptoms NN NN O
, NN NN O
and NN NN O
hence NN NN O
could NN NN O
be NN NN O
variable NN NN O
. NN NN O
   
Screening NN NN O
for NN NN O
stimulant NN NN O
use NN NN O
in NN NN O
adult NN NN O
emergency NN NN O
department NN NN O
seizure NN NN B-Disease
patients NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
The NN NN O
objective NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
the NN NN O
prevalence NN NN O
of NN NN O
positive NN NN O
plasma NN NN O
drug NN NN O
screening NN NN O
for NN NN O
cocaine NN NN O
or NN NN O
amphetamine NN NN O
in NN NN O
adult NN NN O
emergency NN NN O
department NN NN O
seizure NN NN B-Disease
patients NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
This NN NN O
prospective NN NN O
study NN NN O
evaluated NN NN O
consecutive NN NN O
eligible NN NN O
seizure NN NN B-Disease
patients NN NN O
who NN NN O
had NN NN O
a NN NN O
plasma NN NN O
sample NN NN O
collected NN NN O
as NN NN O
part NN NN O
of NN NN O
their NN NN O
clinical NN NN O
evaluation NN NN O
. NN NN O
   
Plasma NN NN O
was NN NN O
tested NN NN O
for NN NN O
amphetamine NN NN O
and NN NN O
the NN NN O
cocaine NN NN O
metabolite NN NN O
benzoylecgonine NN NN O
using NN NN O
enzyme NN NN O
- NN NN O
mediated NN NN O
immunoassay NN NN O
methodology NN NN O
. NN NN O
   
Plasma NN NN O
samples NN NN O
with NN NN O
benzoylecgonine NN NN O
greater NN NN O
than NN NN O
150 NN NN O
ng NN NN O
/ NN NN O
mL NN NN O
or NN NN O
an NN NN O
amphetamine NN NN O
greater NN NN O
than NN NN O
500 NN NN O
ng NN NN O
/ NN NN O
mL NN NN O
were NN NN O
defined NN NN O
as NN NN O
positive NN NN O
. NN NN O
   
Patient NN NN O
demographics NN NN O
, NN NN O
history NN NN O
of NN NN O
underlying NN NN O
drug NN NN O
or NN NN O
alcohol NN NN O
- NN NN O
related NN NN O
seizure NN NN B-Disease
disorder NN NN O
, NN NN O
estimated NN NN O
time NN NN O
from NN NN O
seizure NN NN B-Disease
to NN NN O
sample NN NN O
collection NN NN O
, NN NN O
history NN NN O
or NN NN O
suspicion NN NN O
of NN NN O
cocaine NN NN B-Disease
or NN NN I-Disease
amphetamine NN NN I-Disease
abuse NN NN I-Disease
, NN NN O
results NN NN O
of NN NN O
clinical NN NN O
urine NN NN O
testing NN NN O
for NN NN O
drugs NN NN O
of NN NN O
abuse NN NN O
, NN NN O
and NN NN O
assay NN NN O
results NN NN O
were NN NN O
recorded NN NN O
without NN NN O
patient NN NN O
identifiers NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Fourteen NN NN O
of NN NN O
248 NN NN O
( NN NN O
5 NN NN O
. NN NN O
6 NN NN O
% NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
2 NN NN O
. NN NN O
7 NN NN O
% NN NN O
- NN NN O
8 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
plasma NN NN O
samples NN NN O
were NN NN O
positive NN NN O
by NN NN O
immunoassay NN NN O
testing NN NN O
for NN NN O
benzoylecgonine NN NN O
and NN NN O
no NN NN O
samples NN NN O
( NN NN O
0 NN NN O
% NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
0 NN NN O
- NN NN O
1 NN NN O
. NN NN O
2 NN NN O
% NN NN O
) NN NN O
were NN NN O
positive NN NN O
for NN NN O
amphetamine NN NN O
. NN NN O
   
Positive NN NN O
test NN NN O
results NN NN O
were NN NN O
more NN NN O
common NN NN O
in NN NN O
patient NN NN O
visits NN NN O
where NN NN O
there NN NN O
was NN NN O
a NN NN O
history NN NN O
or NN NN O
suspicion NN NN O
of NN NN O
cocaine NN NN B-Disease
or NN NN I-Disease
amphetamine NN NN I-Disease
abuse NN NN I-Disease
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
0005 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
During NN NN O
this NN NN O
study NN NN O
period NN NN O
, NN NN O
routine NN NN O
plasma NN NN O
screening NN NN O
for NN NN O
cocaine NN NN O
and NN NN O
amphetamines NN NN O
in NN NN O
adult NN NN O
seizure NN NN B-Disease
patients NN NN O
had NN NN O
a NN NN O
low NN NN O
yield NN NN O
. NN NN O
   
As NN NN O
a NN NN O
result NN NN O
, NN NN O
routine NN NN O
plasma NN NN O
screening NN NN O
would NN NN O
yield NN NN O
few NN NN O
cases NN NN O
of NN NN O
stimulant NN NN O
drug NN NN O
in NN NN O
which NN NN O
there NN NN O
was NN NN O
neither NN NN O
a NN NN O
history NN NN O
nor NN NN O
suspicion NN NN O
of NN NN O
drug NN NN B-Disease
abuse NN NN I-Disease
in NN NN O
this NN NN O
population NN NN O
. NN NN O
   
Contribution NN NN O
of NN NN O
sodium NN NN O
valproate NN NN O
to NN NN O
the NN NN O
syndrome NN NN B-Disease
of NN NN I-Disease
inappropriate NN NN I-Disease
secretion NN NN I-Disease
of NN NN I-Disease
antidiuretic NN NN I-Disease
hormone NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
62 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
who NN NN O
was NN NN O
administered NN NN O
sodium NN NN O
valproate NN NN O
( NN NN O
VPA NN NN O
) NN NN O
and NN NN O
who NN NN O
subsequently NN NN O
developed NN NN O
the NN NN O
syndrome NN NN B-Disease
of NN NN I-Disease
inappropriate NN NN I-Disease
secretion NN NN I-Disease
of NN NN I-Disease
antidiuretic NN NN I-Disease
hormone NN NN I-Disease
( NN NN O
SIADH NN NN B-Disease
) NN NN O
. NN NN O
   
He NN NN O
had NN NN O
been NN NN O
taking NN NN O
VPA NN NN O
for NN NN O
treatment NN NN O
of NN NN O
idiopathic NN NN O
generalized NN NN O
tonic NN NN B-Disease
- NN NN I-Disease
clonic NN NN I-Disease
convulsions NN NN I-Disease
since NN NN O
he NN NN O
was NN NN O
56 NN NN O
years NN NN O
old NN NN O
. NN NN O
   
After NN NN O
substituting NN NN O
VPA NN NN O
with NN NN O
zonisamide NN NN O
, NN NN O
the NN NN O
serum NN NN O
sodium NN NN O
level NN NN O
returned NN NN O
to NN NN O
normal NN NN O
. NN NN O
   
We NN NN O
consider NN NN O
this NN NN O
episode NN NN O
of NN NN O
SIADH NN NN B-Disease
to NN NN O
be NN NN O
the NN NN O
result NN NN O
of NN NN O
a NN NN O
combination NN NN O
of NN NN O
factors NN NN O
including NN NN O
a NN NN O
weakness NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
central NN NN I-Disease
nervous NN NN I-Disease
system NN NN I-Disease
and NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
administration NN NN O
of NN NN O
VPA NN NN O
. NN NN O
   
Association NN NN O
of NN NN O
nitric NN NN O
oxide NN NN O
production NN NN O
and NN NN O
apoptosis NN NN O
in NN NN O
a NN NN O
model NN NN O
of NN NN O
experimental NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
In NN NN O
recent NN NN O
studies NN NN O
increased NN NN O
amounts NN NN O
of NN NN O
nitric NN NN O
oxide NN NN O
( NN NN O
NO NN NN O
) NN NN O
and NN NN O
apoptosis NN NN O
have NN NN O
been NN NN O
implicated NN NN O
in NN NN O
various NN NN O
pathological NN NN O
conditions NN NN O
in NN NN O
the NN NN O
kidney NN NN O
. NN NN O
   
We NN NN O
have NN NN O
studied NN NN O
the NN NN O
role NN NN O
of NN NN O
NO NN NN O
and NN NN O
its NN NN O
association NN NN O
with NN NN O
apoptosis NN NN O
in NN NN O
an NN NN O
experimental NN NN O
model NN NN O
of NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
induced NN NN O
by NN NN O
a NN NN O
single NN NN O
injection NN NN O
of NN NN O
adriamycin NN NN O
( NN NN O
ADR NN NN O
) NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
alteration NN NN O
in NN NN O
the NN NN O
NO NN NN O
pathway NN NN O
was NN NN O
assessed NN NN O
by NN NN O
measuring NN NN O
nitrite NN NN O
levels NN NN O
in NN NN O
serum NN NN O
/ NN NN O
urine NN NN O
and NN NN O
by NN NN O
evaluating NN NN O
the NN NN O
changes NN NN O
in NN NN O
vascular NN NN O
reactivity NN NN O
of NN NN O
the NN NN O
isolated NN NN O
perfused NN NN O
rat NN NN O
kidney NN NN O
( NN NN O
IPRK NN NN O
) NN NN O
system NN NN O
. NN NN O
   
Rats NN NN O
were NN NN O
stratified NN NN O
into NN NN O
control NN NN O
groups NN NN O
and NN NN O
ADR NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
groups NN NN O
. NN NN O
   
These NN NN O
two NN NN O
groups NN NN O
were NN NN O
then NN NN O
divided NN NN O
into NN NN O
: NN NN O
group NN NN O
1 NN NN O
, NN NN O
animals NN NN O
receiving NN NN O
saline NN NN O
; NN NN O
and NN NN O
group NN NN O
2 NN NN O
, NN NN O
animals NN NN O
receiving NN NN O
aminoguanidine NN NN O
( NN NN O
AG NN NN O
) NN NN O
which NN NN O
is NN NN O
a NN NN O
specific NN NN O
inhibitor NN NN O
of NN NN O
inducible NN NN O
- NN NN O
NO NN NN O
synthase NN NN O
. NN NN O
   
On NN NN O
day NN NN O
21 NN NN O
, NN NN O
rats NN NN O
were NN NN O
sacrificed NN NN O
after NN NN O
obtaining NN NN O
material NN NN O
for NN NN O
biochemical NN NN O
analysis NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Histopathological NN NN O
examination NN NN O
of NN NN O
the NN NN O
kidneys NN NN O
of NN NN O
rats NN NN O
treated NN NN O
with NN NN O
ADR NN NN O
revealed NN NN O
focal NN NN O
areas NN NN O
of NN NN O
mesangial NN NN B-Disease
proliferation NN NN I-Disease
and NN NN O
mild NN NN O
tubulointerstitial NN NN B-Disease
inflammation NN NN I-Disease
. NN NN O
   
They NN NN O
also NN NN O
had NN NN O
significantly NN NN O
higher NN NN O
levels NN NN O
of NN NN O
proteinuria NN NN B-Disease
compared NN NN O
with NN NN O
control NN NN O
and NN NN O
treatment NN NN O
groups NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Urine NN NN O
nitrite NN NN O
levels NN NN O
were NN NN O
significantly NN NN O
increased NN NN O
in NN NN O
the NN NN O
ADR NN NN O
- NN NN O
nephropathy NN NN B-Disease
group NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
IPRK NN NN O
phenylephrine NN NN O
and NN NN O
acetylcholine NN NN O
related NN NN O
responses NN NN O
were NN NN O
significantly NN NN O
impaired NN NN O
in NN NN O
the NN NN O
ADR NN NN O
- NN NN O
nephropathy NN NN B-Disease
group NN NN O
. NN NN O
   
Apoptosis NN NN O
was NN NN O
not NN NN O
detected NN NN O
in NN NN O
controls NN NN O
. NN NN O
   
However NN NN O
, NN NN O
in NN NN O
the NN NN O
ADR NN NN O
- NN NN O
nephropathy NN NN B-Disease
group NN NN O
, NN NN O
numerous NN NN O
apoptotic NN NN O
cells NN NN O
were NN NN O
identified NN NN O
in NN NN O
the NN NN O
tubulointerstitial NN NN O
areas NN NN O
. NN NN O
   
Double NN NN O
staining NN NN O
revealed NN NN O
numerous NN NN O
interstitial NN NN O
apoptotic NN NN O
cells NN NN O
to NN NN O
stain NN NN O
for NN NN O
ED1 NN NN O
, NN NN O
a NN NN O
marker NN NN O
for NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
AG NN NN O
prevented NN NN O
the NN NN O
impairment NN NN O
of NN NN O
renal NN NN O
vascular NN NN O
bed NN NN O
responses NN NN O
and NN NN O
reduced NN NN O
both NN NN O
urine NN NN O
nitrite NN NN O
levels NN NN O
and NN NN O
apoptosis NN NN O
to NN NN O
control NN NN O
levels NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
We NN NN O
suggest NN NN O
that NN NN O
interactions NN NN O
between NN NN O
NO NN NN O
and NN NN O
apoptosis NN NN O
are NN NN O
important NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
the NN NN O
ADR NN NN O
- NN NN O
induced NN NN O
nephrosis NN NN B-Disease
. NN NN O
   
Dual NN NN O
effects NN NN O
of NN NN O
melatonin NN NN O
on NN NN O
barbiturate NN NN O
- NN NN O
induced NN NN O
narcosis NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Melatonin NN NN O
affects NN NN O
the NN NN O
circadian NN NN O
sleep NN NN O
/ NN NN O
wake NN NN O
cycle NN NN O
, NN NN O
but NN NN O
it NN NN O
is NN NN O
not NN NN O
clear NN NN O
whether NN NN O
it NN NN O
may NN NN O
influence NN NN O
drug NN NN O
- NN NN O
induced NN NN O
narcosis NN NN B-Disease
. NN NN O
   
Sodium NN NN O
thiopenthal NN NN O
was NN NN O
administered NN NN O
intraperitoneally NN NN O
into NN NN O
male NN NN O
rats NN NN O
pre NN NN O
- NN NN O
treated NN NN O
with NN NN O
melatonin NN NN O
( NN NN O
0 NN NN O
. NN NN O
05 NN NN O
, NN NN O
0 NN NN O
. NN NN O
5 NN NN O
, NN NN O
5 NN NN O
and NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
. NN NN O
   
Melatonin NN NN O
pre NN NN O
- NN NN O
treatment NN NN O
affected NN NN O
in NN NN O
a NN NN O
dual NN NN O
manner NN NN O
barbiturate NN NN O
narcosis NN NN B-Disease
, NN NN O
however NN NN O
, NN NN O
no NN NN O
dose NN NN O
- NN NN O
effect NN NN O
correlation NN NN O
was NN NN O
found NN NN O
. NN NN O
   
In NN NN O
particular NN NN O
, NN NN O
low NN NN O
doses NN NN O
reduced NN NN O
the NN NN O
latency NN NN O
to NN NN O
and NN NN O
prolonged NN NN O
the NN NN O
duration NN NN O
of NN NN O
barbiturate NN NN O
narcosis NN NN B-Disease
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
highest NN NN O
dose NN NN O
of NN NN O
melatonin NN NN O
( NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
caused NN NN O
a NN NN O
paradoxical NN NN O
increase NN NN O
in NN NN O
the NN NN O
latency NN NN O
and NN NN O
produced NN NN O
a NN NN O
sustained NN NN O
reduction NN NN O
of NN NN O
the NN NN O
duration NN NN O
of NN NN O
narcosis NN NN B-Disease
, NN NN O
and NN NN O
a NN NN O
reduction NN NN O
in NN NN O
mortality NN NN O
rate NN NN O
. NN NN O
   
Melatonin NN NN O
0 NN NN O
. NN NN O
5 NN NN O
and NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
influenced NN NN O
the NN NN O
duration NN NN O
but NN NN O
not NN NN O
the NN NN O
latency NN NN O
of NN NN O
ketamine NN NN O
- NN NN O
or NN NN O
diazepam NN NN O
- NN NN O
induced NN NN O
narcosis NN NN B-Disease
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
dual NN NN O
action NN NN O
of NN NN O
melatonin NN NN O
on NN NN O
pharmacological NN NN O
narcosis NN NN B-Disease
seems NN NN O
to NN NN O
be NN NN O
specific NN NN O
for NN NN O
the NN NN O
barbiturate NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
. NN NN O
   
Reduced NN NN O
cardiotoxicity NN NN B-Disease
and NN NN O
preserved NN NN O
antitumor NN NN O
efficacy NN NN O
of NN NN O
liposome NN NN O
- NN NN O
encapsulated NN NN O
doxorubicin NN NN O
and NN NN O
cyclophosphamide NN NN O
compared NN NN O
with NN NN O
conventional NN NN O
doxorubicin NN NN O
and NN NN O
cyclophosphamide NN NN O
in NN NN O
a NN NN O
randomized NN NN O
, NN NN O
multicenter NN NN O
trial NN NN O
of NN NN O
metastatic NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
PURPOSE NN NN O
: NN NN O
To NN NN O
determine NN NN O
whether NN NN O
Myocet NN NN O
( NN NN O
liposome NN NN O
- NN NN O
encapsulated NN NN O
doxorubicin NN NN O
; NN NN O
The NN NN O
Liposome NN NN O
Company NN NN O
, NN NN O
Elan NN NN O
Corporation NN NN O
, NN NN O
Princeton NN NN O
, NN NN O
NJ NN NN O
) NN NN O
in NN NN O
combination NN NN O
with NN NN O
cyclophosphamide NN NN O
significantly NN NN O
reduces NN NN O
doxorubicin NN NN O
cardiotoxicity NN NN B-Disease
while NN NN O
providing NN NN O
comparable NN NN O
antitumor NN NN O
efficacy NN NN O
in NN NN O
first NN NN O
- NN NN O
line NN NN O
treatment NN NN O
of NN NN O
metastatic NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
( NN NN O
MBC NN NN B-Disease
) NN NN O
. NN NN O
   
PATIENTS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
Two NN NN O
hundred NN NN O
ninety NN NN O
- NN NN O
seven NN NN O
patients NN NN O
with NN NN O
MBC NN NN B-Disease
and NN NN O
no NN NN O
prior NN NN O
chemotherapy NN NN O
for NN NN O
metastatic NN NN O
disease NN NN O
were NN NN O
randomized NN NN O
to NN NN O
receive NN NN O
either NN NN O
60 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
of NN NN O
Myocet NN NN O
( NN NN O
M NN NN O
) NN NN O
or NN NN O
conventional NN NN O
doxorubicin NN NN O
( NN NN O
A NN NN O
) NN NN O
, NN NN O
in NN NN O
combination NN NN O
with NN NN O
600 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
of NN NN O
cyclophosphamide NN NN O
( NN NN O
C NN NN O
) NN NN O
, NN NN O
every NN NN O
3 NN NN O
weeks NN NN O
until NN NN O
disease NN NN O
progression NN NN O
or NN NN O
unacceptable NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Cardiotoxicity NN NN B-Disease
was NN NN O
defined NN NN O
by NN NN O
reductions NN NN O
in NN NN O
left NN NN O
- NN NN O
ventricular NN NN O
ejection NN NN O
fraction NN NN O
, NN NN O
assessed NN NN O
by NN NN O
serial NN NN O
multigated NN NN O
radionuclide NN NN O
angiography NN NN O
scans NN NN O
, NN NN O
or NN NN O
congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
( NN NN O
CHF NN NN B-Disease
) NN NN O
. NN NN O
   
Antitumor NN NN O
efficacy NN NN O
was NN NN O
assessed NN NN O
by NN NN O
objective NN NN O
tumor NN NN B-Disease
response NN NN O
rates NN NN O
( NN NN O
World NN NN O
Health NN NN O
Organization NN NN O
criteria NN NN O
) NN NN O
, NN NN O
time NN NN O
to NN NN O
progression NN NN O
, NN NN O
and NN NN O
survival NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Six NN NN O
percent NN NN O
of NN NN O
MC NN NN O
patients NN NN O
versus NN NN O
21 NN NN O
% NN NN O
( NN NN O
including NN NN O
five NN NN O
cases NN NN O
of NN NN O
CHF NN NN B-Disease
) NN NN O
of NN NN O
AC NN NN O
patients NN NN O
developed NN NN O
cardiotoxicity NN NN B-Disease
( NN NN O
P NN NN O
= NN NN O
. NN NN O
0002 NN NN O
) NN NN O
. NN NN O
   
Median NN NN O
cumulative NN NN O
doxorubicin NN NN O
dose NN NN O
at NN NN O
onset NN NN O
was NN NN O
more NN NN O
than NN NN O
2 NN NN O
, NN NN O
220 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
for NN NN O
MC NN NN O
versus NN NN O
480 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
for NN NN O
AC NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O
0001 NN NN O
, NN NN O
hazard NN NN O
ratio NN NN O
, NN NN O
5 NN NN O
. NN NN O
04 NN NN O
) NN NN O
. NN NN O
   
MC NN NN O
patients NN NN O
also NN NN O
experienced NN NN O
less NN NN O
grade NN NN O
4 NN NN O
neutropenia NN NN B-Disease
. NN NN O
   
Antitumor NN NN O
efficacy NN NN O
of NN NN O
MC NN NN O
versus NN NN O
AC NN NN O
was NN NN O
comparable NN NN O
: NN NN O
objective NN NN O
response NN NN O
rates NN NN O
, NN NN O
43 NN NN O
% NN NN O
versus NN NN O
43 NN NN O
% NN NN O
; NN NN O
median NN NN O
time NN NN O
to NN NN O
progression NN NN O
, NN NN O
5 NN NN O
. NN NN O
1 NN NN O
% NN NN O
versus NN NN O
5 NN NN O
. NN NN O
5 NN NN O
months NN NN O
; NN NN O
median NN NN O
time NN NN O
to NN NN O
treatment NN NN O
failure NN NN O
, NN NN O
4 NN NN O
. NN NN O
6 NN NN O
versus NN NN O
4 NN NN O
. NN NN O
4 NN NN O
months NN NN O
; NN NN O
and NN NN O
median NN NN O
survival NN NN O
, NN NN O
19 NN NN O
versus NN NN O
16 NN NN O
months NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Myocet NN NN O
improves NN NN O
the NN NN O
therapeutic NN NN O
index NN NN O
of NN NN O
doxorubicin NN NN O
by NN NN O
significantly NN NN O
reducing NN NN O
cardiotoxicity NN NN B-Disease
and NN NN O
grade NN NN O
4 NN NN O
neutropenia NN NN B-Disease
and NN NN O
provides NN NN O
comparable NN NN O
antitumor NN NN O
efficacy NN NN O
, NN NN O
when NN NN O
used NN NN O
in NN NN O
combination NN NN O
with NN NN O
cyclophosphamide NN NN O
as NN NN O
first NN NN O
- NN NN O
line NN NN O
therapy NN NN O
for NN NN O
MBC NN NN B-Disease
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
nitrergic NN NN O
system NN NN O
in NN NN O
lidocaine NN NN O
- NN NN O
induced NN NN O
convulsion NN NN B-Disease
in NN NN O
the NN NN O
mouse NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
N NN NN O
- NN NN O
nitro NN NN O
- NN NN O
L NN NN O
- NN NN O
arginine NN NN O
- NN NN O
methyl NN NN O
ester NN NN O
( NN NN O
L NN NN O
- NN NN O
NAME NN NN O
) NN NN O
a NN NN O
nitric NN NN O
oxide NN NN O
( NN NN O
NO NN NN O
) NN NN O
synthase NN NN O
inhibitor NN NN O
and NN NN O
L NN NN O
- NN NN O
arginine NN NN O
, NN NN O
a NN NN O
NO NN NN O
precursor NN NN O
, NN NN O
were NN NN O
investigated NN NN O
on NN NN O
lidocaine NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
. NN NN O
   
In NN NN O
the NN NN O
first NN NN O
experiment NN NN O
, NN NN O
four NN NN O
groups NN NN O
of NN NN O
mice NN NN O
received NN NN O
physiological NN NN O
saline NN NN O
( NN NN O
0 NN NN O
. NN NN O
9 NN NN O
% NN NN O
) NN NN O
, NN NN O
L NN NN O
- NN NN O
arginine NN NN O
( NN NN O
300 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
, NN NN O
L NN NN O
- NN NN O
NAME NN NN O
( NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
and NN NN O
diazepam NN NN O
( NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Thirty NN NN O
minutes NN NN O
after NN NN O
these NN NN O
injections NN NN O
, NN NN O
all NN NN O
mice NN NN O
received NN NN O
lidocaine NN NN O
( NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
second NN NN O
experiment NN NN O
, NN NN O
four NN NN O
groups NN NN O
of NN NN O
mice NN NN O
received NN NN O
similar NN NN O
treatment NN NN O
in NN NN O
the NN NN O
first NN NN O
experiment NN NN O
, NN NN O
and NN NN O
30 NN NN O
min NN NN O
after NN NN O
these NN NN O
injections NN NN O
, NN NN O
all NN NN O
mice NN NN O
received NN NN O
a NN NN O
higher NN NN O
dose NN NN O
of NN NN O
lidocaine NN NN O
( NN NN O
80 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
. NN NN O
   
L NN NN O
- NN NN O
NAME NN NN O
( NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
and NN NN O
diazepam NN NN O
( NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
significantly NN NN O
decreased NN NN O
the NN NN O
incidence NN NN O
of NN NN O
lidocaine NN NN O
( NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
L NN NN O
- NN NN O
arginine NN NN O
treatment NN NN O
increased NN NN O
the NN NN O
incidence NN NN O
of NN NN O
lidocaine NN NN O
( NN NN O
80 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
significantly NN NN O
. NN NN O
   
These NN NN O
results NN NN O
may NN NN O
suggest NN NN O
that NN NN O
NO NN NN O
is NN NN O
a NN NN O
proconvulsant NN NN O
mediator NN NN O
in NN NN O
lidocaine NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
. NN NN O
   
Erythropoietin NN NN O
restores NN NN O
the NN NN O
anemia NN NN B-Disease
- NN NN O
induced NN NN O
reduction NN NN O
in NN NN O
cyclophosphamide NN NN O
cytotoxicity NN NN B-Disease
in NN NN O
rat NN NN O
tumors NN NN B-Disease
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
examine NN NN O
the NN NN O
impact NN NN O
of NN NN O
anemia NN NN B-Disease
prevention NN NN O
by NN NN O
recombinant NN NN O
human NN NN O
erythropoietin NN NN O
( NN NN O
rHuEPO NN NN O
) NN NN O
treatment NN NN O
on NN NN O
the NN NN O
cytotoxicity NN NN B-Disease
of NN NN O
cyclophosphamide NN NN O
in NN NN O
solid NN NN O
experimental NN NN O
tumors NN NN B-Disease
. NN NN O
   
Anemia NN NN B-Disease
was NN NN O
induced NN NN O
using NN NN O
a NN NN O
single NN NN O
dose NN NN O
of NN NN O
carboplatin NN NN O
( NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
resulting NN NN O
in NN NN O
a NN NN O
long NN NN O
- NN NN O
lasting NN NN O
reduction NN NN O
( NN NN O
30 NN NN O
% NN NN O
) NN NN O
of NN NN O
the NN NN O
hemoglobin NN NN O
concentration NN NN O
. NN NN O
   
In NN NN O
a NN NN O
second NN NN O
group NN NN O
, NN NN O
the NN NN O
development NN NN O
of NN NN O
anemia NN NN B-Disease
was NN NN O
prevented NN NN O
by NN NN O
rHuEPO NN NN O
( NN NN O
1000 NN NN O
IU NN NN O
/ NN NN O
kg NN NN O
) NN NN O
administered NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
three NN NN O
times NN NN O
/ NN NN O
week NN NN O
starting NN NN O
7 NN NN O
days NN NN O
before NN NN O
carboplatin NN NN O
application NN NN O
. NN NN O
   
Four NN NN O
days NN NN O
after NN NN O
carboplatin NN NN O
treatment NN NN O
, NN NN O
tumors NN NN B-Disease
( NN NN O
DS NN NN O
- NN NN O
sarcoma NN NN B-Disease
of NN NN O
the NN NN O
rat NN NN O
) NN NN O
were NN NN O
implanted NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
onto NN NN O
the NN NN O
hind NN NN O
food NN NN O
dorsum NN NN O
. NN NN O
   
Neither NN NN O
carboplatin NN NN O
nor NN NN O
rHuEPO NN NN O
treatment NN NN O
influenced NN NN O
tumor NN NN B-Disease
growth NN NN O
rate NN NN O
per NN NN O
se NN NN O
. NN NN O
   
When NN NN O
tumors NN NN B-Disease
were NN NN O
treated NN NN O
with NN NN O
a NN NN O
single NN NN O
dose NN NN O
of NN NN O
cyclophosphamide NN NN O
( NN NN O
60 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
5 NN NN O
days NN NN O
after NN NN O
implantation NN NN O
, NN NN O
a NN NN O
growth NN NN O
delay NN NN O
with NN NN O
a NN NN O
subsequent NN NN O
regrowth NN NN O
of NN NN O
the NN NN O
tumors NN NN B-Disease
was NN NN O
observed NN NN O
. NN NN O
   
In NN NN O
the NN NN O
anemia NN NN B-Disease
group NN NN O
, NN NN O
the NN NN O
growth NN NN O
delay NN NN O
was NN NN O
significantly NN NN O
shorter NN NN O
compared NN NN O
with NN NN O
nonanemic NN NN O
controls NN NN O
( NN NN O
13 NN NN O
. NN NN O
3 NN NN O
days NN NN O
versus NN NN O
8 NN NN O
. NN NN O
6 NN NN O
days NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
group NN NN O
where NN NN O
anemia NN NN B-Disease
was NN NN O
prevented NN NN O
by NN NN O
rHuEPO NN NN O
treatment NN NN O
, NN NN O
growth NN NN O
delay NN NN O
was NN NN O
comparable NN NN O
with NN NN O
that NN NN O
of NN NN O
nonanemic NN NN O
controls NN NN O
( NN NN O
13 NN NN O
. NN NN O
3 NN NN O
days NN NN O
) NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
chemotherapy NN NN O
- NN NN O
induced NN NN O
anemia NN NN B-Disease
reduces NN NN O
cytotoxicity NN NN B-Disease
of NN NN O
cyclophosphamide NN NN O
in NN NN O
tumors NN NN B-Disease
, NN NN O
whereas NN NN O
correction NN NN O
of NN NN O
anemia NN NN B-Disease
by NN NN O
rHuEPO NN NN O
treatment NN NN O
( NN NN O
epoetin NN NN O
alpha NN NN O
) NN NN O
increases NN NN O
the NN NN O
sensitivity NN NN O
, NN NN O
probably NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
an NN NN O
improved NN NN O
oxygen NN NN O
supply NN NN O
to NN NN O
tumor NN NN B-Disease
tissue NN NN O
. NN NN O
   
Fatal NN NN O
haemorrhagic NN NN B-Disease
myocarditis NN NN I-Disease
secondary NN NN O
to NN NN O
cyclophosphamide NN NN O
therapy NN NN O
. NN NN O
   
Haemorrhagic NN NN B-Disease
myocarditis NN NN I-Disease
is NN NN O
a NN NN O
rare NN NN O
but NN NN O
important NN NN O
complication NN NN O
of NN NN O
cyclophosphamide NN NN O
therapy NN NN O
. NN NN O
   
Echocardiographic NN NN O
identification NN NN O
of NN NN O
the NN NN O
disorder NN NN O
can NN NN O
be NN NN O
made NN NN O
. NN NN O
   
We NN NN O
believe NN NN O
that NN NN O
the NN NN O
ultrasound NN NN O
features NN NN O
of NN NN O
this NN NN O
disorder NN NN O
have NN NN O
not NN NN O
been NN NN O
previously NN NN O
reported NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
verapamil NN NN O
on NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
and NN NN O
its NN NN O
electrophysiological NN NN O
determinants NN NN O
in NN NN O
dogs NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Atrial NN NN B-Disease
tachycardia NN NN I-Disease
- NN NN O
induced NN NN O
remodeling NN NN O
promotes NN NN O
the NN NN O
occurrence NN NN O
and NN NN O
maintenance NN NN O
of NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
( NN NN O
AF NN NN B-Disease
) NN NN O
and NN NN O
decreases NN NN O
L NN NN O
- NN NN O
type NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
current NN NN O
. NN NN O
   
There NN NN O
is NN NN O
also NN NN O
a NN NN O
clinical NN NN O
suggestion NN NN O
that NN NN O
acute NN NN O
L NN NN O
- NN NN O
type NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
) NN NN O
channel NN NN O
blockade NN NN O
can NN NN O
promote NN NN O
AF NN NN B-Disease
, NN NN O
consistent NN NN O
with NN NN O
an NN NN O
AF NN NN B-Disease
promoting NN NN O
effect NN NN O
of NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
channel NN NN O
inhibition NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
To NN NN O
evaluate NN NN O
the NN NN O
potential NN NN O
mechanisms NN NN O
of NN NN O
AF NN NN B-Disease
promotion NN NN O
by NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
channel NN NN O
blockers NN NN O
, NN NN O
we NN NN O
administered NN NN O
verapamil NN NN O
to NN NN O
morphine NN NN O
- NN NN O
chloralose NN NN O
anesthetized NN NN O
dogs NN NN O
. NN NN O
   
Diltiazem NN NN O
was NN NN O
used NN NN O
as NN NN O
a NN NN O
comparison NN NN O
drug NN NN O
and NN NN O
autonomic NN NN O
blockade NN NN O
with NN NN O
atropine NN NN O
and NN NN O
nadolol NN NN O
was NN NN O
applied NN NN O
in NN NN O
some NN NN O
experiments NN NN O
. NN NN O
   
Epicardial NN NN O
mapping NN NN O
with NN NN O
240 NN NN O
epicardial NN NN O
electrodes NN NN O
was NN NN O
used NN NN O
to NN NN O
evaluate NN NN O
activation NN NN O
during NN NN O
AF NN NN B-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
Verapamil NN NN O
caused NN NN O
AF NN NN B-Disease
promotion NN NN O
in NN NN O
six NN NN O
dogs NN NN O
, NN NN O
increasing NN NN O
mean NN NN O
duration NN NN O
of NN NN O
AF NN NN B-Disease
induced NN NN O
by NN NN O
burst NN NN O
pacing NN NN O
, NN NN O
from NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
s NN NN O
( NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
S NN NN O
. NN NN O
E NN NN O
. NN NN O
) NN NN O
to NN NN O
95 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
39 NN NN O
s NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
vs NN NN O
. NN NN O
control NN NN O
) NN NN O
at NN NN O
a NN NN O
loading NN NN O
dose NN NN O
of NN NN O
0 NN NN O
. NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
and NN NN O
228 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
101 NN NN O
s NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
0005 NN NN O
vs NN NN O
. NN NN O
control NN NN O
) NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
0 NN NN O
. NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
Underlying NN NN O
electrophysiological NN NN O
mechanisms NN NN O
were NN NN O
studied NN NN O
in NN NN O
detail NN NN O
in NN NN O
five NN NN O
additional NN NN O
dogs NN NN O
under NN NN O
control NN NN O
conditions NN NN O
and NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
higher NN NN O
dose NN NN O
of NN NN O
verapamil NN NN O
. NN NN O
   
In NN NN O
these NN NN O
experiments NN NN O
, NN NN O
verapamil NN NN O
shortened NN NN O
mean NN NN O
effective NN NN O
refractory NN NN O
period NN NN O
( NN NN O
ERP NN NN O
) NN NN O
from NN NN O
122 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
to NN NN O
114 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
ms NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
02 NN NN O
) NN NN O
at NN NN O
a NN NN O
cycle NN NN O
length NN NN O
of NN NN O
300 NN NN O
ms NN NN O
, NN NN O
decreased NN NN O
ERP NN NN O
heterogeneity NN NN O
( NN NN O
from NN NN O
15 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
to NN NN O
10 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
% NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
heterogeneously NN NN O
accelerated NN NN O
atrial NN NN O
conduction NN NN O
and NN NN O
decreased NN NN O
the NN NN O
cycle NN NN O
length NN NN O
of NN NN O
AF NN NN B-Disease
( NN NN O
94 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
to NN NN O
84 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
ms NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
005 NN NN O
) NN NN O
. NN NN O
   
Diltiazem NN NN O
did NN NN O
not NN NN O
affect NN NN O
ERP NN NN O
, NN NN O
AF NN NN B-Disease
cycle NN NN O
length NN NN O
or NN NN O
AF NN NN B-Disease
duration NN NN O
, NN NN O
but NN NN O
produced NN NN O
conduction NN NN O
acceleration NN NN O
similar NN NN O
to NN NN O
that NN NN O
caused NN NN O
by NN NN O
verapamil NN NN O
( NN NN O
n NN NN O
= NN NN O
5 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
presence NN NN O
of NN NN O
autonomic NN NN O
blockade NN NN O
, NN NN O
verapamil NN NN O
failed NN NN O
to NN NN O
promote NN NN O
AF NN NN B-Disease
and NN NN O
increased NN NN O
, NN NN O
rather NN NN O
than NN NN O
decreasing NN NN O
, NN NN O
refractoriness NN NN O
. NN NN O
   
Neither NN NN O
verapamil NN NN O
nor NN NN O
diltiazem NN NN O
affected NN NN O
atrial NN NN O
conduction NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
autonomic NN NN O
blockade NN NN O
. NN NN O
   
Epicardial NN NN O
mapping NN NN O
suggested NN NN O
that NN NN O
verapamil NN NN O
promoted NN NN O
AF NN NN B-Disease
by NN NN O
increasing NN NN O
the NN NN O
number NN NN O
of NN NN O
simultaneous NN NN O
wavefronts NN NN O
reflected NN NN O
by NN NN O
separate NN NN O
zones NN NN O
of NN NN O
reactivation NN NN O
in NN NN O
each NN NN O
cycle NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Verapamil NN NN O
promotes NN NN O
AF NN NN B-Disease
in NN NN O
normal NN NN O
dogs NN NN O
by NN NN O
promoting NN NN O
multiple NN NN O
circuit NN NN O
reentry NN NN O
, NN NN O
an NN NN O
effect NN NN O
dependent NN NN O
on NN NN O
intact NN NN O
autonomic NN NN O
tone NN NN O
and NN NN O
not NN NN O
shared NN NN O
by NN NN O
diltiazem NN NN O
. NN NN O
   
Calcitonin NN NN O
gene NN NN O
- NN NN O
related NN NN O
peptide NN NN O
levels NN NN O
during NN NN O
nitric NN NN O
oxide NN NN O
- NN NN O
induced NN NN O
headache NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
chronic NN NN O
tension NN NN B-Disease
- NN NN I-Disease
type NN NN I-Disease
headache NN NN I-Disease
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
proposed NN NN O
that NN NN O
nitric NN NN O
oxide NN NN O
( NN NN O
NO NN NN O
) NN NN O
induced NN NN O
headache NN NN B-Disease
in NN NN O
primary NN NN B-Disease
headaches NN NN I-Disease
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
release NN NN O
of NN NN O
calcitonin NN NN O
gene NN NN O
- NN NN O
related NN NN O
peptide NN NN O
( NN NN O
CGRP NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
we NN NN O
aimed NN NN O
to NN NN O
investigate NN NN O
plasma NN NN O
levels NN NN O
of NN NN O
CGRP NN NN O
during NN NN O
headache NN NN B-Disease
induced NN NN O
by NN NN O
the NN NN O
NO NN NN O
donor NN NN O
glyceryl NN NN O
trinitrate NN NN O
( NN NN O
GTN NN NN O
) NN NN O
in NN NN O
16 NN NN O
patients NN NN O
with NN NN O
chronic NN NN O
tension NN NN B-Disease
- NN NN I-Disease
type NN NN I-Disease
headache NN NN I-Disease
and NN NN O
16 NN NN O
healthy NN NN O
controls NN NN O
. NN NN O
   
The NN NN O
subjects NN NN O
were NN NN O
randomly NN NN O
allocated NN NN O
to NN NN O
receive NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
GTN NN NN O
or NN NN O
placebo NN NN O
over NN NN O
20 NN NN O
min NN NN O
on NN NN O
two NN NN O
headache NN NN B-Disease
- NN NN O
free NN NN O
days NN NN O
. NN NN O
   
Blood NN NN O
samples NN NN O
were NN NN O
collected NN NN O
at NN NN O
baseline NN NN O
, NN NN O
10 NN NN O
, NN NN O
20 NN NN O
and NN NN O
60 NN NN O
min NN NN O
after NN NN O
start NN NN O
of NN NN O
infusion NN NN O
. NN NN O
   
Both NN NN O
patients NN NN O
and NN NN O
controls NN NN O
developed NN NN O
significantly NN NN O
stronger NN NN O
immediate NN NN O
headache NN NN B-Disease
on NN NN O
the NN NN O
GTN NN NN O
day NN NN O
than NN NN O
on NN NN O
the NN NN O
placebo NN NN O
day NN NN O
and NN NN O
the NN NN O
headache NN NN B-Disease
was NN NN O
significantly NN NN O
more NN NN O
pronounced NN NN O
in NN NN O
patients NN NN O
than NN NN O
in NN NN O
controls NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
difference NN NN O
between NN NN O
the NN NN O
area NN NN O
under NN NN O
the NN NN O
CGRP NN NN O
curve NN NN O
( NN NN O
AUCCGRP NN NN O
) NN NN O
on NN NN O
GTN NN NN O
vs NN NN O
. NN NN O
placebo NN NN O
day NN NN O
in NN NN O
either NN NN O
patients NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
65 NN NN O
) NN NN O
or NN NN O
controls NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
48 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
AUCCGRP NN NN O
recorded NN NN O
on NN NN O
the NN NN O
GTN NN NN O
day NN NN O
did NN NN O
not NN NN O
differ NN NN O
between NN NN O
patients NN NN O
and NN NN O
controls NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
36 NN NN O
) NN NN O
. NN NN O
   
Both NN NN O
in NN NN O
patients NN NN O
and NN NN O
controls NN NN O
, NN NN O
CGRP NN NN O
levels NN NN O
changed NN NN O
significantly NN NN O
over NN NN O
time NN NN O
, NN NN O
on NN NN O
both NN NN O
the NN NN O
GTN NN NN O
and NN NN O
placebo NN NN O
days NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
indicates NN NN O
that NN NN O
NO NN NN O
- NN NN O
induced NN NN O
immediate NN NN O
headache NN NN B-Disease
is NN NN O
not NN NN O
associated NN NN O
with NN NN O
release NN NN O
of NN NN O
CGRP NN NN O
. NN NN O
   
Fluconazole NN NN O
- NN NN O
induced NN NN O
torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
present NN NN O
a NN NN O
case NN NN O
of NN NN O
fluconazole NN NN O
- NN NN O
associated NN NN O
torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
( NN NN O
TDP NN NN B-Disease
) NN NN O
and NN NN O
discuss NN NN O
fluconazole NN NN O
' NN NN O
s NN NN O
role NN NN O
in NN NN O
causing NN NN O
TDP NN NN B-Disease
. NN NN O
   
CASE NN NN O
SUMMARY NN NN O
: NN NN O
A NN NN O
68 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
white NN NN O
woman NN NN O
with NN NN O
Candida NN NN O
glabrata NN NN O
isolated NN NN O
from NN NN O
a NN NN O
presacral NN NN O
abscess NN NN O
developed NN NN O
TDP NN NN B-Disease
eight NN NN O
days NN NN O
after NN NN O
commencing NN NN O
oral NN NN O
fluconazole NN NN O
The NN NN O
patient NN NN O
had NN NN O
no NN NN O
other NN NN O
risk NN NN O
factors NN NN O
for NN NN O
TDP NN NN B-Disease
, NN NN O
including NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
, NN NN O
cardiomyopathy NN NN B-Disease
, NN NN O
congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
, NN NN O
and NN NN O
electrolyte NN NN O
abnormalities NN NN O
There NN NN O
was NN NN O
a NN NN O
temporal NN NN O
association NN NN O
between NN NN O
the NN NN O
initiation NN NN O
of NN NN O
fluconazole NN NN O
and NN NN O
TDP NN NN B-Disease
. NN NN O
   
The NN NN O
TDP NN NN B-Disease
resolved NN NN O
when NN NN O
fluconazole NN NN O
was NN NN O
discontinued NN NN O
; NN NN O
however NN NN O
, NN NN O
the NN NN O
patient NN NN O
continued NN NN O
to NN NN O
have NN NN O
premature NN NN B-Disease
ventricular NN NN I-Disease
contractions NN NN I-Disease
and NN NN O
nonsustained NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
( NN NN O
NSVT NN NN B-Disease
) NN NN O
until NN NN O
six NN NN O
days NN NN O
after NN NN O
drug NN NN O
cessation NN NN O
DISCUSSION NN NN O
: NN NN O
Use NN NN O
of NN NN O
the NN NN O
Naranjo NN NN O
probability NN NN O
scale NN NN O
indicates NN NN O
a NN NN O
probable NN NN O
relationship NN NN O
between NN NN O
the NN NN O
use NN NN O
of NN NN O
fluconazole NN NN O
and NN NN O
the NN NN O
development NN NN O
of NN NN O
TDP NN NN B-Disease
. NN NN O
   
The NN NN O
possible NN NN O
mechanism NN NN O
is NN NN O
depression NN NN B-Disease
of NN NN O
rapidly NN NN O
activating NN NN O
delayed NN NN O
rectifier NN NN O
potassium NN NN O
currents NN NN O
. NN NN O
   
In NN NN O
our NN NN O
patient NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
other NN NN O
etiology NN NN O
identified NN NN O
that NN NN O
could NN NN O
explain NN NN O
QT NN NN B-Disease
prolongation NN NN I-Disease
or NN NN O
TDP NN NN B-Disease
The NN NN O
complete NN NN O
disappearance NN NN O
of NN NN O
NSVT NN NN B-Disease
and NN NN O
premature NN NN B-Disease
ventricular NN NN I-Disease
contractions NN NN I-Disease
followed NN NN O
by NN NN O
normalization NN NN O
of NN NN O
QT NN NN O
interval NN NN O
after NN NN O
the NN NN O
drug NN NN O
was NN NN O
stopped NN NN O
strongly NN NN O
suggests NN NN O
fluconazole NN NN O
as NN NN O
the NN NN O
etiology NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Clinicians NN NN O
should NN NN O
be NN NN O
aware NN NN O
that NN NN O
fluconazole NN NN O
, NN NN O
even NN NN O
at NN NN O
low NN NN O
doses NN NN O
, NN NN O
may NN NN O
cause NN NN O
prolongation NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
QT NN NN I-Disease
interval NN NN I-Disease
, NN NN O
leading NN NN O
to NN NN O
TDP NN NN B-Disease
. NN NN O
   
Serial NN NN O
electrocardiographic NN NN O
monitoring NN NN O
may NN NN O
be NN NN O
considered NN NN O
when NN NN O
fluconazole NN NN O
is NN NN O
administered NN NN O
in NN NN O
patients NN NN O
who NN NN O
are NN NN O
at NN NN O
risk NN NN O
for NN NN O
ventricular NN NN B-Disease
arrhythmias NN NN I-Disease
. NN NN O
   
Cutaneous NN NN B-Disease
leucocytoclastic NN NN I-Disease
vasculitis NN NN I-Disease
associated NN NN O
with NN NN O
oxacillin NN NN O
. NN NN O
   
A NN NN O
67 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
who NN NN O
was NN NN O
treated NN NN O
with NN NN O
oxacillin NN NN O
for NN NN O
one NN NN O
week NN NN O
because NN NN O
of NN NN O
Staphylococcus NN NN B-Disease
aureus NN NN I-Disease
bacteremia NN NN I-Disease
, NN NN O
developed NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
and NN NN O
diffuse NN NN O
, NN NN O
symmetric NN NN O
, NN NN O
palpable NN NN O
purpuric NN NN B-Disease
lesions NN NN I-Disease
on NN NN O
his NN NN O
feet NN NN O
. NN NN O
   
Necrotic NN NN B-Disease
blisters NN NN I-Disease
were NN NN O
noted NN NN O
on NN NN O
his NN NN O
fingers NN NN O
. NN NN O
   
Skin NN NN O
biopsies NN NN O
showed NN NN O
findings NN NN O
diagnostic NN NN O
of NN NN O
leucocytoclastic NN NN B-Disease
vasculitis NN NN I-Disease
. NN NN O
   
Oxacillin NN NN O
was NN NN O
discontinued NN NN O
and NN NN O
patient NN NN O
was NN NN O
treated NN NN O
with NN NN O
corticosteroids NN NN O
. NN NN O
   
The NN NN O
rash NN NN B-Disease
disappeared NN NN O
after NN NN O
three NN NN O
weeks NN NN O
and NN NN O
renal NN NN O
function NN NN O
returned NN NN O
to NN NN O
normal NN NN O
. NN NN O
   
Leucocytoclastic NN NN B-Disease
vasculitis NN NN I-Disease
presents NN NN O
as NN NN O
palpable NN NN O
purpura NN NN B-Disease
of NN NN O
the NN NN O
lower NN NN O
extremities NN NN O
often NN NN O
accompanied NN NN O
by NN NN O
abdominal NN NN B-Disease
pain NN NN I-Disease
, NN NN O
arthralgia NN NN B-Disease
, NN NN O
and NN NN O
renal NN NN B-Disease
involvement NN NN I-Disease
. NN NN O
   
Etiologic NN NN O
factors NN NN O
or NN NN O
associated NN NN O
disorders NN NN O
include NN NN O
infections NN NN B-Disease
, NN NN O
medications NN NN O
, NN NN O
collagen NN NN B-Disease
vascular NN NN I-Disease
disease NN NN I-Disease
and NN NN O
neoplasia NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
in NN NN O
half NN NN O
of NN NN O
the NN NN O
cases NN NN O
no NN NN O
etiologic NN NN O
factor NN NN O
is NN NN O
identified NN NN O
. NN NN O
   
Usually NN NN O
it NN NN O
is NN NN O
a NN NN O
self NN NN O
- NN NN O
limited NN NN O
disorder NN NN O
, NN NN O
but NN NN O
corticosteroid NN NN O
therapy NN NN O
may NN NN O
be NN NN O
needed NN NN O
in NN NN O
life NN NN O
- NN NN O
threatening NN NN O
cases NN NN O
since NN NN O
early NN NN O
treatment NN NN O
with NN NN O
corticosteroids NN NN O
in NN NN O
severe NN NN O
cases NN NN O
can NN NN O
prevent NN NN O
complications NN NN O
. NN NN O
   
Oxacillin NN NN O
should NN NN O
be NN NN O
included NN NN O
among NN NN O
the NN NN O
drugs NN NN O
that NN NN O
can NN NN O
cause NN NN O
leucocytoclastic NN NN B-Disease
vasculitis NN NN I-Disease
. NN NN O
   
The NN NN O
renal NN NN O
pathology NN NN O
in NN NN O
a NN NN O
case NN NN O
of NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
diabetes NN NN B-Disease
insipidus NN NN I-Disease
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
diabetes NN NN B-Disease
insipidus NN NN I-Disease
is NN NN O
reported NN NN O
. NN NN O
   
At NN NN O
necropsy NN NN O
microscopy NN NN O
shoed NN NN O
unique NN NN O
and NN NN O
extensive NN NN O
damage NN NN O
to NN NN O
cells NN NN O
lining NN NN O
the NN NN O
distal NN NN O
nephron NN NN O
. NN NN O
   
It NN NN O
is NN NN O
suggested NN NN O
that NN NN O
these NN NN O
changes NN NN O
represent NN NN O
a NN NN O
specific NN NN O
toxic NN NN O
effect NN NN O
of NN NN O
lithium NN NN O
, NN NN O
reported NN NN O
here NN NN O
for NN NN O
the NN NN O
first NN NN O
time NN NN O
in NN NN O
man NN NN O
. NN NN O
   
Cholestatic NN NN B-Disease
jaundice NN NN I-Disease
associated NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
metformin NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
patient NN NN O
who NN NN O
developed NN NN O
cholestatic NN NN B-Disease
jaundice NN NN I-Disease
shortly NN NN O
after NN NN O
initiation NN NN O
of NN NN O
treatment NN NN O
with NN NN O
metformin NN NN O
hydrochloride NN NN O
. NN NN O
   
Ultrasound NN NN O
of NN NN O
the NN NN O
liver NN NN O
and NN NN O
abdominal NN NN O
CT NN NN O
were NN NN O
normal NN NN O
. NN NN O
   
An NN NN O
ERCP NN NN O
showed NN NN O
normal NN NN O
biliary NN NN O
anatomy NN NN O
. NN NN O
   
A NN NN O
percutaneous NN NN O
liver NN NN O
biopsy NN NN O
was NN NN O
obtained NN NN O
showing NN NN O
marked NN NN O
cholestasis NN NN B-Disease
, NN NN O
with NN NN O
portal NN NN O
edema NN NN B-Disease
, NN NN O
ductular NN NN O
proliferation NN NN O
, NN NN O
and NN NN O
acute NN NN O
inflammation NN NN B-Disease
. NN NN O
   
Metformin NN NN O
hydrochloride NN NN O
was NN NN O
discontinued NN NN O
, NN NN O
and NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
jaundice NN NN B-Disease
resolved NN NN O
slowly NN NN O
over NN NN O
a NN NN O
period NN NN O
of NN NN O
several NN NN O
months NN NN O
. NN NN O
   
Given NN NN O
the NN NN O
onset NN NN O
of NN NN O
his NN NN O
jaundice NN NN B-Disease
2 NN NN O
wk NN NN O
after NN NN O
the NN NN O
initiation NN NN O
of NN NN O
metformin NN NN O
, NN NN O
we NN NN O
believe NN NN O
that NN NN O
this NN NN O
case NN NN O
represents NN NN O
an NN NN O
example NN NN O
of NN NN O
metformin NN NN O
- NN NN O
associated NN NN O
hepatotoxicity NN NN B-Disease
, NN NN O
the NN NN O
first NN NN O
such NN NN O
case NN NN O
reported NN NN O
. NN NN O
   
Systemic NN NN O
toxicity NN NN B-Disease
and NN NN O
resuscitation NN NN O
in NN NN O
bupivacaine NN NN O
- NN NN O
, NN NN O
levobupivacaine NN NN O
- NN NN O
, NN NN O
or NN NN O
ropivacaine NN NN O
- NN NN O
infused NN NN O
rats NN NN O
. NN NN O
   
We NN NN O
compared NN NN O
the NN NN O
systemic NN NN O
toxicity NN NN B-Disease
of NN NN O
bupivacaine NN NN O
, NN NN O
levobupivacaine NN NN O
, NN NN O
and NN NN O
ropivacaine NN NN O
in NN NN O
anesthetized NN NN O
rats NN NN O
. NN NN O
   
We NN NN O
also NN NN O
compared NN NN O
the NN NN O
ability NN NN O
to NN NN O
resuscitate NN NN O
rats NN NN O
after NN NN O
lethal NN NN O
doses NN NN O
of NN NN O
these NN NN O
local NN NN O
anesthetics NN NN O
. NN NN O
   
Bupivacaine NN NN O
, NN NN O
levobupivacaine NN NN O
, NN NN O
or NN NN O
ropivacaine NN NN O
was NN NN O
infused NN NN O
at NN NN O
a NN NN O
rate NN NN O
of NN NN O
2 NN NN O
mg NN NN O
. NN NN O
   
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
min NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
while NN NN O
electrocardiogram NN NN O
, NN NN O
electroencephalogram NN NN O
, NN NN O
and NN NN O
arterial NN NN O
pressure NN NN O
were NN NN O
continuously NN NN O
monitored NN NN O
. NN NN O
   
When NN NN O
asystole NN NN B-Disease
was NN NN O
recorded NN NN O
, NN NN O
drug NN NN O
infusion NN NN O
was NN NN O
stopped NN NN O
and NN NN O
a NN NN O
resuscitation NN NN O
sequence NN NN O
was NN NN O
begun NN NN O
. NN NN O
   
Epinephrine NN NN O
0 NN NN O
. NN NN O
01 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
was NN NN O
administered NN NN O
at NN NN O
1 NN NN O
- NN NN O
min NN NN O
intervals NN NN O
while NN NN O
external NN NN O
cardiac NN NN O
compressions NN NN O
were NN NN O
applied NN NN O
. NN NN O
   
Resuscitation NN NN O
was NN NN O
considered NN NN O
successful NN NN O
when NN NN O
a NN NN O
systolic NN NN O
arterial NN NN O
pressure NN NN O
> NN NN O
or NN NN O
= NN NN O
100 NN NN O
mm NN NN O
Hg NN NN O
was NN NN O
achieved NN NN O
within NN NN O
5 NN NN O
min NN NN O
. NN NN O
   
The NN NN O
cumulative NN NN O
doses NN NN O
of NN NN O
levobupivacaine NN NN O
and NN NN O
ropivacaine NN NN O
that NN NN O
produced NN NN O
seizures NN NN B-Disease
were NN NN O
similar NN NN O
and NN NN O
were NN NN O
larger NN NN O
than NN NN O
those NN NN O
of NN NN O
bupivacaine NN NN O
. NN NN O
   
The NN NN O
cumulative NN NN O
doses NN NN O
of NN NN O
levobupivacaine NN NN O
that NN NN O
produced NN NN O
dysrhythmias NN NN B-Disease
and NN NN O
asystole NN NN B-Disease
were NN NN O
smaller NN NN O
than NN NN O
the NN NN O
corresponding NN NN O
doses NN NN O
of NN NN O
ropivacaine NN NN O
, NN NN O
but NN NN O
they NN NN O
were NN NN O
larger NN NN O
than NN NN O
those NN NN O
of NN NN O
bupivacaine NN NN O
. NN NN O
   
The NN NN O
number NN NN O
of NN NN O
successful NN NN O
resuscitations NN NN O
did NN NN O
not NN NN O
differ NN NN O
among NN NN O
groups NN NN O
. NN NN O
   
However NN NN O
, NN NN O
a NN NN O
smaller NN NN O
dose NN NN O
of NN NN O
epinephrine NN NN O
was NN NN O
required NN NN O
in NN NN O
the NN NN O
Ropivacaine NN NN O
group NN NN O
than NN NN O
in NN NN O
the NN NN O
other NN NN O
groups NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
systemic NN NN O
toxicity NN NN B-Disease
of NN NN O
levobupivacaine NN NN O
is NN NN O
intermediate NN NN O
between NN NN O
that NN NN O
of NN NN O
ropivacaine NN NN O
and NN NN O
bupivacaine NN NN O
when NN NN O
administered NN NN O
at NN NN O
the NN NN O
same NN NN O
rate NN NN O
and NN NN O
that NN NN O
ropivacaine NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
arrest NN NN I-Disease
appears NN NN O
to NN NN O
be NN NN O
more NN NN O
susceptible NN NN O
to NN NN O
treatment NN NN O
than NN NN O
that NN NN O
induced NN NN O
by NN NN O
bupivacaine NN NN O
or NN NN O
levobupivacaine NN NN O
. NN NN O
   
Amphotericin NN NN O
B NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
AIDS NN NN B-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
multiple NN NN O
episodes NN NN O
of NN NN O
seizure NN NN B-Disease
activity NN NN O
in NN NN O
an NN NN O
AIDS NN NN B-Disease
patent NN NN O
following NN NN O
amphotericin NN NN O
B NN NN O
infusion NN NN O
. NN NN O
   
CASE NN NN O
SUMMARY NN NN O
: NN NN O
A NN NN O
46 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
African NN NN O
- NN NN O
American NN NN O
man NN NN O
experienced NN NN O
recurrent NN NN O
grand NN NN B-Disease
mal NN NN I-Disease
seizures NN NN I-Disease
during NN NN O
intravenous NN NN O
infusion NN NN O
of NN NN O
amphotericin NN NN O
B NN NN O
, NN NN O
then NN NN O
petit NN NN O
mal NN NN O
seizures NN NN B-Disease
as NN NN O
the NN NN O
infusion NN NN O
was NN NN O
stopped NN NN O
and NN NN O
the NN NN O
drug NN NN O
concentrations NN NN O
decreased NN NN O
with NN NN O
time NN NN O
. NN NN O
   
The NN NN O
patients NN NN O
concurrent NN NN O
medications NN NN O
included NN NN O
didanosine NN NN O
, NN NN O
hydroxyzine NN NN O
, NN NN O
promethazine NN NN O
, NN NN O
hydrocortisone NN NN O
, NN NN O
and NN NN O
prochlorperazine NN NN O
. NN NN O
   
Despite NN NN O
administration NN NN O
of NN NN O
phenytoin NN NN O
and NN NN O
lorazepam NN NN O
, NN NN O
the NN NN O
seizures NN NN B-Disease
persisted NN NN O
and NN NN O
occurred NN NN O
only NN NN O
during NN NN O
amphotercin NN NN O
B NN NN O
administration NN NN O
. NN NN O
   
DISCUSSION NN NN O
: NN NN O
AIDS NN NN B-Disease
and NN NN O
cryptococcal NN NN B-Disease
meningitis NN NN I-Disease
, NN NN O
both NN NN O
of NN NN O
which NN NN O
the NN NN O
patient NN NN O
had NN NN O
, NN NN O
can NN NN O
potentially NN NN O
cause NN NN O
seizures NN NN B-Disease
. NN NN O
   
The NN NN O
patient NN NN O
had NN NN O
a NN NN O
history NN NN O
of NN NN O
alcohol NN NN B-Disease
abuse NN NN I-Disease
; NN NN O
alcohol NN NN O
intake NN NN O
as NN NN O
well NN NN O
as NN NN O
withdrawal NN NN O
can NN NN O
also NN NN O
cause NN NN O
seizures NN NN B-Disease
. NN NN O
   
Didanosine NN NN O
also NN NN O
has NN NN O
a NN NN O
potential NN NN O
for NN NN O
inducing NN NN O
seizures NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
these NN NN O
other NN NN O
potential NN NN O
causes NN NN O
of NN NN O
seizure NN NN B-Disease
were NN NN O
ruled NN NN O
out NN NN O
. NN NN O
   
The NN NN O
time NN NN O
course NN NN O
of NN NN O
events NN NN O
suggested NN NN O
that NN NN O
amphotericin NN NN O
B NN NN O
was NN NN O
the NN NN O
cause NN NN O
of NN NN O
the NN NN O
seizures NN NN B-Disease
in NN NN O
this NN NN O
AIDS NN NN B-Disease
patient NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Amphotericin NN NN O
B NN NN O
seems NN NN O
to NN NN O
be NN NN O
the NN NN O
probable NN NN O
cause NN NN O
of NN NN O
the NN NN O
seizures NN NN B-Disease
. NN NN O
   
To NN NN O
date NN NN O
, NN NN O
only NN NN O
three NN NN O
cases NN NN O
of NN NN O
seizures NN NN B-Disease
associated NN NN O
with NN NN O
amphotericin NN NN O
B NN NN O
have NN NN O
been NN NN O
reported NN NN O
in NN NN O
the NN NN O
literature NN NN O
, NN NN O
but NN NN O
healthcare NN NN O
providers NN NN O
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
the NN NN O
potential NN NN O
for NN NN O
this NN NN O
rare NN NN O
adverse NN NN O
effect NN NN O
. NN NN O
   
Sirolimus NN NN O
and NN NN O
mycophenolate NN NN O
mofetil NN NN O
for NN NN O
calcineurin NN NN O
- NN NN O
free NN NN O
immunosuppression NN NN O
in NN NN O
renal NN NN O
transplant NN NN O
recipients NN NN O
. NN NN O
   
Calcineurin NN NN O
inhibitors NN NN O
, NN NN O
such NN NN O
as NN NN O
cyclosporine NN NN O
and NN NN O
tacrolimus NN NN O
, NN NN O
have NN NN O
been NN NN O
available NN NN O
for NN NN O
almost NN NN O
20 NN NN O
years NN NN O
. NN NN O
   
Although NN NN O
these NN NN O
drugs NN NN O
are NN NN O
highly NN NN O
effective NN NN O
and NN NN O
represent NN NN O
the NN NN O
mainstay NN NN O
of NN NN O
transplant NN NN O
immunosuppression NN NN O
, NN NN O
they NN NN O
are NN NN O
associated NN NN O
with NN NN O
acute NN NN O
and NN NN O
chronic NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
Acute NN NN O
nephrotoxicity NN NN B-Disease
, NN NN O
which NN NN O
occurs NN NN O
in NN NN O
the NN NN O
early NN NN O
period NN NN O
after NN NN O
transplantation NN NN O
, NN NN O
leads NN NN O
to NN NN O
a NN NN O
higher NN NN O
rate NN NN O
of NN NN O
dialysis NN NN O
, NN NN O
and NN NN O
chronic NN NN O
nephrotoxicity NN NN B-Disease
may NN NN O
eventually NN NN O
result NN NN O
in NN NN O
graft NN NN O
loss NN NN O
. NN NN O
   
Acute NN NN O
and NN NN O
chronic NN NN O
nephrotoxicity NN NN B-Disease
is NN NN O
becoming NN NN O
more NN NN O
common NN NN O
as NN NN O
the NN NN O
use NN NN O
of NN NN O
marginal NN NN O
kidneys NN NN O
for NN NN O
transplantation NN NN O
increases NN NN O
. NN NN O
   
Two NN NN O
recently NN NN O
available NN NN O
immunosuppressive NN NN O
agents NN NN O
, NN NN O
mycophenolate NN NN O
mofetil NN NN O
and NN NN O
sirolimus NN NN O
( NN NN O
rapamycin NN NN O
) NN NN O
, NN NN O
have NN NN O
no NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
The NN NN O
use NN NN O
of NN NN O
these NN NN O
drugs NN NN O
in NN NN O
combination NN NN O
with NN NN O
other NN NN O
agents NN NN O
has NN NN O
led NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
new NN NN O
paradigms NN NN O
of NN NN O
immunosuppressive NN NN O
therapy NN NN O
. NN NN O
   
This NN NN O
paper NN NN O
reviews NN NN O
the NN NN O
results NN NN O
of NN NN O
clinical NN NN O
trials NN NN O
that NN NN O
have NN NN O
investigated NN NN O
these NN NN O
new NN NN O
approaches NN NN O
to NN NN O
immunosuppression NN NN O
in NN NN O
renal NN NN O
transplant NN NN O
recipients NN NN O
. NN NN O
   
Tolerability NN NN O
of NN NN O
nimesulide NN NN O
and NN NN O
paracetamol NN NN O
in NN NN O
patients NN NN O
with NN NN O
NSAID NN NN O
- NN NN O
induced NN NN O
urticaria NN NN B-Disease
/ NN NN O
angioedema NN NN B-Disease
. NN NN O
   
Previous NN NN O
studies NN NN O
evaluated NN NN O
the NN NN O
tolerance NN NN O
of NN NN O
nimesulide NN NN O
and NN NN O
paracetamol NN NN O
in NN NN O
subjects NN NN O
with NN NN O
cutaneous NN NN O
, NN NN O
respiratory NN NN O
and NN NN O
anaphylactoid NN NN O
reactions NN NN O
induced NN NN O
by NN NN O
nonsteroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
( NN NN O
NSAIDs NN NN O
) NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
investigated NN NN O
tolerability NN NN O
and NN NN O
reliability NN NN O
of NN NN O
nimesulide NN NN O
and NN NN O
paracetamol NN NN O
in NN NN O
a NN NN O
very NN NN O
large NN NN O
number NN NN O
of NN NN O
patients NN NN O
with NN NN O
an NN NN O
exclusive NN NN O
well NN NN O
- NN NN O
documented NN NN O
history NN NN O
of NN NN O
NSAID NN NN O
- NN NN O
induced NN NN O
urticaria NN NN B-Disease
/ NN NN O
angioedema NN NN B-Disease
. NN NN O
   
Furthermore NN NN O
, NN NN O
we NN NN O
evaluated NN NN O
whether NN NN O
some NN NN O
factors NN NN O
have NN NN O
the NN NN O
potential NN NN O
to NN NN O
increase NN NN O
the NN NN O
risk NN NN O
of NN NN O
reaction NN NN O
to NN NN O
paracetamol NN NN O
and NN NN O
nimesulide NN NN O
. NN NN O
   
A NN NN O
single NN NN O
- NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
oral NN NN O
challenge NN NN O
procedure NN NN O
with NN NN O
nimesulide NN NN O
or NN NN O
paracetamol NN NN O
was NN NN O
applied NN NN O
to NN NN O
829 NN NN O
patients NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
NSAID NN NN O
- NN NN O
induced NN NN O
urticaria NN NN B-Disease
/ NN NN O
angioedema NN NN B-Disease
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
75 NN NN O
/ NN NN O
829 NN NN O
( NN NN O
9 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
patients NN NN O
experienced NN NN O
reactions NN NN O
to NN NN O
nimesulide NN NN O
or NN NN O
paracetamol NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
715 NN NN O
patients NN NN O
tested NN NN O
with NN NN O
nimesulide NN NN O
62 NN NN O
( NN NN O
8 NN NN O
. NN NN O
6 NN NN O
% NN NN O
) NN NN O
showed NN NN O
a NN NN O
positive NN NN O
test NN NN O
, NN NN O
while NN NN O
of NN NN O
114 NN NN O
subjects NN NN O
submitted NN NN O
to NN NN O
the NN NN O
challenge NN NN O
with NN NN O
paracetamol NN NN O
, NN NN O
13 NN NN O
( NN NN O
9 NN NN O
. NN NN O
6 NN NN O
% NN NN O
) NN NN O
did NN NN O
not NN NN O
tolerate NN NN O
this NN NN O
drug NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
18 NN NN O
. NN NN O
28 NN NN O
% NN NN O
of NN NN O
patients NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
chronic NN NN O
urticaria NN NN B-Disease
and NN NN O
11 NN NN O
. NN NN O
8 NN NN O
% NN NN O
of NN NN O
subjects NN NN O
with NN NN O
an NN NN O
history NN NN O
of NN NN O
NSAID NN NN O
- NN NN O
induced NN NN O
urticaria NN NN B-Disease
/ NN NN O
angioedema NN NN B-Disease
or NN NN O
angioedema NN NN B-Disease
alone NN NN O
( NN NN O
with NN NN O
or NN NN O
without NN NN O
chronic NN NN O
urticaria NN NN B-Disease
) NN NN O
resulted NN NN O
to NN NN O
be NN NN O
intolerant NN NN O
to NN NN O
alternative NN NN O
drugs NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
our NN NN O
results NN NN O
confirm NN NN O
the NN NN O
good NN NN O
tolerability NN NN O
of NN NN O
nimesulide NN NN O
and NN NN O
paracetamol NN NN O
in NN NN O
patients NN NN O
who NN NN O
experienced NN NN O
urticaria NN NN B-Disease
/ NN NN O
angioedema NN NN B-Disease
caused NN NN O
by NN NN O
NSAIDs NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
risk NN NN O
of NN NN O
reaction NN NN O
to NN NN O
these NN NN O
alternative NN NN O
study NN NN O
drugs NN NN O
is NN NN O
statistically NN NN O
increased NN NN O
by NN NN O
a NN NN O
history NN NN O
of NN NN O
chronic NN NN O
urticaria NN NN B-Disease
and NN NN O
, NN NN O
above NN NN O
all NN NN O
, NN NN O
by NN NN O
a NN NN O
history NN NN O
of NN NN O
NSAID NN NN O
- NN NN O
induced NN NN O
angioedema NN NN B-Disease
. NN NN O
   
Comparison NN NN O
of NN NN O
aqueous NN NN O
and NN NN O
gellan NN NN O
ophthalmic NN NN O
timolol NN NN O
with NN NN O
placebo NN NN O
on NN NN O
the NN NN O
24 NN NN O
- NN NN O
hour NN NN O
heart NN NN O
rate NN NN O
response NN NN O
in NN NN O
patients NN NN O
on NN NN O
treatment NN NN O
for NN NN O
glaucoma NN NN B-Disease
. NN NN O
   
PURPOSE NN NN O
: NN NN O
Topical NN NN O
beta NN NN O
- NN NN O
blocker NN NN O
treatment NN NN O
is NN NN O
routine NN NN O
therapy NN NN O
in NN NN O
the NN NN O
management NN NN O
of NN NN O
patients NN NN O
with NN NN O
glaucoma NN NN B-Disease
. NN NN O
   
Therapy NN NN O
results NN NN O
in NN NN O
systemic NN NN O
absorption NN NN O
, NN NN O
however NN NN O
, NN NN O
the NN NN O
degree NN NN O
of NN NN O
reduction NN NN O
of NN NN O
resting NN NN O
and NN NN O
peak NN NN O
heart NN NN O
rate NN NN O
has NN NN O
not NN NN O
been NN NN O
quantified NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
This NN NN O
trial NN NN O
evaluated NN NN O
the NN NN O
effect NN NN O
of NN NN O
placebo NN NN O
, NN NN O
0 NN NN O
. NN NN O
5 NN NN O
% NN NN O
aqueous NN NN O
timolol NN NN O
( NN NN O
timolol NN NN O
solution NN NN O
) NN NN O
and NN NN O
a NN NN O
0 NN NN O
. NN NN O
5 NN NN O
% NN NN O
timolol NN NN O
suspension NN NN O
that NN NN O
forms NN NN O
a NN NN O
gel NN NN O
on NN NN O
application NN NN O
to NN NN O
the NN NN O
conjunctiva NN NN O
( NN NN O
timolol NN NN O
gellan NN NN O
) NN NN O
on NN NN O
the NN NN O
24 NN NN O
- NN NN O
hour NN NN O
heart NN NN O
rate NN NN O
in NN NN O
patients NN NN O
currently NN NN O
being NN NN O
treated NN NN O
for NN NN O
glaucoma NN NN B-Disease
to NN NN O
quantify NN NN O
the NN NN O
reduction NN NN O
in NN NN O
mean NN NN O
heart NN NN O
rate NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Forty NN NN O
- NN NN O
three NN NN O
Caucasian NN NN O
patients NN NN O
with NN NN O
primary NN NN O
open NN NN B-Disease
- NN NN I-Disease
angle NN NN I-Disease
glaucoma NN NN I-Disease
or NN NN O
ocular NN NN B-Disease
hypertension NN NN I-Disease
with NN NN O
a NN NN O
mean NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
) NN NN O
age NN NN O
of NN NN O
63 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
8 NN NN O
) NN NN O
years NN NN O
were NN NN O
randomized NN NN O
and NN NN O
crossed NN NN O
over NN NN O
in NN NN O
a NN NN O
double NN NN O
- NN NN O
masked NN NN O
manner NN NN O
to NN NN O
14 NN NN O
days NN NN O
of NN NN O
treatment NN NN O
with NN NN O
placebo NN NN O
( NN NN O
morning NN NN O
and NN NN O
evening NN NN O
in NN NN O
both NN NN O
eyes NN NN O
) NN NN O
, NN NN O
timolol NN NN O
solution NN NN O
( NN NN O
morning NN NN O
and NN NN O
evening NN NN O
in NN NN O
both NN NN O
eyes NN NN O
) NN NN O
, NN NN O
or NN NN O
timolol NN NN O
gellan NN NN O
( NN NN O
morning NN NN O
in NN NN O
both NN NN O
eyes NN NN O
with NN NN O
placebo NN NN O
in NN NN O
the NN NN O
evening NN NN O
) NN NN O
. NN NN O
   
On NN NN O
the NN NN O
13th NN NN O
day NN NN O
of NN NN O
each NN NN O
period NN NN O
, NN NN O
heart NN NN O
rate NN NN O
was NN NN O
recorded NN NN O
continuously NN NN O
during NN NN O
a NN NN O
typical NN NN O
, NN NN O
ambulant NN NN O
24 NN NN O
- NN NN O
hour NN NN O
period NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Both NN NN O
timolol NN NN O
solution NN NN O
and NN NN O
timolol NN NN O
gellan NN NN O
reduced NN NN O
the NN NN O
mean NN NN O
24 NN NN O
- NN NN O
hour NN NN O
heart NN NN O
rate NN NN O
compared NN NN O
with NN NN O
placebo NN NN O
( NN NN O
P NN NN O
< NN NN O
or NN NN O
= NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
and NN NN O
this NN NN O
reduction NN NN O
was NN NN O
most NN NN O
pronounced NN NN O
during NN NN O
the NN NN O
daytime NN NN O
( NN NN O
- NN NN O
7 NN NN O
. NN NN O
5 NN NN O
% NN NN O
change NN NN O
in NN NN O
mean NN NN O
heart NN NN O
rate NN NN O
, NN NN O
- NN NN O
5 NN NN O
. NN NN O
7 NN NN O
beats NN NN O
/ NN NN O
min NN NN O
) NN NN O
. NN NN O
   
Timolol NN NN O
gellan NN NN O
showed NN NN O
a NN NN O
numerically NN NN O
but NN NN O
not NN NN O
significantly NN NN O
smaller NN NN O
reduction NN NN O
in NN NN O
24 NN NN O
- NN NN O
hour NN NN O
heart NN NN O
rate NN NN O
, NN NN O
compared NN NN O
with NN NN O
timolol NN NN O
solution NN NN O
. NN NN O
   
During NN NN O
the NN NN O
night NN NN O
, NN NN O
the NN NN O
mean NN NN O
12 NN NN O
- NN NN O
hour NN NN O
heart NN NN O
rate NN NN O
on NN NN O
placebo NN NN O
and NN NN O
timolol NN NN O
gellan NN NN O
were NN NN O
both NN NN O
significantly NN NN O
less NN NN O
than NN NN O
on NN NN O
timolol NN NN O
solution NN NN O
; NN NN O
the NN NN O
difference NN NN O
between NN NN O
solution NN NN O
and NN NN O
gellan NN NN O
treatments NN NN O
was NN NN O
statistically NN NN O
significant NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Both NN NN O
timolol NN NN O
solution NN NN O
and NN NN O
timolol NN NN O
gellan NN NN O
decrease NN NN O
the NN NN O
mean NN NN O
24 NN NN O
- NN NN O
hour NN NN O
heart NN NN O
rate NN NN O
compared NN NN O
with NN NN O
placebo NN NN O
. NN NN O
   
This NN NN O
response NN NN O
was NN NN O
most NN NN O
pronounced NN NN O
during NN NN O
the NN NN O
active NN NN O
daytime NN NN O
period NN NN O
. NN NN O
   
These NN NN O
data NN NN O
quantify NN NN O
the NN NN O
modest NN NN O
bradycardia NN NN B-Disease
associated NN NN O
with NN NN O
ophthalmic NN NN O
beta NN NN O
- NN NN O
blocker NN NN O
therapy NN NN O
in NN NN O
a NN NN O
typical NN NN O
patient NN NN O
population NN NN O
on NN NN O
therapy NN NN O
for NN NN O
glaucoma NN NN B-Disease
. NN NN O
   
Although NN NN O
exercise NN NN O
performance NN NN O
was NN NN O
not NN NN O
assessed NN NN O
in NN NN O
this NN NN O
trial NN NN O
, NN NN O
reductions NN NN O
of NN NN O
this NN NN O
magnitude NN NN O
should NN NN O
not NN NN O
have NN NN O
substantial NN NN O
clinical NN NN O
consequences NN NN O
. NN NN O
   
Management NN NN O
strategies NN NN O
for NN NN O
ribavirin NN NN O
- NN NN O
induced NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
hepatitis NN NN B-Disease
C NN NN I-Disease
: NN NN O
clinical NN NN O
and NN NN O
economic NN NN O
implications NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
Recently NN NN O
published NN NN O
studies NN NN O
have NN NN O
demonstrated NN NN O
increased NN NN O
efficacy NN NN O
and NN NN O
cost NN NN O
- NN NN O
effectiveness NN NN O
of NN NN O
combination NN NN O
therapy NN NN O
with NN NN O
interferon NN NN O
and NN NN O
alpha NN NN O
- NN NN O
2b NN NN O
/ NN NN O
ribavirin NN NN O
compared NN NN O
with NN NN O
interferon NN NN O
- NN NN O
alpha NN NN O
monotherapy NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
chronic NN NN B-Disease
hepatitis NN NN I-Disease
C NN NN I-Disease
( NN NN O
CHC NN NN B-Disease
) NN NN O
. NN NN O
   
Combination NN NN O
therapy NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
clinically NN NN O
important NN NN O
adverse NN NN O
effect NN NN O
: NN NN O
ribavirin NN NN O
- NN NN O
induced NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
( NN NN O
RIHA NN NN B-Disease
) NN NN O
. NN NN O
   
The NN NN O
objective NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
direct NN NN O
health NN NN O
- NN NN O
care NN NN O
costs NN NN O
and NN NN O
management NN NN O
of NN NN O
RIHA NN NN B-Disease
during NN NN O
treatment NN NN O
of NN NN O
CHC NN NN B-Disease
in NN NN O
a NN NN O
clinical NN NN O
trial NN NN O
setting NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
A NN NN O
systematic NN NN O
literature NN NN O
review NN NN O
was NN NN O
conducted NN NN O
to NN NN O
synthesize NN NN O
information NN NN O
on NN NN O
the NN NN O
incidence NN NN O
and NN NN O
management NN NN O
of NN NN O
RIHA NN NN B-Disease
. NN NN O
   
Decision NN NN O
- NN NN O
analytic NN NN O
techniques NN NN O
were NN NN O
used NN NN O
to NN NN O
estimate NN NN O
the NN NN O
cost NN NN O
of NN NN O
treating NN NN O
RIHA NN NN B-Disease
. NN NN O
   
Uncertainty NN NN O
was NN NN O
evaluated NN NN O
using NN NN O
sensitivity NN NN O
analyses NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
RIHA NN NN B-Disease
, NN NN O
defined NN NN O
as NN NN O
a NN NN O
reduction NN NN O
in NN NN O
hemoglobin NN NN O
to NN NN O
less NN NN O
than NN NN O
100 NN NN O
g NN NN O
/ NN NN O
L NN NN O
, NN NN O
occurs NN NN O
in NN NN O
approximately NN NN O
7 NN NN O
% NN NN O
to NN NN O
9 NN NN O
% NN NN O
of NN NN O
patients NN NN O
treated NN NN O
with NN NN O
combination NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
standard NN NN O
of NN NN O
care NN NN O
for NN NN O
management NN NN O
of NN NN O
RIHA NN NN B-Disease
is NN NN O
reduction NN NN O
or NN NN O
discontinuation NN NN O
of NN NN O
the NN NN O
ribavirin NN NN O
dosage NN NN O
. NN NN O
   
We NN NN O
estimated NN NN O
the NN NN O
direct NN NN O
cost NN NN O
of NN NN O
treating NN NN O
clinically NN NN O
significant NN NN O
RIHA NN NN B-Disease
to NN NN O
be NN NN O
170 NN NN O
per NN NN O
patient NN NN O
receiving NN NN O
combination NN NN O
therapy NN NN O
per NN NN O
48 NN NN O
- NN NN O
week NN NN O
treatment NN NN O
course NN NN O
( NN NN O
range NN NN O
68 NN NN O
- NN NN O
692 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
results NN NN O
of NN NN O
the NN NN O
one NN NN O
- NN NN O
way NN NN O
sensitivity NN NN O
analyses NN NN O
ranged NN NN O
from NN NN O
57 NN NN O
to NN NN O
317 NN NN O
. NN NN O
   
In NN NN O
comparison NN NN O
, NN NN O
the NN NN O
cost NN NN O
of NN NN O
48 NN NN O
weeks NN NN O
of NN NN O
combination NN NN O
therapy NN NN O
is NN NN O
16 NN NN O
, NN NN O
459 NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
direct NN NN O
cost NN NN O
of NN NN O
treating NN NN O
clinically NN NN O
significant NN NN O
RIHA NN NN B-Disease
is NN NN O
1 NN NN O
% NN NN O
( NN NN O
170 NN NN O
/ NN NN O
16 NN NN O
, NN NN O
459 NN NN O
) NN NN O
of NN NN O
drug NN NN O
treatment NN NN O
costs NN NN O
. NN NN O
   
Questions NN NN O
remain NN NN O
about NN NN O
the NN NN O
optimal NN NN O
dose NN NN O
of NN NN O
ribavirin NN NN O
and NN NN O
the NN NN O
incidence NN NN O
of NN NN O
RIHA NN NN B-Disease
in NN NN O
a NN NN O
real NN NN O
- NN NN O
world NN NN O
population NN NN O
. NN NN O
   
Despite NN NN O
these NN NN O
uncertainties NN NN O
, NN NN O
this NN NN O
initial NN NN O
evaluation NN NN O
of NN NN O
the NN NN O
direct NN NN O
cost NN NN O
of NN NN O
treating NN NN O
RIHA NN NN B-Disease
provides NN NN O
an NN NN O
estimate NN NN O
of NN NN O
the NN NN O
cost NN NN O
and NN NN O
management NN NN O
implications NN NN O
of NN NN O
this NN NN O
clinically NN NN O
important NN NN O
adverse NN NN O
effect NN NN O
. NN NN O
   
Preliminary NN NN O
efficacy NN NN O
assessment NN NN O
of NN NN O
intrathecal NN NN O
injection NN NN O
of NN NN O
an NN NN O
American NN NN O
formulation NN NN O
of NN NN O
adenosine NN NN O
in NN NN O
humans NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Preclinical NN NN O
studies NN NN O
of NN NN O
intrathecal NN NN O
adenosine NN NN O
suggest NN NN O
it NN NN O
may NN NN O
be NN NN O
effective NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
acute NN NN B-Disease
and NN NN I-Disease
chronic NN NN I-Disease
pain NN NN I-Disease
in NN NN O
humans NN NN O
, NN NN O
and NN NN O
preliminary NN NN O
studies NN NN O
in NN NN O
volunteers NN NN O
and NN NN O
patients NN NN O
with NN NN O
a NN NN O
Swedish NN NN O
formulation NN NN O
of NN NN O
adenosine NN NN O
suggests NN NN O
it NN NN O
may NN NN O
be NN NN O
effective NN NN O
in NN NN O
hypersensitivity NN NN B-Disease
states NN NN O
but NN NN O
not NN NN O
with NN NN O
acute NN NN O
noxious NN NN O
stimulation NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
screen NN NN O
for NN NN O
efficacy NN NN O
of NN NN O
a NN NN O
different NN NN O
formulation NN NN O
of NN NN O
adenosine NN NN O
marketed NN NN O
in NN NN O
the NN NN O
US NN NN O
, NN NN O
using NN NN O
both NN NN O
acute NN NN O
noxious NN NN O
stimulation NN NN O
and NN NN O
capsaicin NN NN O
- NN NN O
evoked NN NN O
mechanical NN NN O
hypersensitivity NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Following NN NN O
Food NN NN O
and NN NN O
Drug NN NN O
Administration NN NN O
and NN NN O
institutional NN NN O
review NN NN O
board NN NN O
approval NN NN O
and NN NN O
written NN NN O
informed NN NN O
consent NN NN O
, NN NN O
65 NN NN O
volunteers NN NN O
were NN NN O
studied NN NN O
in NN NN O
two NN NN O
trials NN NN O
: NN NN O
an NN NN O
open NN NN O
- NN NN O
label NN NN O
, NN NN O
dose NN NN O
- NN NN O
escalating NN NN O
trial NN NN O
with NN NN O
intrathecal NN NN O
adenosine NN NN O
doses NN NN O
of NN NN O
0 NN NN O
. NN NN O
25 NN NN O
- NN NN O
2 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
and NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
trial NN NN O
of NN NN O
adenosine NN NN O
, NN NN O
2 NN NN O
mg NN NN O
. NN NN O
   
Cerebrospinal NN NN O
fluid NN NN O
was NN NN O
obtained NN NN O
for NN NN O
pharmacokinetic NN NN O
analysis NN NN O
, NN NN O
and NN NN O
pain NN NN B-Disease
ratings NN NN O
in NN NN O
response NN NN O
to NN NN O
acute NN NN O
heat NN NN O
stimuli NN NN O
and NN NN O
areas NN NN O
of NN NN O
mechanical NN NN B-Disease
hyperalgesia NN NN I-Disease
and NN NN O
allodynia NN NN B-Disease
after NN NN O
intradermal NN NN O
capsaicin NN NN O
injection NN NN O
were NN NN O
determined NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Adenosine NN NN O
produced NN NN O
no NN NN O
effect NN NN O
on NN NN O
pain NN NN B-Disease
report NN NN O
to NN NN O
acute NN NN O
noxious NN NN O
thermal NN NN O
or NN NN O
chemical NN NN O
stimulation NN NN O
but NN NN O
reduced NN NN O
mechanical NN NN B-Disease
hyperalgesia NN NN I-Disease
and NN NN O
allodynia NN NN B-Disease
from NN NN O
intradermal NN NN O
capsaicin NN NN O
injection NN NN O
for NN NN O
at NN NN O
least NN NN O
24 NN NN O
h NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
residence NN NN O
time NN NN O
of NN NN O
adenosine NN NN O
in NN NN O
cerebrospinal NN NN O
fluid NN NN O
was NN NN O
short NN NN O
( NN NN O
< NN NN O
4 NN NN O
h NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
These NN NN O
results NN NN O
show NN NN O
selective NN NN O
inhibition NN NN O
by NN NN O
intrathecal NN NN O
adenosine NN NN O
of NN NN O
hypersensitivity NN NN B-Disease
, NN NN O
presumed NN NN O
to NN NN O
reflect NN NN O
central NN NN O
sensitization NN NN O
in NN NN O
humans NN NN O
after NN NN O
peripheral NN NN O
capsaicin NN NN O
injection NN NN O
. NN NN O
   
The NN NN O
long NN NN O
- NN NN O
lasting NN NN O
effect NN NN O
is NN NN O
consistent NN NN O
with NN NN O
that NN NN O
observed NN NN O
in NN NN O
preliminary NN NN O
reports NN NN O
of NN NN O
patients NN NN O
with NN NN O
chronic NN NN O
neuropathic NN NN B-Disease
pain NN NN I-Disease
and NN NN O
is NN NN O
not NN NN O
due NN NN O
to NN NN O
prolonged NN NN O
residence NN NN O
of NN NN O
adenosine NN NN O
in NN NN O
cerebrospinal NN NN O
fluid NN NN O
. NN NN O
   
Delayed NN NN O
- NN NN O
onset NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
presents NN NN O
5 NN NN O
to NN NN O
12 NN NN O
days NN NN O
after NN NN O
heparin NN NN O
exposure NN NN O
, NN NN O
with NN NN O
or NN NN O
without NN NN O
arterial NN NN B-Disease
or NN NN I-Disease
venous NN NN I-Disease
thromboemboli NN NN I-Disease
. NN NN O
   
Delayed NN NN O
recognition NN NN O
and NN NN O
treatment NN NN O
of NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
contribute NN NN O
to NN NN O
poor NN NN O
patient NN NN O
outcomes NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
describe NN NN O
and NN NN O
increase NN NN O
awareness NN NN O
of NN NN O
a NN NN O
clinical NN NN O
scenario NN NN O
in NN NN O
which NN NN O
the NN NN O
onset NN NN O
or NN NN O
manifestations NN NN O
of NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
are NN NN O
delayed NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
Retrospective NN NN O
case NN NN O
series NN NN O
. NN NN O
   
SETTING NN NN O
: NN NN O
Three NN NN O
large NN NN O
urban NN NN O
hospitals NN NN O
( NN NN O
with NN NN O
active NN NN O
cardiovascular NN NN O
surgery NN NN O
programs NN NN O
) NN NN O
. NN NN O
   
PATIENTS NN NN O
: NN NN O
14 NN NN O
patients NN NN O
seen NN NN O
over NN NN O
a NN NN O
3 NN NN O
- NN NN O
year NN NN O
period NN NN O
in NN NN O
whom NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
became NN NN O
apparent NN NN O
on NN NN O
delayed NN NN O
presentation NN NN O
with NN NN O
thromboembolic NN NN B-Disease
complications NN NN O
. NN NN O
   
MEASUREMENTS NN NN O
: NN NN O
Platelet NN NN O
counts NN NN O
, NN NN O
onset NN NN O
of NN NN O
objectively NN NN O
determined NN NN O
thromboembolism NN NN B-Disease
, NN NN O
results NN NN O
of NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
platelet NN NN O
factor NN NN O
4 NN NN O
antibody NN NN O
tests NN NN O
, NN NN O
and NN NN O
outcomes NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Patients NN NN O
went NN NN O
home NN NN O
after NN NN O
hospitalizations NN NN O
that NN NN O
had NN NN O
included NN NN O
heparin NN NN O
exposure NN NN O
- NN NN O
- NN NN O
in NN NN O
most NN NN O
cases NN NN O
, NN NN O
with NN NN O
no NN NN O
thrombocytopenia NN NN B-Disease
recognized NN NN O
- NN NN O
- NN NN O
only NN NN O
to NN NN O
return NN NN O
to NN NN O
the NN NN O
hospital NN NN O
( NN NN O
median NN NN O
, NN NN O
day NN NN O
14 NN NN O
) NN NN O
with NN NN O
thromboembolic NN NN B-Disease
complications NN NN O
. NN NN O
   
Thromboemboli NN NN B-Disease
were NN NN O
venous NN NN O
( NN NN O
12 NN NN O
patients NN NN O
, NN NN O
7 NN NN O
with NN NN O
pulmonary NN NN B-Disease
emboli NN NN I-Disease
) NN NN O
or NN NN O
arterial NN NN O
( NN NN O
4 NN NN O
patients NN NN O
) NN NN O
or NN NN O
both NN NN O
. NN NN O
   
Platelet NN NN O
counts NN NN O
were NN NN O
mildly NN NN O
decreased NN NN O
in NN NN O
all NN NN O
but NN NN O
2 NN NN O
patients NN NN O
on NN NN O
second NN NN O
presentation NN NN O
. NN NN O
   
On NN NN O
readmission NN NN O
, NN NN O
11 NN NN O
patients NN NN O
received NN NN O
therapeutic NN NN O
heparin NN NN O
, NN NN O
which NN NN O
worsened NN NN O
the NN NN O
patients NN NN O
' NN NN O
clinical NN NN O
condition NN NN O
and NN NN O
, NN NN O
in NN NN O
all NN NN O
11 NN NN O
cases NN NN O
, NN NN O
decreased NN NN O
the NN NN O
platelet NN NN O
count NN NN O
( NN NN O
mean NN NN O
at NN NN O
readmission NN NN O
, NN NN O
143 NN NN O
x NN NN O
10 NN NN O
( NN NN O
9 NN NN O
) NN NN O
cells NN NN O
/ NN NN O
L NN NN O
; NN NN O
mean NN NN O
nadir NN NN O
after NN NN O
heparin NN NN O
re NN NN O
- NN NN O
exposure NN NN O
, NN NN O
39 NN NN O
x NN NN O
10 NN NN O
( NN NN O
9 NN NN O
) NN NN O
cells NN NN O
/ NN NN O
L NN NN O
) NN NN O
. NN NN O
   
Results NN NN O
of NN NN O
serologic NN NN O
tests NN NN O
for NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
antibodies NN NN O
were NN NN O
positive NN NN O
in NN NN O
all NN NN O
patients NN NN O
. NN NN O
   
Subsequent NN NN O
treatments NN NN O
included NN NN O
alternative NN NN O
anticoagulants NN NN O
( NN NN O
11 NN NN O
patients NN NN O
) NN NN O
, NN NN O
thrombolytic NN NN O
drugs NN NN O
( NN NN O
3 NN NN O
patients NN NN O
) NN NN O
, NN NN O
inferior NN NN O
vena NN NN O
cava NN NN O
filters NN NN O
( NN NN O
3 NN NN O
patients NN NN O
) NN NN O
and NN NN O
, NN NN O
eventually NN NN O
, NN NN O
warfarin NN NN O
( NN NN O
11 NN NN O
patients NN NN O
) NN NN O
. NN NN O
   
Three NN NN O
patients NN NN O
died NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Delayed NN NN O
- NN NN O
onset NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
is NN NN O
increasingly NN NN O
being NN NN O
recognized NN NN O
. NN NN O
   
To NN NN O
avoid NN NN O
disastrous NN NN O
outcomes NN NN O
, NN NN O
physicians NN NN O
must NN NN O
consider NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
whenever NN NN O
a NN NN O
recently NN NN O
hospitalized NN NN O
patient NN NN O
returns NN NN O
with NN NN O
thromboembolism NN NN B-Disease
; NN NN O
therapy NN NN O
with NN NN O
alternative NN NN O
anticoagulants NN NN O
, NN NN O
not NN NN O
heparin NN NN O
, NN NN O
should NN NN O
be NN NN O
initiated NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
risperidone NN NN O
- NN NN O
induced NN NN O
hyperprolactinemia NN NN B-Disease
with NN NN O
a NN NN O
dopamine NN NN O
agonist NN NN O
in NN NN O
children NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Risperidone NN NN O
, NN NN O
a NN NN O
potent NN NN O
antagonist NN NN O
of NN NN O
both NN NN O
serotonergic NN NN O
( NN NN O
5HT2A NN NN O
) NN NN O
and NN NN O
dopaminergic NN NN O
D2 NN NN O
receptors NN NN O
is NN NN O
associated NN NN O
with NN NN O
hyperprolactinemia NN NN B-Disease
in NN NN O
adults NN NN O
and NN NN O
children NN NN O
. NN NN O
   
Chronically NN NN O
elevated NN NN O
prolactin NN NN O
levels NN NN O
in NN NN O
children NN NN O
with NN NN O
prolactinomas NN NN B-Disease
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
arrested NN NN O
growth NN NN O
and NN NN O
development NN NN O
resulting NN NN O
in NN NN O
either NN NN O
delayed NN NN B-Disease
puberty NN NN I-Disease
or NN NN O
short NN NN O
stature NN NN O
. NN NN O
   
These NN NN O
possibilities NN NN O
stress NN NN O
the NN NN O
importance NN NN O
of NN NN O
developing NN NN O
a NN NN O
safe NN NN O
and NN NN O
effective NN NN O
approach NN NN O
to NN NN O
drug NN NN O
- NN NN O
induced NN NN O
hyperprolactinemia NN NN B-Disease
in NN NN O
youth NN NN O
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
successful NN NN O
treatment NN NN O
of NN NN O
risperidone NN NN O
- NN NN O
induced NN NN O
hyperprolactinemia NN NN B-Disease
with NN NN O
cabergoline NN NN O
in NN NN O
youth NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
undertook NN NN O
a NN NN O
retrospective NN NN O
case NN NN O
review NN NN O
of NN NN O
four NN NN O
children NN NN O
with NN NN O
risperidone NN NN O
- NN NN O
induced NN NN O
hyperprolactinemia NN NN B-Disease
treated NN NN O
with NN NN O
cabergoline NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Four NN NN O
males NN NN O
( NN NN O
age NN NN O
6 NN NN O
- NN NN O
11 NN NN O
years NN NN O
) NN NN O
with NN NN O
Diagnostic NN NN O
and NN NN O
Statistical NN NN O
Manual NN NN O
of NN NN O
Mental NN NN B-Disease
Disorders NN NN I-Disease
( NN NN O
fourth NN NN O
edition NN NN O
) NN NN O
bipolar NN NN B-Disease
disorder NN NN I-Disease
or NN NN O
psychoses NN NN B-Disease
, NN NN O
with NN NN O
risperidone NN NN O
- NN NN O
induced NN NN O
elevations NN NN O
in NN NN O
serum NN NN O
prolactin NN NN O
levels NN NN O
( NN NN O
57 NN NN O
. NN NN O
5 NN NN O
- NN NN O
129 NN NN O
ng NN NN O
/ NN NN O
mL NN NN O
, NN NN O
normal NN NN O
5 NN NN O
- NN NN O
15 NN NN O
ng NN NN O
/ NN NN O
mL NN NN O
) NN NN O
, NN NN O
were NN NN O
treated NN NN O
with NN NN O
cabergoline NN NN O
( NN NN O
mean NN NN O
dose NN NN O
2 NN NN O
. NN NN O
13 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
09 NN NN O
mg NN NN O
/ NN NN O
week NN NN O
) NN NN O
. NN NN O
   
When NN NN O
serum NN NN O
prolactin NN NN O
levels NN NN O
normalized NN NN O
in NN NN O
all NN NN O
four NN NN O
subjects NN NN O
( NN NN O
mean NN NN O
11 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
10 NN NN O
. NN NN O
9 NN NN O
ng NN NN O
/ NN NN O
mL NN NN O
) NN NN O
, NN NN O
the NN NN O
cabergoline NN NN O
dose NN NN O
was NN NN O
reduced NN NN O
to NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
week NN NN O
in NN NN O
three NN NN O
of NN NN O
four NN NN O
subjects NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
duration NN NN O
of NN NN O
therapy NN NN O
with NN NN O
cabergoline NN NN O
was NN NN O
523 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
129 NN NN O
. NN NN O
7 NN NN O
days NN NN O
, NN NN O
and NN NN O
the NN NN O
mean NN NN O
duration NN NN O
of NN NN O
therapy NN NN O
with NN NN O
risperidone NN NN O
was NN NN O
788 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
162 NN NN O
. NN NN O
5 NN NN O
days NN NN O
. NN NN O
   
Cabergoline NN NN O
was NN NN O
well NN NN O
tolerated NN NN O
without NN NN O
adverse NN NN O
effects NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Cabergoline NN NN O
may NN NN O
be NN NN O
useful NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
risperidone NN NN O
- NN NN O
induced NN NN O
hyperprolactinemia NN NN B-Disease
in NN NN O
youth NN NN O
; NN NN O
however NN NN O
, NN NN O
further NN NN O
research NN NN O
is NN NN O
needed NN NN O
. NN NN O
   
Acute NN NN O
cholestatic NN NN B-Disease
hepatitis NN NN I-Disease
after NN NN O
exposure NN NN O
to NN NN O
isoflurane NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
acute NN NN O
cholestatic NN NN B-Disease
hepatitis NN NN I-Disease
following NN NN O
exposure NN NN O
to NN NN O
the NN NN O
inhalational NN NN O
anesthetic NN NN O
isoflurane NN NN O
. NN NN O
   
CASE NN NN O
SUMMARY NN NN O
: NN NN O
A NN NN O
70 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
healthy NN NN O
woman NN NN O
from NN NN O
Iraq NN NN O
developed NN NN O
acute NN NN O
cholestatic NN NN B-Disease
hepatitis NN NN I-Disease
3 NN NN O
weeks NN NN O
following NN NN O
repair NN NN O
of NN NN O
the NN NN O
right NN NN O
rotator NN NN O
cuff NN NN O
under NN NN O
general NN NN O
anesthesia NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
evidence NN NN O
for NN NN O
viral NN NN O
, NN NN O
autoimmune NN NN O
, NN NN O
or NN NN O
metabolic NN NN O
causes NN NN O
of NN NN O
hepatitis NN NN B-Disease
. NN NN O
   
No NN NN O
other NN NN O
medications NN NN O
were NN NN O
involved NN NN O
except NN NN O
for NN NN O
dipyrone NN NN O
for NN NN O
analgesia NN NN B-Disease
. NN NN O
   
The NN NN O
alanine NN NN O
aminotransferase NN NN O
was NN NN O
elevated NN NN O
to NN NN O
a NN NN O
peak NN NN O
concentration NN NN O
of NN NN O
1533 NN NN O
U NN NN O
/ NN NN O
L NN NN O
and NN NN O
the NN NN O
serum NN NN O
bilirubin NN NN O
reached NN NN O
a NN NN O
peak NN NN O
of NN NN O
17 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
. NN NN O
   
There NN NN O
was NN NN O
slow NN NN O
improvement NN NN O
over NN NN O
4 NN NN O
months NN NN O
. NN NN O
   
Accidental NN NN O
reexposure NN NN O
by NN NN O
the NN NN O
patient NN NN O
to NN NN O
dipyrone NN NN O
was NN NN O
uneventful NN NN O
. NN NN O
   
DISCUSSION NN NN O
: NN NN O
The NN NN O
clinical NN NN O
and NN NN O
histologic NN NN O
picture NN NN O
of NN NN O
this NN NN O
case NN NN O
resembles NN NN O
halothane NN NN B-Disease
hepatitis NN NN I-Disease
, NN NN O
which NN NN O
has NN NN O
a NN NN O
significant NN NN O
mortality NN NN O
rate NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Isoflurane NN NN O
, NN NN O
a NN NN O
common NN NN O
anesthetic NN NN O
agent NN NN O
, NN NN O
can NN NN O
cause NN NN O
severe NN NN O
cholestatic NN NN B-Disease
hepatitis NN NN I-Disease
. NN NN O
   
Torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
induced NN NN O
by NN NN O
metoclopramide NN NN O
in NN NN O
an NN NN O
elderly NN NN O
woman NN NN O
with NN NN O
preexisting NN NN O
complete NN NN O
left NN NN B-Disease
bundle NN NN I-Disease
branch NN NN I-Disease
block NN NN I-Disease
. NN NN O
   
There NN NN O
is NN NN O
a NN NN O
growing NN NN O
list NN NN O
of NN NN O
drugs NN NN O
implicated NN NN O
in NN NN O
acquired NN NN O
long NN NN B-Disease
QT NN NN I-Disease
syndrome NN NN I-Disease
and NN NN O
torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
torsadogenic NN NN O
potential NN NN O
of NN NN O
metoclopramide NN NN O
, NN NN O
a NN NN O
commonly NN NN O
used NN NN O
antiemetic NN NN O
and NN NN O
prokinetic NN NN O
drug NN NN O
, NN NN O
has NN NN O
not NN NN O
been NN NN O
reported NN NN O
in NN NN O
the NN NN O
literature NN NN O
, NN NN O
despite NN NN O
its NN NN O
chemical NN NN O
similarity NN NN O
to NN NN O
procainamide NN NN O
. NN NN O
   
We NN NN O
report NN NN O
on NN NN O
a NN NN O
92 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
preexisting NN NN O
complete NN NN O
left NN NN B-Disease
bundle NN NN I-Disease
branch NN NN I-Disease
block NN NN I-Disease
who NN NN O
developed NN NN O
torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
after NN NN O
intravenous NN NN O
and NN NN O
oral NN NN O
administration NN NN O
of NN NN O
metoclopramide NN NN O
. NN NN O
   
This NN NN O
patient NN NN O
also NN NN O
developed NN NN O
torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
when NN NN O
cisapride NN NN O
and NN NN O
erythromycin NN NN O
were NN NN O
given NN NN O
simultaneously NN NN O
. NN NN O
   
These NN NN O
two NN NN O
episodes NN NN O
were NN NN O
suppressed NN NN O
successfully NN NN O
after NN NN O
discontinuing NN NN O
the NN NN O
offending NN NN O
drugs NN NN O
and NN NN O
administering NN NN O
class NN NN O
IB NN NN O
drugs NN NN O
. NN NN O
   
This NN NN O
is NN NN O
the NN NN O
first NN NN O
documentation NN NN O
that NN NN O
metoclopramide NN NN O
provokes NN NN O
torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
clinically NN NN O
. NN NN O
   
Metoclopramide NN NN O
should NN NN O
be NN NN O
used NN NN O
cautiously NN NN O
in NN NN O
patients NN NN O
with NN NN O
a NN NN O
risk NN NN O
of NN NN O
torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
. NN NN O
   
Dopamine NN NN O
D2 NN NN O
receptor NN NN O
signaling NN NN O
controls NN NN O
neuronal NN NN O
cell NN NN O
death NN NN O
induced NN NN O
by NN NN O
muscarinic NN NN O
and NN NN O
glutamatergic NN NN O
drugs NN NN O
. NN NN O
   
Dopamine NN NN O
( NN NN O
DA NN NN O
) NN NN O
, NN NN O
through NN NN O
D1 NN NN O
/ NN NN O
D2 NN NN O
receptor NN NN O
- NN NN O
mediated NN NN O
signaling NN NN O
, NN NN O
plays NN NN O
a NN NN O
major NN NN O
role NN NN O
in NN NN O
the NN NN O
control NN NN O
of NN NN O
epileptic NN NN B-Disease
seizures NN NN I-Disease
arising NN NN O
in NN NN O
the NN NN O
limbic NN NN O
system NN NN O
. NN NN O
   
Excitotoxicity NN NN B-Disease
leading NN NN O
to NN NN O
neuronal NN NN O
cell NN NN O
death NN NN O
in NN NN O
the NN NN O
affected NN NN O
areas NN NN O
is NN NN O
a NN NN O
major NN NN O
consequence NN NN O
of NN NN O
seizures NN NN B-Disease
at NN NN O
the NN NN O
cellular NN NN O
level NN NN O
. NN NN O
   
In NN NN O
this NN NN O
respect NN NN O
, NN NN O
little NN NN O
is NN NN O
known NN NN O
about NN NN O
the NN NN O
role NN NN O
of NN NN O
DA NN NN O
receptors NN NN O
in NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
epilepsy NN NN B-Disease
- NN NN O
induced NN NN O
neuronal NN NN O
cell NN NN O
death NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
analyze NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
seizures NN NN B-Disease
and NN NN O
neurotoxicity NN NN B-Disease
in NN NN O
D2R NN NN O
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
treated NN NN O
with NN NN O
the NN NN O
cholinergic NN NN O
agonist NN NN O
pilocarpine NN NN O
. NN NN O
   
We NN NN O
compared NN NN O
these NN NN O
results NN NN O
with NN NN O
those NN NN O
previously NN NN O
obtained NN NN O
with NN NN O
kainic NN NN O
acid NN NN O
( NN NN O
KA NN NN O
) NN NN O
, NN NN O
a NN NN O
potent NN NN O
glutamate NN NN O
agonist NN NN O
. NN NN O
   
Importantly NN NN O
, NN NN O
D2R NN NN O
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
develop NN NN O
seizures NN NN B-Disease
at NN NN O
doses NN NN O
of NN NN O
both NN NN O
drugs NN NN O
that NN NN O
are NN NN O
not NN NN O
epileptogenic NN NN O
for NN NN O
WT NN NN O
littermates NN NN O
and NN NN O
show NN NN O
greater NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
result NN NN O
in NN NN O
a NN NN O
more NN NN O
widespread NN NN O
neuronal NN NN O
death NN NN O
in NN NN O
both NN NN O
WT NN NN O
and NN NN O
D2R NN NN O
- NN NN O
/ NN NN O
- NN NN O
brains NN NN O
in NN NN O
comparison NN NN O
to NN NN O
KA NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
absence NN NN O
of NN NN O
D2R NN NN O
lowers NN NN O
the NN NN O
threshold NN NN O
for NN NN O
seizures NN NN B-Disease
induced NN NN O
by NN NN O
both NN NN O
glutamate NN NN O
and NN NN O
acetylcholine NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
the NN NN O
dopaminergic NN NN O
control NN NN O
of NN NN O
epilepsy NN NN B-Disease
- NN NN O
induced NN NN O
neurodegeneration NN NN B-Disease
seems NN NN O
to NN NN O
be NN NN O
mediated NN NN O
by NN NN O
distinct NN NN O
interactions NN NN O
of NN NN O
D2R NN NN O
signaling NN NN O
with NN NN O
these NN NN O
two NN NN O
neurotransmitters NN NN O
. NN NN O
   
Steroid NN NN O
structure NN NN O
and NN NN O
pharmacological NN NN O
properties NN NN O
determine NN NN O
the NN NN O
anti NN NN O
- NN NN O
amnesic NN NN B-Disease
effects NN NN O
of NN NN O
pregnenolone NN NN O
sulphate NN NN O
in NN NN O
the NN NN O
passive NN NN O
avoidance NN NN O
task NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Pregnenolone NN NN O
sulphate NN NN O
( NN NN O
PREGS NN NN O
) NN NN O
has NN NN O
generated NN NN O
interest NN NN O
as NN NN O
one NN NN O
of NN NN O
the NN NN O
most NN NN O
potent NN NN O
memory NN NN O
- NN NN O
enhancing NN NN O
neurosteroids NN NN O
to NN NN O
be NN NN O
examined NN NN O
in NN NN O
rodent NN NN O
learning NN NN O
studies NN NN O
, NN NN O
with NN NN O
particular NN NN O
importance NN NN O
in NN NN O
the NN NN O
ageing NN NN O
process NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
this NN NN O
endogenous NN NN O
steroid NN NN O
enhances NN NN O
memory NN NN O
formation NN NN O
is NN NN O
hypothesized NN NN O
to NN NN O
involve NN NN O
actions NN NN O
on NN NN O
glutamatergic NN NN O
and NN NN O
GABAergic NN NN O
systems NN NN O
. NN NN O
   
This NN NN O
hypothesis NN NN O
stems NN NN O
from NN NN O
findings NN NN O
that NN NN O
PREGS NN NN O
is NN NN O
a NN NN O
potent NN NN O
positive NN NN O
modulator NN NN O
of NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
d NN NN O
- NN NN O
aspartate NN NN O
receptors NN NN O
( NN NN O
NMDARs NN NN O
) NN NN O
and NN NN O
a NN NN O
negative NN NN O
modulator NN NN O
of NN NN O
gamma NN NN O
- NN NN O
aminobutyric NN NN O
acid NN NN O
( NN NN O
A NN NN O
) NN NN O
receptors NN NN O
( NN NN O
GABA NN NN O
( NN NN O
A NN NN O
) NN NN O
Rs NN NN O
) NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
PREGS NN NN O
is NN NN O
able NN NN O
to NN NN O
reverse NN NN O
the NN NN O
amnesic NN NN B-Disease
- NN NN O
like NN NN O
effects NN NN O
of NN NN O
NMDAR NN NN O
and NN NN O
GABA NN NN O
( NN NN O
A NN NN O
) NN NN O
R NN NN O
ligands NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
this NN NN O
hypothesis NN NN O
, NN NN O
the NN NN O
present NN NN O
study NN NN O
in NN NN O
rats NN NN O
examined NN NN O
the NN NN O
memory NN NN O
- NN NN O
altering NN NN O
abilities NN NN O
of NN NN O
structural NN NN O
analogs NN NN O
of NN NN O
PREGS NN NN O
, NN NN O
which NN NN O
differ NN NN O
in NN NN O
their NN NN O
modulation NN NN O
of NN NN O
NMDAR NN NN O
and NN NN O
/ NN NN O
or NN NN O
GABA NN NN O
( NN NN O
A NN NN O
) NN NN O
R NN NN O
function NN NN O
. NN NN O
   
The NN NN O
analogs NN NN O
tested NN NN O
were NN NN O
: NN NN O
11 NN NN O
- NN NN O
ketopregnenolone NN NN O
sulphate NN NN O
( NN NN O
an NN NN O
agent NN NN O
that NN NN O
is NN NN O
inactive NN NN O
at NN NN O
GABA NN NN O
( NN NN O
A NN NN O
) NN NN O
Rs NN NN O
and NN NN O
NMDARs NN NN O
) NN NN O
, NN NN O
epipregnanolone NN NN O
( NN NN O
[ NN NN O
3beta NN NN O
- NN NN O
hydroxy NN NN O
- NN NN O
5beta NN NN O
- NN NN O
pregnan NN NN O
- NN NN O
20 NN NN O
- NN NN O
one NN NN O
] NN NN O
sulphate NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
both NN NN O
GABA NN NN O
( NN NN O
A NN NN O
) NN NN O
Rs NN NN O
and NN NN O
NMDARs NN NN O
) NN NN O
, NN NN O
and NN NN O
a NN NN O
newly NN NN O
synthesized NN NN O
( NN NN O
- NN NN O
) NN NN O
PREGS NN NN O
enantiomer NN NN O
( NN NN O
which NN NN O
is NN NN O
identical NN NN O
to NN NN O
PREGS NN NN O
in NN NN O
effects NN NN O
on NN NN O
GABA NN NN O
( NN NN O
A NN NN O
) NN NN O
Rs NN NN O
and NN NN O
NMDARs NN NN O
) NN NN O
. NN NN O
   
The NN NN O
memory NN NN O
- NN NN O
enhancing NN NN O
effects NN NN O
of NN NN O
PREGS NN NN O
and NN NN O
its NN NN O
analogs NN NN O
were NN NN O
tested NN NN O
in NN NN O
the NN NN O
passive NN NN O
avoidance NN NN O
task NN NN O
using NN NN O
the NN NN O
model NN NN O
of NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
. NN NN O
   
Both NN NN O
PREGS NN NN O
and NN NN O
its NN NN O
( NN NN O
- NN NN O
) NN NN O
enantiomer NN NN O
blocked NN NN O
the NN NN O
effects NN NN O
of NN NN O
scopolamine NN NN O
. NN NN O
   
The NN NN O
results NN NN O
show NN NN O
that NN NN O
, NN NN O
unlike NN NN O
PREGS NN NN O
, NN NN O
11 NN NN O
- NN NN O
ketopregnenolone NN NN O
sulphate NN NN O
and NN NN O
epipregnanolone NN NN O
sulphate NN NN O
failed NN NN O
to NN NN O
block NN NN O
the NN NN O
effect NN NN O
of NN NN O
scopolamine NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
altering NN NN O
the NN NN O
modulation NN NN O
of NN NN O
NMDA NN NN O
receptors NN NN O
diminishes NN NN O
the NN NN O
memory NN NN O
- NN NN O
enhancing NN NN O
effects NN NN O
of NN NN O
PREGS NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
enantioselectivity NN NN O
was NN NN O
demonstrated NN NN O
by NN NN O
the NN NN O
ability NN NN O
of NN NN O
natural NN NN O
PREGS NN NN O
to NN NN O
be NN NN O
an NN NN O
order NN NN O
of NN NN O
magnitude NN NN O
more NN NN O
effective NN NN O
than NN NN O
its NN NN O
synthetic NN NN O
enantiomer NN NN O
in NN NN O
reversing NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
. NN NN O
   
These NN NN O
results NN NN O
identify NN NN O
a NN NN O
novel NN NN O
neuropharmacological NN NN O
site NN NN O
for NN NN O
the NN NN O
modulation NN NN O
of NN NN O
memory NN NN O
processes NN NN O
by NN NN O
neuroactive NN NN O
steroids NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
poly NN NN O
( NN NN O
ADP NN NN O
- NN NN O
ribose NN NN O
) NN NN O
polymerase NN NN O
contributes NN NN O
to NN NN O
development NN NN O
of NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
Activation NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
enzyme NN NN O
poly NN NN O
( NN NN O
ADP NN NN O
- NN NN O
ribose NN NN O
) NN NN O
polymerase NN NN O
( NN NN O
PARP NN NN O
) NN NN O
by NN NN O
oxidant NN NN O
- NN NN O
mediated NN NN O
DNA NN NN O
damage NN NN O
is NN NN O
an NN NN O
important NN NN O
pathway NN NN O
of NN NN O
cell NN NN O
dysfunction NN NN O
and NN NN O
tissue NN NN O
injury NN NN O
in NN NN O
conditions NN NN O
associated NN NN O
with NN NN O
oxidative NN NN O
stress NN NN O
. NN NN O
   
Increased NN NN O
oxidative NN NN O
stress NN NN O
is NN NN O
a NN NN O
major NN NN O
factor NN NN O
implicated NN NN O
in NN NN O
the NN NN O
cardiotoxicity NN NN B-Disease
of NN NN O
doxorubicin NN NN O
( NN NN O
DOX NN NN O
) NN NN O
, NN NN O
a NN NN O
widely NN NN O
used NN NN O
antitumor NN NN O
anthracycline NN NN O
antibiotic NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
we NN NN O
hypothesized NN NN O
that NN NN O
the NN NN O
activation NN NN O
of NN NN O
PARP NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
DOX NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
Using NN NN O
a NN NN O
dual NN NN O
approach NN NN O
of NN NN O
PARP NN NN O
- NN NN O
1 NN NN O
suppression NN NN O
, NN NN O
by NN NN O
genetic NN NN O
deletion NN NN O
or NN NN O
pharmacological NN NN O
inhibition NN NN O
with NN NN O
the NN NN O
phenanthridinone NN NN O
PARP NN NN O
inhibitor NN NN O
PJ34 NN NN O
, NN NN O
we NN NN O
now NN NN O
demonstrate NN NN O
the NN NN O
role NN NN O
of NN NN O
PARP NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
cardiac NN NN B-Disease
dysfunction NN NN I-Disease
induced NN NN O
by NN NN O
DOX NN NN O
. NN NN O
   
PARP NN NN O
- NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
+ NN NN O
and NN NN O
PARP NN NN O
- NN NN O
1 NN NN O
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
received NN NN O
a NN NN O
single NN NN O
injection NN NN O
of NN NN O
DOX NN NN O
( NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
) NN NN O
. NN NN O
   
Five NN NN O
days NN NN O
after NN NN O
DOX NN NN O
administration NN NN O
, NN NN O
left NN NN O
ventricular NN NN O
performance NN NN O
was NN NN O
significantly NN NN O
depressed NN NN O
in NN NN O
PARP NN NN O
- NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
+ NN NN O
mice NN NN O
, NN NN O
but NN NN O
only NN NN O
to NN NN O
a NN NN O
smaller NN NN O
extent NN NN O
in NN NN O
PARP NN NN O
- NN NN O
1 NN NN O
- NN NN O
/ NN NN O
- NN NN O
ones NN NN O
. NN NN O
   
Similar NN NN O
experiments NN NN O
were NN NN O
conducted NN NN O
in NN NN O
BALB NN NN O
/ NN NN O
c NN NN O
mice NN NN O
treated NN NN O
with NN NN O
PJ34 NN NN O
or NN NN O
vehicle NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
a NN NN O
PJ34 NN NN O
significantly NN NN O
improved NN NN O
cardiac NN NN B-Disease
dysfunction NN NN I-Disease
and NN NN O
increased NN NN O
the NN NN O
survival NN NN O
of NN NN O
the NN NN O
animals NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
PJ34 NN NN O
significantly NN NN O
reduced NN NN O
the NN NN O
DOX NN NN O
- NN NN O
induced NN NN O
increase NN NN O
in NN NN O
the NN NN O
serum NN NN O
lactate NN NN O
dehydrogenase NN NN O
and NN NN O
creatine NN NN O
kinase NN NN O
activities NN NN O
but NN NN O
not NN NN O
metalloproteinase NN NN O
activation NN NN O
in NN NN O
the NN NN O
heart NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
PARP NN NN O
activation NN NN O
contributes NN NN O
to NN NN O
the NN NN O
cardiotoxicity NN NN B-Disease
of NN NN O
DOX NN NN O
. NN NN O
   
PARP NN NN O
inhibitors NN NN O
may NN NN O
exert NN NN O
protective NN NN O
effects NN NN O
against NN NN O
the NN NN O
development NN NN O
of NN NN O
severe NN NN O
cardiac NN NN B-Disease
complications NN NN I-Disease
associated NN NN O
with NN NN O
the NN NN O
DOX NN NN O
treatment NN NN O
. NN NN O
   
Spironolactone NN NN O
: NN NN O
is NN NN O
it NN NN O
a NN NN O
novel NN NN O
drug NN NN O
for NN NN O
the NN NN O
prevention NN NN O
of NN NN O
amphotericin NN NN O
B NN NN O
- NN NN O
related NN NN O
hypokalemia NN NN B-Disease
in NN NN O
cancer NN NN B-Disease
patients NN NN O
? NN NN O
   
OBJECTIVE NN NN O
: NN NN O
Nephrotoxicity NN NN B-Disease
is NN NN O
the NN NN O
major NN NN O
adverse NN NN O
effect NN NN O
of NN NN O
amphotericin NN NN O
B NN NN O
( NN NN O
AmB NN NN O
) NN NN O
, NN NN O
often NN NN O
limiting NN NN O
administration NN NN O
of NN NN O
full NN NN O
dosage NN NN O
. NN NN O
   
Selective NN NN O
distal NN NN O
tubular NN NN O
epithelial NN NN O
toxicity NN NN B-Disease
seems NN NN O
to NN NN O
be NN NN O
responsible NN NN O
for NN NN O
the NN NN O
profound NN NN O
potassium NN NN O
wasting NN NN O
that NN NN O
is NN NN O
a NN NN O
major NN NN O
clinical NN NN O
side NN NN O
effect NN NN O
of NN NN O
treatment NN NN O
with NN NN O
AmB NN NN O
. NN NN O
   
Potassium NN NN O
depletion NN NN O
also NN NN O
potentiates NN NN O
the NN NN O
tubular NN NN O
toxicity NN NN B-Disease
of NN NN O
AmB NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
assess NN NN O
the NN NN O
ability NN NN O
of NN NN O
spironolactone NN NN O
to NN NN O
reduce NN NN O
potassium NN NN O
requirements NN NN O
and NN NN O
to NN NN O
prevent NN NN O
hypokalemia NN NN B-Disease
in NN NN O
neutropenic NN NN B-Disease
patients NN NN O
on NN NN O
AmB NN NN O
treatment NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
In NN NN O
this NN NN O
study NN NN O
26 NN NN O
patients NN NN O
with NN NN O
various NN NN O
hematological NN NN B-Disease
disorders NN NN I-Disease
were NN NN O
randomized NN NN O
to NN NN O
receive NN NN O
either NN NN O
intravenous NN NN O
AmB NN NN O
alone NN NN O
or NN NN O
AmB NN NN O
and NN NN O
oral NN NN O
spironolactone NN NN O
100 NN NN O
mg NN NN O
twice NN NN O
daily NN NN O
when NN NN O
developing NN NN O
a NN NN O
proven NN NN O
or NN NN O
suspected NN NN O
fungal NN NN B-Disease
infection NN NN I-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
Patients NN NN O
receiving NN NN O
concomitant NN NN O
AmB NN NN O
and NN NN O
spironolactone NN NN O
had NN NN O
significantly NN NN O
higher NN NN O
plasma NN NN O
potassium NN NN O
levels NN NN O
than NN NN O
those NN NN O
receiving NN NN O
AmB NN NN O
alone NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
0027 NN NN O
) NN NN O
. NN NN O
   
Those NN NN O
patients NN NN O
receiving NN NN O
AmB NN NN O
and NN NN O
spironolactone NN NN O
required NN NN O
significantly NN NN O
less NN NN O
potassium NN NN O
supplementation NN NN O
to NN NN O
maintain NN NN O
their NN NN O
plasma NN NN O
potassium NN NN O
within NN NN O
the NN NN O
normal NN NN O
range NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
022 NN NN O
) NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
urinary NN NN O
potassium NN NN O
losses NN NN O
were NN NN O
significantly NN NN O
less NN NN O
in NN NN O
patients NN NN O
receiving NN NN O
AmB NN NN O
and NN NN O
spironolactone NN NN O
than NN NN O
those NN NN O
receiving NN NN O
AmB NN NN O
alone NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
040 NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
This NN NN O
study NN NN O
showed NN NN O
that NN NN O
spironolactone NN NN O
can NN NN O
reduce NN NN O
potassium NN NN O
requirements NN NN O
and NN NN O
prevent NN NN O
hypokalemia NN NN B-Disease
by NN NN O
reducing NN NN O
urinary NN NN O
potassium NN NN O
loss NN NN O
in NN NN O
neutropenic NN NN B-Disease
patients NN NN O
on NN NN O
AmB NN NN O
treatment NN NN O
. NN NN O
   
Erectile NN NN B-Disease
dysfunction NN NN I-Disease
occurs NN NN O
following NN NN O
substantia NN NN O
nigra NN NN O
lesions NN NN O
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Erectile NN NN O
function NN NN O
was NN NN O
assessed NN NN O
6 NN NN O
weeks NN NN O
following NN NN O
uni NN NN O
- NN NN O
and NN NN O
bilateral NN NN O
injections NN NN O
of NN NN O
6 NN NN O
- NN NN O
hydroxydopamine NN NN O
in NN NN O
the NN NN O
substantia NN NN O
nigra NN NN O
nucleus NN NN O
of NN NN O
the NN NN O
brain NN NN O
. NN NN O
   
Behavioral NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
penile NN NN O
erections NN NN O
were NN NN O
reduced NN NN O
( NN NN O
5 NN NN O
/ NN NN O
8 NN NN O
) NN NN O
and NN NN O
increased NN NN O
( NN NN O
3 NN NN O
/ NN NN O
8 NN NN O
) NN NN O
in NN NN O
uni NN NN O
- NN NN O
and NN NN O
bilateral NN NN O
lesioned NN NN O
animals NN NN O
. NN NN O
   
Intracavernous NN NN O
pressures NN NN O
, NN NN O
following NN NN O
electrical NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
cavernous NN NN O
nerve NN NN O
, NN NN O
decreased NN NN O
in NN NN O
lesioned NN NN O
animals NN NN O
. NN NN O
   
Lesions NN NN O
of NN NN O
the NN NN O
substantia NN NN O
nigra NN NN O
were NN NN O
confirmed NN NN O
by NN NN O
histology NN NN O
. NN NN O
   
Concentration NN NN O
of NN NN O
dopamine NN NN O
and NN NN O
its NN NN O
metabolites NN NN O
were NN NN O
decreased NN NN O
in NN NN O
the NN NN O
striatum NN NN O
of NN NN O
substantia NN NN O
nigra NN NN O
lesioned NN NN O
rats NN NN O
. NN NN O
   
Lesions NN NN O
of NN NN O
the NN NN O
substantia NN NN O
nigra NN NN O
are NN NN O
therefore NN NN O
associated NN NN O
with NN NN O
erectile NN NN B-Disease
dysfunction NN NN I-Disease
in NN NN O
rats NN NN O
and NN NN O
may NN NN O
serve NN NN O
as NN NN O
a NN NN O
model NN NN O
to NN NN O
study NN NN O
erectile NN NN B-Disease
dysfunction NN NN I-Disease
in NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Nicotine NN NN O
potentiation NN NN O
of NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
in NN NN O
mice NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
effects NN NN O
of NN NN O
nicotine NN NN O
on NN NN O
catalepsy NN NN B-Disease
induced NN NN O
by NN NN O
morphine NN NN O
in NN NN O
mice NN NN O
have NN NN O
been NN NN O
investigated NN NN O
. NN NN O
   
Morphine NN NN O
but NN NN O
not NN NN O
nicotine NN NN O
induced NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
catalepsy NN NN B-Disease
. NN NN O
   
The NN NN O
response NN NN O
of NN NN O
morphine NN NN O
was NN NN O
potentiated NN NN O
by NN NN O
nicotine NN NN O
. NN NN O
   
Intraperitoneal NN NN O
administration NN NN O
of NN NN O
atropine NN NN O
, NN NN O
naloxone NN NN O
, NN NN O
mecamylamine NN NN O
, NN NN O
and NN NN O
hexamethonium NN NN O
to NN NN O
mice NN NN O
reduced NN NN O
catalepsy NN NN B-Disease
induced NN NN O
by NN NN O
a NN NN O
combination NN NN O
of NN NN O
morphine NN NN O
with NN NN O
nicotine NN NN O
. NN NN O
   
Intracerebroventricular NN NN O
injection NN NN O
of NN NN O
atropine NN NN O
, NN NN O
hexamethonium NN NN O
, NN NN O
and NN NN O
naloxone NN NN O
also NN NN O
decreased NN NN O
catalepsy NN NN B-Disease
induced NN NN O
by NN NN O
morphine NN NN O
plus NN NN O
nicotine NN NN O
. NN NN O
   
Intraperitoneal NN NN O
administration NN NN O
of NN NN O
atropine NN NN O
, NN NN O
but NN NN O
not NN NN O
intraperitoneal NN NN O
or NN NN O
intracerebroventricular NN NN O
injection NN NN O
of NN NN O
hexamethonium NN NN O
, NN NN O
decreased NN NN O
the NN NN O
effect NN NN O
of NN NN O
a NN NN O
single NN NN O
dose NN NN O
of NN NN O
morphine NN NN O
. NN NN O
   
It NN NN O
was NN NN O
concluded NN NN O
that NN NN O
morphine NN NN O
catalepsy NN NN B-Disease
can NN NN O
be NN NN O
elicited NN NN O
by NN NN O
opioid NN NN O
and NN NN O
cholinergic NN NN O
receptors NN NN O
, NN NN O
and NN NN O
the NN NN O
potentiation NN NN O
of NN NN O
morphine NN NN O
induced NN NN O
by NN NN O
nicotine NN NN O
may NN NN O
also NN NN O
be NN NN O
mediated NN NN O
through NN NN O
cholinergic NN NN O
receptor NN NN O
mechanisms NN NN O
. NN NN O
   
Force NN NN O
overflow NN NN O
and NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
in NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
We NN NN O
assessed NN NN O
force NN NN O
coordination NN NN O
of NN NN O
the NN NN O
hand NN NN O
in NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
and NN NN O
its NN NN O
relationship NN NN O
to NN NN O
motor NN NN O
complications NN NN O
of NN NN O
levodopa NN NN O
therapy NN NN O
, NN NN O
particularly NN NN O
to NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
( NN NN O
LID NN NN B-Disease
) NN NN O
. NN NN O
   
We NN NN O
studied NN NN O
two NN NN O
groups NN NN O
of NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
patients NN NN O
with NN NN O
( NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
+ NN NN O
LID NN NN B-Disease
, NN NN O
n NN NN O
= NN NN O
23 NN NN O
) NN NN O
and NN NN O
without NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
( NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
- NN NN O
LID NN NN B-Disease
, NN NN O
n NN NN O
= NN NN O
10 NN NN O
) NN NN O
, NN NN O
and NN NN O
age NN NN O
- NN NN O
matched NN NN O
healthy NN NN O
controls NN NN O
. NN NN O
   
The NN NN O
motor NN NN O
score NN NN O
of NN NN O
the NN NN O
Unified NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
Disease NN NN I-Disease
Rating NN NN O
Scale NN NN O
, NN NN O
a NN NN O
dyskinesia NN NN B-Disease
score NN NN O
and NN NN O
force NN NN O
in NN NN O
a NN NN O
grip NN NN O
- NN NN O
lift NN NN O
paradigm NN NN O
were NN NN O
assessed NN NN O
ON NN NN O
and NN NN O
OFF NN NN O
levodopa NN NN O
. NN NN O
   
A NN NN O
pathological NN NN O
increase NN NN O
of NN NN O
forces NN NN O
was NN NN O
seen NN NN O
in NN NN O
ON NN NN O
- NN NN O
state NN NN O
in NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
+ NN NN O
LID NN NN B-Disease
only NN NN O
. NN NN O
   
In NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
+ NN NN O
LID NN NN B-Disease
, NN NN O
the NN NN O
force NN NN O
involved NN NN O
in NN NN O
pressing NN NN O
down NN NN O
the NN NN O
object NN NN O
before NN NN O
lifting NN NN O
was NN NN O
significantly NN NN O
increased NN NN O
by NN NN O
levodopa NN NN O
( NN NN O
by NN NN O
61 NN NN O
% NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
An NN NN O
overshooting NN NN O
of NN NN O
peak NN NN O
grip NN NN O
force NN NN O
by NN NN O
51 NN NN O
% NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
and NN NN O
of NN NN O
static NN NN O
grip NN NN O
force NN NN O
by NN NN O
45 NN NN O
% NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
ON NN NN O
- NN NN O
compared NN NN O
with NN NN O
the NN NN O
OFF NN NN O
- NN NN O
drug NN NN O
condition NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
no NN NN O
excessive NN NN O
force NN NN O
was NN NN O
found NN NN O
in NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
- NN NN O
LID NN NN B-Disease
. NN NN O
   
Peak NN NN O
grip NN NN O
force NN NN O
in NN NN O
ON NN NN O
- NN NN O
state NN NN O
was NN NN O
140 NN NN O
% NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
higher NN NN O
in NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
+ NN NN O
LID NN NN B-Disease
than NN NN O
in NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
- NN NN O
LID NN NN B-Disease
, NN NN O
while NN NN O
static NN NN O
grip NN NN O
force NN NN O
was NN NN O
increased NN NN O
by NN NN O
138 NN NN O
% NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
between NN NN O
groups NN NN O
. NN NN O
   
Severity NN NN O
of NN NN O
peak NN NN O
- NN NN O
dose NN NN O
dyskinesias NN NN B-Disease
was NN NN O
strongly NN NN O
correlated NN NN O
with NN NN O
grip NN NN O
force NN NN O
in NN NN O
ON NN NN O
- NN NN O
state NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
79 NN NN O
with NN NN O
peak NN NN O
force NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
No NN NN O
correlation NN NN O
was NN NN O
observed NN NN O
between NN NN O
forces NN NN O
and NN NN O
the NN NN O
motor NN NN O
score NN NN O
as NN NN O
well NN NN O
as NN NN O
with NN NN O
the NN NN O
daily NN NN O
dose NN NN O
of NN NN O
dopaminergic NN NN O
medication NN NN O
. NN NN O
   
Force NN NN O
excess NN NN O
was NN NN O
only NN NN O
observed NN NN O
in NN NN O
patients NN NN O
with NN NN O
LID NN NN B-Disease
and NN NN O
motor NN NN O
fluctuations NN NN O
. NN NN O
   
A NN NN O
close NN NN O
relationship NN NN O
was NN NN O
seen NN NN O
between NN NN O
the NN NN O
overshooting NN NN O
of NN NN O
forces NN NN O
and NN NN O
dyskinesias NN NN B-Disease
in NN NN O
the NN NN O
ON NN NN O
- NN NN O
drug NN NN O
condition NN NN O
. NN NN O
   
We NN NN O
postulate NN NN O
that NN NN O
both NN NN O
LID NN NN B-Disease
and NN NN O
grip NN NN O
force NN NN O
excess NN NN O
share NN NN O
common NN NN O
pathophysiological NN NN O
mechanisms NN NN O
related NN NN O
to NN NN O
motor NN NN O
fluctuations NN NN O
. NN NN O
   
Behavioral NN NN O
effects NN NN O
of NN NN O
MK NN NN O
- NN NN O
801 NN NN O
on NN NN O
reserpine NN NN O
- NN NN O
treated NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
dizocilpine NN NN O
( NN NN O
MK NN NN O
- NN NN O
801 NN NN O
) NN NN O
, NN NN O
a NN NN O
noncompetitive NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
D NN NN O
- NN NN O
aspartate NN NN O
( NN NN O
NMDA NN NN O
) NN NN O
receptor NN NN O
antagonist NN NN O
, NN NN O
were NN NN O
studied NN NN O
on NN NN O
dopamine NN NN O
- NN NN O
related NN NN O
behaviors NN NN O
induced NN NN O
by NN NN O
reserpine NN NN O
treatments NN NN O
. NN NN O
   
This NN NN O
study NN NN O
focuses NN NN O
on NN NN O
behavioral NN NN O
syndromes NN NN O
that NN NN O
may NN NN O
used NN NN O
as NN NN O
models NN NN O
for NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
, NN NN O
or NN NN O
tardive NN NN B-Disease
dyskinesia NN NN I-Disease
, NN NN O
and NN NN O
its NN NN O
response NN NN O
after NN NN O
glutamatergic NN NN O
blockage NN NN O
. NN NN O
   
Reserpine NN NN O
( NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
administered NN NN O
once NN NN O
every NN NN O
other NN NN O
day NN NN O
for NN NN O
4 NN NN O
days NN NN O
, NN NN O
produced NN NN O
increases NN NN O
in NN NN O
orofacial NN NN B-Disease
dyskinesia NN NN I-Disease
, NN NN O
tongue NN NN O
protrusion NN NN O
and NN NN O
vacuous NN NN O
chewing NN NN O
in NN NN O
mice NN NN O
, NN NN O
which NN NN O
are NN NN O
signs NN NN O
indicative NN NN O
of NN NN O
tardive NN NN B-Disease
dyskinesia NN NN I-Disease
. NN NN O
   
Reserpine NN NN O
also NN NN O
produced NN NN O
tremor NN NN B-Disease
and NN NN O
catalepsy NN NN B-Disease
, NN NN O
which NN NN O
are NN NN O
signs NN NN O
suggestive NN NN O
of NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
MK NN NN O
- NN NN O
801 NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
administered NN NN O
30 NN NN O
min NN NN O
before NN NN O
the NN NN O
observation NN NN O
test NN NN O
, NN NN O
prevented NN NN O
the NN NN O
vacuous NN NN O
chewing NN NN O
movements NN NN O
, NN NN O
tongue NN NN O
protrusions NN NN O
and NN NN O
catalepsy NN NN B-Disease
induced NN NN O
by NN NN O
reserpine NN NN O
. NN NN O
   
However NN NN O
, NN NN O
MK NN NN O
- NN NN O
801 NN NN O
injection NN NN O
produced NN NN O
a NN NN O
significant NN NN O
increase NN NN O
of NN NN O
tremor NN NN B-Disease
in NN NN O
reserpine NN NN O
- NN NN O
treated NN NN O
mice NN NN O
. NN NN O
   
Reserpine NN NN O
( NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
administered NN NN O
90 NN NN O
min NN NN O
before NN NN O
the NN NN O
test NN NN O
and NN NN O
followed NN NN O
by NN NN O
apomophine NN NN O
injection NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
5 NN NN O
min NN NN O
before NN NN O
the NN NN O
test NN NN O
, NN NN O
did NN NN O
not NN NN O
produce NN NN O
oral NN NN B-Disease
dyskinesia NN NN I-Disease
in NN NN O
mice NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
reserpine NN NN O
induced NN NN O
increases NN NN O
in NN NN O
tremor NN NN B-Disease
and NN NN O
catalepsy NN NN B-Disease
compared NN NN O
to NN NN O
control NN NN O
mice NN NN O
. NN NN O
   
MK NN NN O
- NN NN O
801 NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
administration NN NN O
attenuated NN NN O
the NN NN O
catalepsy NN NN B-Disease
and NN NN O
tremor NN NN B-Disease
induced NN NN O
by NN NN O
reserpine NN NN O
. NN NN O
   
Pretreatment NN NN O
with NN NN O
reserpine NN NN O
( NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
24 NN NN O
h NN NN O
before NN NN O
the NN NN O
observation NN NN O
test NN NN O
produced NN NN O
increases NN NN O
in NN NN O
vacuous NN NN O
chewing NN NN O
movements NN NN O
and NN NN O
tongue NN NN O
protrusion NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
increases NN NN O
in NN NN O
tremor NN NN B-Disease
and NN NN O
catalepsy NN NN B-Disease
, NN NN O
whereas NN NN O
MK NN NN O
- NN NN O
801 NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
injection NN NN O
90 NN NN O
min NN NN O
before NN NN O
the NN NN O
test NN NN O
reversed NN NN O
the NN NN O
effects NN NN O
of NN NN O
reserpine NN NN O
. NN NN O
   
These NN NN O
results NN NN O
show NN NN O
that NN NN O
reserpine NN NN O
produces NN NN O
different NN NN O
and NN NN O
abnormal NN NN B-Disease
movements NN NN I-Disease
, NN NN O
which NN NN O
are NN NN O
related NN NN O
to NN NN O
dose NN NN O
and NN NN O
schedule NN NN O
employed NN NN O
and NN NN O
can NN NN O
be NN NN O
considered NN NN O
as NN NN O
parkinsonian NN NN B-Disease
- NN NN O
like NN NN O
and NN NN O
tardive NN NN B-Disease
dsykinesia NN NN I-Disease
signs NN NN O
. NN NN O
   
The NN NN O
glutamatergic NN NN O
blockage NN NN O
produced NN NN O
by NN NN O
NMDA NN NN O
can NN NN O
restore NN NN O
these NN NN O
signs NN NN O
, NN NN O
such NN NN O
as NN NN O
vacuous NN NN O
chewing NN NN O
movements NN NN O
, NN NN O
tongue NN NN O
protrusions NN NN O
, NN NN O
catalepsy NN NN B-Disease
and NN NN O
tremor NN NN B-Disease
according NN NN O
to NN NN O
the NN NN O
employed NN NN O
model NN NN O
. NN NN O
   
Risperidone NN NN O
- NN NN O
associated NN NN O
, NN NN O
benign NN NN O
transient NN NN O
visual NN NN B-Disease
disturbances NN NN I-Disease
in NN NN O
schizophrenic NN NN B-Disease
patients NN NN O
with NN NN O
a NN NN O
past NN NN O
history NN NN O
of NN NN O
LSD NN NN O
abuse NN NN O
. NN NN O
   
Two NN NN O
schizophrenic NN NN B-Disease
patients NN NN O
, NN NN O
who NN NN O
had NN NN O
a NN NN O
prior NN NN O
history NN NN O
of NN NN O
LSD NN NN O
abuse NN NN O
and NN NN O
who NN NN O
had NN NN O
previously NN NN O
developed NN NN O
EPS NN NN B-Disease
with NN NN O
classic NN NN O
antipsychotics NN NN O
, NN NN O
were NN NN O
successfully NN NN O
treated NN NN O
with NN NN O
risperidone NN NN O
. NN NN O
   
They NN NN O
both NN NN O
reported NN NN O
short NN NN O
episodes NN NN O
of NN NN O
transient NN NN O
visual NN NN B-Disease
disturbances NN NN I-Disease
, NN NN O
which NN NN O
appeared NN NN O
immediately NN NN O
after NN NN O
starting NN NN O
treatment NN NN O
with NN NN O
risperidone NN NN O
. NN NN O
   
This NN NN O
imagery NN NN O
resembled NN NN O
visual NN NN B-Disease
disturbances NN NN I-Disease
previously NN NN O
experienced NN NN O
as NN NN O
"""""""" NN NN O
flashbacks NN NN O
"""""""" NN NN O
related NN NN O
to NN NN O
prior NN NN O
LSD NN NN O
consumption NN NN O
. NN NN O
   
Risperidone NN NN O
administration NN NN O
was NN NN O
continued NN NN O
and NN NN O
the NN NN O
visual NN NN B-Disease
disturbances NN NN I-Disease
gradually NN NN O
wore NN NN O
off NN NN O
. NN NN O
   
During NN NN O
a NN NN O
six NN NN O
- NN NN O
month NN NN O
follow NN NN O
- NN NN O
up NN NN O
period NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
recurrence NN NN O
of NN NN O
visual NN NN B-Disease
disturbances NN NN I-Disease
. NN NN O
   
This NN NN O
phenomenon NN NN O
may NN NN O
be NN NN O
interpreted NN NN O
as NN NN O
a NN NN O
benign NN NN O
, NN NN O
short NN NN O
- NN NN O
term NN NN O
and NN NN O
self NN NN O
- NN NN O
limiting NN NN O
side NN NN O
effect NN NN O
which NN NN O
does NN NN O
not NN NN O
contraindicate NN NN O
the NN NN O
use NN NN O
of NN NN O
risperidone NN NN O
or NN NN O
interfere NN NN O
with NN NN O
treatment NN NN O
. NN NN O
   
Conclusions NN NN O
based NN NN O
on NN NN O
two NN NN O
case NN NN O
reports NN NN O
should NN NN O
be NN NN O
taken NN NN O
with NN NN O
appropriate NN NN O
caution NN NN O
. NN NN O
   
Topiramate NN NN O
- NN NN O
induced NN NN O
nephrolithiasis NN NN B-Disease
. NN NN O
   
Topiramate NN NN O
is NN NN O
a NN NN O
recently NN NN O
developed NN NN O
antiepileptic NN NN O
medication NN NN O
that NN NN O
is NN NN O
becoming NN NN O
more NN NN O
widely NN NN O
prescribed NN NN O
because NN NN O
of NN NN O
its NN NN O
efficacy NN NN O
in NN NN O
treating NN NN O
refractory NN NN B-Disease
seizures NN NN I-Disease
. NN NN O
   
Urologists NN NN O
should NN NN O
be NN NN O
aware NN NN O
that NN NN O
this NN NN O
medication NN NN O
can NN NN O
cause NN NN O
metabolic NN NN B-Disease
acidosis NN NN I-Disease
in NN NN O
patients NN NN O
secondary NN NN O
to NN NN O
inhibition NN NN O
of NN NN O
carbonic NN NN O
anhydrase NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
a NN NN O
distal NN NN O
tubular NN NN O
acidification NN NN O
defect NN NN O
may NN NN O
result NN NN O
, NN NN O
thus NN NN O
impairing NN NN O
the NN NN O
normal NN NN O
compensatory NN NN O
drop NN NN O
in NN NN O
urine NN NN O
pH NN NN O
. NN NN O
   
These NN NN O
factors NN NN O
can NN NN O
lead NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
calcium NN NN O
phosphate NN NN O
nephrolithiasis NN NN B-Disease
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
first NN NN O
two NN NN O
cases NN NN O
of NN NN O
topiramate NN NN O
- NN NN O
induced NN NN O
nephrolithiasis NN NN B-Disease
in NN NN O
the NN NN O
urologic NN NN O
literature NN NN O
. NN NN O
   
Ketamine NN NN O
in NN NN O
war NN NN O
/ NN NN O
tropical NN NN O
surgery NN NN O
( NN NN O
a NN NN O
final NN NN O
tribute NN NN O
to NN NN O
the NN NN O
racemic NN NN O
mixture NN NN O
) NN NN O
. NN NN O
   
A NN NN O
technique NN NN O
of NN NN O
continuous NN NN O
intravenous NN NN O
anaesthesia NN NN O
with NN NN O
ketamine NN NN O
was NN NN O
used NN NN O
successfully NN NN O
during NN NN O
the NN NN O
Somalia NN NN O
civil NN NN O
war NN NN O
in NN NN O
1994 NN NN O
and NN NN O
in NN NN O
north NN NN O
Uganda NN NN O
in NN NN O
1999 NN NN O
for NN NN O
64 NN NN O
operations NN NN O
in NN NN O
62 NN NN O
patients NN NN O
, NN NN O
aged NN NN O
from NN NN O
6 NN NN O
weeks NN NN O
to NN NN O
70 NN NN O
years NN NN O
, NN NN O
undergoing NN NN O
limb NN NN O
and NN NN O
abdominal NN NN O
surgery NN NN O
including NN NN O
caesarian NN NN O
sections NN NN O
and NN NN O
interventions NN NN O
in NN NN O
neonates NN NN O
. NN NN O
   
Operations NN NN O
lasting NN NN O
up NN NN O
to NN NN O
2h NN NN O
could NN NN O
be NN NN O
performed NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
sophisticated NN NN O
equipment NN NN O
such NN NN O
as NN NN O
pulse NN NN O
oximeters NN NN O
or NN NN O
ventilators NN NN O
in NN NN O
patients NN NN O
on NN NN O
spontaneous NN NN O
ventilation NN NN O
breathing NN NN O
air NN NN O
/ NN NN O
oxygen NN NN O
only NN NN O
. NN NN O
   
After NN NN O
premedication NN NN O
with NN NN O
diazepam NN NN O
, NN NN O
glycopyrrolate NN NN O
and NN NN O
local NN NN O
anaesthesia NN NN O
, NN NN O
and NN NN O
induction NN NN O
with NN NN O
standard NN NN O
doses NN NN O
of NN NN O
ketamine NN NN O
, NN NN O
a NN NN O
maintenance NN NN O
dose NN NN O
of NN NN O
10 NN NN O
- NN NN O
20 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
of NN NN O
ketamine NN NN O
proved NN NN O
safe NN NN O
and NN NN O
effective NN NN O
. NN NN O
   
Emphasis NN NN O
was NN NN O
placed NN NN O
on NN NN O
bedside NN NN O
clinical NN NN O
monitoring NN NN O
, NN NN O
relying NN NN O
heavily NN NN O
on NN NN O
the NN NN O
heart NN NN O
rate NN NN O
. NN NN O
   
Diazepam NN NN O
, NN NN O
unless NN NN O
contraindicated NN NN O
or NN NN O
risky NN NN O
, NN NN O
remains NN NN O
the NN NN O
only NN NN O
necessary NN NN O
complementary NN NN O
drug NN NN O
to NN NN O
ketamine NN NN O
as NN NN O
it NN NN O
buffers NN NN O
its NN NN O
cardiovascular NN NN O
response NN NN O
and NN NN O
decreases NN NN O
the NN NN O
duration NN NN O
and NN NN O
intensity NN NN O
of NN NN O
operative NN NN O
and NN NN O
postoperative NN NN O
hallucinations NN NN B-Disease
. NN NN O
   
Local NN NN O
anaesthetic NN NN O
blocks NN NN O
were NN NN O
useful NN NN O
in NN NN O
decreasing NN NN O
the NN NN O
requirement NN NN O
for NN NN O
postoperative NN NN O
analgesia NN NN B-Disease
. NN NN O
   
An NN NN O
antisialogue NN NN O
was NN NN O
usually NN NN O
unnecessary NN NN O
in NN NN O
operations NN NN O
lasting NN NN O
up NN NN O
to NN NN O
2 NN NN O
h NN NN O
, NN NN O
glycopyrrolate NN NN O
being NN NN O
the NN NN O
best NN NN O
choice NN NN O
for NN NN O
its NN NN O
lowest NN NN O
psychotropic NN NN O
and NN NN O
chronotropic NN NN O
effects NN NN O
, NN NN O
especially NN NN O
in NN NN O
a NN NN O
hot NN NN O
climate NN NN O
. NN NN O
   
Experience NN NN O
in NN NN O
war NN NN O
/ NN NN O
tropical NN NN O
settings NN NN O
suggests NN NN O
this NN NN O
technique NN NN O
could NN NN O
be NN NN O
useful NN NN O
in NN NN O
civilian NN NN O
contexts NN NN O
such NN NN O
as NN NN O
outdoor NN NN O
life NN NN O
- NN NN O
saving NN NN O
emergency NN NN O
surgery NN NN O
or NN NN O
in NN NN O
mass NN NN O
casualties NN NN O
where NN NN O
, NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
amputation NN NN O
and NN NN O
rapid NN NN O
extrication NN NN O
were NN NN O
required NN NN O
. NN NN O
   
Intravenous NN NN O
ribavirin NN NN O
treatment NN NN O
for NN NN O
severe NN NN O
adenovirus NN NN B-Disease
disease NN NN I-Disease
in NN NN O
immunocompromised NN NN O
children NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Adenovirus NN NN O
is NN NN O
an NN NN O
important NN NN O
cause NN NN O
of NN NN O
morbidity NN NN O
and NN NN O
mortality NN NN O
in NN NN O
the NN NN O
immunocompromised NN NN O
host NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
severe NN NN O
adenovirus NN NN B-Disease
disease NN NN I-Disease
in NN NN O
pediatrics NN NN O
is NN NN O
increasing NN NN O
in NN NN O
association NN NN O
with NN NN O
growing NN NN O
numbers NN NN O
of NN NN O
immunocompromised NN NN O
children NN NN O
, NN NN O
where NN NN O
case NN NN O
fatality NN NN O
rates NN NN O
as NN NN O
high NN NN O
as NN NN O
50 NN NN O
% NN NN O
to NN NN O
80 NN NN O
% NN NN O
have NN NN O
been NN NN O
reported NN NN O
. NN NN O
   
There NN NN O
are NN NN O
no NN NN O
approved NN NN O
antiviral NN NN O
agents NN NN O
with NN NN O
proven NN NN O
efficacy NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
severe NN NN O
adenovirus NN NN B-Disease
disease NN NN I-Disease
, NN NN O
nor NN NN O
are NN NN O
there NN NN O
any NN NN O
prospective NN NN O
randomized NN NN O
, NN NN O
controlled NN NN O
trials NN NN O
of NN NN O
potentially NN NN O
useful NN NN O
anti NN NN O
- NN NN O
adenovirus NN NN O
therapies NN NN O
. NN NN O
   
Apparent NN NN O
clinical NN NN O
success NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
severe NN NN O
adenovirus NN NN B-Disease
disease NN NN I-Disease
is NN NN O
limited NN NN O
to NN NN O
a NN NN O
few NN NN O
case NN NN O
reports NN NN O
and NN NN O
small NN NN O
series NN NN O
. NN NN O
   
Experience NN NN O
is NN NN O
greatest NN NN O
with NN NN O
intravenous NN NN O
ribavirin NN NN O
and NN NN O
cidofovir NN NN O
. NN NN O
   
Ribavirin NN NN O
, NN NN O
a NN NN O
guanosine NN NN O
analogue NN NN O
, NN NN O
has NN NN O
broad NN NN O
antiviral NN NN O
activity NN NN O
against NN NN O
both NN NN O
RNA NN NN O
and NN NN O
DNA NN NN O
viruses NN NN O
, NN NN O
including NN NN O
documented NN NN O
activity NN NN O
against NN NN O
adenovirus NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
Ribavirin NN NN O
is NN NN O
licensed NN NN O
in NN NN O
aerosol NN NN O
form NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
respiratory NN NN B-Disease
syncytial NN NN I-Disease
virus NN NN I-Disease
infection NN NN I-Disease
, NN NN O
and NN NN O
orally NN NN O
in NN NN O
combination NN NN O
with NN NN O
interferon NN NN O
to NN NN O
treat NN NN O
hepatitis NN NN B-Disease
C NN NN I-Disease
. NN NN O
   
Intravenous NN NN O
ribavirin NN NN O
is NN NN O
the NN NN O
treatment NN NN O
of NN NN O
choice NN NN O
for NN NN O
infection NN NN B-Disease
with NN NN I-Disease
hemorrhagic NN NN I-Disease
fever NN NN I-Disease
viruses NN NN I-Disease
. NN NN O
   
The NN NN O
most NN NN O
common NN NN O
adverse NN NN O
effect NN NN O
of NN NN O
intravenous NN NN O
ribavirin NN NN O
is NN NN O
reversible NN NN O
mild NN NN O
anemia NN NN B-Disease
. NN NN O
   
The NN NN O
use NN NN O
of NN NN O
cidofovir NN NN O
in NN NN O
severe NN NN O
adenovirus NN NN B-Disease
infection NN NN I-Disease
has NN NN O
been NN NN O
limited NN NN O
by NN NN O
adverse NN NN O
effects NN NN O
, NN NN O
the NN NN O
most NN NN O
significant NN NN O
of NN NN O
which NN NN O
is NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
We NN NN O
report NN NN O
our NN NN O
experience NN NN O
with NN NN O
intravenous NN NN O
ribavirin NN NN O
therapy NN NN O
for NN NN O
severe NN NN O
adenovirus NN NN B-Disease
disease NN NN I-Disease
in NN NN O
a NN NN O
series NN NN O
of NN NN O
immunocompromised NN NN O
children NN NN O
and NN NN O
review NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
DESIGN NN NN O
/ NN NN O
METHODS NN NN O
: NN NN O
We NN NN O
retrospectively NN NN O
reviewed NN NN O
the NN NN O
medical NN NN O
records NN NN O
of NN NN O
5 NN NN O
children NN NN O
treated NN NN O
with NN NN O
intravenous NN NN O
ribavirin NN NN O
for NN NN O
documented NN NN O
severe NN NN O
adenovirus NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
Two NN NN O
patients NN NN O
developed NN NN O
adenovirus NN NN O
hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
after NN NN O
cardiac NN NN O
and NN NN O
bone NN NN O
marrow NN NN O
transplants NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
The NN NN O
bone NN NN O
marrow NN NN O
transplant NN NN O
patient NN NN O
also NN NN O
received NN NN O
intravenous NN NN O
cidofovir NN NN O
for NN NN O
progressive NN NN O
disseminated NN NN O
disease NN NN O
. NN NN O
   
An NN NN O
additional NN NN O
3 NN NN O
children NN NN O
developed NN NN O
adenovirus NN NN B-Disease
pneumonia NN NN I-Disease
; NN NN O
2 NN NN O
were NN NN O
neonates NN NN O
, NN NN O
1 NN NN O
of NN NN O
whom NN NN O
had NN NN O
partial NN NN O
DiGeorge NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
The NN NN O
remaining NN NN O
infant NN NN O
had NN NN O
recently NN NN O
undergone NN NN O
a NN NN O
cardiac NN NN O
transplant NN NN O
. NN NN O
   
Intravenous NN NN O
ribavirin NN NN O
was NN NN O
administered NN NN O
on NN NN O
a NN NN O
compassionate NN NN O
- NN NN O
use NN NN O
protocol NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Complete NN NN O
clinical NN NN O
recovery NN NN O
followed NN NN O
later NN NN O
by NN NN O
viral NN NN O
clearance NN NN O
was NN NN O
observed NN NN O
in NN NN O
2 NN NN O
children NN NN O
: NN NN O
the NN NN O
cardiac NN NN O
transplant NN NN O
recipient NN NN O
with NN NN O
adenovirus NN NN O
hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
and NN NN O
the NN NN O
immunocompetent NN NN O
neonate NN NN O
with NN NN O
adenovirus NN NN B-Disease
pneumonia NN NN I-Disease
. NN NN O
   
The NN NN O
remaining NN NN O
3 NN NN O
children NN NN O
died NN NN O
of NN NN O
adenovirus NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
Intravenous NN NN O
ribavirin NN NN O
therapy NN NN O
was NN NN O
well NN NN O
tolerated NN NN O
. NN NN O
   
Use NN NN O
of NN NN O
cidofovir NN NN O
in NN NN O
1 NN NN O
child NN NN O
was NN NN O
associated NN NN O
with NN NN O
progressive NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
and NN NN O
neutropenia NN NN B-Disease
. NN NN O
   
DISCUSSION NN NN O
: NN NN O
Our NN NN O
series NN NN O
of NN NN O
patients NN NN O
is NN NN O
representative NN NN O
of NN NN O
the NN NN O
spectrum NN NN O
of NN NN O
immunocompromised NN NN O
children NN NN O
at NN NN O
greatest NN NN O
risk NN NN O
for NN NN O
severe NN NN O
adenovirus NN NN B-Disease
disease NN NN I-Disease
, NN NN O
namely NN NN O
solid NN NN O
- NN NN O
organ NN NN O
and NN NN O
bone NN NN O
marrow NN NN O
transplant NN NN O
recipients NN NN O
, NN NN O
neonates NN NN O
, NN NN O
and NN NN O
children NN NN O
with NN NN O
immunodeficiency NN NN B-Disease
. NN NN O
   
Although NN NN O
intravenous NN NN O
ribavirin NN NN O
was NN NN O
not NN NN O
effective NN NN O
for NN NN O
all NN NN O
children NN NN O
with NN NN O
severe NN NN O
adenovirus NN NN B-Disease
disease NN NN I-Disease
in NN NN O
this NN NN O
series NN NN O
or NN NN O
in NN NN O
the NN NN O
literature NN NN O
, NN NN O
therapy NN NN O
is NN NN O
unlikely NN NN O
to NN NN O
be NN NN O
of NN NN O
benefit NN NN O
if NN NN O
begun NN NN O
late NN NN O
in NN NN O
the NN NN O
course NN NN O
of NN NN O
the NN NN O
infection NN NN B-Disease
. NN NN O
   
Early NN NN O
identification NN NN O
, NN NN O
eg NN NN O
by NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
of NN NN O
those NN NN O
patients NN NN O
at NN NN O
risk NN NN O
of NN NN O
disseminated NN NN O
adenovirus NN NN B-Disease
disease NN NN I-Disease
may NN NN O
permit NN NN O
earlier NN NN O
antiviral NN NN O
treatment NN NN O
and NN NN O
better NN NN O
evaluation NN NN O
of NN NN O
therapeutic NN NN O
response NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Two NN NN O
of NN NN O
5 NN NN O
children NN NN O
with NN NN O
severe NN NN O
adenovirus NN NN B-Disease
disease NN NN I-Disease
treated NN NN O
with NN NN O
intravenous NN NN O
ribavirin NN NN O
recovered NN NN O
. NN NN O
   
The NN NN O
availability NN NN O
of NN NN O
newer NN NN O
rapid NN NN O
diagnostic NN NN O
techniques NN NN O
, NN NN O
such NN NN O
as NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
, NN NN O
may NN NN O
make NN NN O
earlier NN NN O
, NN NN O
more NN NN O
effective NN NN O
treatment NN NN O
of NN NN O
adenovirus NN NN B-Disease
infection NN NN I-Disease
possible NN NN O
. NN NN O
   
Given NN NN O
the NN NN O
seriousness NN NN O
and NN NN O
increasing NN NN O
prevalence NN NN O
of NN NN O
adenovirus NN NN B-Disease
disease NN NN I-Disease
in NN NN O
certain NN NN O
hosts NN NN O
, NN NN O
especially NN NN O
children NN NN O
, NN NN O
a NN NN O
large NN NN O
, NN NN O
multicenter NN NN O
clinical NN NN O
trial NN NN O
of NN NN O
potentially NN NN O
useful NN NN O
anti NN NN O
- NN NN O
adenoviral NN NN O
therapies NN NN O
, NN NN O
such NN NN O
as NN NN O
intravenous NN NN O
ribavirin NN NN O
, NN NN O
is NN NN O
clearly NN NN O
required NN NN O
to NN NN O
demonstrate NN NN O
the NN NN O
most NN NN O
effective NN NN O
and NN NN O
least NN NN O
toxic NN NN O
therapy NN NN O
. NN NN O
   
Delayed NN NN O
asystolic NN NN B-Disease
cardiac NN NN B-Disease
arrest NN NN I-Disease
after NN NN O
diltiazem NN NN O
overdose NN NN B-Disease
; NN NN O
resuscitation NN NN O
with NN NN O
high NN NN O
dose NN NN O
intravenous NN NN O
calcium NN NN O
. NN NN O
   
A NN NN O
51 NN NN O
year NN NN O
old NN NN O
man NN NN O
took NN NN O
a NN NN O
mixed NN NN O
overdose NN NN B-Disease
including NN NN O
1 NN NN O
. NN NN O
8 NN NN O
- NN NN O
3 NN NN O
. NN NN O
6 NN NN O
g NN NN O
of NN NN O
diltiazem NN NN O
, NN NN O
paracetamol NN NN O
, NN NN O
aspirin NN NN O
, NN NN O
isosorbide NN NN O
nitrate NN NN O
, NN NN O
and NN NN O
alcohol NN NN O
. NN NN O
   
He NN NN O
initially NN NN O
presented NN NN O
to NN NN O
hospital NN NN O
after NN NN O
six NN NN O
hours NN NN O
with NN NN O
mild NN NN O
hypotension NN NN B-Disease
and NN NN O
was NN NN O
treated NN NN O
with NN NN O
activated NN NN O
charcoal NN NN O
and NN NN O
intravenous NN NN O
fluids NN NN O
. NN NN O
   
Eighteen NN NN O
hours NN NN O
after NN NN O
the NN NN O
overdose NN NN B-Disease
he NN NN O
had NN NN O
two NN NN O
generalised NN NN O
tonic NN NN B-Disease
- NN NN I-Disease
clonic NN NN I-Disease
seizures NN NN I-Disease
. NN NN O
   
The NN NN O
patient NN NN O
remained NN NN O
unresponsive NN NN O
with NN NN O
junctional NN NN O
bradycardia NN NN B-Disease
, NN NN O
unrecordable NN NN O
blood NN NN O
pressure NN NN O
, NN NN O
and NN NN O
then NN NN O
became NN NN O
asystolic NN NN B-Disease
. NN NN O
   
He NN NN O
was NN NN O
resuscitated NN NN O
with NN NN O
high NN NN O
dose NN NN O
( NN NN O
13 NN NN O
. NN NN O
5 NN NN O
g NN NN O
) NN NN O
intravenous NN NN O
calcium NN NN O
and NN NN O
adrenaline NN NN O
( NN NN O
epinephrine NN NN O
) NN NN O
. NN NN O
   
He NN NN O
required NN NN O
inotropic NN NN O
support NN NN O
and NN NN O
temporary NN NN O
pacing NN NN O
over NN NN O
the NN NN O
next NN NN O
48 NN NN O
hours NN NN O
. NN NN O
   
This NN NN O
case NN NN O
suggests NN NN O
there NN NN O
is NN NN O
a NN NN O
role NN NN O
for NN NN O
aggressive NN NN O
high NN NN O
dose NN NN O
intravenous NN NN O
calcium NN NN O
therapy NN NN O
in NN NN O
severe NN NN O
diltiazem NN NN O
overdose NN NN B-Disease
, NN NN O
particularly NN NN O
with NN NN O
the NN NN O
onset NN NN O
of NN NN O
asystole NN NN B-Disease
. NN NN O
   
It NN NN O
should NN NN O
be NN NN O
considered NN NN O
early NN NN O
in NN NN O
cases NN NN O
of NN NN O
cardiac NN NN B-Disease
arrest NN NN I-Disease
after NN NN O
diltiazem NN NN O
overdose NN NN B-Disease
. NN NN O
   
The NN NN O
case NN NN O
also NN NN O
highlights NN NN O
the NN NN O
problems NN NN O
with NN NN O
delayed NN NN O
toxicity NN NN B-Disease
when NN NN O
whole NN NN O
bowel NN NN O
irrigation NN NN O
is NN NN O
not NN NN O
administered NN NN O
. NN NN O
   
Low NN NN O
- NN NN O
molecular NN NN O
- NN NN O
weight NN NN O
heparin NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
patients NN NN O
with NN NN O
mechanical NN NN O
heart NN NN O
valves NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
interruption NN NN O
of NN NN O
oral NN NN O
anticoagulant NN NN O
( NN NN O
OAC NN NN O
) NN NN O
administration NN NN O
is NN NN O
sometimes NN NN O
indicated NN NN O
in NN NN O
patients NN NN O
with NN NN O
mechanical NN NN O
heart NN NN O
valves NN NN O
, NN NN O
mainly NN NN O
before NN NN O
noncardiac NN NN O
surgery NN NN O
, NN NN O
non NN NN O
- NN NN O
surgical NN NN O
interventions NN NN O
, NN NN O
and NN NN O
pregnancy NN NN O
. NN NN O
   
Unfractionated NN NN O
heparin NN NN O
( NN NN O
UH NN NN O
) NN NN O
is NN NN O
currently NN NN O
the NN NN O
substitute NN NN O
for NN NN O
selected NN NN O
patients NN NN O
. NN NN O
   
Low NN NN O
- NN NN O
molecular NN NN O
- NN NN O
weight NN NN O
heparin NN NN O
( NN NN O
LMWH NN NN O
) NN NN O
offers NN NN O
theoretical NN NN O
advantages NN NN O
over NN NN O
UH NN NN O
, NN NN O
but NN NN O
is NN NN O
not NN NN O
currently NN NN O
considered NN NN O
in NN NN O
clinical NN NN O
guidelines NN NN O
as NN NN O
an NN NN O
alternative NN NN O
to NN NN O
UH NN NN O
in NN NN O
patients NN NN O
with NN NN O
prosthetic NN NN O
valves NN NN O
. NN NN O
   
HYPOTHESIS NN NN O
: NN NN O
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
review NN NN O
the NN NN O
data NN NN O
accumulated NN NN O
so NN NN O
far NN NN O
on NN NN O
the NN NN O
use NN NN O
of NN NN O
LMWH NN NN O
in NN NN O
this NN NN O
patient NN NN O
population NN NN O
and NN NN O
to NN NN O
discuss NN NN O
its NN NN O
applicability NN NN O
in NN NN O
common NN NN O
practice NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
For NN NN O
this NN NN O
paper NN NN O
, NN NN O
the NN NN O
current NN NN O
medical NN NN O
literature NN NN O
on NN NN O
LMWH NN NN O
in NN NN O
patients NN NN O
with NN NN O
mechanical NN NN O
heart NN NN O
valves NN NN O
was NN NN O
extensively NN NN O
reviewed NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
There NN NN O
were NN NN O
eight NN NN O
series NN NN O
and NN NN O
six NN NN O
case NN NN O
reports NN NN O
. NN NN O
   
   O
of NN NN O
the NN NN O
studies NN NN O
was NN NN O
randomized NN NN O
, NN NN O
and NN NN O
only NN NN O
one NN NN O
was NN NN O
prospective NN NN O
. NN NN O
   
Data NN NN O
to NN NN O
establish NN NN O
the NN NN O
thromboembolic NN NN B-Disease
risk NN NN O
were NN NN O
incomplete NN NN O
. NN NN O
   
After NN NN O
excluding NN NN O
case NN NN O
reports NN NN O
, NN NN O
the NN NN O
following NN NN O
groups NN NN O
were NN NN O
constructed NN NN O
: NN NN O
( NN NN O
a NN NN O
) NN NN O
short NN NN O
- NN NN O
term NN NN O
administration NN NN O
, NN NN O
after NN NN O
valve NN NN O
insertion NN NN O
( NN NN O
n NN NN O
= NN NN O
212 NN NN O
) NN NN O
; NN NN O
( NN NN O
b NN NN O
) NN NN O
short NN NN O
- NN NN O
term NN NN O
, NN NN O
perioperative NN NN O
( NN NN O
noncardiac NN NN O
) NN NN O
/ NN NN O
periprocedural NN NN O
( NN NN O
n NN NN O
= NN NN O
114 NN NN O
) NN NN O
; NN NN O
( NN NN O
c NN NN O
) NN NN O
long NN NN O
- NN NN O
term NN NN O
, NN NN O
due NN NN O
to NN NN O
intolerance NN NN O
to NN NN O
OAC NN NN O
( NN NN O
n NN NN O
= NN NN O
16 NN NN O
) NN NN O
; NN NN O
( NN NN O
d NN NN O
) NN NN O
long NN NN O
- NN NN O
term NN NN O
, NN NN O
in NN NN O
pregnancy NN NN O
( NN NN O
n NN NN O
= NN NN O
10 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
rate NN NN O
of NN NN O
thromboembolism NN NN B-Disease
was NN NN O
0 NN NN O
. NN NN O
9 NN NN O
% NN NN O
for NN NN O
all NN NN O
the NN NN O
studies NN NN O
and NN NN O
0 NN NN O
. NN NN O
5 NN NN O
, NN NN O
0 NN NN O
, NN NN O
20 NN NN O
, NN NN O
and NN NN O
0 NN NN O
% NN NN O
in NN NN O
groups NN NN O
a NN NN O
, NN NN O
b NN NN O
, NN NN O
c NN NN O
, NN NN O
and NN NN O
d NN NN O
, NN NN O
respectively NN NN O
; NN NN O
for NN NN O
hemorrhage NN NN B-Disease
, NN NN O
the NN NN O
overall NN NN O
rate NN NN O
was NN NN O
3 NN NN O
. NN NN O
4 NN NN O
% NN NN O
( NN NN O
3 NN NN O
. NN NN O
8 NN NN O
, NN NN O
2 NN NN O
. NN NN O
6 NN NN O
, NN NN O
10 NN NN O
, NN NN O
and NN NN O
0 NN NN O
% NN NN O
for NN NN O
the NN NN O
respective NN NN O
groups NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
In NN NN O
patients NN NN O
with NN NN O
mechanical NN NN O
heart NN NN O
valves NN NN O
, NN NN O
short NN NN O
- NN NN O
term NN NN O
LMWH NN NN O
therapy NN NN O
compares NN NN O
favorably NN NN O
with NN NN O
UH NN NN O
. NN NN O
   
Data NN NN O
on NN NN O
mid NN NN O
- NN NN O
and NN NN O
long NN NN O
- NN NN O
term NN NN O
LMWH NN NN O
administration NN NN O
in NN NN O
these NN NN O
patients NN NN O
are NN NN O
sparse NN NN O
. NN NN O
   
Further NN NN O
randomized NN NN O
studies NN NN O
are NN NN O
needed NN NN O
to NN NN O
confirm NN NN O
the NN NN O
safety NN NN O
and NN NN O
precise NN NN O
indications NN NN O
for NN NN O
the NN NN O
use NN NN O
of NN NN O
LMWH NN NN O
in NN NN O
patients NN NN O
with NN NN O
mechanical NN NN O
heart NN NN O
valves NN NN O
. NN NN O
   
Cardiac NN NN B-Disease
arrest NN NN I-Disease
after NN NN O
intravenous NN NN O
metoclopramide NN NN O
- NN NN O
a NN NN O
case NN NN O
of NN NN O
five NN NN O
repeated NN NN O
injections NN NN O
of NN NN O
metoclopramide NN NN O
causing NN NN O
five NN NN O
episodes NN NN O
of NN NN O
cardiac NN NN B-Disease
arrest NN NN I-Disease
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
patient NN NN O
where NN NN O
intravenous NN NN O
injection NN NN O
of NN NN O
metoclopramide NN NN O
was NN NN O
immediately NN NN O
followed NN NN O
by NN NN O
asystole NN NN B-Disease
repeatedly NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
received NN NN O
metoclopramide NN NN O
10 NN NN O
mg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
five NN NN O
times NN NN O
during NN NN O
48 NN NN O
h NN NN O
. NN NN O
   
After NN NN O
interviewing NN NN O
the NN NN O
attending NN NN O
nurses NN NN O
and NN NN O
reviewing NN NN O
the NN NN O
written NN NN O
documentation NN NN O
, NN NN O
it NN NN O
is NN NN O
clear NN NN O
that NN NN O
every NN NN O
administration NN NN O
of NN NN O
metoclopramide NN NN O
was NN NN O
immediately NN NN O
( NN NN O
within NN NN O
s NN NN O
) NN NN O
followed NN NN O
by NN NN O
asystole NN NN B-Disease
. NN NN O
   
The NN NN O
asystole NN NN B-Disease
lasted NN NN O
15 NN NN O
- NN NN O
30 NN NN O
s NN NN O
on NN NN O
four NN NN O
occasions NN NN O
, NN NN O
on NN NN O
one NN NN O
occasion NN NN O
it NN NN O
lasted NN NN O
2 NN NN O
min NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
received NN NN O
atropine NN NN O
0 NN NN O
. NN NN O
5 NN NN O
- NN NN O
1 NN NN O
mg NN NN O
and NN NN O
chest NN NN O
compressions NN NN O
, NN NN O
before NN NN O
sinus NN NN O
rhythm NN NN O
again NN NN O
took NN NN O
over NN NN O
. NN NN O
   
We NN NN O
interpret NN NN O
this NN NN O
as NN NN O
episodes NN NN O
of NN NN O
cardiac NN NN B-Disease
arrest NN NN I-Disease
caused NN NN O
by NN NN O
metoclopramide NN NN O
. NN NN O
   
The NN NN O
rapid NN NN O
injection NN NN O
via NN NN O
the NN NN O
central NN NN O
venous NN NN O
route NN NN O
and NN NN O
the NN NN O
concomitant NN NN O
tapering NN NN O
of NN NN O
dopamine NN NN O
infusion NN NN O
might NN NN O
have NN NN O
contributed NN NN O
in NN NN O
precipitating NN NN O
the NN NN O
adverse NN NN O
drug NN NN O
reaction NN NN O
. NN NN O
   
Immunohistochemical NN NN O
study NN NN O
on NN NN O
inducible NN NN O
type NN NN O
of NN NN O
nitric NN NN O
oxide NN NN O
( NN NN O
iNOS NN NN O
) NN NN O
, NN NN O
basic NN NN O
fibroblast NN NN O
growth NN NN O
factor NN NN O
( NN NN O
bFGF NN NN O
) NN NN O
and NN NN O
tumor NN NN B-Disease
growth NN NN O
factor NN NN O
- NN NN O
beta1 NN NN O
( NN NN O
TGF NN NN O
- NN NN O
beta1 NN NN O
) NN NN O
in NN NN O
arteritis NN NN B-Disease
induced NN NN O
in NN NN O
rats NN NN O
by NN NN O
fenoldopam NN NN O
and NN NN O
theophylline NN NN O
, NN NN O
vasodilators NN NN O
. NN NN O
   
Arteritis NN NN B-Disease
induced NN NN O
in NN NN O
rats NN NN O
by NN NN O
vasodilators NN NN O
, NN NN O
fenoldopam NN NN O
and NN NN O
theophylline NN NN O
, NN NN O
was NN NN O
examined NN NN O
immunohistochemically NN NN O
for NN NN O
expressions NN NN O
of NN NN O
inducible NN NN O
type NN NN O
of NN NN O
nitric NN NN O
oxide NN NN O
synthase NN NN O
( NN NN O
iNOS NN NN O
) NN NN O
, NN NN O
basic NN NN O
fibroblast NN NN O
growth NN NN O
factor NN NN O
( NN NN O
bFGF NN NN O
) NN NN O
and NN NN O
tumor NN NN B-Disease
growth NN NN O
factor NN NN O
- NN NN O
beta1 NN NN O
( NN NN O
TGF NN NN O
- NN NN O
beta1 NN NN O
) NN NN O
. NN NN O
   
Rats NN NN O
were NN NN O
administered NN NN O
fenoldopam NN NN O
for NN NN O
24 NN NN O
hours NN NN O
by NN NN O
intravenous NN NN O
infusion NN NN O
with NN NN O
or NN NN O
without NN NN O
following NN NN O
repeated NN NN O
daily NN NN O
oral NN NN O
administrations NN NN O
of NN NN O
theophylline NN NN O
. NN NN O
   
Irrespective NN NN O
of NN NN O
theophylline NN NN O
administration NN NN O
, NN NN O
iNOS NN NN O
antigens NN NN O
were NN NN O
remarkably NN NN O
abundant NN NN O
in NN NN O
ED NN NN O
- NN NN O
1 NN NN O
- NN NN O
positive NN NN O
cells NN NN O
on NN NN O
day NN NN O
5 NN NN O
and NN NN O
8 NN NN O
post NN NN O
- NN NN O
fenoldopam NN NN O
- NN NN O
infusion NN NN O
( NN NN O
DPI NN NN O
) NN NN O
; NN NN O
bFGF NN NN O
antigens NN NN O
were NN NN O
remarkably NN NN O
abundant NN NN O
in NN NN O
ED NN NN O
- NN NN O
1 NN NN O
- NN NN O
positive NN NN O
cells NN NN O
on NN NN O
1 NN NN O
and NN NN O
3 NN NN O
DPI NN NN O
; NN NN O
TGF NN NN O
- NN NN O
beta1 NN NN O
antigens NN NN O
were NN NN O
observed NN NN O
in NN NN O
ED NN NN O
- NN NN O
1 NN NN O
- NN NN O
positive NN NN O
cells NN NN O
on NN NN O
and NN NN O
after NN NN O
5 NN NN O
DPI NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
peak NN NN O
expression NN NN O
of NN NN O
iNOS NN NN O
antigen NN NN O
was NN NN O
followed NN NN O
by NN NN O
that NN NN O
of NN NN O
bFGF NN NN O
antigen NN NN O
, NN NN O
and NN NN O
bFGF NN NN O
may NN NN O
have NN NN O
a NN NN O
suppressive NN NN O
effect NN NN O
on NN NN O
iNOS NN NN O
expression NN NN O
in NN NN O
these NN NN O
rat NN NN O
arteritis NN NN B-Disease
models NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
TGF NN NN O
- NN NN O
beta1 NN NN O
was NN NN O
not NN NN O
considered NN NN O
to NN NN O
have NN NN O
a NN NN O
suppressive NN NN O
effect NN NN O
on NN NN O
iNOS NN NN O
expression NN NN O
in NN NN O
these NN NN O
models NN NN O
. NN NN O
   
The NN NN O
striatum NN NN O
as NN NN O
a NN NN O
target NN NN O
for NN NN O
anti NN NN O
- NN NN O
rigor NN NN O
effects NN NN O
of NN NN O
an NN NN O
antagonist NN NN O
of NN NN O
mGluR1 NN NN O
, NN NN O
but NN NN O
not NN NN O
an NN NN O
agonist NN NN O
of NN NN O
group NN NN O
II NN NN O
metabotropic NN NN O
glutamate NN NN O
receptors NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
find NN NN O
out NN NN O
whether NN NN O
the NN NN O
metabotropic NN NN O
receptor NN NN O
1 NN NN O
( NN NN O
mGluR1 NN NN O
) NN NN O
and NN NN O
group NN NN O
II NN NN O
mGluRs NN NN O
, NN NN O
localized NN NN O
in NN NN O
the NN NN O
striatum NN NN O
, NN NN O
are NN NN O
involved NN NN O
in NN NN O
antiparkinsonian NN NN O
- NN NN O
like NN NN O
effects NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Haloperidol NN NN O
( NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
ip NN NN O
) NN NN O
induced NN NN O
parkinsonian NN NN B-Disease
- NN NN O
like NN NN O
muscle NN NN B-Disease
rigidity NN NN I-Disease
, NN NN O
measured NN NN O
as NN NN O
an NN NN O
increased NN NN O
resistance NN NN O
of NN NN O
a NN NN O
rat NN NN O
' NN NN O
s NN NN O
hind NN NN O
foot NN NN O
to NN NN O
passive NN NN O
flexion NN NN O
and NN NN O
extension NN NN O
at NN NN O
the NN NN O
ankle NN NN O
joint NN NN O
. NN NN O
   
( NN NN O
RS NN NN O
) NN NN O
- NN NN O
1 NN NN O
- NN NN O
aminoindan NN NN O
- NN NN O
1 NN NN O
, NN NN O
5 NN NN O
- NN NN O
dicarboxylic NN NN O
acid NN NN O
( NN NN O
AIDA NN NN O
; NN NN O
0 NN NN O
. NN NN O
5 NN NN O
- NN NN O
15 NN NN O
microg NN NN O
/ NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microl NN NN O
) NN NN O
, NN NN O
a NN NN O
potent NN NN O
and NN NN O
selective NN NN O
mGluR1 NN NN O
antagonist NN NN O
, NN NN O
or NN NN O
( NN NN O
2R NN NN O
, NN NN O
4R NN NN O
) NN NN O
- NN NN O
4 NN NN O
- NN NN O
aminopyrrolidine NN NN O
- NN NN O
2 NN NN O
, NN NN O
4 NN NN O
- NN NN O
dicarboxylate NN NN O
( NN NN O
2R NN NN O
, NN NN O
4R NN NN O
- NN NN O
APDC NN NN O
; NN NN O
7 NN NN O
. NN NN O
5 NN NN O
- NN NN O
15 NN NN O
microg NN NN O
/ NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microl NN NN O
) NN NN O
, NN NN O
a NN NN O
selective NN NN O
group NN NN O
II NN NN O
agonist NN NN O
, NN NN O
was NN NN O
injected NN NN O
bilaterally NN NN O
into NN NN O
the NN NN O
striatum NN NN O
of NN NN O
haloperidol NN NN O
- NN NN O
treated NN NN O
animals NN NN O
. NN NN O
   
AIDA NN NN O
in NN NN O
doses NN NN O
of NN NN O
7 NN NN O
. NN NN O
5 NN NN O
- NN NN O
15 NN NN O
microg NN NN O
/ NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microl NN NN O
diminished NN NN O
the NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
muscle NN NN B-Disease
rigidity NN NN I-Disease
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
2R NN NN O
, NN NN O
4R NN NN O
- NN NN O
APDC NN NN O
injections NN NN O
were NN NN O
ineffective NN NN O
. NN NN O
   
The NN NN O
present NN NN O
results NN NN O
may NN NN O
suggest NN NN O
that NN NN O
the NN NN O
blockade NN NN O
of NN NN O
striatal NN NN O
mGluR1 NN NN O
, NN NN O
but NN NN O
not NN NN O
the NN NN O
stimulation NN NN O
of NN NN O
group NN NN O
II NN NN O
mGluRs NN NN O
, NN NN O
may NN NN O
ameliorate NN NN O
parkinsonian NN NN B-Disease
muscle NN NN B-Disease
rigidity NN NN I-Disease
. NN NN O
   
A NN NN O
phase NN NN O
II NN NN O
study NN NN O
of NN NN O
thalidomide NN NN O
in NN NN O
advanced NN NN O
metastatic NN NN O
renal NN NN B-Disease
cell NN NN I-Disease
carcinoma NN NN I-Disease
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
To NN NN O
evaluate NN NN O
the NN NN O
toxicity NN NN B-Disease
and NN NN O
activity NN NN O
of NN NN O
thalidomide NN NN O
in NN NN O
patients NN NN O
with NN NN O
advanced NN NN O
metastatic NN NN O
renal NN NN B-Disease
cell NN NN I-Disease
cancer NN NN I-Disease
and NN NN O
to NN NN O
measure NN NN O
changes NN NN O
of NN NN O
one NN NN O
angiogenic NN NN O
factor NN NN O
, NN NN O
vascular NN NN O
endothelial NN NN O
growth NN NN O
factor NN NN O
( NN NN O
VEGF NN NN O
) NN NN O
165 NN NN O
, NN NN O
with NN NN O
therapy NN NN O
. NN NN O
   
PATIENTS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
29 NN NN O
patients NN NN O
were NN NN O
enrolled NN NN O
on NN NN O
a NN NN O
study NN NN O
of NN NN O
thalidomide NN NN O
using NN NN O
an NN NN O
intra NN NN O
- NN NN O
patient NN NN O
dose NN NN O
escalation NN NN O
schedule NN NN O
. NN NN O
   
Patients NN NN O
began NN NN O
thalidomide NN NN O
at NN NN O
400 NN NN O
mg NN NN O
/ NN NN O
d NN NN O
and NN NN O
escalated NN NN O
as NN NN O
tolerated NN NN O
to NN NN O
1200 NN NN O
mg NN NN O
/ NN NN O
d NN NN O
by NN NN O
day NN NN O
54 NN NN O
. NN NN O
   
Fifty NN NN O
- NN NN O
nine NN NN O
per NN NN O
cent NN NN O
of NN NN O
patients NN NN O
had NN NN O
had NN NN O
previous NN NN O
therapy NN NN O
with NN NN O
IL NN NN O
- NN NN O
2 NN NN O
and NN NN O
52 NN NN O
% NN NN O
were NN NN O
performance NN NN O
status NN NN O
2 NN NN O
or NN NN O
3 NN NN O
. NN NN O
   
Systemic NN NN O
plasma NN NN O
VEGF165 NN NN O
levels NN NN O
were NN NN O
measured NN NN O
by NN NN O
dual NN NN O
monoclonal NN NN O
ELISA NN NN O
in NN NN O
8 NN NN O
patients NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
24 NN NN O
patients NN NN O
were NN NN O
evaluable NN NN O
for NN NN O
response NN NN O
with NN NN O
one NN NN O
partial NN NN O
response NN NN O
of NN NN O
11 NN NN O
months NN NN O
duration NN NN O
of NN NN O
a NN NN O
patient NN NN O
with NN NN O
hepatic NN NN O
and NN NN O
pulmonary NN NN O
metastases NN NN B-Disease
( NN NN O
4 NN NN O
% NN NN O
) NN NN O
, NN NN O
one NN NN O
minor NN NN O
response NN NN O
, NN NN O
and NN NN O
2 NN NN O
patients NN NN O
stable NN NN O
for NN NN O
over NN NN O
6 NN NN O
months NN NN O
. NN NN O
   
Somnolence NN NN B-Disease
and NN NN O
constipation NN NN B-Disease
were NN NN O
prominent NN NN O
toxicities NN NN B-Disease
and NN NN O
most NN NN O
patients NN NN O
could NN NN O
not NN NN O
tolerate NN NN O
the NN NN O
1200 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
dose NN NN O
level NN NN O
. NN NN O
   
Systemic NN NN O
plasma NN NN O
VEGF165 NN NN O
levels NN NN O
did NN NN O
not NN NN O
change NN NN O
with NN NN O
therapy NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
These NN NN O
results NN NN O
are NN NN O
consistent NN NN O
with NN NN O
a NN NN O
low NN NN O
level NN NN O
of NN NN O
activity NN NN O
of NN NN O
thalidomide NN NN O
in NN NN O
renal NN NN B-Disease
cell NN NN I-Disease
carcinoma NN NN I-Disease
. NN NN O
   
Administration NN NN O
of NN NN O
doses NN NN O
over NN NN O
800 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
was NN NN O
difficult NN NN O
to NN NN O
achieve NN NN O
in NN NN O
this NN NN O
patient NN NN O
population NN NN O
, NN NN O
however NN NN O
lower NN NN O
doses NN NN O
were NN NN O
practical NN NN O
. NN NN O
   
The NN NN O
dose NN NN O
- NN NN O
response NN NN O
relationship NN NN O
, NN NN O
if NN NN O
any NN NN O
, NN NN O
of NN NN O
thalidomide NN NN O
for NN NN O
renal NN NN B-Disease
cell NN NN I-Disease
carcinoma NN NN I-Disease
is NN NN O
unclear NN NN O
. NN NN O
   
Can NN NN O
lidocaine NN NN O
reduce NN NN O
succinylcholine NN NN O
induced NN NN O
postoperative NN NN B-Disease
myalgia NN NN I-Disease
? NN NN O
   
This NN NN O
study NN NN O
was NN NN O
undertaken NN NN O
to NN NN O
determine NN NN O
the NN NN O
effect NN NN O
of NN NN O
lidocaine NN NN O
pretreatment NN NN O
on NN NN O
reduction NN NN O
of NN NN O
succinylcholine NN NN O
- NN NN O
induced NN NN O
myalgia NN NN B-Disease
in NN NN O
patients NN NN O
undergoing NN NN O
general NN NN O
anesthesia NN NN O
for NN NN O
gynecological NN NN O
surgery NN NN O
. NN NN O
   
One NN NN O
hundred NN NN O
and NN NN O
thirty NN NN O
- NN NN O
five NN NN O
patients NN NN O
were NN NN O
assigned NN NN O
to NN NN O
one NN NN O
of NN NN O
three NN NN O
groups NN NN O
in NN NN O
a NN NN O
prospective NN NN O
, NN NN O
double NN NN O
blind NN NN O
, NN NN O
randomized NN NN O
manner NN NN O
. NN NN O
   
Group NN NN O
PS NN NN O
, NN NN O
the NN NN O
control NN NN O
group NN NN O
, NN NN O
received NN NN O
normal NN NN O
saline NN NN O
and NN NN O
succinylcholine NN NN O
1 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
x NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
; NN NN O
Group NN NN O
LS NN NN O
, NN NN O
lidocaine NN NN O
1 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
x NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
and NN NN O
succinylcholine NN NN O
1 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
x NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
; NN NN O
Group NN NN O
PR NN NN O
, NN NN O
normal NN NN O
saline NN NN O
and NN NN O
rocuronium NN NN O
0 NN NN O
. NN NN O
6 NN NN O
mg NN NN O
x NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
Morphine NN NN O
0 NN NN O
. NN NN O
1 NN NN O
mg NN NN O
x NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
iv NN NN O
was NN NN O
given NN NN O
for NN NN O
premedication NN NN O
and NN NN O
all NN NN O
patients NN NN O
were NN NN O
monitored NN NN O
with NN NN O
a NN NN O
noninvasive NN NN O
blood NN NN O
pressure NN NN O
monitor NN NN O
, NN NN O
ECG NN NN O
and NN NN O
pulse NN NN O
oximetry NN NN O
. NN NN O
   
Anesthesia NN NN O
was NN NN O
induced NN NN O
with NN NN O
5 NN NN O
mg NN NN O
. NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
thiopental NN NN O
iv NN NN O
. NN NN O
followed NN NN O
by NN NN O
succinylcholine NN NN O
( NN NN O
Group NN NN O
PS NN NN O
, NN NN O
LS NN NN O
) NN NN O
or NN NN O
rocuronium NN NN O
( NN NN O
Group NN NN O
PR NN NN O
) NN NN O
for NN NN O
tracheal NN NN O
intubation NN NN O
. NN NN O
   
Following NN NN O
administration NN NN O
of NN NN O
these NN NN O
agents NN NN O
, NN NN O
the NN NN O
presence NN NN O
, NN NN O
and NN NN O
degree NN NN O
of NN NN O
fasciculation NN NN B-Disease
were NN NN O
assessed NN NN O
visually NN NN O
on NN NN O
a NN NN O
four NN NN O
point NN NN O
scale NN NN O
by NN NN O
one NN NN O
investigator NN NN O
who NN NN O
was NN NN O
blinded NN NN O
to NN NN O
the NN NN O
drug NN NN O
administered NN NN O
. NN NN O
   
The NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
heart NN NN O
rate NN NN O
of NN NN O
each NN NN O
patient NN NN O
were NN NN O
monitored NN NN O
on NN NN O
nine NN NN O
occasions NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
four NN NN O
hours NN NN O
later NN NN O
, NN NN O
any NN NN O
myalgia NN NN B-Disease
experienced NN NN O
was NN NN O
assessed NN NN O
according NN NN O
to NN NN O
a NN NN O
structured NN NN O
questionaire NN NN O
and NN NN O
graded NN NN O
by NN NN O
a NN NN O
four NN NN O
point NN NN O
scale NN NN O
by NN NN O
one NN NN O
investigator NN NN O
blinded NN NN O
to NN NN O
the NN NN O
intraoperative NN NN O
management NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
muscle NN NN B-Disease
fasciculation NN NN I-Disease
was NN NN O
not NN NN O
found NN NN O
in NN NN O
Group NN NN O
PR NN NN O
while NN NN O
the NN NN O
patients NN NN O
in NN NN O
Group NN NN O
LS NN NN O
had NN NN O
a NN NN O
lower NN NN O
incidence NN NN O
of NN NN O
muscle NN NN B-Disease
fasciculation NN NN I-Disease
than NN NN O
those NN NN O
in NN NN O
Group NN NN O
PS NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
At NN NN O
24 NN NN O
h NN NN O
, NN NN O
the NN NN O
incidence NN NN O
of NN NN O
myalgia NN NN B-Disease
was NN NN O
higher NN NN O
in NN NN O
Group NN NN O
PS NN NN O
than NN NN O
in NN NN O
Group NN NN O
LS NN NN O
and NN NN O
PR NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
A NN NN O
correlation NN NN O
was NN NN O
not NN NN O
found NN NN O
between NN NN O
the NN NN O
incidence NN NN O
of NN NN O
myalgia NN NN B-Disease
and NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
muscle NN NN B-Disease
fasciculation NN NN I-Disease
. NN NN O
   
The NN NN O
changes NN NN O
in NN NN O
systolic NN NN O
and NN NN O
diastolic NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
heart NN NN O
rate NN NN O
were NN NN O
not NN NN O
significant NN NN O
among NN NN O
the NN NN O
three NN NN O
groups NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
where NN NN O
succinylcholine NN NN O
is NN NN O
used NN NN O
, NN NN O
lidocaine NN NN O
is NN NN O
proven NN NN O
to NN NN O
be NN NN O
the NN NN O
useful NN NN O
pretreatment NN NN O
agent NN NN O
for NN NN O
the NN NN O
reduction NN NN O
of NN NN O
postoperative NN NN B-Disease
myalgia NN NN I-Disease
. NN NN O
   
Reduced NN NN O
sodium NN NN O
channel NN NN O
density NN NN O
, NN NN O
altered NN NN O
voltage NN NN O
dependence NN NN O
of NN NN O
inactivation NN NN O
, NN NN O
and NN NN O
increased NN NN O
susceptibility NN NN O
to NN NN O
seizures NN NN B-Disease
in NN NN O
mice NN NN O
lacking NN NN O
sodium NN NN O
channel NN NN O
beta NN NN O
2 NN NN O
- NN NN O
subunits NN NN O
. NN NN O
   
Sodium NN NN O
channel NN NN O
beta NN NN O
- NN NN O
subunits NN NN O
modulate NN NN O
channel NN NN O
gating NN NN O
, NN NN O
assembly NN NN O
, NN NN O
and NN NN O
cell NN NN O
surface NN NN O
expression NN NN O
in NN NN O
heterologous NN NN O
cell NN NN O
systems NN NN O
. NN NN O
   
We NN NN O
generated NN NN O
beta2 NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
to NN NN O
investigate NN NN O
the NN NN O
role NN NN O
of NN NN O
beta2 NN NN O
in NN NN O
control NN NN O
of NN NN O
sodium NN NN O
channel NN NN O
density NN NN O
, NN NN O
localization NN NN O
, NN NN O
and NN NN O
function NN NN O
in NN NN O
neurons NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Measurements NN NN O
of NN NN O
[ NN NN O
( NN NN O
3 NN NN O
) NN NN O
H NN NN O
] NN NN O
saxitoxin NN NN O
( NN NN O
STX NN NN O
) NN NN O
binding NN NN O
showed NN NN O
a NN NN O
significant NN NN O
reduction NN NN O
in NN NN O
the NN NN O
level NN NN O
of NN NN O
plasma NN NN O
membrane NN NN O
sodium NN NN O
channels NN NN O
in NN NN O
beta2 NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
neurons NN NN O
. NN NN O
   
The NN NN O
loss NN NN O
of NN NN O
beta2 NN NN O
resulted NN NN O
in NN NN O
negative NN NN O
shifts NN NN O
in NN NN O
the NN NN O
voltage NN NN O
dependence NN NN O
of NN NN O
inactivation NN NN O
as NN NN O
well NN NN O
as NN NN O
significant NN NN O
decreases NN NN O
in NN NN O
sodium NN NN O
current NN NN O
density NN NN O
in NN NN O
acutely NN NN O
dissociated NN NN O
hippocampal NN NN O
neurons NN NN O
. NN NN O
   
The NN NN O
integral NN NN O
of NN NN O
the NN NN O
compound NN NN O
action NN NN O
potential NN NN O
in NN NN O
optic NN NN O
nerve NN NN O
was NN NN O
significantly NN NN O
reduced NN NN O
, NN NN O
and NN NN O
the NN NN O
threshold NN NN O
for NN NN O
action NN NN O
potential NN NN O
generation NN NN O
was NN NN O
increased NN NN O
, NN NN O
indicating NN NN O
a NN NN O
reduction NN NN O
in NN NN O
the NN NN O
level NN NN O
of NN NN O
functional NN NN O
plasma NN NN O
membrane NN NN O
sodium NN NN O
channels NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
conduction NN NN O
velocity NN NN O
, NN NN O
the NN NN O
number NN NN O
and NN NN O
size NN NN O
of NN NN O
axons NN NN O
in NN NN O
the NN NN O
optic NN NN O
nerve NN NN O
, NN NN O
and NN NN O
the NN NN O
specific NN NN O
localization NN NN O
of NN NN O
Na NN NN O
( NN NN O
v NN NN O
) NN NN O
1 NN NN O
. NN NN O
6 NN NN O
channels NN NN O
in NN NN O
the NN NN O
nodes NN NN O
of NN NN O
Ranvier NN NN O
were NN NN O
unchanged NN NN O
. NN NN O
   
beta2 NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
displayed NN NN O
increased NN NN O
susceptibility NN NN O
to NN NN O
seizures NN NN B-Disease
, NN NN O
as NN NN O
indicated NN NN O
by NN NN O
reduced NN NN O
latency NN NN O
and NN NN O
threshold NN NN O
for NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
, NN NN O
but NN NN O
seemed NN NN O
normal NN NN O
in NN NN O
other NN NN O
neurological NN NN O
tests NN NN O
. NN NN O
   
Our NN NN O
observations NN NN O
show NN NN O
that NN NN O
beta2 NN NN O
- NN NN O
subunits NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
sodium NN NN O
channel NN NN O
density NN NN O
and NN NN O
function NN NN O
in NN NN O
neurons NN NN O
in NN NN O
vivo NN NN O
and NN NN O
are NN NN O
required NN NN O
for NN NN O
normal NN NN O
action NN NN O
potential NN NN O
generation NN NN O
and NN NN O
control NN NN O
of NN NN O
excitability NN NN O
. NN NN O
   
Acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
with NN NN O
concurrent NN NN O
bupropion NN NN O
and NN NN O
carbimazole NN NN O
therapy NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
fatal NN NN O
liver NN NN B-Disease
failure NN NN I-Disease
possibly NN NN O
associated NN NN O
with NN NN O
concurrent NN NN O
use NN NN O
of NN NN O
bupropion NN NN O
and NN NN O
carbimazole NN NN O
. NN NN O
   
CASE NN NN O
SUMMARY NN NN O
: NN NN O
A NN NN O
41 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
Chinese NN NN O
man NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
hyperthyroidism NN NN B-Disease
had NN NN O
been NN NN O
treated NN NN O
with NN NN O
carbimazole NN NN O
and NN NN O
propranolol NN NN O
for NN NN O
the NN NN O
past NN NN O
5 NN NN O
years NN NN O
. NN NN O
   
He NN NN O
received NN NN O
a NN NN O
10 NN NN O
- NN NN O
day NN NN O
course NN NN O
of NN NN O
bupropion NN NN O
as NN NN O
an NN NN O
aid NN NN O
for NN NN O
smoking NN NN O
cessation NN NN O
10 NN NN O
weeks NN NN O
prior NN NN O
to NN NN O
presentation NN NN O
. NN NN O
   
He NN NN O
developed NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
with NN NN O
rapid NN NN O
deterioration NN NN O
of NN NN O
renal NN NN O
function NN NN O
. NN NN O
   
Liver NN NN O
biopsy NN NN O
showed NN NN O
evidence NN NN O
of NN NN O
nonspecific NN NN O
drug NN NN B-Disease
- NN NN I-Disease
induced NN NN I-Disease
acute NN NN I-Disease
liver NN NN I-Disease
injury NN NN I-Disease
. NN NN O
   
His NN NN O
condition NN NN O
was NN NN O
further NN NN O
complicated NN NN O
by NN NN O
sepsis NN NN B-Disease
and NN NN O
coagulopathy NN NN B-Disease
. NN NN O
   
Death NN NN O
resulted NN NN O
19 NN NN O
days NN NN O
after NN NN O
the NN NN O
onset NN NN O
of NN NN O
symptoms NN NN O
. NN NN O
   
The NN NN O
likelihood NN NN O
that NN NN O
bupropion NN NN O
induced NN NN O
hepatotoxicity NN NN B-Disease
in NN NN O
our NN NN O
patient NN NN O
was NN NN O
possible NN NN O
, NN NN O
based NN NN O
on NN NN O
the NN NN O
Naranjo NN NN O
probability NN NN O
scale NN NN O
. NN NN O
   
DISCUSSION NN NN O
: NN NN O
Although NN NN O
there NN NN O
is NN NN O
increasing NN NN O
evidence NN NN O
of NN NN O
hepatotoxicity NN NN B-Disease
induced NN NN O
by NN NN O
bupropion NN NN O
, NN NN O
this NN NN O
is NN NN O
the NN NN O
first NN NN O
case NN NN O
of NN NN O
fatality NN NN O
that NN NN O
could NN NN O
have NN NN O
resulted NN NN O
from NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
in NN NN O
a NN NN O
patient NN NN O
receiving NN NN O
bupropion NN NN O
while NN NN O
on NN NN O
concomitant NN NN O
treatment NN NN O
with NN NN O
carbimazole NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Clinicians NN NN O
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
the NN NN O
possibility NN NN O
of NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
insult NN NN I-Disease
induced NN NN O
by NN NN O
bupropion NN NN O
given NN NN O
concurrently NN NN O
with NN NN O
other NN NN O
hepatotoxic NN NN B-Disease
drugs NN NN O
. NN NN O
   
Pyeloureteral NN NN O
filling NN NN O
defects NN NN O
associated NN NN O
with NN NN O
systemic NN NN O
anticoagulation NN NN O
: NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
The NN NN O
etiology NN NN O
of NN NN O
pyeloureteritis NN NN B-Disease
cystica NN NN I-Disease
has NN NN O
long NN NN O
been NN NN O
attributed NN NN O
to NN NN O
chronic NN NN O
infection NN NN B-Disease
and NN NN O
inflammation NN NN B-Disease
. NN NN O
   
A NN NN O
case NN NN O
is NN NN O
presented NN NN O
that NN NN O
is NN NN O
unique NN NN O
in NN NN O
that NN NN O
the NN NN O
acute NN NN O
onset NN NN O
and NN NN O
the NN NN O
rapid NN NN O
resolution NN NN O
of NN NN O
pyeloureteral NN NN O
filling NN NN O
defects NN NN O
in NN NN O
this NN NN O
patient NN NN O
were NN NN O
documented NN NN O
by NN NN O
radiography NN NN O
. NN NN O
   
There NN NN O
is NN NN O
no NN NN O
evidence NN NN O
of NN NN O
antecedent NN NN O
or NN NN O
concurrent NN NN O
infection NN NN B-Disease
in NN NN O
this NN NN O
patient NN NN O
. NN NN O
   
The NN NN O
disease NN NN O
occurred NN NN O
subsequent NN NN O
to NN NN O
the NN NN O
initiation NN NN O
of NN NN O
heparin NN NN O
therapy NN NN O
for NN NN O
suspected NN NN O
pelvic NN NN O
thrombophlebitis NN NN B-Disease
and NN NN O
cleared NN NN O
rapidly NN NN O
subsequent NN NN O
to NN NN O
its NN NN O
discontinuation NN NN O
. NN NN O
   
The NN NN O
rate NN NN O
of NN NN O
resolution NN NN O
of NN NN O
the NN NN O
radiographic NN NN O
findings NN NN O
may NN NN O
be NN NN O
helpful NN NN O
in NN NN O
distinguishing NN NN O
between NN NN O
true NN NN O
pyeloureteritis NN NN B-Disease
cystica NN NN I-Disease
and NN NN O
submucosal NN NN B-Disease
hemorrhage NN NN I-Disease
. NN NN O
   
Nephrotoxic NN NN B-Disease
effects NN NN O
in NN NN O
high NN NN O
- NN NN O
risk NN NN O
patients NN NN O
undergoing NN NN O
angiography NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
use NN NN O
of NN NN O
iodinated NN NN O
contrast NN NN O
medium NN NN O
can NN NN O
result NN NN O
in NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
Whether NN NN O
iso NN NN O
- NN NN O
osmolar NN NN O
contrast NN NN O
medium NN NN O
is NN NN O
less NN NN O
nephrotoxic NN NN B-Disease
than NN NN O
low NN NN O
- NN NN O
osmolar NN NN O
contrast NN NN O
medium NN NN O
in NN NN O
high NN NN O
- NN NN O
risk NN NN O
patients NN NN O
is NN NN O
uncertain NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
conducted NN NN O
a NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
prospective NN NN O
, NN NN O
multicenter NN NN O
study NN NN O
comparing NN NN O
the NN NN O
nephrotoxic NN NN B-Disease
effects NN NN O
of NN NN O
an NN NN O
iso NN NN O
- NN NN O
osmolar NN NN O
, NN NN O
dimeric NN NN O
, NN NN O
nonionic NN NN O
contrast NN NN O
medium NN NN O
, NN NN O
iodixanol NN NN O
, NN NN O
with NN NN O
those NN NN O
of NN NN O
a NN NN O
low NN NN O
- NN NN O
osmolar NN NN O
, NN NN O
nonionic NN NN O
, NN NN O
monomeric NN NN O
contrast NN NN O
medium NN NN O
, NN NN O
iohexol NN NN O
. NN NN O
   
The NN NN O
study NN NN O
involved NN NN O
129 NN NN O
patients NN NN O
with NN NN O
diabetes NN NN B-Disease
with NN NN O
serum NN NN O
creatinine NN NN O
concentrations NN NN O
of NN NN O
1 NN NN O
. NN NN O
5 NN NN O
to NN NN O
3 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
per NN NN O
deciliter NN NN O
who NN NN O
underwent NN NN O
coronary NN NN O
or NN NN O
aortofemoral NN NN O
angiography NN NN O
. NN NN O
   
The NN NN O
primary NN NN O
end NN NN O
point NN NN O
was NN NN O
the NN NN O
peak NN NN O
increase NN NN O
from NN NN O
base NN NN O
line NN NN O
in NN NN O
the NN NN O
creatinine NN NN O
concentration NN NN O
during NN NN O
the NN NN O
three NN NN O
days NN NN O
after NN NN O
angiography NN NN O
. NN NN O
   
Other NN NN O
end NN NN O
points NN NN O
were NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
creatinine NN NN O
concentration NN NN O
of NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
per NN NN O
deciliter NN NN O
or NN NN O
more NN NN O
, NN NN O
an NN NN O
increase NN NN O
of NN NN O
1 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
per NN NN O
deciliter NN NN O
or NN NN O
more NN NN O
, NN NN O
and NN NN O
a NN NN O
change NN NN O
in NN NN O
the NN NN O
creatinine NN NN O
concentration NN NN O
from NN NN O
day NN NN O
0 NN NN O
to NN NN O
day NN NN O
7 NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
creatinine NN NN O
concentration NN NN O
increased NN NN O
significantly NN NN O
less NN NN O
in NN NN O
patients NN NN O
who NN NN O
received NN NN O
iodixanol NN NN O
. NN NN O
   
From NN NN O
day NN NN O
0 NN NN O
to NN NN O
day NN NN O
3 NN NN O
, NN NN O
the NN NN O
mean NN NN O
peak NN NN O
increase NN NN O
in NN NN O
creatinine NN NN O
was NN NN O
0 NN NN O
. NN NN O
13 NN NN O
mg NN NN O
per NN NN O
deciliter NN NN O
in NN NN O
the NN NN O
iodixanol NN NN O
group NN NN O
and NN NN O
0 NN NN O
. NN NN O
55 NN NN O
mg NN NN O
per NN NN O
deciliter NN NN O
in NN NN O
the NN NN O
iohexol NN NN O
group NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
001 NN NN O
; NN NN O
the NN NN O
increase NN NN O
with NN NN O
iodixanol NN NN O
minus NN NN O
the NN NN O
increase NN NN O
with NN NN O
iohexol NN NN O
, NN NN O
- NN NN O
0 NN NN O
. NN NN O
42 NN NN O
mg NN NN O
per NN NN O
deciliter NN NN O
[ NN NN O
95 NN NN O
percent NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
- NN NN O
0 NN NN O
. NN NN O
73 NN NN O
to NN NN O
- NN NN O
0 NN NN O
. NN NN O
22 NN NN O
] NN NN O
) NN NN O
. NN NN O
   
Two NN NN O
of NN NN O
the NN NN O
64 NN NN O
patients NN NN O
in NN NN O
the NN NN O
iodixanol NN NN O
group NN NN O
( NN NN O
3 NN NN O
percent NN NN O
) NN NN O
had NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
creatinine NN NN O
concentration NN NN O
of NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
per NN NN O
deciliter NN NN O
or NN NN O
more NN NN O
, NN NN O
as NN NN O
compared NN NN O
with NN NN O
17 NN NN O
of NN NN O
the NN NN O
65 NN NN O
patients NN NN O
in NN NN O
the NN NN O
iohexol NN NN O
group NN NN O
( NN NN O
26 NN NN O
percent NN NN O
) NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
002 NN NN O
; NN NN O
odds NN NN O
ratio NN NN O
for NN NN O
such NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
iodixanol NN NN O
group NN NN O
, NN NN O
0 NN NN O
. NN NN O
09 NN NN O
[ NN NN O
95 NN NN O
percent NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
0 NN NN O
. NN NN O
02 NN NN O
to NN NN O
0 NN NN O
. NN NN O
41 NN NN O
] NN NN O
) NN NN O
. NN NN O
   
No NN NN O
patient NN NN O
receiving NN NN O
iodixanol NN NN O
had NN NN O
an NN NN O
increase NN NN O
of NN NN O
1 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
per NN NN O
deciliter NN NN O
or NN NN O
more NN NN O
, NN NN O
but NN NN O
10 NN NN O
patients NN NN O
in NN NN O
the NN NN O
iohexol NN NN O
group NN NN O
( NN NN O
15 NN NN O
percent NN NN O
) NN NN O
did NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
change NN NN O
in NN NN O
the NN NN O
creatinine NN NN O
concentration NN NN O
from NN NN O
day NN NN O
0 NN NN O
to NN NN O
day NN NN O
7 NN NN O
was NN NN O
0 NN NN O
. NN NN O
07 NN NN O
mg NN NN O
per NN NN O
deciliter NN NN O
in NN NN O
the NN NN O
iodixanol NN NN O
group NN NN O
and NN NN O
0 NN NN O
. NN NN O
24 NN NN O
mg NN NN O
per NN NN O
deciliter NN NN O
in NN NN O
the NN NN O
iohexol NN NN O
group NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
003 NN NN O
; NN NN O
value NN NN O
in NN NN O
the NN NN O
iodixanol NN NN O
group NN NN O
minus NN NN O
the NN NN O
value NN NN O
in NN NN O
the NN NN O
iohexol NN NN O
group NN NN O
, NN NN O
- NN NN O
0 NN NN O
. NN NN O
17 NN NN O
mg NN NN O
per NN NN O
deciliter NN NN O
[ NN NN O
95 NN NN O
percent NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
- NN NN O
0 NN NN O
. NN NN O
34 NN NN O
to NN NN O
- NN NN O
0 NN NN O
. NN NN O
07 NN NN O
] NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Nephropathy NN NN B-Disease
induced NN NN O
by NN NN O
contrast NN NN O
medium NN NN O
may NN NN O
be NN NN O
less NN NN O
likely NN NN O
to NN NN O
develop NN NN O
in NN NN O
high NN NN O
- NN NN O
risk NN NN O
patients NN NN O
when NN NN O
iodixanol NN NN O
is NN NN O
used NN NN O
rather NN NN O
than NN NN O
a NN NN O
low NN NN O
- NN NN O
osmolar NN NN O
, NN NN O
nonionic NN NN O
contrast NN NN O
medium NN NN O
. NN NN O
   
Protective NN NN O
effect NN NN O
of NN NN O
edaravone NN NN O
against NN NN O
streptomycin NN NN O
- NN NN O
induced NN NN O
vestibulotoxicity NN NN B-Disease
in NN NN O
the NN NN O
guinea NN NN O
pig NN NN O
. NN NN O
   
This NN NN O
study NN NN O
investigated NN NN O
alleviation NN NN O
of NN NN O
streptomycin NN NN O
- NN NN O
induced NN NN O
vestibulotoxicity NN NN B-Disease
by NN NN O
edaravone NN NN O
in NN NN O
guinea NN NN O
pigs NN NN O
. NN NN O
   
Edaravone NN NN O
, NN NN O
a NN NN O
free NN NN O
radical NN NN O
scavenger NN NN O
, NN NN O
has NN NN O
potent NN NN O
free NN NN O
radical NN NN O
quenching NN NN O
action NN NN O
and NN NN O
is NN NN O
used NN NN O
in NN NN O
clinical NN NN O
practice NN NN O
to NN NN O
treat NN NN O
cerebral NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
Streptomycin NN NN O
was NN NN O
administered NN NN O
to NN NN O
the NN NN O
inner NN NN O
ear NN NN O
by NN NN O
osmotic NN NN O
pump NN NN O
for NN NN O
24 NN NN O
h NN NN O
, NN NN O
and NN NN O
edaravone NN NN O
( NN NN O
n NN NN O
= NN NN O
8 NN NN O
) NN NN O
or NN NN O
saline NN NN O
( NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
was NN NN O
intraperitoneally NN NN O
injected NN NN O
once NN NN O
a NN NN O
day NN NN O
for NN NN O
7 NN NN O
days NN NN O
. NN NN O
   
We NN NN O
observed NN NN O
horizontal NN NN O
vestibulo NN NN O
- NN NN O
ocular NN NN O
reflex NN NN O
as NN NN O
a NN NN O
marker NN NN O
of NN NN O
postoperative NN NN O
vestibular NN NN O
function NN NN O
. NN NN O
   
Animals NN NN O
injected NN NN O
with NN NN O
saline NN NN O
showed NN NN O
statistically NN NN O
smaller NN NN O
gains NN NN O
than NN NN O
those NN NN O
injected NN NN O
with NN NN O
edaravone NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
edaravone NN NN O
suppresses NN NN O
streptomycin NN NN O
- NN NN O
induced NN NN O
vestibulotoxicity NN NN B-Disease
. NN NN O
   
Levodopa NN NN O
- NN NN O
induced NN NN O
oromandibular NN NN O
dystonia NN NN B-Disease
in NN NN O
progressive NN NN B-Disease
supranuclear NN NN I-Disease
palsy NN NN I-Disease
. NN NN O
   
Levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
have NN NN O
been NN NN O
reported NN NN O
in NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
and NN NN O
multiple NN NN B-Disease
system NN NN I-Disease
atrophy NN NN I-Disease
. NN NN O
   
Cranial NN NN O
dystonias NN NN B-Disease
are NN NN O
rare NN NN O
in NN NN O
patients NN NN O
with NN NN O
progressive NN NN B-Disease
supranuclear NN NN I-Disease
palsy NN NN I-Disease
( NN NN O
PSP NN NN B-Disease
) NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
we NN NN O
describe NN NN O
an NN NN O
unusual NN NN O
case NN NN O
of NN NN O
reversible NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
Oromandibular NN NN B-Disease
dystonia NN NN I-Disease
( NN NN O
OMD NN NN B-Disease
) NN NN O
in NN NN O
a NN NN O
PSP NN NN B-Disease
patient NN NN O
to NN NN O
highlight NN NN O
the NN NN O
importance NN NN O
of NN NN O
recognizing NN NN O
this NN NN O
drug NN NN O
related NN NN O
complication NN NN O
in NN NN O
the NN NN O
management NN NN O
of NN NN O
PSP NN NN B-Disease
, NN NN O
and NN NN O
discuss NN NN O
the NN NN O
possible NN NN O
underlying NN NN O
pathophysiology NN NN O
. NN NN O
   
Case NN NN O
report NN NN O
: NN NN O
Dexatrim NN NN O
( NN NN O
Phenylpropanolamine NN NN O
) NN NN O
as NN NN O
a NN NN O
cause NN NN O
of NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
Phenylpropanolamine NN NN O
( NN NN O
PPA NN NN O
) NN NN O
is NN NN O
a NN NN O
sympathetic NN NN O
amine NN NN O
used NN NN O
in NN NN O
over NN NN O
- NN NN O
the NN NN O
- NN NN O
counter NN NN O
cold NN NN O
remedies NN NN O
and NN NN O
weight NN NN O
- NN NN O
control NN NN O
preparations NN NN O
worldwide NN NN O
. NN NN O
   
Its NN NN O
use NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
hypertensive NN NN B-Disease
episodes NN NN O
and NN NN O
hemorrhagic NN NN B-Disease
strokes NN NN I-Disease
in NN NN O
younger NN NN O
women NN NN O
. NN NN O
   
Several NN NN O
reports NN NN O
have NN NN O
linked NN NN O
the NN NN O
abuse NN NN O
of NN NN O
PPA NN NN O
with NN NN O
myocardial NN NN B-Disease
injury NN NN I-Disease
, NN NN O
especially NN NN O
when NN NN O
overdose NN NN B-Disease
is NN NN O
involved NN NN O
. NN NN O
   
We NN NN O
report NN NN O
here NN NN O
the NN NN O
first NN NN O
case NN NN O
of NN NN O
Dexatrim NN NN O
( NN NN O
PPA NN NN O
) NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
injury NN NN I-Disease
in NN NN O
a NN NN O
young NN NN O
woman NN NN O
who NN NN O
was NN NN O
using NN NN O
it NN NN O
at NN NN O
recommended NN NN O
doses NN NN O
for NN NN O
weight NN NN O
control NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
we NN NN O
review NN NN O
the NN NN O
7 NN NN O
other NN NN O
cases NN NN O
of NN NN O
PPA NN NN O
related NN NN O
myocardial NN NN B-Disease
injury NN NN I-Disease
that NN NN O
have NN NN O
been NN NN O
reported NN NN O
so NN NN O
far NN NN O
. NN NN O
   
Physicians NN NN O
and NN NN O
patients NN NN O
should NN NN O
be NN NN O
alert NN NN O
to NN NN O
the NN NN O
potential NN NN O
cardiac NN NN O
risk NN NN O
associated NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
PPA NN NN O
, NN NN O
even NN NN O
at NN NN O
doses NN NN O
generally NN NN O
considered NN NN O
to NN NN O
be NN NN O
safe NN NN O
. NN NN O
   
Differential NN NN O
diagnosis NN NN O
of NN NN O
high NN NN O
serum NN NN O
creatine NN NN O
kinase NN NN O
levels NN NN O
in NN NN O
systemic NN NN B-Disease
lupus NN NN I-Disease
erythematosus NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
clinical NN NN O
and NN NN O
bioptic NN NN O
findings NN NN O
for NN NN O
a NN NN O
57 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
severe NN NN O
chloroquine NN NN O
- NN NN O
induced NN NN O
myopathy NN NN B-Disease
. NN NN O
   
Since NN NN O
1989 NN NN O
, NN NN O
she NN NN O
had NN NN O
been NN NN O
suffering NN NN O
from NN NN O
systemic NN NN B-Disease
lupus NN NN I-Disease
erythematosus NN NN I-Disease
( NN NN O
SLE NN NN B-Disease
) NN NN O
with NN NN O
renal NN NN B-Disease
involvement NN NN I-Disease
and NN NN O
undergone NN NN O
periods NN NN O
of NN NN O
treatment NN NN O
with NN NN O
azathioprine NN NN O
and NN NN O
cyclophosphamide NN NN O
. NN NN O
   
Additional NN NN O
therapy NN NN O
with NN NN O
chloroquine NN NN O
( NN NN O
CQ NN NN O
) NN NN O
was NN NN O
started NN NN O
because NN NN O
of NN NN O
arthralgia NN NN B-Disease
. NN NN O
   
At NN NN O
the NN NN O
same NN NN O
time NN NN O
, NN NN O
slightly NN NN O
increased NN NN O
creatine NN NN O
kinase NN NN O
( NN NN O
CK NN NN O
) NN NN O
levels NN NN O
were NN NN O
noted NN NN O
. NN NN O
   
Myositis NN NN B-Disease
was NN NN O
suspected NN NN O
, NN NN O
and NN NN O
the NN NN O
patient NN NN O
was NN NN O
treated NN NN O
with NN NN O
steroids NN NN O
. NN NN O
   
The NN NN O
CK NN NN O
increase NN NN O
persisted NN NN O
, NN NN O
however NN NN O
, NN NN O
and NN NN O
she NN NN O
developed NN NN O
progressive NN NN O
muscular NN NN B-Disease
weakness NN NN I-Disease
and NN NN O
muscular NN NN B-Disease
atrophy NN NN I-Disease
. NN NN O
   
Routine NN NN O
controls NN NN O
revealed NN NN O
markedly NN NN O
elevated NN NN O
CK NN NN O
levels NN NN O
of NN NN O
1 NN NN O
, NN NN O
700 NN NN O
U NN NN O
/ NN NN O
l NN NN O
. NN NN O
   
The NN NN O
neurological NN NN O
and NN NN O
electrophysiological NN NN O
findings NN NN O
were NN NN O
not NN NN O
typical NN NN O
of NN NN O
myositis NN NN B-Disease
. NN NN O
   
Thus NN NN O
, NN NN O
muscle NN NN O
biopsy NN NN O
of NN NN O
the NN NN O
deltoid NN NN O
muscle NN NN O
was NN NN O
performed NN NN O
in NN NN O
order NN NN O
to NN NN O
exclude NN NN O
polymyositis NN NN B-Disease
or NN NN O
toxic NN NN O
myopathy NN NN B-Disease
. NN NN O
   
As NN NN O
it NN NN O
revealed NN NN O
chloroquine NN NN O
- NN NN O
induced NN NN O
myopathy NN NN B-Disease
, NN NN O
medication NN NN O
was NN NN O
stopped NN NN O
. NN NN O
   
Discriminating NN NN O
between NN NN O
primary NN NN O
SLE NN NN B-Disease
- NN NN O
induced NN NN O
affection NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
musculoskeletal NN NN I-Disease
system NN NN I-Disease
and NN NN O
drug NN NN O
- NN NN O
induced NN NN O
side NN NN O
effects NN NN O
is NN NN O
important NN NN O
for NN NN O
appropriate NN NN O
treatment NN NN O
of NN NN O
SLE NN NN B-Disease
patients NN NN O
. NN NN O
   
Seizure NN NN B-Disease
associated NN NN O
with NN NN O
sleep NN NN B-Disease
deprivation NN NN I-Disease
and NN NN O
sustained NN NN O
- NN NN O
release NN NN O
bupropion NN NN O
. NN NN O
   
This NN NN O
case NN NN O
report NN NN O
describes NN NN O
a NN NN O
generalized NN NN O
seizure NN NN B-Disease
associated NN NN O
with NN NN O
sustained NN NN O
- NN NN O
release NN NN O
bupropion NN NN O
use NN NN O
and NN NN O
sleep NN NN B-Disease
deprivation NN NN I-Disease
. NN NN O
   
The NN NN O
subject NN NN O
, NN NN O
a NN NN O
31 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
female NN NN O
smoker NN NN O
, NN NN O
was NN NN O
participating NN NN O
in NN NN O
a NN NN O
clinical NN NN O
trial NN NN O
evaluating NN NN O
an NN NN O
investigational NN NN O
medication NN NN O
for NN NN O
smoking NN NN O
cessation NN NN O
that NN NN O
used NN NN O
sustained NN NN O
- NN NN O
release NN NN O
bupropion NN NN O
as NN NN O
an NN NN O
active NN NN O
control NN NN O
. NN NN O
   
After NN NN O
5 NN NN O
weeks NN NN O
of NN NN O
bupropion NN NN O
use NN NN O
, NN NN O
the NN NN O
subject NN NN O
experienced NN NN O
a NN NN O
generalized NN NN O
tonic NN NN O
clonic NN NN O
seizure NN NN B-Disease
after NN NN O
staying NN NN O
up NN NN O
nearly NN NN O
all NN NN O
night NN NN O
packing NN NN O
and NN NN O
moving NN NN O
to NN NN O
a NN NN O
new NN NN O
residence NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
had NN NN O
no NN NN O
other NN NN O
risk NN NN O
factors NN NN O
for NN NN O
seizures NN NN B-Disease
. NN NN O
   
We NN NN O
suggest NN NN O
that NN NN O
sleep NN NN B-Disease
deprivation NN NN I-Disease
may NN NN O
add NN NN O
to NN NN O
the NN NN O
risk NN NN O
of NN NN O
bupropion NN NN O
- NN NN O
associated NN NN O
seizures NN NN B-Disease
. NN NN O
   
Postoperative NN NN B-Disease
myalgia NN NN I-Disease
after NN NN O
succinylcholine NN NN O
: NN NN O
no NN NN O
evidence NN NN O
for NN NN O
an NN NN O
inflammatory NN NN O
origin NN NN O
. NN NN O
   
A NN NN O
common NN NN O
side NN NN O
effect NN NN O
associated NN NN O
with NN NN O
succinylcholine NN NN O
is NN NN O
postoperative NN NN B-Disease
myalgia NN NN I-Disease
. NN NN O
   
The NN NN O
pathogenesis NN NN O
of NN NN O
this NN NN O
myalgia NN NN B-Disease
is NN NN O
still NN NN O
unclear NN NN O
; NN NN O
inflammation NN NN B-Disease
has NN NN O
been NN NN O
suggested NN NN O
but NN NN O
without NN NN O
convincing NN NN O
evidence NN NN O
. NN NN O
   
We NN NN O
designed NN NN O
the NN NN O
present NN NN O
study NN NN O
to NN NN O
investigate NN NN O
whether NN NN O
an NN NN O
inflammatory NN NN O
reaction NN NN O
contributes NN NN O
to NN NN O
this NN NN O
myalgia NN NN B-Disease
. NN NN O
   
The NN NN O
incidence NN NN O
and NN NN O
severity NN NN O
of NN NN O
succinylcholine NN NN O
- NN NN O
associated NN NN O
myalgia NN NN B-Disease
was NN NN O
determined NN NN O
in NN NN O
64 NN NN O
patients NN NN O
pretreated NN NN O
with NN NN O
saline NN NN O
or NN NN O
dexamethasone NN NN O
before NN NN O
succinylcholine NN NN O
( NN NN O
n NN NN O
= NN NN O
32 NN NN O
for NN NN O
each NN NN O
) NN NN O
. NN NN O
   
Incidence NN NN O
and NN NN O
severity NN NN O
of NN NN O
myalgia NN NN B-Disease
did NN NN O
not NN NN O
differ NN NN O
significantly NN NN O
between NN NN O
the NN NN O
two NN NN O
groups NN NN O
: NN NN O
15 NN NN O
patients NN NN O
in NN NN O
the NN NN O
dexamethasone NN NN O
group NN NN O
complained NN NN O
of NN NN O
myalgia NN NN B-Disease
compared NN NN O
with NN NN O
18 NN NN O
patients NN NN O
in NN NN O
the NN NN O
saline NN NN O
group NN NN O
, NN NN O
and NN NN O
severe NN NN O
myalgia NN NN B-Disease
was NN NN O
reported NN NN O
by NN NN O
five NN NN O
patients NN NN O
and NN NN O
three NN NN O
patients NN NN O
, NN NN O
respectively NN NN O
( NN NN O
not NN NN O
significant NN NN O
) NN NN O
. NN NN O
   
At NN NN O
48 NN NN O
h NN NN O
after NN NN O
surgery NN NN O
, NN NN O
12 NN NN O
patients NN NN O
in NN NN O
both NN NN O
groups NN NN O
still NN NN O
suffered NN NN O
from NN NN O
myalgia NN NN B-Disease
( NN NN O
not NN NN O
significant NN NN O
) NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
interleukin NN NN O
- NN NN O
6 NN NN O
( NN NN O
IL NN NN O
- NN NN O
6 NN NN O
) NN NN O
as NN NN O
an NN NN O
early NN NN O
marker NN NN O
of NN NN O
inflammation NN NN B-Disease
was NN NN O
assessed NN NN O
in NN NN O
a NN NN O
subgroup NN NN O
of NN NN O
10 NN NN O
patients NN NN O
pretreated NN NN O
with NN NN O
saline NN NN O
. NN NN O
   
We NN NN O
found NN NN O
an NN NN O
increase NN NN O
of NN NN O
IL NN NN O
- NN NN O
6 NN NN O
for NN NN O
only NN NN O
three NN NN O
patients NN NN O
, NN NN O
but NN NN O
only NN NN O
one NN NN O
patient NN NN O
reported NN NN O
myalgia NN NN B-Disease
; NN NN O
no NN NN O
relationship NN NN O
between NN NN O
myalgia NN NN B-Disease
and NN NN O
the NN NN O
increase NN NN O
of NN NN O
IL NN NN O
- NN NN O
6 NN NN O
was NN NN O
found NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
there NN NN O
is NN NN O
no NN NN O
evidence NN NN O
for NN NN O
an NN NN O
inflammatory NN NN O
origin NN NN O
of NN NN O
succinylcholine NN NN O
- NN NN O
associated NN NN O
myalgia NN NN B-Disease
. NN NN O
   
IMPLICATIONS NN NN O
: NN NN O
Administration NN NN O
of NN NN O
dexamethasone NN NN O
before NN NN O
succinylcholine NN NN O
was NN NN O
not NN NN O
effective NN NN O
in NN NN O
decreasing NN NN O
the NN NN O
incidence NN NN O
or NN NN O
the NN NN O
severity NN NN O
of NN NN O
succinylcholine NN NN O
- NN NN O
induced NN NN O
postoperative NN NN B-Disease
myalgia NN NN I-Disease
. NN NN O
   
Furthermore NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
significant NN NN O
relationship NN NN O
between NN NN O
postoperative NN NN B-Disease
myalgia NN NN I-Disease
and NN NN O
time NN NN O
course NN NN O
of NN NN O
interleukin NN NN O
- NN NN O
6 NN NN O
concentrations NN NN O
, NN NN O
a NN NN O
marker NN NN O
of NN NN O
inflammation NN NN B-Disease
. NN NN O
   
Pretreatment NN NN O
with NN NN O
dexamethasone NN NN O
is NN NN O
not NN NN O
justified NN NN O
to NN NN O
prevent NN NN O
postoperative NN NN B-Disease
myalgia NN NN I-Disease
after NN NN O
succinylcholine NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
lindane NN NN O
on NN NN O
hepatic NN NN O
and NN NN O
brain NN NN O
cytochrome NN NN O
P450s NN NN O
and NN NN O
influence NN NN O
of NN NN O
P450 NN NN O
modulation NN NN O
in NN NN O
lindane NN NN O
induced NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
Oral NN NN O
administration NN NN O
of NN NN O
lindane NN NN O
( NN NN O
2 NN NN O
. NN NN O
5 NN NN O
, NN NN O
5 NN NN O
, NN NN O
10 NN NN O
and NN NN O
15 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
body NN NN O
weight NN NN O
) NN NN O
for NN NN O
5 NN NN O
days NN NN O
was NN NN O
found NN NN O
to NN NN O
produce NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
increase NN NN O
in NN NN O
the NN NN O
activity NN NN O
of NN NN O
P450 NN NN O
dependent NN NN O
7 NN NN O
- NN NN O
ethoxyresorufin NN NN O
- NN NN O
O NN NN O
- NN NN O
deethylase NN NN O
( NN NN O
EROD NN NN O
) NN NN O
, NN NN O
7 NN NN O
- NN NN O
pentoxyresorufin NN NN O
- NN NN O
O NN NN O
- NN NN O
dealkylase NN NN O
( NN NN O
PROD NN NN O
) NN NN O
and NN NN O
N NN NN O
- NN NN O
nitrosodimethylamine NN NN O
demethylase NN NN O
( NN NN O
NDMA NN NN O
- NN NN O
d NN NN O
) NN NN O
in NN NN O
rat NN NN O
brain NN NN O
and NN NN O
liver NN NN O
. NN NN O
   
A NN NN O
significant NN NN O
increase NN NN O
in NN NN O
the NN NN O
hepatic NN NN O
and NN NN O
brain NN NN O
P450 NN NN O
monooxygenases NN NN O
was NN NN O
also NN NN O
observed NN NN O
when NN NN O
the NN NN O
duration NN NN O
of NN NN O
exposure NN NN O
of NN NN O
low NN NN O
dose NN NN O
( NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
of NN NN O
lindane NN NN O
was NN NN O
increased NN NN O
from NN NN O
5 NN NN O
days NN NN O
to NN NN O
15 NN NN O
or NN NN O
21 NN NN O
days NN NN O
. NN NN O
   
As NN NN O
observed NN NN O
with NN NN O
different NN NN O
doses NN NN O
, NN NN O
the NN NN O
magnitude NN NN O
of NN NN O
induction NN NN O
in NN NN O
the NN NN O
activity NN NN O
of NN NN O
P450 NN NN O
monooxygenases NN NN O
was NN NN O
several NN NN O
fold NN NN O
higher NN NN O
in NN NN O
liver NN NN O
microsomes NN NN O
when NN NN O
compared NN NN O
with NN NN O
the NN NN O
brain NN NN O
. NN NN O
   
Western NN NN O
blotting NN NN O
studies NN NN O
have NN NN O
indicated NN NN O
that NN NN O
the NN NN O
increase NN NN O
in NN NN O
the NN NN O
P450 NN NN O
enzymes NN NN O
could NN NN O
be NN NN O
due NN NN O
to NN NN O
the NN NN O
increase NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
P450 NN NN O
1A1 NN NN O
/ NN NN O
1A2 NN NN O
, NN NN O
2B1 NN NN O
/ NN NN O
2B2 NN NN O
and NN NN O
2E1 NN NN O
isoenzymes NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
studies NN NN O
using NN NN O
organic NN NN O
inhibitors NN NN O
specific NN NN O
for NN NN O
individual NN NN O
P450 NN NN O
isoenzymes NN NN O
and NN NN O
antibody NN NN O
inhibition NN NN O
experiments NN NN O
have NN NN O
further NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
increase NN NN O
in NN NN O
the NN NN O
activity NN NN O
of NN NN O
PROD NN NN O
, NN NN O
EROD NN NN O
and NN NN O
NDMA NN NN O
- NN NN O
d NN NN O
are NN NN O
due NN NN O
to NN NN O
the NN NN O
increase NN NN O
in NN NN O
the NN NN O
levels NN NN O
of NN NN O
P450 NN NN O
2B1 NN NN O
/ NN NN O
2B2 NN NN O
, NN NN O
1A1 NN NN O
/ NN NN O
1A2 NN NN O
and NN NN O
2E1 NN NN O
isoenzymes NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Induction NN NN O
studies NN NN O
have NN NN O
further NN NN O
shown NN NN O
that NN NN O
while NN NN O
pretreatment NN NN O
of NN NN O
3 NN NN O
- NN NN O
methylcholanthrene NN NN O
( NN NN O
MC NN NN O
) NN NN O
, NN NN O
an NN NN O
inducer NN NN O
of NN NN O
P4501A1 NN NN O
/ NN NN O
1A2 NN NN O
, NN NN O
did NN NN O
not NN NN O
produce NN NN O
any NN NN O
significant NN NN O
effect NN NN O
in NN NN O
the NN NN O
incidence NN NN O
of NN NN O
lindane NN NN O
induced NN NN O
convulsions NN NN B-Disease
, NN NN O
pretreatment NN NN O
with NN NN O
phenobarbital NN NN O
( NN NN O
PB NN NN O
) NN NN O
, NN NN O
an NN NN O
inducer NN NN O
of NN NN O
P450 NN NN O
2B1 NN NN O
/ NN NN O
2B2 NN NN O
or NN NN O
ethanol NN NN O
, NN NN O
an NN NN O
inducer NN NN O
of NN NN O
P450 NN NN O
2E1 NN NN O
catalysed NN NN O
reactions NN NN O
, NN NN O
significantly NN NN O
increased NN NN O
the NN NN O
incidence NN NN O
of NN NN O
lindane NN NN O
induced NN NN O
convulsions NN NN B-Disease
. NN NN O
   
Similarly NN NN O
, NN NN O
when NN NN O
the NN NN O
P450 NN NN O
- NN NN O
mediated NN NN O
metabolism NN NN O
of NN NN O
lindane NN NN O
was NN NN O
blocked NN NN O
by NN NN O
cobalt NN NN O
chloride NN NN O
incidence NN NN O
of NN NN O
convulsions NN NN B-Disease
was NN NN O
increased NN NN O
in NN NN O
animals NN NN O
treated NN NN O
with NN NN O
lindane NN NN O
indicating NN NN O
that NN NN O
lindane NN NN O
per NN NN O
se NN NN O
or NN NN O
its NN NN O
metabolites NN NN O
formed NN NN O
by NN NN O
PB NN NN O
or NN NN O
ethanol NN NN O
inducible NN NN O
P450 NN NN O
isoenzymes NN NN O
are NN NN O
involved NN NN O
in NN NN O
its NN NN O
neurobehavioral NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Absolute NN NN O
and NN NN O
attributable NN NN O
risk NN NN O
of NN NN O
venous NN NN B-Disease
thromboembolism NN NN I-Disease
in NN NN O
women NN NN O
on NN NN O
combined NN NN O
cyproterone NN NN O
acetate NN NN O
and NN NN O
ethinylestradiol NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
achieve NN NN O
absolute NN NN O
risk NN NN O
estimates NN NN O
of NN NN O
venous NN NN B-Disease
thromboembolism NN NN I-Disease
( NN NN O
VTE NN NN B-Disease
) NN NN O
among NN NN O
women NN NN O
on NN NN O
cyproterone NN NN O
acetate NN NN O
plus NN NN O
ethinylestradiol NN NN O
( NN NN O
CPA NN NN O
/ NN NN O
EE NN NN O
) NN NN O
, NN NN O
and NN NN O
among NN NN O
women NN NN O
on NN NN O
combined NN NN O
oral NN NN O
contraceptives NN NN O
( NN NN O
COCs NN NN O
) NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
From NN NN O
the NN NN O
Danish NN NN O
National NN NN O
Register NN NN O
of NN NN O
Patients NN NN O
( NN NN O
NRP NN NN O
) NN NN O
, NN NN O
1996 NN NN O
to NN NN O
1998 NN NN O
, NN NN O
the NN NN O
records NN NN O
of NN NN O
1 NN NN O
. NN NN O
1 NN NN O
million NN NN O
Danish NN NN O
women NN NN O
, NN NN O
ages NN NN O
15 NN NN O
to NN NN O
44 NN NN O
years NN NN O
, NN NN O
were NN NN O
searched NN NN O
for NN NN O
evidence NN NN O
of NN NN O
VTE NN NN B-Disease
. NN NN O
   
COC NN NN O
use NN NN O
was NN NN O
ascertained NN NN O
through NN NN O
mailed NN NN O
questionnaires NN NN O
. NN NN O
   
Sales NN NN O
statistics NN NN O
of NN NN O
COCs NN NN O
and NN NN O
CPA NN NN O
/ NN NN O
EE NN NN O
were NN NN O
provided NN NN O
through NN NN O
Danish NN NN O
Drug NN NN O
Statistics NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
During NN NN O
the NN NN O
time NN NN O
frame NN NN O
of NN NN O
the NN NN O
study NN NN O
, NN NN O
330 NN NN O
women NN NN O
were NN NN O
found NN NN O
to NN NN O
have NN NN O
had NN NN O
VTE NN NN B-Disease
while NN NN O
on NN NN O
COCs NN NN O
. NN NN O
   
Of NN NN O
these NN NN O
women NN NN O
, NN NN O
67 NN NN O
were NN NN O
on NN NN O
levonorgestrel NN NN O
- NN NN O
containing NN NN O
COCs NN NN O
. NN NN O
   
Eleven NN NN O
were NN NN O
on NN NN O
CPA NN NN O
/ NN NN O
EE NN NN O
. NN NN O
   
The NN NN O
corresponding NN NN O
absolute NN NN O
risk NN NN O
of NN NN O
VTE NN NN B-Disease
was NN NN O
3 NN NN O
. NN NN O
4 NN NN O
( NN NN O
range NN NN O
, NN NN O
3 NN NN O
. NN NN O
1 NN NN O
- NN NN O
3 NN NN O
. NN NN O
8 NN NN O
) NN NN O
per NN NN O
10 NN NN O
000 NN NN O
women NN NN O
years NN NN O
among NN NN O
the NN NN O
women NN NN O
on NN NN O
COCs NN NN O
, NN NN O
4 NN NN O
. NN NN O
2 NN NN O
( NN NN O
range NN NN O
, NN NN O
3 NN NN O
. NN NN O
2 NN NN O
- NN NN O
5 NN NN O
. NN NN O
2 NN NN O
) NN NN O
per NN NN O
10 NN NN O
000 NN NN O
women NN NN O
years NN NN O
among NN NN O
women NN NN O
on NN NN O
levonorgestrel NN NN O
- NN NN O
containing NN NN O
COCs NN NN O
, NN NN O
and NN NN O
3 NN NN O
. NN NN O
1 NN NN O
( NN NN O
range NN NN O
, NN NN O
1 NN NN O
. NN NN O
3 NN NN O
- NN NN O
4 NN NN O
. NN NN O
9 NN NN O
) NN NN O
per NN NN O
10 NN NN O
000 NN NN O
women NN NN O
years NN NN O
among NN NN O
the NN NN O
women NN NN O
on NN NN O
CPA NN NN O
/ NN NN O
EE NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Our NN NN O
results NN NN O
suggest NN NN O
the NN NN O
absolute NN NN O
risk NN NN O
of NN NN O
VTE NN NN B-Disease
among NN NN O
Danish NN NN O
women NN NN O
on NN NN O
COCs NN NN O
is NN NN O
similar NN NN O
to NN NN O
that NN NN O
among NN NN O
women NN NN O
taking NN NN O
CPA NN NN O
/ NN NN O
EE NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
developmental NN NN O
toxicology NN NN O
of NN NN O
aspirin NN NN O
( NN NN O
acetylsalicylic NN NN O
acid NN NN O
) NN NN O
in NN NN O
rats NN NN O
using NN NN O
selected NN NN O
dosing NN NN O
paradigms NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Analysis NN NN O
of NN NN O
the NN NN O
literature NN NN O
for NN NN O
nonsteroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
( NN NN O
NSAIDs NN NN O
) NN NN O
suggests NN NN O
that NN NN O
a NN NN O
low NN NN O
incidence NN NN O
of NN NN O
developmental NN NN B-Disease
anomalies NN NN I-Disease
occurs NN NN O
in NN NN O
rats NN NN O
given NN NN O
NSAIDs NN NN O
on NN NN O
specific NN NN O
days NN NN O
during NN NN O
organogenesis NN NN O
. NN NN O
   
Aspirin NN NN O
( NN NN O
acetylsalicylic NN NN O
acid NN NN O
[ NN NN O
ASA NN NN O
] NN NN O
) NN NN O
, NN NN O
an NN NN O
irreversible NN NN O
cyclooxygenase NN NN O
1 NN NN O
and NN NN O
2 NN NN O
inhibitor NN NN O
, NN NN O
induces NN NN O
developmental NN NN B-Disease
anomalies NN NN I-Disease
when NN NN O
administered NN NN O
to NN NN O
Wistar NN NN O
rats NN NN O
on NN NN O
gestational NN NN O
day NN NN O
( NN NN O
GD NN NN O
) NN NN O
9 NN NN O
, NN NN O
10 NN NN O
, NN NN O
or NN NN O
11 NN NN O
( NN NN O
Kimmel NN NN O
CA NN NN O
, NN NN O
Wilson NN NN O
JG NN NN O
, NN NN O
Schumacher NN NN O
HJ NN NN O
. NN NN O
Teratology NN NN O
4 NN NN O
: NN NN O
15 NN NN O
- NN NN O
24 NN NN O
, NN NN O
1971 NN NN O
) NN NN O
. NN NN O
   
There NN NN O
are NN NN O
no NN NN O
published NN NN O
ASA NN NN O
studies NN NN O
using NN NN O
the NN NN O
multiple NN NN O
dosing NN NN O
paradigm NN NN O
of NN NN O
GDs NN NN O
6 NN NN O
to NN NN O
17 NN NN O
. NN NN O
   
Objectives NN NN O
of NN NN O
the NN NN O
current NN NN O
study NN NN O
were NN NN O
to NN NN O
compare NN NN O
results NN NN O
between NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
( NN NN O
SD NN NN O
) NN NN O
and NN NN O
Wistar NN NN O
strains NN NN O
when NN NN O
ASA NN NN O
is NN NN O
administered NN NN O
on NN NN O
GD NN NN O
9 NN NN O
, NN NN O
10 NN NN O
, NN NN O
or NN NN O
11 NN NN O
; NN NN O
to NN NN O
compare NN NN O
the NN NN O
malformation NN NN O
patterns NN NN O
following NN NN O
single NN NN O
and NN NN O
multiple NN NN O
dosings NN NN O
during NN NN O
organogenesis NN NN O
in NN NN O
SD NN NN O
rats NN NN O
; NN NN O
and NN NN O
to NN NN O
test NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
maternal NN NN O
gastrointestinal NN NN B-Disease
toxicity NN NN I-Disease
confounds NN NN O
the NN NN O
detection NN NN O
of NN NN O
low NN NN O
incidence NN NN O
malformations NN NN B-Disease
with NN NN O
ASA NN NN O
when NN NN O
a NN NN O
multiple NN NN O
dosing NN NN O
paradigm NN NN O
is NN NN O
used NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
ASA NN NN O
was NN NN O
administered NN NN O
as NN NN O
a NN NN O
single NN NN O
dose NN NN O
on NN NN O
GD NN NN O
9 NN NN O
( NN NN O
0 NN NN O
, NN NN O
250 NN NN O
, NN NN O
500 NN NN O
, NN NN O
or NN NN O
625 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
10 NN NN O
( NN NN O
0 NN NN O
, NN NN O
500 NN NN O
, NN NN O
625 NN NN O
, NN NN O
or NN NN O
750 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
or NN NN O
11 NN NN O
( NN NN O
0 NN NN O
, NN NN O
500 NN NN O
, NN NN O
750 NN NN O
, NN NN O
or NN NN O
1000 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
and NN NN O
from NN NN O
GD NN NN O
6 NN NN O
to NN NN O
GD NN NN O
17 NN NN O
( NN NN O
0 NN NN O
, NN NN O
50 NN NN O
, NN NN O
125 NN NN O
, NN NN O
or NN NN O
250 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
a NN NN O
day NN NN O
) NN NN O
in NN NN O
the NN NN O
multiple NN NN O
dose NN NN O
study NN NN O
to NN NN O
SD NN NN O
rats NN NN O
. NN NN O
   
Animals NN NN O
were NN NN O
killed NN NN O
on NN NN O
GD NN NN O
21 NN NN O
, NN NN O
and NN NN O
fetuses NN NN O
were NN NN O
examined NN NN O
viscerally NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
literature NN NN O
evaluation NN NN O
suggested NN NN O
that NN NN O
NSAIDs NN NN O
induce NN NN O
ventricular NN NN B-Disease
septal NN NN I-Disease
defects NN NN I-Disease
( NN NN O
VSDs NN NN B-Disease
) NN NN O
and NN NN O
midline NN NN B-Disease
defects NN NN I-Disease
( NN NN O
MDs NN NN B-Disease
) NN NN O
in NN NN O
rats NN NN O
and NN NN O
diaphragmatic NN NN B-Disease
hernia NN NN I-Disease
( NN NN O
DH NN NN B-Disease
) NN NN O
, NN NN O
MDs NN NN B-Disease
, NN NN O
and NN NN O
VSDs NN NN B-Disease
in NN NN O
rabbits NN NN O
( NN NN O
Cook NN NN O
JC NN NN O
et NN NN O
al NN NN O
. NN NN O
, NN NN O
2003 NN NN O
) NN NN O
; NN NN O
hence NN NN O
, NN NN O
the NN NN O
present NN NN O
study NN NN O
focused NN NN O
on NN NN O
these NN NN O
malformations NN NN B-Disease
, NN NN O
even NN NN O
though NN NN O
ASA NN NN O
induces NN NN O
several NN NN O
other NN NN O
low NN NN O
- NN NN O
incidence NN NN O
malformations NN NN B-Disease
. NN NN O
   
In NN NN O
single NN NN O
dose NN NN O
studies NN NN O
, NN NN O
DH NN NN B-Disease
, NN NN O
MD NN NN B-Disease
, NN NN O
and NN NN O
VSD NN NN B-Disease
were NN NN O
induced NN NN O
on NN NN O
GDs NN NN O
9 NN NN O
and NN NN O
10 NN NN O
. NN NN O
   
VSD NN NN B-Disease
also NN NN O
was NN NN O
noted NN NN O
following NN NN O
treatment NN NN O
on NN NN O
GD NN NN O
11 NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
DH NN NN B-Disease
and NN NN O
MD NN NN B-Disease
were NN NN O
noted NN NN O
in NN NN O
the NN NN O
multiple NN NN O
dose NN NN O
study NN NN O
design NN NN O
only NN NN O
in NN NN O
the NN NN O
high NN NN O
- NN NN O
dose NN NN O
group NN NN O
, NN NN O
and NN NN O
VSD NN NN B-Disease
was NN NN O
noted NN NN O
across NN NN O
all NN NN O
dose NN NN O
groups NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
High NN NN O
concordance NN NN O
in NN NN O
major NN NN O
developmental NN NN B-Disease
anomalies NN NN I-Disease
between NN NN O
Wistar NN NN O
and NN NN O
SD NN NN O
rats NN NN O
were NN NN O
noted NN NN O
with NN NN O
the NN NN O
exception NN NN O
of NN NN O
VSD NN NN B-Disease
in NN NN O
the NN NN O
SD NN NN O
rats NN NN O
and NN NN O
hydrocephalus NN NN B-Disease
in NN NN O
the NN NN O
Wistar NN NN O
rats NN NN O
. NN NN O
   
Variations NN NN O
and NN NN O
malformations NN NN B-Disease
were NN NN O
similar NN NN O
when NN NN O
ASA NN NN O
was NN NN O
administered NN NN O
as NN NN O
a NN NN O
single NN NN O
dose NN NN O
or NN NN O
during NN NN O
the NN NN O
period NN NN O
of NN NN O
organogenesis NN NN O
( NN NN O
GDs NN NN O
6 NN NN O
to NN NN O
17 NN NN O
) NN NN O
. NN NN O
   
It NN NN O
was NN NN O
also NN NN O
evident NN NN O
that NN NN O
, NN NN O
by NN NN O
titrating NN NN O
the NN NN O
dose NN NN O
to NN NN O
achieve NN NN O
a NN NN O
maximum NN NN O
tolerated NN NN O
dose NN NN O
, NN NN O
malformations NN NN B-Disease
that NN NN O
normally NN NN O
occur NN NN O
at NN NN O
low NN NN O
incidence NN NN O
, NN NN O
as NN NN O
reported NN NN O
from NN NN O
previous NN NN O
single NN NN O
dose NN NN O
studies NN NN O
, NN NN O
could NN NN O
also NN NN O
be NN NN O
induced NN NN O
with NN NN O
ASA NN NN O
given NN NN O
at NN NN O
multiple NN NN O
doses NN NN O
. NN NN O
   
Reversal NN NN O
of NN NN O
central NN NN O
benzodiazepine NN NN O
effects NN NN O
by NN NN O
flumazenil NN NN O
after NN NN O
intravenous NN NN O
conscious NN NN O
sedation NN NN O
with NN NN O
diazepam NN NN O
and NN NN O
opioids NN NN O
: NN NN O
report NN NN O
of NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
multicenter NN NN O
study NN NN O
. NN NN O
   
The NN NN O
Flumazenil NN NN O
in NN NN O
Intravenous NN NN O
Conscious NN NN O
Sedation NN NN O
with NN NN O
Diazepam NN NN O
Multicenter NN NN O
Study NN NN O
Group NN NN O
II NN NN O
. NN NN O
   
The NN NN O
efficacy NN NN O
and NN NN O
safety NN NN O
of NN NN O
a NN NN O
new NN NN O
benzodiazepine NN NN O
antagonist NN NN O
, NN NN O
flumazenil NN NN O
, NN NN O
were NN NN O
assessed NN NN O
in NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
multicenter NN NN O
study NN NN O
. NN NN O
   
Flumazenil NN NN O
( NN NN O
mean NN NN O
dose NN NN O
, NN NN O
0 NN NN O
. NN NN O
76 NN NN O
mg NN NN O
) NN NN O
or NN NN O
placebo NN NN O
( NN NN O
mean NN NN O
dose NN NN O
, NN NN O
8 NN NN O
. NN NN O
9 NN NN O
ml NN NN O
) NN NN O
was NN NN O
administered NN NN O
intravenously NN NN O
to NN NN O
130 NN NN O
and NN NN O
67 NN NN O
patients NN NN O
, NN NN O
respectively NN NN O
, NN NN O
who NN NN O
had NN NN O
been NN NN O
given NN NN O
diazepam NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
an NN NN O
opioid NN NN O
( NN NN O
fentanyl NN NN O
, NN NN O
meperidine NN NN O
, NN NN O
or NN NN O
morphine NN NN O
) NN NN O
for NN NN O
the NN NN O
induction NN NN O
and NN NN O
maintenance NN NN O
of NN NN O
intravenous NN NN O
conscious NN NN O
sedation NN NN O
for NN NN O
diagnostic NN NN O
or NN NN O
therapeutic NN NN O
surgical NN NN O
procedures NN NN O
. NN NN O
   
The NN NN O
group NN NN O
assessable NN NN O
for NN NN O
efficacy NN NN O
comprised NN NN O
122 NN NN O
patients NN NN O
treated NN NN O
with NN NN O
flumazenil NN NN O
and NN NN O
64 NN NN O
patients NN NN O
given NN NN O
placebo NN NN O
. NN NN O
   
After NN NN O
5 NN NN O
minutes NN NN O
, NN NN O
80 NN NN O
/ NN NN O
115 NN NN O
( NN NN O
70 NN NN O
% NN NN O
) NN NN O
flumazenil NN NN O
- NN NN O
treated NN NN O
patients NN NN O
, NN NN O
compared NN NN O
with NN NN O
21 NN NN O
/ NN NN O
63 NN NN O
( NN NN O
33 NN NN O
% NN NN O
) NN NN O
placebo NN NN O
- NN NN O
treated NN NN O
patients NN NN O
, NN NN O
were NN NN O
completely NN NN O
awake NN NN O
and NN NN O
alert NN NN O
, NN NN O
as NN NN O
indicated NN NN O
by NN NN O
a NN NN O
score NN NN O
of NN NN O
5 NN NN O
on NN NN O
the NN NN O
Observer NN NN O
' NN NN O
s NN NN O
Assessment NN NN O
of NN NN O
Alertness NN NN O
/ NN NN O
Sedation NN NN O
Scale NN NN O
. NN NN O
   
Ninety NN NN O
- NN NN O
five NN NN O
percent NN NN O
of NN NN O
patients NN NN O
in NN NN O
each NN NN O
group NN NN O
who NN NN O
attained NN NN O
a NN NN O
score NN NN O
of NN NN O
5 NN NN O
at NN NN O
the NN NN O
5 NN NN O
- NN NN O
minute NN NN O
assessment NN NN O
showed NN NN O
no NN NN O
loss NN NN O
of NN NN O
alertness NN NN O
throughout NN NN O
the NN NN O
180 NN NN O
- NN NN O
minute NN NN O
assessment NN NN O
period NN NN O
. NN NN O
   
Flumazenil NN NN O
- NN NN O
treated NN NN O
patients NN NN O
also NN NN O
performed NN NN O
significantly NN NN O
better NN NN O
on NN NN O
the NN NN O
Finger NN NN O
- NN NN O
to NN NN O
- NN NN O
Nose NN NN O
Test NN NN O
and NN NN O
the NN NN O
recall NN NN O
of NN NN O
pictures NN NN O
shown NN NN O
at NN NN O
the NN NN O
5 NN NN O
- NN NN O
minute NN NN O
assessment NN NN O
. NN NN O
   
Flumazenil NN NN O
was NN NN O
well NN NN O
tolerated NN NN O
, NN NN O
with NN NN O
no NN NN O
serious NN NN O
adverse NN NN O
effects NN NN O
reported NN NN O
. NN NN O
   
Thirty NN NN O
- NN NN O
nine NN NN O
( NN NN O
30 NN NN O
% NN NN O
) NN NN O
of NN NN O
flumazenil NN NN O
- NN NN O
treated NN NN O
patients NN NN O
, NN NN O
compared NN NN O
with NN NN O
17 NN NN O
( NN NN O
25 NN NN O
% NN NN O
) NN NN O
of NN NN O
placebo NN NN O
- NN NN O
treated NN NN O
patients NN NN O
had NN NN O
one NN NN O
or NN NN O
more NN NN O
drug NN NN O
- NN NN O
related NN NN O
adverse NN NN O
experiences NN NN O
. NN NN O
   
The NN NN O
most NN NN O
common NN NN O
adverse NN NN O
effects NN NN O
were NN NN O
nausea NN NN B-Disease
and NN NN O
vomiting NN NN B-Disease
in NN NN O
the NN NN O
flumazenil NN NN O
group NN NN O
and NN NN O
nausea NN NN B-Disease
and NN NN O
injection NN NN O
- NN NN O
site NN NN O
pain NN NN B-Disease
in NN NN O
the NN NN O
placebo NN NN O
group NN NN O
. NN NN O
   
Flumazenil NN NN O
was NN NN O
found NN NN O
to NN NN O
promptly NN NN O
reverse NN NN O
sedation NN NN O
induced NN NN O
by NN NN O
diazepam NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
opioids NN NN O
. NN NN O
   
Methylphenidate NN NN O
- NN NN O
induced NN NN O
obsessive NN NN B-Disease
- NN NN I-Disease
compulsive NN NN I-Disease
symptoms NN NN I-Disease
in NN NN O
an NN NN O
elderly NN NN O
man NN NN O
. NN NN O
   
An NN NN O
82 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
with NN NN O
treatment NN NN B-Disease
- NN NN I-Disease
resistant NN NN I-Disease
depression NN NN I-Disease
and NN NN O
early NN NN O
Alzheimer NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
was NN NN O
started NN NN O
on NN NN O
methylphenidate NN NN O
. NN NN O
   
Significant NN NN O
obsessive NN NN B-Disease
- NN NN I-Disease
compulsive NN NN I-Disease
behavior NN NN I-Disease
ensued NN NN O
but NN NN O
diminished NN NN O
over NN NN O
several NN NN O
weeks NN NN O
when NN NN O
methylphenidate NN NN O
was NN NN O
replaced NN NN O
by NN NN O
fluvoxamine NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
had NN NN O
no NN NN O
prior NN NN O
psychiatric NN NN B-Disease
history NN NN O
, NN NN O
but NN NN O
he NN NN O
had NN NN O
a NN NN O
sister NN NN O
with NN NN O
obsessive NN NN B-Disease
- NN NN I-Disease
compulsive NN NN I-Disease
disorder NN NN I-Disease
. NN NN O
   
It NN NN O
appears NN NN O
that NN NN O
methylphenidate NN NN O
precipitated NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
pathological NN NN O
behavior NN NN O
. NN NN O
   
Ciprofloxacin NN NN O
- NN NN O
induced NN NN O
acute NN NN O
interstitial NN NN B-Disease
nephritis NN NN I-Disease
and NN NN O
autoimmune NN NN B-Disease
hemolytic NN NN I-Disease
anemia NN NN I-Disease
. NN NN O
   
Ciprofloxacin NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
several NN NN O
side NN NN O
effects NN NN O
including NN NN O
interstitial NN NN B-Disease
nephritis NN NN I-Disease
and NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
. NN NN O
   
The NN NN O
combination NN NN O
of NN NN O
both NN NN O
side NN NN O
effects NN NN O
is NN NN O
extremely NN NN O
rare NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
describe NN NN O
a NN NN O
case NN NN O
of NN NN O
ciprofloxacin NN NN O
- NN NN O
induced NN NN O
interstitial NN NN B-Disease
nephritis NN NN I-Disease
and NN NN O
autoimmune NN NN B-Disease
hemolytic NN NN I-Disease
anemia NN NN I-Disease
. NN NN O
   
Hemolytic NN NN B-Disease
anemia NN NN I-Disease
improved NN NN O
after NN NN O
stopping NN NN O
the NN NN O
drug NN NN O
and NN NN O
initiation NN NN O
of NN NN O
steroid NN NN O
therapy NN NN O
. NN NN O
   
Unfortunately NN NN O
, NN NN O
acute NN NN O
interstitial NN NN B-Disease
nephritis NN NN I-Disease
was NN NN O
irreversible NN NN O
and NN NN O
the NN NN O
patient NN NN O
developed NN NN O
end NN NN B-Disease
- NN NN I-Disease
stage NN NN I-Disease
renal NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Potential NN NN O
deleterious NN NN O
effect NN NN O
of NN NN O
furosemide NN NN O
in NN NN O
radiocontrast NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
the NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
the NN NN O
efficacy NN NN O
of NN NN O
furosemide NN NN O
in NN NN O
addition NN NN O
to NN NN O
intravenous NN NN O
fluids NN NN O
in NN NN O
the NN NN O
prevention NN NN O
of NN NN O
radiocontrast NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
18 NN NN O
patients NN NN O
, NN NN O
referred NN NN O
to NN NN O
a NN NN O
radiocontrast NN NN O
study NN NN O
, NN NN O
considered NN NN O
at NN NN O
risk NN NN O
because NN NN O
of NN NN O
preexisting NN NN O
renal NN NN B-Disease
insufficiency NN NN I-Disease
, NN NN O
were NN NN O
enrolled NN NN O
in NN NN O
a NN NN O
prospective NN NN O
, NN NN O
randomized NN NN O
, NN NN O
controlled NN NN O
trial NN NN O
, NN NN O
performed NN NN O
at NN NN O
the NN NN O
secondary NN NN O
care NN NN O
center NN NN O
of NN NN O
a NN NN O
1 NN NN O
, NN NN O
100 NN NN O
- NN NN O
bed NN NN O
private NN NN O
university NN NN O
hospital NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
fluids NN NN O
, NN NN O
the NN NN O
treatment NN NN O
group NN NN O
received NN NN O
furosemide NN NN O
( NN NN O
mean NN NN O
dose NN NN O
110 NN NN O
mg NN NN O
) NN NN O
intravenously NN NN O
30 NN NN O
min NN NN O
prior NN NN O
to NN NN O
the NN NN O
injection NN NN O
of NN NN O
contrast NN NN O
material NN NN O
. NN NN O
   
The NN NN O
control NN NN O
group NN NN O
received NN NN O
fluids NN NN O
( NN NN O
mean NN NN O
3 NN NN O
liters NN NN O
) NN NN O
. NN NN O
   
Radiological NN NN O
studies NN NN O
were NN NN O
mostly NN NN O
angiographies NN NN O
performed NN NN O
with NN NN O
both NN NN O
ionic NN NN O
and NN NN O
non NN NN O
- NN NN O
ionic NN NN O
contrast NN NN O
material NN NN O
, NN NN O
at NN NN O
an NN NN O
average NN NN O
dose NN NN O
of NN NN O
245 NN NN O
ml NN NN O
. NN NN O
   
Renal NN NN B-Disease
function NN NN I-Disease
significantly NN NN I-Disease
deteriorated NN NN I-Disease
in NN NN O
the NN NN O
group NN NN O
pretreated NN NN O
with NN NN O
furosemide NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
005 NN NN O
by NN NN O
ANOVA NN NN O
) NN NN O
, NN NN O
with NN NN O
a NN NN O
rise NN NN O
in NN NN O
serum NN NN O
creatinine NN NN O
from NN NN O
145 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
13 NN NN O
to NN NN O
182 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
16 NN NN O
mumol NN NN O
/ NN NN O
l NN NN O
at NN NN O
24 NN NN O
h NN NN O
, NN NN O
while NN NN O
no NN NN O
change NN NN O
occurred NN NN O
in NN NN O
the NN NN O
control NN NN O
group NN NN O
( NN NN O
from NN NN O
141 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
to NN NN O
142 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
mumol NN NN O
/ NN NN O
l NN NN O
) NN NN O
. NN NN O
   
Renal NN NN B-Disease
failure NN NN I-Disease
was NN NN O
associated NN NN O
with NN NN O
weight NN NN B-Disease
loss NN NN I-Disease
in NN NN O
the NN NN O
furosemide NN NN O
- NN NN O
treated NN NN O
group NN NN O
. NN NN O
   
Furosemide NN NN O
may NN NN O
be NN NN O
deleterious NN NN O
in NN NN O
the NN NN O
prevention NN NN O
of NN NN O
radiocontrast NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
Progestational NN NN O
agents NN NN O
and NN NN O
blood NN NN B-Disease
coagulation NN NN I-Disease
. NN NN O
   
VII NN NN O
. NN NN O
   
Thromboembolic NN NN B-Disease
and NN NN O
other NN NN O
complications NN NN O
of NN NN O
oral NN NN O
contraceptive NN NN O
therapy NN NN O
in NN NN O
relationship NN NN O
to NN NN O
pretreatment NN NN O
levels NN NN O
of NN NN O
blood NN NN B-Disease
coagulation NN NN I-Disease
factors NN NN O
: NN NN O
summary NN NN O
report NN NN O
of NN NN O
a NN NN O
ten NN NN O
- NN NN O
year NN NN O
study NN NN O
. NN NN O
   
During NN NN O
a NN NN O
ten NN NN O
- NN NN O
year NN NN O
period NN NN O
, NN NN O
348 NN NN O
women NN NN O
were NN NN O
studied NN NN O
for NN NN O
a NN NN O
total NN NN O
of NN NN O
5 NN NN O
, NN NN O
877 NN NN O
patient NN NN O
months NN NN O
in NN NN O
four NN NN O
separate NN NN O
studies NN NN O
relating NN NN O
oral NN NN O
contraceptives NN NN O
to NN NN O
changes NN NN O
in NN NN O
hematologic NN NN O
parameters NN NN O
. NN NN O
   
Significant NN NN O
increases NN NN O
in NN NN O
certain NN NN O
factors NN NN O
of NN NN O
the NN NN O
blood NN NN B-Disease
coagulation NN NN I-Disease
and NN NN O
fibrinolysin NN NN O
systems NN NN O
( NN NN O
factors NN NN O
I NN NN O
, NN NN O
II NN NN O
, NN NN O
VII NN NN O
, NN NN O
VIII NN NN O
, NN NN O
IX NN NN O
, NN NN O
and NN NN O
X NN NN O
and NN NN O
plasminogen NN NN O
) NN NN O
were NN NN O
observed NN NN O
in NN NN O
the NN NN O
treated NN NN O
groups NN NN O
. NN NN O
   
Severe NN NN O
complications NN NN O
developed NN NN O
in NN NN O
four NN NN O
patients NN NN O
. NN NN O
   
All NN NN O
four NN NN O
had NN NN O
an NN NN O
abnormal NN NN O
blood NN NN B-Disease
coagulation NN NN I-Disease
profile NN NN O
, NN NN O
suggesting NN NN O
"""""""" NN NN O
hypercoagulability NN NN B-Disease
"""""""" NN NN O
before NN NN O
initiation NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
Some NN NN O
of NN NN O
these NN NN O
findings NN NN O
represented NN NN O
the NN NN O
most NN NN O
extreme NN NN O
abnormalities NN NN O
seen NN NN O
in NN NN O
the NN NN O
entire NN NN O
group NN NN O
of NN NN O
patients NN NN O
; NN NN O
some NN NN O
increased NN NN O
further NN NN O
during NN NN O
therapy NN NN O
. NN NN O
   
One NN NN O
of NN NN O
these NN NN O
patients NN NN O
developed NN NN O
a NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
before NN NN O
receiving NN NN O
any NN NN O
medication NN NN O
, NN NN O
shortly NN NN O
after NN NN O
the NN NN O
base NN NN O
- NN NN O
line NN NN O
values NN NN O
were NN NN O
obtained NN NN O
. NN NN O
   
One NN NN O
patient NN NN O
developed NN NN O
retinopathy NN NN B-Disease
19 NN NN O
months NN NN O
after NN NN O
she NN NN O
began NN NN O
therapy NN NN O
, NN NN O
and NN NN O
another NN NN O
developed NN NN O
thrombophlebitis NN NN B-Disease
after NN NN O
27 NN NN O
months NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
fourth NN NN O
patient NN NN O
developed NN NN O
thrombophlebitis NN NN B-Disease
14 NN NN O
days NN NN O
after NN NN O
initiation NN NN O
of NN NN O
contraceptive NN NN O
therapy NN NN O
. NN NN O
   
All NN NN O
four NN NN O
patients NN NN O
were NN NN O
of NN NN O
the NN NN O
A NN NN O
or NN NN O
AB NN NN O
blood NN NN O
group NN NN O
. NN NN O
   
Previous NN NN O
studies NN NN O
suggested NN NN O
the NN NN O
possiblility NN NN O
of NN NN O
increased NN NN O
propensity NN NN O
for NN NN O
thromboembolic NN NN B-Disease
episodes NN NN I-Disease
in NN NN O
patients NN NN O
possessing NN NN O
the NN NN O
A NN NN O
antigen NN NN O
. NN NN O
   
It NN NN O
appears NN NN O
from NN NN O
these NN NN O
data NN NN O
that NN NN O
hematologic NN NN O
work NN NN O
- NN NN O
ups NN NN O
may NN NN O
be NN NN O
useful NN NN O
in NN NN O
women NN NN O
who NN NN O
are NN NN O
about NN NN O
to NN NN O
start NN NN O
long NN NN O
- NN NN O
term NN NN O
oral NN NN O
contraceptive NN NN O
therapy NN NN O
. NN NN O
   
Orthostatic NN NN B-Disease
hypotension NN NN I-Disease
occurs NN NN O
following NN NN O
alpha NN NN O
2 NN NN O
- NN NN O
adrenoceptor NN NN O
blockade NN NN O
in NN NN O
chronic NN NN O
prazosin NN NN O
- NN NN O
pretreated NN NN O
conscious NN NN O
spontaneously NN NN O
hypertensive NN NN B-Disease
rats NN NN O
. NN NN O
   
1 NN NN O
. NN NN O
   
Studies NN NN O
were NN NN O
performed NN NN O
to NN NN O
evaluate NN NN O
whether NN NN O
chronic NN NN O
prazosin NN NN O
treatment NN NN O
alters NN NN O
the NN NN O
alpha NN NN O
2 NN NN O
- NN NN O
adrenoceptor NN NN O
function NN NN O
for NN NN O
orthostatic NN NN O
control NN NN O
of NN NN O
arterial NN NN O
blood NN NN O
pressure NN NN O
in NN NN O
conscious NN NN O
spontaneously NN NN O
hypertensive NN NN B-Disease
rats NN NN O
( NN NN O
SHR NN NN O
) NN NN O
. NN NN O
   
2 NN NN O
. NN NN O
   
Conscious NN NN O
SHR NN NN O
( NN NN O
male NN NN O
300 NN NN O
- NN NN O
350 NN NN O
g NN NN O
) NN NN O
were NN NN O
subjected NN NN O
to NN NN O
90 NN NN O
degrees NN NN O
head NN NN O
- NN NN O
up NN NN O
tilts NN NN O
for NN NN O
60 NN NN O
s NN NN O
following NN NN O
acute NN NN O
administration NN NN O
of NN NN O
prazosin NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
mg NN NN O
kg NN NN O
- NN NN O
1 NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
or NN NN O
rauwolscine NN NN O
( NN NN O
3 NN NN O
mg NN NN O
kg NN NN O
- NN NN O
1 NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
. NN NN O
   
Orthostatic NN NN B-Disease
hypotension NN NN I-Disease
was NN NN O
determined NN NN O
by NN NN O
the NN NN O
average NN NN O
decrease NN NN O
( NN NN O
% NN NN O
) NN NN O
in NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
( NN NN O
MAP NN NN O
femoral NN NN O
) NN NN O
over NN NN O
the NN NN O
60 NN NN O
- NN NN O
s NN NN O
tilt NN NN O
period NN NN O
. NN NN O
   
The NN NN O
basal NN NN O
MAP NN NN O
of NN NN O
conscious NN NN O
SHR NN NN O
was NN NN O
reduced NN NN O
to NN NN O
a NN NN O
similar NN NN O
extent NN NN O
by NN NN O
prazosin NN NN O
( NN NN O
- NN NN O
23 NN NN O
% NN NN O
( NN NN O
- NN NN O
) NN NN O
- NN NN O
26 NN NN O
% NN NN O
MAP NN NN O
) NN NN O
and NN NN O
rauwolscine NN NN O
( NN NN O
- NN NN O
16 NN NN O
% NN NN O
( NN NN O
- NN NN O
) NN NN O
- NN NN O
33 NN NN O
% NN NN O
MAP NN NN O
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
head NN NN O
- NN NN O
up NN NN O
tilt NN NN O
induced NN NN O
orthostatic NN NN B-Disease
hypotension NN NN I-Disease
in NN NN O
the NN NN O
SHR NN NN O
treated NN NN O
with NN NN O
prazosin NN NN O
( NN NN O
- NN NN O
16 NN NN O
% NN NN O
MAP NN NN O
, NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
the NN NN O
SHR NN NN O
treated NN NN O
with NN NN O
rauwolscine NN NN O
( NN NN O
less NN NN O
than NN NN O
+ NN NN O
2 NN NN O
% NN NN O
MAP NN NN O
, NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
. NN NN O
   
3 NN NN O
. NN NN O
   
Conscious NN NN O
SHR NN NN O
were NN NN O
treated NN NN O
for NN NN O
4 NN NN O
days NN NN O
with NN NN O
prazosin NN NN O
at NN NN O
2 NN NN O
mg NN NN O
kg NN NN O
- NN NN O
1 NN NN O
day NN NN O
- NN NN O
1 NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
for NN NN O
chronic NN NN O
alpha NN NN O
1 NN NN O
- NN NN O
adrenoceptor NN NN O
blockade NN NN O
. NN NN O
   
MAP NN NN O
in NN NN O
conscious NN NN O
SHR NN NN O
after NN NN O
chronic NN NN O
prazosin NN NN O
treatment NN NN O
was NN NN O
14 NN NN O
% NN NN O
lower NN NN O
than NN NN O
in NN NN O
the NN NN O
untreated NN NN O
SHR NN NN O
( NN NN O
n NN NN O
= NN NN O
8 NN NN O
) NN NN O
. NN NN O
   
Head NN NN O
- NN NN O
up NN NN O
tilts NN NN O
in NN NN O
these NN NN O
rats NN NN O
did NN NN O
not NN NN O
produce NN NN O
orthostatic NN NN B-Disease
hypotension NN NN I-Disease
when NN NN O
performed NN NN O
either NN NN O
prior NN NN O
to NN NN O
or NN NN O
after NN NN O
acute NN NN O
dosing NN NN O
of NN NN O
prazosin NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
mg NN NN O
kg NN NN O
- NN NN O
1 NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
. NN NN O
   
Conversely NN NN O
, NN NN O
administration NN NN O
of NN NN O
rauwolscine NN NN O
( NN NN O
3 NN NN O
mg NN NN O
kg NN NN O
- NN NN O
1 NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
in NN NN O
chronic NN NN O
prazosin NN NN O
treated NN NN O
SHR NN NN O
decreased NN NN O
the NN NN O
basal NN NN O
MAP NN NN O
by NN NN O
12 NN NN O
- NN NN O
31 NN NN O
% NN NN O
( NN NN O
n NN NN O
= NN NN O
4 NN NN O
) NN NN O
, NN NN O
and NN NN O
subsequent NN NN O
tilts NN NN O
induced NN NN O
further NN NN O
drops NN NN O
of NN NN O
MAP NN NN O
by NN NN O
19 NN NN O
- NN NN O
23 NN NN O
% NN NN O
in NN NN O
these NN NN O
rats NN NN O
. NN NN O
   
4 NN NN O
. NN NN O
   
The NN NN O
pressor NN NN O
responses NN NN O
and NN NN O
bradycardia NN NN B-Disease
to NN NN O
the NN NN O
alpha NN NN O
1 NN NN O
- NN NN O
agonist NN NN O
cirazoline NN NN O
( NN NN O
0 NN NN O
. NN NN O
6 NN NN O
and NN NN O
2 NN NN O
micrograms NN NN O
kg NN NN O
- NN NN O
1 NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
, NN NN O
the NN NN O
alpha NN NN O
2 NN NN O
- NN NN O
agonist NN NN O
Abbott NN NN O
- NN NN O
53693 NN NN O
( NN NN O
1 NN NN O
and NN NN O
3 NN NN O
micrograms NN NN O
kg NN NN O
- NN NN O
1 NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
, NN NN O
and NN NN O
noradrenaline NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
and NN NN O
1 NN NN O
. NN NN O
0 NN NN O
micrograms NN NN O
kg NN NN O
- NN NN O
1 NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
were NN NN O
determined NN NN O
in NN NN O
conscious NN NN O
SHR NN NN O
with NN NN O
and NN NN O
without NN NN O
chronic NN NN O
prazosin NN NN O
pretreatment NN NN O
. NN NN O
   
Both NN NN O
the NN NN O
pressor NN NN O
and NN NN O
bradycardia NN NN B-Disease
effects NN NN O
of NN NN O
cirazoline NN NN O
were NN NN O
abolished NN NN O
in NN NN O
chronic NN NN O
prazosin NN NN O
treated NN NN O
SHR NN NN O
( NN NN O
n NN NN O
= NN NN O
4 NN NN O
) NN NN O
as NN NN O
compared NN NN O
to NN NN O
the NN NN O
untreated NN NN O
SHR NN NN O
( NN NN O
n NN NN O
= NN NN O
4 NN NN O
) NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
the NN NN O
pressor NN NN O
effects NN NN O
of NN NN O
Abbott NN NN O
- NN NN O
53693 NN NN O
were NN NN O
similar NN NN O
in NN NN O
both NN NN O
groups NN NN O
of NN NN O
SHR NN NN O
, NN NN O
but NN NN O
the NN NN O
accompanying NN NN O
bradycardia NN NN B-Disease
was NN NN O
greater NN NN O
in NN NN O
SHR NN NN O
with NN NN O
chronic NN NN O
prazosin NN NN O
treatment NN NN O
than NN NN O
without NN NN O
such NN NN O
treatment NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
bradycardia NN NN B-Disease
that NN NN O
accompanied NN NN O
the NN NN O
noradrenaline NN NN O
- NN NN O
induced NN NN O
pressor NN NN O
effect NN NN O
in NN NN O
SHR NN NN O
was NN NN O
similar NN NN O
with NN NN O
and NN NN O
without NN NN O
chronic NN NN O
prazosin NN NN O
treatment NN NN O
despite NN NN O
a NN NN O
47 NN NN O
- NN NN O
71 NN NN O
% NN NN O
reduction NN NN O
of NN NN O
the NN NN O
pressor NN NN O
effect NN NN O
in NN NN O
chronic NN NN O
alpha NN NN O
1 NN NN O
- NN NN O
receptor NN NN O
blocked NN NN O
SHR NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
400 NN NN O
WORDS NN NN O
) NN NN O
   
Hemolytic NN NN B-Disease
- NN NN I-Disease
uremic NN NN I-Disease
syndrome NN NN I-Disease
associated NN NN O
with NN NN O
ingestion NN NN O
of NN NN O
quinine NN NN O
. NN NN O
   
Hemolytic NN NN B-Disease
- NN NN I-Disease
uremic NN NN I-Disease
syndrome NN NN I-Disease
following NN NN O
quinine NN NN O
ingestion NN NN O
is NN NN O
a NN NN O
newly NN NN O
described NN NN O
phenomenon NN NN O
, NN NN O
with NN NN O
just NN NN O
two NN NN O
previous NN NN O
descriptions NN NN O
of NN NN O
4 NN NN O
cases NN NN O
in NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
5th NN NN O
case NN NN O
. NN NN O
   
The NN NN O
reaction NN NN O
may NN NN O
be NN NN O
mediated NN NN O
by NN NN O
the NN NN O
presence NN NN O
of NN NN O
antibodies NN NN O
reactive NN NN O
against NN NN O
platelets NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
quinine NN NN O
. NN NN O
   
Treatment NN NN O
has NN NN O
included NN NN O
use NN NN O
of NN NN O
plasma NN NN O
exchange NN NN O
, NN NN O
prednisone NN NN O
, NN NN O
aspirin NN NN O
, NN NN O
and NN NN O
dipyridamole NN NN O
. NN NN O
   
The NN NN O
patients NN NN O
have NN NN O
all NN NN O
regained NN NN O
some NN NN O
degree NN NN O
of NN NN O
renal NN NN O
function NN NN O
. NN NN O
   
However NN NN O
, NN NN O
it NN NN O
is NN NN O
unclear NN NN O
whether NN NN O
pharmacological NN NN O
treatment NN NN O
or NN NN O
spontaneous NN NN O
resolution NN NN O
is NN NN O
responsible NN NN O
for NN NN O
the NN NN O
improvement NN NN O
. NN NN O
   
Quinine NN NN O
- NN NN O
associated NN NN O
hemolytic NN NN B-Disease
- NN NN I-Disease
uremic NN NN I-Disease
syndrome NN NN I-Disease
probably NN NN O
occurs NN NN O
more NN NN O
often NN NN O
than NN NN O
is NN NN O
recognized NN NN O
. NN NN O
   
It NN NN O
is NN NN O
important NN NN O
to NN NN O
recognize NN NN O
this NN NN O
reaction NN NN O
when NN NN O
it NN NN O
occurs NN NN O
and NN NN O
to NN NN O
avoid NN NN O
further NN NN O
quinine NN NN O
exposure NN NN O
, NN NN O
since NN NN O
the NN NN O
reaction NN NN O
seems NN NN O
to NN NN O
be NN NN O
recurrent NN NN O
. NN NN O
   
Amnestic NN NN B-Disease
syndrome NN NN I-Disease
associated NN NN O
with NN NN O
propranolol NN NN O
toxicity NN NN B-Disease
: NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
An NN NN O
elderly NN NN O
woman NN NN O
developed NN NN O
an NN NN O
Alzheimer NN NN B-Disease
- NN NN O
like NN NN O
subacute NN NN O
dementia NN NN B-Disease
as NN NN O
a NN NN O
result NN NN O
of NN NN O
propranolol NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Analysis NN NN O
of NN NN O
the NN NN O
manifestations NN NN O
showed NN NN O
that NN NN O
severe NN NN O
impairment NN NN O
of NN NN O
memory NN NN O
accounted NN NN O
for NN NN O
virtually NN NN O
all NN NN O
of NN NN O
the NN NN O
abnormalities NN NN O
. NN NN O
   
There NN NN O
is NN NN O
evidence NN NN O
that NN NN O
cerebral NN NN O
reactions NN NN O
to NN NN O
drug NN NN O
toxicity NN NN B-Disease
can NN NN O
exhibit NN NN O
patterns NN NN O
that NN NN O
suggest NN NN O
highly NN NN O
selective NN NN O
involvement NN NN O
of NN NN O
functional NN NN O
subdivisions NN NN O
of NN NN O
the NN NN O
brain NN NN O
. NN NN O
   
Cefotetan NN NN O
- NN NN O
induced NN NN O
immune NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
. NN NN O
   
Immune NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
due NN NN O
to NN NN O
a NN NN O
drug NN NN O
- NN NN O
adsorption NN NN O
mechanism NN NN O
has NN NN O
been NN NN O
described NN NN O
primarily NN NN O
in NN NN O
patients NN NN O
receiving NN NN O
penicillins NN NN O
and NN NN O
first NN NN O
- NN NN O
generation NN NN O
cephalosporins NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
patient NN NN O
who NN NN O
developed NN NN O
anemia NN NN B-Disease
while NN NN O
receiving NN NN O
intravenous NN NN O
cefotetan NN NN O
. NN NN O
   
Cefotetan NN NN O
- NN NN O
dependent NN NN O
antibodies NN NN O
were NN NN O
detected NN NN O
in NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
serum NN NN O
and NN NN O
in NN NN O
an NN NN O
eluate NN NN O
prepared NN NN O
from NN NN O
his NN NN O
red NN NN O
blood NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
eluate NN NN O
also NN NN O
reacted NN NN O
weakly NN NN O
with NN NN O
red NN NN O
blood NN NN O
cells NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
cefotetan NN NN O
, NN NN O
suggesting NN NN O
the NN NN O
concomitant NN NN O
formation NN NN O
of NN NN O
warm NN NN O
- NN NN O
reactive NN NN O
autoantibodies NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
, NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
clinical NN NN O
and NN NN O
laboratory NN NN O
evidence NN NN O
of NN NN O
extravascular NN NN O
hemolysis NN NN B-Disease
, NN NN O
are NN NN O
consistent NN NN O
with NN NN O
drug NN NN O
- NN NN O
induced NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
, NN NN O
possibly NN NN O
involving NN NN O
both NN NN O
drug NN NN O
- NN NN O
adsorption NN NN O
and NN NN O
autoantibody NN NN O
formation NN NN O
mechanisms NN NN O
. NN NN O
   
This NN NN O
case NN NN O
emphasizes NN NN O
the NN NN O
need NN NN O
for NN NN O
increased NN NN O
awareness NN NN O
of NN NN O
hemolytic NN NN O
reactions NN NN O
to NN NN O
all NN NN O
cephalosporins NN NN O
. NN NN O
   
Use NN NN O
of NN NN O
dexamethasone NN NN O
with NN NN O
mesna NN NN O
for NN NN O
the NN NN O
prevention NN NN O
of NN NN O
ifosfamide NN NN O
- NN NN O
induced NN NN O
hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
. NN NN O
   
AIM NN NN O
: NN NN O
Hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
( NN NN O
HC NN NN B-Disease
) NN NN O
is NN NN O
a NN NN O
limiting NN NN O
side NN NN O
- NN NN O
effect NN NN O
of NN NN O
chemotherapy NN NN O
with NN NN O
ifosfamide NN NN O
( NN NN O
IFS NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
study NN NN O
presented NN NN O
here NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
use NN NN O
of NN NN O
dexamethasone NN NN O
in NN NN O
combination NN NN O
with NN NN O
mesna NN NN O
for NN NN O
the NN NN O
prevention NN NN O
of NN NN O
IFS NN NN O
- NN NN O
induced NN NN O
HC NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Male NN NN O
Wistar NN NN O
rats NN NN O
( NN NN O
150 NN NN O
- NN NN O
200 NN NN O
g NN NN O
; NN NN O
6 NN NN O
rats NN NN O
per NN NN O
group NN NN O
) NN NN O
were NN NN O
treated NN NN O
with NN NN O
saline NN NN O
or NN NN O
mesna NN NN O
5 NN NN O
min NN NN O
( NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
before NN NN O
and NN NN O
2 NN NN O
and NN NN O
6 NN NN O
h NN NN O
after NN NN O
( NN NN O
v NN NN O
. NN NN O
o NN NN O
. NN NN O
) NN NN O
administration NN NN O
of NN NN O
IFS NN NN O
. NN NN O
   
One NN NN O
, NN NN O
two NN NN O
or NN NN O
three NN NN O
doses NN NN O
of NN NN O
mesna NN NN O
were NN NN O
replaced NN NN O
with NN NN O
dexamethasone NN NN O
alone NN NN O
or NN NN O
with NN NN O
dexamethasone NN NN O
plus NN NN O
mesna NN NN O
. NN NN O
   
Cystitis NN NN B-Disease
was NN NN O
evaluated NN NN O
24 NN NN O
h NN NN O
after NN NN O
its NN NN O
induction NN NN O
by NN NN O
the NN NN O
changes NN NN O
in NN NN O
bladder NN NN O
wet NN NN O
weight NN NN O
and NN NN O
by NN NN O
macroscopic NN NN O
and NN NN O
microscopic NN NN O
analysis NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
replacement NN NN O
of NN NN O
the NN NN O
last NN NN O
dose NN NN O
or NN NN O
the NN NN O
last NN NN O
two NN NN O
doses NN NN O
of NN NN O
mesna NN NN O
with NN NN O
dexamethasone NN NN O
reduced NN NN O
the NN NN O
increase NN NN O
in NN NN O
bladder NN NN O
wet NN NN O
weight NN NN O
induced NN NN O
by NN NN O
IFS NN NN O
by NN NN O
84 NN NN O
. NN NN O
79 NN NN O
% NN NN O
and NN NN O
89 NN NN O
. NN NN O
13 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
it NN NN O
almost NN NN O
abolished NN NN O
the NN NN O
macroscopic NN NN O
and NN NN O
microscopic NN NN O
alterations NN NN O
induced NN NN O
by NN NN O
IFS NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
the NN NN O
addition NN NN O
of NN NN O
dexamethasone NN NN O
to NN NN O
the NN NN O
last NN NN O
two NN NN O
doses NN NN O
of NN NN O
mesna NN NN O
was NN NN O
more NN NN O
efficient NN NN O
than NN NN O
three NN NN O
doses NN NN O
of NN NN O
mesna NN NN O
alone NN NN O
when NN NN O
evaluated NN NN O
microscopically NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Dexamethasone NN NN O
in NN NN O
combination NN NN O
with NN NN O
mesna NN NN O
was NN NN O
efficient NN NN O
in NN NN O
blocking NN NN O
IFS NN NN O
- NN NN O
induced NN NN O
HC NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
replacement NN NN O
of NN NN O
last NN NN O
two NN NN O
doses NN NN O
of NN NN O
mesna NN NN O
with NN NN O
saline NN NN O
or NN NN O
all NN NN O
of NN NN O
the NN NN O
mesna NN NN O
doses NN NN O
with NN NN O
dexamethasone NN NN O
did NN NN O
not NN NN O
prevent NN NN O
HC NN NN B-Disease
. NN NN O
   
All NN NN O
- NN NN O
trans NN NN O
- NN NN O
retinoic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
erythema NN NN B-Disease
nodosum NN NN I-Disease
in NN NN O
patients NN NN O
with NN NN O
acute NN NN B-Disease
promyelocytic NN NN I-Disease
leukemia NN NN I-Disease
. NN NN O
   
Erythema NN NN B-Disease
nodosum NN NN I-Disease
associated NN NN O
with NN NN O
all NN NN O
- NN NN O
trans NN NN O
- NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
ATRA NN NN O
) NN NN O
for NN NN O
acute NN NN B-Disease
promyelocytic NN NN I-Disease
leukemia NN NN I-Disease
( NN NN O
APL NN NN B-Disease
) NN NN O
is NN NN O
very NN NN O
rare NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
four NN NN O
patients NN NN O
with NN NN O
classic NN NN O
APL NN NN B-Disease
who NN NN O
developed NN NN O
erythema NN NN B-Disease
nodosum NN NN I-Disease
during NN NN O
ATRA NN NN O
therapy NN NN O
. NN NN O
   
Fever NN NN B-Disease
and NN NN O
subsequent NN NN O
multiple NN NN O
painful NN NN B-Disease
erythematous NN NN B-Disease
nodules NN NN I-Disease
over NN NN O
extremities NN NN O
developed NN NN O
on NN NN O
D11 NN NN O
, NN NN O
D16 NN NN O
, NN NN O
D17 NN NN O
, NN NN O
and NN NN O
D19 NN NN O
, NN NN O
respectively NN NN O
, NN NN O
after NN NN O
ATRA NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
skin NN NN O
biopsy NN NN O
taken NN NN O
from NN NN O
each NN NN O
patient NN NN O
was NN NN O
consistent NN NN O
with NN NN O
erythema NN NN B-Disease
nodosum NN NN I-Disease
. NN NN O
   
All NN NN O
patients NN NN O
received NN NN O
short NN NN O
course NN NN O
of NN NN O
steroids NN NN O
. NN NN O
   
Fever NN NN B-Disease
subsided NN NN O
rapidly NN NN O
and NN NN O
the NN NN O
skin NN NN O
lesions NN NN O
regressed NN NN O
completely NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
achieved NN NN O
complete NN NN O
remission NN NN O
without NN NN O
withdrawal NN NN O
of NN NN O
ATRA NN NN O
. NN NN O
   
ATRA NN NN O
seemed NN NN O
to NN NN O
be NN NN O
the NN NN O
most NN NN O
possible NN NN O
etiology NN NN O
of NN NN O
erythema NN NN B-Disease
nodosum NN NN I-Disease
in NN NN O
our NN NN O
patients NN NN O
. NN NN O
   
Short NN NN O
- NN NN O
term NN NN O
use NN NN O
of NN NN O
steroid NN NN O
is NN NN O
very NN NN O
effective NN NN O
in NN NN O
ATRA NN NN O
- NN NN O
induced NN NN O
erythema NN NN B-Disease
nodosum NN NN I-Disease
. NN NN O
   
Effect NN NN O
of NN NN O
some NN NN O
convulsants NN NN O
on NN NN O
the NN NN O
protective NN NN O
activity NN NN O
of NN NN O
loreclezole NN NN O
and NN NN O
its NN NN O
combinations NN NN O
with NN NN O
valproate NN NN O
or NN NN O
clonazepam NN NN O
in NN NN O
amygdala NN NN O
- NN NN O
kindled NN NN O
rats NN NN O
. NN NN O
   
Loreclezole NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
exerted NN NN O
a NN NN O
significant NN NN O
protective NN NN O
action NN NN O
in NN NN O
amygdala NN NN O
- NN NN O
kindled NN NN O
rats NN NN O
, NN NN O
reducing NN NN O
both NN NN O
seizure NN NN B-Disease
and NN NN O
afterdischarge NN NN O
durations NN NN O
. NN NN O
   
The NN NN O
combinations NN NN O
of NN NN O
loreclezole NN NN O
( NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
with NN NN O
valproate NN NN O
, NN NN O
clonazepam NN NN O
, NN NN O
or NN NN O
carbamazepine NN NN O
( NN NN O
applied NN NN O
at NN NN O
their NN NN O
subprotective NN NN O
doses NN NN O
) NN NN O
also NN NN O
exhibited NN NN O
antiseizure NN NN O
effect NN NN O
in NN NN O
this NN NN O
test NN NN O
. NN NN O
   
However NN NN O
, NN NN O
only NN NN O
two NN NN O
first NN NN O
combinations NN NN O
occurred NN NN O
to NN NN O
be NN NN O
of NN NN O
pharmacodynamic NN NN O
nature NN NN O
. NN NN O
   
Among NN NN O
several NN NN O
chemoconvulsants NN NN O
, NN NN O
bicuculline NN NN O
, NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
D NN NN O
- NN NN O
aspartic NN NN O
acid NN NN O
and NN NN O
BAY NN NN O
k NN NN O
- NN NN O
8644 NN NN O
( NN NN O
the NN NN O
opener NN NN O
of NN NN O
L NN NN O
- NN NN O
type NN NN O
calcium NN NN O
channels NN NN O
) NN NN O
reversed NN NN O
the NN NN O
protective NN NN O
activity NN NN O
of NN NN O
loreclezole NN NN O
alone NN NN O
and NN NN O
its NN NN O
combination NN NN O
with NN NN O
valproate NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
bicuculline NN NN O
, NN NN O
aminophylline NN NN O
and NN NN O
BAY NN NN O
k NN NN O
- NN NN O
8644 NN NN O
inhibited NN NN O
the NN NN O
anticonvulsive NN NN O
action NN NN O
of NN NN O
loreclezole NN NN O
combined NN NN O
with NN NN O
clonazepam NN NN O
. NN NN O
   
The NN NN O
results NN NN O
support NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
the NN NN O
protective NN NN O
activity NN NN O
of NN NN O
loreclezole NN NN O
and NN NN O
its NN NN O
combinations NN NN O
with NN NN O
other NN NN O
antiepileptics NN NN O
may NN NN O
involve NN NN O
potentiation NN NN O
of NN NN O
GABAergic NN NN O
neurotransmission NN NN O
and NN NN O
blockade NN NN O
of NN NN O
L NN NN O
- NN NN O
type NN NN O
of NN NN O
calcium NN NN O
channels NN NN O
. NN NN O
   
Mitochondrial NN NN O
DNA NN NN O
and NN NN O
its NN NN O
respiratory NN NN O
chain NN NN O
products NN NN O
are NN NN O
defective NN NN O
in NN NN O
doxorubicin NN NN O
nephrosis NN NN B-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Doxorubicin NN NN O
induces NN NN O
a NN NN O
self NN NN O
- NN NN O
perpetuating NN NN O
nephropathy NN NN B-Disease
characterized NN NN O
by NN NN O
early NN NN O
glomerular NN NN B-Disease
and NN NN I-Disease
late NN NN I-Disease
- NN NN I-Disease
onset NN NN I-Disease
tubular NN NN I-Disease
lesions NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
potential NN NN O
role NN NN O
of NN NN O
mitochondrial NN NN B-Disease
injury NN NN I-Disease
in NN NN O
the NN NN O
onset NN NN O
of NN NN O
these NN NN O
lesions NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Rats NN NN O
were NN NN O
treated NN NN O
with NN NN O
intravenous NN NN O
doxorubicin NN NN O
( NN NN O
1 NN NN O
mg NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
week NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
) NN NN O
for NN NN O
7 NN NN O
weeks NN NN O
and NN NN O
were NN NN O
sacrificed NN NN O
either NN NN O
1 NN NN O
week NN NN O
( NN NN O
' NN NN O
short NN NN O
- NN NN O
term NN NN O
' NN NN O
) NN NN O
or NN NN O
30 NN NN O
weeks NN NN O
( NN NN O
' NN NN O
long NN NN O
- NN NN O
term NN NN O
' NN NN O
) NN NN O
following NN NN O
the NN NN O
last NN NN O
dose NN NN O
. NN NN O
   
Additional NN NN O
rats NN NN O
received NN NN O
a NN NN O
single NN NN O
dose NN NN O
either NN NN O
6 NN NN O
days NN NN O
or NN NN O
2 NN NN O
h NN NN O
prior NN NN O
to NN NN O
euthanasia NN NN O
. NN NN O
   
All NN NN O
rats NN NN O
were NN NN O
killed NN NN O
at NN NN O
48 NN NN O
weeks NN NN O
of NN NN O
age NN NN O
. NN NN O
   
Glomerular NN NN B-Disease
and NN NN I-Disease
tubular NN NN I-Disease
injury NN NN I-Disease
was NN NN O
monitored NN NN O
and NN NN O
correlated NN NN O
to NN NN O
the NN NN O
activity NN NN O
or NN NN O
expression NN NN O
of NN NN O
respiratory NN NN O
chain NN NN O
components NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
we NN NN O
quantified NN NN O
both NN NN O
nuclear NN NN O
and NN NN O
mitochondrial NN NN O
DNA NN NN O
( NN NN O
mtDNA NN NN O
) NN NN O
as NN NN O
well NN NN O
as NN NN O
superoxide NN NN O
production NN NN O
and NN NN O
the NN NN O
4834 NN NN O
base NN NN O
pair NN NN O
' NN NN O
common NN NN O
' NN NN O
mtDNA NN NN O
deletion NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
' NN NN O
long NN NN O
- NN NN O
term NN NN O
' NN NN O
group NN NN O
had NN NN O
significant NN NN O
glomerular NN NN B-Disease
and NN NN I-Disease
tubular NN NN I-Disease
lesions NN NN I-Disease
, NN NN O
depressed NN NN O
activities NN NN O
of NN NN O
mtDNA NN NN O
- NN NN O
encoded NN NN O
NADH NN NN O
dehydrogenase NN NN O
and NN NN O
cytochrome NN NN O
- NN NN O
c NN NN O
oxidase NN NN O
( NN NN O
COX NN NN O
) NN NN O
and NN NN O
increased NN NN O
citrate NN NN O
synthase NN NN O
activity NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
expression NN NN O
of NN NN O
the NN NN O
mtDNA NN NN O
- NN NN O
encoded NN NN O
COX NN NN O
subunit NN NN O
I NN NN O
was NN NN O
reduced NN NN O
and NN NN O
mtDNA NN NN O
levels NN NN O
were NN NN O
decreased NN NN O
. NN NN O
   
In NN NN O
' NN NN O
short NN NN O
- NN NN O
term NN NN O
' NN NN O
rats NN NN O
, NN NN O
there NN NN O
were NN NN O
fewer NN NN O
tubular NN NN B-Disease
lesions NN NN I-Disease
, NN NN O
but NN NN O
similar NN NN O
numbers NN NN O
of NN NN O
glomerular NN NN B-Disease
lesions NN NN I-Disease
activity NN NN O
. NN NN O
   
Among NN NN O
all NN NN O
animals NN NN O
, NN NN O
glomerular NN NN B-Disease
and NN NN I-Disease
tubular NN NN I-Disease
injury NN NN I-Disease
were NN NN O
inversely NN NN O
correlated NN NN O
with NN NN O
mtDNA NN NN O
levels NN NN O
, NN NN O
mtDNA NN NN O
- NN NN O
encoded NN NN O
respiratory NN NN O
chain NN NN O
activities NN NN O
and NN NN O
with NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
mtDNA NN NN O
- NN NN O
encoded NN NN O
respiratory NN NN O
chain NN NN O
subunit NN NN O
COX NN NN O
- NN NN O
I NN NN O
. NN NN O
   
Injury NN NN O
was NN NN O
positively NN NN O
correlated NN NN O
with NN NN O
superoxide NN NN O
production NN NN O
and NN NN O
the NN NN O
activities NN NN O
of NN NN O
nucleus NN NN O
- NN NN O
encoded NN NN O
mitochondrial NN NN O
or NN NN O
cytoplasmic NN NN O
enzymes NN NN O
. NN NN O
   
Kidneys NN NN O
from NN NN O
the NN NN O
' NN NN O
long NN NN O
- NN NN O
term NN NN O
' NN NN O
group NN NN O
showed NN NN O
more NN NN O
mtDNA NN NN O
deletions NN NN O
than NN NN O
in NN NN O
' NN NN O
short NN NN O
- NN NN O
term NN NN O
' NN NN O
animals NN NN O
and NN NN O
these NN NN O
were NN NN O
not NN NN O
observed NN NN O
in NN NN O
the NN NN O
other NN NN O
groups NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
These NN NN O
results NN NN O
suggest NN NN O
an NN NN O
important NN NN O
role NN NN O
for NN NN O
quantitative NN NN O
and NN NN O
qualitative NN NN O
mtDNA NN NN O
alterations NN NN O
through NN NN O
the NN NN O
reduction NN NN O
of NN NN O
mtDNA NN NN O
- NN NN O
encoded NN NN O
respiratory NN NN O
chain NN NN O
function NN NN O
and NN NN O
induction NN NN O
of NN NN O
superoxide NN NN O
in NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
renal NN NN B-Disease
lesions NN NN I-Disease
. NN NN O
   
A NN NN O
randomized NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
, NN NN O
crossover NN NN O
study NN NN O
of NN NN O
ephedrine NN NN O
for NN NN O
SSRI NN NN O
- NN NN O
induced NN NN O
female NN NN O
sexual NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
The NN NN O
objective NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
whether NN NN O
ephedrine NN NN O
, NN NN O
an NN NN O
alpha NN NN O
- NN NN O
and NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
agonist NN NN O
previously NN NN O
shown NN NN O
to NN NN O
enhance NN NN O
genital NN NN O
blood NN NN O
flow NN NN O
in NN NN O
women NN NN O
, NN NN O
has NN NN O
beneficial NN NN O
effects NN NN O
in NN NN O
reversing NN NN O
antidepressant NN NN O
- NN NN O
induced NN NN O
sexual NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Nineteen NN NN O
sexually NN NN B-Disease
dysfunctional NN NN I-Disease
women NN NN O
receiving NN NN O
either NN NN O
fluoxetine NN NN O
, NN NN O
sertraline NN NN O
, NN NN O
or NN NN O
paroxetine NN NN O
participated NN NN O
in NN NN O
an NN NN O
eight NN NN O
- NN NN O
week NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
, NN NN O
cross NN NN O
- NN NN O
over NN NN O
study NN NN O
of NN NN O
the NN NN O
effects NN NN O
of NN NN O
ephedrine NN NN O
( NN NN O
50 NN NN O
mg NN NN O
) NN NN O
on NN NN O
self NN NN O
- NN NN O
report NN NN O
measures NN NN O
of NN NN O
sexual NN NN O
desire NN NN O
, NN NN O
arousal NN NN O
, NN NN O
orgasm NN NN O
, NN NN O
and NN NN O
sexual NN NN O
satisfaction NN NN O
. NN NN O
   
Although NN NN O
there NN NN O
were NN NN O
significant NN NN O
improvements NN NN O
relative NN NN O
to NN NN O
baseline NN NN O
in NN NN O
sexual NN NN O
desire NN NN O
and NN NN O
orgasm NN NN O
intensity NN NN O
/ NN NN O
pleasure NN NN O
on NN NN O
50 NN NN O
mg NN NN O
ephedrine NN NN O
1 NN NN O
- NN NN O
hr NN NN O
prior NN NN O
to NN NN O
sexual NN NN O
activity NN NN O
, NN NN O
significant NN NN O
improvements NN NN O
in NN NN O
these NN NN O
measures NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
sexual NN NN O
arousal NN NN O
and NN NN O
orgasmic NN NN O
ability NN NN O
also NN NN O
were NN NN O
noted NN NN O
with NN NN O
placebo NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
highlight NN NN O
the NN NN O
importance NN NN O
of NN NN O
conducting NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
trials NN NN O
for NN NN O
this NN NN O
condition NN NN O
. NN NN O
   
Does NN NN O
hormone NN NN O
therapy NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
have NN NN O
a NN NN O
detrimental NN NN B-Disease
effect NN NN I-Disease
on NN NN I-Disease
memory NN NN I-Disease
and NN NN I-Disease
cognition NN NN I-Disease
? NN NN O
   
A NN NN O
pilot NN NN O
study NN NN O
. NN NN O
   
This NN NN O
pilot NN NN O
study NN NN O
examines NN NN O
whether NN NN O
hormone NN NN O
therapy NN NN O
for NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
affects NN NN O
cognition NN NN O
. NN NN O
   
Patients NN NN O
participating NN NN O
in NN NN O
a NN NN O
randomised NN NN O
trial NN NN O
of NN NN O
anastrozole NN NN O
, NN NN O
tamoxifen NN NN O
alone NN NN O
or NN NN O
combined NN NN O
( NN NN O
ATAC NN NN O
) NN NN O
( NN NN O
n NN NN O
= NN NN O
94 NN NN O
) NN NN O
and NN NN O
a NN NN O
group NN NN O
of NN NN O
women NN NN O
without NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
( NN NN O
n NN NN O
= NN NN O
35 NN NN O
) NN NN O
completed NN NN O
a NN NN O
battery NN NN O
of NN NN O
neuropsychological NN NN O
measures NN NN O
. NN NN O
   
Compared NN NN O
with NN NN O
the NN NN O
control NN NN O
group NN NN O
, NN NN O
the NN NN O
patients NN NN O
were NN NN O
impaired NN NN O
on NN NN O
a NN NN O
processing NN NN O
speed NN NN O
task NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
032 NN NN O
) NN NN O
and NN NN O
on NN NN O
a NN NN O
measure NN NN O
of NN NN O
immediate NN NN O
verbal NN NN O
memory NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
026 NN NN O
) NN NN O
after NN NN O
controlling NN NN O
for NN NN O
the NN NN O
use NN NN O
of NN NN O
hormone NN NN O
replacement NN NN O
therapy NN NN O
in NN NN O
both NN NN O
groups NN NN O
. NN NN O
   
Patient NN NN O
group NN NN O
performance NN NN O
was NN NN O
not NN NN O
significantly NN NN O
related NN NN O
to NN NN O
length NN NN O
of NN NN O
treatment NN NN O
or NN NN O
measures NN NN O
of NN NN O
psychological NN NN O
morbidity NN NN O
. NN NN O
   
The NN NN O
results NN NN O
showed NN NN O
specific NN NN O
impairments NN NN O
in NN NN O
processing NN NN O
speed NN NN O
and NN NN O
verbal NN NN O
memory NN NN O
in NN NN O
women NN NN O
receiving NN NN O
hormonal NN NN O
therapy NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
Verbal NN NN O
memory NN NN O
may NN NN O
be NN NN O
especially NN NN O
sensitive NN NN O
to NN NN O
changes NN NN O
in NN NN O
oestrogen NN NN O
levels NN NN O
, NN NN O
a NN NN O
finding NN NN O
commonly NN NN O
reported NN NN O
in NN NN O
studies NN NN O
of NN NN O
hormone NN NN O
replacement NN NN O
therapy NN NN O
in NN NN O
healthy NN NN O
women NN NN O
. NN NN O
   
In NN NN O
view NN NN O
of NN NN O
the NN NN O
increased NN NN O
use NN NN O
of NN NN O
hormone NN NN O
therapies NN NN O
in NN NN O
an NN NN O
adjuvant NN NN O
and NN NN O
preventative NN NN O
setting NN NN O
their NN NN O
impact NN NN O
on NN NN O
cognitive NN NN O
functioning NN NN O
should NN NN O
be NN NN O
investigated NN NN O
more NN NN O
thoroughly NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
p300 NN NN O
protects NN NN O
cardiac NN NN O
myocytes NN NN O
from NN NN O
apoptosis NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Doxorubicin NN NN O
is NN NN O
an NN NN O
anti NN NN O
- NN NN O
tumor NN NN B-Disease
agent NN NN O
that NN NN O
represses NN NN O
cardiac NN NN O
- NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
and NN NN O
induces NN NN O
myocardial NN NN O
cell NN NN O
apoptosis NN NN O
. NN NN O
   
Doxorubicin NN NN O
depletes NN NN O
cardiac NN NN O
p300 NN NN O
, NN NN O
a NN NN O
transcriptional NN NN O
coactivator NN NN O
that NN NN O
is NN NN O
required NN NN O
for NN NN O
the NN NN O
maintenance NN NN O
of NN NN O
the NN NN O
differentiated NN NN O
phenotype NN NN O
of NN NN O
cardiac NN NN O
myocytes NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
role NN NN O
of NN NN O
p300 NN NN O
in NN NN O
protection NN NN O
against NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
is NN NN O
unknown NN NN O
. NN NN O
   
Transgenic NN NN O
mice NN NN O
overexpressing NN NN O
p300 NN NN O
in NN NN O
the NN NN O
heart NN NN O
and NN NN O
wild NN NN O
- NN NN O
type NN NN O
mice NN NN O
were NN NN O
subjected NN NN O
to NN NN O
doxorubicin NN NN O
treatment NN NN O
. NN NN O
   
Compared NN NN O
with NN NN O
wild NN NN O
- NN NN O
type NN NN O
mice NN NN O
, NN NN O
transgenic NN NN O
mice NN NN O
exhibited NN NN O
higher NN NN O
survival NN NN O
rate NN NN O
as NN NN O
well NN NN O
as NN NN O
more NN NN O
preserved NN NN O
left NN NN O
ventricular NN NN O
function NN NN O
and NN NN O
cardiac NN NN O
expression NN NN O
of NN NN O
alpha NN NN O
- NN NN O
sarcomeric NN NN O
actin NN NN O
. NN NN O
   
Doxorubicin NN NN O
induced NN NN O
myocardial NN NN O
cell NN NN O
apoptosis NN NN O
in NN NN O
wild NN NN O
- NN NN O
type NN NN O
mice NN NN O
but NN NN O
not NN NN O
in NN NN O
transgenic NN NN O
mice NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
p300 NN NN O
increased NN NN O
the NN NN O
cardiac NN NN O
level NN NN O
of NN NN O
bcl NN NN O
- NN NN O
2 NN NN O
and NN NN O
mdm NN NN O
- NN NN O
2 NN NN O
, NN NN O
but NN NN O
not NN NN O
that NN NN O
of NN NN O
p53 NN NN O
or NN NN O
other NN NN O
members NN NN O
of NN NN O
the NN NN O
bcl NN NN O
- NN NN O
2 NN NN O
family NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
demonstrate NN NN O
that NN NN O
overexpression NN NN O
of NN NN O
p300 NN NN O
protects NN NN O
cardiac NN NN O
myocytes NN NN O
from NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
and NN NN O
reduces NN NN O
the NN NN O
extent NN NN O
of NN NN O
acute NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
in NN NN O
adult NN NN O
mice NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Methimazole NN NN O
- NN NN O
induced NN NN O
cholestatic NN NN B-Disease
jaundice NN NN I-Disease
. NN NN O
   
Methimazole NN NN O
is NN NN O
a NN NN O
widely NN NN O
used NN NN O
and NN NN O
generally NN NN O
well NN NN O
- NN NN O
tolerated NN NN O
antithyroid NN NN O
agent NN NN O
. NN NN O
   
A NN NN O
43 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
had NN NN O
severe NN NN O
jaundice NN NN B-Disease
and NN NN O
itching NN NN B-Disease
1 NN NN O
month NN NN O
after NN NN O
receiving NN NN O
methimazole NN NN O
( NN NN O
10 NN NN O
mg NN NN O
tid NN NN O
) NN NN O
and NN NN O
propranolol NN NN O
( NN NN O
20 NN NN O
mg NN NN O
tid NN NN O
) NN NN O
for NN NN O
treatment NN NN O
of NN NN O
hyperthyroidism NN NN B-Disease
. NN NN O
   
The NN NN O
patient NN NN O
continued NN NN O
treatment NN NN O
for NN NN O
another NN NN O
4 NN NN O
days NN NN O
after NN NN O
the NN NN O
appearance NN NN O
of NN NN O
jaundice NN NN B-Disease
until NN NN O
she NN NN O
finished NN NN O
both NN NN O
medications NN NN O
. NN NN O
   
When NN NN O
seen NN NN O
at NN NN O
the NN NN O
emergency NN NN O
department NN NN O
2 NN NN O
weeks NN NN O
later NN NN O
, NN NN O
she NN NN O
still NN NN O
had NN NN O
severe NN NN O
icterus NN NN B-Disease
, NN NN O
pruritus NN NN B-Disease
, NN NN O
and NN NN O
hyperbilirubinemia NN NN B-Disease
, NN NN O
formed NN NN O
mainly NN NN O
of NN NN O
the NN NN O
conjugated NN NN O
fraction NN NN O
. NN NN O
   
Methimazole NN NN O
- NN NN O
induced NN NN O
cholestasis NN NN B-Disease
was NN NN O
diagnosed NN NN O
, NN NN O
and NN NN O
propranolol NN NN O
therapy NN NN O
was NN NN O
resumed NN NN O
. NN NN O
   
Over NN NN O
the NN NN O
following NN NN O
9 NN NN O
days NN NN O
, NN NN O
the NN NN O
symptoms NN NN O
improved NN NN O
and NN NN O
plasma NN NN O
bilirubin NN NN O
levels NN NN O
were NN NN O
normal NN NN O
after NN NN O
12 NN NN O
weeks NN NN O
without NN NN O
methimazole NN NN O
. NN NN O
   
In NN NN O
rare NN NN O
cases NN NN O
within NN NN O
the NN NN O
first NN NN O
few NN NN O
weeks NN NN O
of NN NN O
therapy NN NN O
, NN NN O
this NN NN O
drug NN NN O
can NN NN O
cause NN NN O
severe NN NN O
and NN NN O
reversible NN NN O
cholestatic NN NN B-Disease
jaundice NN NN I-Disease
. NN NN O
   
Physicians NN NN O
and NN NN O
patients NN NN O
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
this NN NN O
adverse NN NN O
effect NN NN O
so NN NN O
that NN NN O
, NN NN O
upon NN NN O
occurrence NN NN O
, NN NN O
they NN NN O
can NN NN O
discontinue NN NN O
methimazole NN NN O
therapy NN NN O
and NN NN O
avoid NN NN O
unnecessary NN NN O
invasive NN NN O
procedures NN NN O
. NN NN O
   
Atrial NN NN B-Disease
fibrillation NN NN I-Disease
following NN NN O
chemotherapy NN NN O
for NN NN O
stage NN NN O
IIIE NN NN O
diffuse NN NN O
large NN NN O
B NN NN O
- NN NN O
cell NN NN O
gastric NN NN B-Disease
lymphoma NN NN I-Disease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
myotonic NN NN B-Disease
dystrophy NN NN I-Disease
( NN NN O
Steinert NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
) NN NN O
. NN NN O
   
The NN NN O
authors NN NN O
describe NN NN O
the NN NN O
unusual NN NN O
association NN NN O
between NN NN O
diffuse NN NN O
B NN NN O
- NN NN O
cell NN NN O
gastric NN NN B-Disease
lymphoma NN NN I-Disease
and NN NN O
myotonic NN NN B-Disease
dystrophy NN NN I-Disease
, NN NN O
the NN NN O
most NN NN O
common NN NN O
form NN NN O
of NN NN O
adult NN NN O
muscular NN NN B-Disease
dystrophy NN NN I-Disease
, NN NN O
and NN NN O
sudden NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
following NN NN O
one NN NN O
cycle NN NN O
of NN NN O
doxorubicin NN NN O
- NN NN O
based NN NN O
chemotherapy NN NN O
in NN NN O
the NN NN O
same NN NN O
patient NN NN O
. NN NN O
   
Atrial NN NN B-Disease
fibrillation NN NN I-Disease
or NN NN O
other NN NN O
cardiac NN NN B-Disease
arrhythmias NN NN I-Disease
are NN NN O
unusual NN NN O
complications NN NN O
in NN NN O
patients NN NN O
treated NN NN O
with NN NN O
chemotherapy NN NN O
. NN NN O
   
The NN NN O
cardiac NN NN B-Disease
toxicity NN NN I-Disease
intrinsically NN NN O
associated NN NN O
with NN NN O
the NN NN O
aggressive NN NN O
chemotherapy NN NN O
employed NN NN O
could NN NN O
function NN NN O
as NN NN O
a NN NN O
triggering NN NN O
factor NN NN O
for NN NN O
the NN NN O
arrhythmia NN NN B-Disease
in NN NN O
the NN NN O
predisposed NN NN O
myocardium NN NN O
of NN NN O
this NN NN O
patient NN NN O
. NN NN O
   
Hypersensitivity NN NN B-Disease
immune NN NN O
reaction NN NN O
as NN NN O
a NN NN O
mechanism NN NN O
for NN NN O
dilevalol NN NN O
- NN NN O
associated NN NN O
hepatitis NN NN B-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
assess NN NN O
lymphocyte NN NN O
reactivity NN NN O
to NN NN O
dilevalol NN NN O
and NN NN O
to NN NN O
serum NN NN O
containing NN NN O
putative NN NN O
ex NN NN O
vivo NN NN O
dilevalol NN NN O
antigens NN NN O
or NN NN O
metabolites NN NN O
in NN NN O
a NN NN O
case NN NN O
of NN NN O
dilevalol NN NN O
- NN NN O
induced NN NN O
liver NN NN B-Disease
injury NN NN I-Disease
. NN NN O
   
PATIENT NN NN O
: NN NN O
A NN NN O
58 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
a NN NN O
clinical NN NN O
diagnosis NN NN O
of NN NN O
dilevalol NN NN O
- NN NN O
induced NN NN O
liver NN NN B-Disease
injury NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
collected NN NN O
from NN NN O
the NN NN O
patient NN NN O
were NN NN O
cultured NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
solution NN NN O
of NN NN O
dilevalol NN NN O
and NN NN O
also NN NN O
with NN NN O
sera NN NN O
collected NN NN O
from NN NN O
a NN NN O
volunteer NN NN O
before NN NN O
and NN NN O
after NN NN O
dilevalol NN NN O
intake NN NN O
. NN NN O
   
A NN NN O
similar NN NN O
protocol NN NN O
was NN NN O
performed NN NN O
with NN NN O
lymphocytes NN NN O
from NN NN O
a NN NN O
healthy NN NN O
subject NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
No NN NN O
lymphocyte NN NN O
proliferation NN NN O
was NN NN O
observed NN NN O
either NN NN O
in NN NN O
the NN NN O
patient NN NN O
or NN NN O
in NN NN O
the NN NN O
healthy NN NN O
volunteer NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
dilevalol NN NN O
solutions NN NN O
. NN NN O
   
A NN NN O
significant NN NN O
proliferative NN NN O
response NN NN O
to NN NN O
serum NN NN O
collected NN NN O
after NN NN O
dilevalol NN NN O
intake NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
case NN NN O
of NN NN O
the NN NN O
patient NN NN O
compared NN NN O
with NN NN O
the NN NN O
proliferative NN NN O
response NN NN O
to NN NN O
the NN NN O
serum NN NN O
collected NN NN O
before NN NN O
the NN NN O
drug NN NN O
intake NN NN O
. NN NN O
   
No NN NN O
reactivity NN NN O
was NN NN O
found NN NN O
when NN NN O
lymphocytes NN NN O
from NN NN O
the NN NN O
healthy NN NN O
subject NN NN O
were NN NN O
tested NN NN O
under NN NN O
similar NN NN O
conditions NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
methodology NN NN O
used NN NN O
allowed NN NN O
the NN NN O
detection NN NN O
of NN NN O
lymphocyte NN NN O
sensitization NN NN O
to NN NN O
sera NN NN O
containing NN NN O
ex NN NN O
vivo NN NN O
- NN NN O
prepared NN NN O
dilevalol NN NN O
antigens NN NN O
, NN NN O
suggesting NN NN O
the NN NN O
involvement NN NN O
of NN NN O
an NN NN O
immunologic NN NN O
mechanism NN NN O
in NN NN O
dilevalol NN NN O
- NN NN O
induced NN NN O
liver NN NN B-Disease
injury NN NN I-Disease
. NN NN O
   
Increased NN NN O
expression NN NN O
and NN NN O
apical NN NN O
targeting NN NN O
of NN NN O
renal NN NN O
ENaC NN NN O
subunits NN NN O
in NN NN O
puromycin NN NN O
aminonucleoside NN NN O
- NN NN O
induced NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Nephrotic NN NN B-Disease
syndrome NN NN I-Disease
is NN NN O
often NN NN O
accompanied NN NN O
by NN NN O
sodium NN NN O
retention NN NN O
and NN NN O
generalized NN NN O
edema NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
for NN NN O
the NN NN O
decreased NN NN O
renal NN NN O
sodium NN NN O
excretion NN NN O
remains NN NN O
undefined NN NN O
. NN NN O
   
We NN NN O
hypothesized NN NN O
that NN NN O
epithelial NN NN O
Na NN NN O
channel NN NN O
( NN NN O
ENaC NN NN O
) NN NN O
subunit NN NN O
dysregulation NN NN O
may NN NN O
be NN NN O
responsible NN NN O
for NN NN O
the NN NN O
increased NN NN O
sodium NN NN O
retention NN NN O
. NN NN O
   
An NN NN O
experimental NN NN O
group NN NN O
of NN NN O
rats NN NN O
was NN NN O
treated NN NN O
with NN NN O
puromycin NN NN O
aminonucleoside NN NN O
( NN NN O
PAN NN NN O
; NN NN O
180 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
iv NN NN O
) NN NN O
, NN NN O
whereas NN NN O
the NN NN O
control NN NN O
group NN NN O
received NN NN O
only NN NN O
vehicle NN NN O
. NN NN O
   
After NN NN O
7 NN NN O
days NN NN O
, NN NN O
PAN NN NN O
treatment NN NN O
induced NN NN O
significant NN NN O
proteinuria NN NN B-Disease
, NN NN O
hypoalbuminemia NN NN B-Disease
, NN NN O
decreased NN NN O
urinary NN NN O
sodium NN NN O
excretion NN NN O
, NN NN O
and NN NN O
extensive NN NN O
ascites NN NN B-Disease
. NN NN O
   
The NN NN O
protein NN NN O
abundance NN NN O
of NN NN O
alpha NN NN O
- NN NN O
ENaC NN NN O
and NN NN O
beta NN NN O
- NN NN O
ENaC NN NN O
was NN NN O
increased NN NN O
in NN NN O
the NN NN O
inner NN NN O
stripe NN NN O
of NN NN O
the NN NN O
outer NN NN O
medulla NN NN O
( NN NN O
ISOM NN NN O
) NN NN O
and NN NN O
in NN NN O
the NN NN O
inner NN NN O
medulla NN NN O
( NN NN O
IM NN NN O
) NN NN O
but NN NN O
was NN NN O
not NN NN O
altered NN NN O
in NN NN O
the NN NN O
cortex NN NN O
. NN NN O
   
gamma NN NN O
- NN NN O
ENaC NN NN O
abundance NN NN O
was NN NN O
increased NN NN O
in NN NN O
the NN NN O
cortex NN NN O
, NN NN O
ISOM NN NN O
, NN NN O
and NN NN O
IM NN NN O
. NN NN O
   
Immunoperoxidase NN NN O
brightfield NN NN O
- NN NN O
and NN NN O
laser NN NN O
- NN NN O
scanning NN NN O
confocal NN NN O
fluorescence NN NN O
microscopy NN NN O
demonstrated NN NN O
increased NN NN O
targeting NN NN O
of NN NN O
alpha NN NN O
- NN NN O
ENaC NN NN O
, NN NN O
beta NN NN O
- NN NN O
ENaC NN NN O
, NN NN O
and NN NN O
gamma NN NN O
- NN NN O
ENaC NN NN O
subunits NN NN O
to NN NN O
the NN NN O
apical NN NN O
plasma NN NN O
membrane NN NN O
in NN NN O
the NN NN O
distal NN NN O
convoluted NN NN O
tubule NN NN O
( NN NN O
DCT2 NN NN O
) NN NN O
, NN NN O
connecting NN NN O
tubule NN NN O
, NN NN O
and NN NN O
cortical NN NN O
and NN NN O
medullary NN NN O
collecting NN NN O
duct NN NN O
segments NN NN O
. NN NN O
   
Immunoelectron NN NN O
microscopy NN NN O
further NN NN O
revealed NN NN O
an NN NN O
increased NN NN O
labeling NN NN O
of NN NN O
alpha NN NN O
- NN NN O
ENaC NN NN O
in NN NN O
the NN NN O
apical NN NN O
plasma NN NN O
membrane NN NN O
of NN NN O
cortical NN NN O
collecting NN NN O
duct NN NN O
principal NN NN O
cells NN NN O
of NN NN O
PAN NN NN O
- NN NN O
treated NN NN O
rats NN NN O
, NN NN O
indicating NN NN O
enhanced NN NN O
apical NN NN O
targeting NN NN O
of NN NN O
alpha NN NN O
- NN NN O
ENaC NN NN O
subunits NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
protein NN NN O
abundances NN NN O
of NN NN O
Na NN NN O
( NN NN O
+ NN NN O
) NN NN O
/ NN NN O
H NN NN O
( NN NN O
+ NN NN O
) NN NN O
exchanger NN NN O
type NN NN O
3 NN NN O
( NN NN O
NHE3 NN NN O
) NN NN O
, NN NN O
Na NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
K NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
2Cl NN NN O
( NN NN O
- NN NN O
) NN NN O
cotransporter NN NN O
( NN NN O
BSC NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
and NN NN O
thiazide NN NN O
- NN NN O
sensitive NN NN O
Na NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
Cl NN NN O
( NN NN O
- NN NN O
) NN NN O
cotransporter NN NN O
( NN NN O
TSC NN NN O
) NN NN O
were NN NN O
decreased NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
the NN NN O
abundance NN NN O
of NN NN O
the NN NN O
alpha NN NN O
( NN NN O
1 NN NN O
) NN NN O
- NN NN O
subunit NN NN O
of NN NN O
the NN NN O
Na NN NN O
- NN NN O
K NN NN O
- NN NN O
ATPase NN NN O
was NN NN O
decreased NN NN O
in NN NN O
the NN NN O
cortex NN NN O
and NN NN O
ISOM NN NN O
, NN NN O
but NN NN O
it NN NN O
remained NN NN O
unchanged NN NN O
in NN NN O
the NN NN O
IM NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
the NN NN O
increased NN NN O
or NN NN O
sustained NN NN O
expression NN NN O
of NN NN O
ENaC NN NN O
subunits NN NN O
combined NN NN O
with NN NN O
increased NN NN O
apical NN NN O
targeting NN NN O
in NN NN O
the NN NN O
DCT2 NN NN O
, NN NN O
connecting NN NN O
tubule NN NN O
, NN NN O
and NN NN O
collecting NN NN O
duct NN NN O
are NN NN O
likely NN NN O
to NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
sodium NN NN O
retention NN NN O
associated NN NN O
with NN NN O
PAN NN NN O
- NN NN O
induced NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
The NN NN O
decreased NN NN O
abundance NN NN O
of NN NN O
NHE3 NN NN O
, NN NN O
BSC NN NN O
- NN NN O
1 NN NN O
, NN NN O
TSC NN NN O
, NN NN O
and NN NN O
Na NN NN O
- NN NN O
K NN NN O
- NN NN O
ATPase NN NN O
may NN NN O
play NN NN O
a NN NN O
compensatory NN NN O
role NN NN O
to NN NN O
promote NN NN O
sodium NN NN O
excretion NN NN O
. NN NN O
   
Pallidal NN NN O
stimulation NN NN O
: NN NN O
an NN NN O
alternative NN NN O
to NN NN O
pallidotomy NN NN O
? NN NN O
   
A NN NN O
resurgence NN NN O
of NN NN O
interest NN NN O
in NN NN O
the NN NN O
surgical NN NN O
treatment NN NN O
of NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
( NN NN O
PD NN NN B-Disease
) NN NN O
came NN NN O
with NN NN O
the NN NN O
rediscovery NN NN O
of NN NN O
posteroventral NN NN O
pallidotomy NN NN O
by NN NN O
Laitinen NN NN O
in NN NN O
1985 NN NN O
. NN NN O
   
Laitinen NN NN O
' NN NN O
s NN NN O
procedure NN NN O
improved NN NN O
most NN NN O
symptoms NN NN O
in NN NN O
drug NN NN O
- NN NN O
resistant NN NN O
PD NN NN B-Disease
, NN NN O
which NN NN O
engendered NN NN O
wide NN NN O
interest NN NN O
in NN NN O
the NN NN O
neurosurgical NN NN O
community NN NN O
. NN NN O
   
Another NN NN O
lesioning NN NN O
procedure NN NN O
, NN NN O
ventrolateral NN NN O
thalamotomy NN NN O
, NN NN O
has NN NN O
become NN NN O
a NN NN O
powerful NN NN O
alternative NN NN O
to NN NN O
stimulate NN NN O
the NN NN O
nucleus NN NN O
ventralis NN NN O
intermedius NN NN O
, NN NN O
producing NN NN O
high NN NN O
long NN NN O
- NN NN O
term NN NN O
success NN NN O
rates NN NN O
and NN NN O
low NN NN O
morbidity NN NN O
rates NN NN O
. NN NN O
   
Pallidal NN NN O
stimulation NN NN O
has NN NN O
not NN NN O
met NN NN O
with NN NN O
the NN NN O
same NN NN O
success NN NN O
. NN NN O
   
According NN NN O
to NN NN O
the NN NN O
literature NN NN O
pallidotomy NN NN O
improves NN NN O
the NN NN O
"""""""" NN NN O
on NN NN O
"""""""" NN NN O
symptoms NN NN O
of NN NN O
PD NN NN B-Disease
, NN NN O
such NN NN O
as NN NN O
dyskinesias NN NN B-Disease
, NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
"""""""" NN NN O
off NN NN O
"""""""" NN NN O
symptoms NN NN O
, NN NN O
such NN NN O
as NN NN O
rigidity NN NN B-Disease
, NN NN O
bradykinesia NN NN B-Disease
, NN NN O
and NN NN O
on NN NN O
- NN NN O
off NN NN O
fluctuations NN NN O
. NN NN O
   
Pallidal NN NN O
stimulation NN NN O
improves NN NN O
bradykinesia NN NN B-Disease
and NN NN O
rigidity NN NN B-Disease
to NN NN O
a NN NN O
minor NN NN O
extent NN NN O
; NN NN O
however NN NN O
, NN NN O
its NN NN O
strength NN NN O
seems NN NN O
to NN NN O
be NN NN O
in NN NN O
improving NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
. NN NN O
   
Stimulation NN NN O
often NN NN O
produces NN NN O
an NN NN O
improvement NN NN O
in NN NN O
the NN NN O
hyper NN NN B-Disease
- NN NN I-Disease
or NN NN I-Disease
dyskinetic NN NN I-Disease
upper NN NN O
limbs NN NN O
, NN NN O
but NN NN O
increases NN NN O
the NN NN O
"""""""" NN NN O
freezing NN NN O
"""""""" NN NN O
phenomenon NN NN O
in NN NN O
the NN NN O
lower NN NN O
limbs NN NN O
at NN NN O
the NN NN O
same NN NN O
time NN NN O
. NN NN O
   
Considering NN NN O
the NN NN O
small NN NN O
increase NN NN O
in NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
independence NN NN O
, NN NN O
the NN NN O
high NN NN O
costs NN NN O
of NN NN O
bilateral NN NN O
implants NN NN O
, NN NN O
and NN NN O
the NN NN O
difficulty NN NN O
most NN NN O
patients NN NN O
experience NN NN O
in NN NN O
handling NN NN O
the NN NN O
devices NN NN O
, NN NN O
the NN NN O
question NN NN O
arises NN NN O
as NN NN O
to NN NN O
whether NN NN O
bilateral NN NN O
pallidal NN NN O
stimulation NN NN O
is NN NN O
a NN NN O
real NN NN O
alternative NN NN O
to NN NN O
pallidotomy NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
the NN NN O
cyclooxygenase NN NN O
- NN NN O
2 NN NN O
specific NN NN O
inhibitor NN NN O
valdecoxib NN NN O
versus NN NN O
nonsteroidal NN NN O
antiinflammatory NN NN O
agents NN NN O
and NN NN O
placebo NN NN O
on NN NN O
cardiovascular NN NN O
thrombotic NN NN B-Disease
events NN NN O
in NN NN O
patients NN NN O
with NN NN O
arthritis NN NN B-Disease
. NN NN O
   
There NN NN O
have NN NN O
been NN NN O
concerns NN NN O
that NN NN O
the NN NN O
risk NN NN O
of NN NN O
cardiovascular NN NN O
thrombotic NN NN B-Disease
events NN NN O
may NN NN O
be NN NN O
higher NN NN O
with NN NN O
cyclooxygenase NN NN O
( NN NN O
COX NN NN O
) NN NN O
- NN NN O
2 NN NN O
- NN NN O
specific NN NN O
inhibitors NN NN O
than NN NN O
nonselective NN NN O
nonsteroidal NN NN O
antiinflammatory NN NN O
drugs NN NN O
( NN NN O
NSAIDs NN NN O
) NN NN O
. NN NN O
   
We NN NN O
evaluated NN NN O
cardiovascular NN NN O
event NN NN O
data NN NN O
for NN NN O
valdecoxib NN NN O
, NN NN O
a NN NN O
new NN NN O
COX NN NN O
- NN NN O
2 NN NN O
- NN NN O
specific NN NN O
inhibitor NN NN O
in NN NN O
approximately NN NN O
8000 NN NN O
patients NN NN O
with NN NN O
osteoarthritis NN NN B-Disease
and NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
treated NN NN O
with NN NN O
this NN NN O
agent NN NN O
in NN NN O
randomized NN NN O
clinical NN NN O
trials NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
cardiovascular NN NN O
thrombotic NN NN B-Disease
events NN NN O
( NN NN O
cardiac NN NN O
, NN NN O
cerebrovascular NN NN O
and NN NN O
peripheral NN NN O
vascular NN NN O
, NN NN O
or NN NN O
arterial NN NN O
thrombotic NN NN B-Disease
) NN NN O
was NN NN O
determined NN NN O
by NN NN O
analyzing NN NN O
pooled NN NN O
valdecoxib NN NN O
( NN NN O
10 NN NN O
- NN NN O
80 NN NN O
mg NN NN O
daily NN NN O
) NN NN O
, NN NN O
nonselective NN NN O
NSAID NN NN O
( NN NN O
diclofenac NN NN O
75 NN NN O
mg NN NN O
bid NN NN O
, NN NN O
ibuprofen NN NN O
800 NN NN O
mg NN NN O
tid NN NN O
, NN NN O
or NN NN O
naproxen NN NN O
500 NN NN O
mg NN NN O
bid NN NN O
) NN NN O
and NN NN O
placebo NN NN O
data NN NN O
from NN NN O
10 NN NN O
randomized NN NN O
osteoarthritis NN NN B-Disease
and NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
trials NN NN O
that NN NN O
were NN NN O
6 NN NN O
- NN NN O
52 NN NN O
weeks NN NN O
in NN NN O
duration NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
rates NN NN O
of NN NN O
events NN NN O
were NN NN O
determined NN NN O
in NN NN O
all NN NN O
patients NN NN O
( NN NN O
n NN NN O
= NN NN O
7934 NN NN O
) NN NN O
and NN NN O
in NN NN O
users NN NN O
of NN NN O
low NN NN O
- NN NN O
dose NN NN O
( NN NN O
< NN NN O
or NN NN O
= NN NN O
325 NN NN O
mg NN NN O
daily NN NN O
) NN NN O
aspirin NN NN O
( NN NN O
n NN NN O
= NN NN O
1051 NN NN O
) NN NN O
and NN NN O
nonusers NN NN O
of NN NN O
aspirin NN NN O
( NN NN O
n NN NN O
= NN NN O
6883 NN NN O
) NN NN O
. NN NN O
   
Crude NN NN O
and NN NN O
exposure NN NN O
- NN NN O
adjusted NN NN O
incidences NN NN O
of NN NN O
thrombotic NN NN B-Disease
events NN NN O
were NN NN O
similar NN NN O
for NN NN O
valdecoxib NN NN O
, NN NN O
NSAIDs NN NN O
, NN NN O
and NN NN O
placebo NN NN O
. NN NN O
   
The NN NN O
risk NN NN O
of NN NN O
serious NN NN O
thrombotic NN NN B-Disease
events NN NN O
was NN NN O
also NN NN O
similar NN NN O
for NN NN O
each NN NN O
valdecoxib NN NN O
dose NN NN O
. NN NN O
   
Thrombotic NN NN B-Disease
risk NN NN O
was NN NN O
consistently NN NN O
higher NN NN O
for NN NN O
users NN NN O
of NN NN O
aspirin NN NN O
users NN NN O
than NN NN O
nonusers NN NN O
of NN NN O
aspirin NN NN O
( NN NN O
placebo NN NN O
, NN NN O
1 NN NN O
. NN NN O
4 NN NN O
% NN NN O
vs NN NN O
. NN NN O
0 NN NN O
% NN NN O
; NN NN O
valdecoxib NN NN O
, NN NN O
1 NN NN O
. NN NN O
7 NN NN O
% NN NN O
vs NN NN O
. NN NN O
0 NN NN O
. NN NN O
2 NN NN O
% NN NN O
; NN NN O
NSAIDs NN NN O
, NN NN O
1 NN NN O
. NN NN O
9 NN NN O
% NN NN O
vs NN NN O
. NN NN O
0 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
The NN NN O
rates NN NN O
of NN NN O
events NN NN O
in NN NN O
users NN NN O
of NN NN O
aspirin NN NN O
were NN NN O
similar NN NN O
for NN NN O
all NN NN O
3 NN NN O
treatment NN NN O
groups NN NN O
and NN NN O
across NN NN O
valdecoxib NN NN O
doses NN NN O
. NN NN O
   
Short NN NN O
- NN NN O
and NN NN O
intermediate NN NN O
- NN NN O
term NN NN O
treatment NN NN O
with NN NN O
therapeutic NN NN O
( NN NN O
10 NN NN O
or NN NN O
20 NN NN O
mg NN NN O
daily NN NN O
) NN NN O
and NN NN O
supratherapeutic NN NN O
( NN NN O
40 NN NN O
or NN NN O
80 NN NN O
mg NN NN O
daily NN NN O
) NN NN O
valdecoxib NN NN O
doses NN NN O
was NN NN O
not NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
incidence NN NN O
of NN NN O
thrombotic NN NN B-Disease
events NN NN O
relative NN NN O
to NN NN O
nonselective NN NN O
NSAIDs NN NN O
or NN NN O
placebo NN NN O
in NN NN O
osteoarthritis NN NN B-Disease
and NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
patients NN NN O
in NN NN O
controlled NN NN O
clinical NN NN O
trials NN NN O
. NN NN O
   
Hypersensitivity NN NN B-Disease
myocarditis NN NN B-Disease
complicating NN NN O
hypertrophic NN NN B-Disease
cardiomyopathy NN NN I-Disease
heart NN NN O
. NN NN O
   
The NN NN O
present NN NN O
report NN NN O
describes NN NN O
a NN NN O
case NN NN O
of NN NN O
eosinophilic NN NN B-Disease
myocarditis NN NN I-Disease
complicating NN NN O
hypertrophic NN NN B-Disease
cardiomyopathy NN NN I-Disease
. NN NN O
   
The NN NN O
47 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
female NN NN O
patient NN NN O
, NN NN O
known NN NN O
to NN NN O
have NN NN O
hypertrophic NN NN B-Disease
cardiomyopathy NN NN I-Disease
, NN NN O
was NN NN O
admitted NN NN O
with NN NN O
biventricular NN NN B-Disease
failure NN NN I-Disease
and NN NN O
managed NN NN O
aggressively NN NN O
with NN NN O
dobutamine NN NN O
infusion NN NN O
and NN NN O
other NN NN O
drugs NN NN O
while NN NN O
being NN NN O
assessed NN NN O
for NN NN O
heart NN NN O
transplantation NN NN O
. NN NN O
   
On NN NN O
transthoracic NN NN O
echocardiogram NN NN O
, NN NN O
she NN NN O
had NN NN O
moderate NN NN O
left NN NN B-Disease
ventricular NN NN I-Disease
dysfunction NN NN I-Disease
with NN NN O
regional NN NN O
variability NN NN O
and NN NN O
moderate NN NN O
mitral NN NN B-Disease
regurgitation NN NN I-Disease
. NN NN O
   
The NN NN O
recipient NN NN O
' NN NN O
s NN NN O
heart NN NN O
showed NN NN O
the NN NN O
features NN NN O
of NN NN O
apical NN NN O
hypertrophic NN NN B-Disease
cardiomyopathy NN NN I-Disease
and NN NN O
myocarditis NN NN B-Disease
with NN NN O
abundant NN NN O
eosinophils NN NN O
. NN NN O
   
Myocarditis NN NN B-Disease
is NN NN O
rare NN NN O
and NN NN O
eosinophilic NN NN B-Disease
myocarditis NN NN I-Disease
is NN NN O
rarer NN NN O
. NN NN O
   
It NN NN O
is NN NN O
likely NN NN O
that NN NN O
the NN NN O
hypersensitivity NN NN B-Disease
( NN NN O
eosinophilic NN NN B-Disease
) NN NN O
myocarditis NN NN B-Disease
was NN NN O
related NN NN O
to NN NN O
dobutamine NN NN O
infusion NN NN O
therapy NN NN O
. NN NN O
   
Eosinophilic NN NN B-Disease
myocarditis NN NN I-Disease
has NN NN O
been NN NN O
reported NN NN O
with NN NN O
an NN NN O
incidence NN NN O
of NN NN O
2 NN NN O
. NN NN O
4 NN NN O
% NN NN O
to NN NN O
7 NN NN O
. NN NN O
2 NN NN O
% NN NN O
in NN NN O
explanted NN NN O
hearts NN NN O
and NN NN O
may NN NN O
be NN NN O
related NN NN O
to NN NN O
multidrug NN NN O
therapy NN NN O
. NN NN O
   
Time NN NN O
trends NN NN O
in NN NN O
warfarin NN NN O
- NN NN O
associated NN NN O
hemorrhage NN NN B-Disease
. NN NN O
   
The NN NN O
annual NN NN O
incidence NN NN O
of NN NN O
warfarin NN NN O
- NN NN O
related NN NN O
bleeding NN NN B-Disease
at NN NN O
Brigham NN NN O
and NN NN O
Women NN NN O
' NN NN O
s NN NN O
Hospital NN NN O
increased NN NN O
from NN NN O
0 NN NN O
. NN NN O
97 NN NN O
/ NN NN O
1 NN NN O
, NN NN O
000 NN NN O
patient NN NN O
admissions NN NN O
in NN NN O
the NN NN O
first NN NN O
time NN NN O
period NN NN O
( NN NN O
January NN NN O
1995 NN NN O
to NN NN O
October NN NN O
1998 NN NN O
) NN NN O
to NN NN O
1 NN NN O
. NN NN O
19 NN NN O
/ NN NN O
1 NN NN O
, NN NN O
000 NN NN O
patient NN NN O
admissions NN NN O
in NN NN O
the NN NN O
second NN NN O
time NN NN O
period NN NN O
( NN NN O
November NN NN O
1998 NN NN O
to NN NN O
August NN NN O
2002 NN NN O
) NN NN O
of NN NN O
this NN NN O
study NN NN O
. NN NN O
   
The NN NN O
proportion NN NN O
of NN NN O
patients NN NN O
with NN NN O
major NN NN O
and NN NN O
intracranial NN NN B-Disease
bleeding NN NN I-Disease
increased NN NN O
from NN NN O
20 NN NN O
. NN NN O
2 NN NN O
% NN NN O
and NN NN O
1 NN NN O
. NN NN O
9 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
, NN NN O
in NN NN O
the NN NN O
first NN NN O
time NN NN O
period NN NN O
, NN NN O
to NN NN O
33 NN NN O
. NN NN O
3 NN NN O
% NN NN O
and NN NN O
7 NN NN O
. NN NN O
8 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
, NN NN O
in NN NN O
the NN NN O
second NN NN O
. NN NN O
   
Yohimbine NN NN O
treatment NN NN O
of NN NN O
sexual NN NN B-Disease
side NN NN I-Disease
effects NN NN I-Disease
induced NN NN O
by NN NN O
serotonin NN NN O
reuptake NN NN O
blockers NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Preclinical NN NN O
and NN NN O
clinical NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
yohimbine NN NN O
facilitates NN NN O
sexual NN NN O
behavior NN NN O
and NN NN O
may NN NN O
be NN NN O
helpful NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
male NN NN B-Disease
impotence NN NN I-Disease
. NN NN O
   
A NN NN O
single NN NN O
case NN NN O
report NN NN O
suggests NN NN O
that NN NN O
yohimbine NN NN O
may NN NN O
be NN NN O
used NN NN O
to NN NN O
treat NN NN O
the NN NN O
sexual NN NN B-Disease
side NN NN I-Disease
effects NN NN I-Disease
of NN NN O
clomipramine NN NN O
. NN NN O
   
This NN NN O
study NN NN O
evaluated NN NN O
yohimbine NN NN O
as NN NN O
a NN NN O
treatment NN NN O
for NN NN O
the NN NN O
sexual NN NN B-Disease
side NN NN I-Disease
effects NN NN I-Disease
caused NN NN O
by NN NN O
serotonin NN NN O
reuptake NN NN O
blockers NN NN O
. NN NN O
   
METHOD NN NN O
: NN NN O
Six NN NN O
patients NN NN O
with NN NN O
either NN NN O
obsessive NN NN B-Disease
compulsive NN NN I-Disease
disorder NN NN I-Disease
, NN NN O
trichotillomania NN NN B-Disease
, NN NN O
anxiety NN NN B-Disease
, NN NN O
or NN NN O
affective NN NN B-Disease
disorders NN NN I-Disease
who NN NN O
suffered NN NN O
sexual NN NN B-Disease
side NN NN I-Disease
effects NN NN I-Disease
after NN NN O
treatment NN NN O
with NN NN O
serotonin NN NN O
reuptake NN NN O
blockers NN NN O
were NN NN O
given NN NN O
yohimbine NN NN O
on NN NN O
a NN NN O
p NN NN O
. NN NN O
r NN NN O
. NN NN O
n NN NN O
. NN NN O
basis NN NN O
in NN NN O
an NN NN O
open NN NN O
clinical NN NN O
trial NN NN O
. NN NN O
   
Various NN NN O
doses NN NN O
of NN NN O
yohimbine NN NN O
were NN NN O
used NN NN O
to NN NN O
determine NN NN O
the NN NN O
ideal NN NN O
dose NN NN O
for NN NN O
each NN NN O
patient NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Five NN NN O
of NN NN O
the NN NN O
six NN NN O
patients NN NN O
experienced NN NN O
improved NN NN O
sexual NN NN O
functioning NN NN O
after NN NN O
taking NN NN O
yohimbine NN NN O
. NN NN O
   
One NN NN O
patient NN NN O
who NN NN O
failed NN NN O
to NN NN O
comply NN NN O
with NN NN O
yohimbine NN NN O
treatment NN NN O
had NN NN O
no NN NN O
therapeutic NN NN O
effects NN NN O
. NN NN O
   
Side NN NN O
effects NN NN O
of NN NN O
yohimbine NN NN O
included NN NN O
excessive NN NN O
sweating NN NN O
, NN NN O
increased NN NN O
anxiety NN NN B-Disease
, NN NN O
and NN NN O
a NN NN O
wound NN NN O
- NN NN O
up NN NN O
feeling NN NN O
in NN NN O
some NN NN O
patients NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
results NN NN O
of NN NN O
this NN NN O
study NN NN O
indicate NN NN O
that NN NN O
yohimbine NN NN O
may NN NN O
be NN NN O
an NN NN O
effective NN NN O
treatment NN NN O
for NN NN O
the NN NN O
sexual NN NN B-Disease
side NN NN I-Disease
effects NN NN I-Disease
caused NN NN O
by NN NN O
serotonin NN NN O
reuptake NN NN O
blockers NN NN O
. NN NN O
   
Future NN NN O
controlled NN NN O
studies NN NN O
are NN NN O
needed NN NN O
to NN NN O
further NN NN O
investigate NN NN O
the NN NN O
effectiveness NN NN O
and NN NN O
safety NN NN O
of NN NN O
yohimbine NN NN O
for NN NN O
this NN NN O
indication NN NN O
. NN NN O
   
Hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
complicating NN NN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
. NN NN O
   
Hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
is NN NN O
a NN NN O
potentially NN NN O
serious NN NN O
complication NN NN O
of NN NN O
high NN NN O
- NN NN O
dose NN NN O
cyclophosphamide NN NN O
therapy NN NN O
administered NN NN O
before NN NN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
. NN NN O
   
As NN NN O
standard NN NN O
practice NN NN O
at NN NN O
our NN NN O
institution NN NN O
, NN NN O
patients NN NN O
who NN NN O
are NN NN O
scheduled NN NN O
to NN NN O
receive NN NN O
a NN NN O
bone NN NN O
marrow NN NN O
transplant NN NN O
are NN NN O
treated NN NN O
prophylactically NN NN O
with NN NN O
forced NN NN O
hydration NN NN O
and NN NN O
bladder NN NN O
irrigation NN NN O
. NN NN O
   
In NN NN O
an NN NN O
attempt NN NN O
to NN NN O
obviate NN NN O
the NN NN O
inconvenience NN NN O
of NN NN O
bladder NN NN O
irrigation NN NN O
, NN NN O
we NN NN O
conducted NN NN O
a NN NN O
feasibility NN NN O
trial NN NN O
of NN NN O
uroprophylaxis NN NN O
with NN NN O
mesna NN NN O
, NN NN O
which NN NN O
neutralizes NN NN O
the NN NN O
hepatic NN NN O
metabolite NN NN O
of NN NN O
cyclophosphamide NN NN O
that NN NN O
causes NN NN O
hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
. NN NN O
   
Of NN NN O
97 NN NN O
patients NN NN O
who NN NN O
received NN NN O
standard NN NN O
prophylaxis NN NN O
, NN NN O
4 NN NN O
had NN NN O
symptomatic NN NN O
hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
two NN NN O
of NN NN O
four NN NN O
consecutive NN NN O
patients NN NN O
who NN NN O
received NN NN O
mesna NN NN O
uroprophylaxis NN NN O
before NN NN O
allogeneic NN NN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
had NN NN O
severe NN NN O
hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
for NN NN O
at NN NN O
least NN NN O
2 NN NN O
weeks NN NN O
. NN NN O
   
Because NN NN O
of NN NN O
this NN NN O
suboptimal NN NN O
result NN NN O
, NN NN O
we NN NN O
resumed NN NN O
the NN NN O
use NN NN O
of NN NN O
bladder NN NN O
irrigation NN NN O
and NN NN O
forced NN NN O
hydration NN NN O
to NN NN O
minimize NN NN O
the NN NN O
risk NN NN O
of NN NN O
hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
. NN NN O
   
Consensus NN NN O
statement NN NN O
concerning NN NN O
cardiotoxicity NN NN B-Disease
occurring NN NN O
during NN NN O
haematopoietic NN NN O
stem NN NN O
cell NN NN O
transplantation NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
autoimmune NN NN B-Disease
diseases NN NN I-Disease
, NN NN O
with NN NN O
special NN NN O
reference NN NN O
to NN NN O
systemic NN NN B-Disease
sclerosis NN NN I-Disease
and NN NN O
multiple NN NN B-Disease
sclerosis NN NN I-Disease
. NN NN O
   
Autologous NN NN O
haematopoietic NN NN O
stem NN NN O
cell NN NN O
transplantation NN NN O
is NN NN O
now NN NN O
a NN NN O
feasible NN NN O
and NN NN O
effective NN NN O
treatment NN NN O
for NN NN O
selected NN NN O
patients NN NN O
with NN NN O
severe NN NN O
autoimmune NN NN B-Disease
diseases NN NN I-Disease
. NN NN O
   
Worldwide NN NN O
, NN NN O
over NN NN O
650 NN NN O
patients NN NN O
have NN NN O
been NN NN O
transplanted NN NN O
in NN NN O
the NN NN O
context NN NN O
of NN NN O
phase NN NN O
I NN NN O
and NN NN O
II NN NN O
clinical NN NN O
trials NN NN O
. NN NN O
   
The NN NN O
results NN NN O
are NN NN O
encouraging NN NN O
enough NN NN O
to NN NN O
begin NN NN O
randomised NN NN O
phase NN NN O
III NN NN O
trials NN NN O
. NN NN O
   
However NN NN O
, NN NN O
as NN NN O
predicted NN NN O
, NN NN O
significant NN NN O
transplant NN NN O
- NN NN O
related NN NN O
morbidity NN NN O
and NN NN O
mortality NN NN O
have NN NN O
been NN NN O
observed NN NN O
. NN NN O
   
This NN NN O
is NN NN O
primarily NN NN O
due NN NN O
to NN NN O
complications NN NN O
related NN NN O
to NN NN O
either NN NN O
the NN NN O
stage NN NN O
of NN NN O
the NN NN O
disease NN NN O
at NN NN O
transplant NN NN O
or NN NN O
due NN NN O
to NN NN O
infections NN NN B-Disease
. NN NN O
   
The NN NN O
number NN NN O
of NN NN O
deaths NN NN O
related NN NN O
to NN NN O
cardiac NN NN B-Disease
toxicity NN NN I-Disease
is NN NN O
low NN NN O
. NN NN O
   
However NN NN O
, NN NN O
caution NN NN O
is NN NN O
required NN NN O
when NN NN O
cyclophosphamide NN NN O
or NN NN O
anthracyclines NN NN O
such NN NN O
as NN NN O
mitoxantrone NN NN O
are NN NN O
used NN NN O
in NN NN O
patients NN NN O
with NN NN O
a NN NN O
possible NN NN O
underlying NN NN O
heart NN NN B-Disease
damage NN NN I-Disease
, NN NN O
for NN NN O
example NN NN O
, NN NN O
systemic NN NN B-Disease
sclerosis NN NN I-Disease
patients NN NN O
. NN NN O
   
In NN NN O
November NN NN O
2002 NN NN O
, NN NN O
a NN NN O
meeting NN NN O
was NN NN O
held NN NN O
in NN NN O
Florence NN NN O
, NN NN O
bringing NN NN O
together NN NN O
a NN NN O
number NN NN O
of NN NN O
experts NN NN O
in NN NN O
various NN NN O
fields NN NN O
, NN NN O
including NN NN O
rheumatology NN NN O
, NN NN O
cardiology NN NN O
, NN NN O
neurology NN NN O
, NN NN O
pharmacology NN NN O
and NN NN O
transplantation NN NN O
medicine NN NN O
. NN NN O
   
The NN NN O
object NN NN O
of NN NN O
the NN NN O
meeting NN NN O
was NN NN O
to NN NN O
analyse NN NN O
existing NN NN O
data NN NN O
, NN NN O
both NN NN O
published NN NN O
or NN NN O
available NN NN O
, NN NN O
in NN NN O
the NN NN O
European NN NN O
Group NN NN O
for NN NN O
Blood NN NN O
and NN NN O
Marrow NN NN O
Transplantation NN NN O
autoimmune NN NN B-Disease
disease NN NN I-Disease
database NN NN O
, NN NN O
and NN NN O
to NN NN O
propose NN NN O
a NN NN O
safe NN NN O
approach NN NN O
to NN NN O
such NN NN O
patients NN NN O
. NN NN O
   
A NN NN O
full NN NN O
cardiological NN NN O
assessment NN NN O
before NN NN O
and NN NN O
during NN NN O
the NN NN O
transplant NN NN O
emerged NN NN O
as NN NN O
the NN NN O
major NN NN O
recommendation NN NN O
. NN NN O
   
Does NN NN O
supplemental NN NN O
vitamin NN NN O
C NN NN O
increase NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
risk NN NN O
in NN NN O
women NN NN O
with NN NN O
diabetes NN NN B-Disease
? NN NN O
   
BACKGROUND NN NN O
: NN NN O
Vitamin NN NN O
C NN NN O
acts NN NN O
as NN NN O
a NN NN O
potent NN NN O
antioxidant NN NN O
; NN NN O
however NN NN O
, NN NN O
it NN NN O
can NN NN O
also NN NN O
be NN NN O
a NN NN O
prooxidant NN NN O
and NN NN O
glycate NN NN O
protein NN NN O
under NN NN O
certain NN NN O
circumstances NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
led NN NN O
us NN NN O
to NN NN O
hypothesize NN NN O
that NN NN O
a NN NN O
high NN NN O
intake NN NN O
of NN NN O
vitamin NN NN O
C NN NN O
in NN NN O
diabetic NN NN B-Disease
persons NN NN O
might NN NN O
promote NN NN O
atherosclerosis NN NN B-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
The NN NN O
objective NN NN O
was NN NN O
to NN NN O
examine NN NN O
the NN NN O
relation NN NN O
between NN NN O
vitamin NN NN O
C NN NN O
intake NN NN O
and NN NN O
mortality NN NN O
from NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
DESIGN NN NN O
: NN NN O
We NN NN O
studied NN NN O
the NN NN O
relation NN NN O
between NN NN O
vitamin NN NN O
C NN NN O
intake NN NN O
and NN NN O
mortality NN NN O
from NN NN O
total NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
( NN NN O
n NN NN O
= NN NN O
281 NN NN O
) NN NN O
, NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
( NN NN O
n NN NN O
= NN NN O
175 NN NN O
) NN NN O
, NN NN O
and NN NN O
stroke NN NN B-Disease
( NN NN O
n NN NN O
= NN NN O
57 NN NN O
) NN NN O
in NN NN O
1923 NN NN O
postmenopausal NN NN O
women NN NN O
who NN NN O
reported NN NN O
being NN NN O
diabetic NN NN B-Disease
at NN NN O
baseline NN NN O
. NN NN O
   
Diet NN NN O
was NN NN O
assessed NN NN O
with NN NN O
a NN NN O
food NN NN O
- NN NN O
frequency NN NN O
questionnaire NN NN O
at NN NN O
baseline NN NN O
, NN NN O
and NN NN O
subjects NN NN O
initially NN NN O
free NN NN O
of NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
were NN NN O
prospectively NN NN O
followed NN NN O
for NN NN O
15 NN NN O
y NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
After NN NN O
adjustment NN NN O
for NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
risk NN NN O
factors NN NN O
, NN NN O
type NN NN O
of NN NN O
diabetes NN NN B-Disease
medication NN NN O
used NN NN O
, NN NN O
duration NN NN O
of NN NN O
diabetes NN NN B-Disease
, NN NN O
and NN NN O
intakes NN NN O
of NN NN O
folate NN NN O
, NN NN O
vitamin NN NN O
E NN NN O
, NN NN O
and NN NN O
beta NN NN O
- NN NN O
carotene NN NN O
, NN NN O
the NN NN O
adjusted NN NN O
relative NN NN O
risks NN NN O
of NN NN O
total NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
mortality NN NN O
were NN NN O
1 NN NN O
. NN NN O
0 NN NN O
, NN NN O
0 NN NN O
. NN NN O
97 NN NN O
, NN NN O
1 NN NN O
. NN NN O
11 NN NN O
, NN NN O
1 NN NN O
. NN NN O
47 NN NN O
, NN NN O
and NN NN O
1 NN NN O
. NN NN O
84 NN NN O
( NN NN O
P NN NN O
for NN NN O
trend NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
across NN NN O
quintiles NN NN O
of NN NN O
total NN NN O
vitamin NN NN O
C NN NN O
intake NN NN O
from NN NN O
food NN NN O
and NN NN O
supplements NN NN O
. NN NN O
   
Adjusted NN NN O
relative NN NN O
risks NN NN O
of NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
were NN NN O
1 NN NN O
. NN NN O
0 NN NN O
, NN NN O
0 NN NN O
. NN NN O
81 NN NN O
, NN NN O
0 NN NN O
. NN NN O
99 NN NN O
, NN NN O
1 NN NN O
. NN NN O
26 NN NN O
, NN NN O
and NN NN O
1 NN NN O
. NN NN O
91 NN NN O
( NN NN O
P NN NN O
for NN NN O
trend NN NN O
= NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
and NN NN O
of NN NN O
stroke NN NN B-Disease
were NN NN O
1 NN NN O
. NN NN O
0 NN NN O
, NN NN O
0 NN NN O
. NN NN O
52 NN NN O
, NN NN O
1 NN NN O
. NN NN O
23 NN NN O
, NN NN O
2 NN NN O
. NN NN O
22 NN NN O
, NN NN O
and NN NN O
2 NN NN O
. NN NN O
57 NN NN O
( NN NN O
P NN NN O
for NN NN O
trend NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
When NN NN O
dietary NN NN O
and NN NN O
supplemental NN NN O
vitamin NN NN O
C NN NN O
were NN NN O
analyzed NN NN O
separately NN NN O
, NN NN O
only NN NN O
supplemental NN NN O
vitamin NN NN O
C NN NN O
showed NN NN O
a NN NN O
positive NN NN O
association NN NN O
with NN NN O
mortality NN NN O
endpoints NN NN O
. NN NN O
   
Vitamin NN NN O
C NN NN O
intake NN NN O
was NN NN O
unrelated NN NN O
to NN NN O
mortality NN NN O
from NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
in NN NN O
the NN NN O
nondiabetic NN NN O
subjects NN NN O
at NN NN O
baseline NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
A NN NN O
high NN NN O
vitamin NN NN O
C NN NN O
intake NN NN O
from NN NN O
supplements NN NN O
is NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
mortality NN NN O
in NN NN O
postmenopausal NN NN O
women NN NN O
with NN NN O
diabetes NN NN B-Disease
. NN NN O
   
Optical NN NN O
coherence NN NN O
tomography NN NN O
can NN NN O
measure NN NN O
axonal NN NN O
loss NN NN O
in NN NN O
patients NN NN O
with NN NN O
ethambutol NN NN O
- NN NN O
induced NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
. NN NN O
   
PURPOSE NN NN O
: NN NN O
To NN NN O
map NN NN O
and NN NN O
identify NN NN O
the NN NN O
pattern NN NN O
, NN NN O
in NN NN O
vivo NN NN O
, NN NN O
of NN NN O
axonal NN NN B-Disease
degeneration NN NN I-Disease
in NN NN O
ethambutol NN NN O
- NN NN O
induced NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
using NN NN O
optical NN NN O
coherence NN NN O
tomography NN NN O
( NN NN O
OCT NN NN O
) NN NN O
. NN NN O
   
Ethambutol NN NN O
is NN NN O
an NN NN O
antimycobacterial NN NN O
agent NN NN O
often NN NN O
used NN NN O
to NN NN O
treat NN NN O
tuberculosis NN NN B-Disease
. NN NN O
   
A NN NN O
serious NN NN O
complication NN NN O
of NN NN O
ethambutol NN NN O
is NN NN O
an NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
that NN NN O
impairs NN NN O
visual NN NN O
acuity NN NN O
, NN NN O
contrast NN NN O
sensitivity NN NN O
, NN NN O
and NN NN O
color NN NN O
vision NN NN O
. NN NN O
   
However NN NN O
, NN NN O
early NN NN O
on NN NN O
, NN NN O
when NN NN O
the NN NN O
toxic NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
is NN NN O
mild NN NN O
and NN NN O
partly NN NN O
reversible NN NN O
, NN NN O
the NN NN O
funduscopic NN NN O
findings NN NN O
are NN NN O
often NN NN O
subtle NN NN O
and NN NN O
easy NN NN O
to NN NN O
miss NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Three NN NN O
subjects NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
ethambutol NN NN O
( NN NN O
EMB NN NN O
) NN NN O
- NN NN O
induced NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
of NN NN O
short NN NN O
- NN NN O
, NN NN O
intermediate NN NN O
- NN NN O
, NN NN O
and NN NN O
long NN NN O
- NN NN O
term NN NN O
visual NN NN B-Disease
deficits NN NN I-Disease
were NN NN O
administered NN NN O
a NN NN O
full NN NN O
neuro NN NN O
- NN NN O
ophthalmologic NN NN O
examination NN NN O
including NN NN O
visual NN NN O
acuity NN NN O
, NN NN O
color NN NN O
vision NN NN O
, NN NN O
contrast NN NN O
sensitivity NN NN O
, NN NN O
and NN NN O
fundus NN NN O
examination NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
OCT NN NN O
( NN NN O
OCT NN NN O
3000 NN NN O
, NN NN O
Humphrey NN NN O
- NN NN O
Zeiss NN NN O
, NN NN O
Dublin NN NN O
, NN NN O
CA NN NN O
) NN NN O
was NN NN O
performed NN NN O
on NN NN O
both NN NN O
eyes NN NN O
of NN NN O
each NN NN O
subject NN NN O
using NN NN O
the NN NN O
retinal NN NN O
nerve NN NN O
fiber NN NN O
layer NN NN O
( NN NN O
RNFL NN NN O
) NN NN O
analysis NN NN O
protocol NN NN O
. NN NN O
   
OCT NN NN O
interpolates NN NN O
data NN NN O
from NN NN O
100 NN NN O
points NN NN O
around NN NN O
the NN NN O
optic NN NN O
nerve NN NN O
to NN NN O
effectively NN NN O
map NN NN O
out NN NN O
the NN NN O
RNFL NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
results NN NN O
were NN NN O
compared NN NN O
to NN NN O
the NN NN O
calculated NN NN O
average NN NN O
RNFL NN NN O
of NN NN O
normal NN NN O
eyes NN NN O
accumulated NN NN O
from NN NN O
four NN NN O
prior NN NN O
studies NN NN O
using NN NN O
OCT NN NN O
, NN NN O
n NN NN O
= NN NN O
661 NN NN O
. NN NN O
   
In NN NN O
all NN NN O
subjects NN NN O
with NN NN O
history NN NN O
of NN NN O
EMB NN NN O
- NN NN O
induced NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
, NN NN O
there NN NN O
was NN NN O
a NN NN O
mean NN NN O
loss NN NN O
of NN NN O
72 NN NN O
% NN NN O
nerve NN NN O
fiber NN NN O
layer NN NN O
thickness NN NN O
in NN NN O
the NN NN O
temporal NN NN O
quadrant NN NN O
( NN NN O
patient NN NN O
A NN NN O
, NN NN O
with NN NN O
eventual NN NN O
recovery NN NN O
of NN NN O
visual NN NN O
acuity NN NN O
and NN NN O
fields NN NN O
, NN NN O
58 NN NN O
% NN NN O
loss NN NN O
; NN NN O
patient NN NN O
B NN NN O
, NN NN O
with NN NN O
intermediate NN NN O
visual NN NN B-Disease
deficits NN NN I-Disease
, NN NN O
68 NN NN O
% NN NN O
loss NN NN O
; NN NN O
patient NN NN O
C NN NN O
, NN NN O
with NN NN O
chronic NN NN O
visual NN NN B-Disease
deficits NN NN I-Disease
, NN NN O
90 NN NN O
% NN NN O
loss NN NN O
) NN NN O
, NN NN O
with NN NN O
an NN NN O
average NN NN O
mean NN NN O
optic NN NN O
nerve NN NN O
thickness NN NN O
of NN NN O
26 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
16 NN NN O
microm NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
combined NN NN O
mean NN NN O
loss NN NN O
of NN NN O
46 NN NN O
% NN NN O
of NN NN O
fibers NN NN O
from NN NN O
the NN NN O
superior NN NN O
, NN NN O
inferior NN NN O
, NN NN O
and NN NN O
nasal NN NN O
quadrants NN NN O
in NN NN O
the NN NN O
( NN NN O
six NN NN O
) NN NN O
eyes NN NN O
of NN NN O
all NN NN O
three NN NN O
subjects NN NN O
( NN NN O
mean NN NN O
average NN NN O
thickness NN NN O
of NN NN O
55 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
29 NN NN O
microm NN NN O
) NN NN O
. NN NN O
   
In NN NN O
both NN NN O
sets NN NN O
( NN NN O
four NN NN O
) NN NN O
of NN NN O
eyes NN NN O
of NN NN O
the NN NN O
subjects NN NN O
with NN NN O
persistent NN NN O
visual NN NN B-Disease
deficits NN NN I-Disease
( NN NN O
patients NN NN O
B NN NN O
and NN NN O
C NN NN O
) NN NN O
, NN NN O
there NN NN O
was NN NN O
an NN NN O
average NN NN O
loss NN NN O
of NN NN O
79 NN NN O
% NN NN O
of NN NN O
nerve NN NN O
fiber NN NN O
thickness NN NN O
in NN NN O
the NN NN O
temporal NN NN O
quadrant NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
OCT NN NN O
results NN NN O
in NN NN O
these NN NN O
patients NN NN O
with NN NN O
EMB NN NN O
- NN NN O
induced NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
show NN NN O
considerable NN NN O
loss NN NN O
especially NN NN O
of NN NN O
the NN NN O
temporal NN NN O
fibers NN NN O
. NN NN O
   
This NN NN O
is NN NN O
consistent NN NN O
with NN NN O
prior NN NN O
histopathological NN NN O
studies NN NN O
that NN NN O
show NN NN O
predominant NN NN O
loss NN NN O
of NN NN O
parvo NN NN O
- NN NN O
cellular NN NN O
axons NN NN O
( NN NN O
or NN NN O
small NN NN O
- NN NN O
caliber NN NN O
axons NN NN O
) NN NN O
within NN NN O
the NN NN O
papillo NN NN O
- NN NN O
macular NN NN O
bundle NN NN O
in NN NN O
toxic NN NN O
or NN NN O
hereditary NN NN O
optic NN NN B-Disease
neuropathies NN NN I-Disease
. NN NN O
   
OCT NN NN O
can NN NN O
be NN NN O
a NN NN O
valuable NN NN O
tool NN NN O
in NN NN O
the NN NN O
quantitative NN NN O
analysis NN NN O
of NN NN O
optic NN NN B-Disease
neuropathies NN NN I-Disease
. NN NN O
   
Additionally NN NN O
, NN NN O
in NN NN O
terms NN NN O
of NN NN O
management NN NN O
of NN NN O
EMB NN NN O
- NN NN O
induced NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
, NN NN O
it NN NN O
is NN NN O
important NN NN O
to NN NN O
properly NN NN O
manage NN NN O
ethambutol NN NN O
dosing NN NN O
in NN NN O
patients NN NN O
with NN NN O
renal NN NN B-Disease
impairment NN NN I-Disease
and NN NN O
to NN NN O
achieve NN NN O
proper NN NN O
transition NN NN O
to NN NN O
a NN NN O
maintenance NN NN O
dose NN NN O
once NN NN O
an NN NN O
appropriate NN NN O
loading NN NN O
dose NN NN O
has NN NN O
been NN NN O
reached NN NN O
. NN NN O
   
Hypoxia NN NN B-Disease
in NN NN O
renal NN NN B-Disease
disease NN NN I-Disease
with NN NN O
proteinuria NN NN B-Disease
and NN NN O
/ NN NN O
or NN NN O
glomerular NN NN O
hypertension NN NN B-Disease
. NN NN O
   
Despite NN NN O
the NN NN O
increasing NN NN O
need NN NN O
to NN NN O
identify NN NN O
and NN NN O
quantify NN NN O
tissue NN NN O
oxygenation NN NN O
at NN NN O
the NN NN O
cellular NN NN O
level NN NN O
, NN NN O
relatively NN NN O
few NN NN O
methods NN NN O
have NN NN O
been NN NN O
available NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
developed NN NN O
a NN NN O
new NN NN O
hypoxia NN NN B-Disease
- NN NN O
responsive NN NN O
reporter NN NN O
vector NN NN O
using NN NN O
a NN NN O
hypoxia NN NN B-Disease
- NN NN O
responsive NN NN O
element NN NN O
of NN NN O
the NN NN O
5 NN NN O
' NN NN O
vascular NN NN O
endothelial NN NN O
growth NN NN O
factor NN NN O
untranslated NN NN O
region NN NN O
and NN NN O
generated NN NN O
a NN NN O
novel NN NN O
hypoxia NN NN B-Disease
- NN NN O
sensing NN NN O
transgenic NN NN O
rat NN NN O
. NN NN O
   
We NN NN O
then NN NN O
applied NN NN O
this NN NN O
animal NN NN O
model NN NN O
to NN NN O
the NN NN O
detection NN NN O
of NN NN O
tubulointerstitial NN NN O
hypoxia NN NN B-Disease
in NN NN O
the NN NN O
diseased NN NN B-Disease
kidney NN NN I-Disease
. NN NN O
   
With NN NN O
this NN NN O
model NN NN O
, NN NN O
we NN NN O
were NN NN O
able NN NN O
to NN NN O
identify NN NN O
diffuse NN NN O
cortical NN NN O
hypoxia NN NN B-Disease
in NN NN O
the NN NN O
puromycin NN NN O
aminonucleoside NN NN O
- NN NN O
induced NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
and NN NN O
focal NN NN O
and NN NN O
segmental NN NN O
hypoxia NN NN B-Disease
in NN NN O
the NN NN O
remnant NN NN O
kidney NN NN O
model NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
the NN NN O
hypoxia NN NN B-Disease
- NN NN O
responsive NN NN O
transgene NN NN O
increased NN NN O
throughout NN NN O
the NN NN O
observation NN NN O
period NN NN O
, NN NN O
reaching NN NN O
2 NN NN O
. NN NN O
2 NN NN O
- NN NN O
fold NN NN O
at NN NN O
2 NN NN O
weeks NN NN O
in NN NN O
the NN NN O
puromycin NN NN O
aminonucleoside NN NN O
model NN NN O
and NN NN O
2 NN NN O
. NN NN O
6 NN NN O
- NN NN O
fold NN NN O
at NN NN O
4 NN NN O
weeks NN NN O
in NN NN O
the NN NN O
remnant NN NN O
kidney NN NN O
model NN NN O
, NN NN O
whereas NN NN O
that NN NN O
of NN NN O
vascular NN NN O
endothelial NN NN O
growth NN NN O
factor NN NN O
showed NN NN O
a NN NN O
mild NN NN O
decrease NN NN O
, NN NN O
reflecting NN NN O
distinct NN NN O
behaviors NN NN O
of NN NN O
the NN NN O
two NN NN O
genes NN NN O
. NN NN O
   
The NN NN O
degree NN NN O
of NN NN O
hypoxia NN NN B-Disease
showed NN NN O
a NN NN O
positive NN NN O
correlation NN NN O
with NN NN O
microscopic NN NN O
tubulointerstitial NN NN B-Disease
injury NN NN I-Disease
in NN NN O
both NN NN O
models NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
we NN NN O
identified NN NN O
the NN NN O
localization NN NN O
of NN NN O
proliferating NN NN O
cell NN NN O
nuclear NN NN O
antigen NN NN O
- NN NN O
positive NN NN O
, NN NN O
ED NN NN O
- NN NN O
1 NN NN O
- NN NN O
positive NN NN O
, NN NN O
and NN NN O
terminal NN NN O
dUTP NN NN O
nick NN NN O
- NN NN O
end NN NN O
labeled NN NN O
- NN NN O
positive NN NN O
cells NN NN O
in NN NN O
the NN NN O
hypoxic NN NN B-Disease
cortical NN NN O
area NN NN O
in NN NN O
the NN NN O
remnant NN NN O
kidney NN NN O
model NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
here NN NN O
a NN NN O
possible NN NN O
pathological NN NN O
tie NN NN O
between NN NN O
chronic NN NN O
tubulointerstitial NN NN O
hypoxia NN NN B-Disease
and NN NN O
progressive NN NN O
glomerular NN NN B-Disease
diseases NN NN I-Disease
. NN NN O
   
Adequate NN NN O
timing NN NN O
of NN NN O
ribavirin NN NN O
reduction NN NN O
in NN NN O
patients NN NN O
with NN NN O
hemolysis NN NN B-Disease
during NN NN O
combination NN NN O
therapy NN NN O
of NN NN O
interferon NN NN O
and NN NN O
ribavirin NN NN O
for NN NN O
chronic NN NN B-Disease
hepatitis NN NN I-Disease
C NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Hemolytic NN NN B-Disease
anemia NN NN I-Disease
is NN NN O
one NN NN O
of NN NN O
the NN NN O
major NN NN O
adverse NN NN O
events NN NN O
of NN NN O
the NN NN O
combination NN NN O
therapy NN NN O
of NN NN O
interferon NN NN O
and NN NN O
ribavirin NN NN O
. NN NN O
   
Because NN NN O
of NN NN O
ribavirin NN NN O
- NN NN O
related NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
, NN NN O
dose NN NN O
reduction NN NN O
is NN NN O
a NN NN O
common NN NN O
event NN NN O
in NN NN O
this NN NN O
therapy NN NN O
. NN NN O
   
In NN NN O
this NN NN O
clinical NN NN O
retrospective NN NN O
cohort NN NN O
study NN NN O
we NN NN O
have NN NN O
examined NN NN O
the NN NN O
suitable NN NN O
timing NN NN O
of NN NN O
ribavirin NN NN O
reduction NN NN O
in NN NN O
patients NN NN O
with NN NN O
hemolysis NN NN B-Disease
during NN NN O
combination NN NN O
therapy NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Thirty NN NN O
- NN NN O
seven NN NN O
of NN NN O
160 NN NN O
patients NN NN O
who NN NN O
had NN NN O
HCV NN NN O
- NN NN O
genotype NN NN O
1b NN NN O
, NN NN O
had NN NN O
high NN NN O
virus NN NN O
load NN NN O
, NN NN O
and NN NN O
received NN NN O
24 NN NN O
- NN NN O
week NN NN O
combination NN NN O
therapy NN NN O
developed NN NN O
anemia NN NN B-Disease
with NN NN O
hemoglobin NN NN O
level NN NN O
< NN NN O
10 NN NN O
g NN NN O
/ NN NN O
dl NN NN O
or NN NN O
anemia NN NN B-Disease
- NN NN O
related NN NN O
signs NN NN O
during NN NN O
therapy NN NN O
. NN NN O
   
After NN NN O
that NN NN O
, NN NN O
these NN NN O
37 NN NN O
patients NN NN O
were NN NN O
reduced NN NN O
one NN NN O
tablet NN NN O
of NN NN O
ribavirin NN NN O
( NN NN O
200 NN NN O
mg NN NN O
) NN NN O
per NN NN O
day NN NN O
. NN NN O
   
After NN NN O
reduction NN NN O
of NN NN O
ribavirin NN NN O
, NN NN O
27 NN NN O
of NN NN O
37 NN NN O
patients NN NN O
could NN NN O
continue NN NN O
combination NN NN O
therapy NN NN O
for NN NN O
a NN NN O
total NN NN O
of NN NN O
24 NN NN O
weeks NN NN O
( NN NN O
group NN NN O
A NN NN O
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
10 NN NN O
of NN NN O
37 NN NN O
patients NN NN O
with NN NN O
reduction NN NN O
of NN NN O
ribavirin NN NN O
could NN NN O
not NN NN O
continue NN NN O
combination NN NN O
therapy NN NN O
because NN NN O
their NN NN O
< NN NN O
8 NN NN O
. NN NN O
5 NN NN O
g NN NN O
/ NN NN O
dl NN NN O
hemoglobin NN NN O
values NN NN O
decreased NN NN O
to NN NN O
or NN NN O
anemia NN NN B-Disease
- NN NN O
related NN NN O
severe NN NN O
side NN NN O
effects NN NN O
occurred NN NN O
( NN NN O
group NN NN O
B NN NN O
) NN NN O
. NN NN O
   
We NN NN O
assessed NN NN O
the NN NN O
final NN NN O
efficacy NN NN O
and NN NN O
safety NN NN O
after NN NN O
reduction NN NN O
of NN NN O
ribavirin NN NN O
in NN NN O
groups NN NN O
A NN NN O
and NN NN O
B NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
A NN NN O
sustained NN NN O
virological NN NN O
response NN NN O
( NN NN O
SVR NN NN O
) NN NN O
was NN NN O
29 NN NN O
. NN NN O
6 NN NN O
% NN NN O
( NN NN O
8 NN NN O
/ NN NN O
27 NN NN O
) NN NN O
in NN NN O
group NN NN O
A NN NN O
and NN NN O
10 NN NN O
% NN NN O
( NN NN O
1 NN NN O
/ NN NN O
10 NN NN O
) NN NN O
in NN NN O
group NN NN O
B NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
A NN NN O
34 NN NN O
. NN NN O
4 NN NN O
% NN NN O
( NN NN O
12 NN NN O
/ NN NN O
27 NN NN O
) NN NN O
of NN NN O
SVR NN NN O
+ NN NN O
biological NN NN O
response NN NN O
in NN NN O
group NN NN O
A NN NN O
was NN NN O
higher NN NN O
than NN NN O
10 NN NN O
% NN NN O
( NN NN O
1 NN NN O
/ NN NN O
10 NN NN O
) NN NN O
in NN NN O
group NN NN O
B NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
051 NN NN O
) NN NN O
, NN NN O
with NN NN O
slight NN NN O
significance NN NN O
. NN NN O
   
With NN NN O
respect NN NN O
to NN NN O
hemoglobin NN NN O
level NN NN O
at NN NN O
the NN NN O
time NN NN O
of NN NN O
ribavirin NN NN O
reduction NN NN O
, NN NN O
a NN NN O
rate NN NN O
of NN NN O
continuation NN NN O
of NN NN O
therapy NN NN O
in NN NN O
patients NN NN O
with NN NN O
> NN NN O
or NN NN O
= NN NN O
10 NN NN O
g NN NN O
/ NN NN O
dl NN NN O
hemoglobin NN NN O
was NN NN O
higher NN NN O
than NN NN O
that NN NN O
in NN NN O
patients NN NN O
with NN NN O
< NN NN O
10 NN NN O
g NN NN O
/ NN NN O
dl NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
036 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Reduction NN NN O
of NN NN O
ribavirin NN NN O
at NN NN O
hemoglobin NN NN O
level NN NN O
> NN NN O
or NN NN O
= NN NN O
10 NN NN O
g NN NN O
/ NN NN O
dl NN NN O
is NN NN O
suitable NN NN O
in NN NN O
terms NN NN O
of NN NN O
efficacy NN NN O
and NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
Aging NN NN O
process NN NN O
of NN NN O
epithelial NN NN O
cells NN NN O
of NN NN O
the NN NN O
rat NN NN O
prostate NN NN O
lateral NN NN O
lobe NN NN O
in NN NN O
experimental NN NN O
hyperprolactinemia NN NN B-Disease
induced NN NN O
by NN NN O
haloperidol NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
study NN NN O
was NN NN O
to NN NN O
examine NN NN O
the NN NN O
influence NN NN O
of NN NN O
hyperprolactinemia NN NN B-Disease
, NN NN O
induced NN NN O
by NN NN O
haloperidol NN NN O
( NN NN O
HAL NN NN O
) NN NN O
on NN NN O
age NN NN O
related NN NN O
morphology NN NN O
and NN NN O
function NN NN O
changes NN NN O
of NN NN O
epithelial NN NN O
cells NN NN O
in NN NN O
rat NN NN O
prostate NN NN O
lateral NN NN O
lobe NN NN O
. NN NN O
   
The NN NN O
study NN NN O
was NN NN O
performed NN NN O
on NN NN O
sexually NN NN O
mature NN NN O
male NN NN O
rats NN NN O
. NN NN O
   
Serum NN NN O
concentrations NN NN O
of NN NN O
prolactin NN NN O
( NN NN O
PRL NN NN O
) NN NN O
and NN NN O
testosterone NN NN O
( NN NN O
T NN NN O
) NN NN O
were NN NN O
measured NN NN O
. NN NN O
   
Tissue NN NN O
sections NN NN O
were NN NN O
evaluated NN NN O
with NN NN O
light NN NN O
and NN NN O
electron NN NN O
microscopy NN NN O
. NN NN O
   
Immunohistochemical NN NN O
reactions NN NN O
for NN NN O
Anti NN NN O
- NN NN O
Proliferating NN NN O
Cell NN NN O
Nuclear NN NN O
Antigen NN NN O
( NN NN O
PCNA NN NN O
) NN NN O
were NN NN O
performed NN NN O
. NN NN O
   
In NN NN O
rats NN NN O
of NN NN O
the NN NN O
experimental NN NN O
group NN NN O
, NN NN O
the NN NN O
mean NN NN O
concentration NN NN O
of NN NN O
: NN NN O
PRL NN NN O
was NN NN O
more NN NN O
than NN NN O
twice NN NN O
higher NN NN O
, NN NN O
whereas NN NN O
T NN NN O
concentration NN NN O
was NN NN O
almost NN NN O
twice NN NN O
lower NN NN O
than NN NN O
that NN NN O
in NN NN O
the NN NN O
control NN NN O
group NN NN O
. NN NN O
   
Light NN NN O
microscopy NN NN O
visualized NN NN O
the NN NN O
following NN NN O
: NN NN O
hypertrophy NN NN B-Disease
and NN NN O
epithelium NN NN O
hyperplasia NN NN B-Disease
of NN NN O
the NN NN O
glandular NN NN O
ducts NN NN O
, NN NN O
associated NN NN O
with NN NN O
increased NN NN O
PCNA NN NN O
expression NN NN O
. NN NN O
   
Electron NN NN O
microscopy NN NN O
revealed NN NN O
changes NN NN O
in NN NN O
columnar NN NN O
epithelial NN NN O
cells NN NN O
, NN NN O
concerning NN NN O
organelles NN NN O
, NN NN O
engaged NN NN O
in NN NN O
protein NN NN O
synthesis NN NN O
and NN NN O
secretion NN NN O
. NN NN O
   
Relation NN NN O
of NN NN O
perfusion NN NN O
defects NN NN O
observed NN NN O
with NN NN O
myocardial NN NN O
contrast NN NN O
echocardiography NN NN O
to NN NN O
the NN NN O
severity NN NN O
of NN NN O
coronary NN NN B-Disease
stenosis NN NN I-Disease
: NN NN O
correlation NN NN O
with NN NN O
thallium NN NN O
- NN NN O
201 NN NN O
single NN NN O
- NN NN O
photon NN NN O
emission NN NN O
tomography NN NN O
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
previously NN NN O
shown NN NN O
that NN NN O
myocardial NN NN O
contrast NN NN O
echocardiography NN NN O
is NN NN O
a NN NN O
valuable NN NN O
technique NN NN O
for NN NN O
delineating NN NN O
regions NN NN O
of NN NN O
myocardial NN NN O
underperfusion NN NN O
secondary NN NN O
to NN NN O
coronary NN NN B-Disease
occlusion NN NN I-Disease
and NN NN O
to NN NN O
critical NN NN O
coronary NN NN B-Disease
stenoses NN NN I-Disease
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
hyperemic NN NN B-Disease
stimulation NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
whether NN NN O
myocardial NN NN O
contrast NN NN O
echocardiography NN NN O
performed NN NN O
with NN NN O
a NN NN O
stable NN NN O
solution NN NN O
of NN NN O
sonicated NN NN O
albumin NN NN O
could NN NN O
detect NN NN O
regions NN NN O
of NN NN O
myocardial NN NN O
underperfusion NN NN O
resulting NN NN O
from NN NN O
various NN NN O
degrees NN NN O
of NN NN O
coronary NN NN B-Disease
stenosis NN NN I-Disease
. NN NN O
   
The NN NN O
perfusion NN NN O
defect NN NN O
produced NN NN O
in NN NN O
16 NN NN O
open NN NN O
chest NN NN O
dogs NN NN O
was NN NN O
compared NN NN O
with NN NN O
the NN NN O
anatomic NN NN O
area NN NN O
at NN NN O
risk NN NN O
measured NN NN O
by NN NN O
the NN NN O
postmortem NN NN O
dual NN NN O
- NN NN O
perfusion NN NN O
technique NN NN O
and NN NN O
with NN NN O
thallium NN NN O
- NN NN O
201 NN NN O
single NN NN O
- NN NN O
photon NN NN O
emission NN NN O
tomography NN NN O
( NN NN O
SPECT NN NN O
) NN NN O
. NN NN O
   
During NN NN O
a NN NN O
transient NN NN O
( NN NN O
20 NN NN O
- NN NN O
s NN NN O
) NN NN O
coronary NN NN B-Disease
occlusion NN NN I-Disease
, NN NN O
a NN NN O
perfusion NN NN O
defect NN NN O
was NN NN O
observed NN NN O
with NN NN O
contrast NN NN O
echocardiography NN NN O
in NN NN O
14 NN NN O
of NN NN O
the NN NN O
15 NN NN O
dogs NN NN O
in NN NN O
which NN NN O
the NN NN O
occlusion NN NN O
was NN NN O
produced NN NN O
. NN NN O
   
The NN NN O
perfusion NN NN O
defect NN NN O
correlated NN NN O
significantly NN NN O
with NN NN O
the NN NN O
anatomic NN NN O
area NN NN O
at NN NN O
risk NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
74 NN NN O
; NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
002 NN NN O
) NN NN O
. NN NN O
   
During NN NN O
dipyridamole NN NN O
- NN NN O
induced NN NN O
hyperemia NN NN B-Disease
, NN NN O
12 NN NN O
of NN NN O
the NN NN O
16 NN NN O
dogs NN NN O
with NN NN O
a NN NN O
partial NN NN O
coronary NN NN B-Disease
stenosis NN NN I-Disease
had NN NN O
a NN NN O
visible NN NN O
area NN NN O
of NN NN O
hypoperfusion NN NN O
by NN NN O
contrast NN NN O
echocardiography NN NN O
. NN NN O
   
The NN NN O
four NN NN O
dogs NN NN O
without NN NN O
a NN NN O
perfusion NN NN O
defect NN NN O
had NN NN O
a NN NN O
stenosis NN NN O
that NN NN O
resulted NN NN O
in NN NN O
a NN NN O
mild NN NN O
( NN NN O
0 NN NN O
% NN NN O
to NN NN O
50 NN NN O
% NN NN O
) NN NN O
reduction NN NN O
in NN NN O
dipyridamole NN NN O
- NN NN O
induced NN NN O
hyperemia NN NN B-Disease
. NN NN O
   
The NN NN O
size NN NN O
of NN NN O
the NN NN O
perfusion NN NN O
defect NN NN O
during NN NN O
stenosis NN NN O
correlated NN NN O
significantly NN NN O
with NN NN O
the NN NN O
anatomic NN NN O
area NN NN O
at NN NN O
risk NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
61 NN NN O
; NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
02 NN NN O
) NN NN O
. NN NN O
   
Thallium NN NN O
- NN NN O
201 NN NN O
SPECT NN NN O
demonstrated NN NN O
a NN NN O
perfusion NN NN O
defect NN NN O
in NN NN O
all NN NN O
14 NN NN O
dogs NN NN O
analyzed NN NN O
during NN NN O
dipyridamole NN NN O
- NN NN O
induced NN NN O
hyperemia NN NN B-Disease
; NN NN O
the NN NN O
size NN NN O
of NN NN O
the NN NN O
perfusion NN NN O
defect NN NN O
correlated NN NN O
with NN NN O
the NN NN O
anatomic NN NN O
area NN NN O
at NN NN O
risk NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
58 NN NN O
; NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
03 NN NN O
) NN NN O
and NN NN O
with NN NN O
the NN NN O
perfusion NN NN O
defect NN NN O
by NN NN O
contrast NN NN O
echocardiography NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
58 NN NN O
; NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
03 NN NN O
) NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
myocardial NN NN O
contrast NN NN O
echocardiography NN NN O
can NN NN O
be NN NN O
used NN NN O
to NN NN O
visualize NN NN O
and NN NN O
quantitate NN NN O
the NN NN O
amount NN NN O
of NN NN O
jeopardized NN NN O
myocardium NN NN O
during NN NN O
moderate NN NN O
to NN NN O
severe NN NN O
degrees NN NN O
of NN NN O
coronary NN NN B-Disease
stenosis NN NN I-Disease
. NN NN O
   
The NN NN O
results NN NN O
obtained NN NN O
show NN NN O
a NN NN O
correlation NN NN O
with NN NN O
the NN NN O
anatomic NN NN O
area NN NN O
at NN NN O
risk NN NN O
similar NN NN O
to NN NN O
that NN NN O
obtained NN NN O
with NN NN O
thallium NN NN O
- NN NN O
201 NN NN O
SPECT NN NN O
. NN NN O
   
The NN NN O
activation NN NN O
of NN NN O
spinal NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
D NN NN O
- NN NN O
aspartate NN NN O
receptors NN NN O
may NN NN O
contribute NN NN O
to NN NN O
degeneration NN NN O
of NN NN O
spinal NN NN O
motor NN NN O
neurons NN NN O
induced NN NN O
by NN NN O
neuraxial NN NN O
morphine NN NN O
after NN NN O
a NN NN O
noninjurious NN NN O
interval NN NN O
of NN NN O
spinal NN NN B-Disease
cord NN NN I-Disease
ischemia NN NN I-Disease
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
relationship NN NN O
between NN NN O
the NN NN O
degeneration NN NN O
of NN NN O
spinal NN NN O
motor NN NN O
neurons NN NN O
and NN NN O
activation NN NN O
of NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
d NN NN O
- NN NN O
aspartate NN NN O
( NN NN O
NMDA NN NN O
) NN NN O
receptors NN NN O
after NN NN O
neuraxial NN NN O
morphine NN NN O
following NN NN O
a NN NN O
noninjurious NN NN O
interval NN NN O
of NN NN O
aortic NN NN B-Disease
occlusion NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Spinal NN NN B-Disease
cord NN NN I-Disease
ischemia NN NN I-Disease
was NN NN O
induced NN NN O
by NN NN O
aortic NN NN B-Disease
occlusion NN NN I-Disease
for NN NN O
6 NN NN O
min NN NN O
with NN NN O
a NN NN O
balloon NN NN O
catheter NN NN O
. NN NN O
   
In NN NN O
a NN NN O
microdialysis NN NN O
study NN NN O
, NN NN O
10 NN NN O
muL NN NN O
of NN NN O
saline NN NN O
( NN NN O
group NN NN O
C NN NN O
; NN NN O
n NN NN O
= NN NN O
8 NN NN O
) NN NN O
or NN NN O
30 NN NN O
mug NN NN O
of NN NN O
morphine NN NN O
( NN NN O
group NN NN O
M NN NN O
; NN NN O
n NN NN O
= NN NN O
8 NN NN O
) NN NN O
was NN NN O
injected NN NN O
intrathecally NN NN O
( NN NN O
IT NN NN O
) NN NN O
0 NN NN O
. NN NN O
5 NN NN O
h NN NN O
after NN NN O
reflow NN NN O
, NN NN O
and NN NN O
30 NN NN O
mug NN NN O
of NN NN O
morphine NN NN O
( NN NN O
group NN NN O
SM NN NN O
; NN NN O
n NN NN O
= NN NN O
8 NN NN O
) NN NN O
or NN NN O
10 NN NN O
muL NN NN O
of NN NN O
saline NN NN O
( NN NN O
group NN NN O
SC NN NN O
; NN NN O
n NN NN O
= NN NN O
8 NN NN O
) NN NN O
was NN NN O
injected NN NN O
IT NN NN O
0 NN NN O
. NN NN O
5 NN NN O
h NN NN O
after NN NN O
sham NN NN O
operation NN NN O
. NN NN O
   
Microdialysis NN NN O
samples NN NN O
were NN NN O
collected NN NN O
preischemia NN NN O
, NN NN O
before NN NN O
IT NN NN O
injection NN NN O
, NN NN O
and NN NN O
at NN NN O
2 NN NN O
, NN NN O
4 NN NN O
, NN NN O
8 NN NN O
, NN NN O
24 NN NN O
, NN NN O
and NN NN O
48 NN NN O
h NN NN O
of NN NN O
reperfusion NN NN O
( NN NN O
after NN NN O
IT NN NN O
injection NN NN O
) NN NN O
. NN NN O
   
Second NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
effect NN NN O
of NN NN O
IT NN NN O
MK NN NN O
- NN NN O
801 NN NN O
( NN NN O
30 NN NN O
mug NN NN O
) NN NN O
on NN NN O
the NN NN O
histopathologic NN NN O
changes NN NN O
in NN NN O
the NN NN O
spinal NN NN O
cord NN NN O
after NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
spastic NN NN B-Disease
paraparesis NN NN I-Disease
. NN NN O
   
After NN NN O
IT NN NN O
morphine NN NN O
, NN NN O
the NN NN O
cerebrospinal NN NN O
fluid NN NN O
( NN NN O
CSF NN NN O
) NN NN O
glutamate NN NN O
concentration NN NN O
was NN NN O
increased NN NN O
in NN NN O
group NN NN O
M NN NN O
relative NN NN O
to NN NN O
both NN NN O
baseline NN NN O
and NN NN O
group NN NN O
C NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
This NN NN O
increase NN NN O
persisted NN NN O
for NN NN O
8 NN NN O
hrs NN NN O
. NN NN O
   
IT NN NN O
MK NN NN O
- NN NN O
801 NN NN O
significantly NN NN O
reduced NN NN O
the NN NN O
number NN NN O
of NN NN O
dark NN NN O
- NN NN O
stained NN NN O
alpha NN NN O
- NN NN O
motoneurons NN NN O
after NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
spastic NN NN B-Disease
paraparesis NN NN I-Disease
compared NN NN O
with NN NN O
the NN NN O
saline NN NN O
group NN NN O
. NN NN O
   
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
IT NN NN O
morphine NN NN O
induces NN NN O
spastic NN NN B-Disease
paraparesis NN NN I-Disease
with NN NN O
a NN NN O
concomitant NN NN O
increase NN NN O
in NN NN O
CSF NN NN O
glutamate NN NN O
, NN NN O
which NN NN O
is NN NN O
involved NN NN O
in NN NN O
NMDA NN NN O
receptor NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
suggest NN NN O
that NN NN O
opioids NN NN O
may NN NN O
be NN NN O
neurotoxic NN NN B-Disease
in NN NN O
the NN NN O
setting NN NN O
of NN NN O
spinal NN NN B-Disease
cord NN NN I-Disease
ischemia NN NN I-Disease
via NN NN O
NMDA NN NN O
receptor NN NN O
activation NN NN O
. NN NN O
   
Acute NN NN O
low NN NN B-Disease
back NN NN I-Disease
pain NN NN I-Disease
during NN NN O
intravenous NN NN O
administration NN NN O
of NN NN O
amiodarone NN NN O
: NN NN O
a NN NN O
report NN NN O
of NN NN O
two NN NN O
cases NN NN O
. NN NN O
   
Amiodarone NN NN O
represents NN NN O
an NN NN O
effective NN NN O
antiarrhythmic NN NN O
drug NN NN O
for NN NN O
cardioversion NN NN O
of NN NN O
recent NN NN O
- NN NN O
onset NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
( NN NN O
AF NN NN B-Disease
) NN NN O
and NN NN O
maintenance NN NN O
of NN NN O
sinus NN NN O
rhythm NN NN O
. NN NN O
   
We NN NN O
briefly NN NN O
describe NN NN O
two NN NN O
patients NN NN O
suffering NN NN O
from NN NN O
recent NN NN O
- NN NN O
onset NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
, NN NN O
who NN NN O
experienced NN NN O
an NN NN O
acute NN NN O
devastating NN NN O
low NN NN B-Disease
back NN NN I-Disease
pain NN NN I-Disease
a NN NN O
few NN NN O
minutes NN NN O
after NN NN O
initiation NN NN O
of NN NN O
intravenous NN NN O
amiodarone NN NN O
loading NN NN O
. NN NN O
   
Notably NN NN O
, NN NN O
this NN NN O
side NN NN O
effect NN NN O
has NN NN O
not NN NN O
been NN NN O
ever NN NN O
reported NN NN O
in NN NN O
the NN NN O
medical NN NN O
literature NN NN O
. NN NN O
   
Clinicians NN NN O
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
this NN NN O
reaction NN NN O
since NN NN O
prompt NN NN O
termination NN NN O
of NN NN O
parenteral NN NN O
administration NN NN O
leads NN NN O
to NN NN O
complete NN NN O
resolution NN NN O
. NN NN O
   
Quantitative NN NN O
drug NN NN O
levels NN NN O
in NN NN O
stimulant NN NN O
psychosis NN NN B-Disease
: NN NN O
relationship NN NN O
to NN NN O
symptom NN NN O
severity NN NN O
, NN NN O
catecholamines NN NN O
and NN NN O
hyperkinesia NN NN B-Disease
. NN NN O
   
To NN NN O
examine NN NN O
the NN NN O
relationship NN NN O
between NN NN O
quantitative NN NN O
stimulant NN NN O
drug NN NN O
levels NN NN O
, NN NN O
catecholamines NN NN O
, NN NN O
and NN NN O
psychotic NN NN B-Disease
symptoms NN NN I-Disease
, NN NN O
nineteen NN NN O
patients NN NN O
in NN NN O
a NN NN O
psychiatric NN NN B-Disease
emergency NN NN O
service NN NN O
with NN NN O
a NN NN O
diagnosis NN NN O
of NN NN O
amphetamine NN NN O
- NN NN O
or NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
psychosis NN NN B-Disease
were NN NN O
interviewed NN NN O
, NN NN O
and NN NN O
plasma NN NN O
and NN NN O
urine NN NN O
were NN NN O
collected NN NN O
for NN NN O
quantitative NN NN O
assays NN NN O
of NN NN O
stimulant NN NN O
drug NN NN O
and NN NN O
catecholamine NN NN O
metabolite NN NN O
levels NN NN O
. NN NN O
   
Methamphetamine NN NN O
or NN NN O
amphetamine NN NN O
levels NN NN O
were NN NN O
related NN NN O
to NN NN O
several NN NN O
psychopathology NN NN O
scores NN NN O
and NN NN O
the NN NN O
global NN NN O
hyperkinesia NN NN B-Disease
rating NN NN O
. NN NN O
   
HVA NN NN O
levels NN NN O
were NN NN O
related NN NN O
to NN NN O
global NN NN O
hyperkinesia NN NN B-Disease
but NN NN O
not NN NN O
to NN NN O
psychopathology NN NN O
ratings NN NN O
. NN NN O
   
Although NN NN O
many NN NN O
other NN NN O
factors NN NN O
such NN NN O
as NN NN O
sensitization NN NN O
may NN NN O
play NN NN O
a NN NN O
role NN NN O
, NN NN O
intensity NN NN O
of NN NN O
stimulant NN NN O
- NN NN O
induced NN NN O
psychotic NN NN B-Disease
symptoms NN NN I-Disease
and NN NN O
stereotypies NN NN B-Disease
appears NN NN O
to NN NN O
be NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
dose NN NN O
- NN NN O
related NN NN O
. NN NN O
   
Pheochromocytoma NN NN B-Disease
unmasked NN NN O
by NN NN O
amisulpride NN NN O
and NN NN O
tiapride NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
describe NN NN O
the NN NN O
unmasking NN NN O
of NN NN O
pheochromocytoma NN NN B-Disease
in NN NN O
a NN NN O
patient NN NN O
treated NN NN O
with NN NN O
amisulpride NN NN O
and NN NN O
tiapride NN NN O
. NN NN O
   
CASE NN NN O
SUMMARY NN NN O
: NN NN O
A NN NN O
42 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
white NN NN O
man NN NN O
developed NN NN O
acute NN NN O
hypertension NN NN B-Disease
with NN NN O
severe NN NN O
headache NN NN B-Disease
and NN NN O
vomiting NN NN B-Disease
2 NN NN O
hours NN NN O
after NN NN O
the NN NN O
first NN NN O
doses NN NN O
of NN NN O
amisulpride NN NN O
100 NN NN O
mg NN NN O
and NN NN O
tiapride NN NN O
100 NN NN O
mg NN NN O
. NN NN O
   
Both NN NN O
drugs NN NN O
were NN NN O
immediately NN NN O
discontinued NN NN O
, NN NN O
and NN NN O
the NN NN O
patient NN NN O
recovered NN NN O
after NN NN O
subsequent NN NN O
nicardipine NN NN O
and NN NN O
verapamil NN NN O
treatment NN NN O
. NN NN O
   
Abdominal NN NN O
ultrasound NN NN O
showed NN NN O
an NN NN O
adrenal NN NN O
mass NN NN O
, NN NN O
and NN NN O
postoperative NN NN O
histologic NN NN O
examination NN NN O
confirmed NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
pheochromocytoma NN NN B-Disease
. NN NN O
   
DISCUSSION NN NN O
: NN NN O
Drug NN NN O
- NN NN O
induced NN NN O
symptoms NN NN O
of NN NN O
pheochromocytoma NN NN B-Disease
are NN NN O
often NN NN O
associated NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
substituted NN NN O
benzamide NN NN O
drugs NN NN O
, NN NN O
but NN NN O
the NN NN O
underlying NN NN O
mechanism NN NN O
is NN NN O
unknown NN NN O
. NN NN O
   
In NN NN O
our NN NN O
case NN NN O
, NN NN O
use NN NN O
of NN NN O
the NN NN O
Naranjo NN NN O
probability NN NN O
scale NN NN O
indicated NN NN O
a NN NN O
possible NN NN O
relationship NN NN O
between NN NN O
the NN NN O
hypertensive NN NN B-Disease
crisis NN NN O
and NN NN O
amisulpride NN NN O
and NN NN O
tiapride NN NN O
therapy NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
As NN NN O
of NN NN O
March NN NN O
24 NN NN O
, NN NN O
2005 NN NN O
, NN NN O
this NN NN O
is NN NN O
the NN NN O
first NN NN O
reported NN NN O
case NN NN O
of NN NN O
amisulpride NN NN O
- NN NN O
and NN NN O
tiapride NN NN O
- NN NN O
induced NN NN O
hypertensive NN NN B-Disease
crisis NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
pheochromocytoma NN NN B-Disease
. NN NN O
   
Physicians NN NN O
and NN NN O
other NN NN O
healthcare NN NN O
professionals NN NN O
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
this NN NN O
potential NN NN O
adverse NN NN O
effect NN NN O
of NN NN O
tiapride NN NN O
and NN NN O
amisulpride NN NN O
. NN NN O
   
Minor NN NN O
neurological NN NN B-Disease
dysfunction NN NN I-Disease
, NN NN O
cognitive NN NN O
development NN NN O
, NN NN O
and NN NN O
somatic NN NN O
development NN NN O
at NN NN O
the NN NN O
age NN NN O
of NN NN O
3 NN NN O
to NN NN O
7 NN NN O
years NN NN O
after NN NN O
dexamethasone NN NN O
treatment NN NN O
in NN NN O
very NN NN O
- NN NN O
low NN NN O
birth NN NN O
- NN NN O
weight NN NN O
infants NN NN O
. NN NN O
   
The NN NN O
objective NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
assess NN NN O
minor NN NN O
neurological NN NN B-Disease
dysfunction NN NN I-Disease
, NN NN O
cognitive NN NN O
development NN NN O
, NN NN O
and NN NN O
somatic NN NN O
development NN NN O
after NN NN O
dexamethasone NN NN O
therapy NN NN O
in NN NN O
very NN NN O
- NN NN O
low NN NN O
- NN NN O
birthweight NN NN O
infants NN NN O
. NN NN O
   
Thirty NN NN O
- NN NN O
three NN NN O
children NN NN O
after NN NN O
dexamethasone NN NN O
treatment NN NN O
were NN NN O
matched NN NN O
to NN NN O
33 NN NN O
children NN NN O
without NN NN O
dexamethasone NN NN O
treatment NN NN O
. NN NN O
   
Data NN NN O
were NN NN O
assessed NN NN O
at NN NN O
the NN NN O
age NN NN O
of NN NN O
3 NN NN O
- NN NN O
7 NN NN O
years NN NN O
. NN NN O
   
Dexamethasone NN NN O
was NN NN O
started NN NN O
between NN NN O
the NN NN O
7th NN NN O
and NN NN O
the NN NN O
28th NN NN O
day NN NN O
of NN NN O
life NN NN O
over NN NN O
7 NN NN O
days NN NN O
with NN NN O
a NN NN O
total NN NN O
dose NN NN O
of NN NN O
2 NN NN O
. NN NN O
35 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
. NN NN O
   
Exclusion NN NN O
criteria NN NN O
were NN NN O
asphyxia NN NN B-Disease
, NN NN O
malformations NN NN B-Disease
, NN NN O
major NN NN O
surgical NN NN O
interventions NN NN O
, NN NN O
small NN NN O
for NN NN O
gestational NN NN O
age NN NN O
, NN NN O
intraventricular NN NN O
haemorrhage NN NN B-Disease
grades NN NN O
III NN NN O
and NN NN O
IV NN NN O
, NN NN O
periventricular NN NN B-Disease
leukomalacia NN NN I-Disease
, NN NN O
and NN NN O
severe NN NN O
psychomotor NN NN B-Disease
retardation NN NN I-Disease
. NN NN O
   
Each NN NN O
child NN NN O
was NN NN O
examined NN NN O
by NN NN O
a NN NN O
neuropediatrician NN NN O
for NN NN O
minor NN NN O
neurological NN NN B-Disease
dysfunctions NN NN I-Disease
and NN NN O
tested NN NN O
by NN NN O
a NN NN O
psychologist NN NN O
for NN NN O
cognitive NN NN O
development NN NN O
with NN NN O
a NN NN O
Kaufman NN NN O
Assessment NN NN O
Battery NN NN O
for NN NN O
Children NN NN O
and NN NN O
a NN NN O
Draw NN NN O
- NN NN O
a NN NN O
- NN NN O
Man NN NN O
Test NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
differences NN NN O
in NN NN O
demographic NN NN O
data NN NN O
, NN NN O
growth NN NN O
, NN NN O
and NN NN O
socio NN NN O
- NN NN O
economic NN NN O
status NN NN O
between NN NN O
the NN NN O
two NN NN O
groups NN NN O
. NN NN O
   
Fine NN NN O
motor NN NN O
skills NN NN O
and NN NN O
gross NN NN O
motor NN NN O
function NN NN O
were NN NN O
significantly NN NN O
better NN NN O
in NN NN O
the NN NN O
control NN NN O
group NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
Draw NN NN O
- NN NN O
a NN NN O
- NN NN O
Man NN NN O
Test NN NN O
, NN NN O
the NN NN O
control NN NN O
group NN NN O
showed NN NN O
better NN NN O
results NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
differences NN NN O
in NN NN O
development NN NN O
of NN NN O
speech NN NN O
, NN NN O
social NN NN O
development NN NN O
, NN NN O
and NN NN O
the NN NN O
Kaufman NN NN O
Assessment NN NN O
Battery NN NN O
for NN NN O
Children NN NN O
. NN NN O
   
After NN NN O
dexamethasone NN NN O
treatment NN NN O
, NN NN O
children NN NN O
showed NN NN O
a NN NN O
higher NN NN O
rate NN NN O
of NN NN O
minor NN NN O
neurological NN NN B-Disease
dysfunctions NN NN I-Disease
. NN NN O
   
Neurological NN NN O
development NN NN O
was NN NN O
affected NN NN O
even NN NN O
without NN NN O
neurological NN NN O
diagnosis NN NN O
. NN NN O
   
Further NN NN O
long NN NN O
- NN NN O
term NN NN O
follow NN NN O
- NN NN O
up NN NN O
studies NN NN O
will NN NN O
be NN NN O
necessary NN NN O
to NN NN O
fully NN NN O
evaluate NN NN O
the NN NN O
impact NN NN O
of NN NN O
dexamethasone NN NN O
on NN NN O
neurological NN NN O
and NN NN O
cognitive NN NN O
development NN NN O
. NN NN O
   
Valproic NN NN O
acid NN NN O
I NN NN O
: NN NN O
time NN NN O
course NN NN O
of NN NN O
lipid NN NN O
peroxidation NN NN O
biomarkers NN NN O
, NN NN O
liver NN NN B-Disease
toxicity NN NN I-Disease
, NN NN O
and NN NN O
valproic NN NN O
acid NN NN O
metabolite NN NN O
levels NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
A NN NN O
single NN NN O
dose NN NN O
of NN NN O
valproic NN NN O
acid NN NN O
( NN NN O
VPA NN NN O
) NN NN O
, NN NN O
which NN NN O
is NN NN O
a NN NN O
widely NN NN O
used NN NN O
antiepileptic NN NN O
drug NN NN O
, NN NN O
is NN NN O
associated NN NN O
with NN NN O
oxidative NN NN O
stress NN NN O
in NN NN O
rats NN NN O
, NN NN O
as NN NN O
recently NN NN O
demonstrated NN NN O
by NN NN O
elevated NN NN O
levels NN NN O
of NN NN O
15 NN NN O
- NN NN O
F NN NN O
( NN NN O
2t NN NN O
) NN NN O
- NN NN O
isoprostane NN NN O
( NN NN O
15 NN NN O
- NN NN O
F NN NN O
( NN NN O
2t NN NN O
) NN NN O
- NN NN O
IsoP NN NN O
) NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
whether NN NN O
there NN NN O
was NN NN O
a NN NN O
temporal NN NN O
relationship NN NN O
between NN NN O
VPA NN NN O
- NN NN O
associated NN NN O
oxidative NN NN O
stress NN NN O
and NN NN O
hepatotoxicity NN NN B-Disease
, NN NN O
adult NN NN O
male NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
were NN NN O
treated NN NN O
ip NN NN O
with NN NN O
VPA NN NN O
( NN NN O
500 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
or NN NN O
0 NN NN O
. NN NN O
9 NN NN O
% NN NN O
saline NN NN O
( NN NN O
vehicle NN NN O
) NN NN O
once NN NN O
daily NN NN O
for NN NN O
2 NN NN O
, NN NN O
4 NN NN O
, NN NN O
7 NN NN O
, NN NN O
10 NN NN O
, NN NN O
or NN NN O
14 NN NN O
days NN NN O
. NN NN O
   
Oxidative NN NN O
stress NN NN O
was NN NN O
assessed NN NN O
by NN NN O
determining NN NN O
plasma NN NN O
and NN NN O
liver NN NN O
levels NN NN O
of NN NN O
15 NN NN O
- NN NN O
F NN NN O
( NN NN O
2t NN NN O
) NN NN O
- NN NN O
IsoP NN NN O
, NN NN O
lipid NN NN O
hydroperoxides NN NN O
( NN NN O
LPO NN NN O
) NN NN O
, NN NN O
and NN NN O
thiobarbituric NN NN O
acid NN NN O
reactive NN NN O
substances NN NN O
( NN NN O
TBARs NN NN O
) NN NN O
. NN NN O
   
Plasma NN NN O
and NN NN O
liver NN NN O
15 NN NN O
- NN NN O
F NN NN O
( NN NN O
2t NN NN O
) NN NN O
- NN NN O
IsoP NN NN O
were NN NN O
elevated NN NN O
and NN NN O
reached NN NN O
a NN NN O
plateau NN NN O
after NN NN O
day NN NN O
2 NN NN O
of NN NN O
VPA NN NN O
treatment NN NN O
compared NN NN O
to NN NN O
control NN NN O
. NN NN O
   
Liver NN NN O
LPO NN NN O
levels NN NN O
were NN NN O
not NN NN O
elevated NN NN O
until NN NN O
day NN NN O
7 NN NN O
of NN NN O
treatment NN NN O
( NN NN O
1 NN NN O
. NN NN O
8 NN NN O
- NN NN O
fold NN NN O
versus NN NN O
control NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Liver NN NN O
and NN NN O
plasma NN NN O
TBARs NN NN O
were NN NN O
not NN NN O
increased NN NN O
until NN NN O
14 NN NN O
days NN NN O
( NN NN O
2 NN NN O
- NN NN O
fold NN NN O
vs NN NN O
. NN NN O
control NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Liver NN NN B-Disease
toxicity NN NN I-Disease
was NN NN O
evaluated NN NN O
based NN NN O
on NN NN O
serum NN NN O
levels NN NN O
of NN NN O
alpha NN NN O
- NN NN O
glutathione NN NN O
S NN NN O
- NN NN O
transferase NN NN O
( NN NN O
alpha NN NN O
- NN NN O
GST NN NN O
) NN NN O
and NN NN O
by NN NN O
histology NN NN O
. NN NN O
   
Serum NN NN O
alpha NN NN O
- NN NN O
GST NN NN O
levels NN NN O
were NN NN O
significantly NN NN O
elevated NN NN O
by NN NN O
day NN NN O
4 NN NN O
, NN NN O
which NN NN O
corresponded NN NN O
to NN NN O
hepatotoxicity NN NN B-Disease
as NN NN O
shown NN NN O
by NN NN O
the NN NN O
increasing NN NN O
incidence NN NN O
of NN NN O
inflammation NN NN B-Disease
of NN NN O
the NN NN O
liver NN NN O
capsule NN NN O
, NN NN O
necrosis NN NN B-Disease
, NN NN O
and NN NN O
steatosis NN NN B-Disease
throughout NN NN O
the NN NN O
study NN NN O
. NN NN O
   
The NN NN O
liver NN NN O
levels NN NN O
of NN NN O
beta NN NN O
- NN NN O
oxidation NN NN O
metabolites NN NN O
of NN NN O
VPA NN NN O
were NN NN O
decreased NN NN O
by NN NN O
day NN NN O
14 NN NN O
, NN NN O
while NN NN O
the NN NN O
levels NN NN O
of NN NN O
4 NN NN O
- NN NN O
ene NN NN O
- NN NN O
VPA NN NN O
and NN NN O
( NN NN O
E NN NN O
) NN NN O
- NN NN O
2 NN NN O
, NN NN O
4 NN NN O
- NN NN O
diene NN NN O
- NN NN O
VPA NN NN O
were NN NN O
not NN NN O
elevated NN NN O
throughout NN NN O
the NN NN O
study NN NN O
. NN NN O
   
Overall NN NN O
, NN NN O
these NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
VPA NN NN O
treatment NN NN O
results NN NN O
in NN NN O
oxidative NN NN O
stress NN NN O
, NN NN O
as NN NN O
measured NN NN O
by NN NN O
levels NN NN O
of NN NN O
15 NN NN O
- NN NN O
F NN NN O
( NN NN O
2t NN NN O
) NN NN O
- NN NN O
IsoP NN NN O
, NN NN O
which NN NN O
precedes NN NN O
the NN NN O
onset NN NN O
of NN NN O
necrosis NN NN B-Disease
, NN NN O
steatosis NN NN B-Disease
, NN NN O
and NN NN O
elevated NN NN O
levels NN NN O
of NN NN O
serum NN NN O
alpha NN NN O
- NN NN O
GST NN NN O
. NN NN O
   
Assessment NN NN O
of NN NN O
perinatal NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
and NN NN O
rubella NN NN B-Disease
prevention NN NN O
in NN NN O
New NN NN O
Hampshire NN NN O
delivery NN NN O
hospitals NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
evaluate NN NN O
current NN NN O
performance NN NN O
on NN NN O
recommended NN NN O
perinatal NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
and NN NN O
rubella NN NN B-Disease
prevention NN NN O
practices NN NN O
in NN NN O
New NN NN O
Hampshire NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Data NN NN O
were NN NN O
extracted NN NN O
from NN NN O
2021 NN NN O
paired NN NN O
mother NN NN O
- NN NN O
infant NN NN O
records NN NN O
for NN NN O
the NN NN O
year NN NN O
2000 NN NN O
birth NN NN O
cohort NN NN O
in NN NN O
New NN NN O
Hampshire NN NN O
' NN NN O
s NN NN O
25 NN NN O
delivery NN NN O
hospitals NN NN O
. NN NN O
   
Assessment NN NN O
was NN NN O
done NN NN O
on NN NN O
the NN NN O
following NN NN O
: NN NN O
prenatal NN NN O
screening NN NN O
for NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
and NN NN O
rubella NN NN B-Disease
, NN NN O
administration NN NN O
of NN NN O
the NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
vaccine NN NN O
birth NN NN O
dose NN NN O
to NN NN O
all NN NN O
infants NN NN O
, NN NN O
administration NN NN O
of NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
immune NN NN O
globulin NN NN O
to NN NN O
infants NN NN O
who NN NN O
were NN NN O
born NN NN O
to NN NN O
hepatitis NN NN O
B NN NN O
surface NN NN O
antigen NN NN O
- NN NN O
positive NN NN O
mothers NN NN O
, NN NN O
rubella NN NN B-Disease
immunity NN NN O
, NN NN O
and NN NN O
administration NN NN O
of NN NN O
in NN NN O
- NN NN O
hospital NN NN O
postpartum NN NN O
rubella NN NN B-Disease
vaccine NN NN O
to NN NN O
rubella NN NN B-Disease
nonimmune NN NN O
women NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Prenatal NN NN O
screening NN NN O
rates NN NN O
for NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
( NN NN O
98 NN NN O
. NN NN O
8 NN NN O
% NN NN O
) NN NN O
and NN NN O
rubella NN NN B-Disease
( NN NN O
99 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
were NN NN O
high NN NN O
. NN NN O
   
Hepatitis NN NN B-Disease
B NN NN I-Disease
vaccine NN NN O
birth NN NN O
dose NN NN O
was NN NN O
administered NN NN O
to NN NN O
76 NN NN O
. NN NN O
2 NN NN O
% NN NN O
of NN NN O
all NN NN O
infants NN NN O
. NN NN O
   
All NN NN O
infants NN NN O
who NN NN O
were NN NN O
born NN NN O
to NN NN O
hepatitis NN NN O
B NN NN O
surface NN NN O
antigen NN NN O
- NN NN O
positive NN NN O
mothers NN NN O
also NN NN O
received NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
immune NN NN O
globulin NN NN O
. NN NN O
   
Multivariate NN NN O
logistic NN NN O
regression NN NN O
showed NN NN O
that NN NN O
the NN NN O
month NN NN O
of NN NN O
delivery NN NN O
and NN NN O
infant NN NN O
birth NN NN O
weight NN NN O
were NN NN O
independent NN NN O
predictors NN NN O
of NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
vaccination NN NN O
. NN NN O
   
The NN NN O
proportion NN NN O
of NN NN O
infants NN NN O
who NN NN O
were NN NN O
vaccinated NN NN O
in NN NN O
January NN NN O
and NN NN O
February NN NN O
2000 NN NN O
( NN NN O
48 NN NN O
. NN NN O
5 NN NN O
% NN NN O
and NN NN O
67 NN NN O
. NN NN O
5 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
) NN NN O
was NN NN O
less NN NN O
than NN NN O
any NN NN O
other NN NN O
months NN NN O
, NN NN O
whereas NN NN O
the NN NN O
proportion NN NN O
who NN NN O
were NN NN O
vaccinated NN NN O
in NN NN O
December NN NN O
2000 NN NN O
( NN NN O
88 NN NN O
. NN NN O
2 NN NN O
% NN NN O
) NN NN O
was NN NN O
the NN NN O
highest NN NN O
. NN NN O
   
Women NN NN O
who NN NN O
were NN NN O
born NN NN O
between NN NN O
1971 NN NN O
and NN NN O
1975 NN NN O
had NN NN O
the NN NN O
highest NN NN O
rate NN NN O
of NN NN O
rubella NN NN B-Disease
nonimmunity NN NN O
( NN NN O
9 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
In NN NN O
- NN NN O
hospital NN NN O
postpartum NN NN O
rubella NN NN B-Disease
vaccine NN NN O
administration NN NN O
was NN NN O
documented NN NN O
for NN NN O
75 NN NN O
. NN NN O
6 NN NN O
% NN NN O
of NN NN O
nonimmune NN NN O
women NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
This NN NN O
study NN NN O
documents NN NN O
good NN NN O
compliance NN NN O
in NN NN O
New NN NN O
Hampshire NN NN O
' NN NN O
s NN NN O
birthing NN NN O
hospitals NN NN O
with NN NN O
national NN NN O
guidelines NN NN O
for NN NN O
perinatal NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
and NN NN O
rubella NN NN B-Disease
prevention NN NN O
and NN NN O
highlights NN NN O
potential NN NN O
areas NN NN O
for NN NN O
improvement NN NN O
. NN NN O
   
Succinylcholine NN NN O
- NN NN O
induced NN NN O
masseter NN NN B-Disease
muscle NN NN I-Disease
rigidity NN NN I-Disease
during NN NN O
bronchoscopic NN NN O
removal NN NN O
of NN NN O
a NN NN O
tracheal NN NN O
foreign NN NN O
body NN NN O
. NN NN O
   
Masseter NN NN B-Disease
muscle NN NN I-Disease
rigidity NN NN I-Disease
during NN NN O
general NN NN O
anesthesia NN NN O
is NN NN O
considered NN NN O
an NN NN O
early NN NN O
warning NN NN O
sign NN NN O
of NN NN O
a NN NN O
possible NN NN O
episode NN NN O
of NN NN O
malignant NN NN B-Disease
hyperthermia NN NN I-Disease
. NN NN O
   
The NN NN O
decision NN NN O
whether NN NN O
to NN NN O
continue NN NN O
or NN NN O
discontinue NN NN O
the NN NN O
procedure NN NN O
depends NN NN O
on NN NN O
the NN NN O
urgency NN NN O
of NN NN O
the NN NN O
surgery NN NN O
and NN NN O
severity NN NN O
of NN NN O
masseter NN NN B-Disease
muscle NN NN I-Disease
rigidity NN NN I-Disease
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
describe NN NN O
a NN NN O
case NN NN O
of NN NN O
severe NN NN O
masseter NN NN B-Disease
muscle NN NN I-Disease
rigidity NN NN I-Disease
( NN NN O
jaw NN NN B-Disease
of NN NN I-Disease
steel NN NN I-Disease
) NN NN O
after NN NN O
succinylcholine NN NN O
( NN NN O
Sch NN NN O
) NN NN O
administration NN NN O
during NN NN O
general NN NN O
anesthetic NN NN O
management NN NN O
for NN NN O
rigid NN NN O
bronchoscopic NN NN O
removal NN NN O
of NN NN O
a NN NN O
tracheal NN NN O
foreign NN NN O
body NN NN O
. NN NN O
   
Anesthesia NN NN O
was NN NN O
continued NN NN O
uneventfully NN NN O
with NN NN O
propofol NN NN O
infusion NN NN O
while NN NN O
all NN NN O
facilities NN NN O
were NN NN O
available NN NN O
to NN NN O
detect NN NN O
and NN NN O
treat NN NN O
malignant NN NN B-Disease
hyperthermia NN NN I-Disease
. NN NN O
   
Dexrazoxane NN NN O
protects NN NN O
against NN NN O
myelosuppression NN NN B-Disease
from NN NN O
the NN NN O
DNA NN NN O
cleavage NN NN O
- NN NN O
enhancing NN NN O
drugs NN NN O
etoposide NN NN O
and NN NN O
daunorubicin NN NN O
but NN NN O
not NN NN O
doxorubicin NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
The NN NN O
anthracyclines NN NN O
daunorubicin NN NN O
and NN NN O
doxorubicin NN NN O
and NN NN O
the NN NN O
epipodophyllotoxin NN NN O
etoposide NN NN O
are NN NN O
potent NN NN O
DNA NN NN O
cleavage NN NN O
- NN NN O
enhancing NN NN O
drugs NN NN O
that NN NN O
are NN NN O
widely NN NN O
used NN NN O
in NN NN O
clinical NN NN O
oncology NN NN O
; NN NN O
however NN NN O
, NN NN O
myelosuppression NN NN B-Disease
and NN NN O
cardiac NN NN B-Disease
toxicity NN NN I-Disease
limit NN NN O
their NN NN O
use NN NN O
. NN NN O
   
Dexrazoxane NN NN O
( NN NN O
ICRF NN NN O
- NN NN O
187 NN NN O
) NN NN O
is NN NN O
recommended NN NN O
for NN NN O
protection NN NN O
against NN NN O
anthracycline NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
EXPERIMENTAL NN NN O
DESIGN NN NN O
: NN NN O
Because NN NN O
of NN NN O
their NN NN O
widespread NN NN O
use NN NN O
, NN NN O
the NN NN O
hematologic NN NN B-Disease
toxicity NN NN I-Disease
following NN NN O
coadministration NN NN O
of NN NN O
dexrazoxane NN NN O
and NN NN O
these NN NN O
three NN NN O
structurally NN NN O
different NN NN O
DNA NN NN O
cleavage NN NN O
enhancers NN NN O
was NN NN O
investigated NN NN O
: NN NN O
Sensitivity NN NN O
of NN NN O
human NN NN O
and NN NN O
murine NN NN O
blood NN NN O
progenitor NN NN O
cells NN NN O
to NN NN O
etoposide NN NN O
, NN NN O
daunorubicin NN NN O
, NN NN O
and NN NN O
doxorubicin NN NN O
+ NN NN O
/ NN NN O
- NN NN O
dexrazoxane NN NN O
was NN NN O
determined NN NN O
in NN NN O
granulocyte NN NN O
- NN NN O
macrophage NN NN O
colony NN NN O
forming NN NN O
assays NN NN O
. NN NN O
   
Likewise NN NN O
, NN NN O
in NN NN O
vivo NN NN O
, NN NN O
B6D2F1 NN NN O
mice NN NN O
were NN NN O
treated NN NN O
with NN NN O
etoposide NN NN O
, NN NN O
daunorubicin NN NN O
, NN NN O
and NN NN O
doxorubicin NN NN O
, NN NN O
with NN NN O
or NN NN O
without NN NN O
dexrazoxane NN NN O
over NN NN O
a NN NN O
wide NN NN O
range NN NN O
of NN NN O
doses NN NN O
: NN NN O
posttreatment NN NN O
, NN NN O
a NN NN O
full NN NN O
hematologic NN NN O
evaluation NN NN O
was NN NN O
done NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Nontoxic NN NN O
doses NN NN O
of NN NN O
dexrazoxane NN NN O
reduced NN NN O
myelosuppression NN NN B-Disease
and NN NN O
weight NN NN B-Disease
loss NN NN I-Disease
from NN NN O
daunorubicin NN NN O
and NN NN O
etoposide NN NN O
in NN NN O
mice NN NN O
and NN NN O
antagonized NN NN O
their NN NN O
antiproliferative NN NN O
effects NN NN O
in NN NN O
the NN NN O
colony NN NN O
assay NN NN O
; NN NN O
however NN NN O
, NN NN O
dexrazoxane NN NN O
neither NN NN O
reduced NN NN O
myelosuppression NN NN B-Disease
, NN NN O
weight NN NN B-Disease
loss NN NN I-Disease
, NN NN O
nor NN NN O
the NN NN O
in NN NN O
vitro NN NN O
cytotoxicity NN NN B-Disease
from NN NN O
doxorubicin NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Although NN NN O
our NN NN O
findings NN NN O
support NN NN O
the NN NN O
observation NN NN O
that NN NN O
dexrazoxane NN NN O
reduces NN NN O
neither NN NN O
hematologic NN NN O
activity NN NN O
nor NN NN O
antitumor NN NN O
activity NN NN O
from NN NN O
doxorubicin NN NN O
clinically NN NN O
, NN NN O
the NN NN O
potent NN NN O
antagonism NN NN O
of NN NN O
daunorubicin NN NN O
activity NN NN O
raises NN NN O
concern NN NN O
; NN NN O
a NN NN O
possible NN NN O
interference NN NN O
with NN NN O
anticancer NN NN O
efficacy NN NN O
certainly NN NN O
would NN NN O
call NN NN O
for NN NN O
renewed NN NN O
attention NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
also NN NN O
suggest NN NN O
that NN NN O
significant NN NN O
etoposide NN NN O
dose NN NN O
escalation NN NN O
is NN NN O
perhaps NN NN O
possible NN NN O
by NN NN O
the NN NN O
use NN NN O
of NN NN O
dexrazoxane NN NN O
. NN NN O
   
Clinical NN NN O
trials NN NN O
in NN NN O
patients NN NN O
with NN NN O
brain NN NN O
metastases NN NN B-Disease
combining NN NN O
dexrazoxane NN NN O
and NN NN O
high NN NN O
doses NN NN O
of NN NN O
etoposide NN NN O
is NN NN O
ongoing NN NN O
with NN NN O
the NN NN O
aim NN NN O
of NN NN O
improving NN NN O
efficacy NN NN O
without NN NN O
aggravating NN NN O
hematologic NN NN B-Disease
toxicity NN NN I-Disease
. NN NN O
   
If NN NN O
successful NN NN O
, NN NN O
this NN NN O
represents NN NN O
an NN NN O
exciting NN NN O
mechanism NN NN O
for NN NN O
pharmacologic NN NN O
regulation NN NN O
of NN NN O
side NN NN O
effects NN NN O
from NN NN O
cytotoxic NN NN O
chemotherapy NN NN O
. NN NN O
   
Assessment NN NN O
of NN NN O
the NN NN O
onset NN NN O
and NN NN O
persistence NN NN O
of NN NN O
amnesia NN NN B-Disease
during NN NN O
procedural NN NN O
sedation NN NN O
with NN NN O
propofol NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
To NN NN O
assess NN NN O
patients NN NN O
' NN NN O
ability NN NN O
to NN NN O
repeat NN NN O
and NN NN O
recall NN NN O
words NN NN O
presented NN NN O
to NN NN O
them NN NN O
while NN NN O
undergoing NN NN O
procedural NN NN O
sedation NN NN O
with NN NN O
propofol NN NN O
, NN NN O
and NN NN O
correlate NN NN O
their NN NN O
recall NN NN O
with NN NN O
their NN NN O
level NN NN O
of NN NN O
awareness NN NN O
as NN NN O
measured NN NN O
by NN NN O
bispectral NN NN O
index NN NN O
( NN NN O
BIS NN NN O
) NN NN O
monitoring NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
This NN NN O
was NN NN O
a NN NN O
prospective NN NN O
, NN NN O
single NN NN O
- NN NN O
intervention NN NN O
study NN NN O
of NN NN O
consenting NN NN O
adult NN NN O
patients NN NN O
undergoing NN NN O
procedural NN NN O
sedation NN NN O
with NN NN O
propofol NN NN O
between NN NN O
December NN NN O
28 NN NN O
, NN NN O
2002 NN NN O
, NN NN O
and NN NN O
October NN NN O
31 NN NN O
, NN NN O
2003 NN NN O
. NN NN O
   
BIS NN NN O
monitoring NN NN O
was NN NN O
initiated NN NN O
starting NN NN O
3 NN NN O
minutes NN NN O
before NN NN O
the NN NN O
procedure NN NN O
and NN NN O
continuing NN NN O
until NN NN O
the NN NN O
patient NN NN O
had NN NN O
regained NN NN O
baseline NN NN O
mental NN NN O
status NN NN O
. NN NN O
   
At NN NN O
1 NN NN O
- NN NN O
minute NN NN O
intervals NN NN O
during NN NN O
the NN NN O
procedural NN NN O
sedation NN NN O
, NN NN O
until NN NN O
the NN NN O
patient NN NN O
regained NN NN O
baseline NN NN O
mental NN NN O
status NN NN O
at NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
procedure NN NN O
, NN NN O
a NN NN O
word NN NN O
from NN NN O
a NN NN O
standardized NN NN O
list NN NN O
was NN NN O
read NN NN O
aloud NN NN O
, NN NN O
and NN NN O
the NN NN O
patient NN NN O
was NN NN O
asked NN NN O
to NN NN O
immediately NN NN O
repeat NN NN O
the NN NN O
word NN NN O
to NN NN O
the NN NN O
investigator NN NN O
. NN NN O
   
The NN NN O
BIS NN NN O
score NN NN O
at NN NN O
the NN NN O
time NN NN O
the NN NN O
word NN NN O
was NN NN O
read NN NN O
and NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
ability NN NN O
to NN NN O
repeat NN NN O
the NN NN O
word NN NN O
were NN NN O
recorded NN NN O
. NN NN O
   
After NN NN O
the NN NN O
procedure NN NN O
, NN NN O
the NN NN O
patient NN NN O
was NN NN O
asked NN NN O
to NN NN O
state NN NN O
all NN NN O
of NN NN O
the NN NN O
words NN NN O
from NN NN O
the NN NN O
list NN NN O
that NN NN O
he NN NN O
or NN NN O
she NN NN O
could NN NN O
recall NN NN O
, NN NN O
and NN NN O
to NN NN O
identify NN NN O
the NN NN O
last NN NN O
word NN NN O
recalled NN NN O
from NN NN O
prior NN NN O
to NN NN O
the NN NN O
start NN NN O
of NN NN O
the NN NN O
procedure NN NN O
and NN NN O
the NN NN O
first NN NN O
word NN NN O
recalled NN NN O
from NN NN O
after NN NN O
the NN NN O
procedure NN NN O
was NN NN O
completed NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Seventy NN NN O
- NN NN O
five NN NN O
consenting NN NN O
patients NN NN O
were NN NN O
enrolled NN NN O
; NN NN O
one NN NN O
patient NN NN O
was NN NN O
excluded NN NN O
from NN NN O
data NN NN O
analysis NN NN O
for NN NN O
a NN NN O
protocol NN NN O
violation NN NN O
. NN NN O
   
No NN NN O
serious NN NN O
adverse NN NN O
events NN NN O
were NN NN O
noted NN NN O
during NN NN O
the NN NN O
procedural NN NN O
sedations NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
standard NN NN O
deviation NN NN O
) NN NN O
time NN NN O
of NN NN O
data NN NN O
collection NN NN O
was NN NN O
16 NN NN O
. NN NN O
4 NN NN O
minutes NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
. NN NN O
1 NN NN O
; NN NN O
range NN NN O
5 NN NN O
to NN NN O
34 NN NN O
minutes NN NN O
) NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
initial NN NN O
( NN NN O
preprocedure NN NN O
) NN NN O
BIS NN NN O
score NN NN O
was NN NN O
97 NN NN O
. NN NN O
1 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
3 NN NN O
; NN NN O
range NN NN O
92 NN NN O
to NN NN O
99 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
lowest NN NN O
BIS NN NN O
score NN NN O
occurring NN NN O
during NN NN O
these NN NN O
procedural NN NN O
sedations NN NN O
was NN NN O
66 NN NN O
. NN NN O
9 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
14 NN NN O
. NN NN O
4 NN NN O
; NN NN O
range NN NN O
33 NN NN O
to NN NN O
91 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
lowest NN NN O
BIS NN NN O
score NN NN O
corresponding NN NN O
to NN NN O
the NN NN O
ability NN NN O
of NN NN O
the NN NN O
patient NN NN O
to NN NN O
immediately NN NN O
repeat NN NN O
words NN NN O
read NN NN O
from NN NN O
the NN NN O
list NN NN O
was NN NN O
77 NN NN O
. NN NN O
1 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
74 NN NN O
. NN NN O
3 NN NN O
to NN NN O
80 NN NN O
. NN NN O
0 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
highest NN NN O
BIS NN NN O
score NN NN O
corresponding NN NN O
to NN NN O
the NN NN O
inability NN NN B-Disease
to NN NN I-Disease
repeat NN NN I-Disease
words NN NN I-Disease
was NN NN O
81 NN NN O
. NN NN O
5 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
78 NN NN O
. NN NN O
1 NN NN O
to NN NN O
84 NN NN O
. NN NN O
8 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
BIS NN NN O
score NN NN O
corresponding NN NN O
to NN NN O
the NN NN O
last NN NN O
word NN NN O
recalled NN NN O
from NN NN O
prior NN NN O
to NN NN O
the NN NN O
initiation NN NN O
of NN NN O
the NN NN O
sedation NN NN O
was NN NN O
96 NN NN O
. NN NN O
7 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
4 NN NN O
; NN NN O
range NN NN O
84 NN NN O
to NN NN O
98 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
BIS NN NN O
score NN NN O
corresponding NN NN O
to NN NN O
the NN NN O
first NN NN O
word NN NN O
recalled NN NN O
after NN NN O
the NN NN O
procedure NN NN O
was NN NN O
completed NN NN O
was NN NN O
91 NN NN O
. NN NN O
2 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
88 NN NN O
. NN NN O
1 NN NN O
to NN NN O
94 NN NN O
. NN NN O
3 NN NN O
) NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
recalled NN NN O
at NN NN O
least NN NN O
one NN NN O
word NN NN O
that NN NN O
had NN NN O
been NN NN O
read NN NN O
to NN NN O
them NN NN O
during NN NN O
the NN NN O
protocol NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
lowest NN NN O
BIS NN NN O
score NN NN O
for NN NN O
any NN NN O
recalled NN NN O
word NN NN O
was NN NN O
91 NN NN O
. NN NN O
5 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
11 NN NN O
. NN NN O
1 NN NN O
; NN NN O
range NN NN O
79 NN NN O
to NN NN O
98 NN NN O
) NN NN O
, NN NN O
and NN NN O
no NN NN O
words NN NN O
were NN NN O
recalled NN NN O
when NN NN O
the NN NN O
corresponding NN NN O
BIS NN NN O
score NN NN O
was NN NN O
less NN NN O
than NN NN O
90 NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
There NN NN O
is NN NN O
a NN NN O
range NN NN O
of NN NN O
BIS NN NN O
scores NN NN O
during NN NN O
which NN NN O
sedated NN NN O
patients NN NN O
are NN NN O
able NN NN O
to NN NN O
repeat NN NN O
words NN NN O
read NN NN O
to NN NN O
them NN NN O
but NN NN O
are NN NN O
not NN NN O
able NN NN O
to NN NN O
subsequently NN NN O
recall NN NN O
these NN NN O
words NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
patients NN NN O
had NN NN O
no NN NN O
recall NN NN O
of NN NN O
words NN NN O
repeated NN NN O
prior NN NN O
to NN NN O
procedural NN NN O
sedation NN NN O
in NN NN O
BIS NN NN O
ranges NN NN O
associated NN NN O
with NN NN O
recall NN NN O
after NN NN O
procedural NN NN O
sedation NN NN O
, NN NN O
suggestive NN NN O
of NN NN O
retrograde NN NN B-Disease
amnesia NN NN I-Disease
. NN NN O
   
Amiodarone NN NN O
pulmonary NN NN B-Disease
toxicity NN NN I-Disease
. NN NN O
   
Amiodarone NN NN O
is NN NN O
an NN NN O
effective NN NN O
antiarrhythmic NN NN O
agent NN NN O
whose NN NN O
utility NN NN O
is NN NN O
limited NN NN O
by NN NN O
many NN NN O
side NN NN O
- NN NN O
effects NN NN O
, NN NN O
the NN NN O
most NN NN O
problematic NN NN O
being NN NN O
pneumonitis NN NN B-Disease
. NN NN O
   
The NN NN O
pulmonary NN NN B-Disease
toxicity NN NN I-Disease
of NN NN O
amiodarone NN NN O
is NN NN O
thought NN NN O
to NN NN O
result NN NN O
from NN NN O
direct NN NN O
injury NN NN O
related NN NN O
to NN NN O
the NN NN O
intracellular NN NN O
accumulation NN NN O
of NN NN O
phospholipid NN NN O
and NN NN O
T NN NN O
cell NN NN O
- NN NN O
mediated NN NN O
hypersensitivity NN NN B-Disease
pneumonitis NN NN I-Disease
. NN NN O
   
The NN NN O
clinical NN NN O
and NN NN O
radiographic NN NN O
features NN NN O
of NN NN O
amiodarone NN NN O
- NN NN O
induced NN NN O
pulmonary NN NN B-Disease
toxicity NN NN I-Disease
are NN NN O
characteristic NN NN O
but NN NN O
nonspecific NN NN O
. NN NN O
   
The NN NN O
diagnosis NN NN O
depends NN NN O
on NN NN O
exclusion NN NN O
of NN NN O
other NN NN O
entities NN NN O
, NN NN O
such NN NN O
as NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
, NN NN O
infection NN NN B-Disease
, NN NN O
and NN NN O
malignancy NN NN B-Disease
. NN NN O
   
While NN NN O
withdrawal NN NN O
of NN NN O
amiodarone NN NN O
leads NN NN O
to NN NN O
clinical NN NN O
improvement NN NN O
in NN NN O
majority NN NN O
of NN NN O
cases NN NN O
, NN NN O
this NN NN O
is NN NN O
not NN NN O
always NN NN O
possible NN NN O
or NN NN O
advisable NN NN O
. NN NN O
   
Dose NN NN O
reduction NN NN O
or NN NN O
concomitant NN NN O
steroid NN NN O
therapy NN NN O
may NN NN O
have NN NN O
a NN NN O
role NN NN O
in NN NN O
selected NN NN O
patients NN NN O
. NN NN O
   
Two NN NN O
prodrugs NN NN O
of NN NN O
potent NN NN O
and NN NN O
selective NN NN O
GluR5 NN NN O
kainate NN NN O
receptor NN NN O
antagonists NN NN O
actives NN NN O
in NN NN O
three NN NN O
animal NN NN O
models NN NN O
of NN NN O
pain NN NN B-Disease
. NN NN O
   
Amino NN NN O
acids NN NN O
5 NN NN O
and NN NN O
7 NN NN O
, NN NN O
two NN NN O
potent NN NN O
and NN NN O
selective NN NN O
competitive NN NN O
GluR5 NN NN O
KA NN NN O
receptor NN NN O
antagonists NN NN O
, NN NN O
exhibited NN NN O
high NN NN O
GluR5 NN NN O
receptor NN NN O
affinity NN NN O
over NN NN O
other NN NN O
glutamate NN NN O
receptors NN NN O
. NN NN O
   
Their NN NN O
ester NN NN O
prodrugs NN NN O
6 NN NN O
and NN NN O
8 NN NN O
were NN NN O
orally NN NN O
active NN NN O
in NN NN O
three NN NN O
models NN NN O
of NN NN O
pain NN NN B-Disease
: NN NN O
reversal NN NN O
of NN NN O
formalin NN NN O
- NN NN O
induced NN NN O
paw NN NN O
licking NN NN O
, NN NN O
carrageenan NN NN O
- NN NN O
induced NN NN O
thermal NN NN B-Disease
hyperalgesia NN NN I-Disease
, NN NN O
and NN NN O
capsaicin NN NN O
- NN NN O
induced NN NN O
mechanical NN NN B-Disease
hyperalgesia NN NN I-Disease
. NN NN O
   
Possible NN NN O
azithromycin NN NN O
- NN NN O
associated NN NN O
hiccups NN NN B-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
persistent NN NN O
hiccups NN NN B-Disease
associated NN NN O
by NN NN O
azithromycin NN NN O
therapy NN NN O
. NN NN O
   
CASE NN NN O
SUMMARY NN NN O
: NN NN O
A NN NN O
76 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
presented NN NN O
with NN NN O
persistent NN NN O
hiccups NN NN B-Disease
after NN NN O
beginning NN NN O
azithromycin NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
pharyngitis NN NN B-Disease
. NN NN O
   
Hiccups NN NN B-Disease
were NN NN O
persistent NN NN O
and NN NN O
exhausting NN NN O
. NN NN O
   
Discontinuation NN NN O
of NN NN O
azithromycin NN NN O
and NN NN O
therapy NN NN O
with NN NN O
baclofen NN NN O
finally NN NN O
resolved NN NN O
hiccups NN NN B-Disease
. NN NN O
   
No NN NN O
organic NN NN O
cause NN NN O
of NN NN O
hiccups NN NN B-Disease
was NN NN O
identified NN NN O
despite NN NN O
extensive NN NN O
investigation NN NN O
. NN NN O
   
DISCUSSION NN NN O
: NN NN O
Pharmacotherapeutic NN NN O
agents NN NN O
have NN NN O
been NN NN O
uncommonly NN NN O
associated NN NN O
with NN NN O
hiccups NN NN B-Disease
. NN NN O
   
Corticosteroids NN NN O
( NN NN O
dexamethasone NN NN O
and NN NN O
methylprednisolone NN NN O
) NN NN O
, NN NN O
benzodiazepines NN NN O
( NN NN O
midazolam NN NN O
) NN NN O
and NN NN O
general NN NN O
anaesthesia NN NN O
have NN NN O
been NN NN O
the NN NN O
specific NN NN O
agents NN NN O
mentioned NN NN O
most NN NN O
frequently NN NN O
in NN NN O
the NN NN O
literature NN NN O
as NN NN O
being NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
hiccups NN NN B-Disease
. NN NN O
   
Few NN NN O
cases NN NN O
of NN NN O
drug NN NN O
- NN NN O
induced NN NN O
hiccups NN NN B-Disease
have NN NN O
been NN NN O
reported NN NN O
related NN NN O
to NN NN O
macrolide NN NN O
antimicrobials NN NN O
. NN NN O
   
Using NN NN O
the NN NN O
Naranjo NN NN O
adverse NN NN O
effect NN NN O
reaction NN NN O
probability NN NN O
scale NN NN O
this NN NN O
event NN NN O
could NN NN O
be NN NN O
classified NN NN O
as NN NN O
possible NN NN O
( NN NN O
score NN NN O
5 NN NN O
points NN NN O
) NN NN O
, NN NN O
mostly NN NN O
because NN NN O
of NN NN O
the NN NN O
close NN NN O
temporal NN NN O
sequence NN NN O
, NN NN O
previous NN NN O
reports NN NN O
on NN NN O
this NN NN O
reaction NN NN O
with NN NN O
other NN NN O
macrolides NN NN O
and NN NN O
the NN NN O
absence NN NN O
of NN NN O
any NN NN O
alternative NN NN O
explanation NN NN O
for NN NN O
hiccups NN NN B-Disease
. NN NN O
   
Our NN NN O
hypothesis NN NN O
is NN NN O
that NN NN O
a NN NN O
vagal NN NN O
mechanism NN NN O
mediated NN NN O
by NN NN O
azithromycin NN NN O
could NN NN O
be NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
hiccups NN NN B-Disease
in NN NN O
our NN NN O
patient NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Diagnosis NN NN O
of NN NN O
drug NN NN O
- NN NN O
induced NN NN O
hiccups NN NN B-Disease
is NN NN O
difficult NN NN O
and NN NN O
often NN NN O
achieved NN NN O
only NN NN O
by NN NN O
a NN NN O
process NN NN O
of NN NN O
elimination NN NN O
. NN NN O
   
However NN NN O
, NN NN O
macrolide NN NN O
antimicrobials NN NN O
have NN NN O
been NN NN O
reported NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
hiccups NN NN B-Disease
and NN NN O
vagal NN NN O
mechanism NN NN O
could NN NN O
explain NN NN O
the NN NN O
development NN NN O
of NN NN O
this NN NN O
side NN NN O
- NN NN O
effect NN NN O
. NN NN O
   
Calcium NN NN O
carbonate NN NN O
toxicity NN NN B-Disease
: NN NN O
the NN NN O
updated NN NN O
milk NN NN B-Disease
- NN NN I-Disease
alkali NN NN I-Disease
syndrome NN NN I-Disease
; NN NN O
report NN NN O
of NN NN O
3 NN NN O
cases NN NN O
and NN NN O
review NN NN O
of NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
describe NN NN O
3 NN NN O
patients NN NN O
with NN NN O
calcium NN NN O
carbonate NN NN O
- NN NN O
induced NN NN O
hypercalcemia NN NN B-Disease
and NN NN O
gain NN NN O
insights NN NN O
into NN NN O
the NN NN O
cause NN NN O
and NN NN O
management NN NN O
of NN NN O
the NN NN O
milk NN NN B-Disease
- NN NN I-Disease
alkali NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
report NN NN O
the NN NN O
clinical NN NN O
and NN NN O
laboratory NN NN O
data NN NN O
in NN NN O
3 NN NN O
patients NN NN O
who NN NN O
presented NN NN O
with NN NN O
severe NN NN O
hypercalcemia NN NN B-Disease
( NN NN O
corrected NN NN O
serum NN NN O
calcium NN NN O
> NN NN O
or NN NN O
= NN NN O
14 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
) NN NN O
and NN NN O
review NN NN O
the NN NN O
pertinent NN NN O
literature NN NN O
on NN NN O
milk NN NN B-Disease
- NN NN I-Disease
alkali NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
3 NN NN O
patients NN NN O
had NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
insufficiency NN NN I-Disease
, NN NN O
relative NN NN O
metabolic NN NN B-Disease
alkalosis NN NN I-Disease
, NN NN O
and NN NN O
low NN NN O
parathyroid NN NN O
hormone NN NN O
( NN NN O
PTH NN NN O
) NN NN O
, NN NN O
PTH NN NN O
- NN NN O
related NN NN O
peptide NN NN O
, NN NN O
and NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D NN NN O
concentrations NN NN O
. NN NN O
   
No NN NN O
malignant NN NN O
lesion NN NN O
was NN NN O
found NN NN O
. NN NN O
   
Treatment NN NN O
included NN NN O
aggressive NN NN O
hydration NN NN O
and NN NN O
varied NN NN O
amounts NN NN O
of NN NN O
furosemide NN NN O
. NN NN O
   
The NN NN O
2 NN NN O
patients NN NN O
with NN NN O
the NN NN O
higher NN NN O
serum NN NN O
calcium NN NN O
concentrations NN NN O
received NN NN O
pamidronate NN NN O
intravenously NN NN O
( NN NN O
60 NN NN O
and NN NN O
30 NN NN O
mg NN NN O
, NN NN O
respectively NN NN O
) NN NN O
, NN NN O
which NN NN O
caused NN NN O
severe NN NN O
hypocalcemia NN NN B-Disease
. NN NN O
   
Of NN NN O
the NN NN O
3 NN NN O
patients NN NN O
, NN NN O
2 NN NN O
were NN NN O
ingesting NN NN O
acceptable NN NN O
doses NN NN O
of NN NN O
elemental NN NN O
calcium NN NN O
( NN NN O
1 NN NN O
g NN NN O
and NN NN O
2 NN NN O
g NN NN O
daily NN NN O
, NN NN O
respectively NN NN O
) NN NN O
in NN NN O
the NN NN O
form NN NN O
of NN NN O
calcium NN NN O
carbonate NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
our NN NN O
highlighted NN NN O
cases NN NN O
, NN NN O
we NN NN O
review NN NN O
the NN NN O
history NN NN O
, NN NN O
classification NN NN O
, NN NN O
pathophysiologic NN NN O
features NN NN O
, NN NN O
and NN NN O
treatment NN NN O
of NN NN O
milk NN NN B-Disease
- NN NN I-Disease
alkali NN NN I-Disease
syndrome NN NN I-Disease
and NN NN O
summarize NN NN O
the NN NN O
cases NN NN O
reported NN NN O
from NN NN O
early NN NN O
1995 NN NN O
to NN NN O
November NN NN O
2003 NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Milk NN NN B-Disease
- NN NN I-Disease
alkali NN NN I-Disease
syndrome NN NN I-Disease
may NN NN O
be NN NN O
a NN NN O
common NN NN O
cause NN NN O
of NN NN O
unexplained NN NN O
hypercalcemia NN NN B-Disease
and NN NN O
can NN NN O
be NN NN O
precipitated NN NN O
by NN NN O
small NN NN O
amounts NN NN O
of NN NN O
orally NN NN O
ingested NN NN O
calcium NN NN O
carbonate NN NN O
in NN NN O
susceptible NN NN O
persons NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
hydration NN NN O
, NN NN O
furosemide NN NN O
, NN NN O
and NN NN O
discontinuation NN NN O
of NN NN O
the NN NN O
calcium NN NN O
and NN NN O
vitamin NN NN O
D NN NN O
source NN NN O
is NN NN O
adequate NN NN O
. NN NN O
   
Pamidronate NN NN O
treatment NN NN O
is NN NN O
associated NN NN O
with NN NN O
considerable NN NN O
risk NN NN O
for NN NN O
hypocalcemia NN NN B-Disease
, NN NN O
even NN NN O
in NN NN O
cases NN NN O
of NN NN O
initially NN NN O
severe NN NN O
hypercalcemia NN NN B-Disease
. NN NN O
   
Warfarin NN NN O
- NN NN O
induced NN NN O
leukocytoclastic NN NN B-Disease
vasculitis NN NN I-Disease
. NN NN O
   
Skin NN NN O
reactions NN NN O
associated NN NN O
with NN NN O
oral NN NN O
coumarin NN NN O
- NN NN O
derived NN NN O
anticoagulants NN NN O
are NN NN O
an NN NN O
uncommon NN NN O
occurrence NN NN O
. NN NN O
   
Leukocytoclastic NN NN B-Disease
vasculitis NN NN I-Disease
( NN NN O
LV NN NN B-Disease
) NN NN O
is NN NN O
primarily NN NN O
a NN NN O
cutaneous NN NN B-Disease
small NN NN I-Disease
vessel NN NN I-Disease
vasculitis NN NN I-Disease
, NN NN O
though NN NN O
systemic NN NN O
involvement NN NN O
may NN NN O
be NN NN O
encountered NN NN O
. NN NN O
   
We NN NN O
report NN NN O
4 NN NN O
patients NN NN O
with NN NN O
late NN NN O
- NN NN O
onset NN NN O
LV NN NN B-Disease
probably NN NN O
due NN NN O
to NN NN O
warfarin NN NN O
. NN NN O
   
All NN NN O
4 NN NN O
patients NN NN O
presented NN NN O
with NN NN O
skin NN NN B-Disease
eruptions NN NN I-Disease
that NN NN O
developed NN NN O
after NN NN O
receiving NN NN O
warfarin NN NN O
for NN NN O
several NN NN O
years NN NN O
. NN NN O
   
The NN NN O
results NN NN O
of NN NN O
skin NN NN B-Disease
lesion NN NN I-Disease
biopsies NN NN O
were NN NN O
available NN NN O
in NN NN O
3 NN NN O
patients NN NN O
, NN NN O
confirming NN NN O
LV NN NN B-Disease
Cutaneous NN NN I-Disease
lesions NN NN I-Disease
resolved NN NN O
in NN NN O
all NN NN O
patients NN NN O
after NN NN O
warfarin NN NN O
was NN NN O
discontinued NN NN O
. NN NN O
   
In NN NN O
2 NN NN O
of NN NN O
the NN NN O
4 NN NN O
patients NN NN O
, NN NN O
rechallenge NN NN O
with NN NN O
warfarin NN NN O
led NN NN O
to NN NN O
recurrence NN NN O
of NN NN O
the NN NN O
lesions NN NN O
. NN NN O
   
LV NN NN B-Disease
may NN NN O
be NN NN O
a NN NN O
late NN NN O
- NN NN O
onset NN NN O
adverse NN NN O
reaction NN NN O
associated NN NN O
with NN NN O
warfarin NN NN O
therapy NN NN O
. NN NN O
   
Cocaine NN NN O
- NN NN O
induced NN NN O
brainstem NN NN O
seizures NN NN B-Disease
and NN NN O
behavior NN NN O
. NN NN O
   
A NN NN O
variety NN NN O
of NN NN O
abnormal NN NN O
sensory NN NN O
/ NN NN O
motor NN NN O
behaviors NN NN O
associated NN NN O
with NN NN O
electrical NN NN O
discharges NN NN O
recorded NN NN O
from NN NN O
the NN NN O
bilateral NN NN O
brainstem NN NN O
were NN NN O
induced NN NN O
in NN NN O
adult NN NN O
WKY NN NN O
rats NN NN O
by NN NN O
mechanical NN NN O
( NN NN O
electrode NN NN O
implants NN NN O
) NN NN O
and NN NN O
DC NN NN O
electrical NN NN O
current NN NN O
stimulations NN NN O
and NN NN O
by NN NN O
acute NN NN O
and NN NN O
chronic NN NN O
administration NN NN O
of NN NN O
cocaine NN NN O
. NN NN O
   
The NN NN O
electrode NN NN O
implant NN NN O
implicated NN NN O
one NN NN O
side NN NN O
or NN NN O
the NN NN O
other NN NN O
of NN NN O
the NN NN O
reticular NN NN O
system NN NN O
of NN NN O
the NN NN O
brainstem NN NN O
but NN NN O
subjects NN NN O
were NN NN O
not NN NN O
incapacitated NN NN O
by NN NN O
the NN NN O
stimulations NN NN O
. NN NN O
   
Cocaine NN NN O
( NN NN O
40 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
was NN NN O
injected NN NN O
subcutaneously NN NN O
for NN NN O
an NN NN O
acute NN NN O
experiment NN NN O
and NN NN O
subsequent NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
doses NN NN O
twice NN NN O
daily NN NN O
for NN NN O
3 NN NN O
days NN NN O
in NN NN O
a NN NN O
chronic NN NN O
study NN NN O
. NN NN O
   
Cocaine NN NN O
generated NN NN O
more NN NN O
abnormal NN NN O
behaviors NN NN O
in NN NN O
the NN NN O
brainstem NN NN O
perturbation NN NN O
group NN NN O
, NN NN O
especially NN NN O
the NN NN O
electrically NN NN O
perturbated NN NN O
subjects NN NN O
. NN NN O
   
The NN NN O
abnormal NN NN O
behaviors NN NN O
were NN NN O
yawning NN NN O
, NN NN O
retrocollis NN NN O
, NN NN O
hyperactivity NN NN B-Disease
, NN NN O
hypersensitivity NN NN B-Disease
, NN NN O
"""""""" NN NN O
beating NN NN O
drum NN NN O
"""""""" NN NN O
behavior NN NN O
, NN NN O
squealing NN NN O
, NN NN O
head NN NN O
bobbing NN NN O
, NN NN O
circling NN NN O
, NN NN O
sniffing NN NN O
, NN NN O
abnormal NN NN O
posturing NN NN O
, NN NN O
and NN NN O
facial NN NN O
twitching NN NN O
. NN NN O
   
Shifts NN NN O
in NN NN O
the NN NN O
power NN NN O
frequency NN NN O
spectra NN NN O
of NN NN O
the NN NN O
discharge NN NN O
patterns NN NN O
were NN NN O
noted NN NN O
between NN NN O
quiet NN NN O
and NN NN O
pacing NN NN O
behavioral NN NN O
states NN NN O
. NN NN O
   
Hypersensitivity NN NN B-Disease
to NN NN O
various NN NN O
auditory NN NN O
, NN NN O
tactile NN NN O
, NN NN O
and NN NN O
visual NN NN O
stimulation NN NN O
was NN NN O
present NN NN O
and NN NN O
shifts NN NN O
in NN NN O
the NN NN O
brainstem NN NN O
ambient NN NN O
power NN NN O
spectral NN NN O
frequency NN NN O
occurred NN NN O
in NN NN O
response NN NN O
to NN NN O
tactile NN NN O
stimulation NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
the NN NN O
brainstem NN NN O
generates NN NN O
and NN NN O
propagates NN NN O
pathological NN NN O
discharges NN NN O
that NN NN O
can NN NN O
be NN NN O
elicited NN NN O
by NN NN O
mechanical NN NN O
and NN NN O
DC NN NN O
electrical NN NN O
perturbation NN NN O
. NN NN O
   
Cocaine NN NN O
was NN NN O
found NN NN O
to NN NN O
activate NN NN O
the NN NN O
discharge NN NN O
system NN NN O
and NN NN O
thus NN NN O
induce NN NN O
abnormal NN NN O
behaviors NN NN O
that NN NN O
are NN NN O
generated NN NN O
at NN NN O
the NN NN O
discharge NN NN O
site NN NN O
and NN NN O
at NN NN O
distant NN NN O
sites NN NN O
to NN NN O
which NN NN O
the NN NN O
discharge NN NN O
propagates NN NN O
. NN NN O
   
Cognitive NN NN O
functions NN NN O
may NN NN O
also NN NN O
be NN NN O
involved NN NN O
since NN NN O
dopaminergic NN NN O
and NN NN O
serotonergic NN NN O
cellular NN NN O
elements NN NN O
at NN NN O
the NN NN O
brainstem NN NN O
level NN NN O
are NN NN O
also NN NN O
implicated NN NN O
. NN NN O
   
rTMS NN NN O
of NN NN O
supplementary NN NN O
motor NN NN O
area NN NN O
modulates NN NN O
therapy NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
in NN NN O
Parkinson NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
The NN NN O
neural NN NN O
mechanisms NN NN O
and NN NN O
circuitry NN NN O
involved NN NN O
in NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesia NN NN B-Disease
are NN NN O
unclear NN NN O
. NN NN O
   
Using NN NN O
repetitive NN NN O
transcranial NN NN O
magnetic NN NN O
stimulation NN NN O
( NN NN O
rTMS NN NN O
) NN NN O
over NN NN O
the NN NN O
supplementary NN NN O
motor NN NN O
area NN NN O
( NN NN O
SMA NN NN O
) NN NN O
in NN NN O
a NN NN O
group NN NN O
of NN NN O
patients NN NN O
with NN NN O
advanced NN NN O
Parkinson NN NN B-Disease
disease NN NN I-Disease
, NN NN O
the NN NN O
authors NN NN O
investigated NN NN O
whether NN NN O
modulation NN NN O
of NN NN O
SMA NN NN O
excitability NN NN O
may NN NN O
result NN NN O
in NN NN O
a NN NN O
modification NN NN O
of NN NN O
a NN NN O
dyskinetic NN NN B-Disease
state NN NN O
induced NN NN O
by NN NN O
continuous NN NN O
apomorphine NN NN O
infusion NN NN O
. NN NN O
   
rTMS NN NN O
at NN NN O
1 NN NN O
Hz NN NN O
was NN NN O
observed NN NN O
to NN NN O
markedly NN NN O
reduce NN NN O
drug NN NN B-Disease
- NN NN I-Disease
induced NN NN I-Disease
dyskinesias NN NN I-Disease
, NN NN O
whereas NN NN O
5 NN NN O
- NN NN O
Hz NN NN O
rTMS NN NN O
induced NN NN O
a NN NN O
slight NN NN O
but NN NN O
not NN NN O
significant NN NN O
increase NN NN O
. NN NN O
   
Intracavitary NN NN O
chemotherapy NN NN O
( NN NN O
paclitaxel NN NN O
/ NN NN O
carboplatin NN NN O
liquid NN NN O
crystalline NN NN O
cubic NN NN O
phases NN NN O
) NN NN O
for NN NN O
recurrent NN NN O
glioblastoma NN NN B-Disease
- NN NN O
- NN NN O
clinical NN NN O
observations NN NN O
. NN NN O
   
Human NN NN O
malignant NN NN O
brain NN NN B-Disease
tumors NN NN I-Disease
have NN NN O
a NN NN O
poor NN NN O
prognosis NN NN O
in NN NN O
spite NN NN O
of NN NN O
surgery NN NN O
and NN NN O
radiation NN NN O
therapy NN NN O
. NN NN O
   
Cubic NN NN O
phases NN NN O
consist NN NN O
of NN NN O
curved NN NN O
biocontinuous NN NN O
lipid NN NN O
bilayers NN NN O
, NN NN O
separating NN NN O
two NN NN O
congruent NN NN O
networks NN NN O
of NN NN O
water NN NN O
channels NN NN O
. NN NN O
   
Used NN NN O
as NN NN O
a NN NN O
host NN NN O
for NN NN O
cytotoxic NN NN O
drugs NN NN O
, NN NN O
the NN NN O
gel NN NN O
- NN NN O
like NN NN O
matrix NN NN O
can NN NN O
easily NN NN O
be NN NN O
applied NN NN O
to NN NN O
the NN NN O
walls NN NN O
of NN NN O
a NN NN O
surgical NN NN O
resection NN NN O
cavity NN NN O
. NN NN O
   
For NN NN O
human NN NN O
glioblastoma NN NN B-Disease
recurrences NN NN O
, NN NN O
the NN NN O
feasibility NN NN O
, NN NN O
safety NN NN O
, NN NN O
and NN NN O
short NN NN O
- NN NN O
term NN NN O
effects NN NN O
of NN NN O
a NN NN O
surgical NN NN O
intracavitary NN NN O
application NN NN O
of NN NN O
paclitaxel NN NN O
and NN NN O
carboplatin NN NN O
encapsulated NN NN O
by NN NN O
liquid NN NN O
crystalline NN NN O
cubic NN NN O
phases NN NN O
are NN NN O
examined NN NN O
in NN NN O
a NN NN O
pilot NN NN O
study NN NN O
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
12 NN NN O
patients NN NN O
with NN NN O
a NN NN O
recurrence NN NN O
of NN NN O
a NN NN O
glioblastoma NN NN B-Disease
multiforme NN NN O
underwent NN NN O
re NN NN O
- NN NN O
resection NN NN O
and NN NN O
received NN NN O
an NN NN O
intracavitary NN NN O
application NN NN O
of NN NN O
paclitaxel NN NN O
and NN NN O
carboplatin NN NN O
cubic NN NN O
phases NN NN O
in NN NN O
different NN NN O
dosages NN NN O
. NN NN O
   
Six NN NN O
of NN NN O
the NN NN O
patients NN NN O
received NN NN O
more NN NN O
than NN NN O
15 NN NN O
mg NN NN O
paclitaxel NN NN O
and NN NN O
suffered NN NN O
from NN NN O
moderate NN NN O
to NN NN O
severe NN NN O
brain NN NN B-Disease
edema NN NN I-Disease
, NN NN O
while NN NN O
the NN NN O
remaining NN NN O
patients NN NN O
received NN NN O
only NN NN O
a NN NN O
total NN NN O
of NN NN O
15 NN NN O
mg NN NN O
paclitaxel NN NN O
. NN NN O
   
In NN NN O
the NN NN O
latter NN NN O
group NN NN O
, NN NN O
brain NN NN B-Disease
edema NN NN I-Disease
was NN NN O
markedly NN NN O
reduced NN NN O
and NN NN O
dealt NN NN O
medically NN NN O
. NN NN O
   
Intracavitary NN NN O
chemotherapy NN NN O
in NN NN O
recurrent NN NN O
glioblastoma NN NN B-Disease
using NN NN O
cubic NN NN O
phases NN NN O
is NN NN O
feasible NN NN O
and NN NN O
safe NN NN O
, NN NN O
yet NN NN O
the NN NN O
clinical NN NN O
benefit NN NN O
remains NN NN O
to NN NN O
be NN NN O
examined NN NN O
in NN NN O
a NN NN O
clinical NN NN O
phase NN NN O
II NN NN O
study NN NN O
. NN NN O
   
Lamotrigine NN NN O
associated NN NN O
with NN NN O
exacerbation NN NN O
or NN NN O
de NN NN O
novo NN NN O
myoclonus NN NN B-Disease
in NN NN O
idiopathic NN NN B-Disease
generalized NN NN I-Disease
epilepsies NN NN I-Disease
. NN NN O
   
Five NN NN O
patients NN NN O
with NN NN O
idiopathic NN NN B-Disease
generalized NN NN I-Disease
epilepsies NN NN I-Disease
( NN NN O
IGE NN NN B-Disease
) NN NN O
treated NN NN O
with NN NN O
lamotrigine NN NN O
( NN NN O
LTG NN NN O
) NN NN O
experienced NN NN O
exacerbation NN NN O
or NN NN O
de NN NN O
novo NN NN O
appearance NN NN O
of NN NN O
myoclonic NN NN B-Disease
jerks NN NN I-Disease
( NN NN O
MJ NN NN B-Disease
) NN NN O
. NN NN O
   
In NN NN O
three NN NN O
patients NN NN O
, NN NN O
LTG NN NN O
exacerbated NN NN O
MJ NN NN B-Disease
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
with NN NN O
early NN NN O
aggravation NN NN O
during NN NN O
titration NN NN O
. NN NN O
   
MJ NN NN B-Disease
disappeared NN NN O
when NN NN O
LTG NN NN O
dose NN NN O
was NN NN O
decreased NN NN O
by NN NN O
25 NN NN O
to NN NN O
50 NN NN O
% NN NN O
. NN NN O
   
In NN NN O
two NN NN O
patients NN NN O
, NN NN O
LTG NN NN O
exacerbated NN NN O
MJ NN NN B-Disease
in NN NN O
a NN NN O
delayed NN NN O
but NN NN O
more NN NN O
severe NN NN O
manner NN NN O
, NN NN O
with NN NN O
myoclonic NN NN B-Disease
status NN NN I-Disease
that NN NN O
only NN NN O
ceased NN NN O
after NN NN O
LTG NN NN O
withdrawal NN NN O
. NN NN O
   
Absence NN NN O
of NN NN O
acute NN NN O
cerebral NN NN O
vasoconstriction NN NN O
after NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
subarachnoid NN NN B-Disease
hemorrhage NN NN I-Disease
. NN NN O
   
INTRODUCTION NN NN O
: NN NN O
Cocaine NN NN O
use NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
neurovascular NN NN B-Disease
complications NN NN I-Disease
, NN NN O
including NN NN O
arterial NN NN O
vasoconstriction NN NN O
and NN NN O
vasculitis NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
there NN NN O
are NN NN O
few NN NN O
studies NN NN O
of NN NN O
angiographic NN NN O
effects NN NN O
of NN NN O
cocaine NN NN O
on NN NN O
human NN NN O
cerebral NN NN O
arteries NN NN O
. NN NN O
   
Information NN NN O
on NN NN O
these NN NN O
effects NN NN O
could NN NN O
be NN NN O
obtained NN NN O
from NN NN O
angiograms NN NN O
of NN NN O
patients NN NN O
with NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
subarachnoid NN NN B-Disease
hemorrhage NN NN I-Disease
( NN NN O
SAH NN NN B-Disease
) NN NN O
who NN NN O
underwent NN NN O
angiography NN NN O
shortly NN NN O
after NN NN O
cocaine NN NN O
use NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
screened NN NN O
patients NN NN O
with NN NN O
SAH NN NN B-Disease
retrospectively NN NN O
and NN NN O
identified NN NN O
those NN NN O
with NN NN O
positive NN NN O
urine NN NN O
toxicology NN NN O
for NN NN O
cocaine NN NN O
or NN NN O
its NN NN O
metabolites NN NN O
. NN NN O
   
Quantitative NN NN O
arterial NN NN O
diameter NN NN O
measurements NN NN O
from NN NN O
angiograms NN NN O
of NN NN O
these NN NN O
patients NN NN O
were NN NN O
compared NN NN O
to NN NN O
measurements NN NN O
from NN NN O
control NN NN O
patients NN NN O
with NN NN O
SAH NN NN B-Disease
who NN NN O
were NN NN O
matched NN NN O
for NN NN O
factors NN NN O
known NN NN O
to NN NN O
influence NN NN O
arterial NN NN O
diameter NN NN O
. NN NN O
   
Qualitative NN NN O
comparisons NN NN O
of NN NN O
small NN NN O
artery NN NN O
changes NN NN O
also NN NN O
were NN NN O
made NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Thirteen NN NN O
patients NN NN O
with NN NN O
positive NN NN O
cocaine NN NN O
toxicology NN NN O
were NN NN O
compared NN NN O
to NN NN O
26 NN NN O
controls NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
significant NN NN O
differences NN NN O
between NN NN O
groups NN NN O
in NN NN O
the NN NN O
mean NN NN O
diameters NN NN O
of NN NN O
the NN NN O
intradural NN NN O
internal NN NN O
carotid NN NN O
, NN NN O
sphenoidal NN NN O
segment NN NN O
of NN NN O
the NN NN O
middle NN NN O
cerebral NN NN O
, NN NN O
precommunicating NN NN O
segment NN NN O
of NN NN O
the NN NN O
anterior NN NN O
cerebral NN NN O
, NN NN O
or NN NN O
basilar NN NN O
arteries NN NN O
( NN NN O
p NN NN O
greater NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
for NN NN O
all NN NN O
comparisons NN NN O
, NN NN O
unpaired NN NN O
t NN NN O
- NN NN O
tests NN NN O
) NN NN O
. NN NN O
   
There NN NN O
also NN NN O
were NN NN O
no NN NN O
significant NN NN O
differences NN NN O
between NN NN O
groups NN NN O
when NN NN O
expressing NN NN O
diameters NN NN O
as NN NN O
the NN NN O
sum NN NN O
of NN NN O
the NN NN O
precommunicating NN NN O
segment NN NN O
of NN NN O
the NN NN O
anterior NN NN O
cerebral NN NN O
+ NN NN O
sphenoidal NN NN O
segment NN NN O
of NN NN O
the NN NN O
middle NN NN O
cerebral NN NN O
+ NN NN O
supraclinoid NN NN O
internal NN NN O
carotid NN NN O
artery NN NN O
+ NN NN O
basilar NN NN O
artery NN NN O
divided NN NN O
by NN NN O
the NN NN O
diameter NN NN O
of NN NN O
the NN NN O
petrous NN NN O
internal NN NN O
carotid NN NN O
artery NN NN O
( NN NN O
p NN NN O
greater NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
, NN NN O
unpaired NN NN O
t NN NN O
- NN NN O
tests NN NN O
) NN NN O
. NN NN O
   
Qualitative NN NN O
assessments NN NN O
showed NN NN O
two NN NN O
arterial NN NN O
irregularities NN NN O
in NN NN O
the NN NN O
distal NN NN O
vasculature NN NN O
in NN NN O
each NN NN O
group NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
No NN NN O
quantitative NN NN O
evidence NN NN O
for NN NN O
narrowing NN NN O
of NN NN O
large NN NN O
cerebral NN NN O
arteries NN NN O
or NN NN O
qualitative NN NN O
angiographic NN NN O
evidence NN NN O
for NN NN O
distal NN NN O
narrowing NN NN O
or NN NN O
vasculitis NN NN B-Disease
could NN NN O
be NN NN O
found NN NN O
in NN NN O
patients NN NN O
who NN NN O
underwent NN NN O
angiography NN NN O
after NN NN O
aneurysmal NN NN B-Disease
SAH NN NN B-Disease
associated NN NN O
with NN NN O
cocaine NN NN O
use NN NN O
. NN NN O
   
Methamphetamine NN NN O
causes NN NN O
alterations NN NN O
in NN NN O
the NN NN O
MAP NN NN O
kinase NN NN O
- NN NN O
related NN NN O
pathways NN NN O
in NN NN O
the NN NN O
brains NN NN O
of NN NN O
mice NN NN O
that NN NN O
display NN NN O
increased NN NN O
aggressiveness NN NN B-Disease
. NN NN O
   
Aggressive NN NN B-Disease
behaviors NN NN I-Disease
have NN NN O
been NN NN O
reported NN NN O
in NN NN O
patients NN NN O
who NN NN O
suffer NN NN O
from NN NN O
some NN NN O
psychiatric NN NN B-Disease
disorders NN NN I-Disease
, NN NN O
and NN NN O
are NN NN O
common NN NN O
in NN NN O
methamphetamine NN NN O
( NN NN O
METH NN NN O
) NN NN O
abusers NN NN O
. NN NN O
   
Herein NN NN O
, NN NN O
we NN NN O
report NN NN O
that NN NN O
multiple NN NN O
( NN NN O
but NN NN O
not NN NN O
single NN NN O
) NN NN O
injections NN NN O
of NN NN O
METH NN NN O
significantly NN NN O
increased NN NN O
aggressiveness NN NN B-Disease
in NN NN O
male NN NN O
CD NN NN O
- NN NN O
1 NN NN O
mice NN NN O
. NN NN O
   
This NN NN O
increase NN NN O
in NN NN O
aggressiveness NN NN B-Disease
was NN NN O
not NN NN O
secondary NN NN O
to NN NN O
METH NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
. NN NN O
   
Analysis NN NN O
of NN NN O
protein NN NN O
expression NN NN O
using NN NN O
antibody NN NN O
microarrays NN NN O
and NN NN O
Western NN NN O
blotting NN NN O
revealed NN NN O
differential NN NN O
changes NN NN O
in NN NN O
MAP NN NN O
kinase NN NN O
- NN NN O
related NN NN O
pathways NN NN O
after NN NN O
multiple NN NN O
and NN NN O
single NN NN O
METH NN NN O
injections NN NN O
. NN NN O
   
There NN NN O
were NN NN O
statistically NN NN O
significant NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
decreases NN NN O
in NN NN O
MEK1 NN NN O
, NN NN O
Erk2p NN NN O
, NN NN O
GSK3alpha NN NN O
, NN NN O
14 NN NN O
- NN NN O
3 NN NN O
- NN NN O
3e NN NN O
, NN NN O
and NN NN O
MEK7 NN NN O
in NN NN O
the NN NN O
striata NN NN O
of NN NN O
mice NN NN O
after NN NN O
multiple NN NN O
injections NN NN O
of NN NN O
METH NN NN O
. NN NN O
   
MEK1 NN NN O
was NN NN O
significantly NN NN O
decreased NN NN O
also NN NN O
after NN NN O
a NN NN O
single NN NN O
injection NN NN O
of NN NN O
METH NN NN O
, NN NN O
but NN NN O
to NN NN O
a NN NN O
much NN NN O
lesser NN NN O
degree NN NN O
than NN NN O
after NN NN O
multiple NN NN O
injections NN NN O
of NN NN O
METH NN NN O
. NN NN O
   
In NN NN O
the NN NN O
frontal NN NN O
cortex NN NN O
, NN NN O
there NN NN O
was NN NN O
a NN NN O
statistically NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
GSK3alpha NN NN O
after NN NN O
multiple NN NN O
( NN NN O
but NN NN O
not NN NN O
single NN NN O
) NN NN O
injections NN NN O
of NN NN O
METH NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
alterations NN NN O
in NN NN O
MAP NN NN O
kinase NN NN O
- NN NN O
related NN NN O
pathways NN NN O
in NN NN O
the NN NN O
prefronto NN NN O
- NN NN O
striatal NN NN O
circuitries NN NN O
might NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
manifestation NN NN O
of NN NN O
aggressive NN NN B-Disease
behaviors NN NN I-Disease
in NN NN O
mice NN NN O
. NN NN O
   
Amisulpride NN NN O
related NN NN O
tic NN NN B-Disease
- NN NN I-Disease
like NN NN I-Disease
symptoms NN NN I-Disease
in NN NN O
an NN NN O
adolescent NN NN O
schizophrenic NN NN B-Disease
. NN NN O
   
Tic NN NN B-Disease
disorders NN NN I-Disease
can NN NN O
be NN NN O
effectively NN NN O
treated NN NN O
by NN NN O
atypical NN NN O
antipsychotics NN NN O
such NN NN O
as NN NN O
risperidone NN NN O
, NN NN O
olanzapine NN NN O
and NN NN O
ziprasidone NN NN O
. NN NN O
   
However NN NN O
, NN NN O
there NN NN O
are NN NN O
two NN NN O
case NN NN O
reports NN NN O
that NN NN O
show NN NN O
tic NN NN B-Disease
- NN NN I-Disease
like NN NN I-Disease
symptoms NN NN I-Disease
, NN NN O
including NN NN O
motor NN NN O
and NN NN O
phonic NN NN O
variants NN NN O
, NN NN O
occurring NN NN O
during NN NN O
treatment NN NN O
with NN NN O
quetiapine NN NN O
or NN NN O
clozapine NN NN O
. NN NN O
   
We NN NN O
present NN NN O
a NN NN O
15 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
girl NN NN O
schizophrenic NN NN B-Disease
who NN NN O
developed NN NN O
frequent NN NN O
involuntary NN NN B-Disease
eye NN NN I-Disease
- NN NN I-Disease
blinking NN NN I-Disease
movements NN NN I-Disease
after NN NN O
5 NN NN O
months NN NN O
of NN NN O
amisulpride NN NN O
treatment NN NN O
( NN NN O
1000 NN NN O
mg NN NN O
per NN NN O
day NN NN O
) NN NN O
. NN NN O
   
The NN NN O
tic NN NN B-Disease
- NN NN I-Disease
like NN NN I-Disease
symptoms NN NN I-Disease
resolved NN NN O
completely NN NN O
after NN NN O
we NN NN O
reduced NN NN O
the NN NN O
dose NN NN O
of NN NN O
amisulpride NN NN O
down NN NN O
to NN NN O
800 NN NN O
mg NN NN O
per NN NN O
day NN NN O
. NN NN O
   
However NN NN O
, NN NN O
her NN NN O
psychosis NN NN B-Disease
recurred NN NN O
after NN NN O
the NN NN O
dose NN NN O
reduction NN NN O
. NN NN O
   
We NN NN O
then NN NN O
placed NN NN O
her NN NN O
on NN NN O
an NN NN O
additional NN NN O
100 NN NN O
mg NN NN O
per NN NN O
day NN NN O
of NN NN O
quetiapine NN NN O
. NN NN O
   
She NN NN O
has NN NN O
been NN NN O
in NN NN O
complete NN NN O
remission NN NN O
under NN NN O
the NN NN O
combined NN NN O
medications NN NN O
for NN NN O
more NN NN O
than NN NN O
one NN NN O
year NN NN O
and NN NN O
maintains NN NN O
a NN NN O
fair NN NN O
role NN NN O
function NN NN O
. NN NN O
   
No NN NN O
more NN NN O
tic NN NN B-Disease
- NN NN I-Disease
like NN NN I-Disease
symptoms NN NN I-Disease
or NN NN O
other NN NN O
side NN NN O
effects NN NN O
have NN NN O
been NN NN O
reported NN NN O
. NN NN O
   
Together NN NN O
with NN NN O
previously NN NN O
reported NN NN O
cases NN NN O
, NN NN O
our NN NN O
patient NN NN O
suggests NN NN O
that NN NN O
tic NN NN B-Disease
- NN NN I-Disease
like NN NN I-Disease
symptoms NN NN I-Disease
might NN NN O
occur NN NN O
in NN NN O
certain NN NN O
vulnerable NN NN O
individuals NN NN O
during NN NN O
treatment NN NN O
with NN NN O
atypical NN NN O
antipsychotics NN NN O
such NN NN O
as NN NN O
quetiapine NN NN O
, NN NN O
clozapine NN NN O
, NN NN O
or NN NN O
amisulpride NN NN O
. NN NN O
   
Chloroquine NN NN O
related NN NN O
complete NN NN O
heart NN NN B-Disease
block NN NN I-Disease
with NN NN O
blindness NN NN B-Disease
: NN NN O
case NN NN O
report NN NN O
. NN NN O
   
A NN NN O
27 NN NN O
- NN NN O
year NN NN O
old NN NN O
African NN NN O
woman NN NN O
with NN NN O
history NN NN O
of NN NN O
regular NN NN O
chloroquine NN NN O
ingestion NN NN O
presented NN NN O
with NN NN O
progressive NN NN O
deterioration NN NN B-Disease
of NN NN I-Disease
vision NN NN I-Disease
, NN NN O
easy NN NN O
fatiguability NN NN B-Disease
, NN NN O
dyspnoea NN NN B-Disease
, NN NN O
dizziness NN NN B-Disease
progressing NN NN O
to NN NN O
syncopal NN NN B-Disease
attacks NN NN I-Disease
. NN NN O
   
Ophthalmological NN NN O
assessment NN NN O
revealed NN NN O
features NN NN O
of NN NN O
chloroquine NN NN O
retinopathy NN NN B-Disease
, NN NN O
cardiac NN NN O
assessment NN NN O
revealed NN NN O
features NN NN O
of NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
and NN NN O
a NN NN O
complete NN NN O
heart NN NN B-Disease
block NN NN I-Disease
with NN NN O
right NN NN B-Disease
bundle NN NN I-Disease
branch NN NN I-Disease
block NN NN I-Disease
pattern NN NN O
. NN NN O
   
The NN NN O
heart NN NN B-Disease
block NN NN I-Disease
was NN NN O
treated NN NN O
by NN NN O
pacemaker NN NN O
insertion NN NN O
and NN NN O
the NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
resolved NN NN O
spontaneously NN NN O
following NN NN O
chloroquine NN NN O
discontinuation NN NN O
. NN NN O
   
She NN NN O
however NN NN O
remains NN NN O
blind NN NN B-Disease
. NN NN O
   
Effects NN NN O
of NN NN O
suprofen NN NN O
on NN NN O
the NN NN O
isolated NN NN O
perfused NN NN O
rat NN NN O
kidney NN NN O
. NN NN O
   
Although NN NN O
suprofen NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
in NN NN O
greater NN NN O
than NN NN O
100 NN NN O
subjects NN NN O
, NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
damage NN NN O
remains NN NN O
unclear NN NN O
. NN NN O
   
The NN NN O
direct NN NN O
nephrotoxic NN NN B-Disease
effects NN NN O
of NN NN O
a NN NN O
single NN NN O
dose NN NN O
of NN NN O
15 NN NN O
mg NN NN O
of NN NN O
suprofen NN NN O
were NN NN O
compared NN NN O
in NN NN O
the NN NN O
recirculating NN NN O
isolated NN NN O
rat NN NN O
kidney NN NN O
perfused NN NN O
with NN NN O
cell NN NN O
- NN NN O
free NN NN O
buffer NN NN O
with NN NN O
or NN NN O
without NN NN O
the NN NN O
addition NN NN O
of NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
of NN NN O
uric NN NN O
acid NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
significant NN NN O
differences NN NN O
in NN NN O
renal NN NN O
sodium NN NN O
excretion NN NN O
, NN NN O
oxygen NN NN O
consumption NN NN O
, NN NN O
or NN NN O
urinary NN NN O
flow NN NN O
rates NN NN O
in NN NN O
kidneys NN NN O
perfused NN NN O
with NN NN O
suprofen NN NN O
compared NN NN O
with NN NN O
the NN NN O
drug NN NN O
- NN NN O
free NN NN O
control NN NN O
groups NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
a NN NN O
significant NN NN O
decline NN NN O
in NN NN O
glomerular NN NN O
filtration NN NN O
rate NN NN O
was NN NN O
found NN NN O
after NN NN O
the NN NN O
introduction NN NN O
of NN NN O
suprofen NN NN O
to NN NN O
the NN NN O
kidney NN NN O
perfused NN NN O
with NN NN O
uric NN NN O
acid NN NN O
; NN NN O
no NN NN O
changes NN NN O
were NN NN O
found NN NN O
with NN NN O
suprofen NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
uric NN NN O
acid NN NN O
. NN NN O
   
A NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
the NN NN O
baseline NN NN O
excretion NN NN O
rate NN NN O
of NN NN O
uric NN NN O
acid NN NN O
was NN NN O
found NN NN O
in NN NN O
rats NN NN O
given NN NN O
suprofen NN NN O
, NN NN O
compared NN NN O
with NN NN O
drug NN NN O
- NN NN O
free NN NN O
controls NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
fractional NN NN O
excretion NN NN O
of NN NN O
uric NN NN O
acid NN NN O
was NN NN O
unchanged NN NN O
between NN NN O
the NN NN O
groups NN NN O
over NN NN O
the NN NN O
experimental NN NN O
period NN NN O
. NN NN O
   
In NN NN O
summary NN NN O
, NN NN O
suprofen NN NN O
causes NN NN O
acute NN NN B-Disease
declines NN NN I-Disease
in NN NN I-Disease
renal NN NN I-Disease
function NN NN I-Disease
, NN NN O
most NN NN O
likely NN NN O
by NN NN O
directly NN NN O
altering NN NN O
the NN NN O
intrarenal NN NN O
distribution NN NN O
of NN NN O
uric NN NN O
acid NN NN O
. NN NN O
   
Microinjection NN NN O
of NN NN O
ritanserin NN NN O
into NN NN O
the NN NN O
CA1 NN NN O
region NN NN O
of NN NN O
hippocampus NN NN O
improves NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
in NN NN O
adult NN NN O
male NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
ritanserin NN NN O
( NN NN O
5 NN NN O
- NN NN O
HT2 NN NN O
antagonist NN NN O
) NN NN O
on NN NN O
scopolamine NN NN O
( NN NN O
muscarinic NN NN O
cholinergic NN NN O
antagonist NN NN O
) NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
in NN NN O
Morris NN NN O
water NN NN O
maze NN NN O
( NN NN O
MWM NN NN O
) NN NN O
was NN NN O
investigated NN NN O
. NN NN O
   
Rats NN NN O
were NN NN O
divided NN NN O
into NN NN O
eight NN NN O
groups NN NN O
and NN NN O
bilaterally NN NN O
cannulated NN NN O
into NN NN O
CA1 NN NN O
region NN NN O
of NN NN O
the NN NN O
hippocampus NN NN O
. NN NN O
   
One NN NN O
week NN NN O
later NN NN O
, NN NN O
they NN NN O
received NN NN O
repeatedly NN NN O
vehicles NN NN O
( NN NN O
saline NN NN O
, NN NN O
DMSO NN NN O
, NN NN O
saline NN NN O
+ NN NN O
DMSO NN NN O
) NN NN O
, NN NN O
scopolamine NN NN O
( NN NN O
2 NN NN O
microg NN NN O
/ NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microl NN NN O
saline NN NN O
/ NN NN O
side NN NN O
; NN NN O
30 NN NN O
min NN NN O
before NN NN O
training NN NN O
) NN NN O
, NN NN O
ritanserin NN NN O
( NN NN O
2 NN NN O
, NN NN O
4 NN NN O
and NN NN O
8 NN NN O
microg NN NN O
/ NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microl NN NN O
DMSO NN NN O
/ NN NN O
side NN NN O
; NN NN O
20 NN NN O
min NN NN O
before NN NN O
training NN NN O
) NN NN O
and NN NN O
scopolamine NN NN O
( NN NN O
2 NN NN O
microg NN NN O
/ NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microl NN NN O
; NN NN O
30 NN NN O
min NN NN O
before NN NN O
ritanserin NN NN O
injection NN NN O
) NN NN O
+ NN NN O
ritanserin NN NN O
( NN NN O
4 NN NN O
microg NN NN O
/ NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microl NN NN O
DMSO NN NN O
) NN NN O
through NN NN O
cannulae NN NN O
each NN NN O
day NN NN O
. NN NN O
   
Animals NN NN O
were NN NN O
tested NN NN O
for NN NN O
four NN NN O
consecutive NN NN O
days NN NN O
( NN NN O
4 NN NN O
trial NN NN O
/ NN NN O
day NN NN O
) NN NN O
in NN NN O
MWM NN NN O
during NN NN O
which NN NN O
the NN NN O
position NN NN O
of NN NN O
hidden NN NN O
platform NN NN O
was NN NN O
unchanged NN NN O
. NN NN O
   
In NN NN O
the NN NN O
fifth NN NN O
day NN NN O
, NN NN O
the NN NN O
platform NN NN O
was NN NN O
elevated NN NN O
above NN NN O
the NN NN O
water NN NN O
surface NN NN O
in NN NN O
another NN NN O
position NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
function NN NN O
of NN NN O
motor NN NN O
, NN NN O
motivational NN NN O
and NN NN O
visual NN NN O
systems NN NN O
. NN NN O
   
The NN NN O
results NN NN O
showed NN NN O
a NN NN O
significant NN NN O
increase NN NN O
in NN NN O
escape NN NN O
latencies NN NN O
and NN NN O
traveled NN NN O
distances NN NN O
to NN NN O
find NN NN O
platform NN NN O
in NN NN O
scopolamine NN NN O
- NN NN O
treated NN NN O
group NN NN O
as NN NN O
compared NN NN O
to NN NN O
saline NN NN O
group NN NN O
. NN NN O
   
Ritanserin NN NN O
- NN NN O
treated NN NN O
rats NN NN O
( NN NN O
4 NN NN O
microg NN NN O
/ NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microl NN NN O
/ NN NN O
side NN NN O
) NN NN O
showed NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
the NN NN O
mentioned NN NN O
parameters NN NN O
as NN NN O
compared NN NN O
to NN NN O
DMSO NN NN O
- NN NN O
treated NN NN O
group NN NN O
. NN NN O
   
However NN NN O
, NN NN O
scopolamine NN NN O
and NN NN O
ritanserin NN NN O
co NN NN O
- NN NN O
administration NN NN O
resulted NN NN O
in NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
escape NN NN O
latencies NN NN O
and NN NN O
traveled NN NN O
distances NN NN O
as NN NN O
compared NN NN O
to NN NN O
the NN NN O
scopolamine NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
Our NN NN O
findings NN NN O
show NN NN O
that NN NN O
microinjection NN NN O
of NN NN O
ritanserin NN NN O
into NN NN O
the NN NN O
CA1 NN NN O
region NN NN O
of NN NN O
the NN NN O
hippocampus NN NN O
improves NN NN O
the NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
. NN NN O
   
PTU NN NN O
- NN NN O
associated NN NN O
vasculitis NN NN B-Disease
in NN NN O
a NN NN O
girl NN NN O
with NN NN O
Turner NN NN B-Disease
Syndrome NN NN I-Disease
and NN NN O
Graves NN NN B-Disease
' NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Palpable NN NN O
purpura NN NN B-Disease
is NN NN O
a NN NN O
concerning NN NN O
clinical NN NN O
finding NN NN O
in NN NN O
pediatric NN NN O
patients NN NN O
and NN NN O
can NN NN O
have NN NN O
many NN NN O
causes NN NN O
, NN NN O
including NN NN O
infectious NN NN O
and NN NN O
autoimmune NN NN O
processes NN NN O
. NN NN O
   
A NN NN O
rare NN NN O
cause NN NN O
, NN NN O
drug NN NN O
- NN NN O
induced NN NN O
vasculitis NN NN B-Disease
, NN NN O
may NN NN O
result NN NN O
from NN NN O
the NN NN O
production NN NN O
of NN NN O
antineutrophil NN NN O
cytoplasmic NN NN O
antibodies NN NN O
( NN NN O
ANCAs NN NN O
) NN NN O
in NN NN O
response NN NN O
to NN NN O
a NN NN O
medication NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
girl NN NN O
with NN NN O
Turner NN NN B-Disease
syndrome NN NN I-Disease
and NN NN O
Graves NN NN B-Disease
' NN NN I-Disease
disease NN NN I-Disease
who NN NN O
presented NN NN O
with NN NN O
palpable NN NN O
purpuric NN NN B-Disease
lesions NN NN I-Disease
. NN NN O
   
The NN NN O
diagnosis NN NN O
of NN NN O
propylthiouracil NN NN O
( NN NN O
PTU NN NN O
) NN NN O
- NN NN O
associated NN NN O
vasculitis NN NN B-Disease
was NN NN O
made NN NN O
by NN NN O
observation NN NN O
of NN NN O
consistent NN NN O
clinical NN NN O
features NN NN O
, NN NN O
the NN NN O
detection NN NN O
of NN NN O
elevated NN NN O
ANA NN NN O
and NN NN O
ANCA NN NN O
in NN NN O
the NN NN O
blood NN NN O
, NN NN O
and NN NN O
the NN NN O
observed NN NN O
clinical NN NN O
resolution NN NN O
of NN NN O
symptoms NN NN O
following NN NN O
withdrawal NN NN O
of NN NN O
PTU NN NN O
. NN NN O
   
Subsequent NN NN O
treatment NN NN O
of NN NN O
persistent NN NN O
hyperthyroidism NN NN B-Disease
with NN NN O
radioablation NN NN O
did NN NN O
not NN NN O
result NN NN O
in NN NN O
an NN NN O
exacerbation NN NN O
of NN NN O
the NN NN O
vasculitis NN NN B-Disease
, NN NN O
a NN NN O
complication NN NN O
described NN NN O
in NN NN O
prior NN NN O
case NN NN O
reports NN NN O
. NN NN O
   
Daidzein NN NN O
activates NN NN O
choline NN NN O
acetyltransferase NN NN O
from NN NN O
MC NN NN O
- NN NN O
IXC NN NN O
cells NN NN O
and NN NN O
improves NN NN O
drug NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
. NN NN O
   
The NN NN O
choline NN NN O
acetyltransferase NN NN O
( NN NN O
ChAT NN NN O
) NN NN O
activator NN NN O
, NN NN O
which NN NN O
enhances NN NN O
cholinergic NN NN O
transmission NN NN O
via NN NN O
an NN NN O
augmentation NN NN O
of NN NN O
the NN NN O
enzymatic NN NN O
production NN NN O
of NN NN O
acetylcholine NN NN O
( NN NN O
ACh NN NN O
) NN NN O
, NN NN O
is NN NN O
an NN NN O
important NN NN O
factor NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
Alzheimer NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
( NN NN O
AD NN NN B-Disease
) NN NN O
. NN NN O
   
Methanolic NN NN O
extracts NN NN O
from NN NN O
Pueraria NN NN O
thunbergiana NN NN O
exhibited NN NN O
an NN NN O
activation NN NN O
effect NN NN O
( NN NN O
46 NN NN O
% NN NN O
) NN NN O
on NN NN O
ChAT NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
Via NN NN O
the NN NN O
sequential NN NN O
isolation NN NN O
of NN NN O
Pueraria NN NN O
thunbergiana NN NN O
, NN NN O
the NN NN O
active NN NN O
component NN NN O
was NN NN O
ultimately NN NN O
identified NN NN O
as NN NN O
daidzein NN NN O
( NN NN O
4 NN NN O
' NN NN O
, NN NN O
7 NN NN O
- NN NN O
dihydroxy NN NN O
- NN NN O
isoflavone NN NN O
) NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
investigate NN NN O
the NN NN O
effects NN NN O
of NN NN O
daidzein NN NN O
from NN NN O
Pueraria NN NN O
thunbergiana NN NN O
on NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
impairments NN NN B-Disease
of NN NN I-Disease
learning NN NN I-Disease
and NN NN I-Disease
memory NN NN I-Disease
, NN NN O
we NN NN O
conducted NN NN O
a NN NN O
series NN NN O
of NN NN O
in NN NN O
vivo NN NN O
tests NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
daidzein NN NN O
( NN NN O
4 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
) NN NN O
to NN NN O
mice NN NN O
was NN NN O
shown NN NN O
significantly NN NN O
to NN NN O
reverse NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
, NN NN O
according NN NN O
to NN NN O
the NN NN O
results NN NN O
of NN NN O
a NN NN O
Y NN NN O
- NN NN O
maze NN NN O
test NN NN O
. NN NN O
   
Injections NN NN O
of NN NN O
scopolamine NN NN O
into NN NN O
mice NN NN O
resulted NN NN O
in NN NN O
impaired NN NN O
performance NN NN O
on NN NN O
Y NN NN O
- NN NN O
maze NN NN O
tests NN NN O
( NN NN O
a NN NN O
37 NN NN O
% NN NN O
decreases NN NN O
in NN NN O
alternation NN NN O
behavior NN NN O
) NN NN O
. NN NN O
   
By NN NN O
way NN NN O
of NN NN O
contrast NN NN O
, NN NN O
mice NN NN O
treated NN NN O
with NN NN O
daidzein NN NN O
prior NN NN O
to NN NN O
the NN NN O
scopolamine NN NN O
injections NN NN O
were NN NN O
noticeably NN NN O
protected NN NN O
from NN NN O
this NN NN O
performance NN NN O
impairment NN NN O
( NN NN O
an NN NN O
approximately NN NN O
12 NN NN O
% NN NN O
- NN NN O
21 NN NN O
% NN NN O
decrease NN NN O
in NN NN O
alternation NN NN O
behavior NN NN O
) NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
daidzein NN NN O
might NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
acetylcholine NN NN O
biosynthesis NN NN O
as NN NN O
a NN NN O
ChAT NN NN O
activator NN NN O
, NN NN O
and NN NN O
that NN NN O
it NN NN O
also NN NN O
ameliorates NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
. NN NN O
   
Urinary NN NN O
symptoms NN NN O
and NN NN O
quality NN NN O
of NN NN O
life NN NN O
changes NN NN O
in NN NN O
Thai NN NN O
women NN NN O
with NN NN O
overactive NN NN B-Disease
bladder NN NN I-Disease
after NN NN O
tolterodine NN NN O
treatment NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
To NN NN O
study NN NN O
the NN NN O
urinary NN NN O
symptoms NN NN O
and NN NN O
quality NN NN O
of NN NN O
life NN NN O
changes NN NN O
in NN NN O
Thai NN NN O
women NN NN O
with NN NN O
overactive NN NN B-Disease
bladder NN NN I-Disease
( NN NN O
OAB NN NN B-Disease
) NN NN O
after NN NN O
tolterodine NN NN O
treatment NN NN O
. NN NN O
   
MATERIAL NN NN O
AND NN NN O
METHOD NN NN O
: NN NN O
Thirty NN NN O
women NN NN O
( NN NN O
aged NN NN O
30 NN NN O
- NN NN O
77 NN NN O
years NN NN O
) NN NN O
diagnosed NN NN O
as NN NN O
having NN NN O
OAB NN NN B-Disease
at NN NN O
the NN NN O
Gynecology NN NN O
Clinic NN NN O
, NN NN O
King NN NN O
Chulalongkorn NN NN O
Memorial NN NN O
Hospital NN NN O
from NN NN O
January NN NN O
to NN NN O
April NN NN O
2004 NN NN O
were NN NN O
included NN NN O
in NN NN O
the NN NN O
present NN NN O
study NN NN O
. NN NN O
   
Tolterodine NN NN O
2 NN NN O
mg NN NN O
, NN NN O
twice NN NN O
daily NN NN O
was NN NN O
given NN NN O
. NN NN O
   
After NN NN O
8 NN NN O
weeks NN NN O
treatment NN NN O
, NN NN O
changes NN NN O
in NN NN O
micturition NN NN O
diary NN NN O
variables NN NN O
and NN NN O
tolerability NN NN O
were NN NN O
determined NN NN O
. NN NN O
   
Short NN NN O
form NN NN O
36 NN NN O
( NN NN O
SF36 NN NN O
) NN NN O
questionaires NN NN O
( NN NN O
Thai NN NN O
version NN NN O
) NN NN O
were NN NN O
given NN NN O
before NN NN O
and NN NN O
after NN NN O
8 NN NN O
weeks NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
At NN NN O
8 NN NN O
weeks NN NN O
, NN NN O
all NN NN O
micturition NN NN O
per NN NN O
day NN NN O
decreased NN NN O
from NN NN O
16 NN NN O
. NN NN O
   
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
. NN NN O
   
3 NN NN O
to NN NN O
6 NN NN O
. NN NN O
   
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
4 NN NN O
times NN NN O
per NN NN O
day NN NN O
. NN NN O
   
The NN NN O
number NN NN O
of NN NN O
nocturia NN NN B-Disease
episodes NN NN O
decreased NN NN O
from NN NN O
5 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
. NN NN O
2 NN NN O
to NN NN O
1 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
0 NN NN O
times NN NN O
per NN NN O
night NN NN O
. NN NN O
   
The NN NN O
most NN NN O
common NN NN O
side NN NN O
effect NN NN O
was NN NN O
dry NN NN B-Disease
month NN NN I-Disease
in NN NN O
5 NN NN O
cases NN NN O
( NN NN O
16 NN NN O
. NN NN O
7 NN NN O
% NN NN O
) NN NN O
with NN NN O
2 NN NN O
cases NN NN O
reporting NN NN O
a NN NN O
moderate NN NN O
degree NN NN O
and NN NN O
1 NN NN O
case NN NN O
with NN NN O
severe NN NN O
degree NN NN O
. NN NN O
   
Only NN NN O
one NN NN O
case NN NN O
( NN NN O
3 NN NN O
. NN NN O
3 NN NN O
% NN NN O
) NN NN O
withdrew NN NN O
from NN NN O
the NN NN O
present NN NN O
study NN NN O
due NN NN O
to NN NN O
a NN NN O
severe NN NN O
dry NN NN B-Disease
mouth NN NN I-Disease
. NN NN O
   
The NN NN O
SF NN NN O
- NN NN O
36 NN NN O
scores NN NN O
changed NN NN O
significantly NN NN O
in NN NN O
the NN NN O
domains NN NN O
of NN NN O
physical NN NN O
functioning NN NN O
, NN NN O
role NN NN O
function NN NN O
emotional NN NN O
, NN NN O
social NN NN O
function NN NN O
and NN NN O
mental NN NN O
heath NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Tolterodine NN NN O
was NN NN O
well NN NN O
tolerated NN NN O
and NN NN O
its NN NN O
effects NN NN O
improved NN NN O
the NN NN O
quality NN NN O
of NN NN O
life NN NN O
in NN NN O
Thai NN NN O
women NN NN O
with NN NN O
OAB NN NN B-Disease
. NN NN O
   
Remifentanil NN NN O
pretreatment NN NN O
reduces NN NN O
myoclonus NN NN B-Disease
after NN NN O
etomidate NN NN O
. NN NN O
   
STUDY NN NN O
OBJECTIVE NN NN O
: NN NN O
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
study NN NN O
was NN NN O
to NN NN O
compare NN NN O
the NN NN O
effect NN NN O
of NN NN O
pretreatment NN NN O
with NN NN O
remifentanil NN NN O
1 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
and NN NN O
the NN NN O
effect NN NN O
of NN NN O
gender NN NN O
on NN NN O
the NN NN O
incidence NN NN O
of NN NN O
myoclonus NN NN B-Disease
after NN NN O
anesthesia NN NN O
induction NN NN O
with NN NN O
etomidate NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
This NN NN O
was NN NN O
a NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
study NN NN O
. NN NN O
   
SETTING NN NN O
: NN NN O
The NN NN O
study NN NN O
was NN NN O
conducted NN NN O
at NN NN O
a NN NN O
university NN NN O
hospital NN NN O
. NN NN O
   
PATIENTS NN NN O
: NN NN O
Sixty NN NN O
patients NN NN O
were NN NN O
pretreated NN NN O
in NN NN O
a NN NN O
randomized NN NN O
double NN NN O
- NN NN O
blinded NN NN O
fashion NN NN O
with NN NN O
remifentanil NN NN O
1 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
or NN NN O
placebo NN NN O
. NN NN O
   
Two NN NN O
minutes NN NN O
after NN NN O
remifentanil NN NN O
or NN NN O
placebo NN NN O
injection NN NN O
, NN NN O
etomidate NN NN O
0 NN NN O
. NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
was NN NN O
given NN NN O
. NN NN O
   
MEASUREMENTS NN NN O
: NN NN O
Myoclonus NN NN B-Disease
was NN NN O
recorded NN NN O
with NN NN O
a NN NN O
scale NN NN O
of NN NN O
0 NN NN O
to NN NN O
3 NN NN O
. NN NN O
   
The NN NN O
grade NN NN O
of NN NN O
sedation NN NN O
( NN NN O
none NN NN O
, NN NN O
mild NN NN O
, NN NN O
moderate NN NN O
, NN NN O
severe NN NN O
) NN NN O
, NN NN O
nausea NN NN B-Disease
, NN NN O
pruritus NN NN B-Disease
, NN NN O
and NN NN O
apnea NN NN B-Disease
were NN NN O
recorded NN NN O
after NN NN O
injection NN NN O
of NN NN O
both NN NN O
drugs NN NN O
. NN NN O
   
MAIN NN NN O
RESULTS NN NN O
: NN NN O
The NN NN O
incidence NN NN O
of NN NN O
myoclonus NN NN B-Disease
was NN NN O
significantly NN NN O
lower NN NN O
in NN NN O
the NN NN O
remifentanil NN NN O
group NN NN O
( NN NN O
6 NN NN O
. NN NN O
7 NN NN O
% NN NN O
) NN NN O
than NN NN O
in NN NN O
the NN NN O
placebo NN NN O
group NN NN O
( NN NN O
70 NN NN O
% NN NN O
) NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
   O
of NN NN O
the NN NN O
patients NN NN O
experienced NN NN O
sedation NN NN O
, NN NN O
apnea NN NN B-Disease
, NN NN O
nausea NN NN B-Disease
, NN NN O
or NN NN O
pruritus NN NN B-Disease
after NN NN O
injection NN NN O
of NN NN O
both NN NN O
drugs NN NN O
. NN NN O
   
In NN NN O
the NN NN O
placebo NN NN O
group NN NN O
, NN NN O
male NN NN O
patients NN NN O
were NN NN O
associated NN NN O
with NN NN O
significantly NN NN O
increased NN NN O
incidence NN NN O
of NN NN O
myoclonus NN NN B-Disease
after NN NN O
etomidate NN NN O
administration NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Pretreatment NN NN O
with NN NN O
remifentanil NN NN O
1 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
reduced NN NN O
myoclonus NN NN B-Disease
after NN NN O
etomidate NN NN O
induction NN NN O
without NN NN O
side NN NN O
effects NN NN O
such NN NN O
as NN NN O
sedation NN NN O
, NN NN O
apnea NN NN B-Disease
, NN NN O
nausea NN NN B-Disease
, NN NN O
or NN NN O
pruritus NN NN B-Disease
. NN NN O
   
Men NN NN O
experience NN NN O
increased NN NN O
incidence NN NN O
of NN NN O
myoclonus NN NN B-Disease
than NN NN O
women NN NN O
after NN NN O
etomidate NN NN O
administration NN NN O
. NN NN O
   
Memory NN NN O
function NN NN O
and NN NN O
serotonin NN NN O
transporter NN NN O
promoter NN NN O
gene NN NN O
polymorphism NN NN O
in NN NN O
ecstasy NN NN O
( NN NN O
MDMA NN NN O
) NN NN O
users NN NN O
. NN NN O
   
Although NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
methylenedioxymethamphetamine NN NN O
( NN NN O
MDMA NN NN O
or NN NN O
ecstasy NN NN O
) NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
damage NN NN O
brain NN NN O
serotonin NN NN O
( NN NN O
5 NN NN O
- NN NN O
HT NN NN O
) NN NN O
neurons NN NN O
in NN NN O
animals NN NN O
and NN NN O
possibly NN NN O
humans NN NN O
, NN NN O
little NN NN O
is NN NN O
known NN NN O
about NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
consequences NN NN O
of NN NN O
MDMA NN NN O
- NN NN O
induced NN NN O
5 NN NN O
- NN NN O
HT NN NN O
neurotoxic NN NN B-Disease
lesions NN NN I-Disease
on NN NN O
functions NN NN O
in NN NN O
which NN NN O
5 NN NN O
- NN NN O
HT NN NN O
is NN NN O
involved NN NN O
, NN NN O
such NN NN O
as NN NN O
cognitive NN NN O
function NN NN O
. NN NN O
   
Because NN NN O
5 NN NN O
- NN NN O
HT NN NN O
transporters NN NN O
play NN NN O
a NN NN O
key NN NN O
element NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
synaptic NN NN O
5 NN NN O
- NN NN O
HT NN NN O
transmission NN NN O
it NN NN O
may NN NN O
be NN NN O
important NN NN O
to NN NN O
control NN NN O
for NN NN O
the NN NN O
potential NN NN O
covariance NN NN O
effect NN NN O
of NN NN O
a NN NN O
polymorphism NN NN O
in NN NN O
the NN NN O
5 NN NN O
- NN NN O
HT NN NN O
transporter NN NN O
promoter NN NN O
gene NN NN O
region NN NN O
( NN NN O
5 NN NN O
- NN NN O
HTTLPR NN NN O
) NN NN O
when NN NN O
studying NN NN O
the NN NN O
effects NN NN O
of NN NN O
MDMA NN NN O
as NN NN O
well NN NN O
as NN NN O
cognitive NN NN O
functioning NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
the NN NN O
effects NN NN O
of NN NN O
moderate NN NN O
and NN NN O
heavy NN NN O
MDMA NN NN O
use NN NN O
on NN NN O
cognitive NN NN O
function NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
effects NN NN O
of NN NN O
long NN NN O
- NN NN O
term NN NN O
abstention NN NN O
from NN NN O
MDMA NN NN O
, NN NN O
in NN NN O
subjects NN NN O
genotyped NN NN O
for NN NN O
5 NN NN O
- NN NN O
HTTLPR NN NN O
. NN NN O
   
A NN NN O
second NN NN O
aim NN NN O
of NN NN O
the NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
whether NN NN O
these NN NN O
effects NN NN O
differ NN NN O
for NN NN O
females NN NN O
and NN NN O
males NN NN O
. NN NN O
   
Fifteen NN NN O
moderate NN NN O
MDMA NN NN O
users NN NN O
( NN NN O
< NN NN O
55 NN NN O
lifetime NN NN O
tablets NN NN O
) NN NN O
, NN NN O
22 NN NN O
heavy NN NN O
MDMA NN NN O
+ NN NN O
users NN NN O
( NN NN O
> NN NN O
55 NN NN O
lifetime NN NN O
tablets NN NN O
) NN NN O
, NN NN O
16 NN NN O
ex NN NN O
- NN NN O
MDMA NN NN O
+ NN NN O
users NN NN O
( NN NN O
last NN NN O
tablet NN NN O
> NN NN O
1 NN NN O
year NN NN O
ago NN NN O
) NN NN O
and NN NN O
13 NN NN O
controls NN NN O
were NN NN O
compared NN NN O
on NN NN O
a NN NN O
battery NN NN O
of NN NN O
neuropsychological NN NN O
tests NN NN O
. NN NN O
   
DNA NN NN O
from NN NN O
peripheral NN NN O
nuclear NN NN O
blood NN NN O
cells NN NN O
was NN NN O
genotyped NN NN O
for NN NN O
5 NN NN O
- NN NN O
HTTLPR NN NN O
using NN NN O
standard NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
methods NN NN O
. NN NN O
A NN NN O
significant NN NN O
group NN NN O
effect NN NN O
was NN NN O
observed NN NN O
only NN NN O
on NN NN O
memory NN NN O
function NN NN O
tasks NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
04 NN NN O
) NN NN O
but NN NN O
not NN NN O
on NN NN O
reaction NN NN O
times NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
61 NN NN O
) NN NN O
or NN NN O
attention NN NN O
/ NN NN O
executive NN NN O
functioning NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
59 NN NN O
) NN NN O
. NN NN O
   
Heavy NN NN O
and NN NN O
ex NN NN O
- NN NN O
MDMA NN NN O
+ NN NN O
users NN NN O
performed NN NN O
significantly NN NN O
poorer NN NN O
on NN NN O
memory NN NN O
tasks NN NN O
than NN NN O
controls NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
no NN NN O
evidence NN NN O
of NN NN O
memory NN NN B-Disease
impairment NN NN I-Disease
was NN NN O
observed NN NN O
in NN NN O
moderate NN NN O
MDMA NN NN O
users NN NN O
. NN NN O
   
No NN NN O
significant NN NN O
effect NN NN O
of NN NN O
5 NN NN O
- NN NN O
HTTLPR NN NN O
or NN NN O
gender NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
While NN NN O
the NN NN O
use NN NN O
of NN NN O
MDMA NN NN O
in NN NN O
quantities NN NN O
that NN NN O
may NN NN O
be NN NN O
considered NN NN O
"""""""" NN NN O
moderate NN NN O
"""""""" NN NN O
is NN NN O
not NN NN O
associated NN NN O
with NN NN O
impaired NN NN B-Disease
memory NN NN I-Disease
functioning NN NN I-Disease
, NN NN O
heavy NN NN O
use NN NN O
of NN NN O
MDMA NN NN O
use NN NN O
may NN NN O
lead NN NN O
to NN NN O
long NN NN O
lasting NN NN O
memory NN NN B-Disease
impairments NN NN I-Disease
. NN NN O
   
No NN NN O
effect NN NN O
of NN NN O
5 NN NN O
- NN NN O
HTTLPR NN NN O
or NN NN O
gender NN NN O
on NN NN O
memory NN NN O
function NN NN O
or NN NN O
MDMA NN NN O
use NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
Role NN NN O
of NN NN O
mangiferin NN NN O
on NN NN O
biochemical NN NN O
alterations NN NN O
and NN NN O
antioxidant NN NN O
status NN NN O
in NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
current NN NN O
study NN NN O
dealt NN NN O
with NN NN O
the NN NN O
protective NN NN O
role NN NN O
of NN NN O
mangiferin NN NN O
, NN NN O
a NN NN O
polyphenol NN NN O
from NN NN O
Mangifera NN NN O
indica NN NN O
Linn NN NN O
. NN NN O
   
( NN NN O
Anacardiaceae NN NN O
) NN NN O
, NN NN O
on NN NN O
isoproterenol NN NN O
( NN NN O
ISPH NN NN O
) NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
( NN NN O
MI NN NN B-Disease
) NN NN O
in NN NN O
rats NN NN O
through NN NN O
its NN NN O
antioxidative NN NN O
mechanism NN NN O
. NN NN O
   
Subcutaneous NN NN O
injection NN NN O
of NN NN O
ISPH NN NN O
( NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
in NN NN O
1 NN NN O
ml NN NN O
saline NN NN O
) NN NN O
to NN NN O
rats NN NN O
for NN NN O
2 NN NN O
consecutive NN NN O
days NN NN O
caused NN NN O
myocardial NN NN B-Disease
damage NN NN I-Disease
in NN NN O
rat NN NN O
heart NN NN O
, NN NN O
which NN NN O
was NN NN O
determined NN NN O
by NN NN O
the NN NN O
increased NN NN O
activity NN NN O
of NN NN O
serum NN NN O
lactate NN NN O
dehydrogenase NN NN O
( NN NN O
LDH NN NN O
) NN NN O
and NN NN O
creatine NN NN O
phosphokinase NN NN O
isoenzymes NN NN O
( NN NN O
CK NN NN O
- NN NN O
MB NN NN O
) NN NN O
, NN NN O
increased NN NN O
uric NN NN O
acid NN NN O
level NN NN O
and NN NN O
reduced NN NN O
plasma NN NN O
iron NN NN O
binding NN NN O
capacity NN NN O
. NN NN O
   
The NN NN O
protective NN NN O
role NN NN O
of NN NN O
mangiferin NN NN O
was NN NN O
analyzed NN NN O
by NN NN O
triphenyl NN NN O
tetrazolium NN NN O
chloride NN NN O
( NN NN O
TTC NN NN O
) NN NN O
test NN NN O
used NN NN O
for NN NN O
macroscopic NN NN O
enzyme NN NN O
mapping NN NN O
assay NN NN O
of NN NN O
the NN NN O
ischemic NN NN B-Disease
myocardium NN NN I-Disease
. NN NN O
   
The NN NN O
heart NN NN O
tissue NN NN O
antioxidant NN NN O
enzymes NN NN O
such NN NN O
as NN NN O
superoxide NN NN O
dismutase NN NN O
, NN NN O
catalase NN NN O
, NN NN O
glutathione NN NN O
peroxidase NN NN O
, NN NN O
glutathione NN NN O
transferase NN NN O
and NN NN O
glutathione NN NN O
reductase NN NN O
activities NN NN O
, NN NN O
non NN NN O
- NN NN O
enzymic NN NN O
antioxidants NN NN O
such NN NN O
as NN NN O
cerruloplasmin NN NN O
, NN NN O
Vitamin NN NN O
C NN NN O
, NN NN O
Vitamin NN NN O
E NN NN O
and NN NN O
glutathione NN NN O
levels NN NN O
were NN NN O
altered NN NN O
in NN NN O
MI NN NN B-Disease
rats NN NN O
. NN NN O
   
Upon NN NN O
pretreatment NN NN O
with NN NN O
mangiferin NN NN O
( NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
suspended NN NN O
in NN NN O
2 NN NN O
ml NN NN O
of NN NN O
dimethyl NN NN O
sulphoxide NN NN O
) NN NN O
given NN NN O
intraperitoneally NN NN O
for NN NN O
28 NN NN O
days NN NN O
to NN NN O
MI NN NN B-Disease
rats NN NN O
protected NN NN O
the NN NN O
above NN NN O
- NN NN O
mentioned NN NN O
parameters NN NN O
to NN NN O
fall NN NN O
from NN NN O
the NN NN O
normal NN NN O
levels NN NN O
. NN NN O
   
Activities NN NN O
of NN NN O
heart NN NN O
tissue NN NN O
enzymic NN NN O
antioxidants NN NN O
and NN NN O
serum NN NN O
non NN NN O
- NN NN O
enzymic NN NN O
antioxidants NN NN O
levels NN NN O
rose NN NN O
significantly NN NN O
upon NN NN O
mangiferin NN NN O
administration NN NN O
as NN NN O
compared NN NN O
to NN NN O
ISPH NN NN O
- NN NN O
induced NN NN O
MI NN NN B-Disease
rats NN NN O
. NN NN O
   
From NN NN O
the NN NN O
present NN NN O
study NN NN O
it NN NN O
is NN NN O
concluded NN NN O
that NN NN O
mangiferin NN NN O
exerts NN NN O
a NN NN O
beneficial NN NN O
effect NN NN O
against NN NN O
ISPH NN NN O
- NN NN O
induced NN NN O
MI NN NN B-Disease
due NN NN O
to NN NN O
its NN NN O
antioxidant NN NN O
potential NN NN O
, NN NN O
which NN NN O
regulated NN NN O
the NN NN O
tissues NN NN O
defense NN NN O
system NN NN O
against NN NN O
cardiac NN NN B-Disease
damage NN NN I-Disease
. NN NN O
   
Cardiovascular NN NN O
risk NN NN O
with NN NN O
cyclooxygenase NN NN O
inhibitors NN NN O
: NN NN O
general NN NN O
problem NN NN O
with NN NN O
substance NN NN O
specific NN NN O
differences NN NN O
? NN NN O
   
Randomised NN NN O
clinical NN NN O
trials NN NN O
and NN NN O
observational NN NN O
studies NN NN O
have NN NN O
shown NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
, NN NN O
stroke NN NN B-Disease
, NN NN O
hypertension NN NN B-Disease
and NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
during NN NN O
treatment NN NN O
with NN NN O
cyclooxygenase NN NN O
inhibitors NN NN O
. NN NN O
   
Adverse NN NN O
cardiovascular NN NN O
effects NN NN O
occurred NN NN O
mainly NN NN O
, NN NN O
but NN NN O
not NN NN O
exclusively NN NN O
, NN NN O
in NN NN O
patients NN NN O
with NN NN O
concomitant NN NN O
risk NN NN O
factors NN NN O
. NN NN O
   
Cyclooxygenase NN NN O
inhibitors NN NN O
cause NN NN O
complex NN NN O
changes NN NN O
in NN NN O
renal NN NN O
, NN NN O
vascular NN NN O
and NN NN O
cardiac NN NN O
prostanoid NN NN O
profiles NN NN O
thereby NN NN O
increasing NN NN O
vascular NN NN O
resistance NN NN O
and NN NN O
fluid NN NN O
retention NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
cardiovascular NN NN O
adverse NN NN O
events NN NN O
tends NN NN O
to NN NN O
increase NN NN O
with NN NN O
the NN NN O
daily NN NN O
dose NN NN O
and NN NN O
total NN NN O
exposure NN NN O
time NN NN O
. NN NN O
   
A NN NN O
comparison NN NN O
of NN NN O
individual NN NN O
selective NN NN O
and NN NN O
unselective NN NN O
cyclooxygenase NN NN O
inhibitors NN NN O
suggests NN NN O
substance NN NN O
- NN NN O
specific NN NN O
differences NN NN O
, NN NN O
which NN NN O
may NN NN O
depend NN NN O
on NN NN O
differences NN NN O
in NN NN O
pharmacokinetic NN NN O
parameters NN NN O
or NN NN O
inhibitory NN NN O
potency NN NN O
and NN NN O
may NN NN O
be NN NN O
contributed NN NN O
by NN NN O
prostaglandin NN NN O
- NN NN O
independent NN NN O
effects NN NN O
. NN NN O
   
Diagnostic NN NN O
markers NN NN O
such NN NN O
as NN NN O
N NN NN O
- NN NN O
terminal NN NN O
pro NN NN O
brain NN NN O
natriuretic NN NN O
peptide NN NN O
( NN NN O
NT NN NN O
- NN NN O
proBNP NN NN O
) NN NN O
or NN NN O
high NN NN O
- NN NN O
sensitive NN NN O
C NN NN O
- NN NN O
reactive NN NN O
protein NN NN O
might NN NN O
help NN NN O
in NN NN O
the NN NN O
early NN NN O
identification NN NN O
of NN NN O
patients NN NN O
at NN NN O
risk NN NN O
, NN NN O
thus NN NN O
avoiding NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
serious NN NN O
cardiovascular NN NN B-Disease
toxicity NN NN I-Disease
. NN NN O
   
Pilocarpine NN NN O
seizures NN NN B-Disease
cause NN NN O
age NN NN O
- NN NN O
dependent NN NN O
impairment NN NN B-Disease
in NN NN I-Disease
auditory NN NN I-Disease
location NN NN I-Disease
discrimination NN NN I-Disease
. NN NN O
   
Children NN NN O
who NN NN O
have NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
have NN NN O
continuous NN NN O
or NN NN O
rapidly NN NN O
repeating NN NN O
seizures NN NN B-Disease
that NN NN O
may NN NN O
be NN NN O
life NN NN O
- NN NN O
threatening NN NN O
and NN NN O
may NN NN O
cause NN NN O
life NN NN O
- NN NN O
long NN NN O
changes NN NN O
in NN NN O
brain NN NN O
and NN NN O
behavior NN NN O
. NN NN O
   
The NN NN O
extent NN NN O
to NN NN O
which NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
causes NN NN O
deficits NN NN B-Disease
in NN NN I-Disease
auditory NN NN I-Disease
discrimination NN NN I-Disease
is NN NN O
unknown NN NN O
. NN NN O
   
A NN NN O
naturalistic NN NN O
auditory NN NN O
location NN NN O
discrimination NN NN O
method NN NN O
was NN NN O
used NN NN O
to NN NN O
evaluate NN NN O
this NN NN O
question NN NN O
using NN NN O
an NN NN O
animal NN NN O
model NN NN O
of NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
. NN NN O
   
Male NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
were NN NN O
injected NN NN O
with NN NN O
saline NN NN O
on NN NN O
postnatal NN NN O
day NN NN O
( NN NN O
P NN NN O
) NN NN O
20 NN NN O
, NN NN O
or NN NN O
a NN NN O
convulsant NN NN O
dose NN NN O
of NN NN O
pilocarpine NN NN O
on NN NN O
P20 NN NN O
or NN NN O
P45 NN NN O
. NN NN O
   
Pilocarpine NN NN O
on NN NN O
either NN NN O
day NN NN O
induced NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
; NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
at NN NN O
P45 NN NN O
resulted NN NN O
in NN NN O
CA3 NN NN O
cell NN NN O
loss NN NN O
and NN NN O
spontaneous NN NN O
seizures NN NN B-Disease
, NN NN O
whereas NN NN O
P20 NN NN O
rats NN NN O
had NN NN O
no NN NN O
cell NN NN O
loss NN NN O
or NN NN O
spontaneous NN NN O
seizures NN NN B-Disease
. NN NN O
   
Mature NN NN O
rats NN NN O
were NN NN O
trained NN NN O
with NN NN O
sound NN NN O
- NN NN O
source NN NN O
location NN NN O
and NN NN O
sound NN NN O
- NN NN O
silence NN NN O
discriminations NN NN O
. NN NN O
   
Control NN NN O
( NN NN O
saline NN NN O
P20 NN NN O
) NN NN O
rats NN NN O
acquired NN NN O
both NN NN O
discriminations NN NN O
immediately NN NN O
. NN NN O
   
In NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
( NN NN O
P20 NN NN O
) NN NN O
rats NN NN O
, NN NN O
acquisition NN NN O
of NN NN O
the NN NN O
sound NN NN O
- NN NN O
source NN NN O
location NN NN O
discrimination NN NN O
was NN NN O
moderately NN NN O
impaired NN NN O
. NN NN O
   
Status NN NN B-Disease
epilepticus NN NN I-Disease
( NN NN O
P45 NN NN O
) NN NN O
rats NN NN O
failed NN NN O
to NN NN O
acquire NN NN O
either NN NN O
sound NN NN O
- NN NN O
source NN NN O
location NN NN O
or NN NN O
sound NN NN O
- NN NN O
silence NN NN O
discriminations NN NN O
. NN NN O
   
Status NN NN B-Disease
epilepticus NN NN I-Disease
in NN NN O
rat NN NN O
causes NN NN O
an NN NN O
age NN NN O
- NN NN O
dependent NN NN O
, NN NN O
long NN NN O
- NN NN O
term NN NN O
impairment NN NN B-Disease
in NN NN I-Disease
auditory NN NN I-Disease
discrimination NN NN I-Disease
. NN NN O
   
This NN NN O
impairment NN NN O
may NN NN O
explain NN NN O
one NN NN O
cause NN NN O
of NN NN O
impaired NN NN B-Disease
auditory NN NN I-Disease
location NN NN I-Disease
discrimination NN NN I-Disease
in NN NN O
humans NN NN O
. NN NN O
   
Nerve NN NN O
growth NN NN O
factor NN NN O
and NN NN O
prostaglandins NN NN O
in NN NN O
the NN NN O
urine NN NN O
of NN NN O
female NN NN O
patients NN NN O
with NN NN O
overactive NN NN B-Disease
bladder NN NN I-Disease
. NN NN O
   
PURPOSE NN NN O
: NN NN O
NGF NN NN O
and NN NN O
PGs NN NN O
in NN NN O
the NN NN O
bladder NN NN O
can NN NN O
be NN NN O
affected NN NN O
by NN NN O
pathological NN NN O
changes NN NN O
in NN NN O
the NN NN O
bladder NN NN O
and NN NN O
these NN NN O
changes NN NN O
can NN NN O
be NN NN O
detected NN NN O
in NN NN O
urine NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
changes NN NN O
in NN NN O
urinary NN NN O
NGF NN NN O
and NN NN O
PGs NN NN O
in NN NN O
women NN NN O
with NN NN O
OAB NN NN B-Disease
. NN NN O
   
MATERIALS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
The NN NN O
study NN NN O
groups NN NN O
included NN NN O
65 NN NN O
women NN NN O
with NN NN O
OAB NN NN B-Disease
and NN NN O
20 NN NN O
without NN NN O
bladder NN NN O
symptoms NN NN O
who NN NN O
served NN NN O
as NN NN O
controls NN NN O
. NN NN O
   
Evaluation NN NN O
included NN NN O
patient NN NN O
history NN NN O
, NN NN O
urinalysis NN NN O
, NN NN O
a NN NN O
voiding NN NN O
diary NN NN O
and NN NN O
urodynamic NN NN O
studies NN NN O
. NN NN O
   
Urine NN NN O
samples NN NN O
were NN NN O
collected NN NN O
. NN NN O
   
NGF NN NN O
, NN NN O
PGE2 NN NN O
, NN NN O
PGF2alpha NN NN O
and NN NN O
PGI2 NN NN O
were NN NN O
measured NN NN O
using NN NN O
enzyme NN NN O
- NN NN O
linked NN NN O
immunosorbent NN NN O
assay NN NN O
and NN NN O
compared NN NN O
between NN NN O
the NN NN O
groups NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
correlations NN NN O
between NN NN O
urinary NN NN O
NGF NN NN O
and NN NN O
PG NN NN O
, NN NN O
and NN NN O
urodynamic NN NN O
parameters NN NN O
in NN NN O
patients NN NN O
with NN NN O
OAB NN NN B-Disease
were NN NN O
examined NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Urinary NN NN O
NGF NN NN O
, NN NN O
PGE2 NN NN O
and NN NN O
PGF2alpha NN NN O
were NN NN O
significantly NN NN O
increased NN NN O
in NN NN O
patients NN NN O
with NN NN O
OAB NN NN B-Disease
compared NN NN O
with NN NN O
controls NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
urinary NN NN O
PGI2 NN NN O
was NN NN O
not NN NN O
different NN NN O
between NN NN O
controls NN NN O
and NN NN O
patients NN NN O
with NN NN O
OAB NN NN B-Disease
. NN NN O
   
In NN NN O
patients NN NN O
with NN NN O
OAB NN NN B-Disease
urinary NN NN O
PGE2 NN NN O
positively NN NN O
correlated NN NN O
with NN NN O
volume NN NN O
at NN NN O
first NN NN O
desire NN NN O
to NN NN O
void NN NN O
and NN NN O
maximum NN NN O
cystometric NN NN O
capacity NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Urinary NN NN O
NGF NN NN O
, NN NN O
PGF2alpha NN NN O
and NN NN O
PGI2 NN NN O
did NN NN O
not NN NN O
correlate NN NN O
with NN NN O
urodynamic NN NN O
parameters NN NN O
in NN NN O
patients NN NN O
with NN NN O
OAB NN NN B-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
NGF NN NN O
and NN NN O
PGs NN NN O
have NN NN O
important NN NN O
roles NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
OAB NN NN B-Disease
symptoms NN NN O
in NN NN O
female NN NN O
patients NN NN O
. NN NN O
   
Urinary NN NN O
levels NN NN O
of NN NN O
these NN NN O
factors NN NN O
may NN NN O
be NN NN O
used NN NN O
as NN NN O
markers NN NN O
to NN NN O
evaluate NN NN O
OAB NN NN B-Disease
symptoms NN NN O
. NN NN O
   
Definition NN NN O
and NN NN O
management NN NN O
of NN NN O
anemia NN NN B-Disease
in NN NN O
patients NN NN O
infected NN NN B-Disease
with NN NN I-Disease
hepatitis NN NN I-Disease
C NN NN I-Disease
virus NN NN I-Disease
. NN NN O
   
Chronic NN NN B-Disease
infection NN NN I-Disease
with NN NN I-Disease
hepatitis NN NN I-Disease
C NN NN I-Disease
virus NN NN I-Disease
( NN NN O
HCV NN NN O
) NN NN O
can NN NN O
progress NN NN O
to NN NN O
cirrhosis NN NN B-Disease
, NN NN O
hepatocellular NN NN B-Disease
carcinoma NN NN I-Disease
, NN NN O
and NN NN O
end NN NN B-Disease
- NN NN I-Disease
stage NN NN I-Disease
liver NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
The NN NN O
current NN NN O
best NN NN O
treatment NN NN O
for NN NN O
HCV NN NN B-Disease
infection NN NN I-Disease
is NN NN O
combination NN NN O
therapy NN NN O
with NN NN O
pegylated NN NN O
interferon NN NN O
and NN NN O
ribavirin NN NN O
. NN NN O
   
Although NN NN O
this NN NN O
regimen NN NN O
produces NN NN O
sustained NN NN O
virologic NN NN O
responses NN NN O
( NN NN O
SVRs NN NN O
) NN NN O
in NN NN O
approximately NN NN O
50 NN NN O
% NN NN O
of NN NN O
patients NN NN O
, NN NN O
it NN NN O
can NN NN O
be NN NN O
associated NN NN O
with NN NN O
a NN NN O
potentially NN NN O
dose NN NN O
- NN NN O
limiting NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
. NN NN O
   
Hemoglobin NN NN O
concentrations NN NN O
decrease NN NN O
mainly NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
ribavirin NN NN O
- NN NN O
induced NN NN O
hemolysis NN NN B-Disease
, NN NN O
and NN NN O
this NN NN O
anemia NN NN B-Disease
can NN NN O
be NN NN O
problematic NN NN O
in NN NN O
patients NN NN O
with NN NN O
HCV NN NN B-Disease
infection NN NN I-Disease
, NN NN O
especially NN NN O
those NN NN O
who NN NN O
have NN NN O
comorbid NN NN O
renal NN NN B-Disease
or NN NN I-Disease
cardiovascular NN NN I-Disease
disorders NN NN I-Disease
. NN NN O
   
In NN NN O
general NN NN O
, NN NN O
anemia NN NN B-Disease
can NN NN O
increase NN NN O
the NN NN O
risk NN NN O
of NN NN O
morbidity NN NN O
and NN NN O
mortality NN NN O
, NN NN O
and NN NN O
may NN NN O
have NN NN O
negative NN NN O
effects NN NN O
on NN NN O
cerebral NN NN O
function NN NN O
and NN NN O
quality NN NN O
of NN NN O
life NN NN O
. NN NN O
   
Although NN NN O
ribavirin NN NN O
- NN NN O
associated NN NN O
anemia NN NN B-Disease
can NN NN O
be NN NN O
reversed NN NN O
by NN NN O
dose NN NN O
reduction NN NN O
or NN NN O
discontinuation NN NN O
, NN NN O
this NN NN O
approach NN NN O
compromises NN NN O
outcomes NN NN O
by NN NN O
significantly NN NN O
decreasing NN NN O
SVR NN NN O
rates NN NN O
. NN NN O
   
Recombinant NN NN O
human NN NN O
erythropoietin NN NN O
has NN NN O
been NN NN O
used NN NN O
to NN NN O
manage NN NN O
ribavirin NN NN O
- NN NN O
associated NN NN O
anemia NN NN B-Disease
but NN NN O
has NN NN O
other NN NN O
potential NN NN O
disadvantages NN NN O
. NN NN O
   
Viramidine NN NN O
, NN NN O
a NN NN O
liver NN NN O
- NN NN O
targeting NN NN O
prodrug NN NN O
of NN NN O
ribavirin NN NN O
, NN NN O
has NN NN O
the NN NN O
potential NN NN O
to NN NN O
maintain NN NN O
the NN NN O
virologic NN NN O
efficacy NN NN O
of NN NN O
ribavirin NN NN O
while NN NN O
decreasing NN NN O
the NN NN O
risk NN NN O
of NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
in NN NN O
patients NN NN O
with NN NN O
chronic NN NN B-Disease
hepatitis NN NN I-Disease
C NN NN I-Disease
. NN NN O
   
Impact NN NN O
of NN NN O
alcohol NN NN O
exposure NN NN O
after NN NN O
pregnancy NN NN O
recognition NN NN O
on NN NN O
ultrasonographic NN NN O
fetal NN NN O
growth NN NN O
measures NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
More NN NN O
than NN NN O
3 NN NN O
decades NN NN O
after NN NN O
Jones NN NN O
and NN NN O
Smith NN NN O
( NN NN O
1973 NN NN O
) NN NN O
reported NN NN O
on NN NN O
the NN NN O
devastation NN NN O
caused NN NN O
by NN NN O
alcohol NN NN O
exposure NN NN O
on NN NN O
fetal NN NN O
development NN NN O
, NN NN O
the NN NN O
rates NN NN O
of NN NN O
heavy NN NN O
drinking NN NN O
during NN NN O
pregnancy NN NN O
remain NN NN O
relatively NN NN O
unchanged NN NN O
. NN NN O
   
Early NN NN O
identification NN NN O
of NN NN O
fetal NN NN O
alcohol NN NN O
exposure NN NN O
and NN NN O
maternal NN NN O
abstinence NN NN O
led NN NN O
to NN NN O
better NN NN O
infant NN NN O
outcomes NN NN O
. NN NN O
   
This NN NN O
study NN NN O
examined NN NN O
the NN NN O
utility NN NN O
of NN NN O
biometry NN NN O
for NN NN O
detecting NN NN O
alcohol NN NN O
- NN NN O
related NN NN O
fetal NN NN O
growth NN NN B-Disease
impairment NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
obtained NN NN O
fetal NN NN O
ultrasound NN NN O
measures NN NN O
from NN NN O
routine NN NN O
ultrasound NN NN O
examinations NN NN O
for NN NN O
167 NN NN O
pregnant NN NN O
hazardous NN NN O
drinkers NN NN O
who NN NN O
were NN NN O
enrolled NN NN O
in NN NN O
a NN NN O
brief NN NN O
alcohol NN NN O
intervention NN NN O
study NN NN O
. NN NN O
   
The NN NN O
fetal NN NN O
measures NN NN O
for NN NN O
women NN NN O
who NN NN O
quit NN NN O
after NN NN O
learning NN NN O
of NN NN O
their NN NN O
pregnancies NN NN O
were NN NN O
compared NN NN O
with NN NN O
measures NN NN O
for NN NN O
women NN NN O
who NN NN O
continued NN NN O
some NN NN O
drinking NN NN O
throughout NN NN O
the NN NN O
course NN NN O
of NN NN O
their NN NN O
pregnancies NN NN O
. NN NN O
   
Because NN NN O
intensity NN NN O
of NN NN O
alcohol NN NN O
consumption NN NN O
is NN NN O
associated NN NN O
with NN NN O
poorer NN NN O
fetal NN NN O
outcomes NN NN O
, NN NN O
separate NN NN O
analyses NN NN O
were NN NN O
conducted NN NN O
for NN NN O
the NN NN O
heavy NN NN O
( NN NN O
average NN NN O
of NN NN O
> NN NN O
or NN NN O
= NN NN O
5 NN NN O
drinks NN NN O
per NN NN O
drinking NN NN O
day NN NN O
) NN NN O
alcohol NN NN O
consumers NN NN O
. NN NN O
   
Fetal NN NN O
measures NN NN O
from NN NN O
the NN NN O
heavy NN NN O
- NN NN O
exposed NN NN O
fetuses NN NN O
were NN NN O
also NN NN O
compared NN NN O
with NN NN O
measures NN NN O
from NN NN O
a NN NN O
nondrinking NN NN O
group NN NN O
that NN NN O
was NN NN O
representative NN NN O
of NN NN O
normal NN NN O
, NN NN O
uncomplicated NN NN O
pregnancies NN NN O
from NN NN O
our NN NN O
clinics NN NN O
. NN NN O
   
Analyses NN NN O
of NN NN O
covariance NN NN O
were NN NN O
used NN NN O
to NN NN O
determine NN NN O
whether NN NN O
there NN NN O
were NN NN O
differences NN NN O
between NN NN O
groups NN NN O
after NN NN O
controlling NN NN O
for NN NN O
influences NN NN O
of NN NN O
gestational NN NN O
age NN NN O
and NN NN O
drug NN NN B-Disease
abuse NN NN I-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
Nearly NN NN O
half NN NN O
of NN NN O
the NN NN O
pregnant NN NN O
drinkers NN NN O
abstained NN NN O
after NN NN O
learning NN NN O
of NN NN O
their NN NN O
pregnancies NN NN O
. NN NN O
   
When NN NN O
women NN NN O
reportedly NN NN O
quit NN NN O
drinking NN NN O
early NN NN O
in NN NN O
their NN NN O
pregnancies NN NN O
, NN NN O
fetal NN NN O
growth NN NN O
measures NN NN O
were NN NN O
not NN NN O
significantly NN NN O
different NN NN O
from NN NN O
a NN NN O
non NN NN O
- NN NN O
alcohol NN NN O
- NN NN O
exposed NN NN O
group NN NN O
, NN NN O
regardless NN NN O
of NN NN O
prior NN NN O
drinking NN NN O
patterns NN NN O
. NN NN O
   
Any NN NN O
alcohol NN NN O
consumption NN NN O
postpregnancy NN NN O
recognition NN NN O
among NN NN O
the NN NN O
heavy NN NN O
drinkers NN NN O
resulted NN NN O
in NN NN O
reduced NN NN B-Disease
cerebellar NN NN I-Disease
growth NN NN I-Disease
as NN NN O
well NN NN O
as NN NN O
decreased NN NN B-Disease
cranial NN NN I-Disease
to NN NN I-Disease
body NN NN I-Disease
growth NN NN I-Disease
in NN NN O
comparison NN NN O
with NN NN O
women NN NN O
who NN NN O
either NN NN O
quit NN NN O
drinking NN NN O
or NN NN O
who NN NN O
were NN NN O
nondrinkers NN NN O
. NN NN O
   
Amphetamine NN NN O
abuse NN NN O
was NN NN O
predictive NN NN O
of NN NN O
larger NN NN O
cranial NN NN O
to NN NN O
body NN NN O
growth NN NN O
ratios NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Alterations NN NN O
in NN NN O
fetal NN NN O
biometric NN NN O
measurements NN NN O
were NN NN O
observed NN NN O
among NN NN O
the NN NN O
heavy NN NN O
drinkers NN NN O
only NN NN O
when NN NN O
they NN NN O
continued NN NN O
drinking NN NN O
after NN NN O
becoming NN NN O
aware NN NN O
of NN NN O
their NN NN O
pregnancies NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
reliance NN NN O
on NN NN O
self NN NN O
- NN NN O
reported NN NN O
drinking NN NN O
is NN NN O
a NN NN O
limitation NN NN O
in NN NN O
this NN NN O
study NN NN O
, NN NN O
these NN NN O
findings NN NN O
support NN NN O
the NN NN O
benefits NN NN O
of NN NN O
early NN NN O
abstinence NN NN O
and NN NN O
the NN NN O
potential NN NN O
for NN NN O
ultrasound NN NN O
examinations NN NN O
in NN NN O
the NN NN O
detection NN NN O
of NN NN O
fetal NN NN O
alcohol NN NN O
effects NN NN O
. NN NN O
   
Ethambutol NN NN O
- NN NN O
associated NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
. NN NN O
   
INTRODUCTION NN NN O
: NN NN O
Ethambutol NN NN O
is NN NN O
used NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
tuberculosis NN NN B-Disease
, NN NN O
which NN NN O
is NN NN O
still NN NN O
prevalent NN NN O
in NN NN O
Southeast NN NN O
Asia NN NN O
, NN NN O
and NN NN O
can NN NN O
be NN NN O
associated NN NN O
with NN NN O
permanent NN NN O
visual NN NN B-Disease
loss NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
3 NN NN O
cases NN NN O
which NN NN O
presented NN NN O
with NN NN O
bitemporal NN NN B-Disease
hemianopia NN NN I-Disease
. NN NN O
   
CLINICAL NN NN O
PICTURE NN NN O
: NN NN O
Three NN NN O
patients NN NN O
with NN NN O
ethambutol NN NN O
- NN NN O
associated NN NN O
toxic NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
are NN NN O
described NN NN O
. NN NN O
   
All NN NN O
3 NN NN O
patients NN NN O
had NN NN O
loss NN NN B-Disease
of NN NN I-Disease
central NN NN I-Disease
visual NN NN I-Disease
acuity NN NN I-Disease
, NN NN I-Disease
colour NN NN I-Disease
vision NN NN I-Disease
( NN NN I-Disease
Ishihara NN NN I-Disease
) NN NN I-Disease
and NN NN I-Disease
visual NN NN I-Disease
field NN NN I-Disease
. NN NN O
   
The NN NN O
visual NN NN B-Disease
field NN NN I-Disease
loss NN NN I-Disease
had NN NN O
a NN NN O
bitemporal NN NN O
flavour NN NN O
, NN NN O
suggesting NN NN O
involvement NN NN O
of NN NN O
the NN NN O
optic NN NN O
chiasm NN NN O
. NN NN O
   
TREATMENT NN NN O
: NN NN O
Despite NN NN O
stopping NN NN O
ethambutol NN NN O
on NN NN O
diagnosis NN NN O
, NN NN O
visual NN NN O
function NN NN O
continued NN NN O
to NN NN O
deteriorate NN NN O
for NN NN O
a NN NN O
few NN NN O
months NN NN O
. NN NN O
   
Subsequent NN NN O
improvement NN NN O
was NN NN O
mild NN NN O
in NN NN O
2 NN NN O
cases NN NN O
. NN NN O
   
In NN NN O
the NN NN O
third NN NN O
case NN NN O
, NN NN O
visual NN NN O
acuity NN NN O
and NN NN O
colour NN NN O
vision NN NN O
normalised NN NN O
but NN NN O
the NN NN O
optic NN NN O
discs NN NN O
were NN NN O
pale NN NN O
. NN NN O
   
OUTCOME NN NN O
: NN NN O
All NN NN O
3 NN NN O
patients NN NN O
had NN NN O
some NN NN O
permanent NN NN O
loss NN NN B-Disease
of NN NN I-Disease
visual NN NN I-Disease
function NN NN I-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Ethambutol NN NN O
usage NN NN O
is NN NN O
associated NN NN O
with NN NN O
permanent NN NN O
visual NN NN B-Disease
loss NN NN I-Disease
and NN NN O
should NN NN O
be NN NN O
avoided NN NN O
if NN NN O
possible NN NN O
or NN NN O
used NN NN O
with NN NN O
caution NN NN O
and NN NN O
proper NN NN O
ophthalmological NN NN O
follow NN NN O
- NN NN O
up NN NN O
. NN NN O
   
The NN NN O
author NN NN O
postulates NN NN O
that NN NN O
in NN NN O
cases NN NN O
of NN NN O
ethambutol NN NN O
associated NN NN O
chiasmopathy NN NN O
, NN NN O
ethambutol NN NN O
may NN NN O
initially NN NN O
affect NN NN O
the NN NN O
optic NN NN O
nerves NN NN O
and NN NN O
subsequently NN NN O
progress NN NN O
to NN NN O
involve NN NN O
the NN NN O
optic NN NN O
chiasm NN NN O
. NN NN O
   
Possible NN NN O
neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
related NN NN O
to NN NN O
concomitant NN NN O
treatment NN NN O
with NN NN O
paroxetine NN NN O
and NN NN O
alprazolam NN NN O
. NN NN O
   
A NN NN O
74 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
with NN NN O
depressive NN NN B-Disease
symptoms NN NN I-Disease
was NN NN O
admitted NN NN O
to NN NN O
a NN NN O
psychiatric NN NN B-Disease
hospital NN NN O
due NN NN O
to NN NN O
insomnia NN NN B-Disease
, NN NN O
loss NN NN B-Disease
of NN NN I-Disease
appetite NN NN I-Disease
, NN NN O
exhaustion NN NN O
, NN NN O
and NN NN O
agitation NN NN B-Disease
. NN NN O
   
Medical NN NN O
treatment NN NN O
was NN NN O
initiated NN NN O
at NN NN O
a NN NN O
daily NN NN O
dose NN NN O
of NN NN O
20 NN NN O
mg NN NN O
paroxetine NN NN O
and NN NN O
1 NN NN O
. NN NN O
2 NN NN O
mg NN NN O
alprazolam NN NN O
. NN NN O
   
On NN NN O
the NN NN O
10th NN NN O
day NN NN O
of NN NN O
paroxetine NN NN O
and NN NN O
alprazolam NN NN O
treatment NN NN O
, NN NN O
the NN NN O
patient NN NN O
exhibited NN NN O
marked NN NN O
psychomotor NN NN B-Disease
retardation NN NN I-Disease
, NN NN O
disorientation NN NN O
, NN NN O
and NN NN O
severe NN NN O
muscle NN NN B-Disease
rigidity NN NN I-Disease
with NN NN O
tremors NN NN B-Disease
. NN NN O
   
The NN NN O
patient NN NN O
had NN NN O
a NN NN O
fever NN NN B-Disease
( NN NN O
38 NN NN O
. NN NN O
2 NN NN O
degrees NN NN O
C NN NN O
) NN NN O
, NN NN O
fluctuating NN NN O
blood NN NN O
pressure NN NN O
( NN NN O
between NN NN O
165 NN NN O
/ NN NN O
90 NN NN O
and NN NN O
130 NN NN O
/ NN NN O
70 NN NN O
mg NN NN O
mm NN NN O
Hg NN NN O
) NN NN O
, NN NN O
and NN NN O
severe NN NN O
extrapyramidal NN NN B-Disease
symptoms NN NN I-Disease
. NN NN O
   
Laboratory NN NN O
tests NN NN O
showed NN NN O
an NN NN O
elevation NN NN O
of NN NN O
creatine NN NN O
phosphokinase NN NN O
( NN NN O
2218 NN NN O
IU NN NN O
/ NN NN O
L NN NN O
) NN NN O
, NN NN O
aspartate NN NN O
aminotransferase NN NN O
( NN NN O
134 NN NN O
IU NN NN O
/ NN NN O
L NN NN O
) NN NN O
, NN NN O
alanine NN NN O
aminotransferase NN NN O
( NN NN O
78 NN NN O
IU NN NN O
/ NN NN O
L NN NN O
) NN NN O
, NN NN O
and NN NN O
BUN NN NN O
( NN NN O
27 NN NN O
. NN NN O
9 NN NN O
mg NN NN O
/ NN NN O
ml NN NN O
) NN NN O
levels NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
received NN NN O
bromocriptine NN NN O
and NN NN O
diazepam NN NN O
to NN NN O
treat NN NN O
his NN NN O
symptoms NN NN O
. NN NN O
   
7 NN NN O
days NN NN O
later NN NN O
, NN NN O
the NN NN O
fever NN NN B-Disease
disappeared NN NN O
and NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
serum NN NN O
CPK NN NN O
levels NN NN O
were NN NN O
normalized NN NN O
( NN NN O
175 NN NN O
IU NN NN O
/ NN NN O
L NN NN O
) NN NN O
. NN NN O
   
This NN NN O
patient NN NN O
presented NN NN O
with NN NN O
symptoms NN NN O
of NN NN O
neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
NMS NN NN B-Disease
) NN NN O
, NN NN O
thus NN NN O
demonstrating NN NN O
that NN NN O
NMS NN NN B-Disease
- NN NN O
like NN NN O
symptoms NN NN O
can NN NN O
occur NN NN O
after NN NN O
combined NN NN O
paroxetine NN NN O
and NN NN O
alprazolam NN NN O
treatment NN NN O
. NN NN O
   
The NN NN O
adverse NN NN O
drug NN NN O
reaction NN NN O
score NN NN O
obtained NN NN O
by NN NN O
the NN NN O
Naranjo NN NN O
algorithm NN NN O
was NN NN O
6 NN NN O
in NN NN O
our NN NN O
case NN NN O
, NN NN O
indicating NN NN O
a NN NN O
probable NN NN O
relationship NN NN O
between NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
NMS NN NN B-Disease
- NN NN O
like NN NN O
adverse NN NN O
symptoms NN NN O
and NN NN O
the NN NN O
combined NN NN O
treatment NN NN O
used NN NN O
in NN NN O
this NN NN O
case NN NN O
. NN NN O
   
The NN NN O
involvement NN NN O
of NN NN O
physiologic NN NN O
and NN NN O
environmental NN NN O
aspects NN NN O
specific NN NN O
to NN NN O
this NN NN O
patient NN NN O
was NN NN O
suspected NN NN O
. NN NN O
   
Several NN NN O
risk NN NN O
factors NN NN O
for NN NN O
NMS NN NN B-Disease
should NN NN O
be NN NN O
noted NN NN O
in NN NN O
elderly NN NN O
depressive NN NN B-Disease
patients NN NN O
whose NN NN O
symptoms NN NN O
often NN NN O
include NN NN O
dehydration NN NN B-Disease
, NN NN O
agitation NN NN B-Disease
, NN NN O
malnutrition NN NN B-Disease
, NN NN O
and NN NN O
exhaustion NN NN O
. NN NN O
   
Careful NN NN O
therapeutic NN NN O
intervention NN NN O
is NN NN O
necessary NN NN O
in NN NN O
cases NN NN O
involving NN NN O
elderly NN NN O
patients NN NN O
who NN NN O
suffer NN NN O
from NN NN O
depression NN NN B-Disease
. NN NN O
   
Down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
norepinephrine NN NN O
transporter NN NN O
function NN NN O
induced NN NN O
by NN NN O
chronic NN NN O
administration NN NN O
of NN NN O
desipramine NN NN O
linking NN NN O
to NN NN O
the NN NN O
alteration NN NN O
of NN NN O
sensitivity NN NN O
of NN NN O
local NN NN O
- NN NN O
anesthetics NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
and NN NN O
the NN NN O
counteraction NN NN O
by NN NN O
co NN NN O
- NN NN O
administration NN NN O
with NN NN O
local NN NN O
anesthetics NN NN O
. NN NN O
   
Alterations NN NN O
of NN NN O
norepinephrine NN NN O
transporter NN NN O
( NN NN O
NET NN NN O
) NN NN O
function NN NN O
by NN NN O
chronic NN NN O
inhibition NN NN O
of NN NN O
NET NN NN O
in NN NN O
relation NN NN O
to NN NN O
sensitization NN NN O
to NN NN O
seizures NN NN B-Disease
induce NN NN O
by NN NN O
cocaine NN NN O
and NN NN O
local NN NN O
anesthetics NN NN O
were NN NN O
studied NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Daily NN NN O
administration NN NN O
of NN NN O
desipramine NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
the NN NN O
NET NN NN O
, NN NN O
for NN NN O
5 NN NN O
days NN NN O
decreased NN NN O
[ NN NN O
( NN NN O
3 NN NN O
) NN NN O
H NN NN O
] NN NN O
norepinephrine NN NN O
uptake NN NN O
in NN NN O
the NN NN O
P2 NN NN O
fractions NN NN O
of NN NN O
hippocampus NN NN O
but NN NN O
not NN NN O
cortex NN NN O
, NN NN O
striatum NN NN O
or NN NN O
amygdalae NN NN O
. NN NN O
   
Co NN NN O
- NN NN O
administration NN NN O
of NN NN O
lidocaine NN NN O
, NN NN O
bupivacaine NN NN O
or NN NN O
tricaine NN NN O
with NN NN O
desipramine NN NN O
reversed NN NN O
this NN NN O
effect NN NN O
. NN NN O
   
Daily NN NN O
treatment NN NN O
of NN NN O
cocaine NN NN O
increased NN NN O
[ NN NN O
( NN NN O
3 NN NN O
) NN NN O
H NN NN O
] NN NN O
norepinephrine NN NN O
uptake NN NN O
into NN NN O
the NN NN O
hippocampus NN NN O
. NN NN O
   
Daily NN NN O
administration NN NN O
of NN NN O
desipramine NN NN O
increased NN NN O
the NN NN O
incidence NN NN O
of NN NN O
appearance NN NN O
of NN NN O
lidocaine NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
and NN NN O
decreased NN NN O
that NN NN O
of NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
. NN NN O
   
Co NN NN O
- NN NN O
administration NN NN O
of NN NN O
lidocaine NN NN O
with NN NN O
desipramine NN NN O
reversed NN NN O
the NN NN O
changes NN NN O
of NN NN O
convulsive NN NN B-Disease
activity NN NN O
of NN NN O
lidocaine NN NN O
and NN NN O
cocaine NN NN O
induced NN NN O
by NN NN O
repeated NN NN O
administration NN NN O
of NN NN O
desipramine NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
hippocampal NN NN O
NET NN NN O
induced NN NN O
by NN NN O
chronic NN NN O
administration NN NN O
of NN NN O
desipramine NN NN O
may NN NN O
be NN NN O
relevant NN NN O
to NN NN O
desipramine NN NN O
- NN NN O
induced NN NN O
sensitization NN NN O
of NN NN O
lidocaine NN NN O
convulsions NN NN B-Disease
. NN NN O
   
Inhibition NN NN O
of NN NN O
Na NN NN O
( NN NN O
+ NN NN O
) NN NN O
channels NN NN O
by NN NN O
local NN NN O
anesthetics NN NN O
may NN NN O
regulate NN NN O
desipramine NN NN O
- NN NN O
induced NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
NET NN NN O
function NN NN O
. NN NN O
   
Repeated NN NN O
administration NN NN O
of NN NN O
cocaine NN NN O
induces NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
hippocampal NN NN O
NET NN NN O
function NN NN O
. NN NN O
   
Desipramine NN NN O
- NN NN O
induced NN NN O
sensitization NN NN O
of NN NN O
lidocaine NN NN O
seizures NN NN B-Disease
may NN NN O
have NN NN O
a NN NN O
mechanism NN NN O
distinct NN NN O
from NN NN O
kindling NN NN O
resulting NN NN O
from NN NN O
repeated NN NN O
administration NN NN O
of NN NN O
cocaine NN NN O
. NN NN O
   
Atorvastatin NN NN O
prevented NN NN O
and NN NN O
reversed NN NN O
dexamethasone NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
To NN NN O
assess NN NN O
the NN NN O
antioxidant NN NN O
effects NN NN O
of NN NN O
atorvastatin NN NN O
( NN NN O
atorva NN NN O
) NN NN O
on NN NN O
dexamethasone NN NN O
( NN NN O
dex NN NN O
) NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
, NN NN O
60 NN NN O
male NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
were NN NN O
treated NN NN O
with NN NN O
atorva NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
or NN NN O
tap NN NN O
water NN NN O
for NN NN O
15 NN NN O
days NN NN O
. NN NN O
   
Dex NN NN O
increased NN NN O
systolic NN NN O
blood NN NN O
pressure NN NN O
( NN NN O
SBP NN NN O
) NN NN O
from NN NN O
109 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
8 NN NN O
to NN NN O
135 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
6 NN NN O
mmHg NN NN O
and NN NN O
plasma NN NN O
superoxide NN NN O
( NN NN O
5711 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
284 NN NN O
. NN NN O
9 NN NN O
saline NN NN O
, NN NN O
7931 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
392 NN NN O
. NN NN O
8 NN NN O
U NN NN O
/ NN NN O
ml NN NN O
dex NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
this NN NN O
prevention NN NN O
study NN NN O
, NN NN O
SBP NN NN O
in NN NN O
the NN NN O
atorva NN NN O
+ NN NN O
dex NN NN O
group NN NN O
was NN NN O
increased NN NN O
from NN NN O
115 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
4 NN NN O
to NN NN O
124 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
5 NN NN O
mmHg NN NN O
, NN NN O
but NN NN O
this NN NN O
was NN NN O
significantly NN NN O
lower NN NN O
than NN NN O
in NN NN O
the NN NN O
dex NN NN O
- NN NN O
only NN NN O
group NN NN O
( NN NN O
P NN NN O
' NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Atorva NN NN O
reversed NN NN O
dex NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
( NN NN O
129 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
6 NN NN O
mmHg NN NN O
, NN NN O
vs NN NN O
. NN NN O
135 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
6 NN NN O
mmHg NN NN O
P NN NN O
' NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
and NN NN O
decreased NN NN O
plasma NN NN O
superoxide NN NN O
( NN NN O
7931 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
392 NN NN O
. NN NN O
8 NN NN O
dex NN NN O
, NN NN O
1187 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
441 NN NN O
. NN NN O
2 NN NN O
atorva NN NN O
+ NN NN O
dex NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
) NN NN O
. NN NN O
   
Plasma NN NN O
nitrate NN NN O
/ NN NN O
nitrite NN NN O
( NN NN O
NOx NN NN O
) NN NN O
was NN NN O
decreased NN NN O
in NN NN O
dex NN NN O
- NN NN O
treated NN NN O
rats NN NN O
compared NN NN O
to NN NN O
saline NN NN O
- NN NN O
treated NN NN O
rats NN NN O
( NN NN O
11 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
08 NN NN O
microm NN NN O
, NN NN O
15 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
17 NN NN O
microm NN NN O
, NN NN O
respectively NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Atorva NN NN O
affected NN NN O
neither NN NN O
plasma NN NN O
NOx NN NN O
nor NN NN O
thymus NN NN O
weight NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
atorvastatin NN NN O
prevented NN NN O
and NN NN O
reversed NN NN O
dexamethasone NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Peripheral NN NN B-Disease
neuropathy NN NN I-Disease
caused NN NN O
by NN NN O
high NN NN O
- NN NN O
dose NN NN O
cytosine NN NN O
arabinoside NN NN O
treatment NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
acute NN NN B-Disease
myeloid NN NN I-Disease
leukemia NN NN I-Disease
. NN NN O
   
The NN NN O
central NN NN O
nervous NN NN O
system NN NN O
toxicity NN NN B-Disease
of NN NN O
high NN NN O
- NN NN O
dose NN NN O
cytosine NN NN O
arabinoside NN NN O
is NN NN O
well NN NN O
recognized NN NN O
, NN NN O
but NN NN O
the NN NN O
toxicity NN NN B-Disease
of NN NN O
cytosine NN NN O
arabinoside NN NN O
in NN NN O
the NN NN O
peripheral NN NN O
nervous NN NN O
system NN NN O
has NN NN O
been NN NN O
infrequently NN NN O
reported NN NN O
. NN NN O
   
A NN NN O
49 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
Japanese NN NN O
man NN NN O
was NN NN O
diagnosed NN NN O
with NN NN O
acute NN NN B-Disease
myeloid NN NN I-Disease
leukemia NN NN I-Disease
. NN NN O
   
After NN NN O
he NN NN O
achieved NN NN O
complete NN NN O
remission NN NN O
, NN NN O
he NN NN O
received NN NN O
high NN NN O
- NN NN O
dose NN NN O
cytosine NN NN O
arabinoside NN NN O
treatment NN NN O
( NN NN O
2 NN NN O
g NN NN O
/ NN NN O
m2 NN NN O
twice NN NN O
a NN NN O
day NN NN O
for NN NN O
5 NN NN O
days NN NN O
; NN NN O
total NN NN O
, NN NN O
20 NN NN O
g NN NN O
/ NN NN O
m2 NN NN O
) NN NN O
as NN NN O
consolidation NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
first NN NN O
course NN NN O
of NN NN O
high NN NN O
- NN NN O
dose NN NN O
cytosine NN NN O
arabinoside NN NN O
resulted NN NN O
in NN NN O
no NN NN O
unusual NN NN O
symptoms NN NN O
, NN NN O
but NN NN O
on NN NN O
day NN NN O
21 NN NN O
of NN NN O
the NN NN O
second NN NN O
course NN NN O
of NN NN O
treatment NN NN O
, NN NN O
the NN NN O
patient NN NN O
complained NN NN O
of NN NN O
numbness NN NN B-Disease
in NN NN O
his NN NN O
right NN NN O
foot NN NN O
. NN NN O
   
Electromyogram NN NN O
and NN NN O
nerve NN NN O
- NN NN O
conduction NN NN O
studies NN NN O
showed NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
in NN NN O
both NN NN O
peroneal NN NN O
nerves NN NN O
. NN NN O
   
This NN NN O
neuropathy NN NN B-Disease
was NN NN O
gradually NN NN O
resolving NN NN O
; NN NN O
however NN NN O
, NN NN O
after NN NN O
the NN NN O
patient NN NN O
received NN NN O
allogeneic NN NN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
, NN NN O
the NN NN O
symptoms NN NN O
worsened NN NN O
, NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
graft NN NN B-Disease
- NN NN I-Disease
versus NN NN I-Disease
- NN NN I-Disease
host NN NN I-Disease
disease NN NN I-Disease
, NN NN O
and NN NN O
the NN NN O
symptoms NN NN O
subsequently NN NN O
responded NN NN O
to NN NN O
methylprednisolone NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
mechanisms NN NN O
of NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
are NN NN O
still NN NN O
unclear NN NN O
, NN NN O
high NN NN O
- NN NN O
dose NN NN O
cytosine NN NN O
arabinoside NN NN O
is NN NN O
a NN NN O
therapy NN NN O
that NN NN O
is NN NN O
potentially NN NN O
toxic NN NN O
to NN NN O
the NN NN O
peripheral NN NN O
nervous NN NN O
system NN NN O
, NN NN O
and NN NN O
auto NN NN O
/ NN NN O
alloimmunity NN NN O
may NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
these NN NN O
mechanisms NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
alpha NN NN O
- NN NN O
tocopherol NN NN O
and NN NN O
deferoxamine NN NN O
on NN NN O
methamphetamine NN NN O
- NN NN O
induced NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
Methamphetamine NN NN O
( NN NN O
MA NN NN O
) NN NN O
- NN NN O
induced NN NN O
dopaminergic NN NN O
neurotoxicity NN NN B-Disease
is NN NN O
believed NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
the NN NN O
increased NN NN O
formation NN NN O
of NN NN O
free NN NN O
radicals NN NN O
. NN NN O
   
This NN NN O
study NN NN O
examined NN NN O
the NN NN O
effect NN NN O
of NN NN O
alpha NN NN O
- NN NN O
tocopherol NN NN O
( NN NN O
alpha NN NN O
- NN NN O
TC NN NN O
) NN NN O
, NN NN O
a NN NN O
scavenger NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
, NN NN O
and NN NN O
deferoxamine NN NN O
( NN NN O
DFO NN NN O
) NN NN O
, NN NN O
an NN NN O
iron NN NN O
chelator NN NN O
, NN NN O
on NN NN O
the NN NN O
MA NN NN O
- NN NN O
induced NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
Male NN NN O
rats NN NN O
were NN NN O
treated NN NN O
with NN NN O
MA NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
every NN NN O
2 NN NN O
h NN NN O
for NN NN O
four NN NN O
injections NN NN O
) NN NN O
. NN NN O
   
The NN NN O
rat NN NN O
received NN NN O
either NN NN O
alpha NN NN O
- NN NN O
TC NN NN O
( NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
intraperitoneally NN NN O
for NN NN O
3 NN NN O
days NN NN O
and NN NN O
30 NN NN O
min NN NN O
prior NN NN O
to NN NN O
MA NN NN O
administration NN NN O
or NN NN O
DFO NN NN O
( NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
subcutaneously NN NN O
30 NN NN O
min NN NN O
before NN NN O
MA NN NN O
administration NN NN O
. NN NN O
   
The NN NN O
concentrations NN NN O
of NN NN O
dopamine NN NN O
( NN NN O
DA NN NN O
) NN NN O
, NN NN O
serotonin NN NN O
and NN NN O
their NN NN O
metabolites NN NN O
decreased NN NN O
significantly NN NN O
after NN NN O
MA NN NN O
administration NN NN O
, NN NN O
which NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
the NN NN O
alpha NN NN O
- NN NN O
TC NN NN O
and NN NN O
DFO NN NN O
pretreatment NN NN O
. NN NN O
   
alpha NN NN O
- NN NN O
TC NN NN O
and NN NN O
DFO NN NN O
attenuated NN NN O
the NN NN O
MA NN NN O
- NN NN O
induced NN NN O
hyperthermia NN NN B-Disease
as NN NN O
well NN NN O
as NN NN O
the NN NN O
alterations NN NN O
in NN NN O
the NN NN O
locomotor NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
level NN NN O
of NN NN O
lipid NN NN O
peroxidation NN NN O
was NN NN O
higher NN NN O
and NN NN O
the NN NN O
reduced NN NN O
glutathione NN NN O
concentration NN NN O
was NN NN O
lower NN NN O
in NN NN O
the NN NN O
MA NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
These NN NN O
changes NN NN O
were NN NN O
significantly NN NN O
attenuated NN NN O
by NN NN O
alpha NN NN O
- NN NN O
TC NN NN O
and NN NN O
DFO NN NN O
. NN NN O
   
This NN NN O
suggests NN NN O
that NN NN O
alpha NN NN O
- NN NN O
TC NN NN O
and NN NN O
DFO NN NN O
ameliorate NN NN O
the NN NN O
MA NN NN O
- NN NN O
induced NN NN O
neuronal NN NN B-Disease
damage NN NN I-Disease
by NN NN O
decreasing NN NN O
the NN NN O
level NN NN O
of NN NN O
oxidative NN NN O
stress NN NN O
. NN NN O
   
Blockade NN NN O
of NN NN O
both NN NN O
D NN NN O
- NN NN O
1 NN NN O
and NN NN O
D NN NN O
- NN NN O
2 NN NN O
dopamine NN NN O
receptors NN NN O
may NN NN O
induce NN NN O
catalepsy NN NN B-Disease
in NN NN O
mice NN NN O
. NN NN O
   
1 NN NN O
. NN NN O
   
The NN NN O
catalepsy NN NN B-Disease
induced NN NN O
by NN NN O
dopamine NN NN O
antagonists NN NN O
has NN NN O
been NN NN O
tested NN NN O
and NN NN O
the NN NN O
possible NN NN O
dopamine NN NN O
subtypes NN NN O
involved NN NN O
in NN NN O
catalepsy NN NN B-Disease
was NN NN O
determined NN NN O
. NN NN O
   
2 NN NN O
. NN NN O
   
Dopamine NN NN O
antagonist NN NN O
fluphenazine NN NN O
, NN NN O
D NN NN O
- NN NN O
1 NN NN O
antagonist NN NN O
SCH NN NN O
23390 NN NN O
or NN NN O
D NN NN O
- NN NN O
2 NN NN O
antagonist NN NN O
sulpiride NN NN O
induced NN NN O
catalepsy NN NN B-Disease
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
fluphenazine NN NN O
and NN NN O
sulpiride NN NN O
was NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
. NN NN O
   
Combination NN NN O
of NN NN O
SCH NN NN O
23390 NN NN O
with NN NN O
sulpiride NN NN O
did NN NN O
not NN NN O
induce NN NN O
catalepsy NN NN B-Disease
potentiation NN NN O
. NN NN O
   
3 NN NN O
. NN NN O
   
D NN NN O
- NN NN O
1 NN NN O
agonist NN NN O
SKF NN NN O
38393 NN NN O
or NN NN O
D NN NN O
- NN NN O
2 NN NN O
agonist NN NN O
quinpirole NN NN O
decreased NN NN O
the NN NN O
catalepsy NN NN B-Disease
induced NN NN O
by NN NN O
fluphenazine NN NN O
, NN NN O
SCH NN NN O
23390 NN NN O
or NN NN O
sulpiride NN NN O
. NN NN O
   
4 NN NN O
. NN NN O
   
Combination NN NN O
of NN NN O
SKF NN NN O
38393 NN NN O
with NN NN O
quinpirole NN NN O
did NN NN O
not NN NN O
cause NN NN O
potentiated NN NN O
inhibitory NN NN O
effect NN NN O
on NN NN O
catalepsy NN NN B-Disease
induced NN NN O
by NN NN O
dopamine NN NN O
antagonists NN NN O
. NN NN O
   
5 NN NN O
. NN NN O
   
The NN NN O
data NN NN O
may NN NN O
indicate NN NN O
that NN NN O
although NN NN O
D NN NN O
- NN NN O
2 NN NN O
receptor NN NN O
blockade NN NN O
is NN NN O
involved NN NN O
in NN NN O
catalepsy NN NN B-Disease
, NN NN O
the NN NN O
D NN NN O
- NN NN O
1 NN NN O
receptor NN NN O
may NN NN O
plan NN NN O
a NN NN O
role NN NN O
. NN NN O
   
Sustained NN NN O
clinical NN NN O
improvement NN NN O
of NN NN O
a NN NN O
patient NN NN O
with NN NN O
decompensated NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
virus NN NN O
- NN NN O
related NN NN O
cirrhosis NN NN B-Disease
after NN NN O
treatment NN NN O
with NN NN O
lamivudine NN NN O
monotherapy NN NN O
. NN NN O
   
Hepatitis NN NN B-Disease
B NN NN I-Disease
virus NN NN I-Disease
( NN NN I-Disease
HBV NN NN I-Disease
) NN NN I-Disease
infection NN NN I-Disease
, NN NN O
which NN NN O
causes NN NN O
liver NN NN B-Disease
cirrhosis NN NN I-Disease
and NN NN O
hepatocellular NN NN B-Disease
carcinoma NN NN I-Disease
, NN NN O
remains NN NN O
a NN NN O
major NN NN O
health NN NN O
problem NN NN O
in NN NN O
Asian NN NN O
countries NN NN O
. NN NN O
   
Recent NN NN O
development NN NN O
of NN NN O
vaccine NN NN O
for NN NN O
prevention NN NN O
is NN NN O
reported NN NN O
to NN NN O
be NN NN O
successful NN NN O
in NN NN O
reducing NN NN O
the NN NN O
size NN NN O
of NN NN O
chronically NN NN O
infected NN NN O
carriers NN NN O
, NN NN O
although NN NN O
the NN NN O
standard NN NN O
medical NN NN O
therapies NN NN O
have NN NN O
not NN NN O
been NN NN O
established NN NN O
up NN NN O
to NN NN O
now NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
encountered NN NN O
a NN NN O
patient NN NN O
with NN NN O
decompensated NN NN O
HBV NN NN O
- NN NN O
related NN NN O
cirrhosis NN NN B-Disease
who NN NN O
exhibited NN NN O
the NN NN O
dramatic NN NN O
improvements NN NN O
after NN NN O
antiviral NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
was NN NN O
a NN NN O
50 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
. NN NN O
   
Previous NN NN O
conventional NN NN O
medical NN NN O
treatments NN NN O
were NN NN O
not NN NN O
effective NN NN O
for NN NN O
this NN NN O
patient NN NN O
, NN NN O
thus NN NN O
this NN NN O
patient NN NN O
had NN NN O
been NN NN O
referred NN NN O
to NN NN O
our NN NN O
hospital NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
administration NN NN O
of NN NN O
lamivudine NN NN O
, NN NN O
a NN NN O
reverse NN NN O
transcriptase NN NN O
inhibitor NN NN O
, NN NN O
for NN NN O
23 NN NN O
months NN NN O
dramatically NN NN O
improved NN NN O
her NN NN O
liver NN NN O
severity NN NN O
. NN NN O
   
During NN NN O
this NN NN O
period NN NN O
, NN NN O
no NN NN O
drug NN NN O
resistant NN NN O
mutant NN NN O
HBV NN NN O
emerged NN NN O
, NN NN O
and NN NN O
the NN NN O
serum NN NN O
HBV NN NN O
- NN NN O
DNA NN NN O
level NN NN O
was NN NN O
continuously NN NN O
suppressed NN NN O
. NN NN O
   
These NN NN O
virological NN NN O
responses NN NN O
were NN NN O
also NN NN O
maintained NN NN O
even NN NN O
after NN NN O
the NN NN O
antiviral NN NN O
therapy NN NN O
was NN NN O
discontinued NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
both NN NN O
hepatitis NN NN O
B NN NN O
surface NN NN O
antigen NN NN O
and NN NN O
e NN NN O
antigen NN NN O
were NN NN O
observed NN NN O
to NN NN O
have NN NN O
disappeared NN NN O
in NN NN O
this NN NN O
patient NN NN O
. NN NN O
   
The NN NN O
administration NN NN O
of NN NN O
lamivudine NN NN O
to NN NN O
patients NN NN O
with NN NN O
HBV NN NN O
- NN NN O
related NN NN O
cirrhosis NN NN B-Disease
, NN NN O
like NN NN O
our NN NN O
present NN NN O
case NN NN O
, NN NN O
should NN NN O
be NN NN O
considered NN NN O
as NN NN O
an NN NN O
initial NN NN O
medical NN NN O
therapeutic NN NN O
option NN NN O
, NN NN O
especially NN NN O
in NN NN O
countries NN NN O
where NN NN O
liver NN NN O
transplantation NN NN O
is NN NN O
not NN NN O
reliably NN NN O
available NN NN O
. NN NN O
   
Antiarrhythmic NN NN O
effects NN NN O
of NN NN O
optical NN NN O
isomers NN NN O
of NN NN O
cibenzoline NN NN O
on NN NN O
canine NN NN O
ventricular NN NN B-Disease
arrhythmias NN NN I-Disease
. NN NN O
   
Antiarrhythmic NN NN O
effects NN NN O
of NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
cibenzoline NN NN O
and NN NN O
( NN NN O
- NN NN O
) NN NN O
- NN NN O
cibenzoline NN NN O
were NN NN O
examined NN NN O
using NN NN O
two NN NN O
canine NN NN O
ventricular NN NN B-Disease
arrhythmia NN NN I-Disease
models NN NN O
. NN NN O
   
Digitalis NN NN O
arrhythmia NN NN B-Disease
, NN NN O
which NN NN O
is NN NN O
suppressed NN NN O
by NN NN O
Na NN NN O
channel NN NN O
blockers NN NN O
, NN NN O
was NN NN O
induced NN NN O
by NN NN O
intermittent NN NN O
intravenous NN NN O
( NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
injection NN NN O
of NN NN O
ouabain NN NN O
in NN NN O
pentobarbital NN NN O
- NN NN O
anesthetized NN NN O
dogs NN NN O
. NN NN O
   
Adrenaline NN NN B-Disease
arrhythmia NN NN I-Disease
, NN NN O
which NN NN O
is NN NN O
suppressed NN NN O
by NN NN O
Ca NN NN O
channel NN NN O
blockers NN NN O
, NN NN O
was NN NN O
induced NN NN O
by NN NN O
adrenaline NN NN O
infusion NN NN O
in NN NN O
halothane NN NN O
- NN NN O
anesthetized NN NN O
dogs NN NN O
. NN NN O
   
Ten NN NN O
and NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
cibenzoline NN NN O
suppressed NN NN O
digitalis NN NN O
- NN NN O
and NN NN O
adrenaline NN NN O
- NN NN O
induced NN NN O
arrhythmias NN NN B-Disease
, NN NN O
respectively NN NN O
. NN NN O
   
The NN NN O
minimum NN NN O
effective NN NN O
plasma NN NN O
concentrations NN NN O
of NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
cibenzoline NN NN O
for NN NN O
digitalis NN NN O
- NN NN O
and NN NN O
adrenaline NN NN O
- NN NN O
induced NN NN O
arrhythmias NN NN B-Disease
were NN NN O
1 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
4 NN NN O
and NN NN O
2 NN NN O
. NN NN O
0 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
6 NN NN O
micrograms NN NN O
/ NN NN O
ml NN NN O
, NN NN O
respectively NN NN O
( NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
, NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
. NN NN O
   
A NN NN O
lower NN NN O
dose NN NN O
of NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
of NN NN O
( NN NN O
- NN NN O
) NN NN O
- NN NN O
cibenzoline NN NN O
suppressed NN NN O
the NN NN O
digitalis NN NN O
- NN NN O
induced NN NN O
arrhythmia NN NN B-Disease
, NN NN O
whereas NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
was NN NN O
needed NN NN O
to NN NN O
suppress NN NN O
adrenaline NN NN O
- NN NN O
induced NN NN O
arrhythmias NN NN B-Disease
. NN NN O
   
The NN NN O
minimum NN NN O
effective NN NN O
plasma NN NN O
concentrations NN NN O
of NN NN O
( NN NN O
- NN NN O
) NN NN O
- NN NN O
cibenzoline NN NN O
for NN NN O
digitalis NN NN O
- NN NN O
and NN NN O
adrenaline NN NN O
- NN NN O
induced NN NN O
arrhythmia NN NN B-Disease
were NN NN O
0 NN NN O
. NN NN O
06 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
04 NN NN O
and NN NN O
0 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
1 NN NN O
micrograms NN NN O
/ NN NN O
ml NN NN O
, NN NN O
respectively NN NN O
( NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
, NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
stronger NN NN O
antiarrhythmic NN NN O
effect NN NN O
of NN NN O
( NN NN O
- NN NN O
) NN NN O
- NN NN O
cibenzoline NN NN O
indicates NN NN O
that NN NN O
( NN NN O
- NN NN O
) NN NN O
- NN NN O
isomer NN NN O
may NN NN O
have NN NN O
an NN NN O
effect NN NN O
nearly NN NN O
5 NN NN O
- NN NN O
20 NN NN O
times NN NN O
stronger NN NN O
in NN NN O
suppressing NN NN O
Na NN NN O
channels NN NN O
, NN NN O
but NN NN O
effects NN NN O
of NN NN O
both NN NN O
drugs NN NN O
on NN NN O
Ca NN NN O
channels NN NN O
may NN NN O
be NN NN O
almost NN NN O
equipotent NN NN O
. NN NN O
   
Passage NN NN O
of NN NN O
mannitol NN NN O
into NN NN O
the NN NN O
brain NN NN O
around NN NN O
gliomas NN NN B-Disease
: NN NN O
a NN NN O
potential NN NN O
cause NN NN O
of NN NN O
rebound NN NN O
phenomenon NN NN O
. NN NN O
   
A NN NN O
study NN NN O
on NN NN O
21 NN NN O
patients NN NN O
. NN NN O
   
AIM NN NN O
: NN NN O
Widespread NN NN O
use NN NN O
of NN NN O
mannitol NN NN O
to NN NN O
reduce NN NN O
brain NN NN B-Disease
edema NN NN I-Disease
and NN NN O
lower NN NN O
elevated NN NN B-Disease
ICP NN NN I-Disease
in NN NN O
brain NN NN B-Disease
tumor NN NN I-Disease
patients NN NN O
continues NN NN O
to NN NN O
be NN NN O
afflicted NN NN O
by NN NN O
the NN NN O
so NN NN O
- NN NN O
called NN NN O
rebound NN NN O
phenomenon NN NN O
. NN NN O
   
Leakage NN NN O
of NN NN O
mannitol NN NN O
into NN NN O
the NN NN O
brain NN NN O
parenchyma NN NN O
through NN NN O
an NN NN O
altered NN NN O
BBB NN NN O
and NN NN O
secondary NN NN O
reversal NN NN O
of NN NN O
osmotic NN NN O
gradient NN NN O
is NN NN O
considered NN NN O
the NN NN O
major NN NN O
cause NN NN O
of NN NN O
rebound NN NN O
. NN NN O
   
This NN NN O
has NN NN O
only NN NN O
been NN NN O
demonstrated NN NN O
experimentally NN NN O
in NN NN O
animals NN NN O
. NN NN O
   
As NN NN O
a NN NN O
contribution NN NN O
to NN NN O
this NN NN O
issue NN NN O
we NN NN O
decided NN NN O
to NN NN O
research NN NN O
the NN NN O
possible NN NN O
passage NN NN O
of NN NN O
mannitol NN NN O
into NN NN O
the NN NN O
brain NN NN O
after NN NN O
administration NN NN O
to NN NN O
21 NN NN O
brain NN NN B-Disease
tumor NN NN I-Disease
patients NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Mannitol NN NN O
( NN NN O
18 NN NN O
% NN NN O
solution NN NN O
; NN NN O
1 NN NN O
g NN NN O
/ NN NN O
kg NN NN O
) NN NN O
was NN NN O
administered NN NN O
as NN NN O
a NN NN O
bolus NN NN O
to NN NN O
patients NN NN O
( NN NN O
ten NN NN O
had NN NN O
malignant NN NN B-Disease
glioma NN NN I-Disease
, NN NN O
seven NN NN O
brain NN NN O
metastases NN NN B-Disease
and NN NN O
four NN NN O
meningioma NN NN B-Disease
) NN NN O
about NN NN O
30 NN NN O
minutes NN NN O
before NN NN O
craniotomy NN NN O
. NN NN O
   
During NN NN O
resection NN NN O
, NN NN O
a NN NN O
sample NN NN O
of NN NN O
the NN NN O
surrounding NN NN O
edematous NN NN B-Disease
white NN NN O
matter NN NN O
was NN NN O
taken NN NN O
at NN NN O
the NN NN O
same NN NN O
time NN NN O
as NN NN O
a NN NN O
10 NN NN O
ml NN NN O
venous NN NN O
blood NN NN O
sample NN NN O
. NN NN O
   
Mannitol NN NN O
concentrations NN NN O
were NN NN O
measured NN NN O
in NN NN O
plasma NN NN O
and NN NN O
white NN NN O
matter NN NN O
by NN NN O
a NN NN O
modified NN NN O
version NN NN O
of NN NN O
the NN NN O
enzyme NN NN O
assay NN NN O
of NN NN O
Blonquist NN NN O
et NN NN O
al NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
In NN NN O
most NN NN O
glioma NN NN B-Disease
patients NN NN O
, NN NN O
mannitol NN NN O
concentrations NN NN O
in NN NN O
white NN NN O
matter NN NN O
were NN NN O
2 NN NN O
to NN NN O
6 NN NN O
times NN NN O
higher NN NN O
than NN NN O
in NN NN O
plasma NN NN O
( NN NN O
mean NN NN O
3 NN NN O
. NN NN O
5 NN NN O
times NN NN O
) NN NN O
. NN NN O
   
In NN NN O
meningioma NN NN B-Disease
and NN NN O
metastases NN NN B-Disease
patients NN NN O
plasma NN NN O
concentrations NN NN O
of NN NN O
mannitol NN NN O
were NN NN O
higher NN NN O
than NN NN O
white NN NN O
matter NN NN O
concentrations NN NN O
except NN NN O
in NN NN O
three NN NN O
cases NN NN O
with NN NN O
infiltration NN NN O
by NN NN O
neoplastic NN NN O
cells NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
results NN NN O
of NN NN O
our NN NN O
study NN NN O
show NN NN O
that NN NN O
even NN NN O
after NN NN O
a NN NN O
single NN NN O
bolus NN NN O
, NN NN O
mannitol NN NN O
may NN NN O
leak NN NN O
through NN NN O
the NN NN O
altered NN NN O
BBB NN NN O
near NN NN O
gliomas NN NN B-Disease
, NN NN O
reversing NN NN O
the NN NN O
initial NN NN O
plasma NN NN O
- NN NN O
to NN NN O
- NN NN O
blood NN NN O
osmotic NN NN O
gradient NN NN O
, NN NN O
aggravating NN NN O
peritumoral NN NN O
edema NN NN B-Disease
and NN NN O
promoting NN NN O
rebound NN NN O
of NN NN O
ICP NN NN O
. NN NN O
   
Placebo NN NN O
- NN NN O
level NN NN O
incidence NN NN O
of NN NN O
extrapyramidal NN NN B-Disease
symptoms NN NN I-Disease
( NN NN O
EPS NN NN B-Disease
) NN NN O
with NN NN O
quetiapine NN NN O
in NN NN O
controlled NN NN O
studies NN NN O
of NN NN O
patients NN NN O
with NN NN O
bipolar NN NN B-Disease
mania NN NN I-Disease
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
To NN NN O
evaluate NN NN O
extrapyramidal NN NN B-Disease
symptoms NN NN I-Disease
( NN NN O
EPS NN NN B-Disease
) NN NN O
, NN NN O
including NN NN O
akathisia NN NN B-Disease
, NN NN O
with NN NN O
quetiapine NN NN O
in NN NN O
patients NN NN O
with NN NN O
bipolar NN NN B-Disease
mania NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Data NN NN O
were NN NN O
analyzed NN NN O
from NN NN O
four NN NN O
similarly NN NN O
designed NN NN O
, NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
3 NN NN O
- NN NN O
to NN NN O
12 NN NN O
- NN NN O
week NN NN O
studies NN NN O
. NN NN O
   
Two NN NN O
studies NN NN O
evaluated NN NN O
quetiapine NN NN O
monotherapy NN NN O
( NN NN O
up NN NN O
to NN NN O
800 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
( NN NN O
n NN NN O
= NN NN O
209 NN NN O
) NN NN O
versus NN NN O
placebo NN NN O
( NN NN O
n NN NN O
= NN NN O
198 NN NN O
) NN NN O
, NN NN O
with NN NN O
lithium NN NN O
or NN NN O
haloperidol NN NN O
monotherapy NN NN O
as NN NN O
respective NN NN O
active NN NN O
controls NN NN O
. NN NN O
   
Two NN NN O
studies NN NN O
evaluated NN NN O
quetiapine NN NN O
( NN NN O
up NN NN O
to NN NN O
800 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
in NN NN O
combination NN NN O
with NN NN O
a NN NN O
mood NN NN O
stabilizer NN NN O
( NN NN O
lithium NN NN O
or NN NN O
divalproex NN NN O
, NN NN O
QTP NN NN O
+ NN NN O
Li NN NN O
/ NN NN O
DVP NN NN O
) NN NN O
( NN NN O
n NN NN O
= NN NN O
196 NN NN O
) NN NN O
compared NN NN O
to NN NN O
placebo NN NN O
and NN NN O
mood NN NN O
stabilizer NN NN O
( NN NN O
PBO NN NN O
+ NN NN O
Li NN NN O
/ NN NN O
DVP NN NN O
) NN NN O
( NN NN O
n NN NN O
= NN NN O
203 NN NN O
) NN NN O
. NN NN O
   
Extrapyramidal NN NN B-Disease
symptoms NN NN I-Disease
were NN NN O
evaluated NN NN O
using NN NN O
the NN NN O
Simpson NN NN O
- NN NN O
Angus NN NN O
Scale NN NN O
( NN NN O
SAS NN NN O
) NN NN O
, NN NN O
the NN NN O
Barnes NN NN O
Akathisia NN NN O
Rating NN NN O
Scale NN NN O
( NN NN O
BARS NN NN O
) NN NN O
, NN NN O
adverse NN NN O
event NN NN O
reports NN NN O
and NN NN O
anticholinergic NN NN O
drug NN NN O
usage NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
incidence NN NN O
of NN NN O
EPS NN NN B-Disease
- NN NN O
related NN NN O
adverse NN NN O
events NN NN O
, NN NN O
including NN NN O
akathisia NN NN B-Disease
, NN NN O
was NN NN O
no NN NN O
different NN NN O
with NN NN O
quetiapine NN NN O
monotherapy NN NN O
( NN NN O
12 NN NN O
. NN NN O
9 NN NN O
% NN NN O
) NN NN O
than NN NN O
with NN NN O
placebo NN NN O
( NN NN O
13 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
EPS NN NN B-Disease
- NN NN O
related NN NN O
adverse NN NN O
events NN NN O
with NN NN O
QTP NN NN O
+ NN NN O
Li NN NN O
/ NN NN O
DVP NN NN O
( NN NN O
21 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
were NN NN O
no NN NN O
different NN NN O
than NN NN O
with NN NN O
PBO NN NN O
+ NN NN O
Li NN NN O
/ NN NN O
DVP NN NN O
( NN NN O
19 NN NN O
. NN NN O
2 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Adverse NN NN O
events NN NN O
related NN NN O
to NN NN O
EPS NN NN B-Disease
occurred NN NN O
in NN NN O
59 NN NN O
. NN NN O
6 NN NN O
% NN NN O
of NN NN O
patients NN NN O
treated NN NN O
with NN NN O
haloperidol NN NN O
( NN NN O
n NN NN O
= NN NN O
99 NN NN O
) NN NN O
monotherapy NN NN O
, NN NN O
whereas NN NN O
26 NN NN O
. NN NN O
5 NN NN O
% NN NN O
of NN NN O
patients NN NN O
treated NN NN O
with NN NN O
lithium NN NN O
( NN NN O
n NN NN O
= NN NN O
98 NN NN O
) NN NN O
monotherapy NN NN O
experienced NN NN O
adverse NN NN O
events NN NN O
related NN NN O
to NN NN O
EPS NN NN B-Disease
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
akathisia NN NN B-Disease
was NN NN O
low NN NN O
and NN NN O
similar NN NN O
with NN NN O
quetiapine NN NN O
monotherapy NN NN O
( NN NN O
3 NN NN O
. NN NN O
3 NN NN O
% NN NN O
) NN NN O
and NN NN O
placebo NN NN O
( NN NN O
6 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
, NN NN O
and NN NN O
with NN NN O
QTP NN NN O
+ NN NN O
Li NN NN O
/ NN NN O
DVP NN NN O
( NN NN O
3 NN NN O
. NN NN O
6 NN NN O
% NN NN O
) NN NN O
and NN NN O
PBO NN NN O
+ NN NN O
Li NN NN O
/ NN NN O
DVP NN NN O
( NN NN O
4 NN NN O
. NN NN O
9 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Lithium NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
significantly NN NN O
higher NN NN O
incidence NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
of NN NN O
tremor NN NN B-Disease
( NN NN O
18 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
than NN NN O
quetiapine NN NN O
( NN NN O
5 NN NN O
. NN NN O
6 NN NN O
% NN NN O
) NN NN O
; NN NN O
cerebellar NN NN O
tremor NN NN B-Disease
, NN NN O
which NN NN O
is NN NN O
a NN NN O
known NN NN O
adverse NN NN O
effect NN NN O
of NN NN O
lithium NN NN O
, NN NN O
may NN NN O
have NN NN O
contributed NN NN O
to NN NN O
the NN NN O
elevated NN NN O
rate NN NN O
of NN NN O
tremor NN NN B-Disease
in NN NN O
patients NN NN O
receiving NN NN O
lithium NN NN O
therapy NN NN O
. NN NN O
   
Haloperidol NN NN O
induced NN NN O
a NN NN O
significantly NN NN O
higher NN NN O
incidence NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
of NN NN O
akathisia NN NN B-Disease
( NN NN O
33 NN NN O
. NN NN O
3 NN NN O
% NN NN O
versus NN NN O
5 NN NN O
. NN NN O
9 NN NN O
% NN NN O
) NN NN O
, NN NN O
tremor NN NN B-Disease
( NN NN O
30 NN NN O
. NN NN O
3 NN NN O
% NN NN O
versus NN NN O
7 NN NN O
. NN NN O
8 NN NN O
% NN NN O
) NN NN O
, NN NN O
and NN NN O
extrapyramidal NN NN B-Disease
syndrome NN NN I-Disease
( NN NN O
35 NN NN O
. NN NN O
4 NN NN O
% NN NN O
versus NN NN O
5 NN NN O
. NN NN O
9 NN NN O
% NN NN O
) NN NN O
than NN NN O
quetiapine NN NN O
. NN NN O
   
No NN NN O
significant NN NN O
differences NN NN O
were NN NN O
observed NN NN O
between NN NN O
quetiapine NN NN O
and NN NN O
placebo NN NN O
on NN NN O
SAS NN NN O
and NN NN O
BARS NN NN O
scores NN NN O
. NN NN O
   
Anticholinergic NN NN O
use NN NN O
was NN NN O
low NN NN O
and NN NN O
similar NN NN O
with NN NN O
quetiapine NN NN O
or NN NN O
placebo NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
In NN NN O
bipolar NN NN B-Disease
mania NN NN I-Disease
, NN NN O
the NN NN O
incidence NN NN O
of NN NN O
EPS NN NN B-Disease
, NN NN O
including NN NN O
akathisia NN NN B-Disease
, NN NN O
with NN NN O
quetiapine NN NN O
therapy NN NN O
is NN NN O
similar NN NN O
to NN NN O
that NN NN O
with NN NN O
placebo NN NN O
. NN NN O
   
Is NN NN O
phenytoin NN NN O
administration NN NN O
safe NN NN O
in NN NN O
a NN NN O
hypothermic NN NN B-Disease
child NN NN O
? NN NN O
   
A NN NN O
male NN NN O
neonate NN NN O
with NN NN O
a NN NN O
Chiari NN NN B-Disease
malformation NN NN I-Disease
and NN NN O
a NN NN O
leaking NN NN O
myelomeningocoele NN NN O
underwent NN NN O
ventriculoperitoneal NN NN O
shunt NN NN O
insertion NN NN O
followed NN NN O
by NN NN O
repair NN NN O
of NN NN O
myelomeningocoele NN NN O
. NN NN O
   
During NN NN O
anaesthesia NN NN O
and NN NN O
surgery NN NN O
, NN NN O
he NN NN O
inadvertently NN NN O
became NN NN O
moderately NN NN O
hypothermic NN NN B-Disease
. NN NN O
   
Intravenous NN NN O
phenytoin NN NN O
was NN NN O
administered NN NN O
during NN NN O
the NN NN O
later NN NN O
part NN NN O
of NN NN O
the NN NN O
surgery NN NN O
for NN NN O
seizure NN NN B-Disease
prophylaxis NN NN O
. NN NN O
   
Following NN NN O
phenytoin NN NN O
administration NN NN O
, NN NN O
the NN NN O
patient NN NN O
developed NN NN O
acute NN NN O
severe NN NN O
bradycardia NN NN B-Disease
, NN NN O
refractory NN NN O
to NN NN O
atropine NN NN O
and NN NN O
adrenaline NN NN O
. NN NN O
   
The NN NN O
cardiac NN NN O
depressant NN NN O
actions NN NN O
of NN NN O
phenytoin NN NN O
and NN NN O
hypothermia NN NN B-Disease
can NN NN O
be NN NN O
additive NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
phenytoin NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
hypothermia NN NN B-Disease
may NN NN O
lead NN NN O
to NN NN O
an NN NN O
adverse NN NN O
cardiac NN NN O
event NN NN O
in NN NN O
children NN NN O
. NN NN O
   
As NN NN O
phenytoin NN NN O
is NN NN O
a NN NN O
commonly NN NN O
used NN NN O
drug NN NN O
, NN NN O
clinicians NN NN O
need NN NN O
to NN NN O
be NN NN O
aware NN NN O
of NN NN O
this NN NN O
interaction NN NN O
. NN NN O
   
Valproate NN NN O
- NN NN O
induced NN NN O
chorea NN NN B-Disease
and NN NN O
encephalopathy NN NN B-Disease
in NN NN O
atypical NN NN O
nonketotic NN NN B-Disease
hyperglycinemia NN NN I-Disease
. NN NN O
   
Nonketotic NN NN B-Disease
hyperglycinemia NN NN I-Disease
is NN NN O
a NN NN O
disorder NN NN B-Disease
of NN NN I-Disease
amino NN NN I-Disease
acid NN NN I-Disease
metabolism NN NN I-Disease
in NN NN O
which NN NN O
a NN NN O
defect NN NN O
in NN NN O
the NN NN O
glycine NN NN O
cleavage NN NN O
system NN NN O
leads NN NN O
to NN NN O
an NN NN O
accumulation NN NN O
of NN NN O
glycine NN NN O
in NN NN O
the NN NN O
brain NN NN O
and NN NN O
other NN NN O
body NN NN O
compartments NN NN O
. NN NN O
   
In NN NN O
the NN NN O
classical NN NN O
form NN NN O
it NN NN O
presents NN NN O
as NN NN O
neonatal NN NN O
apnea NN NN B-Disease
, NN NN O
intractable NN NN O
seizures NN NN B-Disease
, NN NN O
and NN NN O
hypotonia NN NN B-Disease
, NN NN O
followed NN NN O
by NN NN O
significant NN NN O
psychomotor NN NN B-Disease
retardation NN NN I-Disease
. NN NN O
   
An NN NN O
important NN NN O
subset NN NN O
of NN NN O
children NN NN O
with NN NN O
nonketotic NN NN B-Disease
hyperglycinemia NN NN I-Disease
are NN NN O
atypical NN NN O
variants NN NN O
who NN NN O
present NN NN O
in NN NN O
a NN NN O
heterogeneous NN NN O
manner NN NN O
. NN NN O
   
This NN NN O
report NN NN O
describes NN NN O
a NN NN O
patient NN NN O
with NN NN O
mild NN NN O
language NN NN B-Disease
delay NN NN I-Disease
and NN NN O
mental NN NN B-Disease
retardation NN NN I-Disease
, NN NN O
who NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
nonketotic NN NN B-Disease
hyperglycinemia NN NN I-Disease
following NN NN O
her NN NN O
presentation NN NN O
with NN NN O
acute NN NN O
encephalopathy NN NN B-Disease
and NN NN O
chorea NN NN B-Disease
shortly NN NN O
after NN NN O
initiation NN NN O
of NN NN O
valproate NN NN O
therapy NN NN O
. NN NN O
   
Delayed NN NN O
institution NN NN O
of NN NN O
hypertension NN NN B-Disease
during NN NN O
focal NN NN O
cerebral NN NN B-Disease
ischemia NN NN I-Disease
: NN NN O
effect NN NN O
on NN NN O
brain NN NN B-Disease
edema NN NN I-Disease
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
induced NN NN O
hypertension NN NN B-Disease
instituted NN NN O
after NN NN O
a NN NN O
2 NN NN O
- NN NN O
h NN NN O
delay NN NN O
following NN NN O
middle NN NN B-Disease
cerebral NN NN I-Disease
artery NN NN I-Disease
occlusion NN NN I-Disease
( NN NN O
MCAO NN NN B-Disease
) NN NN O
on NN NN O
brain NN NN B-Disease
edema NN NN I-Disease
formation NN NN O
and NN NN O
histochemical NN NN O
injury NN NN O
was NN NN O
studied NN NN O
. NN NN O
   
Under NN NN O
isoflurane NN NN O
anesthesia NN NN O
, NN NN O
the NN NN O
MCA NN NN O
of NN NN O
14 NN NN O
spontaneously NN NN O
hypertensive NN NN B-Disease
rats NN NN O
was NN NN O
occluded NN NN O
. NN NN O
   
In NN NN O
the NN NN O
control NN NN O
group NN NN O
( NN NN O
n NN NN O
= NN NN O
7 NN NN O
) NN NN O
, NN NN O
the NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
( NN NN O
MAP NN NN O
) NN NN O
was NN NN O
not NN NN O
manipulated NN NN O
. NN NN O
   
In NN NN O
the NN NN O
hypertensive NN NN B-Disease
group NN NN O
( NN NN O
n NN NN O
= NN NN O
7 NN NN O
) NN NN O
, NN NN O
the NN NN O
MAP NN NN O
was NN NN O
elevated NN NN O
by NN NN O
25 NN NN O
- NN NN O
30 NN NN O
mm NN NN O
Hg NN NN O
beginning NN NN O
2 NN NN O
h NN NN O
after NN NN O
MCAO NN NN B-Disease
. NN NN O
   
Four NN NN O
hours NN NN O
after NN NN O
MCAO NN NN B-Disease
, NN NN O
the NN NN O
rats NN NN O
were NN NN O
killed NN NN O
and NN NN O
the NN NN O
brains NN NN O
harvested NN NN O
. NN NN O
   
The NN NN O
brains NN NN O
were NN NN O
sectioned NN NN O
along NN NN O
coronal NN NN O
planes NN NN O
spanning NN NN O
the NN NN O
distribution NN NN O
of NN NN O
ischemia NN NN B-Disease
produced NN NN O
by NN NN O
MCAO NN NN B-Disease
. NN NN O
   
Specific NN NN O
gravity NN NN O
( NN NN O
SG NN NN O
) NN NN O
was NN NN O
determined NN NN O
in NN NN O
the NN NN O
subcortex NN NN O
and NN NN O
in NN NN O
two NN NN O
sites NN NN O
in NN NN O
the NN NN O
cortex NN NN O
( NN NN O
core NN NN O
and NN NN O
periphery NN NN O
of NN NN O
the NN NN O
ischemic NN NN B-Disease
territory NN NN O
) NN NN O
. NN NN O
   
The NN NN O
extent NN NN O
of NN NN O
neuronal NN NN B-Disease
injury NN NN I-Disease
was NN NN O
determined NN NN O
by NN NN O
2 NN NN O
, NN NN O
3 NN NN O
, NN NN O
5 NN NN O
- NN NN O
triphenyltetrazolium NN NN O
staining NN NN O
. NN NN O
   
In NN NN O
the NN NN O
ischemic NN NN B-Disease
core NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
difference NN NN O
in NN NN O
SG NN NN O
in NN NN O
the NN NN O
subcortex NN NN O
and NN NN O
cortex NN NN O
in NN NN O
the NN NN O
two NN NN O
groups NN NN O
. NN NN O
   
In NN NN O
the NN NN O
periphery NN NN O
of NN NN O
the NN NN O
ischemic NN NN B-Disease
territory NN NN O
, NN NN O
SG NN NN O
in NN NN O
the NN NN O
cortex NN NN O
was NN NN O
greater NN NN O
( NN NN O
less NN NN O
edema NN NN B-Disease
accumulation NN NN O
) NN NN O
in NN NN O
the NN NN O
hypertensive NN NN B-Disease
group NN NN O
( NN NN O
1 NN NN O
. NN NN O
041 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
001 NN NN O
vs NN NN O
1 NN NN O
. NN NN O
039 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
001 NN NN O
, NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
area NN NN O
of NN NN O
histochemical NN NN O
injury NN NN O
( NN NN O
as NN NN O
a NN NN O
percent NN NN O
of NN NN O
the NN NN O
cross NN NN O
- NN NN O
sectional NN NN O
area NN NN O
of NN NN O
the NN NN O
hemisphere NN NN O
) NN NN O
was NN NN O
less NN NN O
in NN NN O
the NN NN O
hypertensive NN NN B-Disease
group NN NN O
( NN NN O
33 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
% NN NN O
vs NN NN O
21 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
% NN NN O
, NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
data NN NN O
indicate NN NN O
that NN NN O
phenylephrine NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
instituted NN NN O
2 NN NN O
h NN NN O
after NN NN O
MCAO NN NN B-Disease
does NN NN O
not NN NN O
aggravate NN NN O
edema NN NN B-Disease
in NN NN O
the NN NN O
ischemic NN NN B-Disease
core NN NN O
, NN NN O
that NN NN O
it NN NN O
improves NN NN O
edema NN NN B-Disease
in NN NN O
the NN NN O
periphery NN NN O
of NN NN O
the NN NN O
ischemic NN NN B-Disease
territory NN NN O
, NN NN O
and NN NN O
that NN NN O
it NN NN O
reduces NN NN O
the NN NN O
area NN NN O
of NN NN O
histochemical NN NN O
neuronal NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Behavioral NN NN O
effects NN NN O
of NN NN O
pubertal NN NN O
anabolic NN NN O
androgenic NN NN O
steroid NN NN O
exposure NN NN O
in NN NN O
male NN NN O
rats NN NN O
with NN NN O
low NN NN O
serotonin NN NN O
. NN NN O
   
The NN NN O
goal NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
assess NN NN O
the NN NN O
interactive NN NN O
effects NN NN O
of NN NN O
chronic NN NN O
anabolic NN NN O
androgenic NN NN O
steroid NN NN O
( NN NN O
AAS NN NN O
) NN NN O
exposure NN NN O
and NN NN O
brain NN NN O
serotonin NN NN O
( NN NN O
5 NN NN O
- NN NN O
hydroxytryptamine NN NN O
, NN NN O
5 NN NN O
- NN NN O
HT NN NN O
) NN NN O
depletion NN NN O
on NN NN O
behavior NN NN O
of NN NN O
pubertal NN NN O
male NN NN O
rats NN NN O
. NN NN O
   
Serotonin NN NN O
was NN NN O
depleted NN NN O
beginning NN NN O
on NN NN O
postnatal NN NN O
day NN NN O
26 NN NN O
with NN NN O
parachlorophenylalanine NN NN O
( NN NN O
PCPA NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
every NN NN O
other NN NN O
day NN NN O
) NN NN O
; NN NN O
controls NN NN O
received NN NN O
saline NN NN O
. NN NN O
   
At NN NN O
puberty NN NN O
( NN NN O
P40 NN NN O
) NN NN O
, NN NN O
half NN NN O
the NN NN O
PCPA NN NN O
- NN NN O
treated NN NN O
rats NN NN O
and NN NN O
half NN NN O
the NN NN O
saline NN NN O
- NN NN O
treated NN NN O
rats NN NN O
began NN NN O
treatment NN NN O
with NN NN O
testosterone NN NN O
( NN NN O
T NN NN O
, NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
5 NN NN O
days NN NN O
/ NN NN O
week NN NN O
) NN NN O
. NN NN O
   
Behavioral NN NN O
measures NN NN O
included NN NN O
locomotion NN NN O
, NN NN O
irritability NN NN B-Disease
, NN NN O
copulation NN NN O
, NN NN O
partner NN NN O
preference NN NN O
, NN NN O
and NN NN O
aggression NN NN B-Disease
. NN NN O
   
Animals NN NN O
were NN NN O
tested NN NN O
for NN NN O
aggression NN NN B-Disease
in NN NN O
their NN NN O
home NN NN O
cage NN NN O
, NN NN O
both NN NN O
with NN NN O
and NN NN O
without NN NN O
physical NN NN O
provocation NN NN O
( NN NN O
mild NN NN O
tail NN NN O
pinch NN NN O
) NN NN O
. NN NN O
   
Brain NN NN O
levels NN NN O
of NN NN O
5 NN NN O
- NN NN O
HT NN NN O
and NN NN O
its NN NN O
metabolite NN NN O
, NN NN O
5 NN NN O
- NN NN O
hydroxyindoleacetic NN NN O
acid NN NN O
( NN NN O
5 NN NN O
- NN NN O
HIAA NN NN O
) NN NN O
, NN NN O
were NN NN O
determined NN NN O
using NN NN O
HPLC NN NN O
. NN NN O
   
PCPA NN NN O
significantly NN NN O
and NN NN O
substantially NN NN O
depleted NN NN O
5 NN NN O
- NN NN O
HT NN NN O
and NN NN O
5 NN NN O
- NN NN O
HIAA NN NN O
in NN NN O
all NN NN O
brain NN NN O
regions NN NN O
examined NN NN O
. NN NN O
   
Chronic NN NN O
T NN NN O
treatment NN NN O
significantly NN NN O
decreased NN NN O
5 NN NN O
- NN NN O
HT NN NN O
and NN NN O
5 NN NN O
- NN NN O
HIAA NN NN O
in NN NN O
certain NN NN O
brain NN NN O
areas NN NN O
, NN NN O
but NN NN O
to NN NN O
a NN NN O
much NN NN O
lesser NN NN O
extent NN NN O
than NN NN O
PCPA NN NN O
. NN NN O
   
Chronic NN NN O
exposure NN NN O
to NN NN O
PCPA NN NN O
alone NN NN O
significantly NN NN O
decreased NN NN O
locomotor NN NN O
activity NN NN O
and NN NN O
increased NN NN O
irritability NN NN B-Disease
but NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
sexual NN NN O
behavior NN NN O
, NN NN O
partner NN NN O
preference NN NN O
, NN NN O
or NN NN O
aggression NN NN B-Disease
. NN NN O
   
T NN NN O
alone NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
locomotion NN NN O
, NN NN O
irritability NN NN B-Disease
, NN NN O
or NN NN O
sexual NN NN O
behavior NN NN O
but NN NN O
increased NN NN O
partner NN NN O
preference NN NN O
and NN NN O
aggression NN NN B-Disease
. NN NN O
   
The NN NN O
most NN NN O
striking NN NN O
effect NN NN O
of NN NN O
combining NN NN O
T NN NN O
+ NN NN O
PCPA NN NN O
was NN NN O
a NN NN O
significant NN NN O
increase NN NN O
in NN NN O
attack NN NN O
frequency NN NN O
as NN NN O
well NN NN O
as NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
the NN NN O
latency NN NN O
to NN NN O
attack NN NN O
, NN NN O
particularly NN NN O
following NN NN O
physical NN NN O
provocation NN NN O
. NN NN O
   
Based NN NN O
on NN NN O
these NN NN O
data NN NN O
, NN NN O
it NN NN O
can NN NN O
be NN NN O
speculated NN NN O
that NN NN O
pubertal NN NN O
AAS NN NN O
users NN NN O
with NN NN O
low NN NN O
central NN NN O
5 NN NN O
- NN NN O
HT NN NN O
may NN NN O
be NN NN O
especially NN NN O
prone NN NN O
to NN NN O
exhibit NN NN O
aggressive NN NN B-Disease
behavior NN NN I-Disease
. NN NN O
   
Effects NN NN O
of NN NN O
UMB24 NN NN O
and NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
- NN NN O
SM NN NN O
21 NN NN O
, NN NN O
putative NN NN O
sigma2 NN NN O
- NN NN O
preferring NN NN O
antagonists NN NN O
, NN NN O
on NN NN O
behavioral NN NN O
toxic NN NN O
and NN NN O
stimulant NN NN O
effects NN NN O
of NN NN O
cocaine NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Earlier NN NN O
studies NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
antagonism NN NN O
of NN NN O
sigma1 NN NN O
receptors NN NN O
attenuates NN NN O
the NN NN O
convulsive NN NN B-Disease
, NN NN O
lethal NN NN O
, NN NN O
locomotor NN NN O
stimulatory NN NN O
and NN NN O
rewarding NN NN O
actions NN NN O
of NN NN O
cocaine NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
contribution NN NN O
of NN NN O
sigma2 NN NN O
receptors NN NN O
is NN NN O
unclear NN NN O
because NN NN O
experimental NN NN O
tools NN NN O
to NN NN O
selectively NN NN O
target NN NN O
this NN NN O
subtype NN NN O
are NN NN O
unavailable NN NN O
. NN NN O
   
To NN NN O
begin NN NN O
addressing NN NN O
this NN NN O
need NN NN O
, NN NN O
we NN NN O
characterized NN NN O
UMB24 NN NN O
( NN NN O
1 NN NN O
- NN NN O
( NN NN O
2 NN NN O
- NN NN O
phenethyl NN NN O
) NN NN O
- NN NN O
4 NN NN O
- NN NN O
( NN NN O
2 NN NN O
- NN NN O
pyridyl NN NN O
) NN NN O
- NN NN O
piperazine NN NN O
) NN NN O
and NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
- NN NN O
SM NN NN O
21 NN NN O
( NN NN O
3alpha NN NN O
- NN NN O
tropanyl NN NN O
- NN NN O
2 NN NN O
- NN NN O
( NN NN O
4 NN NN O
- NN NN O
chorophenoxy NN NN O
) NN NN O
butyrate NN NN O
) NN NN O
in NN NN O
receptor NN NN O
binding NN NN O
and NN NN O
behavioral NN NN O
studies NN NN O
. NN NN O
   
Receptor NN NN O
binding NN NN O
studies NN NN O
confirmed NN NN O
that NN NN O
UMB24 NN NN O
and NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
- NN NN O
SM NN NN O
21 NN NN O
display NN NN O
preferential NN NN O
affinity NN NN O
for NN NN O
sigma2 NN NN O
over NN NN O
sigma1 NN NN O
receptors NN NN O
. NN NN O
   
In NN NN O
behavioral NN NN O
studies NN NN O
, NN NN O
pretreatment NN NN O
of NN NN O
Swiss NN NN O
Webster NN NN O
mice NN NN O
with NN NN O
UMB24 NN NN O
or NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
- NN NN O
SM NN NN O
21 NN NN O
significantly NN NN O
attenuated NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
and NN NN O
locomotor NN NN O
activity NN NN O
, NN NN O
but NN NN O
not NN NN O
lethality NN NN O
. NN NN O
   
When NN NN O
administered NN NN O
alone NN NN O
, NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
- NN NN O
SM NN NN O
21 NN NN O
produced NN NN O
no NN NN O
significant NN NN O
effects NN NN O
compared NN NN O
to NN NN O
control NN NN O
injections NN NN O
of NN NN O
saline NN NN O
, NN NN O
but NN NN O
UMB24 NN NN O
had NN NN O
locomotor NN NN O
depressant NN NN O
actions NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
the NN NN O
data NN NN O
suggest NN NN O
that NN NN O
sigma2 NN NN O
receptor NN NN O
antagonists NN NN O
have NN NN O
the NN NN O
potential NN NN O
to NN NN O
attenuate NN NN O
some NN NN O
of NN NN O
the NN NN O
behavioral NN NN O
effects NN NN O
of NN NN O
cocaine NN NN O
, NN NN O
and NN NN O
further NN NN O
development NN NN O
of NN NN O
more NN NN O
selective NN NN O
, NN NN O
high NN NN O
affinity NN NN O
ligands NN NN O
are NN NN O
warranted NN NN O
. NN NN O
   
Cardiac NN NN B-Disease
arrest NN NN I-Disease
in NN NN O
a NN NN O
child NN NN O
with NN NN O
cerebral NN NN B-Disease
palsy NN NN I-Disease
undergoing NN NN O
sevoflurane NN NN O
induction NN NN O
of NN NN O
anesthesia NN NN O
after NN NN O
preoperative NN NN O
clonidine NN NN O
. NN NN O
   
Clonidine NN NN O
is NN NN O
a NN NN O
frequently NN NN O
administered NN NN O
alpha2 NN NN O
- NN NN O
adrenergic NN NN O
agonist NN NN O
which NN NN O
can NN NN O
decrease NN NN O
heart NN NN O
rate NN NN O
and NN NN O
blood NN NN O
pressure NN NN O
. NN NN O
   
We NN NN O
present NN NN O
a NN NN O
case NN NN O
of NN NN O
a NN NN O
5 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
child NN NN O
with NN NN O
cerebral NN NN B-Disease
palsy NN NN I-Disease
and NN NN O
seizure NN NN B-Disease
disorder NN NN I-Disease
, NN NN O
receiving NN NN O
clonidine NN NN O
for NN NN O
restlessness NN NN B-Disease
, NN NN O
who NN NN O
presented NN NN O
for NN NN O
placement NN NN O
of NN NN O
a NN NN O
baclofen NN NN O
pump NN NN O
. NN NN O
   
Without NN NN O
the NN NN O
knowledge NN NN O
of NN NN O
the NN NN O
medical NN NN O
personnel NN NN O
, NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
mother NN NN O
administered NN NN O
three NN NN O
doses NN NN O
of NN NN O
clonidine NN NN O
during NN NN O
the NN NN O
evening NN NN O
before NN NN O
and NN NN O
morning NN NN O
of NN NN O
surgery NN NN O
to NN NN O
reduce NN NN O
anxiety NN NN B-Disease
. NN NN O
   
During NN NN O
induction NN NN O
of NN NN O
anesthesia NN NN O
, NN NN O
the NN NN O
patient NN NN O
developed NN NN O
bradycardia NN NN B-Disease
and NN NN O
hypotension NN NN B-Disease
requiring NN NN O
cardiac NN NN O
resuscitation NN NN O
. NN NN O
   
There NN NN O
are NN NN O
no NN NN O
previous NN NN O
reports NN NN O
of NN NN O
clonidine NN NN O
- NN NN O
associated NN NN O
cardiac NN NN B-Disease
arrest NN NN I-Disease
in NN NN O
a NN NN O
child NN NN O
undergoing NN NN O
induction NN NN O
of NN NN O
anesthesia NN NN O
. NN NN O
   
Angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
( NN NN O
ACE NN NN O
) NN NN O
inhibitor NN NN O
- NN NN O
associated NN NN O
angioedema NN NN B-Disease
of NN NN O
the NN NN O
stomach NN NN O
and NN NN O
small NN NN O
intestine NN NN O
: NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
This NN NN O
is NN NN O
a NN NN O
case NN NN O
report NN NN O
on NN NN O
a NN NN O
45 NN NN O
- NN NN O
year NN NN O
old NN NN O
African NN NN O
- NN NN O
American NN NN O
female NN NN O
with NN NN O
newly NN NN O
diagnosed NN NN O
hypertension NN NN B-Disease
, NN NN O
who NN NN O
was NN NN O
started NN NN O
on NN NN O
a NN NN O
combination NN NN O
pill NN NN O
of NN NN O
amlodipine NN NN O
/ NN NN O
benazapril NN NN O
10 NN NN O
/ NN NN O
5 NN NN O
mg NN NN O
. NN NN O
   
The NN NN O
very NN NN O
next NN NN O
day NN NN O
, NN NN O
she NN NN O
presented NN NN O
at NN NN O
the NN NN O
emergency NN NN O
room NN NN O
( NN NN O
ER NN NN O
) NN NN O
with NN NN O
abdominal NN NN B-Disease
pain NN NN I-Disease
, NN NN O
nausea NN NN B-Disease
and NN NN O
vomiting NN NN B-Disease
. NN NN O
   
Physical NN NN O
exam NN NN O
, NN NN O
complete NN NN O
metabolic NN NN O
panel NN NN O
, NN NN O
and NN NN O
hemogram NN NN O
were NN NN O
in NN NN O
the NN NN O
normal NN NN O
range NN NN O
. NN NN O
   
She NN NN O
was NN NN O
discharged NN NN O
from NN NN O
the NN NN O
ER NN NN O
after NN NN O
a NN NN O
few NN NN O
hours NN NN O
of NN NN O
treatment NN NN O
with NN NN O
fluid NN NN O
and NN NN O
analgesics NN NN O
. NN NN O
   
However NN NN O
, NN NN O
she NN NN O
returned NN NN O
to NN NN O
the NN NN O
ER NN NN O
the NN NN O
next NN NN O
day NN NN O
with NN NN O
the NN NN O
same NN NN O
complaints NN NN O
. NN NN O
   
This NN NN O
time NN NN O
the NN NN O
physical NN NN O
exam NN NN O
was NN NN O
significant NN NN O
for NN NN O
a NN NN O
distended NN NN O
abdomen NN NN O
with NN NN O
dullness NN NN O
to NN NN O
percussion NN NN O
. NN NN O
   
CT NN NN O
scan NN NN O
of NN NN O
the NN NN O
abdomen NN NN O
revealed NN NN O
markedly NN NN O
thickened NN NN O
antrum NN NN O
of NN NN O
the NN NN O
stomach NN NN O
, NN NN O
duodenum NN NN O
and NN NN O
jejunum NN NN O
, NN NN O
along NN NN O
with NN NN O
fluid NN NN O
in NN NN O
the NN NN O
abdominal NN NN O
and NN NN O
pelvic NN NN O
cavity NN NN O
. NN NN O
   
Angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
inhibitor NN NN O
( NN NN O
ACEI NN NN O
) NN NN O
- NN NN O
induced NN NN O
angioedema NN NN B-Disease
was NN NN O
suspected NN NN O
, NN NN O
and NN NN O
anti NN NN O
- NN NN O
hypertensive NN NN B-Disease
medications NN NN O
were NN NN O
discontinued NN NN O
. NN NN O
   
Her NN NN O
symptoms NN NN O
improved NN NN O
within NN NN O
the NN NN O
next NN NN O
24 NN NN O
hours NN NN O
, NN NN O
and NN NN O
repeat NN NN O
CT NN NN O
after NN NN O
72 NN NN O
hours NN NN O
revealed NN NN O
marked NN NN O
improvement NN NN O
in NN NN O
stomach NN NN O
and NN NN O
small NN NN O
bowel NN NN O
thickening NN NN O
and NN NN O
resolution NN NN O
of NN NN O
ascites NN NN B-Disease
. NN NN O
   
The NN NN O
recognition NN NN O
of NN NN O
angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
( NN NN O
ACE NN NN O
) NN NN O
and NN NN O
angiotensin NN NN O
receptor NN NN O
blocker NN NN O
( NN NN O
ARB NN NN O
) NN NN O
intestinal NN NN B-Disease
angioedema NN NN I-Disease
constitutes NN NN O
a NN NN O
challenge NN NN O
to NN NN O
primary NN NN O
care NN NN O
physicians NN NN O
, NN NN O
internists NN NN O
, NN NN O
emergency NN NN O
room NN NN O
personal NN NN O
and NN NN O
surgeons NN NN O
. NN NN O
   
Carbamazepine NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Characterization NN NN O
of NN NN O
two NN NN O
distinct NN NN O
clinical NN NN O
syndromes NN NN O
. NN NN O
   
A NN NN O
patient NN NN O
with NN NN O
sinus NN NN O
bradycardia NN NN B-Disease
and NN NN O
atrioventricular NN NN B-Disease
block NN NN I-Disease
, NN NN O
induced NN NN O
by NN NN O
carbamazepine NN NN O
, NN NN O
prompted NN NN O
an NN NN O
extensive NN NN O
literature NN NN O
review NN NN O
of NN NN O
all NN NN O
previously NN NN O
reported NN NN O
cases NN NN O
. NN NN O
   
From NN NN O
the NN NN O
analysis NN NN O
of NN NN O
these NN NN O
cases NN NN O
, NN NN O
two NN NN O
distinct NN NN O
forms NN NN O
of NN NN O
carbamazepine NN NN O
- NN NN O
associated NN NN O
cardiac NN NN B-Disease
dysfunction NN NN I-Disease
emerged NN NN O
. NN NN O
   
One NN NN O
patient NN NN O
group NN NN O
developed NN NN O
sinus NN NN B-Disease
tachycardias NN NN I-Disease
in NN NN O
the NN NN O
setting NN NN O
of NN NN O
a NN NN O
massive NN NN O
carbamazepine NN NN O
overdose NN NN B-Disease
. NN NN O
   
The NN NN O
second NN NN O
group NN NN O
consisted NN NN O
almost NN NN O
exclusively NN NN O
of NN NN O
elderly NN NN O
women NN NN O
who NN NN O
developed NN NN O
potentially NN NN O
life NN NN O
- NN NN O
threatening NN NN O
bradyarrhythmias NN NN B-Disease
or NN NN O
atrioventricular NN NN B-Disease
conduction NN NN I-Disease
delay NN NN I-Disease
, NN NN O
associated NN NN O
with NN NN O
either NN NN O
therapeutic NN NN O
or NN NN O
modestly NN NN O
elevated NN NN O
carbamazepine NN NN O
serum NN NN O
levels NN NN O
. NN NN O
   
Because NN NN O
carbamazepine NN NN O
is NN NN O
widely NN NN O
used NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
many NN NN O
neurologic NN NN O
and NN NN O
psychiatric NN NN B-Disease
conditions NN NN O
, NN NN O
the NN NN O
recognition NN NN O
of NN NN O
the NN NN O
latter NN NN O
syndrome NN NN O
has NN NN O
important NN NN O
implications NN NN O
for NN NN O
the NN NN O
use NN NN O
of NN NN O
this NN NN O
drug NN NN O
in NN NN O
elderly NN NN O
patients NN NN O
. NN NN O
   
Detection NN NN O
of NN NN O
abnormal NN NN O
cardiac NN NN O
adrenergic NN NN O
neuron NN NN O
activity NN NN O
in NN NN O
adriamycin NN NN O
- NN NN O
induced NN NN O
cardiomyopathy NN NN B-Disease
with NN NN O
iodine NN NN O
- NN NN O
125 NN NN O
- NN NN O
metaiodobenzylguanidine NN NN O
. NN NN O
   
Radiolabeled NN NN O
metaiodobenzylguanidine NN NN O
( NN NN O
MIBG NN NN O
) NN NN O
, NN NN O
an NN NN O
analog NN NN O
of NN NN O
norepinephrine NN NN O
( NN NN O
NE NN NN O
) NN NN O
, NN NN O
serves NN NN O
as NN NN O
an NN NN O
index NN NN O
of NN NN O
adrenergic NN NN O
neuron NN NN O
integrity NN NN O
and NN NN O
function NN NN O
. NN NN O
   
Using NN NN O
a NN NN O
rat NN NN O
model NN NN O
of NN NN O
adriamycin NN NN O
- NN NN O
induced NN NN O
cardiomyopathy NN NN B-Disease
, NN NN O
we NN NN O
tested NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
abnormal NN NN O
cardiac NN NN O
adrenergic NN NN O
neuron NN NN O
activity NN NN O
may NN NN O
appear NN NN O
and NN NN O
be NN NN O
exacerbated NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
in NN NN O
adriamycin NN NN O
cardiomyopathy NN NN B-Disease
. NN NN O
   
The NN NN O
degree NN NN O
of NN NN O
vacuolar NN NN B-Disease
degeneration NN NN I-Disease
of NN NN I-Disease
myocardial NN NN I-Disease
cells NN NN I-Disease
was NN NN O
analyzed NN NN O
in NN NN O
relation NN NN O
to NN NN O
the NN NN O
duration NN NN O
of NN NN O
adriamycin NN NN O
treatment NN NN O
( NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
once NN NN O
a NN NN O
week NN NN O
) NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
abnormalities NN NN O
or NN NN O
only NN NN O
isolated NN NN O
degeneration NN NN O
in NN NN O
the NN NN O
1 NN NN O
- NN NN O
or NN NN O
2 NN NN O
- NN NN O
wk NN NN O
treatment NN NN O
groups NN NN O
, NN NN O
isolated NN NN O
or NN NN O
scattered NN NN O
degeneration NN NN O
in NN NN O
half NN NN O
of NN NN O
the NN NN O
3 NN NN O
- NN NN O
wk NN NN O
group NN NN O
, NN NN O
frequent NN NN O
scattered NN NN O
degeneration NN NN O
in NN NN O
the NN NN O
4 NN NN O
- NN NN O
wk NN NN O
group NN NN O
, NN NN O
scattered NN NN O
or NN NN O
focal NN NN O
degeneration NN NN O
in NN NN O
the NN NN O
5 NN NN O
- NN NN O
wk NN NN O
group NN NN O
, NN NN O
and NN NN O
extensive NN NN O
degeneration NN NN O
in NN NN O
the NN NN O
8 NN NN O
- NN NN O
wk NN NN O
group NN NN O
. NN NN O
   
Myocardial NN NN O
accumulation NN NN O
of NN NN O
[ NN NN O
125I NN NN O
] NN NN O
MIBG NN NN O
4 NN NN O
hr NN NN O
after NN NN O
intravenous NN NN O
injection NN NN O
did NN NN O
not NN NN O
differ NN NN O
between NN NN O
the NN NN O
controls NN NN O
and NN NN O
the NN NN O
groups NN NN O
treated NN NN O
3 NN NN O
wk NN NN O
or NN NN O
less NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
4 NN NN O
- NN NN O
wk NN NN O
group NN NN O
had NN NN O
a NN NN O
slightly NN NN O
lower NN NN O
accumulation NN NN O
in NN NN O
the NN NN O
right NN NN O
ventricular NN NN O
wall NN NN O
( NN NN O
82 NN NN O
% NN NN O
of NN NN O
the NN NN O
control NN NN O
) NN NN O
and NN NN O
significantly NN NN O
lower NN NN O
accumulation NN NN O
in NN NN O
the NN NN O
left NN NN O
ventricular NN NN O
wall NN NN O
( NN NN O
about NN NN O
66 NN NN O
% NN NN O
of NN NN O
the NN NN O
control NN NN O
: NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
5 NN NN O
- NN NN O
wk NN NN O
group NN NN O
, NN NN O
MIBG NN NN O
accumulation NN NN O
in NN NN O
the NN NN O
right NN NN O
and NN NN O
left NN NN O
ventricular NN NN O
wall NN NN O
was NN NN O
35 NN NN O
% NN NN O
and NN NN O
27 NN NN O
% NN NN O
of NN NN O
that NN NN O
in NN NN O
controls NN NN O
, NN NN O
respectively NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
8 NN NN O
- NN NN O
wk NN NN O
group NN NN O
, NN NN O
MIBG NN NN O
accumulation NN NN O
in NN NN O
the NN NN O
right NN NN O
and NN NN O
left NN NN O
ventricular NN NN O
wall NN NN O
was NN NN O
18 NN NN O
% NN NN O
and NN NN O
14 NN NN O
% NN NN O
of NN NN O
that NN NN O
in NN NN O
controls NN NN O
, NN NN O
respectively NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
MIBG NN NN O
accumulation NN NN O
in NN NN O
the NN NN O
myocardium NN NN O
decreased NN NN O
in NN NN O
an NN NN O
adriamycin NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
The NN NN O
appearance NN NN O
of NN NN O
impaired NN NN O
cardiac NN NN O
adrenergic NN NN O
neuron NN NN O
activity NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
slight NN NN O
myocardial NN NN B-Disease
impairment NN NN I-Disease
( NN NN O
scattered NN NN O
or NN NN O
focal NN NN O
vacuolar NN NN B-Disease
degeneration NN NN I-Disease
) NN NN O
indicates NN NN O
that NN NN O
MIBG NN NN O
scintigraphy NN NN O
may NN NN O
be NN NN O
a NN NN O
useful NN NN O
method NN NN O
for NN NN O
detection NN NN O
of NN NN O
adriamycin NN NN O
- NN NN O
induced NN NN O
cardiomyopathy NN NN B-Disease
. NN NN O
   
Syncope NN NN B-Disease
and NN NN O
QT NN NN B-Disease
prolongation NN NN I-Disease
among NN NN O
patients NN NN O
treated NN NN O
with NN NN O
methadone NN NN O
for NN NN O
heroin NN NN O
dependence NN NN O
in NN NN O
the NN NN O
city NN NN O
of NN NN O
Copenhagen NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Methadone NN NN O
is NN NN O
prescribed NN NN O
to NN NN O
heroin NN NN O
addicts NN NN O
to NN NN O
decrease NN NN O
illicit NN NN O
opioid NN NN O
use NN NN O
. NN NN O
   
Prolongation NN NN O
of NN NN O
the NN NN O
QT NN NN O
interval NN NN O
in NN NN O
the NN NN O
ECG NN NN O
of NN NN O
patients NN NN O
with NN NN O
torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
( NN NN O
TdP NN NN B-Disease
) NN NN O
has NN NN O
been NN NN O
reported NN NN O
in NN NN O
methadone NN NN O
users NN NN O
. NN NN O
   
As NN NN O
heroin NN NN O
addicts NN NN O
sometimes NN NN O
faint NN NN O
while NN NN O
using NN NN O
illicit NN NN O
drugs NN NN O
, NN NN O
doctors NN NN O
might NN NN O
attribute NN NN O
too NN NN O
many NN NN O
episodes NN NN O
of NN NN O
syncope NN NN B-Disease
to NN NN O
illicit NN NN O
drug NN NN O
use NN NN O
and NN NN O
thereby NN NN O
underestimate NN NN O
the NN NN O
incidence NN NN O
of NN NN O
TdP NN NN B-Disease
in NN NN O
this NN NN O
special NN NN O
population NN NN O
, NN NN O
and NN NN O
the NN NN O
high NN NN O
mortality NN NN O
in NN NN O
this NN NN O
population NN NN O
may NN NN O
, NN NN O
in NN NN O
part NN NN O
, NN NN O
be NN NN O
caused NN NN O
by NN NN O
the NN NN O
proarrhythmic NN NN O
effect NN NN O
of NN NN O
methadone NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
In NN NN O
this NN NN O
cross NN NN O
- NN NN O
sectional NN NN O
study NN NN O
interview NN NN O
, NN NN O
ECGs NN NN O
and NN NN O
blood NN NN O
samples NN NN O
were NN NN O
collected NN NN O
in NN NN O
a NN NN O
population NN NN O
of NN NN O
adult NN NN O
heroin NN NN O
addicts NN NN O
treated NN NN O
with NN NN O
methadone NN NN O
or NN NN O
buprenorphine NN NN O
on NN NN O
a NN NN O
daily NN NN O
basis NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
patients NN NN O
at NN NN O
the NN NN O
Drug NN NN O
Addiction NN NN O
Service NN NN O
in NN NN O
the NN NN O
municipal NN NN O
of NN NN O
Copenhagen NN NN O
, NN NN O
450 NN NN O
( NN NN O
approximately NN NN O
52 NN NN O
% NN NN O
) NN NN O
were NN NN O
included NN NN O
. NN NN O
   
The NN NN O
QT NN NN O
interval NN NN O
was NN NN O
estimated NN NN O
from NN NN O
12 NN NN O
lead NN NN O
ECGs NN NN O
. NN NN O
   
All NN NN O
participants NN NN O
were NN NN O
interviewed NN NN O
about NN NN O
any NN NN O
experience NN NN O
of NN NN O
syncope NN NN B-Disease
. NN NN O
   
The NN NN O
association NN NN O
between NN NN O
opioid NN NN O
dose NN NN O
and NN NN O
QT NN NN O
, NN NN O
and NN NN O
methadone NN NN O
dose NN NN O
and NN NN O
reporting NN NN O
of NN NN O
syncope NN NN B-Disease
was NN NN O
assessed NN NN O
using NN NN O
multivariate NN NN O
linear NN NN O
regression NN NN O
and NN NN O
logistic NN NN O
regression NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Methadone NN NN O
dose NN NN O
was NN NN O
associated NN NN O
with NN NN O
longer NN NN O
QT NN NN O
interval NN NN O
of NN NN O
0 NN NN O
. NN NN O
140 NN NN O
ms NN NN O
/ NN NN O
mg NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
002 NN NN O
) NN NN O
. NN NN O
   
No NN NN O
association NN NN O
between NN NN O
buprenorphine NN NN O
and NN NN O
QTc NN NN O
was NN NN O
found NN NN O
. NN NN O
   
Among NN NN O
the NN NN O
subjects NN NN O
treated NN NN O
with NN NN O
methadone NN NN O
, NN NN O
28 NN NN O
% NN NN O
men NN NN O
and NN NN O
32 NN NN O
% NN NN O
women NN NN O
had NN NN O
prolonged NN NN B-Disease
QTc NN NN I-Disease
interval NN NN I-Disease
. NN NN O
   
   O
of NN NN O
the NN NN O
subjects NN NN O
treated NN NN O
with NN NN O
buprenorphine NN NN O
had NN NN O
QTc NN NN O
interval NN NN O
> NN NN O
0 NN NN O
. NN NN O
440 NN NN O
s NN NN O
( NN NN O
( NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
) NN NN O
) NN NN O
. NN NN O
   
A NN NN O
50 NN NN O
mg NN NN O
higher NN NN O
methadone NN NN O
dose NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
1 NN NN O
. NN NN O
2 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
1 NN NN O
. NN NN O
1 NN NN O
to NN NN O
1 NN NN O
. NN NN O
4 NN NN O
) NN NN O
times NN NN O
higher NN NN O
odds NN NN O
for NN NN O
syncope NN NN B-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Methadone NN NN O
is NN NN O
associated NN NN O
with NN NN O
QT NN NN B-Disease
prolongation NN NN I-Disease
and NN NN O
higher NN NN O
reporting NN NN O
of NN NN O
syncope NN NN B-Disease
in NN NN O
a NN NN O
population NN NN O
of NN NN O
heroin NN NN O
addicts NN NN O
. NN NN O
   
Neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
induced NN NN O
by NN NN O
ziprasidone NN NN O
on NN NN O
the NN NN O
second NN NN O
day NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
Neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
NMS NN NN B-Disease
) NN NN O
is NN NN O
the NN NN O
rarest NN NN O
and NN NN O
most NN NN O
serious NN NN O
of NN NN O
the NN NN O
neuroleptic NN NN O
- NN NN O
induced NN NN O
movement NN NN B-Disease
disorders NN NN I-Disease
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
case NN NN O
of NN NN O
neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
NMS NN NN B-Disease
) NN NN O
associated NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
ziprasidone NN NN O
. NN NN O
   
Although NN NN O
conventional NN NN O
neuroleptics NN NN O
are NN NN O
more NN NN O
frequently NN NN O
associated NN NN O
with NN NN O
NMS NN NN B-Disease
, NN NN O
atypical NN NN O
antipsychotic NN NN O
drugs NN NN O
like NN NN O
ziprasidone NN NN O
may NN NN O
also NN NN O
be NN NN O
a NN NN O
cause NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
24 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
male NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
schizophrenia NN NN B-Disease
who NN NN O
developed NN NN O
signs NN NN O
and NN NN O
symptoms NN NN O
of NN NN O
NMS NN NN B-Disease
after NN NN O
2 NN NN O
days NN NN O
of NN NN O
treatment NN NN O
with NN NN O
an NN NN O
80 NN NN O
- NN NN O
mg NN NN O
/ NN NN O
day NN NN O
dose NN NN O
of NN NN O
orally NN NN O
administrated NN NN O
ziprasidone NN NN O
. NN NN O
   
This NN NN O
case NN NN O
is NN NN O
the NN NN O
earliest NN NN O
( NN NN O
second NN NN O
day NN NN O
of NN NN O
treatment NN NN O
) NN NN O
NMS NN NN B-Disease
due NN NN O
to NN NN O
ziprasidone NN NN O
reported NN NN O
in NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
Peripheral NN NN O
iron NN NN O
dextran NN NN O
induced NN NN O
degeneration NN NN B-Disease
of NN NN I-Disease
dopaminergic NN NN I-Disease
neurons NN NN I-Disease
in NN NN O
rat NN NN O
substantia NN NN O
nigra NN NN O
. NN NN O
   
Iron NN NN O
accumulation NN NN O
is NN NN O
considered NN NN O
to NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
To NN NN O
demonstrate NN NN O
the NN NN O
relationship NN NN O
between NN NN O
peripheral NN NN O
iron NN NN O
overload NN NN O
and NN NN O
dopaminergic NN NN O
neuron NN NN O
loss NN NN O
in NN NN O
rat NN NN O
substantia NN NN O
nigra NN NN O
( NN NN O
SN NN NN O
) NN NN O
, NN NN O
in NN NN O
the NN NN O
present NN NN O
study NN NN O
we NN NN O
used NN NN O
fast NN NN O
cyclic NN NN O
voltammetry NN NN O
, NN NN O
tyrosine NN NN O
hydroxylase NN NN O
( NN NN O
TH NN NN O
) NN NN O
immunohistochemistry NN NN O
, NN NN O
Perls NN NN O
' NN NN O
iron NN NN O
staining NN NN O
, NN NN O
and NN NN O
high NN NN O
performance NN NN O
liquid NN NN O
chromatography NN NN O
- NN NN O
electrochemical NN NN O
detection NN NN O
to NN NN O
study NN NN O
the NN NN O
degeneration NN NN B-Disease
of NN NN I-Disease
dopaminergic NN NN I-Disease
neurons NN NN I-Disease
and NN NN O
increased NN NN O
iron NN NN O
content NN NN O
in NN NN O
the NN NN O
SN NN NN O
of NN NN O
iron NN NN O
dextran NN NN O
overloaded NN NN O
animals NN NN O
. NN NN O
   
The NN NN O
findings NN NN O
showed NN NN O
that NN NN O
peripheral NN NN O
iron NN NN O
dextran NN NN O
overload NN NN O
increased NN NN O
the NN NN O
iron NN NN O
staining NN NN O
positive NN NN O
cells NN NN O
and NN NN O
reduced NN NN O
the NN NN O
number NN NN O
of NN NN O
TH NN NN O
- NN NN O
immunoreactive NN NN O
neurons NN NN O
in NN NN O
the NN NN O
SN NN NN O
. NN NN O
   
As NN NN O
a NN NN O
result NN NN O
, NN NN O
dopamine NN NN O
release NN NN O
and NN NN O
content NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
its NN NN O
metabolites NN NN O
contents NN NN O
were NN NN O
decreased NN NN O
in NN NN O
caudate NN NN O
putamen NN NN O
. NN NN O
   
Even NN NN O
more NN NN O
dramatic NN NN O
changes NN NN O
were NN NN O
found NN NN O
in NN NN O
chronic NN NN O
overload NN NN O
group NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
peripheral NN NN O
iron NN NN O
dextran NN NN O
can NN NN O
increase NN NN O
the NN NN O
iron NN NN O
level NN NN O
in NN NN O
the NN NN O
SN NN NN O
, NN NN O
where NN NN O
excessive NN NN O
iron NN NN O
causes NN NN O
the NN NN O
degeneration NN NN B-Disease
of NN NN I-Disease
dopaminergic NN NN I-Disease
neurons NN NN I-Disease
. NN NN O
   
The NN NN O
chronic NN NN O
iron NN NN O
overload NN NN O
may NN NN O
be NN NN O
more NN NN O
destructive NN NN O
to NN NN O
dopaminergic NN NN O
neurons NN NN O
than NN NN O
the NN NN O
acute NN NN O
iron NN NN O
overload NN NN O
. NN NN O
   
Attenuated NN NN O
disruption NN NN O
of NN NN O
prepulse NN NN O
inhibition NN NN O
by NN NN O
dopaminergic NN NN O
stimulation NN NN O
after NN NN O
maternal NN NN O
deprivation NN NN O
and NN NN O
adolescent NN NN O
corticosterone NN NN O
treatment NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
development NN NN O
of NN NN O
schizophrenia NN NN B-Disease
may NN NN O
include NN NN O
an NN NN O
early NN NN O
neurodevelopmental NN NN O
stress NN NN O
component NN NN O
which NN NN O
increases NN NN O
vulnerability NN NN O
to NN NN O
later NN NN O
stressful NN NN O
life NN NN O
events NN NN O
, NN NN O
in NN NN O
combination NN NN O
leading NN NN O
to NN NN O
overt NN NN O
disease NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
effect NN NN O
of NN NN O
an NN NN O
early NN NN O
stress NN NN O
, NN NN O
in NN NN O
the NN NN O
form NN NN O
of NN NN O
maternal NN NN O
deprivation NN NN O
, NN NN O
combined NN NN O
with NN NN O
a NN NN O
later NN NN O
stress NN NN O
, NN NN O
simulated NN NN O
by NN NN O
chronic NN NN O
periadolescent NN NN O
corticosterone NN NN O
treatment NN NN O
, NN NN O
on NN NN O
behaviour NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Acute NN NN O
treatment NN NN O
with NN NN O
apomorphine NN NN O
caused NN NN O
disruption NN NN O
of NN NN O
prepulse NN NN O
inhibition NN NN O
( NN NN O
PPI NN NN O
) NN NN O
in NN NN O
controls NN NN O
and NN NN O
in NN NN O
rats NN NN O
that NN NN O
had NN NN O
undergone NN NN O
either NN NN O
maternal NN NN O
deprivation NN NN O
or NN NN O
corticosterone NN NN O
treatment NN NN O
, NN NN O
but NN NN O
was NN NN O
surprisingly NN NN O
absent NN NN O
in NN NN O
rats NN NN O
that NN NN O
had NN NN O
undergone NN NN O
the NN NN O
combined NN NN O
early NN NN O
and NN NN O
late NN NN O
stress NN NN O
. NN NN O
   
Amphetamine NN NN O
treatment NN NN O
significantly NN NN O
disrupted NN NN O
PPI NN NN O
in NN NN O
both NN NN O
non NN NN O
- NN NN O
deprived NN NN O
groups NN NN O
, NN NN O
but NN NN O
was NN NN O
absent NN NN O
in NN NN O
both NN NN O
maternally NN NN O
deprived NN NN O
groups NN NN O
. NN NN O
   
The NN NN O
serotonin NN NN O
- NN NN O
1A NN NN O
receptor NN NN O
agonist NN NN O
, NN NN O
8 NN NN O
- NN NN O
OH NN NN O
- NN NN O
DPAT NN NN O
, NN NN O
induced NN NN O
a NN NN O
significant NN NN O
disruption NN NN O
of NN NN O
PPI NN NN O
in NN NN O
all NN NN O
groups NN NN O
. NN NN O
   
Amphetamine NN NN O
- NN NN O
induced NN NN O
locomotor NN NN B-Disease
hyperactivity NN NN I-Disease
was NN NN O
similar NN NN O
in NN NN O
all NN NN O
groups NN NN O
. NN NN O
   
These NN NN O
results NN NN O
show NN NN O
an NN NN O
inhibitory NN NN O
interaction NN NN O
of NN NN O
early NN NN O
stress NN NN O
, NN NN O
caused NN NN O
by NN NN O
maternal NN NN O
deprivation NN NN O
, NN NN O
combined NN NN O
with NN NN O
' NN NN O
adolescent NN NN O
' NN NN O
stress NN NN O
, NN NN O
simulated NN NN O
by NN NN O
corticosterone NN NN O
treatment NN NN O
, NN NN O
on NN NN O
dopaminergic NN NN O
regulation NN NN O
of NN NN O
PPI NN NN O
. NN NN O
   
The NN NN O
altered NN NN O
effects NN NN O
of NN NN O
apomorphine NN NN O
and NN NN O
amphetamine NN NN O
could NN NN O
indicate NN NN O
differential NN NN O
changes NN NN O
in NN NN O
dopamine NN NN O
receptor NN NN O
signalling NN NN O
leading NN NN O
to NN NN O
functional NN NN O
desensitisation NN NN O
, NN NN O
or NN NN O
altered NN NN O
modulation NN NN O
of NN NN O
sensory NN NN O
gating NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
accumbens NN NN O
by NN NN O
limbic NN NN O
structures NN NN O
such NN NN O
as NN NN O
the NN NN O
hippocampus NN NN O
. NN NN O
   
An NN NN O
extremely NN NN O
rare NN NN O
case NN NN O
of NN NN O
delusional NN NN B-Disease
parasitosis NN NN I-Disease
in NN NN O
a NN NN O
chronic NN NN B-Disease
hepatitis NN NN I-Disease
C NN NN I-Disease
patient NN NN O
during NN NN O
pegylated NN NN O
interferon NN NN O
alpha NN NN O
- NN NN O
2b NN NN O
and NN NN O
ribavirin NN NN O
treatment NN NN O
. NN NN O
   
During NN NN O
treatment NN NN O
of NN NN O
chronic NN NN B-Disease
hepatitis NN NN I-Disease
C NN NN I-Disease
patients NN NN O
with NN NN O
interferon NN NN O
and NN NN O
ribavirin NN NN O
, NN NN O
a NN NN O
lot NN NN O
of NN NN O
side NN NN O
effects NN NN O
are NN NN O
described NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
three NN NN O
percent NN NN O
to NN NN O
44 NN NN O
% NN NN O
of NN NN O
patients NN NN O
develop NN NN O
depression NN NN B-Disease
. NN NN O
   
A NN NN O
minority NN NN O
of NN NN O
patients NN NN O
evolve NN NN O
to NN NN O
psychosis NN NN B-Disease
. NN NN O
   
To NN NN O
the NN NN O
best NN NN O
of NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
no NN NN O
cases NN NN O
of NN NN O
psychogenic NN NN B-Disease
parasitosis NN NN I-Disease
occurring NN NN O
during NN NN O
interferon NN NN O
therapy NN NN O
have NN NN O
been NN NN O
described NN NN O
in NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
We NN NN O
present NN NN O
a NN NN O
49 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
who NN NN O
developed NN NN O
a NN NN O
delusional NN NN B-Disease
parasitosis NN NN I-Disease
during NN NN O
treatment NN NN O
with NN NN O
pegylated NN NN O
interferon NN NN O
alpha NN NN O
- NN NN O
2b NN NN O
weekly NN NN O
and NN NN O
ribavirin NN NN O
. NN NN O
   
She NN NN O
complained NN NN O
of NN NN O
seeing NN NN O
parasites NN NN O
and NN NN O
the NN NN O
larvae NN NN O
of NN NN O
fleas NN NN O
in NN NN O
her NN NN O
stools NN NN O
. NN NN O
   
This NN NN O
could NN NN O
not NN NN O
be NN NN O
confirmed NN NN O
by NN NN O
any NN NN O
technical NN NN O
examination NN NN O
. NN NN O
   
All NN NN O
the NN NN O
complaints NN NN O
disappeared NN NN O
after NN NN O
stopping NN NN O
pegylated NN NN O
interferon NN NN O
alpha NN NN O
- NN NN O
2b NN NN O
and NN NN O
reappeared NN NN O
after NN NN O
restarting NN NN O
it NN NN O
. NN NN O
   
She NN NN O
had NN NN O
a NN NN O
complete NN NN O
sustained NN NN O
viral NN NN O
response NN NN O
. NN NN O
   
Hepatonecrosis NN NN B-Disease
and NN NN O
cholangitis NN NN B-Disease
related NN NN O
to NN NN O
long NN NN O
- NN NN O
term NN NN O
phenobarbital NN NN O
therapy NN NN O
: NN NN O
an NN NN O
autopsy NN NN O
report NN NN O
of NN NN O
two NN NN O
patients NN NN O
. NN NN O
   
Phenobarbital NN NN O
( NN NN O
PB NN NN O
) NN NN O
has NN NN O
a NN NN O
reputation NN NN O
for NN NN O
safety NN NN O
, NN NN O
and NN NN O
it NN NN O
is NN NN O
commonly NN NN O
believed NN NN O
that NN NN O
PB NN NN O
- NN NN O
related NN NN O
increases NN NN O
in NN NN O
serum NN NN O
aminotransferase NN NN O
levels NN NN O
do NN NN O
not NN NN O
indicate NN NN O
or NN NN O
predict NN NN O
the NN NN O
development NN NN O
of NN NN O
significant NN NN O
chronic NN NN O
liver NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
of NN NN O
two NN NN O
adult NN NN O
patients NN NN O
with NN NN O
a NN NN O
long NN NN O
history NN NN O
of NN NN O
epilepsy NN NN B-Disease
treated NN NN O
with NN NN O
PB NN NN O
who NN NN O
died NN NN O
suddenly NN NN O
: NN NN O
one NN NN O
as NN NN O
consequence NN NN O
of NN NN O
cardiac NN NN B-Disease
arrest NN NN I-Disease
, NN NN O
the NN NN O
other NN NN O
of NN NN O
acute NN NN O
bronchopneumonia NN NN B-Disease
. NN NN O
   
At NN NN O
autopsy NN NN O
, NN NN O
analysis NN NN O
of NN NN O
liver NN NN O
parenchyma NN NN O
revealed NN NN O
rich NN NN O
portal NN NN O
inflammatory NN NN O
infiltrate NN NN O
, NN NN O
which NN NN O
consisted NN NN O
of NN NN O
mixed NN NN O
eosinophil NN NN O
and NN NN O
monocyte NN NN O
cells NN NN O
, NN NN O
associated NN NN O
with NN NN O
several NN NN O
foci NN NN O
of NN NN O
necrosis NN NN B-Disease
surrounded NN NN O
by NN NN O
a NN NN O
hard NN NN O
ring NN NN O
of NN NN O
non NN NN O
- NN NN O
specific NN NN O
granulomatous NN NN O
tissue NN NN O
. NN NN O
   
Inflammatory NN NN O
reactions NN NN O
of NN NN O
internal NN NN O
and NN NN O
external NN NN O
hepatic NN NN O
biliary NN NN O
ducts NN NN O
were NN NN O
also NN NN O
seen NN NN O
. NN NN O
   
Our NN NN O
findings NN NN O
illustrate NN NN O
that NN NN O
PB NN NN O
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
chronic NN NN O
liver NN NN B-Disease
damage NN NN I-Disease
, NN NN O
which NN NN O
may NN NN O
lead NN NN O
to NN NN O
more NN NN O
serious NN NN O
and NN NN O
deleterious NN NN O
consequences NN NN O
. NN NN O
   
For NN NN O
this NN NN O
reason NN NN O
, NN NN O
each NN NN O
clinician NN NN O
should NN NN O
recognize NN NN O
this NN NN O
entity NN NN O
in NN NN O
the NN NN O
differential NN NN O
diagnosis NN NN O
of NN NN O
PB NN NN O
- NN NN O
related NN NN O
asymptomatic NN NN O
chronic NN NN B-Disease
hepatic NN NN I-Disease
enzyme NN NN I-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Delayed NN NN O
leukoencephalopathy NN NN B-Disease
with NN NN O
stroke NN NN B-Disease
- NN NN O
like NN NN O
presentation NN NN O
in NN NN O
chemotherapy NN NN O
recipients NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
A NN NN O
transient NN NN O
leukoencephalopathy NN NN B-Disease
mimicking NN NN O
cerebrovascular NN NN B-Disease
accident NN NN I-Disease
has NN NN O
been NN NN O
described NN NN O
as NN NN O
a NN NN O
complication NN NN O
of NN NN O
chemotherapy NN NN O
, NN NN O
most NN NN O
commonly NN NN O
in NN NN O
recipients NN NN O
of NN NN O
intrathecal NN NN O
methotrexate NN NN O
for NN NN O
childhood NN NN O
leukaemia NN NN B-Disease
. NN NN O
   
Recently NN NN O
published NN NN O
neuroimaging NN NN O
data NN NN O
suggest NN NN O
a NN NN O
common NN NN O
pathophysiology NN NN O
associated NN NN O
with NN NN O
a NN NN O
variety NN NN O
of NN NN O
chemotherapy NN NN O
agents NN NN O
and NN NN O
modes NN NN O
of NN NN O
administration NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
reviewed NN NN O
the NN NN O
medical NN NN O
literature NN NN O
for NN NN O
single NN NN O
reports NN NN O
and NN NN O
case NN NN O
series NN NN O
of NN NN O
patients NN NN O
presenting NN NN O
with NN NN O
stroke NN NN B-Disease
- NN NN O
like NN NN O
episodes NN NN O
while NN NN O
receiving NN NN O
systemic NN NN O
or NN NN O
intrathecal NN NN O
chemotherapy NN NN O
. NN NN O
   
We NN NN O
only NN NN O
included NN NN O
studies NN NN O
providing NN NN O
detailed NN NN O
neuroimaging NN NN O
data NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
cerebrovascular NN NN B-Disease
accidents NN NN I-Disease
were NN NN O
excluded NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
We NN NN O
identified NN NN O
27 NN NN O
reports NN NN O
of NN NN O
toxic NN NN O
leukoencephalopathy NN NN B-Disease
in NN NN O
patients NN NN O
treated NN NN O
with NN NN O
methotrexate NN NN O
( NN NN O
intrathecal NN NN O
, NN NN O
systemic NN NN O
) NN NN O
, NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
and NN NN O
its NN NN O
derivative NN NN O
carmofur NN NN O
, NN NN O
and NN NN O
capecitabine NN NN O
. NN NN O
   
Diffusion NN NN O
weighted NN NN O
imaging NN NN O
( NN NN O
DWI NN NN O
) NN NN O
of NN NN O
all NN NN O
patients NN NN O
revealed NN NN O
well NN NN O
demarcated NN NN O
hyperintense NN NN O
lesions NN NN B-Disease
within NN NN I-Disease
the NN NN I-Disease
subcortical NN NN I-Disease
white NN NN I-Disease
matter NN NN I-Disease
of NN NN O
the NN NN O
cerebral NN NN O
hemispheres NN NN O
and NN NN O
the NN NN O
corpus NN NN O
callosum NN NN O
, NN NN O
corresponding NN NN O
to NN NN O
areas NN NN O
of NN NN O
decreased NN NN O
proton NN NN O
diffusion NN NN O
on NN NN O
apparent NN NN O
diffusion NN NN O
coefficient NN NN O
( NN NN O
ADC NN NN O
) NN NN O
maps NN NN O
( NN NN O
available NN NN O
in NN NN O
21 NN NN O
/ NN NN O
27 NN NN O
patients NN NN O
) NN NN O
. NN NN O
   
Lesions NN NN O
exceeded NN NN O
the NN NN O
confines NN NN O
of NN NN O
adjacent NN NN O
vascular NN NN O
territories NN NN O
. NN NN O
   
Complete NN NN O
resolution NN NN O
of NN NN O
symptoms NN NN O
within NN NN O
1 NN NN O
- NN NN O
4 NN NN O
days NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
normalisation NN NN O
of NN NN O
ADC NN NN O
abnormalities NN NN O
. NN NN O
   
However NN NN O
, NN NN O
fluid NN NN O
attenuated NN NN O
inversion NN NN O
recovery NN NN O
( NN NN O
FLAIR NN NN O
) NN NN O
sequences NN NN O
frequently NN NN O
revealed NN NN O
persistent NN NN O
white NN NN B-Disease
matter NN NN I-Disease
abnormalities NN NN I-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Several NN NN O
pathophysiological NN NN O
models NN NN O
of NN NN O
delayed NN NN O
leukoencephalopathy NN NN B-Disease
after NN NN O
exposure NN NN O
to NN NN O
intrathecal NN NN O
or NN NN O
systemic NN NN O
chemotherapy NN NN O
have NN NN O
been NN NN O
proposed NN NN O
. NN NN O
   
DWI NN NN O
findings NN NN O
in NN NN O
this NN NN O
cohort NN NN O
are NN NN O
indicative NN NN O
of NN NN O
cytotoxic NN NN B-Disease
oedema NN NN I-Disease
within NN NN I-Disease
cerebral NN NN I-Disease
white NN NN I-Disease
matter NN NN I-Disease
and NN NN O
lend NN NN O
support NN NN O
to NN NN O
an NN NN O
at NN NN O
least NN NN O
partially NN NN O
reversible NN NN O
metabolic NN NN O
derangement NN NN O
as NN NN O
the NN NN O
basis NN NN O
for NN NN O
this NN NN O
syndrome NN NN O
. NN NN O
   
Prenatal NN NN O
exposure NN NN O
to NN NN O
fluoxetine NN NN O
induces NN NN O
fetal NN NN B-Disease
pulmonary NN NN I-Disease
hypertension NN NN I-Disease
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
RATIONALE NN NN O
: NN NN O
Fluoxetine NN NN O
is NN NN O
a NN NN O
selective NN NN O
serotonin NN NN O
reuptake NN NN O
inhibitor NN NN O
antidepressant NN NN O
widely NN NN O
used NN NN O
by NN NN O
pregnant NN NN O
women NN NN O
. NN NN O
   
Epidemiological NN NN O
data NN NN O
suggest NN NN O
that NN NN O
fluoxetine NN NN O
exposure NN NN O
prenatally NN NN O
increases NN NN O
the NN NN O
prevalence NN NN O
of NN NN O
persistent NN NN O
pulmonary NN NN B-Disease
hypertension NN NN I-Disease
syndrome NN NN I-Disease
of NN NN O
the NN NN O
newborn NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
responsible NN NN O
for NN NN O
this NN NN O
effect NN NN O
is NN NN O
unclear NN NN O
and NN NN O
paradoxical NN NN O
, NN NN O
considering NN NN O
the NN NN O
current NN NN O
evidence NN NN O
of NN NN O
a NN NN O
pulmonary NN NN B-Disease
hypertension NN NN I-Disease
protective NN NN O
fluoxetine NN NN O
effect NN NN O
in NN NN O
adult NN NN O
rodents NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
To NN NN O
evaluate NN NN O
the NN NN O
fluoxetine NN NN O
effect NN NN O
on NN NN O
fetal NN NN O
rat NN NN O
pulmonary NN NN O
vascular NN NN O
smooth NN NN O
muscle NN NN O
mechanical NN NN O
properties NN NN O
and NN NN O
cell NN NN O
proliferation NN NN O
rate NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Pregnant NN NN O
rats NN NN O
were NN NN O
treated NN NN O
with NN NN O
fluoxetine NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
from NN NN O
Day NN NN O
11 NN NN O
through NN NN O
Day NN NN O
21 NN NN O
of NN NN O
gestation NN NN O
. NN NN O
   
MEASUREMENTS NN NN O
AND NN NN O
MAIN NN NN O
RESULTS NN NN O
: NN NN O
Fetuses NN NN O
were NN NN O
delivered NN NN O
by NN NN O
cesarean NN NN O
section NN NN O
. NN NN O
   
As NN NN O
compared NN NN O
with NN NN O
controls NN NN O
, NN NN O
fluoxetine NN NN O
exposure NN NN O
resulted NN NN O
in NN NN O
fetal NN NN B-Disease
pulmonary NN NN I-Disease
hypertension NN NN I-Disease
as NN NN O
evidenced NN NN O
by NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
weight NN NN O
ratio NN NN O
of NN NN O
the NN NN O
right NN NN O
ventricle NN NN O
to NN NN O
the NN NN O
left NN NN O
ventricle NN NN O
plus NN NN O
septum NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
02 NN NN O
) NN NN O
and NN NN O
by NN NN O
an NN NN O
increase NN NN O
in NN NN O
pulmonary NN NN O
arterial NN NN O
medial NN NN O
thickness NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Postnatal NN NN O
mortality NN NN O
was NN NN O
increased NN NN O
among NN NN O
experimental NN NN O
animals NN NN O
, NN NN O
and NN NN O
arterial NN NN O
oxygen NN NN O
saturation NN NN O
was NN NN O
96 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
% NN NN O
in NN NN O
1 NN NN O
- NN NN O
day NN NN O
- NN NN O
old NN NN O
control NN NN O
animals NN NN O
and NN NN O
significantly NN NN O
lower NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
in NN NN O
fluoxetine NN NN O
- NN NN O
exposed NN NN O
pups NN NN O
( NN NN O
79 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
, NN NN O
fluoxetine NN NN O
induced NN NN O
pulmonary NN NN O
arterial NN NN O
muscle NN NN O
contraction NN NN O
in NN NN O
fetal NN NN O
, NN NN O
but NN NN O
not NN NN O
adult NN NN O
, NN NN O
animals NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
and NN NN O
reduced NN NN O
serotonin NN NN O
- NN NN O
induced NN NN O
contraction NN NN O
at NN NN O
both NN NN O
ages NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
After NN NN O
in NN NN O
utero NN NN O
exposure NN NN O
to NN NN O
a NN NN O
low NN NN O
fluoxetine NN NN O
concentration NN NN O
the NN NN O
pulmonary NN NN O
arterial NN NN O
smooth NN NN O
muscle NN NN O
cell NN NN O
proliferation NN NN O
rate NN NN O
was NN NN O
significantly NN NN O
increased NN NN O
in NN NN O
fetal NN NN O
, NN NN O
but NN NN O
not NN NN O
adult NN NN O
, NN NN O
cells NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
In NN NN O
contrast NN NN O
to NN NN O
the NN NN O
adult NN NN O
, NN NN O
fluoxetine NN NN O
exposure NN NN O
in NN NN O
utero NN NN O
induces NN NN O
pulmonary NN NN B-Disease
hypertension NN NN I-Disease
in NN NN O
the NN NN O
fetal NN NN O
rat NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
a NN NN O
developmentally NN NN O
regulated NN NN O
increase NN NN O
in NN NN O
pulmonary NN NN O
vascular NN NN O
smooth NN NN O
muscle NN NN O
proliferation NN NN O
. NN NN O
   
Disulfiram NN NN O
- NN NN O
induced NN NN O
transient NN NN O
optic NN NN B-Disease
and NN NN I-Disease
peripheral NN NN I-Disease
neuropathy NN NN I-Disease
: NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
AIM NN NN O
: NN NN O
To NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
optic NN NN B-Disease
and NN NN I-Disease
peripheral NN NN I-Disease
neuropathy NN NN I-Disease
after NN NN O
chronic NN NN O
use NN NN O
of NN NN O
disulfiram NN NN O
for NN NN O
alcohol NN NN B-Disease
dependence NN NN I-Disease
management NN NN O
. NN NN O
   
MATERIALS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
A NN NN O
case NN NN O
report NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
A NN NN O
57 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
male NN NN O
presented NN NN O
with NN NN O
gradual NN NN O
loss NN NN B-Disease
of NN NN I-Disease
vision NN NN I-Disease
in NN NN O
both NN NN O
eyes NN NN O
with NN NN O
intermittent NN NN O
headaches NN NN B-Disease
for NN NN O
2 NN NN O
months NN NN O
. NN NN O
   
He NN NN O
also NN NN O
complained NN NN O
of NN NN O
paraesthesia NN NN B-Disease
with NN NN O
numbness NN NN B-Disease
in NN NN O
both NN NN O
feet NN NN O
. NN NN O
   
His NN NN O
vision NN NN O
was NN NN O
6 NN NN O
/ NN NN O
15 NN NN O
and NN NN O
2 NN NN O
/ NN NN O
60 NN NN O
in NN NN O
the NN NN O
right NN NN O
and NN NN O
left NN NN O
eyes NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Fundoscopy NN NN O
revealed NN NN O
bilaterally NN NN O
swollen NN NN O
optic NN NN O
nerve NN NN O
heads NN NN O
. NN NN O
   
Visual NN NN O
field NN NN O
testing NN NN O
confirmed NN NN O
bilateral NN NN O
central NN NN O
- NN NN O
caecal NN NN O
scotomata NN NN B-Disease
. NN NN O
   
He NN NN O
had NN NN O
been NN NN O
taking NN NN O
disulfiram NN NN O
for NN NN O
alcohol NN NN B-Disease
dependence NN NN I-Disease
for NN NN O
the NN NN O
preceding NN NN O
3 NN NN O
years NN NN O
. NN NN O
   
Disulfiram NN NN O
discontinuation NN NN O
lead NN NN O
to NN NN O
an NN NN O
immediate NN NN O
symptomatic NN NN O
improvement NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Physicians NN NN O
initiating NN NN O
long NN NN O
- NN NN O
term NN NN O
disulfiram NN NN O
therapy NN NN O
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
these NN NN O
adverse NN NN O
effects NN NN O
. NN NN O
   
They NN NN O
should NN NN O
recommend NN NN O
annual NN NN O
ophthalmic NN NN O
reviews NN NN O
with NN NN O
visual NN NN O
field NN NN O
testing NN NN O
. NN NN O
   
Patients NN NN O
should NN NN O
be NN NN O
reassured NN NN O
with NN NN O
respect NN NN O
to NN NN O
the NN NN O
reversibility NN NN O
of NN NN O
these NN NN O
adverse NN NN O
effects NN NN O
. NN NN O
   
Intraocular NN NN O
pressure NN NN O
in NN NN O
patients NN NN O
with NN NN O
uveitis NN NN B-Disease
treated NN NN O
with NN NN O
fluocinolone NN NN O
acetonide NN NN O
implants NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
report NN NN O
the NN NN O
incidence NN NN O
and NN NN O
management NN NN O
of NN NN O
elevated NN NN B-Disease
intraocular NN NN I-Disease
pressure NN NN I-Disease
( NN NN O
IOP NN NN O
) NN NN O
in NN NN O
patients NN NN O
with NN NN O
uveitis NN NN B-Disease
treated NN NN O
with NN NN O
the NN NN O
fluocinolone NN NN O
acetonide NN NN O
( NN NN O
FA NN NN O
) NN NN O
intravitreal NN NN O
implant NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
Pooled NN NN O
data NN NN O
from NN NN O
3 NN NN O
multicenter NN NN O
, NN NN O
double NN NN O
- NN NN O
masked NN NN O
, NN NN O
randomized NN NN O
, NN NN O
controlled NN NN O
, NN NN O
phase NN NN O
2b NN NN O
/ NN NN O
3 NN NN O
clinical NN NN O
trials NN NN O
evaluating NN NN O
the NN NN O
safety NN NN O
and NN NN O
efficacy NN NN O
of NN NN O
the NN NN O
0 NN NN O
. NN NN O
59 NN NN O
- NN NN O
mg NN NN O
or NN NN O
2 NN NN O
. NN NN O
1 NN NN O
- NN NN O
mg NN NN O
FA NN NN O
intravitreal NN NN O
implant NN NN O
or NN NN O
standard NN NN O
therapy NN NN O
were NN NN O
analyzed NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
During NN NN O
the NN NN O
3 NN NN O
- NN NN O
year NN NN O
follow NN NN O
- NN NN O
up NN NN O
, NN NN O
71 NN NN O
. NN NN O
0 NN NN O
% NN NN O
of NN NN O
implanted NN NN O
eyes NN NN O
had NN NN O
an NN NN O
IOP NN NN O
increase NN NN O
of NN NN O
10 NN NN O
mm NN NN O
Hg NN NN O
or NN NN O
more NN NN O
than NN NN O
baseline NN NN O
and NN NN O
55 NN NN O
. NN NN O
1 NN NN O
% NN NN O
, NN NN O
24 NN NN O
. NN NN O
7 NN NN O
% NN NN O
, NN NN O
and NN NN O
6 NN NN O
. NN NN O
2 NN NN O
% NN NN O
of NN NN O
eyes NN NN O
reached NN NN O
an NN NN O
IOP NN NN O
of NN NN O
30 NN NN O
mm NN NN O
Hg NN NN O
or NN NN O
more NN NN O
, NN NN O
40 NN NN O
mm NN NN O
Hg NN NN O
or NN NN O
more NN NN O
, NN NN O
and NN NN O
50 NN NN O
mm NN NN O
Hg NN NN O
or NN NN O
more NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Topical NN NN O
IOP NN NN O
- NN NN O
lowering NN NN O
medication NN NN O
was NN NN O
administered NN NN O
in NN NN O
74 NN NN O
. NN NN O
8 NN NN O
% NN NN O
of NN NN O
implanted NN NN O
eyes NN NN O
, NN NN O
and NN NN O
IOP NN NN O
- NN NN O
lowering NN NN O
surgeries NN NN O
, NN NN O
most NN NN O
of NN NN O
which NN NN O
were NN NN O
trabeculectomies NN NN O
( NN NN O
76 NN NN O
. NN NN O
2 NN NN O
% NN NN O
) NN NN O
, NN NN O
were NN NN O
performed NN NN O
on NN NN O
36 NN NN O
. NN NN O
6 NN NN O
% NN NN O
of NN NN O
implanted NN NN O
eyes NN NN O
. NN NN O
   
Intraocular NN NN O
pressure NN NN O
- NN NN O
lowering NN NN O
surgeries NN NN O
were NN NN O
considered NN NN O
a NN NN O
success NN NN O
( NN NN O
postoperative NN NN O
IOP NN NN O
of NN NN O
6 NN NN O
- NN NN O
21 NN NN O
mm NN NN O
Hg NN NN O
with NN NN O
or NN NN O
without NN NN O
additional NN NN O
IOP NN NN O
- NN NN O
lowering NN NN O
medication NN NN O
) NN NN O
in NN NN O
85 NN NN O
. NN NN O
1 NN NN O
% NN NN O
of NN NN O
eyes NN NN O
at NN NN O
1 NN NN O
year NN NN O
. NN NN O
   
The NN NN O
rate NN NN O
of NN NN O
hypotony NN NN B-Disease
( NN NN O
IOP NN NN O
< NN NN O
/ NN NN O
= NN NN O
5 NN NN O
mm NN NN O
Hg NN NN O
) NN NN O
following NN NN O
IOP NN NN O
- NN NN O
lowering NN NN O
surgery NN NN O
( NN NN O
42 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
was NN NN O
not NN NN O
different NN NN O
from NN NN O
that NN NN O
of NN NN O
implanted NN NN O
eyes NN NN O
not NN NN O
subjected NN NN O
to NN NN O
surgery NN NN O
( NN NN O
35 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O
09 NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Elevated NN NN O
IOP NN NN O
is NN NN O
a NN NN O
significant NN NN O
complication NN NN O
with NN NN O
the NN NN O
FA NN NN O
intravitreal NN NN O
implant NN NN O
but NN NN O
may NN NN O
be NN NN O
controlled NN NN O
with NN NN O
medication NN NN O
and NN NN O
surgery NN NN O
. NN NN O
   
Myocardial NN NN O
Fas NN NN O
ligand NN NN O
expression NN NN O
increases NN NN O
susceptibility NN NN O
to NN NN O
AZT NN NN O
- NN NN O
induced NN NN O
cardiomyopathy NN NN B-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Dilated NN NN B-Disease
cardiomyopathy NN NN I-Disease
( NN NN O
DCM NN NN B-Disease
) NN NN O
and NN NN O
myocarditis NN NN B-Disease
occur NN NN O
in NN NN O
many NN NN O
HIV NN NN B-Disease
- NN NN I-Disease
infected NN NN I-Disease
individuals NN NN O
, NN NN O
resulting NN NN O
in NN NN O
symptomatic NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
in NN NN O
up NN NN O
to NN NN O
5 NN NN O
% NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
Highly NN NN O
active NN NN O
antiretroviral NN NN O
therapy NN NN O
( NN NN O
HAART NN NN O
) NN NN O
has NN NN O
significantly NN NN O
reduced NN NN O
morbidity NN NN O
and NN NN O
mortality NN NN O
of NN NN O
acquired NN NN B-Disease
immunodeficiency NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
AIDS NN NN B-Disease
) NN NN O
, NN NN O
but NN NN O
has NN NN O
resulted NN NN O
in NN NN O
an NN NN O
increase NN NN O
in NN NN O
cardiac NN NN B-Disease
and NN NN I-Disease
skeletal NN NN I-Disease
myopathies NN NN I-Disease
. NN NN O
   
METHODS NN NN O
AND NN NN O
RESULTS NN NN O
: NN NN O
In NN NN O
order NN NN O
to NN NN O
investigate NN NN O
whether NN NN O
the NN NN O
HAART NN NN O
component NN NN O
zidovudine NN NN O
( NN NN O
3 NN NN O
' NN NN O
- NN NN O
azido NN NN O
- NN NN O
2 NN NN O
' NN NN O
, NN NN O
3 NN NN O
' NN NN O
- NN NN O
deoxythymidine NN NN O
; NN NN O
AZT NN NN O
) NN NN O
triggers NN NN O
the NN NN O
Fas NN NN O
- NN NN O
dependent NN NN O
cell NN NN O
- NN NN O
death NN NN O
pathway NN NN O
and NN NN O
cause NN NN O
cytoskeletal NN NN O
disruption NN NN O
in NN NN O
a NN NN O
murine NN NN O
model NN NN O
of NN NN O
DCM NN NN B-Disease
, NN NN O
8 NN NN O
- NN NN O
week NN NN O
- NN NN O
old NN NN O
transgenic NN NN O
( NN NN O
expressing NN NN O
Fas NN NN O
ligand NN NN O
in NN NN O
the NN NN O
myocardium NN NN O
: NN NN O
FasL NN NN O
Tg NN NN O
) NN NN O
and NN NN O
non NN NN O
- NN NN O
transgenic NN NN O
( NN NN O
NTg NN NN O
) NN NN O
mice NN NN O
received NN NN O
water NN NN O
ad NN NN O
libitum NN NN O
containing NN NN O
different NN NN O
concentrations NN NN O
of NN NN O
AZT NN NN O
( NN NN O
0 NN NN O
, NN NN O
0 NN NN O
. NN NN O
07 NN NN O
, NN NN O
0 NN NN O
. NN NN O
2 NN NN O
, NN NN O
and NN NN O
0 NN NN O
. NN NN O
7 NN NN O
mg NN NN O
/ NN NN O
ml NN NN O
) NN NN O
. NN NN O
   
After NN NN O
6 NN NN O
weeks NN NN O
, NN NN O
cardiac NN NN O
function NN NN O
was NN NN O
assessed NN NN O
by NN NN O
echocardiography NN NN O
and NN NN O
morphology NN NN O
was NN NN O
assessed NN NN O
by NN NN O
histopathologic NN NN O
and NN NN O
immunohistochemical NN NN O
methods NN NN O
. NN NN O
   
NTg NN NN O
and NN NN O
untreated NN NN O
FasL NN NN O
Tg NN NN O
mice NN NN O
showed NN NN O
little NN NN O
or NN NN O
no NN NN O
change NN NN O
in NN NN O
cardiac NN NN O
structure NN NN O
or NN NN O
function NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
AZT NN NN O
- NN NN O
treated NN NN O
FasL NN NN O
Tg NN NN O
mice NN NN O
developed NN NN O
cardiac NN NN B-Disease
dilation NN NN I-Disease
and NN NN O
depressed NN NN O
cardiac NN NN O
function NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
, NN NN O
with NN NN O
concomitant NN NN O
inflammatory NN NN O
infiltration NN NN O
of NN NN O
both NN NN O
ventricles NN NN O
. NN NN O
   
These NN NN O
changes NN NN O
were NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
sarcolemmal NN NN O
expression NN NN O
of NN NN O
Fas NN NN O
and NN NN O
FasL NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
increased NN NN O
activation NN NN O
of NN NN O
caspase NN NN O
3 NN NN O
, NN NN O
translocation NN NN O
of NN NN O
calpain NN NN O
1 NN NN O
to NN NN O
the NN NN O
sarcolemma NN NN O
and NN NN O
sarcomere NN NN O
, NN NN O
and NN NN O
increased NN NN O
numbers NN NN O
of NN NN O
cells NN NN O
undergoing NN NN O
apoptosis NN NN O
. NN NN O
   
These NN NN O
were NN NN O
associated NN NN O
with NN NN O
changes NN NN O
in NN NN O
dystrophin NN NN O
and NN NN O
cardiac NN NN O
troponin NN NN O
I NN NN O
localization NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
loss NN NN O
of NN NN O
sarcolemmal NN NN O
integrity NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
expression NN NN O
of NN NN O
Fas NN NN O
ligand NN NN O
in NN NN O
the NN NN O
myocardium NN NN O
, NN NN O
as NN NN O
identified NN NN O
in NN NN O
HIV NN NN O
- NN NN O
positive NN NN O
patients NN NN O
, NN NN O
might NN NN O
increase NN NN O
the NN NN O
susceptibility NN NN O
to NN NN O
HAART NN NN O
- NN NN O
induced NN NN O
cardiomyopathy NN NN B-Disease
due NN NN O
to NN NN O
activation NN NN O
of NN NN O
apoptotic NN NN O
pathways NN NN O
, NN NN O
resulting NN NN O
in NN NN O
cardiac NN NN B-Disease
dilation NN NN I-Disease
and NN NN I-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Gastrointestinal NN NN O
tolerability NN NN O
of NN NN O
etoricoxib NN NN O
in NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
patients NN NN O
: NN NN O
results NN NN O
of NN NN O
the NN NN O
etoricoxib NN NN O
vs NN NN O
diclofenac NN NN O
sodium NN NN O
gastrointestinal NN NN O
tolerability NN NN O
and NN NN O
effectiveness NN NN O
trial NN NN O
( NN NN O
EDGE NN NN O
- NN NN O
II NN NN O
) NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
A NN NN O
randomised NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
study NN NN O
to NN NN O
compare NN NN O
the NN NN O
gastrointestinal NN NN O
( NN NN O
GI NN NN O
) NN NN O
tolerability NN NN O
, NN NN O
safety NN NN O
and NN NN O
efficacy NN NN O
of NN NN O
etoricoxib NN NN O
and NN NN O
diclofenac NN NN O
in NN NN O
patients NN NN O
with NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
( NN NN O
RA NN NN B-Disease
) NN NN O
. NN NN O
   
PATIENTS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
A NN NN O
total NN NN O
of NN NN O
4086 NN NN O
patients NN NN O
( NN NN O
mean NN NN O
age NN NN O
60 NN NN O
. NN NN O
8 NN NN O
years NN NN O
) NN NN O
diagnosed NN NN O
with NN NN O
RA NN NN B-Disease
were NN NN O
enrolled NN NN O
and NN NN O
received NN NN O
etoricoxib NN NN O
90 NN NN O
mg NN NN O
daily NN NN O
( NN NN O
n NN NN O
= NN NN O
2032 NN NN O
) NN NN O
or NN NN O
diclofenac NN NN O
75 NN NN O
mg NN NN O
twice NN NN O
daily NN NN O
( NN NN O
n NN NN O
= NN NN O
2054 NN NN O
) NN NN O
. NN NN O
   
Use NN NN O
of NN NN O
gastroprotective NN NN O
agents NN NN O
and NN NN O
low NN NN O
- NN NN O
dose NN NN O
aspirin NN NN O
was NN NN O
allowed NN NN O
. NN NN O
   
The NN NN O
prespecified NN NN O
primary NN NN O
end NN NN O
point NN NN O
consisted NN NN O
of NN NN O
the NN NN O
cumulative NN NN O
rate NN NN O
of NN NN O
patient NN NN O
discontinuations NN NN O
due NN NN O
to NN NN O
clinical NN NN O
and NN NN O
laboratory NN NN O
GI NN NN O
adverse NN NN O
experiences NN NN O
( NN NN O
AEs NN NN O
) NN NN O
. NN NN O
   
General NN NN O
safety NN NN O
was NN NN O
also NN NN O
assessed NN NN O
, NN NN O
including NN NN O
adjudicated NN NN O
thrombotic NN NN B-Disease
cardiovascular NN NN I-Disease
event NN NN O
data NN NN O
. NN NN O
   
Efficacy NN NN O
was NN NN O
evaluated NN NN O
using NN NN O
the NN NN O
Patient NN NN O
Global NN NN O
Assessment NN NN O
of NN NN O
Disease NN NN O
Status NN NN O
( NN NN O
PGADS NN NN O
; NN NN O
0 NN NN O
- NN NN O
4 NN NN O
point NN NN O
scale NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Mean NN NN O
( NN NN O
SD NN NN O
; NN NN O
maximum NN NN O
) NN NN O
duration NN NN O
of NN NN O
treatment NN NN O
was NN NN O
19 NN NN O
. NN NN O
3 NN NN O
( NN NN O
10 NN NN O
. NN NN O
3 NN NN O
; NN NN O
32 NN NN O
. NN NN O
9 NN NN O
) NN NN O
and NN NN O
19 NN NN O
. NN NN O
1 NN NN O
( NN NN O
10 NN NN O
. NN NN O
4 NN NN O
; NN NN O
33 NN NN O
. NN NN O
1 NN NN O
) NN NN O
months NN NN O
in NN NN O
the NN NN O
etoricoxib NN NN O
and NN NN O
diclofenac NN NN O
groups NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
The NN NN O
cumulative NN NN O
discontinuation NN NN O
rate NN NN O
due NN NN O
to NN NN O
GI NN NN B-Disease
AEs NN NN I-Disease
was NN NN O
significantly NN NN O
lower NN NN O
with NN NN O
etoricoxib NN NN O
than NN NN O
diclofenac NN NN O
( NN NN O
5 NN NN O
. NN NN O
2 NN NN O
vs NN NN O
8 NN NN O
. NN NN O
5 NN NN O
events NN NN O
per NN NN O
100 NN NN O
patient NN NN O
- NN NN O
years NN NN O
, NN NN O
respectively NN NN O
; NN NN O
hazard NN NN O
ratio NN NN O
0 NN NN O
. NN NN O
62 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
: NN NN O
0 NN NN O
. NN NN O
47 NN NN O
, NN NN O
0 NN NN O
. NN NN O
81 NN NN O
; NN NN O
p NN NN O
< NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
) NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
discontinuations NN NN O
for NN NN O
hypertension NN NN B-Disease
- NN NN O
related NN NN O
and NN NN O
oedema NN NN B-Disease
- NN NN O
related NN NN O
AEs NN NN O
were NN NN O
significantly NN NN O
higher NN NN O
with NN NN O
etoricoxib NN NN O
( NN NN O
2 NN NN O
. NN NN O
5 NN NN O
% NN NN O
and NN NN O
1 NN NN O
. NN NN O
1 NN NN O
% NN NN O
respectively NN NN O
) NN NN O
compared NN NN O
with NN NN O
diclofenac NN NN O
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
% NN NN O
and NN NN O
0 NN NN O
. NN NN O
4 NN NN O
% NN NN O
respectively NN NN O
; NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
for NN NN O
hypertension NN NN B-Disease
and NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
for NN NN O
oedema NN NN B-Disease
) NN NN O
. NN NN O
   
Etoricoxib NN NN O
and NN NN O
diclofenac NN NN O
treatment NN NN O
resulted NN NN O
in NN NN O
similar NN NN O
efficacy NN NN O
( NN NN O
PGADS NN NN O
mean NN NN O
changes NN NN O
from NN NN O
baseline NN NN O
- NN NN O
0 NN NN O
. NN NN O
62 NN NN O
vs NN NN O
- NN NN O
0 NN NN O
. NN NN O
58 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Etoricoxib NN NN O
90 NN NN O
mg NN NN O
demonstrated NN NN O
a NN NN O
significantly NN NN O
lower NN NN O
risk NN NN O
for NN NN O
discontinuing NN NN O
treatment NN NN O
due NN NN O
to NN NN O
GI NN NN B-Disease
AEs NN NN I-Disease
compared NN NN O
with NN NN O
diclofenac NN NN O
150 NN NN O
mg NN NN O
. NN NN O
   
Discontinuations NN NN O
from NN NN O
renovascular NN NN O
AEs NN NN O
, NN NN O
although NN NN O
less NN NN O
common NN NN O
than NN NN O
discontinuations NN NN O
from NN NN O
GI NN NN B-Disease
AEs NN NN I-Disease
, NN NN O
were NN NN O
significantly NN NN O
higher NN NN O
with NN NN O
etoricoxib NN NN O
. NN NN O
   
Anxiogenic NN NN O
potential NN NN O
of NN NN O
ciprofloxacin NN NN O
and NN NN O
norfloxacin NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
INTRODUCTION NN NN O
: NN NN O
The NN NN O
possible NN NN O
anxiogenic NN NN O
effects NN NN O
of NN NN O
fluoroquinolones NN NN O
, NN NN O
namely NN NN O
ciprofloxacin NN NN O
and NN NN O
norfloxacin NN NN O
, NN NN O
were NN NN O
investigated NN NN O
in NN NN O
adult NN NN O
Charles NN NN O
Foster NN NN O
albino NN NN O
rats NN NN O
of NN NN O
either NN NN O
sex NN NN O
, NN NN O
weighing NN NN O
150 NN NN O
- NN NN O
200 NN NN O
g NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
drugs NN NN O
were NN NN O
given NN NN O
orally NN NN O
, NN NN O
in NN NN O
doses NN NN O
of NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
for NN NN O
five NN NN O
consecutive NN NN O
days NN NN O
and NN NN O
the NN NN O
experiments NN NN O
were NN NN O
performed NN NN O
on NN NN O
the NN NN O
fifth NN NN O
day NN NN O
. NN NN O
   
The NN NN O
tests NN NN O
included NN NN O
open NN NN O
- NN NN O
field NN NN O
exploratory NN NN O
behaviour NN NN O
, NN NN O
elevated NN NN O
plus NN NN O
maze NN NN O
and NN NN O
elevated NN NN O
zero NN NN O
maze NN NN O
, NN NN O
social NN NN O
interaction NN NN O
and NN NN O
novelty NN NN O
- NN NN O
suppressed NN NN O
feeding NN NN O
latency NN NN O
behaviour NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
ciprofloxacin NN NN O
- NN NN O
and NN NN O
norfloxacin NN NN O
- NN NN O
treated NN NN O
rats NN NN O
showed NN NN O
anxious NN NN B-Disease
behaviour NN NN I-Disease
in NN NN O
comparison NN NN O
to NN NN O
control NN NN O
rats NN NN O
in NN NN O
all NN NN O
the NN NN O
parameters NN NN O
studied NN NN O
. NN NN O
   
However NN NN O
, NN NN O
ciprofloxacin NN NN O
- NN NN O
and NN NN O
norfloxacin NN NN O
- NN NN O
treated NN NN O
rats NN NN O
did NN NN O
not NN NN O
differ NN NN O
significantly NN NN O
from NN NN O
each NN NN O
other NN NN O
in NN NN O
various NN NN O
behavioural NN NN O
parameters NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
present NN NN O
experimental NN NN O
findings NN NN O
substantiate NN NN O
the NN NN O
clinically NN NN O
observed NN NN O
anxiogenic NN NN O
potential NN NN O
of NN NN O
ciprofloxacin NN NN O
and NN NN O
norfloxacin NN NN O
. NN NN O
   
Reduction NN NN O
of NN NN O
pain NN NN B-Disease
during NN NN O
induction NN NN O
with NN NN O
target NN NN O
- NN NN O
controlled NN NN O
propofol NN NN O
and NN NN O
remifentanil NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Pain NN NN B-Disease
on NN NN O
injection NN NN O
of NN NN O
propofol NN NN O
is NN NN O
unpleasant NN NN O
. NN NN O
   
We NN NN O
hypothesized NN NN O
that NN NN O
propofol NN NN O
infusion NN NN O
pain NN NN B-Disease
might NN NN O
be NN NN O
prevented NN NN O
by NN NN O
infusing NN NN O
remifentanil NN NN O
before NN NN O
starting NN NN O
the NN NN O
propofol NN NN O
infusion NN NN O
in NN NN O
a NN NN O
clinical NN NN O
setting NN NN O
where NN NN O
target NN NN O
- NN NN O
controlled NN NN O
infusions NN NN O
( NN NN O
TCI NN NN O
) NN NN O
of NN NN O
both NN NN O
drugs NN NN O
were NN NN O
used NN NN O
. NN NN O
   
A NN NN O
prospective NN NN O
, NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
trial NN NN O
was NN NN O
performed NN NN O
to NN NN O
determine NN NN O
the NN NN O
effect NN NN O
- NN NN O
site NN NN O
concentration NN NN O
( NN NN O
Ce NN NN O
) NN NN O
of NN NN O
remifentanil NN NN O
to NN NN O
prevent NN NN O
the NN NN O
pain NN NN B-Disease
without NN NN O
producing NN NN O
complications NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
A NN NN O
total NN NN O
of NN NN O
128 NN NN O
patients NN NN O
undergoing NN NN O
general NN NN O
surgery NN NN O
were NN NN O
randomly NN NN O
allocated NN NN O
to NN NN O
receive NN NN O
normal NN NN O
saline NN NN O
( NN NN O
control NN NN O
) NN NN O
or NN NN O
remifentanil NN NN O
to NN NN O
a NN NN O
target NN NN O
Ce NN NN O
of NN NN O
2 NN NN O
ng NN NN O
ml NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
( NN NN O
R2 NN NN O
) NN NN O
, NN NN O
4 NN NN O
ng NN NN O
ml NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
( NN NN O
R4 NN NN O
) NN NN O
, NN NN O
or NN NN O
6 NN NN O
ng NN NN O
ml NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
( NN NN O
R6 NN NN O
) NN NN O
administered NN NN O
via NN NN O
TCI NN NN O
. NN NN O
   
After NN NN O
the NN NN O
target NN NN O
Ce NN NN O
was NN NN O
achieved NN NN O
, NN NN O
the NN NN O
infusion NN NN O
of NN NN O
propofol NN NN O
was NN NN O
started NN NN O
. NN NN O
   
Remifentanil NN NN O
- NN NN O
related NN NN O
complications NN NN O
were NN NN O
assessed NN NN O
during NN NN O
the NN NN O
remifentanil NN NN O
infusion NN NN O
, NN NN O
and NN NN O
pain NN NN B-Disease
caused NN NN O
by NN NN O
propofol NN NN O
was NN NN O
evaluated NN NN O
using NN NN O
a NN NN O
four NN NN O
- NN NN O
point NN NN O
scale NN NN O
during NN NN O
the NN NN O
propofol NN NN O
infusion NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
incidence NN NN O
of NN NN O
pain NN NN B-Disease
was NN NN O
significantly NN NN O
lower NN NN O
in NN NN O
Groups NN NN O
R4 NN NN O
and NN NN O
R6 NN NN O
than NN NN O
in NN NN O
the NN NN O
control NN NN O
and NN NN O
R2 NN NN O
groups NN NN O
( NN NN O
12 NN NN O
/ NN NN O
32 NN NN O
and NN NN O
6 NN NN O
/ NN NN O
31 NN NN O
vs NN NN O
26 NN NN O
/ NN NN O
31 NN NN O
and NN NN O
25 NN NN O
/ NN NN O
32 NN NN O
, NN NN O
respectively NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Pain NN NN B-Disease
was NN NN O
less NN NN O
severe NN NN O
in NN NN O
Groups NN NN O
R4 NN NN O
and NN NN O
R6 NN NN O
than NN NN O
in NN NN O
the NN NN O
control NN NN O
and NN NN O
R2 NN NN O
groups NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
both NN NN O
incidence NN NN O
and NN NN O
severity NN NN O
of NN NN O
pain NN NN B-Disease
were NN NN O
not NN NN O
different NN NN O
between NN NN O
Groups NN NN O
R4 NN NN O
and NN NN O
R6 NN NN O
. NN NN O
   
No NN NN O
significant NN NN O
complications NN NN O
were NN NN O
observed NN NN O
during NN NN O
the NN NN O
study NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
During NN NN O
induction NN NN O
of NN NN O
anaesthesia NN NN O
with NN NN O
TCI NN NN O
of NN NN O
propofol NN NN O
and NN NN O
remifentanil NN NN O
, NN NN O
a NN NN O
significant NN NN O
reduction NN NN O
in NN NN O
propofol NN NN O
infusion NN NN O
pain NN NN B-Disease
was NN NN O
achieved NN NN O
without NN NN O
significant NN NN O
complications NN NN O
by NN NN O
prior NN NN O
administration NN NN O
of NN NN O
remifentanil NN NN O
at NN NN O
a NN NN O
target NN NN O
Ce NN NN O
of NN NN O
4 NN NN O
ng NN NN O
ml NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
Dexmedetomidine NN NN O
and NN NN O
cardiac NN NN O
protection NN NN O
for NN NN O
non NN NN O
- NN NN O
cardiac NN NN O
surgery NN NN O
: NN NN O
a NN NN O
meta NN NN O
- NN NN O
analysis NN NN O
of NN NN O
randomised NN NN O
controlled NN NN O
trials NN NN O
. NN NN O
   
We NN NN O
conducted NN NN O
a NN NN O
systematic NN NN O
review NN NN O
of NN NN O
the NN NN O
effects NN NN O
of NN NN O
dexmedetomidine NN NN O
on NN NN O
cardiac NN NN O
outcomes NN NN O
following NN NN O
non NN NN O
- NN NN O
cardiac NN NN O
surgery NN NN O
. NN NN O
   
We NN NN O
included NN NN O
prospective NN NN O
, NN NN O
randomised NN NN O
peri NN NN O
- NN NN O
operative NN NN O
studies NN NN O
of NN NN O
dexmedetomidine NN NN O
that NN NN O
reported NN NN O
mortality NN NN O
, NN NN O
cardiac NN NN O
morbidity NN NN O
or NN NN O
adverse NN NN O
drug NN NN O
events NN NN O
. NN NN O
   
A NN NN O
PubMed NN NN O
Central NN NN O
and NN NN O
EMBASE NN NN O
search NN NN O
was NN NN O
conducted NN NN O
up NN NN O
to NN NN O
July NN NN O
2007 NN NN O
. NN NN O
   
The NN NN O
reference NN NN O
lists NN NN O
of NN NN O
identified NN NN O
papers NN NN O
were NN NN O
examined NN NN O
for NN NN O
further NN NN O
trials NN NN O
. NN NN O
   
Of NN NN O
425 NN NN O
studies NN NN O
identified NN NN O
, NN NN O
20 NN NN O
were NN NN O
included NN NN O
in NN NN O
the NN NN O
meta NN NN O
- NN NN O
analysis NN NN O
( NN NN O
840 NN NN O
patients NN NN O
) NN NN O
. NN NN O
   
Dexmedetomidine NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
trend NN NN O
towards NN NN O
improved NN NN O
cardiac NN NN O
outcomes NN NN O
; NN NN O
all NN NN O
- NN NN O
cause NN NN O
mortality NN NN O
( NN NN O
OR NN NN O
0 NN NN O
. NN NN O
27 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
0 NN NN O
. NN NN O
01 NN NN O
- NN NN O
7 NN NN O
. NN NN O
13 NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
44 NN NN O
) NN NN O
, NN NN O
non NN NN O
- NN NN O
fatal NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
( NN NN O
OR NN NN O
0 NN NN O
. NN NN O
26 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
0 NN NN O
. NN NN O
04 NN NN O
- NN NN O
1 NN NN O
. NN NN O
60 NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
14 NN NN O
) NN NN O
, NN NN O
and NN NN O
myocardial NN NN B-Disease
ischaemia NN NN I-Disease
( NN NN O
OR NN NN O
0 NN NN O
. NN NN O
65 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
0 NN NN O
. NN NN O
26 NN NN O
- NN NN O
1 NN NN O
. NN NN O
63 NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
36 NN NN O
) NN NN O
. NN NN O
   
Peri NN NN O
- NN NN O
operative NN NN O
hypotension NN NN B-Disease
( NN NN O
26 NN NN O
% NN NN O
, NN NN O
OR NN NN O
3 NN NN O
. NN NN O
80 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
1 NN NN O
. NN NN O
91 NN NN O
- NN NN O
7 NN NN O
. NN NN O
54 NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
) NN NN O
and NN NN O
bradycardia NN NN B-Disease
( NN NN O
17 NN NN O
% NN NN O
, NN NN O
OR NN NN O
5 NN NN O
. NN NN O
45 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
2 NN NN O
. NN NN O
98 NN NN O
- NN NN O
9 NN NN O
. NN NN O
95 NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
00001 NN NN O
) NN NN O
were NN NN O
significantly NN NN O
increased NN NN O
. NN NN O
   
An NN NN O
anticholinergic NN NN O
did NN NN O
not NN NN O
reduce NN NN O
the NN NN O
incidence NN NN O
of NN NN O
bradycardia NN NN B-Disease
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
43 NN NN O
) NN NN O
. NN NN O
   
A NN NN O
randomised NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
trial NN NN O
of NN NN O
dexmedetomidine NN NN O
is NN NN O
warranted NN NN O
. NN NN O
   
Myocardial NN NN B-Disease
infarction NN NN I-Disease
in NN NN O
pregnancy NN NN O
associated NN NN O
with NN NN O
clomiphene NN NN O
citrate NN NN O
for NN NN O
ovulation NN NN O
induction NN NN O
: NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Clomiphene NN NN O
citrate NN NN O
( NN NN O
CC NN NN O
) NN NN O
is NN NN O
commonly NN NN O
prescribed NN NN O
for NN NN O
ovulation NN NN O
induction NN NN O
. NN NN O
   
It NN NN O
is NN NN O
considered NN NN O
safe NN NN O
, NN NN O
with NN NN O
minimal NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
Thromboembolism NN NN B-Disease
is NN NN O
a NN NN O
rare NN NN O
but NN NN O
life NN NN O
- NN NN O
threatening NN NN O
complication NN NN O
that NN NN O
has NN NN O
been NN NN O
reported NN NN O
after NN NN O
ovulation NN NN O
induction NN NN O
with NN NN O
CC NN NN O
. NN NN O
   
Spontaneous NN NN O
coronary NN NN B-Disease
thrombosis NN NN I-Disease
or NN NN O
thromboembolism NN NN B-Disease
with NN NN O
subsequent NN NN O
clot NN NN O
lysis NN NN O
has NN NN O
been NN NN O
suggested NN NN O
as NN NN O
one NN NN O
of NN NN O
the NN NN O
most NN NN O
common NN NN O
causes NN NN O
of NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
( NN NN O
MI NN NN B-Disease
) NN NN O
during NN NN O
pregnancy NN NN O
, NN NN O
with NN NN O
a NN NN O
subsequently NN NN O
normal NN NN O
coronary NN NN O
angiogram NN NN O
. NN NN O
   
CASE NN NN O
: NN NN O
A NN NN O
33 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
a NN NN O
5 NN NN O
- NN NN O
week NN NN O
gestation NN NN O
had NN NN O
recently NN NN O
received NN NN O
CC NN NN O
for NN NN O
ovulation NN NN O
induction NN NN O
and NN NN O
presented NN NN O
with NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
An NN NN O
electrocardiogram NN NN O
showed NN NN O
a NN NN O
lateral NN NN O
and NN NN O
anterior NN NN O
wall NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
Cardiac NN NN O
enzymes NN NN O
showed NN NN O
a NN NN O
peak NN NN O
rise NN NN O
in NN NN O
troponin NN NN O
I NN NN O
to NN NN O
9 NN NN O
. NN NN O
10 NN NN O
ng NN NN O
/ NN NN O
mL NN NN O
. NN NN O
   
An NN NN O
initial NN NN O
exercise NN NN O
stress NN NN O
test NN NN O
was NN NN O
normal NN NN O
. NN NN O
   
At NN NN O
the NN NN O
time NN NN O
of NN NN O
admission NN NN O
, NN NN O
the NN NN O
patient NN NN O
was NN NN O
at NN NN O
high NN NN O
risk NN NN O
of NN NN O
radiation NN NN B-Disease
injury NN NN I-Disease
to NN NN O
the NN NN O
fetus NN NN O
, NN NN O
so NN NN O
a NN NN O
coronary NN NN O
angiogram NN NN O
was NN NN O
postponed NN NN O
until NN NN O
the NN NN O
second NN NN O
trimester NN NN O
. NN NN O
   
It NN NN O
showed NN NN O
normal NN NN O
coronary NN NN O
vessels NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
This NN NN O
appears NN NN O
to NN NN O
be NN NN O
the NN NN O
first NN NN O
reported NN NN O
case NN NN O
documenting NN NN O
a NN NN O
possible NN NN O
association NN NN O
between NN NN O
CC NN NN O
and NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
Thrombosis NN NN B-Disease
might NN NN O
be NN NN O
a NN NN O
rare NN NN O
but NN NN O
hazardous NN NN O
complication NN NN O
of NN NN O
CC NN NN O
. NN NN O
   
Given NN NN O
this NN NN O
life NN NN O
- NN NN O
threatening NN NN O
complication NN NN O
, NN NN O
appropriate NN NN O
prophylactic NN NN O
measures NN NN O
should NN NN O
be NN NN O
used NN NN O
in NN NN O
high NN NN O
- NN NN O
risk NN NN O
woman NN NN O
undergoing NN NN O
ovarian NN NN O
stimulation NN NN O
. NN NN O
   
Reverse NN NN O
or NN NN O
inverted NN NN O
left NN NN B-Disease
ventricular NN NN I-Disease
apical NN NN I-Disease
ballooning NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
reverse NN NN O
Takotsubo NN NN B-Disease
cardiomyopathy NN NN I-Disease
) NN NN O
in NN NN O
a NN NN O
young NN NN O
woman NN NN O
in NN NN O
the NN NN O
setting NN NN O
of NN NN O
amphetamine NN NN O
use NN NN O
. NN NN O
   
Transient NN NN O
left NN NN B-Disease
ventricular NN NN I-Disease
apical NN NN I-Disease
ballooning NN NN I-Disease
syndrome NN NN I-Disease
was NN NN O
first NN NN O
described NN NN O
in NN NN O
Japan NN NN O
as NN NN O
"""""""" NN NN O
Takotsubo NN NN B-Disease
cardiomyopathy NN NN I-Disease
. NN NN O
"""""""" NN NN O
This NN NN O
syndrome NN NN O
has NN NN O
been NN NN O
identified NN NN O
in NN NN O
many NN NN O
other NN NN O
countries NN NN O
. NN NN O
   
Many NN NN O
variations NN NN O
of NN NN O
this NN NN O
syndrome NN NN O
have NN NN O
been NN NN O
recently NN NN O
described NN NN O
in NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
rarest NN NN O
is NN NN O
the NN NN O
reverse NN NN O
type NN NN O
of NN NN O
this NN NN O
syndrome NN NN O
, NN NN O
with NN NN O
hyperdynamic NN NN O
apex NN NN O
and NN NN O
complete NN NN O
akinesia NN NN B-Disease
of NN NN O
the NN NN O
base NN NN O
( NN NN O
as NN NN O
opposed NN NN O
to NN NN O
the NN NN O
classic NN NN O
apical NN NN B-Disease
ballooning NN NN I-Disease
) NN NN O
. NN NN O
   
In NN NN O
this NN NN O
article NN NN O
, NN NN O
we NN NN O
report NN NN O
an NN NN O
interesting NN NN O
case NN NN O
of NN NN O
a NN NN O
young NN NN O
woman NN NN O
who NN NN O
presented NN NN O
with NN NN O
this NN NN O
rare NN NN O
type NN NN O
of NN NN O
reverse NN NN O
apical NN NN B-Disease
ballooning NN NN I-Disease
syndrome NN NN I-Disease
occurring NN NN O
after NN NN O
amphetamine NN NN O
use NN NN O
. NN NN O
   
This NN NN O
report NN NN O
is NN NN O
followed NN NN O
by NN NN O
review NN NN O
of NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
Results NN NN O
of NN NN O
a NN NN O
comparative NN NN O
, NN NN O
phase NN NN O
III NN NN O
, NN NN O
12 NN NN O
- NN NN O
week NN NN O
, NN NN O
multicenter NN NN O
, NN NN O
prospective NN NN O
, NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
assessment NN NN O
of NN NN O
the NN NN O
efficacy NN NN O
and NN NN O
tolerability NN NN O
of NN NN O
a NN NN O
fixed NN NN O
- NN NN O
dose NN NN O
combination NN NN O
of NN NN O
telmisartan NN NN O
and NN NN O
amlodipine NN NN O
versus NN NN O
amlodipine NN NN O
monotherapy NN NN O
in NN NN O
Indian NN NN O
adults NN NN O
with NN NN O
stage NN NN O
II NN NN O
hypertension NN NN B-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
efficacy NN NN O
and NN NN O
tolerability NN NN O
of NN NN O
a NN NN O
new NN NN O
fixed NN NN O
- NN NN O
dose NN NN O
combination NN NN O
( NN NN O
FDC NN NN O
) NN NN O
of NN NN O
telmisartan NN NN O
40 NN NN O
mg NN NN O
+ NN NN O
amlodipine NN NN O
5 NN NN O
mg NN NN O
( NN NN O
T NN NN O
+ NN NN O
A NN NN O
) NN NN O
compared NN NN O
with NN NN O
amlodipine NN NN O
5 NN NN O
- NN NN O
mg NN NN O
monotherapy NN NN O
( NN NN O
A NN NN O
) NN NN O
in NN NN O
adult NN NN O
Indian NN NN O
patients NN NN O
with NN NN O
stage NN NN O
II NN NN O
hypertension NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
This NN NN O
comparative NN NN O
, NN NN O
Phase NN NN O
III NN NN O
, NN NN O
12 NN NN O
- NN NN O
week NN NN O
, NN NN O
multicenter NN NN O
, NN NN O
prospective NN NN O
, NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
study NN NN O
was NN NN O
conducted NN NN O
in NN NN O
Indian NN NN O
patients NN NN O
aged NN NN O
18 NN NN O
to NN NN O
65 NN NN O
years NN NN O
with NN NN O
established NN NN O
stage NN NN O
II NN NN O
hypertension NN NN B-Disease
. NN NN O
   
Patients NN NN O
were NN NN O
treated NN NN O
with NN NN O
oral NN NN O
FDC NN NN O
of NN NN O
T NN NN O
+ NN NN O
A NN NN O
or NN NN O
A NN NN O
QD NN NN O
before NN NN O
breakfast NN NN O
for NN NN O
12 NN NN O
weeks NN NN O
; NN NN O
blood NN NN O
pressure NN NN O
( NN NN O
BP NN NN O
) NN NN O
and NN NN O
heart NN NN O
rate NN NN O
were NN NN O
measured NN NN O
in NN NN O
the NN NN O
sitting NN NN O
position NN NN O
. NN NN O
   
Primary NN NN O
efficacy NN NN O
end NN NN O
points NN NN O
were NN NN O
reduction NN NN O
in NN NN O
clinical NN NN O
systolic NN NN O
BP NN NN O
( NN NN O
SBP NN NN O
) NN NN O
/ NN NN O
diastolic NN NN O
BP NN NN O
( NN NN O
DBP NN NN O
) NN NN O
from NN NN O
baseline NN NN O
to NN NN O
study NN NN O
end NN NN O
and NN NN O
number NN NN O
of NN NN O
responders NN NN O
( NN NN O
ie NN NN O
, NN NN O
patients NN NN O
who NN NN O
achieved NN NN O
target NN NN O
SBP NN NN O
/ NN NN O
DBP NN NN O
< NN NN O
130 NN NN O
/ NN NN O
< NN NN O
80 NN NN O
mm NN NN O
Hg NN NN O
) NN NN O
at NN NN O
end NN NN O
of NN NN O
study NN NN O
. NN NN O
   
Tolerability NN NN O
was NN NN O
assessed NN NN O
by NN NN O
treatment NN NN O
- NN NN O
emergent NN NN O
adverse NN NN O
events NN NN O
, NN NN O
identified NN NN O
using NN NN O
physical NN NN O
examination NN NN O
, NN NN O
laboratory NN NN O
analysis NN NN O
, NN NN O
and NN NN O
electrocardiography NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
A NN NN O
total NN NN O
of NN NN O
210 NN NN O
patients NN NN O
were NN NN O
enrolled NN NN O
in NN NN O
the NN NN O
study NN NN O
; NN NN O
203 NN NN O
patients NN NN O
( NN NN O
143 NN NN O
men NN NN O
, NN NN O
60 NN NN O
women NN NN O
) NN NN O
completed NN NN O
the NN NN O
study NN NN O
while NN NN O
7 NN NN O
were NN NN O
lost NN NN O
to NN NN O
follow NN NN O
- NN NN O
up NN NN O
( NN NN O
4 NN NN O
patients NN NN O
in NN NN O
the NN NN O
T NN NN O
+ NN NN O
A NN NN O
group NN NN O
and NN NN O
3 NN NN O
in NN NN O
the NN NN O
A NN NN O
group NN NN O
) NN NN O
and NN NN O
considered NN NN O
with NN NN O
- NN NN O
drawn NN NN O
. NN NN O
   
At NN NN O
study NN NN O
end NN NN O
, NN NN O
statistically NN NN O
significant NN NN O
percentage NN NN O
reductions NN NN O
from NN NN O
baseline NN NN O
within NN NN O
groups NN NN O
and NN NN O
between NN NN O
groups NN NN O
were NN NN O
observed NN NN O
in NN NN O
SBP NN NN O
( NN NN O
T NN NN O
+ NN NN O
A NN NN O
[ NN NN O
- NN NN O
27 NN NN O
. NN NN O
4 NN NN O
% NN NN O
] NN NN O
; NN NN O
A NN NN O
[ NN NN O
- NN NN O
16 NN NN O
. NN NN O
6 NN NN O
% NN NN O
] NN NN O
) NN NN O
and NN NN O
DBP NN NN O
( NN NN O
T NN NN O
+ NN NN O
A NN NN O
[ NN NN O
- NN NN O
20 NN NN O
. NN NN O
1 NN NN O
% NN NN O
] NN NN O
; NN NN O
A NN NN O
[ NN NN O
- NN NN O
13 NN NN O
. NN NN O
3 NN NN O
% NN NN O
] NN NN O
) NN NN O
( NN NN O
all NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Response NN NN O
rates NN NN O
were NN NN O
87 NN NN O
. NN NN O
3 NN NN O
% NN NN O
( NN NN O
89 NN NN O
/ NN NN O
102 NN NN O
) NN NN O
in NN NN O
the NN NN O
T NN NN O
+ NN NN O
A NN NN O
group NN NN O
and NN NN O
69 NN NN O
. NN NN O
3 NN NN O
% NN NN O
( NN NN O
70 NN NN O
/ NN NN O
101 NN NN O
) NN NN O
in NN NN O
the NN NN O
A NN NN O
group NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
prevalences NN NN O
of NN NN O
adverse NN NN O
events NN NN O
were NN NN O
not NN NN O
significantly NN NN O
different NN NN O
between NN NN O
the NN NN O
2 NN NN O
treatment NN NN O
groups NN NN O
( NN NN O
T NN NN O
+ NN NN O
A NN NN O
, NN NN O
16 NN NN O
. NN NN O
0 NN NN O
% NN NN O
[ NN NN O
17 NN NN O
/ NN NN O
106 NN NN O
] NN NN O
; NN NN O
A NN NN O
, NN NN O
15 NN NN O
. NN NN O
4 NN NN O
% NN NN O
[ NN NN O
16 NN NN O
/ NN NN O
104 NN NN O
] NN NN O
) NN NN O
. NN NN O
   
Peripheral NN NN O
edema NN NN B-Disease
was NN NN O
reported NN NN O
in NN NN O
8 NN NN O
. NN NN O
5 NN NN O
% NN NN O
patients NN NN O
( NN NN O
9 NN NN O
/ NN NN O
106 NN NN O
) NN NN O
in NN NN O
the NN NN O
T NN NN O
+ NN NN O
A NN NN O
group NN NN O
compared NN NN O
with NN NN O
13 NN NN O
. NN NN O
5 NN NN O
% NN NN O
( NN NN O
14 NN NN O
/ NN NN O
104 NN NN O
) NN NN O
in NN NN O
the NN NN O
A NN NN O
group NN NN O
, NN NN O
and NN NN O
cough NN NN B-Disease
was NN NN O
reported NN NN O
in NN NN O
3 NN NN O
. NN NN O
8 NN NN O
% NN NN O
patients NN NN O
( NN NN O
4 NN NN O
/ NN NN O
106 NN NN O
) NN NN O
in NN NN O
the NN NN O
T NN NN O
+ NN NN O
A NN NN O
group NN NN O
and NN NN O
1 NN NN O
. NN NN O
0 NN NN O
% NN NN O
( NN NN O
1 NN NN O
/ NN NN O
104 NN NN O
) NN NN O
patients NN NN O
in NN NN O
the NN NN O
A NN NN O
group NN NN O
; NN NN O
these NN NN O
differences NN NN O
did NN NN O
not NN NN O
reach NN NN O
statistical NN NN O
significance NN NN O
. NN NN O
   
The NN NN O
incidences NN NN O
of NN NN O
headache NN NN B-Disease
, NN NN O
dizziness NN NN B-Disease
, NN NN O
and NN NN O
diarrhea NN NN B-Disease
were NN NN O
similar NN NN O
between NN NN O
the NN NN O
2 NN NN O
groups NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Among NN NN O
these NN NN O
Indian NN NN O
patients NN NN O
with NN NN O
stage NN NN O
II NN NN O
hypertension NN NN B-Disease
, NN NN O
the NN NN O
FDC NN NN O
of NN NN O
T NN NN O
+ NN NN O
A NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
significantly NN NN O
more NN NN O
effective NN NN O
, NN NN O
with NN NN O
regard NN NN O
to NN NN O
BP NN NN O
reductions NN NN O
, NN NN O
than NN NN O
A NN NN O
, NN NN O
and NN NN O
both NN NN O
treatments NN NN O
were NN NN O
well NN NN O
tolerated NN NN O
. NN NN O
   
Increased NN NN O
mental NN NN B-Disease
slowing NN NN I-Disease
associated NN NN O
with NN NN O
the NN NN O
APOE NN NN O
epsilon4 NN NN O
allele NN NN O
after NN NN O
trihexyphenidyl NN NN O
oral NN NN O
anticholinergic NN NN O
challenge NN NN O
in NN NN O
healthy NN NN O
elderly NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
The NN NN O
objectives NN NN O
of NN NN O
this NN NN O
study NN NN O
were NN NN O
to NN NN O
examine NN NN O
the NN NN O
relationship NN NN O
between NN NN O
APOE NN NN O
epsilon4 NN NN O
and NN NN O
subjective NN NN O
effects NN NN O
of NN NN O
trihexyphenidyl NN NN O
on NN NN O
measures NN NN O
reflecting NN NN O
sedation NN NN O
and NN NN O
confusion NN NN B-Disease
and NN NN O
to NN NN O
investigate NN NN O
the NN NN O
relationship NN NN O
between NN NN O
trihexyphenidyl NN NN O
- NN NN O
induced NN NN O
subjective NN NN O
effects NN NN O
and NN NN O
objective NN NN O
memory NN NN O
performance NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
This NN NN O
study NN NN O
comprised NN NN O
24 NN NN O
cognitively NN NN O
intact NN NN O
, NN NN O
health NN NN O
elderly NN NN O
adults NN NN O
( NN NN O
12 NN NN O
APOE NN NN O
epsilon4 NN NN O
carriers NN NN O
) NN NN O
at NN NN O
an NN NN O
outpatient NN NN O
geriatric NN NN O
psychiatry NN NN O
research NN NN O
clinic NN NN O
. NN NN O
   
This NN NN O
was NN NN O
a NN NN O
randomized NN NN O
, NN NN O
double NN NN O
blind NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
, NN NN O
three NN NN O
- NN NN O
way NN NN O
, NN NN O
crossover NN NN O
experimental NN NN O
design NN NN O
. NN NN O
   
All NN NN O
participants NN NN O
received NN NN O
1 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
or NN NN O
2 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
trihexyphenidyl NN NN O
or NN NN O
placebo NN NN O
administered NN NN O
in NN NN O
counterbalanced NN NN O
sequences NN NN O
over NN NN O
a NN NN O
period NN NN O
of NN NN O
three NN NN O
consecutive NN NN O
weeks NN NN O
. NN NN O
   
Bond NN NN O
and NN NN O
Lader NN NN O
' NN NN O
s NN NN O
visual NN NN O
analog NN NN O
scales NN NN O
and NN NN O
alternate NN NN O
versions NN NN O
of NN NN O
the NN NN O
Buschke NN NN O
Selective NN NN O
Reminding NN NN O
Test NN NN O
were NN NN O
administered NN NN O
in NN NN O
a NN NN O
repeated NN NN O
measures NN NN O
design NN NN O
at NN NN O
baseline NN NN O
, NN NN O
1 NN NN O
, NN NN O
2 NN NN O
. NN NN O
5 NN NN O
, NN NN O
and NN NN O
5 NN NN O
hours NN NN O
postdrug NN NN O
administration NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
A NN NN O
2 NN NN O
. NN NN O
0 NN NN O
- NN NN O
mg NN NN O
oral NN NN O
dose NN NN O
of NN NN O
trihexyphenidyl NN NN O
resulted NN NN O
in NN NN O
increased NN NN O
subjective NN NN O
ratings NN NN O
of NN NN O
mental NN NN B-Disease
slowness NN NN I-Disease
in NN NN O
carriers NN NN O
of NN NN O
the NN NN O
APOE NN NN O
epsilon4 NN NN O
allele NN NN O
only NN NN O
. NN NN O
   
Drug NN NN O
effects NN NN O
as NN NN O
determined NN NN O
by NN NN O
difference NN NN O
scores NN NN O
between NN NN O
2 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
trihexyphenidyl NN NN O
and NN NN O
placebo NN NN O
on NN NN O
ratings NN NN O
of NN NN O
mental NN NN B-Disease
slowness NN NN I-Disease
significantly NN NN O
correlated NN NN O
with NN NN O
total NN NN O
and NN NN O
delayed NN NN O
recall NN NN O
on NN NN O
the NN NN O
Buschke NN NN O
Selective NN NN O
Reminding NN NN O
Test NN NN O
in NN NN O
carriers NN NN O
of NN NN O
the NN NN O
APOE NN NN O
epsilon4 NN NN O
allele NN NN O
only NN NN O
. NN NN O
   
However NN NN O
, NN NN O
no NN NN O
significant NN NN O
effects NN NN O
were NN NN O
found NN NN O
with NN NN O
other NN NN O
visual NN NN O
analog NN NN O
scales NN NN O
reflecting NN NN O
subjective NN NN O
sedation NN NN O
and NN NN O
clear NN NN O
- NN NN O
headedness NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
epsilon4 NN NN O
allele NN NN O
in NN NN O
healthy NN NN O
elderly NN NN O
was NN NN O
associated NN NN O
with NN NN O
increased NN NN O
subjective NN NN O
mental NN NN B-Disease
slowing NN NN I-Disease
after NN NN O
trihexyphenidyl NN NN O
anticholinergic NN NN O
challenge NN NN O
. NN NN O
   
An NN NN O
evaluation NN NN O
of NN NN O
amikacin NN NN O
nephrotoxicity NN NN B-Disease
in NN NN O
the NN NN O
hematology NN NN O
/ NN NN O
oncology NN NN O
population NN NN O
. NN NN O
   
Amikacin NN NN O
is NN NN O
an NN NN O
aminoglycoside NN NN O
commonly NN NN O
used NN NN O
to NN NN O
provide NN NN O
empirical NN NN O
double NN NN O
gram NN NN O
- NN NN O
negative NN NN O
treatment NN NN O
for NN NN O
febrile NN NN B-Disease
neutropenia NN NN I-Disease
and NN NN O
other NN NN O
suspected NN NN O
infections NN NN B-Disease
. NN NN O
   
Strategies NN NN O
of NN NN O
extended NN NN O
- NN NN O
interval NN NN O
and NN NN O
conventional NN NN O
dosing NN NN O
have NN NN O
been NN NN O
utilized NN NN O
extensively NN NN O
in NN NN O
the NN NN O
general NN NN O
medical NN NN O
population NN NN O
; NN NN O
however NN NN O
, NN NN O
data NN NN O
are NN NN O
lacking NN NN O
to NN NN O
support NN NN O
a NN NN O
dosing NN NN O
strategy NN NN O
in NN NN O
the NN NN O
hematology NN NN O
/ NN NN O
oncology NN NN O
population NN NN O
. NN NN O
   
To NN NN O
evaluate NN NN O
amikacin NN NN O
- NN NN O
associated NN NN O
nephrotoxicity NN NN B-Disease
in NN NN O
an NN NN O
adult NN NN O
hematology NN NN O
/ NN NN O
oncology NN NN O
population NN NN O
, NN NN O
a NN NN O
prospective NN NN O
, NN NN O
randomized NN NN O
, NN NN O
open NN NN O
- NN NN O
label NN NN O
trial NN NN O
was NN NN O
conducted NN NN O
at NN NN O
a NN NN O
university NN NN O
- NN NN O
affiliated NN NN O
medical NN NN O
center NN NN O
. NN NN O
   
Forty NN NN O
patients NN NN O
with NN NN O
a NN NN O
diagnosis NN NN O
consistent NN NN O
with NN NN O
a NN NN O
hematologic NN NN B-Disease
/ NN NN I-Disease
oncologic NN NN I-Disease
disorder NN NN I-Disease
that NN NN O
required NN NN O
treatment NN NN O
with NN NN O
an NN NN O
aminoglycoside NN NN O
were NN NN O
randomized NN NN O
to NN NN O
either NN NN O
conventional NN NN O
or NN NN O
extended NN NN O
- NN NN O
interval NN NN O
amikacin NN NN O
. NN NN O
   
The NN NN O
occurrence NN NN O
of NN NN O
nephrotoxicity NN NN B-Disease
by NN NN O
means NN NN O
of NN NN O
an NN NN O
increase NN NN O
in NN NN O
serum NN NN O
creatinine NN NN O
and NN NN O
evaluation NN NN O
of NN NN O
efficacy NN NN O
via NN NN O
amikacin NN NN O
serum NN NN O
concentrations NN NN O
with NN NN O
respective NN NN O
pathogens NN NN O
were NN NN O
assessed NN NN O
. NN NN O
   
The NN NN O
occurrence NN NN O
of NN NN O
nephrotoxicity NN NN B-Disease
was NN NN O
similar NN NN O
between NN NN O
the NN NN O
conventional NN NN O
and NN NN O
extended NN NN O
- NN NN O
interval NN NN O
groups NN NN O
, NN NN O
at NN NN O
10 NN NN O
% NN NN O
and NN NN O
5 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
( NN NN O
P NN NN O
= NN NN O
1 NN NN O
. NN NN O
00 NN NN O
) NN NN O
. NN NN O
   
Six NN NN O
patients NN NN O
in NN NN O
the NN NN O
conventional NN NN O
group NN NN O
had NN NN O
a NN NN O
positive NN NN O
culture NN NN O
, NN NN O
compared NN NN O
with NN NN O
none NN NN O
in NN NN O
the NN NN O
extended NN NN O
- NN NN O
interval NN NN O
group NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
002 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
occurrence NN NN O
of NN NN O
nephrotoxicity NN NN B-Disease
was NN NN O
similar NN NN O
between NN NN O
the NN NN O
two NN NN O
dosing NN NN O
regimens NN NN O
, NN NN O
but NN NN O
the NN NN O
distribution NN NN O
of NN NN O
risk NN NN O
factors NN NN O
was NN NN O
variable NN NN O
between NN NN O
the NN NN O
two NN NN O
groups NN NN O
. NN NN O
   
Efficacy NN NN O
could NN NN O
not NN NN O
be NN NN O
assessed NN NN O
. NN NN O
   
High NN NN O
dose NN NN O
dexmedetomidine NN NN O
as NN NN O
the NN NN O
sole NN NN O
sedative NN NN O
for NN NN O
pediatric NN NN O
MRI NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
This NN NN O
large NN NN O
- NN NN O
scale NN NN O
retrospective NN NN O
review NN NN O
evaluates NN NN O
the NN NN O
sedation NN NN O
profile NN NN O
of NN NN O
dexmedetomidine NN NN O
. NN NN O
   
AIM NN NN O
: NN NN O
To NN NN O
determine NN NN O
the NN NN O
hemodynamic NN NN O
responses NN NN O
, NN NN O
efficacy NN NN O
and NN NN O
adverse NN NN O
events NN NN O
associated NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
high NN NN O
dose NN NN O
dexmedetomidine NN NN O
as NN NN O
the NN NN O
sole NN NN O
sedative NN NN O
for NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
( NN NN O
MRI NN NN O
) NN NN O
studies NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Dexmedetomidine NN NN O
has NN NN O
been NN NN O
used NN NN O
at NN NN O
our NN NN O
institution NN NN O
since NN NN O
2005 NN NN O
to NN NN O
provide NN NN O
sedation NN NN O
for NN NN O
pediatric NN NN O
radiological NN NN O
imaging NN NN O
studies NN NN O
. NN NN O
   
Over NN NN O
time NN NN O
, NN NN O
an NN NN O
effective NN NN O
protocol NN NN O
utilizing NN NN O
high NN NN O
dose NN NN O
dexmedetomidine NN NN O
as NN NN O
the NN NN O
sole NN NN O
sedative NN NN O
agent NN NN O
has NN NN O
evolved NN NN O
. NN NN O
   
METHODS NN NN O
/ NN NN O
MATERIALS NN NN O
: NN NN O
As NN NN O
part NN NN O
of NN NN O
the NN NN O
ongoing NN NN O
Quality NN NN O
Assurance NN NN O
process NN NN O
, NN NN O
data NN NN O
on NN NN O
all NN NN O
sedations NN NN O
are NN NN O
reviewed NN NN O
monthly NN NN O
and NN NN O
protocols NN NN O
modified NN NN O
as NN NN O
needed NN NN O
. NN NN O
   
Data NN NN O
were NN NN O
analyzed NN NN O
from NN NN O
all NN NN O
747 NN NN O
consecutive NN NN O
patients NN NN O
who NN NN O
received NN NN O
dexmedetomidine NN NN O
for NN NN O
MRI NN NN O
sedation NN NN O
from NN NN O
April NN NN O
2005 NN NN O
to NN NN O
April NN NN O
2007 NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Since NN NN O
2005 NN NN O
, NN NN O
the NN NN O
10 NN NN O
- NN NN O
min NN NN O
loading NN NN O
dose NN NN O
of NN NN O
our NN NN O
dexmedetomidine NN NN O
protocol NN NN O
increased NN NN O
from NN NN O
2 NN NN O
to NN NN O
3 NN NN O
microg NN NN O
. NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
and NN NN O
the NN NN O
infusion NN NN O
rate NN NN O
increased NN NN O
from NN NN O
1 NN NN O
to NN NN O
1 NN NN O
. NN NN O
5 NN NN O
to NN NN O
2 NN NN O
microg NN NN O
. NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
h NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
current NN NN O
sedation NN NN O
protocol NN NN O
progressively NN NN O
increased NN NN O
the NN NN O
rate NN NN O
of NN NN O
successful NN NN O
sedation NN NN O
( NN NN O
able NN NN O
to NN NN O
complete NN NN O
the NN NN O
imaging NN NN O
study NN NN O
) NN NN O
when NN NN O
using NN NN O
dexmedetomidine NN NN O
alone NN NN O
from NN NN O
91 NN NN O
. NN NN O
8 NN NN O
% NN NN O
to NN NN O
97 NN NN O
. NN NN O
6 NN NN O
% NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
009 NN NN O
) NN NN O
, NN NN O
reducing NN NN O
the NN NN O
requirement NN NN O
for NN NN O
adjuvant NN NN O
pentobarbital NN NN O
in NN NN O
the NN NN O
event NN NN O
of NN NN O
sedation NN NN O
failure NN NN O
with NN NN O
dexmedetomidine NN NN O
alone NN NN O
and NN NN O
decreased NN NN O
the NN NN O
mean NN NN O
recovery NN NN O
time NN NN O
by NN NN O
10 NN NN O
min NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Although NN NN O
dexmedetomidine NN NN O
sedation NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
16 NN NN O
% NN NN O
incidence NN NN O
of NN NN O
bradycardia NN NN B-Disease
, NN NN O
all NN NN O
concomitant NN NN O
mean NN NN O
arterial NN NN O
blood NN NN O
pressures NN NN O
were NN NN O
within NN NN O
20 NN NN O
% NN NN O
of NN NN O
age NN NN O
- NN NN O
adjusted NN NN O
normal NN NN O
range NN NN O
and NN NN O
oxygen NN NN O
saturations NN NN O
were NN NN O
95 NN NN O
% NN NN O
or NN NN O
higher NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Dexmedetomidine NN NN O
in NN NN O
high NN NN O
doses NN NN O
provides NN NN O
adequate NN NN O
sedation NN NN O
for NN NN O
pediatric NN NN O
MRI NN NN O
studies NN NN O
. NN NN O
   
While NN NN O
use NN NN O
of NN NN O
high NN NN O
dose NN NN O
dexmedetomidine NN NN O
is NN NN O
associated NN NN O
with NN NN O
decreases NN NN O
in NN NN O
heart NN NN O
rate NN NN O
and NN NN O
blood NN NN O
pressure NN NN O
outside NN NN O
the NN NN O
established NN NN O
' NN NN O
awake NN NN O
' NN NN O
norms NN NN O
, NN NN O
this NN NN O
deviation NN NN O
is NN NN O
generally NN NN O
within NN NN O
20 NN NN O
% NN NN O
of NN NN O
norms NN NN O
, NN NN O
and NN NN O
is NN NN O
not NN NN O
associated NN NN O
with NN NN O
adverse NN NN O
sequelae NN NN O
. NN NN O
   
Dexmedetomidine NN NN O
is NN NN O
useful NN NN O
as NN NN O
the NN NN O
sole NN NN O
sedative NN NN O
for NN NN O
pediatric NN NN O
MRI NN NN O
. NN NN O
   
Hepatotoxicity NN NN B-Disease
associated NN NN O
with NN NN O
sulfasalazine NN NN O
in NN NN O
inflammatory NN NN O
arthritis NN NN B-Disease
: NN NN O
A NN NN O
case NN NN O
series NN NN O
from NN NN O
a NN NN O
local NN NN O
surveillance NN NN O
of NN NN O
serious NN NN O
adverse NN NN O
events NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Spontaneous NN NN O
reporting NN NN O
systems NN NN O
for NN NN O
adverse NN NN O
drug NN NN O
reactions NN NN O
( NN NN O
ADRs NN NN O
) NN NN O
are NN NN O
handicapped NN NN O
by NN NN O
under NN NN O
- NN NN O
reporting NN NN O
and NN NN O
limited NN NN O
detail NN NN O
on NN NN O
individual NN NN O
cases NN NN O
. NN NN O
   
We NN NN O
report NN NN O
an NN NN O
investigation NN NN O
from NN NN O
a NN NN O
local NN NN O
surveillance NN NN O
for NN NN O
serious NN NN O
adverse NN NN O
drug NN NN O
reactions NN NN O
associated NN NN O
with NN NN O
disease NN NN O
modifying NN NN O
anti NN NN O
- NN NN O
rheumatic NN NN O
drugs NN NN O
that NN NN O
was NN NN O
triggered NN NN O
by NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
liver NN NN B-Disease
failure NN NN I-Disease
in NN NN O
two NN NN O
of NN NN O
our NN NN O
patients NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Serious NN NN O
ADR NN NN O
reports NN NN O
have NN NN O
been NN NN O
solicited NN NN O
from NN NN O
local NN NN O
clinicians NN NN O
by NN NN O
regular NN NN O
postcards NN NN O
over NN NN O
the NN NN O
past NN NN O
seven NN NN O
years NN NN O
. NN NN O
   
Patients NN NN O
' NN NN O
, NN NN O
who NN NN O
had NN NN O
hepatotoxicity NN NN B-Disease
on NN NN O
sulfasalazine NN NN O
and NN NN O
met NN NN O
a NN NN O
definition NN NN O
of NN NN O
a NN NN O
serious NN NN O
ADR NN NN O
, NN NN O
were NN NN O
identified NN NN O
. NN NN O
   
Two NN NN O
clinicians NN NN O
reviewed NN NN O
structured NN NN O
case NN NN O
reports NN NN O
and NN NN O
assessed NN NN O
causality NN NN O
by NN NN O
consensus NN NN O
and NN NN O
by NN NN O
using NN NN O
a NN NN O
causality NN NN O
assessment NN NN O
instrument NN NN O
. NN NN O
   
The NN NN O
likely NN NN O
frequency NN NN O
of NN NN O
hepatotoxicity NN NN B-Disease
with NN NN O
sulfasalazine NN NN O
was NN NN O
estimated NN NN O
by NN NN O
making NN NN O
a NN NN O
series NN NN O
of NN NN O
conservative NN NN O
assumptions NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Ten NN NN O
cases NN NN O
were NN NN O
identified NN NN O
: NN NN O
eight NN NN O
occurred NN NN O
during NN NN O
surveillance NN NN O
. NN NN O
   
Eight NN NN O
patients NN NN O
were NN NN O
hospitalised NN NN O
, NN NN O
two NN NN O
in NN NN O
hepatic NN NN B-Disease
failure NN NN I-Disease
- NN NN O
one NN NN O
died NN NN O
after NN NN O
a NN NN O
liver NN NN O
transplant NN NN O
. NN NN O
   
All NN NN O
but NN NN O
one NN NN O
event NN NN O
occurred NN NN O
within NN NN O
6 NN NN O
weeks NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
Seven NN NN O
patients NN NN O
had NN NN O
a NN NN O
skin NN NN B-Disease
rash NN NN I-Disease
, NN NN O
three NN NN O
eosinophilia NN NN B-Disease
and NN NN O
one NN NN O
interstitial NN NN B-Disease
nephritis NN NN I-Disease
. NN NN O
   
Five NN NN O
patients NN NN O
were NN NN O
of NN NN O
Black NN NN O
British NN NN O
of NN NN O
African NN NN O
or NN NN O
Caribbean NN NN O
descent NN NN O
. NN NN O
   
Liver NN NN O
enzymes NN NN O
showed NN NN O
a NN NN O
hepatocellular NN NN O
pattern NN NN O
in NN NN O
four NN NN O
cases NN NN O
and NN NN O
a NN NN O
mixed NN NN O
pattern NN NN O
in NN NN O
six NN NN O
. NN NN O
   
Drug NN NN O
- NN NN O
related NN NN O
hepatotoxicity NN NN B-Disease
was NN NN O
judged NN NN O
probable NN NN O
or NN NN O
highly NN NN O
probable NN NN O
in NN NN O
8 NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
likely NN NN O
frequency NN NN O
of NN NN O
serious NN NN O
hepatotoxicity NN NN B-Disease
with NN NN O
sulfasalazine NN NN O
was NN NN O
estimated NN NN O
at NN NN O
0 NN NN O
. NN NN O
4 NN NN O
% NN NN O
of NN NN O
treated NN NN O
patients NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Serious NN NN O
hepatotoxicity NN NN B-Disease
associated NN NN O
with NN NN O
sulfasalazine NN NN O
appears NN NN O
to NN NN O
be NN NN O
under NN NN O
- NN NN O
appreciated NN NN O
and NN NN O
intensive NN NN O
monitoring NN NN O
and NN NN O
vigilance NN NN O
in NN NN O
the NN NN O
first NN NN O
6 NN NN O
weeks NN NN O
of NN NN O
treatment NN NN O
is NN NN O
especially NN NN O
important NN NN O
. NN NN O
   
Complete NN NN O
atrioventricular NN NN B-Disease
block NN NN I-Disease
secondary NN NN O
to NN NN O
lithium NN NN O
therapy NN NN O
. NN NN O
   
Sinus NN NN B-Disease
node NN NN I-Disease
dysfunction NN NN I-Disease
has NN NN O
been NN NN O
reported NN NN O
most NN NN O
frequently NN NN O
among NN NN O
the NN NN O
adverse NN NN O
cardiovascular NN NN O
effects NN NN O
of NN NN O
lithium NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
case NN NN O
, NN NN O
complete NN NN O
atrioventricular NN NN B-Disease
( NN NN I-Disease
AV NN NN I-Disease
) NN NN I-Disease
block NN NN I-Disease
with NN NN O
syncopal NN NN B-Disease
attacks NN NN I-Disease
developed NN NN O
secondary NN NN O
to NN NN O
lithium NN NN O
therapy NN NN O
, NN NN O
necessitating NN NN O
permanent NN NN O
pacemaker NN NN O
implantation NN NN O
. NN NN O
   
Serum NN NN O
lithium NN NN O
levels NN NN O
remained NN NN O
under NN NN O
or NN NN O
within NN NN O
the NN NN O
therapeutic NN NN O
range NN NN O
during NN NN O
the NN NN O
syncopal NN NN B-Disease
attacks NN NN I-Disease
. NN NN O
   
Lithium NN NN O
should NN NN O
be NN NN O
used NN NN O
with NN NN O
extreme NN NN O
caution NN NN O
, NN NN O
especially NN NN O
in NN NN O
patients NN NN O
with NN NN O
mild NN NN O
disturbance NN NN O
of NN NN O
AV NN NN O
conduction NN NN O
. NN NN O
   
Exaggerated NN NN O
expression NN NN O
of NN NN O
inflammatory NN NN O
mediators NN NN O
in NN NN O
vasoactive NN NN O
intestinal NN NN O
polypeptide NN NN O
knockout NN NN O
( NN NN O
VIP NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
with NN NN O
cyclophosphamide NN NN O
( NN NN O
CYP NN NN O
) NN NN O
- NN NN O
induced NN NN O
cystitis NN NN B-Disease
. NN NN O
   
Vasoactive NN NN O
intestinal NN NN O
polypeptide NN NN O
( NN NN O
VIP NN NN O
) NN NN O
is NN NN O
an NN NN O
immunomodulatory NN NN O
neuropeptide NN NN O
distributed NN NN O
in NN NN O
micturition NN NN O
pathways NN NN O
. NN NN O
   
VIP NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
exhibit NN NN O
altered NN NN O
bladder NN NN O
function NN NN O
and NN NN O
neurochemical NN NN O
properties NN NN O
in NN NN O
micturition NN NN O
pathways NN NN O
after NN NN O
cyclophosphamide NN NN O
( NN NN O
CYP NN NN O
) NN NN O
- NN NN O
induced NN NN O
cystitis NN NN B-Disease
. NN NN O
   
Given NN NN O
VIP NN NN O
' NN NN O
s NN NN O
role NN NN O
as NN NN O
an NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
mediator NN NN O
, NN NN O
we NN NN O
hypothesized NN NN O
that NN NN O
VIP NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
would NN NN O
exhibit NN NN O
enhanced NN NN O
inflammatory NN NN O
mediator NN NN O
expression NN NN O
after NN NN O
cystitis NN NN B-Disease
. NN NN O
   
A NN NN O
mouse NN NN O
inflammatory NN NN O
cytokine NN NN O
and NN NN O
receptor NN NN O
RT2 NN NN O
profiler NN NN O
array NN NN O
was NN NN O
used NN NN O
to NN NN O
determine NN NN O
regulated NN NN O
transcripts NN NN O
in NN NN O
the NN NN O
urinary NN NN O
bladder NN NN O
of NN NN O
wild NN NN O
type NN NN O
( NN NN O
WT NN NN O
) NN NN O
and NN NN O
VIP NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
with NN NN O
or NN NN O
without NN NN O
CYP NN NN O
- NN NN O
induced NN NN O
cystitis NN NN B-Disease
( NN NN O
150 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
; NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
; NN NN O
48 NN NN O
h NN NN O
) NN NN O
. NN NN O
   
Four NN NN O
binary NN NN O
comparisons NN NN O
were NN NN O
made NN NN O
: NN NN O
WT NN NN O
control NN NN O
versus NN NN O
CYP NN NN O
treatment NN NN O
( NN NN O
48 NN NN O
h NN NN O
) NN NN O
, NN NN O
VIP NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
control NN NN O
versus NN NN O
CYP NN NN O
treatment NN NN O
( NN NN O
48 NN NN O
h NN NN O
) NN NN O
, NN NN O
WT NN NN O
control NN NN O
versus NN NN O
VIP NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
control NN NN O
, NN NN O
and NN NN O
WT NN NN O
with NN NN O
CYP NN NN O
treatment NN NN O
( NN NN O
48 NN NN O
h NN NN O
) NN NN O
versus NN NN O
VIP NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
with NN NN O
CYP NN NN O
treatment NN NN O
( NN NN O
48 NN NN O
h NN NN O
) NN NN O
. NN NN O
   
The NN NN O
genes NN NN O
presented NN NN O
represent NN NN O
( NN NN O
1 NN NN O
) NN NN O
greater NN NN O
than NN NN O
1 NN NN O
. NN NN O
5 NN NN O
- NN NN O
fold NN NN O
change NN NN O
in NN NN O
either NN NN O
direction NN NN O
and NN NN O
( NN NN O
2 NN NN O
) NN NN O
the NN NN O
p NN NN O
value NN NN O
is NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
for NN NN O
the NN NN O
comparison NN NN O
being NN NN O
made NN NN O
. NN NN O
   
Several NN NN O
regulated NN NN O
genes NN NN O
were NN NN O
validated NN NN O
using NN NN O
enzyme NN NN O
- NN NN O
linked NN NN O
immunoassays NN NN O
including NN NN O
IL NN NN O
- NN NN O
1beta NN NN O
and NN NN O
CXCL1 NN NN O
. NN NN O
   
CYP NN NN O
treatment NN NN O
significantly NN NN O
( NN NN O
p NN NN O
< NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
increased NN NN O
expression NN NN O
of NN NN O
CXCL1 NN NN O
and NN NN O
IL NN NN O
- NN NN O
1beta NN NN O
in NN NN O
the NN NN O
urinary NN NN O
bladder NN NN O
of NN NN O
WT NN NN O
and NN NN O
VIP NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
, NN NN O
but NN NN O
expression NN NN O
in NN NN O
VIP NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
with NN NN O
CYP NN NN O
treatment NN NN O
was NN NN O
significantly NN NN O
( NN NN O
p NN NN O
< NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
greater NN NN O
( NN NN O
4 NN NN O
. NN NN O
2 NN NN O
- NN NN O
to NN NN O
13 NN NN O
- NN NN O
fold NN NN O
increase NN NN O
) NN NN O
than NN NN O
that NN NN O
observed NN NN O
in NN NN O
WT NN NN O
urinary NN NN O
bladder NN NN O
( NN NN O
3 NN NN O
. NN NN O
6 NN NN O
- NN NN O
to NN NN O
5 NN NN O
- NN NN O
fold NN NN O
increase NN NN O
) NN NN O
. NN NN O
   
The NN NN O
data NN NN O
suggest NN NN O
that NN NN O
in NN NN O
VIP NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
with NN NN O
bladder NN NN B-Disease
inflammation NN NN I-Disease
, NN NN O
inflammatory NN NN O
mediators NN NN O
are NN NN O
increased NN NN O
above NN NN O
that NN NN O
observed NN NN O
in NN NN O
WT NN NN O
with NN NN O
CYP NN NN O
. NN NN O
   
This NN NN O
shift NN NN O
in NN NN O
balance NN NN O
may NN NN O
contribute NN NN O
to NN NN O
increased NN NN O
bladder NN NN B-Disease
dysfunction NN NN I-Disease
in NN NN O
VIP NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
with NN NN O
bladder NN NN B-Disease
inflammation NN NN I-Disease
and NN NN O
altered NN NN O
neurochemical NN NN O
expression NN NN O
in NN NN O
micturition NN NN O
pathways NN NN O
. NN NN O
   
Debrisoquine NN NN O
phenotype NN NN O
and NN NN O
the NN NN O
pharmacokinetics NN NN O
and NN NN O
beta NN NN O
- NN NN O
2 NN NN O
receptor NN NN O
pharmacodynamics NN NN O
of NN NN O
metoprolol NN NN O
and NN NN O
its NN NN O
enantiomers NN NN O
. NN NN O
   
The NN NN O
metabolism NN NN O
of NN NN O
the NN NN O
cardioselective NN NN O
beta NN NN O
- NN NN O
blocker NN NN O
metoprolol NN NN O
is NN NN O
under NN NN O
genetic NN NN O
control NN NN O
of NN NN O
the NN NN O
debrisoquine NN NN O
/ NN NN O
sparteine NN NN O
type NN NN O
. NN NN O
   
The NN NN O
two NN NN O
metabolic NN NN O
phenotypes NN NN O
, NN NN O
extensive NN NN O
( NN NN O
EM NN NN O
) NN NN O
and NN NN O
poor NN NN O
metabolizers NN NN O
( NN NN O
PM NN NN O
) NN NN O
, NN NN O
show NN NN O
different NN NN O
stereoselective NN NN O
metabolism NN NN O
, NN NN O
resulting NN NN O
in NN NN O
apparently NN NN O
higher NN NN O
beta NN NN O
- NN NN O
1 NN NN O
adrenoceptor NN NN O
antagonistic NN NN O
potency NN NN O
of NN NN O
racemic NN NN O
metoprolol NN NN O
in NN NN O
EMs NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
if NN NN O
the NN NN O
latter NN NN O
also NN NN O
applies NN NN O
to NN NN O
the NN NN O
beta NN NN O
- NN NN O
2 NN NN O
adrenoceptor NN NN O
antagonism NN NN O
by NN NN O
metoprolol NN NN O
. NN NN O
   
The NN NN O
drug NN NN O
effect NN NN O
studied NN NN O
was NN NN O
the NN NN O
antagonism NN NN O
by NN NN O
metoprolol NN NN O
of NN NN O
terbutaline NN NN O
- NN NN O
induced NN NN O
hypokalemia NN NN B-Disease
. NN NN O
   
By NN NN O
using NN NN O
pharmacokinetic NN NN O
pharmacodynamic NN NN O
modeling NN NN O
the NN NN O
pharmacodynamics NN NN O
of NN NN O
racemic NN NN O
metoprolol NN NN O
and NN NN O
the NN NN O
active NN NN O
S NN NN O
- NN NN O
isomer NN NN O
, NN NN O
were NN NN O
quantitated NN NN O
in NN NN O
EMs NN NN O
and NN NN O
PMs NN NN O
in NN NN O
terms NN NN O
of NN NN O
IC50 NN NN O
values NN NN O
, NN NN O
representing NN NN O
metoprolol NN NN O
plasma NN NN O
concentrations NN NN O
resulting NN NN O
in NN NN O
half NN NN O
- NN NN O
maximum NN NN O
receptor NN NN O
occupancy NN NN O
. NN NN O
   
Six NN NN O
EMs NN NN O
received NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
of NN NN O
terbutaline NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
on NN NN O
two NN NN O
different NN NN O
occasions NN NN O
: NN NN O
1 NN NN O
) NN NN O
1 NN NN O
hr NN NN O
after NN NN O
administration NN NN O
of NN NN O
a NN NN O
placebo NN NN O
and NN NN O
2 NN NN O
) NN NN O
1 NN NN O
hr NN NN O
after NN NN O
150 NN NN O
mg NN NN O
of NN NN O
metoprolol NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
   
Five NN NN O
PMs NN NN O
were NN NN O
studied NN NN O
according NN NN O
to NN NN O
the NN NN O
same NN NN O
protocol NN NN O
, NN NN O
except NN NN O
for NN NN O
a NN NN O
higher NN NN O
terbutaline NN NN O
dose NN NN O
( NN NN O
0 NN NN O
. NN NN O
75 NN NN O
mg NN NN O
) NN NN O
on NN NN O
day NN NN O
2 NN NN O
. NN NN O
   
Blood NN NN O
samples NN NN O
for NN NN O
the NN NN O
analysis NN NN O
of NN NN O
plasma NN NN O
potassium NN NN O
, NN NN O
terbutaline NN NN O
, NN NN O
metoprolol NN NN O
( NN NN O
racemic NN NN O
, NN NN O
R NN NN O
- NN NN O
and NN NN O
S NN NN O
- NN NN O
isomer NN NN O
) NN NN O
, NN NN O
and NN NN O
alpha NN NN O
- NN NN O
hydroxymetoprolol NN NN O
concentrations NN NN O
were NN NN O
taken NN NN O
at NN NN O
regular NN NN O
time NN NN O
intervals NN NN O
, NN NN O
during NN NN O
8 NN NN O
hr NN NN O
after NN NN O
metoprolol NN NN O
. NN NN O
   
In NN NN O
PMs NN NN O
, NN NN O
metoprolol NN NN O
increased NN NN O
the NN NN O
terbutaline NN NN O
area NN NN O
under NN NN O
the NN NN O
plasma NN NN O
concentration NN NN O
vs NN NN O
. NN NN O
time NN NN O
curve NN NN O
( NN NN O
+ NN NN O
67 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Higher NN NN O
metoprolol NN NN O
/ NN NN O
alpha NN NN O
- NN NN O
hydroxymetoprolol NN NN O
ratios NN NN O
in NN NN O
PMs NN NN O
were NN NN O
predictive NN NN O
for NN NN O
higher NN NN O
R NN NN O
- NN NN O
/ NN NN O
S NN NN O
- NN NN O
isomer NN NN O
ratios NN NN O
of NN NN O
unchanged NN NN O
drug NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
difference NN NN O
in NN NN O
metoprolol NN NN O
potency NN NN O
with NN NN O
higher NN NN O
racemic NN NN O
metoprolol NN NN O
IC50 NN NN O
values NN NN O
in NN NN O
PMs NN NN O
( NN NN O
72 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
ng NN NN O
. NN NN O
ml NN NN O
- NN NN O
1 NN NN O
) NN NN O
than NN NN O
EMs NN NN O
( NN NN O
42 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
8 NN NN O
ng NN NN O
. NN NN O
ml NN NN O
- NN NN O
1 NN NN O
, NN NN O
P NN NN O
less NN NN O
than NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
The NN NN O
hemodynamics NN NN O
of NN NN O
oxytocin NN NN O
and NN NN O
other NN NN O
vasoactive NN NN O
agents NN NN O
during NN NN O
neuraxial NN NN O
anesthesia NN NN O
for NN NN O
cesarean NN NN O
delivery NN NN O
: NN NN O
findings NN NN O
in NN NN O
six NN NN O
cases NN NN O
. NN NN O
   
Oxytocin NN NN O
is NN NN O
a NN NN O
commonly NN NN O
used NN NN O
uterotonic NN NN O
that NN NN O
can NN NN O
cause NN NN O
significant NN NN O
and NN NN O
even NN NN O
fatal NN NN O
hypotension NN NN B-Disease
, NN NN O
particularly NN NN O
when NN NN O
given NN NN O
as NN NN O
a NN NN O
bolus NN NN O
. NN NN O
   
The NN NN O
resulting NN NN O
hypotension NN NN B-Disease
can NN NN O
be NN NN O
produced NN NN O
by NN NN O
a NN NN O
decrease NN NN O
in NN NN O
systemic NN NN O
vascular NN NN O
resistance NN NN O
or NN NN O
cardiac NN NN O
output NN NN O
through NN NN O
a NN NN O
decrease NN NN O
in NN NN O
venous NN NN O
return NN NN O
. NN NN O
   
Parturients NN NN O
with NN NN O
normal NN NN O
volume NN NN O
status NN NN O
, NN NN O
heart NN NN O
valves NN NN O
and NN NN O
pulmonary NN NN O
vasculature NN NN O
most NN NN O
often NN NN O
respond NN NN O
to NN NN O
this NN NN O
hypotension NN NN B-Disease
with NN NN O
a NN NN O
compensatory NN NN O
increase NN NN O
in NN NN O
heart NN NN O
rate NN NN O
and NN NN O
stroke NN NN B-Disease
volume NN NN O
. NN NN O
   
Oxytocin NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
at NN NN O
cesarean NN NN O
delivery NN NN O
may NN NN O
be NN NN O
incorrectly NN NN O
attributed NN NN O
to NN NN O
blood NN NN B-Disease
loss NN NN I-Disease
. NN NN O
   
Pulse NN NN O
power NN NN O
analysis NN NN O
( NN NN O
also NN NN O
called NN NN O
"""""""" NN NN O
pulse NN NN O
contour NN NN O
analysis NN NN O
"""""""" NN NN O
) NN NN O
of NN NN O
an NN NN O
arterial NN NN O
pressure NN NN O
wave NN NN O
form NN NN O
allows NN NN O
continuous NN NN O
evaluation NN NN O
of NN NN O
systemic NN NN O
vascular NN NN O
resistance NN NN O
and NN NN O
cardiac NN NN O
output NN NN O
in NN NN O
real NN NN O
time NN NN O
, NN NN O
thereby NN NN O
elucidating NN NN O
the NN NN O
causative NN NN O
factors NN NN O
behind NN NN O
changes NN NN O
in NN NN O
blood NN NN O
pressure NN NN O
. NN NN O
   
Pulse NN NN O
power NN NN O
analysis NN NN O
was NN NN O
conducted NN NN O
in NN NN O
six NN NN O
cases NN NN O
of NN NN O
cesarean NN NN O
delivery NN NN O
performed NN NN O
under NN NN O
neuraxial NN NN O
anesthesia NN NN O
. NN NN O
   
Hypotension NN NN B-Disease
in NN NN O
response NN NN O
to NN NN O
oxytocin NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
decrease NN NN O
in NN NN O
systemic NN NN O
vascular NN NN O
resistance NN NN O
and NN NN O
a NN NN O
compensatory NN NN O
increase NN NN O
in NN NN O
stroke NN NN B-Disease
volume NN NN O
, NN NN O
heart NN NN O
rate NN NN O
and NN NN O
cardiac NN NN O
output NN NN O
. NN NN O
   
Pulse NN NN O
power NN NN O
analysis NN NN O
may NN NN O
be NN NN O
helpful NN NN O
in NN NN O
determining NN NN O
the NN NN O
etiology NN NN O
of NN NN O
and NN NN O
treating NN NN O
hypotension NN NN B-Disease
during NN NN O
cesarean NN NN O
delivery NN NN O
under NN NN O
neuraxial NN NN O
anesthesia NN NN O
. NN NN O
   
Protective NN NN O
effects NN NN O
of NN NN O
antithrombin NN NN O
on NN NN O
puromycin NN NN O
aminonucleoside NN NN O
nephrosis NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
antithrombin NN NN O
, NN NN O
a NN NN O
plasma NN NN O
inhibitor NN NN O
of NN NN O
coagulation NN NN O
factors NN NN O
, NN NN O
in NN NN O
rats NN NN O
with NN NN O
puromycin NN NN O
aminonucleoside NN NN O
- NN NN O
induced NN NN O
nephrosis NN NN B-Disease
, NN NN O
which NN NN O
is NN NN O
an NN NN O
experimental NN NN O
model NN NN O
of NN NN O
human NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
Antithrombin NN NN O
( NN NN O
50 NN NN O
or NN NN O
500 NN NN O
IU NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
was NN NN O
administered NN NN O
to NN NN O
rats NN NN O
once NN NN O
a NN NN O
day NN NN O
for NN NN O
10 NN NN O
days NN NN O
immediately NN NN O
after NN NN O
the NN NN O
injection NN NN O
of NN NN O
puromycin NN NN O
aminonucleoside NN NN O
( NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
antithrombin NN NN O
attenuated NN NN O
the NN NN O
puromycin NN NN O
aminonucleoside NN NN O
- NN NN O
induced NN NN O
hematological NN NN B-Disease
abnormalities NN NN I-Disease
. NN NN O
   
Puromycin NN NN O
aminonucleoside NN NN O
- NN NN O
induced NN NN O
renal NN NN B-Disease
dysfunction NN NN I-Disease
and NN NN O
hyperlipidemia NN NN B-Disease
were NN NN O
also NN NN O
suppressed NN NN O
. NN NN O
   
Histopathological NN NN O
examination NN NN O
revealed NN NN O
severe NN NN O
renal NN NN B-Disease
damage NN NN I-Disease
such NN NN O
as NN NN O
proteinaceous NN NN O
casts NN NN O
in NN NN O
tubuli NN NN O
and NN NN O
tubular NN NN O
expansion NN NN O
in NN NN O
the NN NN O
kidney NN NN O
of NN NN O
control NN NN O
rats NN NN O
, NN NN O
while NN NN O
an NN NN O
improvement NN NN O
of NN NN O
the NN NN O
damage NN NN O
was NN NN O
seen NN NN O
in NN NN O
antithrombin NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
antithrombin NN NN O
treatment NN NN O
markedly NN NN O
suppressed NN NN O
puromycin NN NN O
aminonucleoside NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
of NN NN O
renal NN NN O
tubular NN NN O
epithelial NN NN O
cells NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
puromycin NN NN O
aminonucleoside NN NN O
- NN NN O
induced NN NN O
increases NN NN O
in NN NN O
renal NN NN O
cytokine NN NN O
content NN NN O
were NN NN O
also NN NN O
decreased NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
thrombin NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
puromycin NN NN O
aminonucleoside NN NN O
- NN NN O
induced NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
Treatment NN NN O
with NN NN O
antithrombin NN NN O
may NN NN O
be NN NN O
clinically NN NN O
effective NN NN O
in NN NN O
patients NN NN O
with NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
Heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
after NN NN O
liver NN NN O
transplantation NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Unfractionated NN NN O
heparin NN NN O
sodium NN NN O
( NN NN O
UFH NN NN O
) NN NN O
or NN NN O
low NN NN O
- NN NN O
molecular NN NN O
weight NN NN O
heparin NN NN O
( NN NN O
LMWH NN NN O
) NN NN O
is NN NN O
used NN NN O
in NN NN O
anticoagulant NN NN O
protocols NN NN O
at NN NN O
several NN NN O
institutions NN NN O
to NN NN O
prevent NN NN O
thrombosis NN NN B-Disease
after NN NN O
liver NN NN O
transplantation NN NN O
. NN NN O
   
Heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
( NN NN O
HIT NN NN B-Disease
) NN NN O
is NN NN O
an NN NN O
adverse NN NN O
immune NN NN O
- NN NN O
mediated NN NN O
reaction NN NN O
to NN NN O
heparin NN NN O
, NN NN O
resulting NN NN O
in NN NN O
platelet NN NN O
count NN NN O
decreases NN NN O
of NN NN O
more NN NN O
than NN NN O
50 NN NN O
% NN NN O
. NN NN O
   
The NN NN O
frequencies NN NN O
of NN NN O
HIT NN NN B-Disease
after NN NN O
liver NN NN O
transplantation NN NN O
and NN NN O
platelet NN NN O
factor NN NN O
4 NN NN O
/ NN NN O
heparin NN NN O
- NN NN O
reactive NN NN O
antibody NN NN O
( NN NN O
HIT NN NN B-Disease
antibody NN NN O
) NN NN O
positivity NN NN O
in NN NN O
liver NN NN O
transplantation NN NN O
patients NN NN O
, NN NN O
however NN NN O
, NN NN O
are NN NN O
unknown NN NN O
. NN NN O
   
PATIENTS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
The NN NN O
32 NN NN O
men NN NN O
and NN NN O
20 NN NN O
women NN NN O
underwent NN NN O
living NN NN O
donor NN NN O
liver NN NN O
transplantation NN NN O
. NN NN O
   
We NN NN O
started NN NN O
LMWH NN NN O
( NN NN O
25 NN NN O
IU NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
h NN NN O
) NN NN O
on NN NN O
postoperative NN NN O
day NN NN O
( NN NN O
POD NN NN O
) NN NN O
1 NN NN O
, NN NN O
switching NN NN O
to NN NN O
UFH NN NN O
( NN NN O
5000 NN NN O
U NN NN O
/ NN NN O
d NN NN O
) NN NN O
on NN NN O
POD NN NN O
2 NN NN O
or NN NN O
3 NN NN O
. NN NN O
   
The NN NN O
dose NN NN O
of NN NN O
UFH NN NN O
was NN NN O
changed NN NN O
according NN NN O
to NN NN O
the NN NN O
activated NN NN O
clotting NN NN O
time NN NN O
level NN NN O
. NN NN O
   
HIT NN NN B-Disease
antibody NN NN O
levels NN NN O
were NN NN O
measured NN NN O
the NN NN O
day NN NN O
before NN NN O
surgery NN NN O
and NN NN O
on NN NN O
POD NN NN O
7 NN NN O
and NN NN O
14 NN NN O
. NN NN O
   
Platelet NN NN O
count NN NN O
was NN NN O
measured NN NN O
daily NN NN O
for NN NN O
3 NN NN O
weeks NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
average NN NN O
platelet NN NN O
counts NN NN O
preoperatively NN NN O
, NN NN O
and NN NN O
on NN NN O
POD NN NN O
7 NN NN O
, NN NN O
14 NN NN O
, NN NN O
and NN NN O
21 NN NN O
were NN NN O
65 NN NN O
, NN NN O
88 NN NN O
, NN NN O
149 NN NN O
, NN NN O
and NN NN O
169 NN NN O
x NN NN O
10 NN NN O
( NN NN O
9 NN NN O
) NN NN O
/ NN NN O
L NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Two NN NN O
patients NN NN O
developed NN NN O
hepatic NN NN O
artery NN NN O
thrombosis NN NN B-Disease
on NN NN O
POD NN NN O
11 NN NN O
and NN NN O
19 NN NN O
, NN NN O
respectively NN NN O
, NN NN O
although NN NN O
they NN NN O
were NN NN O
HIT NN NN B-Disease
antibody NN NN O
- NN NN O
negative NN NN O
and NN NN O
their NN NN O
platelet NN NN O
counts NN NN O
were NN NN O
stable NN NN O
. NN NN O
   
In NN NN O
2 NN NN O
other NN NN O
patients NN NN O
, NN NN O
the NN NN O
platelet NN NN O
count NN NN O
decreased NN NN O
suddenly NN NN O
from NN NN O
107 NN NN O
x NN NN O
10 NN NN O
( NN NN O
9 NN NN O
) NN NN O
/ NN NN O
L NN NN O
on NN NN O
POD NN NN O
4 NN NN O
to NN NN O
65 NN NN O
x NN NN O
10 NN NN O
( NN NN O
9 NN NN O
) NN NN O
/ NN NN O
L NN NN O
on NN NN O
POD NN NN O
6 NN NN O
and NN NN O
from NN NN O
76 NN NN O
x NN NN O
10 NN NN O
( NN NN O
9 NN NN O
) NN NN O
/ NN NN O
L NN NN O
on NN NN O
POD NN NN O
7 NN NN O
to NN NN O
33 NN NN O
x NN NN O
10 NN NN O
( NN NN O
9 NN NN O
) NN NN O
/ NN NN O
L NN NN O
on NN NN O
POD NN NN O
9 NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
The NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
platelet NN NN B-Disease
aggregation NN NN I-Disease
test NN NN O
was NN NN O
negative NN NN O
in NN NN O
these NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
percentage NN NN O
of NN NN O
HIT NN NN B-Disease
antibody NN NN O
- NN NN O
positive NN NN O
patients NN NN O
was NN NN O
0 NN NN O
. NN NN O
5 NN NN O
% NN NN O
preoperatively NN NN O
, NN NN O
5 NN NN O
. NN NN O
6 NN NN O
% NN NN O
on NN NN O
POD NN NN O
7 NN NN O
, NN NN O
and NN NN O
5 NN NN O
. NN NN O
6 NN NN O
% NN NN O
on NN NN O
POD NN NN O
14 NN NN O
. NN NN O
   
   O
of NN NN O
the NN NN O
subjects NN NN O
/ NN NN O
patients NN NN O
developed NN NN O
UFH NN NN O
- NN NN O
related NN NN O
HIT NN NN B-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
In NN NN O
our NN NN O
series NN NN O
, NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
HIT NN NN B-Disease
after NN NN O
liver NN NN O
transplantation NN NN O
was NN NN O
uncommon NN NN O
. NN NN O
   
Doxorubicin NN NN O
cardiomyopathy NN NN B-Disease
- NN NN O
induced NN NN O
inflammation NN NN B-Disease
and NN NN O
apoptosis NN NN O
are NN NN O
attenuated NN NN O
by NN NN O
gene NN NN O
deletion NN NN O
of NN NN O
the NN NN O
kinin NN NN O
B1 NN NN O
receptor NN NN O
. NN NN O
   
Clinical NN NN O
use NN NN O
of NN NN O
the NN NN O
anthracycline NN NN O
doxorubicin NN NN O
( NN NN O
DOX NN NN O
) NN NN O
is NN NN O
limited NN NN O
by NN NN O
its NN NN O
cardiotoxic NN NN B-Disease
effects NN NN O
, NN NN O
which NN NN O
are NN NN O
attributed NN NN O
to NN NN O
the NN NN O
induction NN NN O
of NN NN O
apoptosis NN NN O
. NN NN O
   
To NN NN O
elucidate NN NN O
the NN NN O
possible NN NN O
role NN NN O
of NN NN O
the NN NN O
kinin NN NN O
B1 NN NN O
receptor NN NN O
( NN NN O
B1R NN NN O
) NN NN O
during NN NN O
the NN NN O
development NN NN O
of NN NN O
DOX NN NN O
cardiomyopathy NN NN B-Disease
, NN NN O
we NN NN O
studied NN NN O
B1R NN NN O
knockout NN NN O
mice NN NN O
( NN NN O
B1R NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
) NN NN O
by NN NN O
investigating NN NN O
cardiac NN NN O
inflammation NN NN B-Disease
and NN NN O
apoptosis NN NN O
after NN NN O
induction NN NN O
of NN NN O
DOX NN NN O
- NN NN O
induced NN NN O
cardiomyopathy NN NN B-Disease
. NN NN O
   
DOX NN NN O
control NN NN O
mice NN NN O
showed NN NN O
cardiac NN NN B-Disease
dysfunction NN NN I-Disease
measured NN NN O
by NN NN O
pressure NN NN O
- NN NN O
volume NN NN O
loops NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
This NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
reduced NN NN O
activation NN NN O
state NN NN O
of NN NN O
AKT NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
an NN NN O
increased NN NN O
bax NN NN O
/ NN NN O
bcl2 NN NN O
ratio NN NN O
in NN NN O
Western NN NN O
blots NN NN O
, NN NN O
indicating NN NN O
cardiac NN NN B-Disease
apoptosis NN NN I-Disease
. NN NN O
   
Furthermore NN NN O
, NN NN O
mRNA NN NN O
levels NN NN O
of NN NN O
the NN NN O
proinflammatory NN NN O
cytokine NN NN O
interleukin NN NN O
6 NN NN O
were NN NN O
increased NN NN O
in NN NN O
the NN NN O
cardiac NN NN O
tissue NN NN O
. NN NN O
   
In NN NN O
DOX NN NN O
B1R NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
, NN NN O
cardiac NN NN B-Disease
dysfunction NN NN I-Disease
was NN NN O
improved NN NN O
compared NN NN O
to NN NN O
DOX NN NN O
control NN NN O
mice NN NN O
, NN NN O
which NN NN O
was NN NN O
associated NN NN O
with NN NN O
normalization NN NN O
of NN NN O
the NN NN O
bax NN NN O
/ NN NN O
bcl NN NN O
- NN NN O
2 NN NN O
ratio NN NN O
and NN NN O
interleukin NN NN O
6 NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
AKT NN NN O
activation NN NN O
state NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
B1R NN NN O
is NN NN O
detrimental NN NN O
in NN NN O
DOX NN NN O
cardiomyopathy NN NN B-Disease
in NN NN O
that NN NN O
it NN NN O
mediates NN NN O
the NN NN O
inflammatory NN NN O
response NN NN O
and NN NN O
apoptosis NN NN O
. NN NN O
   
These NN NN O
insights NN NN O
might NN NN O
have NN NN O
useful NN NN O
implications NN NN O
for NN NN O
future NN NN O
studies NN NN O
utilizing NN NN O
B1R NN NN O
antagonists NN NN O
for NN NN O
treatment NN NN O
of NN NN O
human NN NN O
DOX NN NN O
cardiomyopathy NN NN B-Disease
. NN NN O
   
Detailed NN NN O
spectral NN NN O
profile NN NN O
analysis NN NN O
of NN NN O
penicillin NN NN O
- NN NN O
induced NN NN O
epileptiform NN NN B-Disease
activity NN NN I-Disease
in NN NN O
anesthetized NN NN O
rats NN NN O
. NN NN O
   
Penicillin NN NN O
model NN NN O
is NN NN O
a NN NN O
widely NN NN O
used NN NN O
experimental NN NN O
model NN NN O
for NN NN O
epilepsy NN NN B-Disease
research NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
we NN NN O
aimed NN NN O
to NN NN O
portray NN NN O
a NN NN O
detailed NN NN O
spectral NN NN O
analysis NN NN O
of NN NN O
penicillin NN NN O
- NN NN O
induced NN NN O
epileptiform NN NN B-Disease
activity NN NN I-Disease
in NN NN O
comparison NN NN O
with NN NN O
basal NN NN O
brain NN NN O
activity NN NN O
in NN NN O
anesthetized NN NN O
Wistar NN NN O
rats NN NN O
. NN NN O
   
Male NN NN O
Wistar NN NN O
rats NN NN O
were NN NN O
anesthetized NN NN O
with NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
urethane NN NN O
and NN NN O
connected NN NN O
to NN NN O
an NN NN O
electrocorticogram NN NN O
setup NN NN O
. NN NN O
   
After NN NN O
a NN NN O
short NN NN O
period NN NN O
of NN NN O
basal NN NN O
activity NN NN O
recording NN NN O
, NN NN O
epileptic NN NN B-Disease
focus NN NN O
was NN NN O
induced NN NN O
by NN NN O
injecting NN NN O
400IU NN NN O
/ NN NN O
2 NN NN O
microl NN NN O
penicillin NN NN O
- NN NN O
G NN NN O
potassium NN NN O
into NN NN O
the NN NN O
left NN NN O
lateral NN NN O
ventricle NN NN O
while NN NN O
the NN NN O
cortical NN NN O
activity NN NN O
was NN NN O
continuously NN NN O
recorded NN NN O
. NN NN O
   
Basal NN NN O
activity NN NN O
, NN NN O
latent NN NN O
period NN NN O
and NN NN O
the NN NN O
penicillin NN NN O
- NN NN O
induced NN NN O
epileptiform NN NN B-Disease
activity NN NN I-Disease
periods NN NN O
were NN NN O
then NN NN O
analyzed NN NN O
using NN NN O
both NN NN O
conventional NN NN O
methods NN NN O
and NN NN O
spectral NN NN O
analysis NN NN O
. NN NN O
   
Spectral NN NN O
analyses NN NN O
were NN NN O
conducted NN NN O
by NN NN O
dividing NN NN O
the NN NN O
whole NN NN O
spectrum NN NN O
into NN NN O
different NN NN O
frequency NN NN O
bands NN NN O
including NN NN O
delta NN NN O
, NN NN O
theta NN NN O
( NN NN O
slow NN NN O
and NN NN O
fast NN NN O
) NN NN O
, NN NN O
alpha NN NN O
- NN NN O
sigma NN NN O
, NN NN O
beta NN NN O
( NN NN O
1 NN NN O
and NN NN O
2 NN NN O
) NN NN O
and NN NN O
gamma NN NN O
( NN NN O
1 NN NN O
and NN NN O
2 NN NN O
) NN NN O
bands NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
show NN NN O
that NN NN O
the NN NN O
most NN NN O
affected NN NN O
frequency NN NN O
bands NN NN O
were NN NN O
delta NN NN O
, NN NN O
theta NN NN O
, NN NN O
beta NN NN O
- NN NN O
2 NN NN O
and NN NN O
gamma NN NN O
- NN NN O
2 NN NN O
bands NN NN O
during NN NN O
the NN NN O
epileptiform NN NN B-Disease
activity NN NN I-Disease
and NN NN O
there NN NN O
were NN NN O
marked NN NN O
differences NN NN O
in NN NN O
terms NN NN O
of NN NN O
spectral NN NN O
densities NN NN O
between NN NN O
three NN NN O
investigated NN NN O
episodes NN NN O
( NN NN O
basal NN NN O
activity NN NN O
, NN NN O
latent NN NN O
period NN NN O
and NN NN O
epileptiform NN NN B-Disease
activity NN NN I-Disease
) NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
may NN NN O
help NN NN O
to NN NN O
analyze NN NN O
novel NN NN O
data NN NN O
obtained NN NN O
using NN NN O
similar NN NN O
experimental NN NN O
models NN NN O
and NN NN O
the NN NN O
simple NN NN O
analysis NN NN O
method NN NN O
described NN NN O
here NN NN O
can NN NN O
be NN NN O
used NN NN O
in NN NN O
similar NN NN O
studies NN NN O
to NN NN O
investigate NN NN O
the NN NN O
basic NN NN O
neuronal NN NN O
mechanism NN NN O
of NN NN O
this NN NN O
or NN NN O
other NN NN O
types NN NN O
of NN NN O
experimental NN NN O
epilepsies NN NN B-Disease
. NN NN O
   
High NN NN O
fat NN NN O
diet NN NN O
- NN NN O
fed NN NN O
obese NN NN B-Disease
rats NN NN O
are NN NN O
highly NN NN O
sensitive NN NN O
to NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
Often NN NN O
, NN NN O
chemotherapy NN NN O
by NN NN O
doxorubicin NN NN O
( NN NN O
Adriamycin NN NN O
) NN NN O
is NN NN O
limited NN NN O
due NN NN O
to NN NN O
life NN NN O
threatening NN NN O
cardiotoxicity NN NN B-Disease
in NN NN O
patients NN NN O
during NN NN O
and NN NN O
posttherapy NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
we NN NN O
have NN NN O
shown NN NN O
that NN NN O
moderate NN NN O
diet NN NN O
restriction NN NN O
remarkably NN NN O
protects NN NN O
against NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
This NN NN O
cardioprotection NN NN O
is NN NN O
accompanied NN NN O
by NN NN O
decreased NN NN O
cardiac NN NN O
oxidative NN NN O
stress NN NN O
and NN NN O
triglycerides NN NN O
and NN NN O
increased NN NN O
cardiac NN NN O
fatty NN NN O
- NN NN O
acid NN NN O
oxidation NN NN O
, NN NN O
ATP NN NN O
synthesis NN NN O
, NN NN O
and NN NN O
upregulated NN NN O
JAK NN NN O
/ NN NN O
STAT3 NN NN O
pathway NN NN O
. NN NN O
   
In NN NN O
the NN NN O
current NN NN O
study NN NN O
, NN NN O
we NN NN O
investigated NN NN O
whether NN NN O
a NN NN O
physiological NN NN O
intervention NN NN O
by NN NN O
feeding NN NN O
40 NN NN O
% NN NN O
high NN NN O
fat NN NN O
diet NN NN O
( NN NN O
HFD NN NN O
) NN NN O
, NN NN O
which NN NN O
induces NN NN O
obesity NN NN B-Disease
in NN NN O
male NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
( NN NN O
250 NN NN O
- NN NN O
275 NN NN O
g NN NN O
) NN NN O
, NN NN O
sensitizes NN NN O
to NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
A NN NN O
LD NN NN O
( NN NN O
10 NN NN O
) NN NN O
dose NN NN O
( NN NN O
8 NN NN O
mg NN NN O
doxorubicin NN NN O
/ NN NN O
kg NN NN O
, NN NN O
ip NN NN O
) NN NN O
administered NN NN O
on NN NN O
day NN NN O
43 NN NN O
of NN NN O
the NN NN O
HFD NN NN O
feeding NN NN O
regimen NN NN O
led NN NN O
to NN NN O
higher NN NN O
cardiotoxicity NN NN B-Disease
, NN NN O
cardiac NN NN B-Disease
dysfunction NN NN I-Disease
, NN NN O
lipid NN NN O
peroxidation NN NN O
, NN NN O
and NN NN O
80 NN NN O
% NN NN O
mortality NN NN O
in NN NN O
the NN NN O
obese NN NN B-Disease
( NN NN O
OB NN NN B-Disease
) NN NN O
rats NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
any NN NN O
significant NN NN O
renal NN NN B-Disease
or NN NN I-Disease
hepatic NN NN I-Disease
toxicity NN NN I-Disease
. NN NN O
   
Doxorubicin NN NN O
toxicokinetics NN NN O
studies NN NN O
revealed NN NN O
no NN NN O
change NN NN O
in NN NN O
accumulation NN NN O
of NN NN O
doxorubicin NN NN O
and NN NN O
doxorubicinol NN NN O
( NN NN O
toxic NN NN O
metabolite NN NN O
) NN NN O
in NN NN O
the NN NN O
normal NN NN O
diet NN NN O
- NN NN O
fed NN NN O
( NN NN O
ND NN NN O
) NN NN O
and NN NN O
OB NN NN B-Disease
hearts NN NN O
. NN NN O
   
Mechanistic NN NN O
studies NN NN O
revealed NN NN O
that NN NN O
OB NN NN B-Disease
rats NN NN O
are NN NN O
sensitized NN NN O
due NN NN O
to NN NN O
: NN NN O
( NN NN O
1 NN NN O
) NN NN O
higher NN NN O
oxyradical NN NN O
stress NN NN O
leading NN NN O
to NN NN O
upregulation NN NN O
of NN NN O
uncoupling NN NN O
proteins NN NN O
2 NN NN O
and NN NN O
3 NN NN O
, NN NN O
( NN NN O
2 NN NN O
) NN NN O
downregulation NN NN O
of NN NN O
cardiac NN NN O
peroxisome NN NN O
proliferators NN NN O
activated NN NN O
receptor NN NN O
- NN NN O
alpha NN NN O
, NN NN O
( NN NN O
3 NN NN O
) NN NN O
decreased NN NN O
plasma NN NN O
adiponectin NN NN O
levels NN NN O
, NN NN O
( NN NN O
4 NN NN O
) NN NN O
decreased NN NN O
cardiac NN NN O
fatty NN NN O
- NN NN O
acid NN NN O
oxidation NN NN O
( NN NN O
666 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
14 NN NN O
. NN NN O
0 NN NN O
nmol NN NN O
/ NN NN O
min NN NN O
/ NN NN O
g NN NN O
heart NN NN O
in NN NN O
ND NN NN O
versus NN NN O
400 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
11 NN NN O
. NN NN O
8 NN NN O
nmol NN NN O
/ NN NN O
min NN NN O
/ NN NN O
g NN NN O
heart NN NN O
in NN NN O
OB NN NN B-Disease
) NN NN O
, NN NN O
( NN NN O
5 NN NN O
) NN NN O
decreased NN NN O
mitochondrial NN NN O
AMP NN NN O
- NN NN O
alpha2 NN NN O
protein NN NN O
kinase NN NN O
, NN NN O
and NN NN O
( NN NN O
6 NN NN O
) NN NN O
86 NN NN O
% NN NN O
drop NN NN O
in NN NN O
cardiac NN NN O
ATP NN NN O
levels NN NN O
accompanied NN NN O
by NN NN O
decreased NN NN O
ATP NN NN O
/ NN NN O
ADP NN NN O
ratio NN NN O
after NN NN O
doxorubicin NN NN O
administration NN NN O
. NN NN O
   
Decreased NN NN O
cardiac NN NN O
erythropoietin NN NN O
and NN NN O
increased NN NN O
SOCS3 NN NN O
further NN NN O
downregulated NN NN O
the NN NN O
cardioprotective NN NN O
JAK NN NN O
/ NN NN O
STAT3 NN NN O
pathway NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
HFD NN NN O
- NN NN O
induced NN NN O
obese NN NN B-Disease
rats NN NN O
are NN NN O
highly NN NN O
sensitized NN NN O
to NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
by NN NN O
substantially NN NN O
downregulating NN NN O
cardiac NN NN O
mitochondrial NN NN O
ATP NN NN O
generation NN NN O
, NN NN O
increasing NN NN O
oxidative NN NN O
stress NN NN O
and NN NN O
downregulating NN NN O
the NN NN O
JAK NN NN O
/ NN NN O
STAT3 NN NN O
pathway NN NN O
. NN NN O
   
Isoproterenol NN NN O
induces NN NN O
primary NN NN O
loss NN NN O
of NN NN O
dystrophin NN NN O
in NN NN O
rat NN NN O
hearts NN NN O
: NN NN O
correlation NN NN O
with NN NN O
myocardial NN NN B-Disease
injury NN NN I-Disease
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
damage NN NN I-Disease
is NN NN O
unknown NN NN O
, NN NN O
but NN NN O
a NN NN O
mismatch NN NN O
of NN NN O
oxygen NN NN O
supply NN NN O
vs NN NN O
. NN NN O
demand NN NN O
following NN NN O
coronary NN NN O
hypotension NN NN B-Disease
and NN NN O
myocardial NN NN B-Disease
hyperactivity NN NN I-Disease
is NN NN O
the NN NN O
best NN NN O
explanation NN NN O
for NN NN O
the NN NN O
complex NN NN O
morphological NN NN O
alterations NN NN O
observed NN NN O
. NN NN O
   
Severe NN NN O
alterations NN NN O
in NN NN O
the NN NN O
structural NN NN O
integrity NN NN O
of NN NN O
the NN NN O
sarcolemma NN NN O
of NN NN O
cardiomyocytes NN NN O
have NN NN O
been NN NN O
demonstrated NN NN O
to NN NN O
be NN NN O
caused NN NN O
by NN NN O
isoproterenol NN NN O
. NN NN O
   
Taking NN NN O
into NN NN O
account NN NN O
that NN NN O
the NN NN O
sarcolemmal NN NN O
integrity NN NN O
is NN NN O
stabilized NN NN O
by NN NN O
the NN NN O
dystrophin NN NN O
- NN NN O
glycoprotein NN NN O
complex NN NN O
( NN NN O
DGC NN NN O
) NN NN O
that NN NN O
connects NN NN O
actin NN NN O
and NN NN O
laminin NN NN O
in NN NN O
contractile NN NN O
machinery NN NN O
and NN NN O
extracellular NN NN O
matrix NN NN O
and NN NN O
by NN NN O
integrins NN NN O
, NN NN O
this NN NN O
study NN NN O
tests NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
isoproterenol NN NN O
affects NN NN O
sarcolemmal NN NN O
stability NN NN O
through NN NN O
changes NN NN O
in NN NN O
the NN NN O
DGC NN NN O
and NN NN O
integrins NN NN O
. NN NN O
   
We NN NN O
found NN NN O
different NN NN O
sensitivity NN NN O
of NN NN O
the NN NN O
DGC NN NN O
and NN NN O
integrin NN NN O
to NN NN O
isoproterenol NN NN O
subcutaneous NN NN O
administration NN NN O
. NN NN O
   
Immunofluorescent NN NN O
staining NN NN O
revealed NN NN O
that NN NN O
dystrophin NN NN O
is NN NN O
the NN NN O
most NN NN O
sensitive NN NN O
among NN NN O
the NN NN O
structures NN NN O
connecting NN NN O
the NN NN O
actin NN NN O
in NN NN O
the NN NN O
cardiomyocyte NN NN O
cytoskeleton NN NN O
and NN NN O
the NN NN O
extracellular NN NN O
matrix NN NN O
. NN NN O
   
The NN NN O
sarcomeric NN NN O
actin NN NN O
dissolution NN NN O
occurred NN NN O
after NN NN O
the NN NN O
reduction NN NN O
or NN NN O
loss NN NN O
of NN NN O
dystrophin NN NN O
. NN NN O
   
Subsequently NN NN O
, NN NN O
after NN NN O
lysis NN NN O
of NN NN O
myofilaments NN NN O
, NN NN O
gamma NN NN O
- NN NN O
sarcoglycan NN NN O
, NN NN O
beta NN NN O
- NN NN O
dystroglycan NN NN O
, NN NN O
beta1 NN NN O
- NN NN O
integrin NN NN O
, NN NN O
and NN NN O
laminin NN NN O
alpha NN NN O
- NN NN O
2 NN NN O
expressions NN NN O
were NN NN O
reduced NN NN O
followed NN NN O
by NN NN O
their NN NN O
breakdown NN NN O
, NN NN O
as NN NN O
epiphenomena NN NN O
of NN NN O
the NN NN O
myocytolytic NN NN O
process NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
administration NN NN O
of NN NN O
isoproterenol NN NN O
to NN NN O
rats NN NN O
results NN NN O
in NN NN O
primary NN NN O
loss NN NN O
of NN NN O
dystrophin NN NN O
, NN NN O
the NN NN O
most NN NN O
sensitive NN NN O
among NN NN O
the NN NN O
structural NN NN O
proteins NN NN O
that NN NN O
form NN NN O
the NN NN O
DGC NN NN O
that NN NN O
connects NN NN O
the NN NN O
extracellular NN NN O
matrix NN NN O
and NN NN O
the NN NN O
cytoskeleton NN NN O
in NN NN O
cardiomyocyte NN NN O
. NN NN O
   
These NN NN O
changes NN NN O
, NN NN O
related NN NN O
to NN NN O
ischaemic NN NN B-Disease
injury NN NN I-Disease
, NN NN O
explain NN NN O
the NN NN O
severe NN NN O
alterations NN NN O
in NN NN O
the NN NN O
structural NN NN O
integrity NN NN O
of NN NN O
the NN NN O
sarcolemma NN NN O
of NN NN O
cardiomyocytes NN NN O
and NN NN O
hence NN NN O
severe NN NN O
and NN NN O
irreversible NN NN O
injury NN NN O
induced NN NN O
by NN NN O
isoproterenol NN NN O
. NN NN O
   
Etiologic NN NN O
factors NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
liver NN NN B-Disease
tumors NN NN I-Disease
associated NN NN O
with NN NN O
oral NN NN O
contraceptives NN NN O
. NN NN O
   
Within NN NN O
the NN NN O
last NN NN O
several NN NN O
years NN NN O
, NN NN O
previously NN NN O
rare NN NN O
liver NN NN B-Disease
tumors NN NN I-Disease
have NN NN O
been NN NN O
seen NN NN O
in NN NN O
young NN NN O
women NN NN O
using NN NN O
oral NN NN O
contraceptive NN NN O
steroids NN NN O
. NN NN O
   
The NN NN O
Registry NN NN O
for NN NN O
Liver NN NN B-Disease
Tumors NN NN I-Disease
Associated NN NN O
with NN NN O
Oral NN NN O
Contraceptives NN NN O
at NN NN O
the NN NN O
University NN NN O
of NN NN O
California NN NN O
, NN NN O
Irvine NN NN O
, NN NN O
has NN NN O
clearly NN NN O
identified NN NN O
27 NN NN O
cases NN NN O
. NN NN O
   
The NN NN O
recent NN NN O
literature NN NN O
contains NN NN O
44 NN NN O
case NN NN O
reports NN NN O
. NN NN O
   
Common NN NN O
to NN NN O
these NN NN O
71 NN NN O
cases NN NN O
has NN NN O
been NN NN O
a NN NN O
histopathologic NN NN O
diagnosis NN NN O
of NN NN O
focal NN NN B-Disease
nodular NN NN I-Disease
hyperplasia NN NN I-Disease
, NN NN O
adenoma NN NN B-Disease
, NN NN O
hamartoma NN NN B-Disease
, NN NN O
and NN NN O
hepatoma NN NN B-Disease
. NN NN O
   
Significant NN NN O
statistical NN NN O
etiologic NN NN O
factors NN NN O
include NN NN O
prolonged NN NN O
uninterrupted NN NN O
usage NN NN O
of NN NN O
oral NN NN O
contraceptive NN NN O
steroids NN NN O
. NN NN O
   
Eight NN NN O
deaths NN NN O
and NN NN O
liver NN NN O
rupture NN NN B-Disease
in NN NN O
18 NN NN O
patients NN NN O
attest NN NN O
to NN NN O
the NN NN O
seriousness NN NN O
of NN NN O
this NN NN O
new NN NN O
potentially NN NN O
lethal NN NN O
adverse NN NN O
phenomenon NN NN O
. NN NN O
   
Ifosfamide NN NN O
continuous NN NN O
infusion NN NN O
without NN NN O
mesna NN NN O
. NN NN O
   
A NN NN O
phase NN NN O
I NN NN O
trial NN NN O
of NN NN O
a NN NN O
14 NN NN O
- NN NN O
day NN NN O
cycle NN NN O
. NN NN O
   
Twenty NN NN O
patients NN NN O
received NN NN O
27 NN NN O
courses NN NN O
of NN NN O
ifosfamide NN NN O
administered NN NN O
as NN NN O
a NN NN O
24 NN NN O
- NN NN O
hour NN NN O
continuous NN NN O
infusion NN NN O
for NN NN O
14 NN NN O
days NN NN O
without NN NN O
Mesna NN NN O
. NN NN O
   
The NN NN O
goal NN NN O
of NN NN O
the NN NN O
study NN NN O
was NN NN O
to NN NN O
deliver NN NN O
a NN NN O
dose NN NN O
rate NN NN O
and NN NN O
total NN NN O
cumulative NN NN O
dose NN NN O
of NN NN O
ifosfamide NN NN O
that NN NN O
would NN NN O
be NN NN O
comparable NN NN O
to NN NN O
standard NN NN O
bolus NN NN O
or NN NN O
short NN NN O
- NN NN O
term NN NN O
infusions NN NN O
administered NN NN O
with NN NN O
Mesna NN NN O
. NN NN O
   
Dose NN NN O
escalations NN NN O
proceeded NN NN O
from NN NN O
200 NN NN O
to NN NN O
300 NN NN O
, NN NN O
400 NN NN O
, NN NN O
450 NN NN O
, NN NN O
500 NN NN O
, NN NN O
and NN NN O
550 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d NN NN O
. NN NN O
   
Four NN NN O
patients NN NN O
developed NN NN O
transient NN NN O
microscopic NN NN O
hematuria NN NN B-Disease
at NN NN O
400 NN NN O
, NN NN O
450 NN NN O
, NN NN O
and NN NN O
500 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
instances NN NN O
of NN NN O
macroscopic NN NN O
hematuria NN NN B-Disease
. NN NN O
   
At NN NN O
550 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d NN NN O
, NN NN O
three NN NN O
patients NN NN O
experienced NN NN O
nonurologic NN NN O
toxicity NN NN B-Disease
; NN NN O
confusion NN NN B-Disease
( NN NN O
1 NN NN O
) NN NN O
, NN NN O
nausea NN NN B-Disease
( NN NN O
1 NN NN O
) NN NN O
, NN NN O
and NN NN O
Grade NN NN O
2 NN NN O
leukopenia NN NN B-Disease
( NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
recommended NN NN O
dose NN NN O
of NN NN O
500 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d NN NN O
delivers NN NN O
a NN NN O
total NN NN O
dose NN NN O
of NN NN O
7 NN NN O
g NN NN O
/ NN NN O
m2 NN NN O
per NN NN O
cycle NN NN O
, NN NN O
which NN NN O
is NN NN O
comparable NN NN O
to NN NN O
that NN NN O
delivered NN NN O
in NN NN O
clinical NN NN O
practice NN NN O
for NN NN O
bolus NN NN O
or NN NN O
short NN NN O
- NN NN O
term NN NN O
infusion NN NN O
. NN NN O
   
Because NN NN O
few NN NN O
patients NN NN O
received NN NN O
multiple NN NN O
courses NN NN O
over NN NN O
time NN NN O
, NN NN O
the NN NN O
cumulative NN NN O
effects NN NN O
are NN NN O
indeterminate NN NN O
in NN NN O
the NN NN O
present NN NN O
trial NN NN O
. NN NN O
   
The NN NN O
frequency NN NN O
and NN NN O
predictability NN NN O
of NN NN O
hematuria NN NN B-Disease
are NN NN O
not NN NN O
precise NN NN O
, NN NN O
and NN NN O
at NN NN O
least NN NN O
daily NN NN O
monitoring NN NN O
by NN NN O
urine NN NN O
Hematest NN NN O
is NN NN O
essential NN NN O
, NN NN O
adding NN NN O
Mesna NN NN O
to NN NN O
the NN NN O
infusate NN NN O
in NN NN O
patients NN NN O
with NN NN O
persistent NN NN O
hematuria NN NN B-Disease
. NN NN O
   
The NN NN O
protracted NN NN O
infusion NN NN O
schedule NN NN O
for NN NN O
ifosfamide NN NN O
permits NN NN O
convenient NN NN O
outpatient NN NN O
administration NN NN O
without NN NN O
Mesna NN NN O
and NN NN O
reduces NN NN O
the NN NN O
drug NN NN O
cost NN NN O
of NN NN O
clinical NN NN O
usage NN NN O
of NN NN O
this NN NN O
agent NN NN O
by NN NN O
up NN NN O
to NN NN O
890 NN NN O
per NN NN O
cycle NN NN O
. NN NN O
   
Clinical NN NN O
activity NN NN O
was NN NN O
demonstrated NN NN O
in NN NN O
a NN NN O
single NN NN O
patient NN NN O
, NN NN O
but NN NN O
a NN NN O
comparative NN NN O
trial NN NN O
of NN NN O
standard NN NN O
bolus NN NN O
schedules NN NN O
with NN NN O
the NN NN O
protracted NN NN O
infusion NN NN O
schedule NN NN O
will NN NN O
be NN NN O
necessary NN NN O
to NN NN O
determine NN NN O
if NN NN O
the NN NN O
clinical NN NN O
effectiveness NN NN O
of NN NN O
the NN NN O
drug NN NN O
is NN NN O
maintained NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
related NN NN O
to NN NN O
caffeine NN NN O
pretreatment NN NN O
. NN NN O
   
Suboptimal NN NN O
seizure NN NN B-Disease
duration NN NN O
is NN NN O
commonly NN NN O
encountered NN NN O
in NN NN O
electroconvulsive NN NN O
therapy NN NN O
practice NN NN O
, NN NN O
especially NN NN O
in NN NN O
older NN NN O
patients NN NN O
with NN NN O
higher NN NN O
seizure NN NN B-Disease
thresholds NN NN O
. NN NN O
   
Intravenous NN NN O
caffeine NN NN O
is NN NN O
commonly NN NN O
used NN NN O
to NN NN O
improve NN NN O
seizure NN NN B-Disease
duration NN NN O
and NN NN O
quality NN NN O
in NN NN O
such NN NN O
patients NN NN O
and NN NN O
is NN NN O
generally NN NN O
well NN NN O
tolerated NN NN O
aside NN NN O
from NN NN O
occasional NN NN O
reports NN NN O
of NN NN O
relatively NN NN O
benign NN NN O
ventricular NN NN B-Disease
ectopy NN NN I-Disease
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
patient NN NN O
with NN NN O
no NN NN O
previous NN NN O
history NN NN O
of NN NN O
cardiac NN NN B-Disease
disease NN NN I-Disease
or NN NN O
arrhythmia NN NN B-Disease
who NN NN O
developed NN NN O
sustained NN NN O
bigeminy NN NN O
and NN NN O
2 NN NN O
brief NN NN O
runs NN NN O
of NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
after NN NN O
caffeine NN NN O
administration NN NN O
. NN NN O
   
Although NN NN O
intravenous NN NN O
caffeine NN NN O
is NN NN O
generally NN NN O
well NN NN O
tolerated NN NN O
, NN NN O
the NN NN O
clinician NN NN O
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
the NN NN O
potential NN NN O
for NN NN O
unpredictable NN NN O
and NN NN O
serious NN NN O
ventricular NN NN B-Disease
arrhythmias NN NN I-Disease
. NN NN O
   
Fatal NN NN O
haemopericardium NN NN B-Disease
and NN NN O
gastrointestinal NN NN B-Disease
haemorrhage NN NN I-Disease
due NN NN O
to NN NN O
possible NN NN O
interaction NN NN O
of NN NN O
cranberry NN NN O
juice NN NN O
with NN NN O
warfarin NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
fatal NN NN O
internal NN NN O
haemorrhage NN NN B-Disease
in NN NN O
an NN NN O
elderly NN NN O
man NN NN O
who NN NN O
consumed NN NN O
only NN NN O
cranberry NN NN O
juice NN NN O
for NN NN O
two NN NN O
weeks NN NN O
while NN NN O
maintaining NN NN O
his NN NN O
usual NN NN O
dosage NN NN O
of NN NN O
warfarin NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
that NN NN O
naturally NN NN O
occurring NN NN O
compounds NN NN O
such NN NN O
as NN NN O
flavonoids NN NN O
, NN NN O
which NN NN O
are NN NN O
present NN NN O
in NN NN O
fruit NN NN O
juices NN NN O
, NN NN O
may NN NN O
increase NN NN O
the NN NN O
potency NN NN O
of NN NN O
warfarin NN NN O
by NN NN O
competing NN NN O
for NN NN O
the NN NN O
enzymes NN NN O
that NN NN O
normally NN NN O
inactivate NN NN O
warfarin NN NN O
. NN NN O
   
While NN NN O
traditionally NN NN O
regarded NN NN O
as NN NN O
foodstuffs NN NN O
, NN NN O
consumption NN NN O
of NN NN O
fruit NN NN O
juices NN NN O
should NN NN O
be NN NN O
considered NN NN O
when NN NN O
patients NN NN O
develop NN NN O
adverse NN NN O
drug NN NN O
reactions NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
increasing NN NN O
intraperitoneal NN NN O
infusion NN NN O
rates NN NN O
on NN NN O
bupropion NN NN O
hydrochloride NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
in NN NN O
mice NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
It NN NN O
is NN NN O
not NN NN O
known NN NN O
if NN NN O
there NN NN O
is NN NN O
a NN NN O
relationship NN NN O
between NN NN O
input NN NN O
rate NN NN O
and NN NN O
incidence NN NN O
of NN NN O
bupropion NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
. NN NN O
   
This NN NN O
is NN NN O
important NN NN O
, NN NN O
since NN NN O
different NN NN O
controlled NN NN O
release NN NN O
formulations NN NN O
of NN NN O
bupropion NN NN O
release NN NN O
the NN NN O
active NN NN O
drug NN NN O
at NN NN O
different NN NN O
rates NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
investigated NN NN O
the NN NN O
effect NN NN O
of NN NN O
varying NN NN O
the NN NN O
intraperitoneal NN NN O
infusion NN NN O
rates NN NN O
of NN NN O
bupropion NN NN O
HCl NN NN O
120 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
a NN NN O
known NN NN O
convulsive NN NN B-Disease
dose NN NN O
50 NN NN O
( NN NN O
CD50 NN NN O
) NN NN O
, NN NN O
on NN NN O
the NN NN O
incidence NN NN O
and NN NN O
severity NN NN O
of NN NN O
bupropion NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
in NN NN O
the NN NN O
Swiss NN NN O
albino NN NN O
mice NN NN O
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
69 NN NN O
mice NN NN O
, NN NN O
approximately NN NN O
7 NN NN O
weeks NN NN O
of NN NN O
age NN NN O
, NN NN O
and NN NN O
weighing NN NN O
21 NN NN O
. NN NN O
0 NN NN O
to NN NN O
29 NN NN O
. NN NN O
1 NN NN O
g NN NN O
were NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
bupropion NN NN O
HCl NN NN O
120 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
treatment NN NN O
by NN NN O
intraperitoneal NN NN O
( NN NN O
IP NN NN O
) NN NN O
administration NN NN O
in NN NN O
7 NN NN O
groups NN NN O
( NN NN O
9 NN NN O
to NN NN O
10 NN NN O
animals NN NN O
per NN NN O
group NN NN O
) NN NN O
. NN NN O
   
Bupropion NN NN O
HCl NN NN O
was NN NN O
infused NN NN O
through NN NN O
a NN NN O
surgically NN NN O
implanted NN NN O
IP NN NN O
dosing NN NN O
catheter NN NN O
with NN NN O
infusions NN NN O
in NN NN O
each NN NN O
group NN NN O
of NN NN O
0 NN NN O
min NN NN O
, NN NN O
15 NN NN O
min NN NN O
, NN NN O
30 NN NN O
min NN NN O
, NN NN O
60 NN NN O
min NN NN O
, NN NN O
90 NN NN O
min NN NN O
, NN NN O
120 NN NN O
min NN NN O
, NN NN O
and NN NN O
240 NN NN O
min NN NN O
. NN NN O
   
The NN NN O
number NN NN O
, NN NN O
time NN NN O
of NN NN O
onset NN NN O
, NN NN O
duration NN NN O
and NN NN O
the NN NN O
intensity NN NN O
of NN NN O
the NN NN O
convulsions NN NN B-Disease
or NN NN O
absence NN NN O
of NN NN O
convulsions NN NN B-Disease
were NN NN O
recorded NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
results NN NN O
showed NN NN O
that NN NN O
IP NN NN O
administration NN NN O
of NN NN O
bupropion NN NN O
HCl NN NN O
120 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
by NN NN O
bolus NN NN O
injection NN NN O
induced NN NN O
convulsions NN NN B-Disease
in NN NN O
6 NN NN O
out NN NN O
of NN NN O
10 NN NN O
mice NN NN O
( NN NN O
60 NN NN O
% NN NN O
of NN NN O
convulsing NN NN O
mice NN NN O
) NN NN O
in NN NN O
group NN NN O
1 NN NN O
. NN NN O
   
Logistic NN NN O
regression NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
infusion NN NN O
time NN NN O
was NN NN O
significant NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
0004 NN NN O
; NN NN O
odds NN NN O
ratio NN NN O
= NN NN O
0 NN NN O
. NN NN O
974 NN NN O
) NN NN O
and NN NN O
increasing NN NN O
the NN NN O
IP NN NN O
infusion NN NN O
time NN NN O
of NN NN O
bupropion NN NN O
HCl NN NN O
120 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
91 NN NN O
% NN NN O
reduced NN NN O
odds NN NN O
of NN NN O
convulsions NN NN B-Disease
at NN NN O
infusion NN NN O
times NN NN O
of NN NN O
15 NN NN O
to NN NN O
90 NN NN O
min NN NN O
compared NN NN O
to NN NN O
bolus NN NN O
injection NN NN O
. NN NN O
   
Further NN NN O
increase NN NN O
in NN NN O
infusion NN NN O
time NN NN O
resulted NN NN O
in NN NN O
further NN NN O
reduction NN NN O
in NN NN O
the NN NN O
odds NN NN O
of NN NN O
convulsions NN NN B-Disease
to NN NN O
99 NN NN O
. NN NN O
8 NN NN O
% NN NN O
reduction NN NN O
at NN NN O
240 NN NN O
min NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
In NN NN O
conclusion NN NN O
, NN NN O
the NN NN O
demonstration NN NN O
of NN NN O
an NN NN O
inverse NN NN O
relationship NN NN O
between NN NN O
infusion NN NN O
time NN NN O
of NN NN O
a NN NN O
fixed NN NN O
and NN NN O
convulsive NN NN B-Disease
dose NN NN O
of NN NN O
bupropion NN NN O
and NN NN O
the NN NN O
risk NN NN O
of NN NN O
convulsions NN NN B-Disease
in NN NN O
a NN NN O
prospective NN NN O
study NN NN O
is NN NN O
novel NN NN O
. NN NN O
   
Graft NN NN B-Disease
- NN NN I-Disease
versus NN NN I-Disease
- NN NN I-Disease
host NN NN I-Disease
disease NN NN I-Disease
prophylaxis NN NN O
with NN NN O
everolimus NN NN O
and NN NN O
tacrolimus NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
high NN NN O
incidence NN NN O
of NN NN O
sinusoidal NN NN B-Disease
obstruction NN NN I-Disease
syndrome NN NN I-Disease
and NN NN O
microangiopathy NN NN B-Disease
: NN NN O
results NN NN O
of NN NN O
the NN NN O
EVTAC NN NN O
trial NN NN O
. NN NN O
   
A NN NN O
calcineurin NN NN O
inhibitor NN NN O
combined NN NN O
with NN NN O
methotrexate NN NN O
is NN NN O
the NN NN O
standard NN NN O
prophylaxis NN NN O
for NN NN O
graft NN NN B-Disease
- NN NN I-Disease
versus NN NN I-Disease
- NN NN I-Disease
host NN NN I-Disease
disease NN NN I-Disease
( NN NN O
GVHD NN NN B-Disease
) NN NN O
after NN NN O
allogeneic NN NN O
hematopoietic NN NN O
stem NN NN O
cell NN NN O
transplantation NN NN O
( NN NN O
HSCT NN NN O
) NN NN O
. NN NN O
   
Everolimus NN NN O
, NN NN O
a NN NN O
derivative NN NN O
of NN NN O
sirolimus NN NN O
, NN NN O
seems NN NN O
to NN NN O
mediate NN NN O
antileukemia NN NN O
effects NN NN O
. NN NN O
   
We NN NN O
report NN NN O
on NN NN O
a NN NN O
combination NN NN O
of NN NN O
everolimus NN NN O
and NN NN O
tacrolimus NN NN O
in NN NN O
24 NN NN O
patients NN NN O
( NN NN O
median NN NN O
age NN NN O
, NN NN O
62 NN NN O
years NN NN O
) NN NN O
with NN NN O
either NN NN O
myelodysplastic NN NN B-Disease
syndrome NN NN I-Disease
( NN NN O
MDS NN NN B-Disease
; NN NN O
n NN NN O
= NN NN O
17 NN NN O
) NN NN O
or NN NN O
acute NN NN B-Disease
myeloid NN NN I-Disease
leukemia NN NN I-Disease
( NN NN O
AML NN NN B-Disease
; NN NN O
n NN NN O
= NN NN O
7 NN NN O
) NN NN O
undergoing NN NN O
intensive NN NN O
conditioning NN NN O
followed NN NN O
by NN NN O
HSCT NN NN O
from NN NN O
related NN NN O
( NN NN O
n NN NN O
= NN NN O
4 NN NN O
) NN NN O
or NN NN O
unrelated NN NN O
( NN NN O
n NN NN O
= NN NN O
20 NN NN O
) NN NN O
donors NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
engrafted NN NN O
, NN NN O
and NN NN O
only NN NN O
1 NN NN O
patient NN NN O
experienced NN NN O
grade NN NN O
IV NN NN O
mucositis NN NN B-Disease
. NN NN O
   
Nine NN NN O
patients NN NN O
( NN NN O
37 NN NN O
% NN NN O
) NN NN O
developed NN NN O
acute NN NN O
grade NN NN O
II NN NN O
- NN NN O
IV NN NN O
GVHD NN NN B-Disease
, NN NN O
and NN NN O
11 NN NN O
of NN NN O
17 NN NN O
evaluable NN NN O
patients NN NN O
( NN NN O
64 NN NN O
% NN NN O
) NN NN O
developed NN NN O
chronic NN NN O
extensive NN NN O
GVHD NN NN B-Disease
. NN NN O
   
Transplantation NN NN B-Disease
- NN NN I-Disease
associated NN NN I-Disease
microangiopathy NN NN I-Disease
( NN NN O
TMA NN NN B-Disease
) NN NN O
occurred NN NN O
in NN NN O
7 NN NN O
patients NN NN O
( NN NN O
29 NN NN O
% NN NN O
) NN NN O
, NN NN O
with NN NN O
2 NN NN O
cases NN NN O
of NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
The NN NN O
study NN NN O
was NN NN O
terminated NN NN O
prematurely NN NN O
because NN NN O
an NN NN O
additional NN NN O
6 NN NN O
patients NN NN O
( NN NN O
25 NN NN O
% NN NN O
) NN NN O
developed NN NN O
sinusoidal NN NN B-Disease
obstruction NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
SOS NN NN B-Disease
) NN NN O
, NN NN O
which NN NN O
was NN NN O
fatal NN NN O
in NN NN O
2 NN NN O
cases NN NN O
. NN NN O
   
With NN NN O
a NN NN O
median NN NN O
follow NN NN O
- NN NN O
up NN NN O
of NN NN O
26 NN NN O
months NN NN O
, NN NN O
the NN NN O
2 NN NN O
- NN NN O
year NN NN O
overall NN NN O
survival NN NN O
rate NN NN O
was NN NN O
47 NN NN O
% NN NN O
. NN NN O
   
Although NN NN O
this NN NN O
new NN NN O
combination NN NN O
appears NN NN O
to NN NN O
be NN NN O
effective NN NN O
as NN NN O
a NN NN O
prophylactic NN NN O
regimen NN NN O
for NN NN O
acute NN NN O
GVHD NN NN B-Disease
, NN NN O
the NN NN O
incidence NN NN O
of NN NN O
TMA NN NN B-Disease
and NN NN O
SOS NN NN B-Disease
is NN NN O
considerably NN NN O
higher NN NN O
than NN NN O
seen NN NN O
with NN NN O
other NN NN O
regimens NN NN O
. NN NN O
   
Longitudinal NN NN O
assessment NN NN O
of NN NN O
air NN NN O
conduction NN NN O
audiograms NN NN O
in NN NN O
a NN NN O
phase NN NN O
III NN NN O
clinical NN NN O
trial NN NN O
of NN NN O
difluoromethylornithine NN NN O
and NN NN O
sulindac NN NN O
for NN NN O
prevention NN NN O
of NN NN O
sporadic NN NN O
colorectal NN NN B-Disease
adenomas NN NN I-Disease
. NN NN O
   
A NN NN O
phase NN NN O
III NN NN O
clinical NN NN O
trial NN NN O
assessed NN NN O
the NN NN O
recurrence NN NN O
of NN NN O
adenomatous NN NN B-Disease
polyps NN NN I-Disease
after NN NN O
treatment NN NN O
for NN NN O
36 NN NN O
months NN NN O
with NN NN O
difluoromethylornithine NN NN O
( NN NN O
DFMO NN NN O
) NN NN O
plus NN NN O
sulindac NN NN O
or NN NN O
matched NN NN O
placebos NN NN O
. NN NN O
   
Temporary NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
is NN NN O
a NN NN O
known NN NN O
toxicity NN NN B-Disease
of NN NN O
treatment NN NN O
with NN NN O
DFMO NN NN O
, NN NN O
thus NN NN O
a NN NN O
comprehensive NN NN O
approach NN NN O
was NN NN O
developed NN NN O
to NN NN O
analyze NN NN O
serial NN NN O
air NN NN O
conduction NN NN O
audiograms NN NN O
. NN NN O
   
The NN NN O
generalized NN NN O
estimating NN NN O
equation NN NN O
method NN NN O
estimated NN NN O
the NN NN O
mean NN NN O
difference NN NN O
between NN NN O
treatment NN NN O
arms NN NN O
with NN NN O
regard NN NN O
to NN NN O
change NN NN O
in NN NN O
air NN NN O
conduction NN NN O
pure NN NN O
tone NN NN O
thresholds NN NN O
while NN NN O
accounting NN NN O
for NN NN O
within NN NN O
- NN NN O
subject NN NN O
correlation NN NN O
due NN NN O
to NN NN O
repeated NN NN O
measurements NN NN O
at NN NN O
frequencies NN NN O
. NN NN O
   
Based NN NN O
on NN NN O
290 NN NN O
subjects NN NN O
, NN NN O
there NN NN O
was NN NN O
an NN NN O
average NN NN O
difference NN NN O
of NN NN O
0 NN NN O
. NN NN O
50 NN NN O
dB NN NN O
between NN NN O
subjects NN NN O
treated NN NN O
with NN NN O
DFMO NN NN O
plus NN NN O
sulindac NN NN O
compared NN NN O
with NN NN O
those NN NN O
treated NN NN O
with NN NN O
placebo NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
- NN NN O
0 NN NN O
. NN NN O
64 NN NN O
to NN NN O
1 NN NN O
. NN NN O
63 NN NN O
dB NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
39 NN NN O
) NN NN O
, NN NN O
adjusted NN NN O
for NN NN O
baseline NN NN O
values NN NN O
, NN NN O
age NN NN O
, NN NN O
and NN NN O
frequencies NN NN O
. NN NN O
   
In NN NN O
the NN NN O
normal NN NN O
speech NN NN O
range NN NN O
of NN NN O
500 NN NN O
to NN NN O
3 NN NN O
, NN NN O
000 NN NN O
Hz NN NN O
, NN NN O
an NN NN O
estimated NN NN O
difference NN NN O
of NN NN O
0 NN NN O
. NN NN O
99 NN NN O
dB NN NN O
( NN NN O
- NN NN O
0 NN NN O
. NN NN O
17 NN NN O
to NN NN O
2 NN NN O
. NN NN O
14 NN NN O
dB NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
09 NN NN O
) NN NN O
was NN NN O
detected NN NN O
. NN NN O
   
Dose NN NN O
intensity NN NN O
did NN NN O
not NN NN O
add NN NN O
information NN NN O
to NN NN O
models NN NN O
. NN NN O
   
There NN NN O
were NN NN O
14 NN NN O
of NN NN O
151 NN NN O
( NN NN O
9 NN NN O
. NN NN O
3 NN NN O
% NN NN O
) NN NN O
in NN NN O
the NN NN O
DFMO NN NN O
plus NN NN O
sulindac NN NN O
group NN NN O
and NN NN O
4 NN NN O
of NN NN O
139 NN NN O
( NN NN O
2 NN NN O
. NN NN O
9 NN NN O
% NN NN O
) NN NN O
in NN NN O
the NN NN O
placebo NN NN O
group NN NN O
who NN NN O
experienced NN NN O
at NN NN O
least NN NN O
15 NN NN O
dB NN NN O
hearing NN NN O
reduction NN NN O
from NN NN O
baseline NN NN O
in NN NN O
2 NN NN O
or NN NN O
more NN NN O
consecutive NN NN O
frequencies NN NN O
across NN NN O
the NN NN O
entire NN NN O
range NN NN O
tested NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
02 NN NN O
) NN NN O
. NN NN O
   
Follow NN NN O
- NN NN O
up NN NN O
air NN NN O
conduction NN NN O
done NN NN O
at NN NN O
least NN NN O
6 NN NN O
months NN NN O
after NN NN O
end NN NN O
of NN NN O
treatment NN NN O
showed NN NN O
an NN NN O
adjusted NN NN O
mean NN NN O
difference NN NN O
in NN NN O
hearing NN NN O
thresholds NN NN O
of NN NN O
1 NN NN O
. NN NN O
08 NN NN O
dB NN NN O
( NN NN O
- NN NN O
0 NN NN O
. NN NN O
81 NN NN O
to NN NN O
2 NN NN O
. NN NN O
96 NN NN O
dB NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
26 NN NN O
) NN NN O
between NN NN O
treatment NN NN O
arms NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
significant NN NN O
difference NN NN O
in NN NN O
the NN NN O
proportion NN NN O
of NN NN O
subjects NN NN O
in NN NN O
the NN NN O
DFMO NN NN O
plus NN NN O
sulindac NN NN O
group NN NN O
who NN NN O
experienced NN NN O
clinically NN NN O
significant NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
compared NN NN O
with NN NN O
the NN NN O
placebo NN NN O
group NN NN O
. NN NN O
   
The NN NN O
estimated NN NN O
attributable NN NN O
risk NN NN O
of NN NN O
ototoxicity NN NN B-Disease
from NN NN O
exposure NN NN O
to NN NN O
the NN NN O
drug NN NN O
is NN NN O
8 NN NN O
. NN NN O
4 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
- NN NN O
2 NN NN O
. NN NN O
0 NN NN O
% NN NN O
to NN NN O
18 NN NN O
. NN NN O
8 NN NN O
% NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
12 NN NN O
) NN NN O
. NN NN O
   
There NN NN O
is NN NN O
a NN NN O
< NN NN O
2 NN NN O
dB NN NN O
difference NN NN O
in NN NN O
mean NN NN O
threshold NN NN O
for NN NN O
patients NN NN O
treated NN NN O
with NN NN O
DFMO NN NN O
plus NN NN O
sulindac NN NN O
compared NN NN O
with NN NN O
those NN NN O
treated NN NN O
with NN NN O
placebo NN NN O
. NN NN O
   
Proteinase NN NN O
3 NN NN O
- NN NN O
antineutrophil NN NN O
cytoplasmic NN NN O
antibody NN NN O
- NN NN O
( NN NN O
PR3 NN NN O
- NN NN O
ANCA NN NN O
) NN NN O
positive NN NN O
necrotizing NN NN O
glomerulonephritis NN NN B-Disease
after NN NN O
restarting NN NN O
sulphasalazine NN NN O
treatment NN NN O
. NN NN O
   
A NN NN O
59 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
ulcerative NN NN B-Disease
colitis NN NN I-Disease
developed NN NN O
red NN NN B-Disease
eyes NN NN I-Disease
, NN NN O
pleural NN NN B-Disease
effusion NN NN I-Disease
, NN NN O
eosinophilia NN NN B-Disease
and NN NN O
urinary NN NN B-Disease
abnormalities NN NN I-Disease
after NN NN O
restarting NN NN O
of NN NN O
sulphasalazine NN NN O
treatment NN NN O
. NN NN O
   
Light NN NN O
microscopy NN NN O
of NN NN O
a NN NN O
kidney NN NN O
biopsy NN NN O
revealed NN NN O
segmental NN NN B-Disease
necrotizing NN NN I-Disease
glomerulonephritis NN NN I-Disease
without NN NN O
deposition NN NN O
of NN NN O
immunoglobulin NN NN O
or NN NN O
complement NN NN O
. NN NN O
   
Proteinase NN NN O
3 NN NN O
- NN NN O
antineutrophil NN NN O
cytoplasmic NN NN O
antibody NN NN O
( NN NN O
PR3 NN NN O
- NN NN O
ANCA NN NN O
) NN NN O
titer NN NN O
was NN NN O
elevated NN NN O
at NN NN O
183 NN NN O
ELISA NN NN O
units NN NN O
( NN NN O
EU NN NN O
) NN NN O
in NN NN O
sera NN NN O
( NN NN O
normal NN NN O
range NN NN O
less NN NN O
than NN NN O
10 NN NN O
EU NN NN O
) NN NN O
, NN NN O
myeloperoxidase NN NN O
- NN NN O
ANCA NN NN O
was NN NN O
negative NN NN O
. NN NN O
   
PR3 NN NN O
- NN NN O
ANCA NN NN O
titer NN NN O
was NN NN O
250 NN NN O
and NN NN O
1 NN NN O
, NN NN O
070 NN NN O
EU NN NN O
in NN NN O
pleural NN NN B-Disease
effusions NN NN I-Disease
on NN NN O
right NN NN O
and NN NN O
left NN NN O
side NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Although NN NN O
cessation NN NN O
of NN NN O
sulphasalazine NN NN O
treatment NN NN O
resulted NN NN O
in NN NN O
improvements NN NN O
in NN NN O
fever NN NN B-Disease
, NN NN O
red NN NN B-Disease
eyes NN NN I-Disease
, NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
, NN NN O
titer NN NN O
of NN NN O
C NN NN O
- NN NN O
reactive NN NN O
protein NN NN O
and NN NN O
volume NN NN O
of NN NN O
the NN NN O
pleural NN NN B-Disease
effusions NN NN I-Disease
, NN NN O
we NN NN O
initiated NN NN O
steroid NN NN O
therapy NN NN O
, NN NN O
because NN NN O
PR3 NN NN O
- NN NN O
ANCA NN NN O
titer NN NN O
rose NN NN O
to NN NN O
320 NN NN O
EU NN NN O
, NN NN O
eosinophil NN NN O
count NN NN O
increased NN NN O
to NN NN O
1 NN NN O
, NN NN O
100 NN NN O
cells NN NN O
/ NN NN O
microl NN NN O
, NN NN O
and NN NN O
the NN NN O
pleural NN NN B-Disease
effusion NN NN I-Disease
remained NN NN O
. NN NN O
   
One NN NN O
month NN NN O
after NN NN O
steroid NN NN O
therapy NN NN O
, NN NN O
the NN NN O
pleural NN NN B-Disease
effusion NN NN I-Disease
disappeared NN NN O
, NN NN O
and NN NN O
PR3 NN NN O
- NN NN O
ANCA NN NN O
titer NN NN O
normalized NN NN O
3 NN NN O
months NN NN O
later NN NN O
. NN NN O
   
This NN NN O
case NN NN O
suggests NN NN O
that NN NN O
sulphasalazine NN NN O
can NN NN O
induce NN NN O
PR3 NN NN O
- NN NN O
ANCA NN NN O
- NN NN O
positive NN NN O
necrotizing NN NN O
glomerulonephritis NN NN B-Disease
. NN NN O
   
Comparison NN NN O
of NN NN O
unilateral NN NN O
pallidotomy NN NN O
and NN NN O
subthalamotomy NN NN O
findings NN NN O
in NN NN O
advanced NN NN O
idiopathic NN NN B-Disease
Parkinson NN NN I-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
A NN NN O
prospective NN NN O
, NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
pilot NN NN O
study NN NN O
to NN NN O
compare NN NN O
the NN NN O
results NN NN O
of NN NN O
stereotactic NN NN O
unilateral NN NN O
pallidotomy NN NN O
and NN NN O
subthalamotomy NN NN O
in NN NN O
advanced NN NN O
idiopathic NN NN B-Disease
Parkinson NN NN I-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
( NN NN O
PD NN NN B-Disease
) NN NN O
refractory NN NN O
to NN NN O
medical NN NN O
treatment NN NN O
was NN NN O
designed NN NN O
. NN NN O
   
Ten NN NN O
consecutive NN NN O
patients NN NN O
( NN NN O
mean NN NN O
age NN NN O
, NN NN O
58 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
. NN NN O
8 NN NN O
years NN NN O
; NN NN O
7 NN NN O
men NN NN O
, NN NN O
3 NN NN O
women NN NN O
) NN NN O
with NN NN O
similar NN NN O
characteristics NN NN O
at NN NN O
the NN NN O
duration NN NN O
of NN NN O
disease NN NN O
( NN NN O
mean NN NN O
disease NN NN O
time NN NN O
, NN NN O
8 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
5 NN NN O
years NN NN O
) NN NN O
, NN NN O
disabling NN NN O
motor NN NN O
fluctuations NN NN O
( NN NN O
Hoehn NN NN O
_ NN NN O
Yahr NN NN O
stage NN NN O
3 NN NN O
- NN NN O
5 NN NN O
in NN NN O
off NN NN O
- NN NN O
drug NN NN O
phases NN NN O
) NN NN O
and NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
were NN NN O
selected NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
had NN NN O
bilateral NN NN O
symptoms NN NN O
and NN NN O
their NN NN O
levodopa NN NN O
equivalent NN NN O
dosing NN NN O
were NN NN O
analysed NN NN O
. NN NN O
   
Six NN NN O
patients NN NN O
were NN NN O
operated NN NN O
on NN NN O
in NN NN O
the NN NN O
globus NN NN O
pallidus NN NN O
interna NN NN O
( NN NN O
GPi NN NN O
) NN NN O
and NN NN O
four NN NN O
in NN NN O
the NN NN O
subthalamic NN NN O
nucleus NN NN O
( NN NN O
STN NN NN O
) NN NN O
. NN NN O
   
Clinical NN NN O
evaluation NN NN O
included NN NN O
the NN NN O
use NN NN O
of NN NN O
the NN NN O
Unified NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
Disease NN NN I-Disease
Rating NN NN O
Scale NN NN O
( NN NN O
UPDRS NN NN O
) NN NN O
, NN NN O
Hoehn NN NN O
_ NN NN O
Yahr NN NN O
score NN NN O
and NN NN O
Schwab NN NN O
England NN NN O
activities NN NN O
of NN NN O
daily NN NN O
living NN NN O
( NN NN O
ADL NN NN O
) NN NN O
score NN NN O
in NN NN O
' NN NN O
on NN NN O
' NN NN O
- NN NN O
and NN NN O
' NN NN O
off NN NN O
' NN NN O
- NN NN O
drug NN NN O
conditions NN NN O
before NN NN O
surgery NN NN O
and NN NN O
6 NN NN O
months NN NN O
after NN NN O
surgery NN NN O
. NN NN O
   
There NN NN O
was NN NN O
statistically NN NN O
significant NN NN O
improvement NN NN O
in NN NN O
all NN NN O
contralateral NN NN O
major NN NN O
parkinsonian NN NN B-Disease
motor NN NN O
signs NN NN O
in NN NN O
all NN NN O
patients NN NN O
followed NN NN O
for NN NN O
6 NN NN O
months NN NN O
. NN NN O
   
Levodopa NN NN O
equivalent NN NN O
daily NN NN O
intake NN NN O
was NN NN O
significantly NN NN O
reduced NN NN O
in NN NN O
the NN NN O
STN NN NN O
group NN NN O
. NN NN O
   
Changes NN NN O
in NN NN O
UPDRS NN NN O
, NN NN O
Hoehn NN NN O
_ NN NN O
Yahr NN NN O
and NN NN O
Schwab NN NN O
England NN NN O
ADL NN NN O
scores NN NN O
were NN NN O
similar NN NN O
in NN NN O
both NN NN O
groups NN NN O
. NN NN O
   
Cognitive NN NN O
functions NN NN O
were NN NN O
unchanged NN NN O
in NN NN O
both NN NN O
groups NN NN O
. NN NN O
   
Complications NN NN O
were NN NN O
observed NN NN O
in NN NN O
two NN NN O
patients NN NN O
: NN NN O
one NN NN O
had NN NN O
a NN NN O
left NN NN O
homonymous NN NN B-Disease
hemianopsia NN NN I-Disease
after NN NN O
pallidotomy NN NN O
and NN NN O
another NN NN O
one NN NN O
developed NN NN O
left NN NN O
hemiballistic NN NN O
movements NN NN O
3 NN NN O
days NN NN O
after NN NN O
subthalamotomy NN NN O
which NN NN O
partly NN NN O
improved NN NN O
within NN NN O
1 NN NN O
month NN NN O
with NN NN O
Valproate NN NN O
1000 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
. NN NN O
   
The NN NN O
findings NN NN O
of NN NN O
this NN NN O
study NN NN O
suggest NN NN O
that NN NN O
lesions NN NN O
of NN NN O
the NN NN O
unilateral NN NN O
STN NN NN O
and NN NN O
GPi NN NN O
are NN NN O
equally NN NN O
effective NN NN O
treatment NN NN O
for NN NN O
patients NN NN O
with NN NN O
advanced NN NN O
PD NN NN B-Disease
refractory NN NN O
to NN NN O
medical NN NN O
treatment NN NN O
. NN NN O
   
DSMM NN NN O
XI NN NN O
study NN NN O
: NN NN O
dose NN NN O
definition NN NN O
for NN NN O
intravenous NN NN O
cyclophosphamide NN NN O
in NN NN O
combination NN NN O
with NN NN O
bortezomib NN NN O
/ NN NN O
dexamethasone NN NN O
for NN NN O
remission NN NN O
induction NN NN O
in NN NN O
patients NN NN O
with NN NN O
newly NN NN O
diagnosed NN NN O
myeloma NN NN B-Disease
. NN NN O
   
A NN NN O
clinical NN NN O
trial NN NN O
was NN NN O
initiated NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
recommended NN NN O
dose NN NN O
of NN NN O
cyclophosphamide NN NN O
in NN NN O
combination NN NN O
with NN NN O
bortezomib NN NN O
and NN NN O
dexamethasone NN NN O
as NN NN O
induction NN NN O
treatment NN NN O
before NN NN O
stem NN NN O
cell NN NN O
transplantation NN NN O
for NN NN O
younger NN NN O
patients NN NN O
with NN NN O
newly NN NN O
diagnosed NN NN O
multiple NN NN B-Disease
myeloma NN NN I-Disease
( NN NN O
MM NN NN B-Disease
) NN NN O
. NN NN O
   
Thirty NN NN O
patients NN NN O
were NN NN O
treated NN NN O
with NN NN O
three NN NN O
21 NN NN O
- NN NN O
day NN NN O
cycles NN NN O
of NN NN O
bortezomib NN NN O
1 NN NN O
. NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
on NN NN O
days NN NN O
1 NN NN O
, NN NN O
4 NN NN O
, NN NN O
8 NN NN O
, NN NN O
and NN NN O
11 NN NN O
plus NN NN O
dexamethasone NN NN O
40 NN NN O
mg NN NN O
on NN NN O
the NN NN O
day NN NN O
of NN NN O
bortezomib NN NN O
injection NN NN O
and NN NN O
the NN NN O
day NN NN O
after NN NN O
plus NN NN O
cyclophosphamide NN NN O
at NN NN O
900 NN NN O
, NN NN O
1 NN NN O
, NN NN O
200 NN NN O
, NN NN O
or NN NN O
1 NN NN O
, NN NN O
500 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
on NN NN O
day NN NN O
1 NN NN O
. NN NN O
   
The NN NN O
maximum NN NN O
tolerated NN NN O
dose NN NN O
of NN NN O
cyclophosphamide NN NN O
was NN NN O
defined NN NN O
as NN NN O
900 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
. NN NN O
   
At NN NN O
this NN NN O
dose NN NN O
level NN NN O
, NN NN O
92 NN NN O
% NN NN O
of NN NN O
patients NN NN O
achieved NN NN O
at NN NN O
least NN NN O
a NN NN O
partial NN NN O
response NN NN O
. NN NN O
   
The NN NN O
overall NN NN O
response NN NN O
rate NN NN O
[ NN NN O
complete NN NN O
response NN NN O
( NN NN O
CR NN NN O
) NN NN O
plus NN NN O
partial NN NN O
response NN NN O
( NN NN O
PR NN NN O
) NN NN O
] NN NN O
across NN NN O
all NN NN O
dose NN NN O
levels NN NN O
was NN NN O
77 NN NN O
% NN NN O
, NN NN O
with NN NN O
a NN NN O
10 NN NN O
% NN NN O
CR NN NN O
rate NN NN O
. NN NN O
   
No NN NN O
patient NN NN O
experienced NN NN O
progressive NN NN O
disease NN NN O
. NN NN O
   
The NN NN O
most NN NN O
frequent NN NN O
adverse NN NN O
events NN NN O
were NN NN O
hematological NN NN B-Disease
and NN NN I-Disease
gastrointestinal NN NN I-Disease
toxicities NN NN I-Disease
as NN NN O
well NN NN O
as NN NN O
neuropathy NN NN B-Disease
. NN NN O
   
The NN NN O
results NN NN O
suggest NN NN O
that NN NN O
bortezomib NN NN O
in NN NN O
combination NN NN O
with NN NN O
cyclophosphamide NN NN O
at NN NN O
900 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
and NN NN O
dexamethasone NN NN O
is NN NN O
an NN NN O
effective NN NN O
induction NN NN O
treatment NN NN O
for NN NN O
patients NN NN O
with NN NN O
newly NN NN O
diagnosed NN NN O
MM NN NN B-Disease
that NN NN O
warrants NN NN O
further NN NN O
investigation NN NN O
. NN NN O
   
Naloxone NN NN O
reversal NN NN O
of NN NN O
hypotension NN NN B-Disease
due NN NN O
to NN NN O
captopril NN NN O
overdose NN NN B-Disease
. NN NN O
   
The NN NN O
hemodynamic NN NN O
effects NN NN O
of NN NN O
captopril NN NN O
and NN NN O
other NN NN O
angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
inhibitors NN NN O
may NN NN O
be NN NN O
mediated NN NN O
by NN NN O
the NN NN O
endogenous NN NN O
opioid NN NN O
system NN NN O
. NN NN O
   
The NN NN O
opioid NN NN O
antagonist NN NN O
naloxone NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
block NN NN O
or NN NN O
reverse NN NN O
the NN NN O
hypotensive NN NN B-Disease
actions NN NN O
of NN NN O
captopril NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
an NN NN O
intentional NN NN O
captopril NN NN O
overdose NN NN B-Disease
, NN NN O
manifested NN NN O
by NN NN O
marked NN NN O
hypotension NN NN B-Disease
, NN NN O
that NN NN O
resolved NN NN O
promptly NN NN O
with NN NN O
the NN NN O
administration NN NN O
of NN NN O
naloxone NN NN O
. NN NN O
   
To NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
this NN NN O
is NN NN O
the NN NN O
first NN NN O
reported NN NN O
case NN NN O
of NN NN O
captopril NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
treated NN NN O
with NN NN O
naloxone NN NN O
. NN NN O
   
Our NN NN O
experience NN NN O
demonstrates NN NN O
a NN NN O
possible NN NN O
role NN NN O
of NN NN O
naloxone NN NN O
in NN NN O
the NN NN O
reversal NN NN O
of NN NN O
hypotension NN NN B-Disease
resulting NN NN O
from NN NN O
captopril NN NN O
. NN NN O
   
Identification NN NN O
of NN NN O
a NN NN O
simple NN NN O
and NN NN O
sensitive NN NN O
microplate NN NN O
method NN NN O
for NN NN O
the NN NN O
detection NN NN O
of NN NN O
oversulfated NN NN O
chondroitin NN NN O
sulfate NN NN O
in NN NN O
heparin NN NN O
products NN NN O
. NN NN O
   
Heparin NN NN O
is NN NN O
a NN NN O
commonly NN NN O
implemented NN NN O
anticoagulant NN NN O
used NN NN O
to NN NN O
treat NN NN O
critically NN NN O
ill NN NN O
patients NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
a NN NN O
number NN NN O
of NN NN O
commercial NN NN O
lots NN NN O
of NN NN O
heparin NN NN O
products NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
contaminated NN NN O
with NN NN O
an NN NN O
oversulfated NN NN O
chondroitin NN NN O
sulfate NN NN O
( NN NN O
OSCS NN NN O
) NN NN O
derivative NN NN O
that NN NN O
could NN NN O
elicit NN NN O
a NN NN O
hypotensive NN NN B-Disease
response NN NN O
in NN NN O
pigs NN NN O
following NN NN O
a NN NN O
single NN NN O
high NN NN O
- NN NN O
dose NN NN O
infusion NN NN O
. NN NN O
   
Using NN NN O
both NN NN O
contaminated NN NN O
heparin NN NN O
products NN NN O
and NN NN O
the NN NN O
synthetically NN NN O
produced NN NN O
derivative NN NN O
, NN NN O
we NN NN O
showed NN NN O
that NN NN O
the NN NN O
OSCS NN NN O
produces NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
hypotension NN NN B-Disease
in NN NN O
pigs NN NN O
. NN NN O
   
The NN NN O
no NN NN O
observed NN NN O
effect NN NN O
level NN NN O
( NN NN O
NOEL NN NN O
) NN NN O
for NN NN O
this NN NN O
contaminant NN NN O
appears NN NN O
to NN NN O
be NN NN O
approximately NN NN O
1mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
corresponding NN NN O
to NN NN O
a NN NN O
contamination NN NN O
level NN NN O
of NN NN O
approximately NN NN O
3 NN NN O
% NN NN O
. NN NN O
   
We NN NN O
also NN NN O
demonstrated NN NN O
that NN NN O
OSCS NN NN O
can NN NN O
be NN NN O
identified NN NN O
in NN NN O
heparin NN NN O
products NN NN O
using NN NN O
a NN NN O
simple NN NN O
, NN NN O
inexpensive NN NN O
, NN NN O
commercially NN NN O
available NN NN O
heparin NN NN O
enzyme NN NN O
immunoassay NN NN O
( NN NN O
EIA NN NN O
) NN NN O
kit NN NN O
that NN NN O
has NN NN O
a NN NN O
limit NN NN O
of NN NN O
detection NN NN O
of NN NN O
approximately NN NN O
0 NN NN O
. NN NN O
1 NN NN O
% NN NN O
, NN NN O
well NN NN O
below NN NN O
the NN NN O
NOEL NN NN O
. NN NN O
   
This NN NN O
kit NN NN O
may NN NN O
provide NN NN O
a NN NN O
useful NN NN O
method NN NN O
to NN NN O
test NN NN O
heparin NN NN O
products NN NN O
for NN NN O
contamination NN NN O
with NN NN O
oversulfated NN NN O
GAG NN NN O
derivatives NN NN O
. NN NN O
   
5 NN NN O
flourouracil NN NN O
- NN NN O
induced NN NN O
apical NN NN B-Disease
ballooning NN NN I-Disease
syndrome NN NN I-Disease
: NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
The NN NN O
apical NN NN B-Disease
ballooning NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
ABS NN NN B-Disease
) NN NN O
is NN NN O
a NN NN O
recently NN NN O
described NN NN O
stress NN NN O
- NN NN O
mediated NN NN O
acute NN NN B-Disease
cardiac NN NN I-Disease
syndrome NN NN I-Disease
characterized NN NN O
by NN NN O
transient NN NN O
wall NN NN O
- NN NN O
motion NN NN O
abnormalities NN NN O
involving NN NN O
the NN NN O
apex NN NN O
and NN NN O
midventricle NN NN O
with NN NN O
hyperkinesis NN NN B-Disease
of NN NN O
the NN NN O
basal NN NN O
left NN NN O
ventricular NN NN O
( NN NN O
LV NN NN O
) NN NN O
segments NN NN O
without NN NN O
obstructive NN NN O
epicardial NN NN B-Disease
coronary NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Cardiotoxicity NN NN B-Disease
is NN NN O
not NN NN O
an NN NN O
uncommon NN NN O
adverse NN NN O
effect NN NN O
of NN NN O
chemotherapeutic NN NN O
agents NN NN O
. NN NN O
   
However NN NN O
, NN NN O
there NN NN O
are NN NN O
no NN NN O
reports NN NN O
of NN NN O
ABS NN NN B-Disease
secondary NN NN O
to NN NN O
chemotherapeutic NN NN O
agents NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
woman NN NN O
who NN NN O
developed NN NN O
the NN NN O
syndrome NN NN O
after NN NN O
chemotherapy NN NN O
for NN NN O
metastatic NN NN O
cancer NN NN B-Disease
. NN NN O
   
A NN NN O
79 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
presented NN NN O
with NN NN O
typical NN NN O
ischemic NN NN B-Disease
chest NN NN B-Disease
pain NN NN I-Disease
, NN NN O
elevated NN NN O
cardiac NN NN O
enzymes NN NN O
with NN NN O
significant NN NN O
ST NN NN O
- NN NN O
segment NN NN O
abnormalities NN NN O
on NN NN O
her NN NN O
electrocardiogram NN NN O
. NN NN O
   
She NN NN O
underwent NN NN O
recent NN NN O
chemotherapy NN NN O
with NN NN O
fluorouracil NN NN O
for NN NN O
metastatic NN NN O
colorectal NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
Echocardiography NN NN O
revealed NN NN O
a NN NN O
wall NN NN O
- NN NN O
motion NN NN O
abnormality NN NN O
involving NN NN O
the NN NN O
apical NN NN O
and NN NN O
periapical NN NN O
segments NN NN O
which NN NN O
appeared NN NN O
akinetic NN NN B-Disease
. NN NN O
   
Coronary NN NN O
angiography NN NN O
revealed NN NN O
no NN NN O
obstructive NN NN O
coronary NN NN O
lesions NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
was NN NN O
stabilized NN NN O
with NN NN O
medical NN NN O
therapy NN NN O
. NN NN O
   
Four NN NN O
weeks NN NN O
later NN NN O
she NN NN O
remained NN NN O
completely NN NN O
asymptomatic NN NN O
. NN NN O
   
Echocardiogram NN NN O
revealed NN NN O
a NN NN O
normal NN NN O
ejection NN NN O
fraction NN NN O
and NN NN O
a NN NN O
resolution NN NN O
of NN NN O
the NN NN O
apical NN NN O
akinesis NN NN B-Disease
. NN NN O
   
Pathogenetic NN NN O
mechanisms NN NN O
of NN NN O
cardiac NN NN B-Disease
complications NN NN I-Disease
in NN NN O
cancer NN NN B-Disease
patients NN NN O
undergoing NN NN O
chemotherapy NN NN O
include NN NN O
coronary NN NN B-Disease
vasospasm NN NN I-Disease
, NN NN O
endothelial NN NN O
damage NN NN O
and NN NN O
consequent NN NN O
thrombus NN NN B-Disease
formation NN NN O
. NN NN O
   
In NN NN O
our NN NN O
patient NN NN O
, NN NN O
both NN NN O
supraphysiologic NN NN O
levels NN NN O
of NN NN O
plasma NN NN O
catecholamines NN NN O
and NN NN O
stress NN NN O
related NN NN O
neuropeptides NN NN O
caused NN NN O
by NN NN O
cancer NN NN B-Disease
diagnosis NN NN O
as NN NN O
well NN NN O
as NN NN O
chemotherapy NN NN O
may NN NN O
have NN NN O
contributed NN NN O
the NN NN O
development NN NN O
of NN NN O
ABS NN NN B-Disease
. NN NN O
   
Rapid NN NN O
reversal NN NN O
of NN NN O
anticoagulation NN NN O
reduces NN NN O
hemorrhage NN NN B-Disease
volume NN NN O
in NN NN O
a NN NN O
mouse NN NN O
model NN NN O
of NN NN O
warfarin NN NN O
- NN NN O
associated NN NN O
intracerebral NN NN B-Disease
hemorrhage NN NN I-Disease
. NN NN O
   
Warfarin NN NN O
- NN NN O
associated NN NN O
intracerebral NN NN B-Disease
hemorrhage NN NN I-Disease
( NN NN O
W NN NN O
- NN NN O
ICH NN NN B-Disease
) NN NN O
is NN NN O
a NN NN O
severe NN NN O
type NN NN O
of NN NN O
stroke NN NN B-Disease
. NN NN O
   
There NN NN O
is NN NN O
no NN NN O
consensus NN NN O
on NN NN O
the NN NN O
optimal NN NN O
treatment NN NN O
for NN NN O
W NN NN O
- NN NN O
ICH NN NN B-Disease
. NN NN O
   
Using NN NN O
a NN NN O
mouse NN NN O
model NN NN O
, NN NN O
we NN NN O
tested NN NN O
whether NN NN O
the NN NN O
rapid NN NN O
reversal NN NN O
of NN NN O
anticoagulation NN NN O
using NN NN O
human NN NN O
prothrombin NN NN O
complex NN NN O
concentrate NN NN O
( NN NN O
PCC NN NN O
) NN NN O
can NN NN O
reduce NN NN O
hemorrhagic NN NN O
blood NN NN O
volume NN NN O
. NN NN O
   
Male NN NN O
CD NN NN O
- NN NN O
1 NN NN O
mice NN NN O
were NN NN O
treated NN NN O
with NN NN O
warfarin NN NN O
( NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
over NN NN O
24 NN NN O
h NN NN O
) NN NN O
, NN NN O
resulting NN NN O
in NN NN O
a NN NN O
mean NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
s NN NN O
. NN NN O
d NN NN O
. NN NN O
) NN NN O
International NN NN O
Normalized NN NN O
Ratio NN NN O
of NN NN O
3 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
9 NN NN O
. NN NN O
   
First NN NN O
, NN NN O
we NN NN O
showed NN NN O
that NN NN O
an NN NN O
intravenous NN NN O
administration NN NN O
of NN NN O
human NN NN O
PCC NN NN O
rapidly NN NN O
reversed NN NN O
anticoagulation NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Second NN NN O
, NN NN O
a NN NN O
stereotactic NN NN O
injection NN NN O
of NN NN O
collagenase NN NN O
was NN NN O
administered NN NN O
to NN NN O
induce NN NN O
hemorrhage NN NN B-Disease
in NN NN O
the NN NN O
right NN NN O
striatum NN NN O
. NN NN O
   
Forty NN NN O
- NN NN O
five NN NN O
minutes NN NN O
later NN NN O
, NN NN O
the NN NN O
animals NN NN O
were NN NN O
randomly NN NN O
treated NN NN O
with NN NN O
PCC NN NN O
( NN NN O
100 NN NN O
U NN NN O
/ NN NN O
kg NN NN O
) NN NN O
or NN NN O
saline NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
( NN NN O
n NN NN O
= NN NN O
12 NN NN O
per NN NN O
group NN NN O
) NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
four NN NN O
hours NN NN O
after NN NN O
hemorrhage NN NN B-Disease
induction NN NN O
, NN NN O
hemorrhagic NN NN O
blood NN NN O
volume NN NN O
was NN NN O
quantified NN NN O
using NN NN O
a NN NN O
photometric NN NN O
hemoglobin NN NN O
assay NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
hemorrhagic NN NN O
blood NN NN O
volume NN NN O
was NN NN O
reduced NN NN O
in NN NN O
PCC NN NN O
- NN NN O
treated NN NN O
animals NN NN O
( NN NN O
6 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
1 NN NN O
microL NN NN O
) NN NN O
compared NN NN O
with NN NN O
saline NN NN O
controls NN NN O
( NN NN O
15 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
11 NN NN O
. NN NN O
2 NN NN O
microL NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
015 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
saline NN NN O
group NN NN O
, NN NN O
45 NN NN O
% NN NN O
of NN NN O
the NN NN O
mice NN NN O
developed NN NN O
large NN NN O
hematomas NN NN B-Disease
( NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
> NN NN O
15 NN NN O
microL NN NN O
) NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
such NN NN O
extensive NN NN O
lesions NN NN O
were NN NN O
never NN NN O
found NN NN O
in NN NN O
the NN NN O
PCC NN NN O
group NN NN O
. NN NN O
   
We NN NN O
provide NN NN O
experimental NN NN O
data NN NN O
suggesting NN NN O
PCC NN NN O
to NN NN O
be NN NN O
an NN NN O
effective NN NN O
acute NN NN O
treatment NN NN O
for NN NN O
W NN NN O
- NN NN O
ICH NN NN B-Disease
in NN NN O
terms NN NN O
of NN NN O
reducing NN NN O
hemorrhagic NN NN O
blood NN NN O
volume NN NN O
. NN NN O
   
Future NN NN O
studies NN NN O
are NN NN O
needed NN NN O
to NN NN O
assess NN NN O
the NN NN O
therapeutic NN NN O
potential NN NN O
emerging NN NN O
from NN NN O
our NN NN O
finding NN NN O
for NN NN O
human NN NN O
W NN NN O
- NN NN O
ICH NN NN B-Disease
. NN NN O
   
Long NN NN O
term NN NN O
hormone NN NN O
therapy NN NN O
for NN NN O
perimenopausal NN NN O
and NN NN O
postmenopausal NN NN O
women NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Hormone NN NN O
therapy NN NN O
( NN NN O
HT NN NN O
) NN NN O
is NN NN O
widely NN NN O
used NN NN O
for NN NN O
controlling NN NN O
menopausal NN NN O
symptoms NN NN O
and NN NN O
has NN NN O
also NN NN O
been NN NN O
used NN NN O
for NN NN O
the NN NN O
management NN NN O
and NN NN O
prevention NN NN O
of NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
, NN NN O
osteoporosis NN NN B-Disease
and NN NN O
dementia NN NN B-Disease
in NN NN O
older NN NN O
women NN NN O
. NN NN O
   
This NN NN O
is NN NN O
an NN NN O
updated NN NN O
version NN NN O
of NN NN O
the NN NN O
original NN NN O
Cochrane NN NN O
review NN NN O
first NN NN O
published NN NN O
in NN NN O
2005 NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
To NN NN O
assess NN NN O
the NN NN O
effect NN NN O
of NN NN O
long NN NN O
- NN NN O
term NN NN O
HT NN NN O
on NN NN O
mortality NN NN O
, NN NN O
cardiovascular NN NN O
outcomes NN NN O
, NN NN O
cancer NN NN B-Disease
, NN NN O
gallbladder NN NN B-Disease
disease NN NN I-Disease
, NN NN O
cognition NN NN O
, NN NN O
fractures NN NN B-Disease
and NN NN O
quality NN NN O
of NN NN O
life NN NN O
. NN NN O
   
SEARCH NN NN O
STRATEGY NN NN O
: NN NN O
We NN NN O
searched NN NN O
the NN NN O
following NN NN O
databases NN NN O
to NN NN O
November NN NN O
2007 NN NN O
: NN NN O
Trials NN NN O
Register NN NN O
of NN NN O
the NN NN O
Cochrane NN NN O
Menstrual NN NN B-Disease
Disorders NN NN I-Disease
and NN NN O
Subfertility NN NN O
Group NN NN O
, NN NN O
Cochrane NN NN O
Central NN NN O
Register NN NN O
of NN NN O
Controlled NN NN O
Trials NN NN O
, NN NN O
MEDLINE NN NN O
, NN NN O
EMBASE NN NN O
, NN NN O
Biological NN NN O
Abstracts NN NN O
. NN NN O
   
Also NN NN O
relevant NN NN O
non NN NN O
- NN NN O
indexed NN NN O
journals NN NN O
and NN NN O
conference NN NN O
abstracts NN NN O
. NN NN O
   
SELECTION NN NN O
CRITERIA NN NN O
: NN NN O
Randomised NN NN O
double NN NN O
- NN NN O
blind NN NN O
trials NN NN O
of NN NN O
HT NN NN O
versus NN NN O
placebo NN NN O
, NN NN O
taken NN NN O
for NN NN O
at NN NN O
least NN NN O
one NN NN O
year NN NN O
by NN NN O
perimenopausal NN NN O
or NN NN O
postmenopausal NN NN O
women NN NN O
. NN NN O
   
HT NN NN O
included NN NN O
oestrogens NN NN O
, NN NN O
with NN NN O
or NN NN O
without NN NN O
progestogens NN NN O
, NN NN O
via NN NN O
oral NN NN O
, NN NN O
transdermal NN NN O
, NN NN O
subcutaneous NN NN O
or NN NN O
transnasal NN NN O
routes NN NN O
. NN NN O
   
DATA NN NN O
COLLECTION NN NN O
AND NN NN O
ANALYSIS NN NN O
: NN NN O
Two NN NN O
authors NN NN O
independently NN NN O
assessed NN NN O
trial NN NN O
quality NN NN O
and NN NN O
extracted NN NN O
data NN NN O
. NN NN O
   
MAIN NN NN O
RESULTS NN NN O
: NN NN O
Nineteen NN NN O
trials NN NN O
involving NN NN O
41 NN NN O
, NN NN O
904 NN NN O
women NN NN O
were NN NN O
included NN NN O
. NN NN O
   
In NN NN O
relatively NN NN O
healthy NN NN O
women NN NN O
, NN NN O
combined NN NN O
continuous NN NN O
HT NN NN O
significantly NN NN O
increased NN NN O
the NN NN O
risk NN NN O
of NN NN O
venous NN NN B-Disease
thrombo NN NN I-Disease
- NN NN I-Disease
embolism NN NN I-Disease
or NN NN O
coronary NN NN O
event NN NN O
( NN NN O
after NN NN O
one NN NN O
year NN NN O
' NN NN O
s NN NN O
use NN NN O
) NN NN O
, NN NN O
stroke NN NN B-Disease
( NN NN O
after NN NN O
three NN NN O
years NN NN O
) NN NN O
, NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
and NN NN O
gallbladder NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
oestrogen NN NN O
- NN NN O
only NN NN O
HT NN NN O
significantly NN NN O
increased NN NN O
the NN NN O
risk NN NN O
of NN NN O
venous NN NN B-Disease
thrombo NN NN I-Disease
- NN NN I-Disease
embolism NN NN I-Disease
, NN NN O
stroke NN NN B-Disease
and NN NN O
gallbladder NN NN B-Disease
disease NN NN I-Disease
( NN NN O
after NN NN O
one NN NN O
to NN NN O
two NN NN O
years NN NN O
, NN NN O
three NN NN O
years NN NN O
and NN NN O
seven NN NN O
years NN NN O
' NN NN O
use NN NN O
respectively NN NN O
) NN NN O
, NN NN O
but NN NN O
did NN NN O
not NN NN O
significantly NN NN O
increase NN NN O
the NN NN O
risk NN NN O
of NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
The NN NN O
only NN NN O
statistically NN NN O
significant NN NN O
benefits NN NN O
of NN NN O
HT NN NN O
were NN NN O
a NN NN O
decreased NN NN O
incidence NN NN O
of NN NN O
fractures NN NN B-Disease
and NN NN O
( NN NN O
for NN NN O
combined NN NN O
HT NN NN O
) NN NN O
colon NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
with NN NN O
long NN NN O
- NN NN O
term NN NN O
use NN NN O
. NN NN O
   
Among NN NN O
women NN NN O
aged NN NN O
over NN NN O
65 NN NN O
who NN NN O
were NN NN O
relatively NN NN O
healthy NN NN O
( NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
generally NN NN O
fit NN NN O
, NN NN O
without NN NN O
overt NN NN O
disease NN NN O
) NN NN O
and NN NN O
taking NN NN O
continuous NN NN O
combined NN NN O
HT NN NN O
, NN NN O
there NN NN O
was NN NN O
a NN NN O
statistically NN NN O
significant NN NN O
increase NN NN O
in NN NN O
the NN NN O
incidence NN NN O
of NN NN O
dementia NN NN B-Disease
. NN NN O
   
Among NN NN O
women NN NN O
with NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
, NN NN O
long NN NN O
- NN NN O
term NN NN O
use NN NN O
of NN NN O
combined NN NN O
continuous NN NN O
HT NN NN O
significantly NN NN O
increased NN NN O
the NN NN O
risk NN NN O
of NN NN O
venous NN NN B-Disease
thrombo NN NN I-Disease
- NN NN I-Disease
embolism NN NN I-Disease
. NN NN O
One NN NN O
trial NN NN O
analysed NN NN O
subgroups NN NN O
of NN NN O
2839 NN NN O
relatively NN NN O
healthy NN NN O
50 NN NN O
to NN NN O
59 NN NN O
year NN NN O
old NN NN O
women NN NN O
taking NN NN O
combined NN NN O
continuous NN NN O
HT NN NN O
and NN NN O
1637 NN NN O
taking NN NN O
oestrogen NN NN O
- NN NN O
only NN NN O
HT NN NN O
, NN NN O
versus NN NN O
similar NN NN O
- NN NN O
sized NN NN O
placebo NN NN O
groups NN NN O
. NN NN O
   
The NN NN O
only NN NN O
significantly NN NN O
increased NN NN O
risk NN NN O
reported NN NN O
was NN NN O
for NN NN O
venous NN NN B-Disease
thrombo NN NN I-Disease
- NN NN I-Disease
embolism NN NN I-Disease
in NN NN O
women NN NN O
taking NN NN O
combined NN NN O
continuous NN NN O
HT NN NN O
: NN NN O
their NN NN O
absolute NN NN O
risk NN NN O
remained NN NN O
low NN NN O
, NN NN O
at NN NN O
less NN NN O
than NN NN O
1 NN NN O
/ NN NN O
500 NN NN O
. NN NN O
   
However NN NN O
, NN NN O
this NN NN O
study NN NN O
was NN NN O
not NN NN O
powered NN NN O
to NN NN O
detect NN NN O
differences NN NN O
between NN NN O
groups NN NN O
of NN NN O
younger NN NN O
women NN NN O
. NN NN O
   
AUTHORS NN NN O
' NN NN O
CONCLUSIONS NN NN O
: NN NN O
HT NN NN O
is NN NN O
not NN NN O
indicated NN NN O
for NN NN O
the NN NN O
routine NN NN O
management NN NN O
of NN NN O
chronic NN NN O
disease NN NN O
. NN NN O
   
We NN NN O
need NN NN O
more NN NN O
evidence NN NN O
on NN NN O
the NN NN O
safety NN NN O
of NN NN O
HT NN NN O
for NN NN O
menopausal NN NN O
symptom NN NN O
control NN NN O
, NN NN O
though NN NN O
short NN NN O
- NN NN O
term NN NN O
use NN NN O
appears NN NN O
to NN NN O
be NN NN O
relatively NN NN O
safe NN NN O
for NN NN O
healthy NN NN O
younger NN NN O
women NN NN O
. NN NN O
   
Acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
in NN NN O
patients NN NN O
with NN NN O
AIDS NN NN B-Disease
on NN NN O
tenofovir NN NN O
while NN NN O
receiving NN NN O
prolonged NN NN O
vancomycin NN NN O
course NN NN O
for NN NN O
osteomyelitis NN NN B-Disease
. NN NN O
   
Renal NN NN B-Disease
failure NN NN I-Disease
developed NN NN O
after NN NN O
a NN NN O
prolonged NN NN O
course NN NN O
of NN NN O
vancomycin NN NN O
therapy NN NN O
in NN NN O
2 NN NN O
patients NN NN O
who NN NN O
were NN NN O
receiving NN NN O
tenofovir NN NN O
disoproxil NN NN O
fumarate NN NN O
as NN NN O
part NN NN O
of NN NN O
an NN NN O
antiretroviral NN NN O
regimen NN NN O
. NN NN O
   
Tenofovir NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
Fanconi NN NN B-Disease
syndrome NN NN I-Disease
and NN NN O
renal NN NN B-Disease
insufficiency NN NN I-Disease
because NN NN O
of NN NN O
its NN NN O
effects NN NN O
on NN NN O
the NN NN O
proximal NN NN O
renal NN NN O
tubule NN NN O
. NN NN O
   
Vancomycin NN NN O
nephrotoxicity NN NN B-Disease
is NN NN O
infrequent NN NN O
but NN NN O
may NN NN O
result NN NN O
from NN NN O
coadministration NN NN O
with NN NN O
a NN NN O
nephrotoxic NN NN B-Disease
agent NN NN O
. NN NN O
   
Clinicians NN NN O
should NN NN O
be NN NN O
aware NN NN O
that NN NN O
tenofovir NN NN O
may NN NN O
raise NN NN O
the NN NN O
risk NN NN O
of NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
during NN NN O
prolonged NN NN O
administration NN NN O
of NN NN O
vancomycin NN NN O
. NN NN O
   
Recurrent NN NN O
dysosmia NN NN B-Disease
induced NN NN O
by NN NN O
pyrazinamide NN NN O
. NN NN O
   
Pyrazinamide NN NN O
can NN NN O
have NN NN O
adverse NN NN O
effects NN NN O
such NN NN O
as NN NN O
hepatic NN NN B-Disease
toxicity NN NN I-Disease
, NN NN O
hyperuricemia NN NN B-Disease
or NN NN O
digestive NN NN O
disorders NN NN O
. NN NN O
   
In NN NN O
rare NN NN O
cases NN NN O
, NN NN O
alterations NN NN O
in NN NN O
taste NN NN O
and NN NN O
smell NN NN O
function NN NN O
have NN NN O
been NN NN O
reported NN NN O
for NN NN O
pyrazinamide NN NN O
when NN NN O
combined NN NN O
with NN NN O
other NN NN O
drugs NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
reversible NN NN O
olfactory NN NN B-Disease
disorder NN NN I-Disease
related NN NN O
to NN NN O
pyrazinamide NN NN O
in NN NN O
a NN NN O
woman NN NN O
, NN NN O
with NN NN O
a NN NN O
positive NN NN O
rechallenge NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
presented NN NN O
every NN NN O
day NN NN O
a NN NN O
sensation NN NN O
of NN NN O
smelling NN NN O
something NN NN O
burning NN NN O
15 NN NN O
min NN NN O
after NN NN O
drug NN NN O
intake NN NN O
. NN NN O
   
Dysosmia NN NN B-Disease
disappeared NN NN O
completely NN NN O
after NN NN O
pyrazinamide NN NN O
withdrawal NN NN O
and NN NN O
recurred NN NN O
after NN NN O
its NN NN O
rechallenge NN NN O
. NN NN O
   
The NN NN O
case NN NN O
was NN NN O
reported NN NN O
to NN NN O
the NN NN O
Tunisian NN NN O
Centre NN NN O
of NN NN O
Pharmacovigilance NN NN O
. NN NN O
   
Mice NN NN O
lacking NN NN O
mPGES NN NN O
- NN NN O
1 NN NN O
are NN NN O
resistant NN NN O
to NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
polyuria NN NN B-Disease
. NN NN O
   
Cyclooxygenase NN NN O
- NN NN O
2 NN NN O
activity NN NN O
is NN NN O
required NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
polyuria NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
involvement NN NN O
of NN NN O
a NN NN O
specific NN NN O
, NN NN O
terminal NN NN O
prostaglandin NN NN O
( NN NN O
PG NN NN O
) NN NN O
isomerase NN NN O
has NN NN O
not NN NN O
been NN NN O
evaluated NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
undertaken NN NN O
to NN NN O
assess NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
polyuria NN NN B-Disease
in NN NN O
mice NN NN O
deficient NN NN O
in NN NN O
microsomal NN NN O
prostaglandin NN NN O
E NN NN O
synthase NN NN O
- NN NN O
1 NN NN O
( NN NN O
mPGES NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
A NN NN O
2 NN NN O
- NN NN O
wk NN NN O
administration NN NN O
of NN NN O
LiCl NN NN O
( NN NN O
4 NN NN O
mmol NN NN O
. NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
day NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
ip NN NN O
) NN NN O
in NN NN O
mPGES NN NN O
- NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
+ NN NN O
mice NN NN O
led NN NN O
to NN NN O
a NN NN O
marked NN NN O
polyuria NN NN B-Disease
with NN NN O
hyposmotic NN NN O
urine NN NN O
. NN NN O
   
This NN NN O
was NN NN O
associated NN NN O
with NN NN O
elevated NN NN O
renal NN NN O
mPGES NN NN O
- NN NN O
1 NN NN O
protein NN NN O
expression NN NN O
and NN NN O
increased NN NN O
urine NN NN O
PGE NN NN O
( NN NN O
2 NN NN O
) NN NN O
excretion NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
mPGES NN NN O
- NN NN O
1 NN NN O
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
were NN NN O
largely NN NN O
resistant NN NN O
to NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
polyuria NN NN B-Disease
and NN NN O
a NN NN O
urine NN NN O
concentrating NN NN O
defect NN NN O
, NN NN O
accompanied NN NN O
by NN NN O
nearly NN NN O
complete NN NN O
blockade NN NN O
of NN NN O
high NN NN O
urine NN NN O
PGE NN NN O
( NN NN O
2 NN NN O
) NN NN O
and NN NN O
cAMP NN NN O
output NN NN O
. NN NN O
   
Immunoblotting NN NN O
, NN NN O
immunohistochemistry NN NN O
, NN NN O
and NN NN O
quantitative NN NN O
( NN NN O
q NN NN O
) NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
consistently NN NN O
detected NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
aquaporin NN NN O
- NN NN O
2 NN NN O
( NN NN O
AQP2 NN NN O
) NN NN O
protein NN NN O
expression NN NN O
in NN NN O
both NN NN O
the NN NN O
renal NN NN O
cortex NN NN O
and NN NN O
medulla NN NN O
of NN NN O
lithium NN NN O
- NN NN O
treated NN NN O
+ NN NN O
/ NN NN O
+ NN NN O
mice NN NN O
. NN NN O
   
This NN NN O
decrease NN NN O
was NN NN O
significantly NN NN O
attenuated NN NN O
in NN NN O
the NN NN O
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
. NN NN O
   
qRT NN NN O
- NN NN O
PCR NN NN O
detected NN NN O
similar NN NN O
patterns NN NN O
of NN NN O
changes NN NN O
in NN NN O
AQP2 NN NN O
mRNA NN NN O
in NN NN O
the NN NN O
medulla NN NN O
but NN NN O
not NN NN O
in NN NN O
the NN NN O
cortex NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
the NN NN O
total NN NN O
protein NN NN O
abundance NN NN O
of NN NN O
the NN NN O
Na NN NN O
- NN NN O
K NN NN O
- NN NN O
2Cl NN NN O
cotransporter NN NN O
( NN NN O
NKCC2 NN NN O
) NN NN O
in NN NN O
the NN NN O
medulla NN NN O
but NN NN O
not NN NN O
in NN NN O
the NN NN O
cortex NN NN O
of NN NN O
the NN NN O
+ NN NN O
/ NN NN O
+ NN NN O
mice NN NN O
was NN NN O
significantly NN NN O
reduced NN NN O
by NN NN O
lithium NN NN O
treatment NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
dowregulation NN NN O
of NN NN O
renal NN NN O
medullary NN NN O
NKCC2 NN NN O
expression NN NN O
was NN NN O
significantly NN NN O
attenuated NN NN O
in NN NN O
the NN NN O
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
mPGES NN NN O
- NN NN O
1 NN NN O
- NN NN O
derived NN NN O
PGE NN NN O
( NN NN O
2 NN NN O
) NN NN O
mediates NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
polyuria NN NN B-Disease
likely NN NN O
via NN NN O
inhibition NN NN O
of NN NN O
AQP2 NN NN O
and NN NN O
NKCC2 NN NN O
expression NN NN O
. NN NN O
   
Preservation NN NN O
of NN NN O
renal NN NN O
blood NN NN O
flow NN NN O
during NN NN O
hypotension NN NN B-Disease
induced NN NN O
with NN NN O
fenoldopam NN NN O
in NN NN O
dogs NN NN O
. NN NN O
   
The NN NN O
introduction NN NN O
of NN NN O
drugs NN NN O
that NN NN O
could NN NN O
induce NN NN O
hypotension NN NN B-Disease
with NN NN O
different NN NN O
pharmacological NN NN O
actions NN NN O
would NN NN O
be NN NN O
advantageous NN NN O
because NN NN O
side NN NN O
effects NN NN O
unique NN NN O
to NN NN O
a NN NN O
specific NN NN O
drug NN NN O
could NN NN O
be NN NN O
minimized NN NN O
by NN NN O
selecting NN NN O
appropriate NN NN O
therapy NN NN O
. NN NN O
   
Specific NN NN O
dopamine NN NN O
- NN NN O
1 NN NN O
, NN NN O
( NN NN O
DA1 NN NN O
) NN NN O
and NN NN O
dopamine NN NN O
- NN NN O
2 NN NN O
( NN NN O
DA2 NN NN O
) NN NN O
receptor NN NN O
agonists NN NN O
are NN NN O
now NN NN O
under NN NN O
clinical NN NN O
investigation NN NN O
. NN NN O
   
Fenoldopam NN NN O
mesylate NN NN O
is NN NN O
a NN NN O
specific NN NN O
DA1 NN NN O
receptor NN NN O
agonist NN NN O
that NN NN O
lowers NN NN O
blood NN NN O
pressure NN NN O
by NN NN O
vasodilatation NN NN O
. NN NN O
   
The NN NN O
hypothesis NN NN O
that NN NN O
fenoldopam NN NN O
could NN NN O
be NN NN O
used NN NN O
to NN NN O
induce NN NN O
hypotension NN NN B-Disease
and NN NN O
preserve NN NN O
blood NN NN O
flow NN NN O
to NN NN O
the NN NN O
kidney NN NN O
was NN NN O
tested NN NN O
. NN NN O
   
Systemic NN NN O
aortic NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
renal NN NN O
blood NN NN O
flow NN NN O
were NN NN O
measured NN NN O
continuously NN NN O
with NN NN O
a NN NN O
carotid NN NN O
arterial NN NN O
catheter NN NN O
and NN NN O
an NN NN O
electromagnetic NN NN O
flow NN NN O
probe NN NN O
respectively NN NN O
, NN NN O
in NN NN O
order NN NN O
to NN NN O
compare NN NN O
the NN NN O
cardiovascular NN NN O
and NN NN O
renal NN NN O
vascular NN NN O
effects NN NN O
of NN NN O
fenoldopam NN NN O
and NN NN O
sodium NN NN O
nitroprusside NN NN O
in NN NN O
ten NN NN O
dogs NN NN O
under NN NN O
halothane NN NN O
general NN NN O
anaesthesia NN NN O
. NN NN O
   
Mean NN NN O
arterial NN NN O
pressure NN NN O
was NN NN O
decreased NN NN O
30 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
8 NN NN O
per NN NN O
cent NN NN O
from NN NN O
control NN NN O
with NN NN O
infusion NN NN O
of NN NN O
fenoldopam NN NN O
( NN NN O
3 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
0 NN NN O
micrograms NN NN O
. NN NN O
kg NN NN O
- NN NN O
1 NN NN O
. NN NN O
min NN NN O
- NN NN O
1 NN NN O
) NN NN O
and NN NN O
34 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
per NN NN O
cent NN NN O
with NN NN O
infusion NN NN O
of NN NN O
sodium NN NN O
nitroprusside NN NN O
( NN NN O
5 NN NN O
. NN NN O
9 NN NN O
micrograms NN NN O
. NN NN O
kg NN NN O
- NN NN O
1 NN NN O
. NN NN O
min NN NN O
- NN NN O
1 NN NN O
) NN NN O
( NN NN O
NS NN NN O
) NN NN O
. NN NN O
   
Renal NN NN O
blood NN NN O
flow NN NN O
( NN NN O
RBF NN NN O
) NN NN O
increased NN NN O
during NN NN O
fenoldopam NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
11 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
per NN NN O
cent NN NN O
and NN NN O
decreased NN NN O
21 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
8 NN NN O
per NN NN O
cent NN NN O
during NN NN O
sodium NN NN O
nitroprusside NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Sodium NN NN O
nitroprusside NN NN O
is NN NN O
a NN NN O
non NN NN O
- NN NN O
selective NN NN O
arteriolar NN NN O
and NN NN O
venous NN NN O
vasodilator NN NN O
that NN NN O
can NN NN O
produce NN NN O
redistribution NN NN O
of NN NN O
blood NN NN O
flow NN NN O
away NN NN O
from NN NN O
the NN NN O
kidney NN NN O
during NN NN O
induced NN NN O
hypotension NN NN B-Disease
. NN NN O
   
Fenoldopam NN NN O
is NN NN O
a NN NN O
selective NN NN O
dopamine NN NN O
- NN NN O
1 NN NN O
( NN NN O
DA1 NN NN O
) NN NN O
receptor NN NN O
agonist NN NN O
that NN NN O
causes NN NN O
vasodilatation NN NN O
to NN NN O
the NN NN O
kidney NN NN O
and NN NN O
other NN NN O
organs NN NN O
with NN NN O
DA1 NN NN O
receptors NN NN O
and NN NN O
preserves NN NN O
blood NN NN O
flow NN NN O
to NN NN O
the NN NN O
kidney NN NN O
during NN NN O
induced NN NN O
hypotension NN NN B-Disease
. NN NN O
   
Seizures NN NN B-Disease
associated NN NN O
with NN NN O
levofloxacin NN NN O
: NN NN O
case NN NN O
presentation NN NN O
and NN NN O
literature NN NN O
review NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
We NN NN O
present NN NN O
a NN NN O
case NN NN O
of NN NN O
a NN NN O
patient NN NN O
who NN NN O
developed NN NN O
seizures NN NN B-Disease
shortly NN NN O
after NN NN O
initiating NN NN O
treatment NN NN O
with NN NN O
levofloxacin NN NN O
and NN NN O
to NN NN O
discuss NN NN O
the NN NN O
potential NN NN O
drug NN NN O
- NN NN O
drug NN NN O
interactions NN NN O
related NN NN O
to NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
cytochrome NN NN O
P450 NN NN O
( NN NN O
CYP NN NN O
) NN NN O
1A2 NN NN O
in NN NN O
this NN NN O
case NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
other NN NN O
cases NN NN O
, NN NN O
of NN NN O
levofloxacin NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Several NN NN O
biomedical NN NN O
databases NN NN O
were NN NN O
searched NN NN O
including NN NN O
MEDLINE NN NN O
, NN NN O
Cochrane NN NN O
and NN NN O
Ovid NN NN O
. NN NN O
   
The NN NN O
main NN NN O
search NN NN O
terms NN NN O
utilized NN NN O
were NN NN O
case NN NN O
report NN NN O
and NN NN O
levofloxacin NN NN O
. NN NN O
   
The NN NN O
search NN NN O
was NN NN O
limited NN NN O
to NN NN O
studies NN NN O
published NN NN O
in NN NN O
English NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Six NN NN O
cases NN NN O
of NN NN O
levofloxacin NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
have NN NN O
been NN NN O
reported NN NN O
in NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
Drug NN NN O
- NN NN O
drug NN NN O
interactions NN NN O
related NN NN O
to NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
CYP1A2 NN NN O
by NN NN O
levofloxacin NN NN O
are NN NN O
likely NN NN O
involved NN NN O
in NN NN O
the NN NN O
clinical NN NN O
outcome NN NN O
of NN NN O
these NN NN O
cases NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Clinicians NN NN O
are NN NN O
exhorted NN NN O
to NN NN O
pay NN NN O
close NN NN O
attention NN NN O
when NN NN O
initiating NN NN O
levofloxacin NN NN O
therapy NN NN O
in NN NN O
patients NN NN O
taking NN NN O
medications NN NN O
with NN NN O
epileptogenic NN NN O
properties NN NN O
that NN NN O
are NN NN O
CYP1A2 NN NN O
substrates NN NN O
. NN NN O
   
Dextran NN NN O
- NN NN O
etodolac NN NN O
conjugates NN NN O
: NN NN O
synthesis NN NN O
, NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
evaluation NN NN O
. NN NN O
   
Etodolac NN NN O
( NN NN O
E NN NN O
) NN NN O
, NN NN O
is NN NN O
a NN NN O
non NN NN O
- NN NN O
narcotic NN NN O
analgesic NN NN O
and NN NN O
antiinflammatory NN NN O
drug NN NN O
. NN NN O
   
A NN NN O
biodegradable NN NN O
polymer NN NN O
dextran NN NN O
has NN NN O
been NN NN O
utilized NN NN O
as NN NN O
a NN NN O
carrier NN NN O
for NN NN O
synthesis NN NN O
of NN NN O
etodolac NN NN O
- NN NN O
dextran NN NN O
conjugates NN NN O
( NN NN O
ED NN NN O
) NN NN O
to NN NN O
improve NN NN O
its NN NN O
aqueous NN NN O
solubility NN NN O
and NN NN O
reduce NN NN O
gastrointestinal NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
An NN NN O
activated NN NN O
moiety NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
N NN NN O
- NN NN O
acylimidazole NN NN O
derivative NN NN O
of NN NN O
etodolac NN NN O
( NN NN O
EAI NN NN O
) NN NN O
, NN NN O
was NN NN O
condensed NN NN O
with NN NN O
the NN NN O
polysaccharide NN NN O
polymer NN NN O
dextran NN NN O
of NN NN O
different NN NN O
molecular NN NN O
weights NN NN O
( NN NN O
40000 NN NN O
, NN NN O
60000 NN NN O
, NN NN O
110000 NN NN O
and NN NN O
200000 NN NN O
) NN NN O
. NN NN O
   
IR NN NN O
spectral NN NN O
data NN NN O
confirmed NN NN O
formation NN NN O
of NN NN O
ester NN NN O
bonding NN NN O
in NN NN O
the NN NN O
conjugates NN NN O
. NN NN O
   
Etodolac NN NN O
contents NN NN O
were NN NN O
evaluated NN NN O
by NN NN O
UV NN NN O
- NN NN O
spectrophotometric NN NN O
analysis NN NN O
. NN NN O
   
The NN NN O
molecular NN NN O
weights NN NN O
were NN NN O
determined NN NN O
by NN NN O
measuring NN NN O
viscosity NN NN O
using NN NN O
the NN NN O
Mark NN NN O
- NN NN O
Howink NN NN O
- NN NN O
Sakurada NN NN O
equation NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
hydrolysis NN NN O
of NN NN O
ED NN NN O
was NN NN O
done NN NN O
in NN NN O
aqueous NN NN O
buffers NN NN O
( NN NN O
pH NN NN O
1 NN NN O
. NN NN O
2 NN NN O
, NN NN O
7 NN NN O
. NN NN O
4 NN NN O
, NN NN O
9 NN NN O
) NN NN O
and NN NN O
in NN NN O
80 NN NN O
% NN NN O
( NN NN O
v NN NN O
/ NN NN O
v NN NN O
) NN NN O
human NN NN O
plasma NN NN O
( NN NN O
pH NN NN O
7 NN NN O
. NN NN O
4 NN NN O
) NN NN O
. NN NN O
   
At NN NN O
pH NN NN O
9 NN NN O
, NN NN O
a NN NN O
higher NN NN O
rate NN NN O
of NN NN O
etodolac NN NN O
release NN NN O
from NN NN O
ED NN NN O
was NN NN O
observed NN NN O
as NN NN O
compared NN NN O
to NN NN O
aqueous NN NN O
buffer NN NN O
of NN NN O
pH NN NN O
7 NN NN O
. NN NN O
4 NN NN O
and NN NN O
80 NN NN O
% NN NN O
human NN NN O
plasma NN NN O
( NN NN O
pH NN NN O
7 NN NN O
. NN NN O
4 NN NN O
) NN NN O
, NN NN O
following NN NN O
first NN NN O
- NN NN O
order NN NN O
kinetics NN NN O
. NN NN O
   
In NN NN O
vivo NN NN O
investigations NN NN O
were NN NN O
performed NN NN O
in NN NN O
animals NN NN O
. NN NN O
   
Acute NN NN O
analgesic NN NN O
and NN NN O
antiinflammatory NN NN O
activities NN NN O
were NN NN O
ascertained NN NN O
using NN NN O
acetic NN NN O
acid NN NN O
induced NN NN O
writhing NN NN B-Disease
model NN NN O
( NN NN O
mice NN NN O
) NN NN O
and NN NN O
carrageenan NN NN O
- NN NN O
induced NN NN O
rat NN NN O
paw NN NN O
edema NN NN B-Disease
model NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
In NN NN O
comparison NN NN O
to NN NN O
control NN NN O
, NN NN O
E NN NN O
and NN NN O
ED1 NN NN O
- NN NN O
ED4 NN NN O
showed NN NN O
highly NN NN O
significant NN NN O
analgesic NN NN O
and NN NN O
antiinflammatory NN NN O
activities NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Biological NN NN O
evaluation NN NN O
suggested NN NN O
that NN NN O
conjugates NN NN O
( NN NN O
ED1 NN NN O
- NN NN O
ED4 NN NN O
) NN NN O
retained NN NN O
comparable NN NN O
analgesic NN NN O
and NN NN O
antiinflammatory NN NN O
activities NN NN O
with NN NN O
remarkably NN NN O
reduced NN NN O
ulcerogenicity NN NN O
as NN NN O
compared NN NN O
to NN NN O
their NN NN O
parent NN NN O
drug NN NN O
- NN NN O
- NN NN O
etodolac NN NN O
. NN NN O
   
The NN NN O
antiarrhythmic NN NN O
effect NN NN O
and NN NN O
possible NN NN O
ionic NN NN O
mechanisms NN NN O
of NN NN O
pilocarpine NN NN O
on NN NN O
animal NN NN O
models NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
effects NN NN O
of NN NN O
pilocarpine NN NN O
and NN NN O
explore NN NN O
the NN NN O
underlying NN NN O
ionic NN NN O
mechanism NN NN O
, NN NN O
using NN NN O
both NN NN O
aconitine NN NN O
- NN NN O
induced NN NN O
rat NN NN O
and NN NN O
ouabain NN NN O
- NN NN O
induced NN NN O
guinea NN NN O
pig NN NN O
arrhythmia NN NN B-Disease
models NN NN O
. NN NN O
   
Confocal NN NN O
microscopy NN NN O
was NN NN O
used NN NN O
to NN NN O
measure NN NN O
intracellular NN NN O
free NN NN O
- NN NN O
calcium NN NN O
concentrations NN NN O
( NN NN O
[ NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
] NN NN O
( NN NN O
i NN NN O
) NN NN O
) NN NN O
in NN NN O
isolated NN NN O
myocytes NN NN O
. NN NN O
   
The NN NN O
current NN NN O
data NN NN O
showed NN NN O
that NN NN O
pilocarpine NN NN O
significantly NN NN O
delayed NN NN O
onset NN NN O
of NN NN O
arrhythmias NN NN B-Disease
, NN NN O
decreased NN NN O
the NN NN O
time NN NN O
course NN NN O
of NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
and NN NN I-Disease
fibrillation NN NN I-Disease
, NN NN O
reduced NN NN O
arrhythmia NN NN B-Disease
score NN NN O
, NN NN O
and NN NN O
increased NN NN O
the NN NN O
survival NN NN O
time NN NN O
of NN NN O
arrhythmic NN NN B-Disease
rats NN NN O
and NN NN O
guinea NN NN O
pigs NN NN O
. NN NN O
   
[ NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
] NN NN O
( NN NN O
i NN NN O
) NN NN O
overload NN NN O
induced NN NN O
by NN NN O
aconitine NN NN O
or NN NN O
ouabain NN NN O
was NN NN O
reduced NN NN O
in NN NN O
isolated NN NN O
myocytes NN NN O
pretreated NN NN O
with NN NN O
pilocarpine NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
M NN NN O
( NN NN O
3 NN NN O
) NN NN O
- NN NN O
muscarinic NN NN O
acetylcholine NN NN O
receptor NN NN O
( NN NN O
mAChR NN NN O
) NN NN O
antagonist NN NN O
4 NN NN O
- NN NN O
DAMP NN NN O
( NN NN O
4 NN NN O
- NN NN O
diphenylacetoxy NN NN O
- NN NN O
N NN NN O
- NN NN O
methylpiperidine NN NN O
- NN NN O
methiodide NN NN O
) NN NN O
partially NN NN O
abolished NN NN O
the NN NN O
beneficial NN NN O
effects NN NN O
of NN NN O
pilocarpine NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
pilocarpine NN NN O
produced NN NN O
antiarrhythmic NN NN O
actions NN NN O
on NN NN O
arrhythmic NN NN B-Disease
rat NN NN O
and NN NN O
guinea NN NN O
pig NN NN O
models NN NN O
induced NN NN O
by NN NN O
aconitine NN NN O
or NN NN O
ouabain NN NN O
via NN NN O
stimulating NN NN O
the NN NN O
cardiac NN NN O
M NN NN O
( NN NN O
3 NN NN O
) NN NN O
- NN NN O
mAChR NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
may NN NN O
be NN NN O
related NN NN O
to NN NN O
the NN NN O
improvement NN NN O
of NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
handling NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
Hibiscus NN NN O
rosa NN NN O
sinensis NN NN O
on NN NN O
reserpine NN NN O
- NN NN O
induced NN NN O
neurobehavioral NN NN O
and NN NN O
biochemical NN NN O
alterations NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
methanolic NN NN O
extract NN NN O
of NN NN O
Hibiscus NN NN O
rosa NN NN O
sinensis NN NN O
( NN NN O
100 NN NN O
- NN NN O
300 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
was NN NN O
studied NN NN O
on NN NN O
reserpine NN NN O
- NN NN O
induced NN NN O
orofacial NN NN O
dyskinesia NN NN B-Disease
and NN NN O
neurochemical NN NN O
alterations NN NN O
. NN NN O
   
The NN NN O
rats NN NN O
were NN NN O
treated NN NN O
with NN NN O
intraperitoneal NN NN O
reserpine NN NN O
( NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
ip NN NN O
) NN NN O
for NN NN O
3 NN NN O
days NN NN O
every NN NN O
other NN NN O
day NN NN O
. NN NN O
   
On NN NN O
day NN NN O
5 NN NN O
, NN NN O
vacuous NN NN O
chewing NN NN O
movements NN NN O
and NN NN O
tongue NN NN O
protrusions NN NN O
were NN NN O
counted NN NN O
for NN NN O
5 NN NN O
min NN NN O
. NN NN O
   
Reserpine NN NN O
treated NN NN O
rats NN NN O
significantly NN NN O
developed NN NN O
vacuous NN NN O
chewing NN NN O
movements NN NN O
and NN NN O
tongue NN NN O
protrusions NN NN O
however NN NN O
, NN NN O
coadministration NN NN O
of NN NN O
Hibiscus NN NN O
rosa NN NN O
sinensis NN NN O
roots NN NN O
extract NN NN O
( NN NN O
100 NN NN O
, NN NN O
200 NN NN O
and NN NN O
300 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
per NN NN O
orally NN NN O
) NN NN O
attenuated NN NN O
the NN NN O
effects NN NN O
. NN NN O
   
Biochemical NN NN O
analysis NN NN O
of NN NN O
brain NN NN O
revealed NN NN O
that NN NN O
the NN NN O
reserpine NN NN O
treatment NN NN O
significantly NN NN O
increased NN NN O
lipid NN NN O
peroxidation NN NN O
and NN NN O
decreased NN NN O
levels NN NN O
of NN NN O
superoxide NN NN O
dismutase NN NN O
( NN NN O
SOD NN NN O
) NN NN O
, NN NN O
catalase NN NN O
( NN NN O
CAT NN NN O
) NN NN O
and NN NN O
glutathione NN NN O
reductase NN NN O
( NN NN O
GSH NN NN O
) NN NN O
, NN NN O
an NN NN O
index NN NN O
of NN NN O
oxidative NN NN O
stress NN NN O
process NN NN O
. NN NN O
   
Coadministration NN NN O
of NN NN O
extract NN NN O
significantly NN NN O
reduced NN NN O
the NN NN O
lipid NN NN O
peroxidation NN NN O
and NN NN O
reversed NN NN O
the NN NN O
decrease NN NN O
in NN NN O
brain NN NN O
SOD NN NN O
, NN NN O
CAT NN NN O
and NN NN O
GSH NN NN O
levels NN NN O
. NN NN O
   
The NN NN O
results NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
suggested NN NN O
that NN NN O
Hibiscus NN NN O
rosa NN NN O
sinensis NN NN O
had NN NN O
a NN NN O
protective NN NN O
role NN NN O
against NN NN O
reserpine NN NN O
- NN NN O
induced NN NN O
orofacial NN NN O
dyskinesia NN NN B-Disease
and NN NN O
oxidative NN NN O
stress NN NN O
. NN NN O
   
Dynamic NN NN O
response NN NN O
of NN NN O
blood NN NN O
vessel NN NN O
in NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
postulated NN NN O
that NN NN O
during NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
induced NN NN O
by NN NN O
gentamicin NN NN O
the NN NN O
transient NN NN O
or NN NN O
dynamic NN NN O
response NN NN O
of NN NN O
blood NN NN O
vessels NN NN O
could NN NN O
be NN NN O
affected NN NN O
, NN NN O
and NN NN O
that NN NN O
antioxidants NN NN O
can NN NN O
prevent NN NN O
the NN NN O
changes NN NN O
in NN NN O
dynamic NN NN O
responses NN NN O
of NN NN O
blood NN NN O
vessels NN NN O
. NN NN O
   
The NN NN O
new NN NN O
approach NN NN O
to NN NN O
ex NN NN O
vivo NN NN O
blood NN NN O
vessel NN NN O
experiments NN NN O
in NN NN O
which NN NN O
not NN NN O
only NN NN O
the NN NN O
end NN NN O
points NN NN O
of NN NN O
vessels NN NN O
response NN NN O
within NN NN O
the NN NN O
time NN NN O
interval NN NN O
is NN NN O
considered NN NN O
, NN NN O
but NN NN O
also NN NN O
dynamics NN NN O
of NN NN O
this NN NN O
response NN NN O
, NN NN O
was NN NN O
used NN NN O
in NN NN O
this NN NN O
paper NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
confirm NN NN O
the NN NN O
alteration NN NN O
in NN NN O
dynamic NN NN O
response NN NN O
of NN NN O
blood NN NN O
vessels NN NN O
during NN NN O
the NN NN O
change NN NN O
of NN NN O
pressure NN NN O
in NN NN O
gentamicin NN NN O
- NN NN O
treated NN NN O
animals NN NN O
. NN NN O
   
The NN NN O
beneficial NN NN O
effects NN NN O
of NN NN O
vitamin NN NN O
C NN NN O
administration NN NN O
to NN NN O
gentamicin NN NN O
- NN NN O
treated NN NN O
animals NN NN O
are NN NN O
also NN NN O
confirmed NN NN O
through NN NN O
: NN NN O
lower NN NN O
level NN NN O
of NN NN O
blood NN NN O
urea NN NN O
and NN NN O
creatinine NN NN O
and NN NN O
higher NN NN O
level NN NN O
of NN NN O
potassium NN NN O
. NN NN O
   
The NN NN O
pressure NN NN O
dynamic NN NN O
responses NN NN O
of NN NN O
isolated NN NN O
blood NN NN O
vessels NN NN O
show NN NN O
a NN NN O
faster NN NN O
pressure NN NN O
change NN NN O
in NN NN O
gentamicin NN NN O
- NN NN O
treated NN NN O
animals NN NN O
( NN NN O
8 NN NN O
. NN NN O
07 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
7 NN NN O
s NN NN O
vs NN NN O
. NN NN O
5 NN NN O
. NN NN O
64 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
18 NN NN O
s NN NN O
) NN NN O
. NN NN O
   
Vitamin NN NN O
C NN NN O
administration NN NN O
induced NN NN O
slowdown NN NN O
of NN NN O
pressure NN NN O
change NN NN O
back NN NN O
to NN NN O
the NN NN O
control NN NN O
values NN NN O
. NN NN O
   
The NN NN O
pressure NN NN O
dynamic NN NN O
properties NN NN O
, NN NN O
quantitatively NN NN O
defined NN NN O
by NN NN O
comparative NN NN O
pressure NN NN O
dynamic NN NN O
and NN NN O
total NN NN O
pressure NN NN O
dynamic NN NN O
, NN NN O
confirm NN NN O
the NN NN O
alteration NN NN O
in NN NN O
dynamic NN NN O
response NN NN O
of NN NN O
blood NN NN O
vessels NN NN O
during NN NN O
the NN NN O
change NN NN O
of NN NN O
pressure NN NN O
in NN NN O
gentamicin NN NN O
- NN NN O
treated NN NN O
animals NN NN O
and NN NN O
beneficial NN NN O
effects NN NN O
of NN NN O
vitamin NN NN O
C NN NN O
administration NN NN O
. NN NN O
   
Reversible NN NN O
myocardial NN NN B-Disease
hypertrophy NN NN I-Disease
induced NN NN O
by NN NN O
tacrolimus NN NN O
in NN NN O
a NN NN O
pediatric NN NN O
heart NN NN O
transplant NN NN O
recipient NN NN O
: NN NN O
case NN NN O
report NN NN O
. NN NN O
   
Tacrolimus NN NN O
is NN NN O
a NN NN O
potent NN NN O
immunosuppressant NN NN O
that NN NN O
is NN NN O
frequently NN NN O
used NN NN O
in NN NN O
organ NN NN O
transplantation NN NN O
. NN NN O
   
However NN NN O
, NN NN O
adverse NN NN O
effects NN NN O
include NN NN O
cardiac NN NN B-Disease
toxicity NN NN I-Disease
. NN NN O
   
Herein NN NN O
we NN NN O
describe NN NN O
transient NN NN O
myocardial NN NN B-Disease
hypertrophy NN NN I-Disease
induced NN NN O
by NN NN O
tacrolimus NN NN O
after NN NN O
heart NN NN O
transplantation NN NN O
. NN NN O
   
The NN NN O
hypertrophy NN NN B-Disease
caused NN NN O
no NN NN O
clinical NN NN O
symptoms NN NN O
but NN NN O
was NN NN O
noted NN NN O
because NN NN O
of NN NN O
elevation NN NN O
of NN NN O
plasma NN NN O
brain NN NN O
natriuretic NN NN O
peptide NN NN O
concentration NN NN O
and NN NN O
confirmed NN NN O
at NN NN O
echocardiography NN NN O
. NN NN O
   
Initially NN NN O
, NN NN O
allograft NN NN O
rejection NN NN O
was NN NN O
feared NN NN O
; NN NN O
however NN NN O
, NN NN O
myocardial NN NN O
biopsy NN NN O
samples NN NN O
revealed NN NN O
only NN NN O
interstitial NN NN O
edema NN NN B-Disease
and NN NN O
mild NN NN O
myocardial NN NN B-Disease
hypertrophy NN NN I-Disease
; NN NN O
neither NN NN O
cellular NN NN O
nor NN NN O
humoral NN NN O
rejection NN NN O
was NN NN O
detected NN NN O
. NN NN O
   
The NN NN O
blood NN NN O
tacrolimus NN NN O
concentration NN NN O
was NN NN O
higher NN NN O
than NN NN O
usual NN NN O
at NN NN O
that NN NN O
time NN NN O
; NN NN O
thus NN NN O
, NN NN O
tacrolimus NN NN O
dosage NN NN O
was NN NN O
reduced NN NN O
. NN NN O
   
Myocardial NN NN B-Disease
hypertrophy NN NN I-Disease
completely NN NN O
resolved NN NN O
upon NN NN O
reducing NN NN O
the NN NN O
target NN NN O
concentration NN NN O
of NN NN O
tacrolimus NN NN O
and NN NN O
did NN NN O
not NN NN O
recur NN NN O
, NN NN O
as NN NN O
confirmed NN NN O
at NN NN O
echocardiography NN NN O
and NN NN O
myocardial NN NN O
biopsy NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
tacrolimus NN NN O
induces NN NN O
reversible NN NN O
myocardial NN NN B-Disease
hypertrophy NN NN I-Disease
. NN NN O
   
In NN NN O
patients NN NN O
receiving NN NN O
tacrolimus NN NN O
therapy NN NN O
, NN NN O
blood NN NN O
concentration NN NN O
should NN NN O
be NN NN O
carefully NN NN O
controlled NN NN O
and NN NN O
extreme NN NN O
attention NN NN O
paid NN NN O
to NN NN O
cardiac NN NN O
involvement NN NN O
. NN NN O
   
Nimodipine NN NN O
prevents NN NN O
memory NN NN B-Disease
impairment NN NN I-Disease
caused NN NN O
by NN NN O
nitroglycerin NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
in NN NN O
adult NN NN O
mice NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Hypotension NN NN B-Disease
and NN NN O
a NN NN O
resultant NN NN O
decrease NN NN O
in NN NN O
cerebral NN NN O
blood NN NN O
flow NN NN O
have NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
cognitive NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
We NN NN O
tested NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
nimodipine NN NN O
( NN NN O
NIMO NN NN O
) NN NN O
administered NN NN O
at NN NN O
the NN NN O
onset NN NN O
of NN NN O
nitroglycerin NN NN O
( NN NN O
NTG NN NN O
) NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
would NN NN O
preserve NN NN O
long NN NN O
- NN NN O
term NN NN O
associative NN NN O
memory NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
passive NN NN O
avoidance NN NN O
( NN NN O
PA NN NN O
) NN NN O
paradigm NN NN O
was NN NN O
used NN NN O
to NN NN O
assess NN NN O
memory NN NN O
retention NN NN O
. NN NN O
   
For NN NN O
PA NN NN O
training NN NN O
, NN NN O
latencies NN NN O
( NN NN O
seconds NN NN O
) NN NN O
were NN NN O
recorded NN NN O
for NN NN O
entry NN NN O
from NN NN O
a NN NN O
suspended NN NN O
platform NN NN O
into NN NN O
a NN NN O
Plexiglas NN NN O
tube NN NN O
where NN NN O
a NN NN O
shock NN NN O
was NN NN O
automatically NN NN O
delivered NN NN O
. NN NN O
   
Latencies NN NN O
were NN NN O
recorded NN NN O
48 NN NN O
h NN NN O
later NN NN O
for NN NN O
a NN NN O
testing NN NN O
trial NN NN O
. NN NN O
   
Ninety NN NN O
- NN NN O
six NN NN O
Swiss NN NN O
- NN NN O
Webster NN NN O
mice NN NN O
( NN NN O
30 NN NN O
- NN NN O
35 NN NN O
g NN NN O
, NN NN O
6 NN NN O
- NN NN O
8 NN NN O
wk NN NN O
) NN NN O
, NN NN O
were NN NN O
randomized NN NN O
into NN NN O
6 NN NN O
groups NN NN O
1 NN NN O
) NN NN O
saline NN NN O
( NN NN O
control NN NN O
) NN NN O
, NN NN O
2 NN NN O
) NN NN O
NTG NN NN O
immediately NN NN O
after NN NN O
learning NN NN O
, NN NN O
3 NN NN O
) NN NN O
NTG NN NN O
3 NN NN O
h NN NN O
after NN NN O
learning NN NN O
, NN NN O
4 NN NN O
) NN NN O
NTG NN NN O
and NN NN O
NIMO NN NN O
, NN NN O
5 NN NN O
) NN NN O
vehicle NN NN O
, NN NN O
and NN NN O
6 NN NN O
) NN NN O
NIMO NN NN O
alone NN NN O
. NN NN O
   
The NN NN O
extent NN NN O
of NN NN O
hypotension NN NN B-Disease
and NN NN O
changes NN NN O
in NN NN O
brain NN NN O
tissue NN NN O
oxygenation NN NN O
( NN NN O
PbtO NN NN O
( NN NN O
2 NN NN O
) NN NN O
) NN NN O
and NN NN O
in NN NN O
cerebral NN NN O
blood NN NN O
flow NN NN O
were NN NN O
studied NN NN O
in NN NN O
a NN NN O
separate NN NN O
group NN NN O
of NN NN O
animals NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
All NN NN O
groups NN NN O
exhibited NN NN O
similar NN NN O
training NN NN O
latencies NN NN O
( NN NN O
17 NN NN O
. NN NN O
0 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
. NN NN O
6 NN NN O
s NN NN O
) NN NN O
. NN NN O
   
Mice NN NN O
subjected NN NN O
to NN NN O
hypotensive NN NN B-Disease
episodes NN NN O
showed NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
latency NN NN O
time NN NN O
( NN NN O
178 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
156 NN NN O
s NN NN O
) NN NN O
compared NN NN O
with NN NN O
those NN NN O
injected NN NN O
with NN NN O
saline NN NN O
, NN NN O
NTG NN NN O
+ NN NN O
NIMO NN NN O
, NN NN O
or NN NN O
delayed NN NN O
NTG NN NN O
( NN NN O
580 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
81 NN NN O
s NN NN O
, NN NN O
557 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
67 NN NN O
s NN NN O
, NN NN O
and NN NN O
493 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
146 NN NN O
s NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
A NN NN O
Kruskal NN NN O
- NN NN O
Wallis NN NN O
1 NN NN O
- NN NN O
way NN NN O
analysis NN NN O
of NN NN O
variance NN NN O
indicated NN NN O
a NN NN O
significant NN NN O
difference NN NN O
among NN NN O
the NN NN O
4 NN NN O
treatment NN NN O
groups NN NN O
( NN NN O
H NN NN O
= NN NN O
15 NN NN O
. NN NN O
34 NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
a NN NN O
separate NN NN O
group NN NN O
of NN NN O
mice NN NN O
not NN NN O
subjected NN NN O
to NN NN O
behavioral NN NN O
studies NN NN O
, NN NN O
the NN NN O
same NN NN O
dose NN NN O
of NN NN O
NTG NN NN O
( NN NN O
n NN NN O
= NN NN O
3 NN NN O
) NN NN O
and NN NN O
NTG NN NN O
+ NN NN O
NIMO NN NN O
( NN NN O
n NN NN O
= NN NN O
3 NN NN O
) NN NN O
caused NN NN O
mean NN NN O
arterial NN NN O
blood NN NN O
pressure NN NN O
to NN NN O
decrease NN NN O
from NN NN O
85 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
8 NN NN O
mm NN NN O
Hg NN NN O
sem NN NN O
to NN NN O
31 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
8 NN NN O
mm NN NN O
Hg NN NN O
sem NN NN O
and NN NN O
from NN NN O
86 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
7 NN NN O
mm NN NN O
Hg NN NN O
sem NN NN O
to NN NN O
32 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
2 NN NN O
mm NN NN O
Hg NN NN O
sem NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Mean NN NN O
arterial NN NN O
blood NN NN O
pressure NN NN O
in NN NN O
mice NN NN O
treated NN NN O
with NN NN O
NIMO NN NN O
alone NN NN O
decreased NN NN O
from NN NN O
88 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
8 NN NN O
mm NN NN O
Hg NN NN O
to NN NN O
80 NN NN O
. NN NN O
0 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
9 NN NN O
mm NN NN O
Hg NN NN O
. NN NN O
   
The NN NN O
intergroup NN NN O
difference NN NN O
was NN NN O
statistically NN NN O
significant NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
PbtO NN NN O
( NN NN O
2 NN NN O
) NN NN O
decreased NN NN O
from NN NN O
51 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
. NN NN O
5 NN NN O
mm NN NN O
Hg NN NN O
sem NN NN O
to NN NN O
33 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
. NN NN O
2 NN NN O
mm NN NN O
Hg NN NN O
sem NN NN O
in NN NN O
the NN NN O
NTG NN NN O
group NN NN O
and NN NN O
from NN NN O
38 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
. NN NN O
1 NN NN O
mm NN NN O
Hg NN NN O
sem NN NN O
to NN NN O
25 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
0 NN NN O
mm NN NN O
Hg NN NN O
sem NN NN O
in NN NN O
the NN NN O
NTG NN NN O
+ NN NN O
NIMO NN NN O
groups NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
significant NN NN O
differences NN NN O
among NN NN O
groups NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
In NN NN O
a NN NN O
PA NN NN O
retention NN NN O
paradigm NN NN O
, NN NN O
the NN NN O
injection NN NN O
of NN NN O
NTG NN NN O
immediately NN NN O
after NN NN O
learning NN NN O
produced NN NN O
a NN NN O
significant NN NN O
impairment NN NN O
of NN NN O
long NN NN O
- NN NN O
term NN NN O
associative NN NN O
memory NN NN O
in NN NN O
mice NN NN O
, NN NN O
whereas NN NN O
delayed NN NN O
induced NN NN O
hypotension NN NN B-Disease
had NN NN O
no NN NN O
effect NN NN O
. NN NN O
   
NIMO NN NN O
attenuated NN NN O
the NN NN O
disruption NN NN O
in NN NN O
consolidation NN NN O
of NN NN O
long NN NN O
- NN NN O
term NN NN O
memory NN NN O
caused NN NN O
by NN NN O
NTG NN NN O
but NN NN O
did NN NN O
not NN NN O
improve NN NN O
latency NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
hypotension NN NN B-Disease
. NN NN O
   
The NN NN O
observed NN NN O
effect NN NN O
of NN NN O
NIMO NN NN O
may NN NN O
have NN NN O
been NN NN O
attributable NN NN O
to NN NN O
the NN NN O
preservation NN NN O
of NN NN O
calcium NN NN O
homeostasis NN NN O
during NN NN O
hypotension NN NN B-Disease
, NN NN O
because NN NN O
there NN NN O
were NN NN O
no NN NN O
differences NN NN O
in NN NN O
the NN NN O
PbtO NN NN O
( NN NN O
2 NN NN O
) NN NN O
indices NN NN O
among NN NN O
groups NN NN O
. NN NN O
   
Metabotropic NN NN O
glutamate NN NN O
7 NN NN O
receptor NN NN O
subtype NN NN O
modulates NN NN O
motor NN NN O
symptoms NN NN O
in NN NN O
rodent NN NN O
models NN NN O
of NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Metabotropic NN NN O
glutamate NN NN O
( NN NN O
mGlu NN NN O
) NN NN O
receptors NN NN O
modulate NN NN O
synaptic NN NN O
transmission NN NN O
in NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
and NN NN O
represent NN NN O
promising NN NN O
therapeutic NN NN O
targets NN NN O
for NN NN O
symptomatic NN NN O
treatment NN NN O
of NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
( NN NN O
PD NN NN B-Disease
) NN NN O
. NN NN O
   
Among NN NN O
the NN NN O
eight NN NN O
mGlu NN NN O
receptor NN NN O
subtypes NN NN O
, NN NN O
mGlu7 NN NN O
receptor NN NN O
is NN NN O
prominently NN NN O
expressed NN NN O
in NN NN O
the NN NN O
basal NN NN O
ganglia NN NN O
, NN NN O
but NN NN O
its NN NN O
role NN NN O
in NN NN O
restoring NN NN O
motor NN NN O
function NN NN O
in NN NN O
animal NN NN O
models NN NN O
of NN NN O
PD NN NN B-Disease
is NN NN O
not NN NN O
known NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
N NN NN O
, NN NN O
N NN NN O
' NN NN O
- NN NN O
dibenzhydrylethane NN NN O
- NN NN O
1 NN NN O
, NN NN O
2 NN NN O
- NN NN O
diamine NN NN O
dihydrochloride NN NN O
( NN NN O
AMN082 NN NN O
) NN NN O
, NN NN O
the NN NN O
first NN NN O
selective NN NN O
allosteric NN NN O
activator NN NN O
of NN NN O
mGlu7 NN NN O
receptors NN NN O
, NN NN O
were NN NN O
thus NN NN O
tested NN NN O
in NN NN O
different NN NN O
rodent NN NN O
models NN NN O
of NN NN O
PD NN NN B-Disease
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
oral NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
or NN NN O
intrastriatal NN NN O
administration NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
and NN NN O
0 NN NN O
. NN NN O
5 NN NN O
nmol NN NN O
) NN NN O
of NN NN O
AMN082 NN NN O
reverses NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
AMN082 NN NN O
( NN NN O
2 NN NN O
. NN NN O
5 NN NN O
and NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
reduces NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
rotations NN NN O
in NN NN O
unilateral NN NN O
6 NN NN O
- NN NN O
hydroxydopamine NN NN O
( NN NN O
6 NN NN O
- NN NN O
OHDA NN NN O
) NN NN O
- NN NN O
lesioned NN NN O
rats NN NN O
. NN NN O
   
In NN NN O
a NN NN O
more NN NN O
complex NN NN O
task NN NN O
commonly NN NN O
used NN NN O
to NN NN O
evaluate NN NN O
major NN NN O
akinetic NN NN B-Disease
symptoms NN NN O
of NN NN O
PD NN NN B-Disease
patients NN NN O
, NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
AMN082 NN NN O
reverses NN NN O
the NN NN O
increased NN NN O
reaction NN NN O
time NN NN O
to NN NN O
respond NN NN O
to NN NN O
a NN NN O
cue NN NN O
of NN NN O
bilateral NN NN O
6 NN NN O
- NN NN O
OHDA NN NN O
- NN NN O
lesioned NN NN O
rats NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
AMN082 NN NN O
reduces NN NN O
the NN NN O
duration NN NN O
of NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
in NN NN O
a NN NN O
mGlu7 NN NN O
receptor NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
in NN NN O
wild NN NN O
- NN NN O
type NN NN O
but NN NN O
not NN NN O
mGlu7 NN NN O
receptor NN NN O
knockout NN NN O
mice NN NN O
. NN NN O
   
Higher NN NN O
doses NN NN O
of NN NN O
AMN082 NN NN O
( NN NN O
10 NN NN O
and NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
) NN NN O
have NN NN O
no NN NN O
effect NN NN O
on NN NN O
the NN NN O
same NN NN O
models NN NN O
of NN NN O
PD NN NN B-Disease
. NN NN O
   
Overall NN NN O
these NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
mGlu7 NN NN O
receptor NN NN O
activation NN NN O
can NN NN O
reverse NN NN O
motor NN NN O
dysfunction NN NN O
associated NN NN O
with NN NN O
reduced NN NN O
dopamine NN NN O
activity NN NN O
. NN NN O
   
Selective NN NN O
ligands NN NN O
of NN NN O
mGlu7 NN NN O
receptor NN NN O
subtypes NN NN O
may NN NN O
thus NN NN O
be NN NN O
considered NN NN O
as NN NN O
promising NN NN O
compounds NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
antiparkinsonian NN NN O
therapeutic NN NN O
strategies NN NN O
. NN NN O
   
Sorafenib NN NN O
- NN NN O
induced NN NN O
acute NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
due NN NN O
to NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
spasm NN NN I-Disease
. NN NN O
   
A NN NN O
65 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
with NN NN O
advanced NN NN O
renal NN NN B-Disease
cell NN NN I-Disease
carcinoma NN NN I-Disease
was NN NN O
admitted NN NN O
due NN NN O
to NN NN O
continuing NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
at NN NN O
rest NN NN O
. NN NN O
   
Two NN NN O
weeks NN NN O
before NN NN O
his NN NN O
admission NN NN O
, NN NN O
sorafenib NN NN O
had NN NN O
been NN NN O
started NN NN O
. NN NN O
   
He NN NN O
was NN NN O
diagnosed NN NN O
with NN NN O
non NN NN O
- NN NN O
ST NN NN O
- NN NN O
elevation NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
by NN NN O
laboratory NN NN O
data NN NN O
and NN NN O
electrocardiogram NN NN O
. NN NN O
   
Enhanced NN NN O
heart NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
also NN NN O
showed NN NN O
subendocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
However NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
stenosis NN NN O
in NN NN O
coronary NN NN O
arteries NN NN O
on NN NN O
angiography NN NN O
. NN NN O
   
Coronary NN NN B-Disease
artery NN NN I-Disease
spasm NN NN I-Disease
was NN NN O
induced NN NN O
by NN NN O
a NN NN O
provocative NN NN O
test NN NN O
. NN NN O
   
Cessation NN NN O
of NN NN O
sorafenib NN NN O
and NN NN O
administration NN NN O
of NN NN O
Ca NN NN O
- NN NN O
channel NN NN O
blocker NN NN O
and NN NN O
nitrates NN NN O
ameliorated NN NN O
his NN NN O
symptoms NN NN O
, NN NN O
but NN NN O
relapse NN NN O
occurred NN NN O
after NN NN O
resumption NN NN O
of NN NN O
sorafenib NN NN O
. NN NN O
   
Addition NN NN O
of NN NN O
oral NN NN O
nicorandil NN NN O
reduced NN NN O
his NN NN O
symptoms NN NN O
and NN NN O
maintained NN NN O
stable NN NN B-Disease
angina NN NN I-Disease
status NN NN O
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
first NN NN O
case NN NN O
of NN NN O
sorafenib NN NN O
- NN NN O
induced NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
spasm NN NN I-Disease
. NN NN O
   
Sorafenib NN NN O
is NN NN O
a NN NN O
multikinase NN NN O
inhibitor NN NN O
that NN NN O
targets NN NN O
signaling NN NN O
pathways NN NN O
necessary NN NN O
for NN NN O
cellular NN NN O
proliferation NN NN O
and NN NN O
survival NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
the NN NN O
Rho NN NN O
/ NN NN O
ROCK NN NN O
pathway NN NN O
has NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
spasm NN NN I-Disease
. NN NN O
   
Our NN NN O
report NN NN O
may NN NN O
show NN NN O
an NN NN O
adverse NN NN O
effect NN NN O
on NN NN O
the NN NN O
Rho NN NN O
/ NN NN O
ROCK NN NN O
pathway NN NN O
by NN NN O
sorafenib NN NN O
use NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
animal NN NN O
model NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
ability NN NN O
of NN NN O
a NN NN O
drug NN NN O
delivery NN NN O
system NN NN O
to NN NN O
promote NN NN O
the NN NN O
passage NN NN O
through NN NN O
the NN NN O
BBB NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
investigation NN NN O
was NN NN O
to NN NN O
explore NN NN O
the NN NN O
potentiality NN NN O
of NN NN O
a NN NN O
novel NN NN O
animal NN NN O
model NN NN O
to NN NN O
be NN NN O
used NN NN O
for NN NN O
the NN NN O
in NN NN O
vivo NN NN O
evaluation NN NN O
of NN NN O
the NN NN O
ability NN NN O
of NN NN O
a NN NN O
drug NN NN O
delivery NN NN O
system NN NN O
to NN NN O
promote NN NN O
the NN NN O
passage NN NN O
through NN NN O
the NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
( NN NN O
BBB NN NN O
) NN NN O
and NN NN O
/ NN NN O
or NN NN O
to NN NN O
improve NN NN O
the NN NN O
brain NN NN O
localization NN NN O
of NN NN O
a NN NN O
bioactive NN NN O
compound NN NN O
. NN NN O
   
A NN NN O
Tween NN NN O
80 NN NN O
- NN NN O
coated NN NN O
poly NN NN O
- NN NN O
L NN NN O
- NN NN O
lactid NN NN O
acid NN NN O
nanoparticles NN NN O
was NN NN O
used NN NN O
as NN NN O
a NN NN O
model NN NN O
of NN NN O
colloidal NN NN O
drug NN NN O
delivery NN NN O
system NN NN O
, NN NN O
able NN NN O
to NN NN O
trespass NN NN O
the NN NN O
BBB NN NN O
. NN NN O
   
Tacrine NN NN O
, NN NN O
administered NN NN O
in NN NN O
LiCl NN NN O
pre NN NN O
- NN NN O
treated NN NN O
rats NN NN O
, NN NN O
induces NN NN O
electrocorticographic NN NN O
seizures NN NN B-Disease
and NN NN O
delayed NN NN O
hippocampal NN NN B-Disease
damage NN NN I-Disease
. NN NN O
   
The NN NN O
toxic NN NN O
effects NN NN O
of NN NN O
tacrine NN NN O
- NN NN O
loaded NN NN O
poly NN NN O
- NN NN O
L NN NN O
- NN NN O
lactid NN NN O
acid NN NN O
nanoparticles NN NN O
( NN NN O
5mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
a NN NN O
saline NN NN O
solution NN NN O
of NN NN O
tacrine NN NN O
( NN NN O
5mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
and NN NN O
an NN NN O
empty NN NN O
colloidal NN NN O
nanoparticle NN NN O
suspension NN NN O
were NN NN O
compared NN NN O
following NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
administration NN NN O
in NN NN O
LiCl NN NN O
- NN NN O
pre NN NN O
- NN NN O
treated NN NN O
Wistar NN NN O
rats NN NN O
. NN NN O
   
All NN NN O
the NN NN O
animals NN NN O
treated NN NN O
with NN NN O
tacrine NN NN O
- NN NN O
loaded NN NN O
nanoparticles NN NN O
showed NN NN O
an NN NN O
earlier NN NN O
outcome NN NN O
of NN NN O
CNS NN NN O
adverse NN NN O
symptoms NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
epileptic NN NN B-Disease
onset NN NN O
, NN NN O
with NN NN O
respect NN NN O
to NN NN O
those NN NN O
animals NN NN O
treated NN NN O
with NN NN O
the NN NN O
free NN NN O
compound NN NN O
( NN NN O
10 NN NN O
min NN NN O
vs NN NN O
. NN NN O
22 NN NN O
min NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
tacrine NN NN O
- NN NN O
loaded NN NN O
nanoparticles NN NN O
administration NN NN O
induced NN NN O
damage NN NN B-Disease
of NN NN I-Disease
neuronal NN NN I-Disease
cells NN NN I-Disease
in NN NN O
CA1 NN NN O
field NN NN O
of NN NN O
the NN NN O
hippocampus NN NN O
in NN NN O
all NN NN O
treated NN NN O
animals NN NN O
, NN NN O
while NN NN O
the NN NN O
saline NN NN O
solution NN NN O
of NN NN O
tacrine NN NN O
only NN NN O
in NN NN O
60 NN NN O
% NN NN O
of NN NN O
animals NN NN O
. NN NN O
   
Empty NN NN O
nanoparticles NN NN O
provided NN NN O
similar NN NN O
results NN NN O
to NN NN O
control NN NN O
( NN NN O
saline NN NN O
- NN NN O
treated NN NN O
) NN NN O
group NN NN O
of NN NN O
animals NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
the NN NN O
evaluation NN NN O
of NN NN O
time NN NN O
- NN NN O
to NN NN O
- NN NN O
onset NN NN O
of NN NN O
symptoms NN NN O
and NN NN O
the NN NN O
severity NN NN O
of NN NN O
neurodegenerative NN NN O
processes NN NN O
induced NN NN O
by NN NN O
the NN NN O
tacrine NN NN O
- NN NN O
lithium NN NN O
model NN NN O
of NN NN O
epilepsy NN NN B-Disease
in NN NN O
the NN NN O
rat NN NN O
, NN NN O
could NN NN O
be NN NN O
used NN NN O
to NN NN O
evaluate NN NN O
preliminarily NN NN O
the NN NN O
capability NN NN O
of NN NN O
a NN NN O
drug NN NN O
delivery NN NN O
system NN NN O
to NN NN O
trespass NN NN O
( NN NN O
or NN NN O
not NN NN O
) NN NN O
the NN NN O
BBB NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
High NN NN O
- NN NN O
dose NN NN O
tranexamic NN NN O
Acid NN NN O
is NN NN O
associated NN NN O
with NN NN O
nonischemic NN NN O
clinical NN NN O
seizures NN NN B-Disease
in NN NN O
cardiac NN NN O
surgical NN NN O
patients NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
In NN NN O
2 NN NN O
separate NN NN O
centers NN NN O
, NN NN O
we NN NN O
observed NN NN O
a NN NN O
notable NN NN O
increase NN NN O
in NN NN O
the NN NN O
incidence NN NN O
of NN NN O
postoperative NN NN O
convulsive NN NN B-Disease
seizures NN NN B-Disease
from NN NN O
1 NN NN O
. NN NN O
3 NN NN O
% NN NN O
to NN NN O
3 NN NN O
. NN NN O
8 NN NN O
% NN NN O
in NN NN O
patients NN NN O
having NN NN O
undergone NN NN O
major NN NN O
cardiac NN NN O
surgical NN NN O
procedures NN NN O
. NN NN O
   
These NN NN O
events NN NN O
were NN NN O
temporally NN NN O
coincident NN NN O
with NN NN O
the NN NN O
initial NN NN O
use NN NN O
of NN NN O
high NN NN O
- NN NN O
dose NN NN O
tranexamic NN NN O
acid NN NN O
( NN NN O
TXA NN NN O
) NN NN O
therapy NN NN O
after NN NN O
withdrawal NN NN O
of NN NN O
aprotinin NN NN O
from NN NN O
general NN NN O
clinical NN NN O
usage NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
review NN NN O
was NN NN O
to NN NN O
perform NN NN O
a NN NN O
retrospective NN NN O
analysis NN NN O
to NN NN O
examine NN NN O
whether NN NN O
there NN NN O
was NN NN O
a NN NN O
relation NN NN O
between NN NN O
TXA NN NN O
usage NN NN O
and NN NN O
seizures NN NN B-Disease
after NN NN O
cardiac NN NN O
surgery NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
An NN NN O
in NN NN O
- NN NN O
depth NN NN O
chart NN NN O
review NN NN O
was NN NN O
undertaken NN NN O
in NN NN O
all NN NN O
24 NN NN O
patients NN NN O
who NN NN O
developed NN NN O
perioperative NN NN O
seizures NN NN B-Disease
. NN NN O
   
Electroencephalographic NN NN O
activity NN NN O
was NN NN O
recorded NN NN O
in NN NN O
11 NN NN O
of NN NN O
these NN NN O
patients NN NN O
, NN NN O
and NN NN O
all NN NN O
patients NN NN O
had NN NN O
a NN NN O
formal NN NN O
neurological NN NN O
evaluation NN NN O
and NN NN O
brain NN NN O
imaging NN NN O
studies NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Twenty NN NN O
- NN NN O
one NN NN O
of NN NN O
the NN NN O
24 NN NN O
patients NN NN O
did NN NN O
not NN NN O
have NN NN O
evidence NN NN O
of NN NN O
new NN NN O
cerebral NN NN B-Disease
ischemic NN NN I-Disease
injury NN NN I-Disease
, NN NN O
but NN NN O
seizures NN NN B-Disease
were NN NN O
likely NN NN O
due NN NN O
to NN NN O
ischemic NN NN B-Disease
brain NN NN I-Disease
injury NN NN I-Disease
in NN NN O
3 NN NN O
patients NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
with NN NN O
seizures NN NN B-Disease
did NN NN O
not NN NN O
have NN NN O
permanent NN NN O
neurological NN NN B-Disease
abnormalities NN NN I-Disease
. NN NN O
   
All NN NN O
24 NN NN O
patients NN NN O
with NN NN O
seizures NN NN B-Disease
received NN NN O
high NN NN O
doses NN NN O
of NN NN O
TXA NN NN O
intraoperatively NN NN O
ranging NN NN O
from NN NN O
61 NN NN O
to NN NN O
259 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
had NN NN O
a NN NN O
mean NN NN O
age NN NN O
of NN NN O
69 NN NN O
. NN NN O
9 NN NN O
years NN NN O
, NN NN O
and NN NN O
21 NN NN O
of NN NN O
24 NN NN O
had NN NN O
undergone NN NN O
open NN NN O
chamber NN NN O
rather NN NN O
than NN NN O
coronary NN NN O
bypass NN NN O
procedures NN NN O
. NN NN O
   
All NN NN O
but NN NN O
one NN NN O
patient NN NN O
were NN NN O
managed NN NN O
using NN NN O
cardiopulmonary NN NN O
bypass NN NN O
. NN NN O
   
No NN NN O
evidence NN NN O
of NN NN O
brain NN NN B-Disease
ischemic NN NN I-Disease
, NN NN O
metabolic NN NN O
, NN NN O
or NN NN O
hyperthermia NN NN B-Disease
- NN NN O
induced NN NN O
causes NN NN O
for NN NN O
their NN NN O
seizures NN NN B-Disease
was NN NN O
apparent NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
use NN NN O
of NN NN O
high NN NN O
- NN NN O
dose NN NN O
TXA NN NN O
in NN NN O
older NN NN O
patients NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
cardiopulmonary NN NN O
bypass NN NN O
and NN NN O
open NN NN O
- NN NN O
chamber NN NN O
cardiac NN NN O
surgery NN NN O
is NN NN O
associated NN NN O
with NN NN O
clinical NN NN O
seizures NN NN B-Disease
in NN NN O
susceptible NN NN O
patients NN NN O
. NN NN O
   
Electrocardiographic NN NN O
changes NN NN O
and NN NN O
cardiac NN NN B-Disease
arrhythmias NN NN I-Disease
in NN NN O
patients NN NN O
receiving NN NN O
psychotropic NN NN O
drugs NN NN O
. NN NN O
   
Eight NN NN O
patients NN NN O
had NN NN O
cardiac NN NN O
manifestations NN NN O
that NN NN O
were NN NN O
life NN NN O
- NN NN O
threatening NN NN O
in NN NN O
five NN NN O
while NN NN O
taking NN NN O
psychotropic NN NN O
drugs NN NN O
, NN NN O
either NN NN O
phenothiazines NN NN O
or NN NN O
tricyclic NN NN O
antidepressants NN NN O
. NN NN O
   
Although NN NN O
most NN NN O
patients NN NN O
were NN NN O
receiving NN NN O
several NN NN O
drugs NN NN O
, NN NN O
Mellaril NN NN O
( NN NN O
thioridazine NN NN O
) NN NN O
appeared NN NN O
to NN NN O
be NN NN O
responsible NN NN O
for NN NN O
five NN NN O
cases NN NN O
of NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
, NN NN O
one NN NN O
of NN NN O
which NN NN O
was NN NN O
fatal NN NN O
in NN NN O
a NN NN O
35 NN NN O
year NN NN O
old NN NN O
woman NN NN O
. NN NN O
   
Supraventricular NN NN B-Disease
tachycardia NN NN I-Disease
developed NN NN O
in NN NN O
one NN NN O
patient NN NN O
receiving NN NN O
Thorazine NN NN O
( NN NN O
chlorpromazine NN NN O
) NN NN O
. NN NN O
   
Aventyl NN NN O
( NN NN O
nortriptyline NN NN O
) NN NN O
and NN NN O
Elavil NN NN O
( NN NN O
amitriptyline NN NN O
) NN NN O
each NN NN O
produced NN NN O
left NN NN B-Disease
bundle NN NN I-Disease
branch NN NN I-Disease
block NN NN I-Disease
in NN NN O
a NN NN O
73 NN NN O
year NN NN O
old NN NN O
woman NN NN O
. NN NN O
   
Electrocardiographic NN NN O
T NN NN O
and NN NN O
U NN NN O
wave NN NN O
abnormalities NN NN O
were NN NN O
present NN NN O
in NN NN O
most NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
ventricular NN NN B-Disease
arrhythmias NN NN I-Disease
responded NN NN O
to NN NN O
intravenous NN NN O
administration NN NN O
of NN NN O
lidocaine NN NN O
and NN NN O
to NN NN O
direct NN NN O
current NN NN O
electric NN NN O
shock NN NN O
; NN NN O
ventricular NN NN O
pacing NN NN O
was NN NN O
required NN NN O
in NN NN O
some NN NN O
instances NN NN O
and NN NN O
intravenous NN NN O
administration NN NN O
of NN NN O
propranolol NN NN O
combined NN NN O
with NN NN O
ventricular NN NN O
pacing NN NN O
in NN NN O
one NN NN O
. NN NN O
   
The NN NN O
tachyarrhythmias NN NN B-Disease
generally NN NN O
subsided NN NN O
within NN NN O
48 NN NN O
hours NN NN O
after NN NN O
administration NN NN O
of NN NN O
the NN NN O
drugs NN NN O
was NN NN O
stopped NN NN O
. NN NN O
   
Five NN NN O
of NN NN O
the NN NN O
eight NN NN O
patients NN NN O
were NN NN O
50 NN NN O
years NN NN O
of NN NN O
age NN NN O
or NN NN O
younger NN NN O
; NN NN O
only NN NN O
one NN NN O
clearly NN NN O
had NN NN O
antecedent NN NN O
heart NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
Major NN NN O
cardiac NN NN B-Disease
arrhythmias NN NN I-Disease
are NN NN O
a NN NN O
potential NN NN O
hazard NN NN O
in NN NN O
patients NN NN O
without NN NN O
heart NN NN B-Disease
disease NN NN I-Disease
who NN NN O
are NN NN O
receiving NN NN O
customary NN NN O
therapeutic NN NN O
doses NN NN O
of NN NN O
psychotropic NN NN O
drugs NN NN O
. NN NN O
   
A NN NN O
prospective NN NN O
clinical NN NN O
trial NN NN O
is NN NN O
suggested NN NN O
to NN NN O
quantify NN NN O
the NN NN O
risk NN NN O
of NN NN O
cardiac NN NN B-Disease
complications NN NN I-Disease
to NN NN O
patients NN NN O
receiving NN NN O
phenothiazines NN NN O
or NN NN O
tricyclic NN NN O
antidepressant NN NN O
drugs NN NN O
. NN NN O
   
Sensitivity NN NN O
of NN NN O
erythroid NN NN O
progenitor NN NN O
colonies NN NN O
to NN NN O
erythropoietin NN NN O
in NN NN O
azidothymidine NN NN O
treated NN NN O
immunodeficient NN NN B-Disease
mice NN NN O
. NN NN O
   
The NN NN O
anaemia NN NN B-Disease
induced NN NN O
by NN NN O
3 NN NN O
' NN NN O
- NN NN O
azido NN NN O
- NN NN O
3 NN NN O
' NN NN O
dideoxythymidine NN NN O
( NN NN O
AZT NN NN O
) NN NN O
is NN NN O
poorly NN NN O
understood NN NN O
. NN NN O
   
We NN NN O
have NN NN O
used NN NN O
a NN NN O
murine NN NN O
model NN NN O
of NN NN O
AIDS NN NN B-Disease
, NN NN O
infection NN NN B-Disease
of NN NN O
female NN NN O
C57BL NN NN O
/ NN NN O
6 NN NN O
mice NN NN O
with NN NN O
LP NN NN O
- NN NN O
BM5 NN NN O
murine NN NN O
leukaemia NN NN B-Disease
( NN NN O
MuLV NN NN O
) NN NN O
virus NN NN O
, NN NN O
to NN NN O
determine NN NN O
if NN NN O
AZT NN NN O
- NN NN O
induced NN NN O
anaemia NN NN B-Disease
is NN NN O
due NN NN O
, NN NN O
in NN NN O
part NN NN O
, NN NN O
to NN NN O
decreased NN NN O
responsiveness NN NN O
of NN NN O
erythropoietic NN NN O
precursors NN NN O
( NN NN O
BFU NN NN O
- NN NN O
e NN NN O
) NN NN O
to NN NN O
erythropoietin NN NN O
( NN NN O
EPO NN NN O
) NN NN O
. NN NN O
   
Mice NN NN O
in NN NN O
the NN NN O
early NN NN O
stage NN NN O
of NN NN O
LP NN NN O
- NN NN O
BM5 NN NN O
MuLV NN NN O
disease NN NN O
were NN NN O
given NN NN O
AZT NN NN O
in NN NN O
their NN NN O
drinking NN NN O
water NN NN O
at NN NN O
1 NN NN O
. NN NN O
0 NN NN O
and NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
ml NN NN O
. NN NN O
   
AZT NN NN O
produced NN NN O
anaemia NN NN B-Disease
in NN NN O
both NN NN O
groups NN NN O
, NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
fashion NN NN O
. NN NN O
   
Despite NN NN O
the NN NN O
anaemia NN NN B-Disease
, NN NN O
the NN NN O
number NN NN O
of NN NN O
splenic NN NN O
and NN NN O
bone NN NN O
marrow NN NN O
BFU NN NN O
- NN NN O
e NN NN O
in NN NN O
AZT NN NN O
treated NN NN O
mice NN NN O
increased NN NN O
up NN NN O
to NN NN O
five NN NN O
- NN NN O
fold NN NN O
over NN NN O
levels NN NN O
observed NN NN O
in NN NN O
infected NN NN O
untreated NN NN O
animals NN NN O
after NN NN O
15 NN NN O
d NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
Colony NN NN O
formation NN NN O
by NN NN O
splenic NN NN O
and NN NN O
bone NN NN O
marrow NN NN O
BFUe NN NN O
was NN NN O
stimulated NN NN O
at NN NN O
lower NN NN O
concentrations NN NN O
of NN NN O
EPO NN NN O
in NN NN O
mice NN NN O
receiving NN NN O
AZT NN NN O
for NN NN O
15 NN NN O
d NN NN O
than NN NN O
for NN NN O
infected NN NN O
, NN NN O
untreated NN NN O
mice NN NN O
. NN NN O
   
By NN NN O
day NN NN O
30 NN NN O
, NN NN O
sensitivity NN NN O
of NN NN O
both NN NN O
splenic NN NN O
and NN NN O
bone NN NN O
marrow NN NN O
BFU NN NN O
- NN NN O
e NN NN O
of NN NN O
treated NN NN O
animals NN NN O
returned NN NN O
to NN NN O
that NN NN O
observed NN NN O
from NN NN O
cells NN NN O
of NN NN O
infected NN NN O
untreated NN NN O
animals NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
plasma NN NN O
levels NN NN O
of NN NN O
EPO NN NN O
observed NN NN O
in NN NN O
AZT NN NN O
treated NN NN O
mice NN NN O
were NN NN O
appropriate NN NN O
for NN NN O
the NN NN O
degree NN NN O
of NN NN O
anaemia NN NN B-Disease
observed NN NN O
when NN NN O
compared NN NN O
with NN NN O
phenylhydrazine NN NN O
( NN NN O
PHZ NN NN O
) NN NN O
treated NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
numbers NN NN O
of NN NN O
BFU NN NN O
- NN NN O
e NN NN O
and NN NN O
the NN NN O
percentage NN NN O
of NN NN O
bone NN NN O
marrow NN NN O
erythroblasts NN NN O
observed NN NN O
were NN NN O
comparable NN NN O
in NN NN O
AZT NN NN O
and NN NN O
PHZ NN NN O
treated NN NN O
mice NN NN O
with NN NN O
similar NN NN O
degrees NN NN O
of NN NN O
anaemia NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
reticulocytosis NN NN B-Disease
was NN NN O
inappropriate NN NN O
for NN NN O
the NN NN O
degree NN NN O
of NN NN O
anaemia NN NN B-Disease
observed NN NN O
in NN NN O
AZT NN NN O
treated NN NN O
infected NN NN O
mice NN NN O
. NN NN O
   
AZT NN NN O
- NN NN O
induced NN NN O
peripheral NN NN O
anaemia NN NN B-Disease
in NN NN O
the NN NN O
face NN NN O
of NN NN O
increased NN NN O
numbers NN NN O
of NN NN O
BFU NN NN O
- NN NN O
e NN NN O
and NN NN O
increased NN NN O
levels NN NN O
of NN NN O
plasma NN NN O
EPO NN NN O
suggest NN NN O
a NN NN O
lesion NN NN O
in NN NN O
terminal NN NN O
differentiation NN NN O
. NN NN O
   
Sedation NN NN O
depth NN NN O
during NN NN O
spinal NN NN O
anesthesia NN NN O
and NN NN O
the NN NN O
development NN NN O
of NN NN O
postoperative NN NN B-Disease
delirium NN NN I-Disease
in NN NN O
elderly NN NN O
patients NN NN O
undergoing NN NN O
hip NN NN B-Disease
fracture NN NN I-Disease
repair NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
determine NN NN O
whether NN NN O
limiting NN NN O
intraoperative NN NN O
sedation NN NN O
depth NN NN O
during NN NN O
spinal NN NN O
anesthesia NN NN O
for NN NN O
hip NN NN B-Disease
fracture NN NN I-Disease
repair NN NN O
in NN NN O
elderly NN NN O
patients NN NN O
can NN NN O
decrease NN NN O
the NN NN O
prevalence NN NN O
of NN NN O
postoperative NN NN B-Disease
delirium NN NN I-Disease
. NN NN O
   
PATIENTS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
We NN NN O
performed NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
randomized NN NN O
controlled NN NN O
trial NN NN O
at NN NN O
an NN NN O
academic NN NN O
medical NN NN O
center NN NN O
of NN NN O
elderly NN NN O
patients NN NN O
( NN NN O
> NN NN O
or NN NN O
= NN NN O
65 NN NN O
years NN NN O
) NN NN O
without NN NN O
preoperative NN NN O
delirium NN NN B-Disease
or NN NN O
severe NN NN O
dementia NN NN B-Disease
who NN NN O
underwent NN NN O
hip NN NN B-Disease
fracture NN NN I-Disease
repair NN NN O
under NN NN O
spinal NN NN O
anesthesia NN NN O
with NN NN O
propofol NN NN O
sedation NN NN O
. NN NN O
   
Sedation NN NN O
depth NN NN O
was NN NN O
titrated NN NN O
using NN NN O
processed NN NN O
electroencephalography NN NN O
with NN NN O
the NN NN O
bispectral NN NN O
index NN NN O
( NN NN O
BIS NN NN O
) NN NN O
, NN NN O
and NN NN O
patients NN NN O
were NN NN O
randomized NN NN O
to NN NN O
receive NN NN O
either NN NN O
deep NN NN O
( NN NN O
BIS NN NN O
, NN NN O
approximately NN NN O
50 NN NN O
) NN NN O
or NN NN O
light NN NN O
( NN NN O
BIS NN NN O
, NN NN O
> NN NN O
or NN NN O
= NN NN O
80 NN NN O
) NN NN O
sedation NN NN O
. NN NN O
   
Postoperative NN NN B-Disease
delirium NN NN I-Disease
was NN NN O
assessed NN NN O
as NN NN O
defined NN NN O
by NN NN O
Diagnostic NN NN O
and NN NN O
Statistical NN NN O
Manual NN NN O
of NN NN O
Mental NN NN B-Disease
Disorders NN NN I-Disease
( NN NN O
Third NN NN O
Edition NN NN O
Revised NN NN O
) NN NN O
criteria NN NN O
using NN NN O
the NN NN O
Confusion NN NN O
Assessment NN NN O
Method NN NN O
beginning NN NN O
at NN NN O
any NN NN O
time NN NN O
from NN NN O
the NN NN O
second NN NN O
day NN NN O
after NN NN O
surgery NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
From NN NN O
April NN NN O
2 NN NN O
, NN NN O
2005 NN NN O
, NN NN O
through NN NN O
October NN NN O
30 NN NN O
, NN NN O
2008 NN NN O
, NN NN O
a NN NN O
total NN NN O
of NN NN O
114 NN NN O
patients NN NN O
were NN NN O
randomized NN NN O
. NN NN O
   
The NN NN O
prevalence NN NN O
of NN NN O
postoperative NN NN B-Disease
delirium NN NN I-Disease
was NN NN O
significantly NN NN O
lower NN NN O
in NN NN O
the NN NN O
light NN NN O
sedation NN NN O
group NN NN O
( NN NN O
11 NN NN O
/ NN NN O
57 NN NN O
[ NN NN O
19 NN NN O
% NN NN O
] NN NN O
vs NN NN O
23 NN NN O
/ NN NN O
57 NN NN O
[ NN NN O
40 NN NN O
% NN NN O
] NN NN O
in NN NN O
the NN NN O
deep NN NN O
sedation NN NN O
group NN NN O
; NN NN O
P NN NN O
= NN NN O
. NN NN O
02 NN NN O
) NN NN O
, NN NN O
indicating NN NN O
that NN NN O
1 NN NN O
incident NN NN O
of NN NN O
delirium NN NN B-Disease
will NN NN O
be NN NN O
prevented NN NN O
for NN NN O
every NN NN O
4 NN NN O
. NN NN O
7 NN NN O
patients NN NN O
treated NN NN O
with NN NN O
light NN NN O
sedation NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
number NN NN O
of NN NN O
days NN NN O
of NN NN O
delirium NN NN B-Disease
during NN NN O
hospitalization NN NN O
was NN NN O
lower NN NN O
in NN NN O
the NN NN O
light NN NN O
sedation NN NN O
group NN NN O
than NN NN O
in NN NN O
the NN NN O
deep NN NN O
sedation NN NN O
group NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
5 NN NN O
days NN NN O
vs NN NN O
1 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
. NN NN O
0 NN NN O
days NN NN O
; NN NN O
P NN NN O
= NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
use NN NN O
of NN NN O
light NN NN O
propofol NN NN O
sedation NN NN O
decreased NN NN O
the NN NN O
prevalence NN NN O
of NN NN O
postoperative NN NN B-Disease
delirium NN NN I-Disease
by NN NN O
50 NN NN O
% NN NN O
compared NN NN O
with NN NN O
deep NN NN O
sedation NN NN O
. NN NN O
   
Limiting NN NN O
depth NN NN O
of NN NN O
sedation NN NN O
during NN NN O
spinal NN NN O
anesthesia NN NN O
is NN NN O
a NN NN O
simple NN NN O
, NN NN O
safe NN NN O
, NN NN O
and NN NN O
cost NN NN O
- NN NN O
effective NN NN O
intervention NN NN O
for NN NN O
preventing NN NN O
postoperative NN NN B-Disease
delirium NN NN I-Disease
in NN NN O
elderly NN NN O
patients NN NN O
that NN NN O
could NN NN O
be NN NN O
widely NN NN O
and NN NN O
readily NN NN O
adopted NN NN O
. NN NN O
   
The NN NN O
protective NN NN O
role NN NN O
of NN NN O
Nrf2 NN NN O
in NN NN O
streptozotocin NN NN O
- NN NN O
induced NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
Diabetic NN NN B-Disease
nephropathy NN NN I-Disease
is NN NN O
one NN NN O
of NN NN O
the NN NN O
major NN NN O
causes NN NN O
of NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
, NN NN O
which NN NN O
is NN NN O
accompanied NN NN O
by NN NN O
the NN NN O
production NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
( NN NN O
ROS NN NN O
) NN NN O
. NN NN O
   
Nrf2 NN NN O
is NN NN O
the NN NN O
primary NN NN O
transcription NN NN O
factor NN NN O
that NN NN O
controls NN NN O
the NN NN O
antioxidant NN NN O
response NN NN O
essential NN NN O
for NN NN O
maintaining NN NN O
cellular NN NN O
redox NN NN O
homeostasis NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
report NN NN O
our NN NN O
findings NN NN O
demonstrating NN NN O
a NN NN O
protective NN NN O
role NN NN O
of NN NN O
Nrf2 NN NN O
against NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
. NN NN O
   
RESEARCH NN NN O
DESIGN NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
We NN NN O
explore NN NN O
the NN NN O
protective NN NN O
role NN NN O
of NN NN O
Nrf2 NN NN O
against NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
using NN NN O
human NN NN O
kidney NN NN O
biopsy NN NN O
tissues NN NN O
from NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
patients NN NN O
, NN NN O
a NN NN O
streptozotocin NN NN O
- NN NN O
induced NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
model NN NN O
in NN NN O
Nrf2 NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
, NN NN O
and NN NN O
cultured NN NN O
human NN NN O
mesangial NN NN O
cells NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
glomeruli NN NN O
of NN NN O
human NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
patients NN NN O
were NN NN O
under NN NN O
oxidative NN NN O
stress NN NN O
and NN NN O
had NN NN O
elevated NN NN O
Nrf2 NN NN O
levels NN NN O
. NN NN O
   
In NN NN O
the NN NN O
animal NN NN O
study NN NN O
, NN NN O
Nrf2 NN NN O
was NN NN O
demonstrated NN NN O
to NN NN O
be NN NN O
crucial NN NN O
in NN NN O
ameliorating NN NN O
streptozotocin NN NN O
- NN NN O
induced NN NN O
renal NN NN B-Disease
damage NN NN I-Disease
. NN NN O
   
This NN NN O
is NN NN O
evident NN NN O
by NN NN O
Nrf2 NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
having NN NN O
higher NN NN O
ROS NN NN O
production NN NN O
and NN NN O
suffering NN NN O
from NN NN O
greater NN NN O
oxidative NN NN O
DNA NN NN O
damage NN NN O
and NN NN O
renal NN NN B-Disease
injury NN NN I-Disease
compared NN NN O
with NN NN O
Nrf2 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
+ NN NN O
) NN NN O
mice NN NN O
. NN NN O
   
Mechanistic NN NN O
studies NN NN O
in NN NN O
both NN NN O
in NN NN O
vivo NN NN O
and NN NN O
in NN NN O
vitro NN NN O
systems NN NN O
showed NN NN O
that NN NN O
the NN NN O
Nrf2 NN NN O
- NN NN O
mediated NN NN O
protection NN NN O
against NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
is NN NN O
, NN NN O
at NN NN O
least NN NN O
, NN NN O
partially NN NN O
through NN NN O
inhibition NN NN O
of NN NN O
transforming NN NN O
growth NN NN O
factor NN NN O
- NN NN O
beta1 NN NN O
( NN NN O
TGF NN NN O
- NN NN O
beta1 NN NN O
) NN NN O
and NN NN O
reduction NN NN O
of NN NN O
extracellular NN NN O
matrix NN NN O
production NN NN O
. NN NN O
   
In NN NN O
human NN NN O
renal NN NN O
mesangial NN NN O
cells NN NN O
, NN NN O
high NN NN O
glucose NN NN O
induced NN NN O
ROS NN NN O
production NN NN O
and NN NN O
activated NN NN O
expression NN NN O
of NN NN O
Nrf2 NN NN O
and NN NN O
its NN NN O
downstream NN NN O
genes NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
activation NN NN O
or NN NN O
overexpression NN NN O
of NN NN O
Nrf2 NN NN O
inhibited NN NN O
the NN NN O
promoter NN NN O
activity NN NN O
of NN NN O
TGF NN NN O
- NN NN O
beta1 NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
, NN NN O
whereas NN NN O
knockdown NN NN O
of NN NN O
Nrf2 NN NN O
by NN NN O
siRNA NN NN O
enhanced NN NN O
TGF NN NN O
- NN NN O
beta1 NN NN O
transcription NN NN O
and NN NN O
fibronectin NN NN O
production NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
This NN NN O
work NN NN O
clearly NN NN O
indicates NN NN O
a NN NN O
protective NN NN O
role NN NN O
of NN NN O
Nrf2 NN NN O
in NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
, NN NN O
suggesting NN NN O
that NN NN O
dietary NN NN O
or NN NN O
therapeutic NN NN O
activation NN NN O
of NN NN O
Nrf2 NN NN O
could NN NN O
be NN NN O
used NN NN O
as NN NN O
a NN NN O
strategy NN NN O
to NN NN O
prevent NN NN O
or NN NN O
slow NN NN O
down NN NN O
the NN NN O
progression NN NN O
of NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
. NN NN O
   
Metformin NN NN O
prevents NN NN O
experimental NN NN O
gentamicin NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
by NN NN O
a NN NN O
mitochondria NN NN O
- NN NN O
dependent NN NN O
pathway NN NN O
. NN NN O
   
The NN NN O
antidiabetic NN NN O
drug NN NN O
metformin NN NN O
can NN NN O
diminish NN NN O
apoptosis NN NN O
induced NN NN O
by NN NN O
oxidative NN NN O
stress NN NN O
in NN NN O
endothelial NN NN O
cells NN NN O
and NN NN O
prevent NN NN O
vascular NN NN B-Disease
dysfunction NN NN I-Disease
even NN NN O
in NN NN O
nondiabetic NN NN O
patients NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
tested NN NN O
whether NN NN O
it NN NN O
has NN NN O
a NN NN O
beneficial NN NN O
effect NN NN O
in NN NN O
a NN NN O
rat NN NN O
model NN NN O
of NN NN O
gentamicin NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Mitochondrial NN NN O
analysis NN NN O
, NN NN O
respiration NN NN O
intensity NN NN O
, NN NN O
levels NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
, NN NN O
permeability NN NN O
transition NN NN O
, NN NN O
and NN NN O
cytochrome NN NN O
c NN NN O
release NN NN O
were NN NN O
assessed NN NN O
3 NN NN O
and NN NN O
6 NN NN O
days NN NN O
after NN NN O
gentamicin NN NN O
administration NN NN O
. NN NN O
   
Metformin NN NN O
treatment NN NN O
fully NN NN O
blocked NN NN O
gentamicin NN NN O
- NN NN O
mediated NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
This NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
a NN NN O
lower NN NN O
activity NN NN O
of NN NN O
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
beta NN NN O
- NN NN O
D NN NN O
- NN NN O
glucosaminidase NN NN O
, NN NN O
together NN NN O
with NN NN O
a NN NN O
decrease NN NN O
of NN NN O
lipid NN NN O
peroxidation NN NN O
and NN NN O
increase NN NN O
of NN NN O
antioxidant NN NN O
systems NN NN O
. NN NN O
   
Metformin NN NN O
also NN NN O
protected NN NN O
the NN NN O
kidney NN NN O
from NN NN O
histological NN NN O
damage NN NN O
6 NN NN O
days NN NN O
after NN NN O
gentamicin NN NN O
administration NN NN O
. NN NN O
   
These NN NN O
in NN NN O
vivo NN NN O
markers NN NN O
of NN NN O
kidney NN NN B-Disease
dysfunction NN NN I-Disease
and NN NN O
their NN NN O
correction NN NN O
by NN NN O
metformin NN NN O
were NN NN O
complemented NN NN O
by NN NN O
in NN NN O
vitro NN NN O
studies NN NN O
of NN NN O
mitochondrial NN NN O
function NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
gentamicin NN NN O
treatment NN NN O
depleted NN NN O
respiratory NN NN O
components NN NN O
( NN NN O
cytochrome NN NN O
c NN NN O
, NN NN O
NADH NN NN O
) NN NN O
, NN NN O
probably NN NN O
due NN NN O
to NN NN O
the NN NN O
opening NN NN O
of NN NN O
mitochondrial NN NN O
transition NN NN O
pores NN NN O
. NN NN O
   
These NN NN O
injuries NN NN O
, NN NN O
partly NN NN O
mediated NN NN O
by NN NN O
a NN NN O
rise NN NN O
in NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
from NN NN O
the NN NN O
electron NN NN O
transfer NN NN O
chain NN NN O
, NN NN O
were NN NN O
significantly NN NN O
decreased NN NN O
by NN NN O
metformin NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
our NN NN O
study NN NN O
suggests NN NN O
that NN NN O
pleiotropic NN NN O
effects NN NN O
of NN NN O
metformin NN NN O
can NN NN O
lessen NN NN O
gentamicin NN NN O
nephrotoxicity NN NN B-Disease
and NN NN O
improve NN NN O
mitochondrial NN NN O
homeostasis NN NN O
. NN NN O
   
Risk NN NN O
of NN NN O
nephropathy NN NN B-Disease
after NN NN O
consumption NN NN O
of NN NN O
nonionic NN NN O
contrast NN NN O
media NN NN O
by NN NN O
children NN NN O
undergoing NN NN O
cardiac NN NN O
angiography NN NN O
: NN NN O
a NN NN O
prospective NN NN O
study NN NN O
. NN NN O
   
Despite NN NN O
increasing NN NN O
reports NN NN O
on NN NN O
nonionic NN NN O
contrast NN NN O
media NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
( NN NN O
CIN NN NN B-Disease
) NN NN O
in NN NN O
hospitalized NN NN O
adult NN NN O
patients NN NN O
during NN NN O
cardiac NN NN O
procedures NN NN O
, NN NN O
the NN NN O
studies NN NN O
in NN NN O
pediatrics NN NN O
are NN NN O
limited NN NN O
, NN NN O
with NN NN O
even NN NN O
less NN NN O
focus NN NN O
on NN NN O
possible NN NN O
predisposing NN NN O
factors NN NN O
and NN NN O
preventive NN NN O
measures NN NN O
for NN NN O
patients NN NN O
undergoing NN NN O
cardiac NN NN O
angiography NN NN O
. NN NN O
   
This NN NN O
prospective NN NN O
study NN NN O
determined NN NN O
the NN NN O
incidence NN NN O
of NN NN O
CIN NN NN B-Disease
for NN NN O
two NN NN O
nonionic NN NN O
contrast NN NN O
media NN NN O
( NN NN O
CM NN NN O
) NN NN O
, NN NN O
iopromide NN NN O
and NN NN O
iohexol NN NN O
, NN NN O
among NN NN O
80 NN NN O
patients NN NN O
younger NN NN O
than NN NN O
18 NN NN O
years NN NN O
and NN NN O
compared NN NN O
the NN NN O
rates NN NN O
for NN NN O
this NN NN O
complication NN NN O
in NN NN O
relation NN NN O
to NN NN O
the NN NN O
type NN NN O
and NN NN O
dosage NN NN O
of NN NN O
CM NN NN O
and NN NN O
the NN NN O
presence NN NN O
of NN NN O
cyanosis NN NN B-Disease
. NN NN O
   
The NN NN O
80 NN NN O
patients NN NN O
in NN NN O
the NN NN O
study NN NN O
consecutively NN NN O
received NN NN O
either NN NN O
iopromide NN NN O
( NN NN O
group NN NN O
A NN NN O
, NN NN O
n NN NN O
= NN NN O
40 NN NN O
) NN NN O
or NN NN O
iohexol NN NN O
( NN NN O
group NN NN O
B NN NN O
, NN NN O
n NN NN O
= NN NN O
40 NN NN O
) NN NN O
. NN NN O
   
Serum NN NN O
sodium NN NN O
( NN NN O
Na NN NN O
) NN NN O
, NN NN O
potassium NN NN O
( NN NN O
K NN NN O
) NN NN O
, NN NN O
and NN NN O
creatinine NN NN O
( NN NN O
Cr NN NN O
) NN NN O
were NN NN O
measured NN NN O
24 NN NN O
h NN NN O
before NN NN O
angiography NN NN O
as NN NN O
baseline NN NN O
values NN NN O
, NN NN O
then NN NN O
measured NN NN O
again NN NN O
at NN NN O
12 NN NN O
- NN NN O
, NN NN O
24 NN NN O
- NN NN O
, NN NN O
and NN NN O
48 NN NN O
- NN NN O
h NN NN O
intervals NN NN O
after NN NN O
CM NN NN O
use NN NN O
. NN NN O
   
Urine NN NN O
samples NN NN O
for NN NN O
Na NN NN O
and NN NN O
Cr NN NN O
also NN NN O
were NN NN O
checked NN NN O
at NN NN O
the NN NN O
same NN NN O
intervals NN NN O
. NN NN O
   
Risk NN NN O
of NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
, NN NN O
Injury NN NN B-Disease
to NN NN I-Disease
the NN NN I-Disease
kidney NN NN I-Disease
, NN NN O
Failure NN NN B-Disease
of NN NN I-Disease
kidney NN NN I-Disease
function NN NN I-Disease
, NN NN O
Loss NN NN B-Disease
of NN NN I-Disease
kidney NN NN I-Disease
function NN NN I-Disease
, NN NN O
and NN NN O
End NN NN O
- NN NN O
stage NN NN O
renal NN NN B-Disease
damage NN NN I-Disease
( NN NN O
RIFLE NN NN O
criteria NN NN O
) NN NN O
were NN NN O
used NN NN O
to NN NN O
define NN NN O
CIN NN NN B-Disease
and NN NN O
its NN NN O
incidence NN NN O
in NN NN O
the NN NN O
study NN NN O
population NN NN O
. NN NN O
   
Accordingly NN NN O
, NN NN O
among NN NN O
the NN NN O
15 NN NN O
CIN NN NN B-Disease
patients NN NN O
( NN NN O
18 NN NN O
. NN NN O
75 NN NN O
% NN NN O
) NN NN O
, NN NN O
7 NN NN O
. NN NN O
5 NN NN O
% NN NN O
of NN NN O
the NN NN O
patients NN NN O
in NN NN O
group NN NN O
A NN NN O
had NN NN O
increased NN NN O
risk NN NN O
and NN NN O
3 NN NN O
. NN NN O
75 NN NN O
% NN NN O
had NN NN O
renal NN NN B-Disease
injury NN NN I-Disease
, NN NN O
whereas NN NN O
5 NN NN O
% NN NN O
of NN NN O
group NN NN O
B NN NN O
had NN NN O
increased NN NN O
risk NN NN O
and NN NN O
2 NN NN O
. NN NN O
5 NN NN O
% NN NN O
had NN NN O
renal NN NN B-Disease
injury NN NN I-Disease
. NN NN O
   
Whereas NN NN O
33 NN NN O
. NN NN O
3 NN NN O
% NN NN O
of NN NN O
the NN NN O
patients NN NN O
with NN NN O
CIN NN NN B-Disease
were NN NN O
among NN NN O
those NN NN O
who NN NN O
received NN NN O
the NN NN O
proper NN NN O
dosage NN NN O
of NN NN O
CM NN NN O
, NN NN O
the NN NN O
percentage NN NN O
increased NN NN O
to NN NN O
66 NN NN O
. NN NN O
6 NN NN O
% NN NN O
among NN NN O
those NN NN O
who NN NN O
received NN NN O
larger NN NN O
doses NN NN O
, NN NN O
with NN NN O
a NN NN O
significant NN NN O
difference NN NN O
in NN NN O
the NN NN O
incidence NN NN O
of NN NN O
CIN NN NN B-Disease
related NN NN O
to NN NN O
the NN NN O
different NN NN O
dosages NN NN O
of NN NN O
CM NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
014 NN NN O
) NN NN O
. NN NN O
   
Among NN NN O
the NN NN O
15 NN NN O
patients NN NN O
with NN NN O
CIN NN NN B-Disease
, NN NN O
6 NN NN O
had NN NN O
cyanotic NN NN O
congenital NN NN B-Disease
heart NN NN I-Disease
diseases NN NN I-Disease
, NN NN O
but NN NN O
the NN NN O
incidence NN NN O
did NN NN O
not NN NN O
differ NN NN O
significantly NN NN O
from NN NN O
that NN NN O
for NN NN O
the NN NN O
noncyanotic NN NN O
patients NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
243 NN NN O
) NN NN O
. NN NN O
   
Although NN NN O
clinically NN NN O
silent NN NN O
, NN NN O
CIN NN NN B-Disease
is NN NN O
not NN NN O
rare NN NN O
in NN NN O
pediatrics NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
depends NN NN O
on NN NN O
dosage NN NN O
but NN NN O
not NN NN O
on NN NN O
the NN NN O
type NN NN O
of NN NN O
consumed NN NN O
nonionic NN NN O
CM NN NN O
, NN NN O
nor NN NN O
on NN NN O
the NN NN O
presence NN NN O
of NN NN O
cyanosis NN NN B-Disease
, NN NN O
and NN NN O
although NN NN O
CIN NN NN B-Disease
usually NN NN O
is NN NN O
reversible NN NN O
, NN NN O
more NN NN O
concern NN NN O
is NN NN O
needed NN NN O
for NN NN O
the NN NN O
prevention NN NN O
of NN NN O
such NN NN O
a NN NN O
complication NN NN O
in NN NN O
children NN NN O
. NN NN O
   
Renal NN NN O
function NN NN O
and NN NN O
hemodynamics NN NN O
during NN NN O
prolonged NN NN O
isoflurane NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
in NN NN O
humans NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
isoflurane NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
on NN NN O
glomerular NN NN O
function NN NN O
and NN NN O
renal NN NN O
blood NN NN O
flow NN NN O
was NN NN O
investigated NN NN O
in NN NN O
20 NN NN O
human NN NN O
subjects NN NN O
. NN NN O
   
Glomerular NN NN O
filtration NN NN O
rate NN NN O
( NN NN O
GFR NN NN O
) NN NN O
and NN NN O
effective NN NN O
renal NN NN O
plasma NN NN O
flow NN NN O
( NN NN O
ERPF NN NN O
) NN NN O
were NN NN O
measured NN NN O
by NN NN O
inulin NN NN O
and NN NN O
para NN NN O
- NN NN O
aminohippurate NN NN O
( NN NN O
PAH NN NN O
) NN NN O
clearance NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Anesthesia NN NN O
was NN NN O
maintained NN NN O
with NN NN O
fentanyl NN NN O
, NN NN O
nitrous NN NN O
oxide NN NN O
, NN NN O
oxygen NN NN O
, NN NN O
and NN NN O
isoflurane NN NN O
. NN NN O
   
Hypotension NN NN B-Disease
was NN NN O
induced NN NN O
for NN NN O
236 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
15 NN NN O
. NN NN O
1 NN NN O
min NN NN O
by NN NN O
increasing NN NN O
the NN NN O
isoflurane NN NN O
inspired NN NN O
concentration NN NN O
to NN NN O
maintain NN NN O
a NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
of NN NN O
59 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
4 NN NN O
mmHg NN NN O
. NN NN O
   
GFR NN NN O
and NN NN O
ERPF NN NN O
decreased NN NN O
with NN NN O
the NN NN O
induction NN NN O
of NN NN O
anesthesia NN NN O
but NN NN O
not NN NN O
significantly NN NN O
more NN NN O
during NN NN O
hypotension NN NN B-Disease
. NN NN O
   
Postoperatively NN NN O
, NN NN O
ERPF NN NN O
returned NN NN O
to NN NN O
preoperative NN NN O
values NN NN O
, NN NN O
whereas NN NN O
GFR NN NN O
was NN NN O
higher NN NN O
than NN NN O
preoperative NN NN O
values NN NN O
. NN NN O
   
Renal NN NN O
vascular NN NN O
resistance NN NN O
increased NN NN O
during NN NN O
anesthesia NN NN O
but NN NN O
decreased NN NN O
when NN NN O
hypotension NN NN B-Disease
was NN NN O
induced NN NN O
, NN NN O
allowing NN NN O
the NN NN O
maintenance NN NN O
of NN NN O
renal NN NN O
blood NN NN O
flow NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
renal NN NN O
compensatory NN NN O
mechanisms NN NN O
are NN NN O
preserved NN NN O
during NN NN O
isoflurane NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
and NN NN O
that NN NN O
renal NN NN O
function NN NN O
and NN NN O
hemodynamics NN NN O
quickly NN NN O
return NN NN O
to NN NN O
normal NN NN O
when NN NN O
normotension NN NN O
is NN NN O
resumed NN NN O
. NN NN O
   
Brainstem NN NN B-Disease
dysgenesis NN NN I-Disease
in NN NN O
an NN NN O
infant NN NN O
prenatally NN NN O
exposed NN NN O
to NN NN O
cocaine NN NN O
. NN NN O
   
Many NN NN O
authors NN NN O
described NN NN O
the NN NN O
effects NN NN O
on NN NN O
the NN NN O
fetus NN NN O
of NN NN O
maternal NN NN O
cocaine NN NN B-Disease
abuse NN NN I-Disease
during NN NN O
pregnancy NN NN O
. NN NN O
   
Vasoconstriction NN NN O
appears NN NN O
to NN NN O
be NN NN O
the NN NN O
common NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
leading NN NN O
to NN NN O
a NN NN O
wide NN NN O
range NN NN O
of NN NN O
fetal NN NN B-Disease
anomalies NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
on NN NN O
an NN NN O
infant NN NN O
with NN NN O
multiple NN NN B-Disease
cranial NN NN I-Disease
- NN NN I-Disease
nerve NN NN I-Disease
involvement NN NN I-Disease
attributable NN NN O
to NN NN O
brainstem NN NN B-Disease
dysgenesis NN NN I-Disease
, NN NN O
born NN NN O
to NN NN O
a NN NN O
cocaine NN NN B-Disease
- NN NN I-Disease
addicted NN NN I-Disease
mother NN NN O
. NN NN O
   
A NN NN O
cross NN NN O
- NN NN O
sectional NN NN O
evaluation NN NN O
of NN NN O
the NN NN O
effect NN NN O
of NN NN O
risperidone NN NN O
and NN NN O
selective NN NN O
serotonin NN NN O
reuptake NN NN O
inhibitors NN NN O
on NN NN O
bone NN NN O
mineral NN NN O
density NN NN O
in NN NN O
boys NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
the NN NN O
effect NN NN O
of NN NN O
risperidone NN NN O
- NN NN O
induced NN NN O
hyperprolactinemia NN NN B-Disease
on NN NN O
trabecular NN NN O
bone NN NN O
mineral NN NN O
density NN NN O
( NN NN O
BMD NN NN O
) NN NN O
in NN NN O
children NN NN O
and NN NN O
adolescents NN NN O
. NN NN O
   
METHOD NN NN O
: NN NN O
Medically NN NN O
healthy NN NN O
7 NN NN O
- NN NN O
to NN NN O
17 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
males NN NN O
chronically NN NN O
treated NN NN O
, NN NN O
in NN NN O
a NN NN O
naturalistic NN NN O
setting NN NN O
, NN NN O
with NN NN O
risperidone NN NN O
were NN NN O
recruited NN NN O
for NN NN O
this NN NN O
cross NN NN O
- NN NN O
sectional NN NN O
study NN NN O
through NN NN O
child NN NN O
psychiatry NN NN O
outpatient NN NN O
clinics NN NN O
between NN NN O
November NN NN O
2005 NN NN O
and NN NN O
June NN NN O
2007 NN NN O
. NN NN O
   
Anthropometric NN NN O
measurements NN NN O
and NN NN O
laboratory NN NN O
testing NN NN O
were NN NN O
conducted NN NN O
. NN NN O
   
The NN NN O
clinical NN NN O
diagnoses NN NN O
were NN NN O
based NN NN O
on NN NN O
chart NN NN O
review NN NN O
, NN NN O
and NN NN O
developmental NN NN O
and NN NN O
treatment NN NN O
history NN NN O
was NN NN O
obtained NN NN O
from NN NN O
the NN NN O
medical NN NN O
record NN NN O
. NN NN O
   
Volumetric NN NN O
BMD NN NN O
of NN NN O
the NN NN O
ultradistal NN NN O
radius NN NN O
was NN NN O
measured NN NN O
using NN NN O
peripheral NN NN O
quantitative NN NN O
computed NN NN O
tomography NN NN O
, NN NN O
and NN NN O
areal NN NN O
BMD NN NN O
of NN NN O
the NN NN O
lumbar NN NN O
spine NN NN O
was NN NN O
estimated NN NN O
using NN NN O
dual NN NN O
- NN NN O
energy NN NN O
x NN NN O
- NN NN O
ray NN NN O
absorptiometry NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Hyperprolactinemia NN NN B-Disease
was NN NN O
present NN NN O
in NN NN O
49 NN NN O
% NN NN O
of NN NN O
83 NN NN O
boys NN NN O
( NN NN O
n NN NN O
= NN NN O
41 NN NN O
) NN NN O
treated NN NN O
with NN NN O
risperidone NN NN O
for NN NN O
a NN NN O
mean NN NN O
of NN NN O
2 NN NN O
. NN NN O
9 NN NN O
years NN NN O
. NN NN O
   
Serum NN NN O
testosterone NN NN O
concentration NN NN O
increased NN NN O
with NN NN O
pubertal NN NN O
status NN NN O
but NN NN O
was NN NN O
not NN NN O
affected NN NN O
by NN NN O
hyperprolactinemia NN NN B-Disease
. NN NN O
   
As NN NN O
expected NN NN O
, NN NN O
bone NN NN O
mineral NN NN O
content NN NN O
and NN NN O
BMD NN NN O
increased NN NN O
with NN NN O
sexual NN NN O
maturity NN NN O
. NN NN O
   
After NN NN O
adjusting NN NN O
for NN NN O
the NN NN O
stage NN NN O
of NN NN O
sexual NN NN O
development NN NN O
and NN NN O
height NN NN O
and NN NN O
BMI NN NN O
z NN NN O
scores NN NN O
, NN NN O
serum NN NN O
prolactin NN NN O
was NN NN O
negatively NN NN O
associated NN NN O
with NN NN O
trabecular NN NN O
volumetric NN NN O
BMD NN NN O
at NN NN O
the NN NN O
ultradistal NN NN O
radius NN NN O
( NN NN O
P NN NN O
< NN NN O
. NN NN O
03 NN NN O
) NN NN O
. NN NN O
   
Controlling NN NN O
for NN NN O
relevant NN NN O
covariates NN NN O
, NN NN O
we NN NN O
also NN NN O
found NN NN O
treatment NN NN O
with NN NN O
selective NN NN O
serotonin NN NN O
reuptake NN NN O
inhibitors NN NN O
( NN NN O
SSRIs NN NN O
) NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
lower NN NN O
trabecular NN NN O
BMD NN NN O
at NN NN O
the NN NN O
radius NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O
03 NN NN O
) NN NN O
and NN NN O
BMD NN NN O
z NN NN O
score NN NN O
at NN NN O
the NN NN O
lumbar NN NN O
spine NN NN O
( NN NN O
P NN NN O
< NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
became NN NN O
more NN NN O
marked NN NN O
when NN NN O
the NN NN O
analysis NN NN O
was NN NN O
restricted NN NN O
to NN NN O
non NN NN O
- NN NN O
Hispanic NN NN O
white NN NN O
patients NN NN O
. NN NN O
   
Of NN NN O
13 NN NN O
documented NN NN O
fractures NN NN B-Disease
, NN NN O
3 NN NN O
occurred NN NN O
after NN NN O
risperidone NN NN O
and NN NN O
SSRIs NN NN O
were NN NN O
started NN NN O
, NN NN O
and NN NN O
none NN NN O
occurred NN NN O
in NN NN O
patients NN NN O
with NN NN O
hyperprolactinemia NN NN B-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
This NN NN O
is NN NN O
the NN NN O
first NN NN O
study NN NN O
to NN NN O
link NN NN O
risperidone NN NN O
- NN NN O
induced NN NN O
hyperprolactinemia NN NN B-Disease
and NN NN O
SSRI NN NN O
treatment NN NN O
to NN NN O
lower NN NN O
BMD NN NN O
in NN NN O
children NN NN O
and NN NN O
adolescents NN NN O
. NN NN O
   
Future NN NN O
research NN NN O
should NN NN O
evaluate NN NN O
the NN NN O
longitudinal NN NN O
course NN NN O
of NN NN O
this NN NN O
adverse NN NN O
event NN NN O
to NN NN O
determine NN NN O
its NN NN O
temporal NN NN O
stability NN NN O
and NN NN O
whether NN NN O
a NN NN O
higher NN NN O
fracture NN NN O
rate NN NN O
ensues NN NN O
. NN NN O
   
Fear NN NN O
- NN NN O
potentiated NN NN O
startle NN NN B-Disease
, NN NN O
but NN NN O
not NN NN O
light NN NN O
- NN NN O
enhanced NN NN O
startle NN NN B-Disease
, NN NN O
is NN NN O
enhanced NN NN O
by NN NN O
anxiogenic NN NN O
drugs NN NN O
. NN NN O
   
RATIONALE NN NN O
AND NN NN O
OBJECTIVES NN NN O
: NN NN O
The NN NN O
light NN NN O
- NN NN O
enhanced NN NN O
startle NN NN B-Disease
paradigm NN NN O
( NN NN O
LES NN NN O
) NN NN O
is NN NN O
suggested NN NN O
to NN NN O
model NN NN O
anxiety NN NN B-Disease
, NN NN O
because NN NN O
of NN NN O
the NN NN O
non NN NN O
- NN NN O
specific NN NN O
cue NN NN O
and NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
effect NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
fear NN NN O
- NN NN O
potentiated NN NN O
startle NN NN B-Disease
( NN NN O
FPS NN NN O
) NN NN O
is NN NN O
suggested NN NN O
to NN NN O
model NN NN O
conditioned NN NN O
fear NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
pharmacological NN NN O
profiles NN NN O
of NN NN O
these NN NN O
two NN NN O
paradigms NN NN O
are NN NN O
very NN NN O
similar NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
putative NN NN O
anxiogenic NN NN O
drugs NN NN O
on NN NN O
LES NN NN O
and NN NN O
FPS NN NN O
and NN NN O
aimed NN NN O
at NN NN O
determining NN NN O
the NN NN O
sensitivity NN NN O
of NN NN O
LES NN NN O
for NN NN O
anxiogenic NN NN O
drugs NN NN O
and NN NN O
to NN NN O
potentially NN NN O
showing NN NN O
a NN NN O
pharmacological NN NN O
differentiation NN NN O
between NN NN O
these NN NN O
two NN NN O
paradigms NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Male NN NN O
Wistar NN NN O
rats NN NN O
received NN NN O
each NN NN O
dose NN NN O
of NN NN O
the NN NN O
alpha NN NN O
( NN NN O
2 NN NN O
) NN NN O
- NN NN O
adrenoceptor NN NN O
antagonist NN NN O
yohimbine NN NN O
( NN NN O
0 NN NN O
. NN NN O
25 NN NN O
- NN NN O
1 NN NN O
. NN NN O
0mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
the NN NN O
5 NN NN O
- NN NN O
HT NN NN O
( NN NN O
2C NN NN O
) NN NN O
receptor NN NN O
agonist NN NN O
m NN NN O
- NN NN O
chlorophenylpiperazine NN NN O
( NN NN O
mCPP NN NN O
, NN NN O
0 NN NN O
. NN NN O
5 NN NN O
- NN NN O
2 NN NN O
. NN NN O
0mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
or NN NN O
the NN NN O
GABA NN NN O
( NN NN O
A NN NN O
) NN NN O
inverse NN NN O
receptor NN NN O
agonist NN NN O
pentylenetetrazole NN NN O
( NN NN O
PTZ NN NN O
, NN NN O
3 NN NN O
- NN NN O
30mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
and NN NN O
were NN NN O
subsequently NN NN O
tested NN NN O
in NN NN O
either NN NN O
LES NN NN O
or NN NN O
FPS NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
   O
of NN NN O
the NN NN O
drugs NN NN O
enhanced NN NN O
LES NN NN O
, NN NN O
whereas NN NN O
mCPP NN NN O
increased NN NN O
percentage NN NN O
FPS NN NN O
and NN NN O
yohimbine NN NN O
increased NN NN O
absolute NN NN O
FPS NN NN O
values NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
yohimbine NN NN O
increased NN NN O
baseline NN NN O
startle NN NN B-Disease
amplitude NN NN O
in NN NN O
the NN NN O
LES NN NN O
, NN NN O
while NN NN O
mCPP NN NN O
suppressed NN NN O
baseline NN NN O
startle NN NN B-Disease
in NN NN O
both NN NN O
the NN NN O
LES NN NN O
and NN NN O
FPS NN NN O
and NN NN O
PTZ NN NN O
suppressed NN NN O
baseline NN NN O
startle NN NN B-Disease
in NN NN O
the NN NN O
FPS NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
In NN NN O
contrast NN NN O
to NN NN O
findings NN NN O
in NN NN O
the NN NN O
FPS NN NN O
paradigm NN NN O
, NN NN O
none NN NN O
of NN NN O
the NN NN O
drugs NN NN O
were NN NN O
able NN NN O
to NN NN O
exacerbate NN NN O
the NN NN O
LES NN NN O
response NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
a NN NN O
clear NN NN O
pharmacological NN NN O
differentiation NN NN O
was NN NN O
found NN NN O
between NN NN O
LES NN NN O
and NN NN O
FPS NN NN O
. NN NN O
   
Rosaceiform NN NN O
dermatitis NN NN B-Disease
associated NN NN O
with NN NN O
topical NN NN O
tacrolimus NN NN O
treatment NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
herein NN NN O
3 NN NN O
patients NN NN O
who NN NN O
developed NN NN O
rosacea NN NN B-Disease
- NN NN O
like NN NN O
dermatitis NN NN B-Disease
eruptions NN NN B-Disease
while NN NN O
using NN NN O
0 NN NN O
. NN NN O
03 NN NN O
% NN NN O
or NN NN O
0 NN NN O
. NN NN O
1 NN NN O
% NN NN O
tacrolimus NN NN O
ointment NN NN O
for NN NN O
facial NN NN B-Disease
dermatitis NN NN I-Disease
. NN NN O
   
Skin NN NN O
biopsy NN NN O
specimens NN NN O
showed NN NN O
telangiectasia NN NN B-Disease
and NN NN O
noncaseating NN NN O
epithelioid NN NN O
granulomatous NN NN O
tissue NN NN O
formation NN NN O
in NN NN O
the NN NN O
papillary NN NN O
to NN NN O
mid NN NN O
dermis NN NN O
. NN NN O
   
Continuous NN NN O
topical NN NN O
use NN NN O
of NN NN O
immunomodulators NN NN O
such NN NN O
as NN NN O
tacrolimus NN NN O
or NN NN O
pimecrolimus NN NN O
should NN NN O
be NN NN O
regarded NN NN O
as NN NN O
a NN NN O
potential NN NN O
cause NN NN O
of NN NN O
rosaceiform NN NN O
dermatitis NN NN B-Disease
, NN NN O
although NN NN O
many NN NN O
cases NN NN O
have NN NN O
not NN NN O
been NN NN O
reported NN NN O
. NN NN O
   
Coenzyme NN NN O
Q10 NN NN O
treatment NN NN O
ameliorates NN NN O
acute NN NN O
cisplatin NN NN O
nephrotoxicity NN NN B-Disease
in NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
nephroprotective NN NN O
effect NN NN O
of NN NN O
coenzyme NN NN O
Q10 NN NN O
was NN NN O
investigated NN NN O
in NN NN O
mice NN NN O
with NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
injury NN NN I-Disease
induced NN NN O
by NN NN O
a NN NN O
single NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
injection NN NN O
of NN NN O
cisplatin NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
. NN NN O
   
Coenzyme NN NN O
Q10 NN NN O
treatment NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
was NN NN O
applied NN NN O
for NN NN O
6 NN NN O
consecutive NN NN O
days NN NN O
, NN NN O
starting NN NN O
1 NN NN O
day NN NN O
before NN NN O
cisplatin NN NN O
administration NN NN O
. NN NN O
   
Coenzyme NN NN O
Q10 NN NN O
significantly NN NN O
reduced NN NN O
blood NN NN O
urea NN NN O
nitrogen NN NN O
and NN NN O
serum NN NN O
creatinine NN NN O
levels NN NN O
which NN NN O
were NN NN O
increased NN NN O
by NN NN O
cisplatin NN NN O
. NN NN O
   
Coenzyme NN NN O
Q10 NN NN O
significantly NN NN O
compensated NN NN O
deficits NN NN O
in NN NN O
the NN NN O
antioxidant NN NN O
defense NN NN O
mechanisms NN NN O
( NN NN O
reduced NN NN O
glutathione NN NN O
level NN NN O
and NN NN O
superoxide NN NN O
dismutase NN NN O
activity NN NN O
) NN NN O
, NN NN O
suppressed NN NN O
lipid NN NN O
peroxidation NN NN O
, NN NN O
decreased NN NN O
the NN NN O
elevations NN NN O
of NN NN O
tumor NN NN B-Disease
necrosis NN NN B-Disease
factor NN NN O
- NN NN O
alpha NN NN O
, NN NN O
nitric NN NN O
oxide NN NN O
and NN NN O
platinum NN NN O
ion NN NN O
concentration NN NN O
, NN NN O
and NN NN O
attenuated NN NN O
the NN NN O
reductions NN NN O
of NN NN O
selenium NN NN O
and NN NN O
zinc NN NN O
ions NN NN O
in NN NN O
renal NN NN O
tissue NN NN O
resulted NN NN O
from NN NN O
cisplatin NN NN O
administration NN NN O
. NN NN O
   
Also NN NN O
, NN NN O
histopathological NN NN O
renal NN NN B-Disease
tissue NN NN I-Disease
damage NN NN I-Disease
mediated NN NN O
by NN NN O
cisplatin NN NN O
was NN NN O
ameliorated NN NN O
by NN NN O
coenzyme NN NN O
Q10 NN NN O
treatment NN NN O
. NN NN O
   
Immunohistochemical NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
coenzyme NN NN O
Q10 NN NN O
significantly NN NN O
decreased NN NN O
the NN NN O
cisplatin NN NN O
- NN NN O
induced NN NN O
overexpression NN NN O
of NN NN O
inducible NN NN O
nitric NN NN O
oxide NN NN O
synthase NN NN O
, NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
caspase NN NN O
- NN NN O
3 NN NN O
and NN NN O
p53 NN NN O
in NN NN O
renal NN NN O
tissue NN NN O
. NN NN O
   
It NN NN O
was NN NN O
concluded NN NN O
that NN NN O
coenzyme NN NN O
Q10 NN NN O
represents NN NN O
a NN NN O
potential NN NN O
therapeutic NN NN O
option NN NN O
to NN NN O
protect NN NN O
against NN NN O
acute NN NN O
cisplatin NN NN O
nephrotoxicity NN NN B-Disease
commonly NN NN O
encountered NN NN O
in NN NN O
clinical NN NN O
practice NN NN O
. NN NN O
   
Reversible NN NN O
cholestasis NN NN B-Disease
with NN NN O
bile NN NN B-Disease
duct NN NN I-Disease
injury NN NN I-Disease
following NN NN O
azathioprine NN NN O
therapy NN NN O
. NN NN O
   
A NN NN O
case NN NN O
report NN NN O
. NN NN O
   
A NN NN O
67 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
patient NN NN O
, NN NN O
with NN NN O
primary NN NN O
polymyositis NN NN B-Disease
and NN NN O
without NN NN O
previous NN NN O
evidence NN NN O
of NN NN O
liver NN NN B-Disease
disease NN NN I-Disease
, NN NN O
developed NN NN O
clinical NN NN O
and NN NN O
biochemical NN NN O
features NN NN O
of NN NN O
severe NN NN O
cholestasis NN NN B-Disease
3 NN NN O
months NN NN O
after NN NN O
initiation NN NN O
of NN NN O
azathioprine NN NN O
therapy NN NN O
. NN NN O
   
Liver NN NN O
biopsy NN NN O
showed NN NN O
cholestasis NN NN B-Disease
with NN NN O
both NN NN O
cytological NN NN O
and NN NN O
architectural NN NN O
alterations NN NN O
of NN NN O
interlobular NN NN O
bile NN NN O
ducts NN NN O
. NN NN O
   
Azathioprine NN NN O
withdrawal NN NN O
resulted NN NN O
after NN NN O
7 NN NN O
weeks NN NN O
in NN NN O
the NN NN O
resolution NN NN O
of NN NN O
clinical NN NN O
and NN NN O
biochemical NN NN O
abnormalities NN NN O
. NN NN O
   
It NN NN O
is NN NN O
believed NN NN O
that NN NN O
this NN NN O
is NN NN O
the NN NN O
first NN NN O
reported NN NN O
case NN NN O
of NN NN O
reversible NN NN O
azathioprine NN NN O
- NN NN O
induced NN NN O
cholestasis NN NN B-Disease
associated NN NN O
with NN NN O
histological NN NN O
evidence NN NN O
of NN NN O
bile NN NN B-Disease
duct NN NN I-Disease
injury NN NN I-Disease
. NN NN O
   
Dopamine NN NN O
is NN NN O
not NN NN O
essential NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
methamphetamine NN NN O
- NN NN O
induced NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
It NN NN O
is NN NN O
widely NN NN O
believed NN NN O
that NN NN O
dopamine NN NN O
( NN NN O
DA NN NN O
) NN NN O
mediates NN NN O
methamphetamine NN NN O
( NN NN O
METH NN NN O
) NN NN O
- NN NN O
induced NN NN O
toxicity NN NN B-Disease
to NN NN O
brain NN NN O
dopaminergic NN NN O
neurons NN NN O
, NN NN O
because NN NN O
drugs NN NN O
that NN NN O
interfere NN NN O
with NN NN O
DA NN NN O
neurotransmission NN NN O
decrease NN NN O
toxicity NN NN B-Disease
, NN NN O
whereas NN NN O
drugs NN NN O
that NN NN O
increase NN NN O
DA NN NN O
neurotransmission NN NN O
enhance NN NN O
toxicity NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
temperature NN NN O
effects NN NN O
of NN NN O
drugs NN NN O
that NN NN O
have NN NN O
been NN NN O
used NN NN O
to NN NN O
manipulate NN NN O
brain NN NN O
DA NN NN O
neurotransmission NN NN O
confound NN NN O
interpretation NN NN O
of NN NN O
the NN NN O
data NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
recently NN NN O
reported NN NN O
ability NN NN O
of NN NN O
L NN NN O
- NN NN O
dihydroxyphenylalanine NN NN O
to NN NN O
reverse NN NN O
the NN NN O
protective NN NN O
effect NN NN O
of NN NN O
alpha NN NN O
- NN NN O
methyl NN NN O
- NN NN O
para NN NN O
- NN NN O
tyrosine NN NN O
on NN NN O
METH NN NN O
- NN NN O
induced NN NN O
DA NN NN O
neurotoxicity NN NN B-Disease
is NN NN O
also NN NN O
confounded NN NN O
by NN NN O
drug NN NN O
effects NN NN O
on NN NN O
body NN NN O
temperature NN NN O
. NN NN O
   
Further NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
mice NN NN O
genetically NN NN O
engineered NN NN O
to NN NN O
be NN NN O
deficient NN NN O
in NN NN O
brain NN NN O
DA NN NN O
develop NN NN O
METH NN NN O
neurotoxicity NN NN B-Disease
, NN NN O
as NN NN O
long NN NN O
as NN NN O
the NN NN O
thermic NN NN O
effects NN NN O
of NN NN O
METH NN NN O
are NN NN O
preserved NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
mice NN NN O
genetically NN NN O
engineered NN NN O
to NN NN O
have NN NN O
unilateral NN NN O
brain NN NN O
DA NN NN O
deficits NN NN O
develop NN NN O
METH NN NN O
- NN NN O
induced NN NN O
dopaminergic NN NN B-Disease
deficits NN NN I-Disease
that NN NN O
are NN NN O
of NN NN O
comparable NN NN O
magnitude NN NN O
on NN NN O
both NN NN O
sides NN NN O
of NN NN O
the NN NN O
brain NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
findings NN NN O
demonstrate NN NN O
that NN NN O
DA NN NN O
is NN NN O
not NN NN O
essential NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
METH NN NN O
- NN NN O
induced NN NN O
dopaminergic NN NN O
neurotoxicity NN NN B-Disease
and NN NN O
suggest NN NN O
that NN NN O
mechanisms NN NN O
independent NN NN O
of NN NN O
DA NN NN O
warrant NN NN O
more NN NN O
intense NN NN O
investigation NN NN O
. NN NN O
   
Swallowing NN NN O
- NN NN O
induced NN NN O
atrial NN NN B-Disease
tachyarrhythmia NN NN I-Disease
triggered NN NN O
by NN NN O
salbutamol NN NN O
: NN NN O
case NN NN O
report NN NN O
and NN NN O
review NN NN O
of NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
CASE NN NN O
: NN NN O
A NN NN O
49 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
patient NN NN O
experienced NN NN O
chest NN NN O
discomfort NN NN O
while NN NN O
swallowing NN NN O
. NN NN O
   
On NN NN O
electrocardiogram NN NN O
, NN NN O
episodes NN NN O
of NN NN O
atrial NN NN B-Disease
tachyarrhythmia NN NN I-Disease
were NN NN O
recorded NN NN O
immediately NN NN O
after NN NN O
swallowing NN NN O
; NN NN O
24 NN NN O
- NN NN O
hour NN NN O
Holter NN NN O
monitoring NN NN O
recorded NN NN O
several NN NN O
events NN NN O
. NN NN O
   
The NN NN O
arrhythmia NN NN B-Disease
resolved NN NN O
after NN NN O
therapy NN NN O
with NN NN O
atenolol NN NN O
, NN NN O
but NN NN O
recurred NN NN O
a NN NN O
year NN NN O
later NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
noticed NN NN O
that NN NN O
before NN NN O
these NN NN O
episodes NN NN O
he NN NN O
had NN NN O
been NN NN O
using NN NN O
an NN NN O
inhalator NN NN O
of NN NN O
salbutamol NN NN O
. NN NN O
   
After NN NN O
stopping NN NN O
the NN NN O
beta NN NN O
- NN NN O
agonist NN NN O
, NN NN O
and NN NN O
after NN NN O
a NN NN O
week NN NN O
with NN NN O
the NN NN O
atenolol NN NN O
, NN NN O
the NN NN O
arrhythmia NN NN B-Disease
disappeared NN NN O
. NN NN O
   
DISCUSSION NN NN O
: NN NN O
Swallowing NN NN O
- NN NN O
induced NN NN O
atrial NN NN B-Disease
tachyarrhythmia NN NN I-Disease
( NN NN O
SIAT NN NN B-Disease
) NN NN O
is NN NN O
a NN NN O
rare NN NN O
phenomenon NN NN O
. NN NN O
   
Fewer NN NN O
than NN NN O
50 NN NN O
cases NN NN O
of NN NN O
SIAT NN NN B-Disease
have NN NN O
been NN NN O
described NN NN O
in NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
This NN NN O
article NN NN O
summarizes NN NN O
all NN NN O
the NN NN O
cases NN NN O
published NN NN O
, NN NN O
creating NN NN O
a NN NN O
comprehensive NN NN O
review NN NN O
of NN NN O
the NN NN O
current NN NN O
knowledge NN NN O
and NN NN O
approach NN NN O
to NN NN O
SIAT NN NN B-Disease
. NN NN O
   
It NN NN O
discusses NN NN O
demographics NN NN O
, NN NN O
clinical NN NN O
characteristics NN NN O
and NN NN O
types NN NN O
of NN NN O
arrhythmia NN NN B-Disease
, NN NN O
postulated NN NN O
mechanisms NN NN O
of NN NN O
SIAT NN NN B-Disease
, NN NN O
and NN NN O
different NN NN O
treatment NN NN O
possibilities NN NN O
such NN NN O
as NN NN O
medications NN NN O
, NN NN O
surgery NN NN O
, NN NN O
and NN NN O
radiofrequency NN NN O
catheter NN NN O
ablation NN NN O
( NN NN O
RFCA NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Salbutamol NN NN O
is NN NN O
presented NN NN O
here NN NN O
as NN NN O
a NN NN O
possible NN NN O
trigger NN NN O
for NN NN O
SIAT NN NN B-Disease
. NN NN O
   
Although NN NN O
it NN NN O
is NN NN O
difficult NN NN O
to NN NN O
define NN NN O
causality NN NN O
in NN NN O
a NN NN O
case NN NN O
report NN NN O
, NN NN O
it NN NN O
is NN NN O
logical NN NN O
to NN NN O
think NN NN O
that NN NN O
a NN NN O
beta NN NN O
- NN NN O
agonist NN NN O
like NN NN O
salbutamol NN NN O
( NN NN O
known NN NN O
to NN NN O
induce NN NN O
tachycardia NN NN B-Disease
) NN NN O
may NN NN O
be NN NN O
the NN NN O
trigger NN NN O
of NN NN O
adrenergic NN NN O
reflexes NN NN O
originating NN NN O
in NN NN O
the NN NN O
esophagus NN NN O
while NN NN O
swallowing NN NN O
and NN NN O
that NN NN O
a NN NN O
beta NN NN O
- NN NN O
blocker NN NN O
such NN NN O
as NN NN O
atenolol NN NN O
( NN NN O
that NN NN O
blocks NN NN O
the NN NN O
adrenergic NN NN O
activity NN NN O
) NN NN O
may NN NN O
relieve NN NN O
it NN NN O
. NN NN O
   
The NN NN O
ability NN NN O
of NN NN O
insulin NN NN O
treatment NN NN O
to NN NN O
reverse NN NN O
or NN NN O
prevent NN NN O
the NN NN O
changes NN NN O
in NN NN O
urinary NN NN O
bladder NN NN O
function NN NN O
caused NN NN O
by NN NN O
streptozotocin NN NN O
- NN NN O
induced NN NN O
diabetes NN NN B-Disease
mellitus NN NN I-Disease
. NN NN O
   
1 NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
insulin NN NN O
treatment NN NN O
on NN NN O
in NN NN O
vivo NN NN O
and NN NN O
in NN NN O
vitro NN NN O
urinary NN NN O
bladder NN NN O
function NN NN O
in NN NN O
streptozotocin NN NN O
- NN NN O
diabetic NN NN B-Disease
rats NN NN O
were NN NN O
investigated NN NN O
. NN NN O
   
2 NN NN O
. NN NN O
   
Diabetes NN NN B-Disease
of NN NN O
2 NN NN O
months NN NN O
duration NN NN O
resulted NN NN O
in NN NN O
decreases NN NN O
in NN NN O
body NN NN O
weight NN NN O
and NN NN O
increases NN NN O
in NN NN O
fluid NN NN O
consumption NN NN O
, NN NN O
urine NN NN O
volume NN NN O
, NN NN O
frequency NN NN O
of NN NN O
micturition NN NN O
, NN NN O
and NN NN O
average NN NN O
volume NN NN O
per NN NN O
micturition NN NN O
; NN NN O
effects NN NN O
which NN NN O
were NN NN O
prevented NN NN O
by NN NN O
insulin NN NN O
treatment NN NN O
. NN NN O
   
3 NN NN O
. NN NN O
   
Insulin NN NN O
treatment NN NN O
also NN NN O
prevented NN NN O
the NN NN O
increases NN NN O
in NN NN O
contractile NN NN O
responses NN NN O
of NN NN O
bladder NN NN O
body NN NN O
strips NN NN O
from NN NN O
diabetic NN NN B-Disease
rats NN NN O
to NN NN O
nerve NN NN O
stimulation NN NN O
, NN NN O
ATP NN NN O
, NN NN O
and NN NN O
bethanechol NN NN O
. NN NN O
   
4 NN NN O
. NN NN O
   
Diabetes NN NN B-Disease
of NN NN O
4 NN NN O
months NN NN O
duration NN NN O
also NN NN O
resulted NN NN O
in NN NN O
decreases NN NN O
in NN NN O
body NN NN O
weight NN NN O
, NN NN O
and NN NN O
increases NN NN O
in NN NN O
fluid NN NN O
consumption NN NN O
, NN NN O
urine NN NN O
volume NN NN O
, NN NN O
frequency NN NN O
of NN NN O
micturition NN NN O
, NN NN O
and NN NN O
average NN NN O
volume NN NN O
per NN NN O
micturition NN NN O
, NN NN O
effects NN NN O
which NN NN O
were NN NN O
reversed NN NN O
by NN NN O
insulin NN NN O
treatment NN NN O
for NN NN O
the NN NN O
final NN NN O
2 NN NN O
months NN NN O
of NN NN O
the NN NN O
study NN NN O
. NN NN O
   
5 NN NN O
. NN NN O
   
Insulin NN NN O
treatment NN NN O
reversed NN NN O
the NN NN O
increases NN NN O
in NN NN O
contractile NN NN O
responses NN NN O
of NN NN O
bladder NN NN O
body NN NN O
strips NN NN O
from NN NN O
diabetic NN NN B-Disease
rats NN NN O
to NN NN O
nerve NN NN O
stimulation NN NN O
, NN NN O
ATP NN NN O
, NN NN O
and NN NN O
bethanechol NN NN O
. NN NN O
   
6 NN NN O
. NN NN O
   
The NN NN O
data NN NN O
indicate NN NN O
that NN NN O
the NN NN O
effects NN NN O
of NN NN O
streptozotocin NN NN O
- NN NN O
induced NN NN O
diabetes NN NN B-Disease
on NN NN O
urinary NN NN O
bladder NN NN O
function NN NN O
are NN NN O
both NN NN O
prevented NN NN O
and NN NN O
reversed NN NN O
by NN NN O
insulin NN NN O
treatment NN NN O
. NN NN O
   
Glutamatergic NN NN O
neurotransmission NN NN O
mediated NN NN O
by NN NN O
NMDA NN NN O
receptors NN NN O
in NN NN O
the NN NN O
inferior NN NN O
colliculus NN NN O
can NN NN O
modulate NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
. NN NN O
   
The NN NN O
inferior NN NN O
colliculus NN NN O
( NN NN O
IC NN NN O
) NN NN O
is NN NN O
primarily NN NN O
involved NN NN O
in NN NN O
the NN NN O
processing NN NN O
of NN NN O
auditory NN NN O
information NN NN O
, NN NN O
but NN NN O
it NN NN O
is NN NN O
distinguished NN NN O
from NN NN O
other NN NN O
auditory NN NN O
nuclei NN NN O
in NN NN O
the NN NN O
brainstem NN NN O
by NN NN O
its NN NN O
connections NN NN O
with NN NN O
structures NN NN O
of NN NN O
the NN NN O
motor NN NN O
system NN NN O
. NN NN O
   
Functional NN NN O
evidence NN NN O
relating NN NN O
the NN NN O
IC NN NN O
to NN NN O
motor NN NN O
behavior NN NN O
derives NN NN O
from NN NN O
experiments NN NN O
showing NN NN O
that NN NN O
activation NN NN O
of NN NN O
the NN NN O
IC NN NN O
by NN NN O
electrical NN NN O
stimulation NN NN O
or NN NN O
excitatory NN NN O
amino NN NN O
acid NN NN O
microinjection NN NN O
causes NN NN O
freezing NN NN O
, NN NN O
escape NN NN O
- NN NN O
like NN NN O
behavior NN NN O
, NN NN O
and NN NN O
immobility NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
nature NN NN O
of NN NN O
this NN NN O
immobility NN NN O
is NN NN O
still NN NN O
unclear NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
examined NN NN O
the NN NN O
influence NN NN O
of NN NN O
excitatory NN NN O
amino NN NN O
acid NN NN O
- NN NN O
mediated NN NN O
mechanisms NN NN O
in NN NN O
the NN NN O
IC NN NN O
on NN NN O
the NN NN O
catalepsy NN NN B-Disease
induced NN NN O
by NN NN O
the NN NN O
dopamine NN NN O
receptor NN NN O
blocker NN NN O
haloperidol NN NN O
administered NN NN O
systemically NN NN O
( NN NN O
1 NN NN O
or NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
was NN NN O
challenged NN NN O
with NN NN O
prior NN NN O
intracollicular NN NN O
microinjections NN NN O
of NN NN O
glutamate NN NN O
NMDA NN NN O
receptor NN NN O
antagonists NN NN O
, NN NN O
MK NN NN O
- NN NN O
801 NN NN O
( NN NN O
15 NN NN O
or NN NN O
30 NN NN O
mmol NN NN O
/ NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microl NN NN O
) NN NN O
and NN NN O
AP7 NN NN O
( NN NN O
10 NN NN O
or NN NN O
20 NN NN O
nmol NN NN O
/ NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microl NN NN O
) NN NN O
, NN NN O
or NN NN O
of NN NN O
the NN NN O
NMDA NN NN O
receptor NN NN O
agonist NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
d NN NN O
- NN NN O
aspartate NN NN O
( NN NN O
NMDA NN NN O
, NN NN O
20 NN NN O
or NN NN O
30 NN NN O
nmol NN NN O
/ NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microl NN NN O
) NN NN O
. NN NN O
   
The NN NN O
results NN NN O
showed NN NN O
that NN NN O
intracollicular NN NN O
microinjection NN NN O
of NN NN O
MK NN NN O
- NN NN O
801 NN NN O
and NN NN O
AP7 NN NN O
previous NN NN O
to NN NN O
systemic NN NN O
injections NN NN O
of NN NN O
haloperidol NN NN O
significantly NN NN O
attenuated NN NN O
the NN NN O
catalepsy NN NN B-Disease
, NN NN O
as NN NN O
indicated NN NN O
by NN NN O
a NN NN O
reduced NN NN O
latency NN NN O
to NN NN O
step NN NN O
down NN NN O
from NN NN O
a NN NN O
horizontal NN NN O
bar NN NN O
. NN NN O
   
Accordingly NN NN O
, NN NN O
intracollicular NN NN O
microinjection NN NN O
of NN NN O
NMDA NN NN O
increased NN NN O
the NN NN O
latency NN NN O
to NN NN O
step NN NN O
down NN NN O
the NN NN O
bar NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
glutamate NN NN O
- NN NN O
mediated NN NN O
mechanisms NN NN O
in NN NN O
the NN NN O
neural NN NN O
circuits NN NN O
at NN NN O
the NN NN O
IC NN NN O
level NN NN O
influence NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
and NN NN O
participate NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
motor NN NN O
activity NN NN O
. NN NN O
   
Severe NN NN O
congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
patient NN NN O
on NN NN O
amiodarone NN NN O
presenting NN NN O
with NN NN O
myxedemic NN NN B-Disease
coma NN NN I-Disease
: NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
This NN NN O
is NN NN O
a NN NN O
case NN NN O
report NN NN O
of NN NN O
myxedema NN NN B-Disease
coma NN NN I-Disease
secondary NN NN O
to NN NN O
amiodarone NN NN O
- NN NN O
induced NN NN O
hypothyroidism NN NN B-Disease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
severe NN NN O
congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
( NN NN O
CHF NN NN B-Disease
) NN NN O
. NN NN O
   
To NN NN O
our NN NN O
knowledge NN NN O
and NN NN O
after NN NN O
reviewing NN NN O
the NN NN O
literature NN NN O
there NN NN O
is NN NN O
one NN NN O
case NN NN O
report NN NN O
of NN NN O
myxedema NN NN B-Disease
coma NN NN I-Disease
during NN NN O
long NN NN O
term NN NN O
amiodarone NN NN O
therapy NN NN O
. NN NN O
   
Myxedema NN NN B-Disease
coma NN NN I-Disease
is NN NN O
a NN NN O
life NN NN O
threatening NN NN O
condition NN NN O
that NN NN O
carries NN NN O
a NN NN O
mortality NN NN O
reaching NN NN O
as NN NN O
high NN NN O
as NN NN O
20 NN NN O
% NN NN O
with NN NN O
treatment NN NN O
. NN NN O
   
The NN NN O
condition NN NN O
is NN NN O
treated NN NN O
with NN NN O
intravenous NN NN O
thyroxine NN NN O
( NN NN O
T4 NN NN O
) NN NN O
or NN NN O
intravenous NN NN O
tri NN NN O
- NN NN O
iodo NN NN O
- NN NN O
thyronine NN NN O
( NN NN O
T3 NN NN O
) NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
CHF NN NN B-Disease
on NN NN O
amiodarone NN NN O
may NN NN O
suffer NN NN O
serious NN NN O
morbidity NN NN O
and NN NN O
mortality NN NN O
from NN NN O
hypothyroidism NN NN B-Disease
, NN NN O
and NN NN O
thus NN NN O
may NN NN O
deserve NN NN O
closer NN NN O
follow NN NN O
up NN NN O
for NN NN O
thyroid NN NN O
stimulating NN NN O
hormone NN NN O
( NN NN O
TSH NN NN O
) NN NN O
levels NN NN O
. NN NN O
   
This NN NN O
case NN NN O
report NN NN O
carries NN NN O
an NN NN O
important NN NN O
clinical NN NN O
application NN NN O
given NN NN O
the NN NN O
frequent NN NN O
usage NN NN O
of NN NN O
amiodarone NN NN O
among NN NN O
CHF NN NN B-Disease
patients NN NN O
. NN NN O
   
The NN NN O
myriad NN NN O
clinical NN NN O
presentation NN NN O
of NN NN O
myxedema NN NN B-Disease
coma NN NN I-Disease
and NN NN O
its NN NN O
serious NN NN O
morbidity NN NN O
and NN NN O
mortality NN NN O
stresses NN NN O
the NN NN O
need NN NN O
to NN NN O
suspect NN NN O
this NN NN O
clinical NN NN O
syndrome NN NN O
among NN NN O
CHF NN NN B-Disease
patients NN NN O
presenting NN NN O
with NN NN O
hypotension NN NN B-Disease
, NN NN O
weakness NN NN B-Disease
or NN NN O
other NN NN O
unexplained NN NN O
symptoms NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
active NN NN O
constituents NN NN O
of NN NN O
Crocus NN NN O
sativus NN NN O
L NN NN O
. NN NN O
, NN NN O
crocin NN NN O
on NN NN O
streptozocin NN NN O
- NN NN O
induced NN NN O
model NN NN O
of NN NN O
sporadic NN NN O
Alzheimer NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
in NN NN O
male NN NN O
rats NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
involvement NN NN O
of NN NN O
water NN NN O
- NN NN O
soluble NN NN O
carotenoids NN NN O
, NN NN O
crocins NN NN O
, NN NN O
as NN NN O
the NN NN O
main NN NN O
and NN NN O
active NN NN O
components NN NN O
of NN NN O
Crocus NN NN O
sativus NN NN O
L NN NN O
. NN NN O
extract NN NN O
in NN NN O
learning NN NN O
and NN NN O
memory NN NN O
processes NN NN O
has NN NN O
been NN NN O
proposed NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
the NN NN O
effect NN NN O
of NN NN O
crocins NN NN O
on NN NN O
sporadic NN NN O
Alzheimer NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
induced NN NN O
by NN NN O
intracerebroventricular NN NN O
( NN NN O
icv NN NN O
) NN NN O
streptozocin NN NN O
( NN NN O
STZ NN NN O
) NN NN O
in NN NN O
male NN NN O
rats NN NN O
was NN NN O
investigated NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Male NN NN O
adult NN NN O
Wistar NN NN O
rats NN NN O
( NN NN O
n NN NN O
= NN NN O
90 NN NN O
and NN NN O
260 NN NN O
- NN NN O
290 NN NN O
g NN NN O
) NN NN O
were NN NN O
divided NN NN O
into NN NN O
1 NN NN O
, NN NN O
control NN NN O
; NN NN O
2 NN NN O
and NN NN O
3 NN NN O
, NN NN O
crocins NN NN O
( NN NN O
15 NN NN O
and NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
; NN NN O
4 NN NN O
, NN NN O
STZ NN NN O
; NN NN O
5 NN NN O
and NN NN O
6 NN NN O
, NN NN O
STZ NN NN O
+ NN NN O
crocins NN NN O
( NN NN O
15 NN NN O
and NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
groups NN NN O
. NN NN O
   
In NN NN O
Alzheimer NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
groups NN NN O
, NN NN O
rats NN NN O
were NN NN O
injected NN NN O
with NN NN O
STZ NN NN O
- NN NN O
icv NN NN O
bilaterally NN NN O
( NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
in NN NN O
first NN NN O
day NN NN O
and NN NN O
3 NN NN O
days NN NN O
later NN NN O
, NN NN O
a NN NN O
similar NN NN O
STZ NN NN O
- NN NN O
icv NN NN O
application NN NN O
was NN NN O
repeated NN NN O
. NN NN O
   
In NN NN O
STZ NN NN O
+ NN NN O
crocin NN NN O
animal NN NN O
groups NN NN O
, NN NN O
crocin NN NN O
was NN NN O
applied NN NN O
in NN NN O
doses NN NN O
of NN NN O
15 NN NN O
and NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
, NN NN O
one NN NN O
day NN NN O
pre NN NN O
- NN NN O
surgery NN NN O
and NN NN O
continued NN NN O
for NN NN O
three NN NN O
weeks NN NN O
. NN NN O
   
Prescription NN NN O
of NN NN O
crocin NN NN O
in NN NN O
each NN NN O
dose NN NN O
was NN NN O
repeated NN NN O
once NN NN O
for NN NN O
two NN NN O
days NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
learning NN NN O
and NN NN O
memory NN NN O
performance NN NN O
was NN NN O
assessed NN NN O
using NN NN O
passive NN NN O
avoidance NN NN O
paradigm NN NN O
, NN NN O
and NN NN O
for NN NN O
spatial NN NN O
cognition NN NN O
evaluation NN NN O
, NN NN O
Y NN NN O
- NN NN O
maze NN NN O
task NN NN O
was NN NN O
used NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
It NN NN O
was NN NN O
found NN NN O
out NN NN O
that NN NN O
crocin NN NN O
( NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
- NN NN O
treated NN NN O
STZ NN NN O
- NN NN O
injected NN NN O
rats NN NN O
show NN NN O
higher NN NN O
correct NN NN O
choices NN NN O
and NN NN O
lower NN NN O
errors NN NN O
in NN NN O
Y NN NN O
- NN NN O
maze NN NN O
than NN NN O
vehicle NN NN O
- NN NN O
treated NN NN O
STZ NN NN O
- NN NN O
injected NN NN O
rats NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
crocin NN NN O
in NN NN O
the NN NN O
mentioned NN NN O
dose NN NN O
could NN NN O
significantly NN NN O
attenuated NN NN O
learning NN NN B-Disease
and NN NN I-Disease
memory NN NN I-Disease
impairment NN NN I-Disease
in NN NN O
treated NN NN O
STZ NN NN O
- NN NN O
injected NN NN O
group NN NN O
in NN NN O
passive NN NN O
avoidance NN NN O
test NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Therefore NN NN O
, NN NN O
these NN NN O
results NN NN O
demonstrate NN NN O
the NN NN O
effectiveness NN NN O
of NN NN O
crocin NN NN O
( NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
in NN NN O
antagonizing NN NN O
the NN NN O
cognitive NN NN B-Disease
deficits NN NN I-Disease
caused NN NN O
by NN NN O
STZ NN NN O
- NN NN O
icv NN NN O
in NN NN O
rats NN NN O
and NN NN O
its NN NN O
potential NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
neurodegenerative NN NN B-Disease
diseases NN NN I-Disease
such NN NN O
as NN NN O
Alzheimer NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Serotonin NN NN O
6 NN NN O
receptor NN NN O
gene NN NN O
is NN NN O
associated NN NN O
with NN NN O
methamphetamine NN NN O
- NN NN O
induced NN NN O
psychosis NN NN B-Disease
in NN NN O
a NN NN O
Japanese NN NN O
population NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Altered NN NN O
serotonergic NN NN O
neural NN NN O
transmission NN NN O
is NN NN O
hypothesized NN NN O
to NN NN O
be NN NN O
a NN NN O
susceptibility NN NN O
factor NN NN O
for NN NN O
psychotic NN NN B-Disease
disorders NN NN I-Disease
such NN NN O
as NN NN O
schizophrenia NN NN B-Disease
. NN NN O
   
The NN NN O
serotonin NN NN O
6 NN NN O
( NN NN O
5 NN NN O
- NN NN O
HT6 NN NN O
) NN NN O
receptor NN NN O
is NN NN O
therapeutically NN NN O
targeted NN NN O
by NN NN O
several NN NN O
second NN NN O
generation NN NN O
antipsychotics NN NN O
, NN NN O
such NN NN O
as NN NN O
clozapine NN NN O
and NN NN O
olanzapine NN NN O
, NN NN O
and NN NN O
d NN NN O
- NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
in NN NN O
rats NN NN O
is NN NN O
corrected NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
a NN NN O
selective NN NN O
5 NN NN O
- NN NN O
HT6 NN NN O
receptor NN NN O
antagonist NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
disrupted NN NN O
prepulse NN NN O
inhibition NN NN O
induced NN NN O
by NN NN O
d NN NN O
- NN NN O
amphetamine NN NN O
or NN NN O
phencyclidine NN NN O
was NN NN O
restored NN NN O
by NN NN O
5 NN NN O
- NN NN O
HT6 NN NN O
receptor NN NN O
antagonist NN NN O
in NN NN O
an NN NN O
animal NN NN O
study NN NN O
using NN NN O
rats NN NN O
. NN NN O
   
These NN NN O
animal NN NN O
models NN NN O
were NN NN O
considered NN NN O
to NN NN O
reflect NN NN O
the NN NN O
positive NN NN O
symptoms NN NN O
of NN NN O
schizophrenia NN NN B-Disease
, NN NN O
and NN NN O
the NN NN O
above NN NN O
evidence NN NN O
suggests NN NN O
that NN NN O
altered NN NN O
5 NN NN O
- NN NN O
HT6 NN NN O
receptors NN NN O
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
pathophysiology NN NN O
of NN NN O
psychotic NN NN B-Disease
disorders NN NN I-Disease
. NN NN O
   
The NN NN O
symptoms NN NN O
of NN NN O
methamphetamine NN NN O
( NN NN O
METH NN NN O
) NN NN O
- NN NN O
induced NN NN O
psychosis NN NN B-Disease
are NN NN O
similar NN NN O
to NN NN O
those NN NN O
of NN NN O
paranoid NN NN B-Disease
type NN NN I-Disease
schizophrenia NN NN I-Disease
. NN NN O
   
Therefore NN NN O
, NN NN O
we NN NN O
conducted NN NN O
an NN NN O
analysis NN NN O
of NN NN O
the NN NN O
association NN NN O
of NN NN O
the NN NN O
5 NN NN O
- NN NN O
HT6 NN NN O
gene NN NN O
( NN NN O
HTR6 NN NN O
) NN NN O
with NN NN O
METH NN NN O
- NN NN O
induced NN NN O
psychosis NN NN B-Disease
. NN NN O
   
METHOD NN NN O
: NN NN O
Using NN NN O
five NN NN O
tagging NN NN O
SNPs NN NN O
( NN NN O
rs6693503 NN NN O
, NN NN O
rs1805054 NN NN O
, NN NN O
rs4912138 NN NN O
, NN NN O
rs3790757 NN NN O
and NN NN O
rs9659997 NN NN O
) NN NN O
, NN NN O
we NN NN O
conducted NN NN O
a NN NN O
genetic NN NN O
association NN NN O
analysis NN NN O
of NN NN O
case NN NN O
- NN NN O
control NN NN O
samples NN NN O
( NN NN O
197 NN NN O
METH NN NN O
- NN NN O
induced NN NN O
psychosis NN NN B-Disease
patients NN NN O
and NN NN O
337 NN NN O
controls NN NN O
) NN NN O
in NN NN O
the NN NN O
Japanese NN NN O
population NN NN O
. NN NN O
   
The NN NN O
age NN NN O
and NN NN O
sex NN NN O
of NN NN O
the NN NN O
control NN NN O
subjects NN NN O
did NN NN O
not NN NN O
differ NN NN O
from NN NN O
those NN NN O
of NN NN O
the NN NN O
methamphetamine NN NN O
dependence NN NN O
patients NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
rs6693503 NN NN O
was NN NN O
associated NN NN O
with NN NN O
METH NN NN O
- NN NN O
induced NN NN O
psychosis NN NN B-Disease
patients NN NN O
in NN NN O
the NN NN O
allele NN NN O
/ NN NN O
genotype NN NN O
- NN NN O
wise NN NN O
analysis NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
this NN NN O
association NN NN O
remained NN NN O
significant NN NN O
after NN NN O
Bonferroni NN NN O
correction NN NN O
. NN NN O
   
In NN NN O
the NN NN O
haplotype NN NN O
- NN NN O
wise NN NN O
analysis NN NN O
, NN NN O
we NN NN O
detected NN NN O
an NN NN O
association NN NN O
between NN NN O
two NN NN O
markers NN NN O
( NN NN O
rs6693503 NN NN O
and NN NN O
rs1805054 NN NN O
) NN NN O
and NN NN O
three NN NN O
markers NN NN O
( NN NN O
rs6693503 NN NN O
, NN NN O
rs1805054 NN NN O
and NN NN O
rs4912138 NN NN O
) NN NN O
in NN NN O
HTR6 NN NN O
and NN NN O
METH NN NN O
- NN NN O
induced NN NN O
psychosis NN NN B-Disease
patients NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
HTR6 NN NN O
may NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
pathophysiology NN NN O
of NN NN O
METH NN NN O
- NN NN O
induced NN NN O
psychosis NN NN B-Disease
in NN NN O
the NN NN O
Japanese NN NN O
population NN NN O
. NN NN O
   
Neural NN NN O
correlates NN NN O
of NN NN O
S NN NN O
- NN NN O
ketamine NN NN O
induced NN NN O
psychosis NN NN B-Disease
during NN NN O
overt NN NN O
continuous NN NN O
verbal NN NN O
fluency NN NN O
. NN NN O
   
The NN NN O
glutamatergic NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
D NN NN O
- NN NN O
aspartate NN NN O
( NN NN O
NMDA NN NN O
) NN NN O
receptor NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
pathophysiology NN NN O
of NN NN O
schizophrenia NN NN B-Disease
. NN NN O
   
Administered NN NN O
to NN NN O
healthy NN NN O
volunteers NN NN O
, NN NN O
a NN NN O
subanesthetic NN NN O
dose NN NN O
of NN NN O
the NN NN O
non NN NN O
- NN NN O
competitive NN NN O
NMDA NN NN O
receptor NN NN O
antagonist NN NN O
ketamine NN NN O
leads NN NN O
to NN NN O
psychopathological NN NN O
symptoms NN NN O
similar NN NN O
to NN NN O
those NN NN O
observed NN NN O
in NN NN O
schizophrenia NN NN B-Disease
. NN NN O
   
In NN NN O
patients NN NN O
with NN NN O
schizophrenia NN NN B-Disease
, NN NN O
ketamine NN NN O
exacerbates NN NN O
the NN NN O
core NN NN O
symptoms NN NN O
of NN NN O
illness NN NN O
, NN NN O
supporting NN NN O
the NN NN O
hypothesis NN NN O
of NN NN O
a NN NN O
glutamatergic NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
In NN NN O
a NN NN O
counterbalanced NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
study NN NN O
design NN NN O
, NN NN O
healthy NN NN O
subjects NN NN O
were NN NN O
administered NN NN O
a NN NN O
continuous NN NN O
subanesthetic NN NN O
S NN NN O
- NN NN O
ketamine NN NN O
infusion NN NN O
while NN NN O
differences NN NN O
in NN NN O
BOLD NN NN O
responses NN NN O
measured NN NN O
with NN NN O
fMRI NN NN O
were NN NN O
detected NN NN O
. NN NN O
   
During NN NN O
the NN NN O
scanning NN NN O
period NN NN O
, NN NN O
subjects NN NN O
performed NN NN O
continuous NN NN O
overt NN NN O
verbal NN NN O
fluency NN NN O
tasks NN NN O
( NN NN O
phonological NN NN O
, NN NN O
lexical NN NN O
and NN NN O
semantic NN NN O
) NN NN O
. NN NN O
   
Ketamine NN NN O
- NN NN O
induced NN NN O
psychopathological NN NN O
symptoms NN NN O
were NN NN O
assessed NN NN O
with NN NN O
the NN NN O
Positive NN NN O
and NN NN O
Negative NN NN O
Syndrome NN NN O
Scale NN NN O
( NN NN O
PANSS NN NN O
) NN NN O
. NN NN O
   
Ketamine NN NN O
elicited NN NN O
psychosis NN NN B-Disease
like NN NN O
psychopathology NN NN O
. NN NN O
   
Post NN NN O
- NN NN O
hoc NN NN O
t NN NN O
- NN NN O
tests NN NN O
revealed NN NN O
significant NN NN O
differences NN NN O
between NN NN O
placebo NN NN O
and NN NN O
ketamine NN NN O
for NN NN O
the NN NN O
amounts NN NN O
of NN NN O
words NN NN O
generated NN NN O
during NN NN O
lexical NN NN O
and NN NN O
semantic NN NN O
verbal NN NN O
fluency NN NN O
, NN NN O
while NN NN O
the NN NN O
phonological NN NN O
domain NN NN O
remained NN NN O
unaffected NN NN O
. NN NN O
   
Ketamine NN NN O
led NN NN O
to NN NN O
enhanced NN NN O
cortical NN NN O
activations NN NN O
in NN NN O
supramarginal NN NN O
and NN NN O
frontal NN NN O
brain NN NN O
regions NN NN O
for NN NN O
phonological NN NN O
and NN NN O
lexical NN NN O
verbal NN NN O
fluency NN NN O
, NN NN O
but NN NN O
not NN NN O
for NN NN O
semantic NN NN O
verbal NN NN O
fluency NN NN O
. NN NN O
   
Ketamine NN NN O
induces NN NN O
activation NN NN O
changes NN NN O
in NN NN O
healthy NN NN O
subjects NN NN O
similar NN NN O
to NN NN O
those NN NN O
observed NN NN O
in NN NN O
patients NN NN O
with NN NN O
schizophrenia NN NN B-Disease
, NN NN O
particularly NN NN O
in NN NN O
frontal NN NN O
and NN NN O
temporal NN NN O
brain NN NN O
regions NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
provide NN NN O
further NN NN O
support NN NN O
for NN NN O
the NN NN O
hypothesis NN NN O
of NN NN O
an NN NN O
NMDA NN NN O
receptor NN NN O
dysfunction NN NN O
in NN NN O
the NN NN O
pathophysiology NN NN O
of NN NN O
schizophrenia NN NN B-Disease
. NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
prognosis NN NN O
for NN NN O
transplant NN NN O
- NN NN O
free NN NN O
survivors NN NN O
of NN NN O
paracetamol NN NN O
- NN NN O
induced NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
prognosis NN NN O
for NN NN O
transplant NN NN O
- NN NN O
free NN NN O
survivors NN NN O
of NN NN O
paracetamol NN NN O
- NN NN O
induced NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
remains NN NN O
unknown NN NN O
. NN NN O
   
AIM NN NN O
: NN NN O
To NN NN O
examine NN NN O
whether NN NN O
paracetamol NN NN O
- NN NN O
induced NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
increases NN NN O
long NN NN O
- NN NN O
term NN NN O
mortality NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
followed NN NN O
up NN NN O
all NN NN O
transplant NN NN O
- NN NN O
free NN NN O
survivors NN NN O
of NN NN O
paracetamol NN NN O
- NN NN O
induced NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
injury NN NN I-Disease
, NN NN O
hospitalized NN NN O
in NN NN O
a NN NN O
Danish NN NN O
national NN NN O
referral NN NN O
centre NN NN O
during NN NN O
1984 NN NN O
- NN NN O
2004 NN NN O
. NN NN O
   
We NN NN O
compared NN NN O
age NN NN O
- NN NN O
specific NN NN O
mortality NN NN O
rates NN NN O
from NN NN O
1 NN NN O
year NN NN O
post NN NN O
- NN NN O
discharge NN NN O
through NN NN O
2008 NN NN O
between NN NN O
those NN NN O
in NN NN O
whom NN NN O
the NN NN O
liver NN NN B-Disease
injury NN NN I-Disease
led NN NN O
to NN NN O
an NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
and NN NN O
those NN NN O
in NN NN O
whom NN NN O
it NN NN O
did NN NN O
not NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
We NN NN O
included NN NN O
641 NN NN O
patients NN NN O
. NN NN O
   
On NN NN O
average NN NN O
, NN NN O
age NN NN O
- NN NN O
specific NN NN O
mortality NN NN O
rates NN NN O
were NN NN O
slightly NN NN O
higher NN NN O
for NN NN O
the NN NN O
101 NN NN O
patients NN NN O
whose NN NN O
paracetamol NN NN O
- NN NN O
induced NN NN O
liver NN NN B-Disease
injury NN NN I-Disease
had NN NN O
caused NN NN O
an NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
( NN NN O
adjusted NN NN O
mortality NN NN O
rate NN NN O
ratio NN NN O
= NN NN O
1 NN NN O
. NN NN O
70 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
1 NN NN O
. NN NN O
02 NN NN O
- NN NN O
2 NN NN O
. NN NN O
85 NN NN O
) NN NN O
, NN NN O
but NN NN O
the NN NN O
association NN NN O
was NN NN O
age NN NN O
- NN NN O
dependent NN NN O
, NN NN O
and NN NN O
no NN NN O
survivors NN NN O
of NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
died NN NN O
of NN NN O
liver NN NN B-Disease
disease NN NN I-Disease
, NN NN O
whereas NN NN O
suicides NN NN O
were NN NN O
frequent NN NN O
in NN NN O
both NN NN O
groups NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
speak NN NN O
against NN NN O
long NN NN O
- NN NN O
term NN NN O
effects NN NN O
of NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
More NN NN O
likely NN NN O
, NN NN O
the NN NN O
elevated NN NN O
mortality NN NN O
rate NN NN O
ratio NN NN O
resulted NN NN O
from NN NN O
incomplete NN NN O
adjustment NN NN O
for NN NN O
the NN NN O
greater NN NN O
prevalence NN NN O
of NN NN O
substance NN NN B-Disease
abuse NN NN I-Disease
among NN NN O
survivors NN NN O
of NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Paracetamol NN NN O
- NN NN O
induced NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
did NN NN O
not NN NN O
affect NN NN O
long NN NN O
- NN NN O
term NN NN O
mortality NN NN O
. NN NN O
   
Clinical NN NN O
follow NN NN O
- NN NN O
up NN NN O
may NN NN O
be NN NN O
justified NN NN O
by NN NN O
the NN NN O
cause NN NN O
of NN NN O
the NN NN O
liver NN NN B-Disease
failure NN NN I-Disease
, NN NN O
but NN NN O
not NN NN O
by NN NN O
the NN NN O
liver NN NN B-Disease
failure NN NN I-Disease
itself NN NN O
. NN NN O
   
In NN NN O
vivo NN NN O
characterization NN NN O
of NN NN O
a NN NN O
dual NN NN O
adenosine NN NN O
A2A NN NN O
/ NN NN O
A1 NN NN O
receptor NN NN O
antagonist NN NN O
in NN NN O
animal NN NN O
models NN NN O
of NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
The NN NN O
in NN NN O
vivo NN NN O
characterization NN NN O
of NN NN O
a NN NN O
dual NN NN O
adenosine NN NN O
A NN NN O
( NN NN O
2A NN NN O
) NN NN O
/ NN NN O
A NN NN O
( NN NN O
1 NN NN O
) NN NN O
receptor NN NN O
antagonist NN NN O
in NN NN O
several NN NN O
animal NN NN O
models NN NN O
of NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
is NN NN O
described NN NN O
. NN NN O
   
Discovery NN NN O
and NN NN O
scale NN NN O
- NN NN O
up NN NN O
syntheses NN NN O
of NN NN O
compound NN NN O
1 NN NN O
are NN NN O
described NN NN O
in NN NN O
detail NN NN O
, NN NN O
highlighting NN NN O
optimization NN NN O
steps NN NN O
that NN NN O
increased NN NN O
the NN NN O
overall NN NN O
yield NN NN O
of NN NN O
1 NN NN O
from NN NN O
10 NN NN O
. NN NN O
0 NN NN O
% NN NN O
to NN NN O
30 NN NN O
. NN NN O
5 NN NN O
% NN NN O
. NN NN O
   
Compound NN NN O
1 NN NN O
is NN NN O
a NN NN O
potent NN NN O
A NN NN O
( NN NN O
2A NN NN O
) NN NN O
/ NN NN O
A NN NN O
( NN NN O
1 NN NN O
) NN NN O
receptor NN NN O
antagonist NN NN O
in NN NN O
vitro NN NN O
( NN NN O
A NN NN O
( NN NN O
2A NN NN O
) NN NN O
K NN NN O
( NN NN O
i NN NN O
) NN NN O
= NN NN O
4 NN NN O
. NN NN O
1 NN NN O
nM NN NN O
; NN NN O
A NN NN O
( NN NN O
1 NN NN O
) NN NN O
K NN NN O
( NN NN O
i NN NN O
) NN NN O
= NN NN O
17 NN NN O
. NN NN O
0 NN NN O
nM NN NN O
) NN NN O
that NN NN O
has NN NN O
excellent NN NN O
activity NN NN O
, NN NN O
after NN NN O
oral NN NN O
administration NN NN O
, NN NN O
across NN NN O
a NN NN O
number NN NN O
of NN NN O
animal NN NN O
models NN NN O
of NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
including NN NN O
mouse NN NN O
and NN NN O
rat NN NN O
models NN NN O
of NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
, NN NN O
mouse NN NN O
model NN NN O
of NN NN O
reserpine NN NN O
- NN NN O
induced NN NN O
akinesia NN NN B-Disease
, NN NN O
rat NN NN O
6 NN NN O
- NN NN O
hydroxydopamine NN NN O
( NN NN O
6 NN NN O
- NN NN O
OHDA NN NN O
) NN NN O
lesion NN NN O
model NN NN O
of NN NN O
drug NN NN O
- NN NN O
induced NN NN O
rotation NN NN O
, NN NN O
and NN NN O
MPTP NN NN O
- NN NN O
treated NN NN O
non NN NN O
- NN NN O
human NN NN O
primate NN NN O
model NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
the NN NN O
hippocampal NN NN O
deep NN NN O
brain NN NN O
stimulation NN NN O
on NN NN O
cortical NN NN O
epileptic NN NN B-Disease
discharges NN NN O
in NN NN O
penicillin NN NN O
- NN NN O
induced NN NN O
epilepsy NN NN B-Disease
model NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
AIM NN NN O
: NN NN O
Experimental NN NN O
and NN NN O
clinical NN NN O
studies NN NN O
have NN NN O
revealed NN NN O
that NN NN O
hippocampal NN NN O
DBS NN NN O
can NN NN O
control NN NN O
epileptic NN NN B-Disease
activity NN NN O
, NN NN O
but NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
is NN NN O
obscure NN NN O
and NN NN O
optimal NN NN O
stimulation NN NN O
parameters NN NN O
are NN NN O
not NN NN O
clearly NN NN O
defined NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
was NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
effects NN NN O
of NN NN O
high NN NN O
frequency NN NN O
hippocampal NN NN O
stimulation NN NN O
on NN NN O
cortical NN NN O
epileptic NN NN B-Disease
activity NN NN O
in NN NN O
penicillin NN NN O
- NN NN O
induced NN NN O
epilepsy NN NN B-Disease
model NN NN O
. NN NN O
   
MATERIAL NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
Twenty NN NN O
- NN NN O
five NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
were NN NN O
implanted NN NN O
DBS NN NN O
electrodes NN NN O
. NN NN O
   
In NN NN O
group NN NN O
- NN NN O
1 NN NN O
( NN NN O
n NN NN O
= NN NN O
10 NN NN O
) NN NN O
hippocampal NN NN O
DBS NN NN O
was NN NN O
off NN NN O
and NN NN O
in NN NN O
the NN NN O
group NN NN O
- NN NN O
2 NN NN O
( NN NN O
n NN NN O
= NN NN O
10 NN NN O
) NN NN O
hippocampal NN NN O
DBS NN NN O
was NN NN O
on NN NN O
( NN NN O
185 NN NN O
Hz NN NN O
, NN NN O
0 NN NN O
. NN NN O
5V NN NN O
, NN NN O
1V NN NN O
, NN NN O
2V NN NN O
, NN NN O
and NN NN O
5V NN NN O
for NN NN O
60 NN NN O
sec NN NN O
) NN NN O
following NN NN O
penicillin NN NN O
G NN NN O
injection NN NN O
intracortically NN NN O
. NN NN O
   
In NN NN O
the NN NN O
control NN NN O
group NN NN O
hippocampal NN NN O
DBS NN NN O
was NN NN O
on NN NN O
following NN NN O
8 NN NN O
l NN NN O
saline NN NN O
injection NN NN O
intracortically NN NN O
. NN NN O
   
EEG NN NN O
recordings NN NN O
were NN NN O
obtained NN NN O
before NN NN O
and NN NN O
15 NN NN O
minutes NN NN O
following NN NN O
penicillin NN NN O
- NN NN O
G NN NN O
injection NN NN O
, NN NN O
and NN NN O
at NN NN O
10th NN NN O
minutes NN NN O
following NN NN O
each NN NN O
stimulus NN NN O
for NN NN O
analysis NN NN O
in NN NN O
terms NN NN O
of NN NN O
frequency NN NN O
, NN NN O
amplitude NN NN O
, NN NN O
and NN NN O
power NN NN O
spectrum NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
High NN NN O
frequency NN NN O
hippocampal NN NN O
DBS NN NN O
suppressed NN NN O
the NN NN O
acute NN NN O
penicillin NN NN O
- NN NN O
induced NN NN O
cortical NN NN O
epileptic NN NN B-Disease
activity NN NN O
independent NN NN O
from NN NN O
stimulus NN NN O
intensity NN NN O
. NN NN O
   
In NN NN O
the NN NN O
control NN NN O
group NN NN O
, NN NN O
hippocampal NN NN O
stimulation NN NN O
alone NN NN O
lead NN NN O
only NN NN O
to NN NN O
diffuse NN NN O
slowing NN NN O
of NN NN O
cerebral NN NN O
bioelectrical NN NN O
activity NN NN O
at NN NN O
5V NN NN O
stimulation NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Our NN NN O
results NN NN O
revealed NN NN O
that NN NN O
continuous NN NN O
high NN NN O
frequency NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
hippocampus NN NN O
suppressed NN NN O
acute NN NN O
cortical NN NN O
epileptic NN NN B-Disease
activity NN NN O
effectively NN NN O
without NN NN O
causing NN NN O
secondary NN NN O
epileptic NN NN B-Disease
discharges NN NN O
. NN NN O
   
These NN NN O
results NN NN O
are NN NN O
important NN NN O
in NN NN O
terms NN NN O
of NN NN O
defining NN NN O
the NN NN O
optimal NN NN O
parameters NN NN O
of NN NN O
hippocampal NN NN O
DBS NN NN O
in NN NN O
patients NN NN O
with NN NN O
epilepsy NN NN B-Disease
. NN NN O
   
CCNU NN NN O
( NN NN O
lomustine NN NN O
) NN NN O
toxicity NN NN B-Disease
in NN NN O
dogs NN NN O
: NN NN O
a NN NN O
retrospective NN NN O
study NN NN O
( NN NN O
2002 NN NN O
- NN NN O
07 NN NN O
) NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
describe NN NN O
the NN NN O
incidence NN NN O
of NN NN O
haematological NN NN B-Disease
, NN NN I-Disease
renal NN NN I-Disease
, NN NN I-Disease
hepatic NN NN I-Disease
and NN NN I-Disease
gastrointestinal NN NN I-Disease
toxicities NN NN I-Disease
in NN NN O
tumour NN NN O
- NN NN O
bearing NN NN O
dogs NN NN O
receiving NN NN O
1 NN NN O
- NN NN O
( NN NN O
2 NN NN O
- NN NN O
chloroethyl NN NN O
) NN NN O
- NN NN O
3 NN NN O
- NN NN O
cyclohexyl NN NN O
- NN NN O
1 NN NN O
- NN NN O
nitrosourea NN NN O
( NN NN O
CCNU NN NN O
) NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
The NN NN O
medical NN NN O
records NN NN O
of NN NN O
206 NN NN O
dogs NN NN O
that NN NN O
were NN NN O
treated NN NN O
with NN NN O
CCNU NN NN O
at NN NN O
the NN NN O
Melbourne NN NN O
Veterinary NN NN O
Specialist NN NN O
Centre NN NN O
between NN NN O
February NN NN O
2002 NN NN O
and NN NN O
December NN NN O
2007 NN NN O
were NN NN O
retrospectively NN NN O
evaluated NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Of NN NN O
the NN NN O
206 NN NN O
dogs NN NN O
treated NN NN O
with NN NN O
CCNU NN NN O
, NN NN O
185 NN NN O
met NN NN O
the NN NN O
inclusion NN NN O
criteria NN NN O
for NN NN O
at NN NN O
least NN NN O
one NN NN O
class NN NN O
of NN NN O
toxicity NN NN B-Disease
. NN NN O
   
CCNU NN NN O
was NN NN O
used NN NN O
most NN NN O
commonly NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
lymphoma NN NN B-Disease
, NN NN O
mast NN NN B-Disease
cell NN NN I-Disease
tumour NN NN I-Disease
, NN NN O
brain NN NN B-Disease
tumour NN NN I-Disease
, NN NN O
histiocytic NN NN B-Disease
tumours NN NN I-Disease
and NN NN O
epitheliotropic NN NN B-Disease
lymphoma NN NN I-Disease
. NN NN O
   
Throughout NN NN O
treatment NN NN O
, NN NN O
56 NN NN O
. NN NN O
9 NN NN O
% NN NN O
of NN NN O
dogs NN NN O
experienced NN NN O
neutropenia NN NN B-Disease
, NN NN O
34 NN NN O
. NN NN O
2 NN NN O
% NN NN O
experienced NN NN O
anaemia NN NN B-Disease
and NN NN O
14 NN NN O
. NN NN O
2 NN NN O
% NN NN O
experienced NN NN O
thrombocytopenia NN NN B-Disease
. NN NN O
   
Gastrointestinal NN NN B-Disease
toxicosis NN NN I-Disease
was NN NN O
detected NN NN O
in NN NN O
37 NN NN O
. NN NN O
8 NN NN O
% NN NN O
of NN NN O
dogs NN NN O
, NN NN O
the NN NN O
most NN NN O
common NN NN O
sign NN NN O
of NN NN O
which NN NN O
was NN NN O
vomiting NN NN B-Disease
( NN NN O
24 NN NN O
. NN NN O
3 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Potential NN NN O
renal NN NN O
toxicity NN NN B-Disease
and NN NN O
elevated NN NN O
alanine NN NN O
transaminase NN NN O
( NN NN O
ALT NN NN O
) NN NN O
concentration NN NN O
were NN NN O
reported NN NN O
in NN NN O
12 NN NN O
. NN NN O
2 NN NN O
% NN NN O
and NN NN O
48 NN NN O
. NN NN O
8 NN NN O
% NN NN O
of NN NN O
dogs NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
hepatic NN NN B-Disease
failure NN NN I-Disease
was NN NN O
1 NN NN O
. NN NN O
2 NN NN O
% NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
CCNU NN NN O
- NN NN O
associated NN NN O
toxicity NN NN B-Disease
in NN NN O
dogs NN NN O
is NN NN O
common NN NN O
, NN NN O
but NN NN O
is NN NN O
usually NN NN O
not NN NN O
life NN NN O
threatening NN NN O
. NN NN O
   
Central NN NN O
vein NN NN B-Disease
thrombosis NN NN I-Disease
and NN NN O
topical NN NN O
dipivalyl NN NN O
epinephrine NN NN O
. NN NN O
   
A NN NN O
report NN NN O
is NN NN O
given NN NN O
on NN NN O
an NN NN O
83 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
female NN NN O
who NN NN O
acquired NN NN O
central NN NN O
vein NN NN B-Disease
thrombosis NN NN I-Disease
in NN NN O
her NN NN O
seeing NN NN O
eye NN NN O
one NN NN O
day NN NN O
after NN NN O
having NN NN O
started NN NN O
topical NN NN O
medication NN NN O
with NN NN O
dipivalyl NN NN O
epinephrine NN NN O
for NN NN O
advanced NN NN O
glaucoma NN NN B-Disease
discovered NN NN O
in NN NN O
the NN NN O
other NN NN O
eye NN NN O
. NN NN O
   
From NN NN O
present NN NN O
knowledge NN NN O
about NN NN O
the NN NN O
effects NN NN O
of NN NN O
adrenergic NN NN O
eye NN NN O
drops NN NN O
on NN NN O
ocular NN NN O
blood NN NN O
circulation NN NN O
, NN NN O
it NN NN O
is NN NN O
difficult NN NN O
to NN NN O
suggest NN NN O
an NN NN O
association NN NN O
between NN NN O
the NN NN O
two NN NN O
events NN NN O
, NN NN O
which NN NN O
may NN NN O
be NN NN O
coincidental NN NN O
only NN NN O
. NN NN O
   
Benzylacyclouridine NN NN O
reverses NN NN O
azidothymidine NN NN O
- NN NN O
induced NN NN O
marrow NN NN B-Disease
suppression NN NN I-Disease
without NN NN O
impairment NN NN O
of NN NN O
anti NN NN O
- NN NN O
human NN NN O
immunodeficiency NN NN B-Disease
virus NN NN O
activity NN NN O
. NN NN O
   
Increased NN NN O
extracellular NN NN O
concentrations NN NN O
of NN NN O
uridine NN NN O
( NN NN O
Urd NN NN O
) NN NN O
have NN NN O
been NN NN O
reported NN NN O
to NN NN O
reduce NN NN O
, NN NN O
in NN NN O
vitro NN NN O
, NN NN O
azidothymidine NN NN O
( NN NN O
AZT NN NN O
) NN NN O
- NN NN O
induced NN NN O
inhibition NN NN O
of NN NN O
human NN NN O
granulocyte NN NN O
- NN NN O
macrophage NN NN O
progenitor NN NN O
cells NN NN O
without NN NN O
impairment NN NN O
of NN NN O
its NN NN O
antihuman NN NN O
immunodeficiency NN NN B-Disease
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
activity NN NN O
. NN NN O
   
Because NN NN O
of NN NN O
the NN NN O
clinical NN NN O
toxicities NN NN B-Disease
associated NN NN O
with NN NN O
chronic NN NN O
Urd NN NN O
administration NN NN O
, NN NN O
the NN NN O
ability NN NN O
of NN NN O
benzylacyclouridine NN NN O
( NN NN O
BAU NN NN O
) NN NN O
to NN NN O
effect NN NN O
, NN NN O
in NN NN O
vivo NN NN O
, NN NN O
AZT NN NN O
- NN NN O
induced NN NN O
anemia NN NN B-Disease
and NN NN O
leukopenia NN NN B-Disease
was NN NN O
assessed NN NN O
. NN NN O
   
This NN NN O
agent NN NN O
inhibits NN NN O
Urd NN NN O
catabolism NN NN O
and NN NN O
, NN NN O
in NN NN O
vivo NN NN O
, NN NN O
increases NN NN O
the NN NN O
plasma NN NN O
concentration NN NN O
of NN NN O
Urd NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
, NN NN O
without NN NN O
Urd NN NN O
- NN NN O
related NN NN O
toxicity NN NN B-Disease
. NN NN O
   
In NN NN O
mice NN NN O
rendered NN NN O
anemic NN NN B-Disease
and NN NN O
leukopenic NN NN B-Disease
by NN NN O
the NN NN O
administration NN NN O
of NN NN O
AZT NN NN O
for NN NN O
28 NN NN O
days NN NN O
in NN NN O
drinking NN NN O
water NN NN O
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
mL NN NN O
) NN NN O
, NN NN O
the NN NN O
continued NN NN O
administration NN NN O
of NN NN O
AZT NN NN O
plus NN NN O
daily NN NN O
BAU NN NN O
( NN NN O
300 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
orally NN NN O
) NN NN O
partially NN NN O
reversed NN NN O
AZT NN NN O
- NN NN O
induced NN NN O
anemia NN NN B-Disease
and NN NN O
leukopenia NN NN B-Disease
( NN NN O
P NN NN O
less NN NN O
than NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
increased NN NN O
peripheral NN NN O
reticulocytes NN NN O
( NN NN O
to NN NN O
4 NN NN O
. NN NN O
9 NN NN O
% NN NN O
, NN NN O
P NN NN O
less NN NN O
than NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
increased NN NN O
cellularity NN NN O
in NN NN O
the NN NN O
marrow NN NN O
, NN NN O
and NN NN O
improved NN NN O
megaloblastosis NN NN B-Disease
. NN NN O
   
When NN NN O
coadministered NN NN O
with NN NN O
AZT NN NN O
from NN NN O
the NN NN O
onset NN NN O
of NN NN O
drug NN NN O
administration NN NN O
, NN NN O
BAU NN NN O
reduced NN NN O
AZT NN NN O
- NN NN O
induced NN NN O
marrow NN NN B-Disease
toxicity NN NN I-Disease
. NN NN O
   
In NN NN O
vitro NN NN O
, NN NN O
at NN NN O
a NN NN O
concentration NN NN O
of NN NN O
100 NN NN O
mumol NN NN O
/ NN NN O
L NN NN O
, NN NN O
BAU NN NN O
possesses NN NN O
minimal NN NN O
anti NN NN O
- NN NN O
HIV NN NN O
activity NN NN O
and NN NN O
has NN NN O
no NN NN O
effect NN NN O
on NN NN O
the NN NN O
ability NN NN O
of NN NN O
AZT NN NN O
to NN NN O
reverse NN NN O
the NN NN O
HIV NN NN O
- NN NN O
induced NN NN O
cytopathic NN NN O
effect NN NN O
in NN NN O
MT4 NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
clinical NN NN O
and NN NN O
biochemical NN NN O
implications NN NN O
of NN NN O
these NN NN O
findings NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Lethal NN NN O
anuria NN NN B-Disease
complicating NN NN O
high NN NN O
dose NN NN O
ifosfamide NN NN O
chemotherapy NN NN O
in NN NN O
a NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
patient NN NN O
with NN NN O
an NN NN O
impaired NN NN B-Disease
renal NN NN I-Disease
function NN NN I-Disease
. NN NN O
   
A NN NN O
sixty NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
advanced NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
previously NN NN O
treated NN NN O
with NN NN O
cisplatin NN NN O
, NN NN O
developed NN NN O
an NN NN O
irreversible NN NN O
lethal NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
with NN NN O
anuria NN NN B-Disease
, NN NN O
the NN NN O
day NN NN O
after NN NN O
5 NN NN O
g NN NN O
/ NN NN O
m2 NN NN O
bolus NN NN O
ifosfamide NN NN O
. NN NN O
   
Postrenal NN NN B-Disease
failure NN NN I-Disease
was NN NN O
excluded NN NN O
by NN NN O
echography NN NN O
. NN NN O
   
A NN NN O
prerenal NN NN O
component NN NN O
could NN NN O
have NN NN O
contributed NN NN O
to NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
because NN NN O
of NN NN O
a NN NN O
transient NN NN O
hypotension NN NN B-Disease
, NN NN O
due NN NN O
to NN NN O
an NN NN O
increasing NN NN O
ascitis NN NN O
, NN NN O
occurring NN NN O
just NN NN O
before NN NN O
anuria NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
correction NN NN O
of NN NN O
the NN NN O
hemodynamic NN NN O
parameters NN NN O
did NN NN O
not NN NN O
improve NN NN O
renal NN NN O
function NN NN O
. NN NN O
   
Ifosfamide NN NN O
is NN NN O
a NN NN O
known NN NN O
nephrotoxic NN NN B-Disease
drug NN NN O
with NN NN O
demonstrated NN NN O
tubulopathies NN NN B-Disease
. NN NN O
   
We NN NN O
strongly NN NN O
suspect NN NN O
that NN NN O
this NN NN O
lethal NN NN O
anuria NN NN B-Disease
was NN NN O
mainly NN NN O
due NN NN O
to NN NN O
ifosfamide NN NN O
, NN NN O
occurring NN NN O
in NN NN O
a NN NN O
patient NN NN O
having NN NN O
received NN NN O
previous NN NN O
cisplatin NN NN O
chemotherapy NN NN O
and NN NN O
with NN NN O
poor NN NN O
kidney NN NN O
perfusion NN NN O
due NN NN O
to NN NN O
transient NN NN O
hypotension NN NN B-Disease
. NN NN O
   
We NN NN O
recommend NN NN O
careful NN NN O
use NN NN O
of NN NN O
ifosfamide NN NN O
in NN NN O
patients NN NN O
pretreated NN NN O
with NN NN O
nephrotoxic NN NN B-Disease
chemotherapy NN NN O
and NN NN O
inadequate NN NN O
renal NN NN O
perfusion NN NN O
. NN NN O
   
Nociceptive NN NN O
effects NN NN O
induced NN NN O
by NN NN O
intrathecal NN NN O
administration NN NN O
of NN NN O
prostaglandin NN NN O
D2 NN NN O
, NN NN O
E2 NN NN O
, NN NN O
or NN NN O
F2 NN NN O
alpha NN NN O
to NN NN O
conscious NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
intrathecal NN NN O
administration NN NN O
of NN NN O
prostaglandins NN NN O
on NN NN O
pain NN NN B-Disease
responses NN NN O
in NN NN O
conscious NN NN O
mice NN NN O
were NN NN O
evaluated NN NN O
by NN NN O
using NN NN O
hot NN NN O
plate NN NN O
and NN NN O
acetic NN NN O
acid NN NN O
writhing NN NN O
tests NN NN O
. NN NN O
   
Prostaglandin NN NN O
D2 NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
- NN NN O
3 NN NN O
ng NN NN O
/ NN NN O
mouse NN NN O
) NN NN O
had NN NN O
a NN NN O
hyperalgesic NN NN B-Disease
action NN NN O
on NN NN O
the NN NN O
response NN NN O
to NN NN O
a NN NN O
hot NN NN O
plate NN NN O
during NN NN O
a NN NN O
3 NN NN O
- NN NN O
60 NN NN O
min NN NN O
period NN NN O
after NN NN O
injection NN NN O
. NN NN O
   
Prostaglandin NN NN O
E2 NN NN O
showed NN NN O
a NN NN O
hyperalgesic NN NN B-Disease
effect NN NN O
at NN NN O
doses NN NN O
of NN NN O
1 NN NN O
pg NN NN O
to NN NN O
10 NN NN O
ng NN NN O
/ NN NN O
mouse NN NN O
, NN NN O
but NN NN O
the NN NN O
effect NN NN O
lasted NN NN O
shorter NN NN O
( NN NN O
3 NN NN O
- NN NN O
30 NN NN O
min NN NN O
) NN NN O
than NN NN O
that NN NN O
of NN NN O
prostaglandin NN NN O
D2 NN NN O
. NN NN O
   
Similar NN NN O
results NN NN O
were NN NN O
obtained NN NN O
by NN NN O
acetic NN NN O
acid NN NN O
writhing NN NN O
tests NN NN O
. NN NN O
   
The NN NN O
hyperalgesic NN NN B-Disease
effect NN NN O
of NN NN O
prostaglandin NN NN O
D2 NN NN O
was NN NN O
blocked NN NN O
by NN NN O
simultaneous NN NN O
injection NN NN O
of NN NN O
a NN NN O
substance NN NN O
P NN NN O
antagonist NN NN O
( NN NN O
greater NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
100 NN NN O
ng NN NN O
) NN NN O
but NN NN O
not NN NN O
by NN NN O
AH6809 NN NN O
, NN NN O
a NN NN O
prostanoid NN NN O
EP1 NN NN O
- NN NN O
receptor NN NN O
antagonist NN NN O
. NN NN O
   
Conversely NN NN O
, NN NN O
prostaglandin NN NN O
E2 NN NN O
- NN NN O
induced NN NN O
hyperalgesia NN NN B-Disease
was NN NN O
blocked NN NN O
by NN NN O
AH6809 NN NN O
( NN NN O
greater NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
500 NN NN O
ng NN NN O
) NN NN O
but NN NN O
not NN NN O
by NN NN O
the NN NN O
substance NN NN O
P NN NN O
antagonist NN NN O
. NN NN O
   
Prostaglandin NN NN O
F2 NN NN O
alpha NN NN O
had NN NN O
little NN NN O
effect NN NN O
on NN NN O
pain NN NN B-Disease
responses NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
both NN NN O
prostaglandin NN NN O
D2 NN NN O
and NN NN O
prostaglandin NN NN O
E2 NN NN O
exert NN NN O
hyperalgesia NN NN B-Disease
in NN NN O
the NN NN O
spinal NN NN O
cord NN NN O
, NN NN O
but NN NN O
in NN NN O
different NN NN O
ways NN NN O
. NN NN O
   
D NN NN O
- NN NN O
penicillamine NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
localized NN NN B-Disease
scleroderma NN NN I-Disease
. NN NN O
   
Localized NN NN B-Disease
scleroderma NN NN I-Disease
has NN NN O
no NN NN O
recognized NN NN O
internal NN NN O
organ NN NN O
involvement NN NN O
but NN NN O
may NN NN O
be NN NN O
disfiguring NN NN O
and NN NN O
disabling NN NN O
when NN NN O
the NN NN O
cutaneous NN NN O
lesions NN NN O
are NN NN O
extensive NN NN O
or NN NN O
affect NN NN O
children NN NN O
. NN NN O
   
There NN NN O
is NN NN O
no NN NN O
accepted NN NN O
or NN NN O
proven NN NN O
treatment NN NN O
for NN NN O
localized NN NN B-Disease
scleroderma NN NN I-Disease
. NN NN O
   
Case NN NN O
reports NN NN O
of NN NN O
11 NN NN O
patients NN NN O
with NN NN O
severe NN NN O
, NN NN O
extensive NN NN O
localized NN NN B-Disease
scleroderma NN NN I-Disease
who NN NN O
were NN NN O
treated NN NN O
with NN NN O
D NN NN O
- NN NN O
penicillamine NN NN O
are NN NN O
summarized NN NN O
in NN NN O
this NN NN O
article NN NN O
. NN NN O
   
This NN NN O
drug NN NN O
was NN NN O
judged NN NN O
to NN NN O
have NN NN O
a NN NN O
favorable NN NN O
effect NN NN O
on NN NN O
the NN NN O
disease NN NN O
course NN NN O
in NN NN O
7 NN NN O
( NN NN O
64 NN NN O
% NN NN O
) NN NN O
of NN NN O
11 NN NN O
patients NN NN O
. NN NN O
   
Improvement NN NN O
began NN NN O
within NN NN O
3 NN NN O
to NN NN O
6 NN NN O
months NN NN O
and NN NN O
consisted NN NN O
of NN NN O
cessation NN NN O
of NN NN O
active NN NN O
cutaneous NN NN O
lesions NN NN O
in NN NN O
all NN NN O
7 NN NN O
patients NN NN O
, NN NN O
skin NN NN O
softening NN NN O
in NN NN O
5 NN NN O
, NN NN O
and NN NN O
more NN NN O
normal NN NN O
growth NN NN O
of NN NN O
the NN NN O
affected NN NN O
limb NN NN O
in NN NN O
2 NN NN O
of NN NN O
3 NN NN O
children NN NN O
. NN NN O
   
Joint NN NN O
stiffness NN NN O
and NN NN O
contractures NN NN B-Disease
also NN NN O
improved NN NN O
. NN NN O
   
The NN NN O
dose NN NN O
of NN NN O
D NN NN O
- NN NN O
penicillamine NN NN O
associated NN NN O
with NN NN O
a NN NN O
favorable NN NN O
response NN NN O
was NN NN O
as NN NN O
low NN NN O
as NN NN O
2 NN NN O
to NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
day NN NN O
given NN NN O
over NN NN O
a NN NN O
period NN NN O
ranging NN NN O
from NN NN O
15 NN NN O
to NN NN O
53 NN NN O
months NN NN O
. NN NN O
   
D NN NN O
- NN NN O
Penicillamine NN NN O
caused NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
in NN NN O
1 NN NN O
patient NN NN O
and NN NN O
milder NN NN O
reversible NN NN O
proteinuria NN NN B-Disease
in NN NN O
3 NN NN O
other NN NN O
patients NN NN O
; NN NN O
none NN NN O
developed NN NN O
renal NN NN B-Disease
insufficiency NN NN I-Disease
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
D NN NN O
- NN NN O
penicillamine NN NN O
may NN NN O
be NN NN O
effective NN NN O
in NN NN O
severe NN NN O
cases NN NN O
of NN NN O
localized NN NN B-Disease
scleroderma NN NN I-Disease
. NN NN O
   
Cerebral NN NN B-Disease
sinus NN NN I-Disease
thrombosis NN NN I-Disease
as NN NN O
a NN NN O
potential NN NN O
hazard NN NN O
of NN NN O
antifibrinolytic NN NN O
treatment NN NN O
in NN NN O
menorrhagia NN NN B-Disease
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
42 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
who NN NN O
developed NN NN O
superior NN NN O
sagittal NN NN B-Disease
and NN NN I-Disease
left NN NN I-Disease
transverse NN NN I-Disease
sinus NN NN I-Disease
thrombosis NN NN I-Disease
associated NN NN O
with NN NN O
prolonged NN NN O
epsilon NN NN O
- NN NN O
aminocaproic NN NN O
acid NN NN O
therapy NN NN O
for NN NN O
menorrhagia NN NN B-Disease
. NN NN O
   
This NN NN O
antifibrinolytic NN NN O
agent NN NN O
has NN NN O
been NN NN O
used NN NN O
in NN NN O
women NN NN O
with NN NN O
menorrhagia NN NN B-Disease
to NN NN O
promote NN NN O
clotting NN NN O
and NN NN O
reduce NN NN O
blood NN NN B-Disease
loss NN NN I-Disease
. NN NN O
   
Although NN NN O
increased NN NN O
risk NN NN O
of NN NN O
thromboembolic NN NN B-Disease
disease NN NN I-Disease
has NN NN O
been NN NN O
reported NN NN O
during NN NN O
treatment NN NN O
with NN NN O
epsilon NN NN O
- NN NN O
aminocaproic NN NN O
acid NN NN O
, NN NN O
cerebral NN NN B-Disease
sinus NN NN I-Disease
thrombosis NN NN I-Disease
has NN NN O
not NN NN O
been NN NN O
previously NN NN O
described NN NN O
. NN NN O
   
Careful NN NN O
use NN NN O
of NN NN O
epsilon NN NN O
- NN NN O
aminocaproic NN NN O
acid NN NN O
therapy NN NN O
is NN NN O
recommended NN NN O
. NN NN O
   
Seizure NN NN B-Disease
activity NN NN O
with NN NN O
imipenem NN NN O
therapy NN NN O
: NN NN O
incidence NN NN O
and NN NN O
risk NN NN O
factors NN NN O
. NN NN O
   
Two NN NN O
elderly NN NN O
patients NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
either NN NN O
cerebral NN NN B-Disease
vascular NN NN I-Disease
accident NN NN I-Disease
( NN NN O
CVA NN NN B-Disease
) NN NN O
or NN NN O
head NN NN B-Disease
trauma NN NN I-Disease
and NN NN O
no NN NN O
evidence NN NN O
of NN NN O
renal NN NN B-Disease
disease NN NN I-Disease
developed NN NN O
seizures NN NN B-Disease
while NN NN O
receiving NN NN O
maximum NN NN O
doses NN NN O
of NN NN O
imipenem NN NN O
/ NN NN O
cilastatin NN NN O
. NN NN O
   
Neither NN NN O
patient NN NN O
had NN NN O
reported NN NN O
previous NN NN O
seizures NN NN B-Disease
or NN NN O
seizure NN NN B-Disease
- NN NN O
like NN NN O
activity NN NN O
nor NN NN O
was NN NN O
receiving NN NN O
anticonvulsant NN NN O
agents NN NN O
. NN NN O
   
All NN NN O
seizures NN NN B-Disease
were NN NN O
controlled NN NN O
with NN NN O
therapeutic NN NN O
doses NN NN O
of NN NN O
phenytoin NN NN O
. NN NN O
   
Both NN NN O
patients NN NN O
had NN NN O
received NN NN O
maximum NN NN O
doses NN NN O
of NN NN O
other NN NN O
beta NN NN O
- NN NN O
lactam NN NN O
antibiotics NN NN O
without NN NN O
evidence NN NN O
of NN NN O
seizure NN NN B-Disease
activity NN NN O
. NN NN O
   
Midline NN NN O
B3 NN NN O
serotonin NN NN O
nerves NN NN O
in NN NN O
rat NN NN O
medulla NN NN O
are NN NN O
involved NN NN O
in NN NN O
hypotensive NN NN B-Disease
effect NN NN O
of NN NN O
methyldopa NN NN O
. NN NN O
   
Previous NN NN O
experiments NN NN O
in NN NN O
this NN NN O
laboratory NN NN O
have NN NN O
shown NN NN O
that NN NN O
microinjection NN NN O
of NN NN O
methyldopa NN NN O
onto NN NN O
the NN NN O
ventrolateral NN NN O
cells NN NN O
of NN NN O
the NN NN O
B3 NN NN O
serotonin NN NN O
neurons NN NN O
in NN NN O
the NN NN O
medulla NN NN O
elicits NN NN O
a NN NN O
hypotensive NN NN B-Disease
response NN NN O
mediated NN NN O
by NN NN O
a NN NN O
projection NN NN O
descending NN NN O
into NN NN O
the NN NN O
spinal NN NN O
cord NN NN O
. NN NN O
   
The NN NN O
present NN NN O
experiments NN NN O
were NN NN O
designed NN NN O
to NN NN O
investigate NN NN O
the NN NN O
role NN NN O
of NN NN O
the NN NN O
midline NN NN O
cells NN NN O
of NN NN O
the NN NN O
B3 NN NN O
serotonin NN NN O
neurons NN NN O
in NN NN O
the NN NN O
medulla NN NN O
, NN NN O
coinciding NN NN O
with NN NN O
the NN NN O
raphe NN NN O
magnus NN NN O
. NN NN O
   
In NN NN O
spontaneously NN NN O
hypertensive NN NN B-Disease
, NN NN O
stroke NN NN B-Disease
- NN NN O
prone NN NN O
rats NN NN O
, NN NN O
microinjection NN NN O
of NN NN O
methyldopa NN NN O
into NN NN O
the NN NN O
area NN NN O
of NN NN O
the NN NN O
midline NN NN O
B3 NN NN O
serotonin NN NN O
cell NN NN O
group NN NN O
in NN NN O
the NN NN O
ventral NN NN O
medulla NN NN O
caused NN NN O
a NN NN O
potent NN NN O
hypotension NN NN B-Disease
of NN NN O
30 NN NN O
- NN NN O
40 NN NN O
mm NN NN O
Hg NN NN O
, NN NN O
which NN NN O
was NN NN O
maximal NN NN O
2 NN NN O
- NN NN O
3 NN NN O
h NN NN O
after NN NN O
administration NN NN O
and NN NN O
was NN NN O
abolished NN NN O
by NN NN O
the NN NN O
serotonin NN NN O
neurotoxin NN NN O
5 NN NN O
, NN NN O
7 NN NN O
- NN NN O
dihydroxytryptamine NN NN O
( NN NN O
5 NN NN O
, NN NN O
7 NN NN O
- NN NN O
DHT NN NN O
) NN NN O
injected NN NN O
intracerebroventricularly NN NN O
. NN NN O
   
However NN NN O
, NN NN O
intraspinal NN NN O
injection NN NN O
of NN NN O
5 NN NN O
, NN NN O
7 NN NN O
- NN NN O
DHT NN NN O
to NN NN O
produce NN NN O
a NN NN O
more NN NN O
selective NN NN O
lesion NN NN O
of NN NN O
only NN NN O
descending NN NN O
serotonin NN NN O
projections NN NN O
in NN NN O
the NN NN O
spinal NN NN O
cord NN NN O
did NN NN O
not NN NN O
affect NN NN O
this NN NN O
hypotension NN NN B-Disease
. NN NN O
   
Further NN NN O
, NN NN O
5 NN NN O
, NN NN O
7 NN NN O
- NN NN O
DHT NN NN O
lesion NN NN O
of NN NN O
serotonin NN NN O
nerves NN NN O
travelling NN NN O
in NN NN O
the NN NN O
median NN NN O
forebrain NN NN O
bundle NN NN O
, NN NN O
one NN NN O
of NN NN O
the NN NN O
main NN NN O
ascending NN NN O
pathways NN NN O
from NN NN O
the NN NN O
B3 NN NN O
serotonin NN NN O
cells NN NN O
, NN NN O
did NN NN O
not NN NN O
affect NN NN O
the NN NN O
fall NN NN O
in NN NN O
blood NN NN O
pressure NN NN O
associated NN NN O
with NN NN O
a NN NN O
midline NN NN O
B3 NN NN O
serotonin NN NN O
methyldopa NN NN O
injection NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
therefore NN NN O
that NN NN O
, NN NN O
unlike NN NN O
the NN NN O
ventrolateral NN NN O
B3 NN NN O
cells NN NN O
which NN NN O
mediate NN NN O
a NN NN O
methyldopa NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
via NN NN O
descending NN NN O
projections NN NN O
, NN NN O
the NN NN O
midline NN NN O
serotonin NN NN O
B3 NN NN O
cells NN NN O
in NN NN O
the NN NN O
medulla NN NN O
contribute NN NN O
to NN NN O
the NN NN O
hypotensive NN NN B-Disease
action NN NN O
of NN NN O
methyldopa NN NN O
, NN NN O
either NN NN O
by NN NN O
way NN NN O
of NN NN O
an NN NN O
ascending NN NN O
projection NN NN O
which NN NN O
does NN NN O
not NN NN O
pass NN NN O
through NN NN O
the NN NN O
median NN NN O
forebrain NN NN O
bundle NN NN O
, NN NN O
or NN NN O
through NN NN O
a NN NN O
projection NN NN O
restricted NN NN O
to NN NN O
the NN NN O
caudal NN NN O
brainstem NN NN O
. NN NN O
   
Antiarrhythmic NN NN O
plasma NN NN O
concentrations NN NN O
of NN NN O
cibenzoline NN NN O
on NN NN O
canine NN NN O
ventricular NN NN B-Disease
arrhythmias NN NN I-Disease
. NN NN O
   
Using NN NN O
two NN NN O
- NN NN O
stage NN NN O
coronary NN NN O
ligation NN NN O
- NN NN O
, NN NN O
digitalis NN NN O
- NN NN O
, NN NN O
and NN NN O
adrenaline NN NN O
- NN NN O
induced NN NN O
canine NN NN O
ventricular NN NN B-Disease
arrhythmias NN NN I-Disease
, NN NN O
antiarrhythmic NN NN O
effects NN NN O
of NN NN O
cibenzoline NN NN O
were NN NN O
examined NN NN O
and NN NN O
the NN NN O
minimum NN NN O
effective NN NN O
plasma NN NN O
concentration NN NN O
for NN NN O
each NN NN O
arrhythmia NN NN B-Disease
model NN NN O
was NN NN O
determined NN NN O
. NN NN O
   
Cibenzoline NN NN O
suppressed NN NN O
all NN NN O
the NN NN O
arrhythmias NN NN B-Disease
, NN NN O
and NN NN O
the NN NN O
minimum NN NN O
effective NN NN O
plasma NN NN O
concentrations NN NN O
for NN NN O
arrhythmias NN NN B-Disease
induced NN NN O
by NN NN O
24 NN NN O
- NN NN O
h NN NN O
coronary NN NN O
ligation NN NN O
, NN NN O
48 NN NN O
- NN NN O
h NN NN O
coronary NN NN O
ligation NN NN O
, NN NN O
digitalis NN NN O
, NN NN O
and NN NN O
adrenaline NN NN O
were NN NN O
1 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
9 NN NN O
( NN NN O
by NN NN O
8 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
, NN NN O
1 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
5 NN NN O
( NN NN O
by NN NN O
8 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
, NN NN O
0 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
2 NN NN O
( NN NN O
by NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
, NN NN O
and NN NN O
3 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
3 NN NN O
( NN NN O
by NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
micrograms NN NN O
/ NN NN O
ml NN NN O
, NN NN O
respectively NN NN O
( NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SDM NN NN O
, NN NN O
n NN NN O
= NN NN O
6 NN NN O
- NN NN O
7 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
concentration NN NN O
for NN NN O
adrenaline NN NN O
- NN NN O
induced NN NN O
arrhythmia NN NN B-Disease
was NN NN O
significantly NN NN O
higher NN NN O
than NN NN O
those NN NN O
for NN NN O
the NN NN O
other NN NN O
types NN NN O
of NN NN O
arrhythmias NN NN B-Disease
. NN NN O
   
This NN NN O
pharmacological NN NN O
profile NN NN O
is NN NN O
similar NN NN O
to NN NN O
those NN NN O
of NN NN O
mexiletine NN NN O
and NN NN O
tocainide NN NN O
, NN NN O
and NN NN O
all NN NN O
three NN NN O
drugs NN NN O
have NN NN O
central NN NN O
nervous NN NN O
system NN NN O
( NN NN O
CNS NN NN O
) NN NN O
stimulant NN NN O
action NN NN O
. NN NN O
   
Because NN NN O
cibenzoline NN NN O
had NN NN O
only NN NN O
weak NN NN O
hypotensive NN NN B-Disease
and NN NN O
sinus NN NN O
node NN NN O
depressive NN NN B-Disease
effects NN NN O
and NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
orally NN NN O
active NN NN O
when NN NN O
given NN NN O
to NN NN O
coronary NN NN O
ligation NN NN O
arrhythmia NN NN B-Disease
dogs NN NN O
, NN NN O
its NN NN O
clinical NN NN O
usefulness NN NN O
is NN NN O
expected NN NN O
. NN NN O
   
Continuous NN NN O
ambulatory NN NN O
ECG NN NN O
monitoring NN NN O
during NN NN O
fluorouracil NN NN O
therapy NN NN O
: NN NN O
a NN NN O
prospective NN NN O
study NN NN O
. NN NN O
   
Although NN NN O
there NN NN O
have NN NN O
been NN NN O
anecdotal NN NN O
reports NN NN O
of NN NN O
cardiac NN NN B-Disease
toxicity NN NN I-Disease
associated NN NN O
with NN NN O
fluorouracil NN NN O
( NN NN O
5 NN NN O
- NN NN O
FU NN NN O
) NN NN O
therapy NN NN O
, NN NN O
this NN NN O
phenomenon NN NN O
has NN NN O
not NN NN O
been NN NN O
studied NN NN O
in NN NN O
a NN NN O
systematic NN NN O
fashion NN NN O
. NN NN O
   
We NN NN O
prospectively NN NN O
performed NN NN O
continuous NN NN O
ambulatory NN NN O
ECG NN NN O
monitoring NN NN O
on NN NN O
25 NN NN O
patients NN NN O
undergoing NN NN O
5 NN NN O
- NN NN O
FU NN NN O
infusion NN NN O
for NN NN O
treatment NN NN O
of NN NN O
solid NN NN O
tumors NN NN B-Disease
in NN NN O
order NN NN O
to NN NN O
assess NN NN O
the NN NN O
incidence NN NN O
of NN NN O
ischemic NN NN B-Disease
ST NN NN O
changes NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
monitored NN NN O
for NN NN O
23 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
hours NN NN O
before NN NN O
5 NN NN O
- NN NN O
FU NN NN O
infusion NN NN O
, NN NN O
and NN NN O
98 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
9 NN NN O
hours NN NN O
during NN NN O
5 NN NN O
- NN NN O
FU NN NN O
infusion NN NN O
. NN NN O
   
Anginal NN NN B-Disease
episodes NN NN O
were NN NN O
rare NN NN O
: NN NN O
only NN NN O
one NN NN O
patient NN NN O
had NN NN O
angina NN NN B-Disease
( NN NN O
during NN NN O
5 NN NN O
- NN NN O
FU NN NN O
infusion NN NN O
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
asymptomatic NN NN O
ST NN NN O
changes NN NN O
( NN NN O
greater NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
1 NN NN O
mm NN NN O
ST NN NN O
deviation NN NN O
) NN NN O
were NN NN O
common NN NN O
: NN NN O
six NN NN O
of NN NN O
25 NN NN O
patients NN NN O
( NN NN O
24 NN NN O
% NN NN O
) NN NN O
had NN NN O
ST NN NN O
changes NN NN O
before NN NN O
5 NN NN O
- NN NN O
FU NN NN O
infusion NN NN O
v NN NN O
17 NN NN O
( NN NN O
68 NN NN O
% NN NN O
) NN NN O
during NN NN O
5 NN NN O
- NN NN O
FU NN NN O
infusion NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
. NN NN O
002 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
ischemic NN NN B-Disease
episodes NN NN O
per NN NN O
patient NN NN O
per NN NN O
hour NN NN O
was NN NN O
0 NN NN O
. NN NN O
05 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
02 NN NN O
prior NN NN O
to NN NN O
5 NN NN O
- NN NN O
FU NN NN O
infusion NN NN O
v NN NN O
0 NN NN O
. NN NN O
13 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
03 NN NN O
during NN NN O
5 NN NN O
- NN NN O
FU NN NN O
infusion NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
. NN NN O
001 NN NN O
) NN NN O
; NN NN O
the NN NN O
duration NN NN O
of NN NN O
ECG NN NN O
changes NN NN O
was NN NN O
0 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
3 NN NN O
minutes NN NN O
per NN NN O
patient NN NN O
per NN NN O
hour NN NN O
before NN NN O
5 NN NN O
- NN NN O
FU NN NN O
v NN NN O
1 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
5 NN NN O
minutes NN NN O
per NN NN O
patient NN NN O
per NN NN O
hour NN NN O
during NN NN O
5 NN NN O
- NN NN O
FU NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
ECG NN NN O
changes NN NN O
were NN NN O
more NN NN O
common NN NN O
among NN NN O
patients NN NN O
with NN NN O
known NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
There NN NN O
were NN NN O
two NN NN O
cases NN NN O
of NN NN O
sudden NN NN B-Disease
death NN NN I-Disease
, NN NN O
both NN NN O
of NN NN O
which NN NN O
occurred NN NN O
at NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
chemotherapy NN NN O
course NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
5 NN NN O
- NN NN O
FU NN NN O
infusion NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
significant NN NN O
increase NN NN O
in NN NN O
silent NN NN O
ST NN NN O
segment NN NN O
deviation NN NN O
suggestive NN NN O
of NN NN O
ischemia NN NN B-Disease
, NN NN O
particularly NN NN O
among NN NN O
patients NN NN O
with NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
The NN NN O
mechanism NN NN O
and NN NN O
clinical NN NN O
significance NN NN O
of NN NN O
these NN NN O
ECG NN NN O
changes NN NN O
remain NN NN O
to NN NN O
be NN NN O
determined NN NN O
. NN NN O
   
Nature NN NN O
, NN NN O
time NN NN O
course NN NN O
and NN NN O
dose NN NN O
dependence NN NN O
of NN NN O
zidovudine NN NN O
- NN NN O
related NN NN O
side NN NN O
effects NN NN O
: NN NN O
results NN NN O
from NN NN O
the NN NN O
Multicenter NN NN O
Canadian NN NN O
Azidothymidine NN NN O
Trial NN NN O
. NN NN O
   
To NN NN O
characterize NN NN O
the NN NN O
nature NN NN O
, NN NN O
time NN NN O
course NN NN O
and NN NN O
dose NN NN O
dependency NN NN O
of NN NN O
zidovudine NN NN O
- NN NN O
related NN NN O
side NN NN O
effects NN NN O
, NN NN O
we NN NN O
undertook NN NN O
a NN NN O
multicenter NN NN O
, NN NN O
prospective NN NN O
, NN NN O
dose NN NN O
- NN NN O
range NN NN O
finding NN NN O
study NN NN O
. NN NN O
   
Our NN NN O
study NN NN O
group NN NN O
consisted NN NN O
of NN NN O
74 NN NN O
HIV NN NN O
- NN NN O
positive NN NN O
homosexual NN NN O
men NN NN O
belonging NN NN O
to NN NN O
groups NN NN O
II NN NN O
B NN NN O
, NN NN O
III NN NN O
and NN NN O
IV NN NN O
C2 NN NN O
from NN NN O
the NN NN O
Centers NN NN O
for NN NN O
Disease NN NN O
Control NN NN O
( NN NN O
CDC NN NN O
) NN NN O
classification NN NN O
of NN NN O
HIV NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
Following NN NN O
a NN NN O
3 NN NN O
- NN NN O
week NN NN O
observation NN NN O
period NN NN O
, NN NN O
volunteers NN NN O
were NN NN O
treated NN NN O
with NN NN O
zidovudine NN NN O
600 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
for NN NN O
18 NN NN O
weeks NN NN O
, NN NN O
900 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
for NN NN O
9 NN NN O
weeks NN NN O
and NN NN O
1200 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
for NN NN O
9 NN NN O
weeks NN NN O
, NN NN O
followed NN NN O
by NN NN O
a NN NN O
washout NN NN O
period NN NN O
of NN NN O
6 NN NN O
weeks NN NN O
after NN NN O
which NN NN O
they NN NN O
were NN NN O
re NN NN O
- NN NN O
started NN NN O
on NN NN O
1200 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
or NN NN O
the NN NN O
highest NN NN O
tolerated NN NN O
dose NN NN O
at NN NN O
8 NN NN O
- NN NN O
hourly NN NN O
intervals NN NN O
. NN NN O
   
Subjects NN NN O
were NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
4 NN NN O
- NN NN O
hourly NN NN O
or NN NN O
8 NN NN O
- NN NN O
hourly NN NN O
regimens NN NN O
within NN NN O
CDC NN NN O
groups NN NN O
while NN NN O
taking NN NN O
600 NN NN O
and NN NN O
1200 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
. NN NN O
   
Clinical NN NN O
and NN NN O
laboratory NN NN O
evaluations NN NN O
were NN NN O
performed NN NN O
at NN NN O
3 NN NN O
- NN NN O
week NN NN O
intervals NN NN O
. NN NN O
   
Symptomatic NN NN O
adverse NN NN O
effects NN NN O
were NN NN O
present NN NN O
in NN NN O
96 NN NN O
% NN NN O
of NN NN O
subjects NN NN O
, NN NN O
most NN NN O
commonly NN NN O
nausea NN NN B-Disease
( NN NN O
64 NN NN O
% NN NN O
) NN NN O
, NN NN O
fatigue NN NN B-Disease
( NN NN O
55 NN NN O
% NN NN O
) NN NN O
and NN NN O
headache NN NN B-Disease
( NN NN O
49 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
These NN NN O
were NN NN O
generally NN NN O
self NN NN O
- NN NN O
limited NN NN O
, NN NN O
reappearing NN NN O
briefly NN NN O
at NN NN O
each NN NN O
dose NN NN O
increment NN NN O
. NN NN O
   
A NN NN O
decrease NN NN O
in NN NN O
hemoglobin NN NN O
occurred NN NN O
shortly NN NN O
after NN NN O
initiation NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
This NN NN O
was NN NN O
not NN NN O
dose NN NN O
dependent NN NN O
and NN NN O
reversed NN NN O
rapidly NN NN O
upon NN NN O
discontinuation NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
A NN NN O
red NN NN O
blood NN NN O
cell NN NN O
count NN NN O
decrease NN NN O
, NN NN O
a NN NN O
mean NN NN O
cell NN NN O
volume NN NN O
increase NN NN O
and NN NN O
a NN NN O
granulocyte NN NN O
count NN NN O
decrease NN NN O
developed NN NN O
early NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
independent NN NN O
fashion NN NN O
, NN NN O
reverting NN NN O
at NN NN O
least NN NN O
partially NN NN O
during NN NN O
the NN NN O
washout NN NN O
phase NN NN O
. NN NN O
   
The NN NN O
decrease NN NN O
in NN NN O
reticulocyte NN NN O
count NN NN O
was NN NN O
dose NN NN O
related NN NN O
between NN NN O
600 NN NN O
and NN NN O
900 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
with NN NN O
no NN NN O
further NN NN O
change NN NN O
when NN NN O
the NN NN O
dose NN NN O
was NN NN O
escalated NN NN O
to NN NN O
1200 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
. NN NN O
   
Bone NN NN O
marrow NN NN O
changes NN NN O
occurred NN NN O
rapidly NN NN O
as NN NN O
demonstrated NN NN O
by NN NN O
megaloblastosis NN NN B-Disease
in NN NN O
95 NN NN O
% NN NN O
of NN NN O
65 NN NN O
specimens NN NN O
at NN NN O
week NN NN O
18 NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
National NN NN O
project NN NN O
on NN NN O
the NN NN O
prevention NN NN O
of NN NN O
mother NN NN O
- NN NN O
to NN NN O
- NN NN O
infant NN NN O
infection NN NN B-Disease
by NN NN I-Disease
hepatitis NN NN I-Disease
B NN NN I-Disease
virus NN NN I-Disease
in NN NN O
Japan NN NN O
. NN NN O
   
In NN NN O
Japan NN NN O
, NN NN O
a NN NN O
nationwide NN NN O
prevention NN NN O
program NN NN O
against NN NN O
mother NN NN O
- NN NN O
to NN NN O
- NN NN O
infant NN NN O
infection NN NN B-Disease
by NN NN I-Disease
hepatitis NN NN I-Disease
B NN NN I-Disease
virus NN NN I-Disease
( NN NN O
HBV NN NN O
) NN NN O
started NN NN O
in NN NN O
1985 NN NN O
. NN NN O
   
This NN NN O
program NN NN O
consists NN NN O
of NN NN O
double NN NN O
screenings NN NN O
of NN NN O
pregnant NN NN O
women NN NN O
and NN NN O
prophylactic NN NN O
treatment NN NN O
to NN NN O
the NN NN O
infants NN NN O
born NN NN O
to NN NN O
both NN NN O
hepatitis NN NN O
B NN NN O
surface NN NN O
antigen NN NN O
( NN NN O
HBsAg NN NN O
) NN NN O
and NN NN O
hepatitis NN NN O
B NN NN O
e NN NN O
antigen NN NN O
( NN NN O
HBeAg NN NN O
) NN NN O
positive NN NN O
mothers NN NN O
. NN NN O
   
These NN NN O
infants NN NN O
are NN NN O
treated NN NN O
with NN NN O
two NN NN O
injections NN NN O
of NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
immune NN NN O
globulin NN NN O
( NN NN O
HBIG NN NN O
) NN NN O
and NN NN O
at NN NN O
least NN NN O
three NN NN O
injections NN NN O
of NN NN O
plasma NN NN O
derived NN NN O
hepatitis NN NN O
B NN NN O
vaccine NN NN O
. NN NN O
   
We NN NN O
sent NN NN O
questionnaires NN NN O
about NN NN O
the NN NN O
numbers NN NN O
of NN NN O
each NN NN O
procedure NN NN O
or NN NN O
examination NN NN O
during NN NN O
nine NN NN O
months NN NN O
of NN NN O
investigation NN NN O
period NN NN O
to NN NN O
each NN NN O
local NN NN O
government NN NN O
in NN NN O
1986 NN NN O
and NN NN O
1987 NN NN O
. NN NN O
   
93 NN NN O
. NN NN O
4 NN NN O
% NN NN O
pregnant NN NN O
women NN NN O
had NN NN O
the NN NN O
chance NN NN O
to NN NN O
be NN NN O
examined NN NN O
for NN NN O
HBsAg NN NN O
, NN NN O
and NN NN O
the NN NN O
positive NN NN O
rate NN NN O
was NN NN O
1 NN NN O
. NN NN O
4 NN NN O
to NN NN O
1 NN NN O
. NN NN O
5 NN NN O
% NN NN O
. NN NN O
   
The NN NN O
HBeAg NN NN O
positive NN NN O
rate NN NN O
in NN NN O
HBsAg NN NN O
positive NN NN O
was NN NN O
23 NN NN O
to NN NN O
26 NN NN O
% NN NN O
. NN NN O
   
The NN NN O
HBsAg NN NN O
positive NN NN O
rate NN NN O
in NN NN O
neonates NN NN O
and NN NN O
in NN NN O
infants NN NN O
before NN NN O
two NN NN O
months NN NN O
were NN NN O
3 NN NN O
% NN NN O
and NN NN O
2 NN NN O
% NN NN O
respectively NN NN O
. NN NN O
   
Some NN NN O
problems NN NN O
may NN NN O
arise NN NN O
, NN NN O
because NN NN O
27 NN NN O
to NN NN O
30 NN NN O
% NN NN O
of NN NN O
infants NN NN O
need NN NN O
the NN NN O
fourth NN NN O
vaccination NN NN O
in NN NN O
some NN NN O
restricted NN NN O
areas NN NN O
. NN NN O
   
Involvement NN NN O
of NN NN O
the NN NN O
mu NN NN O
- NN NN O
opiate NN NN O
receptor NN NN O
in NN NN O
peripheral NN NN O
analgesia NN NN B-Disease
. NN NN O
   
The NN NN O
intradermal NN NN O
injection NN NN O
of NN NN O
mu NN NN O
( NN NN O
morphine NN NN O
, NN NN O
Tyr NN NN O
- NN NN O
D NN NN O
- NN NN O
Ala NN NN O
- NN NN O
Gly NN NN O
- NN NN O
NMe NN NN O
- NN NN O
Phe NN NN O
- NN NN O
Gly NN NN O
- NN NN O
ol NN NN O
and NN NN O
morphiceptin NN NN O
) NN NN O
, NN NN O
kappa NN NN O
( NN NN O
trans NN NN O
- NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
dichloro NN NN O
- NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
N NN NN O
[ NN NN O
2 NN NN O
- NN NN O
( NN NN O
1 NN NN O
- NN NN O
pyrrolidinyl NN NN O
) NN NN O
cyclohexyl NN NN O
] NN NN O
benzeneactemide NN NN O
) NN NN O
and NN NN O
delta NN NN O
( NN NN O
[ NN NN O
D NN NN O
- NN NN O
Pen2 NN NN O
. NN NN O
5 NN NN O
] NN NN O
- NN NN O
enkephalin NN NN O
and NN NN O
[ NN NN O
D NN NN O
- NN NN O
Ser2 NN NN O
] NN NN O
- NN NN O
[ NN NN O
Leu NN NN O
] NN NN O
enkephalin NN NN O
- NN NN O
Thr NN NN O
) NN NN O
selective NN NN O
opioid NN NN O
- NN NN O
agonists NN NN O
, NN NN O
by NN NN O
themselves NN NN O
, NN NN O
did NN NN O
not NN NN O
significantly NN NN O
affect NN NN O
the NN NN O
mechanical NN NN O
nociceptive NN NN O
threshold NN NN O
in NN NN O
the NN NN O
hindpaw NN NN O
of NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Intradermal NN NN O
injection NN NN O
of NN NN O
mu NN NN O
, NN NN O
but NN NN O
not NN NN O
delta NN NN O
or NN NN O
kappa NN NN O
opioid NN NN O
- NN NN O
agonists NN NN O
, NN NN O
however NN NN O
, NN NN O
produced NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
inhibition NN NN O
of NN NN O
prostaglandin NN NN O
E2 NN NN O
- NN NN O
induced NN NN O
hyperalgesia NN NN B-Disease
. NN NN O
   
The NN NN O
analgesic NN NN O
effect NN NN O
of NN NN O
the NN NN O
mu NN NN O
- NN NN O
agonist NN NN O
morphine NN NN O
was NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
antagonized NN NN O
by NN NN O
naloxone NN NN O
and NN NN O
prevented NN NN O
by NN NN O
co NN NN O
- NN NN O
injection NN NN O
of NN NN O
pertussis NN NN O
toxin NN NN O
. NN NN O
   
Morphine NN NN O
did NN NN O
not NN NN O
, NN NN O
however NN NN O
, NN NN O
alter NN NN O
the NN NN O
hyperalgesia NN NN B-Disease
induced NN NN O
by NN NN O
8 NN NN O
- NN NN O
bromo NN NN O
cyclic NN NN O
adenosine NN NN O
monophosphate NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
analgesic NN NN O
action NN NN O
of NN NN O
opioids NN NN O
on NN NN O
the NN NN O
peripheral NN NN O
terminals NN NN O
of NN NN O
primary NN NN O
afferents NN NN O
is NN NN O
via NN NN O
a NN NN O
binding NN NN O
site NN NN O
with NN NN O
characteristics NN NN O
of NN NN O
the NN NN O
mu NN NN O
- NN NN O
opioid NN NN O
receptor NN NN O
and NN NN O
that NN NN O
this NN NN O
action NN NN O
is NN NN O
mediated NN NN O
by NN NN O
inhibition NN NN O
of NN NN O
the NN NN O
cyclic NN NN O
adenosine NN NN O
monophosphate NN NN O
second NN NN O
messenger NN NN O
system NN NN O
. NN NN O
   
Involvement NN NN O
of NN NN O
locus NN NN O
coeruleus NN NN O
and NN NN O
noradrenergic NN NN O
neurotransmission NN NN O
in NN NN O
fentanyl NN NN O
- NN NN O
induced NN NN O
muscular NN NN B-Disease
rigidity NN NN I-Disease
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Whereas NN NN O
muscular NN NN B-Disease
rigidity NN NN I-Disease
is NN NN O
a NN NN O
well NN NN O
- NN NN O
known NN NN O
side NN NN O
effect NN NN O
that NN NN O
is NN NN O
associated NN NN O
with NN NN O
high NN NN O
- NN NN O
dose NN NN O
fentanyl NN NN O
anesthesia NN NN O
, NN NN O
a NN NN O
paucity NN NN O
of NN NN O
information NN NN O
exists NN NN O
with NN NN O
regard NN NN O
to NN NN O
its NN NN O
underlying NN NN O
mechanism NN NN O
( NN NN O
s NN NN O
) NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
in NN NN O
this NN NN O
study NN NN O
the NN NN O
possible NN NN O
engagement NN NN O
of NN NN O
locus NN NN O
coeruleus NN NN O
of NN NN O
the NN NN O
pons NN NN O
in NN NN O
this NN NN O
phenomenon NN NN O
, NN NN O
using NN NN O
male NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
anesthetized NN NN O
with NN NN O
ketamine NN NN O
. NN NN O
   
Under NN NN O
proper NN NN O
control NN NN O
of NN NN O
respiration NN NN O
, NN NN O
body NN NN O
temperature NN NN O
and NN NN O
end NN NN O
- NN NN O
tidal NN NN O
CO2 NN NN O
, NN NN O
intravenous NN NN O
administration NN NN O
of NN NN O
fentanyl NN NN O
( NN NN O
50 NN NN O
or NN NN O
100 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
) NN NN O
consistently NN NN O
promoted NN NN O
an NN NN O
increase NN NN O
in NN NN O
electromyographic NN NN O
activity NN NN O
recorded NN NN O
from NN NN O
the NN NN O
gastrocnemius NN NN O
and NN NN O
abdominal NN NN O
rectus NN NN O
muscles NN NN O
. NN NN O
   
Such NN NN O
an NN NN O
induced NN NN O
muscular NN NN B-Disease
rigidity NN NN I-Disease
by NN NN O
the NN NN O
narcotic NN NN O
agent NN NN O
was NN NN O
significantly NN NN O
antagonized NN NN O
or NN NN O
even NN NN O
reduced NN NN O
by NN NN O
prior NN NN O
electrolytic NN NN O
lesions NN NN O
of NN NN O
the NN NN O
locus NN NN O
coeruleus NN NN O
or NN NN O
pretreatment NN NN O
with NN NN O
the NN NN O
alpha NN NN O
- NN NN O
adrenoceptor NN NN O
blocker NN NN O
, NN NN O
prazosin NN NN O
. NN NN O
   
Microinjection NN NN O
of NN NN O
fentanyl NN NN O
( NN NN O
2 NN NN O
. NN NN O
5 NN NN O
micrograms NN NN O
/ NN NN O
50 NN NN O
nl NN NN O
) NN NN O
directly NN NN O
into NN NN O
this NN NN O
pontine NN NN O
nucleus NN NN O
, NN NN O
on NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
elicited NN NN O
discernible NN NN O
electromyographic NN NN O
excitation NN NN O
. NN NN O
   
It NN NN O
is NN NN O
speculated NN NN O
that NN NN O
the NN NN O
induction NN NN O
of NN NN O
muscular NN NN B-Disease
rigidity NN NN I-Disease
by NN NN O
fentanyl NN NN O
may NN NN O
involve NN NN O
the NN NN O
coerulospinal NN NN O
noradrenergic NN NN O
fibers NN NN O
to NN NN O
the NN NN O
spinal NN NN O
motoneurons NN NN O
. NN NN O
   
Dexmedetomidine NN NN O
, NN NN O
acting NN NN O
through NN NN O
central NN NN O
alpha NN NN O
- NN NN O
2 NN NN O
adrenoceptors NN NN O
, NN NN O
prevents NN NN O
opiate NN NN O
- NN NN O
induced NN NN O
muscle NN NN B-Disease
rigidity NN NN I-Disease
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
The NN NN O
highly NN NN O
- NN NN O
selective NN NN O
alpha NN NN O
- NN NN O
2 NN NN O
adrenergic NN NN O
agonist NN NN O
dexmedetomidine NN NN O
( NN NN O
D NN NN O
- NN NN O
MED NN NN O
) NN NN O
is NN NN O
capable NN NN O
of NN NN O
inducing NN NN O
muscle NN NN B-Disease
flaccidity NN NN I-Disease
and NN NN O
anesthesia NN NN O
in NN NN O
rats NN NN O
and NN NN O
dogs NN NN O
. NN NN O
   
Intense NN NN O
generalized NN NN O
muscle NN NN B-Disease
rigidity NN NN I-Disease
is NN NN O
an NN NN O
undesirable NN NN O
side NN NN O
effect NN NN O
of NN NN O
potent NN NN O
opiate NN NN O
agonists NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
neurochemistry NN NN O
of NN NN O
opiate NN NN O
- NN NN O
induced NN NN O
rigidity NN NN B-Disease
has NN NN O
yet NN NN O
to NN NN O
be NN NN O
fully NN NN O
elucidated NN NN O
, NN NN O
recent NN NN O
work NN NN O
suggests NN NN O
a NN NN O
role NN NN O
for NN NN O
a NN NN O
central NN NN O
adrenergic NN NN O
mechanism NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
the NN NN O
authors NN NN O
determined NN NN O
if NN NN O
treatment NN NN O
with NN NN O
D NN NN O
- NN NN O
MED NN NN O
prevents NN NN O
the NN NN O
muscle NN NN B-Disease
rigidity NN NN I-Disease
caused NN NN O
by NN NN O
high NN NN O
- NN NN O
dose NN NN O
alfentanil NN NN O
anesthesia NN NN O
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Animals NN NN O
( NN NN O
n NN NN O
= NN NN O
42 NN NN O
) NN NN O
were NN NN O
treated NN NN O
intraperitoneally NN NN O
with NN NN O
one NN NN O
of NN NN O
the NN NN O
following NN NN O
six NN NN O
regimens NN NN O
: NN NN O
1 NN NN O
) NN NN O
L NN NN O
- NN NN O
MED NN NN O
( NN NN O
the NN NN O
inactive NN NN O
L NN NN O
- NN NN O
isomer NN NN O
of NN NN O
medetomidine NN NN O
) NN NN O
, NN NN O
30 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
; NN NN O
2 NN NN O
) NN NN O
D NN NN O
- NN NN O
MED NN NN O
, NN NN O
10 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
; NN NN O
3 NN NN O
) NN NN O
D NN NN O
- NN NN O
MED NN NN O
, NN NN O
30 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
; NN NN O
4 NN NN O
) NN NN O
D NN NN O
- NN NN O
MED NN NN O
[ NN NN O
30 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
] NN NN O
and NN NN O
the NN NN O
central NN NN O
- NN NN O
acting NN NN O
alpha NN NN O
- NN NN O
2 NN NN O
antagonist NN NN O
, NN NN O
idazoxan NN NN O
[ NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
] NN NN O
; NN NN O
5 NN NN O
) NN NN O
D NN NN O
- NN NN O
MED NN NN O
[ NN NN O
30 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
] NN NN O
and NN NN O
the NN NN O
peripheral NN NN O
- NN NN O
acting NN NN O
alpha NN NN O
- NN NN O
2 NN NN O
antagonist NN NN O
DG NN NN O
- NN NN O
5128 NN NN O
[ NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
] NN NN O
, NN NN O
or NN NN O
; NN NN O
6 NN NN O
) NN NN O
saline NN NN O
. NN NN O
   
Baseline NN NN O
electromyographic NN NN O
activity NN NN O
was NN NN O
recorded NN NN O
from NN NN O
the NN NN O
gastrocnemius NN NN O
muscle NN NN O
before NN NN O
and NN NN O
after NN NN O
drug NN NN O
treatment NN NN O
. NN NN O
   
Each NN NN O
rat NN NN O
was NN NN O
then NN NN O
injected NN NN O
with NN NN O
alfentanil NN NN O
( NN NN O
ALF NN NN O
, NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
sc NN NN O
) NN NN O
. NN NN O
   
ALF NN NN O
injection NN NN O
resulted NN NN O
in NN NN O
a NN NN O
marked NN NN O
increase NN NN O
in NN NN O
hindlimb NN NN O
EMG NN NN O
activity NN NN O
in NN NN O
the NN NN O
L NN NN O
- NN NN O
MED NN NN O
treatment NN NN O
group NN NN O
which NN NN O
was NN NN O
indistinguishable NN NN O
from NN NN O
that NN NN O
seen NN NN O
in NN NN O
animals NN NN O
treated NN NN O
with NN NN O
saline NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
D NN NN O
- NN NN O
MED NN NN O
prevented NN NN O
alfentanil NN NN O
- NN NN O
induced NN NN O
muscle NN NN B-Disease
rigidity NN NN I-Disease
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
fashion NN NN O
. NN NN O
   
The NN NN O
small NN NN O
EMG NN NN O
values NN NN O
obtained NN NN O
in NN NN O
the NN NN O
high NN NN O
- NN NN O
dose NN NN O
D NN NN O
- NN NN O
MED NN NN O
group NN NN O
were NN NN O
comparable NN NN O
with NN NN O
those NN NN O
recorded NN NN O
in NN NN O
earlier NN NN O
studies NN NN O
from NN NN O
control NN NN O
animals NN NN O
not NN NN O
given NN NN O
any NN NN O
opiate NN NN O
. NN NN O
   
The NN NN O
high NN NN O
- NN NN O
dose NN NN O
D NN NN O
- NN NN O
MED NN NN O
animals NN NN O
were NN NN O
flaccid NN NN O
, NN NN O
akinetic NN NN B-Disease
, NN NN O
and NN NN O
lacked NN NN O
a NN NN O
startle NN NN B-Disease
response NN NN O
during NN NN O
the NN NN O
entire NN NN O
experimental NN NN O
period NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Some NN NN O
central NN NN O
effects NN NN O
of NN NN O
repeated NN NN O
treatment NN NN O
with NN NN O
fluvoxamine NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
effect NN NN O
of NN NN O
repeated NN NN O
treatment NN NN O
with NN NN O
fluvoxamine NN NN O
, NN NN O
a NN NN O
selective NN NN O
serotonin NN NN O
uptake NN NN O
inhibitor NN NN O
, NN NN O
on NN NN O
behavioral NN NN O
effects NN NN O
of NN NN O
dopaminomimetics NN NN O
and NN NN O
methoxamine NN NN O
and NN NN O
on NN NN O
the NN NN O
animal NN NN O
behavior NN NN O
in NN NN O
the NN NN O
"""""""" NN NN O
behavioral NN NN O
despair NN NN O
"""""""" NN NN O
test NN NN O
. NN NN O
   
A NN NN O
repeated NN NN O
treatment NN NN O
with NN NN O
fluvoxamine NN NN O
( NN NN O
twice NN NN O
daily NN NN O
for NN NN O
14 NN NN O
days NN NN O
) NN NN O
potentiated NN NN O
in NN NN O
mice NN NN O
and NN NN O
in NN NN O
rats NN NN O
( NN NN O
weaker NN NN O
) NN NN O
the NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
. NN NN O
   
The NN NN O
hyperactivity NN NN B-Disease
induced NN NN O
by NN NN O
nomifensine NN NN O
in NN NN O
mice NN NN O
remained NN NN O
unaffected NN NN O
by NN NN O
fluvoxamine NN NN O
. NN NN O
   
The NN NN O
stimulation NN NN O
of NN NN O
locomotor NN NN O
activity NN NN O
by NN NN O
intracerebroventricularly NN NN O
administered NN NN O
methoxamine NN NN O
was NN NN O
not NN NN O
affected NN NN O
by NN NN O
repeated NN NN O
treatment NN NN O
with NN NN O
fluvoxamine NN NN O
. NN NN O
   
Given NN NN O
three NN NN O
times NN NN O
fluvoxamine NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
the NN NN O
immobilization NN NN O
time NN NN O
in NN NN O
the NN NN O
"""""""" NN NN O
behavioral NN NN O
despair NN NN O
"""""""" NN NN O
test NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
fluvoxamine NN NN O
given NN NN O
repeatedly NN NN O
acts NN NN O
differently NN NN O
than NN NN O
citalopram NN NN O
, NN NN O
another NN NN O
selective NN NN O
serotonin NN NN O
uptake NN NN O
inhibitor NN NN O
, NN NN O
and NN NN O
differs NN NN O
also NN NN O
from NN NN O
other NN NN O
antidepressant NN NN O
drugs NN NN O
. NN NN O
   
Protective NN NN O
effect NN NN O
of NN NN O
a NN NN O
specific NN NN O
platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
antagonist NN NN O
, NN NN O
BN NN NN O
52021 NN NN O
, NN NN O
on NN NN O
bupivacaine NN NN O
- NN NN O
induced NN NN O
cardiovascular NN NN B-Disease
impairments NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
the NN NN O
local NN NN O
anaesthetic NN NN O
bupivacaine NN NN O
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
or NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
to NN NN O
rats NN NN O
elicited NN NN O
a NN NN O
marked NN NN O
decrease NN NN B-Disease
of NN NN I-Disease
mean NN NN I-Disease
arterial NN NN I-Disease
blood NN NN I-Disease
pressure NN NN I-Disease
( NN NN I-Disease
MBP NN NN I-Disease
) NN NN I-Disease
and NN NN I-Disease
heart NN NN I-Disease
rate NN NN I-Disease
( NN NN I-Disease
HR NN NN I-Disease
) NN NN I-Disease
leading NN NN O
to NN NN O
death NN NN O
( NN NN O
in NN NN O
67 NN NN O
% NN NN O
or NN NN O
90 NN NN O
% NN NN O
of NN NN O
animals NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
Intravenous NN NN O
injection NN NN O
of NN NN O
the NN NN O
specific NN NN O
platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
( NN NN O
PAF NN NN O
) NN NN O
antagonist NN NN O
BN NN NN O
52021 NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
30 NN NN O
min NN NN O
before NN NN O
bupivacaine NN NN O
administration NN NN O
( NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
suppressed NN NN O
both NN NN O
the NN NN O
decrease NN NN B-Disease
of NN NN I-Disease
MBP NN NN I-Disease
and NN NN I-Disease
HR NN NN I-Disease
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
doses NN NN O
of NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
BN NN NN O
52021 NN NN O
given NN NN O
30 NN NN O
min NN NN O
before NN NN O
or NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
administered NN NN O
5 NN NN O
min NN NN O
before NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
injection NN NN O
of NN NN O
bupivacaine NN NN O
were NN NN O
ineffective NN NN O
. NN NN O
   
When NN NN O
BN NN NN O
52021 NN NN O
( NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
was NN NN O
injected NN NN O
immediately NN NN O
after NN NN O
bupivacaine NN NN O
( NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
a NN NN O
partial NN NN O
reversion NN NN O
of NN NN O
the NN NN O
decrease NN NN B-Disease
of NN NN I-Disease
MBP NN NN I-Disease
and NN NN I-Disease
HR NN NN I-Disease
was NN NN O
observed NN NN O
, NN NN O
whereas NN NN O
the NN NN O
dose NN NN O
of NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
was NN NN O
ineffective NN NN O
. NN NN O
   
A NN NN O
partial NN NN O
recovery NN NN O
of NN NN O
bupivacaine NN NN O
- NN NN O
induced NN NN O
ECG NN NN O
alterations NN NN O
was NN NN O
observed NN NN O
after NN NN O
pretreatment NN NN O
of NN NN O
the NN NN O
rats NN NN O
with NN NN O
BN NN NN O
52021 NN NN O
. NN NN O
   
Since NN NN O
the NN NN O
administration NN NN O
of NN NN O
BN NN NN O
52021 NN NN O
, NN NN O
at NN NN O
all NN NN O
doses NN NN O
studied NN NN O
, NN NN O
did NN NN O
not NN NN O
alter NN NN O
MBP NN NN O
and NN NN O
HR NN NN O
at NN NN O
the NN NN O
doses NN NN O
used NN NN O
, NN NN O
the NN NN O
bulk NN NN O
of NN NN O
these NN NN O
results NN NN O
clearly NN NN O
demonstrate NN NN O
a NN NN O
protective NN NN O
action NN NN O
of NN NN O
BN NN NN O
52021 NN NN O
, NN NN O
a NN NN O
specific NN NN O
antagonist NN NN O
of NN NN O
PAF NN NN O
, NN NN O
against NN NN O
bupivacaine NN NN O
- NN NN O
induced NN NN O
cardiovascular NN NN B-Disease
toxicity NN NN I-Disease
. NN NN O
   
Thus NN NN O
, NN NN O
consistent NN NN O
with NN NN O
its NN NN O
direct NN NN O
effect NN NN O
on NN NN O
heart NN NN O
, NN NN O
PAF NN NN O
appears NN NN O
to NN NN O
be NN NN O
implicated NN NN O
in NN NN O
bupivacaine NN NN O
- NN NN O
induced NN NN O
cardiovascular NN NN B-Disease
alterations NN NN I-Disease
. NN NN O
   
The NN NN O
epidemiology NN NN O
of NN NN O
the NN NN O
acute NN NN O
flank NN NN B-Disease
pain NN NN I-Disease
syndrome NN NN O
from NN NN O
suprofen NN NN O
. NN NN O
   
Suprofen NN NN O
, NN NN O
a NN NN O
new NN NN O
nonsteroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drug NN NN O
, NN NN O
was NN NN O
marketed NN NN O
in NN NN O
early NN NN O
1986 NN NN O
as NN NN O
an NN NN O
analgesic NN NN O
agent NN NN O
. NN NN O
   
Until NN NN O
physicians NN NN O
began NN NN O
reporting NN NN O
an NN NN O
unusual NN NN O
acute NN NN O
flank NN NN B-Disease
pain NN NN I-Disease
syndrome NN NN O
to NN NN O
the NN NN O
spontaneous NN NN O
reporting NN NN O
system NN NN O
, NN NN O
700 NN NN O
, NN NN O
000 NN NN O
persons NN NN O
used NN NN O
the NN NN O
drug NN NN O
in NN NN O
the NN NN O
United NN NN O
States NN NN O
. NN NN O
   
Through NN NN O
August NN NN O
1986 NN NN O
, NN NN O
a NN NN O
total NN NN O
of NN NN O
163 NN NN O
cases NN NN O
of NN NN O
this NN NN O
syndrome NN NN O
were NN NN O
reported NN NN O
. NN NN O
   
To NN NN O
elucidate NN NN O
the NN NN O
epidemiology NN NN O
of NN NN O
the NN NN O
syndrome NN NN O
, NN NN O
a NN NN O
case NN NN O
- NN NN O
control NN NN O
study NN NN O
was NN NN O
performed NN NN O
, NN NN O
comparing NN NN O
62 NN NN O
of NN NN O
the NN NN O
case NN NN O
patients NN NN O
who NN NN O
had NN NN O
been NN NN O
reported NN NN O
to NN NN O
the NN NN O
spontaneous NN NN O
reporting NN NN O
system NN NN O
to NN NN O
185 NN NN O
suprofen NN NN O
- NN NN O
exposed NN NN O
control NN NN O
subjects NN NN O
who NN NN O
did NN NN O
not NN NN O
have NN NN O
the NN NN O
syndrome NN NN O
. NN NN O
   
Case NN NN O
patients NN NN O
were NN NN O
more NN NN O
likely NN NN O
to NN NN O
be NN NN O
men NN NN O
( NN NN O
odds NN NN O
ratio NN NN O
, NN NN O
3 NN NN O
. NN NN O
8 NN NN O
; NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
1 NN NN O
. NN NN O
2 NN NN O
- NN NN O
12 NN NN O
. NN NN O
1 NN NN O
) NN NN O
, NN NN O
suffer NN NN O
from NN NN O
hay NN NN B-Disease
fever NN NN I-Disease
and NN NN O
asthma NN NN B-Disease
( NN NN O
odds NN NN O
ratio NN NN O
, NN NN O
3 NN NN O
. NN NN O
4 NN NN O
; NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
1 NN NN O
. NN NN O
0 NN NN O
- NN NN O
11 NN NN O
. NN NN O
9 NN NN O
) NN NN O
; NN NN O
to NN NN O
participate NN NN O
in NN NN O
regular NN NN O
exercise NN NN O
( NN NN O
odds NN NN O
ratio NN NN O
, NN NN O
5 NN NN O
. NN NN O
9 NN NN O
; NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
1 NN NN O
. NN NN O
1 NN NN O
- NN NN O
30 NN NN O
. NN NN O
7 NN NN O
) NN NN O
, NN NN O
especially NN NN O
in NN NN O
the NN NN O
use NN NN O
of NN NN O
Nautilus NN NN O
equipment NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
02 NN NN O
) NN NN O
; NN NN O
and NN NN O
to NN NN O
use NN NN O
alcohol NN NN O
( NN NN O
odds NN NN O
ratio NN NN O
, NN NN O
4 NN NN O
. NN NN O
4 NN NN O
; NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
1 NN NN O
. NN NN O
1 NN NN O
- NN NN O
17 NN NN O
. NN NN O
5 NN NN O
) NN NN O
. NN NN O
   
Possible NN NN O
risk NN NN O
factors NN NN O
included NN NN O
young NN NN O
age NN NN O
, NN NN O
concurrent NN NN O
use NN NN O
of NN NN O
other NN NN O
analgesic NN NN O
agents NN NN O
( NN NN O
especially NN NN O
ibuprofen NN NN O
) NN NN O
, NN NN O
preexisting NN NN O
renal NN NN B-Disease
disease NN NN I-Disease
, NN NN O
a NN NN O
history NN NN O
of NN NN O
kidney NN NN B-Disease
stones NN NN I-Disease
, NN NN O
a NN NN O
history NN NN O
of NN NN O
gout NN NN B-Disease
, NN NN O
a NN NN O
recent NN NN O
increase NN NN O
in NN NN O
activity NN NN O
, NN NN O
a NN NN O
recent NN NN O
increase NN NN O
in NN NN O
sun NN NN O
exposure NN NN O
, NN NN O
and NN NN O
residence NN NN O
in NN NN O
the NN NN O
Sunbelt NN NN O
. NN NN O
   
These NN NN O
were NN NN O
findings NN NN O
that NN NN O
were NN NN O
suggestive NN NN O
but NN NN O
did NN NN O
not NN NN O
reach NN NN O
conventional NN NN O
statistical NN NN O
significance NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
are NN NN O
consistent NN NN O
with NN NN O
the NN NN O
postulated NN NN O
mechanism NN NN O
for NN NN O
this NN NN O
unusual NN NN O
syndrome NN NN O
: NN NN O
acute NN NN O
diffuse NN NN O
crystallization NN NN O
of NN NN O
uric NN NN O
acid NN NN O
in NN NN O
renal NN NN O
tubules NN NN O
. NN NN O
   
Phlorizin NN NN O
- NN NN O
induced NN NN O
glycosuria NN NN B-Disease
does NN NN O
not NN NN O
prevent NN NN O
gentamicin NN NN O
nephrotoxicity NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Because NN NN O
rats NN NN O
with NN NN O
streptozotocin NN NN O
- NN NN O
induced NN NN O
diabetes NN NN B-Disease
mellitus NN NN I-Disease
( NN NN O
DM NN NN B-Disease
) NN NN O
have NN NN O
a NN NN O
high NN NN O
solute NN NN O
diuresis NN NN O
( NN NN O
glycosuria NN NN B-Disease
of NN NN O
10 NN NN O
to NN NN O
12 NN NN O
g NN NN O
/ NN NN O
day NN NN O
) NN NN O
, NN NN O
we NN NN O
have NN NN O
suggested NN NN O
that NN NN O
this NN NN O
may NN NN O
in NN NN O
part NN NN O
be NN NN O
responsible NN NN O
for NN NN O
their NN NN O
resistance NN NN O
to NN NN O
gentamicin NN NN O
- NN NN O
induced NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
( NN NN O
ARF NN NN B-Disease
) NN NN O
. NN NN O
   
The NN NN O
protection NN NN O
from NN NN O
gentamicin NN NN O
nephrotoxicity NN NN B-Disease
was NN NN O
studied NN NN O
in NN NN O
non NN NN O
- NN NN O
diabetic NN NN B-Disease
rats NN NN O
with NN NN O
chronic NN NN O
solute NN NN O
diuresis NN NN O
induced NN NN O
by NN NN O
blockage NN NN O
of NN NN O
tubular NN NN O
glucose NN NN O
reabsorption NN NN O
with NN NN O
phlorizin NN NN O
( NN NN O
P NN NN O
) NN NN O
. NN NN O
   
DM NN NN B-Disease
rats NN NN O
with NN NN O
mild NN NN O
glycosuria NN NN B-Disease
( NN NN O
similar NN NN O
in NN NN O
degree NN NN O
to NN NN O
that NN NN O
of NN NN O
the NN NN O
P NN NN O
treated NN NN O
animals NN NN O
) NN NN O
were NN NN O
also NN NN O
studied NN NN O
. NN NN O
   
Unanesthetized NN NN O
adult NN NN O
female NN NN O
, NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
were NN NN O
divided NN NN O
in NN NN O
four NN NN O
groups NN NN O
and NN NN O
studied NN NN O
for NN NN O
15 NN NN O
days NN NN O
. NN NN O
   
Group NN NN O
1 NN NN O
( NN NN O
P NN NN O
alone NN NN O
) NN NN O
received NN NN O
P NN NN O
, NN NN O
360 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
, NN NN O
for NN NN O
15 NN NN O
days NN NN O
; NN NN O
Group NN NN O
II NN NN O
( NN NN O
P NN NN O
+ NN NN O
gentamicin NN NN O
) NN NN O
; NN NN O
Group NN NN O
III NN NN O
( NN NN O
gentamicin NN NN O
alone NN NN O
) NN NN O
and NN NN O
Group NN NN O
IV NN NN O
( NN NN O
mild NN NN O
DM NN NN B-Disease
+ NN NN O
gentamicin NN NN O
) NN NN O
. NN NN O
   
Nephrotoxic NN NN B-Disease
doses NN NN O
( NN NN O
40 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
wt NN NN O
/ NN NN O
day NN NN O
) NN NN O
of NN NN O
gentamicin NN NN O
were NN NN O
injected NN NN O
during NN NN O
the NN NN O
last NN NN O
nine NN NN O
days NN NN O
of NN NN O
study NN NN O
to NN NN O
the NN NN O
animals NN NN O
of NN NN O
groups NN NN O
II NN NN O
to NN NN O
IV NN NN O
. NN NN O
   
In NN NN O
Group NN NN O
I NN NN O
, NN NN O
P NN NN O
induced NN NN O
a NN NN O
moderate NN NN O
and NN NN O
stable NN NN O
glycosuria NN NN B-Disease
( NN NN O
3 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
1 NN NN O
g NN NN O
/ NN NN O
day NN NN O
, NN NN O
SE NN NN O
) NN NN O
, NN NN O
and NN NN O
no NN NN O
functional NN NN O
or NN NN O
morphologic NN NN O
evidence NN NN O
of NN NN O
renal NN NN B-Disease
dysfunction NN NN I-Disease
( NN NN O
baseline NN NN O
CCr NN NN O
2 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
1 NN NN O
ml NN NN O
/ NN NN O
min NN NN O
, NN NN O
undetectable NN NN O
lysozymuria NN NN O
) NN NN O
or NN NN O
damage NN NN O
( NN NN O
tubular NN NN B-Disease
necrosis NN NN I-Disease
score NN NN O
[ NN NN O
maximum NN NN O
4 NN NN O
] NN NN O
, NN NN O
zero NN NN O
) NN NN O
. NN NN O
   
In NN NN O
Group NN NN O
II NN NN O
, NN NN O
P NN NN O
did NN NN O
not NN NN O
prevent NN NN O
gentamicin NN NN O
- NN NN O
ARF NN NN B-Disease
( NN NN O
maximal NN NN O
decrease NN NN O
in NN NN O
CCr NN NN O
at NN NN O
day NN NN O
9 NN NN O
. NN NN O
89 NN NN O
% NN NN O
, NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
; NN NN O
peak NN NN O
lysozymuria NN NN O
, NN NN O
1863 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
321 NN NN O
micrograms NN NN O
/ NN NN O
day NN NN O
; NN NN O
and NN NN O
tubular NN NN B-Disease
necrosis NN NN I-Disease
score NN NN O
, NN NN O
3 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
These NN NN O
values NN NN O
were NN NN O
not NN NN O
different NN NN O
from NN NN O
those NN NN O
of NN NN O
Group NN NN O
III NN NN O
: NN NN O
maximal NN NN O
decrease NN NN O
in NN NN O
CCr NN NN O
73 NN NN O
% NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
; NN NN O
lysozymuria NN NN O
, NN NN O
2147 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
701 NN NN O
micrograms NN NN O
/ NN NN O
day NN NN O
; NN NN O
tubular NN NN B-Disease
necrosis NN NN I-Disease
score NN NN O
, NN NN O
3 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
1 NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Catalepsy NN NN B-Disease
induced NN NN O
by NN NN O
combinations NN NN O
of NN NN O
ketamine NN NN O
and NN NN O
morphine NN NN O
: NN NN O
potentiation NN NN O
, NN NN O
antagonism NN NN O
, NN NN O
tolerance NN NN O
and NN NN O
cross NN NN O
- NN NN O
tolerance NN NN O
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Previous NN NN O
studies NN NN O
demonstrated NN NN O
that NN NN O
both NN NN O
ketamine NN NN O
and NN NN O
morphine NN NN O
induced NN NN O
analgesia NN NN B-Disease
and NN NN O
catalepsy NN NN B-Disease
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Pre NN NN O
- NN NN O
treatment NN NN O
with NN NN O
ketamine NN NN O
produced NN NN O
cross NN NN O
- NN NN O
tolerance NN NN O
to NN NN O
morphine NN NN O
, NN NN O
whereas NN NN O
pretreatment NN NN O
with NN NN O
morphine NN NN O
did NN NN O
not NN NN O
induce NN NN O
cross NN NN O
- NN NN O
tolerance NN NN O
to NN NN O
ketamine NN NN O
but NN NN O
rather NN NN O
augmented NN NN O
the NN NN O
cataleptic NN NN B-Disease
response NN NN O
; NN NN O
this NN NN O
augmentation NN NN O
was NN NN O
attributed NN NN O
to NN NN O
residual NN NN O
morphine NN NN O
in NN NN O
the NN NN O
brain NN NN O
. NN NN O
   
The NN NN O
present NN NN O
studies NN NN O
explored NN NN O
the NN NN O
duration NN NN O
of NN NN O
the NN NN O
loss NN NN O
of NN NN O
righting NN NN O
reflex NN NN O
induced NN NN O
by NN NN O
sub NN NN O
- NN NN O
effective NN NN O
doses NN NN O
of NN NN O
ketamine NN NN O
and NN NN O
morphine NN NN O
, NN NN O
administered NN NN O
simultaneously NN NN O
. NN NN O
   
There NN NN O
was NN NN O
mutual NN NN O
potentiation NN NN O
between NN NN O
sub NN NN O
- NN NN O
effective NN NN O
doses NN NN O
of NN NN O
ketamine NN NN O
and NN NN O
morphine NN NN O
, NN NN O
but NN NN O
sub NN NN O
- NN NN O
effective NN NN O
doses NN NN O
of NN NN O
ketamine NN NN O
partly NN NN O
antagonized NN NN O
fully NN NN O
- NN NN O
effective NN NN O
doses NN NN O
of NN NN O
morphine NN NN O
. NN NN O
   
Latency NN NN O
to NN NN O
the NN NN O
loss NN NN O
of NN NN O
righting NN NN O
reflex NN NN O
, NN NN O
rigidity NN NN B-Disease
and NN NN O
behavior NN NN O
on NN NN O
recovery NN NN O
, NN NN O
reflected NN NN O
the NN NN O
relative NN NN O
predominance NN NN O
of NN NN O
ketamine NN NN O
or NN NN O
morphine NN NN O
in NN NN O
each NN NN O
combination NN NN O
. NN NN O
   
Naloxone NN NN O
inhibited NN NN O
the NN NN O
induced NN NN O
cataleptic NN NN B-Disease
effects NN NN O
. NN NN O
   
The NN NN O
degree NN NN O
and NN NN O
time NN NN O
course NN NN O
of NN NN O
development NN NN O
of NN NN O
tolerance NN NN O
to NN NN O
daily NN NN O
administration NN NN O
of NN NN O
sub NN NN O
- NN NN O
effective NN NN O
dose NN NN O
combinations NN NN O
of NN NN O
ketamine NN NN O
and NN NN O
morphine NN NN O
were NN NN O
similar NN NN O
. NN NN O
   
Rats NN NN O
, NN NN O
tolerant NN NN O
to NN NN O
ketamine NN NN O
- NN NN O
dominant NN NN O
combinations NN NN O
, NN NN O
were NN NN O
cross NN NN O
- NN NN O
tolerant NN NN O
to NN NN O
both NN NN O
drugs NN NN O
, NN NN O
while NN NN O
those NN NN O
tolerant NN NN O
to NN NN O
morphine NN NN O
- NN NN O
dominant NN NN O
combinations NN NN O
were NN NN O
cross NN NN O
- NN NN O
tolerant NN NN O
to NN NN O
morphine NN NN O
but NN NN O
showed NN NN O
either NN NN O
no NN NN O
cross NN NN O
- NN NN O
tolerance NN NN O
or NN NN O
an NN NN O
augmented NN NN O
response NN NN O
to NN NN O
ketamine NN NN O
. NN NN O
   
While NN NN O
the NN NN O
mutual NN NN O
potentiation NN NN O
, NN NN O
antagonism NN NN O
and NN NN O
tolerance NN NN O
suggest NN NN O
common NN NN O
mechanisms NN NN O
for NN NN O
the NN NN O
induced NN NN O
catalepsy NN NN B-Disease
, NN NN O
differences NN NN O
in NN NN O
latency NN NN O
, NN NN O
rigidity NN NN B-Disease
and NN NN O
behavior NN NN O
, NN NN O
asymmetry NN NN O
of NN NN O
cross NN NN O
- NN NN O
tolerance NN NN O
and NN NN O
a NN NN O
widely NN NN O
- NN NN O
different NN NN O
ID50 NN NN O
for NN NN O
naloxone NN NN O
would NN NN O
argue NN NN O
against NN NN O
an NN NN O
action NN NN O
at NN NN O
a NN NN O
single NN NN O
opioid NN NN O
site NN NN O
. NN NN O
   
Hydrocortisone NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
in NN NN O
humans NN NN O
: NN NN O
pressor NN NN O
responsiveness NN NN O
and NN NN O
sympathetic NN NN O
function NN NN O
. NN NN O
   
Oral NN NN O
hydrocortisone NN NN O
increases NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
enhances NN NN O
pressor NN NN O
responsiveness NN NN O
in NN NN O
normal NN NN O
human NN NN O
subjects NN NN O
. NN NN O
   
We NN NN O
studied NN NN O
the NN NN O
effects NN NN O
of NN NN O
1 NN NN O
week NN NN O
of NN NN O
oral NN NN O
hydrocortisone NN NN O
( NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
on NN NN O
blood NN NN O
pressure NN NN O
, NN NN O
cardiac NN NN O
output NN NN O
, NN NN O
total NN NN O
peripheral NN NN O
resistance NN NN O
, NN NN O
forearm NN NN O
vascular NN NN O
resistance NN NN O
, NN NN O
and NN NN O
norepinephrine NN NN O
spillover NN NN O
to NN NN O
plasma NN NN O
in NN NN O
eight NN NN O
healthy NN NN O
male NN NN O
volunteers NN NN O
. NN NN O
   
Although NN NN O
diastolic NN NN O
blood NN NN O
pressure NN NN O
remained NN NN O
unchanged NN NN O
, NN NN O
systolic NN NN O
blood NN NN O
pressure NN NN O
increased NN NN O
from NN NN O
119 NN NN O
to NN NN O
135 NN NN O
mm NN NN O
Hg NN NN O
( NN NN O
SED NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
4 NN NN O
, NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN B-Disease
cardiac NN NN I-Disease
output NN NN I-Disease
( NN NN O
5 NN NN O
. NN NN O
85 NN NN O
- NN NN O
7 NN NN O
. NN NN O
73 NN NN O
l NN NN O
/ NN NN O
min NN NN O
, NN NN O
SED NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
46 NN NN O
, NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Total NN NN O
peripheral NN NN O
vascular NN NN O
resistance NN NN O
fell NN NN O
from NN NN O
15 NN NN O
. NN NN O
1 NN NN O
to NN NN O
12 NN NN O
. NN NN O
2 NN NN O
mm NN NN O
Hg NN NN O
/ NN NN O
l NN NN O
/ NN NN O
min NN NN O
( NN NN O
SED NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
03 NN NN O
, NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Resting NN NN O
forearm NN NN O
vascular NN NN O
resistance NN NN O
remained NN NN O
unchanged NN NN O
, NN NN O
but NN NN O
the NN NN O
reflex NN NN O
response NN NN O
to NN NN O
the NN NN O
cold NN NN O
pressor NN NN O
test NN NN O
was NN NN O
accentuated NN NN O
, NN NN O
the NN NN O
rise NN NN O
in NN NN O
resistance NN NN O
increasing NN NN O
from NN NN O
10 NN NN O
. NN NN O
5 NN NN O
mm NN NN O
Hg NN NN O
/ NN NN O
ml NN NN O
/ NN NN O
100 NN NN O
ml NN NN O
/ NN NN O
min NN NN O
( NN NN O
R NN NN O
units NN NN O
) NN NN O
before NN NN O
treatment NN NN O
to NN NN O
32 NN NN O
. NN NN O
6 NN NN O
R NN NN O
units NN NN O
after NN NN O
treatment NN NN O
( NN NN O
SED NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
. NN NN O
4 NN NN O
, NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
025 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
rise NN NN O
in NN NN O
forearm NN NN O
vascular NN NN O
resistance NN NN O
accompanying NN NN O
intra NN NN O
- NN NN O
arterial NN NN O
norepinephrine NN NN O
( NN NN O
25 NN NN O
, NN NN O
50 NN NN O
, NN NN O
and NN NN O
100 NN NN O
ng NN NN O
/ NN NN O
min NN NN O
) NN NN O
was NN NN O
also NN NN O
significantly NN NN O
greater NN NN O
after NN NN O
hydrocortisone NN NN O
, NN NN O
increasing NN NN O
from NN NN O
an NN NN O
average NN NN O
of NN NN O
14 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
4 NN NN O
R NN NN O
units NN NN O
before NN NN O
treatment NN NN O
to NN NN O
35 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
. NN NN O
5 NN NN O
R NN NN O
units NN NN O
after NN NN O
hydrocortisone NN NN O
( NN NN O
SED NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
. NN NN O
0 NN NN O
, NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
A NN NN O
shift NN NN O
to NN NN O
the NN NN O
left NN NN O
in NN NN O
the NN NN O
dose NN NN O
- NN NN O
response NN NN O
relation NN NN O
and NN NN O
fall NN NN O
in NN NN O
threshold NN NN O
suggested NN NN O
increased NN NN O
sensitivity NN NN O
to NN NN O
norepinephrine NN NN O
after NN NN O
treatment NN NN O
. NN NN O
   
Measurement NN NN O
of NN NN O
resting NN NN O
norepinephrine NN NN O
spillover NN NN O
rate NN NN O
to NN NN O
plasma NN NN O
and NN NN O
norepinephrine NN NN O
uptake NN NN O
indicated NN NN O
that NN NN O
overall NN NN O
resting NN NN O
sympathetic NN NN O
nervous NN NN O
system NN NN O
activity NN NN O
was NN NN O
not NN NN O
increased NN NN O
. NN NN O
   
The NN NN O
rise NN NN B-Disease
in NN NN I-Disease
resting NN NN I-Disease
blood NN NN I-Disease
pressure NN NN I-Disease
with NN NN O
hydrocortisone NN NN O
is NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN B-Disease
cardiac NN NN I-Disease
output NN NN I-Disease
( NN NN O
presumably NN NN O
due NN NN O
to NN NN O
increased NN NN O
blood NN NN O
volume NN NN O
) NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Neuromuscular NN NN B-Disease
blockade NN NN I-Disease
with NN NN O
magnesium NN NN O
sulfate NN NN O
and NN NN O
nifedipine NN NN O
. NN NN O
   
A NN NN O
patient NN NN O
who NN NN O
received NN NN O
tocolysis NN NN O
with NN NN O
nifedipine NN NN O
developed NN NN O
neuromuscular NN NN B-Disease
blockade NN NN I-Disease
after NN NN O
500 NN NN O
mg NN NN O
of NN NN O
magnesium NN NN O
sulfate NN NN O
was NN NN O
administered NN NN O
. NN NN O
   
This NN NN O
reaction NN NN O
demonstrates NN NN O
that NN NN O
nifedipine NN NN O
can NN NN O
seriously NN NN O
potentiate NN NN O
the NN NN O
toxicity NN NN B-Disease
of NN NN O
magnesium NN NN O
. NN NN O
   
Caution NN NN O
should NN NN O
be NN NN O
exercised NN NN O
when NN NN O
these NN NN O
two NN NN O
tocolytics NN NN O
are NN NN O
combined NN NN O
. NN NN O
   
Chronic NN NN O
carbamazepine NN NN O
inhibits NN NN O
the NN NN O
development NN NN O
of NN NN O
local NN NN O
anesthetic NN NN O
seizures NN NN B-Disease
kindled NN NN O
by NN NN O
cocaine NN NN O
and NN NN O
lidocaine NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
carbamazepine NN NN O
( NN NN O
CBZ NN NN O
) NN NN O
treatment NN NN O
on NN NN O
local NN NN O
anesthetic NN NN O
- NN NN O
kindled NN NN O
seizures NN NN B-Disease
and NN NN O
lethality NN NN O
were NN NN O
evaluated NN NN O
in NN NN O
different NN NN O
stages NN NN O
of NN NN O
the NN NN O
kindling NN NN O
process NN NN O
and NN NN O
under NN NN O
different NN NN O
methods NN NN O
of NN NN O
CBZ NN NN O
administration NN NN O
. NN NN O
   
Chronic NN NN O
oral NN NN O
CBZ NN NN O
inhibited NN NN O
the NN NN O
development NN NN O
of NN NN O
both NN NN O
lidocaine NN NN O
- NN NN O
and NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
, NN NN O
but NN NN O
had NN NN O
little NN NN O
effect NN NN O
on NN NN O
the NN NN O
fully NN NN O
developed NN NN O
local NN NN O
anesthetic NN NN O
seizures NN NN B-Disease
. NN NN O
   
Chronic NN NN O
CBZ NN NN O
also NN NN O
decreased NN NN O
the NN NN O
incidence NN NN O
of NN NN O
seizure NN NN B-Disease
- NN NN O
related NN NN O
mortality NN NN O
in NN NN O
the NN NN O
cocaine NN NN O
- NN NN O
injected NN NN O
rats NN NN O
. NN NN O
   
Acute NN NN O
CBZ NN NN O
over NN NN O
a NN NN O
range NN NN O
of NN NN O
doses NN NN O
( NN NN O
15 NN NN O
- NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
completed NN NN O
lidocaine NN NN O
- NN NN O
kindled NN NN O
or NN NN O
acute NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
. NN NN O
   
Repeated NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
injection NN NN O
of NN NN O
CBZ NN NN O
( NN NN O
15 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
also NN NN O
was NN NN O
without NN NN O
effect NN NN O
on NN NN O
the NN NN O
development NN NN O
of NN NN O
lidocaine NN NN O
- NN NN O
or NN NN O
cocaine NN NN O
- NN NN O
kindled NN NN O
seizures NN NN B-Disease
. NN NN O
   
The NN NN O
differential NN NN O
effects NN NN O
of NN NN O
CBZ NN NN O
depending NN NN O
upon NN NN O
stage NN NN O
of NN NN O
seizure NN NN B-Disease
development NN NN O
suggest NN NN O
that NN NN O
distinct NN NN O
mechanisms NN NN O
underlie NN NN O
the NN NN O
development NN NN O
versus NN NN O
maintenance NN NN O
of NN NN O
local NN NN O
anesthetic NN NN O
- NN NN O
kindled NN NN O
seizures NN NN B-Disease
. NN NN O
   
The NN NN O
effectiveness NN NN O
of NN NN O
chronic NN NN O
but NN NN O
not NN NN O
repeated NN NN O
, NN NN O
intermittent NN NN O
injections NN NN O
of NN NN O
CBZ NN NN O
suggests NN NN O
that NN NN O
different NN NN O
biochemical NN NN O
consequences NN NN O
result NN NN O
from NN NN O
the NN NN O
different NN NN O
treatment NN NN O
regimens NN NN O
. NN NN O
   
The NN NN O
possible NN NN O
utility NN NN O
of NN NN O
chronic NN NN O
CBZ NN NN O
in NN NN O
preventing NN NN O
the NN NN O
development NN NN O
of NN NN O
toxic NN NN O
side NN NN O
effects NN NN O
in NN NN O
human NN NN O
cocaine NN NN O
users NN NN O
is NN NN O
suggested NN NN O
by NN NN O
these NN NN O
data NN NN O
, NN NN O
but NN NN O
remains NN NN O
to NN NN O
be NN NN O
directly NN NN O
evaluated NN NN O
. NN NN O
   
Magnetic NN NN O
resonance NN NN O
imaging NN NN O
of NN NN O
cerebral NN NN O
venous NN NN B-Disease
thrombosis NN NN I-Disease
secondary NN NN O
to NN NN O
"""""""" NN NN O
low NN NN O
- NN NN O
dose NN NN O
"""""""" NN NN O
birth NN NN O
control NN NN O
pills NN NN O
. NN NN O
   
The NN NN O
clinical NN NN O
and NN NN O
radiographic NN NN O
features NN NN O
of NN NN O
cerebral NN NN O
deep NN NN B-Disease
venous NN NN I-Disease
thrombosis NN NN I-Disease
in NN NN O
a NN NN O
21 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
white NN NN O
woman NN NN O
are NN NN O
presented NN NN O
. NN NN O
   
This NN NN O
nulliparous NN NN O
patient NN NN O
presented NN NN O
with NN NN O
relatively NN NN O
mild NN NN O
clinical NN NN O
symptoms NN NN O
and NN NN O
progressing NN NN O
mental NN NN O
status NN NN O
changes NN NN O
. NN NN O
   
The NN NN O
only NN NN O
known NN NN O
risk NN NN O
factor NN NN O
was NN NN O
"""""""" NN NN O
low NN NN O
- NN NN O
dose NN NN O
"""""""" NN NN O
oral NN NN O
contraceptive NN NN O
pills NN NN O
. NN NN O
   
The NN NN O
magnetic NN NN O
resonance NN NN O
image NN NN O
( NN NN O
MRI NN NN O
) NN NN O
showed NN NN O
increased NN NN O
signal NN NN O
intensity NN NN O
from NN NN O
the NN NN O
internal NN NN O
cerebral NN NN O
veins NN NN O
, NN NN O
vein NN NN O
of NN NN O
Galen NN NN O
, NN NN O
and NN NN O
straight NN NN O
sinus NN NN O
. NN NN O
   
The NN NN O
diagnosis NN NN O
was NN NN O
confirmed NN NN O
by NN NN O
arterial NN NN O
angiography NN NN O
. NN NN O
   
Beta NN NN O
- NN NN O
2 NN NN O
- NN NN O
adrenoceptor NN NN O
- NN NN O
mediated NN NN O
hypokalemia NN NN B-Disease
and NN NN O
its NN NN O
abolishment NN NN O
by NN NN O
oxprenolol NN NN O
. NN NN O
   
The NN NN O
time NN NN O
course NN NN O
and NN NN O
concentration NN NN O
- NN NN O
effect NN NN O
relationship NN NN O
of NN NN O
terbutaline NN NN O
- NN NN O
induced NN NN O
hypokalemia NN NN B-Disease
was NN NN O
studied NN NN O
, NN NN O
using NN NN O
computer NN NN O
- NN NN O
aided NN NN O
pharmacokinetic NN NN O
- NN NN O
dynamic NN NN O
modeling NN NN O
. NN NN O
   
Subsequently NN NN O
we NN NN O
investigated NN NN O
the NN NN O
efficacy NN NN O
of NN NN O
oxprenolol NN NN O
in NN NN O
antagonizing NN NN O
such NN NN O
hypokalemia NN NN B-Disease
, NN NN O
together NN NN O
with NN NN O
the NN NN O
pharmacokinetic NN NN O
interaction NN NN O
between NN NN O
both NN NN O
drugs NN NN O
. NN NN O
   
Six NN NN O
healthy NN NN O
subjects NN NN O
were NN NN O
given NN NN O
a NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
subcutaneous NN NN O
dose NN NN O
of NN NN O
terbutaline NN NN O
on NN NN O
two NN NN O
occasions NN NN O
: NN NN O
1 NN NN O
hour NN NN O
after NN NN O
oral NN NN O
administration NN NN O
of NN NN O
a NN NN O
placebo NN NN O
and NN NN O
1 NN NN O
hour NN NN O
after NN NN O
80 NN NN O
mg NN NN O
oxprenolol NN NN O
orally NN NN O
. NN NN O
   
In NN NN O
the NN NN O
7 NN NN O
- NN NN O
hour NN NN O
period NN NN O
after NN NN O
terbutaline NN NN O
administration NN NN O
, NN NN O
plasma NN NN O
samples NN NN O
were NN NN O
taken NN NN O
for NN NN O
determination NN NN O
of NN NN O
plasma NN NN O
potassium NN NN O
levels NN NN O
and NN NN O
drug NN NN O
concentrations NN NN O
. NN NN O
   
The NN NN O
sigmoid NN NN O
Emax NN NN O
model NN NN O
offered NN NN O
a NN NN O
good NN NN O
description NN NN O
of NN NN O
the NN NN O
relation NN NN O
between NN NN O
terbutaline NN NN O
concentrations NN NN O
and NN NN O
potassium NN NN O
effects NN NN O
. NN NN O
   
Oxprenolol NN NN O
caused NN NN O
decreases NN NN O
of NN NN O
65 NN NN O
% NN NN O
and NN NN O
56 NN NN O
% NN NN O
of NN NN O
terbutaline NN NN O
volume NN NN O
of NN NN O
distribution NN NN O
and NN NN O
clearance NN NN O
, NN NN O
respectively NN NN O
, NN NN O
and NN NN O
an NN NN O
increase NN NN O
of NN NN O
130 NN NN O
% NN NN O
of NN NN O
its NN NN O
AUC NN NN O
. NN NN O
   
In NN NN O
spite NN NN O
of NN NN O
higher NN NN O
terbutaline NN NN O
concentrations NN NN O
after NN NN O
oxprenolol NN NN O
pretreatment NN NN O
, NN NN O
the NN NN O
hypokalemia NN NN B-Disease
was NN NN O
almost NN NN O
completely NN NN O
antagonized NN NN O
by NN NN O
the NN NN O
beta NN NN O
2 NN NN O
- NN NN O
blocking NN NN O
action NN NN O
. NN NN O
   
A NN NN O
dystonia NN NN B-Disease
- NN NN O
like NN NN O
syndrome NN NN O
after NN NN O
neuropeptide NN NN O
( NN NN O
MSH NN NN O
/ NN NN O
ACTH NN NN O
) NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
rat NN NN O
locus NN NN O
ceruleus NN NN O
. NN NN O
   
The NN NN O
movement NN NN B-Disease
disorder NN NN I-Disease
investigated NN NN O
in NN NN O
these NN NN O
studies NN NN O
has NN NN O
some NN NN O
features NN NN O
in NN NN O
common NN NN O
with NN NN O
human NN NN O
idiopathic NN NN O
dystonia NN NN B-Disease
, NN NN O
and NN NN O
information NN NN O
obtained NN NN O
in NN NN O
these NN NN O
studies NN NN O
may NN NN O
be NN NN O
of NN NN O
potential NN NN O
clinical NN NN O
benefit NN NN O
. NN NN O
   
The NN NN O
present NN NN O
experimental NN NN O
results NN NN O
indicated NN NN O
that NN NN O
peptidergic NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
LC NN NN O
resulted NN NN O
in NN NN O
a NN NN O
NE NN NN O
- NN NN O
mediated NN NN O
inhibition NN NN O
of NN NN O
cerebellar NN NN O
Purkinje NN NN O
cells NN NN O
located NN NN O
at NN NN O
terminals NN NN O
of NN NN O
the NN NN O
ceruleo NN NN O
- NN NN O
cerebellar NN NN O
pathway NN NN O
. NN NN O
   
However NN NN O
, NN NN O
it NN NN O
is NN NN O
not NN NN O
certain NN NN O
as NN NN O
to NN NN O
the NN NN O
following NN NN O
: NN NN O
( NN NN O
a NN NN O
) NN NN O
what NN NN O
receptors NN NN O
were NN NN O
stimulated NN NN O
by NN NN O
the NN NN O
ACTH NN NN O
N NN NN O
- NN NN O
terminal NN NN O
fragments NN NN O
at NN NN O
the NN NN O
LC NN NN O
that NN NN O
resulted NN NN O
in NN NN O
this NN NN O
disorder NN NN O
; NN NN O
( NN NN O
b NN NN O
) NN NN O
whether NN NN O
NE NN NN O
, NN NN O
released NN NN O
onto NN NN O
Purkinje NN NN O
cell NN NN O
synapses NN NN O
located NN NN O
at NN NN O
terminals NN NN O
of NN NN O
the NN NN O
ceruleo NN NN O
- NN NN O
cerebellar NN NN O
pathway NN NN O
, NN NN O
did NN NN O
indeed NN NN O
cause NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
depression NN NN B-Disease
at NN NN O
Purkinje NN NN O
cell NN NN O
synapses NN NN O
( NN NN O
previously NN NN O
described NN NN O
by NN NN O
others NN NN O
) NN NN O
that NN NN O
resulted NN NN O
in NN NN O
the NN NN O
long NN NN O
duration NN NN O
of NN NN O
the NN NN O
movement NN NN B-Disease
disorder NN NN I-Disease
; NN NN O
( NN NN O
c NN NN O
) NN NN O
whether NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
inhibitory NN NN O
Purkinje NN NN O
cells NN NN O
resulted NN NN O
in NN NN O
disinhibition NN NN O
or NN NN O
increased NN NN O
excitability NN NN O
of NN NN O
the NN NN O
unilateral NN NN O
cerebellar NN NN O
fastigial NN NN O
or NN NN O
interpositus NN NN O
nuclei NN NN O
, NN NN O
the NN NN O
output NN NN O
targets NN NN O
of NN NN O
the NN NN O
Purkinje NN NN O
cell NN NN O
axons NN NN O
, NN NN O
that NN NN O
may NN NN O
have NN NN O
been NN NN O
an NN NN O
important NN NN O
contributing NN NN O
factor NN NN O
to NN NN O
this NN NN O
disorder NN NN O
. NN NN O
   
These NN NN O
questions NN NN O
are NN NN O
currently NN NN O
being NN NN O
investigated NN NN O
. NN NN O
   
Enhanced NN NN O
stimulus NN NN O
- NN NN O
induced NN NN O
neurotransmitter NN NN O
overflow NN NN O
in NN NN O
epinephrine NN NN O
- NN NN O
induced NN NN O
hypertensive NN NN B-Disease
rats NN NN O
is NN NN O
not NN NN O
mediated NN NN O
by NN NN O
prejunctional NN NN O
beta NN NN O
- NN NN O
adrenoceptor NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
examines NN NN O
the NN NN O
effect NN NN O
of NN NN O
6 NN NN O
- NN NN O
day NN NN O
epinephrine NN NN O
treatment NN NN O
( NN NN O
100 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
per NN NN O
h NN NN O
, NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
on NN NN O
stimulus NN NN O
- NN NN O
induced NN NN O
( NN NN O
1 NN NN O
Hz NN NN O
) NN NN O
endogenous NN NN O
neurotransmitter NN NN O
overflow NN NN O
from NN NN O
the NN NN O
isolated NN NN O
perfused NN NN O
kidney NN NN O
of NN NN O
vehicle NN NN O
- NN NN O
and NN NN O
epinephrine NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
Renal NN NN O
catecholamine NN NN O
stores NN NN O
and NN NN O
stimulus NN NN O
- NN NN O
induced NN NN O
overflow NN NN O
in NN NN O
the NN NN O
vehicle NN NN O
- NN NN O
treated NN NN O
group NN NN O
consisted NN NN O
of NN NN O
norepinephrine NN NN O
only NN NN O
. NN NN O
   
However NN NN O
, NN NN O
epinephrine NN NN O
treatment NN NN O
resulted NN NN O
in NN NN O
the NN NN O
incorporation NN NN O
of NN NN O
epinephrine NN NN O
into NN NN O
renal NN NN O
catecholamine NN NN O
stores NN NN O
such NN NN O
that NN NN O
approximately NN NN O
40 NN NN O
% NN NN O
of NN NN O
the NN NN O
catecholamine NN NN O
present NN NN O
was NN NN O
epinephrine NN NN O
while NN NN O
the NN NN O
norepinephrine NN NN O
content NN NN O
was NN NN O
reduced NN NN O
by NN NN O
a NN NN O
similar NN NN O
degree NN NN O
. NN NN O
   
Total NN NN O
tissue NN NN O
catecholamine NN NN O
content NN NN O
of NN NN O
the NN NN O
kidney NN NN O
on NN NN O
a NN NN O
molar NN NN O
basis NN NN O
was NN NN O
unchanged NN NN O
. NN NN O
   
Stimulus NN NN O
- NN NN O
induced NN NN O
fractional NN NN O
overflow NN NN O
of NN NN O
neurotransmitter NN NN O
from NN NN O
the NN NN O
epinephrine NN NN O
- NN NN O
treated NN NN O
kidneys NN NN O
was NN NN O
approximately NN NN O
twice NN NN O
normal NN NN O
and NN NN O
consisted NN NN O
of NN NN O
both NN NN O
norepinephrine NN NN O
and NN NN O
epinephrine NN NN O
in NN NN O
proportions NN NN O
similar NN NN O
to NN NN O
those NN NN O
found NN NN O
in NN NN O
the NN NN O
kidney NN NN O
. NN NN O
   
This NN NN O
difference NN NN O
in NN NN O
fractional NN NN O
overflow NN NN O
between NN NN O
groups NN NN O
was NN NN O
not NN NN O
affected NN NN O
by NN NN O
neuronal NN NN O
and NN NN O
extraneuronal NN NN O
uptake NN NN O
blockade NN NN O
. NN NN O
   
Propranolol NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
stimulus NN NN O
- NN NN O
induced NN NN O
overflow NN NN O
in NN NN O
either NN NN O
group NN NN O
. NN NN O
   
Phentolamine NN NN O
increased NN NN O
stimulus NN NN O
- NN NN O
induced NN NN O
overflow NN NN O
in NN NN O
both NN NN O
groups NN NN O
although NN NN O
the NN NN O
increment NN NN O
in NN NN O
overflow NN NN O
was NN NN O
greater NN NN O
in NN NN O
the NN NN O
epinephrine NN NN O
- NN NN O
treated NN NN O
group NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
chronic NN NN O
epinephrine NN NN O
treatment NN NN O
results NN NN O
in NN NN O
enhanced NN NN O
fractional NN NN O
neurotransmitter NN NN O
overflow NN NN O
. NN NN O
   
However NN NN O
, NN NN O
neither NN NN O
alterations NN NN O
in NN NN O
prejunctional NN NN O
beta NN NN O
- NN NN O
adrenoceptor NN NN O
influences NN NN O
nor NN NN O
alterations NN NN O
in NN NN O
neuronal NN NN O
and NN NN O
extraneuronal NN NN O
uptake NN NN O
mechanisms NN NN O
appear NN NN O
to NN NN O
be NN NN O
responsible NN NN O
for NN NN O
this NN NN O
alteration NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
data NN NN O
obtained NN NN O
with NN NN O
phentolamine NN NN O
alone NN NN O
do NN NN O
not NN NN O
suggest NN NN O
alpha NN NN O
- NN NN O
adrenoceptor NN NN O
desensitization NN NN O
as NN NN O
the NN NN O
cause NN NN O
of NN NN O
the NN NN O
enhanced NN NN O
neurotransmitter NN NN O
overflow NN NN O
after NN NN O
epinephrine NN NN O
treatment NN NN O
. NN NN O
   
GABA NN NN O
involvement NN NN O
in NN NN O
naloxone NN NN O
induced NN NN O
reversal NN NN O
of NN NN O
respiratory NN NN B-Disease
paralysis NN NN I-Disease
produced NN NN O
by NN NN O
thiopental NN NN O
. NN NN O
   
No NN NN O
agent NN NN O
is NN NN O
yet NN NN O
available NN NN O
to NN NN O
reverse NN NN O
respiratory NN NN B-Disease
paralysis NN NN I-Disease
produced NN NN O
by NN NN O
CNS NN NN O
depressants NN NN O
, NN NN O
such NN NN O
as NN NN O
general NN NN O
anesthetics NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
naloxone NN NN O
reversed NN NN O
respiratory NN NN B-Disease
paralysis NN NN I-Disease
induced NN NN O
by NN NN O
thiopental NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
25 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
thiopental NN NN O
produced NN NN O
anesthesia NN NN O
without NN NN O
altering NN NN O
respiratory NN NN O
rate NN NN O
, NN NN O
increased NN NN O
GABA NN NN O
, NN NN O
decreased NN NN O
glutamate NN NN O
, NN NN O
and NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
aspartate NN NN O
or NN NN O
glycine NN NN O
levels NN NN O
compared NN NN O
to NN NN O
controls NN NN O
in NN NN O
rat NN NN O
cortex NN NN O
and NN NN O
brain NN NN O
stem NN NN O
. NN NN O
   
Pretreatment NN NN O
of NN NN O
rats NN NN O
with NN NN O
thiosemicarbazide NN NN O
for NN NN O
30 NN NN O
minutes NN NN O
abolished NN NN O
the NN NN O
anesthetic NN NN O
action NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
respiratory NN NN O
depressant NN NN O
action NN NN O
of NN NN O
thiopental NN NN O
. NN NN O
   
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
thiopental NN NN O
produced NN NN O
respiratory NN NN B-Disease
arrest NN NN I-Disease
with NN NN O
further NN NN O
increase NN NN O
in NN NN O
GABA NN NN O
and NN NN O
decrease NN NN O
in NN NN O
glutamate NN NN O
again NN NN O
in NN NN O
cortex NN NN O
and NN NN O
brain NN NN O
stem NN NN O
without NN NN O
affecting NN NN O
any NN NN O
of NN NN O
the NN NN O
amino NN NN O
acids NN NN O
studied NN NN O
in NN NN O
four NN NN O
regions NN NN O
of NN NN O
rat NN NN O
brain NN NN O
. NN NN O
   
Naloxone NN NN O
( NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
reversed NN NN O
respiratory NN NN B-Disease
paralysis NN NN I-Disease
, NN NN O
glutamate NN NN O
and NN NN O
GABA NN NN O
levels NN NN O
to NN NN O
control NN NN O
values NN NN O
in NN NN O
brain NN NN O
stem NN NN O
and NN NN O
cortex NN NN O
with NN NN O
no NN NN O
changes NN NN O
in NN NN O
caudate NN NN O
or NN NN O
cerebellum NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
naloxone NN NN O
reverses NN NN O
respiratory NN NN B-Disease
paralysis NN NN I-Disease
produced NN NN O
by NN NN O
thiopental NN NN O
and NN NN O
involves NN NN O
GABA NN NN O
in NN NN O
its NN NN O
action NN NN O
. NN NN O
   
Diazepam NN NN O
facilitates NN NN O
reflex NN NN O
bradycardia NN NN B-Disease
in NN NN O
conscious NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
diazepam NN NN O
on NN NN O
cardiovascular NN NN O
function NN NN O
were NN NN O
assessed NN NN O
in NN NN O
conscious NN NN O
rats NN NN O
. NN NN O
   
Intravenous NN NN O
administration NN NN O
of NN NN O
diazepam NN NN O
( NN NN O
1 NN NN O
- NN NN O
30 NN NN O
mg NN NN O
kg NN NN O
- NN NN O
1 NN NN O
) NN NN O
produced NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
decrease NN NN O
in NN NN O
both NN NN O
the NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
and NN NN O
the NN NN O
heart NN NN O
rate NN NN O
. NN NN O
   
Also NN NN O
, NN NN O
reflex NN NN O
bradycardia NN NN B-Disease
was NN NN O
produced NN NN O
in NN NN O
rats NN NN O
by NN NN O
intravenous NN NN O
infusion NN NN O
of NN NN O
adrenaline NN NN O
( NN NN O
1 NN NN O
. NN NN O
25 NN NN O
- NN NN O
2 NN NN O
. NN NN O
5 NN NN O
micrograms NN NN O
kg NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
Intravenous NN NN O
pretreatment NN NN O
of NN NN O
the NN NN O
rats NN NN O
with NN NN O
diazepam NN NN O
, NN NN O
although NN NN O
causing NN NN O
no NN NN O
change NN NN O
in NN NN O
the NN NN O
adrenaline NN NN O
- NN NN O
induced NN NN O
pressor NN NN O
effect NN NN O
, NN NN O
did NN NN O
enhance NN NN O
the NN NN O
adrenaline NN NN O
- NN NN O
induced NN NN O
reflex NN NN O
bradycardia NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
diazepam NN NN O
enhancement NN NN O
of NN NN O
adrenaline NN NN O
- NN NN O
induced NN NN O
reflex NN NN O
bradycardia NN NN B-Disease
was NN NN O
antagonized NN NN O
by NN NN O
pretreatment NN NN O
of NN NN O
rats NN NN O
with NN NN O
an NN NN O
intravenous NN NN O
dose NN NN O
of NN NN O
picrotoxin NN NN O
( NN NN O
an NN NN O
agent NN NN O
blocks NN NN O
chloride NN NN O
channels NN NN O
by NN NN O
binding NN NN O
to NN NN O
sites NN NN O
associated NN NN O
with NN NN O
the NN NN O
benzodiazepine NN NN O
- NN NN O
GABA NN NN O
- NN NN O
chloride NN NN O
channel NN NN O
macromolecular NN NN O
complex NN NN O
) NN NN O
. NN NN O
   
The NN NN O
data NN NN O
indicate NN NN O
that NN NN O
diazepam NN NN O
acts NN NN O
through NN NN O
the NN NN O
benzodiazepine NN NN O
- NN NN O
GABA NN NN O
- NN NN O
chloride NN NN O
channel NN NN O
macromolecular NN NN O
complex NN NN O
within NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
to NN NN O
facilitate NN NN O
reflex NN NN O
bradycardia NN NN B-Disease
mediated NN NN O
through NN NN O
baroreceptor NN NN O
reflexes NN NN O
in NN NN O
response NN NN O
to NN NN O
an NN NN O
acute NN NN O
increase NN NN O
in NN NN O
arterial NN NN O
pressure NN NN O
. NN NN O
   
Initial NN NN O
potassium NN NN O
loss NN NN O
and NN NN O
hypokalaemia NN NN B-Disease
during NN NN O
chlorthalidone NN NN O
administration NN NN O
in NN NN O
patients NN NN O
with NN NN O
essential NN NN O
hypertension NN NN B-Disease
: NN NN O
the NN NN O
influence NN NN O
of NN NN O
dietary NN NN O
sodium NN NN O
restriction NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
the NN NN O
initial NN NN O
potassium NN NN O
loss NN NN O
and NN NN O
development NN NN O
of NN NN O
hypokalaemia NN NN B-Disease
during NN NN O
the NN NN O
administration NN NN O
of NN NN O
an NN NN O
oral NN NN O
diuretic NN NN O
, NN NN O
metabolic NN NN O
balance NN NN O
studies NN NN O
were NN NN O
performed NN NN O
in NN NN O
ten NN NN O
patients NN NN O
with NN NN O
essential NN NN O
hypertension NN NN B-Disease
who NN NN O
had NN NN O
shown NN NN O
hypokalaemia NN NN B-Disease
under NN NN O
prior NN NN O
oral NN NN O
diuretic NN NN O
treatment NN NN O
. NN NN O
   
Chlorthalidone NN NN O
( NN NN O
50 NN NN O
mg NN NN O
daily NN NN O
) NN NN O
was NN NN O
given NN NN O
for NN NN O
14 NN NN O
days NN NN O
. NN NN O
   
Six NN NN O
patients NN NN O
received NN NN O
a NN NN O
normal NN NN O
- NN NN O
sodium NN NN O
diet NN NN O
and NN NN O
four NN NN O
a NN NN O
low NN NN O
- NN NN O
sodium NN NN O
( NN NN O
17 NN NN O
mmol NN NN O
/ NN NN O
day NN NN O
) NN NN O
diet NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
had NN NN O
a NN NN O
normal NN NN O
initial NN NN O
total NN NN O
body NN NN O
potassium NN NN O
( NN NN O
40K NN NN O
) NN NN O
. NN NN O
   
The NN NN O
electrolyte NN NN O
balances NN NN O
, NN NN O
weight NN NN O
, NN NN O
bromide NN NN O
space NN NN O
, NN NN O
plasma NN NN O
renin NN NN O
activity NN NN O
, NN NN O
and NN NN O
aldosterone NN NN O
secretion NN NN O
rate NN NN O
were NN NN O
measured NN NN O
. NN NN O
   
In NN NN O
both NN NN O
groups NN NN O
a NN NN O
potassium NN NN O
deficit NN NN O
developed NN NN O
, NN NN O
with NN NN O
proportionally NN NN O
larger NN NN O
losses NN NN O
from NN NN O
the NN NN O
extracellular NN NN O
than NN NN O
from NN NN O
the NN NN O
intracellular NN NN O
compartment NN NN O
. NN NN O
   
In NN NN O
the NN NN O
normal NN NN O
- NN NN O
sodium NN NN O
group NN NN O
the NN NN O
highest NN NN O
mean NN NN O
potassium NN NN O
deficit NN NN O
was NN NN O
176 NN NN O
mmol NN NN O
on NN NN O
day NN NN O
9 NN NN O
, NN NN O
after NN NN O
which NN NN O
some NN NN O
potassium NN NN O
was NN NN O
regained NN NN O
; NN NN O
in NN NN O
the NN NN O
low NN NN O
- NN NN O
sodium NN NN O
group NN NN O
the NN NN O
highest NN NN O
deficit NN NN O
was NN NN O
276 NN NN O
mmol NN NN O
on NN NN O
day NN NN O
13 NN NN O
. NN NN O
   
The NN NN O
normal NN NN O
- NN NN O
sodium NN NN O
group NN NN O
showed NN NN O
an NN NN O
immediate NN NN O
but NN NN O
temporary NN NN O
rise NN NN O
of NN NN O
the NN NN O
renin NN NN O
and NN NN O
aldosterone NN NN O
levels NN NN O
; NN NN O
in NN NN O
the NN NN O
low NN NN O
- NN NN O
sodium NN NN O
group NN NN O
renin NN NN O
and NN NN O
aldosterone NN NN O
increased NN NN O
more NN NN O
slowly NN NN O
but NN NN O
remained NN NN O
elevated NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
dietary NN NN O
sodium NN NN O
restriction NN NN O
increases NN NN O
diuretic NN NN O
- NN NN O
induced NN NN O
potassium NN NN O
loss NN NN O
, NN NN O
presumably NN NN O
by NN NN O
an NN NN O
increased NN NN O
activity NN NN O
of NN NN O
the NN NN O
renin NN NN O
- NN NN O
angiotensin NN NN O
- NN NN O
aldosterone NN NN O
system NN NN O
, NN NN O
while NN NN O
sodium NN NN O
delivery NN NN O
to NN NN O
the NN NN O
distal NN NN O
renal NN NN O
tubules NN NN O
remains NN NN O
sufficiently NN NN O
high NN NN O
to NN NN O
allow NN NN O
increased NN NN O
potassium NN NN O
secretion NN NN O
. NN NN O
   
Reversal NN NN O
of NN NN O
neuroleptic NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
by NN NN O
novel NN NN O
aryl NN NN O
- NN NN O
piperazine NN NN O
anxiolytic NN NN O
drugs NN NN O
. NN NN O
   
The NN NN O
novel NN NN O
anxiolytic NN NN O
drug NN NN O
, NN NN O
buspirone NN NN O
, NN NN O
reverses NN NN O
catalepsy NN NN B-Disease
induced NN NN O
by NN NN O
haloperidol NN NN O
. NN NN O
   
A NN NN O
series NN NN O
of NN NN O
aryl NN NN O
- NN NN O
piperazine NN NN O
analogues NN NN O
of NN NN O
buspirone NN NN O
and NN NN O
other NN NN O
5 NN NN O
- NN NN O
hydroxytryptaminergic NN NN O
agonists NN NN O
were NN NN O
tested NN NN O
for NN NN O
their NN NN O
ability NN NN O
to NN NN O
reverse NN NN O
haloperidol NN NN O
induced NN NN O
catalepsy NN NN B-Disease
. NN NN O
   
Those NN NN O
drugs NN NN O
with NN NN O
strong NN NN O
affinity NN NN O
for NN NN O
5 NN NN O
- NN NN O
hydroxytryptamine1a NN NN O
receptors NN NN O
were NN NN O
able NN NN O
to NN NN O
reverse NN NN O
catalepsy NN NN B-Disease
. NN NN O
   
Drugs NN NN O
with NN NN O
affinity NN NN O
for NN NN O
other NN NN O
5 NN NN O
- NN NN O
HT NN NN O
receptors NN NN O
or NN NN O
weak NN NN O
affinity NN NN O
were NN NN O
ineffective NN NN O
. NN NN O
   
However NN NN O
, NN NN O
inhibition NN NN O
of NN NN O
postsynaptic NN NN O
5 NN NN O
- NN NN O
HT NN NN O
receptors NN NN O
neither NN NN O
inhibited NN NN O
nor NN NN O
potentiated NN NN O
reversal NN NN O
of NN NN O
catalepsy NN NN B-Disease
and NN NN O
leaves NN NN O
open NN NN O
the NN NN O
question NN NN O
as NN NN O
to NN NN O
the NN NN O
site NN NN O
or NN NN O
mechanism NN NN O
for NN NN O
this NN NN O
effect NN NN O
. NN NN O
   
Glycopyrronium NN NN O
requirements NN NN O
for NN NN O
antagonism NN NN O
of NN NN O
the NN NN O
muscarinic NN NN O
side NN NN O
effects NN NN O
of NN NN O
edrophonium NN NN O
. NN NN O
   
We NN NN O
have NN NN O
compared NN NN O
, NN NN O
in NN NN O
60 NN NN O
adult NN NN O
patients NN NN O
, NN NN O
the NN NN O
cardiovascular NN NN O
effects NN NN O
of NN NN O
glycopyrronium NN NN O
5 NN NN O
micrograms NN NN O
kg NN NN O
- NN NN O
1 NN NN O
and NN NN O
10 NN NN O
micrograms NN NN O
kg NN NN O
- NN NN O
1 NN NN O
given NN NN O
either NN NN O
simultaneously NN NN O
or NN NN O
1 NN NN O
min NN NN O
before NN NN O
edrophonium NN NN O
1 NN NN O
mg NN NN O
kg NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Significant NN NN O
differences NN NN O
between NN NN O
the NN NN O
four NN NN O
groups NN NN O
were NN NN O
detected NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Both NN NN O
groups NN NN O
receiving NN NN O
10 NN NN O
micrograms NN NN O
kg NN NN O
- NN NN O
1 NN NN O
showed NN NN O
increases NN NN O
in NN NN O
heart NN NN O
rate NN NN O
of NN NN O
up NN NN O
to NN NN O
30 NN NN O
beat NN NN O
min NN NN O
- NN NN O
1 NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
limits NN NN O
28 NN NN O
- NN NN O
32 NN NN O
beat NN NN O
min NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
Use NN NN O
of NN NN O
glycopyrronium NN NN O
5 NN NN O
micrograms NN NN O
kg NN NN O
- NN NN O
1 NN NN O
provided NN NN O
greater NN NN O
cardiovascular NN NN O
stability NN NN O
and NN NN O
, NN NN O
given NN NN O
1 NN NN O
min NN NN O
before NN NN O
the NN NN O
edrophonium NN NN O
, NN NN O
was NN NN O
sufficient NN NN O
to NN NN O
minimize NN NN O
early NN NN O
, NN NN O
edrophonium NN NN O
- NN NN O
induced NN NN O
bradycardias NN NN B-Disease
. NN NN O
   
This NN NN O
low NN NN O
dose NN NN O
of NN NN O
glycopyrronium NN NN O
provided NN NN O
good NN NN O
control NN NN O
of NN NN O
oropharyngeal NN NN O
secretions NN NN O
. NN NN O
   
Selective NN NN O
injection NN NN O
of NN NN O
iopentol NN NN O
, NN NN O
iohexol NN NN O
and NN NN O
metrizoate NN NN O
into NN NN O
the NN NN O
left NN NN O
coronary NN NN O
artery NN NN O
of NN NN O
the NN NN O
dog NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
ventricular NN NN B-Disease
fibrillation NN NN I-Disease
and NN NN O
decrease NN NN O
of NN NN O
aortic NN NN O
pressure NN NN O
. NN NN O
   
In NN NN O
twenty NN NN O
beagle NN NN O
dogs NN NN O
selective NN NN O
injections NN NN O
were NN NN O
made NN NN O
into NN NN O
the NN NN O
left NN NN O
coronary NN NN O
artery NN NN O
with NN NN O
iopentol NN NN O
, NN NN O
iohexol NN NN O
and NN NN O
metrizoate NN NN O
in NN NN O
doses NN NN O
of NN NN O
4 NN NN O
ml NN NN O
, NN NN O
8 NN NN O
ml NN NN O
and NN NN O
16 NN NN O
ml NN NN O
. NN NN O
   
Thirty NN NN O
- NN NN O
six NN NN O
iopentol NN NN O
injections NN NN O
, NN NN O
35 NN NN O
iohexol NN NN O
injections NN NN O
and NN NN O
37 NN NN O
metrizoate NN NN O
injections NN NN O
were NN NN O
made NN NN O
. NN NN O
   
Frequencies NN NN O
of NN NN O
ventricular NN NN B-Disease
fibrillation NN NN I-Disease
were NN NN O
significantly NN NN O
lower NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
after NN NN O
iopentol NN NN O
( NN NN O
0 NN NN O
% NN NN O
) NN NN O
and NN NN O
iohexol NN NN O
( NN NN O
3 NN NN O
% NN NN O
) NN NN O
than NN NN O
after NN NN O
metrizoate NN NN O
( NN NN O
22 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Iopentol NN NN O
and NN NN O
iohexol NN NN O
also NN NN O
produced NN NN O
significantly NN NN O
less NN NN O
decrease NN NN O
in NN NN O
aortic NN NN O
blood NN NN O
pressure NN NN O
than NN NN O
metrizoate NN NN O
at NN NN O
the NN NN O
different NN NN O
doses NN NN O
. NN NN O
   
Thyroid NN NN O
function NN NN O
and NN NN O
urine NN NN O
- NN NN O
concentrating NN NN O
ability NN NN O
during NN NN O
lithium NN NN O
treatment NN NN O
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
suggested NN NN O
that NN NN O
adenylate NN NN O
cyclase NN NN O
inhibition NN NN O
may NN NN O
be NN NN O
important NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
both NN NN O
nephrogenic NN NN B-Disease
diabetes NN NN I-Disease
insipidus NN NN I-Disease
and NN NN O
hypothyroidism NN NN B-Disease
during NN NN O
lithium NN NN O
treatment NN NN O
. NN NN O
   
We NN NN O
measured NN NN O
serum NN NN O
thyroxine NN NN O
and NN NN O
urine NN NN O
- NN NN O
concentrating NN NN O
ability NN NN O
( NN NN O
Umax NN NN O
) NN NN O
in NN NN O
response NN NN O
to NN NN O
desmopressin NN NN O
( NN NN O
DDAVP NN NN O
) NN NN O
in NN NN O
85 NN NN O
patients NN NN O
receiving NN NN O
lithium NN NN O
. NN NN O
   
Hypothyroidism NN NN B-Disease
developed NN NN O
in NN NN O
eight NN NN O
patients NN NN O
while NN NN O
they NN NN O
were NN NN O
taking NN NN O
lithium NN NN O
. NN NN O
   
Impaired NN NN O
Umax NN NN O
was NN NN O
found NN NN O
in NN NN O
both NN NN O
euthyroid NN NN O
and NN NN O
hypothyroid NN NN B-Disease
patients NN NN O
while NN NN O
some NN NN O
hypothyroid NN NN B-Disease
patients NN NN O
concentrated NN NN O
their NN NN O
urine NN NN O
well NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
the NN NN O
dominant NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
lithium NN NN O
exerts NN NN O
these NN NN O
two NN NN O
effects NN NN O
are NN NN O
different NN NN O
. NN NN O
   
Remodelling NN NN O
of NN NN O
nerve NN NN O
structure NN NN O
in NN NN O
experimental NN NN O
isoniazid NN NN O
neuropathy NN NN B-Disease
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
The NN NN O
neuropathy NN NN B-Disease
caused NN NN O
by NN NN O
a NN NN O
single NN NN O
dose NN NN O
of NN NN O
isoniazid NN NN O
in NN NN O
rats NN NN O
was NN NN O
studied NN NN O
with NN NN O
a NN NN O
computer NN NN O
- NN NN O
assisted NN NN O
morphometric NN NN O
method NN NN O
. NN NN O
   
Scatter NN NN O
diagrams NN NN O
of NN NN O
the NN NN O
g NN NN O
ratio NN NN O
( NN NN O
quotient NN NN O
fibre NN NN O
diameter NN NN O
/ NN NN O
axon NN NN O
diameter NN NN O
) NN NN O
define NN NN O
regenerating NN NN O
fibres NN NN O
as NN NN O
a NN NN O
distinct NN NN O
population NN NN O
, NN NN O
distinguishable NN NN O
from NN NN O
the NN NN O
surviving NN NN O
fibres NN NN O
by NN NN O
reduced NN NN O
sheath NN NN O
thickness NN NN O
and NN NN O
reduced NN NN O
axon NN NN O
calibre NN NN O
. NN NN O
   
There NN NN O
was NN NN O
also NN NN O
evidence NN NN O
of NN NN O
a NN NN O
subtle NN NN O
direct NN NN O
toxic NN NN O
effect NN NN O
on NN NN O
the NN NN O
entire NN NN O
fibre NN NN O
population NN NN O
, NN NN O
causing NN NN O
axon NN NN O
shrinkage NN NN O
masked NN NN O
by NN NN O
readjustment NN NN O
of NN NN O
the NN NN O
myelin NN NN O
sheath NN NN O
. NN NN O
   
Multicenter NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
multiple NN NN O
- NN NN O
dose NN NN O
, NN NN O
parallel NN NN O
- NN NN O
groups NN NN O
efficacy NN NN O
and NN NN O
safety NN NN O
trial NN NN O
of NN NN O
azelastine NN NN O
, NN NN O
chlorpheniramine NN NN O
, NN NN O
and NN NN O
placebo NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
spring NN NN B-Disease
allergic NN NN I-Disease
rhinitis NN NN I-Disease
. NN NN O
   
Azelastine NN NN O
, NN NN O
a NN NN O
novel NN NN O
antiallergic NN NN O
medication NN NN O
, NN NN O
was NN NN O
compared NN NN O
with NN NN O
chlorpheniramine NN NN O
maleate NN NN O
and NN NN O
placebo NN NN O
for NN NN O
efficacy NN NN O
and NN NN O
safety NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
spring NN NN B-Disease
allergic NN NN I-Disease
rhinitis NN NN I-Disease
in NN NN O
a NN NN O
multicenter NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
multiple NN NN O
- NN NN O
dose NN NN O
, NN NN O
parallel NN NN O
- NN NN O
groups NN NN O
study NN NN O
. NN NN O
   
One NN NN O
hundred NN NN O
fifty NN NN O
- NN NN O
five NN NN O
subjects NN NN O
participated NN NN O
. NN NN O
   
Subjects NN NN O
ranged NN NN O
in NN NN O
age NN NN O
from NN NN O
18 NN NN O
to NN NN O
60 NN NN O
years NN NN O
of NN NN O
age NN NN O
and NN NN O
had NN NN O
at NN NN O
least NN NN O
a NN NN O
2 NN NN O
- NN NN O
year NN NN O
history NN NN O
of NN NN O
spring NN NN B-Disease
allergic NN NN I-Disease
rhinitis NN NN I-Disease
, NN NN O
confirmed NN NN O
by NN NN O
positive NN NN O
skin NN NN O
test NN NN O
to NN NN O
spring NN NN O
aeroallergens NN NN O
. NN NN O
   
Medications NN NN O
were NN NN O
given NN NN O
four NN NN O
times NN NN O
daily NN NN O
; NN NN O
the NN NN O
azelastine NN NN O
groups NN NN O
received NN NN O
0 NN NN O
. NN NN O
5 NN NN O
, NN NN O
1 NN NN O
. NN NN O
0 NN NN O
, NN NN O
or NN NN O
2 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
in NN NN O
the NN NN O
morning NN NN O
and NN NN O
evening NN NN O
with NN NN O
placebo NN NN O
in NN NN O
the NN NN O
early NN NN O
and NN NN O
late NN NN O
afternoon NN NN O
; NN NN O
the NN NN O
chlorpheniramine NN NN O
group NN NN O
received NN NN O
4 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
four NN NN O
times NN NN O
daily NN NN O
. NN NN O
   
Daily NN NN O
subject NN NN O
symptom NN NN O
cards NN NN O
were NN NN O
completed NN NN O
during NN NN O
a NN NN O
screening NN NN O
period NN NN O
to NN NN O
assess NN NN O
pretreatment NN NN O
symptoms NN NN O
and NN NN O
during NN NN O
a NN NN O
4 NN NN O
- NN NN O
week NN NN O
treatment NN NN O
period NN NN O
while NN NN O
subjects NN NN O
received NN NN O
study NN NN O
medications NN NN O
. NN NN O
   
Individual NN NN O
symptoms NN NN O
, NN NN O
total NN NN O
symptoms NN NN O
, NN NN O
and NN NN O
major NN NN O
symptoms NN NN O
were NN NN O
compared NN NN O
to NN NN O
determine NN NN O
efficacy NN NN O
of NN NN O
medication NN NN O
. NN NN O
   
Elicited NN NN O
, NN NN O
volunteered NN NN O
, NN NN O
and NN NN O
observed NN NN O
adverse NN NN O
experiences NN NN O
were NN NN O
recorded NN NN O
for NN NN O
each NN NN O
subject NN NN O
and NN NN O
compared NN NN O
among NN NN O
groups NN NN O
. NN NN O
   
Vital NN NN O
signs NN NN O
, NN NN O
body NN NN O
weights NN NN O
, NN NN O
serum NN NN O
chemistry NN NN O
values NN NN O
, NN NN O
complete NN NN O
blood NN NN O
cell NN NN O
counts NN NN O
, NN NN O
urine NN NN O
studies NN NN O
, NN NN O
and NN NN O
electrocardiograms NN NN O
were NN NN O
obtained NN NN O
for NN NN O
each NN NN O
subject NN NN O
and NN NN O
compared NN NN O
among NN NN O
groups NN NN O
. NN NN O
   
Symptoms NN NN O
relief NN NN O
in NN NN O
the NN NN O
group NN NN O
receiving NN NN O
the NN NN O
highest NN NN O
concentration NN NN O
of NN NN O
azelastine NN NN O
( NN NN O
2 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
twice NN NN O
daily NN NN O
) NN NN O
was NN NN O
statistically NN NN O
greater NN NN O
than NN NN O
in NN NN O
the NN NN O
placebo NN NN O
group NN NN O
during NN NN O
all NN NN O
weeks NN NN O
of NN NN O
the NN NN O
study NN NN O
. NN NN O
   
Lower NN NN O
doses NN NN O
of NN NN O
azelastine NN NN O
were NN NN O
statistically NN NN O
more NN NN O
effective NN NN O
than NN NN O
placebo NN NN O
only NN NN O
during NN NN O
portions NN NN O
of NN NN O
the NN NN O
first NN NN O
3 NN NN O
weeks NN NN O
of NN NN O
the NN NN O
study NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
although NN NN O
the NN NN O
chlorpheniramine NN NN O
group NN NN O
did NN NN O
have NN NN O
fewer NN NN O
symptoms NN NN O
than NN NN O
the NN NN O
placebo NN NN O
group NN NN O
during NN NN O
the NN NN O
study NN NN O
, NN NN O
the NN NN O
difference NN NN O
never NN NN O
reached NN NN O
statistical NN NN O
significance NN NN O
during NN NN O
any NN NN O
week NN NN O
of NN NN O
the NN NN O
study NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
serious NN NN O
side NN NN O
effects NN NN O
in NN NN O
any NN NN O
of NN NN O
the NN NN O
treatment NN NN O
groups NN NN O
. NN NN O
   
Drowsiness NN NN B-Disease
and NN NN O
altered NN NN B-Disease
taste NN NN I-Disease
perception NN NN I-Disease
were NN NN O
increased NN NN O
significantly NN NN O
over NN NN O
placebo NN NN O
only NN NN O
in NN NN O
the NN NN O
high NN NN O
- NN NN O
dose NN NN O
azelastine NN NN O
group NN NN O
. NN NN O
   
Azelastine NN NN O
appears NN NN O
to NN NN O
be NN NN O
a NN NN O
safe NN NN O
, NN NN O
efficacious NN NN O
medication NN NN O
for NN NN O
seasonal NN NN B-Disease
allergic NN NN I-Disease
rhinitis NN NN I-Disease
. NN NN O
   
Toxicity NN NN B-Disease
due NN NN O
to NN NN O
remission NN NN O
inducing NN NN O
drugs NN NN O
in NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
. NN NN O
   
Association NN NN O
with NN NN O
HLA NN NN O
- NN NN O
B35 NN NN O
and NN NN O
Cw4 NN NN O
antigens NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
five NN NN O
patients NN NN O
with NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
( NN NN O
RA NN NN B-Disease
) NN NN O
who NN NN O
developed NN NN O
toxicity NN NN B-Disease
while NN NN O
taking NN NN O
remission NN NN O
inducing NN NN O
drugs NN NN O
and NN NN O
30 NN NN O
without NN NN O
toxicity NN NN B-Disease
were NN NN O
studied NN NN O
for NN NN O
possible NN NN O
associations NN NN O
with NN NN O
class NN NN O
I NN NN O
and NN NN O
II NN NN O
HLA NN NN O
antigens NN NN O
. NN NN O
   
A NN NN O
strong NN NN O
association NN NN O
has NN NN O
been NN NN O
found NN NN O
between NN NN O
nephritis NN NN B-Disease
and NN NN O
dermatitis NN NN B-Disease
due NN NN O
to NN NN O
Tiopronin NN NN O
( NN NN O
a NN NN O
D NN NN O
- NN NN O
Penicillamine NN NN O
like NN NN O
compound NN NN O
) NN NN O
and NN NN O
class NN NN O
I NN NN O
antigens NN NN O
B35 NN NN O
- NN NN O
Cw4 NN NN O
, NN NN O
and NN NN O
between NN NN O
dermatitis NN NN B-Disease
due NN NN O
to NN NN O
gold NN NN O
thiosulphate NN NN O
and NN NN O
B35 NN NN O
. NN NN O
   
Compared NN NN O
to NN NN O
healthy NN NN O
controls NN NN O
a NN NN O
lower NN NN O
DR5 NN NN O
frequency NN NN O
was NN NN O
observed NN NN O
in NN NN O
patients NN NN O
with NN NN O
RA NN NN B-Disease
except NN NN O
for NN NN O
the NN NN O
Tiopronin NN NN O
related NN NN O
nephritis NN NN B-Disease
group NN NN O
. NN NN O
   
Transient NN NN O
contralateral NN NN B-Disease
rotation NN NN I-Disease
following NN NN O
unilateral NN NN O
substantia NN NN B-Disease
nigra NN NN I-Disease
lesion NN NN I-Disease
reflects NN NN O
susceptibility NN NN O
of NN NN O
the NN NN O
nigrostriatal NN NN O
system NN NN O
to NN NN O
exhaustion NN NN O
by NN NN O
amphetamine NN NN O
. NN NN O
   
Following NN NN O
unilateral NN NN O
6 NN NN O
- NN NN O
OHDA NN NN O
induced NN NN O
SN NN NN B-Disease
lesion NN NN I-Disease
, NN NN O
a NN NN O
transient NN NN O
period NN NN O
of NN NN O
contralateral NN NN B-Disease
rotation NN NN I-Disease
has NN NN O
been NN NN O
reported NN NN O
to NN NN O
precede NN NN O
the NN NN O
predominant NN NN O
ipsilateral NN NN B-Disease
circling NN NN I-Disease
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
clarify NN NN O
the NN NN O
nature NN NN O
of NN NN O
this NN NN O
initial NN NN O
contralateral NN NN B-Disease
rotation NN NN I-Disease
we NN NN O
examined NN NN O
the NN NN O
effect NN NN O
of NN NN O
the NN NN O
duration NN NN O
of NN NN O
recovery NN NN O
period NN NN O
after NN NN O
the NN NN O
lesion NN NN O
, NN NN O
on NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
rotational NN NN B-Disease
behavior NN NN I-Disease
. NN NN O
   
Three NN NN O
days NN NN O
post NN NN O
lesion NN NN O
, NN NN O
most NN NN O
rats NN NN O
circled NN NN O
predominantly NN NN O
contralaterally NN NN O
to NN NN O
the NN NN O
lesion NN NN O
. NN NN O
   
Such NN NN O
contralateral NN NN B-Disease
rotation NN NN I-Disease
may NN NN O
result NN NN O
from NN NN O
either NN NN O
degeneration NN NN O
- NN NN O
induced NN NN O
breakdown NN NN O
of NN NN O
the NN NN O
DA NN NN O
pool NN NN O
, NN NN O
or NN NN O
lesion NN NN O
- NN NN O
induced NN NN O
increase NN NN O
of NN NN O
DA NN NN O
turnover NN NN O
in NN NN O
the NN NN O
spared NN NN O
neurons NN NN O
. NN NN O
   
A NN NN O
substantial NN NN O
degree NN NN O
of NN NN O
contralateral NN NN O
preference NN NN O
was NN NN O
still NN NN O
evident NN NN O
when NN NN O
amphetamine NN NN O
was NN NN O
administered NN NN O
for NN NN O
the NN NN O
first NN NN O
time NN NN O
24 NN NN O
days NN NN O
after NN NN O
lesioning NN NN O
, NN NN O
indicating NN NN O
involvement NN NN O
of NN NN O
spared NN NN O
cells NN NN O
in NN NN O
the NN NN O
contralateral NN NN B-Disease
rotation NN NN I-Disease
. NN NN O
   
However NN NN O
, NN NN O
regardless NN NN O
of NN NN O
the NN NN O
duration NN NN O
of NN NN O
recovery NN NN O
( NN NN O
and NN NN O
irrespective NN NN O
of NN NN O
either NN NN O
lesion NN NN O
volume NN NN O
, NN NN O
amphetamine NN NN O
dose NN NN O
, NN NN O
or NN NN O
post NN NN O
- NN NN O
lesion NN NN O
motor NN NN O
exercise NN NN O
) NN NN O
, NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
rotation NN NN B-Disease
tended NN NN O
to NN NN O
become NN NN O
gradually NN NN O
more NN NN O
ipsilateral NN NN O
as NN NN O
the NN NN O
observation NN NN O
session NN NN O
progressed NN NN O
, NN NN O
and NN NN O
all NN NN O
rats NN NN O
circled NN NN O
ipsilaterally NN NN O
to NN NN O
the NN NN O
lesion NN NN O
in NN NN O
response NN NN O
to NN NN O
further NN NN O
amphetamine NN NN O
injections NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
amphetamine NN NN O
has NN NN O
an NN NN O
irreversible NN NN O
effect NN NN O
on NN NN O
the NN NN O
post NN NN O
- NN NN O
lesion NN NN O
DA NN NN O
pool NN NN O
contributing NN NN O
to NN NN O
contralateral NN NN B-Disease
rotation NN NN I-Disease
. NN NN O
   
Mitomycin NN NN O
C NN NN O
associated NN NN O
hemolytic NN NN B-Disease
uremic NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
Mitomycin NN NN O
C NN NN O
associated NN NN O
Hemolytic NN NN B-Disease
Uremic NN NN I-Disease
Syndrome NN NN I-Disease
( NN NN O
HUS NN NN B-Disease
) NN NN O
is NN NN O
a NN NN O
potentially NN NN O
fatal NN NN O
but NN NN O
uncommon NN NN O
condition NN NN O
that NN NN O
is NN NN O
not NN NN O
yet NN NN O
widely NN NN O
recognised NN NN O
. NN NN O
   
It NN NN O
consists NN NN O
of NN NN O
microangiopathic NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
, NN NN O
thrombocytopenia NN NN B-Disease
and NN NN O
progressive NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
associated NN NN O
with NN NN O
mitomycin NN NN O
C NN NN O
treatment NN NN O
and NN NN O
affects NN NN O
about NN NN O
10 NN NN O
% NN NN O
of NN NN O
patients NN NN O
treated NN NN O
with NN NN O
this NN NN O
agent NN NN O
. NN NN O
   
The NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
usually NN NN O
develops NN NN O
about NN NN O
8 NN NN O
- NN NN O
10 NN NN O
mth NN NN O
after NN NN O
start NN NN O
of NN NN O
mitomycin NN NN O
C NN NN O
treatment NN NN O
and NN NN O
the NN NN O
mortality NN NN O
is NN NN O
approximately NN NN O
60 NN NN O
% NN NN O
from NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
or NN NN O
pulmonary NN NN B-Disease
edema NN NN I-Disease
. NN NN O
   
Renal NN NN B-Disease
lesions NN NN I-Disease
are NN NN O
similar NN NN O
to NN NN O
those NN NN O
seen NN NN O
in NN NN O
idiopathic NN NN O
HUS NN NN B-Disease
and NN NN O
include NN NN O
arteriolar NN NN O
fibrin NN NN O
thrombi NN NN B-Disease
, NN NN O
expanded NN NN O
subendothelial NN NN O
zones NN NN O
in NN NN O
glomerular NN NN O
capillary NN NN O
walls NN NN O
, NN NN O
ischemic NN NN B-Disease
wrinkling NN NN O
of NN NN O
glomerular NN NN O
basement NN NN O
membranes NN NN O
and NN NN O
mesangiolysis NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
is NN NN O
postulated NN NN O
as NN NN O
mitomycin NN NN O
C NN NN O
- NN NN O
induced NN NN O
endothelial NN NN O
cell NN NN O
damage NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
the NN NN O
clinical NN NN O
course NN NN O
and NN NN O
pathological NN NN O
findings NN NN O
in NN NN O
a NN NN O
65 NN NN O
yr NN NN O
- NN NN O
old NN NN O
man NN NN O
with NN NN O
gastric NN NN B-Disease
adenocarcinoma NN NN I-Disease
who NN NN O
developed NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
and NN NN O
thrombocytopenia NN NN B-Disease
while NN NN O
on NN NN O
treatment NN NN O
with NN NN O
mitomycin NN NN O
C NN NN O
and NN NN O
died NN NN O
in NN NN O
pulmonary NN NN B-Disease
edema NN NN I-Disease
. NN NN O
   
Ketanserin NN NN O
pretreatment NN NN O
reverses NN NN O
alfentanil NN NN O
- NN NN O
induced NN NN O
muscle NN NN B-Disease
rigidity NN NN I-Disease
. NN NN O
   
Systemic NN NN O
pretreatment NN NN O
with NN NN O
ketanserin NN NN O
, NN NN O
a NN NN O
relatively NN NN O
specific NN NN O
type NN NN O
- NN NN O
2 NN NN O
serotonin NN NN O
receptor NN NN O
antagonist NN NN O
, NN NN O
significantly NN NN O
attenuated NN NN O
the NN NN O
muscle NN NN B-Disease
rigidity NN NN I-Disease
produced NN NN O
in NN NN O
rats NN NN O
by NN NN O
the NN NN O
potent NN NN O
short NN NN O
- NN NN O
acting NN NN O
opiate NN NN O
agonist NN NN O
alfentanil NN NN O
. NN NN O
   
Following NN NN O
placement NN NN O
of NN NN O
subcutaneous NN NN O
electrodes NN NN O
in NN NN O
each NN NN O
animal NN NN O
' NN NN O
s NN NN O
left NN NN O
gastrocnemius NN NN O
muscle NN NN O
, NN NN O
rigidity NN NN B-Disease
was NN NN O
assessed NN NN O
by NN NN O
analyzing NN NN O
root NN NN O
- NN NN O
mean NN NN O
- NN NN O
square NN NN O
electromyographic NN NN O
activity NN NN O
. NN NN O
   
Intraperitoneal NN NN O
ketanserin NN NN O
administration NN NN O
at NN NN O
doses NN NN O
of NN NN O
0 NN NN O
. NN NN O
63 NN NN O
and NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
prevented NN NN O
the NN NN O
alfentanil NN NN O
- NN NN O
induced NN NN O
increase NN NN O
in NN NN O
electromyographic NN NN O
activity NN NN O
compared NN NN O
with NN NN O
animals NN NN O
pretreated NN NN O
with NN NN O
saline NN NN O
. NN NN O
   
Chlordiazepoxide NN NN O
at NN NN O
doses NN NN O
up NN NN O
to NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
failed NN NN O
to NN NN O
significantly NN NN O
influence NN NN O
the NN NN O
rigidity NN NN B-Disease
produced NN NN O
by NN NN O
alfentanil NN NN O
. NN NN O
   
Despite NN NN O
the NN NN O
absence NN NN O
of NN NN O
rigidity NN NN B-Disease
, NN NN O
animals NN NN O
that NN NN O
received NN NN O
ketanserin NN NN O
( NN NN O
greater NN NN O
than NN NN O
0 NN NN O
. NN NN O
31 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
followed NN NN O
by NN NN O
alfentanil NN NN O
were NN NN O
motionless NN NN O
, NN NN O
flaccid NN NN O
, NN NN O
and NN NN O
less NN NN O
responsive NN NN O
to NN NN O
external NN NN O
stimuli NN NN O
than NN NN O
were NN NN O
animals NN NN O
receiving NN NN O
alfentanil NN NN O
alone NN NN O
. NN NN O
   
Rats NN NN O
that NN NN O
received NN NN O
ketanserin NN NN O
and NN NN O
alfentanil NN NN O
exhibited NN NN O
less NN NN O
rearing NN NN O
and NN NN O
exploratory NN NN O
behavior NN NN O
at NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
60 NN NN O
- NN NN O
min NN NN O
recording NN NN O
period NN NN O
than NN NN O
did NN NN O
animals NN NN O
that NN NN O
received NN NN O
ketanserin NN NN O
alone NN NN O
. NN NN O
   
These NN NN O
results NN NN O
, NN NN O
in NN NN O
combination NN NN O
with NN NN O
previous NN NN O
work NN NN O
, NN NN O
suggest NN NN O
that NN NN O
muscle NN NN B-Disease
rigidity NN NN I-Disease
, NN NN O
a NN NN O
clinically NN NN O
relevant NN NN O
side NN NN O
- NN NN O
effect NN NN O
of NN NN O
parenteral NN NN O
narcotic NN NN O
administration NN NN O
, NN NN O
may NN NN O
be NN NN O
partly NN NN O
mediated NN NN O
via NN NN O
serotonergic NN NN O
pathways NN NN O
. NN NN O
   
Pretreatment NN NN O
with NN NN O
type NN NN O
- NN NN O
2 NN NN O
serotonin NN NN O
antagonists NN NN O
may NN NN O
be NN NN O
clinically NN NN O
useful NN NN O
in NN NN O
attenuating NN NN O
opiate NN NN O
- NN NN O
induced NN NN O
rigidity NN NN B-Disease
, NN NN O
although NN NN O
further NN NN O
studies NN NN O
will NN NN O
be NN NN O
necessary NN NN O
to NN NN O
assess NN NN O
the NN NN O
interaction NN NN O
of NN NN O
possibly NN NN O
enhanced NN NN O
CNS NN NN O
, NN NN O
cardiovascular NN NN B-Disease
, NN NN I-Disease
and NN NN I-Disease
respiratory NN NN I-Disease
depression NN NN I-Disease
. NN NN O
   
Antagonism NN NN O
of NN NN O
diazepam NN NN O
- NN NN O
induced NN NN O
sedative NN NN O
effects NN NN O
by NN NN O
Ro15 NN NN O
- NN NN O
1788 NN NN O
in NN NN O
patients NN NN O
after NN NN O
surgery NN NN O
under NN NN O
lumbar NN NN O
epidural NN NN O
block NN NN O
. NN NN O
   
A NN NN O
double NN NN O
- NN NN O
blind NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
investigation NN NN O
of NN NN O
efficacy NN NN O
and NN NN O
safety NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
assess NN NN O
the NN NN O
efficacy NN NN O
of NN NN O
Ro15 NN NN O
- NN NN O
1788 NN NN O
and NN NN O
a NN NN O
placebo NN NN O
in NN NN O
reversing NN NN O
diazepam NN NN O
- NN NN O
induced NN NN O
effects NN NN O
after NN NN O
surgery NN NN O
under NN NN O
epidural NN NN O
block NN NN O
, NN NN O
and NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
local NN NN O
tolerance NN NN O
and NN NN O
general NN NN O
safety NN NN O
of NN NN O
Ro15 NN NN O
- NN NN O
1788 NN NN O
. NN NN O
   
Fifty NN NN O
- NN NN O
seven NN NN O
patients NN NN O
were NN NN O
sedated NN NN O
with NN NN O
diazepam NN NN O
for NN NN O
surgery NN NN O
under NN NN O
epidural NN NN O
anaesthesia NN NN O
. NN NN O
   
Antagonism NN NN O
of NN NN O
diazepam NN NN O
- NN NN O
induced NN NN O
effects NN NN O
by NN NN O
Ro15 NN NN O
- NN NN O
1788 NN NN O
was NN NN O
investigated NN NN O
postoperatively NN NN O
in NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
trial NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
' NN NN O
s NN NN O
subjective NN NN O
assessment NN NN O
of NN NN O
mood NN NN O
rating NN NN O
, NN NN O
an NN NN O
objective NN NN O
test NN NN O
of NN NN O
performance NN NN O
, NN NN O
a NN NN O
test NN NN O
for NN NN O
amnesia NN NN B-Disease
, NN NN O
and NN NN O
vital NN NN O
signs NN NN O
were NN NN O
recorded NN NN O
for NN NN O
up NN NN O
to NN NN O
300 NN NN O
min NN NN O
after NN NN O
administration NN NN O
of NN NN O
the NN NN O
trial NN NN O
drug NN NN O
. NN NN O
   
No NN NN O
significant NN NN O
differences NN NN O
between NN NN O
the NN NN O
two NN NN O
groups NN NN O
were NN NN O
observed NN NN O
for NN NN O
mood NN NN O
rating NN NN O
, NN NN O
amnesia NN NN B-Disease
, NN NN O
or NN NN O
vital NN NN O
signs NN NN O
. NN NN O
   
The NN NN O
Ro15 NN NN O
- NN NN O
1788 NN NN O
group NN NN O
showed NN NN O
a NN NN O
significant NN NN O
improvement NN NN O
in NN NN O
the NN NN O
performance NN NN O
test NN NN O
up NN NN O
to NN NN O
120 NN NN O
min NN NN O
after NN NN O
administration NN NN O
of NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
evidence NN NN O
of NN NN O
reaction NN NN O
at NN NN O
the NN NN O
injection NN NN O
site NN NN O
. NN NN O
   
Chorea NN NN B-Disease
associated NN NN O
with NN NN O
oral NN NN O
contraception NN NN O
. NN NN O
   
Three NN NN O
patients NN NN O
developed NN NN O
chorea NN NN B-Disease
while NN NN O
receiving NN NN O
oral NN NN O
contraceptives NN NN O
. NN NN O
   
Two NN NN O
were NN NN O
young NN NN O
patients NN NN O
whose NN NN O
chorea NN NN B-Disease
developed NN NN O
long NN NN O
after NN NN O
treatment NN NN O
had NN NN O
been NN NN O
started NN NN O
and NN NN O
disappeared NN NN O
soon NN NN O
after NN NN O
it NN NN O
had NN NN O
been NN NN O
discontinued NN NN O
. NN NN O
   
The NN NN O
third NN NN O
patient NN NN O
had NN NN O
acute NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
chorea NN NN B-Disease
after NN NN O
prolonged NN NN O
oral NN NN O
contraception NN NN O
. NN NN O
   
Prolonged NN NN O
administration NN NN O
of NN NN O
female NN NN O
sex NN NN O
hormones NN NN O
is NN NN O
a NN NN O
possible NN NN O
cause NN NN O
of NN NN O
chorea NN NN B-Disease
in NN NN O
women NN NN O
who NN NN O
have NN NN O
not NN NN O
previously NN NN O
had NN NN O
chorea NN NN B-Disease
or NN NN O
rheumatic NN NN B-Disease
fever NN NN I-Disease
. NN NN O
   
Co NN NN O
- NN NN O
carcinogenic NN NN B-Disease
effect NN NN O
of NN NN O
retinyl NN NN O
acetate NN NN O
on NN NN O
forestomach NN NN B-Disease
carcinogenesis NN NN I-Disease
of NN NN O
male NN NN O
F344 NN NN O
rats NN NN O
induced NN NN O
with NN NN O
butylated NN NN O
hydroxyanisole NN NN O
. NN NN O
   
The NN NN O
potential NN NN O
modifying NN NN O
effect NN NN O
of NN NN O
retinyl NN NN O
acetate NN NN O
( NN NN O
RA NN NN O
) NN NN O
on NN NN O
butylated NN NN O
hydroxyanisole NN NN O
( NN NN O
BHA NN NN O
) NN NN O
- NN NN O
induced NN NN O
rat NN NN O
forestomach NN NN B-Disease
tumorigenesis NN NN I-Disease
was NN NN O
examined NN NN O
. NN NN O
   
Male NN NN O
F344 NN NN O
rats NN NN O
, NN NN O
5 NN NN O
weeks NN NN O
of NN NN O
age NN NN O
, NN NN O
were NN NN O
maintained NN NN O
on NN NN O
diet NN NN O
containing NN NN O
1 NN NN O
% NN NN O
or NN NN O
2 NN NN O
% NN NN O
BHA NN NN O
by NN NN O
weight NN NN O
and NN NN O
simultaneously NN NN O
on NN NN O
drinking NN NN O
water NN NN O
supplemented NN NN O
with NN NN O
RA NN NN O
at NN NN O
various NN NN O
concentrations NN NN O
( NN NN O
w NN NN O
/ NN NN O
v NN NN O
) NN NN O
for NN NN O
52 NN NN O
weeks NN NN O
. NN NN O
   
In NN NN O
groups NN NN O
given NN NN O
2 NN NN O
% NN NN O
BHA NN NN O
, NN NN O
although NN NN O
marked NN NN O
hyperplastic NN NN O
changes NN NN O
of NN NN O
the NN NN O
forestomach NN NN O
epithelium NN NN O
were NN NN O
observed NN NN O
in NN NN O
all NN NN O
animals NN NN O
, NN NN O
co NN NN O
- NN NN O
administration NN NN O
of NN NN O
0 NN NN O
. NN NN O
25 NN NN O
% NN NN O
RA NN NN O
significantly NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
increased NN NN O
the NN NN O
incidence NN NN O
of NN NN O
forestomach NN NN B-Disease
tumors NN NN I-Disease
( NN NN O
squamous NN NN B-Disease
cell NN NN I-Disease
papilloma NN NN I-Disease
and NN NN O
carcinoma NN NN B-Disease
) NN NN O
to NN NN O
60 NN NN O
% NN NN O
( NN NN O
9 NN NN O
/ NN NN O
15 NN NN O
, NN NN O
2 NN NN O
rats NN NN O
with NN NN O
carcinoma NN NN B-Disease
) NN NN O
from NN NN O
15 NN NN O
% NN NN O
( NN NN O
3 NN NN O
/ NN NN O
20 NN NN O
, NN NN O
one NN NN O
rat NN NN O
with NN NN O
carcinoma NN NN B-Disease
) NN NN O
in NN NN O
the NN NN O
group NN NN O
given NN NN O
RA NN NN O
- NN NN O
free NN NN O
water NN NN O
. NN NN O
   
In NN NN O
rats NN NN O
given NN NN O
1 NN NN O
% NN NN O
BHA NN NN O
, NN NN O
RA NN NN O
co NN NN O
- NN NN O
administered NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
0 NN NN O
. NN NN O
05 NN NN O
, NN NN O
0 NN NN O
. NN NN O
1 NN NN O
, NN NN O
0 NN NN O
. NN NN O
2 NN NN O
or NN NN O
0 NN NN O
. NN NN O
25 NN NN O
% NN NN O
showed NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
enhancing NN NN O
effect NN NN O
on NN NN O
the NN NN O
development NN NN O
of NN NN O
the NN NN O
BHA NN NN O
- NN NN O
induced NN NN O
epithelial NN NN B-Disease
hyperplasia NN NN I-Disease
. NN NN O
   
Tumors NN NN B-Disease
, NN NN O
all NN NN O
papillomas NN NN B-Disease
, NN NN O
were NN NN O
induced NN NN O
in NN NN O
3 NN NN O
rats NN NN O
( NN NN O
17 NN NN O
% NN NN O
) NN NN O
with NN NN O
0 NN NN O
. NN NN O
25 NN NN O
% NN NN O
RA NN NN O
and NN NN O
in NN NN O
one NN NN O
rat NN NN O
( NN NN O
10 NN NN O
% NN NN O
) NN NN O
with NN NN O
0 NN NN O
. NN NN O
05 NN NN O
% NN NN O
RA NN NN O
co NN NN O
- NN NN O
administration NN NN O
. NN NN O
   
RA NN NN O
alone NN NN O
did NN NN O
not NN NN O
induce NN NN O
hyperplastic NN NN O
changes NN NN O
in NN NN O
the NN NN O
forestomach NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
RA NN NN O
acted NN NN O
as NN NN O
a NN NN O
co NN NN O
- NN NN O
carcinogen NN NN O
in NN NN O
the NN NN O
BHA NN NN O
forestomach NN NN B-Disease
carcinogenesis NN NN I-Disease
of NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
A NN NN O
prospective NN NN O
study NN NN O
on NN NN O
the NN NN O
dose NN NN O
dependency NN NN O
of NN NN O
cardiotoxicity NN NN B-Disease
induced NN NN O
by NN NN O
mitomycin NN NN O
C NN NN O
. NN NN O
   
Since NN NN O
1975 NN NN O
mitomycin NN NN O
C NN NN O
( NN NN O
MMC NN NN O
) NN NN O
has NN NN O
been NN NN O
suggested NN NN O
to NN NN O
be NN NN O
cardiotoxic NN NN B-Disease
, NN NN O
especially NN NN O
when NN NN O
combined NN NN O
with NN NN O
or NN NN O
given NN NN O
following NN NN O
doxorubicin NN NN O
. NN NN O
   
Data NN NN O
on NN NN O
dose NN NN O
dependency NN NN O
or NN NN O
incidence NN NN O
concerning NN NN O
this NN NN O
side NN NN O
effect NN NN O
were NN NN O
not NN NN O
known NN NN O
. NN NN O
   
We NN NN O
have NN NN O
initiated NN NN O
a NN NN O
prospective NN NN O
study NN NN O
to NN NN O
obtain NN NN O
some NN NN O
more NN NN O
data NN NN O
on NN NN O
these NN NN O
subjects NN NN O
. NN NN O
   
Forty NN NN O
- NN NN O
four NN NN O
MMC NN NN O
- NN NN O
treated NN NN O
patients NN NN O
were NN NN O
studied NN NN O
, NN NN O
37 NN NN O
of NN NN O
them NN NN O
could NN NN O
be NN NN O
evaluated NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
were NN NN O
studied NN NN O
by NN NN O
repeated NN NN O
physical NN NN O
examinations NN NN O
, NN NN O
chest NN NN O
X NN NN O
- NN NN O
rays NN NN O
, NN NN O
electro NN NN O
- NN NN O
and NN NN O
echocardiography NN NN O
and NN NN O
radionuclide NN NN O
left NN NN O
ventricular NN NN O
ejection NN NN O
fraction NN NN O
( NN NN O
EF NN NN O
) NN NN O
determinations NN NN O
. NN NN O
   
The NN NN O
results NN NN O
were NN NN O
evaluated NN NN O
per NN NN O
cumulative NN NN O
dose NN NN O
level NN NN O
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
patients NN NN O
developed NN NN O
cardiac NN NN B-Disease
failure NN NN I-Disease
after NN NN O
30 NN NN O
mg NN NN O
m NN NN O
- NN NN O
2 NN NN O
MMC NN NN O
and NN NN O
only NN NN O
150 NN NN O
mg NN NN O
m NN NN O
- NN NN O
2 NN NN O
doxorubicin NN NN O
. NN NN O
   
The NN NN O
cardiac NN NN B-Disease
failure NN NN I-Disease
was NN NN O
predicted NN NN O
by NN NN O
a NN NN O
drop NN NN O
in NN NN O
EF NN NN O
determined NN NN O
during NN NN O
a NN NN O
cold NN NN O
pressor NN NN O
test NN NN O
. NN NN O
   
   O
of NN NN O
the NN NN O
other NN NN O
patients NN NN O
developed NN NN O
clinical NN NN O
cardiotoxicity NN NN B-Disease
, NN NN O
nor NN NN O
did NN NN O
the NN NN O
studied NN NN O
parameters NN NN O
change NN NN O
. NN NN O
   
The NN NN O
literature NN NN O
on NN NN O
this NN NN O
subject NN NN O
was NN NN O
also NN NN O
reviewed NN NN O
. NN NN O
   
Based NN NN O
on NN NN O
the NN NN O
combined NN NN O
data NN NN O
from NN NN O
the NN NN O
present NN NN O
study NN NN O
and NN NN O
the NN NN O
literature NN NN O
, NN NN O
we NN NN O
suggest NN NN O
that NN NN O
MMC NN NN O
- NN NN O
related NN NN O
cardiotoxicity NN NN B-Disease
is NN NN O
dose NN NN O
dependent NN NN O
, NN NN O
occurring NN NN O
at NN NN O
cumulative NN NN O
dose NN NN O
levels NN NN O
of NN NN O
30 NN NN O
mg NN NN O
m NN NN O
- NN NN O
2 NN NN O
or NN NN O
more NN NN O
, NN NN O
mainly NN NN O
in NN NN O
patients NN NN O
also NN NN O
( NN NN O
previously NN NN O
or NN NN O
simultaneously NN NN O
) NN NN O
treated NN NN O
with NN NN O
doxorubicin NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
is NN NN O
likely NN NN O
to NN NN O
be NN NN O
less NN NN O
than NN NN O
10 NN NN O
% NN NN O
even NN NN O
for NN NN O
this NN NN O
risk NN NN O
group NN NN O
. NN NN O
   
Reversible NN NN O
cerebral NN NN B-Disease
lesions NN NN I-Disease
associated NN NN O
with NN NN O
tiazofurin NN NN O
usage NN NN O
: NN NN O
MR NN NN O
demonstration NN NN O
. NN NN O
   
Tiazofurin NN NN O
is NN NN O
an NN NN O
experimental NN NN O
chemotherapeutic NN NN O
agent NN NN O
currently NN NN O
undergoing NN NN O
clinical NN NN O
evaluation NN NN O
. NN NN O
   
We NN NN O
report NN NN O
our NN NN O
results NN NN O
with NN NN O
magnetic NN NN O
resonance NN NN O
( NN NN O
MR NN NN O
) NN NN O
in NN NN O
demonstrating NN NN O
reversible NN NN O
cerebral NN NN B-Disease
abnormalities NN NN I-Disease
concurrent NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
this NN NN O
drug NN NN O
. NN NN O
   
The NN NN O
abnormalities NN NN O
on NN NN O
MR NN NN O
were NN NN O
correlated NN NN O
with NN NN O
findings NN NN O
on NN NN O
CT NN NN O
as NN NN O
well NN NN O
as NN NN O
with NN NN O
cerebral NN NN O
angiography NN NN O
. NN NN O
   
The NN NN O
utility NN NN O
of NN NN O
MR NN NN O
in NN NN O
the NN NN O
evaluation NN NN O
of NN NN O
patients NN NN O
receiving NN NN O
this NN NN O
new NN NN O
agent NN NN O
is NN NN O
illustrated NN NN O
. NN NN O
   
Receptor NN NN O
mechanisms NN NN O
of NN NN O
nicotine NN NN O
- NN NN O
induced NN NN O
locomotor NN NN B-Disease
hyperactivity NN NN I-Disease
in NN NN O
chronic NN NN O
nicotine NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
Rats NN NN O
were NN NN O
pretreated NN NN O
with NN NN O
saline NN NN O
or NN NN O
nicotine NN NN O
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
day NN NN O
) NN NN O
by NN NN O
subcutaneously NN NN O
implanting NN NN O
each NN NN O
animal NN NN O
with NN NN O
an NN NN O
Alzet NN NN O
osmotic NN NN O
mini NN NN O
- NN NN O
pump NN NN O
which NN NN O
continuously NN NN O
released NN NN O
saline NN NN O
or NN NN O
nicotine NN NN O
for NN NN O
1 NN NN O
, NN NN O
5 NN NN O
and NN NN O
14 NN NN O
days NN NN O
. NN NN O
   
At NN NN O
the NN NN O
end NN NN O
of NN NN O
each NN NN O
pretreatment NN NN O
period NN NN O
, NN NN O
animals NN NN O
were NN NN O
used NN NN O
for NN NN O
( NN NN O
i NN NN O
) NN NN O
determining NN NN O
their NN NN O
locomotor NN NN O
response NN NN O
to NN NN O
acutely NN NN O
injected NN NN O
nicotine NN NN O
( NN NN O
0 NN NN O
. NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
and NN NN O
( NN NN O
ii NN NN O
) NN NN O
measuring NN NN O
the NN NN O
density NN NN O
of NN NN O
L NN NN O
- NN NN O
[ NN NN O
3H NN NN O
] NN NN O
nicotine NN NN O
and NN NN O
[ NN NN O
3H NN NN O
] NN NN O
spiperone NN NN O
binding NN NN O
sites NN NN O
in NN NN O
the NN NN O
striatum NN NN O
. NN NN O
   
We NN NN O
observed NN NN O
no NN NN O
changes NN NN O
in NN NN O
nicotine NN NN O
- NN NN O
induced NN NN O
locomotor NN NN O
response NN NN O
, NN NN O
striatal NN NN O
L NN NN O
- NN NN O
[ NN NN O
3H NN NN O
] NN NN O
nicotine NN NN O
and NN NN O
[ NN NN O
3H NN NN O
] NN NN O
spiperone NN NN O
binding NN NN O
in NN NN O
the NN NN O
animals NN NN O
pretreated NN NN O
with NN NN O
nicotine NN NN O
for NN NN O
1 NN NN O
day NN NN O
. NN NN O
   
In NN NN O
rats NN NN O
which NN NN O
were NN NN O
pretreated NN NN O
with NN NN O
nicotine NN NN O
for NN NN O
5 NN NN O
days NN NN O
, NN NN O
there NN NN O
was NN NN O
a NN NN O
significant NN NN O
increase NN NN O
in NN NN O
the NN NN O
nicotine NN NN O
- NN NN O
stimulated NN NN O
locomotor NN NN O
response NN NN O
which NN NN O
was NN NN O
associated NN NN O
with NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
number NN NN O
of NN NN O
L NN NN O
- NN NN O
[ NN NN O
3H NN NN O
] NN NN O
nicotine NN NN O
binding NN NN O
sites NN NN O
and NN NN O
also NN NN O
with NN NN O
an NN NN O
elevated NN NN O
dopamine NN NN O
( NN NN O
DA NN NN O
) NN NN O
level NN NN O
in NN NN O
the NN NN O
striatum NN NN O
. NN NN O
   
The NN NN O
number NN NN O
of NN NN O
striatal NN NN O
[ NN NN O
3H NN NN O
] NN NN O
spiperone NN NN O
binding NN NN O
sites NN NN O
was NN NN O
not NN NN O
affected NN NN O
. NN NN O
   
In NN NN O
animals NN NN O
pretreated NN NN O
with NN NN O
nicotine NN NN O
for NN NN O
14 NN NN O
days NN NN O
, NN NN O
the NN NN O
nicotine NN NN O
- NN NN O
induced NN NN O
locomotor NN NN O
response NN NN O
remained NN NN O
to NN NN O
be NN NN O
potentiated NN NN O
. NN NN O
   
However NN NN O
, NN NN O
this NN NN O
response NN NN O
was NN NN O
correlated NN NN O
with NN NN O
an NN NN O
elevated NN NN O
number NN NN O
of NN NN O
striatal NN NN O
[ NN NN O
3H NN NN O
] NN NN O
spiperone NN NN O
binding NN NN O
sites NN NN O
, NN NN O
whereas NN NN O
the NN NN O
number NN NN O
of NN NN O
striatal NN NN O
L NN NN O
- NN NN O
[ NN NN O
3H NN NN O
] NN NN O
nicotine NN NN O
binding NN NN O
sites NN NN O
and NN NN O
the NN NN O
striatal NN NN O
DA NN NN O
level NN NN O
were NN NN O
normal NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
chronic NN NN O
nicotine NN NN O
- NN NN O
treated NN NN O
rats NN NN O
develop NN NN O
locomotor NN NN B-Disease
hyperactivity NN NN I-Disease
in NN NN O
response NN NN O
to NN NN O
nicotine NN NN O
initially NN NN O
due NN NN O
to NN NN O
increases NN NN O
of NN NN O
both NN NN O
the NN NN O
density NN NN O
of NN NN O
nicotinic NN NN O
receptors NN NN O
and NN NN O
DA NN NN O
concentration NN NN O
, NN NN O
followed NN NN O
by NN NN O
inducing NN NN O
DA NN NN O
receptor NN NN O
supersensitivity NN NN O
in NN NN O
the NN NN O
striatum NN NN O
. NN NN O
   
Amelioration NN NN O
of NN NN O
bendrofluazide NN NN O
- NN NN O
induced NN NN O
hypokalemia NN NN B-Disease
by NN NN O
timolol NN NN O
. NN NN O
   
The NN NN O
beta NN NN O
adrenergic NN NN O
blocking NN NN O
drug NN NN O
, NN NN O
timolol NN NN O
, NN NN O
tended NN NN O
to NN NN O
correct NN NN O
the NN NN O
hypokalemia NN NN B-Disease
of NN NN O
short NN NN O
- NN NN O
term NN NN O
bendrofluazide NN NN O
treatment NN NN O
in NN NN O
6 NN NN O
healthy NN NN O
male NN NN O
subjects NN NN O
and NN NN O
although NN NN O
the NN NN O
effect NN NN O
was NN NN O
small NN NN O
it NN NN O
was NN NN O
significant NN NN O
. NN NN O
   
Timolol NN NN O
also NN NN O
reduced NN NN O
the NN NN O
rise NN NN O
in NN NN O
plasma NN NN O
aldosterone NN NN O
and NN NN O
urine NN NN O
potassium NN NN O
excretion NN NN O
following NN NN O
bendrofluazide NN NN O
and NN NN O
increased NN NN O
the NN NN O
urine NN NN O
sodium NN NN O
/ NN NN O
potassium NN NN O
ratio NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
evidence NN NN O
of NN NN O
a NN NN O
shift NN NN O
of NN NN O
potassium NN NN O
from NN NN O
the NN NN O
intracellular NN NN O
to NN NN O
the NN NN O
extracellular NN NN O
space NN NN O
. NN NN O
   
St NN NN B-Disease
. NN NN I-Disease
   
Anthony NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
fire NN NN I-Disease
, NN NN O
then NN NN O
and NN NN O
now NN NN O
: NN NN O
a NN NN O
case NN NN O
report NN NN O
and NN NN O
historical NN NN O
review NN NN O
. NN NN O
   
A NN NN O
rare NN NN O
case NN NN O
of NN NN O
morbid NN NN O
vasospasm NN NN B-Disease
, NN NN O
together NN NN O
with NN NN O
striking NN NN O
angiographic NN NN O
findings NN NN O
, NN NN O
is NN NN O
described NN NN O
secondary NN NN O
to NN NN O
the NN NN O
ingestion NN NN O
of NN NN O
methysergide NN NN O
by NN NN O
a NN NN O
48 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
. NN NN O
   
A NN NN O
brief NN NN O
review NN NN O
of NN NN O
the NN NN O
literature NN NN O
on NN NN O
similar NN NN O
cases NN NN O
is NN NN O
presented NN NN O
. NN NN O
   
A NN NN O
discussion NN NN O
of NN NN O
the NN NN O
history NN NN O
of NN NN O
ergot NN NN O
includes NN NN O
its NN NN O
original NN NN O
discovery NN NN O
, NN NN O
the NN NN O
epidemics NN NN O
of NN NN O
gangrene NN NN B-Disease
that NN NN O
it NN NN O
has NN NN O
caused NN NN O
through NN NN O
the NN NN O
ages NN NN O
and NN NN O
its NN NN O
past NN NN O
and NN NN O
present NN NN O
role NN NN O
in NN NN O
the NN NN O
management NN NN O
of NN NN O
migraine NN NN B-Disease
headache NN NN I-Disease
. NN NN O
   
Despite NN NN O
the NN NN O
advent NN NN O
of NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
and NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
antagonists NN NN O
, NN NN O
ergot NN NN O
preparations NN NN O
continue NN NN O
to NN NN O
play NN NN O
a NN NN O
major NN NN O
role NN NN O
in NN NN O
migraine NN NN B-Disease
therapy NN NN O
, NN NN O
so NN NN O
that NN NN O
the NN NN O
danger NN NN O
of NN NN O
St NN NN B-Disease
. NN NN I-Disease
   
Anthony NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
fire NN NN I-Disease
persists NN NN O
. NN NN O
   
Cardiac NN NN O
transplantation NN NN O
: NN NN O
improved NN NN O
quality NN NN O
of NN NN O
survival NN NN O
with NN NN O
a NN NN O
modified NN NN O
immunosuppressive NN NN O
protocol NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
on NN NN O
renal NN NN O
function NN NN O
on NN NN O
two NN NN O
different NN NN O
immunosuppressive NN NN O
protocols NN NN O
were NN NN O
evaluated NN NN O
retrospectively NN NN O
in NN NN O
two NN NN O
subsequent NN NN O
groups NN NN O
of NN NN O
heart NN NN O
transplant NN NN O
recipients NN NN O
. NN NN O
   
In NN NN O
group NN NN O
I NN NN O
, NN NN O
cyclosporine NN NN O
was NN NN O
given NN NN O
before NN NN O
the NN NN O
procedure NN NN O
at NN NN O
a NN NN O
loading NN NN O
dose NN NN O
of NN NN O
17 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
and NN NN O
then NN NN O
continued NN NN O
after NN NN O
the NN NN O
procedure NN NN O
to NN NN O
keep NN NN O
a NN NN O
whole NN NN O
blood NN NN O
level NN NN O
about NN NN O
1000 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
. NN NN O
   
In NN NN O
group NN NN O
II NN NN O
, NN NN O
cyclosporine NN NN O
was NN NN O
started NN NN O
only NN NN O
after NN NN O
the NN NN O
procedure NN NN O
at NN NN O
a NN NN O
lower NN NN O
dosage NN NN O
and NN NN O
was NN NN O
complemented NN NN O
by NN NN O
azathioprine NN NN O
, NN NN O
which NN NN O
was NN NN O
used NN NN O
for NN NN O
the NN NN O
first NN NN O
postoperative NN NN O
week NN NN O
. NN NN O
   
Group NN NN O
II NN NN O
showed NN NN O
a NN NN O
better NN NN O
perioperative NN NN O
renal NN NN O
function NN NN O
as NN NN O
determined NN NN O
by NN NN O
serum NN NN O
blood NN NN O
urea NN NN O
nitrogen NN NN O
and NN NN O
serum NN NN O
creatinine NN NN O
levels NN NN O
. NN NN O
   
Group NN NN O
II NN NN O
also NN NN O
showed NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
of NN NN O
chronic NN NN O
nephrotoxicity NN NN B-Disease
secondary NN NN O
to NN NN O
long NN NN O
- NN NN O
term NN NN O
therapy NN NN O
with NN NN O
cyclosporine NN NN O
. NN NN O
   
Despite NN NN O
this NN NN O
improvement NN NN O
in NN NN O
late NN NN O
renal NN NN O
function NN NN O
, NN NN O
group NN NN O
II NN NN O
still NN NN O
shows NN NN O
a NN NN O
slow NN NN O
rise NN NN O
in NN NN O
serum NN NN O
creatinine NN NN O
. NN NN O
   
We NN NN O
think NN NN O
that NN NN O
even NN NN O
these NN NN O
lower NN NN O
dosages NN NN O
of NN NN O
cyclosporine NN NN O
can NN NN O
cause NN NN O
chronic NN NN O
nephrotoxicity NN NN B-Disease
and NN NN O
that NN NN O
further NN NN O
modification NN NN O
of NN NN O
the NN NN O
immunosuppressive NN NN O
regimen NN NN O
is NN NN O
required NN NN O
to NN NN O
completely NN NN O
abolish NN NN O
this NN NN O
toxic NN NN O
side NN NN O
effect NN NN O
. NN NN O
   
Ethopropazine NN NN O
and NN NN O
benztropine NN NN O
in NN NN O
neuroleptic NN NN O
- NN NN O
induced NN NN O
parkinsonism NN NN B-Disease
. NN NN O
   
In NN NN O
a NN NN O
12 NN NN O
- NN NN O
week NN NN O
controlled NN NN O
study NN NN O
ethopropazine NN NN O
was NN NN O
compared NN NN O
to NN NN O
benztropine NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
parkinsonism NN NN B-Disease
induced NN NN O
by NN NN O
fluphenazine NN NN O
enanthate NN NN O
in NN NN O
60 NN NN O
schizophrenic NN NN B-Disease
outpatients NN NN O
. NN NN O
   
Ethopropazine NN NN O
and NN NN O
benztropine NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
equally NN NN O
effective NN NN O
in NN NN O
controlling NN NN O
parkinsonian NN NN B-Disease
symptoms NN NN I-Disease
and NN NN O
were NN NN O
as NN NN O
efficacious NN NN O
as NN NN O
procyclidine NN NN O
, NN NN O
their NN NN O
previous NN NN O
antiparkinsonian NN NN O
drug NN NN O
. NN NN O
   
However NN NN O
, NN NN O
benztropine NN NN O
treated NN NN O
patients NN NN O
had NN NN O
a NN NN O
significant NN NN O
increase NN NN O
in NN NN O
tardive NN NN B-Disease
dyskinesia NN NN I-Disease
compared NN NN O
to NN NN O
their NN NN O
condition NN NN O
during NN NN O
procyclindine NN NN O
treatment NN NN O
, NN NN O
and NN NN O
significantly NN NN O
more NN NN O
anxiety NN NN B-Disease
and NN NN O
depression NN NN B-Disease
than NN NN O
ethopropazine NN NN O
treated NN NN O
patients NN NN O
. NN NN O
   
This NN NN O
suggests NN NN O
that NN NN O
benztropine NN NN O
is NN NN O
not NN NN O
the NN NN O
anticholinergic NN NN O
drug NN NN O
of NN NN O
choice NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
neuroleptic NN NN O
- NN NN O
induced NN NN O
parkinsonian NN NN B-Disease
symptoms NN NN I-Disease
, NN NN O
because NN NN O
of NN NN O
its NN NN O
more NN NN O
toxic NN NN O
central NN NN O
and NN NN O
peripheral NN NN O
atropinic NN NN O
effect NN NN O
. NN NN O
   
Quinidine NN NN O
phenylethylbarbiturate NN NN O
- NN NN O
induced NN NN O
fulminant NN NN O
hepatitis NN NN B-Disease
in NN NN O
a NN NN O
pregnant NN NN O
woman NN NN O
. NN NN O
   
A NN NN O
case NN NN O
report NN NN O
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
19 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
Laotian NN NN O
patient NN NN O
affected NN NN O
by NN NN O
fulminant NN NN O
hepatitis NN NN B-Disease
during NN NN O
the NN NN O
third NN NN O
trimester NN NN O
of NN NN O
her NN NN O
pregnancy NN NN O
after NN NN O
a NN NN O
1 NN NN O
- NN NN O
month NN NN O
administration NN NN O
of NN NN O
quinidine NN NN O
phenylethylbarbiturate NN NN O
. NN NN O
   
After NN NN O
delivery NN NN O
, NN NN O
the NN NN O
patient NN NN O
underwent NN NN O
orthotopic NN NN O
liver NN NN O
transplantation NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
was NN NN O
in NN NN O
good NN NN O
condition NN NN O
16 NN NN O
months NN NN O
after NN NN O
liver NN NN O
transplantation NN NN O
. NN NN O
   
Quinidine NN NN O
itself NN NN O
or NN NN O
phenylethylbarbiturate NN NN O
may NN NN O
be NN NN O
responsible NN NN O
for NN NN O
fulminant NN NN O
hepatitis NN NN B-Disease
in NN NN O
this NN NN O
patient NN NN O
. NN NN O
   
Mechanisms NN NN O
of NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
induced NN NN O
by NN NN O
epinephrine NN NN O
: NN NN O
comparison NN NN O
with NN NN O
exercise NN NN O
- NN NN O
induced NN NN O
ischemia NN NN B-Disease
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
epinephrine NN NN O
in NN NN O
eliciting NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
was NN NN O
examined NN NN O
in NN NN O
patients NN NN O
with NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Objective NN NN O
signs NN NN O
of NN NN O
ischemia NN NN B-Disease
and NN NN O
factors NN NN O
increasing NN NN O
myocardial NN NN O
oxygen NN NN O
consumption NN NN O
were NN NN O
compared NN NN O
during NN NN O
epinephrine NN NN O
infusion NN NN O
and NN NN O
supine NN NN O
bicycle NN NN O
exercise NN NN O
. NN NN O
   
Both NN NN O
epinephrine NN NN O
and NN NN O
exercise NN NN O
produced NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
as NN NN O
evidenced NN NN O
by NN NN O
ST NN NN O
segment NN NN O
depression NN NN B-Disease
and NN NN O
angina NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
mechanisms NN NN O
of NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
induced NN NN O
by NN NN O
epinephrine NN NN O
were NN NN O
significantly NN NN O
different NN NN O
from NN NN O
those NN NN O
of NN NN O
exercise NN NN O
. NN NN O
   
Exercise NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
was NN NN O
marked NN NN O
predominantly NN NN O
by NN NN O
increased NN NN O
heart NN NN O
rate NN NN O
and NN NN O
rate NN NN O
- NN NN O
pressure NN NN O
product NN NN O
with NN NN O
a NN NN O
minor NN NN O
contribution NN NN O
of NN NN O
end NN NN O
- NN NN O
diastolic NN NN O
volume NN NN O
, NN NN O
while NN NN O
epinephrine NN NN O
- NN NN O
induced NN NN O
ischemia NN NN B-Disease
was NN NN O
characterized NN NN O
by NN NN O
a NN NN O
marked NN NN O
increase NN NN O
in NN NN O
contractility NN NN O
and NN NN O
a NN NN O
less NN NN O
pronounced NN NN O
increase NN NN O
in NN NN O
heart NN NN O
rate NN NN O
and NN NN O
rate NN NN O
- NN NN O
pressure NN NN O
product NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
ischemia NN NN B-Disease
produced NN NN O
by NN NN O
epinephrine NN NN O
, NN NN O
as NN NN O
may NN NN O
occur NN NN O
during NN NN O
states NN NN O
of NN NN O
emotional NN NN O
distress NN NN O
, NN NN O
has NN NN O
a NN NN O
mechanism NN NN O
distinct NN NN O
from NN NN O
that NN NN O
due NN NN O
to NN NN O
physical NN NN O
exertion NN NN O
. NN NN O
   
Recent NN NN O
preclinical NN NN O
and NN NN O
clinical NN NN O
studies NN NN O
with NN NN O
the NN NN O
thymidylate NN NN O
synthase NN NN O
inhibitor NN NN O
N10 NN NN O
- NN NN O
propargyl NN NN O
- NN NN O
5 NN NN O
, NN NN O
8 NN NN O
- NN NN O
dideazafolic NN NN O
acid NN NN O
( NN NN O
CB NN NN O
3717 NN NN O
) NN NN O
. NN NN O
   
CB NN NN O
3717 NN NN O
, NN NN O
N10 NN NN O
- NN NN O
propargyl NN NN O
- NN NN O
5 NN NN O
, NN NN O
8 NN NN O
- NN NN O
dideazafolic NN NN O
acid NN NN O
, NN NN O
is NN NN O
a NN NN O
tight NN NN O
- NN NN O
binding NN NN O
inhibitor NN NN O
of NN NN O
thymidylate NN NN O
synthase NN NN O
( NN NN O
TS NN NN O
) NN NN O
whose NN NN O
cytotoxicity NN NN B-Disease
is NN NN O
mediated NN NN O
solely NN NN O
through NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
this NN NN O
enzyme NN NN O
. NN NN O
   
Recent NN NN O
preclinical NN NN O
studies NN NN O
have NN NN O
focused NN NN O
on NN NN O
the NN NN O
intracellular NN NN O
formation NN NN O
of NN NN O
CB NN NN O
3717 NN NN O
polyglutamates NN NN O
. NN NN O
   
Following NN NN O
a NN NN O
12 NN NN O
- NN NN O
hour NN NN O
exposure NN NN O
of NN NN O
L1210 NN NN O
cells NN NN O
to NN NN O
50 NN NN O
microM NN NN O
[ NN NN O
3H NN NN O
] NN NN O
CB NN NN O
3717 NN NN O
, NN NN O
30 NN NN O
% NN NN O
of NN NN O
the NN NN O
extractable NN NN O
radioactivity NN NN O
could NN NN O
be NN NN O
accounted NN NN O
for NN NN O
as NN NN O
CB NN NN O
3717 NN NN O
tetra NN NN O
- NN NN O
and NN NN O
pentaglutamate NN NN O
, NN NN O
as NN NN O
determined NN NN O
by NN NN O
high NN NN O
- NN NN O
pressure NN NN O
liquid NN NN O
chromatography NN NN O
( NN NN O
HPLC NN NN O
) NN NN O
analyses NN NN O
. NN NN O
   
As NN NN O
inhibitors NN NN O
of NN NN O
isolated NN NN O
L1210 NN NN O
TS NN NN O
, NN NN O
CB NN NN O
3717 NN NN O
di NN NN O
- NN NN O
, NN NN O
tri NN NN O
- NN NN O
, NN NN O
tetra NN NN O
- NN NN O
and NN NN O
pentaglutamate NN NN O
are NN NN O
26 NN NN O
- NN NN O
, NN NN O
87 NN NN O
- NN NN O
, NN NN O
119 NN NN O
- NN NN O
and NN NN O
114 NN NN O
- NN NN O
fold NN NN O
more NN NN O
potent NN NN O
than NN NN O
CB NN NN O
3717 NN NN O
, NN NN O
respectively NN NN O
, NN NN O
and NN NN O
their NN NN O
formation NN NN O
may NN NN O
, NN NN O
therefore NN NN O
, NN NN O
be NN NN O
an NN NN O
important NN NN O
determinant NN NN O
of NN NN O
CB NN NN O
3717 NN NN O
cytotoxicity NN NN B-Disease
. NN NN O
   
In NN NN O
early NN NN O
clinical NN NN O
studies NN NN O
with NN NN O
CB NN NN O
3717 NN NN O
, NN NN O
activity NN NN O
has NN NN O
been NN NN O
seen NN NN O
in NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
ovarian NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
hepatoma NN NN B-Disease
, NN NN O
and NN NN O
mesothelioma NN NN B-Disease
. NN NN O
   
Toxicities NN NN B-Disease
included NN NN O
hepatotoxicity NN NN B-Disease
, NN NN O
malaise NN NN B-Disease
, NN NN O
and NN NN O
dose NN NN O
- NN NN O
limiting NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
This NN NN O
latter NN NN O
effect NN NN O
is NN NN O
thought NN NN O
to NN NN O
be NN NN O
due NN NN O
to NN NN O
drug NN NN O
precipitation NN NN O
within NN NN O
the NN NN O
renal NN NN O
tubule NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
the NN NN O
poor NN NN O
solubility NN NN O
of NN NN O
CB NN NN O
3717 NN NN O
under NN NN O
acidic NN NN O
conditions NN NN O
. NN NN O
   
In NN NN O
an NN NN O
attempt NN NN O
to NN NN O
overcome NN NN O
this NN NN O
problem NN NN O
, NN NN O
a NN NN O
clinical NN NN O
trial NN NN O
of NN NN O
CB NN NN O
3717 NN NN O
administered NN NN O
with NN NN O
alkaline NN NN O
diuresis NN NN O
is NN NN O
under NN NN O
way NN NN O
. NN NN O
   
Preliminary NN NN O
results NN NN O
at NN NN O
400 NN NN O
and NN NN O
500 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
suggest NN NN O
that NN NN O
a NN NN O
reduction NN NN O
in NN NN O
nephrotoxicity NN NN B-Disease
may NN NN O
have NN NN O
been NN NN O
achieved NN NN O
with NN NN O
only NN NN O
1 NN NN O
instance NN NN O
of NN NN O
renal NN NN B-Disease
toxicity NN NN I-Disease
in NN NN O
10 NN NN O
patients NN NN O
. NN NN O
   
Hepatotoxicity NN NN B-Disease
and NN NN O
malaise NN NN B-Disease
are NN NN O
again NN NN O
the NN NN O
most NN NN O
frequent NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
Evidence NN NN O
of NN NN O
antitumor NN NN O
activity NN NN O
has NN NN O
been NN NN O
seen NN NN O
in NN NN O
3 NN NN O
patients NN NN O
. NN NN O
   
Pharmacokinetic NN NN O
investigations NN NN O
have NN NN O
shown NN NN O
that NN NN O
alkaline NN NN O
diuresis NN NN O
does NN NN O
not NN NN O
alter NN NN O
CB NN NN O
3717 NN NN O
plasma NN NN O
levels NN NN O
or NN NN O
urinary NN NN O
excretion NN NN O
and NN NN O
that NN NN O
satisfactory NN NN O
urinary NN NN O
alkalinization NN NN O
can NN NN O
be NN NN O
readily NN NN O
achieved NN NN O
. NN NN O
   
Type NN NN B-Disease
B NN NN I-Disease
hepatitis NN NN I-Disease
after NN NN O
needle NN NN O
- NN NN O
stick NN NN O
exposure NN NN O
: NN NN O
prevention NN NN O
with NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
immune NN NN O
globulin NN NN O
. NN NN O
   
Final NN NN O
report NN NN O
of NN NN O
the NN NN O
Veterans NN NN O
Administration NN NN O
Cooperative NN NN O
Study NN NN O
. NN NN O
   
Hepatitis NN NN B-Disease
B NN NN I-Disease
immune NN NN O
globulin NN NN O
( NN NN O
HBIG NN NN O
) NN NN O
and NN NN O
immune NN NN O
serum NN NN O
globulin NN NN O
( NN NN O
ISG NN NN O
) NN NN O
were NN NN O
examined NN NN O
in NN NN O
a NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
trial NN NN O
to NN NN O
assess NN NN O
their NN NN O
relative NN NN O
efficacies NN NN O
in NN NN O
preventing NN NN O
type NN NN B-Disease
B NN NN I-Disease
hepatitis NN NN I-Disease
after NN NN O
needle NN NN O
- NN NN O
stick NN NN O
exposure NN NN O
to NN NN O
hepatitis NN NN O
B NN NN O
surface NN NN O
antigen NN NN O
( NN NN O
HBsAG NN NN O
) NN NN O
- NN NN O
positive NN NN O
donors NN NN O
. NN NN O
   
Clinical NN NN O
hepatitis NN NN B-Disease
developed NN NN O
in NN NN O
1 NN NN O
. NN NN O
4 NN NN O
% NN NN O
of NN NN O
HBIG NN NN O
and NN NN O
in NN NN O
5 NN NN O
. NN NN O
9 NN NN O
% NN NN O
of NN NN O
ISG NN NN O
recipients NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
016 NN NN O
) NN NN O
, NN NN O
and NN NN O
seroconversion NN NN O
( NN NN O
anti NN NN O
- NN NN O
HBs NN NN O
) NN NN O
occurred NN NN O
in NN NN O
5 NN NN O
. NN NN O
6 NN NN O
% NN NN O
and NN NN O
20 NN NN O
. NN NN O
7 NN NN O
% NN NN O
of NN NN O
them NN NN O
respectively NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Mild NN NN O
and NN NN O
transient NN NN O
side NN NN O
- NN NN O
effects NN NN O
were NN NN O
noted NN NN O
in NN NN O
3 NN NN O
. NN NN O
0 NN NN O
% NN NN O
of NN NN O
ISG NN NN O
and NN NN O
in NN NN O
3 NN NN O
. NN NN O
2 NN NN O
% NN NN O
of NN NN O
HBIG NN NN O
recipients NN NN O
. NN NN O
   
Available NN NN O
donor NN NN O
sera NN NN O
were NN NN O
examined NN NN O
for NN NN O
DNA NN NN O
polymerase NN NN O
( NN NN O
DNAP NN NN O
) NN NN O
and NN NN O
e NN NN O
antigen NN NN O
and NN NN O
antibody NN NN O
( NN NN O
HBeAg NN NN O
; NN NN O
anti NN NN O
- NN NN O
HBE NN NN O
) NN NN O
. NN NN O
   
Both NN NN O
DNAP NN NN O
and NN NN O
HBeAg NN NN O
showed NN NN O
a NN NN O
highly NN NN O
statistically NN NN O
significant NN NN O
correlation NN NN O
with NN NN O
the NN NN O
infectivity NN NN O
of NN NN O
HBsAg NN NN O
- NN NN O
positive NN NN O
donors NN NN O
. NN NN O
   
Hepatitis NN NN B-Disease
B NN NN I-Disease
immune NN NN O
globulin NN NN O
remained NN NN O
significantly NN NN O
superior NN NN O
to NN NN O
ISG NN NN O
in NN NN O
preventing NN NN O
type NN NN B-Disease
B NN NN I-Disease
hepatitis NN NN I-Disease
even NN NN O
when NN NN O
the NN NN O
analysis NN NN O
was NN NN O
confined NN NN O
to NN NN O
these NN NN O
two NN NN O
high NN NN O
- NN NN O
risk NN NN O
subgroups NN NN O
. NN NN O
   
The NN NN O
efficacy NN NN O
of NN NN O
ISG NN NN O
in NN NN O
preventing NN NN O
type NN NN B-Disease
B NN NN I-Disease
hepatitis NN NN I-Disease
cannot NN NN O
be NN NN O
ascertained NN NN O
because NN NN O
a NN NN O
true NN NN O
placebo NN NN O
group NN NN O
was NN NN O
not NN NN O
included NN NN O
. NN NN O
   
Production NN NN O
of NN NN O
autochthonous NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
in NN NN O
Lobund NN NN O
- NN NN O
Wistar NN NN O
rats NN NN O
by NN NN O
treatments NN NN O
with NN NN O
N NN NN O
- NN NN O
nitroso NN NN O
- NN NN O
N NN NN O
- NN NN O
methylurea NN NN O
and NN NN O
testosterone NN NN O
. NN NN O
   
More NN NN O
than NN NN O
50 NN NN O
% NN NN O
of NN NN O
Lobund NN NN O
- NN NN O
Wistar NN NN O
( NN NN O
L NN NN O
- NN NN O
W NN NN O
) NN NN O
strain NN NN O
rats NN NN O
developed NN NN O
large NN NN O
, NN NN O
palpable NN NN O
prostate NN NN B-Disease
adenocarcinomas NN NN I-Disease
( NN NN O
PAs NN NN B-Disease
) NN NN O
following NN NN O
treatments NN NN O
with NN NN O
N NN NN O
- NN NN O
nitroso NN NN O
- NN NN O
N NN NN O
- NN NN O
methylurea NN NN O
( NN NN O
CAS NN NN O
: NN NN O
684 NN NN O
- NN NN O
93 NN NN O
- NN NN O
5 NN NN O
) NN NN O
and NN NN O
testosterone NN NN O
propionate NN NN O
[ NN NN O
( NN NN O
TP NN NN O
) NN NN O
CAS NN NN O
: NN NN O
57 NN NN O
- NN NN O
85 NN NN O
- NN NN O
2 NN NN O
] NN NN O
, NN NN O
and NN NN O
most NN NN O
of NN NN O
the NN NN O
tumor NN NN B-Disease
- NN NN O
bearing NN NN O
rats NN NN O
manifested NN NN O
metastatic NN NN O
lesions NN NN O
. NN NN O
   
The NN NN O
incubation NN NN O
periods NN NN O
averaged NN NN O
10 NN NN O
. NN NN O
6 NN NN O
months NN NN O
. NN NN O
   
Within NN NN O
the NN NN O
same NN NN O
timeframe NN NN O
, NN NN O
no NN NN O
L NN NN O
- NN NN O
W NN NN O
rat NN NN O
developed NN NN O
a NN NN O
similar NN NN O
palpable NN NN O
PA NN NN B-Disease
when NN NN O
treated NN NN O
only NN NN O
with NN NN O
TP NN NN O
. NN NN O
   
In NN NN O
L NN NN O
- NN NN O
W NN NN O
rats NN NN O
, NN NN O
TP NN NN O
acted NN NN O
as NN NN O
a NN NN O
tumor NN NN B-Disease
enhancement NN NN O
agent NN NN O
, NN NN O
with NN NN O
primary NN NN O
emphasis NN NN O
on NN NN O
the NN NN O
development NN NN O
of NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
Relative NN NN O
efficacy NN NN O
and NN NN O
toxicity NN NN B-Disease
of NN NN O
netilmicin NN NN O
and NN NN O
tobramycin NN NN O
in NN NN O
oncology NN NN O
patients NN NN O
. NN NN O
   
We NN NN O
prospectively NN NN O
compared NN NN O
the NN NN O
efficacy NN NN O
and NN NN O
safety NN NN O
of NN NN O
netilmicin NN NN O
sulfate NN NN O
or NN NN O
tobramycin NN NN O
sulfate NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
piperacillin NN NN O
sodium NN NN O
in NN NN O
118 NN NN O
immunocompromised NN NN O
patients NN NN O
with NN NN O
presumed NN NN O
severe NN NN O
infections NN NN B-Disease
. NN NN O
   
The NN NN O
two NN NN O
treatment NN NN O
regimens NN NN O
were NN NN O
equally NN NN O
efficacious NN NN O
. NN NN O
   
Nephrotoxicity NN NN B-Disease
occurred NN NN O
in NN NN O
a NN NN O
similar NN NN O
proportion NN NN O
in NN NN O
patients NN NN O
treated NN NN O
with NN NN O
netilmicin NN NN O
and NN NN O
tobramycin NN NN O
( NN NN O
17 NN NN O
% NN NN O
vs NN NN O
11 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Ototoxicity NN NN B-Disease
occurred NN NN O
in NN NN O
four NN NN O
( NN NN O
9 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
of NN NN O
42 NN NN O
netilmicin NN NN O
and NN NN O
piperacillin NN NN O
and NN NN O
in NN NN O
12 NN NN O
( NN NN O
22 NN NN O
% NN NN O
) NN NN O
of NN NN O
54 NN NN O
tobramycin NN NN O
and NN NN O
piperacillin NN NN O
- NN NN O
treated NN NN O
patients NN NN O
. NN NN O
   
Of NN NN O
those NN NN O
evaluated NN NN O
with NN NN O
posttherapy NN NN O
audiograms NN NN O
, NN NN O
three NN NN O
of NN NN O
four NN NN O
netilmicin NN NN O
and NN NN O
piperacillin NN NN O
- NN NN O
treated NN NN O
patients NN NN O
had NN NN O
auditory NN NN O
thresholds NN NN O
return NN NN O
to NN NN O
baseline NN NN O
compared NN NN O
with NN NN O
one NN NN O
of NN NN O
nine NN NN O
tobramycin NN NN O
and NN NN O
piperacillin NN NN O
- NN NN O
treated NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
number NN NN O
of NN NN O
greater NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
15 NN NN O
- NN NN O
dB NN NN O
increases NN NN O
in NN NN O
auditory NN NN O
threshold NN NN O
as NN NN O
a NN NN O
proportion NN NN O
of NN NN O
total NN NN O
greater NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
15 NN NN O
- NN NN O
dB NN NN O
changes NN NN O
( NN NN O
increases NN NN O
and NN NN O
decreases NN NN O
) NN NN O
was NN NN O
significantly NN NN O
lower NN NN O
in NN NN O
netilmicin NN NN O
and NN NN O
piperacillin NN NN O
- NN NN O
vs NN NN O
tobramycin NN NN O
and NN NN O
piperacillin NN NN O
- NN NN O
treated NN NN O
patients NN NN O
( NN NN O
18 NN NN O
of NN NN O
78 NN NN O
vs NN NN O
67 NN NN O
of NN NN O
115 NN NN O
) NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
aminoglycoside NN NN O
- NN NN O
associated NN NN O
ototoxicity NN NN B-Disease
was NN NN O
less NN NN O
severe NN NN O
and NN NN O
more NN NN O
often NN NN O
reversible NN NN O
with NN NN O
netilmicin NN NN O
than NN NN O
with NN NN O
tobramycin NN NN O
. NN NN O
   
Urinary NN NN O
enzymes NN NN O
and NN NN O
protein NN NN O
patterns NN NN O
as NN NN O
indicators NN NN O
of NN NN O
injury NN NN B-Disease
to NN NN I-Disease
different NN NN I-Disease
regions NN NN I-Disease
of NN NN I-Disease
the NN NN I-Disease
kidney NN NN I-Disease
. NN NN O
   
Acute NN NN B-Disease
experimental NN NN I-Disease
models NN NN I-Disease
of NN NN I-Disease
renal NN NN I-Disease
damage NN NN I-Disease
to NN NN O
the NN NN O
proximal NN NN O
tubular NN NN O
, NN NN O
glomerular NN NN O
, NN NN O
and NN NN O
papillary NN NN O
regions NN NN O
of NN NN O
the NN NN O
rat NN NN O
were NN NN O
produced NN NN O
by NN NN O
administration NN NN O
of NN NN O
hexachloro NN NN O
- NN NN O
1 NN NN O
: NN NN O
3 NN NN O
- NN NN O
butadiene NN NN O
( NN NN O
HCBD NN NN O
) NN NN O
, NN NN O
puromycin NN NN O
aminonucleoside NN NN O
( NN NN O
PAN NN NN O
) NN NN O
, NN NN O
and NN NN O
2 NN NN O
- NN NN O
bromoethylamine NN NN O
( NN NN O
BEA NN NN O
) NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Several NN NN O
routine NN NN O
indicators NN NN O
of NN NN O
nephrotoxicity NN NN B-Disease
, NN NN O
the NN NN O
enzymes NN NN O
alkaline NN NN O
phosphatase NN NN O
and NN NN O
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
beta NN NN O
- NN NN O
glucosaminidase NN NN O
, NN NN O
and NN NN O
the NN NN O
molecular NN NN O
weight NN NN O
of NN NN O
protein NN NN B-Disease
excretion NN NN I-Disease
were NN NN O
determined NN NN O
on NN NN O
urine NN NN O
samples NN NN O
. NN NN O
   
Tubular NN NN O
damage NN NN O
produced NN NN O
by NN NN O
HCBD NN NN O
or NN NN O
BEA NN NN O
was NN NN O
discriminated NN NN O
both NN NN O
quantitatively NN NN O
and NN NN O
qualitatively NN NN O
from NN NN O
glomerular NN NN B-Disease
damage NN NN I-Disease
produced NN NN O
by NN NN O
PAN NN NN O
. NN NN O
   
The NN NN O
latter NN NN O
was NN NN O
characterized NN NN O
by NN NN O
a NN NN O
pronounced NN NN O
increase NN NN O
in NN NN O
protein NN NN B-Disease
excretion NN NN I-Disease
, NN NN O
especially NN NN O
proteins NN NN O
with NN NN O
molecular NN NN O
weight NN NN O
greater NN NN O
than NN NN O
40 NN NN O
, NN NN O
000 NN NN O
Da NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
protein NN NN B-Disease
excretion NN NN I-Disease
in NN NN O
tubular NN NN O
damage NN NN O
was NN NN O
raised NN NN O
only NN NN O
slightly NN NN O
and NN NN O
characterized NN NN O
by NN NN O
excretion NN NN B-Disease
of NN NN I-Disease
proteins NN NN I-Disease
of NN NN O
a NN NN O
wide NN NN O
range NN NN O
of NN NN O
molecular NN NN O
weights NN NN O
. NN NN O
   
Proximal NN NN O
tubular NN NN O
damage NN NN O
caused NN NN O
by NN NN O
HCBD NN NN O
and NN NN O
papillary NN NN O
damage NN NN O
caused NN NN O
by NN NN O
BEA NN NN O
were NN NN O
distinguished NN NN O
both NN NN O
by NN NN O
conventional NN NN O
urinalysis NN NN O
( NN NN O
volume NN NN O
and NN NN O
specific NN NN O
gravity NN NN O
) NN NN O
and NN NN O
by NN NN O
measurement NN NN O
of NN NN O
the NN NN O
two NN NN O
urinary NN NN O
enzymes NN NN O
. NN NN O
   
Alkaline NN NN O
phosphatase NN NN O
and NN NN O
glucose NN NN O
were NN NN O
markedly NN NN O
and NN NN O
transiently NN NN O
elevated NN NN O
in NN NN O
proximal NN NN O
tubular NN NN O
damage NN NN O
and NN NN O
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
beta NN NN O
- NN NN O
glucosaminidase NN NN O
showed NN NN O
a NN NN O
sustained NN NN O
elevation NN NN O
in NN NN O
papillary NN NN O
damage NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
both NN NN O
selective NN NN O
urinary NN NN O
enzymes NN NN O
and NN NN O
the NN NN O
molecular NN NN O
weight NN NN O
pattern NN NN O
of NN NN O
urinary NN NN O
proteins NN NN O
can NN NN O
be NN NN O
used NN NN O
to NN NN O
provide NN NN O
diagnostic NN NN O
information NN NN O
about NN NN O
the NN NN O
possible NN NN O
site NN NN O
of NN NN O
renal NN NN B-Disease
damage NN NN I-Disease
. NN NN O
   
A NN NN O
catch NN NN O
in NN NN O
the NN NN O
Reye NN NN B-Disease
. NN NN O
   
Twenty NN NN O
- NN NN O
six NN NN O
cases NN NN O
of NN NN O
Reye NN NN B-Disease
syndrome NN NN I-Disease
from NN NN O
The NN NN O
Children NN NN O
' NN NN O
s NN NN O
Hospital NN NN O
, NN NN O
Camperdown NN NN O
, NN NN O
Australia NN NN O
, NN NN O
occurring NN NN O
between NN NN O
1973 NN NN O
and NN NN O
1982 NN NN O
were NN NN O
reviewed NN NN O
. NN NN O
   
Of NN NN O
these NN NN O
, NN NN O
20 NN NN O
cases NN NN O
met NN NN O
the NN NN O
US NN NN O
Public NN NN O
Health NN NN O
Service NN NN O
Centers NN NN O
for NN NN O
Disease NN NN O
Control NN NN O
criteria NN NN O
for NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
Reye NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
Aspirin NN NN O
or NN NN O
salicylate NN NN O
ingestion NN NN O
had NN NN O
occurred NN NN O
in NN NN O
only NN NN O
one NN NN O
of NN NN O
the NN NN O
20 NN NN O
cases NN NN O
( NN NN O
5 NN NN O
% NN NN O
) NN NN O
, NN NN O
and NN NN O
paracetamol NN NN O
( NN NN O
acetaminophen NN NN O
) NN NN O
had NN NN O
been NN NN O
administered NN NN O
in NN NN O
only NN NN O
six NN NN O
of NN NN O
the NN NN O
cases NN NN O
( NN NN O
30 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Pathologic NN NN O
confirmation NN NN O
of NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
Reye NN NN B-Disease
syndrome NN NN I-Disease
was NN NN O
accomplished NN NN O
in NN NN O
90 NN NN O
% NN NN O
of NN NN O
the NN NN O
cases NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
Reye NN NN B-Disease
syndrome NN NN I-Disease
in NN NN O
New NN NN O
South NN NN O
Wales NN NN O
, NN NN O
Australia NN NN O
, NN NN O
is NN NN O
estimated NN NN O
from NN NN O
this NN NN O
study NN NN O
to NN NN O
be NN NN O
approximately NN NN O
nine NN NN O
cases NN NN O
per NN NN O
1 NN NN O
million NN NN O
children NN NN O
compared NN NN O
with NN NN O
recent NN NN O
US NN NN O
data NN NN O
of NN NN O
ten NN NN O
to NN NN O
20 NN NN O
cases NN NN O
per NN NN O
1 NN NN O
million NN NN O
children NN NN O
and NN NN O
three NN NN O
to NN NN O
seven NN NN O
cases NN NN O
per NN NN O
1 NN NN O
million NN NN O
children NN NN O
in NN NN O
Great NN NN O
Britain NN NN O
. NN NN O
   
The NN NN O
mortality NN NN O
for NN NN O
these NN NN O
Reye NN NN B-Disease
syndrome NN NN I-Disease
cases NN NN O
in NN NN O
Australia NN NN O
was NN NN O
45 NN NN O
% NN NN O
as NN NN O
compared NN NN O
with NN NN O
a NN NN O
32 NN NN O
% NN NN O
case NN NN O
- NN NN O
fatality NN NN O
rate NN NN O
in NN NN O
the NN NN O
United NN NN O
States NN NN O
. NN NN O
   
In NN NN O
Australia NN NN O
, NN NN O
the NN NN O
pediatric NN NN O
usage NN NN O
of NN NN O
aspirin NN NN O
has NN NN O
been NN NN O
extremely NN NN O
low NN NN O
for NN NN O
the NN NN O
past NN NN O
25 NN NN O
years NN NN O
( NN NN O
less NN NN O
than NN NN O
1 NN NN O
% NN NN O
of NN NN O
total NN NN O
dosage NN NN O
units NN NN O
sold NN NN O
) NN NN O
, NN NN O
with NN NN O
paracetamol NN NN O
( NN NN O
acetaminophen NN NN O
) NN NN O
dominating NN NN O
the NN NN O
pediatric NN NN O
analgesic NN NN O
and NN NN O
antipyretic NN NN O
market NN NN O
. NN NN O
   
Reye NN NN B-Disease
syndrome NN NN I-Disease
may NN NN O
be NN NN O
disappearing NN NN O
from NN NN O
Australia NN NN O
despite NN NN O
a NN NN O
total NN NN O
lack NN NN O
of NN NN O
association NN NN O
with NN NN O
salicylates NN NN O
or NN NN O
aspirin NN NN O
ingestion NN NN O
, NN NN O
since NN NN O
there NN NN O
were NN NN O
no NN NN O
cases NN NN O
found NN NN O
at NN NN O
The NN NN O
Children NN NN O
' NN NN O
s NN NN O
Hospital NN NN O
in NN NN O
1983 NN NN O
, NN NN O
1984 NN NN O
, NN NN O
or NN NN O
1985 NN NN O
. NN NN O
   
Postpartum NN NN O
psychosis NN NN B-Disease
induced NN NN O
by NN NN O
bromocriptine NN NN O
. NN NN O
   
Two NN NN O
multigravida NN NN O
patients NN NN O
with NN NN O
no NN NN O
prior NN NN O
psychiatric NN NN B-Disease
history NN NN O
were NN NN O
seen NN NN O
with NN NN O
postpartum NN NN O
psychosis NN NN B-Disease
, NN NN O
having NN NN O
received NN NN O
bromocriptine NN NN O
for NN NN O
inhibition NN NN B-Disease
of NN NN I-Disease
lactation NN NN I-Disease
. NN NN O
   
Bromocriptine NN NN O
given NN NN O
in NN NN O
high NN NN O
doses NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
psychosis NN NN B-Disease
in NN NN O
patients NN NN O
receiving NN NN O
the NN NN O
drug NN NN O
for NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
These NN NN O
cases NN NN O
demonstrate NN NN O
that NN NN O
bromocriptine NN NN O
may NN NN O
cause NN NN O
psychosis NN NN B-Disease
even NN NN O
when NN NN O
given NN NN O
in NN NN O
low NN NN O
doses NN NN O
. NN NN O
   
Hyperglycemic NN NN B-Disease
acidotic NN NN I-Disease
coma NN NN I-Disease
and NN NN O
death NN NN O
in NN NN O
Kearns NN NN B-Disease
- NN NN I-Disease
Sayre NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
This NN NN O
paper NN NN O
presents NN NN O
the NN NN O
clinical NN NN O
and NN NN O
metabolic NN NN O
findings NN NN O
in NN NN O
two NN NN O
young NN NN O
boys NN NN O
with NN NN O
long NN NN O
- NN NN O
standing NN NN O
Kearns NN NN B-Disease
- NN NN I-Disease
Sayre NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
Following NN NN O
short NN NN O
exposure NN NN O
to NN NN O
oral NN NN O
prednisone NN NN O
, NN NN O
both NN NN O
boys NN NN O
developed NN NN O
lethargy NN NN B-Disease
, NN NN O
increasing NN NN O
somnolence NN NN B-Disease
, NN NN O
polydipsia NN NN B-Disease
, NN NN O
polyphagia NN NN B-Disease
, NN NN O
and NN NN O
polyuria NN NN B-Disease
. NN NN O
   
Both NN NN O
presented NN NN O
in NN NN O
the NN NN O
emergency NN NN O
room NN NN O
with NN NN O
profound NN NN O
coma NN NN B-Disease
, NN NN O
hypotension NN NN B-Disease
, NN NN O
severe NN NN O
hyperglycemia NN NN B-Disease
, NN NN O
and NN NN O
acidosis NN NN B-Disease
. NN NN O
   
Nonketotic NN NN O
lactic NN NN B-Disease
acidosis NN NN I-Disease
was NN NN O
present NN NN O
in NN NN O
one NN NN O
and NN NN O
ketosis NN NN B-Disease
without NN NN O
a NN NN O
known NN NN O
serum NN NN O
lactate NN NN O
level NN NN O
was NN NN O
present NN NN O
in NN NN O
the NN NN O
other NN NN O
. NN NN O
   
Respiratory NN NN B-Disease
failure NN NN I-Disease
rapidly NN NN O
ensued NN NN O
and NN NN O
both NN NN O
patients NN NN O
expired NN NN O
in NN NN O
spite NN NN O
of NN NN O
efforts NN NN O
at NN NN O
resuscitation NN NN O
. NN NN O
   
We NN NN O
believe NN NN O
these NN NN O
two NN NN O
cases NN NN O
represent NN NN O
a NN NN O
newly NN NN O
described NN NN O
and NN NN O
catastrophic NN NN O
metabolic NN NN B-Disease
- NN NN I-Disease
endocrine NN NN I-Disease
failure NN NN I-Disease
in NN NN O
the NN NN O
Kearns NN NN B-Disease
- NN NN I-Disease
Sayre NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
Experimental NN NN O
cyclosporine NN NN O
nephrotoxicity NN NN B-Disease
: NN NN O
risk NN NN O
of NN NN O
concomitant NN NN O
chemotherapy NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
cyclosporine NN NN O
( NN NN O
CSA NN NN O
) NN NN O
alone NN NN O
or NN NN O
in NN NN O
combination NN NN O
with NN NN O
various NN NN O
chemotherapeutics NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
renal NN NN B-Disease
toxicity NN NN I-Disease
was NN NN O
evaluated NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
CSA NN NN O
for NN NN O
4 NN NN O
weeks NN NN O
caused NN NN O
renal NN NN O
functional NN NN O
and NN NN O
structural NN NN O
changes NN NN O
similar NN NN O
to NN NN O
those NN NN O
reported NN NN O
in NN NN O
man NN NN O
. NN NN O
   
The NN NN O
combined NN NN O
administration NN NN O
of NN NN O
CSA NN NN O
and NN NN O
various NN NN O
chemotherapeutic NN NN O
drugs NN NN O
with NN NN O
a NN NN O
nephrotoxic NN NN B-Disease
potential NN NN O
, NN NN O
such NN NN O
as NN NN O
gentamicin NN NN O
( NN NN O
at NN NN O
therapeutic NN NN O
doses NN NN O
) NN NN O
, NN NN O
amphothericin NN NN O
B NN NN O
and NN NN O
ketoconazole NN NN O
, NN NN O
which NN NN O
are NN NN O
frequently NN NN O
used NN NN O
in NN NN O
immunosuppressed NN NN O
patients NN NN O
, NN NN O
did NN NN O
not NN NN O
aggravate NN NN O
the NN NN O
CSA NN NN O
induced NN NN O
toxicity NN NN B-Disease
in NN NN O
the NN NN O
rat NN NN O
model NN NN O
. NN NN O
   
Gentamicin NN NN O
at NN NN O
toxic NN NN O
doses NN NN O
, NN NN O
however NN NN O
, NN NN O
increased NN NN O
CSA NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
nephrotoxicity NN NN B-Disease
induced NN NN O
by NN NN O
CSA NN NN O
has NN NN O
a NN NN O
different NN NN O
pathogenetic NN NN O
mechanism NN NN O
. NN NN O
   
Diuretics NN NN O
, NN NN O
potassium NN NN O
and NN NN O
arrhythmias NN NN B-Disease
in NN NN O
hypertensive NN NN B-Disease
coronary NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
proposed NN NN O
that NN NN O
modest NN NN O
changes NN NN O
in NN NN O
plasma NN NN O
potassium NN NN O
can NN NN O
alter NN NN O
the NN NN O
tendency NN NN O
towards NN NN O
cardiac NN NN B-Disease
arrhythmias NN NN I-Disease
. NN NN O
   
If NN NN O
this NN NN O
were NN NN O
so NN NN O
, NN NN O
patients NN NN O
with NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
might NN NN O
be NN NN O
especially NN NN O
susceptible NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
myocardial NN NN O
electrical NN NN O
excitability NN NN O
was NN NN O
measured NN NN O
in NN NN O
patients NN NN O
with NN NN O
mild NN NN O
essential NN NN O
hypertension NN NN B-Disease
and NN NN O
known NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
after NN NN O
8 NN NN O
weeks NN NN O
of NN NN O
treatment NN NN O
with NN NN O
a NN NN O
potassium NN NN O
- NN NN O
conserving NN NN O
diuretic NN NN O
( NN NN O
amiloride NN NN O
) NN NN O
and NN NN O
a NN NN O
similar NN NN O
period NN NN O
on NN NN O
a NN NN O
potassium NN NN O
- NN NN O
losing NN NN O
diuretic NN NN O
( NN NN O
chlorthalidone NN NN O
) NN NN O
in NN NN O
a NN NN O
randomised NN NN O
study NN NN O
. NN NN O
   
Plasma NN NN O
potassium NN NN O
concentrations NN NN O
were NN NN O
on NN NN O
average NN NN O
1 NN NN O
mmol NN NN O
/ NN NN O
L NN NN O
lower NN NN O
during NN NN O
the NN NN O
chlorthalidone NN NN O
phase NN NN O
compared NN NN O
to NN NN O
amiloride NN NN O
therapy NN NN O
. NN NN O
   
Blood NN NN O
pressure NN NN O
and NN NN O
volume NN NN O
states NN NN O
as NN NN O
assessed NN NN O
by NN NN O
bodyweight NN NN O
, NN NN O
plasma NN NN O
renin NN NN O
and NN NN O
noradrenaline NN NN O
( NN NN O
norepinephrine NN NN O
) NN NN O
concentrations NN NN O
were NN NN O
similar NN NN O
on NN NN O
the NN NN O
2 NN NN O
regimens NN NN O
. NN NN O
   
Compared NN NN O
to NN NN O
amiloride NN NN O
treatment NN NN O
, NN NN O
the NN NN O
chlorthalidone NN NN O
phase NN NN O
was NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
frequency NN NN O
of NN NN O
ventricular NN NN B-Disease
ectopic NN NN I-Disease
beats NN NN I-Disease
( NN NN O
24 NN NN O
- NN NN O
hour NN NN O
Holter NN NN O
monitoring NN NN O
) NN NN O
and NN NN O
a NN NN O
higher NN NN O
Lown NN NN O
grading NN NN O
, NN NN O
increased NN NN O
upslope NN NN O
and NN NN O
duration NN NN O
of NN NN O
the NN NN O
monophasic NN NN O
action NN NN O
potential NN NN O
, NN NN O
prolonged NN NN O
ventricular NN NN O
effective NN NN O
refractory NN NN O
period NN NN O
, NN NN O
and NN NN O
increased NN NN O
electrical NN NN O
instability NN NN O
during NN NN O
programmed NN NN O
ventricular NN NN O
stimulation NN NN O
. NN NN O
   
The NN NN O
above NN NN O
results NN NN O
indicate NN NN O
that NN NN O
because NN NN O
potassium NN NN O
- NN NN O
losing NN NN O
diuretic NN NN O
therapy NN NN O
can NN NN O
increase NN NN O
myocardial NN NN O
electrical NN NN O
excitability NN NN O
in NN NN O
patients NN NN O
with NN NN O
ischaemic NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
, NN NN O
even NN NN O
minor NN NN O
falls NN NN O
in NN NN O
plasma NN NN O
potassium NN NN O
concentrations NN NN O
are NN NN O
probably NN NN O
best NN NN O
avoided NN NN O
in NN NN O
such NN NN O
patients NN NN O
. NN NN O
   
Transketolase NN NN O
abnormality NN NN O
in NN NN O
tolazamide NN NN O
- NN NN O
induced NN NN O
Wernicke NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
encephalopathy NN NN I-Disease
. NN NN O
   
We NN NN O
studied NN NN O
a NN NN O
thiamine NN NN O
- NN NN O
dependent NN NN O
enzyme NN NN O
, NN NN O
transketolase NN NN O
, NN NN O
from NN NN O
fibroblasts NN NN O
of NN NN O
a NN NN O
diabetic NN NN B-Disease
patient NN NN O
who NN NN O
developed NN NN O
Wernicke NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
encephalopathy NN NN I-Disease
when NN NN O
treated NN NN O
with NN NN O
tolazamide NN NN O
, NN NN O
in NN NN O
order NN NN O
to NN NN O
delineate NN NN O
if NN NN O
this NN NN O
patient NN NN O
also NN NN O
had NN NN O
transketolase NN NN O
abnormality NN NN O
[ NN NN O
high NN NN O
Km NN NN O
for NN NN O
thiamine NN NN O
pyrophosphate NN NN O
( NN NN O
TPP NN NN O
) NN NN O
] NN NN O
, NN NN O
as NN NN O
previously NN NN O
reported NN NN O
in NN NN O
postalcoholic NN NN O
Wernicke NN NN B-Disease
- NN NN I-Disease
Korsakoff NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
this NN NN O
patient NN NN O
, NN NN O
we NN NN O
also NN NN O
studied NN NN O
this NN NN O
enzyme NN NN O
from NN NN O
three NN NN O
diabetic NN NN B-Disease
kindreds NN NN O
without NN NN O
any NN NN O
history NN NN O
of NN NN O
Wernicke NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
encephalopathy NN NN I-Disease
and NN NN O
from NN NN O
four NN NN O
normal NN NN O
controls NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
the NN NN O
above NN NN O
- NN NN O
mentioned NN NN O
patient NN NN O
and NN NN O
one NN NN O
of NN NN O
the NN NN O
diabetic NN NN B-Disease
kindreds NN NN O
with NN NN O
no NN NN O
history NN NN O
of NN NN O
Wernicke NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
encephalopathy NN NN I-Disease
had NN NN O
abnormal NN NN O
transketolase NN NN O
as NN NN O
determined NN NN O
by NN NN O
its NN NN O
Km NN NN O
for NN NN O
TPP NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
a NN NN O
similarity NN NN O
between NN NN O
postalcoholic NN NN O
Wernicke NN NN B-Disease
- NN NN I-Disease
Korsakoff NN NN I-Disease
syndrome NN NN I-Disease
and NN NN O
the NN NN O
patient NN NN O
with NN NN O
tolazamide NN NN O
- NN NN O
induced NN NN O
Wernicke NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
encephalopathy NN NN I-Disease
from NN NN O
the NN NN O
standpoint NN NN O
of NN NN O
transketolase NN NN O
abnormality NN NN O
. NN NN O
   
Bradycardia NN NN B-Disease
due NN NN O
to NN NN O
trihexyphenidyl NN NN O
hydrochloride NN NN O
. NN NN O
   
A NN NN O
chronic NN NN O
schizophrenic NN NN B-Disease
patient NN NN O
was NN NN O
treated NN NN O
with NN NN O
an NN NN O
anticholinergic NN NN O
drug NN NN O
, NN NN O
trihexyphenidyl NN NN O
hydrochloride NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
developed NN NN O
, NN NN O
paradoxically NN NN O
, NN NN O
sinus NN NN O
bradycardia NN NN B-Disease
. NN NN O
   
The NN NN O
reaction NN NN O
was NN NN O
specific NN NN O
to NN NN O
trihexyphenidyl NN NN O
and NN NN O
not NN NN O
to NN NN O
other NN NN O
anticholinergic NN NN O
drugs NN NN O
. NN NN O
   
This NN NN O
antidyskinetic NN NN O
drug NN NN O
is NN NN O
widely NN NN O
used NN NN O
in NN NN O
clinical NN NN O
psychiatric NN NN B-Disease
practice NN NN O
and NN NN O
physicians NN NN O
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
this NN NN O
side NN NN O
effect NN NN O
. NN NN O
   
Post NN NN O
- NN NN O
operative NN NN O
rigidity NN NN B-Disease
after NN NN O
fentanyl NN NN O
administration NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
thoraco NN NN O
- NN NN O
abdominal NN NN O
rigidity NN NN B-Disease
leading NN NN O
to NN NN O
respiratory NN NN B-Disease
failure NN NN I-Disease
is NN NN O
described NN NN O
in NN NN O
the NN NN O
post NN NN O
- NN NN O
operative NN NN O
period NN NN O
in NN NN O
an NN NN O
elderly NN NN O
patient NN NN O
who NN NN O
received NN NN O
a NN NN O
moderate NN NN O
dose NN NN O
of NN NN O
fentanyl NN NN O
. NN NN O
   
This NN NN O
was NN NN O
successfully NN NN O
reversed NN NN O
by NN NN O
naloxone NN NN O
. NN NN O
   
The NN NN O
mechanisms NN NN O
possibly NN NN O
implicated NN NN O
in NN NN O
this NN NN O
accident NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Anti NN NN O
- NN NN O
carcinogenic NN NN B-Disease
action NN NN O
of NN NN O
phenobarbital NN NN O
given NN NN O
simultaneously NN NN O
with NN NN O
diethylnitrosamine NN NN O
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
The NN NN O
present NN NN O
work NN NN O
has NN NN O
been NN NN O
planned NN NN O
in NN NN O
order NN NN O
to NN NN O
elucidate NN NN O
the NN NN O
effect NN NN O
of NN NN O
phenobarbital NN NN O
( NN NN O
PB NN NN O
: NN NN O
15 NN NN O
mg NN NN O
per NN NN O
rat NN NN O
of NN NN O
ingested NN NN O
dose NN NN O
) NN NN O
on NN NN O
carcinogenesis NN NN B-Disease
when NN NN O
it NN NN O
is NN NN O
administered NN NN O
simultaneously NN NN O
with NN NN O
diethylnitrosamine NN NN O
( NN NN O
DEN NN NN O
: NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
) NN NN O
. NN NN O
   
Wistar NN NN O
rats NN NN O
( NN NN O
180 NN NN O
g NN NN O
) NN NN O
were NN NN O
treated NN NN O
by NN NN O
DEN NN NN O
alone NN NN O
or NN NN O
by NN NN O
DEN NN NN O
+ NN NN O
PB NN NN O
during NN NN O
2 NN NN O
, NN NN O
4 NN NN O
and NN NN O
6 NN NN O
weeks NN NN O
according NN NN O
to NN NN O
our NN NN O
schedule NN NN O
for NN NN O
hepatocarcinogenesis NN NN B-Disease
. NN NN O
   
After NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
treatment NN NN O
, NN NN O
the NN NN O
number NN NN O
and NN NN O
the NN NN O
size NN NN O
of NN NN O
induced NN NN O
PAS NN NN O
positive NN NN O
preneoplastic NN NN B-Disease
foci NN NN I-Disease
was NN NN O
significantly NN NN O
reduced NN NN O
when NN NN O
PB NN NN O
was NN NN O
given NN NN O
simultaneously NN NN O
with NN NN O
DEN NN NN O
for NN NN O
4 NN NN O
and NN NN O
6 NN NN O
weeks NN NN O
. NN NN O
   
The NN NN O
mitotic NN NN O
inhibition NN NN O
and NN NN O
the NN NN O
production NN NN O
of NN NN O
micronuclei NN NN O
normally NN NN O
observed NN NN O
after NN NN O
partial NN NN O
hepatectomy NN NN O
in NN NN O
DEN NN NN O
treated NN NN O
rats NN NN O
were NN NN O
also NN NN O
significantly NN NN O
decreased NN NN O
in NN NN O
DEN NN NN O
+ NN NN O
PB NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
When NN NN O
the NN NN O
treatment NN NN O
last NN NN O
only NN NN O
2 NN NN O
weeks NN NN O
, NN NN O
the NN NN O
presence NN NN O
of NN NN O
PB NN NN O
did NN NN O
not NN NN O
change NN NN O
significantly NN NN O
the NN NN O
last NN NN O
parameters NN NN O
. NN NN O
   
In NN NN O
DEN NN NN O
+ NN NN O
PB NN NN O
treated NN NN O
rats NN NN O
, NN NN O
the NN NN O
survival NN NN O
was NN NN O
prolonged NN NN O
and NN NN O
the NN NN O
tumor NN NN B-Disease
incidence NN NN O
decreased NN NN O
as NN NN O
compared NN NN O
with NN NN O
the NN NN O
results NN NN O
obtained NN NN O
by NN NN O
DEN NN NN O
alone NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
PB NN NN O
, NN NN O
which NN NN O
promotes NN NN O
carcinogenesis NN NN B-Disease
when NN NN O
administered NN NN O
after NN NN O
the NN NN O
DEN NN NN O
treatment NN NN O
, NN NN O
reduces NN NN O
the NN NN O
carcinogen NN NN O
effect NN NN O
when NN NN O
given NN NN O
simultaneously NN NN O
with NN NN O
DEN NN NN O
. NN NN O
   
This NN NN O
' NN NN O
anti NN NN O
- NN NN O
carcinogen NN NN O
' NN NN O
effect NN NN O
acts NN NN O
on NN NN O
the NN NN O
initiation NN NN O
as NN NN O
well NN NN O
as NN NN O
on NN NN O
the NN NN O
promotion NN NN O
of NN NN O
the NN NN O
precancerous NN NN B-Disease
lesions NN NN I-Disease
. NN NN O
   
Biochemical NN NN O
investigations NN NN O
are NN NN O
in NN NN O
progress NN NN O
to NN NN O
obtain NN NN O
more NN NN O
information NN NN O
about NN NN O
this NN NN O
' NN NN O
paradoxical NN NN O
' NN NN O
PB NN NN O
effect NN NN O
. NN NN O
   
Bilateral NN NN B-Disease
optic NN NN I-Disease
neuropathy NN NN I-Disease
due NN NN O
to NN NN O
combined NN NN O
ethambutol NN NN O
and NN NN O
isoniazid NN NN O
treatment NN NN O
. NN NN O
   
The NN NN O
case NN NN O
of NN NN O
a NN NN O
40 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
patient NN NN O
who NN NN O
underwent NN NN O
an NN NN O
unsuccessful NN NN O
cadaver NN NN O
kidney NN NN O
transplantation NN NN O
and NN NN O
was NN NN O
treated NN NN O
with NN NN O
ethambutol NN NN O
and NN NN O
isoniazid NN NN O
is NN NN O
reported NN NN O
. NN NN O
   
A NN NN O
bilateral NN NN B-Disease
retrobulbar NN NN I-Disease
neuropathy NN NN I-Disease
with NN NN O
an NN NN O
unusual NN NN O
central NN NN O
bitemporal NN NN O
hemianopic NN NN O
scotoma NN NN B-Disease
was NN NN O
found NN NN O
. NN NN O
   
Ethambutol NN NN O
was NN NN O
stopped NN NN O
and NN NN O
only NN NN O
small NN NN O
improvement NN NN O
of NN NN O
the NN NN O
visual NN NN O
acuity NN NN O
followed NN NN O
. NN NN O
   
Isoniazid NN NN O
was NN NN O
discontinued NN NN O
later NN NN O
, NN NN O
followed NN NN O
by NN NN O
a NN NN O
dramatic NN NN O
improvement NN NN O
in NN NN O
the NN NN O
visual NN NN O
acuity NN NN O
. NN NN O
   
The NN NN O
hazards NN NN O
of NN NN O
optic NN NN O
nerve NN NN O
toxicity NN NN B-Disease
due NN NN O
to NN NN O
ethambutol NN NN O
are NN NN O
known NN NN O
. NN NN O
   
We NN NN O
emphasize NN NN O
the NN NN O
potential NN NN O
danger NN NN O
in NN NN O
the NN NN O
use NN NN O
of NN NN O
ethambutol NN NN O
and NN NN O
isoniazid NN NN O
. NN NN O
   
A NN NN O
prospective NN NN O
study NN NN O
of NN NN O
adverse NN NN O
reactions NN NN O
associated NN NN O
with NN NN O
vancomycin NN NN O
therapy NN NN O
. NN NN O
   
A NN NN O
prospective NN NN O
evaluation NN NN O
of NN NN O
the NN NN O
efficacy NN NN O
and NN NN O
safety NN NN O
of NN NN O
vancomycin NN NN O
was NN NN O
conducted NN NN O
in NN NN O
54 NN NN O
consecutive NN NN O
patients NN NN O
over NN NN O
a NN NN O
16 NN NN O
- NN NN O
month NN NN O
period NN NN O
. NN NN O
   
Vancomycin NN NN O
was NN NN O
curative NN NN O
in NN NN O
95 NN NN O
% NN NN O
of NN NN O
43 NN NN O
patients NN NN O
with NN NN O
proven NN NN O
infection NN NN B-Disease
. NN NN O
   
Drugs NN NN O
were NN NN O
ceased NN NN O
in NN NN O
six NN NN O
patients NN NN O
because NN NN O
of NN NN O
adverse NN NN O
reactions NN NN O
; NN NN O
in NN NN O
three NN NN O
of NN NN O
these NN NN O
vancomycin NN NN O
was NN NN O
considered NN NN O
the NN NN O
likely NN NN O
cause NN NN O
. NN NN O
   
Reactions NN NN O
included NN NN O
thrombophlebitis NN NN B-Disease
( NN NN O
20 NN NN O
of NN NN O
54 NN NN O
patients NN NN O
) NN NN O
, NN NN O
rash NN NN B-Disease
( NN NN O
4 NN NN O
of NN NN O
54 NN NN O
) NN NN O
, NN NN O
nephrotoxicity NN NN B-Disease
( NN NN O
4 NN NN O
of NN NN O
50 NN NN O
) NN NN O
, NN NN O
proteinuria NN NN B-Disease
( NN NN O
1 NN NN O
of NN NN O
50 NN NN O
) NN NN O
and NN NN O
ototoxicity NN NN B-Disease
( NN NN O
1 NN NN O
of NN NN O
11 NN NN O
patients NN NN O
tested NN NN O
by NN NN O
audiometry NN NN O
) NN NN O
. NN NN O
   
Thrombophlebitis NN NN B-Disease
occurred NN NN O
only NN NN O
with NN NN O
infusion NN NN O
through NN NN O
peripheral NN NN O
cannulae NN NN O
; NN NN O
nephrotoxicity NN NN B-Disease
and NN NN O
ototoxicity NN NN B-Disease
were NN NN O
confined NN NN O
to NN NN O
patients NN NN O
receiving NN NN O
an NN NN O
aminoglycoside NN NN O
plus NN NN O
vancomycin NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
vancomycin NN NN O
, NN NN O
administered NN NN O
appropriately NN NN O
, NN NN O
constitutes NN NN O
safe NN NN O
, NN NN O
effective NN NN O
therapy NN NN O
for NN NN O
infections NN NN B-Disease
caused NN NN O
by NN NN O
susceptible NN NN O
bacteria NN NN O
. NN NN O
   
Factors NN NN O
associated NN NN O
with NN NN O
nephrotoxicity NN NN B-Disease
and NN NN O
clinical NN NN O
outcome NN NN O
in NN NN O
patients NN NN O
receiving NN NN O
amikacin NN NN O
. NN NN O
   
Data NN NN O
from NN NN O
60 NN NN O
patients NN NN O
treated NN NN O
with NN NN O
amikacin NN NN O
were NN NN O
analyzed NN NN O
for NN NN O
factors NN NN O
associated NN NN O
with NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
In NN NN O
42 NN NN O
of NN NN O
these NN NN O
patients NN NN O
, NN NN O
data NN NN O
were NN NN O
examined NN NN O
for NN NN O
factors NN NN O
associated NN NN O
with NN NN O
clinical NN NN O
outcome NN NN O
. NN NN O
   
Variables NN NN O
evaluated NN NN O
included NN NN O
patient NN NN O
weight NN NN O
, NN NN O
age NN NN O
, NN NN O
sex NN NN O
, NN NN O
serum NN NN O
creatinine NN NN O
level NN NN O
, NN NN O
creatinine NN NN O
clearance NN NN O
, NN NN O
duration NN NN O
of NN NN O
therapy NN NN O
, NN NN O
total NN NN O
dose NN NN O
, NN NN O
mean NN NN O
daily NN NN O
dose NN NN O
, NN NN O
organism NN NN O
minimum NN NN O
inhibitory NN NN O
concentration NN NN O
( NN NN O
MIC NN NN O
) NN NN O
, NN NN O
mean NN NN O
peak NN NN O
levels NN NN O
, NN NN O
mean NN NN O
trough NN NN O
levels NN NN O
, NN NN O
mean NN NN O
area NN NN O
under NN NN O
the NN NN O
serum NN NN O
concentration NN NN O
- NN NN O
time NN NN O
curve NN NN O
( NN NN O
AUC NN NN O
) NN NN O
, NN NN O
total NN NN O
AUC NN NN O
, NN NN O
mean NN NN O
AUC NN NN O
greater NN NN O
than NN NN O
MIC NN NN O
, NN NN O
total NN NN O
AUC NN NN O
greater NN NN O
than NN NN O
MIC NN NN O
, NN NN O
mean NN NN O
Schumacher NN NN O
' NN NN O
s NN NN O
intensity NN NN O
factor NN NN O
( NN NN O
IF NN NN O
) NN NN O
, NN NN O
total NN NN O
IF NN NN O
, NN NN O
In NN NN O
( NN NN O
mean NN NN O
maximum NN NN O
concentration NN NN O
[ NN NN O
Cmax NN NN O
] NN NN O
/ NN NN O
MIC NN NN O
) NN NN O
. NN NN O
   
Model NN NN O
- NN NN O
dependent NN NN O
pharmacokinetic NN NN O
parameters NN NN O
were NN NN O
calculated NN NN O
by NN NN O
computer NN NN O
based NN NN O
on NN NN O
a NN NN O
one NN NN O
- NN NN O
compartment NN NN O
model NN NN O
. NN NN O
   
When NN NN O
the NN NN O
parameters NN NN O
were NN NN O
examined NN NN O
individually NN NN O
, NN NN O
duration NN NN O
of NN NN O
therapy NN NN O
and NN NN O
total NN NN O
AUC NN NN O
correlated NN NN O
significantly NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
. NN NN O
05 NN NN O
) NN NN O
with NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
a NN NN O
stepwise NN NN O
discriminant NN NN O
function NN NN O
analysis NN NN O
identified NN NN O
only NN NN O
duration NN NN O
of NN NN O
therapy NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
. NN NN O
001 NN NN O
) NN NN O
as NN NN O
an NN NN O
important NN NN O
factor NN NN O
. NN NN O
   
Based NN NN O
on NN NN O
this NN NN O
model NN NN O
and NN NN O
on NN NN O
Bayes NN NN O
' NN NN O
theorem NN NN O
, NN NN O
the NN NN O
predictive NN NN O
accuracy NN NN O
of NN NN O
identifying NN NN O
"""""""" NN NN O
nephrotoxic NN NN B-Disease
"""""""" NN NN O
patients NN NN O
increased NN NN O
from NN NN O
0 NN NN O
. NN NN O
17 NN NN O
to NN NN O
0 NN NN O
. NN NN O
39 NN NN O
. NN NN O
   
When NN NN O
examined NN NN O
individually NN NN O
, NN NN O
mean NN NN O
IF NN NN O
, NN NN O
MIC NN NN O
, NN NN O
total NN NN O
dose NN NN O
, NN NN O
mean NN NN O
daily NN NN O
dose NN NN O
, NN NN O
and NN NN O
ln NN NN O
( NN NN O
mean NN NN O
Cmax NN NN O
/ NN NN O
MIC NN NN O
) NN NN O
correlated NN NN O
significantly NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
. NN NN O
05 NN NN O
) NN NN O
with NN NN O
cure NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
a NN NN O
simultaneous NN NN O
multivariable NN NN O
analysis NN NN O
identified NN NN O
IF NN NN O
, NN NN O
MIC NN NN O
, NN NN O
and NN NN O
total NN NN O
dose NN NN O
according NN NN O
to NN NN O
one NN NN O
model NN NN O
and NN NN O
ln NN NN O
( NN NN O
mean NN NN O
Cmax NN NN O
/ NN NN O
MIC NN NN O
) NN NN O
according NN NN O
to NN NN O
a NN NN O
second NN NN O
statistical NN NN O
model NN NN O
of NN NN O
parameters NN NN O
selected NN NN O
to NN NN O
have NN NN O
the NN NN O
greatest NN NN O
prospective NN NN O
value NN NN O
. NN NN O
   
Based NN NN O
on NN NN O
Bayes NN NN O
' NN NN O
theorem NN NN O
and NN NN O
the NN NN O
first NN NN O
model NN NN O
, NN NN O
the NN NN O
predictive NN NN O
accuracy NN NN O
of NN NN O
identifying NN NN O
patients NN NN O
not NN NN O
cured NN NN O
increased NN NN O
from NN NN O
0 NN NN O
. NN NN O
19 NN NN O
to NN NN O
0 NN NN O
. NN NN O
83 NN NN O
. NN NN O
   
For NN NN O
the NN NN O
second NN NN O
model NN NN O
, NN NN O
the NN NN O
predictive NN NN O
accuracy NN NN O
increased NN NN O
from NN NN O
0 NN NN O
. NN NN O
19 NN NN O
to NN NN O
0 NN NN O
. NN NN O
50 NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Cardiac NN NN B-Disease
toxicity NN NN I-Disease
of NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
. NN NN O
   
Report NN NN O
of NN NN O
a NN NN O
case NN NN O
of NN NN O
spontaneous NN NN O
angina NN NN B-Disease
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
a NN NN O
patient NN NN O
with NN NN O
colon NN NN B-Disease
carcinoma NN NN I-Disease
and NN NN O
liver NN NN O
metastasis NN NN B-Disease
who NN NN O
presented NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
after NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
( NN NN O
5 NN NN O
- NN NN O
FU NN NN O
) NN NN O
administration NN NN O
. NN NN O
   
Clinical NN NN O
electrocardiographic NN NN O
evolution NN NN O
was NN NN O
similar NN NN O
to NN NN O
that NN NN O
observed NN NN O
in NN NN O
Prinzmetal NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
angina NN NN I-Disease
, NN NN O
and NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
promptly NN NN O
resolved NN NN O
with NN NN O
nifedipine NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
coronary NN NN B-Disease
spasm NN NN I-Disease
may NN NN O
be NN NN O
the NN NN O
cause NN NN O
of NN NN O
cardiotoxicity NN NN B-Disease
due NN NN O
to NN NN O
5 NN NN O
- NN NN O
FU NN NN O
, NN NN O
and NN NN O
that NN NN O
calcium NN NN O
antagonists NN NN O
may NN NN O
probably NN NN O
be NN NN O
used NN NN O
in NN NN O
the NN NN O
prevention NN NN O
or NN NN O
treatment NN NN O
of NN NN O
5 NN NN O
- NN NN O
FU NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
Dose NN NN O
- NN NN O
related NN NN O
beneficial NN NN O
and NN NN O
adverse NN NN O
effects NN NN O
of NN NN O
dietary NN NN O
corticosterone NN NN O
on NN NN O
organophosphorus NN NN O
- NN NN O
induced NN NN O
delayed NN NN O
neuropathy NN NN B-Disease
in NN NN O
chickens NN NN O
. NN NN O
   
Tri NN NN O
- NN NN O
ortho NN NN O
- NN NN O
tolyl NN NN O
phosphate NN NN O
( NN NN O
TOTP NN NN O
) NN NN O
, NN NN O
360 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
po NN NN O
, NN NN O
and NN NN O
0 NN NN O
, NN NN O
0 NN NN O
' NN NN O
- NN NN O
diisopropyl NN NN O
phosphorofluoridate NN NN O
( NN NN O
DFP NN NN O
) NN NN O
, NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
sc NN NN O
, NN NN O
were NN NN O
administered NN NN O
to NN NN O
adult NN NN O
White NN NN O
Leghorn NN NN O
chickens NN NN O
24 NN NN O
hr NN NN O
after NN NN O
they NN NN O
were NN NN O
placed NN NN O
on NN NN O
diets NN NN O
containing NN NN O
0 NN NN O
to NN NN O
300 NN NN O
ppm NN NN O
corticosterone NN NN O
. NN NN O
   
Supplemented NN NN O
diets NN NN O
were NN NN O
continued NN NN O
until NN NN O
clinical NN NN O
signs NN NN O
and NN NN O
lesions NN NN O
of NN NN O
delayed NN NN O
neuropathy NN NN B-Disease
appeared NN NN O
. NN NN O
   
Although NN NN O
low NN NN O
concentrations NN NN O
( NN NN O
less NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
50 NN NN O
ppm NN NN O
) NN NN O
of NN NN O
corticosterone NN NN O
had NN NN O
beneficial NN NN O
effects NN NN O
on NN NN O
TOTP NN NN O
- NN NN O
induced NN NN O
neuropathy NN NN B-Disease
, NN NN O
greater NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
200 NN NN O
ppm NN NN O
exacerbated NN NN O
clinical NN NN O
signs NN NN O
in NN NN O
chickens NN NN O
given NN NN O
either NN NN O
TOTP NN NN O
or NN NN O
DFP NN NN O
. NN NN O
   
Neurotoxic NN NN B-Disease
esterase NN NN O
activities NN NN O
24 NN NN O
hr NN NN O
after NN NN O
TOTP NN NN O
or NN NN O
DFP NN NN O
were NN NN O
less NN NN O
than NN NN O
20 NN NN O
% NN NN O
of NN NN O
values NN NN O
measured NN NN O
in NN NN O
chickens NN NN O
not NN NN O
given NN NN O
organophosphorous NN NN O
compounds NN NN O
. NN NN O
   
Chickens NN NN O
given NN NN O
200 NN NN O
ppm NN NN O
corticosterone NN NN O
without NN NN O
TOTP NN NN O
or NN NN O
DFP NN NN O
had NN NN O
significantly NN NN O
elevated NN NN O
activity NN NN O
of NN NN O
plasma NN NN O
cholinesterase NN NN O
and NN NN O
significantly NN NN O
inhibited NN NN O
activity NN NN O
of NN NN O
liver NN NN O
carboxylesterase NN NN O
. NN NN O
   
Degenerating NN NN B-Disease
myelinated NN NN I-Disease
fibers NN NN I-Disease
were NN NN O
also NN NN O
evident NN NN O
in NN NN O
distal NN NN O
levels NN NN O
of NN NN O
the NN NN O
peripheral NN NN O
nerves NN NN O
of NN NN O
chickens NN NN O
given NN NN O
TOTP NN NN O
or NN NN O
DFP NN NN O
. NN NN O
   
Hepatotoxicity NN NN B-Disease
of NN NN O
amiodarone NN NN O
. NN NN O
   
Amiodarone NN NN O
has NN NN O
proved NN NN O
very NN NN O
effective NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
otherwise NN NN O
resistant NN NN O
cardiac NN NN O
tachyarrhythmias NN NN B-Disease
. NN NN O
   
The NN NN O
use NN NN O
of NN NN O
amiodarone NN NN O
has NN NN O
, NN NN O
however NN NN O
, NN NN O
been NN NN O
limited NN NN O
due NN NN O
to NN NN O
its NN NN O
serious NN NN O
side NN NN O
- NN NN O
effects NN NN O
. NN NN O
   
A NN NN O
patient NN NN O
with NN NN O
cholestatic NN NN B-Disease
hepatitis NN NN I-Disease
due NN NN O
to NN NN O
amiodarone NN NN O
treatment NN NN O
is NN NN O
presented NN NN O
below NN NN O
and NN NN O
a NN NN O
review NN NN O
of NN NN O
the NN NN O
hepatotoxicity NN NN B-Disease
of NN NN O
amiodarone NN NN O
is NN NN O
given NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
solid NN NN O
evidence NN NN O
exists NN NN O
of NN NN O
hepatic NN NN B-Disease
injury NN NN I-Disease
due NN NN O
to NN NN O
amiodarone NN NN O
treatment NN NN O
, NN NN O
including NN NN O
steatosis NN NN B-Disease
, NN NN O
alterations NN NN O
resembling NN NN O
alcoholic NN NN B-Disease
hepatitis NN NN I-Disease
, NN NN O
cholestatic NN NN B-Disease
hepatitis NN NN I-Disease
and NN NN O
micronodular NN NN O
cirrhosis NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
liver NN NN I-Disease
. NN NN O
   
Patients NN NN O
receiving NN NN O
amiodarone NN NN O
should NN NN O
be NN NN O
regularly NN NN O
screened NN NN O
with NN NN O
respect NN NN O
to NN NN O
hepatic NN NN O
enzyme NN NN O
levels NN NN O
. NN NN O
   
Therapy NN NN O
should NN NN O
be NN NN O
discontinued NN NN O
on NN NN O
the NN NN O
suspicion NN NN O
of NN NN O
cholestatic NN NN B-Disease
injury NN NN I-Disease
or NN NN O
hepatomegaly NN NN B-Disease
. NN NN O
   
Promotional NN NN O
effects NN NN O
of NN NN O
testosterone NN NN O
and NN NN O
dietary NN NN O
fat NN NN O
on NN NN O
prostate NN NN O
carcinogenesis NN NN B-Disease
in NN NN O
genetically NN NN O
susceptible NN NN O
rats NN NN O
. NN NN O
   
Germfree NN NN O
( NN NN O
GF NN NN O
) NN NN O
Lobund NN NN O
strain NN NN O
Wistar NN NN O
( NN NN O
LW NN NN O
) NN NN O
rats NN NN O
, NN NN O
fed NN NN O
vegetable NN NN O
diet NN NN O
L NN NN O
- NN NN O
485 NN NN O
, NN NN O
have NN NN O
developed NN NN O
prostate NN NN B-Disease
adenocarcinomas NN NN I-Disease
spontaneously NN NN O
( NN NN O
10 NN NN O
% NN NN O
incidence NN NN O
) NN NN O
at NN NN O
average NN NN O
age NN NN O
34 NN NN O
months NN NN O
. NN NN O
   
Conventional NN NN O
LW NN NN O
rats NN NN O
, NN NN O
implanted NN NN O
with NN NN O
testosterone NN NN O
at NN NN O
age NN NN O
4 NN NN O
months NN NN O
, NN NN O
developed NN NN O
a NN NN O
higher NN NN O
incidence NN NN O
of NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
after NN NN O
an NN NN O
average NN NN O
interval NN NN O
of NN NN O
14 NN NN O
months NN NN O
: NN NN O
24 NN NN O
% NN NN O
had NN NN O
developed NN NN O
gross NN NN O
tumors NN NN B-Disease
, NN NN O
and NN NN O
40 NN NN O
% NN NN O
when NN NN O
it NN NN O
included NN NN O
microscopic NN NN O
tumors NN NN B-Disease
. NN NN O
   
Preliminary NN NN O
results NN NN O
indicate NN NN O
that NN NN O
testosterone NN NN O
- NN NN O
treated NN NN O
LW NN NN O
rats NN NN O
that NN NN O
were NN NN O
fed NN NN O
the NN NN O
same NN NN O
diet NN NN O
, NN NN O
which NN NN O
was NN NN O
supplemented NN NN O
with NN NN O
corn NN NN O
oil NN NN O
up NN NN O
to NN NN O
20 NN NN O
% NN NN O
fat NN NN O
, NN NN O
developed NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
after NN NN O
intervals NN NN O
of NN NN O
6 NN NN O
- NN NN O
12 NN NN O
months NN NN O
. NN NN O
   
Aged NN NN O
GF NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
( NN NN O
SD NN NN O
) NN NN O
rats NN NN O
have NN NN O
not NN NN O
developed NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
spontaneously NN NN O
. NN NN O
   
Conventional NN NN O
SD NN NN O
rats NN NN O
fed NN NN O
diet NN NN O
L NN NN O
- NN NN O
485 NN NN O
and NN NN O
treated NN NN O
with NN NN O
testosterone NN NN O
developed NN NN O
only NN NN O
prostatitis NN NN B-Disease
. NN NN O
   
Experimental NN NN O
designs NN NN O
should NN NN O
consider NN NN O
genetic NN NN O
susceptibility NN NN O
as NN NN O
a NN NN O
basic NN NN O
prerequisite NN NN O
for NN NN O
studies NN NN O
on NN NN O
experimental NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
Time NN NN O
course NN NN O
alterations NN NN O
of NN NN O
QTC NN NN O
interval NN NN O
due NN NN O
to NN NN O
hypaque NN NN O
76 NN NN O
. NN NN O
   
Sequential NN NN O
measurement NN NN O
of NN NN O
QT NN NN O
interval NN NN O
during NN NN O
left NN NN O
ventricular NN NN O
angiography NN NN O
was NN NN O
made NN NN O
30 NN NN O
seconds NN NN O
and NN NN O
one NN NN O
, NN NN O
three NN NN O
, NN NN O
five NN NN O
and NN NN O
ten NN NN O
minutes NN NN O
after NN NN O
injection NN NN O
of NN NN O
hypaque NN NN O
76 NN NN O
. NN NN O
   
The NN NN O
subjects NN NN O
were NN NN O
ten NN NN O
patients NN NN O
found NN NN O
to NN NN O
have NN NN O
normal NN NN O
left NN NN O
ventricles NN NN O
and NN NN O
coronary NN NN O
arteries NN NN O
. NN NN O
   
Significant NN NN O
QTC NN NN B-Disease
prolongation NN NN I-Disease
occurred NN NN O
in NN NN O
30 NN NN O
seconds NN NN O
to NN NN O
one NN NN O
minute NN NN O
in NN NN O
association NN NN O
with NN NN O
marked NN NN O
hypotension NN NN B-Disease
and NN NN O
elevation NN NN O
of NN NN O
cardiac NN NN O
output NN NN O
. NN NN O
   
Rat NN NN O
extraocular NN NN O
muscle NN NN O
regeneration NN NN O
. NN NN O
   
Repair NN NN O
of NN NN O
local NN NN O
anesthetic NN NN O
- NN NN O
induced NN NN O
damage NN NN O
. NN NN O
   
Local NN NN O
anesthetics NN NN O
that NN NN O
are NN NN O
commonly NN NN O
used NN NN O
in NN NN O
ophthalmic NN NN O
surgery NN NN O
( NN NN O
0 NN NN O
. NN NN O
75 NN NN O
% NN NN O
bupivacaine NN NN O
hydrochloride NN NN O
, NN NN O
2 NN NN O
. NN NN O
0 NN NN O
% NN NN O
mepivacaine NN NN O
hydrochloride NN NN O
, NN NN O
and NN NN O
2 NN NN O
. NN NN O
0 NN NN O
% NN NN O
lidocaine NN NN O
hydrochloride NN NN O
plus NN NN O
1 NN NN O
: NN NN O
100 NN NN O
, NN NN O
000 NN NN O
epinephrine NN NN O
) NN NN O
were NN NN O
injected NN NN O
into NN NN O
the NN NN O
retrobulbar NN NN O
area NN NN O
of NN NN O
rat NN NN O
eyes NN NN O
. NN NN O
   
Controls NN NN O
were NN NN O
injected NN NN O
with NN NN O
physiological NN NN O
saline NN NN O
. NN NN O
   
All NN NN O
three NN NN O
anesthetics NN NN O
produced NN NN O
massive NN NN O
degeneration NN NN O
of NN NN O
the NN NN O
extraocular NN NN O
muscles NN NN O
. NN NN O
   
Muscle NN NN B-Disease
degeneration NN NN I-Disease
is NN NN O
followed NN NN O
by NN NN O
regeneration NN NN O
of NN NN O
the NN NN O
damaged NN NN O
muscle NN NN O
fibers NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
muscle NN NN B-Disease
damage NN NN I-Disease
, NN NN O
severe NN NN O
damage NN NN O
was NN NN O
also NN NN O
seen NN NN O
in NN NN O
harderian NN NN O
glands NN NN O
, NN NN O
especially NN NN O
after NN NN O
exposure NN NN O
to NN NN O
mepivacaine NN NN O
and NN NN O
lidocaine NN NN O
plus NN NN O
epinephrine NN NN O
. NN NN O
   
With NN NN O
these NN NN O
findings NN NN O
in NN NN O
rats NN NN O
, NN NN O
it NN NN O
is NN NN O
hypothesized NN NN O
that NN NN O
the NN NN O
temporary NN NN O
diplopia NN NN B-Disease
sometimes NN NN O
seen NN NN O
in NN NN O
patients NN NN O
after NN NN O
ophthalmic NN NN O
surgery NN NN O
might NN NN O
be NN NN O
due NN NN O
to NN NN O
anesthetic NN NN O
- NN NN O
induced NN NN O
damage NN NN O
to NN NN O
the NN NN O
extraocular NN NN O
muscles NN NN O
. NN NN O
   
Gentamicin NN NN O
nephropathy NN NN B-Disease
in NN NN O
a NN NN O
neonate NN NN O
. NN NN O
   
The NN NN O
clinical NN NN O
and NN NN O
autopsy NN NN O
findings NN NN O
in NN NN O
a NN NN O
premature NN NN O
baby NN NN O
who NN NN O
died NN NN O
of NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
after NN NN O
therapy NN NN O
with NN NN O
gentamicin NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
) NN NN O
and NN NN O
penicillin NN NN O
are NN NN O
presented NN NN O
. NN NN O
   
The NN NN O
serum NN NN O
gentamicin NN NN O
concentration NN NN O
had NN NN O
reached NN NN O
toxic NN NN O
levels NN NN O
when NN NN O
anuria NN NN B-Disease
developed NN NN O
. NN NN O
   
Numerous NN NN O
periodic NN NN O
acid NN NN O
Schiff NN NN O
( NN NN O
PAS NN NN O
) NN NN O
positive NN NN O
, NN NN O
diastase NN NN O
resistant NN NN O
cytoplasmic NN NN O
inclusion NN NN O
bodies NN NN O
which NN NN O
appeared NN NN O
as NN NN O
myelin NN NN O
figures NN NN O
in NN NN O
cytosegresomes NN NN O
under NN NN O
the NN NN O
electron NN NN O
microscope NN NN O
were NN NN O
identified NN NN O
in NN NN O
the NN NN O
proximal NN NN O
convoluted NN NN O
tubules NN NN O
. NN NN O
   
The NN NN O
pathological NN NN O
changes NN NN O
induced NN NN O
by NN NN O
gentamicin NN NN O
in NN NN O
the NN NN O
human NN NN O
neonatal NN NN O
kidneys NN NN O
have NN NN O
not NN NN O
been NN NN O
previously NN NN O
reported NN NN O
. NN NN O
   
Induction NN NN O
by NN NN O
paracetamol NN NN O
of NN NN O
bladder NN NN B-Disease
and NN NN I-Disease
liver NN NN I-Disease
tumours NN NN I-Disease
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Effects NN NN O
on NN NN O
hepatocyte NN NN O
fine NN NN O
structure NN NN O
. NN NN O
   
Groups NN NN O
of NN NN O
male NN NN O
and NN NN O
female NN NN O
inbred NN NN O
Leeds NN NN O
strain NN NN O
rats NN NN O
were NN NN O
fed NN NN O
diets NN NN O
containing NN NN O
either NN NN O
0 NN NN O
. NN NN O
5 NN NN O
% NN NN O
or NN NN O
1 NN NN O
. NN NN O
0 NN NN O
% NN NN O
paracetamol NN NN O
by NN NN O
weight NN NN O
for NN NN O
up NN NN O
to NN NN O
18 NN NN O
months NN NN O
. NN NN O
   
At NN NN O
the NN NN O
1 NN NN O
. NN NN O
0 NN NN O
% NN NN O
dosage NN NN O
level NN NN O
, NN NN O
20 NN NN O
% NN NN O
of NN NN O
rats NN NN O
of NN NN O
both NN NN O
sexes NN NN O
developed NN NN O
neoplastic NN NN O
nodules NN NN O
of NN NN O
the NN NN O
liver NN NN O
, NN NN O
a NN NN O
statistically NN NN O
significant NN NN O
incidence NN NN O
. NN NN O
   
These NN NN O
rats NN NN O
also NN NN O
showed NN NN O
gross NN NN O
enlargement NN NN O
of NN NN O
their NN NN O
livers NN NN O
and NN NN O
an NN NN O
increase NN NN O
in NN NN O
foci NN NN O
of NN NN O
cellular NN NN O
alteration NN NN O
, NN NN O
the NN NN O
latter NN NN O
also NN NN O
being NN NN O
observed NN NN O
in NN NN O
the NN NN O
low NN NN O
dosage NN NN O
male NN NN O
rats NN NN O
. NN NN O
   
Papillomas NN NN B-Disease
of NN NN O
the NN NN O
transitional NN NN O
epithelium NN NN O
of NN NN O
the NN NN O
bladder NN NN O
developed NN NN O
in NN NN O
all NN NN O
paracetamol NN NN O
- NN NN O
treated NN NN O
groups NN NN O
, NN NN O
and NN NN O
three NN NN O
rats NN NN O
bore NN NN O
bladder NN NN B-Disease
carcinomas NN NN I-Disease
. NN NN O
   
However NN NN O
, NN NN O
significant NN NN O
yields NN NN O
of NN NN O
bladder NN NN B-Disease
tumours NN NN I-Disease
were NN NN O
only NN NN O
obtained NN NN O
from NN NN O
low NN NN O
dosage NN NN O
females NN NN O
and NN NN O
high NN NN O
dosage NN NN O
males NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
20 NN NN O
to NN NN O
25 NN NN O
% NN NN O
of NN NN O
paracetamol NN NN O
- NN NN O
treated NN NN O
rats NN NN O
developed NN NN O
hyperplasia NN NN B-Disease
of NN NN O
the NN NN O
bladder NN NN O
epithelium NN NN O
, NN NN O
which NN NN O
was NN NN O
not NN NN O
coincident NN NN O
with NN NN O
the NN NN O
presence NN NN O
of NN NN O
bladder NN NN B-Disease
calculi NN NN I-Disease
. NN NN O
   
A NN NN O
low NN NN O
yield NN NN O
of NN NN O
tumours NN NN B-Disease
at NN NN O
various NN NN O
other NN NN O
sites NN NN O
also NN NN O
arose NN NN O
following NN NN O
paracetamol NN NN O
feeding NN NN O
. NN NN O
   
An NN NN O
electron NN NN O
microscope NN NN O
study NN NN O
of NN NN O
the NN NN O
livers NN NN O
of NN NN O
paracetamol NN NN O
- NN NN O
treated NN NN O
rats NN NN O
revealed NN NN O
ultrastructural NN NN O
changes NN NN O
in NN NN O
the NN NN O
hepatocytes NN NN O
that NN NN O
resemble NN NN O
those NN NN O
that NN NN O
result NN NN O
from NN NN O
exposure NN NN O
to NN NN O
a NN NN O
variety NN NN O
of NN NN O
known NN NN O
hepatocarcinogens NN NN B-Disease
. NN NN O
   
Transient NN NN O
hemiparesis NN NN B-Disease
: NN NN O
a NN NN O
rare NN NN O
manifestation NN NN O
of NN NN O
diphenylhydantoin NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Report NN NN O
of NN NN O
two NN NN O
cases NN NN O
. NN NN O
   
Among NN NN O
the NN NN O
common NN NN O
side NN NN O
effects NN NN O
of NN NN O
diphenylhydantoin NN NN O
( NN NN O
DPH NN NN O
) NN NN O
overdose NN NN B-Disease
, NN NN O
the NN NN O
most NN NN O
frequently NN NN O
encountered NN NN O
neurological NN NN O
signs NN NN O
are NN NN O
those NN NN O
of NN NN O
cerebellar NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Very NN NN O
rarely NN NN O
, NN NN O
the NN NN O
toxic NN NN O
neurological NN NN O
manifestations NN NN O
of NN NN O
this NN NN O
drug NN NN O
are NN NN O
of NN NN O
cerebral NN NN O
origin NN NN O
. NN NN O
   
Two NN NN O
patients NN NN O
are NN NN O
presented NN NN O
who NN NN O
suffered NN NN O
progressive NN NN O
hemiparesis NN NN B-Disease
due NN NN O
to NN NN O
DPH NN NN O
overdose NN NN B-Disease
. NN NN O
   
Both NN NN O
had NN NN O
brain NN NN O
surgery NN NN O
before NN NN O
DPH NN NN O
treatment NN NN O
. NN NN O
   
It NN NN O
is NN NN O
assumed NN NN O
that NN NN O
patients NN NN O
with NN NN O
some NN NN O
cerebral NN NN B-Disease
damage NN NN I-Disease
are NN NN O
liable NN NN O
to NN NN O
manifest NN NN O
DPH NN NN O
toxicity NN NN B-Disease
as NN NN O
focal NN NN O
neurological NN NN O
signs NN NN O
. NN NN O
   
Tiapride NN NN O
in NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
involuntary NN NN B-Disease
movements NN NN I-Disease
. NN NN O
   
Tiapride NN NN O
, NN NN O
a NN NN O
substituted NN NN O
benzamide NN NN O
derivative NN NN O
closely NN NN O
related NN NN O
to NN NN O
metoclopramide NN NN O
, NN NN O
reduced NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
peak NN NN O
dose NN NN O
involuntary NN NN B-Disease
movements NN NN I-Disease
in NN NN O
16 NN NN O
patients NN NN O
with NN NN O
idiopathic NN NN B-Disease
Parkinson NN NN I-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
However NN NN O
, NN NN O
an NN NN O
unacceptable NN NN O
increase NN NN O
in NN NN O
disability NN NN O
from NN NN O
Parkinsonism NN NN B-Disease
with NN NN O
aggravation NN NN O
of NN NN O
end NN NN O
- NN NN O
of NN NN O
- NN NN O
dose NN NN O
akinesia NN NN B-Disease
led NN NN O
to NN NN O
its NN NN O
cessation NN NN O
in NN NN O
14 NN NN O
patients NN NN O
. NN NN O
   
Tiapride NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
early NN NN O
morning NN NN O
of NN NN O
"""""""" NN NN O
off NN NN O
- NN NN O
period NN NN O
"""""""" NN NN O
segmental NN NN O
dystonia NN NN B-Disease
. NN NN O
   
These NN NN O
results NN NN O
fail NN NN O
to NN NN O
support NN NN O
the NN NN O
notion NN NN O
that NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
are NN NN O
caused NN NN O
by NN NN O
overstimulation NN NN O
of NN NN O
a NN NN O
separate NN NN O
group NN NN O
of NN NN O
dopamine NN NN O
receptors NN NN O
. NN NN O
   
Quinidine NN NN O
hepatitis NN NN B-Disease
. NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
administration NN NN O
of NN NN O
quinidine NN NN O
was NN NN O
associated NN NN O
with NN NN O
persistent NN NN O
elevation NN NN O
of NN NN O
serum NN NN O
concentrations NN NN O
of NN NN O
SGOT NN NN O
, NN NN O
lactic NN NN O
acid NN NN O
dehydrogenase NN NN O
, NN NN O
and NN NN O
alkaline NN NN O
phosphatase NN NN O
. NN NN O
   
Liver NN NN O
biopsy NN NN O
showed NN NN O
active NN NN O
hepatitis NN NN B-Disease
. NN NN O
   
Discontinuance NN NN O
of NN NN O
quinidine NN NN O
therapy NN NN O
led NN NN O
to NN NN O
normalization NN NN O
of NN NN O
liver NN NN O
function NN NN O
tests NN NN O
. NN NN O
   
A NN NN O
challenge NN NN O
dose NN NN O
of NN NN O
quinidine NN NN O
caused NN NN O
clinical NN NN O
symptoms NN NN O
and NN NN O
abrupt NN NN O
elevation NN NN O
of NN NN O
SGOT NN NN O
, NN NN O
alkaline NN NN O
phosphatase NN NN O
, NN NN O
and NN NN O
lactic NN NN O
acid NN NN O
dehydrogenase NN NN O
values NN NN O
. NN NN O
   
We NN NN O
concluded NN NN O
that NN NN O
this NN NN O
patient NN NN O
had NN NN O
quinidine NN NN O
hepatotoxicity NN NN B-Disease
and NN NN O
believe NN NN O
that NN NN O
this NN NN O
is NN NN O
the NN NN O
first NN NN O
case NN NN O
reported NN NN O
with NN NN O
liver NN NN O
biopsy NN NN O
documentation NN NN O
. NN NN O
   
This NN NN O
report NN NN O
also NN NN O
suggests NN NN O
that NN NN O
, NN NN O
even NN NN O
after NN NN O
long NN NN O
- NN NN O
term NN NN O
administration NN NN O
, NN NN O
the NN NN O
hepatic NN NN B-Disease
toxicity NN NN I-Disease
is NN NN O
reversible NN NN O
. NN NN O
   
Arterial NN NN O
thromboembolism NN NN B-Disease
in NN NN O
patients NN NN O
receiving NN NN O
systemic NN NN O
heparin NN NN O
therapy NN NN O
: NN NN O
a NN NN O
complication NN NN O
associated NN NN O
with NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
. NN NN O
   
Arterial NN NN O
thromboembolism NN NN B-Disease
is NN NN O
a NN NN O
recognized NN NN O
complication NN NN O
of NN NN O
systemic NN NN O
heparin NN NN O
therapy NN NN O
. NN NN O
   
Characteristic NN NN O
of NN NN O
the NN NN O
entity NN NN O
is NN NN O
arterial NN NN B-Disease
occlusion NN NN I-Disease
by NN NN O
platelet NN NN O
- NN NN O
fibrin NN NN O
thrombi NN NN B-Disease
with NN NN O
distal NN NN O
ischemia NN NN B-Disease
occurring NN NN O
four NN NN O
to NN NN O
twenty NN NN O
days NN NN O
after NN NN O
the NN NN O
initiation NN NN O
of NN NN O
heparin NN NN O
therapy NN NN O
, NN NN O
preceded NN NN O
by NN NN O
profound NN NN O
thrombocytopenia NN NN B-Disease
with NN NN O
platelet NN NN O
counts NN NN O
in NN NN O
the NN NN O
range NN NN O
of NN NN O
30 NN NN O
, NN NN O
000 NN NN O
to NN NN O
40 NN NN O
, NN NN O
000 NN NN O
per NN NN O
cubic NN NN O
millimeter NN NN O
. NN NN O
   
The NN NN O
clinically NN NN O
apparent NN NN O
occlusion NN NN O
may NN NN O
be NN NN O
preceded NN NN O
by NN NN O
gastrointestinal NN NN B-Disease
and NN NN I-Disease
musculoskeletal NN NN I-Disease
symptoms NN NN I-Disease
that NN NN O
appear NN NN O
to NN NN O
be NN NN O
ischemic NN NN B-Disease
in NN NN O
origin NN NN O
, NN NN O
and NN NN O
might NN NN O
serve NN NN O
to NN NN O
warn NN NN O
the NN NN O
clinician NN NN O
of NN NN O
these NN NN O
complications NN NN O
. NN NN O
   
Previous NN NN O
reports NN NN O
of NN NN O
these NN NN O
phenomena NN NN O
as NN NN O
well NN NN O
as NN NN O
recent NN NN O
studies NN NN O
of NN NN O
the NN NN O
effect NN NN O
of NN NN O
heparin NN NN O
are NN NN O
reviewed NN NN O
. NN NN O
   
The NN NN O
common NN NN O
factor NN NN O
relating NN NN O
thromboembolism NN NN B-Disease
and NN NN O
thrombocytopenia NN NN B-Disease
is NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
platelet NN NN B-Disease
aggregation NN NN I-Disease
. NN NN O
   
Appropriate NN NN O
treatment NN NN O
consists NN NN O
of NN NN O
discontinuation NN NN O
of NN NN O
heparin NN NN O
, NN NN O
and NN NN O
anticoagulation NN NN O
with NN NN O
sodium NN NN O
warfarin NN NN O
if NN NN O
necessary NN NN O
. NN NN O
   
Vascular NN NN O
procedures NN NN O
are NN NN O
performed NN NN O
as NN NN O
indicated NN NN O
. NN NN O
   
Pharmacology NN NN O
of NN NN O
GYKI NN NN O
- NN NN O
41 NN NN O
099 NN NN O
( NN NN O
chlorpropanol NN NN O
, NN NN O
Tobanum NN NN O
) NN NN O
a NN NN O
new NN NN O
potent NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
antagonist NN NN O
. NN NN O
   
The NN NN O
compound NN NN O
GYKI NN NN O
- NN NN O
41 NN NN O
099 NN NN O
, NN NN O
as NN NN O
a NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
antagonist NN NN O
, NN NN O
is NN NN O
3 NN NN O
- NN NN O
8 NN NN O
times NN NN O
more NN NN O
potent NN NN O
than NN NN O
propranolol NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Its NN NN O
antiarrhythmic NN NN O
effectiveness NN NN O
surpasses NN NN O
that NN NN O
of NN NN O
propranolol NN NN O
and NN NN O
pindolol NN NN O
inhibiting NN NN O
the NN NN O
ouabain NN NN O
arrhythmia NN NN B-Disease
in NN NN O
dogs NN NN O
and NN NN O
cats NN NN O
. NN NN O
   
GYKI NN NN O
- NN NN O
41 NN NN O
900 NN NN O
has NN NN O
a NN NN O
negligible NN NN O
cardiodepressant NN NN O
activity NN NN O
; NN NN O
it NN NN O
is NN NN O
not NN NN O
cardioselective NN NN O
. NN NN O
   
The NN NN O
compound NN NN O
shows NN NN O
a NN NN O
rapid NN NN O
and NN NN O
long NN NN O
lasting NN NN O
effect NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
prolonged NN NN O
elimination NN NN O
of NN NN O
the NN NN O
radioactivity NN NN O
after NN NN O
the NN NN O
injection NN NN O
of NN NN O
14C NN NN O
- NN NN O
41 NN NN O
099 NN NN O
to NN NN O
rats NN NN O
and NN NN O
dogs NN NN O
. NN NN O
   
The NN NN O
half NN NN O
life NN NN O
of NN NN O
the NN NN O
unlabeled NN NN O
substance NN NN O
in NN NN O
humans NN NN O
was NN NN O
more NN NN O
than NN NN O
10 NN NN O
hours NN NN O
. NN NN O
   
Adverse NN NN O
reactions NN NN O
to NN NN O
bendrofluazide NN NN O
and NN NN O
propranolol NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
mild NN NN O
hypertension NN NN B-Disease
. NN NN O
   
Report NN NN O
of NN NN O
Medical NN NN O
Research NN NN O
Council NN NN O
Working NN NN O
Party NN NN O
on NN NN O
Mild NN NN O
to NN NN O
Moderate NN NN O
Hypertension NN NN B-Disease
. NN NN O
   
Participants NN NN O
in NN NN O
the NN NN O
Medical NN NN O
Research NN NN O
Council NN NN O
treatment NN NN O
trial NN NN O
for NN NN O
mild NN NN O
hypertension NN NN B-Disease
are NN NN O
randomly NN NN O
allocated NN NN O
to NN NN O
one NN NN O
of NN NN O
four NN NN O
treatment NN NN O
groups NN NN O
: NN NN O
bendrofluazide NN NN O
, NN NN O
propranolol NN NN O
, NN NN O
or NN NN O
a NN NN O
placebo NN NN O
for NN NN O
either NN NN O
of NN NN O
these NN NN O
drugs NN NN O
. NN NN O
   
The NN NN O
trial NN NN O
is NN NN O
single NN NN O
- NN NN O
blind NN NN O
. NN NN O
   
23 NN NN O
582 NN NN O
patient NN NN O
- NN NN O
years NN NN O
of NN NN O
observation NN NN O
have NN NN O
been NN NN O
completed NN NN O
so NN NN O
far NN NN O
, NN NN O
10 NN NN O
684 NN NN O
on NN NN O
active NN NN O
drugs NN NN O
and NN NN O
12 NN NN O
898 NN NN O
on NN NN O
placebos NN NN O
. NN NN O
   
The NN NN O
results NN NN O
show NN NN O
an NN NN O
association NN NN O
between NN NN O
bendrofluazide NN NN O
treatment NN NN O
and NN NN O
impotence NN NN B-Disease
, NN NN O
and NN NN O
impotence NN NN B-Disease
also NN NN O
occurred NN NN O
more NN NN O
frequently NN NN O
in NN NN O
patients NN NN O
taking NN NN O
propranolol NN NN O
than NN NN O
in NN NN O
those NN NN O
taking NN NN O
placebos NN NN O
. NN NN O
   
Other NN NN O
adverse NN NN O
reactions NN NN O
significantly NN NN O
linked NN NN O
with NN NN O
active NN NN O
drugs NN NN O
include NN NN O
impaired NN NN B-Disease
glucose NN NN I-Disease
tolerance NN NN I-Disease
in NN NN O
men NN NN O
and NN NN O
women NN NN O
and NN NN O
gout NN NN B-Disease
in NN NN O
men NN NN O
, NN NN O
associated NN NN O
with NN NN O
bendrofluazide NN NN O
treatment NN NN O
, NN NN O
and NN NN O
Raynaud NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
phenomenon NN NN I-Disease
and NN NN O
dyspnoea NN NN B-Disease
in NN NN O
men NN NN O
and NN NN O
women NN NN O
taking NN NN O
propranolol NN NN O
. NN NN O
   
No NN NN O
corneal NN NN B-Disease
disease NN NN I-Disease
is NN NN O
known NN NN O
to NN NN O
have NN NN O
occurred NN NN O
in NN NN O
the NN NN O
propranolol NN NN O
group NN NN O
. NN NN O
   
Mean NN NN O
serum NN NN O
potassium NN NN O
level NN NN O
fell NN NN O
, NN NN O
and NN NN O
urea NN NN O
and NN NN O
uric NN NN O
acid NN NN O
levels NN NN O
rose NN NN O
, NN NN O
in NN NN O
men NN NN O
and NN NN O
women NN NN O
taking NN NN O
bendrofluazide NN NN O
. NN NN O
   
In NN NN O
the NN NN O
propranolol NN NN O
group NN NN O
, NN NN O
serum NN NN O
potassium NN NN O
and NN NN O
uric NN NN O
acid NN NN O
levels NN NN O
rose NN NN O
in NN NN O
both NN NN O
sexes NN NN O
, NN NN O
but NN NN O
the NN NN O
urea NN NN O
level NN NN O
rose NN NN O
significantly NN NN O
in NN NN O
women NN NN O
only NN NN O
. NN NN O
   
Serotonergic NN NN O
drugs NN NN O
, NN NN O
benzodiazepines NN NN O
and NN NN O
baclofen NN NN O
block NN NN O
muscimol NN NN O
- NN NN O
induced NN NN O
myoclonic NN NN B-Disease
jerks NN NN I-Disease
in NN NN O
a NN NN O
strain NN NN O
of NN NN O
mice NN NN O
. NN NN O
   
In NN NN O
male NN NN O
Swiss NN NN O
mice NN NN O
, NN NN O
muscimol NN NN O
produced NN NN O
myoclonic NN NN B-Disease
jerks NN NN I-Disease
. NN NN O
   
A NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
( NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
dose NN NN O
induced NN NN O
this NN NN O
response NN NN O
in NN NN O
all NN NN O
of NN NN O
the NN NN O
mice NN NN O
tested NN NN O
and NN NN O
the NN NN O
peak NN NN O
response NN NN O
of NN NN O
73 NN NN O
jerks NN NN O
per NN NN O
min NN NN O
was NN NN O
observed NN NN O
between NN NN O
27 NN NN O
and NN NN O
45 NN NN O
min NN NN O
. NN NN O
   
Increasing NN NN O
the NN NN O
brain NN NN O
serotonin NN NN O
levels NN NN O
by NN NN O
the NN NN O
administration NN NN O
of NN NN O
5 NN NN O
- NN NN O
hydroxytryptophan NN NN O
( NN NN O
80 NN NN O
- NN NN O
160 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
in NN NN O
combination NN NN O
with NN NN O
a NN NN O
peripheral NN NN O
decarboxylase NN NN O
inhibitor NN NN O
resulted NN NN O
in NN NN O
an NN NN O
inhibition NN NN O
of NN NN O
the NN NN O
muscimol NN NN O
effect NN NN O
. NN NN O
   
However NN NN O
, NN NN O
in NN NN O
a NN NN O
similar NN NN O
experiment NN NN O
l NN NN O
- NN NN O
dopa NN NN O
( NN NN O
80 NN NN O
- NN NN O
160 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
was NN NN O
without NN NN O
effect NN NN O
. NN NN O
   
In NN NN O
doses NN NN O
of NN NN O
3 NN NN O
- NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
the NN NN O
serotonin NN NN O
receptor NN NN O
agonist NN NN O
MK NN NN O
- NN NN O
212 NN NN O
caused NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
blockade NN NN O
of NN NN O
the NN NN O
response NN NN O
of NN NN O
muscimol NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
benzodiazepines NN NN O
, NN NN O
clonazepam NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
- NN NN O
0 NN NN O
. NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
several NN NN O
fold NN NN O
more NN NN O
potent NN NN O
than NN NN O
diazepam NN NN O
( NN NN O
0 NN NN O
. NN NN O
3 NN NN O
- NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
in NN NN O
blocking NN NN O
the NN NN O
myoclonic NN NN B-Disease
jerks NN NN I-Disease
. NN NN O
   
While NN NN O
( NN NN O
- NN NN O
) NN NN O
- NN NN O
baclofen NN NN O
( NN NN O
1 NN NN O
- NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
proved NN NN O
to NN NN O
be NN NN O
an NN NN O
effective NN NN O
antagonist NN NN O
of NN NN O
muscimol NN NN O
, NN NN O
its NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
isomer NN NN O
( NN NN O
5 NN NN O
- NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
lacked NN NN O
this NN NN O
property NN NN O
. NN NN O
   
Considering NN NN O
the NN NN O
fact NN NN O
that NN NN O
5 NN NN O
- NN NN O
HTP NN NN O
and NN NN O
the NN NN O
benzodiazepines NN NN O
have NN NN O
been NN NN O
found NN NN O
to NN NN O
be NN NN O
beneficial NN NN O
in NN NN O
the NN NN O
management NN NN O
of NN NN O
clinical NN NN O
myoclonus NN NN B-Disease
, NN NN O
the NN NN O
muscimol NN NN O
- NN NN O
induced NN NN O
myoclonus NN NN B-Disease
seems NN NN O
to NN NN O
be NN NN O
a NN NN O
satisfactory NN NN O
animal NN NN O
model NN NN O
that NN NN O
may NN NN O
prove NN NN O
useful NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
new NN NN O
drug NN NN O
treatments NN NN O
for NN NN O
this NN NN O
condition NN NN O
. NN NN O
   
Our NN NN O
present NN NN O
study NN NN O
indicated NN NN O
the NN NN O
possible NN NN O
value NN NN O
of NN NN O
MK NN NN O
- NN NN O
212 NN NN O
and NN NN O
( NN NN O
- NN NN O
) NN NN O
- NN NN O
baclofen NN NN O
in NN NN O
the NN NN O
management NN NN O
of NN NN O
clinical NN NN O
myoclonus NN NN B-Disease
. NN NN O
   
Adverse NN NN O
interaction NN NN O
between NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
blocking NN NN O
drugs NN NN O
and NN NN O
verapamil NN NN O
- NN NN O
- NN NN O
report NN NN O
of NN NN O
three NN NN O
cases NN NN O
. NN NN O
   
Three NN NN O
patients NN NN O
with NN NN O
ischaemic NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
developed NN NN O
profound NN NN O
cardiac NN NN B-Disease
failure NN NN I-Disease
, NN NN O
hypotension NN NN B-Disease
and NN NN O
bradycardia NN NN B-Disease
during NN NN O
combined NN NN O
therapy NN NN O
with NN NN O
verapamil NN NN O
and NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
blocking NN NN O
drugs NN NN O
. NN NN O
   
This NN NN O
clinical NN NN O
picture NN NN O
resolved NN NN O
completely NN NN O
with NN NN O
cessation NN NN O
of NN NN O
the NN NN O
combined NN NN O
therapy NN NN O
. NN NN O
   
Baseline NN NN O
left NN NN O
ventricular NN NN O
function NN NN O
, NN NN O
assessed NN NN O
by NN NN O
cardiac NN NN O
catheterisation NN NN O
or NN NN O
nuclear NN NN O
angiography NN NN O
, NN NN O
was NN NN O
normal NN NN O
in NN NN O
two NN NN O
patients NN NN O
and NN NN O
only NN NN O
mildly NN NN O
reduced NN NN O
in NN NN O
the NN NN O
other NN NN O
. NN NN O
   
Simultaneously NN NN O
administration NN NN O
of NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
blocking NN NN O
drugs NN NN O
and NN NN O
verapamil NN NN O
may NN NN O
result NN NN O
in NN NN O
profound NN NN O
adverse NN NN O
interactions NN NN O
and NN NN O
should NN NN O
only NN NN O
be NN NN O
administered NN NN O
with NN NN O
great NN NN O
caution NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
the NN NN O
effectiveness NN NN O
of NN NN O
ranitidine NN NN O
and NN NN O
cimetidine NN NN O
in NN NN O
inhibiting NN NN O
acid NN NN O
secretion NN NN O
in NN NN O
patients NN NN O
with NN NN O
gastric NN NN O
hypersecretory NN NN O
states NN NN O
. NN NN O
   
The NN NN O
H2 NN NN O
- NN NN O
histamine NN NN O
receptor NN NN O
antagonists NN NN O
ranitidine NN NN O
and NN NN O
cimetidine NN NN O
were NN NN O
compared NN NN O
for NN NN O
their NN NN O
abilities NN NN O
to NN NN O
control NN NN O
gastric NN NN O
acid NN NN O
hypersecretion NN NN O
on NN NN O
a NN NN O
short NN NN O
- NN NN O
and NN NN O
long NN NN O
- NN NN O
term NN NN O
basis NN NN O
in NN NN O
22 NN NN O
patients NN NN O
with NN NN O
gastric NN NN O
acid NN NN O
hypersecretory NN NN O
states NN NN O
. NN NN O
   
Nineteen NN NN O
patients NN NN O
had NN NN O
Zollinger NN NN B-Disease
- NN NN I-Disease
Ellison NN NN I-Disease
syndrome NN NN I-Disease
, NN NN O
one NN NN O
patient NN NN O
had NN NN O
systemic NN NN B-Disease
mastocytosis NN NN I-Disease
, NN NN O
and NN NN O
two NN NN O
patients NN NN O
had NN NN O
idiopathic NN NN O
hypersecretion NN NN O
. NN NN O
   
The NN NN O
rates NN NN O
of NN NN O
onset NN NN O
of NN NN O
the NN NN O
action NN NN O
of NN NN O
cimetidine NN NN O
and NN NN O
ranitidine NN NN O
were NN NN O
the NN NN O
same NN NN O
. NN NN O
   
The NN NN O
actions NN NN O
of NN NN O
both NN NN O
drugs NN NN O
were NN NN O
increased NN NN O
by NN NN O
anticholinergic NN NN O
agents NN NN O
, NN NN O
and NN NN O
there NN NN O
was NN NN O
a NN NN O
close NN NN O
correlation NN NN O
between NN NN O
the NN NN O
daily NN NN O
maintenance NN NN O
dose NN NN O
of NN NN O
each NN NN O
drug NN NN O
needed NN NN O
to NN NN O
control NN NN O
acid NN NN O
secretion NN NN O
. NN NN O
   
However NN NN O
, NN NN O
ranitidine NN NN O
was NN NN O
threefold NN NN O
more NN NN O
potent NN NN O
than NN NN O
cimetidine NN NN O
both NN NN O
in NN NN O
acute NN NN O
inhibition NN NN O
studies NN NN O
and NN NN O
in NN NN O
the NN NN O
median NN NN O
maintenance NN NN O
dose NN NN O
needed NN NN O
( NN NN O
1 NN NN O
. NN NN O
2 NN NN O
g NN NN O
per NN NN O
day NN NN O
for NN NN O
ranitidine NN NN O
and NN NN O
3 NN NN O
. NN NN O
6 NN NN O
g NN NN O
per NN NN O
day NN NN O
for NN NN O
cimetidine NN NN O
) NN NN O
. NN NN O
   
Sixty NN NN O
percent NN NN O
of NN NN O
the NN NN O
males NN NN O
developed NN NN O
breast NN NN O
changes NN NN O
or NN NN O
impotence NN NN B-Disease
while NN NN O
taking NN NN O
cimetidine NN NN O
and NN NN O
in NN NN O
all NN NN O
cases NN NN O
these NN NN O
changes NN NN O
disappeared NN NN O
when NN NN O
cimetidine NN NN O
was NN NN O
replaced NN NN O
by NN NN O
ranitidine NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
high NN NN O
doses NN NN O
of NN NN O
cimetidine NN NN O
( NN NN O
one NN NN O
to NN NN O
60 NN NN O
months NN NN O
; NN NN O
median NN NN O
, NN NN O
11 NN NN O
months NN NN O
) NN NN O
or NN NN O
ranitidine NN NN O
( NN NN O
two NN NN O
to NN NN O
31 NN NN O
months NN NN O
; NN NN O
median NN NN O
, NN NN O
14 NN NN O
months NN NN O
) NN NN O
was NN NN O
not NN NN O
associated NN NN O
with NN NN O
hepatic NN NN B-Disease
or NN NN I-Disease
hematologic NN NN I-Disease
toxicity NN NN I-Disease
or NN NN O
alterations NN NN O
of NN NN O
serum NN NN O
gastrin NN NN O
concentrations NN NN O
, NN NN O
but NN NN O
ranitidine NN NN O
therapy NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
significantly NN NN O
lower NN NN O
serum NN NN O
creatinine NN NN O
level NN NN O
than NN NN O
seen NN NN O
with NN NN O
cimetidine NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
results NN NN O
show NN NN O
that NN NN O
both NN NN O
drugs NN NN O
can NN NN O
adequately NN NN O
inhibit NN NN O
acid NN NN O
secretion NN NN O
in NN NN O
patients NN NN O
with NN NN O
gastric NN NN O
hypersecretory NN NN O
states NN NN O
. NN NN O
   
Both NN NN O
are NN NN O
safe NN NN O
at NN NN O
high NN NN O
doses NN NN O
, NN NN O
but NN NN O
ranitidine NN NN O
is NN NN O
threefold NN NN O
more NN NN O
potent NN NN O
and NN NN O
does NN NN O
not NN NN O
cause NN NN O
the NN NN O
antiandrogen NN NN O
side NN NN O
effects NN NN O
frequently NN NN O
seen NN NN O
with NN NN O
high NN NN O
doses NN NN O
of NN NN O
cimetidine NN NN O
. NN NN O
   
Epileptogenic NN NN O
properties NN NN O
of NN NN O
enflurane NN NN O
and NN NN O
their NN NN O
clinical NN NN O
interpretation NN NN O
. NN NN O
   
Three NN NN O
cases NN NN O
of NN NN O
EEG NN NN O
changes NN NN O
induced NN NN O
by NN NN O
single NN NN O
exposure NN NN O
to NN NN O
enflurane NN NN O
anesthesia NN NN O
are NN NN O
reported NN NN O
. NN NN O
   
In NN NN O
one NN NN O
patient NN NN O
, NN NN O
enflurane NN NN O
administered NN NN O
during NN NN O
a NN NN O
donor NN NN O
nephrectomy NN NN O
resulted NN NN O
in NN NN O
unexpected NN NN O
partial NN NN O
motor NN NN O
seizures NN NN B-Disease
. NN NN O
   
Until NN NN O
the NN NN O
cause NN NN O
of NN NN O
the NN NN O
seizures NN NN B-Disease
was NN NN O
correctly NN NN O
identified NN NN O
, NN NN O
the NN NN O
patient NN NN O
was NN NN O
inappropriately NN NN O
treated NN NN O
with NN NN O
anticonvulsants NN NN O
. NN NN O
   
Two NN NN O
other NN NN O
patients NN NN O
suffered NN NN O
from NN NN O
partial NN NN O
, NN NN O
complex NN NN O
and NN NN O
generalized NN NN O
seizures NN NN B-Disease
uncontrolled NN NN O
by NN NN O
medication NN NN O
. NN NN O
   
Epileptic NN NN B-Disease
foci NN NN O
delineated NN NN O
and NN NN O
activated NN NN O
by NN NN O
enflurane NN NN O
were NN NN O
surgically NN NN O
ablated NN NN O
and NN NN O
the NN NN O
patients NN NN O
are NN NN O
now NN NN O
seizure NN NN B-Disease
- NN NN O
free NN NN O
. NN NN O
   
Previous NN NN O
exposures NN NN O
to NN NN O
enflurane NN NN O
have NN NN O
to NN NN O
be NN NN O
disclosed NN NN O
to NN NN O
avoid NN NN O
mistakes NN NN O
in NN NN O
clinical NN NN O
interpretation NN NN O
of NN NN O
the NN NN O
EEG NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
enflurane NN NN O
may NN NN O
prove NN NN O
to NN NN O
be NN NN O
a NN NN O
safe NN NN O
fast NN NN O
acting NN NN O
activator NN NN O
of NN NN O
epileptic NN NN B-Disease
foci NN NN O
during NN NN O
corticography NN NN O
or NN NN O
depth NN NN O
electrode NN NN O
intraoperative NN NN O
recordings NN NN O
. NN NN O
   
Development NN NN O
of NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
hypertrophy NN NN I-Disease
. NN NN O
   
The NN NN O
development NN NN O
of NN NN O
cardiac NN NN B-Disease
hypertrophy NN NN I-Disease
was NN NN O
studied NN NN O
in NN NN O
adult NN NN O
female NN NN O
Wistar NN NN O
rats NN NN O
following NN NN O
daily NN NN O
subcutaneous NN NN O
injections NN NN O
of NN NN O
isoproterenol NN NN O
( NN NN O
ISO NN NN O
) NN NN O
( NN NN O
0 NN NN O
. NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
) NN NN O
. NN NN O
   
A NN NN O
time NN NN O
course NN NN O
was NN NN O
established NN NN O
for NN NN O
the NN NN O
change NN NN O
in NN NN O
tissue NN NN O
mass NN NN O
, NN NN O
RNA NN NN O
and NN NN O
DNA NN NN O
content NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
hydroxyproline NN NN O
content NN NN O
. NN NN O
   
Heart NN NN O
weight NN NN O
increased NN NN O
44 NN NN O
% NN NN O
after NN NN O
8 NN NN O
days NN NN O
of NN NN O
treatment NN NN O
with NN NN O
a NN NN O
half NN NN O
time NN NN O
of NN NN O
3 NN NN O
. NN NN O
4 NN NN O
days NN NN O
. NN NN O
   
Ventricular NN NN O
RNA NN NN O
content NN NN O
was NN NN O
elevated NN NN O
26 NN NN O
% NN NN O
after NN NN O
24 NN NN O
h NN NN O
of NN NN O
a NN NN O
single NN NN O
injection NN NN O
and NN NN O
reached NN NN O
a NN NN O
maximal NN NN O
level NN NN O
following NN NN O
8 NN NN O
days NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
half NN NN O
time NN NN O
for NN NN O
RNA NN NN O
accumulation NN NN O
was NN NN O
2 NN NN O
. NN NN O
0 NN NN O
days NN NN O
. NN NN O
   
The NN NN O
total NN NN O
content NN NN O
of NN NN O
hydroxyproline NN NN O
remained NN NN O
stable NN NN O
during NN NN O
the NN NN O
first NN NN O
2 NN NN O
days NN NN O
of NN NN O
treatment NN NN O
but NN NN O
increased NN NN O
46 NN NN O
% NN NN O
after NN NN O
4 NN NN O
days NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
Ventricular NN NN O
DNA NN NN O
content NN NN O
was NN NN O
unchanged NN NN O
during NN NN O
the NN NN O
early NN NN O
stage NN NN O
( NN NN O
1 NN NN O
- NN NN O
4 NN NN O
days NN NN O
) NN NN O
of NN NN O
hypertrophic NN NN B-Disease
growth NN NN O
but NN NN O
increased NN NN O
to NN NN O
a NN NN O
new NN NN O
steady NN NN O
- NN NN O
state NN NN O
level NN NN O
19 NN NN O
% NN NN O
above NN NN O
the NN NN O
controls NN NN O
after NN NN O
8 NN NN O
days NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
Intraventricular NN NN O
pressures NN NN O
and NN NN O
coronary NN NN O
flow NN NN O
measures NN NN O
were NN NN O
similar NN NN O
for NN NN O
control NN NN O
and NN NN O
experimental NN NN O
animals NN NN O
following NN NN O
4 NN NN O
days NN NN O
of NN NN O
developed NN NN O
hypertrophy NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
dP NN NN O
/ NN NN O
dt NN NN O
in NN NN O
the NN NN O
ISO NN NN O
- NN NN O
treated NN NN O
hearts NN NN O
was NN NN O
slightly NN NN O
but NN NN O
significantly NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
elevated NN NN O
. NN NN O
   
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
the NN NN O
adaptive NN NN O
response NN NN O
to NN NN O
ISO NN NN O
shows NN NN O
an NN NN O
early NN NN O
hypertrophic NN NN B-Disease
phase NN NN O
( NN NN O
1 NN NN O
- NN NN O
4 NN NN O
days NN NN O
) NN NN O
characterized NN NN O
by NN NN O
a NN NN O
substantial NN NN O
increase NN NN O
in NN NN O
RNA NN NN O
content NN NN O
and NN NN O
cardiac NN NN O
mass NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
changes NN NN O
in NN NN O
DNA NN NN O
. NN NN O
   
However NN NN O
, NN NN O
prolonged NN NN O
stimulation NN NN O
( NN NN O
8 NN NN O
- NN NN O
12 NN NN O
days NN NN O
) NN NN O
appears NN NN O
to NN NN O
represent NN NN O
a NN NN O
complex NN NN O
integration NN NN O
of NN NN O
both NN NN O
cellular NN NN O
hypertrophy NN NN B-Disease
and NN NN O
hyperplasia NN NN B-Disease
within NN NN O
the NN NN O
heart NN NN O
. NN NN O
   
Multiple NN NN O
side NN NN O
effects NN NN O
of NN NN O
penicillamine NN NN O
therapy NN NN O
in NN NN O
one NN NN O
patient NN NN O
with NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
. NN NN O
   
Skin NN NN B-Disease
rashes NN NN I-Disease
, NN NN O
proteinuria NN NN B-Disease
, NN NN O
systemic NN NN B-Disease
lupus NN NN I-Disease
erythematosus NN NN I-Disease
, NN NN O
polymyositis NN NN B-Disease
and NN NN O
myasthenia NN NN B-Disease
gravis NN NN I-Disease
have NN NN O
all NN NN O
been NN NN O
recorded NN NN O
as NN NN O
complications NN NN O
of NN NN O
penicillamine NN NN O
therapy NN NN O
in NN NN O
patients NN NN O
with NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
. NN NN O
   
A NN NN O
patient NN NN O
who NN NN O
had NN NN O
developed NN NN O
all NN NN O
5 NN NN O
is NN NN O
now NN NN O
described NN NN O
. NN NN O
   
The NN NN O
skin NN NN B-Disease
lesion NN NN I-Disease
resembled NN NN O
elastosis NN NN B-Disease
perforans NN NN I-Disease
serpiginosa NN NN I-Disease
, NN NN O
which NN NN O
has NN NN O
been NN NN O
reported NN NN O
as NN NN O
a NN NN O
rare NN NN O
side NN NN O
effect NN NN O
in NN NN O
patients NN NN O
with NN NN O
Wilson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
but NN NN O
not NN NN O
in NN NN O
patients NN NN O
with NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
treated NN NN O
with NN NN O
penicillamine NN NN O
. NN NN O
   
Obsolete NN NN O
but NN NN O
dangerous NN NN O
antacid NN NN O
preparations NN NN O
. NN NN O
   
One NN NN O
case NN NN O
of NN NN O
acute NN NN O
hypercalcaemia NN NN B-Disease
and NN NN O
two NN NN O
of NN NN O
recurrent NN NN O
nephrolithiasis NN NN B-Disease
are NN NN O
reported NN NN O
in NN NN O
patients NN NN O
who NN NN O
had NN NN O
regularly NN NN O
consumed NN NN O
large NN NN O
amounts NN NN O
of NN NN O
calcium NN NN O
carbon NN NN O
- NN NN O
ate NN NN O
- NN NN O
sodium NN NN O
bicarbonate NN NN O
powders NN NN O
for NN NN O
more NN NN O
than NN NN O
20 NN NN O
years NN NN O
. NN NN O
   
The NN NN O
powders NN NN O
had NN NN O
been NN NN O
obtained NN NN O
from NN NN O
pharmacists NN NN O
unknown NN NN O
to NN NN O
the NN NN O
patients NN NN O
' NN NN O
medical NN NN O
practitioners NN NN O
. NN NN O
   
It NN NN O
is NN NN O
suggested NN NN O
that NN NN O
these NN NN O
preparations NN NN O
were NN NN O
responsible NN NN O
for NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
problems NN NN O
, NN NN O
and NN NN O
that NN NN O
such NN NN O
powders NN NN O
should NN NN O
no NN NN O
longer NN NN O
be NN NN O
freely NN NN O
obtainable NN NN O
. NN NN O
   
Doxorubicin NN NN O
cardiomyopathy NN NN B-Disease
in NN NN O
children NN NN O
with NN NN O
left NN NN O
- NN NN O
sided NN NN O
Wilms NN NN B-Disease
tumor NN NN I-Disease
. NN NN O
   
Two NN NN O
children NN NN O
with NN NN O
Wilms NN NN B-Disease
tumor NN NN I-Disease
of NN NN O
the NN NN O
left NN NN O
kidney NN NN O
experienced NN NN O
severe NN NN O
anthracycline NN NN O
cardiomyopathy NN NN B-Disease
after NN NN O
irradiation NN NN O
to NN NN O
the NN NN O
tumor NN NN B-Disease
bed NN NN O
and NN NN O
conventional NN NN O
dosage NN NN O
of NN NN O
doxorubicin NN NN O
. NN NN O
   
The NN NN O
cardiomyopathy NN NN B-Disease
is NN NN O
attributed NN NN O
1 NN NN O
) NN NN O
to NN NN O
the NN NN O
fact NN NN O
that NN NN O
radiation NN NN O
fields NN NN O
for NN NN O
left NN NN O
Wilms NN NN B-Disease
tumor NN NN I-Disease
include NN NN O
the NN NN O
lower NN NN O
portion NN NN O
of NN NN O
the NN NN O
heart NN NN O
and NN NN O
2 NN NN O
) NN NN O
to NN NN O
the NN NN O
interaction NN NN O
of NN NN O
doxorubicin NN NN O
and NN NN O
irradiation NN NN O
on NN NN O
cardiac NN NN O
muscle NN NN O
. NN NN O
   
It NN NN O
is NN NN O
recommended NN NN O
that NN NN O
doxorubicin NN NN O
dosage NN NN O
be NN NN O
sharply NN NN O
restricted NN NN O
in NN NN O
children NN NN O
with NN NN O
Wilms NN NN B-Disease
tumor NN NN I-Disease
of NN NN O
the NN NN O
left NN NN O
kidney NN NN O
who NN NN O
receive NN NN O
postoperative NN NN O
irradiation NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
calcitonin NN NN O
on NN NN O
rat NN NN O
extrapyramidal NN NN O
motor NN NN O
system NN NN O
: NN NN O
behavioral NN NN O
and NN NN O
biochemical NN NN O
data NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
c NN NN O
. NN NN O
injection NN NN O
of NN NN O
human NN NN O
and NN NN O
salmon NN NN O
calcitonin NN NN O
on NN NN O
biochemical NN NN O
and NN NN O
behavioral NN NN O
parameters NN NN O
related NN NN O
to NN NN O
the NN NN O
extrapyramidal NN NN O
motor NN NN O
system NN NN O
, NN NN O
were NN NN O
investigated NN NN O
in NN NN O
male NN NN O
rats NN NN O
. NN NN O
   
Calcitonin NN NN O
injection NN NN O
resulted NN NN O
in NN NN O
a NN NN O
potentiation NN NN O
of NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
and NN NN O
a NN NN O
partial NN NN O
prevention NN NN O
of NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
. NN NN O
   
Moreover NN NN O
calcitonin NN NN O
induced NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
nigral NN NN O
GAD NN NN O
activity NN NN O
but NN NN O
no NN NN O
change NN NN O
in NN NN O
striatal NN NN O
DA NN NN O
and NN NN O
DOPAC NN NN O
concentration NN NN O
or NN NN O
GAD NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
results NN NN O
are NN NN O
discussed NN NN O
in NN NN O
view NN NN O
of NN NN O
a NN NN O
primary NN NN O
action NN NN O
of NN NN O
calcitonin NN NN O
on NN NN O
the NN NN O
striatonigral NN NN O
GABAergic NN NN O
pathway NN NN O
mediating NN NN O
the NN NN O
DA NN NN O
- NN NN O
related NN NN O
behavioral NN NN O
messages NN NN O
of NN NN O
striatal NN NN O
origin NN NN O
. NN NN O
   
Naloxazone NN NN O
pretreatment NN NN O
modifies NN NN O
cardiorespiratory NN NN O
, NN NN O
temperature NN NN O
, NN NN O
and NN NN O
behavioral NN NN O
effects NN NN O
of NN NN O
morphine NN NN O
. NN NN O
   
Behavioral NN NN O
and NN NN O
cardiorespiratory NN NN O
responses NN NN O
to NN NN O
a NN NN O
lethal NN NN O
dose NN NN O
of NN NN O
morphine NN NN O
were NN NN O
evaluated NN NN O
in NN NN O
rats NN NN O
pretreated NN NN O
with NN NN O
saline NN NN O
or NN NN O
naloxazone NN NN O
, NN NN O
an NN NN O
antagonist NN NN O
of NN NN O
high NN NN O
- NN NN O
affinity NN NN O
mu NN NN O
1 NN NN O
opioid NN NN O
receptors NN NN O
. NN NN O
   
Pretreatment NN NN O
with NN NN O
naloxazone NN NN O
significantly NN NN O
blocked NN NN O
morphine NN NN O
analgesia NN NN B-Disease
, NN NN O
catalepsy NN NN B-Disease
and NN NN O
hypothermia NN NN B-Disease
at NN NN O
a NN NN O
dose NN NN O
which NN NN O
completely NN NN O
eliminated NN NN O
high NN NN O
- NN NN O
affinity NN NN O
binding NN NN O
in NN NN O
brain NN NN O
membranes NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
naloxazone NN NN O
significantly NN NN O
attenuated NN NN O
the NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
and NN NN O
respiratory NN NN B-Disease
depression NN NN I-Disease
, NN NN O
whereas NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
bradycardia NN NN B-Disease
was NN NN O
less NN NN O
affected NN NN O
. NN NN O
   
Results NN NN O
indicate NN NN O
that NN NN O
subpopulations NN NN O
of NN NN O
mu NN NN O
receptors NN NN O
may NN NN O
mediate NN NN O
selective NN NN O
behavioral NN NN O
and NN NN O
cardiorespiratory NN NN O
responses NN NN O
to NN NN O
morphine NN NN O
. NN NN O
   
Modification NN NN O
of NN NN O
drug NN NN O
action NN NN O
by NN NN O
hyperammonemia NN NN B-Disease
. NN NN O
   
Pretreatment NN NN O
with NN NN O
ammonium NN NN O
acetate NN NN O
( NN NN O
NH4Ac NN NN O
) NN NN O
( NN NN O
6 NN NN O
mmol NN NN O
/ NN NN O
kg NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
approximately NN NN O
doubled NN NN O
the NN NN O
time NN NN O
morphine NN NN O
- NN NN O
treated NN NN O
mice NN NN O
remained NN NN O
on NN NN O
a NN NN O
hot NN NN O
surface NN NN O
and NN NN O
similarly NN NN O
increased NN NN O
muscular NN NN O
incoordination NN NN B-Disease
by NN NN O
diazepam NN NN O
, NN NN O
but NN NN O
NH4Ac NN NN O
treatment NN NN O
alone NN NN O
had NN NN O
no NN NN O
effect NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
hyperammonemia NN NN B-Disease
is NN NN O
capable NN NN O
of NN NN O
altering NN NN O
drug NN NN O
action NN NN O
and NN NN O
must NN NN O
be NN NN O
considered NN NN O
along NN NN O
with NN NN O
impaired NN NN O
drug NN NN O
metabolism NN NN O
in NN NN O
enhanced NN NN O
drug NN NN O
responses NN NN O
associated NN NN O
with NN NN O
liver NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
Experiments NN NN O
in NN NN O
vitro NN NN O
showed NN NN O
that NN NN O
acetylcholine NN NN O
- NN NN O
induced NN NN O
catecholamine NN NN O
release NN NN O
from NN NN O
bovine NN NN O
adrenal NN NN O
medulla NN NN O
is NN NN O
depressed NN NN O
as NN NN O
much NN NN O
as NN NN O
50 NN NN O
% NN NN O
by NN NN O
0 NN NN O
. NN NN O
3 NN NN O
mM NN NN O
NH4Ac NN NN O
and NN NN O
KCl NN NN O
- NN NN O
induced NN NN O
contractions NN NN O
of NN NN O
guinea NN NN O
- NN NN O
pig NN NN O
ileum NN NN O
were NN NN O
inhibited NN NN O
20 NN NN O
% NN NN O
by NN NN O
5 NN NN O
mM NN NN O
NH4Ac NN NN O
. NN NN O
   
Addition NN NN O
of NN NN O
excess NN NN O
calcium NN NN O
reversed NN NN O
the NN NN O
depression NN NN B-Disease
in NN NN O
both NN NN O
tissues NN NN O
, NN NN O
but NN NN O
calcium NN NN O
- NN NN O
independent NN NN O
catecholamine NN NN O
release NN NN O
by NN NN O
acetaldehyde NN NN O
was NN NN O
not NN NN O
blocked NN NN O
by NN NN O
NH4Ac NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggested NN NN O
that NN NN O
ammonia NN NN O
blocks NN NN O
calcium NN NN O
channels NN NN O
. NN NN O
   
Parallels NN NN O
in NN NN O
the NN NN O
actions NN NN O
of NN NN O
NH4Ac NN NN O
and NN NN O
the NN NN O
calcium NN NN O
channel NN NN O
blocker NN NN O
verapamil NN NN O
support NN NN O
this NN NN O
concept NN NN O
. NN NN O
   
Both NN NN O
verapamil NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
and NN NN O
NH4Ac NN NN O
pretreatment NN NN O
enhanced NN NN O
morphine NN NN O
analgesia NN NN B-Disease
- NN NN O
and NN NN O
diazepam NN NN O
- NN NN O
induced NN NN O
muscular NN NN O
incoordination NN NN B-Disease
and NN NN O
antagonized NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
motor NN NN O
activity NN NN O
, NN NN O
and NN NN O
neither NN NN O
verapamil NN NN O
nor NN NN O
NH4Ac NN NN O
affected NN NN O
the NN NN O
convulsant NN NN O
action NN NN O
of NN NN O
metrazol NN NN O
. NN NN O
   
The NN NN O
data NN NN O
suggest NN NN O
that NN NN O
hyperammonemia NN NN B-Disease
exerts NN NN O
a NN NN O
calcium NN NN O
channel NN NN O
blocking NN NN O
action NN NN O
which NN NN O
enhances NN NN O
the NN NN O
effects NN NN O
of NN NN O
central NN NN O
nervous NN NN O
system NN NN O
depressants NN NN O
and NN NN O
certain NN NN O
opioid NN NN O
analgesics NN NN O
. NN NN O
   
Levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesia NN NN B-Disease
and NN NN O
thalamotomy NN NN O
. NN NN O
   
Levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesia NN NN B-Disease
of NN NN O
the NN NN O
limbs NN NN O
in NN NN O
thirteen NN NN O
cases NN NN O
of NN NN O
Parkinsonism NN NN B-Disease
, NN NN O
which NN NN O
was NN NN O
choreic NN NN O
, NN NN O
ballistic NN NN O
or NN NN O
dystonic NN NN B-Disease
in NN NN O
type NN NN O
, NN NN O
was NN NN O
alleviated NN NN O
almost NN NN O
completely NN NN O
by NN NN O
stereotaxic NN NN O
surgery NN NN O
using NN NN O
a NN NN O
microelectrode NN NN O
technique NN NN O
for NN NN O
the NN NN O
ventralis NN NN O
oralis NN NN O
anterior NN NN O
and NN NN O
posterior NN NN O
nuclei NN NN O
of NN NN O
the NN NN O
thalamus NN NN O
, NN NN O
but NN NN O
much NN NN O
less NN NN O
by NN NN O
the NN NN O
ventralis NN NN O
intermedius NN NN O
nucleus NN NN O
. NN NN O
   
Control NN NN O
of NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
by NN NN O
thalamic NN NN B-Disease
lesions NN NN I-Disease
in NN NN O
the NN NN O
course NN NN O
of NN NN O
routine NN NN O
treatment NN NN O
of NN NN O
Parkinsonism NN NN B-Disease
is NN NN O
discussed NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
ifosfamide NN NN O
- NN NN O
induced NN NN O
urothelial NN NN B-Disease
toxicity NN NN I-Disease
by NN NN O
oral NN NN O
administration NN NN O
of NN NN O
sodium NN NN O
2 NN NN O
- NN NN O
mercaptoethane NN NN O
sulphonate NN NN O
( NN NN O
MESNA NN NN O
) NN NN O
to NN NN O
patients NN NN O
with NN NN O
inoperable NN NN O
lung NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
The NN NN O
protective NN NN O
effect NN NN O
of NN NN O
oral NN NN O
administration NN NN O
of NN NN O
the NN NN O
thiol NN NN O
compound NN NN O
sodium NN NN O
2 NN NN O
- NN NN O
mercaptoethane NN NN O
sulphonate NN NN O
( NN NN O
MESNA NN NN O
) NN NN O
against NN NN O
urothelial NN NN B-Disease
toxicity NN NN I-Disease
induced NN NN O
by NN NN O
ifosfamide NN NN O
( NN NN O
IF NN NN O
) NN NN O
was NN NN O
tested NN NN O
in NN NN O
a NN NN O
group NN NN O
of NN NN O
45 NN NN O
patients NN NN O
with NN NN O
inoperable NN NN O
lung NN NN B-Disease
cancer NN NN I-Disease
under NN NN O
treatment NN NN O
with NN NN O
IF NN NN O
( NN NN O
2250 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
on NN NN O
days NN NN O
2 NN NN O
- NN NN O
5 NN NN O
) NN NN O
as NN NN O
part NN NN O
of NN NN O
a NN NN O
polychemotherapy NN NN O
regimen NN NN O
repeated NN NN O
in NN NN O
a NN NN O
4 NN NN O
- NN NN O
week NN NN O
cycle NN NN O
. NN NN O
   
MESNA NN NN O
was NN NN O
given NN NN O
orally NN NN O
on NN NN O
the NN NN O
days NN NN O
of NN NN O
treatment NN NN O
with NN NN O
IF NN NN O
in NN NN O
3 NN NN O
doses NN NN O
of NN NN O
840 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
, NN NN O
each NN NN O
administered NN NN O
at NN NN O
0 NN NN O
hr NN NN O
( NN NN O
= NN NN O
injection NN NN O
of NN NN O
IF NN NN O
) NN NN O
, NN NN O
4 NN NN O
hr NN NN O
and NN NN O
8 NN NN O
hr NN NN O
p NN NN O
. NN NN O
i NN NN O
. NN NN O
   
Out NN NN O
of NN NN O
a NN NN O
total NN NN O
of NN NN O
88 NN NN O
courses NN NN O
of NN NN O
this NN NN O
treatment NN NN O
we NN NN O
observed NN NN O
10 NN NN O
episodes NN NN O
of NN NN O
asymptomatic NN NN O
microscopic NN NN O
haematuria NN NN B-Disease
and NN NN O
no NN NN O
episodes NN NN O
of NN NN O
gross NN NN O
haematuria NN NN B-Disease
. NN NN O
   
In NN NN O
this NN NN O
group NN NN O
of NN NN O
45 NN NN O
patients NN NN O
under NN NN O
protection NN NN O
with NN NN O
MESNA NN NN O
there NN NN O
were NN NN O
5 NN NN O
complete NN NN O
remissions NN NN O
and NN NN O
9 NN NN O
partial NN NN O
remissions NN NN O
( NN NN O
total NN NN O
31 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
A NN NN O
further NN NN O
group NN NN O
of NN NN O
25 NN NN O
patients NN NN O
under NN NN O
polychemotherapy NN NN O
with NN NN O
IF NN NN O
were NN NN O
treated NN NN O
by NN NN O
conventional NN NN O
prophylactic NN NN O
measures NN NN O
( NN NN O
raised NN NN O
fluid NN NN O
intake NN NN O
and NN NN O
forced NN NN O
diuresis NN NN O
) NN NN O
. NN NN O
   
In NN NN O
this NN NN O
group NN NN O
there NN NN O
were NN NN O
1 NN NN O
complete NN NN O
and NN NN O
5 NN NN O
partial NN NN O
remissions NN NN O
( NN NN O
total NN NN O
24 NN NN O
% NN NN O
) NN NN O
, NN NN O
but NN NN O
nearly NN NN O
all NN NN O
patients NN NN O
developed NN NN O
either NN NN O
gross NN NN O
haematuria NN NN B-Disease
and NN NN O
/ NN NN O
or NN NN O
symptoms NN NN O
of NN NN O
bladder NN NN B-Disease
irritation NN NN I-Disease
( NN NN O
cystitis NN NN B-Disease
and NN NN O
pollakisuria NN NN B-Disease
) NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
appreciable NN NN O
differences NN NN O
between NN NN O
the NN NN O
MESNA NN NN O
series NN NN O
and NN NN O
the NN NN O
conventional NN NN O
prophylaxis NN NN O
series NN NN O
with NN NN O
respect NN NN O
to NN NN O
either NN NN O
haematological NN NN O
or NN NN O
systemic NN NN O
toxicity NN NN B-Disease
of NN NN O
the NN NN O
cytostatic NN NN O
treatment NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
support NN NN O
the NN NN O
view NN NN O
that NN NN O
MESNA NN NN O
, NN NN O
given NN NN O
orally NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
combined NN NN O
cytostatic NN NN O
regimens NN NN O
which NN NN O
include NN NN O
IF NN NN O
, NN NN O
simplifies NN NN O
the NN NN O
treatment NN NN O
and NN NN O
provides NN NN O
optimum NN NN O
protection NN NN O
for NN NN O
the NN NN O
urinary NN NN O
epithelium NN NN O
. NN NN O
   
Protection NN NN O
with NN NN O
oral NN NN O
MESNA NN NN O
is NN NN O
particularly NN NN O
suitable NN NN O
for NN NN O
outpatients NN NN O
. NN NN O
   
Myoclonic NN NN B-Disease
, NN NN I-Disease
atonic NN NN I-Disease
, NN NN I-Disease
and NN NN I-Disease
absence NN NN I-Disease
seizures NN NN I-Disease
following NN NN O
institution NN NN O
of NN NN O
carbamazepine NN NN O
therapy NN NN O
in NN NN O
children NN NN O
. NN NN O
   
Five NN NN O
children NN NN O
, NN NN O
aged NN NN O
3 NN NN O
to NN NN O
11 NN NN O
years NN NN O
, NN NN O
treated NN NN O
with NN NN O
carbamazepine NN NN O
for NN NN O
epilepsy NN NN B-Disease
, NN NN O
had NN NN O
an NN NN O
acute NN NN O
aberrant NN NN O
reaction NN NN O
characterized NN NN O
by NN NN O
the NN NN O
onset NN NN O
of NN NN O
myoclonic NN NN B-Disease
, NN NN I-Disease
atypical NN NN I-Disease
absence NN NN I-Disease
and NN NN I-Disease
/ NN NN I-Disease
or NN NN I-Disease
atonic NN NN I-Disease
( NN NN I-Disease
minor NN NN I-Disease
motor NN NN I-Disease
) NN NN I-Disease
seizures NN NN I-Disease
within NN NN O
a NN NN O
few NN NN O
days NN NN O
. NN NN O
   
When NN NN O
the NN NN O
carbamazepine NN NN O
was NN NN O
discontinued NN NN O
, NN NN O
two NN NN O
of NN NN O
the NN NN O
children NN NN O
returned NN NN O
to NN NN O
their NN NN O
former NN NN O
state NN NN O
very NN NN O
quickly NN NN O
, NN NN O
two NN NN O
had NN NN O
the NN NN O
minor NN NN O
motor NN NN O
seizures NN NN B-Disease
resolve NN NN O
in NN NN O
3 NN NN O
and NN NN O
6 NN NN O
months NN NN O
, NN NN O
and NN NN O
one NN NN O
had NN NN O
the NN NN O
seizures NN NN B-Disease
persist NN NN O
. NN NN O
   
The NN NN O
child NN NN O
in NN NN O
whom NN NN O
the NN NN O
seizures NN NN B-Disease
persisted NN NN O
was NN NN O
later NN NN O
found NN NN O
to NN NN O
have NN NN O
ceroid NN NN B-Disease
lipofuscinosis NN NN I-Disease
. NN NN O
   
The NN NN O
other NN NN O
children NN NN O
are NN NN O
doing NN NN O
well NN NN O
on NN NN O
other NN NN O
anticonvulsants NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
prostaglandin NN NN O
synthetase NN NN O
inhibitors NN NN O
on NN NN O
experimentally NN NN O
induced NN NN O
convulsions NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
the NN NN O
relationship NN NN O
of NN NN O
prostaglandins NN NN O
( NN NN O
PGs NN NN O
) NN NN O
to NN NN O
seizure NN NN B-Disease
induction NN NN O
, NN NN O
the NN NN O
effects NN NN O
of NN NN O
six NN NN O
PG NN NN O
synthetase NN NN O
inhibitors NN NN O
on NN NN O
convulsions NN NN B-Disease
induced NN NN O
by NN NN O
flurothyl NN NN O
, NN NN O
picrotoxin NN NN O
, NN NN O
pentetrazol NN NN O
( NN NN O
PTZ NN NN O
) NN NN O
, NN NN O
electroshock NN NN O
or NN NN O
bicuculline NN NN O
were NN NN O
evaluated NN NN O
. NN NN O
   
Ibuprofen NN NN O
, NN NN O
sulindac NN NN O
, NN NN O
mefenamic NN NN O
acid NN NN O
, NN NN O
and NN NN O
low NN NN O
dose NN NN O
meclofenamic NN NN O
acid NN NN O
increased NN NN O
the NN NN O
latency NN NN O
- NN NN O
to NN NN O
- NN NN O
onset NN NN O
in NN NN O
the NN NN O
flurothyl NN NN O
and NN NN O
/ NN NN O
or NN NN O
PTZ NN NN O
models NN NN O
; NN NN O
the NN NN O
electroshock NN NN O
, NN NN O
picrotoxin NN NN O
and NN NN O
bicuculline NN NN O
models NN NN O
were NN NN O
not NN NN O
significantly NN NN O
affected NN NN O
by NN NN O
any NN NN O
of NN NN O
the NN NN O
pretreatment NN NN O
agents NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
PGs NN NN O
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
mechanism NN NN O
( NN NN O
s NN NN O
) NN NN O
underlying NN NN O
fluorthyl NN NN O
- NN NN O
and NN NN O
PTZ NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
, NN NN O
but NN NN O
not NN NN O
picrotoxin NN NN O
- NN NN O
, NN NN O
electroshock NN NN O
- NN NN O
, NN NN O
or NN NN O
bicuculline NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
. NN NN O
   
Acute NN NN O
changes NN NN O
of NN NN O
blood NN NN O
ammonia NN NN O
may NN NN O
predict NN NN O
short NN NN O
- NN NN O
term NN NN O
adverse NN NN O
effects NN NN O
of NN NN O
valproic NN NN O
acid NN NN O
. NN NN O
   
Valproic NN NN O
acid NN NN O
( NN NN O
VPA NN NN O
) NN NN O
was NN NN O
given NN NN O
to NN NN O
24 NN NN O
epileptic NN NN B-Disease
patients NN NN O
who NN NN O
were NN NN O
already NN NN O
being NN NN O
treated NN NN O
with NN NN O
other NN NN O
antiepileptic NN NN O
drugs NN NN O
. NN NN O
   
A NN NN O
standardized NN NN O
loading NN NN O
dose NN NN O
of NN NN O
VPA NN NN O
was NN NN O
administered NN NN O
, NN NN O
and NN NN O
venous NN NN O
blood NN NN O
was NN NN O
sampled NN NN O
at NN NN O
0 NN NN O
, NN NN O
1 NN NN O
, NN NN O
2 NN NN O
, NN NN O
3 NN NN O
, NN NN O
and NN NN O
4 NN NN O
hours NN NN O
. NN NN O
   
Ammonia NN NN O
( NN NN O
NH3 NN NN O
) NN NN O
was NN NN O
higher NN NN O
in NN NN O
patients NN NN O
who NN NN O
, NN NN O
during NN NN O
continuous NN NN O
therapy NN NN O
, NN NN O
complained NN NN O
of NN NN O
drowsiness NN NN B-Disease
( NN NN O
7 NN NN O
patients NN NN O
) NN NN O
than NN NN O
in NN NN O
those NN NN O
who NN NN O
were NN NN O
symptom NN NN O
- NN NN O
free NN NN O
( NN NN O
17 NN NN O
patients NN NN O
) NN NN O
, NN NN O
although NN NN O
VPA NN NN O
plasma NN NN O
levels NN NN O
were NN NN O
similar NN NN O
in NN NN O
both NN NN O
groups NN NN O
. NN NN O
   
By NN NN O
measuring NN NN O
VPA NN NN O
- NN NN O
induced NN NN O
changes NN NN O
of NN NN O
blood NN NN O
NH3 NN NN O
content NN NN O
, NN NN O
it NN NN O
may NN NN O
be NN NN O
possible NN NN O
to NN NN O
identify NN NN O
patients NN NN O
at NN NN O
higher NN NN O
risk NN NN O
of NN NN O
obtundation NN NN O
when NN NN O
VPA NN NN O
is NN NN O
given NN NN O
chronically NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
captopril NN NN O
on NN NN O
pre NN NN O
- NN NN O
existing NN NN O
and NN NN O
aminonucleoside NN NN O
- NN NN O
induced NN NN O
proteinuria NN NN B-Disease
in NN NN O
spontaneously NN NN O
hypertensive NN NN B-Disease
rats NN NN O
. NN NN O
   
Proteinuria NN NN B-Disease
is NN NN O
a NN NN O
side NN NN O
effect NN NN O
of NN NN O
captopril NN NN O
treatment NN NN O
in NN NN O
hypertensive NN NN B-Disease
patients NN NN O
. NN NN O
   
The NN NN O
possibility NN NN O
of NN NN O
reproducing NN NN O
the NN NN O
same NN NN O
renal NN NN B-Disease
abnormality NN NN I-Disease
with NN NN O
captopril NN NN O
was NN NN O
examined NN NN O
in NN NN O
SHR NN NN O
. NN NN O
   
Oral NN NN O
administration NN NN O
of NN NN O
captopril NN NN O
at NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
for NN NN O
14 NN NN O
days NN NN O
failed NN NN O
to NN NN O
aggravate NN NN O
proteinuria NN NN B-Disease
pre NN NN O
- NN NN O
existing NN NN O
in NN NN O
SHR NN NN O
. NN NN O
   
Also NN NN O
, NN NN O
captopril NN NN O
treatment NN NN O
failed NN NN O
to NN NN O
potentiate NN NN O
or NN NN O
facilitate NN NN O
development NN NN O
of NN NN O
massive NN NN O
proteinuria NN NN B-Disease
invoked NN NN O
by NN NN O
puromycin NN NN O
aminonucleoside NN NN O
in NN NN O
SHR NN NN O
. NN NN O
   
Captopril NN NN O
had NN NN O
little NN NN O
or NN NN O
no NN NN O
demonstrable NN NN O
effects NN NN O
on NN NN O
serum NN NN O
electrolyte NN NN O
concentrations NN NN O
, NN NN O
excretion NN NN O
of NN NN O
urine NN NN O
, NN NN O
sodium NN NN O
and NN NN O
potassium NN NN O
, NN NN O
endogenous NN NN O
creatinine NN NN O
clearance NN NN O
, NN NN O
body NN NN O
weight NN NN O
, NN NN O
and NN NN O
food NN NN O
and NN NN O
water NN NN O
consumption NN NN O
. NN NN O
   
However NN NN O
, NN NN O
ketone NN NN O
bodies NN NN O
were NN NN O
consistently NN NN O
present NN NN O
in NN NN O
urine NN NN O
and NN NN O
several NN NN O
lethalities NN NN O
occurred NN NN O
during NN NN O
multiple NN NN O
dosing NN NN O
of NN NN O
captopril NN NN O
in NN NN O
SHR NN NN O
. NN NN O
   
Complete NN NN O
heart NN NN B-Disease
block NN NN I-Disease
following NN NN O
a NN NN O
single NN NN O
dose NN NN O
of NN NN O
trazodone NN NN O
. NN NN O
   
Forty NN NN O
minutes NN NN O
after NN NN O
receiving NN NN O
a NN NN O
single NN NN O
starting NN NN O
dose NN NN O
of NN NN O
trazodone NN NN O
, NN NN O
a NN NN O
patient NN NN O
developed NN NN O
complete NN NN O
heart NN NN B-Disease
block NN NN I-Disease
. NN NN O
   
The NN NN O
case NN NN O
illustrates NN NN O
that NN NN O
, NN NN O
despite NN NN O
the NN NN O
results NN NN O
of NN NN O
earlier NN NN O
studies NN NN O
, NN NN O
trazodone NN NN O
' NN NN O
s NN NN O
effect NN NN O
on NN NN O
cardiac NN NN O
conduction NN NN O
may NN NN O
be NN NN O
severe NN NN O
in NN NN O
individuals NN NN O
at NN NN O
risk NN NN O
for NN NN O
conduction NN NN O
delay NN NN O
. NN NN O
   
Phenobarbital NN NN O
- NN NN O
induced NN NN O
dyskinesia NN NN B-Disease
in NN NN O
a NN NN O
neurologically NN NN B-Disease
- NN NN I-Disease
impaired NN NN I-Disease
child NN NN O
. NN NN O
   
A NN NN O
2 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
child NN NN O
with NN NN O
known NN NN O
neurologic NN NN B-Disease
impairment NN NN I-Disease
developed NN NN O
a NN NN O
dyskinesia NN NN B-Disease
soon NN NN O
after NN NN O
starting NN NN O
phenobarbital NN NN O
therapy NN NN O
for NN NN O
seizures NN NN B-Disease
. NN NN O
   
Known NN NN O
causes NN NN O
of NN NN O
movement NN NN B-Disease
disorders NN NN I-Disease
were NN NN O
eliminated NN NN O
after NN NN O
evaluation NN NN O
. NN NN O
   
On NN NN O
repeat NN NN O
challenge NN NN O
with NN NN O
phenobarbital NN NN O
, NN NN O
the NN NN O
dyskinesia NN NN B-Disease
recurred NN NN O
. NN NN O
   
Phenobarbital NN NN O
should NN NN O
be NN NN O
added NN NN O
to NN NN O
the NN NN O
list NN NN O
of NN NN O
anticonvulsant NN NN O
drugs NN NN O
that NN NN O
can NN NN O
cause NN NN O
movement NN NN B-Disease
disorders NN NN I-Disease
. NN NN O
   
Effects NN NN O
of NN NN O
amine NN NN O
pretreatment NN NN O
on NN NN O
ketamine NN NN O
catatonia NN NN B-Disease
in NN NN O
pinealectomized NN NN O
or NN NN O
hypophysectomized NN NN O
animals NN NN O
. NN NN O
   
The NN NN O
present NN NN O
studies NN NN O
were NN NN O
designed NN NN O
to NN NN O
clarify NN NN O
the NN NN O
role NN NN O
of NN NN O
catecholamines NN NN O
and NN NN O
pineal NN NN O
idolamines NN NN O
on NN NN O
ketamine NN NN O
- NN NN O
induced NN NN O
catatonia NN NN B-Disease
in NN NN O
the NN NN O
intact NN NN O
, NN NN O
pinealectomized NN NN O
or NN NN O
hypophysectomized NN NN O
chick NN NN O
and NN NN O
rat NN NN O
. NN NN O
   
In NN NN O
the NN NN O
pinealectomized NN NN O
chick NN NN O
, NN NN O
pretreatment NN NN O
with NN NN O
dopamine NN NN O
increased NN NN O
the NN NN O
duration NN NN O
of NN NN O
catatonia NN NN B-Disease
( NN NN O
DOC NN NN O
) NN NN O
after NN NN O
ketamine NN NN O
, NN NN O
but NN NN O
pretreatment NN NN O
with NN NN O
norepinephrine NN NN O
did NN NN O
not NN NN O
. NN NN O
   
The NN NN O
pineal NN NN O
indolamines NN NN O
exhibited NN NN O
mixed NN NN O
actions NN NN O
. NN NN O
   
Serotonin NN NN O
and NN NN O
N NN NN O
- NN NN O
acetyl NN NN O
serotonin NN NN O
which NN NN O
augmented NN NN O
ketamine NN NN O
DOC NN NN O
, NN NN O
did NN NN O
not NN NN O
do NN NN O
so NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
the NN NN O
pineal NN NN O
gland NN NN O
, NN NN O
whereas NN NN O
melatonin NN NN O
potentiated NN NN O
the NN NN O
ketamine NN NN O
DOC NN NN O
in NN NN O
both NN NN O
the NN NN O
intact NN NN O
and NN NN O
pinealectomized NN NN O
chick NN NN O
. NN NN O
   
Ketamine NN NN O
was NN NN O
more NN NN O
potent NN NN O
in NN NN O
the NN NN O
hypophysectomized NN NN O
chick NN NN O
and NN NN O
the NN NN O
circadian NN NN O
rhythm NN NN O
noted NN NN O
in NN NN O
the NN NN O
intact NN NN O
chick NN NN O
was NN NN O
absent NN NN O
; NN NN O
furthermore NN NN O
, NN NN O
melatonin NN NN O
did NN NN O
not NN NN O
augment NN NN O
the NN NN O
ketamine NN NN O
DOC NN NN O
whereas NN NN O
dopamine NN NN O
continued NN NN O
to NN NN O
do NN NN O
so NN NN O
. NN NN O
   
This NN NN O
study NN NN O
did NN NN O
not NN NN O
demonstrate NN NN O
a NN NN O
species NN NN O
difference NN NN O
regarding NN NN O
the NN NN O
role NN NN O
of NN NN O
the NN NN O
amines NN NN O
on NN NN O
the NN NN O
pineal NN NN O
in NN NN O
spite NN NN O
of NN NN O
the NN NN O
immature NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
in NN NN O
the NN NN O
young NN NN O
chick NN NN O
and NN NN O
the NN NN O
intact NN NN O
barrier NN NN O
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
these NN NN O
data NN NN O
indicate NN NN O
a NN NN O
direct NN NN O
role NN NN O
of NN NN O
the NN NN O
pituitary NN NN O
in NN NN O
the NN NN O
augmentation NN NN O
of NN NN O
ketamine NN NN O
DOC NN NN O
induced NN NN O
by NN NN O
melatonin NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
dopamine NN NN O
appeared NN NN O
to NN NN O
act NN NN O
on NN NN O
systems NN NN O
more NN NN O
closely NN NN O
involved NN NN O
with NN NN O
the NN NN O
induction NN NN O
of NN NN O
ketamine NN NN O
catatonia NN NN B-Disease
rather NN NN O
than NN NN O
directly NN NN O
on NN NN O
the NN NN O
pituitary NN NN O
. NN NN O
   
Heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
, NN NN O
thrombosis NN NN B-Disease
, NN NN O
and NN NN O
hemorrhage NN NN B-Disease
. NN NN O
   
Sixty NN NN O
- NN NN O
two NN NN O
patients NN NN O
with NN NN O
a NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
are NN NN O
reported NN NN O
. NN NN O
   
Clinical NN NN O
manifestations NN NN O
of NN NN O
this NN NN O
disorder NN NN O
include NN NN O
hemorrhage NN NN B-Disease
or NN NN O
, NN NN O
more NN NN O
frequently NN NN O
, NN NN O
thromboembolic NN NN B-Disease
events NN NN O
in NN NN O
patients NN NN O
receiving NN NN O
heparin NN NN O
. NN NN O
   
Laboratory NN NN O
testing NN NN O
has NN NN O
revealed NN NN O
a NN NN B-Disease
falling NN NN I-Disease
platelet NN NN I-Disease
count NN NN I-Disease
, NN NN O
increased NN NN O
resistance NN NN O
to NN NN O
heparin NN NN O
, NN NN O
and NN NN O
aggregation NN NN O
of NN NN O
platelets NN NN O
by NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
plasma NN NN O
when NN NN O
heparin NN NN O
is NN NN O
added NN NN O
. NN NN O
   
Immunologic NN NN O
testing NN NN O
has NN NN O
demonstrated NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
heparin NN NN O
- NN NN O
dependent NN NN O
platelet NN NN O
membrane NN NN O
antibody NN NN O
. NN NN O
   
The NN NN O
20 NN NN O
deaths NN NN O
, NN NN O
52 NN NN O
hemorrhagic NN NN B-Disease
and NN NN I-Disease
thromboembolic NN NN I-Disease
complications NN NN I-Disease
, NN NN O
and NN NN O
21 NN NN O
surgical NN NN O
procedures NN NN O
to NN NN O
manage NN NN O
the NN NN O
complications NN NN O
confirm NN NN O
the NN NN O
seriousness NN NN O
of NN NN O
the NN NN O
disorder NN NN O
. NN NN O
   
Specific NN NN O
risk NN NN O
factors NN NN O
have NN NN O
not NN NN O
been NN NN O
identified NN NN O
; NN NN O
therefore NN NN O
, NN NN O
all NN NN O
patients NN NN O
receiving NN NN O
heparin NN NN O
should NN NN O
be NN NN O
monitored NN NN O
. NN NN O
   
If NN NN O
the NN NN O
platelet NN NN O
count NN NN O
falls NN NN O
to NN NN O
less NN NN O
than NN NN O
100 NN NN O
, NN NN O
000 NN NN O
/ NN NN O
mm3 NN NN O
, NN NN O
while NN NN O
the NN NN O
patient NN NN O
is NN NN O
receiving NN NN O
heparin NN NN O
, NN NN O
platelet NN NN B-Disease
aggregation NN NN I-Disease
testing NN NN O
, NN NN O
using NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
plasma NN NN O
, NN NN O
is NN NN O
indicated NN NN O
. NN NN O
   
Management NN NN O
consists NN NN O
of NN NN O
cessation NN NN O
of NN NN O
heparin NN NN O
, NN NN O
platelet NN NN O
anti NN NN O
- NN NN O
aggregating NN NN O
agents NN NN O
, NN NN O
and NN NN O
alternate NN NN O
forms NN NN O
of NN NN O
anticoagulation NN NN O
when NN NN O
indicated NN NN O
. NN NN O
   
Ventricular NN NN B-Disease
fibrillation NN NN I-Disease
from NN NN O
diatrizoate NN NN O
with NN NN O
and NN NN O
without NN NN O
chelating NN NN O
agents NN NN O
. NN NN O
   
The NN NN O
toxicity NN NN B-Disease
of NN NN O
Renografin NN NN O
76 NN NN O
% NN NN O
was NN NN O
compared NN NN O
with NN NN O
that NN NN O
of NN NN O
Hypaque NN NN O
76 NN NN O
% NN NN O
by NN NN O
selective NN NN O
injection NN NN O
of NN NN O
each NN NN O
into NN NN O
the NN NN O
right NN NN O
coronary NN NN O
artery NN NN O
of NN NN O
dogs NN NN O
. NN NN O
   
Renografin NN NN O
contains NN NN O
the NN NN O
chelating NN NN O
agents NN NN O
sodium NN NN O
citrate NN NN O
and NN NN O
disodium NN NN O
edetate NN NN O
, NN NN O
while NN NN O
Hypaque NN NN O
contains NN NN O
calcium NN NN O
disodium NN NN O
edetate NN NN O
and NN NN O
no NN NN O
sodium NN NN O
citrate NN NN O
. NN NN O
   
Ventricular NN NN B-Disease
fibrillation NN NN I-Disease
occurred NN NN O
significantly NN NN O
more NN NN O
often NN NN O
with NN NN O
Renografin NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
chelating NN NN O
agents NN NN O
contribute NN NN O
to NN NN O
toxicity NN NN B-Disease
in NN NN O
coronary NN NN O
angiography NN NN O
. NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
efficacy NN NN O
and NN NN O
toxicity NN NN B-Disease
of NN NN O
high NN NN O
- NN NN O
dose NN NN O
amiodarone NN NN O
therapy NN NN O
for NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
or NN NN O
ventricular NN NN B-Disease
fibrillation NN NN I-Disease
. NN NN O
   
Amiodarone NN NN O
was NN NN O
administered NN NN O
to NN NN O
154 NN NN O
patients NN NN O
who NN NN O
had NN NN O
sustained NN NN O
, NN NN O
symptomatic NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
( NN NN O
VT NN NN B-Disease
) NN NN O
( NN NN O
n NN NN O
= NN NN O
118 NN NN O
) NN NN O
or NN NN O
a NN NN O
cardiac NN NN B-Disease
arrest NN NN I-Disease
( NN NN O
n NN NN O
= NN NN O
36 NN NN O
) NN NN O
and NN NN O
who NN NN O
were NN NN O
refractory NN NN O
to NN NN O
conventional NN NN O
antiarrhythmic NN NN O
drugs NN NN O
. NN NN O
   
The NN NN O
loading NN NN O
dose NN NN O
was NN NN O
800 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
for NN NN O
6 NN NN O
weeks NN NN O
and NN NN O
the NN NN O
maintenance NN NN O
dose NN NN O
was NN NN O
600 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
. NN NN O
   
Sixty NN NN O
- NN NN O
nine NN NN O
percent NN NN O
of NN NN O
patients NN NN O
continued NN NN O
treatment NN NN O
with NN NN O
amiodarone NN NN O
and NN NN O
had NN NN O
no NN NN O
recurrence NN NN O
of NN NN O
symptomatic NN NN O
VT NN NN B-Disease
or NN NN O
ventricular NN NN B-Disease
fibrillation NN NN I-Disease
( NN NN O
VF NN NN B-Disease
) NN NN O
over NN NN O
a NN NN O
follow NN NN O
- NN NN O
up NN NN O
of NN NN O
6 NN NN O
to NN NN O
52 NN NN O
months NN NN O
( NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
standard NN NN O
deviation NN NN O
14 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
8 NN NN O
. NN NN O
2 NN NN O
) NN NN O
. NN NN O
   
Six NN NN O
percent NN NN O
of NN NN O
the NN NN O
patients NN NN O
had NN NN O
a NN NN O
nonfatal NN NN O
recurrence NN NN O
of NN NN O
VT NN NN B-Disease
and NN NN O
were NN NN O
successfully NN NN O
managed NN NN O
by NN NN O
continuing NN NN O
amiodarone NN NN O
at NN NN O
a NN NN O
higher NN NN O
dose NN NN O
or NN NN O
by NN NN O
the NN NN O
addition NN NN O
of NN NN O
a NN NN O
conventional NN NN O
antiarrhythmic NN NN O
drug NN NN O
. NN NN O
   
One NN NN O
or NN NN O
more NN NN O
adverse NN NN O
drug NN NN O
reactions NN NN O
occurred NN NN O
in NN NN O
51 NN NN O
% NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
Adverse NN NN O
effects NN NN O
forced NN NN O
a NN NN O
reduction NN NN O
in NN NN O
the NN NN O
dose NN NN O
of NN NN O
amiodarone NN NN O
in NN NN O
41 NN NN O
% NN NN O
and NN NN O
discontinuation NN NN O
of NN NN O
amiodarone NN NN O
in NN NN O
10 NN NN O
% NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
most NN NN O
common NN NN O
symptomatic NN NN O
adverse NN NN O
reactions NN NN O
were NN NN O
tremor NN NN B-Disease
or NN NN O
ataxia NN NN B-Disease
( NN NN O
35 NN NN O
% NN NN O
) NN NN O
, NN NN O
nausea NN NN B-Disease
and NN NN O
anorexia NN NN B-Disease
( NN NN O
8 NN NN O
% NN NN O
) NN NN O
, NN NN O
visual NN NN B-Disease
halos NN NN I-Disease
or NN NN I-Disease
blurring NN NN I-Disease
( NN NN O
6 NN NN O
% NN NN O
) NN NN O
, NN NN O
thyroid NN NN B-Disease
function NN NN I-Disease
abnormalities NN NN I-Disease
( NN NN O
6 NN NN O
% NN NN O
) NN NN O
and NN NN O
pulmonary NN NN B-Disease
interstitial NN NN I-Disease
infiltrates NN NN I-Disease
( NN NN O
5 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Although NN NN O
large NN NN O
- NN NN O
dose NN NN O
amiodarone NN NN O
is NN NN O
highly NN NN O
effective NN NN O
in NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
treatment NN NN O
of NN NN O
VT NN NN B-Disease
or NN NN O
VF NN NN B-Disease
refractory NN NN O
to NN NN O
conventional NN NN O
antiarrhythmic NN NN O
drugs NN NN O
, NN NN O
it NN NN O
causes NN NN O
significant NN NN O
toxicity NN NN B-Disease
in NN NN O
approximately NN NN O
50 NN NN O
% NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
However NN NN O
, NN NN O
when NN NN O
the NN NN O
dose NN NN O
is NN NN O
adjusted NN NN O
based NN NN O
on NN NN O
clinical NN NN O
response NN NN O
or NN NN O
the NN NN O
development NN NN O
of NN NN O
adverse NN NN O
effects NN NN O
, NN NN O
75 NN NN O
% NN NN O
of NN NN O
patients NN NN O
with NN NN O
VT NN NN B-Disease
or NN NN O
VF NN NN B-Disease
can NN NN O
be NN NN O
successfully NN NN O
managed NN NN O
with NN NN O
amiodarone NN NN O
. NN NN O
   
Why NN NN O
may NN NN O
epsilon NN NN O
- NN NN O
aminocaproic NN NN O
acid NN NN O
( NN NN O
EACA NN NN O
) NN NN O
induce NN NN O
myopathy NN NN B-Disease
in NN NN O
man NN NN O
? NN NN O
   
Report NN NN O
of NN NN O
a NN NN O
case NN NN O
and NN NN O
literature NN NN O
review NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
necrotizing NN NN B-Disease
myopathy NN NN I-Disease
due NN NN O
to NN NN O
a NN NN O
short NN NN O
epsilon NN NN O
- NN NN O
aminocaproic NN NN O
acid NN NN O
( NN NN O
EACA NN NN O
) NN NN O
treatment NN NN O
in NN NN O
a NN NN O
72 NN NN O
year NN NN O
- NN NN O
old NN NN O
patient NN NN O
with NN NN O
subarachnoid NN NN B-Disease
haemorrhage NN NN I-Disease
( NN NN O
SAH NN NN B-Disease
) NN NN O
is NN NN O
described NN NN O
. NN NN O
   
Pathogenetic NN NN O
hypotheses NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Cerebral NN NN B-Disease
hemorrhage NN NN I-Disease
associated NN NN O
with NN NN O
phenylpropanolamine NN NN O
in NN NN O
combination NN NN O
with NN NN O
caffeine NN NN O
. NN NN O
   
Phenylpropanolamine NN NN O
( NN NN O
PPA NN NN O
) NN NN O
is NN NN O
a NN NN O
drug NN NN O
that NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
serious NN NN O
side NN NN O
effects NN NN O
including NN NN O
stroke NN NN B-Disease
. NN NN O
   
It NN NN O
is NN NN O
often NN NN O
combined NN NN O
with NN NN O
caffeine NN NN O
in NN NN O
diet NN NN O
preparations NN NN O
and NN NN O
"""""""" NN NN O
look NN NN O
- NN NN O
alike NN NN O
"""""""" NN NN O
pills NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
determine NN NN O
if NN NN O
PPA NN NN O
/ NN NN O
caffeine NN NN O
can NN NN O
lead NN NN O
to NN NN O
stroke NN NN B-Disease
in NN NN O
normotensive NN NN O
and NN NN O
/ NN NN O
or NN NN O
hypertensive NN NN B-Disease
rats NN NN O
, NN NN O
we NN NN O
administered NN NN O
the NN NN O
combination NN NN O
in NN NN O
six NN NN O
times NN NN O
the NN NN O
allowed NN NN O
human NN NN O
dose NN NN O
calculated NN NN O
on NN NN O
a NN NN O
per NN NN O
weight NN NN O
basis NN NN O
for NN NN O
the NN NN O
rats NN NN O
two NN NN O
times NN NN O
per NN NN O
day NN NN O
for NN NN O
five NN NN O
days NN NN O
. NN NN O
   
Subarachnoid NN NN B-Disease
and NN NN I-Disease
cerebral NN NN I-Disease
hemorrhage NN NN I-Disease
was NN NN O
noted NN NN O
in NN NN O
18 NN NN O
% NN NN O
of NN NN O
the NN NN O
hypertensive NN NN B-Disease
rats NN NN O
. NN NN O
   
A NN NN O
single NN NN O
PPA NN NN O
/ NN NN O
caffeine NN NN O
administration NN NN O
( NN NN O
same NN NN O
dose NN NN O
) NN NN O
lead NN NN O
to NN NN O
acute NN NN O
hypertension NN NN B-Disease
in NN NN O
both NN NN O
the NN NN O
normotensive NN NN O
and NN NN O
hypertensive NN NN B-Disease
animals NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
PPA NN NN O
/ NN NN O
caffeine NN NN O
can NN NN O
lead NN NN O
to NN NN O
cerebral NN NN B-Disease
hemorrhage NN NN I-Disease
in NN NN O
previously NN NN O
hypertensive NN NN B-Disease
animals NN NN O
when NN NN O
administered NN NN O
in NN NN O
greater NN NN O
than NN NN O
the NN NN O
allowed NN NN O
dosage NN NN O
. NN NN O
   
An NN NN O
acute NN NN O
elevation NN NN O
in NN NN O
blood NN NN O
pressure NN NN O
may NN NN O
be NN NN O
a NN NN O
contributing NN NN O
factor NN NN O
. NN NN O
   
Renal NN NN B-Disease
papillary NN NN I-Disease
necrosis NN NN I-Disease
due NN NN O
to NN NN O
naproxen NN NN O
. NN NN O
   
A NN NN O
31 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
with NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
, NN NN O
who NN NN O
had NN NN O
previously NN NN O
been NN NN O
treated NN NN O
with NN NN O
sulindac NN NN O
, NN NN O
fenoprofen NN NN O
calcium NN NN O
, NN NN O
high NN NN O
dose NN NN O
salicylates NN NN O
and NN NN O
gold NN NN O
salts NN NN O
, NN NN O
developed NN NN O
renal NN NN B-Disease
papillary NN NN I-Disease
necrosis NN NN I-Disease
( NN NN O
RPN NN NN B-Disease
) NN NN O
4 NN NN O
months NN NN O
after NN NN O
institution NN NN O
of NN NN O
naproxen NN NN O
therapy NN NN O
. NN NN O
   
No NN NN O
other NN NN O
factor NN NN O
predisposing NN NN O
to NN NN O
RPN NN NN B-Disease
could NN NN O
be NN NN O
discovered NN NN O
. NN NN O
   
Sulindac NN NN O
was NN NN O
substituted NN NN O
for NN NN O
naproxen NN NN O
and NN NN O
no NN NN O
further NN NN O
adverse NN NN O
renal NN NN O
effects NN NN O
occurred NN NN O
over NN NN O
the NN NN O
next NN NN O
12 NN NN O
months NN NN O
. NN NN O
   
We NN NN O
review NN NN O
previous NN NN O
reports NN NN O
linking NN NN O
RPN NN NN B-Disease
to NN NN O
antiinflammatory NN NN O
drug NN NN O
use NN NN O
and NN NN O
discuss NN NN O
possible NN NN O
advantages NN NN O
of NN NN O
sulindac NN NN O
in NN NN O
patients NN NN O
who NN NN O
have NN NN O
experienced NN NN O
renal NN NN B-Disease
toxicity NN NN I-Disease
from NN NN O
other NN NN O
antiinflammatory NN NN O
agents NN NN O
. NN NN O
   
Nephrotoxic NN NN B-Disease
effects NN NN O
of NN NN O
aminoglycoside NN NN O
treatment NN NN O
on NN NN O
renal NN NN O
protein NN NN O
reabsorption NN NN O
and NN NN O
accumulation NN NN O
. NN NN O
   
To NN NN O
quantify NN NN O
the NN NN O
effects NN NN O
of NN NN O
gentamicin NN NN O
, NN NN O
kanamycin NN NN O
and NN NN O
netilmicin NN NN O
on NN NN O
renal NN NN O
protein NN NN O
reabsorption NN NN O
and NN NN O
accumulation NN NN O
, NN NN O
these NN NN O
drugs NN NN O
were NN NN O
administered NN NN O
to NN NN O
rats NN NN O
intraperitoneally NN NN O
( NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
) NN NN O
for NN NN O
7 NN NN O
, NN NN O
14 NN NN O
or NN NN O
21 NN NN O
days NN NN O
. NN NN O
   
Scanning NN NN O
electron NN NN O
microscopy NN NN O
of NN NN O
the NN NN O
glomerular NN NN O
endothelia NN NN O
, NN NN O
urinary NN NN O
measurements NN NN O
of NN NN O
sodium NN NN O
, NN NN O
potassium NN NN O
, NN NN O
endogenous NN NN O
lysozyme NN NN O
, NN NN O
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
beta NN NN O
- NN NN O
D NN NN O
- NN NN O
glucosaminidase NN NN O
( NN NN O
NAG NN NN O
) NN NN O
as NN NN O
well NN NN O
as NN NN O
clearance NN NN O
and NN NN O
accumulation NN NN O
experiments NN NN O
after NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
administration NN NN O
of NN NN O
egg NN NN O
- NN NN O
white NN NN O
lysozyme NN NN O
and NN NN O
measurements NN NN O
of NN NN O
inulin NN NN O
clearance NN NN O
( NN NN O
GFR NN NN O
) NN NN O
were NN NN O
done NN NN O
in NN NN O
each NN NN O
treatment NN NN O
group NN NN O
. NN NN O
   
Gentamicin NN NN O
administration NN NN O
decreased NN NN O
diameter NN NN O
, NN NN O
density NN NN O
and NN NN O
shape NN NN O
of NN NN O
endothelial NN NN O
fenestrae NN NN O
. NN NN O
   
Kanamycin NN NN O
and NN NN O
netilmicin NN NN O
appeared NN NN O
to NN NN O
have NN NN O
no NN NN O
effect NN NN O
at NN NN O
the NN NN O
dose NN NN O
used NN NN O
. NN NN O
   
All NN NN O
three NN NN O
aminoglycosides NN NN O
decreased NN NN O
GFR NN NN O
and NN NN O
increased NN NN O
urinary NN NN O
excretion NN NN O
of NN NN O
sodium NN NN O
and NN NN O
potassium NN NN O
. NN NN O
   
While NN NN O
gentamicin NN NN O
and NN NN O
kanamycin NN NN O
decreased NN NN O
the NN NN O
percentage NN NN O
reabsorption NN NN O
and NN NN O
accumulation NN NN O
of NN NN O
lysozyme NN NN O
after NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
administration NN NN O
of NN NN O
egg NN NN O
- NN NN O
white NN NN O
lysozyme NN NN O
netilmicin NN NN O
had NN NN O
no NN NN O
effect NN NN O
. NN NN O
   
Daily NN NN O
excretion NN NN O
of NN NN O
total NN NN O
protein NN NN O
, NN NN O
endogenous NN NN O
lysozyme NN NN O
and NN NN O
NAG NN NN O
increased NN NN O
only NN NN O
after NN NN O
treatment NN NN O
with NN NN O
kanamycin NN NN O
and NN NN O
gentamicin NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
aminoglycosides NN NN O
may NN NN O
act NN NN O
as NN NN O
nephrotoxicants NN NN O
at NN NN O
glomerular NN NN O
and NN NN O
/ NN NN O
or NN NN O
tubular NN NN O
level NN NN O
inducing NN NN O
impairment NN NN B-Disease
of NN NN I-Disease
renal NN NN I-Disease
reabsorption NN NN I-Disease
and NN NN O
accumulation NN NN O
of NN NN O
proteins NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
the NN NN O
obstructive NN NN B-Disease
sleep NN NN I-Disease
apnea NN NN I-Disease
syndrome NN NN I-Disease
in NN NN O
a NN NN O
woman NN NN O
by NN NN O
exogenous NN NN O
androgen NN NN O
administration NN NN O
. NN NN O
   
We NN NN O
documented NN NN O
airway NN NN O
occlusion NN NN O
during NN NN O
sleep NN NN O
and NN NN O
an NN NN O
abnormally NN NN O
high NN NN O
supraglottic NN NN O
resistance NN NN O
while NN NN O
awake NN NN O
in NN NN O
a NN NN O
54 NN NN O
- NN NN O
yr NN NN O
- NN NN O
old NN NN O
woman NN NN O
who NN NN O
had NN NN O
developed NN NN O
physical NN NN O
changes NN NN O
and NN NN O
the NN NN O
syndrome NN NN B-Disease
of NN NN I-Disease
obstructive NN NN I-Disease
sleep NN NN I-Disease
apnea NN NN I-Disease
while NN NN O
being NN NN O
administered NN NN O
exogenous NN NN O
androgens NN NN O
. NN NN O
   
When NN NN O
the NN NN O
androgens NN NN O
were NN NN O
withdrawn NN NN O
, NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
physical NN NN O
changes NN NN O
, NN NN O
symptoms NN NN O
, NN NN O
sleep NN NN O
study NN NN O
, NN NN O
and NN NN O
supraglottic NN NN O
resistance NN NN O
all NN NN O
returned NN NN O
to NN NN O
normal NN NN O
. NN NN O
   
A NN NN O
rechallenge NN NN O
with NN NN O
androgen NN NN O
produced NN NN O
symptoms NN NN O
of NN NN O
obstructive NN NN B-Disease
sleep NN NN I-Disease
apnea NN NN I-Disease
that NN NN O
abated NN NN O
upon NN NN O
withdrawal NN NN O
of NN NN O
the NN NN O
hormone NN NN O
. NN NN O
   
Previous NN NN O
reports NN NN O
have NN NN O
favored NN NN O
a NN NN O
role NN NN O
of NN NN O
androgens NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
sleep NN NN B-Disease
apnea NN NN I-Disease
. NN NN O
   
Our NN NN O
report NN NN O
provides NN NN O
direct NN NN O
evidence NN NN O
for NN NN O
this NN NN O
role NN NN O
. NN NN O
   
Structural NN NN O
and NN NN O
functional NN NN O
measurements NN NN O
indicate NN NN O
that NN NN O
androgens NN NN O
exert NN NN O
a NN NN O
permissive NN NN O
or NN NN O
necessary NN NN O
action NN NN O
on NN NN O
the NN NN O
structural NN NN O
configuration NN NN O
of NN NN O
the NN NN O
oropharynx NN NN O
that NN NN O
predisposes NN NN O
to NN NN O
obstruction NN NN O
during NN NN O
sleep NN NN O
. NN NN O
   
Development NN NN O
of NN NN O
the NN NN O
obstructive NN NN B-Disease
sleep NN NN I-Disease
apnea NN NN I-Disease
syndrome NN NN I-Disease
must NN NN O
be NN NN O
considered NN NN O
a NN NN O
possible NN NN O
side NN NN O
effect NN NN O
of NN NN O
androgen NN NN O
therapy NN NN O
. NN NN O
   
Cardiotoxic NN NN B-Disease
and NN NN O
possible NN NN O
leukemogenic NN NN O
effects NN NN O
of NN NN O
adriamycin NN NN O
in NN NN O
nonhuman NN NN O
primates NN NN O
. NN NN O
   
10 NN NN O
monkeys NN NN O
( NN NN O
macaques NN NN O
) NN NN O
received NN NN O
adriamycin NN NN O
by NN NN O
monthly NN NN O
intravenous NN NN O
injections NN NN O
at NN NN O
12 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
( NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
. NN NN O
   
8 NN NN O
of NN NN O
the NN NN O
10 NN NN O
monkeys NN NN O
developed NN NN O
congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
at NN NN O
an NN NN O
average NN NN O
cumulative NN NN O
adriamycin NN NN O
dose NN NN O
( NN NN O
310 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
) NN NN O
well NN NN O
below NN NN O
that NN NN O
considered NN NN O
the NN NN O
safe NN NN O
upper NN NN O
limit NN NN O
( NN NN O
550 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
) NN NN O
in NN NN O
man NN NN O
. NN NN O
   
Histologically NN NN O
, NN NN O
the NN NN O
myocardial NN NN B-Disease
lesions NN NN I-Disease
resembled NN NN O
those NN NN O
found NN NN O
in NN NN O
human NN NN O
anthracycline NN NN O
- NN NN O
induced NN NN O
cardiomyopathy NN NN B-Disease
. NN NN O
   
1 NN NN O
of NN NN O
the NN NN O
10 NN NN O
monkeys NN NN O
developed NN NN O
acute NN NN B-Disease
myeloblastic NN NN I-Disease
leukemia NN NN I-Disease
after NN NN O
receiving NN NN O
324 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
of NN NN O
adriamycin NN NN O
; NN NN O
the NN NN O
10th NN NN O
monkey NN NN O
is NN NN O
alive NN NN O
and NN NN O
well NN NN O
26 NN NN O
months NN NN O
after NN NN O
the NN NN O
last NN NN O
dose NN NN O
of NN NN O
drug NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
adriamycin NN NN O
is NN NN O
a NN NN O
more NN NN O
potent NN NN O
cardiotoxin NN NN O
in NN NN O
monkeys NN NN O
than NN NN O
in NN NN O
man NN NN O
, NN NN O
and NN NN O
that NN NN O
leukemia NN NN B-Disease
may NN NN O
be NN NN O
a NN NN O
consequence NN NN O
of NN NN O
prolonged NN NN O
treatment NN NN O
with NN NN O
this NN NN O
drug NN NN O
. NN NN O
   
Tricuspid NN NN B-Disease
valve NN NN I-Disease
regurgitation NN NN I-Disease
and NN NN O
lithium NN NN O
carbonate NN NN O
toxicity NN NN B-Disease
in NN NN O
a NN NN O
newborn NN NN O
infant NN NN O
. NN NN O
   
A NN NN O
newborn NN NN O
with NN NN O
massive NN NN O
tricuspid NN NN B-Disease
regurgitation NN NN I-Disease
, NN NN O
atrial NN NN B-Disease
flutter NN NN I-Disease
, NN NN O
congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
, NN NN O
and NN NN O
a NN NN O
high NN NN O
serum NN NN O
lithium NN NN O
level NN NN O
is NN NN O
described NN NN O
. NN NN O
   
This NN NN O
is NN NN O
the NN NN O
first NN NN O
patient NN NN O
to NN NN O
initially NN NN O
manifest NN NN O
tricuspid NN NN B-Disease
regurgitation NN NN I-Disease
and NN NN O
atrial NN NN B-Disease
flutter NN NN I-Disease
, NN NN O
and NN NN O
the NN NN O
11th NN NN O
described NN NN O
patient NN NN O
with NN NN O
cardiac NN NN B-Disease
disease NN NN I-Disease
among NN NN O
infants NN NN O
exposed NN NN O
to NN NN O
lithium NN NN O
compounds NN NN O
in NN NN O
the NN NN O
first NN NN O
trimester NN NN O
of NN NN O
pregnancy NN NN O
. NN NN O
   
Sixty NN NN O
- NN NN O
three NN NN O
percent NN NN O
of NN NN O
these NN NN O
infants NN NN O
had NN NN O
tricuspid NN NN O
valve NN NN O
involvement NN NN O
. NN NN O
   
Lithium NN NN O
carbonate NN NN O
may NN NN O
be NN NN O
a NN NN O
factor NN NN O
in NN NN O
the NN NN O
increasing NN NN O
incidence NN NN O
of NN NN O
congenital NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
when NN NN O
taken NN NN O
during NN NN O
early NN NN O
pregnancy NN NN O
. NN NN O
   
It NN NN O
also NN NN O
causes NN NN O
neurologic NN NN B-Disease
depression NN NN I-Disease
, NN NN O
cyanosis NN NN B-Disease
, NN NN O
and NN NN O
cardiac NN NN B-Disease
arrhythmia NN NN I-Disease
when NN NN O
consumed NN NN O
prior NN NN O
to NN NN O
delivery NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
the NN NN O
novel NN NN O
compound NN NN O
aniracetam NN NN O
( NN NN O
Ro NN NN O
13 NN NN O
- NN NN O
5057 NN NN O
) NN NN O
upon NN NN O
impaired NN NN B-Disease
learning NN NN I-Disease
and NN NN I-Disease
memory NN NN I-Disease
in NN NN O
rodents NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
aniracetam NN NN O
( NN NN O
Ro NN NN O
13 NN NN O
- NN NN O
5057 NN NN O
, NN NN O
1 NN NN O
- NN NN O
anisoyl NN NN O
- NN NN O
2 NN NN O
- NN NN O
pyrrolidinone NN NN O
) NN NN O
was NN NN O
studied NN NN O
on NN NN O
various NN NN O
forms NN NN O
of NN NN O
experimentally NN NN O
impaired NN NN B-Disease
cognitive NN NN I-Disease
functions NN NN I-Disease
( NN NN O
learning NN NN O
and NN NN O
memory NN NN O
) NN NN O
in NN NN O
rodents NN NN O
and NN NN O
produced NN NN O
the NN NN O
following NN NN O
effects NN NN O
: NN NN O
( NN NN O
1 NN NN O
) NN NN O
almost NN NN O
complete NN NN O
prevention NN NN O
of NN NN O
the NN NN O
incapacity NN NN O
to NN NN O
learn NN NN O
a NN NN O
discrete NN NN O
escape NN NN O
response NN NN O
in NN NN O
rats NN NN O
exposed NN NN O
to NN NN O
sublethal NN NN O
hypercapnia NN NN B-Disease
immediately NN NN O
before NN NN O
the NN NN O
acquisition NN NN O
session NN NN O
; NN NN O
( NN NN O
2 NN NN O
) NN NN O
partial NN NN O
( NN NN O
rats NN NN O
) NN NN O
or NN NN O
complete NN NN O
( NN NN O
mice NN NN O
) NN NN O
prevention NN NN O
of NN NN O
the NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
short NN NN O
- NN NN O
term NN NN O
amnesia NN NN B-Disease
for NN NN O
a NN NN O
passive NN NN O
avoidance NN NN O
task NN NN O
; NN NN O
( NN NN O
3 NN NN O
) NN NN O
complete NN NN O
protection NN NN O
against NN NN O
amnesia NN NN B-Disease
for NN NN O
a NN NN O
passive NN NN O
avoidance NN NN O
task NN NN O
in NN NN O
rats NN NN O
submitted NN NN O
to NN NN O
electroconvulsive NN NN O
shock NN NN O
immediately NN NN O
after NN NN O
avoidance NN NN O
acquisition NN NN O
; NN NN O
( NN NN O
4 NN NN O
) NN NN O
prevention NN NN O
of NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
retention NN NN O
- NN NN O
or NN NN O
retrieval NN NN O
- NN NN O
deficit NN NN O
for NN NN O
a NN NN O
passive NN NN O
avoidance NN NN O
task NN NN O
induced NN NN O
in NN NN O
rats NN NN O
and NN NN O
mice NN NN O
by NN NN O
chloramphenicol NN NN O
or NN NN O
cycloheximide NN NN O
administered NN NN O
immediately NN NN O
after NN NN O
acquisition NN NN O
; NN NN O
( NN NN O
5 NN NN O
) NN NN O
reversal NN NN O
, NN NN O
when NN NN O
administered NN NN O
as NN NN O
late NN NN O
as NN NN O
1 NN NN O
h NN NN O
before NN NN O
the NN NN O
retention NN NN O
test NN NN O
, NN NN O
of NN NN O
the NN NN O
deficit NN NN O
in NN NN O
retention NN NN O
or NN NN O
retrieval NN NN O
of NN NN O
a NN NN O
passive NN NN O
avoidance NN NN O
task NN NN O
induced NN NN O
by NN NN O
cycloheximide NN NN O
injected NN NN O
2 NN NN O
days NN NN O
previously NN NN O
; NN NN O
( NN NN O
6 NN NN O
) NN NN O
prevention NN NN O
of NN NN O
the NN NN O
deficit NN NN O
in NN NN O
the NN NN O
retrieval NN NN O
of NN NN O
an NN NN O
active NN NN O
avoidance NN NN O
task NN NN O
induced NN NN O
in NN NN O
mice NN NN O
by NN NN O
subconvulsant NN NN O
electroshock NN NN O
or NN NN O
hypercapnia NN NN B-Disease
applied NN NN O
immediately NN NN O
before NN NN O
retrieval NN NN O
testing NN NN O
( NN NN O
24 NN NN O
h NN NN O
after NN NN O
acquisition NN NN O
) NN NN O
. NN NN O
   
These NN NN O
improvements NN NN O
or NN NN O
normalizations NN NN O
of NN NN O
impaired NN NN B-Disease
cognitive NN NN I-Disease
functions NN NN I-Disease
were NN NN O
seen NN NN O
at NN NN O
oral NN NN O
aniracetam NN NN O
doses NN NN O
of NN NN O
10 NN NN O
- NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
Generally NN NN O
, NN NN O
the NN NN O
dose NN NN O
- NN NN O
response NN NN O
curves NN NN O
were NN NN O
bell NN NN O
- NN NN O
shaped NN NN O
. NN NN O
   
The NN NN O
mechanisms NN NN O
underlying NN NN O
the NN NN O
activity NN NN O
of NN NN O
aniracetam NN NN O
and NN NN O
its NN NN O
' NN NN O
therapeutic NN NN O
window NN NN O
' NN NN O
are NN NN O
unknown NN NN O
. NN NN O
   
Piracetam NN NN O
, NN NN O
another NN NN O
pyrrolidinone NN NN O
derivative NN NN O
was NN NN O
used NN NN O
for NN NN O
comparison NN NN O
. NN NN O
   
It NN NN O
was NN NN O
active NN NN O
only NN NN O
in NN NN O
six NN NN O
of NN NN O
nine NN NN O
tests NN NN O
and NN NN O
had NN NN O
about NN NN O
one NN NN O
- NN NN O
tenth NN NN O
the NN NN O
potency NN NN O
of NN NN O
aniracetam NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
aniracetam NN NN O
improves NN NN O
cognitive NN NN O
functions NN NN O
which NN NN O
are NN NN O
impaired NN NN O
by NN NN O
different NN NN O
procedure NN NN O
and NN NN O
in NN NN O
different NN NN O
phases NN NN O
of NN NN O
the NN NN O
learning NN NN O
and NN NN O
memory NN NN O
process NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
calcium NN NN O
chloride NN NN O
on NN NN O
gross NN NN O
behavioural NN NN O
changes NN NN O
produced NN NN O
by NN NN O
carbachol NN NN O
and NN NN O
eserine NN NN O
in NN NN O
cats NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
calcium NN NN O
chloride NN NN O
injected NN NN O
into NN NN O
the NN NN O
cerebral NN NN O
ventricles NN NN O
of NN NN O
group NN NN O
- NN NN O
housed NN NN O
unanaesthetized NN NN O
cats NN NN O
upon NN NN O
vocalization NN NN O
( NN NN O
rage NN NN O
, NN NN O
hissing NN NN O
and NN NN O
snarling NN NN O
) NN NN O
, NN NN O
fighting NN NN O
( NN NN O
attack NN NN O
with NN NN O
paws NN NN O
and NN NN O
claws NN NN O
, NN NN O
defense NN NN O
with NN NN O
paws NN NN O
and NN NN O
claws NN NN O
and NN NN O
biting NN NN O
) NN NN O
, NN NN O
mydriasis NN NN B-Disease
, NN NN O
tremor NN NN B-Disease
and NN NN O
clonic NN NN B-Disease
- NN NN I-Disease
tonic NN NN I-Disease
convulsions NN NN I-Disease
produced NN NN O
by NN NN O
carbachol NN NN O
and NN NN O
eserine NN NN O
injected NN NN O
similarly NN NN O
was NN NN O
investigated NN NN O
. NN NN O
   
Calcium NN NN O
chloride NN NN O
depressed NN NN O
or NN NN O
almost NN NN O
completely NN NN O
abolished NN NN O
the NN NN O
vocalization NN NN O
and NN NN O
fighting NN NN O
due NN NN O
to NN NN O
carbachol NN NN O
and NN NN O
eserine NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
mydriasis NN NN B-Disease
, NN NN O
tremor NN NN B-Disease
and NN NN O
clonic NN NN B-Disease
- NN NN I-Disease
tonic NN NN I-Disease
convulsions NN NN I-Disease
evoked NN NN O
by NN NN O
carbachol NN NN O
and NN NN O
eserine NN NN O
were NN NN O
not NN NN O
significantly NN NN O
changed NN NN O
by NN NN O
calcium NN NN O
chloride NN NN O
. NN NN O
   
It NN NN O
is NN NN O
apparent NN NN O
that NN NN O
calcium NN NN O
chloride NN NN O
can NN NN O
"""""""" NN NN O
dissociate NN NN O
"""""""" NN NN O
vocalization NN NN O
and NN NN O
fighting NN NN O
from NN NN O
autonomic NN NN O
and NN NN O
motor NN NN O
phenomena NN NN O
such NN NN O
as NN NN O
mydriasis NN NN B-Disease
, NN NN O
tremor NN NN B-Disease
and NN NN O
clonic NN NN B-Disease
- NN NN I-Disease
tonic NN NN I-Disease
convulsions NN NN I-Disease
caused NN NN O
by NN NN O
carbachol NN NN O
and NN NN O
eserine NN NN O
. NN NN O
   
Calcium NN NN O
chloride NN NN O
inhibited NN NN O
the NN NN O
vocalization NN NN O
and NN NN O
fighting NN NN O
produced NN NN O
by NN NN O
carbachol NN NN O
and NN NN O
eserine NN NN O
most NN NN O
probably NN NN O
by NN NN O
a NN NN O
nonspecific NN NN O
stabilizing NN NN O
action NN NN O
on NN NN O
central NN NN O
muscarinic NN NN O
cholinoceptive NN NN O
sites NN NN O
. NN NN O
   
These NN NN O
results NN NN O
further NN NN O
support NN NN O
the NN NN O
view NN NN O
that NN NN O
calcium NN NN O
ions NN NN O
in NN NN O
excess NN NN O
have NN NN O
an NN NN O
atropine NN NN O
- NN NN O
like NN NN O
action NN NN O
also NN NN O
in NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
. NN NN O
   
Thiazide NN NN O
diuretics NN NN O
, NN NN O
hypokalemia NN NN B-Disease
and NN NN O
cardiac NN NN B-Disease
arrhythmias NN NN I-Disease
. NN NN O
   
Thiazide NN NN O
diuretics NN NN O
are NN NN O
widely NN NN O
accepted NN NN O
as NN NN O
the NN NN O
cornerstone NN NN O
of NN NN O
antihypertensive NN NN O
treatment NN NN O
programs NN NN O
. NN NN O
   
Hypokalemia NN NN B-Disease
is NN NN O
a NN NN O
commonly NN NN O
encountered NN NN O
metabolic NN NN O
consequence NN NN O
of NN NN O
chronic NN NN O
thiazide NN NN O
therapy NN NN O
. NN NN O
   
We NN NN O
treated NN NN O
38 NN NN O
patients NN NN O
( NN NN O
22 NN NN O
low NN NN O
renin NN NN O
, NN NN O
16 NN NN O
normal NN NN O
renin NN NN O
) NN NN O
with NN NN O
moderate NN NN O
diastolic NN NN B-Disease
hypertension NN NN I-Disease
with NN NN O
hydrochlorothiazide NN NN O
( NN NN O
HCTC NN NN O
) NN NN O
administered NN NN O
on NN NN O
a NN NN O
twice NN NN O
daily NN NN O
schedule NN NN O
. NN NN O
   
Initial NN NN O
dose NN NN O
was NN NN O
50 NN NN O
mg NN NN O
and NN NN O
the NN NN O
dose NN NN O
was NN NN O
increased NN NN O
at NN NN O
monthly NN NN O
intervals NN NN O
to NN NN O
100 NN NN O
mg NN NN O
, NN NN O
150 NN NN O
mg NN NN O
and NN NN O
200 NN NN O
mg NN NN O
daily NN NN O
until NN NN O
blood NN NN O
pressure NN NN O
normalized NN NN O
. NN NN O
   
The NN NN O
serum NN NN O
K NN NN O
during NN NN O
the NN NN O
control NN NN O
period NN NN O
was NN NN O
4 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
2 NN NN O
mEq NN NN O
/ NN NN O
l NN NN O
an NN NN O
on NN NN O
50 NN NN O
, NN NN O
100 NN NN O
, NN NN O
150 NN NN O
and NN NN O
200 NN NN O
mg NN NN O
HCTZ NN NN O
daily NN NN O
3 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
3 NN NN O
, NN NN O
3 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
2 NN NN O
, NN NN O
2 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
2 NN NN O
, NN NN O
and NN NN O
2 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
3 NN NN O
mEq NN NN O
/ NN NN O
l NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Corresponding NN NN O
figures NN NN O
for NN NN O
whole NN NN O
body NN NN O
K NN NN O
were NN NN O
4107 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
208 NN NN O
, NN NN O
3722 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
319 NN NN O
, NN NN O
3628 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
257 NN NN O
, NN NN O
3551 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
336 NN NN O
, NN NN O
and NN NN O
3269 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
380 NN NN O
mEq NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
In NN NN O
13 NN NN O
patients NN NN O
we NN NN O
observed NN NN O
the NN NN O
effects NN NN O
of NN NN O
HCTZ NN NN O
therapy NN NN O
( NN NN O
100 NN NN O
mg NN NN O
daily NN NN O
) NN NN O
on NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
PVC NN NN O
' NN NN O
s NN NN O
during NN NN O
rest NN NN O
as NN NN O
well NN NN O
as NN NN O
during NN NN O
static NN NN O
and NN NN O
dynamic NN NN O
exercise NN NN O
. NN NN O
   
During NN NN O
rest NN NN O
we NN NN O
observed NN NN O
0 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
08 NN NN O
PVC NN NN O
beats NN NN O
/ NN NN O
min NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SEM NN NN O
and NN NN O
during NN NN O
static NN NN O
and NN NN O
dynamic NN NN O
exercise NN NN O
0 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
06 NN NN O
and NN NN O
0 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
15 NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Corresponding NN NN O
figures NN NN O
during NN NN O
HCTZ NN NN O
therapy NN NN O
100 NN NN O
mg NN NN O
daily NN NN O
were NN NN O
1 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
1 NN NN O
, NN NN O
3 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
7 NN NN O
and NN NN O
5 NN NN O
. NN NN O
7 NN NN O
4 NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
8 NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
The NN NN O
occurrence NN NN O
of NN NN O
PVC NN NN O
' NN NN O
s NN NN O
correlated NN NN O
significantly NN NN O
with NN NN O
the NN NN O
fall NN NN O
in NN NN O
serum NN NN O
K NN NN O
+ NN NN O
observed NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
72 NN NN O
, NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
we NN NN O
found NN NN O
that NN NN O
thiazide NN NN O
diuretics NN NN O
cause NN NN O
hypokalemia NN NN B-Disease
and NN NN O
depletion NN NN O
of NN NN O
body NN NN O
potassium NN NN O
. NN NN O
   
The NN NN O
more NN NN O
profound NN NN O
hypokalemia NN NN B-Disease
, NN NN O
the NN NN O
greater NN NN O
the NN NN O
propensity NN NN O
for NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
PVC NN NN O
' NN NN O
s NN NN O
. NN NN O
   
Circulating NN NN O
lysosomal NN NN O
enzymes NN NN O
and NN NN O
acute NN NN B-Disease
hepatic NN NN I-Disease
necrosis NN NN I-Disease
. NN NN O
   
The NN NN O
activities NN NN O
of NN NN O
the NN NN O
lysosomal NN NN O
enzymes NN NN O
acid NN NN O
and NN NN O
neutral NN NN O
protease NN NN O
, NN NN O
N NN NN O
- NN NN O
acetylglucosaminidase NN NN O
, NN NN O
and NN NN O
acid NN NN O
phosphatase NN NN O
were NN NN O
measured NN NN O
in NN NN O
the NN NN O
serum NN NN O
of NN NN O
patients NN NN O
with NN NN O
fulminant NN NN B-Disease
hepatic NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
Acid NN NN O
protease NN NN O
( NN NN O
cathepsin NN NN O
D NN NN O
) NN NN O
activity NN NN O
was NN NN O
increased NN NN O
about NN NN O
tenfold NN NN O
in NN NN O
patients NN NN O
who NN NN O
died NN NN O
and NN NN O
nearly NN NN O
fourfold NN NN O
in NN NN O
those NN NN O
who NN NN O
survived NN NN O
fulminant NN NN B-Disease
hepatic NN NN I-Disease
failure NN NN I-Disease
after NN NN O
paracetamol NN NN O
overdose NN NN B-Disease
, NN NN O
whereas NN NN O
activities NN NN O
were NN NN O
increased NN NN O
equally NN NN O
in NN NN O
patients NN NN O
with NN NN O
fulminant NN NN B-Disease
hepatic NN NN I-Disease
failure NN NN I-Disease
due NN NN O
to NN NN O
viral NN NN B-Disease
hepatitis NN NN I-Disease
whether NN NN O
or NN NN O
not NN NN O
they NN NN O
survived NN NN O
. NN NN O
   
A NN NN O
correlation NN NN O
was NN NN O
found NN NN O
between NN NN O
serum NN NN O
acid NN NN O
protease NN NN O
activity NN NN O
and NN NN O
prothrombin NN NN O
time NN NN O
, NN NN O
and NN NN O
the NN NN O
increase NN NN O
in NN NN O
cathepsin NN NN O
D NN NN O
activity NN NN O
was NN NN O
sustained NN NN O
over NN NN O
several NN NN O
days NN NN O
compared NN NN O
with NN NN O
aspartate NN NN O
aminotransferase NN NN O
, NN NN O
which NN NN O
showed NN NN O
a NN NN O
sharp NN NN O
early NN NN O
peak NN NN O
and NN NN O
then NN NN O
a NN NN O
fall NN NN O
. NN NN O
   
Circulating NN NN O
lysosomal NN NN O
proteases NN NN O
can NN NN O
damage NN NN O
other NN NN O
organs NN NN O
, NN NN O
and NN NN O
measurement NN NN O
of NN NN O
their NN NN O
activity NN NN O
may NN NN O
therefore NN NN O
be NN NN O
of NN NN O
added NN NN O
value NN NN O
in NN NN O
assessing NN NN O
prognosis NN NN O
in NN NN O
this NN NN O
condition NN NN O
. NN NN O
   
Hepatic NN NN B-Disease
veno NN NN I-Disease
- NN NN I-Disease
occlusive NN NN I-Disease
disease NN NN I-Disease
caused NN NN O
by NN NN O
6 NN NN O
- NN NN O
thioguanine NN NN O
. NN NN O
   
Clinically NN NN O
reversible NN NN O
veno NN NN B-Disease
- NN NN I-Disease
occlusive NN NN I-Disease
disease NN NN I-Disease
of NN NN I-Disease
the NN NN I-Disease
liver NN NN I-Disease
developed NN NN O
in NN NN O
a NN NN O
23 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
with NN NN O
acute NN NN B-Disease
lymphocytic NN NN I-Disease
leukemia NN NN I-Disease
after NN NN O
10 NN NN O
months NN NN O
of NN NN O
maintenance NN NN O
therapy NN NN O
with NN NN O
6 NN NN O
- NN NN O
thioguanine NN NN O
. NN NN O
   
Serial NN NN O
liver NN NN O
biopsies NN NN O
showed NN NN O
the NN NN O
development NN NN O
and NN NN O
resolution NN NN O
of NN NN O
intense NN NN O
sinusoidal NN NN O
engorgement NN NN O
. NN NN O
   
Although NN NN O
this NN NN O
disease NN NN O
was NN NN O
clinically NN NN O
reversible NN NN O
, NN NN O
some NN NN O
subintimal NN NN O
fibrosis NN NN B-Disease
about NN NN O
the NN NN O
terminal NN NN O
hepatic NN NN O
veins NN NN O
persisted NN NN O
. NN NN O
   
This NN NN O
case NN NN O
presented NN NN O
a NN NN O
unique NN NN O
opportunity NN NN O
to NN NN O
observe NN NN O
the NN NN O
histologic NN NN O
features NN NN O
of NN NN O
clinically NN NN O
reversible NN NN O
hepatic NN NN B-Disease
veno NN NN I-Disease
- NN NN I-Disease
occlusive NN NN I-Disease
disease NN NN I-Disease
over NN NN O
time NN NN O
, NN NN O
and NN NN O
may NN NN O
be NN NN O
the NN NN O
first NN NN O
case NN NN O
of NN NN O
veno NN NN O
- NN NN O
occlusive NN NN O
related NN NN O
solely NN NN O
to NN NN O
6 NN NN O
- NN NN O
thioguanine NN NN O
. NN NN O
   
Chlorpropamide NN NN O
- NN NN O
induced NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
. NN NN O
   
A NN NN O
65 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
adult NN NN B-Disease
- NN NN I-Disease
onset NN NN I-Disease
diabetes NN NN I-Disease
treated NN NN O
with NN NN O
chlorpropamide NN NN O
( NN NN O
Diabenese NN NN O
) NN NN O
had NN NN O
a NN NN O
toxic NN NN B-Disease
optic NN NN I-Disease
neuropathy NN NN I-Disease
that NN NN O
resolved NN NN O
with NN NN O
discontinuation NN NN O
of NN NN O
chlorpropamide NN NN O
therapy NN NN O
. NN NN O
   
Visual NN NN B-Disease
loss NN NN I-Disease
occurs NN NN O
in NN NN O
diabetics NN NN B-Disease
for NN NN O
a NN NN O
variety NN NN O
of NN NN O
reasons NN NN O
, NN NN O
and NN NN O
accurate NN NN O
diagnosis NN NN O
is NN NN O
necessary NN NN O
to NN NN O
institute NN NN O
appropriate NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
possibility NN NN O
of NN NN O
a NN NN O
drug NN NN O
- NN NN O
induced NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
should NN NN O
be NN NN O
considered NN NN O
in NN NN O
the NN NN O
differential NN NN O
diagnosis NN NN O
of NN NN O
visual NN NN B-Disease
loss NN NN I-Disease
in NN NN O
diabetics NN NN B-Disease
. NN NN O
   
Plasma NN NN O
and NN NN O
urinary NN NN O
lipids NN NN O
and NN NN O
lipoproteins NN NN O
during NN NN O
the NN NN O
development NN NN O
of NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
induced NN NN O
in NN NN O
the NN NN O
rat NN NN O
by NN NN O
puromycin NN NN O
aminonucleoside NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
undertaken NN NN O
to NN NN O
ascertain NN NN O
whether NN NN O
the NN NN O
alterations NN NN O
of NN NN O
plasma NN NN O
lipoproteins NN NN O
found NN NN O
in NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
induced NN NN O
by NN NN O
puromycin NN NN O
aminonucleoside NN NN O
were NN NN O
due NN NN O
to NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
per NN NN O
se NN NN O
, NN NN O
or NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
to NN NN O
the NN NN O
aminonucleoside NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
the NN NN O
changes NN NN O
in NN NN O
plasma NN NN O
and NN NN O
urinary NN NN O
lipoproteins NN NN O
during NN NN O
the NN NN O
administration NN NN O
of NN NN O
puromycin NN NN O
aminonucleoside NN NN O
( NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
for NN NN O
7 NN NN O
days NN NN O
) NN NN O
and NN NN O
the NN NN O
subsequent NN NN O
development NN NN O
of NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
Since NN NN O
massive NN NN O
albuminuria NN NN B-Disease
occurred NN NN O
after NN NN O
6 NN NN O
days NN NN O
of NN NN O
treatment NN NN O
, NN NN O
the NN NN O
time NN NN O
- NN NN O
course NN NN O
study NN NN O
was NN NN O
divided NN NN O
into NN NN O
two NN NN O
stages NN NN O
: NN NN O
pre NN NN O
- NN NN O
nephrotic NN NN B-Disease
stage NN NN O
( NN NN O
day NN NN O
1 NN NN O
- NN NN O
5 NN NN O
) NN NN O
and NN NN O
nephrotic NN NN B-Disease
stage NN NN O
( NN NN O
day NN NN O
6 NN NN O
- NN NN O
11 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
pre NN NN O
- NN NN O
nephrotic NN NN B-Disease
stage NN NN O
the NN NN O
plasma NN NN O
level NN NN O
of NN NN O
fatty NN NN O
acids NN NN O
, NN NN O
triacylglycerol NN NN O
and NN NN O
VLDL NN NN O
decreased NN NN O
while NN NN O
that NN NN O
of NN NN O
phospholipid NN NN O
, NN NN O
cholesteryl NN NN O
esters NN NN O
and NN NN O
HDL NN NN O
remained NN NN O
constant NN NN O
. NN NN O
   
Plasma NN NN O
apolipoprotein NN NN O
A NN NN O
- NN NN O
I NN NN O
tended NN NN O
to NN NN O
increase NN NN O
( NN NN O
40 NN NN O
% NN NN O
increase NN NN O
at NN NN O
day NN NN O
5 NN NN O
) NN NN O
. NN NN O
   
At NN NN O
the NN NN O
beginning NN NN O
of NN NN O
nephrotic NN NN B-Disease
stage NN NN O
( NN NN O
day NN NN O
6 NN NN O
) NN NN O
the NN NN O
concentration NN NN O
of NN NN O
plasma NN NN O
albumin NN NN O
dropped NN NN O
to NN NN O
a NN NN O
very NN NN O
low NN NN O
level NN NN O
, NN NN O
while NN NN O
that NN NN O
of NN NN O
apolipoprotein NN NN O
A NN NN O
- NN NN O
I NN NN O
increased NN NN O
abruptly NN NN O
( NN NN O
4 NN NN O
- NN NN O
fold NN NN O
increase NN NN O
) NN NN O
and NN NN O
continued NN NN O
to NN NN O
rise NN NN O
, NN NN O
although NN NN O
less NN NN O
steeply NN NN O
, NN NN O
in NN NN O
the NN NN O
following NN NN O
days NN NN O
. NN NN O
   
The NN NN O
plasma NN NN O
concentration NN NN O
of NN NN O
HDL NN NN O
followed NN NN O
the NN NN O
same NN NN O
pattern NN NN O
. NN NN O
   
Plasma NN NN O
VLDL NN NN O
and NN NN O
LDL NN NN O
increased NN NN O
at NN NN O
a NN NN O
later NN NN O
stage NN NN O
( NN NN O
day NN NN O
9 NN NN O
) NN NN O
. NN NN O
   
Plasma NN NN O
apolipoprotein NN NN O
A NN NN O
- NN NN O
I NN NN O
was NN NN O
found NN NN O
not NN NN O
only NN NN O
in NN NN O
HDL NN NN O
( NN NN O
1 NN NN O
. NN NN O
063 NN NN O
- NN NN O
1 NN NN O
. NN NN O
210 NN NN O
g NN NN O
/ NN NN O
ml NN NN O
) NN NN O
but NN NN O
also NN NN O
in NN NN O
the NN NN O
LDL NN NN O
density NN NN O
class NN NN O
( NN NN O
1 NN NN O
. NN NN O
025 NN NN O
- NN NN O
1 NN NN O
. NN NN O
050 NN NN O
g NN NN O
/ NN NN O
ml NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
pre NN NN O
- NN NN O
nephrotic NN NN B-Disease
stage NN NN O
lipoproteinuria NN NN O
was NN NN O
negligible NN NN O
, NN NN O
while NN NN O
in NN NN O
the NN NN O
early NN NN O
nephrotic NN NN B-Disease
stage NN NN O
the NN NN O
urinary NN NN O
loss NN NN O
of NN NN O
plasma NN NN O
lipoproteins NN NN O
consisted NN NN O
mainly NN NN O
of NN NN O
HDL NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
indicate NN NN O
that NN NN O
puromycin NN NN O
aminonucleoside NN NN O
alters NN NN O
plasma NN NN O
lipoproteins NN NN O
by NN NN O
lowering NN NN O
VLDL NN NN O
and NN NN O
increasing NN NN O
HDL NN NN O
. NN NN O
   
It NN NN O
is NN NN O
likely NN NN O
that NN NN O
the NN NN O
early NN NN O
and NN NN O
striking NN NN O
increase NN NN O
of NN NN O
plasma NN NN O
HDL NN NN O
found NN NN O
in NN NN O
nephrotic NN NN B-Disease
rats NN NN O
is NN NN O
related NN NN O
to NN NN O
a NN NN O
direct NN NN O
effect NN NN O
of NN NN O
the NN NN O
drug NN NN O
on NN NN O
HDL NN NN O
metabolism NN NN O
. NN NN O
   
Fatal NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
following NN NN O
topical NN NN O
administration NN NN O
of NN NN O
ophthalmic NN NN O
chloramphenicol NN NN O
. NN NN O
   
A NN NN O
73 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
died NN NN O
of NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
less NN NN O
than NN NN O
two NN NN O
months NN NN O
after NN NN O
undergoing NN NN O
cataract NN NN B-Disease
extraction NN NN O
and NN NN O
beginning NN NN O
topical NN NN O
therapy NN NN O
with NN NN O
chloramphenicol NN NN O
. NN NN O
   
The NN NN O
first NN NN O
signs NN NN O
of NN NN O
pancytopenia NN NN B-Disease
began NN NN O
within NN NN O
one NN NN O
month NN NN O
of NN NN O
the NN NN O
surgery NN NN O
. NN NN O
   
The NN NN O
pattern NN NN O
of NN NN O
the NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
was NN NN O
associated NN NN O
with NN NN O
an NN NN O
idiosyncratic NN NN O
response NN NN O
to NN NN O
chloramphenicol NN NN O
. NN NN O
   
This NN NN O
was NN NN O
the NN NN O
second NN NN O
report NN NN O
of NN NN O
fatal NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
after NN NN O
topical NN NN O
treatment NN NN O
with NN NN O
chloramphenicol NN NN O
for NN NN O
ocular NN NN O
conditions NN NN O
, NN NN O
although NN NN O
two NN NN O
cases NN NN O
of NN NN O
reversible NN NN O
bone NN NN B-Disease
marrow NN NN I-Disease
hypoplasia NN NN I-Disease
have NN NN O
also NN NN O
been NN NN O
reported NN NN O
. NN NN O
   
Any NN NN O
other NN NN O
suspected NN NN O
cases NN NN O
of NN NN O
ocular NN NN B-Disease
toxicity NN NN I-Disease
associated NN NN O
with NN NN O
topically NN NN O
applied NN NN O
chloramphenicol NN NN O
should NN NN O
be NN NN O
reported NN NN O
to NN NN O
the NN NN O
National NN NN O
Registry NN NN O
of NN NN O
Drug NN NN O
- NN NN O
Induced NN NN O
Ocular NN NN O
Side NN NN O
Effects NN NN O
, NN NN O
Oregon NN NN O
Health NN NN O
Sciences NN NN O
University NN NN O
, NN NN O
Portland NN NN O
, NN NN O
OR NN NN O
97201 NN NN O
. NN NN O
   
Midazolam NN NN O
compared NN NN O
with NN NN O
thiopentone NN NN O
as NN NN O
an NN NN O
induction NN NN O
agent NN NN O
. NN NN O
   
In NN NN O
patients NN NN O
premedicated NN NN O
with NN NN O
scopolamine NN NN O
+ NN NN O
morphine NN NN O
( NN NN O
+ NN NN O
5 NN NN O
mg NN NN O
nitrazepam NN NN O
the NN NN O
evening NN NN O
before NN NN O
surgery NN NN O
) NN NN O
, NN NN O
the NN NN O
sleep NN NN O
- NN NN O
inducing NN NN O
effect NN NN O
of NN NN O
midazolam NN NN O
0 NN NN O
. NN NN O
15 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
was NN NN O
clearly NN NN O
slower NN NN O
in NN NN O
onset NN NN O
than NN NN O
that NN NN O
of NN NN O
thiopentone NN NN O
4 NN NN O
. NN NN O
67 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
Somewhat NN NN O
fewer NN NN O
cardiovascular NN NN O
and NN NN O
local NN NN O
sequelae NN NN O
were NN NN O
found NN NN O
in NN NN O
the NN NN O
midazolam NN NN O
group NN NN O
, NN NN O
but NN NN O
, NN NN O
although NN NN O
apnoea NN NN B-Disease
occurred NN NN O
less NN NN O
often NN NN O
in NN NN O
the NN NN O
midazolam NN NN O
group NN NN O
it NN NN O
lasted NN NN O
longer NN NN O
. NN NN O
   
On NN NN O
the NN NN O
whole NN NN O
, NN NN O
the NN NN O
differences NN NN O
between NN NN O
midazolam NN NN O
and NN NN O
thiopentone NN NN O
had NN NN O
no NN NN O
apparent NN NN O
clinical NN NN O
consequences NN NN O
. NN NN O
   
Midazolam NN NN O
is NN NN O
a NN NN O
new NN NN O
alternative NN NN O
agent NN NN O
for NN NN O
induction NN NN O
in NN NN O
combination NN NN O
anaesthesia NN NN O
. NN NN O
   
Extrapyramidal NN NN O
side NN NN O
effects NN NN O
and NN NN O
oral NN NN O
haloperidol NN NN O
: NN NN O
an NN NN O
analysis NN NN O
of NN NN O
explanatory NN NN O
patient NN NN O
and NN NN O
treatment NN NN O
characteristics NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
extrapyramidal NN NN O
side NN NN O
effects NN NN O
( NN NN O
EPS NN NN O
) NN NN O
was NN NN O
evaluated NN NN O
in NN NN O
98 NN NN O
patients NN NN O
treated NN NN O
with NN NN O
haloperidol NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
parkinsonism NN NN B-Disease
was NN NN O
higher NN NN O
at NN NN O
higher NN NN O
doses NN NN O
of NN NN O
haloperidol NN NN O
and NN NN O
in NN NN O
younger NN NN O
patients NN NN O
. NN NN O
   
Prophylactic NN NN O
antiparkinsonian NN NN O
medication NN NN O
was NN NN O
effective NN NN O
in NN NN O
younger NN NN O
but NN NN O
not NN NN O
in NN NN O
older NN NN O
patients NN NN O
. NN NN O
   
However NN NN O
, NN NN O
these NN NN O
medications NN NN O
were NN NN O
more NN NN O
effective NN NN O
in NN NN O
both NN NN O
young NN NN O
and NN NN O
old NN NN O
patients NN NN O
when NN NN O
given NN NN O
after NN NN O
parkinsonism NN NN B-Disease
developed NN NN O
. NN NN O
   
Akathisia NN NN B-Disease
was NN NN O
controlled NN NN O
by NN NN O
the NN NN O
benzodiazepine NN NN O
lorazepam NN NN O
in NN NN O
14 NN NN O
out NN NN O
of NN NN O
16 NN NN O
patients NN NN O
, NN NN O
while NN NN O
prophylactic NN NN O
antiparkinsonians NN NN O
were NN NN O
ineffective NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
points NN NN O
to NN NN O
patient NN NN O
characteristics NN NN O
that NN NN O
may NN NN O
be NN NN O
of NN NN O
significance NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
EPS NN NN O
due NN NN O
to NN NN O
haloperidol NN NN O
. NN NN O
   
Deaths NN NN O
from NN NN O
local NN NN O
anesthetic NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
in NN NN O
mice NN NN O
. NN NN O
   
Median NN NN O
convulsant NN NN O
( NN NN O
CD50 NN NN O
) NN NN O
and NN NN O
median NN NN O
lethal NN NN O
( NN NN O
LD50 NN NN O
) NN NN O
doses NN NN O
of NN NN O
three NN NN O
representative NN NN O
local NN NN O
anesthetics NN NN O
were NN NN O
determined NN NN O
in NN NN O
adult NN NN O
mice NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
threat NN NN O
to NN NN O
life NN NN O
of NN NN O
local NN NN O
anesthetic NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
. NN NN O
   
The NN NN O
CD50 NN NN O
and NN NN O
LD50 NN NN O
, NN NN O
respectively NN NN O
, NN NN O
were NN NN O
57 NN NN O
. NN NN O
7 NN NN O
and NN NN O
58 NN NN O
. NN NN O
7 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
for NN NN O
bupivacaine NN NN O
, NN NN O
111 NN NN O
. NN NN O
0 NN NN O
and NN NN O
133 NN NN O
. NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
for NN NN O
lidocaine NN NN O
, NN NN O
and NN NN O
243 NN NN O
. NN NN O
4 NN NN O
and NN NN O
266 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
for NN NN O
chloroprocaine NN NN O
. NN NN O
   
When NN NN O
given NN NN O
intraperitoneally NN NN O
, NN NN O
bupivacaine NN NN O
thus NN NN O
was NN NN O
only NN NN O
about NN NN O
twice NN NN O
as NN NN O
toxic NN NN O
as NN NN O
lidocaine NN NN O
and NN NN O
four NN NN O
times NN NN O
as NN NN O
toxic NN NN O
as NN NN O
chloroprocaine NN NN O
. NN NN O
   
Convulsions NN NN B-Disease
always NN NN O
preceded NN NN O
death NN NN O
, NN NN O
except NN NN O
after NN NN O
precipitous NN NN O
cardiopulmonary NN NN B-Disease
arrest NN NN I-Disease
from NN NN O
extreme NN NN O
doses NN NN O
. NN NN O
   
A NN NN O
CD50 NN NN O
dose NN NN O
of NN NN O
local NN NN O
anesthetic NN NN O
( NN NN O
causing NN NN O
convulsions NN NN B-Disease
in NN NN O
50 NN NN O
% NN NN O
of NN NN O
mice NN NN O
) NN NN O
was NN NN O
fatal NN NN O
in NN NN O
90 NN NN O
% NN NN O
of NN NN O
bupivacaine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
, NN NN O
in NN NN O
57 NN NN O
% NN NN O
of NN NN O
the NN NN O
chloroprocaine NN NN O
group NN NN O
, NN NN O
and NN NN O
in NN NN O
6 NN NN O
% NN NN O
of NN NN O
the NN NN O
lidocaine NN NN O
group NN NN O
. NN NN O
   
The NN NN O
narrow NN NN O
gap NN NN O
between NN NN O
convulsant NN NN O
and NN NN O
lethal NN NN O
doses NN NN O
of NN NN O
local NN NN O
anesthetics NN NN O
indicates NN NN O
that NN NN O
untreated NN NN O
convulsions NN NN B-Disease
present NN NN O
much NN NN O
more NN NN O
of NN NN O
a NN NN O
threat NN NN O
to NN NN O
life NN NN O
than NN NN O
heretofore NN NN O
appreciated NN NN O
. NN NN O
   
REM NN NN B-Disease
sleep NN NN I-Disease
deprivation NN NN I-Disease
changes NN NN O
behavioral NN NN O
response NN NN O
to NN NN O
catecholaminergic NN NN O
and NN NN O
serotonergic NN NN O
receptor NN NN O
activation NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
REM NN NN B-Disease
sleep NN NN I-Disease
deprivation NN NN I-Disease
( NN NN O
REMD NN NN B-Disease
) NN NN O
on NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
aggressiveness NN NN B-Disease
and NN NN O
quipazine NN NN O
- NN NN O
induced NN NN O
head NN NN B-Disease
twitches NN NN I-Disease
in NN NN O
rats NN NN O
were NN NN O
determined NN NN O
. NN NN O
   
Forty NN NN O
- NN NN O
eight NN NN O
hr NN NN O
of NN NN O
REMD NN NN B-Disease
increased NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
aggressiveness NN NN B-Disease
, NN NN O
and NN NN O
reduced NN NN O
( NN NN O
immediately NN NN O
after NN NN O
completing NN NN O
of NN NN O
REMD NN NN B-Disease
) NN NN O
or NN NN O
increased NN NN O
( NN NN O
96 NN NN O
hr NN NN O
after NN NN O
completing NN NN O
of NN NN O
REMD NN NN B-Disease
) NN NN O
quipazine NN NN O
- NN NN O
induced NN NN O
head NN NN B-Disease
twitches NN NN I-Disease
. NN NN O
   
Results NN NN O
are NN NN O
discussed NN NN O
in NN NN O
terms NN NN O
of NN NN O
similarity NN NN O
to NN NN O
pharmacological NN NN O
effects NN NN O
of NN NN O
other NN NN O
antidepressive NN NN O
treatments NN NN O
. NN NN O
   
Fatal NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
due NN NN O
to NN NN O
indomethacin NN NN O
- NN NN O
- NN NN O
lymphocyte NN NN O
transformation NN NN O
tests NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
Although NN NN O
indomethacin NN NN O
has NN NN O
been NN NN O
implicated NN NN O
as NN NN O
a NN NN O
possible NN NN O
cause NN NN O
of NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
a NN NN O
few NN NN O
clinical NN NN O
observations NN NN O
, NN NN O
its NN NN O
role NN NN O
has NN NN O
not NN NN O
been NN NN O
definitely NN NN O
established NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
fatal NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
is NN NN O
described NN NN O
in NN NN O
which NN NN O
no NN NN O
drugs NN NN O
other NN NN O
than NN NN O
allopurinol NN NN O
and NN NN O
indomethacin NN NN O
were NN NN O
given NN NN O
. NN NN O
   
Indomethacin NN NN O
was NN NN O
first NN NN O
given NN NN O
four NN NN O
weeks NN NN O
prior NN NN O
to NN NN O
the NN NN O
onset NN NN O
of NN NN O
symptoms NN NN O
. NN NN O
   
A NN NN O
positive NN NN O
lymphocyte NN NN O
transformation NN NN O
test NN NN O
with NN NN O
indomethacin NN NN O
in NN NN O
vitro NN NN O
further NN NN O
substantiates NN NN O
the NN NN O
potential NN NN O
role NN NN O
of NN NN O
this NN NN O
drug NN NN O
in NN NN O
causing NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
in NN NN O
a NN NN O
susceptible NN NN O
patient NN NN O
. NN NN O
   
Fortunately NN NN O
, NN NN O
this NN NN O
seems NN NN O
to NN NN O
be NN NN O
a NN NN O
very NN NN O
rare NN NN O
complication NN NN O
. NN NN O
   
Dose NN NN O
- NN NN O
effect NN NN O
and NN NN O
structure NN NN O
- NN NN O
function NN NN O
relationships NN NN O
in NN NN O
doxorubicin NN NN O
cardiomyopathy NN NN B-Disease
. NN NN O
   
The NN NN O
cardiomyopathy NN NN B-Disease
( NN NN O
CM NN NN B-Disease
) NN NN O
produced NN NN O
by NN NN O
the NN NN O
anticancer NN NN O
drug NN NN O
doxorubicin NN NN O
( NN NN O
DXR NN NN O
) NN NN O
( NN NN O
Adriamycin NN NN O
) NN NN O
provides NN NN O
a NN NN O
unique NN NN O
opportunity NN NN O
to NN NN O
analyze NN NN O
dose NN NN O
- NN NN O
effect NN NN O
and NN NN O
structure NN NN O
- NN NN O
function NN NN O
relationships NN NN O
during NN NN O
development NN NN O
of NN NN O
myocardial NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
We NN NN O
measured NN NN O
the NN NN O
degree NN NN O
of NN NN O
morphologic NN NN O
damage NN NN O
by NN NN O
ultrastructural NN NN O
examination NN NN O
of NN NN O
endomyocardial NN NN O
biopsy NN NN O
and NN NN O
the NN NN O
degree NN NN O
of NN NN O
performance NN NN O
abnormally NN NN O
by NN NN O
right NN NN O
heart NN NN O
catheterization NN NN O
in NN NN O
patients NN NN O
receiving NN NN O
DXR NN NN O
. NN NN O
   
Morphologic NN NN O
damage NN NN O
was NN NN O
variable NN NN O
but NN NN O
was NN NN O
proportional NN NN O
to NN NN O
the NN NN O
total NN NN O
cumulative NN NN O
DXR NN NN O
dose NN NN O
between NN NN O
100 NN NN O
and NN NN O
600 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
. NN NN O
   
Performance NN NN O
abnormalities NN NN O
correlated NN NN O
weakly NN NN O
with NN NN O
dose NN NN O
, NN NN O
exhibited NN NN O
a NN NN O
curvilinear NN NN O
relationship NN NN O
, NN NN O
and NN NN O
had NN NN O
a NN NN O
"""""""" NN NN O
threshold NN NN O
"""""""" NN NN O
for NN NN O
expression NN NN O
. NN NN O
   
Catheterization NN NN O
abnormalities NN NN O
correlated NN NN O
well NN NN O
with NN NN O
morphologic NN NN O
damage NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
57 NN NN O
to NN NN O
0 NN NN O
. NN NN O
78 NN NN O
) NN NN O
in NN NN O
a NN NN O
subgroup NN NN O
of NN NN O
patients NN NN O
in NN NN O
whom NN NN O
exercise NN NN O
hemodynamics NN NN O
were NN NN O
measured NN NN O
, NN NN O
and NN NN O
this NN NN O
relationship NN NN O
also NN NN O
exhibited NN NN O
a NN NN O
curvilinear NN NN O
, NN NN O
threshold NN NN O
configuration NN NN O
. NN NN O
   
In NN NN O
DXR NN NN O
- NN NN O
CM NN NN B-Disease
myocardial NN NN B-Disease
damage NN NN I-Disease
is NN NN O
proportional NN NN O
to NN NN O
the NN NN O
degree NN NN O
of NN NN O
cytotoxic NN NN O
insult NN NN O
( NN NN O
DXR NN NN O
dose NN NN O
) NN NN O
while NN NN O
myocardial NN NN O
function NN NN O
is NN NN O
preserved NN NN O
until NN NN O
a NN NN O
critical NN NN O
dose NN NN O
or NN NN O
degree NN NN O
of NN NN O
damage NN NN O
is NN NN O
reached NN NN O
, NN NN O
after NN NN O
which NN NN O
myocardial NN NN O
performance NN NN O
deteriorates NN NN O
rapidly NN NN O
. NN NN O
   
Massive NN NN O
cerebral NN NN B-Disease
edema NN NN I-Disease
associated NN NN O
with NN NN O
fulminant NN NN O
hepatic NN NN B-Disease
failure NN NN I-Disease
in NN NN O
acetaminophen NN NN O
overdose NN NN B-Disease
: NN NN O
possible NN NN O
role NN NN O
of NN NN O
cranial NN NN O
decompression NN NN O
. NN NN O
   
Cerebral NN NN B-Disease
edema NN NN I-Disease
may NN NN O
complicate NN NN O
the NN NN O
course NN NN O
of NN NN O
fulminant NN NN B-Disease
hepatic NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
Response NN NN O
to NN NN O
conventional NN NN O
therapy NN NN O
has NN NN O
been NN NN O
disappointing NN NN O
. NN NN O
   
We NN NN O
present NN NN O
a NN NN O
patient NN NN O
with NN NN O
fatal NN NN O
acetaminophen NN NN O
- NN NN O
induced NN NN O
fulminant NN NN B-Disease
hepatic NN NN I-Disease
failure NN NN I-Disease
, NN NN O
with NN NN O
signs NN NN O
and NN NN O
symptoms NN NN O
of NN NN O
cerebral NN NN B-Disease
edema NN NN I-Disease
, NN NN O
unresponsive NN NN O
to NN NN O
conventional NN NN O
medical NN NN O
therapy NN NN O
. NN NN O
   
Cranial NN NN O
decompression NN NN O
was NN NN O
carried NN NN O
out NN NN O
. NN NN O
   
A NN NN O
justification NN NN O
of NN NN O
the NN NN O
need NN NN O
for NN NN O
further NN NN O
evaluation NN NN O
of NN NN O
cranial NN NN O
decompression NN NN O
in NN NN O
such NN NN O
patients NN NN O
is NN NN O
presented NN NN O
. NN NN O
   
Subjective NN NN O
assessment NN NN O
of NN NN O
sexual NN NN B-Disease
dysfunction NN NN I-Disease
of NN NN O
patients NN NN O
on NN NN O
long NN NN O
- NN NN O
term NN NN O
administration NN NN O
of NN NN O
digoxin NN NN O
. NN NN O
   
Various NN NN O
data NN NN O
suggest NN NN O
that NN NN O
male NN NN O
patients NN NN O
who NN NN O
have NN NN O
received NN NN O
digoxin NN NN O
on NN NN O
a NN NN O
longterm NN NN O
basis NN NN O
have NN NN O
increased NN NN O
levels NN NN O
of NN NN O
serum NN NN O
estrogen NN NN O
and NN NN O
decreased NN NN O
levels NN NN O
of NN NN O
plasma NN NN O
testosterone NN NN O
and NN NN O
luteinizing NN NN O
hormone NN NN O
( NN NN O
LH NN NN O
) NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
undertaken NN NN O
to NN NN O
investigate NN NN O
the NN NN O
links NN NN O
between NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
administration NN NN O
of NN NN O
digoxin NN NN O
therapy NN NN O
and NN NN O
sexual NN NN O
behavior NN NN O
, NN NN O
and NN NN O
the NN NN O
effect NN NN O
of NN NN O
digoxin NN NN O
on NN NN O
plasma NN NN O
levels NN NN O
of NN NN O
estradiol NN NN O
, NN NN O
testosterone NN NN O
, NN NN O
and NN NN O
LH NN NN O
. NN NN O
   
The NN NN O
patients NN NN O
of NN NN O
the NN NN O
study NN NN O
and NN NN O
control NN NN O
group NN NN O
( NN NN O
without NN NN O
digoxin NN NN O
) NN NN O
were NN NN O
of NN NN O
similar NN NN O
cardiac NN NN O
functional NN NN O
capacity NN NN O
and NN NN O
age NN NN O
( NN NN O
25 NN NN O
- NN NN O
40 NN NN O
years NN NN O
) NN NN O
and NN NN O
were NN NN O
randomly NN NN O
selected NN NN O
from NN NN O
the NN NN O
rheumatic NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
patients NN NN O
. NN NN O
   
A NN NN O
subjective NN NN O
assessment NN NN O
of NN NN O
sexual NN NN O
behavior NN NN O
in NN NN O
the NN NN O
study NN NN O
and NN NN O
control NN NN O
groups NN NN O
was NN NN O
carried NN NN O
out NN NN O
, NN NN O
using NN NN O
parameters NN NN O
such NN NN O
as NN NN O
sexual NN NN O
desire NN NN O
, NN NN O
sexual NN NN O
excitement NN NN O
, NN NN O
and NN NN O
frequency NN NN O
of NN NN O
sexual NN NN O
relations NN NN O
. NN NN O
   
Personal NN NN O
interviews NN NN O
and NN NN O
a NN NN O
questionnaire NN NN O
were NN NN O
also NN NN O
used NN NN O
for NN NN O
the NN NN O
evaluation NN NN O
of NN NN O
sexual NN NN O
behavior NN NN O
. NN NN O
   
The NN NN O
findings NN NN O
support NN NN O
the NN NN O
reports NN NN O
concerning NN NN O
digoxin NN NN O
effect NN NN O
on NN NN O
plasma NN NN O
estradiol NN NN O
, NN NN O
testosterone NN NN O
, NN NN O
and NN NN O
LH NN NN O
. NN NN O
   
The NN NN O
differences NN NN O
in NN NN O
the NN NN O
means NN NN O
were NN NN O
significant NN NN O
. NN NN O
   
Tests NN NN O
used NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
changes NN NN O
in NN NN O
sexual NN NN O
behavior NN NN O
showed NN NN O
a NN NN O
significant NN NN O
decrease NN NN B-Disease
in NN NN I-Disease
sexual NN NN I-Disease
desire NN NN I-Disease
, NN NN O
sexual NN NN O
excitement NN NN O
phase NN NN O
( NN NN O
erection NN NN O
) NN NN O
, NN NN O
and NN NN O
frequency NN NN O
of NN NN O
sexual NN NN O
relations NN NN O
in NN NN O
the NN NN O
study NN NN O
group NN NN O
. NN NN O
   
Endometrial NN NN B-Disease
carcinoma NN NN I-Disease
after NN NN O
Hodgkin NN NN B-Disease
disease NN NN I-Disease
in NN NN O
childhood NN NN O
. NN NN O
   
A NN NN O
34 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
patient NN NN O
developed NN NN O
metastic NN NN O
endometrial NN NN B-Disease
carcinoma NN NN I-Disease
after NN NN O
Hodgkin NN NN B-Disease
disease NN NN I-Disease
in NN NN O
childhood NN NN O
. NN NN O
   
She NN NN O
had NN NN O
ovarian NN NN B-Disease
failure NN NN I-Disease
after NN NN O
abdominal NN NN O
irradiation NN NN O
and NN NN O
chemotherapy NN NN O
for NN NN O
Hodgkin NN NN B-Disease
disease NN NN I-Disease
, NN NN O
and NN NN O
received NN NN O
exogenous NN NN O
estrogens NN NN O
, NN NN O
a NN NN O
treatment NN NN O
implicated NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
endometrial NN NN B-Disease
cancer NN NN I-Disease
in NN NN O
menopausal NN NN O
women NN NN O
. NN NN O
   
Young NN NN O
women NN NN O
on NN NN O
replacement NN NN O
estrogens NN NN O
for NN NN O
ovarian NN NN B-Disease
failure NN NN I-Disease
after NN NN O
cancer NN NN B-Disease
therapy NN NN O
may NN NN O
also NN NN O
have NN NN O
increased NN NN O
risk NN NN O
of NN NN O
endometrial NN NN B-Disease
carcinoma NN NN I-Disease
and NN NN O
should NN NN O
be NN NN O
examined NN NN O
periodically NN NN O
. NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
lithium NN NN O
treatment NN NN O
and NN NN O
the NN NN O
kidney NN NN O
. NN NN O
   
Interim NN NN O
report NN NN O
on NN NN O
fifty NN NN O
patients NN NN O
. NN NN O
   
This NN NN O
is NN NN O
a NN NN O
report NN NN O
on NN NN O
the NN NN O
first NN NN O
part NN NN O
of NN NN O
our NN NN O
study NN NN O
of NN NN O
the NN NN O
effects NN NN O
of NN NN O
long NN NN O
- NN NN O
term NN NN O
lithium NN NN O
treatment NN NN O
on NN NN O
the NN NN O
kidney NN NN O
. NN NN O
   
Creatinine NN NN O
clearance NN NN O
, NN NN O
maximum NN NN O
urinary NN NN O
osmolality NN NN O
and NN NN O
24 NN NN O
hour NN NN O
urine NN NN O
volume NN NN O
have NN NN O
been NN NN O
tested NN NN O
in NN NN O
50 NN NN O
affectively NN NN O
ill NN NN O
patients NN NN O
who NN NN O
have NN NN O
been NN NN O
on NN NN O
long NN NN O
- NN NN O
term NN NN O
lithium NN NN O
for NN NN O
more NN NN O
than NN NN O
one NN NN O
year NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
have NN NN O
been NN NN O
compared NN NN O
with NN NN O
norms NN NN O
and NN NN O
with NN NN O
values NN NN O
of NN NN O
the NN NN O
same NN NN O
tests NN NN O
from NN NN O
screening NN NN O
prior NN NN O
to NN NN O
lithium NN NN O
, NN NN O
available NN NN O
for NN NN O
most NN NN O
of NN NN O
our NN NN O
patients NN NN O
. NN NN O
   
No NN NN O
evidence NN NN O
was NN NN O
found NN NN O
for NN NN O
any NN NN O
reduction NN NN O
of NN NN O
glomerular NN NN O
filtration NN NN O
during NN NN O
lithium NN NN O
treatment NN NN O
. NN NN O
   
Low NN NN O
clearance NN NN O
values NN NN O
found NN NN O
in NN NN O
several NN NN O
patients NN NN O
could NN NN O
be NN NN O
accounted NN NN O
for NN NN O
by NN NN O
their NN NN O
age NN NN O
and NN NN O
their NN NN O
pre NN NN O
- NN NN O
lithium NN NN O
values NN NN O
. NN NN O
   
Urinary NN NN O
concentration NN NN O
defect NN NN O
appeared NN NN O
frequent NN NN O
but NN NN O
the NN NN O
extent NN NN O
of NN NN O
the NN NN O
impairment NN NN O
is NN NN O
difficult NN NN O
to NN NN O
assess NN NN O
because NN NN O
of NN NN O
the NN NN O
uncertainty NN NN O
about NN NN O
the NN NN O
norms NN NN O
applicable NN NN O
to NN NN O
this NN NN O
group NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
concentration NN NN O
defect NN NN O
appeared NN NN O
reversible NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
. NN NN O
   
Polyuria NN NN B-Disease
above NN NN O
3 NN NN O
litres NN NN O
/ NN NN O
24 NN NN O
hours NN NN O
was NN NN O
found NN NN O
in NN NN O
10 NN NN O
% NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
An NN NN O
attempt NN NN O
is NN NN O
made NN NN O
to NN NN O
draw NN NN O
practical NN NN O
conclusions NN NN O
from NN NN O
the NN NN O
preliminary NN NN O
findings NN NN O
. NN NN O
   
Nephrotoxicity NN NN B-Disease
of NN NN O
cyclosporin NN NN O
A NN NN O
and NN NN O
FK506 NN NN O
: NN NN O
inhibition NN NN O
of NN NN O
calcineurin NN NN O
phosphatase NN NN O
. NN NN O
   
Cyclosporin NN NN O
A NN NN O
( NN NN O
CsA NN NN O
; NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
and NN NN O
Fujimycine NN NN O
( NN NN O
FK506 NN NN O
; NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
but NN NN O
not NN NN O
the NN NN O
related NN NN O
macrolide NN NN O
immunosuppressant NN NN O
rapamycin NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
caused NN NN O
a NN NN O
reduction NN NN O
of NN NN O
glomerular NN NN O
filtration NN NN O
rate NN NN O
, NN NN O
degenerative NN NN O
changes NN NN O
of NN NN O
proximal NN NN O
tubular NN NN O
epithelium NN NN O
, NN NN O
and NN NN O
hypertrophy NN NN B-Disease
of NN NN O
the NN NN O
juxtaglomerular NN NN O
apparatus NN NN O
in NN NN O
male NN NN O
Wistar NN NN O
rats NN NN O
when NN NN O
given NN NN O
for NN NN O
10 NN NN O
days NN NN O
. NN NN O
   
The NN NN O
molecular NN NN O
mechanisms NN NN O
of NN NN O
CsA NN NN O
and NN NN O
FK506 NN NN O
toxicity NN NN B-Disease
were NN NN O
investigated NN NN O
. NN NN O
   
Cyclophilin NN NN O
A NN NN O
and NN NN O
FK506 NN NN O
- NN NN O
binding NN NN O
protein NN NN O
, NN NN O
the NN NN O
main NN NN O
intracytoplasmic NN NN O
receptors NN NN O
for NN NN O
CsA NN NN O
and NN NN O
FK506 NN NN O
, NN NN O
respectively NN NN O
, NN NN O
were NN NN O
each NN NN O
detected NN NN O
in NN NN O
renal NN NN O
tissue NN NN O
extract NN NN O
. NN NN O
   
In NN NN O
the NN NN O
kidney NN NN O
, NN NN O
high NN NN O
levels NN NN O
of NN NN O
immunoreactive NN NN O
and NN NN O
enzymatically NN NN O
active NN NN O
calcineurin NN NN O
were NN NN O
found NN NN O
which NN NN O
were NN NN O
inhibited NN NN O
by NN NN O
the NN NN O
immunosuppressants NN NN O
CsA NN NN O
and NN NN O
FK506 NN NN O
, NN NN O
but NN NN O
not NN NN O
by NN NN O
rapamycin NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
specific NN NN O
immunophilin NN NN O
- NN NN O
drug NN NN O
- NN NN O
calcineurin NN NN O
complexes NN NN O
formed NN NN O
only NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
CsA NN NN O
and NN NN O
FK506 NN NN O
, NN NN O
but NN NN O
not NN NN O
rapamycin NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
nephrotoxic NN NN B-Disease
effects NN NN O
of NN NN O
CsA NN NN O
and NN NN O
FK506 NN NN O
is NN NN O
likely NN NN O
mediated NN NN O
through NN NN O
binding NN NN O
to NN NN O
renal NN NN O
immunophilin NN NN O
and NN NN O
inhibiting NN NN O
calcineurin NN NN O
phosphatase NN NN O
. NN NN O
   
Acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
in NN NN O
high NN NN O
dose NN NN O
carboplatin NN NN O
chemotherapy NN NN O
. NN NN O
   
Carboplatin NN NN O
has NN NN O
been NN NN O
reported NN NN O
to NN NN O
cause NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
when NN NN O
administered NN NN O
in NN NN O
high NN NN O
doses NN NN O
to NN NN O
adult NN NN O
patients NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
4 NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
girl NN NN O
who NN NN O
was NN NN O
treated NN NN O
with NN NN O
high NN NN O
- NN NN O
dose NN NN O
carboplatin NN NN O
for NN NN O
metastatic NN NN O
parameningeal NN NN O
embryonal NN NN B-Disease
rhabdomyosarcoma NN NN I-Disease
. NN NN O
   
Acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
developed NN NN O
followed NN NN O
by NN NN O
a NN NN O
slow NN NN O
partial NN NN O
recovery NN NN O
of NN NN O
renal NN NN O
function NN NN O
. NN NN O
   
Possible NN NN O
contributing NN NN O
factors NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Clinical NN NN O
evaluation NN NN O
on NN NN O
combined NN NN O
administration NN NN O
of NN NN O
oral NN NN O
prostacyclin NN NN O
analogue NN NN O
beraprost NN NN O
and NN NN O
phosphodiesterase NN NN O
inhibitor NN NN O
cilostazol NN NN O
. NN NN O
   
Among NN NN O
various NN NN O
oral NN NN O
antiplatelets NN NN O
, NN NN O
a NN NN O
combination NN NN O
of NN NN O
a NN NN O
novel NN NN O
prostacyclin NN NN O
analogue NN NN O
beraprost NN NN O
( NN NN O
BPT NN NN O
) NN NN O
and NN NN O
a NN NN O
potent NN NN O
phosphodiesterase NN NN O
inhibitor NN NN O
cilostazol NN NN O
( NN NN O
CLZ NN NN O
) NN NN O
may NN NN O
result NN NN O
in NN NN O
untoward NN NN O
clinical NN NN O
effects NN NN O
due NN NN O
to NN NN O
possible NN NN O
synergistic NN NN O
elevation NN NN O
of NN NN O
intracellular NN NN O
cAMP NN NN O
( NN NN O
cyclic NN NN O
adenosine NN NN O
3 NN NN O
' NN NN O
, NN NN O
5 NN NN O
' NN NN O
- NN NN O
monophosphate NN NN O
) NN NN O
. NN NN O
   
Thereby NN NN O
, NN NN O
a NN NN O
clinical NN NN O
study NN NN O
of NN NN O
the NN NN O
combined NN NN O
administration NN NN O
of NN NN O
the NN NN O
two NN NN O
agents NN NN O
was NN NN O
attempted NN NN O
. NN NN O
   
Twelve NN NN O
healthy NN NN O
volunteers NN NN O
were NN NN O
assigned NN NN O
to NN NN O
take NN NN O
BPT NN NN O
/ NN NN O
CLZ NN NN O
in NN NN O
the NN NN O
following NN NN O
schedule NN NN O
; NN NN O
BPT NN NN O
: NN NN O
40 NN NN O
micrograms NN NN O
at NN NN O
day NN NN O
1 NN NN O
and NN NN O
120 NN NN O
micrograms NN NN O
t NN NN O
. NN NN O
i NN NN O
. NN NN O
d NN NN O
. NN NN O
from NN NN O
day NN NN O
7 NN NN O
to NN NN O
14 NN NN O
, NN NN O
CLZ NN NN O
: NN NN O
200 NN NN O
mg NN NN O
t NN NN O
. NN NN O
i NN NN O
. NN NN O
d NN NN O
. NN NN O
from NN NN O
day NN NN O
3 NN NN O
to NN NN O
14 NN NN O
. NN NN O
   
At NN NN O
various NN NN O
time NN NN O
intervals NN NN O
, NN NN O
physical NN NN O
examination NN NN O
and NN NN O
blood NN NN O
collection NN NN O
for NN NN O
ex NN NN O
vivo NN NN O
platelet NN NN B-Disease
aggregation NN NN I-Disease
and NN NN O
determination NN NN O
of NN NN O
intraplatelet NN NN O
cAMP NN NN O
were NN NN O
performed NN NN O
. NN NN O
   
Throughout NN NN O
the NN NN O
observation NN NN O
period NN NN O
, NN NN O
no NN NN O
significant NN NN O
alteration NN NN O
in NN NN O
vital NN NN O
signs NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
Seven NN NN O
out NN NN O
of NN NN O
12 NN NN O
subjects NN NN O
experienced NN NN O
headache NN NN B-Disease
of NN NN O
a NN NN O
short NN NN O
duration NN NN O
accompanying NN NN O
facial NN NN B-Disease
flush NN NN I-Disease
in NN NN O
one NN NN O
and NN NN O
nausea NN NN B-Disease
in NN NN O
one NN NN O
, NN NN O
especially NN NN O
after NN NN O
ingestion NN NN O
of NN NN O
CLZ NN NN O
. NN NN O
   
All NN NN O
of NN NN O
these NN NN O
symptoms NN NN O
, NN NN O
probably NN NN O
caused NN NN O
by NN NN O
the NN NN O
vasodilating NN NN O
effect NN NN O
of NN NN O
the NN NN O
two NN NN O
agents NN NN O
, NN NN O
were NN NN O
of NN NN O
mild NN NN O
degree NN NN O
and NN NN O
no NN NN O
special NN NN O
treatment NN NN O
was NN NN O
required NN NN O
. NN NN O
   
Intraplatelet NN NN O
cAMP NN NN O
content NN NN O
was NN NN O
gradually NN NN O
but NN NN O
significantly NN NN O
increased NN NN O
to NN NN O
9 NN NN O
. NN NN O
84 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
. NN NN O
59 NN NN O
pmol NN NN O
per NN NN O
10 NN NN O
( NN NN O
9 NN NN O
) NN NN O
platelets NN NN O
at NN NN O
day NN NN O
14 NN NN O
in NN NN O
comparison NN NN O
with NN NN O
the NN NN O
initial NN NN O
value NN NN O
( NN NN O
6 NN NN O
. NN NN O
87 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
25 NN NN O
pmol NN NN O
) NN NN O
. NN NN O
   
The NN NN O
platelet NN NN O
aggregability NN NN O
was NN NN O
significantly NN NN O
suppressed NN NN O
at NN NN O
various NN NN O
time NN NN O
intervals NN NN O
but NN NN O
no NN NN O
additive NN NN O
or NN NN O
synergistic NN NN O
inhibitory NN NN O
effect NN NN O
by NN NN O
the NN NN O
combined NN NN O
administration NN NN O
was NN NN O
noted NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
the NN NN O
combined NN NN O
administration NN NN O
of NN NN O
BPT NN NN O
/ NN NN O
CLZ NN NN O
is NN NN O
safe NN NN O
at NN NN O
doses NN NN O
used NN NN O
in NN NN O
the NN NN O
study NN NN O
, NN NN O
though NN NN O
the NN NN O
beneficial NN NN O
clinical NN NN O
effect NN NN O
of NN NN O
the NN NN O
combined NN NN O
administration NN NN O
has NN NN O
yet NN NN O
to NN NN O
be NN NN O
elucidated NN NN O
. NN NN O
   
Pravastatin NN NN O
- NN NN O
associated NN NN O
myopathy NN NN B-Disease
. NN NN O
   
Report NN NN O
of NN NN O
a NN NN O
case NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
acute NN NN O
inflammatory NN NN B-Disease
myopathy NN NN I-Disease
associated NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
pravastatin NN NN O
, NN NN O
a NN NN O
new NN NN O
hydrophilic NN NN O
3 NN NN O
- NN NN O
hydroxy NN NN O
- NN NN O
3 NN NN O
methylglutaril NN NN O
coenzyme NN NN O
A NN NN O
reductase NN NN O
inhibitor NN NN O
, NN NN O
is NN NN O
reported NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
, NN NN O
a NN NN O
69 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
was NN NN O
affected NN NN O
by NN NN O
non NN NN B-Disease
- NN NN I-Disease
insulin NN NN I-Disease
- NN NN I-Disease
dependent NN NN I-Disease
diabetes NN NN I-Disease
mellitus NN NN I-Disease
and NN NN O
hypertension NN NN B-Disease
. NN NN O
   
He NN NN O
assumed NN NN O
pravastatin NN NN O
( NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
because NN NN O
of NN NN O
hypercholesterolemia NN NN B-Disease
. NN NN O
   
He NN NN O
was NN NN O
admitted NN NN O
with NN NN O
acute NN NN O
myopathy NN NN B-Disease
of NN NN O
the NN NN O
lower NN NN O
limbs NN NN O
which NN NN O
resolved NN NN O
in NN NN O
a NN NN O
few NN NN O
days NN NN O
after NN NN O
pravastatin NN NN O
discontinuation NN NN O
. NN NN O
   
A NN NN O
previously NN NN O
unknown NN NN O
hypothyroidism NN NN B-Disease
, NN NN O
probably NN NN O
due NN NN O
to NN NN O
chronic NN NN O
autoimmune NN NN B-Disease
thyroiditis NN NN I-Disease
, NN NN O
was NN NN O
evidenced NN NN O
. NN NN O
   
Muscle NN NN O
biopsy NN NN O
( NN NN O
left NN NN O
gastrocnemius NN NN O
) NN NN O
revealed NN NN O
a NN NN O
perimysial NN NN O
and NN NN O
endomysial NN NN O
inflammatory NN NN O
infiltrate NN NN O
with NN NN O
a NN NN O
prevalence NN NN O
of NN NN O
CD4 NN NN O
+ NN NN O
lymphocytes NN NN O
. NN NN O
   
While NN NN O
lovastatin NN NN O
and NN NN O
simvastatin NN NN O
have NN NN O
been NN NN O
associated NN NN O
with NN NN O
toxic NN NN O
myopathy NN NN B-Disease
, NN NN O
pravastatin NN NN O
- NN NN O
associated NN NN O
myopathy NN NN B-Disease
could NN NN O
represent NN NN O
a NN NN O
distinct NN NN O
, NN NN O
inflammatory NN NN O
entity NN NN O
. NN NN O
   
Reversal NN NN O
of NN NN O
ammonia NN NN O
coma NN NN B-Disease
in NN NN O
rats NN NN O
by NN NN O
L NN NN O
- NN NN O
dopa NN NN O
: NN NN O
a NN NN O
peripheral NN NN O
effect NN NN O
. NN NN O
   
Ammonia NN NN O
coma NN NN B-Disease
was NN NN O
produced NN NN O
in NN NN O
rats NN NN O
within NN NN O
10 NN NN O
to NN NN O
15 NN NN O
minutes NN NN O
of NN NN O
an NN NN O
intraperitonealinjection NN NN O
of NN NN O
1 NN NN O
. NN NN O
7 NN NN O
mmol NN NN O
NH4CL NN NN O
. NN NN O
   
This NN NN O
coma NN NN B-Disease
was NN NN O
prevented NN NN O
with NN NN O
1 NN NN O
. NN NN O
68 NN NN O
mmol NN NN O
L NN NN O
- NN NN O
dopa NN NN O
given NN NN O
by NN NN O
gastric NN NN O
intubation NN NN O
15 NN NN O
minutes NN NN O
before NN NN O
the NN NN O
ammonium NN NN O
salt NN NN O
injection NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
L NN NN O
- NN NN O
dopa NN NN O
was NN NN O
correlated NN NN O
with NN NN O
a NN NN O
decrease NN NN O
in NN NN O
blood NN NN O
and NN NN O
brain NN NN O
ammonia NN NN O
, NN NN O
an NN NN O
increase NN NN O
in NN NN O
brain NN NN O
dopamine NN NN O
, NN NN O
and NN NN O
an NN NN O
increase NN NN O
in NN NN O
renal NN NN O
excretion NN NN O
of NN NN O
ammonia NN NN O
and NN NN O
urea NN NN O
. NN NN O
   
Intraventricular NN NN O
infusion NN NN O
of NN NN O
dopamine NN NN O
sufficient NN NN O
to NN NN O
raise NN NN O
the NN NN O
brain NN NN O
dopamine NN NN O
to NN NN O
the NN NN O
same NN NN O
extent NN NN O
did NN NN O
not NN NN O
prevent NN NN O
the NN NN O
ammonia NN NN O
coma NN NN B-Disease
nor NN NN O
affect NN NN O
the NN NN O
blood NN NN O
and NN NN O
brain NN NN O
ammonia NN NN O
concentrations NN NN O
. NN NN O
   
Bilateral NN NN O
nephrectomy NN NN O
eliminated NN NN O
the NN NN O
beneficial NN NN O
effect NN NN O
of NN NN O
L NN NN O
- NN NN O
dopa NN NN O
on NN NN O
blood NN NN O
and NN NN O
brain NN NN O
ammonia NN NN O
and NN NN O
the NN NN O
ammonia NN NN O
coma NN NN B-Disease
was NN NN O
not NN NN O
prevented NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
reduction NN NN O
in NN NN O
blood NN NN O
and NN NN O
brain NN NN O
ammonia NN NN O
and NN NN O
the NN NN O
prevention NN NN O
of NN NN O
ammonia NN NN O
coma NN NN B-Disease
after NN NN O
L NN NN O
- NN NN O
dopa NN NN O
, NN NN O
can NN NN O
be NN NN O
accounted NN NN O
for NN NN O
by NN NN O
the NN NN O
peripheral NN NN O
effect NN NN O
of NN NN O
dopamine NN NN O
on NN NN O
renal NN NN O
function NN NN O
rather NN NN O
than NN NN O
its NN NN O
central NN NN O
action NN NN O
. NN NN O
   
These NN NN O
results NN NN O
provide NN NN O
a NN NN O
reasonable NN NN O
explanation NN NN O
for NN NN O
the NN NN O
beneficial NN NN O
effects NN NN O
observed NN NN O
in NN NN O
some NN NN O
encephalopathic NN NN B-Disease
patients NN NN O
receiving NN NN O
L NN NN O
- NN NN O
dopa NN NN O
. NN NN O
   
Etoposide NN NN O
- NN NN O
related NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
The NN NN O
occurrence NN NN O
of NN NN O
a NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
is NN NN O
reported NN NN O
after NN NN O
chemotherapy NN NN O
containing NN NN O
etoposide NN NN O
, NN NN O
in NN NN O
a NN NN O
man NN NN O
with NN NN O
no NN NN O
risk NN NN O
factors NN NN O
for NN NN O
coronary NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Possible NN NN O
causal NN NN O
mechanisms NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Halogenated NN NN O
anesthetics NN NN O
form NN NN O
liver NN NN O
adducts NN NN O
and NN NN O
antigens NN NN O
that NN NN O
cross NN NN O
- NN NN O
react NN NN O
with NN NN O
halothane NN NN O
- NN NN O
induced NN NN O
antibodies NN NN O
. NN NN O
   
Two NN NN O
halogenated NN NN O
anesthetics NN NN O
, NN NN O
enflurane NN NN O
and NN NN O
isoflurane NN NN O
, NN NN O
have NN NN O
been NN NN O
associated NN NN O
with NN NN O
an NN NN O
allergic NN NN O
- NN NN O
type NN NN O
hepatic NN NN B-Disease
injury NN NN I-Disease
both NN NN O
alone NN NN O
and NN NN O
following NN NN O
previous NN NN O
exposure NN NN O
to NN NN O
halothane NN NN O
. NN NN O
   
Halothane NN NN O
hepatitis NN NN B-Disease
appears NN NN O
to NN NN O
involve NN NN O
an NN NN O
aberrant NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
An NN NN O
antibody NN NN O
response NN NN O
to NN NN O
a NN NN O
protein NN NN O
- NN NN O
bound NN NN O
biotransformation NN NN O
product NN NN O
( NN NN O
trifluoroacetyl NN NN O
adduct NN NN O
) NN NN O
has NN NN O
been NN NN O
detected NN NN O
on NN NN O
halothane NN NN O
hepatitis NN NN B-Disease
patients NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
performed NN NN O
to NN NN O
determine NN NN O
cross NN NN O
- NN NN O
reactivity NN NN O
between NN NN O
enflurane NN NN O
and NN NN O
isoflurane NN NN O
with NN NN O
the NN NN O
hypersensitivity NN NN B-Disease
induced NN NN O
by NN NN O
halothane NN NN O
. NN NN O
   
The NN NN O
subcellular NN NN O
and NN NN O
lobular NN NN O
production NN NN O
of NN NN O
hepatic NN NN O
neoantigens NN NN O
recognized NN NN O
by NN NN O
halothane NN NN O
- NN NN O
induced NN NN O
antibodies NN NN O
following NN NN O
enflurane NN NN O
and NN NN O
isoflurane NN NN O
, NN NN O
and NN NN O
the NN NN O
biochemical NN NN O
nature NN NN O
of NN NN O
these NN NN O
neoantigens NN NN O
was NN NN O
investigated NN NN O
in NN NN O
two NN NN O
animal NN NN O
models NN NN O
. NN NN O
   
Enflurane NN NN O
administration NN NN O
resulted NN NN O
in NN NN O
neoantigens NN NN O
detected NN NN O
in NN NN O
both NN NN O
the NN NN O
microsomal NN NN O
and NN NN O
cytosolic NN NN O
fraction NN NN O
of NN NN O
liver NN NN O
homogenates NN NN O
and NN NN O
in NN NN O
the NN NN O
centrilobular NN NN O
region NN NN O
of NN NN O
the NN NN O
liver NN NN O
. NN NN O
   
In NN NN O
the NN NN O
same NN NN O
liver NN NN O
, NN NN O
biochemical NN NN O
analysis NN NN O
detected NN NN O
fluorinated NN NN O
liver NN NN O
adducts NN NN O
that NN NN O
were NN NN O
up NN NN O
to NN NN O
20 NN NN O
- NN NN O
fold NN NN O
greater NN NN O
in NN NN O
guinea NN NN O
pigs NN NN O
than NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
This NN NN O
supports NN NN O
and NN NN O
extends NN NN O
previous NN NN O
evidence NN NN O
for NN NN O
a NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
enflurane NN NN O
and NN NN O
/ NN NN O
or NN NN O
isoflurane NN NN O
could NN NN O
produce NN NN O
a NN NN O
hypersensitivity NN NN B-Disease
condition NN NN O
similar NN NN O
to NN NN O
that NN NN O
of NN NN O
halothane NN NN O
hepatitis NN NN B-Disease
either NN NN O
alone NN NN O
or NN NN O
subsequent NN NN O
to NN NN O
halothane NN NN O
administration NN NN O
. NN NN O
   
The NN NN O
guinea NN NN O
pig NN NN O
would NN NN O
appear NN NN O
to NN NN O
be NN NN O
a NN NN O
useful NN NN O
model NN NN O
for NN NN O
further NN NN O
investigations NN NN O
of NN NN O
the NN NN O
immunological NN NN O
response NN NN O
to NN NN O
these NN NN O
antigens NN NN O
. NN NN O
   
Cholinergic NN NN O
toxicity NN NN B-Disease
resulting NN NN O
from NN NN O
ocular NN NN O
instillation NN NN O
of NN NN O
echothiophate NN NN O
iodide NN NN O
eye NN NN O
drops NN NN O
. NN NN O
   
A NN NN O
patient NN NN O
developed NN NN O
a NN NN O
severe NN NN O
cholinergic NN NN O
syndrome NN NN O
from NN NN O
the NN NN O
use NN NN O
of NN NN O
echothiophate NN NN O
iodide NN NN O
ophthalmic NN NN O
drops NN NN O
, NN NN O
presented NN NN O
with NN NN O
profound NN NN O
muscle NN NN B-Disease
weakness NN NN I-Disease
and NN NN O
was NN NN O
initially NN NN O
given NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
myasthenia NN NN B-Disease
gravis NN NN I-Disease
. NN NN O
   
Red NN NN O
blood NN NN O
cell NN NN O
and NN NN O
serum NN NN O
cholinesterase NN NN O
levels NN NN O
were NN NN O
severely NN NN O
depressed NN NN O
and NN NN O
symptoms NN NN O
resolved NN NN O
spontaneously NN NN O
following NN NN O
discontinuation NN NN O
of NN NN O
the NN NN O
eye NN NN O
drops NN NN O
. NN NN O
   
Seizure NN NN B-Disease
after NN NN O
flumazenil NN NN O
administration NN NN O
in NN NN O
a NN NN O
pediatric NN NN O
patient NN NN O
. NN NN O
   
Flumazenil NN NN O
is NN NN O
a NN NN O
benzodiazepine NN NN O
receptor NN NN O
antagonist NN NN O
used NN NN O
to NN NN O
reverse NN NN O
sedation NN NN O
and NN NN O
respiratory NN NN B-Disease
depression NN NN I-Disease
induced NN NN O
by NN NN O
benzodiazepines NN NN O
. NN NN O
   
Seizures NN NN B-Disease
and NN NN O
cardiac NN NN B-Disease
arrhythmias NN NN I-Disease
have NN NN O
complicated NN NN O
its NN NN O
use NN NN O
in NN NN O
adult NN NN O
patients NN NN O
. NN NN O
   
Overdose NN NN B-Disease
patients NN NN O
who NN NN O
have NN NN O
coingested NN NN O
tricyclic NN NN O
antidepressants NN NN O
have NN NN O
a NN NN O
higher NN NN O
risk NN NN O
of NN NN O
these NN NN O
complications NN NN O
. NN NN O
   
Little NN NN O
information NN NN O
exists NN NN O
concerning NN NN O
adverse NN NN O
effects NN NN O
of NN NN O
flumazenil NN NN O
in NN NN O
children NN NN O
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
a NN NN O
generalized NN NN O
tonic NN NN B-Disease
- NN NN I-Disease
clonic NN NN I-Disease
seizure NN NN I-Disease
in NN NN O
a NN NN O
pediatric NN NN O
patient NN NN O
following NN NN O
the NN NN O
administration NN NN O
of NN NN O
flumazenil NN NN O
. NN NN O
   
Phase NN NN O
I NN NN O
trial NN NN O
of NN NN O
13 NN NN O
- NN NN O
cis NN NN O
- NN NN O
retinoic NN NN O
acid NN NN O
in NN NN O
children NN NN O
with NN NN O
neuroblastoma NN NN B-Disease
following NN NN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
Treatment NN NN O
of NN NN O
neuroblastoma NN NN B-Disease
cell NN NN O
lines NN NN O
with NN NN O
13 NN NN O
- NN NN O
cis NN NN O
- NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
cis NN NN O
- NN NN O
RA NN NN O
) NN NN O
can NN NN O
cause NN NN O
sustained NN NN O
inhibition NN NN O
of NN NN O
proliferation NN NN O
. NN NN O
   
Since NN NN O
cis NN NN O
- NN NN O
RA NN NN O
has NN NN O
demonstrated NN NN O
clinical NN NN O
responses NN NN O
in NN NN O
neuroblastoma NN NN B-Disease
patients NN NN O
, NN NN O
it NN NN O
may NN NN O
be NN NN O
effective NN NN O
in NN NN O
preventing NN NN O
relapse NN NN O
after NN NN O
cytotoxic NN NN O
therapy NN NN O
. NN NN O
   
This NN NN O
phase NN NN O
I NN NN O
trial NN NN O
was NN NN O
designed NN NN O
to NN NN O
determine NN NN O
the NN NN O
maximal NN NN O
- NN NN O
tolerated NN NN O
dosage NN NN O
( NN NN O
MTD NN NN O
) NN NN O
, NN NN O
toxicities NN NN B-Disease
, NN NN O
and NN NN O
pharmacokinetics NN NN O
of NN NN O
cis NN NN O
- NN NN O
RA NN NN O
administered NN NN O
on NN NN O
an NN NN O
intermittent NN NN O
schedule NN NN O
in NN NN O
children NN NN O
with NN NN O
neuroblastoma NN NN B-Disease
following NN NN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
( NN NN O
BMT NN NN O
) NN NN O
. NN NN O
   
PATIENTS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
Fifty NN NN O
- NN NN O
one NN NN O
assessable NN NN O
patients NN NN O
, NN NN O
2 NN NN O
to NN NN O
12 NN NN O
years NN NN O
of NN NN O
age NN NN O
, NN NN O
were NN NN O
treated NN NN O
with NN NN O
oral NN NN O
cis NN NN O
- NN NN O
RA NN NN O
administered NN NN O
in NN NN O
two NN NN O
equally NN NN O
divided NN NN O
doses NN NN O
daily NN NN O
for NN NN O
2 NN NN O
weeks NN NN O
, NN NN O
followed NN NN O
by NN NN O
a NN NN O
2 NN NN O
- NN NN O
week NN NN O
rest NN NN O
period NN NN O
, NN NN O
for NN NN O
up NN NN O
to NN NN O
12 NN NN O
courses NN NN O
. NN NN O
   
The NN NN O
dose NN NN O
was NN NN O
escalated NN NN O
from NN NN O
100 NN NN O
to NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d NN NN O
until NN NN O
dose NN NN O
- NN NN O
limiting NN NN O
toxicity NN NN B-Disease
( NN NN O
DLT NN NN O
) NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
A NN NN O
single NN NN O
intrapatient NN NN O
dose NN NN O
escalation NN NN O
was NN NN O
permitted NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
MTD NN NN O
of NN NN O
cis NN NN O
- NN NN O
RA NN NN O
was NN NN O
160 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d NN NN O
. NN NN O
   
Dose NN NN O
- NN NN O
limiting NN NN O
toxicities NN NN B-Disease
in NN NN O
six NN NN O
of NN NN O
nine NN NN O
patients NN NN O
at NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d NN NN O
included NN NN O
hypercalcemia NN NN B-Disease
( NN NN O
n NN NN O
= NN NN O
3 NN NN O
) NN NN O
, NN NN O
rash NN NN B-Disease
( NN NN O
n NN NN O
= NN NN O
2 NN NN O
) NN NN O
, NN NN O
and NN NN O
anemia NN NN B-Disease
/ NN NN O
thrombocytopenia NN NN B-Disease
/ NN NN O
emesis NN NN B-Disease
/ NN NN O
rash NN NN B-Disease
( NN NN O
n NN NN O
= NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
All NN NN O
toxicities NN NN B-Disease
resolved NN NN O
after NN NN O
cis NN NN O
- NN NN O
RA NN NN O
was NN NN O
discontinued NN NN O
. NN NN O
   
Three NN NN O
complete NN NN O
responses NN NN O
were NN NN O
observed NN NN O
in NN NN O
marrow NN NN O
metastases NN NN B-Disease
. NN NN O
   
Serum NN NN O
levels NN NN O
of NN NN O
7 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
0 NN NN O
mumol NN NN O
/ NN NN O
L NN NN O
( NN NN O
peak NN NN O
) NN NN O
and NN NN O
4 NN NN O
. NN NN O
0 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
8 NN NN O
mumol NN NN O
/ NN NN O
L NN NN O
( NN NN O
trough NN NN O
) NN NN O
at NN NN O
the NN NN O
MTD NN NN O
were NN NN O
maintained NN NN O
during NN NN O
14 NN NN O
days NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
DLT NN NN O
correlated NN NN O
with NN NN O
serum NN NN O
levels NN NN O
> NN NN O
or NN NN O
= NN NN O
10 NN NN O
mumol NN NN O
/ NN NN O
L NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
MTD NN NN O
of NN NN O
cis NN NN O
- NN NN O
RA NN NN O
given NN NN O
on NN NN O
this NN NN O
intermittent NN NN O
schedule NN NN O
was NN NN O
160 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d NN NN O
. NN NN O
   
Serum NN NN O
levels NN NN O
known NN NN O
to NN NN O
be NN NN O
effective NN NN O
against NN NN O
neuroblastoma NN NN B-Disease
in NN NN O
vitro NN NN O
were NN NN O
achieved NN NN O
at NN NN O
this NN NN O
dose NN NN O
. NN NN O
   
The NN NN O
DLT NN NN O
included NN NN O
hypercalcemia NN NN B-Disease
, NN NN O
and NN NN O
may NN NN O
be NN NN O
predicted NN NN O
by NN NN O
serum NN NN O
cis NN NN O
- NN NN O
RA NN NN O
levels NN NN O
. NN NN O
   
Monitoring NN NN O
of NN NN O
serum NN NN O
calcium NN NN O
and NN NN O
cis NN NN O
- NN NN O
RA NN NN O
levels NN NN O
is NN NN O
indicated NN NN O
in NN NN O
future NN NN O
trials NN NN O
. NN NN O
   
Time NN NN O
dependence NN NN O
of NN NN O
plasma NN NN O
malondialdehyde NN NN O
, NN NN O
oxypurines NN NN O
, NN NN O
and NN NN O
nucleosides NN NN O
during NN NN O
incomplete NN NN O
cerebral NN NN B-Disease
ischemia NN NN I-Disease
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Incomplete NN NN O
cerebral NN NN B-Disease
ischemia NN NN I-Disease
( NN NN O
30 NN NN O
min NN NN O
) NN NN O
was NN NN O
induced NN NN O
in NN NN O
the NN NN O
rat NN NN O
by NN NN O
bilaterally NN NN O
clamping NN NN O
the NN NN O
common NN NN O
carotid NN NN O
arteries NN NN O
. NN NN O
   
Peripheral NN NN O
venous NN NN O
blood NN NN O
samples NN NN O
were NN NN O
withdrawn NN NN O
from NN NN O
the NN NN O
femoral NN NN O
vein NN NN O
four NN NN O
times NN NN O
( NN NN O
once NN NN O
every NN NN O
5 NN NN O
min NN NN O
) NN NN O
before NN NN O
ischemia NN NN B-Disease
( NN NN O
0 NN NN O
time NN NN O
) NN NN O
and NN NN O
5 NN NN O
, NN NN O
15 NN NN O
, NN NN O
and NN NN O
30 NN NN O
min NN NN O
after NN NN O
ischemia NN NN B-Disease
. NN NN O
   
Plasma NN NN O
extracts NN NN O
were NN NN O
analyzed NN NN O
by NN NN O
a NN NN O
highly NN NN O
sensitive NN NN O
high NN NN O
- NN NN O
performance NN NN O
liquid NN NN O
chromatographic NN NN O
method NN NN O
for NN NN O
the NN NN O
direct NN NN O
determination NN NN O
of NN NN O
malondialdehyde NN NN O
, NN NN O
oxypurines NN NN O
, NN NN O
and NN NN O
nucleosides NN NN O
. NN NN O
   
During NN NN O
ischemia NN NN B-Disease
, NN NN O
a NN NN O
time NN NN O
- NN NN O
dependent NN NN O
increase NN NN O
of NN NN O
plasma NN NN O
oxypurines NN NN O
and NN NN O
nucleosides NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
Plasma NN NN O
malondialdehyde NN NN O
, NN NN O
which NN NN O
was NN NN O
present NN NN O
in NN NN O
minimal NN NN O
amount NN NN O
at NN NN O
zero NN NN O
time NN NN O
( NN NN O
0 NN NN O
. NN NN O
058 NN NN O
mumol NN NN O
/ NN NN O
liter NN NN O
plasma NN NN O
; NN NN O
SD NN NN O
0 NN NN O
. NN NN O
015 NN NN O
) NN NN O
, NN NN O
increased NN NN O
after NN NN O
5 NN NN O
min NN NN O
of NN NN O
ischemia NN NN B-Disease
, NN NN O
resulting NN NN O
in NN NN O
a NN NN O
fivefold NN NN O
increase NN NN O
after NN NN O
30 NN NN O
min NN NN O
of NN NN O
carotid NN NN O
occlusion NN NN O
( NN NN O
0 NN NN O
. NN NN O
298 NN NN O
mumol NN NN O
/ NN NN O
liter NN NN O
plasma NN NN O
; NN NN O
SD NN NN O
0 NN NN O
. NN NN O
078 NN NN O
) NN NN O
. NN NN O
   
Increased NN NN O
plasma NN NN O
malondialdehyde NN NN O
was NN NN O
also NN NN O
recorded NN NN O
in NN NN O
two NN NN O
other NN NN O
groups NN NN O
of NN NN O
animals NN NN O
subjected NN NN O
to NN NN O
the NN NN O
same NN NN O
experimental NN NN O
model NN NN O
, NN NN O
one NN NN O
receiving NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
b NN NN O
. NN NN O
w NN NN O
. NN NN O
of NN NN O
the NN NN O
cyclooxygenase NN NN O
inhibitor NN NN O
acetylsalicylate NN NN O
intravenously NN NN O
immediately NN NN O
before NN NN O
ischemia NN NN B-Disease
, NN NN O
the NN NN O
other NN NN O
receiving NN NN O
650 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
b NN NN O
. NN NN O
w NN NN O
. NN NN O
of NN NN O
the NN NN O
hypotensive NN NN B-Disease
drug NN NN O
nitroprusside NN NN O
at NN NN O
a NN NN O
flow NN NN O
rate NN NN O
of NN NN O
103 NN NN O
microliters NN NN O
/ NN NN O
min NN NN O
intravenously NN NN O
during NN NN O
ischemia NN NN B-Disease
, NN NN O
although NN NN O
in NN NN O
this NN NN O
latter NN NN O
group NN NN O
malondialdehyde NN NN O
was NN NN O
significantly NN NN O
higher NN NN O
. NN NN O
   
The NN NN O
present NN NN O
data NN NN O
indicate NN NN O
that NN NN O
the NN NN O
determination NN NN O
of NN NN O
malondialdehyde NN NN O
, NN NN O
oxypurines NN NN O
, NN NN O
and NN NN O
nucleosides NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
, NN NN O
may NN NN O
be NN NN O
used NN NN O
to NN NN O
monitor NN NN O
the NN NN O
metabolic NN NN O
alterations NN NN O
of NN NN O
tissues NN NN O
occurring NN NN O
during NN NN O
ischemic NN NN B-Disease
phenomena NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Acute NN NN O
renal NN NN B-Disease
toxicity NN NN I-Disease
of NN NN O
doxorubicin NN NN O
( NN NN O
adriamycin NN NN O
) NN NN O
- NN NN O
loaded NN NN O
cyanoacrylate NN NN O
nanoparticles NN NN O
. NN NN O
   
Acute NN NN O
doxorubicin NN NN O
- NN NN O
loaded NN NN O
nanoparticle NN NN O
( NN NN O
DXNP NN NN O
) NN NN O
renal NN NN B-Disease
toxicity NN NN I-Disease
was NN NN O
explored NN NN O
in NN NN O
both NN NN O
normal NN NN O
rats NN NN O
and NN NN O
rats NN NN O
with NN NN O
experimental NN NN O
glomerulonephritis NN NN B-Disease
. NN NN O
   
In NN NN O
normal NN NN O
rats NN NN O
, NN NN O
2 NN NN O
/ NN NN O
6 NN NN O
rats NN NN O
given NN NN O
free NN NN O
doxorubicin NN NN O
( NN NN O
DX NN NN O
) NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
died NN NN O
within NN NN O
one NN NN O
week NN NN O
, NN NN O
whereas NN NN O
all NN NN O
control NN NN O
animals NN NN O
and NN NN O
all NN NN O
rats NN NN O
having NN NN O
received NN NN O
free NN NN O
NP NN NN O
or NN NN O
DXNP NN NN O
survived NN NN O
. NN NN O
   
A NN NN O
3 NN NN O
times NN NN O
higher NN NN O
proteinuria NN NN B-Disease
appeared NN NN O
in NN NN O
animals NN NN O
treated NN NN O
with NN NN O
DXNP NN NN O
than NN NN O
in NN NN O
those NN NN O
treated NN NN O
with NN NN O
DX NN NN O
. NN NN O
   
Free NN NN O
NP NN NN O
did NN NN O
not NN NN O
provoke NN NN O
any NN NN O
proteinuria NN NN B-Disease
. NN NN O
   
Two NN NN O
hr NN NN O
post NN NN O
- NN NN O
injection NN NN O
, NN NN O
DXNP NN NN O
was NN NN O
2 NN NN O
. NN NN O
7 NN NN O
times NN NN O
more NN NN O
concentrated NN NN O
in NN NN O
kidneys NN NN O
than NN NN O
free NN NN O
DX NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
025 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
rats NN NN O
with NN NN O
immune NN NN O
experimental NN NN O
glomerulonephritis NN NN B-Disease
, NN NN O
5 NN NN O
/ NN NN O
6 NN NN O
rats NN NN O
given NN NN O
DX NN NN O
died NN NN O
within NN NN O
7 NN NN O
days NN NN O
, NN NN O
in NN NN O
contrast NN NN O
to NN NN O
animals NN NN O
treated NN NN O
by NN NN O
DXNP NN NN O
, NN NN O
NP NN NN O
, NN NN O
or NN NN O
untreated NN NN O
, NN NN O
which NN NN O
all NN NN O
survived NN NN O
. NN NN O
   
Proteinuria NN NN B-Disease
appeared NN NN O
in NN NN O
all NN NN O
series NN NN O
, NN NN O
but NN NN O
was NN NN O
2 NN NN O
- NN NN O
5 NN NN O
times NN NN O
more NN NN O
intense NN NN O
( NN NN O
p NN NN O
> NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
and NN NN O
prolonged NN NN O
after NN NN O
doxorubicin NN NN O
treatment NN NN O
( NN NN O
400 NN NN O
- NN NN O
700 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
, NN NN O
without NN NN O
significant NN NN O
difference NN NN O
between NN NN O
DXNP NN NN O
and NN NN O
DX NN NN O
. NN NN O
   
Rats NN NN O
treated NN NN O
by NN NN O
unloaded NN NN O
NP NN NN O
behaved NN NN O
as NN NN O
controls NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
, NN NN O
in NN NN O
these NN NN O
experimental NN NN O
conditions NN NN O
, NN NN O
DXNP NN NN O
killed NN NN O
less NN NN O
animals NN NN O
than NN NN O
free NN NN O
DX NN NN O
, NN NN O
despite NN NN O
of NN NN O
an NN NN O
enhanced NN NN O
renal NN NN B-Disease
toxicity NN NN I-Disease
of NN NN O
the NN NN O
former NN NN O
. NN NN O
   
Both NN NN O
effects NN NN O
( NN NN O
better NN NN O
survival NN NN O
and NN NN O
nephrosis NN NN B-Disease
) NN NN O
are NN NN O
most NN NN O
probably NN NN O
related NN NN O
to NN NN O
an NN NN O
enhanced NN NN O
capture NN NN O
of NN NN O
DXNP NN NN O
by NN NN O
cells NN NN O
of NN NN O
the NN NN O
mononuclear NN NN O
phagocyte NN NN O
system NN NN O
, NN NN O
including NN NN O
mesangial NN NN O
cells NN NN O
. NN NN O
   
Prostaglandin NN NN O
E2 NN NN O
- NN NN O
induced NN NN O
bladder NN NN B-Disease
hyperactivity NN NN I-Disease
in NN NN O
normal NN NN O
, NN NN O
conscious NN NN O
rats NN NN O
: NN NN O
involvement NN NN O
of NN NN O
tachykinins NN NN O
? NN NN O
   
In NN NN O
normal NN NN O
conscious NN NN O
rats NN NN O
investigated NN NN O
by NN NN O
continuous NN NN O
cystometry NN NN O
, NN NN O
intravesically NN NN O
instilled NN NN O
prostaglandin NN NN O
( NN NN O
PG NN NN O
) NN NN O
E2 NN NN O
facilitated NN NN O
micturition NN NN O
and NN NN O
increased NN NN O
basal NN NN O
intravesical NN NN O
pressure NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
was NN NN O
attenuated NN NN O
by NN NN O
both NN NN O
the NN NN O
NK1 NN NN O
receptor NN NN O
selective NN NN O
antagonist NN NN O
RP NN NN O
67 NN NN O
, NN NN O
580 NN NN O
and NN NN O
the NN NN O
NK2 NN NN O
receptor NN NN O
selective NN NN O
antagonist NN NN O
SR NN NN O
48 NN NN O
, NN NN O
968 NN NN O
, NN NN O
given NN NN O
intra NN NN O
- NN NN O
arterially NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
it NN NN O
was NN NN O
mediated NN NN O
by NN NN O
stimulation NN NN O
of NN NN O
both NN NN O
NK1 NN NN O
and NN NN O
NK2 NN NN O
receptors NN NN O
. NN NN O
   
Intra NN NN O
- NN NN O
arterially NN NN O
given NN NN O
PGE2 NN NN O
produced NN NN O
a NN NN O
distinct NN NN O
increase NN NN O
in NN NN O
bladder NN NN O
pressure NN NN O
before NN NN O
initiating NN NN O
a NN NN O
micturition NN NN O
reflex NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
PG NN NN O
had NN NN O
a NN NN O
direct NN NN O
contractant NN NN O
effect NN NN O
on NN NN O
the NN NN O
detrusor NN NN O
smooth NN NN O
muscle NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
intra NN NN O
- NN NN O
arterial NN NN O
PGE2 NN NN O
could NN NN O
not NN NN O
be NN NN O
blocked NN NN O
by NN NN O
intra NN NN O
- NN NN O
arterial NN NN O
RP NN NN O
67 NN NN O
, NN NN O
580 NN NN O
or NN NN O
SR NN NN O
48 NN NN O
, NN NN O
968 NN NN O
, NN NN O
which NN NN O
opens NN NN O
the NN NN O
possibility NN NN O
that NN NN O
the NN NN O
micturition NN NN O
reflex NN NN O
elicited NN NN O
by NN NN O
intra NN NN O
- NN NN O
arterial NN NN O
PGE2 NN NN O
was NN NN O
mediated NN NN O
by NN NN O
pathways NN NN O
other NN NN O
than NN NN O
the NN NN O
reflex NN NN O
initiated NN NN O
when NN NN O
the NN NN O
PG NN NN O
was NN NN O
given NN NN O
intravesically NN NN O
. NN NN O
   
The NN NN O
present NN NN O
results NN NN O
thus NN NN O
suggest NN NN O
that NN NN O
intra NN NN O
- NN NN O
arterial NN NN O
PGE2 NN NN O
, NN NN O
given NN NN O
near NN NN O
the NN NN O
bladder NN NN O
, NN NN O
may NN NN O
initiate NN NN O
micturition NN NN O
in NN NN O
the NN NN O
normal NN NN O
rat NN NN O
chiefly NN NN O
by NN NN O
directly NN NN O
contracting NN NN O
the NN NN O
smooth NN NN O
muscle NN NN O
of NN NN O
the NN NN O
detrusor NN NN O
. NN NN O
   
However NN NN O
, NN NN O
when NN NN O
given NN NN O
intravesically NN NN O
, NN NN O
PGE2 NN NN O
may NN NN O
stimulate NN NN O
micturition NN NN O
by NN NN O
releasing NN NN O
tachykinins NN NN O
from NN NN O
nerves NN NN O
in NN NN O
and NN NN O
/ NN NN O
or NN NN O
immediately NN NN O
below NN NN O
the NN NN O
urothelium NN NN O
. NN NN O
   
These NN NN O
tachykinins NN NN O
, NN NN O
in NN NN O
turn NN NN O
, NN NN O
initiate NN NN O
a NN NN O
micturition NN NN O
reflex NN NN O
by NN NN O
stimulating NN NN O
NK1 NN NN O
and NN NN O
NK2 NN NN O
receptors NN NN O
. NN NN O
   
Prostanoids NN NN O
may NN NN O
, NN NN O
via NN NN O
release NN NN O
of NN NN O
tachykinins NN NN O
, NN NN O
contribute NN NN O
to NN NN O
both NN NN O
urge NN NN O
and NN NN O
bladder NN NN B-Disease
hyperactivity NN NN I-Disease
seen NN NN O
in NN NN O
inflammatory NN NN O
conditions NN NN O
of NN NN O
the NN NN O
lower NN NN O
urinary NN NN O
tract NN NN O
. NN NN O
   
Refractory NN NN O
cardiogenic NN NN B-Disease
shock NN NN I-Disease
and NN NN O
complete NN NN O
heart NN NN B-Disease
block NN NN I-Disease
after NN NN O
verapamil NN NN O
SR NN NN O
and NN NN O
metoprolol NN NN O
treatment NN NN O
. NN NN O
   
A NN NN O
case NN NN O
report NN NN O
. NN NN O
   
A NN NN O
seventy NN NN O
- NN NN O
eight NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
presented NN NN O
with NN NN O
complete NN NN O
heart NN NN B-Disease
block NN NN I-Disease
and NN NN O
refractory NN NN O
hypotension NN NN B-Disease
two NN NN O
days NN NN O
after NN NN O
a NN NN O
therapeutic NN NN O
dose NN NN O
of NN NN O
sustained NN NN O
- NN NN O
release NN NN O
verapamil NN NN O
with NN NN O
concomitant NN NN O
use NN NN O
of NN NN O
metoprolol NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
continued NN NN O
to NN NN O
remain NN NN O
hypotensive NN NN B-Disease
with NN NN O
complete NN NN O
heart NN NN B-Disease
block NN NN I-Disease
, NN NN O
even NN NN O
with NN NN O
multiple NN NN O
uses NN NN O
of NN NN O
intravenous NN NN O
atropine NN NN O
as NN NN O
well NN NN O
as NN NN O
high NN NN O
doses NN NN O
of NN NN O
pressor NN NN O
agents NN NN O
such NN NN O
as NN NN O
dopamine NN NN O
and NN NN O
dobutamine NN NN O
. NN NN O
   
However NN NN O
, NN NN O
shortly NN NN O
after NN NN O
the NN NN O
use NN NN O
of NN NN O
intravenous NN NN O
calcium NN NN O
chloride NN NN O
, NN NN O
the NN NN O
refractory NN NN O
hypotension NN NN B-Disease
and NN NN O
complete NN NN O
heart NN NN B-Disease
block NN NN I-Disease
resolved NN NN O
. NN NN O
   
Protective NN NN O
effect NN NN O
of NN NN O
misoprostol NN NN O
on NN NN O
indomethacin NN NN O
induced NN NN O
renal NN NN B-Disease
dysfunction NN NN I-Disease
in NN NN O
elderly NN NN O
patients NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
evaluate NN NN O
the NN NN O
possible NN NN O
protective NN NN O
effects NN NN O
of NN NN O
misoprostol NN NN O
on NN NN O
renal NN NN O
function NN NN O
in NN NN O
hospitalized NN NN O
elderly NN NN O
patients NN NN O
treated NN NN O
with NN NN O
indomethacin NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Forty NN NN O
- NN NN O
five NN NN O
hospitalized NN NN O
elderly NN NN O
patients NN NN O
( NN NN O
> NN NN O
65 NN NN O
years NN NN O
old NN NN O
) NN NN O
who NN NN O
required NN NN O
therapy NN NN O
with NN NN O
nonsteroidal NN NN O
antiinflammatory NN NN O
drugs NN NN O
( NN NN O
NSAID NN NN O
) NN NN O
were NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
receive NN NN O
either NN NN O
indomethacin NN NN O
, NN NN O
150 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
( NN NN O
Group NN NN O
A NN NN O
) NN NN O
, NN NN O
or NN NN O
indomethacin NN NN O
150 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
plus NN NN O
misoprostol NN NN O
at NN NN O
0 NN NN O
. NN NN O
6 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
( NN NN O
Group NN NN O
B NN NN O
) NN NN O
. NN NN O
   
Laboratory NN NN O
variables NN NN O
of NN NN O
renal NN NN O
function NN NN O
[ NN NN O
serum NN NN O
creatinine NN NN O
, NN NN O
blood NN NN O
urea NN NN O
nitrogen NN NN O
( NN NN O
BUN NN NN O
) NN NN O
and NN NN O
electrolytes NN NN O
] NN NN O
were NN NN O
evaluated NN NN O
before NN NN O
initiation NN NN O
of NN NN O
therapy NN NN O
and NN NN O
every NN NN O
2 NN NN O
days NN NN O
, NN NN O
until NN NN O
termination NN NN O
of NN NN O
the NN NN O
study NN NN O
( NN NN O
a NN NN O
period NN NN O
of NN NN O
at NN NN O
least NN NN O
6 NN NN O
days NN NN O
) NN NN O
. NN NN O
   
Response NN NN O
to NN NN O
treatment NN NN O
was NN NN O
estimated NN NN O
by NN NN O
the NN NN O
visual NN NN O
analog NN NN O
scale NN NN O
for NN NN O
severity NN NN O
of NN NN O
pain NN NN B-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
Forty NN NN O
- NN NN O
two NN NN O
patients NN NN O
completed NN NN O
the NN NN O
study NN NN O
, NN NN O
22 NN NN O
in NN NN O
Group NN NN O
A NN NN O
and NN NN O
20 NN NN O
in NN NN O
Group NN NN O
B NN NN O
. NN NN O
   
BUN NN NN O
and NN NN O
creatinine NN NN O
increased NN NN O
by NN NN O
> NN NN O
50 NN NN O
% NN NN O
of NN NN O
baseline NN NN O
levels NN NN O
in NN NN O
54 NN NN O
and NN NN O
45 NN NN O
% NN NN O
of NN NN O
Group NN NN O
A NN NN O
patients NN NN O
, NN NN O
respectively NN NN O
, NN NN O
compared NN NN O
to NN NN O
only NN NN O
20 NN NN O
and NN NN O
10 NN NN O
% NN NN O
of NN NN O
Group NN NN O
B NN NN O
patients NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Potassium NN NN O
( NN NN O
K NN NN O
) NN NN O
increment NN NN O
of NN NN O
0 NN NN O
. NN NN O
6 NN NN O
mEq NN NN O
/ NN NN O
l NN NN O
or NN NN O
more NN NN O
was NN NN O
observed NN NN O
in NN NN O
50 NN NN O
% NN NN O
of NN NN O
Group NN NN O
A NN NN O
, NN NN O
but NN NN O
in NN NN O
only NN NN O
15 NN NN O
% NN NN O
of NN NN O
Group NN NN O
B NN NN O
patients NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
increments NN NN O
in NN NN O
BUN NN NN O
, NN NN O
creatinine NN NN O
, NN NN O
and NN NN O
K NN NN O
were NN NN O
reduced NN NN O
by NN NN O
63 NN NN O
, NN NN O
80 NN NN O
, NN NN O
and NN NN O
42 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
, NN NN O
in NN NN O
Group NN NN O
B NN NN O
patients NN NN O
compared NN NN O
to NN NN O
Group NN NN O
A NN NN O
. NN NN O
Response NN NN O
to NN NN O
treatment NN NN O
did NN NN O
not NN NN O
differ NN NN O
significantly NN NN O
between NN NN O
the NN NN O
2 NN NN O
groups NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Hospitalized NN NN O
elderly NN NN O
patients NN NN O
are NN NN O
at NN NN O
risk NN NN O
for NN NN O
developing NN NN O
indomethacin NN NN O
related NN NN O
renal NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Addition NN NN O
of NN NN O
misoprostol NN NN O
can NN NN O
minimize NN NN O
this NN NN O
renal NN NN B-Disease
impairment NN NN I-Disease
without NN NN O
affecting NN NN O
pain NN NN B-Disease
control NN NN O
. NN NN O
   
Cognitive NN NN B-Disease
deterioration NN NN I-Disease
from NN NN O
long NN NN O
- NN NN O
term NN NN O
abuse NN NN O
of NN NN O
dextromethorphan NN NN O
: NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
Dextromethorphan NN NN O
( NN NN O
DM NN NN O
) NN NN O
, NN NN O
the NN NN O
dextrorotatory NN NN O
isomer NN NN O
of NN NN O
3 NN NN O
- NN NN O
hydroxy NN NN O
- NN NN O
N NN NN O
- NN NN O
methylmorphinan NN NN O
, NN NN O
is NN NN O
the NN NN O
main NN NN O
ingredient NN NN O
in NN NN O
a NN NN O
number NN NN O
of NN NN O
widely NN NN O
available NN NN O
, NN NN O
over NN NN O
- NN NN O
the NN NN O
- NN NN O
counter NN NN O
antitussives NN NN O
. NN NN O
   
Initial NN NN O
studies NN NN O
( NN NN O
Bornstein NN NN O
1968 NN NN O
) NN NN O
showed NN NN O
that NN NN O
it NN NN O
possessed NN NN O
no NN NN O
respiratory NN NN O
suppressant NN NN O
effects NN NN O
and NN NN O
no NN NN O
addiction NN NN O
liability NN NN O
. NN NN O
   
Subsequently NN NN O
, NN NN O
however NN NN O
, NN NN O
several NN NN O
articles NN NN O
reporting NN NN O
abuse NN NN O
of NN NN O
this NN NN O
drug NN NN O
have NN NN O
appeared NN NN O
in NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
The NN NN O
drug NN NN O
is NN NN O
known NN NN O
to NN NN O
cause NN NN O
a NN NN O
variety NN NN O
of NN NN O
acute NN NN O
toxic NN NN O
effects NN NN O
, NN NN O
ranging NN NN O
from NN NN O
nausea NN NN B-Disease
, NN NN O
restlessness NN NN B-Disease
, NN NN O
insomnia NN NN B-Disease
, NN NN O
ataxia NN NN B-Disease
, NN NN O
slurred NN NN O
speech NN NN O
and NN NN O
nystagmus NN NN B-Disease
to NN NN O
mood NN NN O
changes NN NN O
, NN NN O
perceptual NN NN O
alterations NN NN O
, NN NN O
inattention NN NN O
, NN NN O
disorientation NN NN O
and NN NN O
aggressive NN NN B-Disease
behavior NN NN I-Disease
( NN NN O
Rammer NN NN O
et NN NN O
al NN NN O
1988 NN NN O
; NN NN O
Katona NN NN O
and NN NN O
Watson NN NN O
1986 NN NN O
; NN NN O
Isbell NN NN O
and NN NN O
Fraser NN NN O
1953 NN NN O
; NN NN O
Devlin NN NN O
et NN NN O
al NN NN O
1985 NN NN O
; NN NN O
McCarthy NN NN O
1971 NN NN O
; NN NN O
Dodds NN NN O
and NN NN O
Revai NN NN O
1967 NN NN O
; NN NN O
Degkwitz NN NN O
1964 NN NN O
; NN NN O
Hildebrand NN NN O
et NN NN O
al NN NN O
1989 NN NN O
) NN NN O
. NN NN O
   
There NN NN O
have NN NN O
also NN NN O
been NN NN O
two NN NN O
reported NN NN O
fatalities NN NN O
from NN NN O
DM NN NN O
overdoses NN NN O
( NN NN O
Fleming NN NN O
1986 NN NN O
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
there NN NN O
are NN NN O
no NN NN O
reports NN NN O
describing NN NN O
the NN NN O
effects NN NN O
of NN NN O
chronic NN NN O
abuse NN NN O
. NN NN O
   
This NN NN O
report NN NN O
describes NN NN O
a NN NN O
case NN NN O
of NN NN O
cognitive NN NN B-Disease
deterioration NN NN I-Disease
resulting NN NN O
from NN NN O
prolonged NN NN O
use NN NN O
of NN NN O
DM NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
ouabain NN NN O
on NN NN O
myocardial NN NN O
oxygen NN NN O
supply NN NN O
and NN NN O
demand NN NN O
in NN NN O
patients NN NN O
with NN NN O
chronic NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
A NN NN O
hemodynamic NN NN O
, NN NN O
volumetric NN NN O
, NN NN O
and NN NN O
metabolic NN NN O
study NN NN O
in NN NN O
patients NN NN O
without NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
digitalis NN NN O
glycosides NN NN O
on NN NN O
myocardial NN NN O
oxygen NN NN O
supply NN NN O
and NN NN O
demand NN NN O
are NN NN O
of NN NN O
particular NN NN O
interest NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
obstructive NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
, NN NN O
but NN NN O
have NN NN O
not NN NN O
been NN NN O
measured NN NN O
previously NN NN O
in NN NN O
man NN NN O
. NN NN O
   
We NN NN O
assessed NN NN O
the NN NN O
effects NN NN O
of NN NN O
ouabain NN NN O
( NN NN O
0 NN NN O
. NN NN O
015 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
) NN NN O
on NN NN O
hemodynamic NN NN O
, NN NN O
volumetric NN NN O
, NN NN O
and NN NN O
metabolic NN NN O
parameters NN NN O
in NN NN O
11 NN NN O
patients NN NN O
with NN NN O
severe NN NN O
chronic NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
without NN NN O
clinical NN NN O
congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
Because NN NN O
the NN NN O
protocol NN NN O
was NN NN O
long NN NN O
and NN NN O
involved NN NN O
interventions NN NN O
which NN NN O
might NN NN O
affect NN NN O
the NN NN O
determinations NN NN O
, NN NN O
we NN NN O
also NN NN O
studied NN NN O
in NN NN O
nine NN NN O
patients NN NN O
using NN NN O
an NN NN O
identical NN NN O
protocol NN NN O
except NN NN O
that NN NN O
ouabain NN NN O
administration NN NN O
was NN NN O
omitted NN NN O
. NN NN O
   
Left NN NN O
ventricular NN NN O
end NN NN O
- NN NN O
diastolic NN NN O
pressure NN NN O
and NN NN O
left NN NN O
ventricular NN NN O
end NN NN O
- NN NN O
diastolic NN NN O
volume NN NN O
fell NN NN O
in NN NN O
each NN NN O
patient NN NN O
given NN NN O
ouabain NN NN O
, NN NN O
even NN NN O
though NN NN O
they NN NN O
were NN NN O
initially NN NN O
elevated NN NN O
in NN NN O
only NN NN O
two NN NN O
patients NN NN O
. NN NN O
   
Left NN NN O
ventricular NN NN O
end NN NN O
- NN NN O
diastolic NN NN O
pressure NN NN O
fell NN NN O
from NN NN O
11 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
4 NN NN O
( NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SE NN NN O
) NN NN O
to NN NN O
5 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
9 NN NN O
mm NN NN O
Hg NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
and NN NN O
left NN NN O
ventricular NN NN O
end NN NN O
- NN NN O
diastolic NN NN O
volume NN NN O
fell NN NN O
from NN NN O
100 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
17 NN NN O
to NN NN O
82 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
12 NN NN O
ml NN NN O
/ NN NN O
m2 NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
1 NN NN O
h NN NN O
after NN NN O
ouabain NN NN O
infusion NN NN O
was NN NN O
completed NN NN O
. NN NN O
   
The NN NN O
maximum NN NN O
velocity NN NN O
of NN NN O
contractile NN NN O
element NN NN O
shortening NN NN O
increased NN NN O
from NN NN O
1 NN NN O
. NN NN O
68 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
11 NN NN O
ml NN NN O
/ NN NN O
s NN NN O
to NN NN O
2 NN NN O
. NN NN O
18 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
21 NN NN O
muscle NN NN O
- NN NN O
lengths NN NN O
/ NN NN O
s NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
and NN NN O
is NN NN O
consistent NN NN O
with NN NN O
an NN NN O
increase NN NN O
in NN NN O
contractility NN NN O
. NN NN O
   
No NN NN O
significant NN NN O
change NN NN O
in NN NN O
these NN NN O
parameters NN NN O
occurred NN NN O
in NN NN O
the NN NN O
control NN NN O
patients NN NN O
. NN NN O
   
No NN NN O
significant NN NN O
change NN NN O
in NN NN O
myocardial NN NN O
oxygen NN NN O
consumption NN NN O
occurred NN NN O
after NN NN O
ouabain NN NN O
administration NN NN O
but NN NN O
this NN NN O
may NN NN O
be NN NN O
related NN NN O
to NN NN O
a NN NN O
greater NN NN O
decrease NN NN O
in NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
in NN NN O
the NN NN O
ouabain NN NN O
patients NN NN O
than NN NN O
in NN NN O
the NN NN O
control NN NN O
patients NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
in NN NN O
patients NN NN O
with NN NN O
chronic NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
who NN NN O
are NN NN O
not NN NN O
in NN NN O
clinical NN NN O
congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
left NN NN B-Disease
ventricular NN NN I-Disease
end NN NN I-Disease
- NN NN I-Disease
diastolic NN NN I-Disease
volume NN NN I-Disease
falls NN NN I-Disease
after NN NN O
ouabain NN NN O
administration NN NN O
even NN NN O
when NN NN O
it NN NN O
is NN NN O
initially NN NN O
normal NN NN O
. NN NN O
   
Though NN NN O
this NN NN O
fall NN NN O
would NN NN O
be NN NN O
associated NN NN O
with NN NN O
a NN NN O
decrease NN NN O
in NN NN O
wall NN NN O
tension NN NN O
, NN NN O
and NN NN O
, NN NN O
therefore NN NN O
, NN NN O
of NN NN O
myocardial NN NN O
oxygen NN NN O
consumption NN NN O
, NN NN O
it NN NN O
may NN NN O
not NN NN O
be NN NN O
of NN NN O
sufficient NN NN O
magnitude NN NN O
to NN NN O
prevent NN NN O
a NN NN O
net NN NN O
increase NN NN O
in NN NN O
myocardial NN NN O
oxygen NN NN O
consumption NN NN O
. NN NN O
   
Nevertheless NN NN O
, NN NN O
compensatory NN NN O
mechanisms NN NN O
prevent NN NN O
a NN NN O
deterioration NN NN O
of NN NN O
resting NN NN O
myocardial NN NN O
metabolism NN NN O
. NN NN O
   
Dexamethasone NN NN O
- NN NN O
induced NN NN O
ocular NN NN B-Disease
hypertension NN NN I-Disease
in NN NN O
perfusion NN NN O
- NN NN O
cultured NN NN O
human NN NN O
eyes NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
Glucocorticoid NN NN O
administration NN NN O
can NN NN O
lead NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
ocular NN NN B-Disease
hypertension NN NN I-Disease
and NN NN O
corticosteroid NN NN B-Disease
glaucoma NN NN I-Disease
in NN NN O
a NN NN O
subset NN NN O
of NN NN O
the NN NN O
population NN NN O
through NN NN O
a NN NN O
decrease NN NN O
in NN NN O
the NN NN O
aqueous NN NN O
humor NN NN O
outflow NN NN O
facility NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
whether NN NN O
glucocorticoid NN NN O
treatment NN NN O
can NN NN O
directly NN NN O
affect NN NN O
the NN NN O
outflow NN NN O
facility NN NN O
of NN NN O
isolated NN NN O
, NN NN O
perfusion NN NN O
- NN NN O
cultured NN NN O
human NN NN O
eyes NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
anterior NN NN O
segments NN NN O
of NN NN O
human NN NN O
donor NN NN O
eyes NN NN O
from NN NN O
regional NN NN O
eye NN NN O
banks NN NN O
were NN NN O
placed NN NN O
in NN NN O
a NN NN O
constant NN NN O
flow NN NN O
, NN NN O
variable NN NN O
pressure NN NN O
perfusion NN NN O
culture NN NN O
system NN NN O
. NN NN O
   
Paired NN NN O
eyes NN NN O
were NN NN O
perfused NN NN O
in NN NN O
serum NN NN O
- NN NN O
free NN NN O
media NN NN O
with NN NN O
or NN NN O
without NN NN O
10 NN NN O
( NN NN O
- NN NN O
7 NN NN O
) NN NN O
M NN NN O
dexamethasone NN NN O
for NN NN O
12 NN NN O
days NN NN O
. NN NN O
   
Intraocular NN NN O
pressure NN NN O
was NN NN O
monitored NN NN O
daily NN NN O
. NN NN O
   
After NN NN O
incubation NN NN O
, NN NN O
the NN NN O
eyes NN NN O
were NN NN O
morphologically NN NN O
characterized NN NN O
by NN NN O
light NN NN O
microscopy NN NN O
, NN NN O
transmission NN NN O
and NN NN O
scanning NN NN O
electron NN NN O
microscopy NN NN O
, NN NN O
and NN NN O
scanning NN NN O
laser NN NN O
confocal NN NN O
microscopy NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
A NN NN O
significant NN NN O
increase NN NN O
in NN NN O
intraocular NN NN O
pressure NN NN O
developed NN NN O
in NN NN O
13 NN NN O
of NN NN O
the NN NN O
44 NN NN O
pairs NN NN O
of NN NN O
eyes NN NN O
perfused NN NN O
with NN NN O
dexamethasone NN NN O
with NN NN O
an NN NN O
average NN NN O
pressure NN NN O
rise NN NN O
of NN NN O
17 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
8 NN NN O
mm NN NN O
Hg NN NN O
after NN NN O
12 NN NN O
days NN NN O
of NN NN O
dexamethasone NN NN O
exposure NN NN O
. NN NN O
   
The NN NN O
contralateral NN NN O
control NN NN O
eyes NN NN O
, NN NN O
which NN NN O
did NN NN O
not NN NN O
receive NN NN O
dexamethasone NN NN O
, NN NN O
maintained NN NN O
a NN NN O
stable NN NN O
intraocular NN NN O
pressure NN NN O
during NN NN O
the NN NN O
same NN NN O
period NN NN O
. NN NN O
   
The NN NN O
outflow NN NN O
pathway NN NN O
of NN NN O
the NN NN O
untreated NN NN O
eyes NN NN O
appeared NN NN O
morphologically NN NN O
normal NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
dexamethasone NN NN O
- NN NN O
treated NN NN O
hypertensive NN NN B-Disease
eyes NN NN I-Disease
had NN NN O
thickened NN NN O
trabecular NN NN O
beams NN NN O
, NN NN O
decreased NN NN O
intertrabecular NN NN O
spaces NN NN O
, NN NN O
thickened NN NN O
juxtacanalicular NN NN O
tissue NN NN O
, NN NN O
activated NN NN O
trabecular NN NN O
meshwork NN NN O
cells NN NN O
, NN NN O
and NN NN O
increased NN NN O
amounts NN NN O
of NN NN O
amorphogranular NN NN O
extracellular NN NN O
material NN NN O
, NN NN O
especially NN NN O
in NN NN O
the NN NN O
juxtacanalicular NN NN O
tissue NN NN O
and NN NN O
beneath NN NN O
the NN NN O
endothelial NN NN O
lining NN NN O
of NN NN O
the NN NN O
canal NN NN O
of NN NN O
Schlemm NN NN O
. NN NN O
   
The NN NN O
dexamethasone NN NN O
- NN NN O
treated NN NN O
nonresponder NN NN O
eyes NN NN O
appeared NN NN O
to NN NN O
be NN NN O
morphologically NN NN O
similar NN NN O
to NN NN O
the NN NN O
untreated NN NN O
eyes NN NN O
, NN NN O
although NN NN O
several NN NN O
subtle NN NN O
dexamethasone NN NN O
- NN NN O
induced NN NN O
morphologic NN NN O
changes NN NN O
were NN NN O
evident NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Dexamethasone NN NN O
treatment NN NN O
of NN NN O
isolated NN NN O
, NN NN O
perfusion NN NN O
- NN NN O
cultured NN NN O
human NN NN O
eyes NN NN O
led NN NN O
to NN NN O
the NN NN O
generation NN NN O
of NN NN O
ocular NN NN B-Disease
hypertension NN NN I-Disease
in NN NN O
approximately NN NN O
30 NN NN O
% NN NN O
of NN NN O
the NN NN O
dexamethasone NN NN O
- NN NN O
treated NN NN O
eyes NN NN O
. NN NN O
   
Steroid NN NN O
treatment NN NN O
resulted NN NN O
in NN NN O
morphologic NN NN O
changes NN NN O
in NN NN O
the NN NN O
trabecular NN NN O
meshwork NN NN O
similar NN NN O
to NN NN O
those NN NN O
reported NN NN O
for NN NN O
corticosteroid NN NN B-Disease
glaucoma NN NN I-Disease
and NN NN O
open NN NN B-Disease
angle NN NN I-Disease
glaucoma NN NN I-Disease
. NN NN O
   
This NN NN O
system NN NN O
may NN NN O
provide NN NN O
an NN NN O
acute NN NN O
model NN NN O
in NN NN O
which NN NN O
to NN NN O
study NN NN O
the NN NN O
pathogenic NN NN O
mechanisms NN NN O
involved NN NN O
in NN NN O
steroid NN NN B-Disease
glaucoma NN NN I-Disease
and NN NN O
primary NN NN B-Disease
open NN NN I-Disease
angle NN NN I-Disease
glaucoma NN NN I-Disease
. NN NN O
   
Auditory NN NN O
disturbance NN NN O
associated NN NN O
with NN NN O
interscalene NN NN O
brachial NN NN O
plexus NN NN O
block NN NN O
. NN NN O
   
We NN NN O
performed NN NN O
an NN NN O
audiometric NN NN O
study NN NN O
in NN NN O
20 NN NN O
patients NN NN O
who NN NN O
underwent NN NN O
surgery NN NN O
of NN NN O
the NN NN O
shoulder NN NN O
region NN NN O
under NN NN O
an NN NN O
interscalene NN NN O
brachial NN NN O
plexus NN NN O
block NN NN O
( NN NN O
IBPB NN NN O
) NN NN O
. NN NN O
   
Bupivacaine NN NN O
0 NN NN O
. NN NN O
75 NN NN O
% NN NN O
with NN NN O
adrenaline NN NN O
was NN NN O
given NN NN O
followed NN NN O
by NN NN O
a NN NN O
24 NN NN O
- NN NN O
hr NN NN O
continuous NN NN O
infusion NN NN O
of NN NN O
0 NN NN O
. NN NN O
25 NN NN O
% NN NN O
bupivacaine NN NN O
. NN NN O
   
Three NN NN O
audiometric NN NN O
threshold NN NN O
measurements NN NN O
( NN NN O
0 NN NN O
. NN NN O
25 NN NN O
- NN NN O
18 NN NN O
kHz NN NN O
) NN NN O
were NN NN O
made NN NN O
: NN NN O
the NN NN O
first NN NN O
before NN NN O
IBPB NN NN O
, NN NN O
the NN NN O
second NN NN O
2 NN NN O
- NN NN O
6 NN NN O
h NN NN O
after NN NN O
surgery NN NN O
and NN NN O
the NN NN O
third NN NN O
on NN NN O
the NN NN O
first NN NN O
day NN NN O
after NN NN O
operation NN NN O
. NN NN O
   
In NN NN O
four NN NN O
patients NN NN O
hearing NN NN B-Disease
impairment NN NN I-Disease
on NN NN O
the NN NN O
side NN NN O
of NN NN O
the NN NN O
block NN NN O
was NN NN O
demonstrated NN NN O
after NN NN O
operation NN NN O
, NN NN O
in NN NN O
three NN NN O
measurements NN NN O
on NN NN O
the NN NN O
day NN NN O
of NN NN O
surgery NN NN O
and NN NN O
in NN NN O
one NN NN O
on NN NN O
the NN NN O
following NN NN O
day NN NN O
. NN NN O
   
The NN NN O
frequencies NN NN O
at NN NN O
which NN NN O
the NN NN O
impairment NN NN O
occurred NN NN O
varied NN NN O
between NN NN O
patients NN NN O
; NN NN O
in NN NN O
one NN NN O
only NN NN O
low NN NN O
frequencies NN NN O
( NN NN O
0 NN NN O
. NN NN O
25 NN NN O
- NN NN O
0 NN NN O
. NN NN O
5 NN NN O
kHz NN NN O
) NN NN O
were NN NN O
involved NN NN O
. NN NN O
   
The NN NN O
maximum NN NN O
change NN NN O
in NN NN O
threshold NN NN O
was NN NN O
35 NN NN O
dB NN NN O
at NN NN O
6 NN NN O
kHz NN NN O
measured NN NN O
at NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
continuous NN NN O
infusion NN NN O
of NN NN O
bupivacaine NN NN O
. NN NN O
   
This NN NN O
patient NN NN O
had NN NN O
hearing NN NN O
threshold NN NN O
changes NN NN O
( NN NN O
15 NN NN O
- NN NN O
20 NN NN O
dB NN NN O
) NN NN O
at NN NN O
6 NN NN O
- NN NN O
10 NN NN O
kHz NN NN O
on NN NN O
the NN NN O
opposite NN NN O
side NN NN O
also NN NN O
. NN NN O
   
IBPB NN NN O
may NN NN O
cause NN NN O
transient NN NN O
auditory NN NN B-Disease
dysfunction NN NN I-Disease
in NN NN O
the NN NN O
ipsilateral NN NN O
ear NN NN O
, NN NN O
possibly NN NN O
via NN NN O
an NN NN O
effect NN NN O
on NN NN O
sympathetic NN NN O
innervation NN NN O
. NN NN O
   
The NN NN O
safety NN NN O
and NN NN O
efficacy NN NN O
of NN NN O
combination NN NN O
N NN NN O
- NN NN O
butyl NN NN O
- NN NN O
deoxynojirimycin NN NN O
( NN NN O
SC NN NN O
- NN NN O
48334 NN NN O
) NN NN O
and NN NN O
zidovudine NN NN O
in NN NN O
patients NN NN O
with NN NN O
HIV NN NN B-Disease
- NN NN I-Disease
1 NN NN I-Disease
infection NN NN I-Disease
and NN NN O
200 NN NN O
- NN NN O
500 NN NN O
CD4 NN NN O
cells NN NN O
/ NN NN O
mm3 NN NN O
. NN NN O
   
We NN NN O
conducted NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
randomized NN NN O
phase NN NN O
II NN NN O
study NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
safety NN NN O
and NN NN O
activity NN NN O
of NN NN O
combination NN NN O
therapy NN NN O
with NN NN O
N NN NN O
- NN NN O
butyl NN NN O
- NN NN O
deoxynojirimycin NN NN O
( NN NN O
SC NN NN O
- NN NN O
48334 NN NN O
) NN NN O
( NN NN O
an NN NN O
alpha NN NN O
- NN NN O
glucosidase NN NN O
I NN NN O
inhibitor NN NN O
) NN NN O
and NN NN O
zidovudine NN NN O
versus NN NN O
zidovudine NN NN O
alone NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
200 NN NN O
to NN NN O
500 NN NN O
CD4 NN NN O
cells NN NN O
/ NN NN O
mm3 NN NN O
who NN NN O
tolerated NN NN O
< NN NN O
or NN NN O
= NN NN O
12 NN NN O
weeks NN NN O
of NN NN O
prior NN NN O
zidovudine NN NN O
therapy NN NN O
received NN NN O
SC NN NN O
- NN NN O
48334 NN NN O
( NN NN O
1000 NN NN O
mg NN NN O
every NN NN O
8 NN NN O
h NN NN O
) NN NN O
and NN NN O
zidovudine NN NN O
( NN NN O
100 NN NN O
mg NN NN O
every NN NN O
8 NN NN O
h NN NN O
) NN NN O
or NN NN O
zidovudine NN NN O
and NN NN O
placebo NN NN O
. NN NN O
   
Sixty NN NN O
patients NN NN O
received NN NN O
combination NN NN O
therapy NN NN O
and NN NN O
58 NN NN O
, NN NN O
zidovudine NN NN O
and NN NN O
placebo NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
three NN NN O
patients NN NN O
( NN NN O
38 NN NN O
% NN NN O
) NN NN O
and NN NN O
15 NN NN O
( NN NN O
26 NN NN O
% NN NN O
) NN NN O
, NN NN O
in NN NN O
the NN NN O
combination NN NN O
and NN NN O
zidovudine NN NN O
groups NN NN O
, NN NN O
respectively NN NN O
, NN NN O
discontinued NN NN O
therapy NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
15 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
SC NN NN O
- NN NN O
48334 NN NN O
steady NN NN O
- NN NN O
state NN NN O
trough NN NN O
level NN NN O
( NN NN O
4 NN NN O
. NN NN O
04 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
99 NN NN O
micrograms NN NN O
/ NN NN O
ml NN NN O
) NN NN O
was NN NN O
below NN NN O
the NN NN O
in NN NN O
vitro NN NN O
inhibitory NN NN O
concentration NN NN O
for NN NN O
human NN NN O
immunodeficiency NN NN B-Disease
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
increase NN NN O
in NN NN O
CD4 NN NN O
cells NN NN O
at NN NN O
week NN NN O
4 NN NN O
was NN NN O
73 NN NN O
. NN NN O
8 NN NN O
cells NN NN O
/ NN NN O
mm3 NN NN O
and NN NN O
52 NN NN O
. NN NN O
4 NN NN O
cells NN NN O
/ NN NN O
mm3 NN NN O
for NN NN O
the NN NN O
combination NN NN O
and NN NN O
zidovudine NN NN O
groups NN NN O
, NN NN O
respectively NN NN O
( NN NN O
p NN NN O
> NN NN O
0 NN NN O
. NN NN O
36 NN NN O
) NN NN O
. NN NN O
   
For NN NN O
patients NN NN O
with NN NN O
prior NN NN O
zidovudine NN NN O
therapy NN NN O
, NN NN O
the NN NN O
mean NN NN O
change NN NN O
in NN NN O
CD4 NN NN O
cells NN NN O
in NN NN O
the NN NN O
combination NN NN O
and NN NN O
zidovudine NN NN O
groups NN NN O
was NN NN O
63 NN NN O
. NN NN O
7 NN NN O
cells NN NN O
/ NN NN O
mm3 NN NN O
and NN NN O
4 NN NN O
. NN NN O
9 NN NN O
cells NN NN O
/ NN NN O
mm3 NN NN O
at NN NN O
week NN NN O
8 NN NN O
and NN NN O
6 NN NN O
. NN NN O
8 NN NN O
cells NN NN O
/ NN NN O
mm3 NN NN O
and NN NN O
- NN NN O
45 NN NN O
. NN NN O
1 NN NN O
cells NN NN O
/ NN NN O
mm3 NN NN O
at NN NN O
week NN NN O
16 NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
The NN NN O
number NN NN O
of NN NN O
patients NN NN O
with NN NN O
suppression NN NN O
of NN NN O
HIV NN NN O
p24 NN NN O
antigenemia NN NN O
in NN NN O
the NN NN O
combination NN NN O
and NN NN O
zidovudine NN NN O
groups NN NN O
was NN NN O
six NN NN O
( NN NN O
40 NN NN O
% NN NN O
) NN NN O
and NN NN O
two NN NN O
( NN NN O
11 NN NN O
% NN NN O
) NN NN O
at NN NN O
week NN NN O
4 NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
10 NN NN O
) NN NN O
and NN NN O
five NN NN O
( NN NN O
45 NN NN O
% NN NN O
) NN NN O
and NN NN O
two NN NN O
( NN NN O
14 NN NN O
% NN NN O
) NN NN O
at NN NN O
week NN NN O
24 NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
08 NN NN O
) NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Diarrhea NN NN B-Disease
, NN NN O
flatulence NN NN B-Disease
, NN NN O
abdominal NN NN B-Disease
pain NN NN I-Disease
, NN NN O
and NN NN O
weight NN NN B-Disease
loss NN NN I-Disease
were NN NN O
common NN NN O
for NN NN O
combination NN NN O
recipients NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Prolonged NN NN O
paralysis NN NN B-Disease
due NN NN O
to NN NN O
nondepolarizing NN NN O
neuromuscular NN NN O
blocking NN NN O
agents NN NN O
and NN NN O
corticosteroids NN NN O
. NN NN O
   
The NN NN O
long NN NN O
- NN NN O
term NN NN O
use NN NN O
of NN NN O
nondepolarizing NN NN O
neuromuscular NN NN O
blocking NN NN O
agents NN NN O
( NN NN O
ND NN NN O
- NN NN O
NMBA NN NN O
) NN NN O
has NN NN O
recently NN NN O
been NN NN O
implicated NN NN O
as NN NN O
a NN NN O
cause NN NN O
of NN NN O
prolonged NN NN O
muscle NN NN B-Disease
weakness NN NN I-Disease
, NN NN O
although NN NN O
the NN NN O
site NN NN O
of NN NN O
the NN NN O
lesion NN NN O
and NN NN O
the NN NN O
predisposing NN NN O
factors NN NN O
have NN NN O
been NN NN O
unclear NN NN O
. NN NN O
   
We NN NN O
report NN NN O
3 NN NN O
patients NN NN O
( NN NN O
age NN NN O
37 NN NN O
- NN NN O
52 NN NN O
years NN NN O
) NN NN O
with NN NN O
acute NN NN O
respiratory NN NN B-Disease
insufficiency NN NN I-Disease
who NN NN O
developed NN NN O
prolonged NN NN O
weakness NN NN B-Disease
following NN NN O
the NN NN O
discontinuation NN NN O
of NN NN O
ND NN NN O
- NN NN O
NMBAs NN NN O
. NN NN O
   
Two NN NN O
patients NN NN O
also NN NN O
received NN NN O
intravenous NN NN O
corticosteroids NN NN O
. NN NN O
   
Renal NN NN O
function NN NN O
was NN NN O
normal NN NN O
but NN NN O
hepatic NN NN O
function NN NN O
was NN NN O
impaired NN NN O
in NN NN O
all NN NN O
patients NN NN O
, NN NN O
and NN NN O
all NN NN O
had NN NN O
acidosis NN NN B-Disease
. NN NN O
   
Electrophysiologic NN NN O
studies NN NN O
revealed NN NN O
low NN NN O
amplitude NN NN O
compound NN NN O
motor NN NN O
action NN NN O
potentials NN NN O
, NN NN O
normal NN NN O
sensory NN NN O
studies NN NN O
, NN NN O
and NN NN O
fibrillations NN NN O
. NN NN O
   
Repetitive NN NN O
stimulation NN NN O
at NN NN O
2 NN NN O
Hz NN NN O
showed NN NN O
a NN NN O
decremental NN NN O
response NN NN O
in NN NN O
2 NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
serum NN NN O
vecuronium NN NN O
level NN NN O
measured NN NN O
in NN NN O
1 NN NN O
patient NN NN O
14 NN NN O
days NN NN O
after NN NN O
the NN NN O
drug NN NN O
had NN NN O
been NN NN O
discontinued NN NN O
was NN NN O
172 NN NN O
ng NN NN O
/ NN NN O
mL NN NN O
. NN NN O
   
A NN NN O
muscle NN NN O
biopsy NN NN O
in NN NN O
this NN NN O
patient NN NN O
showed NN NN O
loss NN NN B-Disease
of NN NN I-Disease
thick NN NN I-Disease
, NN NN I-Disease
myosin NN NN I-Disease
filaments NN NN I-Disease
. NN NN O
   
The NN NN O
weakness NN NN B-Disease
in NN NN O
these NN NN O
patients NN NN O
is NN NN O
due NN NN O
to NN NN O
pathology NN NN B-Disease
at NN NN I-Disease
both NN NN I-Disease
the NN NN I-Disease
neuromuscular NN NN I-Disease
junction NN NN I-Disease
( NN NN O
most NN NN O
likely NN NN O
due NN NN O
to NN NN O
ND NN NN O
- NN NN O
NMBA NN NN O
) NN NN O
and NN NN O
muscle NN NN O
( NN NN O
most NN NN O
likely NN NN O
due NN NN O
to NN NN O
corticosteroids NN NN O
) NN NN O
. NN NN O
   
Hepatic NN NN B-Disease
dysfunction NN NN I-Disease
and NN NN O
acidosis NN NN B-Disease
are NN NN O
contributing NN NN O
risk NN NN O
factors NN NN O
. NN NN O
   
Failure NN NN O
of NN NN O
ancrod NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
arterial NN NN O
thrombosis NN NN B-Disease
. NN NN O
   
The NN NN O
morbidity NN NN O
and NN NN O
mortality NN NN O
associated NN NN O
with NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombosis NN NN B-Disease
remain NN NN O
high NN NN O
despite NN NN O
numerous NN NN O
empirical NN NN O
therapies NN NN O
. NN NN O
   
Ancrod NN NN O
has NN NN O
been NN NN O
used NN NN O
successfully NN NN O
for NN NN O
prophylaxis NN NN O
against NN NN O
development NN NN O
of NN NN O
thrombosis NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
heparin NN NN O
induced NN NN O
platelet NN NN B-Disease
aggregation NN NN I-Disease
who NN NN O
require NN NN O
brief NN NN O
reexposure NN NN O
to NN NN O
heparin NN NN O
, NN NN O
but NN NN O
its NN NN O
success NN NN O
in NN NN O
patients NN NN O
who NN NN O
have NN NN O
developed NN NN O
the NN NN O
thrombosis NN NN B-Disease
syndrome NN NN O
is NN NN O
not NN NN O
well NN NN O
defined NN NN O
. NN NN O
   
The NN NN O
authors NN NN O
present NN NN O
a NN NN O
case NN NN O
of NN NN O
failure NN NN O
of NN NN O
ancrod NN NN O
treatment NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombosis NN NN B-Disease
. NN NN O
   
Water NN NN B-Disease
intoxication NN NN I-Disease
associated NN NN O
with NN NN O
oxytocin NN NN O
administration NN NN O
during NN NN O
saline NN NN O
- NN NN O
induced NN NN O
abortion NN NN B-Disease
. NN NN O
   
Four NN NN O
cases NN NN O
of NN NN O
water NN NN B-Disease
intoxication NN NN I-Disease
in NN NN O
connection NN NN O
with NN NN O
oxytocin NN NN O
administration NN NN O
during NN NN O
saline NN NN O
- NN NN O
induced NN NN O
abortions NN NN B-Disease
are NN NN O
described NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
water NN NN B-Disease
intoxication NN NN I-Disease
is NN NN O
discussed NN NN O
in NN NN O
regard NN NN O
to NN NN O
these NN NN O
cases NN NN O
. NN NN O
   
Oxytocin NN NN O
administration NN NN O
during NN NN O
midtrimester NN NN O
- NN NN O
induced NN NN O
abortions NN NN B-Disease
is NN NN O
advocated NN NN O
only NN NN O
if NN NN O
it NN NN O
can NN NN O
be NN NN O
carried NN NN O
out NN NN O
under NN NN O
careful NN NN O
observations NN NN O
of NN NN O
an NN NN O
alert NN NN O
nursing NN NN O
staff NN NN O
, NN NN O
aware NN NN O
of NN NN O
the NN NN O
symptoms NN NN O
of NN NN O
water NN NN B-Disease
intoxication NN NN I-Disease
and NN NN O
instructed NN NN O
to NN NN O
watch NN NN O
the NN NN O
diuresis NN NN O
and NN NN O
report NN NN O
such NN NN O
early NN NN O
signs NN NN O
of NN NN O
the NN NN O
syndrome NN NN O
as NN NN O
asthenia NN NN B-Disease
, NN NN O
muscular NN NN O
irritability NN NN B-Disease
, NN NN O
or NN NN O
headaches NN NN B-Disease
. NN NN O
   
The NN NN O
oxytocin NN NN O
should NN NN O
be NN NN O
given NN NN O
only NN NN O
in NN NN O
Ringers NN NN O
lactate NN NN O
or NN NN O
, NN NN O
alternately NN NN O
, NN NN O
in NN NN O
Ringers NN NN O
lactate NN NN O
and NN NN O
a NN NN O
5 NN NN O
per NN NN O
cent NN NN O
dextrose NN NN O
and NN NN O
water NN NN O
solutions NN NN O
. NN NN O
   
The NN NN O
urinary NN NN O
output NN NN O
should NN NN O
be NN NN O
monitored NN NN O
and NN NN O
the NN NN O
oxytocin NN NN O
administration NN NN O
discontinued NN NN O
and NN NN O
the NN NN O
serum NN NN O
electrolytes NN NN O
checked NN NN O
if NN NN O
the NN NN O
urinary NN NN O
output NN NN O
decreases NN NN O
. NN NN O
   
The NN NN O
oxytocin NN NN O
should NN NN O
not NN NN O
be NN NN O
administered NN NN O
in NN NN O
excess NN NN O
of NN NN O
36 NN NN O
hours NN NN O
. NN NN O
   
If NN NN O
the NN NN O
patient NN NN O
has NN NN O
not NN NN O
aborted NN NN O
by NN NN O
then NN NN O
the NN NN O
oxytocin NN NN O
should NN NN O
be NN NN O
discontinued NN NN O
for NN NN O
10 NN NN O
to NN NN O
12 NN NN O
hours NN NN O
in NN NN O
order NN NN O
to NN NN O
perform NN NN O
electrolyte NN NN O
determinations NN NN O
and NN NN O
correct NN NN O
any NN NN O
electrolyte NN NN O
imbalance NN NN O
. NN NN O
   
Light NN NN O
chain NN NN O
proteinuria NN NN B-Disease
and NN NN O
cellular NN NN O
mediated NN NN O
immunity NN NN O
in NN NN O
rifampin NN NN O
treated NN NN O
patients NN NN O
with NN NN O
tuberculosis NN NN B-Disease
. NN NN O
   
Light NN NN O
chain NN NN O
proteinuria NN NN B-Disease
was NN NN O
found NN NN O
in NN NN O
9 NN NN O
of NN NN O
17 NN NN O
tuberculosis NN NN B-Disease
patients NN NN O
treated NN NN O
with NN NN O
rifampin NN NN O
. NN NN O
   
Concomitant NN NN O
assay NN NN O
of NN NN O
cellular NN NN O
mediated NN NN O
immunity NN NN O
in NN NN O
these NN NN O
patients NN NN O
using NN NN O
skin NN NN O
test NN NN O
antigen NN NN O
and NN NN O
a NN NN O
lymphokine NN NN O
in NN NN O
vitro NN NN O
test NN NN O
provided NN NN O
results NN NN O
that NN NN O
were NN NN O
different NN NN O
. NN NN O
   
Response NN NN O
to NN NN O
Varidase NN NN O
skin NN NN O
test NN NN O
antigen NN NN O
was NN NN O
negative NN NN O
for NN NN O
all NN NN O
eight NN NN O
tuberculosis NN NN B-Disease
patients NN NN O
tested NN NN O
, NN NN O
but NN NN O
there NN NN O
occurred NN NN O
a NN NN O
hyper NN NN O
- NN NN O
responsiveness NN NN O
of NN NN O
the NN NN O
lymphocytes NN NN O
of NN NN O
these NN NN O
eight NN NN O
patients NN NN O
to NN NN O
phytomitogen NN NN O
( NN NN O
PHA NN NN O
- NN NN O
P NN NN O
) NN NN O
. NN NN O
as NN NN O
well NN NN O
as NN NN O
of NN NN O
those NN NN O
of NN NN O
seven NN NN O
other NN NN O
tuberculous NN NN B-Disease
patients NN NN O
. NN NN O
   
This NN NN O
last NN NN O
finding NN NN O
may NN NN O
be NN NN O
related NN NN O
to NN NN O
time NN NN O
of NN NN O
testing NN NN O
and NN NN O
/ NN NN O
or NN NN O
endogenous NN NN O
serum NN NN O
binding NN NN O
of NN NN O
rifampin NN NN O
which NN NN O
could NN NN O
have NN NN O
inhibited NN NN O
mitogen NN NN O
activity NN NN O
for NN NN O
the NN NN O
lymphocyte NN NN O
. NN NN O
   
KF17837 NN NN O
: NN NN O
a NN NN O
novel NN NN O
selective NN NN O
adenosine NN NN O
A2A NN NN O
receptor NN NN O
antagonist NN NN O
with NN NN O
anticataleptic NN NN O
activity NN NN O
. NN NN O
   
KF17837 NN NN O
is NN NN O
a NN NN O
novel NN NN O
selective NN NN O
adenosine NN NN O
A2A NN NN O
receptor NN NN O
antagonist NN NN O
. NN NN O
   
Oral NN NN O
administration NN NN O
of NN NN O
KF17837 NN NN O
( NN NN O
2 NN NN O
. NN NN O
5 NN NN O
, NN NN O
10 NN NN O
. NN NN O
0 NN NN O
and NN NN O
30 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
significantly NN NN O
ameliorated NN NN O
the NN NN O
cataleptic NN NN B-Disease
responses NN NN O
induced NN NN O
by NN NN O
intracerebroventricular NN NN O
administration NN NN O
of NN NN O
an NN NN O
adenosine NN NN O
A2A NN NN O
receptor NN NN O
agonist NN NN O
, NN NN O
CGS NN NN O
21680 NN NN O
( NN NN O
10 NN NN O
micrograms NN NN O
) NN NN O
, NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
KF17837 NN NN O
also NN NN O
reduced NN NN O
the NN NN O
catalepsy NN NN B-Disease
induced NN NN O
by NN NN O
haloperidol NN NN O
( NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
and NN NN O
by NN NN O
reserpine NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
. NN NN O
   
These NN NN O
anticataleptic NN NN O
effects NN NN O
were NN NN O
exhibited NN NN O
dose NN NN O
dependently NN NN O
at NN NN O
doses NN NN O
from NN NN O
0 NN NN O
. NN NN O
625 NN NN O
and NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
KF17837 NN NN O
( NN NN O
0 NN NN O
. NN NN O
625 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
) NN NN O
potentiated NN NN O
the NN NN O
anticataleptic NN NN O
effects NN NN O
of NN NN O
a NN NN O
subthreshold NN NN O
dose NN NN O
of NN NN O
L NN NN O
- NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
dihydroxyphenylalanine NN NN O
( NN NN O
L NN NN O
- NN NN O
DOPA NN NN O
; NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
plus NN NN O
benserazide NN NN O
( NN NN O
6 NN NN O
. NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggested NN NN O
that NN NN O
KF17837 NN NN O
is NN NN O
a NN NN O
centrally NN NN O
active NN NN O
adenosine NN NN O
A2A NN NN O
receptor NN NN O
antagonist NN NN O
and NN NN O
that NN NN O
the NN NN O
dopaminergic NN NN O
function NN NN O
of NN NN O
the NN NN O
nigrostriatal NN NN O
pathway NN NN O
is NN NN O
potentiated NN NN O
by NN NN O
adenosine NN NN O
A2A NN NN O
receptor NN NN O
antagonists NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
KF17837 NN NN O
may NN NN O
be NN NN O
a NN NN O
useful NN NN O
drug NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
parkinsonism NN NN B-Disease
. NN NN O
   
Effect NN NN O
of NN NN O
nondopaminergic NN NN O
drugs NN NN O
on NN NN O
L NN NN O
- NN NN O
dopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
in NN NN O
MPTP NN NN O
- NN NN O
treated NN NN O
monkeys NN NN O
. NN NN O
   
A NN NN O
group NN NN O
of NN NN O
four NN NN O
monkeys NN NN O
was NN NN O
rendered NN NN O
parkinsonian NN NN B-Disease
with NN NN O
the NN NN O
toxin NN NN O
MPTP NN NN O
. NN NN O
   
They NN NN O
were NN NN O
then NN NN O
treated NN NN O
chronically NN NN O
with NN NN O
L NN NN O
- NN NN O
DOPA NN NN O
/ NN NN O
benserazide NN NN O
50 NN NN O
/ NN NN O
12 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
given NN NN O
orally NN NN O
daily NN NN O
for NN NN O
2 NN NN O
months NN NN O
. NN NN O
   
This NN NN O
dose NN NN O
produced NN NN O
a NN NN O
striking NN NN O
antiparkinsonian NN NN O
effect NN NN O
, NN NN O
but NN NN O
all NN NN O
animals NN NN O
manifested NN NN O
dyskinesia NN NN B-Disease
. NN NN O
   
A NN NN O
series NN NN O
of NN NN O
agents NN NN O
acting NN NN O
primarily NN NN O
on NN NN O
neurotransmitters NN NN O
other NN NN O
than NN NN O
dopamine NN NN O
were NN NN O
then NN NN O
tested NN NN O
in NN NN O
combination NN NN O
with NN NN O
L NN NN O
- NN NN O
DOPA NN NN O
to NN NN O
see NN NN O
if NN NN O
the NN NN O
dyskinetic NN NN B-Disease
movements NN NN O
would NN NN O
be NN NN O
modified NN NN O
. NN NN O
   
Several NN NN O
drugs NN NN O
, NN NN O
including NN NN O
clonidine NN NN O
, NN NN O
physostigmine NN NN O
, NN NN O
methysergide NN NN O
, NN NN O
5 NN NN O
- NN NN O
MDOT NN NN O
, NN NN O
propranolol NN NN O
, NN NN O
and NN NN O
MK NN NN O
- NN NN O
801 NN NN O
, NN NN O
markedly NN NN O
reduced NN NN O
the NN NN O
dyskinetic NN NN B-Disease
movements NN NN O
but NN NN O
at NN NN O
the NN NN O
cost NN NN O
of NN NN O
a NN NN O
return NN NN O
of NN NN O
parkinsonian NN NN B-Disease
symptomatology NN NN O
. NN NN O
   
However NN NN O
, NN NN O
yohimbine NN NN O
and NN NN O
meperidine NN NN O
reduced NN NN O
predominantly NN NN O
the NN NN O
dyskinetic NN NN B-Disease
movements NN NN O
. NN NN O
   
Baclofen NN NN O
was NN NN O
also NN NN O
useful NN NN O
in NN NN O
one NN NN O
monkey NN NN O
against NN NN O
a NN NN O
more NN NN O
dystonic NN NN B-Disease
form NN NN O
of NN NN O
dyskinesia NN NN B-Disease
. NN NN O
   
Atropine NN NN O
converted NN NN O
the NN NN O
dystonic NN NN B-Disease
movements NN NN O
into NN NN O
chorea NN NN B-Disease
. NN NN O
   
Hallucinations NN NN B-Disease
and NN NN O
ifosfamide NN NN O
- NN NN O
induced NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Hallucinations NN NN B-Disease
as NN NN O
a NN NN O
symptom NN NN O
of NN NN O
central NN NN O
neurotoxicity NN NN B-Disease
are NN NN O
a NN NN O
known NN NN O
but NN NN O
poorly NN NN O
described NN NN O
side NN NN O
effect NN NN O
of NN NN O
ifosfamide NN NN O
. NN NN O
   
Most NN NN O
cases NN NN O
of NN NN O
ifosfamide NN NN O
- NN NN O
induced NN NN O
hallucinations NN NN B-Disease
have NN NN O
been NN NN O
reported NN NN O
with NN NN O
other NN NN O
mental NN NN O
status NN NN O
changes NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
authors NN NN O
interviewed NN NN O
six NN NN O
persons NN NN O
with NN NN O
ifosfamide NN NN O
- NN NN O
induced NN NN O
hallucinations NN NN B-Disease
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
clear NN NN O
sensorium NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
were NN NN O
receiving NN NN O
high NN NN O
- NN NN O
dose NN NN O
ifosfamide NN NN O
as NN NN O
part NN NN O
of NN NN O
their NN NN O
bone NN NN O
marrow NN NN O
transplant NN NN O
procedure NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Hallucinations NN NN B-Disease
occurred NN NN O
only NN NN O
when NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
eyes NN NN O
were NN NN O
closed NN NN O
and NN NN O
, NN NN O
in NN NN O
all NN NN O
but NN NN O
one NN NN O
case NN NN O
, NN NN O
were NN NN O
reported NN NN O
as NN NN O
disturbing NN NN O
or NN NN O
frightening NN NN O
. NN NN O
   
Underreporting NN NN O
of NN NN O
these NN NN O
hallucinations NN NN B-Disease
by NN NN O
patients NN NN O
is NN NN O
likely NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Hallucinations NN NN B-Disease
may NN NN O
be NN NN O
the NN NN O
sole NN NN O
or NN NN O
first NN NN O
manifestation NN NN O
of NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
The NN NN O
incidence NN NN O
may NN NN O
be NN NN O
dose NN NN O
and NN NN O
infusion NN NN O
- NN NN O
time NN NN O
related NN NN O
. NN NN O
   
The NN NN O
clinician NN NN O
should NN NN O
be NN NN O
alerted NN NN O
for NN NN O
possible NN NN O
ifosfamide NN NN O
- NN NN O
induced NN NN O
hallucinations NN NN B-Disease
, NN NN O
which NN NN O
may NN NN O
occur NN NN O
without NN NN O
other NN NN O
signs NN NN O
of NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
"""""""" NN NN O
Eyes NN NN O
- NN NN O
closed NN NN O
"""""""" NN NN O
hallucinatory NN NN B-Disease
experiences NN NN O
appear NN NN O
to NN NN O
be NN NN O
an NN NN O
unusual NN NN O
feature NN NN O
of NN NN O
this NN NN O
presentation NN NN O
. NN NN O
   
Patients NN NN O
anxious NN NN O
about NN NN O
this NN NN O
experience NN NN O
respond NN NN O
well NN NN O
to NN NN O
support NN NN O
and NN NN O
education NN NN O
about NN NN O
this NN NN O
occurrence NN NN O
. NN NN O
   
Optimal NN NN O
pharmacologic NN NN O
management NN NN O
of NN NN O
disturbed NN NN O
patients NN NN O
is NN NN O
unclear NN NN O
. NN NN O
   
If NN NN O
agitation NN NN B-Disease
becomes NN NN O
marked NN NN O
, NN NN O
high NN NN O
- NN NN O
potency NN NN O
neuroleptics NN NN O
( NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
haloperidol NN NN O
) NN NN O
may NN NN O
be NN NN O
effective NN NN O
. NN NN O
   
Photodistributed NN NN O
nifedipine NN NN O
- NN NN O
induced NN NN O
facial NN NN O
telangiectasia NN NN B-Disease
. NN NN O
   
Five NN NN O
months NN NN O
after NN NN O
starting NN NN O
nifedipine NN NN O
( NN NN O
Adalat NN NN O
) NN NN O
, NN NN O
two NN NN O
patients NN NN O
developed NN NN O
photodistributed NN NN O
facial NN NN O
telangiectasia NN NN B-Disease
, NN NN O
which NN NN O
became NN NN O
more NN NN O
noticeable NN NN O
with NN NN O
time NN NN O
. NN NN O
   
Neither NN NN O
patient NN NN O
complained NN NN O
of NN NN O
photosensitivity NN NN O
or NN NN O
flushing NN NN B-Disease
. NN NN O
   
Both NN NN O
patients NN NN O
reported NN NN O
a NN NN O
significant NN NN O
cosmetic NN NN O
improvement NN NN O
after NN NN O
discontinuing NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
One NN NN O
commenced NN NN O
the NN NN O
closely NN NN O
related NN NN O
drug NN NN O
amlodipine NN NN O
3 NN NN O
years NN NN O
later NN NN O
, NN NN O
with NN NN O
recurrence NN NN O
of NN NN O
telangiectasia NN NN B-Disease
. NN NN O
   
The NN NN O
photodistribution NN NN O
of NN NN O
the NN NN O
telangiectasia NN NN B-Disease
suggests NN NN O
a NN NN O
significant NN NN O
drug NN NN O
/ NN NN O
light NN NN O
interaction NN NN O
. NN NN O
   
Penicillamine NN NN O
- NN NN O
induced NN NN O
rapidly NN NN O
progressive NN NN O
glomerulonephritis NN NN B-Disease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
. NN NN O
   
A NN NN O
67 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
presented NN NN O
rapidly NN NN O
progressive NN NN O
glomerulonephritis NN NN B-Disease
( NN NN O
RPGN NN NN B-Disease
) NN NN O
after NN NN O
5 NN NN O
months NN NN O
of NN NN O
D NN NN O
- NN NN O
penicillamine NN NN O
( NN NN O
250 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
treatment NN NN O
. NN NN O
   
Light NN NN O
microscopy NN NN O
study NN NN O
showed NN NN O
severe NN NN O
glomerulonephritis NN NN B-Disease
with NN NN O
crescent NN NN O
formation NN NN O
in NN NN O
60 NN NN O
% NN NN O
of NN NN O
the NN NN O
glomeruli NN NN O
and NN NN O
infiltration NN NN O
of NN NN O
inflammatory NN NN O
cells NN NN O
in NN NN O
the NN NN O
wall NN NN O
of NN NN O
an NN NN O
arteriole NN NN O
. NN NN O
   
Immunofluorescence NN NN O
revealed NN NN O
scanty NN NN O
granular NN NN O
IgG NN NN O
, NN NN O
IgA NN NN O
and NN NN O
C3 NN NN O
deposits NN NN O
along NN NN O
the NN NN O
capillary NN NN O
walls NN NN O
and NN NN O
mesangium NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
was NN NN O
treated NN NN O
with NN NN O
steroid NN NN O
pulse NN NN O
, NN NN O
plasmapheresis NN NN O
, NN NN O
cyclophosphamide NN NN O
and NN NN O
antiplatelet NN NN O
agents NN NN O
. NN NN O
   
A NN NN O
complete NN NN O
recovery NN NN O
of NN NN O
renal NN NN O
function NN NN O
was NN NN O
achieved NN NN O
in NN NN O
a NN NN O
few NN NN O
weeks NN NN O
. NN NN O
   
This NN NN O
new NN NN O
case NN NN O
of NN NN O
RPGN NN NN B-Disease
in NN NN O
the NN NN O
course NN NN O
of NN NN O
D NN NN O
- NN NN O
penicillamine NN NN O
treatment NN NN O
emphasizes NN NN O
the NN NN O
need NN NN O
for NN NN O
frequent NN NN O
monitoring NN NN O
of NN NN O
renal NN NN O
function NN NN O
and NN NN O
evaluation NN NN O
of NN NN O
urinary NN NN O
sediment NN NN O
and NN NN O
proteinuria NN NN B-Disease
in NN NN O
these NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
prompt NN NN O
discontinuation NN NN O
of NN NN O
D NN NN O
- NN NN O
penicillamine NN NN O
and NN NN O
vigorous NN NN O
treatment NN NN O
measures NN NN O
could NN NN O
allow NN NN O
for NN NN O
a NN NN O
good NN NN O
prognosis NN NN O
as NN NN O
in NN NN O
this NN NN O
case NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
polymyositis NN NN B-Disease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
primary NN NN B-Disease
biliary NN NN I-Disease
cirrhosis NN NN I-Disease
treated NN NN O
with NN NN O
D NN NN O
- NN NN O
penicillamine NN NN O
. NN NN O
   
Although NN NN O
D NN NN O
- NN NN O
penicillamine NN NN O
has NN NN O
been NN NN O
used NN NN O
for NN NN O
many NN NN O
rheumatologic NN NN B-Disease
diseases NN NN I-Disease
, NN NN O
toxicity NN NN B-Disease
limits NN NN O
its NN NN O
usefulness NN NN O
in NN NN O
many NN NN O
patients NN NN O
. NN NN O
   
Polymyositis NN NN B-Disease
/ NN NN O
dermatomyositis NN NN B-Disease
can NN NN O
develop NN NN O
as NN NN O
one NN NN O
of NN NN O
the NN NN O
autoimmune NN NN O
complications NN NN O
of NN NN O
D NN NN O
- NN NN O
penicillamine NN NN O
treatment NN NN O
, NN NN O
but NN NN O
its NN NN O
exact NN NN O
pathogenesis NN NN O
remains NN NN O
unclear NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
patient NN NN O
with NN NN O
primary NN NN B-Disease
biliary NN NN I-Disease
cirrhosis NN NN I-Disease
, NN NN O
who NN NN O
developed NN NN O
polymyositis NN NN B-Disease
while NN NN O
receiving NN NN O
D NN NN O
- NN NN O
penicillamine NN NN O
therapy NN NN O
. NN NN O
   
We NN NN O
described NN NN O
the NN NN O
special NN NN O
clinical NN NN O
course NN NN O
of NN NN O
the NN NN O
patient NN NN O
. NN NN O
   
Patients NN NN O
receiving NN NN O
D NN NN O
- NN NN O
penicillamine NN NN O
therapy NN NN O
should NN NN O
be NN NN O
followed NN NN O
carefully NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
autoimmune NN NN O
complications NN NN O
like NN NN O
polymyositis NN NN B-Disease
/ NN NN O
dermatomyositis NN NN B-Disease
. NN NN O
   
Hyperalgesia NN NN B-Disease
and NN NN O
myoclonus NN NN B-Disease
in NN NN O
terminal NN NN O
cancer NN NN B-Disease
patients NN NN O
treated NN NN O
with NN NN O
continuous NN NN O
intravenous NN NN O
morphine NN NN O
. NN NN O
   
Eight NN NN O
cancer NN NN B-Disease
patients NN NN O
in NN NN O
the NN NN O
terminal NN NN O
stages NN NN O
of NN NN O
the NN NN O
disease NN NN O
treated NN NN O
with NN NN O
high NN NN O
doses NN NN O
of NN NN O
intravenous NN NN O
morphine NN NN O
developed NN NN O
hyperalgesia NN NN B-Disease
. NN NN O
   
All NN NN O
cases NN NN O
were NN NN O
retrospectively NN NN O
sampled NN NN O
from NN NN O
three NN NN O
different NN NN O
hospitals NN NN O
in NN NN O
Copenhagen NN NN O
. NN NN O
   
Five NN NN O
patients NN NN O
developed NN NN O
universal NN NN O
hyperalgesia NN NN B-Disease
and NN NN O
hyperesthesia NN NN B-Disease
which NN NN O
in NN NN O
2 NN NN O
cases NN NN O
were NN NN O
accompanied NN NN O
by NN NN O
myoclonus NN NN B-Disease
. NN NN O
   
In NN NN O
3 NN NN O
patients NN NN O
a NN NN O
pre NN NN O
- NN NN O
existing NN NN O
neuralgia NN NN B-Disease
increased NN NN O
to NN NN O
excruciating NN NN O
intensity NN NN O
and NN NN O
in NN NN O
2 NN NN O
of NN NN O
these NN NN O
cases NN NN O
myoclonus NN NN B-Disease
occurred NN NN O
simultaneously NN NN O
. NN NN O
   
Although NN NN O
only NN NN O
few NN NN O
clinical NN NN O
descriptions NN NN O
of NN NN O
the NN NN O
relationship NN NN O
between NN NN O
hyperalgesia NN NN B-Disease
/ NN NN O
myoclonus NN NN B-Disease
and NN NN O
high NN NN O
doses NN NN O
of NN NN O
morphine NN NN O
are NN NN O
available NN NN O
, NN NN O
experimental NN NN O
support NN NN O
from NN NN O
animal NN NN O
studies NN NN O
indicates NN NN O
that NN NN O
morphine NN NN O
, NN NN O
or NN NN O
its NN NN O
metabolites NN NN O
, NN NN O
plays NN NN O
a NN NN O
causative NN NN O
role NN NN O
for NN NN O
the NN NN O
observed NN NN O
behavioural NN NN O
syndrome NN NN O
. NN NN O
   
The NN NN O
possible NN NN O
mechanisms NN NN O
are NN NN O
discussed NN NN O
and NN NN O
treatment NN NN O
proposals NN NN O
given NN NN O
suggesting NN NN O
the NN NN O
use NN NN O
of NN NN O
more NN NN O
efficacious NN NN O
opioids NN NN O
with NN NN O
less NN NN O
excitatory NN NN O
potency NN NN O
in NN NN O
these NN NN O
situations NN NN O
. NN NN O
   
Liposomal NN NN O
daunorubicin NN NN O
in NN NN O
advanced NN NN O
Kaposi NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
sarcoma NN NN I-Disease
: NN NN O
a NN NN O
phase NN NN O
II NN NN O
study NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
non NN NN O
- NN NN O
randomized NN NN O
Phase NN NN O
II NN NN O
clinical NN NN O
trial NN NN O
to NN NN O
assess NN NN O
the NN NN O
efficacy NN NN O
and NN NN O
safety NN NN O
of NN NN O
liposomal NN NN O
daunorubicin NN NN O
( NN NN O
DaunoXome NN NN O
) NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
AIDS NN NN B-Disease
related NN NN O
Kaposi NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
sarcoma NN NN I-Disease
. NN NN O
   
Eleven NN NN O
homosexual NN NN O
men NN NN O
with NN NN O
advanced NN NN O
Kaposi NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
sarcoma NN NN I-Disease
were NN NN O
entered NN NN O
in NN NN O
the NN NN O
trial NN NN O
. NN NN O
   
Changes NN NN O
in NN NN O
size NN NN O
, NN NN O
colour NN NN O
and NN NN O
associated NN NN O
oedema NN NN B-Disease
of NN NN O
selected NN NN O
' NN NN O
target NN NN O
' NN NN O
lesions NN NN O
were NN NN O
measured NN NN O
. NN NN O
   
Clinical NN NN O
, NN NN O
biochemical NN NN O
and NN NN O
haematological NN NN O
toxicities NN NN B-Disease
were NN NN O
assessed NN NN O
. NN NN O
   
Ten NN NN O
subjects NN NN O
were NN NN O
evaluated NN NN O
. NN NN O
   
A NN NN O
partial NN NN O
response NN NN O
was NN NN O
achieved NN NN O
in NN NN O
four NN NN O
, NN NN O
of NN NN O
whom NN NN O
two NN NN O
subsequently NN NN O
relapsed NN NN O
. NN NN O
   
Stabilization NN NN O
of NN NN O
Kaposi NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
sarcoma NN NN I-Disease
occurred NN NN O
in NN NN O
the NN NN O
remaining NN NN O
six NN NN O
, NN NN O
maintained NN NN O
until NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
trial NN NN O
period NN NN O
in NN NN O
four NN NN O
. NN NN O
   
The NN NN O
drug NN NN O
was NN NN O
generally NN NN O
well NN NN O
tolerated NN NN O
, NN NN O
with NN NN O
few NN NN O
mild NN NN O
symptoms NN NN O
of NN NN O
toxicity NN NN B-Disease
. NN NN O
   
The NN NN O
main NN NN O
problem NN NN O
encountered NN NN O
was NN NN O
haematological NN NN O
toxicity NN NN B-Disease
, NN NN O
with NN NN O
three NN NN O
subjects NN NN O
experiencing NN NN O
severe NN NN O
neutropenia NN NN B-Disease
( NN NN O
neutrophil NN NN O
count NN NN O
< NN NN O
0 NN NN O
. NN NN O
5 NN NN O
x NN NN O
10 NN NN O
( NN NN O
9 NN NN O
) NN NN O
/ NN NN O
l NN NN O
) NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
evidence NN NN O
of NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
In NN NN O
this NN NN O
small NN NN O
patient NN NN O
sample NN NN O
, NN NN O
liposomal NN NN O
daunorubicin NN NN O
was NN NN O
an NN NN O
effective NN NN O
and NN NN O
well NN NN O
tolerated NN NN O
agent NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
Kaposi NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
sarcoma NN NN I-Disease
. NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
effects NN NN O
of NN NN O
vincristine NN NN O
on NN NN O
the NN NN O
peripheral NN NN O
nervous NN NN O
system NN NN O
. NN NN O
   
Forty NN NN O
patients NN NN O
with NN NN O
Non NN NN B-Disease
- NN NN I-Disease
Hodgkin NN NN I-Disease
' NN NN I-Disease
s NN NN I-Disease
Lymphoma NN NN I-Disease
treated NN NN O
with NN NN O
vincristine NN NN O
between NN NN O
1984 NN NN O
and NN NN O
1990 NN NN O
( NN NN O
cumulative NN NN O
dose NN NN O
12 NN NN O
mg NN NN O
in NN NN O
18 NN NN O
- NN NN O
24 NN NN O
weeks NN NN O
) NN NN O
were NN NN O
investigated NN NN O
in NN NN O
order NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
long NN NN O
term NN NN O
effects NN NN O
of NN NN O
vincristine NN NN O
on NN NN O
the NN NN O
peripheral NN NN O
nervous NN NN O
system NN NN O
. NN NN O
   
The NN NN O
patients NN NN O
were NN NN O
interviewed NN NN O
with NN NN O
emphasis NN NN O
on NN NN O
neuropathic NN NN B-Disease
symptoms NN NN I-Disease
. NN NN O
   
Physical NN NN O
and NN NN O
quantitative NN NN O
sensory NN NN O
examination NN NN O
with NN NN O
determination NN NN O
of NN NN O
vibratory NN NN O
perception NN NN O
and NN NN O
thermal NN NN O
discrimination NN NN O
thresholds NN NN O
were NN NN O
performed NN NN O
, NN NN O
four NN NN O
to NN NN O
77 NN NN O
months NN NN O
( NN NN O
median NN NN O
34 NN NN O
months NN NN O
) NN NN O
after NN NN O
vincristine NN NN O
treatment NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
seven NN NN O
patients NN NN O
reported NN NN O
neuropathic NN NN B-Disease
symptoms NN NN I-Disease
. NN NN O
   
In NN NN O
13 NN NN O
of NN NN O
these NN NN O
27 NN NN O
patients NN NN O
symptoms NN NN O
were NN NN O
still NN NN O
present NN NN O
at NN NN O
the NN NN O
time NN NN O
of NN NN O
examination NN NN O
. NN NN O
   
In NN NN O
these NN NN O
patients NN NN O
sensory NN NN O
signs NN NN O
and NN NN O
symptoms NN NN O
predominated NN NN O
. NN NN O
   
In NN NN O
the NN NN O
other NN NN O
14 NN NN O
patients NN NN O
symptoms NN NN O
had NN NN O
been NN NN O
present NN NN O
in NN NN O
the NN NN O
past NN NN O
. NN NN O
   
Symptoms NN NN O
persisted NN NN O
maximally NN NN O
40 NN NN O
months NN NN O
since NN NN O
cessation NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
age NN NN O
difference NN NN O
between NN NN O
patients NN NN O
with NN NN O
and NN NN O
without NN NN O
complaints NN NN O
at NN NN O
the NN NN O
time NN NN O
of NN NN O
examination NN NN O
. NN NN O
   
Normal NN NN O
reflexes NN NN O
were NN NN O
found NN NN O
in NN NN O
two NN NN O
third NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
Neuropathic NN NN O
complaints NN NN O
were NN NN O
not NN NN O
very NN NN O
troublesome NN NN O
on NN NN O
the NN NN O
long NN NN O
term NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
with NN NN O
the NN NN O
above NN NN O
mentioned NN NN O
vincristine NN NN O
dose NN NN O
schedule NN NN O
signs NN NN O
and NN NN O
symptoms NN NN O
of NN NN O
vincristine NN NN O
neuropathy NN NN B-Disease
are NN NN O
reversible NN NN O
for NN NN O
a NN NN O
great NN NN O
deal NN NN O
and NN NN O
prognosis NN NN O
is NN NN O
fairly NN NN O
good NN NN O
. NN NN O
   
Hepatic NN NN O
adenomas NN NN B-Disease
and NN NN O
focal NN NN B-Disease
nodular NN NN I-Disease
hyperplasia NN NN I-Disease
of NN NN O
the NN NN O
liver NN NN O
in NN NN O
young NN NN O
women NN NN O
on NN NN O
oral NN NN O
contraceptives NN NN O
: NN NN O
case NN NN O
reports NN NN O
. NN NN O
   
Two NN NN O
cases NN NN O
of NN NN O
hepatic NN NN O
adenoma NN NN B-Disease
and NN NN O
one NN NN O
of NN NN O
focal NN NN B-Disease
nodular NN NN I-Disease
hyperplasia NN NN I-Disease
presumably NN NN O
associated NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
oral NN NN O
contraceptives NN NN O
, NN NN O
are NN NN O
reported NN NN O
. NN NN O
   
Special NN NN O
reference NN NN O
is NN NN O
made NN NN O
to NN NN O
their NN NN O
clinical NN NN O
presentation NN NN O
, NN NN O
which NN NN O
may NN NN O
be NN NN O
totally NN NN O
asymptomatic NN NN O
. NN NN O
   
Liver NN NN O
- NN NN O
function NN NN O
tests NN NN O
are NN NN O
of NN NN O
little NN NN O
diagnostic NN NN O
value NN NN O
, NN NN O
but NN NN O
valuable NN NN O
information NN NN O
may NN NN O
be NN NN O
obtained NN NN O
from NN NN O
both NN NN O
liver NN NN O
scanning NN NN O
and NN NN O
hepatic NN NN O
angiography NN NN O
. NN NN O
   
Histologic NN NN O
differences NN NN O
and NN NN O
clinical NN NN O
similarities NN NN O
between NN NN O
hepatic NN NN O
adenoma NN NN B-Disease
and NN NN O
focal NN NN B-Disease
nodular NN NN I-Disease
hyperplasia NN NN I-Disease
of NN NN O
the NN NN O
liver NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Loss NN NN O
of NN NN O
glutamate NN NN O
decarboxylase NN NN O
mRNA NN NN O
- NN NN O
containing NN NN O
neurons NN NN O
in NN NN O
the NN NN O
rat NN NN O
dentate NN NN O
gyrus NN NN O
following NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
. NN NN O
   
In NN NN O
situ NN NN O
hybridization NN NN O
methods NN NN O
were NN NN O
used NN NN O
to NN NN O
determine NN NN O
if NN NN O
glutamic NN NN O
acid NN NN O
decarboxylase NN NN O
( NN NN O
GAD NN NN O
) NN NN O
mRNA NN NN O
- NN NN O
containing NN NN O
neurons NN NN O
within NN NN O
the NN NN O
hilus NN NN O
of NN NN O
the NN NN O
dentate NN NN O
gyrus NN NN O
are NN NN O
vulnerable NN NN O
to NN NN O
seizure NN NN B-Disease
- NN NN O
induced NN NN O
damage NN NN O
in NN NN O
a NN NN O
model NN NN O
of NN NN O
chronic NN NN O
seizures NN NN B-Disease
. NN NN O
   
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
were NN NN O
injected NN NN O
intraperitoneally NN NN O
with NN NN O
pilocarpine NN NN O
, NN NN O
and NN NN O
the NN NN O
hippocampal NN NN O
formation NN NN O
was NN NN O
studied NN NN O
histologically NN NN O
at NN NN O
1 NN NN O
, NN NN O
2 NN NN O
, NN NN O
4 NN NN O
, NN NN O
and NN NN O
8 NN NN O
week NN NN O
intervals NN NN O
after NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
. NN NN O
   
In NN NN O
situ NN NN O
hybridization NN NN O
histochemistry NN NN O
, NN NN O
using NN NN O
a NN NN O
digoxigenin NN NN O
- NN NN O
labeled NN NN O
GAD NN NN O
cRNA NN NN O
probe NN NN O
, NN NN O
demonstrated NN NN O
a NN NN O
substantial NN NN O
decrease NN NN O
in NN NN O
the NN NN O
number NN NN O
of NN NN O
GAD NN NN O
mRNA NN NN O
- NN NN O
containing NN NN O
neurons NN NN O
in NN NN O
the NN NN O
hilus NN NN O
of NN NN O
the NN NN O
dentate NN NN O
gyrus NN NN O
in NN NN O
the NN NN O
pilocarpine NN NN O
- NN NN O
treated NN NN O
rats NN NN O
as NN NN O
compared NN NN O
to NN NN O
controls NN NN O
at NN NN O
all NN NN O
time NN NN O
intervals NN NN O
. NN NN O
   
Additional NN NN O
neuronanatomical NN NN O
studies NN NN O
, NN NN O
including NN NN O
cresyl NN NN O
violet NN NN O
staining NN NN O
, NN NN O
neuronal NN NN B-Disease
degeneration NN NN I-Disease
methods NN NN O
, NN NN O
and NN NN O
histochemical NN NN O
localization NN NN O
of NN NN O
glial NN NN O
fibrillary NN NN O
acidic NN NN O
protein NN NN O
, NN NN O
suggested NN NN O
that NN NN O
the NN NN O
decrease NN NN O
in NN NN O
the NN NN O
number NN NN O
of NN NN O
GAD NN NN O
mRNA NN NN O
- NN NN O
containing NN NN O
neurons NN NN O
was NN NN O
related NN NN O
to NN NN O
neuronal NN NN B-Disease
loss NN NN I-Disease
rather NN NN O
than NN NN O
to NN NN O
a NN NN O
decrease NN NN O
in NN NN O
GAD NN NN O
mRNA NN NN O
levels NN NN O
. NN NN O
   
The NN NN O
loss NN NN O
of NN NN O
GAD NN NN O
mRNA NN NN O
- NN NN O
containing NN NN O
neurons NN NN O
in NN NN O
the NN NN O
hilus NN NN O
contrasted NN NN O
with NN NN O
the NN NN O
relative NN NN O
preservation NN NN O
of NN NN O
labeled NN NN O
putative NN NN O
basket NN NN O
cells NN NN O
along NN NN O
the NN NN O
inner NN NN O
margin NN NN O
of NN NN O
the NN NN O
granule NN NN O
cell NN NN O
layer NN NN O
. NN NN O
   
Quantitative NN NN O
analyses NN NN O
of NN NN O
labeled NN NN O
neurons NN NN O
in NN NN O
three NN NN O
regions NN NN O
of NN NN O
the NN NN O
dentate NN NN O
gyrus NN NN O
in NN NN O
the NN NN O
1 NN NN O
and NN NN O
2 NN NN O
week NN NN O
groups NN NN O
showed NN NN O
statistically NN NN O
significant NN NN O
decreases NN NN O
in NN NN O
the NN NN O
mean NN NN O
number NN NN O
of NN NN O
GAD NN NN O
mRNA NN NN O
- NN NN O
containing NN NN O
neurons NN NN O
in NN NN O
the NN NN O
hilus NN NN O
of NN NN O
both NN NN O
groups NN NN O
of NN NN O
experimental NN NN O
animals NN NN O
. NN NN O
   
No NN NN O
significant NN NN O
differences NN NN O
were NN NN O
found NN NN O
in NN NN O
the NN NN O
molecular NN NN O
layer NN NN O
or NN NN O
the NN NN O
granule NN NN O
cell NN NN O
layer NN NN O
, NN NN O
which NN NN O
included NN NN O
labeled NN NN O
neurons NN NN O
along NN NN O
the NN NN O
lower NN NN O
margin NN NN O
of NN NN O
the NN NN O
granule NN NN O
cell NN NN O
layer NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
, NN NN O
in NN NN O
this NN NN O
model NN NN O
, NN NN O
a NN NN O
subpopulation NN NN O
of NN NN O
GAD NN NN O
mRNA NN NN O
- NN NN O
containing NN NN O
neurons NN NN O
within NN NN O
the NN NN O
dentate NN NN O
gyrus NN NN O
is NN NN O
selectively NN NN O
vulnerable NN NN O
to NN NN O
seizure NN NN B-Disease
- NN NN O
induced NN NN O
damage NN NN O
. NN NN O
   
Such NN NN O
differential NN NN O
vulnerability NN NN O
appears NN NN O
to NN NN O
be NN NN O
another NN NN O
indication NN NN O
of NN NN O
the NN NN O
heterogeneity NN NN O
of NN NN O
GABA NN NN O
neurons NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
deliberate NN NN O
hypotension NN NN B-Disease
induced NN NN O
by NN NN O
labetalol NN NN O
with NN NN O
isoflurane NN NN O
on NN NN O
neuropsychological NN NN O
function NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
deliberate NN NN O
hypotension NN NN B-Disease
on NN NN O
brain NN NN O
function NN NN O
measured NN NN O
by NN NN O
neuropsychological NN NN O
tests NN NN O
was NN NN O
studied NN NN O
in NN NN O
41 NN NN O
adult NN NN O
patients NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
four NN NN O
patients NN NN O
were NN NN O
anaesthetized NN NN O
for NN NN O
middle NN NN O
- NN NN O
ear NN NN O
surgery NN NN O
with NN NN O
deliberate NN NN O
hypotension NN NN B-Disease
induced NN NN O
by NN NN O
labetalol NN NN O
with NN NN O
isoflurane NN NN O
( NN NN O
hypotensive NN NN B-Disease
group NN NN O
) NN NN O
. NN NN O
   
Seventeen NN NN O
patients NN NN O
without NN NN O
hypotension NN NN B-Disease
served NN NN O
as NN NN O
a NN NN O
control NN NN O
group NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
was NN NN O
77 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
mmHg NN NN O
( NN NN O
10 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
3 NN NN O
kPa NN NN O
) NN NN O
before NN NN O
hypotension NN NN B-Disease
and NN NN O
50 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
mmHg NN NN O
( NN NN O
6 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
0 NN NN O
kPa NN NN O
) NN NN O
during NN NN O
hypotension NN NN B-Disease
in NN NN O
the NN NN O
hypotensive NN NN B-Disease
group NN NN O
, NN NN O
and NN NN O
86 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
mmHg NN NN O
( NN NN O
11 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
3 NN NN O
kPa NN NN O
) NN NN O
during NN NN O
anaesthesia NN NN O
in NN NN O
the NN NN O
control NN NN O
group NN NN O
. NN NN O
   
The NN NN O
following NN NN O
psychological NN NN O
tests NN NN O
were NN NN O
performed NN NN O
: NN NN O
four NN NN O
subtests NN NN O
of NN NN O
the NN NN O
Wechsler NN NN O
Adult NN NN O
Intelligence NN NN O
Scale NN NN O
( NN NN O
similarities NN NN O
, NN NN O
digit NN NN O
span NN NN O
, NN NN O
vocabulary NN NN O
and NN NN O
digit NN NN O
symbol NN NN O
) NN NN O
, NN NN O
Trail NN NN O
- NN NN O
Making NN NN O
tests NN NN O
A NN NN O
and NN NN O
B NN NN O
, NN NN O
Zung NN NN O
tests NN NN O
( NN NN O
self NN NN O
- NN NN O
rating NN NN O
anxiety NN NN B-Disease
scale NN NN O
and NN NN O
self NN NN O
- NN NN O
rating NN NN O
depression NN NN B-Disease
scale NN NN O
) NN NN O
and NN NN O
two NN NN O
- NN NN O
part NN NN O
memory NN NN O
test NN NN O
battery NN NN O
with NN NN O
immediate NN NN O
and NN NN O
delayed NN NN O
recall NN NN O
. NN NN O
   
The NN NN O
tests NN NN O
were NN NN O
performed NN NN O
preoperatively NN NN O
and NN NN O
2 NN NN O
days NN NN O
postoperatively NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
statistically NN NN O
significant NN NN O
differences NN NN O
between NN NN O
the NN NN O
groups NN NN O
in NN NN O
any NN NN O
of NN NN O
the NN NN O
tests NN NN O
in NN NN O
the NN NN O
changes NN NN O
from NN NN O
preoperative NN NN O
value NN NN O
to NN NN O
postoperative NN NN O
value NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
hypotension NN NN B-Disease
induced NN NN O
by NN NN O
labetalol NN NN O
with NN NN O
isoflurane NN NN O
has NN NN O
no NN NN O
significant NN NN O
harmful NN NN O
effects NN NN O
on NN NN O
mental NN NN O
functions NN NN O
compared NN NN O
to NN NN O
normotensive NN NN O
anaesthesia NN NN O
. NN NN O
   
Apparent NN NN O
cure NN NN O
of NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
by NN NN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
the NN NN O
induction NN NN O
of NN NN O
sustained NN NN O
remissions NN NN O
and NN NN O
possible NN NN O
cure NN NN O
of NN NN O
severe NN NN O
erosive NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
( NN NN O
RA NN NN B-Disease
) NN NN O
by NN NN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
( NN NN O
BMT NN NN O
) NN NN O
in NN NN O
2 NN NN O
patients NN NN O
. NN NN O
   
BMT NN NN O
was NN NN O
used NN NN O
to NN NN O
treat NN NN O
severe NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
which NN NN O
was NN NN O
caused NN NN O
by NN NN O
gold NN NN O
in NN NN O
one NN NN O
case NN NN O
and NN NN O
D NN NN O
- NN NN O
penicillamine NN NN O
in NN NN O
the NN NN O
other NN NN O
. NN NN O
   
In NN NN O
the NN NN O
8 NN NN O
and NN NN O
6 NN NN O
years NN NN O
since NN NN O
the NN NN O
transplants NN NN O
( NN NN O
representing NN NN O
8 NN NN O
and NN NN O
4 NN NN O
years NN NN O
since NN NN O
cessation NN NN O
of NN NN O
all NN NN O
immunosuppressive NN NN O
therapy NN NN O
, NN NN O
respectively NN NN O
) NN NN O
, NN NN O
the NN NN O
RA NN NN B-Disease
in NN NN O
each NN NN O
case NN NN O
has NN NN O
been NN NN O
completely NN NN O
quiescent NN NN O
. NN NN O
   
Although NN NN O
short NN NN O
term NN NN O
remission NN NN O
of NN NN O
severe NN NN O
RA NN NN B-Disease
following NN NN O
BMT NN NN O
has NN NN O
been NN NN O
reported NN NN O
, NN NN O
these NN NN O
are NN NN O
the NN NN O
first NN NN O
cases NN NN O
for NN NN O
which NN NN O
prolonged NN NN O
followup NN NN O
has NN NN O
been NN NN O
available NN NN O
. NN NN O
   
This NN NN O
experience NN NN O
raises NN NN O
the NN NN O
question NN NN O
of NN NN O
the NN NN O
role NN NN O
of NN NN O
BMT NN NN O
itself NN NN O
as NN NN O
a NN NN O
therapeutic NN NN O
option NN NN O
for NN NN O
patients NN NN O
with NN NN O
uncontrolled NN NN O
destructive NN NN O
synovitis NN NN B-Disease
. NN NN O
   
Seizures NN NN B-Disease
induced NN NN O
by NN NN O
combined NN NN O
levomepromazine NN NN O
- NN NN O
fluvoxamine NN NN O
treatment NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
combined NN NN O
levomepromazine NN NN O
- NN NN O
fluvoxamine NN NN O
treatment NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
. NN NN O
   
It NN NN O
seems NN NN O
that NN NN O
combined NN NN O
treatment NN NN O
of NN NN O
fluvoxamine NN NN O
with NN NN O
phenothiazines NN NN O
may NN NN O
possess NN NN O
proconvulsive NN NN O
activity NN NN O
. NN NN O
   
Case NN NN O
report NN NN O
: NN NN O
pentamidine NN NN O
and NN NN O
polymorphic NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
revisited NN NN O
. NN NN O
   
Pentamidine NN NN O
isethionate NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
ventricular NN NN B-Disease
tachyarrhythmias NN NN I-Disease
, NN NN O
including NN NN O
torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
. NN NN O
   
This NN NN O
article NN NN O
reports NN NN O
two NN NN O
cases NN NN O
of NN NN O
this NN NN O
complication NN NN O
and NN NN O
reviews NN NN O
all NN NN O
reported NN NN O
cases NN NN O
to NN NN O
date NN NN O
. NN NN O
   
Pentamidine NN NN O
- NN NN O
induced NN NN O
torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
may NN NN O
be NN NN O
related NN NN O
to NN NN O
serum NN NN O
magnesium NN NN O
levels NN NN O
and NN NN O
hypomagnesemia NN NN B-Disease
may NN NN O
synergistically NN NN O
induce NN NN O
torsade NN NN O
. NN NN O
   
Torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
occurred NN NN O
after NN NN O
an NN NN O
average NN NN O
of NN NN O
10 NN NN O
days NN NN O
of NN NN O
treatment NN NN O
with NN NN O
pentamidine NN NN O
. NN NN O
   
In NN NN O
these NN NN O
patients NN NN O
, NN NN O
no NN NN O
other NN NN O
acute NN NN O
side NN NN O
effects NN NN O
of NN NN O
pentamidine NN NN O
were NN NN O
observed NN NN O
. NN NN O
   
Torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
can NN NN O
be NN NN O
treated NN NN O
when NN NN O
recognized NN NN O
early NN NN O
, NN NN O
possibly NN NN O
without NN NN O
discontinuation NN NN O
of NN NN O
pentamidine NN NN O
. NN NN O
   
When NN NN O
QTc NN NN B-Disease
interval NN NN I-Disease
prolongation NN NN I-Disease
is NN NN O
observed NN NN O
, NN NN O
early NN NN O
magnesium NN NN O
supplementation NN NN O
is NN NN O
advocated NN NN O
. NN NN O
   
Efficacy NN NN O
and NN NN O
tolerability NN NN O
of NN NN O
lovastatin NN NN O
in NN NN O
3390 NN NN O
women NN NN O
with NN NN O
moderate NN NN O
hypercholesterolemia NN NN B-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
evaluate NN NN O
the NN NN O
efficacy NN NN O
and NN NN O
safety NN NN O
of NN NN O
lovastatin NN NN O
in NN NN O
women NN NN O
with NN NN O
moderate NN NN O
hypercholesterolemia NN NN B-Disease
. NN NN O
   
DESIGN NN NN O
: NN NN O
The NN NN O
Expanded NN NN O
Clinical NN NN O
Evaluation NN NN O
of NN NN O
Lovastatin NN NN O
( NN NN O
EXCEL NN NN O
) NN NN O
Study NN NN O
, NN NN O
a NN NN O
multicenter NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
diet NN NN O
- NN NN O
and NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
trial NN NN O
, NN NN O
in NN NN O
which NN NN O
participants NN NN O
were NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
receive NN NN O
placebo NN NN O
or NN NN O
lovastatin NN NN O
at NN NN O
doses NN NN O
of NN NN O
20 NN NN O
or NN NN O
40 NN NN O
mg NN NN O
once NN NN O
daily NN NN O
, NN NN O
or NN NN O
20 NN NN O
or NN NN O
40 NN NN O
mg NN NN O
twice NN NN O
daily NN NN O
for NN NN O
48 NN NN O
weeks NN NN O
. NN NN O
   
SETTING NN NN O
: NN NN O
Ambulatory NN NN O
patients NN NN O
recruited NN NN O
by NN NN O
362 NN NN O
participating NN NN O
centers NN NN O
throughout NN NN O
the NN NN O
United NN NN O
States NN NN O
. NN NN O
   
PATIENTS NN NN O
: NN NN O
Women NN NN O
( NN NN O
n NN NN O
= NN NN O
3390 NN NN O
) NN NN O
from NN NN O
the NN NN O
total NN NN O
cohort NN NN O
of NN NN O
8245 NN NN O
volunteers NN NN O
. NN NN O
   
MEASUREMENTS NN NN O
: NN NN O
Plasma NN NN O
total NN NN O
, NN NN O
low NN NN O
- NN NN O
density NN NN O
lipoprotein NN NN O
( NN NN O
LDL NN NN O
) NN NN O
, NN NN O
and NN NN O
high NN NN O
- NN NN O
density NN NN O
lipoprotein NN NN O
( NN NN O
HDL NN NN O
) NN NN O
cholesterol NN NN O
, NN NN O
and NN NN O
triglycerides NN NN O
; NN NN O
and NN NN O
laboratory NN NN O
and NN NN O
clinical NN NN O
evidence NN NN O
of NN NN O
adverse NN NN O
events NN NN O
monitored NN NN O
periodically NN NN O
throughout NN NN O
the NN NN O
study NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Among NN NN O
women NN NN O
, NN NN O
lovastatin NN NN O
( NN NN O
20 NN NN O
to NN NN O
80 NN NN O
mg NN NN O
/ NN NN O
d NN NN O
) NN NN O
produced NN NN O
sustained NN NN O
( NN NN O
12 NN NN O
- NN NN O
to NN NN O
48 NN NN O
- NN NN O
week NN NN O
) NN NN O
, NN NN O
dose NN NN O
- NN NN O
related NN NN O
changes NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
: NN NN O
decreases NN NN O
in NN NN O
LDL NN NN O
cholesterol NN NN O
( NN NN O
24 NN NN O
% NN NN O
to NN NN O
40 NN NN O
% NN NN O
) NN NN O
and NN NN O
triglycerides NN NN O
( NN NN O
9 NN NN O
% NN NN O
to NN NN O
18 NN NN O
% NN NN O
) NN NN O
, NN NN O
and NN NN O
increases NN NN O
in NN NN O
HDL NN NN O
cholesterol NN NN O
( NN NN O
6 NN NN O
. NN NN O
7 NN NN O
% NN NN O
to NN NN O
8 NN NN O
. NN NN O
6 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Depending NN NN O
on NN NN O
the NN NN O
dose NN NN O
, NN NN O
from NN NN O
82 NN NN O
% NN NN O
to NN NN O
95 NN NN O
% NN NN O
of NN NN O
lovastatin NN NN O
- NN NN O
treated NN NN O
women NN NN O
achieved NN NN O
the NN NN O
National NN NN O
Cholesterol NN NN O
Education NN NN O
Program NN NN O
goal NN NN O
of NN NN O
LDL NN NN O
cholesterol NN NN O
levels NN NN O
less NN NN O
than NN NN O
4 NN NN O
. NN NN O
14 NN NN O
mmol NN NN O
/ NN NN O
L NN NN O
( NN NN O
160 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
) NN NN O
, NN NN O
and NN NN O
40 NN NN O
% NN NN O
to NN NN O
87 NN NN O
% NN NN O
achieved NN NN O
the NN NN O
goal NN NN O
of NN NN O
3 NN NN O
. NN NN O
36 NN NN O
mmol NN NN O
/ NN NN O
L NN NN O
( NN NN O
130 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
) NN NN O
. NN NN O
   
Successive NN NN O
transaminase NN NN O
elevations NN NN O
greater NN NN O
than NN NN O
three NN NN O
times NN NN O
the NN NN O
upper NN NN O
limit NN NN O
of NN NN O
normal NN NN O
occurred NN NN O
in NN NN O
0 NN NN O
. NN NN O
1 NN NN O
% NN NN O
of NN NN O
women NN NN O
and NN NN O
were NN NN O
dose NN NN O
dependent NN NN O
above NN NN O
the NN NN O
20 NN NN O
- NN NN O
mg NN NN O
dose NN NN O
. NN NN O
   
Myopathy NN NN B-Disease
, NN NN O
defined NN NN O
as NN NN O
muscle NN NN O
symptoms NN NN O
with NN NN O
creatine NN NN O
kinase NN NN O
elevations NN NN O
greater NN NN O
than NN NN O
10 NN NN O
times NN NN O
the NN NN O
upper NN NN O
limit NN NN O
of NN NN O
normal NN NN O
, NN NN O
was NN NN O
rare NN NN O
and NN NN O
associated NN NN O
with NN NN O
the NN NN O
highest NN NN O
recommended NN NN O
daily NN NN O
dose NN NN O
of NN NN O
lovastatin NN NN O
( NN NN O
80 NN NN O
mg NN NN O
) NN NN O
. NN NN O
   
Estrogen NN NN O
- NN NN O
replacement NN NN O
therapy NN NN O
appeared NN NN O
to NN NN O
have NN NN O
no NN NN O
effect NN NN O
on NN NN O
either NN NN O
the NN NN O
efficacy NN NN O
or NN NN O
safety NN NN O
profile NN NN O
of NN NN O
lovastatin NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Lovastatin NN NN O
is NN NN O
highly NN NN O
effective NN NN O
and NN NN O
generally NN NN O
well NN NN O
tolerated NN NN O
as NN NN O
therapy NN NN O
for NN NN O
primary NN NN O
hypercholesterolemia NN NN B-Disease
in NN NN O
women NN NN O
. NN NN O
   
Tetany NN NN B-Disease
and NN NN O
rhabdomyolysis NN NN B-Disease
due NN NN O
to NN NN O
surreptitious NN NN O
furosemide NN NN O
- NN NN O
- NN NN O
importance NN NN O
of NN NN O
magnesium NN NN O
supplementation NN NN O
. NN NN O
   
Diuretics NN NN O
may NN NN O
induce NN NN O
hypokalemia NN NN B-Disease
, NN NN O
hypocalcemia NN NN B-Disease
and NN NN O
hypomagnesemia NN NN B-Disease
. NN NN O
   
While NN NN O
severe NN NN O
hypokalemia NN NN B-Disease
may NN NN O
cause NN NN O
muscle NN NN B-Disease
weakness NN NN I-Disease
, NN NN O
severe NN NN O
hypomagnesemia NN NN B-Disease
is NN NN O
associated NN NN O
with NN NN O
muscle NN NN B-Disease
spasms NN NN I-Disease
and NN NN O
tetany NN NN B-Disease
which NN NN O
cannot NN NN O
be NN NN O
corrected NN NN O
by NN NN O
potassium NN NN O
and NN NN O
calcium NN NN O
supplementation NN NN O
alone NN NN O
( NN NN O
1 NN NN O
, NN NN O
2 NN NN O
) NN NN O
. NN NN O
   
Surreptitious NN NN O
diuretic NN NN O
ingestion NN NN O
has NN NN O
been NN NN O
described NN NN O
, NN NN O
mainly NN NN O
in NN NN O
women NN NN O
who NN NN O
are NN NN O
concerned NN NN O
that NN NN O
they NN NN O
are NN NN O
obese NN NN B-Disease
or NN NN O
edematous NN NN B-Disease
. NN NN O
   
Symptomatic NN NN O
hypokalemia NN NN B-Disease
has NN NN O
been NN NN O
reported NN NN O
in NN NN O
such NN NN O
patients NN NN O
( NN NN O
3 NN NN O
- NN NN O
7 NN NN O
) NN NN O
and NN NN O
in NN NN O
one NN NN O
case NN NN O
hypocalcemia NN NN B-Disease
was NN NN O
observed NN NN O
( NN NN O
8 NN NN O
) NN NN O
, NN NN O
but NN NN O
the NN NN O
effects NN NN O
of NN NN O
magnesium NN NN O
depletion NN NN O
were NN NN O
not NN NN O
noted NN NN O
in NN NN O
these NN NN O
patients NN NN O
. NN NN O
   
Ciprofloxacin NN NN O
- NN NN O
induced NN NN O
nephrotoxicity NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
cancer NN NN B-Disease
. NN NN O
   
Nephrotoxicity NN NN B-Disease
associated NN NN O
with NN NN O
ciprofloxacin NN NN O
is NN NN O
uncommon NN NN O
. NN NN O
   
Five NN NN O
patients NN NN O
with NN NN O
cancer NN NN B-Disease
who NN NN O
developed NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
that NN NN O
followed NN NN O
treatment NN NN O
with NN NN O
ciprofloxacin NN NN O
are NN NN O
described NN NN O
and NN NN O
an NN NN O
additional NN NN O
15 NN NN O
cases NN NN O
reported NN NN O
in NN NN O
the NN NN O
literature NN NN O
are NN NN O
reviewed NN NN O
. NN NN O
   
Other NN NN O
than NN NN O
elevation NN NN O
of NN NN O
serum NN NN O
creatinine NN NN O
levels NN NN O
, NN NN O
characteristic NN NN O
clinical NN NN O
manifestations NN NN O
and NN NN O
abnormal NN NN O
laboratory NN NN O
findings NN NN O
are NN NN O
not NN NN O
frequently NN NN O
present NN NN O
. NN NN O
   
Allergic NN NN O
interstitial NN NN B-Disease
nephritis NN NN I-Disease
is NN NN O
believed NN NN O
to NN NN O
be NN NN O
the NN NN O
underlying NN NN O
pathological NN NN O
- NN NN O
process NN NN O
. NN NN O
   
Definitive NN NN O
diagnosis NN NN O
requires NN NN O
performance NN NN O
of NN NN O
renal NN NN O
biopsy NN NN O
, NN NN O
although NN NN O
this NN NN O
is NN NN O
not NN NN O
always NN NN O
feasible NN NN O
. NN NN O
   
An NN NN O
improvement NN NN O
in NN NN O
renal NN NN O
function NN NN O
that NN NN O
followed NN NN O
the NN NN O
discontinuation NN NN O
of NN NN O
the NN NN O
offending NN NN O
antibiotic NN NN O
supports NN NN O
the NN NN O
presumptive NN NN O
diagnosis NN NN O
of NN NN O
ciprofloxacin NN NN O
- NN NN O
induced NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
Venous NN NN B-Disease
complications NN NN I-Disease
of NN NN O
midazolam NN NN O
versus NN NN O
diazepam NN NN O
. NN NN O
   
Although NN NN O
some NN NN O
studies NN NN O
have NN NN O
suggested NN NN O
fewer NN NN O
venous NN NN B-Disease
complications NN NN I-Disease
are NN NN O
associated NN NN O
with NN NN O
midazolam NN NN O
than NN NN O
with NN NN O
diazepam NN NN O
for NN NN O
endoscopic NN NN O
procedures NN NN O
, NN NN O
this NN NN O
variable NN NN O
has NN NN O
not NN NN O
been NN NN O
well NN NN O
documented NN NN O
. NN NN O
   
We NN NN O
prospectively NN NN O
evaluated NN NN O
the NN NN O
incidence NN NN O
of NN NN O
venous NN NN B-Disease
complications NN NN I-Disease
after NN NN O
intravenous NN NN O
injection NN NN O
of NN NN O
diazepam NN NN O
or NN NN O
midazolam NN NN O
in NN NN O
122 NN NN O
consecutive NN NN O
patients NN NN O
undergoing NN NN O
colonoscopy NN NN O
and NN NN O
esophagogastroduodenoscopy NN NN O
. NN NN O
   
Overall NN NN O
, NN NN O
venous NN NN B-Disease
complications NN NN I-Disease
were NN NN O
more NN NN O
frequent NN NN O
with NN NN O
diazepam NN NN O
( NN NN O
22 NN NN O
of NN NN O
62 NN NN O
patients NN NN O
) NN NN O
than NN NN O
with NN NN O
midazolam NN NN O
( NN NN O
4 NN NN O
of NN NN O
60 NN NN O
patients NN NN O
) NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
A NN NN O
palpable NN NN O
venous NN NN O
cord NN NN O
was NN NN O
present NN NN O
in NN NN O
23 NN NN O
% NN NN O
( NN NN O
14 NN NN O
of NN NN O
62 NN NN O
) NN NN O
of NN NN O
patients NN NN O
in NN NN O
the NN NN O
diazepam NN NN O
group NN NN O
, NN NN O
compared NN NN O
with NN NN O
2 NN NN O
% NN NN O
( NN NN O
1 NN NN O
of NN NN O
60 NN NN O
patients NN NN O
) NN NN O
in NN NN O
the NN NN O
midazolam NN NN O
group NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
002 NN NN O
) NN NN O
. NN NN O
   
Pain NN NN B-Disease
at NN NN O
the NN NN O
injection NN NN O
site NN NN O
occurred NN NN O
in NN NN O
35 NN NN O
% NN NN O
( NN NN O
22 NN NN O
of NN NN O
62 NN NN O
) NN NN O
of NN NN O
patients NN NN O
in NN NN O
the NN NN O
diazepam NN NN O
group NN NN O
compared NN NN O
with NN NN O
7 NN NN O
% NN NN O
( NN NN O
4 NN NN O
of NN NN O
60 NN NN O
patients NN NN O
) NN NN O
in NN NN O
the NN NN O
midazolam NN NN O
group NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Swelling NN NN B-Disease
and NN NN O
warmth NN NN O
at NN NN O
the NN NN O
injection NN NN O
site NN NN O
were NN NN O
not NN NN O
significantly NN NN O
different NN NN O
between NN NN O
the NN NN O
two NN NN O
groups NN NN O
. NN NN O
   
Smoking NN NN O
, NN NN O
nonsteroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drug NN NN O
use NN NN O
, NN NN O
intravenous NN NN O
catheter NN NN O
site NN NN O
, NN NN O
dwell NN NN O
time NN NN O
of NN NN O
the NN NN O
needle NN NN O
, NN NN O
alcohol NN NN O
use NN NN O
, NN NN O
and NN NN O
pain NN NN B-Disease
during NN NN O
the NN NN O
injection NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
the NN NN O
incidence NN NN O
of NN NN O
venous NN NN B-Disease
complications NN NN I-Disease
. NN NN O
   
Clarithromycin NN NN O
- NN NN O
associated NN NN O
visual NN NN B-Disease
hallucinations NN NN I-Disease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
chronic NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
on NN NN O
continuous NN NN O
ambulatory NN NN O
peritoneal NN NN O
dialysis NN NN O
. NN NN O
   
Visual NN NN B-Disease
hallucinations NN NN I-Disease
are NN NN O
a NN NN O
rare NN NN O
event NN NN O
in NN NN O
chronic NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
and NN NN O
not NN NN O
related NN NN O
to NN NN O
uremia NN NN B-Disease
per NN NN O
se NN NN O
. NN NN O
   
Unreported NN NN O
in NN NN O
the NN NN O
literature NN NN O
is NN NN O
visual NN NN B-Disease
hallucinations NN NN I-Disease
occurring NN NN O
in NN NN O
association NN NN O
with NN NN O
the NN NN O
new NN NN O
macrolide NN NN O
antibiotic NN NN O
, NN NN O
clarithromycin NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
such NN NN O
a NN NN O
case NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
end NN NN B-Disease
- NN NN I-Disease
stage NN NN I-Disease
renal NN NN I-Disease
disease NN NN I-Disease
( NN NN O
ESRD NN NN B-Disease
) NN NN O
maintained NN NN O
on NN NN O
continuous NN NN O
ambulatory NN NN O
peritoneal NN NN O
dialysis NN NN O
( NN NN O
CAPD NN NN O
) NN NN O
. NN NN O
   
The NN NN O
combination NN NN O
of NN NN O
a NN NN O
relatively NN NN O
high NN NN O
dose NN NN O
of NN NN O
clarithromycin NN NN O
in NN NN O
face NN NN O
of NN NN O
chronic NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
in NN NN O
a NN NN O
functionally NN NN O
anephric NN NN O
patient NN NN O
, NN NN O
with NN NN O
underlying NN NN O
aluminum NN NN O
intoxication NN NN O
, NN NN O
may NN NN O
have NN NN O
facilitated NN NN O
the NN NN O
appearance NN NN O
of NN NN O
this NN NN O
neurotoxic NN NN B-Disease
side NN NN O
effect NN NN O
. NN NN O
   
It NN NN O
is NN NN O
important NN NN O
to NN NN O
understand NN NN O
the NN NN O
pharmacokinetics NN NN O
of NN NN O
medications NN NN O
in NN NN O
face NN NN O
of NN NN O
chronic NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
, NN NN O
the NN NN O
possibility NN NN O
of NN NN O
drug NN NN O
interactions NN NN O
, NN NN O
and NN NN O
how NN NN O
these NN NN O
factors NN NN O
should NN NN O
help NN NN O
guide NN NN O
medication NN NN O
therapy NN NN O
in NN NN O
the NN NN O
ESRD NN NN B-Disease
patient NN NN O
. NN NN O
   
Changes NN NN O
in NN NN O
peroxisomes NN NN O
in NN NN O
preneoplastic NN NN O
liver NN NN O
and NN NN O
hepatoma NN NN B-Disease
of NN NN O
mice NN NN O
induced NN NN O
by NN NN O
alpha NN NN O
- NN NN O
benzene NN NN O
hexachloride NN NN O
. NN NN O
   
Peroxisomes NN NN O
in NN NN O
hepatomas NN NN B-Disease
and NN NN O
hyperplastic NN NN O
preneoplastic NN NN O
liver NN NN B-Disease
lesions NN NN I-Disease
induced NN NN O
in NN NN O
mice NN NN O
by NN NN O
500 NN NN O
ppm NN NN O
alpha NN NN O
- NN NN O
benzene NN NN O
hexachloride NN NN O
were NN NN O
examined NN NN O
histochemically NN NN O
and NN NN O
electron NN NN O
microscopically NN NN O
. NN NN O
   
Although NN NN O
most NN NN O
of NN NN O
the NN NN O
hepatomas NN NN B-Disease
were NN NN O
well NN NN O
- NN NN O
differentiated NN NN O
tumors NN NN B-Disease
and NN NN O
contained NN NN O
a NN NN O
considerable NN NN O
number NN NN O
of NN NN O
peroxisomes NN NN O
, NN NN O
the NN NN O
tumor NN NN B-Disease
cells NN NN O
did NN NN O
not NN NN O
respond NN NN O
to NN NN O
ethyl NN NN O
- NN NN O
alpha NN NN O
- NN NN O
p NN NN O
- NN NN O
chlorophenoxyisobutyrate NN NN O
with NN NN O
proliferation NN NN O
of NN NN O
peroxisomes NN NN O
. NN NN O
   
At NN NN O
the NN NN O
16th NN NN O
week NN NN O
of NN NN O
carcinogen NN NN O
feeding NN NN O
, NN NN O
hyperplastic NN NN O
nodules NN NN O
appeared NN NN O
and NN NN O
advanced NN NN O
to NN NN O
further NN NN O
stages NN NN O
. NN NN O
   
A NN NN O
majority NN NN O
of NN NN O
the NN NN O
nodules NN NN O
showed NN NN O
a NN NN O
considerable NN NN O
number NN NN O
of NN NN O
peroxisomes NN NN O
and NN NN O
the NN NN O
inductive NN NN O
proliferation NN NN O
of NN NN O
peroxisomes NN NN O
. NN NN O
   
Within NN NN O
the NN NN O
nodules NN NN O
, NN NN O
foci NN NN O
of NN NN O
proliferation NN NN O
of NN NN O
the NN NN O
cells NN NN O
that NN NN O
showed NN NN O
no NN NN O
inducibility NN NN O
of NN NN O
proliferation NN NN O
of NN NN O
peroxisomes NN NN O
appeared NN NN O
. NN NN O
   
These NN NN O
cells NN NN O
proliferated NN NN O
further NN NN O
, NN NN O
replacing NN NN O
the NN NN O
most NN NN O
part NN NN O
of NN NN O
the NN NN O
nodules NN NN O
, NN NN O
and NN NN O
with NN NN O
this NN NN O
process NN NN O
hepatomas NN NN B-Disease
appeared NN NN O
to NN NN O
have NN NN O
been NN NN O
formed NN NN O
. NN NN O
   
No NN NN O
abnormal NN NN O
matrical NN NN O
inclusions NN NN O
of NN NN O
peroxisomes NN NN O
were NN NN O
formed NN NN O
in NN NN O
the NN NN O
cells NN NN O
of NN NN O
hyperplastic NN NN O
nodules NN NN O
by NN NN O
ethyl NN NN O
- NN NN O
alpha NN NN O
- NN NN O
p NN NN O
- NN NN O
chlorophenoxyisobutyrate NN NN O
unlike NN NN O
in NN NN O
the NN NN O
case NN NN O
of NN NN O
rats NN NN O
. NN NN O
   
Contribution NN NN O
of NN NN O
the NN NN O
sympathetic NN NN O
nervous NN NN O
system NN NN O
to NN NN O
salt NN NN O
- NN NN O
sensitivity NN NN O
in NN NN O
lifetime NN NN O
captopril NN NN O
- NN NN O
treated NN NN O
spontaneously NN NN O
hypertensive NN NN B-Disease
rats NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
test NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
, NN NN O
in NN NN O
lifetime NN NN O
captopril NN NN O
- NN NN O
treated NN NN O
spontaneously NN NN O
hypertensive NN NN B-Disease
rats NN NN O
( NN NN O
SHR NN NN O
) NN NN O
, NN NN O
the NN NN O
sympathetic NN NN O
nervous NN NN O
system NN NN O
contributes NN NN O
importantly NN NN O
to NN NN O
the NN NN O
hypertensive NN NN B-Disease
effect NN NN O
of NN NN O
dietary NN NN O
sodium NN NN O
chloride NN NN O
supplementation NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Male NN NN O
SHR NN NN O
( NN NN O
aged NN NN O
6 NN NN O
weeks NN NN O
) NN NN O
that NN NN O
had NN NN O
been NN NN O
treated NN NN O
from NN NN O
conception NN NN O
onward NN NN O
with NN NN O
either NN NN O
captopril NN NN O
or NN NN O
vehicle NN NN O
remained NN NN O
on NN NN O
a NN NN O
basal NN NN O
sodium NN NN O
chloride NN NN O
diet NN NN O
or NN NN O
were NN NN O
fed NN NN O
a NN NN O
high NN NN O
sodium NN NN O
chloride NN NN O
diet NN NN O
. NN NN O
   
After NN NN O
2 NN NN O
weeks NN NN O
, NN NN O
the NN NN O
rats NN NN O
were NN NN O
subjected NN NN O
to NN NN O
ganglionic NN NN O
blockade NN NN O
and NN NN O
2 NN NN O
days NN NN O
later NN NN O
, NN NN O
an NN NN O
infusion NN NN O
of NN NN O
clonidine NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Lifetime NN NN O
captopril NN NN O
treatment NN NN O
significantly NN NN O
lowered NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
in NN NN O
both NN NN O
groups NN NN O
. NN NN O
   
Intravenous NN NN O
infusion NN NN O
of NN NN O
the NN NN O
ganglionic NN NN O
blocker NN NN O
hexamethonium NN NN O
resulted NN NN O
in NN NN O
a NN NN O
rapid NN NN O
decline NN NN O
in NN NN O
MAP NN NN O
that NN NN O
eliminated NN NN O
the NN NN O
dietary NN NN O
sodium NN NN O
chloride NN NN O
- NN NN O
induced NN NN O
increase NN NN B-Disease
in NN NN I-Disease
MAP NN NN I-Disease
in NN NN O
both NN NN O
groups NN NN O
. NN NN O
   
Infusion NN NN O
of NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
alpha2 NN NN O
- NN NN O
adrenergic NN NN O
receptor NN NN O
agonist NN NN O
clonidine NN NN O
also NN NN O
resulted NN NN O
in NN NN O
a NN NN O
greater NN NN O
reduction NN NN O
in NN NN O
MAP NN NN O
in NN NN O
both NN NN O
groups NN NN O
of NN NN O
SHR NN NN O
that NN NN O
were NN NN O
fed NN NN O
the NN NN O
high NN NN O
( NN NN O
compared NN NN O
with NN NN O
the NN NN O
basal NN NN O
) NN NN O
sodium NN NN O
chloride NN NN O
diet NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
In NN NN O
both NN NN O
lifetime NN NN O
captopril NN NN O
- NN NN O
treated NN NN O
and NN NN O
control NN NN O
SHR NN NN O
, NN NN O
the NN NN O
sympathetic NN NN O
nervous NN NN O
system NN NN O
contributes NN NN O
to NN NN O
the NN NN O
pressor NN NN O
effects NN NN O
of NN NN O
a NN NN O
high NN NN O
sodium NN NN O
chloride NN NN O
diet NN NN O
. NN NN O
   
Angioedema NN NN B-Disease
associated NN NN O
with NN NN O
droperidol NN NN O
administration NN NN O
. NN NN O
   
Angioedema NN NN B-Disease
, NN NN O
also NN NN O
known NN NN O
as NN NN O
angioneurotic NN NN B-Disease
edema NN NN I-Disease
or NN NN O
Quincke NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
, NN NN O
is NN NN O
a NN NN O
well NN NN O
- NN NN O
demarcated NN NN O
, NN NN O
localized NN NN O
edema NN NN B-Disease
involving NN NN O
the NN NN O
subcutaneous NN NN O
tissues NN NN O
that NN NN O
may NN NN O
cause NN NN O
upper NN NN B-Disease
- NN NN I-Disease
airway NN NN I-Disease
obstruction NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
previously NN NN O
healthy NN NN O
19 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
with NN NN O
no NN NN O
known NN NN O
drug NN NN B-Disease
allergies NN NN I-Disease
in NN NN O
whom NN NN O
angioedema NN NN B-Disease
with NN NN O
significant NN NN O
tongue NN NN B-Disease
swelling NN NN I-Disease
and NN NN O
protrusion NN NN O
developed NN NN O
within NN NN O
10 NN NN O
minutes NN NN O
of NN NN O
the NN NN O
administration NN NN O
of NN NN O
a NN NN O
single NN NN O
IV NN NN O
dose NN NN O
of NN NN O
droperidol NN NN O
. NN NN O
   
Late NN NN O
cardiotoxicity NN NN B-Disease
after NN NN O
treatment NN NN O
for NN NN O
a NN NN O
malignant NN NN O
bone NN NN B-Disease
tumor NN NN I-Disease
. NN NN O
   
Cardiac NN NN O
function NN NN O
was NN NN O
assessed NN NN O
in NN NN O
long NN NN O
- NN NN O
term NN NN O
survivors NN NN O
of NN NN O
malignant NN NN O
bone NN NN B-Disease
tumors NN NN I-Disease
who NN NN O
were NN NN O
treated NN NN O
according NN NN O
to NN NN O
Rosen NN NN O
' NN NN O
s NN NN O
T5 NN NN O
or NN NN O
T10 NN NN O
protocol NN NN O
, NN NN O
both NN NN O
including NN NN O
doxorubicin NN NN O
. NN NN O
   
Thirty NN NN O
- NN NN O
one NN NN O
patients NN NN O
, NN NN O
age NN NN O
10 NN NN O
- NN NN O
45 NN NN O
years NN NN O
( NN NN O
median NN NN O
age NN NN O
17 NN NN O
. NN NN O
8 NN NN O
years NN NN O
) NN NN O
were NN NN O
evaluated NN NN O
2 NN NN O
. NN NN O
3 NN NN O
- NN NN O
14 NN NN O
. NN NN O
1 NN NN O
years NN NN O
( NN NN O
median NN NN O
8 NN NN O
. NN NN O
9 NN NN O
years NN NN O
) NN NN O
following NN NN O
completion NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
Cumulative NN NN O
doses NN NN O
of NN NN O
doxorubicin NN NN O
were NN NN O
225 NN NN O
- NN NN O
550 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
( NN NN O
median NN NN O
dose NN NN O
360 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
evaluation NN NN O
consisted NN NN O
of NN NN O
a NN NN O
history NN NN O
, NN NN O
physical NN NN O
examination NN NN O
, NN NN O
electrocardiogram NN NN O
( NN NN O
ECG NN NN O
) NN NN O
, NN NN O
signal NN NN O
averaged NN NN O
ECG NN NN O
, NN NN O
24 NN NN O
- NN NN O
hour NN NN O
ambulatory NN NN O
ECG NN NN O
, NN NN O
echocardiography NN NN O
and NN NN O
radionuclide NN NN O
angiography NN NN O
. NN NN O
   
Eighteen NN NN O
of NN NN O
31 NN NN O
( NN NN O
58 NN NN O
% NN NN O
) NN NN O
patients NN NN O
showed NN NN O
cardiac NN NN B-Disease
toxicity NN NN I-Disease
, NN NN O
defined NN NN O
as NN NN O
having NN NN O
one NN NN O
or NN NN O
more NN NN O
of NN NN O
the NN NN O
following NN NN O
abnormalities NN NN O
: NN NN O
late NN NN O
potentials NN NN O
, NN NN O
complex NN NN O
ventricular NN NN B-Disease
arrhythmias NN NN I-Disease
, NN NN O
left NN NN O
ventricular NN NN B-Disease
dilation NN NN I-Disease
, NN NN O
decreased NN NN O
shortening NN NN O
fraction NN NN O
, NN NN O
or NN NN O
decreased NN NN O
ejection NN NN O
fraction NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
cardiac NN NN B-Disease
abnormalities NN NN I-Disease
increased NN NN O
with NN NN O
length NN NN O
of NN NN O
follow NN NN O
- NN NN O
up NN NN O
( NN NN O
P NN NN O
< NN NN O
or NN NN O
= NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
No NN NN O
correlation NN NN O
could NN NN O
be NN NN O
demonstrated NN NN O
between NN NN O
cumulative NN NN O
dose NN NN O
of NN NN O
doxorubicin NN NN O
and NN NN O
cardiac NN NN O
status NN NN O
, NN NN O
except NN NN O
for NN NN O
heart NN NN O
rate NN NN O
variability NN NN O
. NN NN O
   
When NN NN O
adjusted NN NN O
to NN NN O
body NN NN O
surface NN NN O
area NN NN O
, NN NN O
the NN NN O
left NN NN O
ventricular NN NN O
posterior NN NN O
wall NN NN O
thickness NN NN O
( NN NN O
LVPW NN NN O
index NN NN O
) NN NN O
was NN NN O
decreased NN NN O
in NN NN O
all NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
is NN NN O
high NN NN O
and NN NN O
increases NN NN O
with NN NN O
follow NN NN O
- NN NN O
up NN NN O
, NN NN O
irrespective NN NN O
of NN NN O
cumulative NN NN O
dose NN NN O
. NN NN O
   
Life NN NN O
- NN NN O
long NN NN O
cardiac NN NN O
follow NN NN O
- NN NN O
up NN NN O
in NN NN O
these NN NN O
patients NN NN O
is NN NN O
warranted NN NN O
. NN NN O
   
The NN NN O
results NN NN O
of NN NN O
our NN NN O
study NN NN O
suggest NN NN O
that NN NN O
heart NN NN O
rate NN NN O
variability NN NN O
and NN NN O
LVPW NN NN O
index NN NN O
could NN NN O
be NN NN O
sensitive NN NN O
indicators NN NN O
for NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
Acute NN NN O
blood NN NN O
pressure NN NN O
elevations NN NN O
with NN NN O
caffeine NN NN O
in NN NN O
men NN NN O
with NN NN O
borderline NN NN O
systemic NN NN O
hypertension NN NN B-Disease
. NN NN O
   
Whether NN NN O
the NN NN O
vasoconstrictive NN NN O
actions NN NN O
of NN NN O
caffeine NN NN O
are NN NN O
enhanced NN NN O
in NN NN O
hypertensive NN NN B-Disease
persons NN NN O
has NN NN O
not NN NN O
been NN NN O
demonstrated NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
caffeine NN NN O
( NN NN O
3 NN NN O
. NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
versus NN NN O
placebo NN NN O
was NN NN O
tested NN NN O
in NN NN O
48 NN NN O
healthy NN NN O
men NN NN O
( NN NN O
aged NN NN O
20 NN NN O
to NN NN O
35 NN NN O
years NN NN O
) NN NN O
selected NN NN O
after NN NN O
screening NN NN O
on NN NN O
2 NN NN O
separate NN NN O
occasions NN NN O
. NN NN O
   
Borderline NN NN O
hypertensive NN NN B-Disease
men NN NN O
( NN NN O
n NN NN O
= NN NN O
24 NN NN O
) NN NN O
were NN NN O
selected NN NN O
with NN NN O
screening NN NN O
systolic NN NN O
blood NN NN O
pressure NN NN O
( NN NN O
BP NN NN O
) NN NN O
of NN NN O
140 NN NN O
to NN NN O
160 NN NN O
mm NN NN O
Hg NN NN O
and NN NN O
/ NN NN O
or NN NN O
diastolic NN NN O
BP NN NN O
90 NN NN O
to NN NN O
99 NN NN O
mm NN NN O
Hg NN NN O
. NN NN O
   
Low NN NN O
- NN NN O
risk NN NN O
controls NN NN O
( NN NN O
n NN NN O
= NN NN O
24 NN NN O
) NN NN O
reported NN NN O
no NN NN O
parental NN NN O
history NN NN O
of NN NN O
hypertension NN NN B-Disease
and NN NN O
had NN NN O
screening NN NN O
BP NN NN O
< NN NN O
130 NN NN O
/ NN NN O
85 NN NN O
mm NN NN O
Hg NN NN O
. NN NN O
   
Participants NN NN O
were NN NN O
then NN NN O
tested NN NN O
on NN NN O
2 NN NN O
occasions NN NN O
after NN NN O
12 NN NN O
- NN NN O
hour NN NN O
abstinence NN NN O
from NN NN O
caffeine NN NN O
in NN NN O
each NN NN O
of NN NN O
2 NN NN O
protocols NN NN O
; NN NN O
this NN NN O
required NN NN O
a NN NN O
total NN NN O
of NN NN O
4 NN NN O
laboratory NN NN O
visits NN NN O
. NN NN O
   
Caffeine NN NN O
- NN NN O
induced NN NN O
changes NN NN O
in NN NN O
diastolic NN NN O
BP NN NN O
were NN NN O
2 NN NN O
to NN NN O
3 NN NN O
times NN NN O
larger NN NN O
in NN NN O
borderline NN NN O
subjects NN NN O
than NN NN O
in NN NN O
controls NN NN O
( NN NN O
+ NN NN O
8 NN NN O
. NN NN O
4 NN NN O
vs NN NN O
+ NN NN O
3 NN NN O
. NN NN O
8 NN NN O
mm NN NN O
Hg NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
) NN NN O
, NN NN O
and NN NN O
were NN NN O
attributable NN NN O
to NN NN O
larger NN NN O
changes NN NN O
in NN NN O
impedance NN NN O
- NN NN O
derived NN NN O
measures NN NN O
of NN NN O
systemic NN NN O
vascular NN NN O
resistance NN NN O
( NN NN O
+ NN NN O
135 NN NN O
vs NN NN O
+ NN NN O
45 NN NN O
dynes NN NN O
. NN NN O
s NN NN O
. NN NN O
cm NN NN O
- NN NN O
5 NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
004 NN NN O
) NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
were NN NN O
consistent NN NN O
and NN NN O
reached NN NN O
significance NN NN O
in NN NN O
both NN NN O
protocols NN NN O
. NN NN O
   
The NN NN O
percentage NN NN O
of NN NN O
borderline NN NN O
subjects NN NN O
in NN NN O
whom NN NN O
diastolic NN NN O
BP NN NN O
changes NN NN O
exceeded NN NN O
the NN NN O
median NN NN O
control NN NN O
response NN NN O
was NN NN O
96 NN NN O
% NN NN O
. NN NN O
   
Consequently NN NN O
, NN NN O
whereas NN NN O
all NN NN O
participants NN NN O
exhibited NN NN O
normotensive NN NN O
levels NN NN O
during NN NN O
the NN NN O
resting NN NN O
predrug NN NN O
baseline NN NN O
, NN NN O
33 NN NN O
% NN NN O
of NN NN O
borderline NN NN O
subjects NN NN O
achieved NN NN O
hypertensive NN NN B-Disease
BP NN NN O
levels NN NN O
after NN NN O
caffeine NN NN O
ingestion NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
in NN NN O
borderline NN NN O
hypertensive NN NN B-Disease
men NN NN O
, NN NN O
exaggerated NN NN O
responses NN NN O
to NN NN O
caffeine NN NN O
were NN NN O
: NN NN O
selective NN NN O
for NN NN O
diastolic NN NN O
BP NN NN O
, NN NN O
consistent NN NN O
with NN NN O
greater NN NN O
vasoconstriction NN NN O
, NN NN O
replicated NN NN O
in NN NN O
2 NN NN O
protocols NN NN O
, NN NN O
and NN NN O
representative NN NN O
of NN NN O
nearly NN NN O
all NN NN O
borderline NN NN O
hypertensives NN NN B-Disease
. NN NN O
   
We NN NN O
suspect NN NN O
that NN NN O
the NN NN O
potential NN NN O
for NN NN O
caffeine NN NN O
to NN NN O
stabilize NN NN O
high NN NN O
resistance NN NN O
states NN NN O
in NN NN O
susceptible NN NN O
persons NN NN O
suggests NN NN O
that NN NN O
its NN NN O
use NN NN O
may NN NN O
facilitate NN NN O
their NN NN O
disease NN NN O
progression NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
hinder NN NN O
accurate NN NN O
diagnosis NN NN O
and NN NN O
treatment NN NN O
. NN NN O
   
Absence NN NN O
of NN NN O
effect NN NN O
of NN NN O
sertraline NN NN O
on NN NN O
time NN NN O
- NN NN O
based NN NN O
sensitization NN NN O
of NN NN O
cognitive NN NN B-Disease
impairment NN NN I-Disease
with NN NN O
haloperidol NN NN O
. NN NN O
   
This NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
randomized NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
study NN NN O
evaluated NN NN O
the NN NN O
effects NN NN O
of NN NN O
haloperidol NN NN O
alone NN NN O
and NN NN O
haloperidol NN NN O
plus NN NN O
sertraline NN NN O
on NN NN O
cognitive NN NN O
and NN NN O
psychomotor NN NN O
function NN NN O
in NN NN O
24 NN NN O
healthy NN NN O
male NN NN O
subjects NN NN O
. NN NN O
   
METHOD NN NN O
: NN NN O
All NN NN O
subjects NN NN O
received NN NN O
placebo NN NN O
on NN NN O
Day NN NN O
1 NN NN O
and NN NN O
haloperidol NN NN O
2 NN NN O
mg NN NN O
on NN NN O
Days NN NN O
2 NN NN O
and NN NN O
25 NN NN O
. NN NN O
   
From NN NN O
Days NN NN O
9 NN NN O
to NN NN O
25 NN NN O
, NN NN O
subjects NN NN O
were NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
either NN NN O
sertraline NN NN O
( NN NN O
12 NN NN O
subjects NN NN O
) NN NN O
or NN NN O
placebo NN NN O
( NN NN O
12 NN NN O
subjects NN NN O
) NN NN O
; NN NN O
the NN NN O
sertraline NN NN O
dose NN NN O
was NN NN O
titrated NN NN O
from NN NN O
50 NN NN O
to NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
from NN NN O
Days NN NN O
9 NN NN O
to NN NN O
16 NN NN O
, NN NN O
and NN NN O
remained NN NN O
at NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
for NN NN O
the NN NN O
final NN NN O
10 NN NN O
days NN NN O
of NN NN O
the NN NN O
drug NN NN O
administration NN NN O
period NN NN O
. NN NN O
   
Cognitive NN NN O
function NN NN O
testing NN NN O
was NN NN O
performed NN NN O
before NN NN O
dosing NN NN O
and NN NN O
over NN NN O
a NN NN O
24 NN NN O
- NN NN O
hour NN NN O
period NN NN O
after NN NN O
dosing NN NN O
on NN NN O
Days NN NN O
1 NN NN O
, NN NN O
2 NN NN O
, NN NN O
and NN NN O
25 NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Impairment NN NN B-Disease
of NN NN I-Disease
cognitive NN NN I-Disease
function NN NN I-Disease
was NN NN O
observed NN NN O
6 NN NN O
to NN NN O
8 NN NN O
hours NN NN O
after NN NN O
administration NN NN O
of NN NN O
haloperidol NN NN O
on NN NN O
Day NN NN O
2 NN NN O
but NN NN O
was NN NN O
not NN NN O
evident NN NN O
23 NN NN O
hours NN NN O
after NN NN O
dosing NN NN O
. NN NN O
   
When NN NN O
single NN NN O
- NN NN O
dose NN NN O
haloperidol NN NN O
was NN NN O
given NN NN O
again NN NN O
25 NN NN O
days NN NN O
later NN NN O
, NN NN O
greater NN NN O
impairment NN NN O
with NN NN O
earlier NN NN O
onset NN NN O
was NN NN O
noted NN NN O
in NN NN O
several NN NN O
tests NN NN O
in NN NN O
both NN NN O
treatment NN NN O
groups NN NN O
, NN NN O
suggesting NN NN O
enhancement NN NN O
of NN NN O
this NN NN O
effect NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
indication NN NN O
that NN NN O
sertraline NN NN O
exacerbated NN NN O
the NN NN O
impairment NN NN O
produced NN NN O
by NN NN O
haloperidol NN NN O
since NN NN O
an NN NN O
equivalent NN NN O
effect NN NN O
also NN NN O
occurred NN NN O
in NN NN O
the NN NN O
placebo NN NN O
group NN NN O
. NN NN O
   
Three NN NN O
subjects NN NN O
( NN NN O
2 NN NN O
on NN NN O
sertraline NN NN O
and NN NN O
1 NN NN O
on NN NN O
placebo NN NN O
) NN NN O
withdrew NN NN O
from NN NN O
the NN NN O
study NN NN O
because NN NN O
of NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
Ten NN NN O
subjects NN NN O
in NN NN O
each NN NN O
group NN NN O
reported NN NN O
side NN NN O
effects NN NN O
related NN NN O
to NN NN O
treatment NN NN O
. NN NN O
   
The NN NN O
side NN NN O
effect NN NN O
profiles NN NN O
of NN NN O
sertraline NN NN O
and NN NN O
of NN NN O
placebo NN NN O
were NN NN O
similar NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Haloperidol NN NN O
produced NN NN O
a NN NN O
clear NN NN O
profile NN NN O
of NN NN O
cognitive NN NN B-Disease
impairment NN NN I-Disease
that NN NN O
was NN NN O
not NN NN O
worsened NN NN O
by NN NN O
concomitant NN NN O
sertraline NN NN O
administration NN NN O
. NN NN O
   
Coexistence NN NN O
of NN NN O
cerebral NN NN B-Disease
venous NN NN I-Disease
sinus NN NN I-Disease
and NN NN I-Disease
internal NN NN I-Disease
carotid NN NN I-Disease
artery NN NN I-Disease
thrombosis NN NN I-Disease
associated NN NN O
with NN NN O
exogenous NN NN O
sex NN NN O
hormones NN NN O
. NN NN O
   
A NN NN O
case NN NN O
report NN NN O
. NN NN O
   
A NN NN O
forty NN NN O
- NN NN O
six NN NN O
year NN NN O
- NN NN O
old NN NN O
premenopausal NN NN O
woman NN NN O
developed NN NN O
headache NN NN B-Disease
, NN NN O
nausea NN NN B-Disease
and NN NN O
vomiting NN NN B-Disease
, NN NN O
left NN NN O
hemiparesis NN NN B-Disease
and NN NN O
seizure NN NN B-Disease
two NN NN O
days NN NN O
after NN NN O
parenteral NN NN O
use NN NN O
of NN NN O
progesterone NN NN O
and NN NN O
estradiol NN NN O
. NN NN O
   
Diabetes NN NN B-Disease
mellitus NN NN I-Disease
( NN NN O
DM NN NN B-Disease
) NN NN O
was NN NN O
found NN NN O
during NN NN O
admission NN NN O
. NN NN O
   
Computed NN NN O
tomography NN NN O
showed NN NN O
a NN NN O
hemorrhagic NN NN B-Disease
infarct NN NN I-Disease
in NN NN O
the NN NN O
right NN NN O
frontal NN NN O
lobe NN NN O
and NN NN O
increased NN NN O
density NN NN O
in NN NN O
the NN NN O
superior NN NN O
sagittal NN NN O
sinus NN NN O
( NN NN O
SSS NN NN O
) NN NN O
. NN NN O
   
Left NN NN O
carotid NN NN O
angiography NN NN O
found NN NN O
occlusion NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
left NN NN I-Disease
internal NN NN I-Disease
carotid NN NN I-Disease
artery NN NN I-Disease
( NN NN O
ICA NN NN O
) NN NN O
. NN NN O
   
Right NN NN O
carotid NN NN O
angiograms NN NN O
failed NN NN O
to NN NN O
show NN NN O
the NN NN O
SSS NN NN O
and NN NN O
inferior NN NN O
sagittal NN NN O
sinus NN NN O
, NN NN O
suggestive NN NN O
of NN NN O
venous NN NN B-Disease
sinus NN NN I-Disease
thrombosis NN NN I-Disease
. NN NN O
   
Coexistence NN NN O
of NN NN O
the NN NN O
cerebral NN NN B-Disease
artery NN NN I-Disease
and NN NN I-Disease
the NN NN I-Disease
venous NN NN I-Disease
sinus NN NN I-Disease
occlusion NN NN I-Disease
has NN NN O
been NN NN O
described NN NN O
infrequently NN NN O
. NN NN O
   
In NN NN O
this NN NN O
case NN NN O
, NN NN O
the NN NN O
authors NN NN O
postulate NN NN O
that NN NN O
the NN NN O
use NN NN O
of NN NN O
estradiol NN NN O
and NN NN O
progesterone NN NN O
and NN NN O
the NN NN O
underlying NN NN O
DM NN NN B-Disease
increased NN NN O
vascular NN NN O
thrombogenicity NN NN O
, NN NN O
which NN NN O
provided NN NN O
a NN NN O
common NN NN O
denominator NN NN O
for NN NN O
thrombosis NN NN B-Disease
of NN NN I-Disease
both NN NN I-Disease
the NN NN I-Disease
ICA NN NN I-Disease
and NN NN I-Disease
the NN NN I-Disease
venous NN NN I-Disease
sinus NN NN I-Disease
. NN NN O
   
Chemotherapy NN NN O
of NN NN O
advanced NN NN O
inoperable NN NN O
non NN NN B-Disease
- NN NN I-Disease
small NN NN I-Disease
cell NN NN I-Disease
lung NN NN I-Disease
cancer NN NN I-Disease
with NN NN O
paclitaxel NN NN O
: NN NN O
a NN NN O
phase NN NN O
II NN NN O
trial NN NN O
. NN NN O
   
Paclitaxel NN NN O
( NN NN O
Taxol NN NN O
; NN NN O
Bristol NN NN O
- NN NN O
Myers NN NN O
Squibb NN NN O
Company NN NN O
, NN NN O
Princeton NN NN O
, NN NN O
NJ NN NN O
) NN NN O
has NN NN O
demonstrated NN NN O
significant NN NN O
antineoplastic NN NN O
activity NN NN O
against NN NN O
different NN NN O
tumor NN NN B-Disease
types NN NN O
, NN NN O
notably NN NN O
ovarian NN NN B-Disease
and NN NN I-Disease
breast NN NN I-Disease
carcinoma NN NN I-Disease
. NN NN O
   
Two NN NN O
phase NN NN O
II NN NN O
trials NN NN O
of NN NN O
24 NN NN O
- NN NN O
hour NN NN O
paclitaxel NN NN O
infusions NN NN O
in NN NN O
chemotherapy NN NN O
- NN NN O
naive NN NN O
patients NN NN O
with NN NN O
stage NN NN O
IIIB NN NN O
or NN NN O
IV NN NN O
non NN NN B-Disease
- NN NN I-Disease
small NN NN I-Disease
cell NN NN I-Disease
lung NN NN I-Disease
cancer NN NN I-Disease
( NN NN O
NSCLC NN NN B-Disease
) NN NN O
reported NN NN O
response NN NN O
rates NN NN O
of NN NN O
21 NN NN O
% NN NN O
and NN NN O
24 NN NN O
% NN NN O
. NN NN O
   
Leukopenia NN NN B-Disease
was NN NN O
dose NN NN O
limiting NN NN O
: NN NN O
as NN NN O
many NN NN O
as NN NN O
62 NN NN O
. NN NN O
5 NN NN O
% NN NN O
of NN NN O
patients NN NN O
experienced NN NN O
grade NN NN O
4 NN NN O
leukopenia NN NN B-Disease
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
efficacy NN NN O
and NN NN O
toxicity NN NN B-Disease
of NN NN O
a NN NN O
3 NN NN O
- NN NN O
hour NN NN O
paclitaxel NN NN O
infusion NN NN O
in NN NN O
a NN NN O
phase NN NN O
II NN NN O
trial NN NN O
in NN NN O
patients NN NN O
with NN NN O
inoperable NN NN O
stage NN NN O
IIIB NN NN O
or NN NN O
IV NN NN O
NSCLC NN NN B-Disease
. NN NN O
   
The NN NN O
58 NN NN O
patients NN NN O
treated NN NN O
( NN NN O
41 NN NN O
men NN NN O
and NN NN O
17 NN NN O
women NN NN O
) NN NN O
had NN NN O
a NN NN O
median NN NN O
age NN NN O
of NN NN O
59 NN NN O
years NN NN O
( NN NN O
age NN NN O
range NN NN O
, NN NN O
25 NN NN O
to NN NN O
75 NN NN O
) NN NN O
and NN NN O
a NN NN O
performance NN NN O
status NN NN O
of NN NN O
0 NN NN O
through NN NN O
2 NN NN O
. NN NN O
   
Most NN NN O
patients NN NN O
( NN NN O
72 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
had NN NN O
stage NN NN O
IV NN NN O
NSCLC NN NN B-Disease
. NN NN O
   
Paclitaxel NN NN O
225 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
was NN NN O
infused NN NN O
over NN NN O
3 NN NN O
hours NN NN O
every NN NN O
3 NN NN O
weeks NN NN O
with NN NN O
standard NN NN O
prophylactic NN NN O
premedication NN NN O
. NN NN O
   
Of NN NN O
50 NN NN O
patients NN NN O
evaluable NN NN O
for NN NN O
response NN NN O
, NN NN O
12 NN NN O
( NN NN O
24 NN NN O
% NN NN O
) NN NN O
had NN NN O
partial NN NN O
remission NN NN O
, NN NN O
26 NN NN O
( NN NN O
52 NN NN O
% NN NN O
) NN NN O
had NN NN O
no NN NN O
change NN NN O
, NN NN O
and NN NN O
12 NN NN O
had NN NN O
disease NN NN O
progression NN NN O
( NN NN O
24 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Hematologic NN NN O
toxicities NN NN B-Disease
were NN NN O
mild NN NN O
: NN NN O
only NN NN O
one NN NN O
patient NN NN O
( NN NN O
2 NN NN O
% NN NN O
) NN NN O
developed NN NN O
grade NN NN O
3 NN NN O
or NN NN O
4 NN NN O
neutropenia NN NN B-Disease
, NN NN O
while NN NN O
29 NN NN O
% NN NN O
had NN NN O
grade NN NN O
1 NN NN O
or NN NN O
2 NN NN O
. NN NN O
   
Grade NN NN O
1 NN NN O
or NN NN O
2 NN NN O
polyneuropathy NN NN B-Disease
affected NN NN O
56 NN NN O
% NN NN O
of NN NN O
patients NN NN O
while NN NN O
only NN NN O
one NN NN O
( NN NN O
2 NN NN O
% NN NN O
) NN NN O
experienced NN NN O
severe NN NN O
polyneuropathy NN NN B-Disease
. NN NN O
   
Similarly NN NN O
, NN NN O
grade NN NN O
1 NN NN O
or NN NN O
2 NN NN O
myalgia NN NN B-Disease
/ NN NN O
arthralgia NN NN B-Disease
was NN NN O
observed NN NN O
in NN NN O
63 NN NN O
. NN NN O
2 NN NN O
% NN NN O
of NN NN O
patients NN NN O
, NN NN O
but NN NN O
only NN NN O
14 NN NN O
. NN NN O
3 NN NN O
% NN NN O
experienced NN NN O
grade NN NN O
3 NN NN O
or NN NN O
4 NN NN O
. NN NN O
   
Nausea NN NN B-Disease
and NN NN O
vomiting NN NN B-Disease
were NN NN O
infrequent NN NN O
, NN NN O
with NN NN O
14 NN NN O
% NN NN O
of NN NN O
patients NN NN O
experiencing NN NN O
grade NN NN O
1 NN NN O
or NN NN O
2 NN NN O
and NN NN O
only NN NN O
2 NN NN O
% NN NN O
experiencing NN NN O
grade NN NN O
3 NN NN O
or NN NN O
4 NN NN O
. NN NN O
   
Paclitaxel NN NN O
is NN NN O
thus NN NN O
an NN NN O
active NN NN O
single NN NN O
agent NN NN O
in NN NN O
this NN NN O
patient NN NN O
population NN NN O
, NN NN O
with NN NN O
a NN NN O
3 NN NN O
- NN NN O
hour NN NN O
infusion NN NN O
proving NN NN O
comparably NN NN O
effective NN NN O
to NN NN O
a NN NN O
24 NN NN O
- NN NN O
hour NN NN O
infusion NN NN O
and NN NN O
superior NN NN O
in NN NN O
terms NN NN O
of NN NN O
the NN NN O
incidence NN NN O
of NN NN O
hematologic NN NN O
and NN NN O
nonhematologic NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Further NN NN O
phase NN NN O
II NN NN O
studies NN NN O
with NN NN O
paclitaxel NN NN O
combined NN NN O
with NN NN O
other NN NN O
drugs NN NN O
active NN NN O
against NN NN O
NSCLC NN NN B-Disease
are NN NN O
indicated NN NN O
, NN NN O
and NN NN O
phase NN NN O
III NN NN O
studies NN NN O
comparing NN NN O
paclitaxel NN NN O
with NN NN O
standard NN NN O
chemotherapy NN NN O
remain NN NN O
to NN NN O
be NN NN O
completed NN NN O
. NN NN O
   
Paclitaxel NN NN O
combined NN NN O
with NN NN O
carboplatin NN NN O
in NN NN O
the NN NN O
first NN NN O
- NN NN O
line NN NN O
treatment NN NN O
of NN NN O
advanced NN NN O
ovarian NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
In NN NN O
a NN NN O
phase NN NN O
I NN NN O
study NN NN O
to NN NN O
determine NN NN O
the NN NN O
maximum NN NN O
tolerated NN NN O
dose NN NN O
of NN NN O
paclitaxel NN NN O
( NN NN O
Taxol NN NN O
; NN NN O
Bristol NN NN O
- NN NN O
Myers NN NN O
Squibb NN NN O
Company NN NN O
, NN NN O
Princeton NN NN O
, NN NN O
NJ NN NN O
) NN NN O
given NN NN O
as NN NN O
a NN NN O
3 NN NN O
- NN NN O
hour NN NN O
infusion NN NN O
in NN NN O
combination NN NN O
with NN NN O
carboplatin NN NN O
administered NN NN O
every NN NN O
21 NN NN O
days NN NN O
to NN NN O
women NN NN O
with NN NN O
advanced NN NN O
ovarian NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
paclitaxel NN NN O
doses NN NN O
were NN NN O
escalated NN NN O
as NN NN O
follows NN NN O
: NN NN O
level NN NN O
1 NN NN O
, NN NN O
135 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
; NN NN O
level NN NN O
2 NN NN O
, NN NN O
160 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
; NN NN O
level NN NN O
3 NN NN O
, NN NN O
185 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
; NN NN O
and NN NN O
level NN NN O
4 NN NN O
, NN NN O
210 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
. NN NN O
   
The NN NN O
fixed NN NN O
dose NN NN O
of NN NN O
carboplatin NN NN O
at NN NN O
levels NN NN O
1 NN NN O
through NN NN O
4 NN NN O
was NN NN O
given NN NN O
to NN NN O
achieve NN NN O
an NN NN O
area NN NN O
under NN NN O
the NN NN O
concentration NN NN O
- NN NN O
time NN NN O
curve NN NN O
( NN NN O
AUC NN NN O
) NN NN O
of NN NN O
5 NN NN O
using NN NN O
the NN NN O
Calvert NN NN O
formula NN NN O
. NN NN O
   
In NN NN O
levels NN NN O
5 NN NN O
and NN NN O
6 NN NN O
the NN NN O
carboplatin NN NN O
dose NN NN O
was NN NN O
targeted NN NN O
at NN NN O
AUCs NN NN O
of NN NN O
6 NN NN O
and NN NN O
7 NN NN O
. NN NN O
5 NN NN O
, NN NN O
respectively NN NN O
, NN NN O
combined NN NN O
with NN NN O
a NN NN O
fixed NN NN O
paclitaxel NN NN O
dose NN NN O
of NN NN O
185 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
. NN NN O
   
To NN NN O
date NN NN O
, NN NN O
30 NN NN O
previously NN NN O
untreated NN NN O
patients NN NN O
, NN NN O
all NN NN O
with NN NN O
a NN NN O
good NN NN O
performance NN NN O
status NN NN O
( NN NN O
Eastern NN NN O
Cooperative NN NN O
Oncology NN NN O
Group NN NN O
0 NN NN O
to NN NN O
2 NN NN O
) NN NN O
have NN NN O
been NN NN O
entered NN NN O
into NN NN O
this NN NN O
ongoing NN NN O
study NN NN O
. NN NN O
   
The NN NN O
dose NN NN O
- NN NN O
limiting NN NN O
toxicity NN NN B-Disease
of NN NN O
the NN NN O
combination NN NN O
was NN NN O
myelosuppression NN NN B-Disease
( NN NN O
leukopenia NN NN B-Disease
, NN NN O
granulocytopenia NN NN B-Disease
, NN NN O
and NN NN O
thrombocytopenia NN NN B-Disease
) NN NN O
. NN NN O
   
Neurotoxicity NN NN B-Disease
was NN NN O
largely NN NN O
moderate NN NN O
. NN NN O
   
So NN NN O
far NN NN O
, NN NN O
14 NN NN O
patients NN NN O
are NN NN O
evaluable NN NN O
for NN NN O
response NN NN O
; NN NN O
of NN NN O
these NN NN O
, NN NN O
eight NN NN O
( NN NN O
57 NN NN O
% NN NN O
) NN NN O
showed NN NN O
objective NN NN O
( NN NN O
complete NN NN O
or NN NN O
partial NN NN O
) NN NN O
response NN NN O
and NN NN O
disease NN NN O
stabilized NN NN O
in NN NN O
six NN NN O
patients NN NN O
. NN NN O
   
No NN NN O
patient NN NN O
had NN NN O
disease NN NN O
progression NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
combination NN NN O
of NN NN O
paclitaxel NN NN O
185 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
administered NN NN O
as NN NN O
a NN NN O
3 NN NN O
- NN NN O
hour NN NN O
infusion NN NN O
followed NN NN O
immediately NN NN O
by NN NN O
a NN NN O
1 NN NN O
- NN NN O
hour NN NN O
infusion NN NN O
of NN NN O
carboplatin NN NN O
at NN NN O
an NN NN O
AUC NN NN O
of NN NN O
6 NN NN O
can NN NN O
be NN NN O
administered NN NN O
safely NN NN O
in NN NN O
a NN NN O
21 NN NN O
- NN NN O
day NN NN O
schedule NN NN O
in NN NN O
the NN NN O
outpatient NN NN O
setting NN NN O
. NN NN O
   
The NN NN O
recommended NN NN O
dose NN NN O
for NN NN O
phase NN NN O
III NN NN O
studies NN NN O
is NN NN O
paclitaxel NN NN O
185 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
and NN NN O
carboplatin NN NN O
AUC NN NN O
6 NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
acute NN NN O
steroid NN NN O
administration NN NN O
on NN NN O
ventilatory NN NN O
and NN NN O
peripheral NN NN O
muscles NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Occasional NN NN O
case NN NN O
reports NN NN O
have NN NN O
shown NN NN O
that NN NN O
acute NN NN O
myopathy NN NN B-Disease
may NN NN O
occur NN NN O
in NN NN O
patients NN NN O
treated NN NN O
with NN NN O
massive NN NN O
doses NN NN O
of NN NN O
corticosteroids NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
this NN NN O
myopathy NN NN B-Disease
is NN NN O
poorly NN NN O
understood NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
60 NN NN O
male NN NN O
rats NN NN O
were NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
receive NN NN O
daily NN NN O
injection NN NN O
of NN NN O
saline NN NN O
( NN NN O
C NN NN O
) NN NN O
, NN NN O
methylprednisolone NN NN O
( NN NN O
M NN NN O
) NN NN O
, NN NN O
or NN NN O
triamcinolone NN NN O
( NN NN O
T NN NN O
) NN NN O
80 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
d NN NN O
for NN NN O
5 NN NN O
d NN NN O
. NN NN O
   
Nutritional NN NN O
intake NN NN O
, NN NN O
measured NN NN O
daily NN NN O
in NN NN O
15 NN NN O
animals NN NN O
, NN NN O
showed NN NN O
a NN NN O
significant NN NN O
reduction NN NN B-Disease
of NN NN I-Disease
food NN NN I-Disease
intake NN NN I-Disease
in NN NN O
the NN NN O
steroid NN NN O
- NN NN O
treated NN NN O
groups NN NN O
( NN NN O
- NN NN O
50 NN NN O
and NN NN O
- NN NN O
79 NN NN O
% NN NN O
in NN NN O
M NN NN O
and NN NN O
T NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
This NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
similar NN NN O
loss NN NN B-Disease
in NN NN I-Disease
body NN NN I-Disease
weight NN NN I-Disease
. NN NN O
   
In NN NN O
the NN NN O
45 NN NN O
remaining NN NN O
animals NN NN O
, NN NN O
diaphragm NN NN O
contractility NN NN O
and NN NN O
histopathologic NN NN O
features NN NN O
of NN NN O
several NN NN O
muscles NN NN O
were NN NN O
studied NN NN O
. NN NN O
   
Weights NN NN O
of NN NN O
respiratory NN NN O
and NN NN O
peripheral NN NN O
muscles NN NN O
were NN NN O
similarly NN NN O
decreased NN NN O
after NN NN O
steroid NN NN O
treatment NN NN O
. NN NN O
   
Maximal NN NN O
twitches NN NN O
of NN NN O
the NN NN O
diaphragm NN NN O
were NN NN O
lower NN NN O
in NN NN O
the NN NN O
C NN NN O
group NN NN O
( NN NN O
653 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
174 NN NN O
g NN NN O
/ NN NN O
cm NN NN O
( NN NN O
2 NN NN O
) NN NN O
) NN NN O
than NN NN O
in NN NN O
the NN NN O
M NN NN O
group NN NN O
( NN NN O
837 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
171 NN NN O
g NN NN O
/ NN NN O
cm NN NN O
( NN NN O
2 NN NN O
) NN NN O
; NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
and NN NN O
the NN NN O
T NN NN O
group NN NN O
( NN NN O
765 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
145 NN NN O
g NN NN O
/ NN NN O
cm NN NN O
( NN NN O
2 NN NN O
) NN NN O
, NN NN O
NS NN NN O
) NN NN O
. NN NN O
   
Half NN NN O
- NN NN O
relaxation NN NN O
time NN NN O
was NN NN O
prolonged NN NN O
in NN NN O
both NN NN O
steroid NN NN O
groups NN NN O
, NN NN O
and NN NN O
time NN NN O
to NN NN O
peak NN NN O
tension NN NN O
was NN NN O
longer NN NN O
with NN NN O
M NN NN O
, NN NN O
whereas NN NN O
tetanic NN NN B-Disease
tensions NN NN O
were NN NN O
similar NN NN O
. NN NN O
   
Steroid NN NN O
treatment NN NN O
also NN NN O
induced NN NN O
a NN NN O
leftward NN NN O
shift NN NN O
of NN NN O
the NN NN O
force NN NN O
- NN NN O
frequency NN NN O
curve NN NN O
at NN NN O
25 NN NN O
and NN NN O
50 NN NN O
Hz NN NN O
when NN NN O
compared NN NN O
with NN NN O
saline NN NN O
treatment NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
ATPase NN NN O
staining NN NN O
of NN NN O
the NN NN O
diaphragm NN NN O
, NN NN O
scalenus NN NN O
medius NN NN O
, NN NN O
and NN NN O
gastrocnemius NN NN O
showed NN NN O
type NN NN O
IIb NN NN O
fiber NN NN O
atrophy NN NN B-Disease
in NN NN O
the NN NN O
steroid NN NN O
groups NN NN O
and NN NN O
also NN NN O
diaphragmatic NN NN O
type NN NN O
IIa NN NN O
atrophy NN NN B-Disease
with NN NN O
T NN NN O
, NN NN O
whereas NN NN O
histologic NN NN O
examinations NN NN O
revealed NN NN O
a NN NN O
normal NN NN O
muscular NN NN O
pattern NN NN O
with NN NN O
absence NN NN O
of NN NN O
necrosis NN NN B-Disease
. NN NN O
   
Finally NN NN O
, NN NN O
a NN NN O
pair NN NN O
- NN NN O
fed NN NN O
( NN NN O
PF NN NN O
) NN NN O
study NN NN O
, NN NN O
performed NN NN O
in NN NN O
18 NN NN O
rats NN NN O
( NN NN O
C NN NN O
, NN NN O
T NN NN O
, NN NN O
and NN NN O
PF NN NN O
) NN NN O
, NN NN O
showed NN NN O
that NN NN O
muscle NN NN B-Disease
atrophy NN NN I-Disease
was NN NN O
considerably NN NN O
less NN NN O
pronounced NN NN O
in NN NN O
PF NN NN O
animals NN NN O
than NN NN O
in NN NN O
T NN NN O
- NN NN O
treated NN NN O
animals NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
( NN NN O
1 NN NN O
) NN NN O
short NN NN O
- NN NN O
term NN NN O
treatment NN NN O
with NN NN O
massive NN NN O
doses NN NN O
of NN NN O
steroids NN NN O
induced NN NN O
severe NN NN O
respiratory NN NN O
and NN NN O
limb NN NN O
muscle NN NN O
wasting NN NN O
; NN NN O
( NN NN O
2 NN NN O
) NN NN O
both NN NN O
types NN NN O
of NN NN O
steroids NN NN O
induced NN NN O
predominantly NN NN O
type NN NN O
IIb NN NN O
atrophy NN NN B-Disease
, NN NN O
resulting NN NN O
in NN NN O
the NN NN O
expected NN NN O
alterations NN NN O
in NN NN O
diaphragm NN NN O
contractile NN NN O
properties NN NN O
; NN NN O
( NN NN O
3 NN NN O
) NN NN O
neither NN NN O
steroid NN NN O
caused NN NN O
muscle NN NN O
necrosis NN NN B-Disease
; NN NN O
( NN NN O
4 NN NN O
) NN NN O
type NN NN O
IIb NN NN O
atrophy NN NN B-Disease
was NN NN O
not NN NN O
caused NN NN O
by NN NN O
acute NN NN O
nutritional NN NN O
deprivation NN NN O
alone NN NN O
. NN NN O
   
Continuous NN NN O
subcutaneous NN NN O
administration NN NN O
of NN NN O
mesna NN NN O
to NN NN O
prevent NN NN O
ifosfamide NN NN O
- NN NN O
induced NN NN O
hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
. NN NN O
   
Hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
is NN NN O
a NN NN O
major NN NN O
potential NN NN O
toxicity NN NN B-Disease
of NN NN O
ifosfamide NN NN O
that NN NN O
can NN NN O
be NN NN O
prevented NN NN O
by NN NN O
administering NN NN O
mesna NN NN O
along NN NN O
with NN NN O
the NN NN O
cytotoxic NN NN O
agent NN NN O
. NN NN O
   
Mesna NN NN O
is NN NN O
generally NN NN O
administered NN NN O
by NN NN O
the NN NN O
intravenous NN NN O
route NN NN O
, NN NN O
although NN NN O
experience NN NN O
with NN NN O
oral NN NN O
delivery NN NN O
of NN NN O
the NN NN O
drug NN NN O
has NN NN O
increased NN NN O
. NN NN O
   
The NN NN O
continuous NN NN O
subcutaneous NN NN O
administration NN NN O
of NN NN O
mesna NN NN O
has NN NN O
the NN NN O
advantage NN NN O
of NN NN O
not NN NN O
requiring NN NN O
intravenous NN NN O
access NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
subcutaneous NN NN O
delivery NN NN O
of NN NN O
the NN NN O
neutralizing NN NN O
agent NN NN O
will NN NN O
not NN NN O
be NN NN O
associated NN NN O
with NN NN O
the NN NN O
risk NN NN O
of NN NN O
inadequate NN NN O
urinary NN NN O
mesna NN NN O
concentrations NN NN O
, NN NN O
such NN NN O
as NN NN O
in NN NN O
a NN NN O
patient NN NN O
taking NN NN O
oral NN NN O
mesna NN NN O
who NN NN O
experiences NN NN O
severe NN NN O
ifosfamide NN NN O
- NN NN O
induced NN NN O
emesis NN NN B-Disease
and NN NN O
is NN NN O
unable NN NN O
to NN NN O
absorb NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
Limited NN NN O
clinical NN NN O
experience NN NN O
with NN NN O
continuous NN NN O
subcutaneous NN NN O
mesna NN NN O
administration NN NN O
suggests NN NN O
it NN NN O
is NN NN O
a NN NN O
safe NN NN O
, NN NN O
practical NN NN O
, NN NN O
and NN NN O
economic NN NN O
method NN NN O
of NN NN O
drug NN NN O
delivery NN NN O
that NN NN O
permits NN NN O
ifosfamide NN NN O
to NN NN O
be NN NN O
administered NN NN O
successfully NN NN O
in NN NN O
the NN NN O
outpatient NN NN O
setting NN NN O
. NN NN O
   
Leg NN NN B-Disease
and NN NN I-Disease
back NN NN I-Disease
pain NN NN I-Disease
after NN NN O
spinal NN NN O
anaesthesia NN NN O
involving NN NN O
hyperbaric NN NN O
5 NN NN O
% NN NN O
lignocaine NN NN O
. NN NN O
   
Fifty NN NN O
- NN NN O
four NN NN O
patients NN NN O
, NN NN O
aged NN NN O
27 NN NN O
- NN NN O
90 NN NN O
years NN NN O
, NN NN O
who NN NN O
were NN NN O
given NN NN O
lignocaine NN NN O
5 NN NN O
% NN NN O
in NN NN O
6 NN NN O
. NN NN O
8 NN NN O
% NN NN O
glucose NN NN O
solution NN NN O
for NN NN O
spinal NN NN O
anaesthesia NN NN O
were NN NN O
studied NN NN O
. NN NN O
   
Thirteen NN NN O
of NN NN O
these NN NN O
patients NN NN O
experienced NN NN O
pain NN NN B-Disease
in NN NN I-Disease
the NN NN I-Disease
legs NN NN I-Disease
and NN NN I-Disease
/ NN NN I-Disease
or NN NN I-Disease
back NN NN I-Disease
after NN NN O
recovery NN NN O
from NN NN O
anaesthesia NN NN O
. NN NN O
   
The NN NN O
patients NN NN O
affected NN NN O
were NN NN O
younger NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
and NN NN O
the NN NN O
site NN NN O
of NN NN O
the NN NN O
dural NN NN O
puncture NN NN O
was NN NN O
higher NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
than NN NN O
those NN NN O
individuals NN NN O
without NN NN O
pain NN NN B-Disease
. NN NN O
   
Five NN NN O
of NN NN O
the NN NN O
13 NN NN O
patients NN NN O
( NN NN O
38 NN NN O
% NN NN O
) NN NN O
with NN NN O
pain NN NN B-Disease
and NN NN O
seven NN NN O
of NN NN O
the NN NN O
41 NN NN O
patients NN NN O
( NN NN O
17 NN NN O
% NN NN O
) NN NN O
without NN NN O
pain NN NN B-Disease
admitted NN NN O
to NN NN O
a NN NN O
high NN NN O
alcohol NN NN O
intake NN NN O
, NN NN O
which NN NN O
might NN NN O
be NN NN O
a NN NN O
contributing NN NN O
factor NN NN O
. NN NN O
   
Leg NN NN B-Disease
and NN NN I-Disease
/ NN NN I-Disease
or NN NN I-Disease
back NN NN I-Disease
pain NN NN I-Disease
is NN NN O
associated NN NN O
with NN NN O
the NN NN O
intrathecal NN NN O
use NN NN O
of NN NN O
hyperbaric NN NN O
5 NN NN O
% NN NN O
lignocaine NN NN O
. NN NN O
   
The NN NN O
use NN NN O
of NN NN O
serum NN NN O
cholinesterase NN NN O
in NN NN O
succinylcholine NN NN O
apnoea NN NN B-Disease
. NN NN O
   
Fifteen NN NN O
patients NN NN O
demonstrating NN NN O
unexpected NN NN O
prolonged NN NN O
apnoea NN NN B-Disease
lasting NN NN O
several NN NN O
hours NN NN O
after NN NN O
succinylcholine NN NN O
have NN NN O
been NN NN O
treated NN NN O
by NN NN O
a NN NN O
new NN NN O
preparation NN NN O
of NN NN O
human NN NN O
serum NN NN O
cholinesterase NN NN O
. NN NN O
   
Adequate NN NN O
spontaneous NN NN O
respiration NN NN O
was NN NN O
re NN NN O
- NN NN O
established NN NN O
in NN NN O
an NN NN O
average NN NN O
period NN NN O
of NN NN O
ten NN NN O
minutes NN NN O
after NN NN O
the NN NN O
injection NN NN O
. NN NN O
   
In NN NN O
12 NN NN O
patients NN NN O
biochemical NN NN O
genetic NN NN O
examinations NN NN O
confirmed NN NN O
the NN NN O
presence NN NN O
of NN NN O
an NN NN O
atypical NN NN O
serum NN NN O
cholinesterase NN NN O
. NN NN O
   
In NN NN O
three NN NN O
patients NN NN O
none NN NN O
of NN NN O
the NN NN O
usual NN NN O
variants NN NN O
were NN NN O
found NN NN O
. NN NN O
   
It NN NN O
is NN NN O
therefore NN NN O
supposed NN NN O
that NN NN O
other NN NN O
unknown NN NN O
variants NN NN O
of NN NN O
serum NN NN O
cholinesterase NN NN O
exist NN NN O
which NN NN O
cannot NN NN O
hydrolyze NN NN O
succinylcholine NN NN O
. NN NN O
   
The NN NN O
use NN NN O
of NN NN O
serum NN NN O
cholinesterase NN NN O
in NN NN O
succinylcholine NN NN O
apnoea NN NN B-Disease
provided NN NN O
considerable NN NN O
relief NN NN O
to NN NN O
both NN NN O
patient NN NN O
and NN NN O
anaesthetist NN NN O
. NN NN O
   
Increased NN NN O
sulfation NN NN O
and NN NN O
decreased NN NN O
7alpha NN NN O
- NN NN O
hydroxylation NN NN O
of NN NN O
deoxycholic NN NN O
acid NN NN O
in NN NN O
ethinyl NN NN O
estradiol NN NN O
- NN NN O
induced NN NN O
cholestasis NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Deoxycholic NN NN O
acid NN NN O
conjugation NN NN O
, NN NN O
transport NN NN O
capacity NN NN O
, NN NN O
and NN NN O
metabolism NN NN O
were NN NN O
compared NN NN O
in NN NN O
control NN NN O
and NN NN O
ethinyl NN NN O
estradiol NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
Control NN NN O
rats NN NN O
were NN NN O
found NN NN O
to NN NN O
have NN NN O
a NN NN O
lower NN NN O
capacity NN NN O
to NN NN O
transport NN NN O
deoxycholic NN NN O
acid NN NN O
than NN NN O
taurodeoxycholic NN NN O
acid NN NN O
, NN NN O
and NN NN O
both NN NN O
were NN NN O
decreased NN NN O
by NN NN O
ethinyl NN NN O
estradiol NN NN O
treatment NN NN O
. NN NN O
   
During NN NN O
[ NN NN O
24 NN NN O
- NN NN O
14C NN NN O
] NN NN O
sodium NN NN O
deoxycholate NN NN O
infusion NN NN O
, NN NN O
[ NN NN O
14C NN NN O
] NN NN O
biliary NN NN O
bile NN NN O
acid NN NN O
secretion NN NN O
increased NN NN O
, NN NN O
but NN NN O
bile NN NN O
flow NN NN O
did NN NN O
not NN NN O
change NN NN O
significantly NN NN O
in NN NN O
either NN NN O
control NN NN O
or NN NN O
ethinyl NN NN O
estradiol NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
Ethinyl NN NN O
estradiol NN NN O
- NN NN O
treated NN NN O
animals NN NN O
excreted NN NN O
significantly NN NN O
less NN NN O
14C NN NN O
as NN NN O
taurocholic NN NN O
acid NN NN O
than NN NN O
did NN NN O
control NN NN O
animals NN NN O
, NN NN O
consistent NN NN O
with NN NN O
an NN NN O
impairment NN NN O
of NN NN O
7alpha NN NN O
- NN NN O
hydroxylation NN NN O
of NN NN O
taurodeoxycholic NN NN O
acid NN NN O
. NN NN O
   
Ethinyl NN NN O
estradiol NN NN O
treatment NN NN O
did NN NN O
not NN NN O
impair NN NN O
conjugation NN NN O
of NN NN O
deoxycholic NN NN O
acid NN NN O
, NN NN O
but NN NN O
did NN NN O
result NN NN O
in NN NN O
an NN NN O
increase NN NN O
in NN NN O
sulfation NN NN O
of NN NN O
taurodeoxycholic NN NN O
acid NN NN O
from NN NN O
1 NN NN O
. NN NN O
5 NN NN O
% NN NN O
in NN NN O
controls NN NN O
to NN NN O
nearly NN NN O
4 NN NN O
. NN NN O
0 NN NN O
% NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
These NN NN O
results NN NN O
are NN NN O
consistent NN NN O
with NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
the NN NN O
rat NN NN O
has NN NN O
a NN NN O
poorer NN NN O
tolerance NN NN O
for NN NN O
deoxycholic NN NN O
acid NN NN O
than NN NN O
do NN NN O
certain NN NN O
other NN NN O
species NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
rat NN NN O
converts NN NN O
deoxycholic NN NN O
acid NN NN O
, NN NN O
a NN NN O
poor NN NN O
choleretic NN NN O
, NN NN O
to NN NN O
taurocholic NN NN O
acid NN NN O
, NN NN O
a NN NN O
good NN NN O
choleretic NN NN O
. NN NN O
   
When NN NN O
this NN NN O
conversion NN NN O
is NN NN O
impaired NN NN O
with NN NN O
ethinyl NN NN O
estradiol NN NN O
treatment NN NN O
, NN NN O
sulfation NN NN O
may NN NN O
be NN NN O
an NN NN O
important NN NN O
alternate NN NN O
pathway NN NN O
for NN NN O
excretion NN NN O
of NN NN O
this NN NN O
potentially NN NN O
harmful NN NN O
bile NN NN O
acid NN NN O
. NN NN O
   
Influence NN NN O
of NN NN O
diet NN NN O
free NN NN O
of NN NN O
NAD NN NN O
- NN NN O
precursors NN NN O
on NN NN O
acetaminophen NN NN O
hepatotoxicity NN NN B-Disease
in NN NN O
mice NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
we NN NN O
demonstrated NN NN O
the NN NN O
hepatoprotective NN NN O
effects NN NN O
of NN NN O
nicotinic NN NN O
acid NN NN O
amide NN NN O
, NN NN O
a NN NN O
selective NN NN O
inhibitor NN NN O
of NN NN O
poly NN NN O
( NN NN O
ADP NN NN O
- NN NN O
ribose NN NN O
) NN NN O
polymerase NN NN O
( NN NN O
PARP NN NN O
; NN NN O
EC NN NN O
2 NN NN O
. NN NN O
4 NN NN O
. NN NN O
2 NN NN O
. NN NN O
30 NN NN O
) NN NN O
on NN NN O
mice NN NN O
suffering NN NN O
from NN NN O
acetaminophen NN NN O
( NN NN O
AAP NN NN O
) NN NN O
- NN NN O
hepatitis NN NN B-Disease
, NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
AAP NN NN O
- NN NN O
induced NN NN O
liver NN NN B-Disease
injury NN NN I-Disease
involves NN NN O
a NN NN O
step NN NN O
which NN NN O
depends NN NN O
on NN NN O
adenoribosylation NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
investigates NN NN O
the NN NN O
effects NN NN O
of NN NN O
a NN NN O
diet NN NN O
free NN NN O
of NN NN O
precursors NN NN O
of NN NN O
NAD NN NN O
, NN NN O
the NN NN O
substrate NN NN O
on NN NN O
which NN NN O
PARP NN NN O
acts NN NN O
, NN NN O
in NN NN O
female NN NN O
NMRI NN NN O
mice NN NN O
with NN NN O
AAP NN NN O
hepatitis NN NN B-Disease
and NN NN O
evaluates NN NN O
the NN NN O
influence NN NN O
of NN NN O
simultaneous NN NN O
ethanol NN NN O
consumption NN NN O
in NN NN O
these NN NN O
animals NN NN O
. NN NN O
   
Liver NN NN B-Disease
injuries NN NN I-Disease
were NN NN O
quantified NN NN O
as NN NN O
serum NN NN O
activities NN NN O
of NN NN O
glutamate NN NN O
- NN NN O
oxaloacetate NN NN O
transaminase NN NN O
( NN NN O
GOT NN NN O
) NN NN O
and NN NN O
glutamate NN NN O
- NN NN O
pyruvate NN NN O
transaminase NN NN O
( NN NN O
GPT NN NN O
) NN NN O
. NN NN O
   
While NN NN O
AAP NN NN O
caused NN NN O
a NN NN O
117 NN NN O
- NN NN O
fold NN NN O
elevation NN NN O
of NN NN O
serum NN NN O
transaminase NN NN O
activities NN NN O
in NN NN O
mice NN NN O
kept NN NN O
on NN NN O
a NN NN O
standard NN NN O
laboratory NN NN O
diet NN NN O
, NN NN O
which NN NN O
was NN NN O
significantly NN NN O
exacerbated NN NN O
by NN NN O
ethanol NN NN O
and NN NN O
inhibited NN NN O
by NN NN O
nicotinic NN NN O
acid NN NN O
amide NN NN O
( NN NN O
NAA NN NN O
) NN NN O
, NN NN O
adverse NN NN O
effects NN NN O
were NN NN O
noted NN NN O
in NN NN O
animals NN NN O
fed NN NN O
a NN NN O
diet NN NN O
free NN NN O
of NN NN O
precursors NN NN O
of NN NN O
NAD NN NN O
. NN NN O
   
In NN NN O
these NN NN O
animals NN NN O
, NN NN O
only NN NN O
minor NN NN O
increases NN NN O
of NN NN O
serum NN NN O
transaminase NN NN O
activities NN NN O
were NN NN O
measured NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
AAP NN NN O
, NN NN O
and NN NN O
unlike NN NN O
the NN NN O
exacerbation NN NN O
caused NN NN O
by NN NN O
ethanol NN NN O
in NN NN O
mice NN NN O
on NN NN O
a NN NN O
standard NN NN O
diet NN NN O
, NN NN O
the NN NN O
liver NN NN B-Disease
damage NN NN I-Disease
was NN NN O
inhibited NN NN O
by NN NN O
50 NN NN O
% NN NN O
by NN NN O
ethanol NN NN O
. NN NN O
   
A NN NN O
further NN NN O
64 NN NN O
% NN NN O
reduction NN NN O
of NN NN O
hepatitis NN NN B-Disease
was NN NN O
observed NN NN O
, NN NN O
when NN NN O
NAA NN NN O
was NN NN O
given NN NN O
to NN NN O
ethanol NN NN O
/ NN NN O
AAP NN NN O
- NN NN O
mice NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
provide NN NN O
evidence NN NN O
that NN NN O
the NN NN O
AAP NN NN O
- NN NN O
induced NN NN O
hepatitis NN NN B-Disease
and NN NN O
its NN NN O
exacerbation NN NN O
by NN NN O
ethanol NN NN O
can NN NN O
either NN NN O
be NN NN O
reduced NN NN O
by NN NN O
end NN NN O
- NN NN O
product NN NN O
inhibition NN NN O
of NN NN O
PARP NN NN O
by NN NN O
NAA NN NN O
or NN NN O
by NN NN O
dietary NN NN O
depletion NN NN O
of NN NN O
the NN NN O
enzyme NN NN O
' NN NN O
s NN NN O
substrate NN NN O
NAD NN NN O
. NN NN O
   
We NN NN O
see NN NN O
the NN NN O
main NN NN O
application NN NN O
of NN NN O
NAA NN NN O
as NN NN O
for NN NN O
the NN NN O
combinational NN NN O
use NN NN O
in NN NN O
pharmaceutical NN NN O
preparations NN NN O
of NN NN O
acetaminophen NN NN O
in NN NN O
order NN NN O
to NN NN O
avoid NN NN O
hepatic NN NN B-Disease
damage NN NN I-Disease
in NN NN O
patients NN NN O
treated NN NN O
with NN NN O
this NN NN O
widely NN NN O
used NN NN O
analgesic NN NN O
. NN NN O
   
Nightmares NN NN O
and NN NN O
hallucinations NN NN B-Disease
after NN NN O
long NN NN O
- NN NN O
term NN NN O
intake NN NN O
of NN NN O
tramadol NN NN O
combined NN NN O
with NN NN O
antidepressants NN NN O
. NN NN O
   
Tramadol NN NN O
is NN NN O
a NN NN O
weak NN NN O
opioid NN NN O
with NN NN O
effects NN NN O
on NN NN O
adrenergic NN NN O
and NN NN O
serotonergic NN NN O
neurotransmission NN NN O
that NN NN O
is NN NN O
used NN NN O
to NN NN O
treat NN NN O
cancer NN NN B-Disease
pain NN NN B-Disease
and NN NN O
chronic NN NN O
non NN NN O
malignant NN NN O
pain NN NN B-Disease
. NN NN O
   
This NN NN O
drug NN NN O
was NN NN O
initiated NN NN O
in NN NN O
association NN NN O
with NN NN O
paroxetine NN NN O
and NN NN O
dosulepine NN NN O
hydrochloride NN NN O
in NN NN O
a NN NN O
tetraparetic NN NN B-Disease
patient NN NN O
with NN NN O
chronic NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
Fifty NN NN O
- NN NN O
six NN NN O
days NN NN O
after NN NN O
initiation NN NN O
of NN NN O
the NN NN O
treatment NN NN O
the NN NN O
patient NN NN O
presented NN NN O
hallucinations NN NN B-Disease
that NN NN O
only NN NN O
stopped NN NN O
after NN NN O
the NN NN O
withdrawal NN NN O
of NN NN O
psycho NN NN O
- NN NN O
active NN NN O
drugs NN NN O
and NN NN O
tramadol NN NN O
. NN NN O
   
The NN NN O
case NN NN O
report NN NN O
questions NN NN O
the NN NN O
long NN NN O
term NN NN O
use NN NN O
of NN NN O
pain NN NN B-Disease
killers NN NN O
combined NN NN O
with NN NN O
psycho NN NN O
- NN NN O
active NN NN O
drugs NN NN O
in NN NN O
chronic NN NN O
non NN NN O
malignant NN NN O
pain NN NN B-Disease
, NN NN O
especially NN NN O
if NN NN O
pain NN NN B-Disease
is NN NN O
under NN NN O
control NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
calcium NN NN O
chloride NN NN O
and NN NN O
4 NN NN O
- NN NN O
aminopyridine NN NN O
therapy NN NN O
on NN NN O
desipramine NN NN O
toxicity NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Hypotension NN NN B-Disease
is NN NN O
a NN NN O
major NN NN O
contributor NN NN O
to NN NN O
mortality NN NN O
in NN NN O
tricyclic NN NN O
antidepressant NN NN O
overdose NN NN B-Disease
. NN NN O
   
Recent NN NN O
data NN NN O
suggest NN NN O
that NN NN O
tricyclic NN NN O
antidepressants NN NN O
inhibit NN NN O
calcium NN NN O
influx NN NN O
in NN NN O
some NN NN O
tissues NN NN O
. NN NN O
   
This NN NN O
study NN NN O
addressed NN NN O
the NN NN O
potential NN NN O
role NN NN O
of NN NN O
calcium NN NN O
channel NN NN O
blockade NN NN O
in NN NN O
tricyclic NN NN O
antidepressant NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Two NN NN O
interventions NN NN O
were NN NN O
studied NN NN O
that NN NN O
have NN NN O
been NN NN O
shown NN NN O
previously NN NN O
to NN NN O
improve NN NN O
blood NN NN O
pressure NN NN O
with NN NN O
calcium NN NN O
channel NN NN O
blocker NN NN O
overdose NN NN B-Disease
. NN NN O
   
CaCl2 NN NN O
and NN NN O
4 NN NN O
- NN NN O
aminopyridine NN NN O
. NN NN O
   
Anesthetized NN NN O
rats NN NN O
received NN NN O
the NN NN O
tricyclic NN NN O
antidepressant NN NN O
desipramine NN NN O
IP NN NN O
to NN NN O
produce NN NN O
hypotension NN NN B-Disease
, NN NN O
QRS NN NN O
prolongation NN NN O
, NN NN O
and NN NN O
bradycardia NN NN B-Disease
. NN NN O
   
Fifteen NN NN O
min NN NN O
later NN NN O
, NN NN O
animals NN NN O
received NN NN O
CaCl2 NN NN O
, NN NN O
NaHCO3 NN NN O
, NN NN O
or NN NN O
saline NN NN O
. NN NN O
   
In NN NN O
a NN NN O
second NN NN O
experiment NN NN O
, NN NN O
rats NN NN O
received NN NN O
tricyclic NN NN O
antidepressant NN NN O
desipramine NN NN O
IP NN NN O
followed NN NN O
in NN NN O
15 NN NN O
min NN NN O
by NN NN O
4 NN NN O
- NN NN O
aminopyridine NN NN O
or NN NN O
saline NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
NaHCO3 NN NN O
briefly NN NN O
( NN NN O
5 NN NN O
min NN NN O
) NN NN O
reversed NN NN O
hypotension NN NN B-Disease
and NN NN O
QRS NN NN O
prolongation NN NN O
. NN NN O
   
CaCl2 NN NN O
and NN NN O
4 NN NN O
- NN NN O
aminopyridine NN NN O
failed NN NN O
to NN NN O
improve NN NN O
blood NN NN O
pressure NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
ventricular NN NN B-Disease
arrhythmias NN NN I-Disease
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
004 NN NN O
) NN NN O
and NN NN O
seizures NN NN B-Disease
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
03 NN NN O
) NN NN O
in NN NN O
the NN NN O
CaCl2 NN NN O
group NN NN O
was NN NN O
higher NN NN O
than NN NN O
the NN NN O
other NN NN O
groups NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
administration NN NN O
of NN NN O
CaCl2 NN NN O
or NN NN O
4 NN NN O
- NN NN O
aminopyridine NN NN O
did NN NN O
not NN NN O
reverse NN NN O
tricyclic NN NN O
antidepressant NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
CaCl2 NN NN O
therapy NN NN O
may NN NN O
possibly NN NN O
worsen NN NN O
both NN NN O
cardiovascular NN NN B-Disease
and NN NN I-Disease
central NN NN I-Disease
nervous NN NN I-Disease
system NN NN I-Disease
toxicity NN NN I-Disease
. NN NN O
   
These NN NN O
findings NN NN O
do NN NN O
not NN NN O
support NN NN O
a NN NN O
role NN NN O
for NN NN O
calcium NN NN O
channel NN NN O
inhibition NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
tricyclic NN NN O
antidepressant NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
. NN NN O
   
Valsartan NN NN O
, NN NN O
a NN NN O
new NN NN O
angiotensin NN NN O
II NN NN O
antagonist NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
essential NN NN O
hypertension NN NN B-Disease
: NN NN O
a NN NN O
comparative NN NN O
study NN NN O
of NN NN O
the NN NN O
efficacy NN NN O
and NN NN O
safety NN NN O
against NN NN O
amlodipine NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
compare NN NN O
the NN NN O
antihypertensive NN NN O
efficacy NN NN O
of NN NN O
a NN NN O
new NN NN O
angiotensin NN NN O
II NN NN O
antagonist NN NN O
, NN NN O
valsartan NN NN O
, NN NN O
with NN NN O
a NN NN O
reference NN NN O
therapy NN NN O
, NN NN O
amlodipine NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
One NN NN O
hundred NN NN O
sixty NN NN O
- NN NN O
eight NN NN O
adult NN NN O
outpatients NN NN O
with NN NN O
mild NN NN O
to NN NN O
moderate NN NN O
hypertension NN NN B-Disease
were NN NN O
randomly NN NN O
allocated NN NN O
in NN NN O
double NN NN O
- NN NN O
blind NN NN O
fashion NN NN O
and NN NN O
equal NN NN O
number NN NN O
to NN NN O
receive NN NN O
80 NN NN O
mg NN NN O
valsartan NN NN O
or NN NN O
5 NN NN O
mg NN NN O
amlodipine NN NN O
for NN NN O
12 NN NN O
weeks NN NN O
. NN NN O
   
After NN NN O
8 NN NN O
weeks NN NN O
of NN NN O
therapy NN NN O
, NN NN O
in NN NN O
patients NN NN O
whose NN NN O
blood NN NN O
pressure NN NN O
remained NN NN O
uncontrolled NN NN O
, NN NN O
5 NN NN O
mg NN NN O
amlodipine NN NN O
was NN NN O
added NN NN O
to NN NN O
the NN NN O
initial NN NN O
therapy NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
assessed NN NN O
at NN NN O
4 NN NN O
, NN NN O
8 NN NN O
, NN NN O
and NN NN O
12 NN NN O
weeks NN NN O
. NN NN O
   
The NN NN O
primary NN NN O
efficacy NN NN O
variable NN NN O
was NN NN O
change NN NN O
from NN NN O
baseline NN NN O
in NN NN O
mean NN NN O
sitting NN NN O
diastolic NN NN O
blood NN NN O
pressure NN NN O
at NN NN O
8 NN NN O
weeks NN NN O
. NN NN O
   
Secondary NN NN O
variables NN NN O
included NN NN O
change NN NN O
in NN NN O
sitting NN NN O
systolic NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
responder NN NN O
rates NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Both NN NN O
valsartan NN NN O
and NN NN O
amlodipine NN NN O
were NN NN O
effective NN NN O
at NN NN O
lowering NN NN O
blood NN NN O
pressure NN NN O
at NN NN O
4 NN NN O
, NN NN O
8 NN NN O
, NN NN O
and NN NN O
12 NN NN O
weeks NN NN O
. NN NN O
   
Similar NN NN O
decreases NN NN O
were NN NN O
observed NN NN O
in NN NN O
both NN NN O
groups NN NN O
, NN NN O
with NN NN O
no NN NN O
statistically NN NN O
significant NN NN O
differences NN NN O
between NN NN O
the NN NN O
groups NN NN O
for NN NN O
any NN NN O
variable NN NN O
analyzed NN NN O
. NN NN O
   
For NN NN O
the NN NN O
primary NN NN O
variable NN NN O
the NN NN O
difference NN NN O
was NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mm NN NN O
Hg NN NN O
in NN NN O
favor NN NN O
of NN NN O
valsartan NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
68 NN NN O
; NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
- NN NN O
2 NN NN O
. NN NN O
7 NN NN O
to NN NN O
1 NN NN O
. NN NN O
7 NN NN O
) NN NN O
. NN NN O
   
Responder NN NN O
rates NN NN O
at NN NN O
8 NN NN O
weeks NN NN O
were NN NN O
66 NN NN O
. NN NN O
7 NN NN O
% NN NN O
for NN NN O
valsartan NN NN O
and NN NN O
60 NN NN O
. NN NN O
2 NN NN O
% NN NN O
for NN NN O
amlodipine NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
39 NN NN O
) NN NN O
. NN NN O
   
Both NN NN O
treatments NN NN O
were NN NN O
well NN NN O
tolerated NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
drug NN NN O
- NN NN O
related NN NN O
dependent NN NN O
edema NN NN B-Disease
was NN NN O
somewhat NN NN O
higher NN NN O
in NN NN O
the NN NN O
amlodipine NN NN O
group NN NN O
, NN NN O
particularly NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
10 NN NN O
mg NN NN O
per NN NN O
day NN NN O
( NN NN O
2 NN NN O
. NN NN O
4 NN NN O
% NN NN O
for NN NN O
80 NN NN O
mg NN NN O
valsartan NN NN O
; NN NN O
3 NN NN O
. NN NN O
6 NN NN O
% NN NN O
for NN NN O
5 NN NN O
mg NN NN O
amlodipine NN NN O
; NN NN O
0 NN NN O
% NN NN O
for NN NN O
valsartan NN NN O
plus NN NN O
5 NN NN O
mg NN NN O
amlodipine NN NN O
; NN NN O
14 NN NN O
. NN NN O
3 NN NN O
% NN NN O
for NN NN O
10 NN NN O
mg NN NN O
amlodipine NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
data NN NN O
show NN NN O
that NN NN O
valsartan NN NN O
is NN NN O
at NN NN O
least NN NN O
as NN NN O
effective NN NN O
as NN NN O
amlodipine NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
mild NN NN O
to NN NN O
moderate NN NN O
hypertension NN NN B-Disease
. NN NN O
   
The NN NN O
results NN NN O
also NN NN O
show NN NN O
valsartan NN NN O
to NN NN O
be NN NN O
well NN NN O
tolerated NN NN O
and NN NN O
suggest NN NN O
that NN NN O
it NN NN O
is NN NN O
not NN NN O
associated NN NN O
with NN NN O
side NN NN O
effects NN NN O
characteristic NN NN O
of NN NN O
this NN NN O
comparator NN NN O
class NN NN O
, NN NN O
dihydropyridine NN NN O
calcium NN NN O
antagonists NN NN O
. NN NN O
   
A NN NN O
measure NN NN O
of NN NN O
pupillary NN NN B-Disease
oscillation NN NN I-Disease
as NN NN O
a NN NN O
marker NN NN O
of NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
paranoia NN NN B-Disease
. NN NN O
   
Cocaine NN NN O
- NN NN O
induced NN NN O
paranoia NN NN B-Disease
( NN NN O
CIP NN NN B-Disease
) NN NN O
remains NN NN O
an NN NN O
important NN NN O
drug NN NN O
- NN NN O
induced NN NN O
model NN NN O
of NN NN O
idiopathic NN NN O
paranoia NN NN B-Disease
for NN NN O
which NN NN O
no NN NN O
psychophysiologic NN NN O
marker NN NN O
has NN NN O
yet NN NN O
emerged NN NN O
. NN NN O
   
Measures NN NN O
of NN NN O
pupillary NN NN B-Disease
oscillation NN NN I-Disease
were NN NN O
able NN NN O
to NN NN O
significantly NN NN O
distinguish NN NN O
a NN NN O
group NN NN O
of NN NN O
abstinent NN NN O
crack NN NN O
cocaine NN NN O
abusers NN NN O
endorsing NN NN O
past NN NN O
CIP NN NN B-Disease
( NN NN O
n NN NN O
= NN NN O
32 NN NN O
) NN NN O
from NN NN O
another NN NN O
group NN NN O
of NN NN O
crack NN NN O
addicts NN NN O
who NN NN O
denied NN NN O
past NN NN O
CIP NN NN B-Disease
( NN NN O
n NN NN O
= NN NN O
29 NN NN O
) NN NN O
. NN NN O
   
Serotonin NN NN B-Disease
syndrome NN NN I-Disease
from NN NN O
venlafaxine NN NN O
- NN NN O
tranylcypromine NN NN O
interaction NN NN O
. NN NN O
   
Excessive NN NN O
stimulation NN NN O
of NN NN O
serotonin NN NN O
5HT1A NN NN O
receptors NN NN O
causes NN NN O
a NN NN O
syndrome NN NN O
of NN NN O
serotonin NN NN O
excess NN NN O
that NN NN O
consists NN NN O
of NN NN O
shivering NN NN O
, NN NN O
muscle NN NN B-Disease
rigidity NN NN I-Disease
, NN NN O
salivation NN NN B-Disease
, NN NN O
confusion NN NN B-Disease
, NN NN O
agitation NN NN B-Disease
and NN NN O
hyperthermia NN NN B-Disease
. NN NN O
   
The NN NN O
most NN NN O
common NN NN O
cause NN NN O
of NN NN O
this NN NN O
syndrome NN NN O
is NN NN O
an NN NN O
interaction NN NN O
between NN NN O
a NN NN O
monoamine NN NN O
oxidase NN NN O
inhibitor NN NN O
( NN NN O
MAOI NN NN O
) NN NN O
and NN NN O
a NN NN O
specific NN NN O
serotonin NN NN O
reuptake NN NN O
inhibitor NN NN O
. NN NN O
   
Venlafaxine NN NN O
is NN NN O
a NN NN O
new NN NN O
antidepressant NN NN O
agent NN NN O
that NN NN O
inhibits NN NN O
the NN NN O
reuptake NN NN O
of NN NN O
serotonin NN NN O
and NN NN O
norepinephrine NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
venlafaxine NN NN O
- NN NN O
MAOI NN NN O
interaction NN NN O
that NN NN O
resulted NN NN O
in NN NN O
the NN NN O
serotonin NN NN B-Disease
syndrome NN NN I-Disease
in NN NN O
a NN NN O
23 NN NN O
- NN NN O
y NN NN O
- NN NN O
old NN NN O
male NN NN O
who NN NN O
was NN NN O
taking NN NN O
tranylcypromine NN NN O
for NN NN O
depression NN NN B-Disease
. NN NN O
   
He NN NN O
had NN NN O
been NN NN O
well NN NN O
until NN NN O
the NN NN O
morning NN NN O
of NN NN O
presentation NN NN O
when NN NN O
he NN NN O
took NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
tab NN NN O
of NN NN O
venlafaxine NN NN O
. NN NN O
   
Within NN NN O
2 NN NN O
h NN NN O
he NN NN O
became NN NN O
confused NN NN O
with NN NN O
jerking NN NN O
movements NN NN O
of NN NN O
his NN NN O
extremities NN NN O
, NN NN O
tremors NN NN B-Disease
and NN NN O
rigidity NN NN B-Disease
. NN NN O
   
He NN NN O
was NN NN O
brought NN NN O
directly NN NN O
to NN NN O
a NN NN O
hospital NN NN O
where NN NN O
he NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
agitated NN NN O
and NN NN O
confused NN NN O
with NN NN O
shivering NN NN O
, NN NN O
myoclonic NN NN B-Disease
jerks NN NN I-Disease
, NN NN O
rigidity NN NN B-Disease
, NN NN O
salivation NN NN B-Disease
and NN NN O
diaphoresis NN NN O
. NN NN O
   
His NN NN O
pupils NN NN O
were NN NN O
7 NN NN O
mm NN NN O
and NN NN O
sluggishly NN NN O
reactive NN NN O
to NN NN O
light NN NN O
. NN NN O
   
Vital NN NN O
signs NN NN O
were NN NN O
: NN NN O
blood NN NN O
pressure NN NN O
120 NN NN O
/ NN NN O
67 NN NN O
mm NN NN O
Hg NN NN O
, NN NN O
heart NN NN O
rate NN NN O
127 NN NN O
/ NN NN O
min NN NN O
, NN NN O
respiratory NN NN O
rate NN NN O
28 NN NN O
/ NN NN O
min NN NN O
, NN NN O
and NN NN O
temperature NN NN O
97 NN NN O
F NN NN O
. NN NN O
   
After NN NN O
180 NN NN O
mg NN NN O
of NN NN O
diazepam NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
he NN NN O
remained NN NN O
tremulous NN NN O
with NN NN O
muscle NN NN B-Disease
rigidity NN NN I-Disease
and NN NN O
clenched NN NN O
jaws NN NN O
. NN NN O
   
He NN NN O
was NN NN O
intubated NN NN O
for NN NN O
airway NN NN O
protection NN NN O
and NN NN O
because NN NN O
of NN NN O
hypoventilation NN NN B-Disease
, NN NN O
and NN NN O
was NN NN O
paralyzed NN NN B-Disease
to NN NN O
control NN NN O
muscle NN NN B-Disease
rigidity NN NN I-Disease
. NN NN O
   
His NN NN O
subsequent NN NN O
course NN NN O
was NN NN O
remarkable NN NN O
for NN NN O
non NN NN O
- NN NN O
immune NN NN O
thrombocytopenia NN NN B-Disease
which NN NN O
resolved NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
' NN NN O
s NN NN O
maximal NN NN O
temperature NN NN O
was NN NN O
101 NN NN O
. NN NN O
2 NN NN O
F NN NN O
and NN NN O
his NN NN O
CPK NN NN O
remained NN NN O
< NN NN O
500 NN NN O
units NN NN O
/ NN NN O
L NN NN O
with NN NN O
no NN NN O
other NN NN O
evidence NN NN O
of NN NN O
rhabdomyolysis NN NN B-Disease
. NN NN O
   
His NN NN O
mental NN NN O
status NN NN O
normalized NN NN O
and NN NN O
he NN NN O
was NN NN O
transferred NN NN O
to NN NN O
a NN NN O
psychiatry NN NN O
ward NN NN O
. NN NN O
   
This NN NN O
patient NN NN O
survived NN NN O
without NN NN O
sequelae NN NN O
due NN NN O
to NN NN O
the NN NN O
aggressive NN NN O
sedation NN NN O
and NN NN O
neuromuscular NN NN O
paralysis NN NN B-Disease
. NN NN O
   
Cyclophosphamide NN NN O
associated NN NN O
bladder NN NN B-Disease
cancer NN NN I-Disease
- NN NN O
- NN NN O
a NN NN O
highly NN NN O
aggressive NN NN O
disease NN NN O
: NN NN O
analysis NN NN O
of NN NN O
12 NN NN O
cases NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
We NN NN O
gained NN NN O
knowledge NN NN O
of NN NN O
the NN NN O
etiology NN NN O
, NN NN O
treatment NN NN O
and NN NN O
prevention NN NN O
of NN NN O
cyclophosphamide NN NN O
associated NN NN O
urothelial NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
MATERIALS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
The NN NN O
medical NN NN O
records NN NN O
of NN NN O
6 NN NN O
men NN NN O
and NN NN O
6 NN NN O
women NN NN O
( NN NN O
mean NN NN O
age NN NN O
55 NN NN O
years NN NN O
) NN NN O
with NN NN O
cyclophosphamide NN NN O
associated NN NN O
bladder NN NN B-Disease
cancer NN NN I-Disease
were NN NN O
reviewed NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
All NN NN O
tumors NN NN B-Disease
were NN NN O
grade NN NN O
3 NN NN O
or NN NN O
4 NN NN O
transitional NN NN O
cell NN NN O
carcinoma NN NN B-Disease
. NN NN O
   
Of NN NN O
the NN NN O
5 NN NN O
patients NN NN O
initially NN NN O
treated NN NN O
with NN NN O
endoscopic NN NN O
resection NN NN O
alone NN NN O
only NN NN O
1 NN NN O
is NN NN O
alive NN NN O
without NN NN O
disease NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
6 NN NN O
patients NN NN O
who NN NN O
underwent NN NN O
early NN NN O
cystectomy NN NN O
4 NN NN O
were NN NN O
alive NN NN O
at NN NN O
24 NN NN O
to NN NN O
111 NN NN O
months NN NN O
. NN NN O
   
The NN NN O
remaining NN NN O
patient NN NN O
with NN NN O
extensive NN NN O
cancer NN NN B-Disease
underwent NN NN O
partial NN NN O
cystectomy NN NN O
for NN NN O
palliation NN NN O
and NN NN O
died NN NN O
3 NN NN O
months NN NN O
later NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Cyclophosphamide NN NN O
associated NN NN O
bladder NN NN B-Disease
tumor NN NN I-Disease
is NN NN O
an NN NN O
aggressive NN NN O
disease NN NN O
. NN NN O
   
However NN NN O
, NN NN O
long NN NN O
- NN NN O
term NN NN O
survival NN NN O
is NN NN O
possible NN NN O
when NN NN O
radical NN NN O
cystectomy NN NN O
is NN NN O
performed NN NN O
for NN NN O
bladder NN NN B-Disease
tumors NN NN I-Disease
with NN NN O
any NN NN O
sign NN NN O
of NN NN O
invasion NN NN O
and NN NN O
for NN NN O
recurrent NN NN O
high NN NN O
grade NN NN O
disease NN NN O
, NN NN O
even NN NN O
when NN NN O
noninvasive NN NN O
. NN NN O
   
A NN NN O
phase NN NN O
I NN NN O
clinical NN NN O
study NN NN O
of NN NN O
the NN NN O
antipurine NN NN O
antifolate NN NN O
lometrexol NN NN O
( NN NN O
DDATHF NN NN O
) NN NN O
given NN NN O
with NN NN O
oral NN NN O
folic NN NN O
acid NN NN O
. NN NN O
   
Lometrexol NN NN O
is NN NN O
an NN NN O
antifolate NN NN O
which NN NN O
inhibits NN NN O
glycinamide NN NN O
ribonucleotide NN NN O
formyltransferase NN NN O
( NN NN O
GARFT NN NN O
) NN NN O
, NN NN O
an NN NN O
enzyme NN NN O
essential NN NN O
for NN NN O
de NN NN O
novo NN NN O
purine NN NN O
synthesis NN NN O
. NN NN O
   
Extensive NN NN O
experimental NN NN O
and NN NN O
limited NN NN O
clinical NN NN O
data NN NN O
have NN NN O
shown NN NN O
that NN NN O
lometrexol NN NN O
has NN NN O
activity NN NN O
against NN NN O
tumours NN NN B-Disease
which NN NN O
are NN NN O
refractory NN NN O
to NN NN O
other NN NN O
drugs NN NN O
, NN NN O
notably NN NN O
methotrexate NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
initial NN NN O
clinical NN NN O
development NN NN O
of NN NN O
lometrexol NN NN O
was NN NN O
curtailed NN NN O
because NN NN O
of NN NN O
severe NN NN O
and NN NN O
cumulative NN NN O
antiproliferative NN NN O
toxicities NN NN B-Disease
. NN NN O
   
Preclinical NN NN O
murine NN NN O
studies NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
toxicity NN NN B-Disease
of NN NN O
lometrexol NN NN O
can NN NN O
be NN NN O
prevented NN NN O
by NN NN O
low NN NN O
dose NN NN O
folic NN NN O
acid NN NN O
administration NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
for NN NN O
7 NN NN O
days NN NN O
prior NN NN O
to NN NN O
and NN NN O
7 NN NN O
days NN NN O
following NN NN O
a NN NN O
single NN NN O
bolus NN NN O
dose NN NN O
. NN NN O
   
This NN NN O
observation NN NN O
prompted NN NN O
a NN NN O
Phase NN NN O
I NN NN O
clinical NN NN O
study NN NN O
of NN NN O
lometrexol NN NN O
given NN NN O
with NN NN O
folic NN NN O
acid NN NN O
supplementation NN NN O
which NN NN O
has NN NN O
confirmed NN NN O
that NN NN O
the NN NN O
toxicity NN NN B-Disease
of NN NN O
lometrexol NN NN O
can NN NN O
be NN NN O
markedly NN NN O
reduced NN NN O
by NN NN O
folic NN NN O
acid NN NN O
supplementation NN NN O
. NN NN O
   
Thrombocytopenia NN NN B-Disease
and NN NN O
mucositis NN NN B-Disease
were NN NN O
the NN NN O
major NN NN O
toxicities NN NN B-Disease
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
clear NN NN O
relationship NN NN O
between NN NN O
clinical NN NN O
toxicity NN NN B-Disease
and NN NN O
the NN NN O
extent NN NN O
of NN NN O
plasma NN NN O
folate NN NN O
elevation NN NN O
. NN NN O
   
Associated NN NN O
studies NN NN O
demonstrated NN NN O
that NN NN O
lometrexol NN NN O
plasma NN NN O
pharmacokinetics NN NN O
were NN NN O
not NN NN O
altered NN NN O
by NN NN O
folic NN NN O
acid NN NN O
administration NN NN O
indicating NN NN O
that NN NN O
supplementation NN NN O
is NN NN O
unlikely NN NN O
to NN NN O
reduce NN NN O
toxicity NN NN B-Disease
by NN NN O
enhancing NN NN O
lometrexol NN NN O
plasma NN NN O
clearance NN NN O
. NN NN O
   
The NN NN O
work NN NN O
described NN NN O
in NN NN O
this NN NN O
report NN NN O
has NN NN O
identified NN NN O
for NN NN O
the NN NN O
first NN NN O
time NN NN O
a NN NN O
clinically NN NN O
acceptable NN NN O
schedule NN NN O
for NN NN O
the NN NN O
administration NN NN O
of NN NN O
a NN NN O
GARFT NN NN O
inhibitor NN NN O
. NN NN O
   
This NN NN O
information NN NN O
will NN NN O
facilitate NN NN O
the NN NN O
future NN NN O
evaluation NN NN O
of NN NN O
this NN NN O
class NN NN O
of NN NN O
compounds NN NN O
in NN NN O
cancer NN NN B-Disease
therapy NN NN O
. NN NN O
   
Fatal NN NN O
excited NN NN O
delirium NN NN B-Disease
following NN NN O
cocaine NN NN O
use NN NN O
: NN NN O
epidemiologic NN NN O
findings NN NN O
provide NN NN O
new NN NN O
evidence NN NN O
for NN NN O
mechanisms NN NN O
of NN NN O
cocaine NN NN O
toxicity NN NN B-Disease
. NN NN O
   
We NN NN O
describe NN NN O
an NN NN O
outbreak NN NN O
of NN NN O
deaths NN NN O
from NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
excited NN NN O
delirium NN NN B-Disease
( NN NN O
EDDs NN NN B-Disease
) NN NN O
in NN NN O
Dade NN NN O
County NN NN O
, NN NN O
Florida NN NN O
between NN NN O
1979 NN NN O
and NN NN O
1990 NN NN O
. NN NN O
   
From NN NN O
a NN NN O
registry NN NN O
of NN NN O
all NN NN O
cocaine NN NN O
- NN NN O
related NN NN O
deaths NN NN O
in NN NN O
Dade NN NN O
County NN NN O
, NN NN O
Florida NN NN O
, NN NN O
from NN NN O
1969 NN NN O
- NN NN O
1990 NN NN O
, NN NN O
58 NN NN O
EDDs NN NN B-Disease
were NN NN O
compared NN NN O
with NN NN O
125 NN NN O
victims NN NN O
of NN NN O
accidental NN NN O
cocaine NN NN O
overdose NN NN B-Disease
without NN NN O
excited NN NN O
delirium NN NN B-Disease
. NN NN O
   
Compared NN NN O
with NN NN O
controls NN NN O
, NN NN O
EDDs NN NN B-Disease
were NN NN O
more NN NN O
frequently NN NN O
black NN NN O
, NN NN O
male NN NN O
, NN NN O
and NN NN O
younger NN NN O
. NN NN O
   
They NN NN O
were NN NN O
less NN NN O
likely NN NN O
to NN NN O
have NN NN O
a NN NN O
low NN NN O
body NN NN O
mass NN NN O
index NN NN O
, NN NN O
and NN NN O
more NN NN O
likely NN NN O
to NN NN O
have NN NN O
died NN NN O
in NN NN O
police NN NN O
custody NN NN O
, NN NN O
to NN NN O
have NN NN O
received NN NN O
medical NN NN O
treatment NN NN O
immediately NN NN O
before NN NN O
death NN NN O
, NN NN O
to NN NN O
have NN NN O
survived NN NN O
for NN NN O
a NN NN O
longer NN NN O
period NN NN O
, NN NN O
to NN NN O
have NN NN O
developed NN NN O
hyperthermia NN NN B-Disease
, NN NN O
and NN NN O
to NN NN O
have NN NN O
died NN NN O
in NN NN O
summer NN NN O
months NN NN O
. NN NN O
   
EDDs NN NN B-Disease
had NN NN O
concentrations NN NN O
of NN NN O
cocaine NN NN O
and NN NN O
benzoylecgonine NN NN O
in NN NN O
autopsy NN NN O
blood NN NN O
that NN NN O
were NN NN O
similar NN NN O
to NN NN O
those NN NN O
for NN NN O
controls NN NN O
. NN NN O
   
The NN NN O
epidemiologic NN NN O
findings NN NN O
are NN NN O
most NN NN O
consistent NN NN O
with NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
chronic NN NN O
cocaine NN NN O
use NN NN O
disrupts NN NN O
dopaminergic NN NN O
function NN NN O
and NN NN O
, NN NN O
when NN NN O
coupled NN NN O
with NN NN O
recent NN NN O
cocaine NN NN O
use NN NN O
, NN NN O
may NN NN O
precipitate NN NN O
agitation NN NN B-Disease
, NN NN O
delirium NN NN B-Disease
, NN NN O
aberrant NN NN O
thermoregulation NN NN O
, NN NN O
rhabdomyolysis NN NN B-Disease
, NN NN O
and NN NN O
sudden NN NN B-Disease
death NN NN I-Disease
. NN NN O
   
Pemoline NN NN O
induced NN NN O
acute NN NN O
choreoathetosis NN NN B-Disease
: NN NN O
case NN NN O
report NN NN O
and NN NN O
review NN NN O
of NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Pemoline NN NN O
is NN NN O
an NN NN O
oxazolidine NN NN O
derivative NN NN O
that NN NN O
is NN NN O
structurally NN NN O
different NN NN O
from NN NN O
amphetamines NN NN O
and NN NN O
used NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
attention NN NN B-Disease
deficit NN NN I-Disease
disorder NN NN I-Disease
. NN NN O
   
Pemoline NN NN O
has NN NN O
not NN NN O
been NN NN O
commonly NN NN O
associated NN NN O
in NN NN O
the NN NN O
literature NN NN O
as NN NN O
a NN NN O
cause NN NN O
of NN NN O
acute NN NN O
movement NN NN B-Disease
disorders NN NN I-Disease
. NN NN O
   
The NN NN O
following NN NN O
case NN NN O
describes NN NN O
two NN NN O
children NN NN O
acutely NN NN O
poisoned NN NN O
with NN NN O
pemoline NN NN O
who NN NN O
experienced NN NN O
profound NN NN O
choreoathetosis NN NN B-Disease
. NN NN O
   
CASE NN NN O
REPORT NN NN O
: NN NN O
Two NN NN O
, NN NN O
3 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
male NN NN O
, NN NN O
identical NN NN O
twin NN NN O
siblings NN NN O
presented NN NN O
to NN NN O
the NN NN O
emergency NN NN O
department NN NN O
after NN NN O
found NN NN O
playing NN NN O
with NN NN O
a NN NN O
an NN NN O
empty NN NN O
bottle NN NN O
of NN NN O
pemoline NN NN O
originally NN NN O
containing NN NN O
59 NN NN O
tablets NN NN O
. NN NN O
   
The NN NN O
children NN NN O
had NN NN O
a NN NN O
medical NN NN O
history NN NN O
significant NN NN O
for NN NN O
attention NN NN B-Disease
deficit NN NN I-Disease
disorder NN NN I-Disease
previously NN NN O
treated NN NN O
with NN NN O
methylphenidate NN NN O
without NN NN O
success NN NN O
. NN NN O
   
This NN NN O
was NN NN O
their NN NN O
first NN NN O
day NN NN O
of NN NN O
pemoline NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
choreoathetoid NN NN B-Disease
movements NN NN O
began NN NN O
45 NN NN O
min NN NN O
to NN NN O
1 NN NN O
h NN NN O
after NN NN O
ingestion NN NN O
. NN NN O
   
The NN NN O
children NN NN O
gave NN NN O
no NN NN O
history NN NN O
of NN NN O
prior NN NN O
movement NN NN B-Disease
disorders NN NN I-Disease
and NN NN O
there NN NN O
was NN NN O
no NN NN O
family NN NN O
history NN NN O
of NN NN O
movement NN NN B-Disease
disorders NN NN I-Disease
. NN NN O
   
The NN NN O
children NN NN O
received NN NN O
gastrointestinal NN NN O
decontamination NN NN O
and NN NN O
high NN NN O
doses NN NN O
of NN NN O
intravenous NN NN O
benzodiazepines NN NN O
in NN NN O
an NN NN O
attempt NN NN O
to NN NN O
control NN NN O
the NN NN O
choreoathetoid NN NN B-Disease
movements NN NN O
. NN NN O
   
Despite NN NN O
treatment NN NN O
, NN NN O
the NN NN O
children NN NN O
continued NN NN O
to NN NN O
have NN NN O
choreoathetosis NN NN B-Disease
for NN NN O
approximately NN NN O
24 NN NN O
hours NN NN O
. NN NN O
   
Forty NN NN O
- NN NN O
eight NN NN O
hours NN NN O
after NN NN O
admission NN NN O
, NN NN O
the NN NN O
children NN NN O
appeared NN NN O
to NN NN O
be NN NN O
at NN NN O
their NN NN O
baseline NN NN O
and NN NN O
were NN NN O
discharged NN NN O
home NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Pemoline NN NN O
associated NN NN O
movement NN NN B-Disease
disorder NN NN I-Disease
has NN NN O
been NN NN O
rarely NN NN O
reported NN NN O
in NN NN O
the NN NN O
acute NN NN O
toxicology NN NN O
literature NN NN O
. NN NN O
   
The NN NN O
possibility NN NN O
of NN NN O
choreoathetoid NN NN B-Disease
movements NN NN O
should NN NN O
be NN NN O
considered NN NN O
in NN NN O
patients NN NN O
presenting NN NN O
after NN NN O
pemoline NN NN O
overdose NN NN B-Disease
. NN NN O
   
Effect NN NN O
of NN NN O
myopic NN NN O
excimer NN NN O
laser NN NN O
photorefractive NN NN O
keratectomy NN NN O
on NN NN O
the NN NN O
electrophysiologic NN NN O
function NN NN O
of NN NN O
the NN NN O
retina NN NN O
and NN NN O
optic NN NN O
nerve NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
To NN NN O
assess NN NN O
by NN NN O
electrophysiologic NN NN O
testing NN NN O
the NN NN O
effect NN NN O
of NN NN O
photorefractive NN NN O
keratectomy NN NN O
( NN NN O
PRK NN NN O
) NN NN O
on NN NN O
the NN NN O
retina NN NN O
and NN NN O
optic NN NN O
nerve NN NN O
. NN NN O
   
SETTING NN NN O
: NN NN O
Eye NN NN O
Clinic NN NN O
, NN NN O
S NN NN O
. NN NN O
   
Salvatore NN NN O
Hospital NN NN O
, NN NN O
L NN NN O
' NN NN O
Aquila NN NN O
University NN NN O
, NN NN O
Italy NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Standard NN NN O
pattern NN NN O
electroretinograms NN NN O
( NN NN O
P NN NN O
- NN NN O
ERGs NN NN O
) NN NN O
and NN NN O
standard NN NN O
pattern NN NN O
visual NN NN O
evoked NN NN O
potentials NN NN O
( NN NN O
P NN NN O
- NN NN O
VEPs NN NN O
) NN NN O
were NN NN O
done NN NN O
in NN NN O
25 NN NN O
eyes NN NN O
of NN NN O
25 NN NN O
patients NN NN O
who NN NN O
had NN NN O
myopic NN NN O
PRK NN NN O
for NN NN O
an NN NN O
attempted NN NN O
correction NN NN O
between NN NN O
5 NN NN O
. NN NN O
00 NN NN O
and NN NN O
15 NN NN O
. NN NN O
00 NN NN O
diopters NN NN O
( NN NN O
D NN NN O
) NN NN O
( NN NN O
mean NN NN O
8 NN NN O
. NN NN O
00 NN NN O
D NN NN O
) NN NN O
. NN NN O
   
Testing NN NN O
was NN NN O
done NN NN O
preoperatively NN NN O
and NN NN O
3 NN NN O
, NN NN O
6 NN NN O
, NN NN O
12 NN NN O
, NN NN O
and NN NN O
18 NN NN O
months NN NN O
postoperatively NN NN O
. NN NN O
   
The NN NN O
contralateral NN NN O
eyes NN NN O
served NN NN O
as NN NN O
controls NN NN O
. NN NN O
   
During NN NN O
the NN NN O
follow NN NN O
- NN NN O
up NN NN O
, NN NN O
3 NN NN O
patients NN NN O
( NN NN O
12 NN NN O
% NN NN O
) NN NN O
developed NN NN O
steroid NN NN O
- NN NN O
induced NN NN O
elevated NN NN B-Disease
intraocular NN NN I-Disease
pressure NN NN I-Disease
( NN NN O
IOP NN NN O
) NN NN O
that NN NN O
resolved NN NN O
after NN NN O
corticosteroid NN NN O
therapy NN NN O
was NN NN O
discontinued NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
No NN NN O
statistically NN NN O
significant NN NN O
differences NN NN O
were NN NN O
seen NN NN O
between NN NN O
treated NN NN O
and NN NN O
control NN NN O
eyes NN NN O
nor NN NN O
between NN NN O
treated NN NN O
eyes NN NN O
preoperatively NN NN O
and NN NN O
postoperatively NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Myopic NN NN O
excimer NN NN O
laser NN NN O
PRK NN NN O
did NN NN O
not NN NN O
seem NN NN O
to NN NN O
affect NN NN O
the NN NN O
posterior NN NN O
segment NN NN O
. NN NN O
   
The NN NN O
transient NN NN O
steroid NN NN O
- NN NN O
induced NN NN O
IOP NN NN B-Disease
rise NN NN I-Disease
did NN NN O
not NN NN O
seem NN NN O
to NN NN O
cause NN NN O
functional NN NN O
impairment NN NN O
. NN NN O
   
Neutrophil NN NN O
superoxide NN NN O
and NN NN O
hydrogen NN NN O
peroxide NN NN O
production NN NN O
in NN NN O
patients NN NN O
with NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
Defects NN NN O
in NN NN O
superoxide NN NN O
and NN NN O
hydrogen NN NN O
peroxide NN NN O
production NN NN O
may NN NN O
be NN NN O
implicated NN NN O
in NN NN O
the NN NN O
high NN NN O
incidence NN NN O
of NN NN O
bacterial NN NN B-Disease
infections NN NN I-Disease
in NN NN O
patients NN NN O
with NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
( NN NN O
ALF NN NN B-Disease
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
oxygen NN NN O
radical NN NN O
production NN NN O
in NN NN O
patients NN NN O
with NN NN O
ALF NN NN B-Disease
due NN NN O
to NN NN O
paracetamol NN NN O
overdose NN NN B-Disease
was NN NN O
compared NN NN O
with NN NN O
that NN NN O
of NN NN O
healthy NN NN O
volunteers NN NN O
. NN NN O
   
Neutrophils NN NN O
from NN NN O
14 NN NN O
ALF NN NN B-Disease
patients NN NN O
were NN NN O
stimulated NN NN O
via NN NN O
the NN NN O
complement NN NN O
receptors NN NN O
using NN NN O
zymosan NN NN O
opsonized NN NN O
with NN NN O
ALF NN NN B-Disease
or NN NN O
control NN NN O
serum NN NN O
. NN NN O
   
Superoxide NN NN O
and NN NN O
hydrogen NN NN O
peroxide NN NN O
production NN NN O
by NN NN O
ALF NN NN B-Disease
neutrophils NN NN O
stimulated NN NN O
with NN NN O
zymosan NN NN O
opsonized NN NN O
with NN NN O
ALF NN NN B-Disease
serum NN NN O
was NN NN O
significantly NN NN O
reduced NN NN O
compared NN NN O
with NN NN O
the NN NN O
control NN NN O
subjects NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
This NN NN O
defect NN NN O
persisted NN NN O
when NN NN O
zymosan NN NN O
opsonized NN NN O
by NN NN O
control NN NN O
serum NN NN O
was NN NN O
used NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Superoxide NN NN O
and NN NN O
hydrogen NN NN O
peroxide NN NN O
production NN NN O
in NN NN O
neutrophils NN NN O
stimulated NN NN O
with NN NN O
formyl NN NN O
- NN NN O
methionyl NN NN O
- NN NN O
leucyl NN NN O
- NN NN O
phenylalanine NN NN O
( NN NN O
fMLP NN NN O
) NN NN O
from NN NN O
a NN NN O
further NN NN O
18 NN NN O
ALF NN NN B-Disease
patients NN NN O
was NN NN O
unaffected NN NN O
compared NN NN O
with NN NN O
control NN NN O
neutrophils NN NN O
. NN NN O
   
Serum NN NN O
C3 NN NN O
complement NN NN O
levels NN NN O
were NN NN O
significantly NN NN O
reduced NN NN O
in NN NN O
ALF NN NN B-Disease
patients NN NN O
compared NN NN O
with NN NN O
control NN NN O
subjects NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
0005 NN NN O
) NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrate NN NN O
a NN NN O
neutrophil NN NN O
defect NN NN O
in NN NN O
ALF NN NN B-Disease
due NN NN O
to NN NN O
paracetamol NN NN O
overdose NN NN B-Disease
, NN NN O
that NN NN O
is NN NN O
complement NN NN O
dependent NN NN O
but NN NN O
independent NN NN O
of NN NN O
serum NN NN O
complement NN NN O
, NN NN O
possibly NN NN O
connected NN NN O
to NN NN O
the NN NN O
complement NN NN O
receptor NN NN O
. NN NN O
   
Cholesteryl NN NN O
hemisuccinate NN NN O
treatment NN NN O
protects NN NN O
rodents NN NN O
from NN NN O
the NN NN O
toxic NN NN O
effects NN NN O
of NN NN O
acetaminophen NN NN O
, NN NN O
adriamycin NN NN O
, NN NN O
carbon NN NN O
tetrachloride NN NN O
, NN NN O
chloroform NN NN O
and NN NN O
galactosamine NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
its NN NN O
use NN NN O
as NN NN O
a NN NN O
stabilizer NN NN O
/ NN NN O
rigidifier NN NN O
of NN NN O
membranes NN NN O
, NN NN O
cholesteryl NN NN O
hemisuccinate NN NN O
, NN NN O
tris NN NN O
salt NN NN O
( NN NN O
CS NN NN O
) NN NN O
administration NN NN O
has NN NN O
also NN NN O
been NN NN O
shown NN NN O
to NN NN O
protect NN NN O
rats NN NN O
from NN NN O
the NN NN O
hepatotoxic NN NN B-Disease
effects NN NN O
of NN NN O
carbon NN NN O
tetrachloride NN NN O
( NN NN O
CCl4 NN NN O
) NN NN O
. NN NN O
   
To NN NN O
further NN NN O
our NN NN O
understanding NN NN O
of NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
CS NN NN O
cytoprotection NN NN O
, NN NN O
we NN NN O
examined NN NN O
in NN NN O
rats NN NN O
and NN NN O
mice NN NN O
the NN NN O
protective NN NN O
abilities NN NN O
of NN NN O
CS NN NN O
and NN NN O
the NN NN O
non NN NN O
- NN NN O
hydrolyzable NN NN O
ether NN NN O
form NN NN O
of NN NN O
CS NN NN O
, NN NN O
gamma NN NN O
- NN NN O
cholesteryloxybutyric NN NN O
acid NN NN O
, NN NN O
tris NN NN O
salt NN NN O
( NN NN O
CSE NN NN O
) NN NN O
against NN NN O
acetaminophen NN NN O
- NN NN O
, NN NN O
adriamycin NN NN O
- NN NN O
, NN NN O
carbon NN NN O
tetrachloride NN NN O
- NN NN O
, NN NN O
chloroform NN NN O
- NN NN O
and NN NN O
galactosamine NN NN O
- NN NN O
induced NN NN O
toxicity NN NN B-Disease
. NN NN O
   
The NN NN O
results NN NN O
of NN NN O
these NN NN O
studies NN NN O
demonstrated NN NN O
that NN NN O
CS NN NN O
- NN NN O
mediated NN NN O
protection NN NN O
is NN NN O
not NN NN O
selective NN NN O
for NN NN O
a NN NN O
particular NN NN O
species NN NN O
, NN NN O
organ NN NN O
system NN NN O
or NN NN O
toxic NN NN O
chemical NN NN O
. NN NN O
   
A NN NN O
24 NN NN O
- NN NN O
h NN NN O
pretreatment NN NN O
of NN NN O
both NN NN O
rats NN NN O
and NN NN O
mice NN NN O
with NN NN O
a NN NN O
single NN NN O
dose NN NN O
of NN NN O
CS NN NN O
( NN NN O
100mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
, NN NN O
resulted NN NN O
in NN NN O
significant NN NN O
protection NN NN O
against NN NN O
the NN NN O
hepatotoxic NN NN B-Disease
effects NN NN O
of NN NN O
CCl4 NN NN O
, NN NN O
CHCl3 NN NN O
, NN NN O
acetaminophen NN NN O
and NN NN O
galactosamine NN NN O
and NN NN O
against NN NN O
the NN NN O
lethal NN NN O
( NN NN O
and NN NN O
presumably NN NN O
cardiotoxic NN NN B-Disease
) NN NN O
effect NN NN O
of NN NN O
adriamycin NN NN O
administration NN NN O
. NN NN O
   
Maximal NN NN O
CS NN NN O
- NN NN O
mediated NN NN O
protection NN NN O
was NN NN O
observed NN NN O
in NN NN O
experimental NN NN O
animals NN NN O
pretreated NN NN O
24 NN NN O
h NN NN O
prior NN NN O
to NN NN O
the NN NN O
toxic NN NN O
insult NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
CS NN NN O
intervenes NN NN O
in NN NN O
a NN NN O
critical NN NN O
cellular NN NN O
event NN NN O
that NN NN O
is NN NN O
an NN NN O
important NN NN O
common NN NN O
pathway NN NN O
to NN NN O
toxic NN NN O
cell NN NN O
death NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
CS NN NN O
protection NN NN O
does NN NN O
not NN NN O
appear NN NN O
to NN NN O
be NN NN O
dependent NN NN O
on NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
chemical NN NN O
bioactivation NN NN O
to NN NN O
a NN NN O
toxic NN NN O
reactive NN NN O
intermediate NN NN O
( NN NN O
in NN NN O
light NN NN O
of NN NN O
the NN NN O
protection NN NN O
observed NN NN O
against NN NN O
galactosamine NN NN O
hepatotoxicity NN NN B-Disease
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
based NN NN O
on NN NN O
the NN NN O
data NN NN O
presented NN NN O
, NN NN O
we NN NN O
can NN NN O
not NN NN O
exclude NN NN O
the NN NN O
possibility NN NN O
that NN NN O
CS NN NN O
administration NN NN O
inhibits NN NN O
chemical NN NN O
bioactivation NN NN O
. NN NN O
   
Our NN NN O
findings NN NN O
do NN NN O
suggest NN NN O
that NN NN O
CS NN NN O
- NN NN O
mediated NN NN O
protection NN NN O
is NN NN O
dependent NN NN O
on NN NN O
the NN NN O
action NN NN O
of NN NN O
the NN NN O
intact NN NN O
anionic NN NN O
CS NN NN O
molecule NN NN O
( NN NN O
non NN NN O
- NN NN O
hydrolyzable NN NN O
CSE NN NN O
was NN NN O
as NN NN O
protective NN NN O
as NN NN O
CS NN NN O
) NN NN O
, NN NN O
whose NN NN O
mechanism NN NN O
has NN NN O
yet NN NN O
to NN NN O
be NN NN O
defined NN NN O
. NN NN O
   
A NN NN O
murine NN NN O
model NN NN O
of NN NN O
adenomyosis NN NN B-Disease
: NN NN O
the NN NN O
effects NN NN O
of NN NN O
hyperprolactinemia NN NN B-Disease
induced NN NN O
by NN NN O
fluoxetine NN NN O
hydrochloride NN NN O
, NN NN O
a NN NN O
selective NN NN O
serotonin NN NN O
reuptake NN NN O
inhibitor NN NN O
, NN NN O
on NN NN O
adenomyosis NN NN B-Disease
induction NN NN O
in NN NN O
Wistar NN NN O
albino NN NN O
rats NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
whether NN NN O
fluoxetine NN NN O
given NN NN O
to NN NN O
castrated NN NN O
and NN NN O
noncastrated NN NN O
rats NN NN O
caused NN NN O
hyperprolactinemia NN NN B-Disease
and NN NN O
its NN NN O
effects NN NN O
with NN NN O
respect NN NN O
to NN NN O
adenomyosis NN NN B-Disease
. NN NN O
   
DESIGN NN NN O
: NN NN O
Fluoxetine NN NN O
, NN NN O
a NN NN O
serotonin NN NN O
reuptake NN NN O
inhibitor NN NN O
, NN NN O
was NN NN O
given NN NN O
to NN NN O
Wistar NN NN O
Albino NN NN O
rats NN NN O
for NN NN O
98 NN NN O
days NN NN O
to NN NN O
produce NN NN O
hyperprolactinemia NN NN B-Disease
. NN NN O
   
The NN NN O
drug NN NN O
was NN NN O
given NN NN O
to NN NN O
two NN NN O
groups NN NN O
consisting NN NN O
of NN NN O
castrated NN NN O
and NN NN O
noncastrated NN NN O
rats NN NN O
and NN NN O
compared NN NN O
to NN NN O
two NN NN O
groups NN NN O
of NN NN O
castrated NN NN O
and NN NN O
noncastrated NN NN O
controls NN NN O
. NN NN O
   
Prolactin NN NN O
levels NN NN O
were NN NN O
measured NN NN O
and NN NN O
the NN NN O
uteri NN NN O
of NN NN O
the NN NN O
rats NN NN O
were NN NN O
removed NN NN O
for NN NN O
histopathological NN NN O
analysis NN NN O
at NN NN O
the NN NN O
end NN NN O
of NN NN O
98 NN NN O
days NN NN O
. NN NN O
   
SETTING NN NN O
: NN NN O
Marmara NN NN O
University NN NN O
School NN NN O
of NN NN O
Medicine NN NN O
, NN NN O
Department NN NN O
of NN NN O
Histology NN NN O
and NN NN O
Embryology NN NN O
, NN NN O
Zeynep NN NN O
Kamil NN NN O
Women NN NN O
and NN NN O
Children NN NN O
' NN NN O
s NN NN O
Hospital NN NN O
. NN NN O
   
MAIN NN NN O
OUTCOME NN NN O
MEASURES NN NN O
: NN NN O
Serum NN NN O
prolactin NN NN O
levels NN NN O
, NN NN O
uterine NN NN O
histopathology NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
prolactin NN NN O
levels NN NN O
of NN NN O
castrated NN NN O
and NN NN O
noncastrated NN NN O
groups NN NN O
treated NN NN O
with NN NN O
fluoxetine NN NN O
were NN NN O
statistically NN NN O
significantly NN NN O
higher NN NN O
when NN NN O
compared NN NN O
to NN NN O
their NN NN O
respective NN NN O
control NN NN O
groups NN NN O
. NN NN O
   
Histological NN NN O
studies NN NN O
revealed NN NN O
11 NN NN O
cases NN NN O
of NN NN O
adenomyosis NN NN B-Disease
, NN NN O
all NN NN O
within NN NN O
the NN NN O
noncastrated NN NN O
group NN NN O
receiving NN NN O
fluoxetine NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
It NN NN O
was NN NN O
suggested NN NN O
that NN NN O
high NN NN O
serum NN NN O
prolactin NN NN O
levels NN NN O
cause NN NN O
degeneration NN NN O
of NN NN O
myometrial NN NN O
cells NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
ovarian NN NN O
steroids NN NN O
that NN NN O
results NN NN O
in NN NN O
a NN NN O
myometrial NN NN O
invasion NN NN O
by NN NN O
endometrial NN NN O
stroma NN NN O
. NN NN O
   
This NN NN O
invasion NN NN O
eventually NN NN O
progresses NN NN O
to NN NN O
adenomyosis NN NN B-Disease
. NN NN O
   
Postinfarction NN NN O
ventricular NN NN B-Disease
septal NN NN I-Disease
defect NN NN I-Disease
associated NN NN O
with NN NN O
long NN NN O
- NN NN O
term NN NN O
steroid NN NN O
therapy NN NN O
. NN NN O
   
Two NN NN O
cases NN NN O
of NN NN O
postinfarction NN NN O
ventricular NN NN B-Disease
septal NN NN I-Disease
rupture NN NN I-Disease
in NN NN O
patients NN NN O
on NN NN O
long NN NN O
- NN NN O
term NN NN O
steroid NN NN O
therapy NN NN O
are NN NN O
presented NN NN O
and NN NN O
the NN NN O
favourable NN NN O
outcome NN NN O
in NN NN O
both NN NN O
cases NN NN O
described NN NN O
. NN NN O
   
A NN NN O
possible NN NN O
association NN NN O
between NN NN O
steroid NN NN O
therapy NN NN O
and NN NN O
subsequent NN NN O
postinfarction NN NN O
septal NN NN B-Disease
rupture NN NN I-Disease
is NN NN O
discussed NN NN O
. NN NN O
   
Neuroactive NN NN O
steroids NN NN O
protect NN NN O
against NN NN O
pilocarpine NN NN O
- NN NN O
and NN NN O
kainic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
limbic NN NN O
seizures NN NN B-Disease
and NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
in NN NN O
mice NN NN O
. NN NN O
   
Several NN NN O
structurally NN NN O
related NN NN O
metabolites NN NN O
of NN NN O
progesterone NN NN O
( NN NN O
3 NN NN O
alpha NN NN O
- NN NN O
hydroxy NN NN O
pregnane NN NN O
- NN NN O
20 NN NN O
- NN NN O
ones NN NN O
) NN NN O
and NN NN O
deoxycorticosterone NN NN O
( NN NN O
3 NN NN O
alpha NN NN O
- NN NN O
hydroxy NN NN O
pregnane NN NN O
- NN NN O
21 NN NN O
- NN NN O
diol NN NN O
- NN NN O
20 NN NN O
- NN NN O
ones NN NN O
) NN NN O
and NN NN O
their NN NN O
3 NN NN O
beta NN NN O
- NN NN O
epimers NN NN O
were NN NN O
evaluated NN NN O
for NN NN O
protective NN NN O
activity NN NN O
against NN NN O
pilocarpine NN NN O
- NN NN O
, NN NN O
kainic NN NN O
acid NN NN O
- NN NN O
and NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
D NN NN O
- NN NN O
aspartate NN NN O
( NN NN O
NMDA NN NN O
) NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
in NN NN O
mice NN NN O
. NN NN O
   
Steroids NN NN O
with NN NN O
the NN NN O
3 NN NN O
- NN NN O
hydroxy NN NN O
group NN NN O
in NN NN O
the NN NN O
alpha NN NN O
- NN NN O
position NN NN O
and NN NN O
5 NN NN O
- NN NN O
H NN NN O
in NN NN O
the NN NN O
alpha NN NN O
- NN NN O
or NN NN O
beta NN NN O
- NN NN O
configurations NN NN O
were NN NN O
highly NN NN O
effective NN NN O
in NN NN O
protecting NN NN O
against NN NN O
pilocarpine NN NN O
( NN NN O
416 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
- NN NN O
induced NN NN O
limbic NN NN O
motor NN NN O
seizures NN NN B-Disease
and NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
( NN NN O
ED50 NN NN O
values NN NN O
, NN NN O
7 NN NN O
. NN NN O
0 NN NN O
- NN NN O
18 NN NN O
. NN NN O
7 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
. NN NN O
   
The NN NN O
corresponding NN NN O
epimers NN NN O
with NN NN O
the NN NN O
3 NN NN O
- NN NN O
hydroxy NN NN O
group NN NN O
in NN NN O
the NN NN O
beta NN NN O
- NN NN O
position NN NN O
were NN NN O
also NN NN O
effective NN NN O
but NN NN O
less NN NN O
potent NN NN O
( NN NN O
ED50 NN NN O
values NN NN O
, NN NN O
33 NN NN O
. NN NN O
8 NN NN O
- NN NN O
63 NN NN O
. NN NN O
5 NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
neuroactive NN NN O
steroids NN NN O
were NN NN O
considerably NN NN O
less NN NN O
potent NN NN O
than NN NN O
the NN NN O
benzodiazepine NN NN O
clonazepam NN NN O
in NN NN O
protecting NN NN O
against NN NN O
pilocarpine NN NN O
seizures NN NN B-Disease
, NN NN O
steroids NN NN O
with NN NN O
the NN NN O
5 NN NN O
alpha NN NN O
, NN NN O
3 NN NN O
alpha NN NN O
- NN NN O
configuration NN NN O
had NN NN O
comparable NN NN O
or NN NN O
higher NN NN O
protective NN NN O
index NN NN O
values NN NN O
( NN NN O
TD50 NN NN O
for NN NN O
motor NN NN O
impairment NN NN O
divided NN NN O
by NN NN O
ED50 NN NN O
for NN NN O
seizure NN NN B-Disease
protection NN NN O
) NN NN O
than NN NN O
clonazepam NN NN O
, NN NN O
indicating NN NN O
that NN NN O
some NN NN O
neuroactive NN NN O
steroids NN NN O
may NN NN O
have NN NN O
lower NN NN O
relative NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Steroids NN NN O
with NN NN O
the NN NN O
5 NN NN O
alpha NN NN O
, NN NN O
3 NN NN O
alpha NN NN O
- NN NN O
or NN NN O
5 NN NN O
beta NN NN O
, NN NN O
3 NN NN O
alpha NN NN O
- NN NN O
configurations NN NN O
also NN NN O
produced NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
delay NN NN O
in NN NN O
the NN NN O
onset NN NN O
of NN NN O
limbic NN NN O
seizures NN NN B-Disease
induced NN NN O
by NN NN O
kainic NN NN O
acid NN NN O
( NN NN O
32 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
, NN NN O
but NN NN O
did NN NN O
not NN NN O
completely NN NN O
protect NN NN O
against NN NN O
the NN NN O
seizures NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
when NN NN O
a NN NN O
second NN NN O
dose NN NN O
of NN NN O
the NN NN O
steroid NN NN O
was NN NN O
administered NN NN O
1 NN NN O
hr NN NN O
after NN NN O
the NN NN O
first NN NN O
dose NN NN O
, NN NN O
complete NN NN O
protection NN NN O
from NN NN O
the NN NN O
kainic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
limbic NN NN O
seizures NN NN B-Disease
and NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
was NN NN O
obtained NN NN O
. NN NN O
   
The NN NN O
steroids NN NN O
also NN NN O
caused NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
delay NN NN O
in NN NN O
NMDA NN NN O
( NN NN O
257 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
- NN NN O
induced NN NN O
lethality NN NN O
, NN NN O
but NN NN O
did NN NN O
not NN NN O
completely NN NN O
protect NN NN O
against NN NN O
NMDA NN NN O
seizures NN NN B-Disease
or NN NN O
lethality NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
neuroactive NN NN O
steroids NN NN O
are NN NN O
highly NN NN O
effective NN NN O
in NN NN O
protecting NN NN O
against NN NN O
pilocarpine NN NN O
- NN NN O
and NN NN O
kainic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
and NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
in NN NN O
mice NN NN O
, NN NN O
and NN NN O
may NN NN O
be NN NN O
of NN NN O
utility NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
some NN NN O
forms NN NN O
of NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
in NN NN O
humans NN NN O
. NN NN O
   
Hepatic NN NN O
and NN NN O
extrahepatic NN NN O
angiotensinogen NN NN O
gene NN NN O
expression NN NN O
in NN NN O
rats NN NN O
with NN NN O
acute NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
Plasma NN NN O
concentration NN NN O
and NN NN O
urine NN NN O
excretion NN NN O
of NN NN O
the NN NN O
renin NN NN O
- NN NN O
angiotensin NN NN O
system NN NN O
proteins NN NN O
are NN NN O
altered NN NN O
in NN NN O
rats NN NN O
with NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
( NN NN O
NS NN NN B-Disease
) NN NN O
. NN NN O
   
In NN NN O
this NN NN O
work NN NN O
the NN NN O
messenger NN NN O
ribonucleic NN NN O
acid NN NN O
( NN NN O
mRNA NN NN O
) NN NN O
levels NN NN O
of NN NN O
angiotensinogen NN NN O
( NN NN O
Ao NN NN O
) NN NN O
were NN NN O
analyzed NN NN O
with NN NN O
the NN NN O
slot NN NN O
- NN NN O
blot NN NN O
hybridization NN NN O
technique NN NN O
in NN NN O
liver NN NN O
and NN NN O
other NN NN O
extrahepatic NN NN O
tissues NN NN O
: NN NN O
kidney NN NN O
, NN NN O
heart NN NN O
, NN NN O
brain NN NN O
, NN NN O
and NN NN O
adrenal NN NN O
gland NN NN O
from NN NN O
control NN NN O
, NN NN O
nephrotic NN NN B-Disease
, NN NN O
and NN NN O
pair NN NN O
- NN NN O
fed NN NN O
( NN NN O
PF NN NN O
) NN NN O
rats NN NN O
. NN NN O
   
NS NN NN B-Disease
was NN NN O
induced NN NN O
by NN NN O
a NN NN O
single NN NN O
injection NN NN O
of NN NN O
puromycin NN NN O
amino NN NN O
- NN NN O
nucleoside NN NN O
( NN NN O
PAN NN NN O
) NN NN O
. NN NN O
   
Although NN NN O
a NN NN O
great NN NN O
urinary NN NN O
excretion NN NN O
and NN NN O
half NN NN O
- NN NN O
normal NN NN O
plasma NN NN O
levels NN NN O
of NN NN O
Ao NN NN O
were NN NN O
observed NN NN O
on NN NN O
day NN NN O
6 NN NN O
after NN NN O
PAN NN NN O
injection NN NN O
, NN NN O
when NN NN O
NS NN NN B-Disease
was NN NN O
clearly NN NN O
established NN NN O
, NN NN O
hepatic NN NN O
Ao NN NN O
mRNA NN NN O
levels NN NN O
did NN NN O
not NN NN O
change NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
Ao NN NN O
mRNA NN NN O
levels NN NN O
did NN NN O
not NN NN O
change NN NN O
in NN NN O
any NN NN O
of NN NN O
the NN NN O
extrahepatic NN NN O
tissues NN NN O
studied NN NN O
on NN NN O
day NN NN O
6 NN NN O
, NN NN O
nor NN NN O
did NN NN O
its NN NN O
hepatic NN NN O
levels NN NN O
at NN NN O
days NN NN O
1 NN NN O
, NN NN O
3 NN NN O
, NN NN O
5 NN NN O
, NN NN O
or NN NN O
7 NN NN O
after NN NN O
PAN NN NN O
injection NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
the NN NN O
hepatic NN NN O
and NN NN O
extrahepatic NN NN O
Ao NN NN O
mRNA NN NN O
levels NN NN O
are NN NN O
unaltered NN NN O
during NN NN O
the NN NN O
development NN NN O
of NN NN O
the NN NN O
acute NN NN O
NS NN NN B-Disease
induced NN NN O
by NN NN O
PAN NN NN O
. NN NN O
   
Neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
with NN NN O
risperidone NN NN O
. NN NN O
   
Neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
is NN NN O
thought NN NN O
to NN NN O
be NN NN O
a NN NN O
result NN NN O
of NN NN O
dopamine NN NN O
D2 NN NN O
receptor NN NN O
blockade NN NN O
in NN NN O
the NN NN O
striatum NN NN O
of NN NN O
the NN NN O
basal NN NN O
ganglia NN NN O
. NN NN O
   
Risperidone NN NN O
, NN NN O
a NN NN O
benzisoxazole NN NN O
derivative NN NN O
antipsychotic NN NN O
, NN NN O
has NN NN O
high NN NN O
serotonin NN NN O
5 NN NN O
- NN NN O
HT2 NN NN O
receptor NN NN O
blockade NN NN O
and NN NN O
dose NN NN O
- NN NN O
related NN NN O
D2 NN NN O
receptor NN NN O
blockade NN NN O
. NN NN O
   
The NN NN O
high NN NN O
ratio NN NN O
is NN NN O
believed NN NN O
to NN NN O
impart NN NN O
the NN NN O
low NN NN O
frequency NN NN O
of NN NN O
extrapyramidal NN NN B-Disease
symptoms NN NN I-Disease
with NN NN O
risperidone NN NN O
at NN NN O
low NN NN O
dosages NN NN O
. NN NN O
   
With NN NN O
this NN NN O
low NN NN O
frequency NN NN O
of NN NN O
extrapyramidal NN NN B-Disease
symptoms NN NN I-Disease
, NN NN O
it NN NN O
was NN NN O
thought NN NN O
the NN NN O
frequency NN NN O
of NN NN O
neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
might NN NN O
also NN NN O
be NN NN O
lowered NN NN O
. NN NN O
   
A NN NN O
73 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
developed NN NN O
neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
after NN NN O
monotherapy NN NN O
with NN NN O
risperidone NN NN O
. NN NN O
   
The NN NN O
syndrome NN NN O
reversed NN NN O
after NN NN O
discontinuing NN NN O
risperidone NN NN O
and NN NN O
starting NN NN O
treatment NN NN O
with NN NN O
dantrolene NN NN O
and NN NN O
bromocriptine NN NN O
. NN NN O
   
It NN NN O
appears NN NN O
that NN NN O
the NN NN O
protection NN NN O
from NN NN O
extrapyramidal NN NN O
side NN NN O
effects NN NN O
observed NN NN O
with NN NN O
risperidone NN NN O
does NN NN O
not NN NN O
ensure NN NN O
protection NN NN O
from NN NN O
neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
The NN NN O
attenuating NN NN O
effect NN NN O
of NN NN O
carteolol NN NN O
hydrochloride NN NN O
, NN NN O
a NN NN O
beta NN NN O
- NN NN O
adrenoceptor NN NN O
antagonist NN NN O
, NN NN O
on NN NN O
neuroleptic NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
It NN NN O
is NN NN O
known NN NN O
that NN NN O
beta NN NN O
- NN NN O
adrenoceptor NN NN O
antagonists NN NN O
are NN NN O
effective NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
akathisia NN NN B-Disease
, NN NN O
one NN NN O
of NN NN O
the NN NN O
extrapyramidal NN NN O
side NN NN O
effects NN NN O
that NN NN O
occur NN NN O
during NN NN O
neuroleptic NN NN O
treatment NN NN O
. NN NN O
   
Neuroleptic NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
, NN NN O
a NN NN O
model NN NN O
of NN NN O
neuroleptic NN NN O
- NN NN O
induced NN NN O
extrapyramidal NN NN O
side NN NN O
effects NN NN O
, NN NN O
was NN NN O
considered NN NN O
suitable NN NN O
as NN NN O
a NN NN O
model NN NN O
for NN NN O
predicting NN NN O
neuroleptic NN NN O
- NN NN O
induced NN NN O
akathisia NN NN B-Disease
in NN NN O
humans NN NN O
, NN NN O
although NN NN O
neuroleptic NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
was NN NN O
not NN NN O
considered NN NN O
a NN NN O
specific NN NN O
test NN NN O
for NN NN O
neuroleptic NN NN O
- NN NN O
induced NN NN O
akathisia NN NN B-Disease
. NN NN O
   
Therefore NN NN O
, NN NN O
the NN NN O
effects NN NN O
of NN NN O
carteolol NN NN O
, NN NN O
a NN NN O
beta NN NN O
- NN NN O
adrenoceptor NN NN O
antagonist NN NN O
, NN NN O
on NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
in NN NN O
rats NN NN O
were NN NN O
behaviorally NN NN O
studied NN NN O
and NN NN O
compared NN NN O
with NN NN O
those NN NN O
of NN NN O
propranolol NN NN O
and NN NN O
biperiden NN NN O
, NN NN O
a NN NN O
muscarinic NN NN O
receptor NN NN O
antagonist NN NN O
. NN NN O
   
Carteolol NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
propranolol NN NN O
and NN NN O
biperiden NN NN O
, NN NN O
inhibited NN NN O
the NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
. NN NN O
   
The NN NN O
inhibitory NN NN O
effect NN NN O
of NN NN O
carteolol NN NN O
was NN NN O
almost NN NN O
comparable NN NN O
to NN NN O
that NN NN O
of NN NN O
propranolol NN NN O
, NN NN O
but NN NN O
was NN NN O
weaker NN NN O
than NN NN O
that NN NN O
of NN NN O
biperiden NN NN O
. NN NN O
   
Carteolol NN NN O
did NN NN O
not NN NN O
evoke NN NN O
postsynaptic NN NN O
dopamine NN NN O
receptor NN NN O
- NN NN O
stimulating NN NN O
behavioral NN NN O
signs NN NN O
such NN NN O
as NN NN O
stereotypy NN NN O
and NN NN O
hyperlocomotion NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Carteolol NN NN O
did NN NN O
not NN NN O
antagonize NN NN O
the NN NN O
inhibitory NN NN O
effects NN NN O
of NN NN O
haloperidol NN NN O
on NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
stereotypy NN NN O
and NN NN O
locomotor NN NN O
activity NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
carteolol NN NN O
did NN NN O
not NN NN O
evoke NN NN O
5 NN NN O
- NN NN O
HT1A NN NN O
receptor NN NN O
- NN NN O
stimulating NN NN O
behavioral NN NN O
signs NN NN O
such NN NN O
as NN NN O
flat NN NN O
body NN NN O
posture NN NN O
and NN NN O
forepaw NN NN O
treading NN NN O
and NN NN O
did NN NN O
not NN NN O
inhibit NN NN O
5 NN NN O
- NN NN O
hydroxytryptophan NN NN O
- NN NN O
induced NN NN O
head NN NN O
twitch NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
carteolol NN NN O
did NN NN O
not NN NN O
inhibit NN NN O
physostigmine NN NN O
- NN NN O
induced NN NN O
lethality NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
These NN NN O
results NN NN O
strongly NN NN O
suggest NN NN O
that NN NN O
carteolol NN NN O
improves NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
via NN NN O
its NN NN O
beta NN NN O
- NN NN O
adrenoceptor NN NN O
antagonistic NN NN O
activity NN NN O
and NN NN O
is NN NN O
expected NN NN O
to NN NN O
be NN NN O
effective NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
akathisia NN NN B-Disease
without NN NN O
attenuating NN NN O
neuroleptic NN NN O
- NN NN O
induced NN NN O
antipsychotic NN NN O
effects NN NN O
due NN NN O
to NN NN O
its NN NN O
postsynaptic NN NN O
dopamine NN NN O
receptor NN NN O
antagonistic NN NN O
activity NN NN O
. NN NN O
   
Granulosa NN NN B-Disease
cell NN NN I-Disease
tumor NN NN I-Disease
of NN NN I-Disease
the NN NN I-Disease
ovary NN NN I-Disease
associated NN NN O
with NN NN O
antecedent NN NN O
tamoxifen NN NN O
use NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Increased NN NN O
attention NN NN O
has NN NN O
been NN NN O
focused NN NN O
recently NN NN O
on NN NN O
the NN NN O
estrogenic NN NN O
effects NN NN O
of NN NN O
tamoxifen NN NN O
. NN NN O
   
Review NN NN O
of NN NN O
the NN NN O
literature NN NN O
reveals NN NN O
an NN NN O
association NN NN O
between NN NN O
tamoxifen NN NN O
use NN NN O
and NN NN O
gynecologic NN NN O
tumors NN NN B-Disease
. NN NN O
   
CASE NN NN O
: NN NN O
A NN NN O
52 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
postmenopausal NN NN O
woman NN NN O
was NN NN O
treated NN NN O
with NN NN O
tamoxifen NN NN O
for NN NN O
stage NN NN O
II NN NN O
estrogen NN NN O
receptor NN NN O
- NN NN O
positive NN NN O
breast NN NN B-Disease
carcinoma NN NN I-Disease
. NN NN O
   
Her NN NN O
aspartate NN NN O
transaminase NN NN O
and NN NN O
alanine NN NN O
transaminase NN NN O
levels NN NN O
increase NN NN O
markedly NN NN O
after NN NN O
6 NN NN O
months NN NN O
of NN NN O
tamoxifen NN NN O
use NN NN O
. NN NN O
   
After NN NN O
an NN NN O
additional NN NN O
17 NN NN O
months NN NN O
of NN NN O
elevated NN NN O
serum NN NN O
transaminases NN NN O
, NN NN O
the NN NN O
patient NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
a NN NN O
stage NN NN O
Ic NN NN O
granulosa NN NN B-Disease
cell NN NN I-Disease
tumor NN NN I-Disease
of NN NN I-Disease
the NN NN I-Disease
ovary NN NN I-Disease
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Patients NN NN O
with NN NN O
tamoxifen NN NN O
- NN NN O
induced NN NN O
liver NN NN B-Disease
dysfunction NN NN I-Disease
may NN NN O
be NN NN O
at NN NN O
increased NN NN O
risk NN NN O
for NN NN O
granulosa NN NN B-Disease
cell NN NN I-Disease
tumors NN NN I-Disease
because NN NN O
of NN NN O
alterations NN NN O
in NN NN O
tamoxifen NN NN O
metabolism NN NN O
. NN NN O
   
Lifetime NN NN O
treatment NN NN O
of NN NN O
mice NN NN O
with NN NN O
azidothymidine NN NN O
( NN NN O
AZT NN NN O
) NN NN O
produces NN NN O
myelodysplasia NN NN B-Disease
. NN NN O
   
AZT NN NN O
has NN NN O
induced NN NN O
a NN NN O
macrocytic NN NN B-Disease
anemia NN NN I-Disease
in NN NN O
AIDS NN NN B-Disease
patients NN NN O
on NN NN O
long NN NN O
term NN NN O
AZT NN NN O
therapy NN NN O
. NN NN O
   
It NN NN O
is NN NN O
generally NN NN O
assumed NN NN O
that NN NN O
DNA NN NN O
elongation NN NN O
is NN NN O
stopped NN NN O
by NN NN O
the NN NN O
insertion NN NN O
of NN NN O
AZT NN NN O
into NN NN O
the NN NN O
chain NN NN O
in NN NN O
place NN NN O
of NN NN O
thymidine NN NN O
thus NN NN O
preventing NN NN O
the NN NN O
phosphate NN NN O
hydroxyl NN NN O
linkages NN NN O
and NN NN O
therefore NN NN O
suppresses NN NN O
hemopoietic NN NN O
progenitor NN NN O
cell NN NN O
proliferation NN NN O
in NN NN O
an NN NN O
early NN NN O
stage NN NN O
of NN NN O
differentiation NN NN O
. NN NN O
   
CBA NN NN O
/ NN NN O
Ca NN NN O
male NN NN O
mice NN NN O
started NN NN O
on NN NN O
AZT NN NN O
0 NN NN O
. NN NN O
75 NN NN O
mg NN NN O
/ NN NN O
ml NN NN O
H2O NN NN O
at NN NN O
84 NN NN O
days NN NN O
of NN NN O
age NN NN O
and NN NN O
kept NN NN O
on NN NN O
it NN NN O
for NN NN O
687 NN NN O
days NN NN O
when NN NN O
dosage NN NN O
reduced NN NN O
to NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
ml NN NN O
H2O NN NN O
for NN NN O
a NN NN O
group NN NN O
, NN NN O
another NN NN O
group NN NN O
removed NN NN O
from NN NN O
AZT NN NN O
to NN NN O
see NN NN O
recovery NN NN O
, NN NN O
and NN NN O
third NN NN O
group NN NN O
remained NN NN O
on NN NN O
0 NN NN O
. NN NN O
75 NN NN O
mg NN NN O
. NN NN O
   
At NN NN O
687 NN NN O
days NN NN O
mice NN NN O
that NN NN O
had NN NN O
been NN NN O
on NN NN O
0 NN NN O
. NN NN O
75 NN NN O
mg NN NN O
had NN NN O
average NN NN O
platelet NN NN O
counts NN NN O
of NN NN O
2 NN NN O
. NN NN O
5 NN NN O
x NN NN O
10 NN NN O
( NN NN O
6 NN NN O
) NN NN O
. NN NN O
   
Histological NN NN O
examination NN NN O
on NN NN O
9 NN NN O
of NN NN O
10 NN NN O
mice NN NN O
with NN NN O
such NN NN O
thrombocytopenia NN NN B-Disease
showed NN NN O
changes NN NN O
compatible NN NN O
with NN NN O
myelodysplastic NN NN B-Disease
syndrome NN NN I-Disease
( NN NN O
MDS NN NN B-Disease
) NN NN O
. NN NN O
   
A NN NN O
variety NN NN O
of NN NN O
histological NN NN O
patterns NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
There NN NN O
were NN NN O
two NN NN O
cases NN NN O
of NN NN O
hypocellular NN NN O
myelodysplasia NN NN B-Disease
, NN NN O
two NN NN O
cases NN NN O
of NN NN O
hypersegmented NN NN O
myelodysplastic NN NN B-Disease
granulocytosis NN NN O
, NN NN O
two NN NN O
cases NN NN O
of NN NN O
hypercellular NN NN O
marrow NN NN O
with NN NN O
abnormal NN NN O
megakaryocytes NN NN O
with NN NN O
bizarre NN NN O
nuclei NN NN O
, NN NN O
one NN NN O
case NN NN O
of NN NN O
megakaryocytic NN NN O
myelosis NN NN O
associated NN NN O
with NN NN O
a NN NN O
hyperplastic NN NN B-Disease
marrow NN NN I-Disease
, NN NN O
dysmyelopoiesis NN NN B-Disease
and NN NN O
a NN NN O
hypocellular NN NN B-Disease
marrow NN NN I-Disease
and NN NN O
two NN NN O
cases NN NN O
of NN NN O
myelodysplasia NN NN B-Disease
with NN NN O
dyserythropoiesis NN NN B-Disease
, NN NN O
hemosiderosis NN NN B-Disease
and NN NN O
a NN NN O
hypocellular NN NN B-Disease
marrow NN NN I-Disease
. NN NN O
   
Above NN NN O
mentioned NN NN O
AZT NN NN O
incorporation NN NN O
may NN NN O
have NN NN O
induced NN NN O
an NN NN O
ineffective NN NN O
hemopoiesis NN NN O
in NN NN O
the NN NN O
primitive NN NN O
hemopoietic NN NN O
progenitor NN NN O
cells NN NN O
, NN NN O
which NN NN O
is NN NN O
known NN NN O
to NN NN O
be NN NN O
seen NN NN O
commonly NN NN O
in NN NN O
the NN NN O
myelodysplastic NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
Biphasic NN NN O
response NN NN O
of NN NN O
the NN NN O
SA NN NN O
node NN NN O
of NN NN O
the NN NN O
dog NN NN O
heart NN NN O
in NN NN O
vivo NN NN O
to NN NN O
selective NN NN O
administration NN NN O
of NN NN O
ketamine NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
ketamine NN NN O
on NN NN O
the NN NN O
SA NN NN O
node NN NN O
of NN NN O
the NN NN O
dog NN NN O
heart NN NN O
was NN NN O
studied NN NN O
in NN NN O
vivo NN NN O
using NN NN O
a NN NN O
selective NN NN O
perfusion NN NN O
technique NN NN O
of NN NN O
the NN NN O
SA NN NN O
node NN NN O
artery NN NN O
. NN NN O
   
Injections NN NN O
of NN NN O
ketamine NN NN O
in NN NN O
doses NN NN O
from NN NN O
100 NN NN O
microgram NN NN O
to NN NN O
3 NN NN O
mg NN NN O
into NN NN O
the NN NN O
artery NN NN O
produced NN NN O
a NN NN O
depression NN NN B-Disease
of NN NN O
the NN NN O
SA NN NN O
nodal NN NN O
activity NN NN O
by NN NN O
a NN NN O
direct NN NN O
action NN NN O
. NN NN O
   
This NN NN O
depression NN NN B-Disease
was NN NN O
followed NN NN O
by NN NN O
the NN NN O
sudden NN NN O
appearance NN NN O
of NN NN O
a NN NN O
stimulatory NN NN O
phase NN NN O
. NN NN O
   
Bilateral NN NN O
vagotomy NN NN O
and NN NN O
sympathectomy NN NN O
or NN NN O
prior NN NN O
administration NN NN O
of NN NN O
a NN NN O
ganglion NN NN O
blocker NN NN O
failed NN NN O
to NN NN O
inhibit NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
the NN NN O
ketamine NN NN O
- NN NN O
induced NN NN O
tachycardia NN NN B-Disease
, NN NN O
while NN NN O
it NN NN O
was NN NN O
completely NN NN O
abolished NN NN O
in NN NN O
the NN NN O
reserpinized NN NN O
dogs NN NN O
or NN NN O
by NN NN O
a NN NN O
prior NN NN O
injection NN NN O
of NN NN O
a NN NN O
beta NN NN O
- NN NN O
blocking NN NN O
agent NN NN O
into NN NN O
the NN NN O
SA NN NN O
node NN NN O
artery NN NN O
. NN NN O
   
This NN NN O
may NN NN O
indicate NN NN O
that NN NN O
an NN NN O
activation NN NN O
of NN NN O
the NN NN O
peripheral NN NN O
adrenergic NN NN O
mechanism NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
the NN NN O
excitatory NN NN O
effect NN NN O
of NN NN O
ketamine NN NN O
injected NN NN O
in NN NN O
the NN NN O
SA NN NN O
node NN NN O
artery NN NN O
. NN NN O
   
Over NN NN O
expression NN NN O
of NN NN O
vascular NN NN O
endothelial NN NN O
growth NN NN O
factor NN NN O
and NN NN O
its NN NN O
receptor NN NN O
during NN NN O
the NN NN O
development NN NN O
of NN NN O
estrogen NN NN O
- NN NN O
induced NN NN O
rat NN NN O
pituitary NN NN B-Disease
tumors NN NN I-Disease
may NN NN O
mediate NN NN O
estrogen NN NN O
- NN NN O
initiated NN NN O
tumor NN NN B-Disease
angiogenesis NN NN O
. NN NN O
   
Estrogens NN NN O
, NN NN O
which NN NN O
have NN NN O
been NN NN O
associated NN NN O
with NN NN O
several NN NN O
types NN NN O
of NN NN O
human NN NN O
and NN NN O
animal NN NN O
cancers NN NN B-Disease
, NN NN O
can NN NN O
induce NN NN O
tumor NN NN B-Disease
angiogenesis NN NN O
in NN NN O
the NN NN O
pituitary NN NN O
of NN NN O
Fischer NN NN O
344 NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
mechanistic NN NN O
details NN NN O
of NN NN O
tumor NN NN B-Disease
angiogenesis NN NN O
induction NN NN O
, NN NN O
during NN NN O
estrogen NN NN O
carcinogenesis NN NN B-Disease
, NN NN O
are NN NN O
still NN NN O
unknown NN NN O
. NN NN O
   
To NN NN O
elucidate NN NN O
the NN NN O
role NN NN O
of NN NN O
estrogen NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
tumor NN NN B-Disease
angiogenesis NN NN O
in NN NN O
the NN NN O
pituitary NN NN O
of NN NN O
female NN NN O
rats NN NN O
, NN NN O
the NN NN O
density NN NN O
of NN NN O
blood NN NN O
vessels NN NN O
was NN NN O
analysed NN NN O
using NN NN O
factor NN NN O
VIII NN NN O
related NN NN O
antigen NN NN O
( NN NN O
FVIIIRAg NN NN O
) NN NN O
immunohistochemistry NN NN O
and NN NN O
the NN NN O
expression NN NN O
of NN NN O
vascular NN NN O
endothelial NN NN O
growth NN NN O
factor NN NN O
/ NN NN O
vascular NN NN O
permeability NN NN O
factor NN NN O
( NN NN O
VEGF NN NN O
/ NN NN O
VPF NN NN O
) NN NN O
was NN NN O
examined NN NN O
by NN NN O
Western NN NN O
blot NN NN O
and NN NN O
immunohistochemical NN NN O
analysis NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
VEGF NN NN O
receptor NN NN O
( NN NN O
VEGFR NN NN O
- NN NN O
2 NN NN O
/ NN NN O
Flk NN NN O
- NN NN O
1 NN NN O
/ NN NN O
KDR NN NN O
) NN NN O
was NN NN O
also NN NN O
examined NN NN O
by NN NN O
immunohistochemistry NN NN O
. NN NN O
   
The NN NN O
results NN NN O
demonstrated NN NN O
that NN NN O
17beta NN NN O
- NN NN O
estradiol NN NN O
( NN NN O
E2 NN NN O
) NN NN O
induces NN NN O
neovascularization NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
growth NN NN O
and NN NN O
enlargement NN NN O
of NN NN O
blood NN NN O
vessels NN NN O
after NN NN O
7 NN NN O
days NN NN O
of NN NN O
exposure NN NN O
. NN NN O
   
The NN NN O
high NN NN O
tumor NN NN B-Disease
angiogenic NN NN O
potential NN NN O
was NN NN O
associated NN NN O
with NN NN O
an NN NN O
elevated NN NN O
VEGF NN NN O
/ NN NN O
VPF NN NN O
protein NN NN O
expression NN NN O
in NN NN O
the NN NN O
E2 NN NN O
exposed NN NN O
pituitary NN NN O
of NN NN O
ovariectomized NN NN O
( NN NN O
OVEX NN NN O
) NN NN O
rats NN NN O
. NN NN O
   
VEGF NN NN O
/ NN NN O
VPF NN NN O
and NN NN O
FVIIIRAg NN NN O
immunohistochemistry NN NN O
and NN NN O
endothelial NN NN O
specific NN NN O
lectin NN NN O
( NN NN O
UEA1 NN NN O
) NN NN O
binding NN NN O
studies NN NN O
, NN NN O
indicate NN NN O
that NN NN O
the NN NN O
elevation NN NN O
of NN NN O
VEGF NN NN O
protein NN NN O
expression NN NN O
initially NN NN O
occurred NN NN O
in NN NN O
both NN NN O
blood NN NN O
vessels NN NN O
and NN NN O
non NN NN O
- NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
After NN NN O
15 NN NN O
days NN NN O
of NN NN O
E2 NN NN O
exposure NN NN O
, NN NN O
VEGF NN NN O
/ NN NN O
VPF NN NN O
protein NN NN O
expression NN NN O
, NN NN O
in NN NN O
the NN NN O
non NN NN O
- NN NN O
endothelial NN NN O
cell NN NN O
population NN NN O
, NN NN O
sharply NN NN O
declined NN NN O
and NN NN O
was NN NN O
restricted NN NN O
to NN NN O
the NN NN O
blood NN NN O
vessels NN NN O
. NN NN O
   
The NN NN O
function NN NN O
of NN NN O
non NN NN O
- NN NN O
endothelial NN NN O
- NN NN O
derived NN NN O
VEGF NN NN O
is NN NN O
not NN NN O
clear NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
immunohistochemical NN NN O
studies NN NN O
demonstrated NN NN O
that NN NN O
VEGFR NN NN O
- NN NN O
2 NN NN O
( NN NN O
flk NN NN O
- NN NN O
1 NN NN O
/ NN NN O
KDR NN NN O
) NN NN O
, NN NN O
expression NN NN O
was NN NN O
elevated NN NN O
significantly NN NN O
in NN NN O
the NN NN O
endothelial NN NN O
cells NN NN O
of NN NN O
microblood NN NN O
vessels NN NN O
after NN NN O
7 NN NN O
days NN NN O
of NN NN O
E2 NN NN O
exposure NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
over NN NN O
expression NN NN O
of NN NN O
VEGF NN NN O
and NN NN O
its NN NN O
receptor NN NN O
( NN NN O
VEGFR NN NN O
- NN NN O
2 NN NN O
) NN NN O
may NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
initial NN NN O
step NN NN O
of NN NN O
the NN NN O
regulation NN NN O
of NN NN O
estrogen NN NN O
induced NN NN O
tumor NN NN B-Disease
angiogenesis NN NN O
in NN NN O
the NN NN O
rat NN NN O
pituitary NN NN O
. NN NN O
   
Persistent NN NN O
nephrogenic NN NN B-Disease
diabetes NN NN I-Disease
insipidus NN NN I-Disease
following NN NN O
lithium NN NN O
therapy NN NN O
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
patient NN NN O
who NN NN O
developed NN NN O
severe NN NN O
hypernatraemic NN NN O
dehydration NN NN B-Disease
following NN NN O
a NN NN O
head NN NN B-Disease
injury NN NN I-Disease
. NN NN O
   
Ten NN NN O
years NN NN O
previously NN NN O
he NN NN O
had NN NN O
been NN NN O
diagnosed NN NN O
to NN NN O
have NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
nephrogenic NN NN B-Disease
diabetes NN NN I-Disease
insipidus NN NN I-Disease
, NN NN O
and NN NN O
lithium NN NN O
therapy NN NN O
had NN NN O
been NN NN O
discontinued NN NN O
. NN NN O
   
He NN NN O
remained NN NN O
thirsty NN NN O
and NN NN O
polyuric NN NN B-Disease
despite NN NN O
cessation NN NN O
of NN NN O
lithium NN NN O
and NN NN O
investigations NN NN O
on NN NN O
admission NN NN O
showed NN NN O
him NN NN O
to NN NN O
have NN NN O
normal NN NN O
osmoregulated NN NN O
thirst NN NN O
and NN NN O
vasopressin NN NN O
secretion NN NN O
, NN NN O
with NN NN O
clear NN NN O
evidence NN NN O
of NN NN O
nephrogenic NN NN B-Disease
diabetes NN NN I-Disease
insipidus NN NN I-Disease
. NN NN O
   
Lithium NN NN O
induced NN NN O
nephrogenic NN NN B-Disease
diabetes NN NN I-Disease
insipidus NN NN I-Disease
is NN NN O
considered NN NN O
to NN NN O
be NN NN O
reversible NN NN O
on NN NN O
cessation NN NN O
of NN NN O
therapy NN NN O
but NN NN O
polyuria NN NN B-Disease
persisted NN NN O
in NN NN O
this NN NN O
patient NN NN O
for NN NN O
ten NN NN O
years NN NN O
after NN NN O
lithium NN NN O
was NN NN O
stopped NN NN O
. NN NN O
   
We NN NN O
discuss NN NN O
the NN NN O
possible NN NN O
renal NN NN O
mechanisms NN NN O
and NN NN O
the NN NN O
implications NN NN O
for NN NN O
management NN NN O
of NN NN O
patients NN NN O
with NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
nephrogenic NN NN B-Disease
diabetes NN NN I-Disease
insipidus NN NN I-Disease
. NN NN O
   
Effects NN NN O
of NN NN O
NIK NN NN O
- NN NN O
247 NN NN O
on NN NN O
cholinesterase NN NN O
and NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
NIK NN NN O
- NN NN O
247 NN NN O
on NN NN O
cholinesterase NN NN O
, NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
and NN NN O
spontaneous NN NN O
movement NN NN O
were NN NN O
examined NN NN O
and NN NN O
compared NN NN O
with NN NN O
those NN NN O
of NN NN O
the NN NN O
well NN NN O
- NN NN O
known NN NN O
cholinesterase NN NN O
inhibitors NN NN O
tacrine NN NN O
and NN NN O
E NN NN O
- NN NN O
2020 NN NN O
. NN NN O
   
NIK NN NN O
- NN NN O
247 NN NN O
, NN NN O
tacrine NN NN O
and NN NN O
E NN NN O
- NN NN O
2020 NN NN O
all NN NN O
strongly NN NN O
inhibited NN NN O
acetylcholinesterase NN NN O
( NN NN O
AChE NN NN O
) NN NN O
in NN NN O
human NN NN O
red NN NN O
blood NN NN O
cells NN NN O
( NN NN O
IC50s NN NN O
= NN NN O
1 NN NN O
. NN NN O
0 NN NN O
x NN NN O
10 NN NN O
( NN NN O
- NN NN O
6 NN NN O
) NN NN O
, NN NN O
2 NN NN O
. NN NN O
9 NN NN O
x NN NN O
10 NN NN O
( NN NN O
- NN NN O
7 NN NN O
) NN NN O
and NN NN O
3 NN NN O
. NN NN O
7 NN NN O
x NN NN O
10 NN NN O
( NN NN O
- NN NN O
8 NN NN O
) NN NN O
M NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
NIK NN NN O
- NN NN O
247 NN NN O
and NN NN O
tacrine NN NN O
, NN NN O
but NN NN O
not NN NN O
E NN NN O
- NN NN O
2020 NN NN O
, NN NN O
strongly NN NN O
inhibited NN NN O
butyrylcholinestrase NN NN O
( NN NN O
BuChE NN NN O
) NN NN O
in NN NN O
human NN NN O
serum NN NN O
. NN NN O
   
All NN NN O
three NN NN O
drugs NN NN O
produced NN NN O
mixed NN NN O
inhibition NN NN O
of NN NN O
AChE NN NN O
activity NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
the NN NN O
inhibitory NN NN O
effect NN NN O
of NN NN O
NIK NN NN O
- NN NN O
247 NN NN O
on NN NN O
AChE NN NN O
was NN NN O
reversible NN NN O
. NN NN O
   
All NN NN O
compounds NN NN O
at NN NN O
0 NN NN O
. NN NN O
1 NN NN O
- NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
significantly NN NN O
improved NN NN O
the NN NN O
amnesia NN NN B-Disease
induced NN NN O
by NN NN O
scopolamine NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
in NN NN O
rats NN NN O
performing NN NN O
a NN NN O
passive NN NN O
avoidance NN NN O
task NN NN O
. NN NN O
   
The NN NN O
three NN NN O
compounds NN NN O
at NN NN O
1 NN NN O
and NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
did NN NN O
not NN NN O
significantly NN NN O
decrease NN NN O
spontaneous NN NN O
movement NN NN O
by NN NN O
rats NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
NIK NN NN O
- NN NN O
247 NN NN O
at NN NN O
a NN NN O
low NN NN O
dose NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
- NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
) NN NN O
improves NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
but NN NN O
does NN NN O
not NN NN O
affect NN NN O
spontaneous NN NN O
movement NN NN O
. NN NN O
   
The NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
NIK NN NN O
- NN NN O
247 NN NN O
may NN NN O
be NN NN O
a NN NN O
useful NN NN O
drug NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
Alzheimer NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Potential NN NN O
therapeutic NN NN O
use NN NN O
of NN NN O
the NN NN O
selective NN NN O
dopamine NN NN O
D1 NN NN O
receptor NN NN O
agonist NN NN O
, NN NN O
A NN NN O
- NN NN O
86929 NN NN O
: NN NN O
an NN NN O
acute NN NN O
study NN NN O
in NN NN O
parkinsonian NN NN B-Disease
levodopa NN NN O
- NN NN O
primed NN NN O
monkeys NN NN O
. NN NN O
   
The NN NN O
clinical NN NN O
utility NN NN O
of NN NN O
dopamine NN NN O
( NN NN O
DA NN NN O
) NN NN O
D1 NN NN O
receptor NN NN O
agonists NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
( NN NN O
PD NN NN B-Disease
) NN NN O
is NN NN O
still NN NN O
unclear NN NN O
. NN NN O
   
The NN NN O
therapeutic NN NN O
use NN NN O
of NN NN O
selective NN NN O
DA NN NN O
D1 NN NN O
receptor NN NN O
agonists NN NN O
such NN NN O
as NN NN O
SKF NN NN O
- NN NN O
82958 NN NN O
( NN NN O
6 NN NN O
- NN NN O
chloro NN NN O
- NN NN O
7 NN NN O
, NN NN O
8 NN NN O
- NN NN O
dihydroxy NN NN O
- NN NN O
3 NN NN O
- NN NN O
allyl NN NN O
- NN NN O
1 NN NN O
- NN NN O
phenyl NN NN O
- NN NN O
2 NN NN O
, NN NN O
3 NN NN O
, NN NN O
4 NN NN O
, NN NN O
5 NN NN O
- NN NN O
tetrahydro NN NN O
- NN NN O
1H NN NN O
- NN NN O
3 NN NN O
- NN NN O
benzaze NN NN O
pine NN NN O
hydrobromide NN NN O
) NN NN O
and NN NN O
A NN NN O
- NN NN O
77636 NN NN O
( NN NN O
[ NN NN O
1R NN NN O
, NN NN O
3S NN NN O
] NN NN O
3 NN NN O
- NN NN O
[ NN NN O
1 NN NN O
' NN NN O
- NN NN O
admantyl NN NN O
] NN NN O
- NN NN O
1 NN NN O
- NN NN O
aminomethyl NN NN O
- NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
dihydro NN NN O
- NN NN O
5 NN NN O
, NN NN O
6 NN NN O
- NN NN O
dihydroxy NN NN O
- NN NN O
1H NN NN O
- NN NN O
2 NN NN O
- NN NN O
benzo NN NN O
pyran NN NN O
hydrochloride NN NN O
) NN NN O
seems NN NN O
limited NN NN O
because NN NN O
of NN NN O
their NN NN O
duration NN NN O
of NN NN O
action NN NN O
, NN NN O
which NN NN O
is NN NN O
too NN NN O
short NN NN O
for NN NN O
SKF NN NN O
- NN NN O
82958 NN NN O
( NN NN O
< NN NN O
1 NN NN O
hr NN NN O
) NN NN O
and NN NN O
too NN NN O
long NN NN O
for NN NN O
A NN NN O
- NN NN O
77636 NN NN O
( NN NN O
> NN NN O
20 NN NN O
hr NN NN O
, NN NN O
leading NN NN O
to NN NN O
behavioral NN NN O
tolerance NN NN O
) NN NN O
. NN NN O
   
We NN NN O
therefore NN NN O
conducted NN NN O
the NN NN O
present NN NN O
acute NN NN O
dose NN NN O
- NN NN O
response NN NN O
study NN NN O
in NN NN O
four NN NN O
1 NN NN O
- NN NN O
methyl NN NN O
- NN NN O
4 NN NN O
- NN NN O
phenyl NN NN O
- NN NN O
1 NN NN O
, NN NN O
2 NN NN O
, NN NN O
3 NN NN O
, NN NN O
6 NN NN O
- NN NN O
tetrahydropyridine NN NN O
( NN NN O
MPTP NN NN O
) NN NN O
- NN NN O
exposed NN NN O
cynomolgus NN NN O
monkeys NN NN O
primed NN NN O
to NN NN O
exhibit NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
to NN NN O
evaluate NN NN O
the NN NN O
locomotor NN NN O
and NN NN O
dyskinetic NN NN B-Disease
effects NN NN O
on NN NN O
challenge NN NN O
with NN NN O
four NN NN O
doses NN NN O
( NN NN O
from NN NN O
0 NN NN O
. NN NN O
03 NN NN O
to NN NN O
1 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
of NN NN O
A NN NN O
- NN NN O
86929 NN NN O
( NN NN O
[ NN NN O
- NN NN O
] NN NN O
- NN NN O
[ NN NN O
5aR NN NN O
, NN NN O
11bS NN NN O
] NN NN O
- NN NN O
4 NN NN O
, NN NN O
5 NN NN O
, NN NN O
5a NN NN O
, NN NN O
6 NN NN O
, NN NN O
7 NN NN O
, NN NN O
11b NN NN O
- NN NN O
hexahydro NN NN O
- NN NN O
2 NN NN O
- NN NN O
propyl NN NN O
- NN NN O
3 NN NN O
- NN NN O
thia NN NN O
- NN NN O
5 NN NN O
- NN NN O
+ NN NN O
+ NN NN O
+ NN NN O
azacyclopent NN NN O
- NN NN O
1 NN NN O
- NN NN O
ena NN NN O
[ NN NN O
c NN NN O
] NN NN O
phenathrene NN NN O
- NN NN O
9 NN NN O
- NN NN O
10 NN NN O
- NN NN O
diol NN NN O
) NN NN O
, NN NN O
a NN NN O
selective NN NN O
and NN NN O
full NN NN O
DA NN NN O
D1 NN NN O
- NN NN O
like NN NN O
receptor NN NN O
agonist NN NN O
with NN NN O
an NN NN O
intermediate NN NN O
duration NN NN O
of NN NN O
action NN NN O
. NN NN O
   
Levodopa NN NN O
and NN NN O
the NN NN O
DA NN NN O
D2 NN NN O
- NN NN O
like NN NN O
receptor NN NN O
agonist NN NN O
, NN NN O
LY NN NN O
- NN NN O
171555 NN NN O
( NN NN O
[ NN NN O
4aR NN NN O
- NN NN O
trans NN NN O
] NN NN O
- NN NN O
4 NN NN O
, NN NN O
4a NN NN O
, NN NN O
5 NN NN O
, NN NN O
6 NN NN O
, NN NN O
7 NN NN O
, NN NN O
8 NN NN O
, NN NN O
8a NN NN O
, NN NN O
9 NN NN O
- NN NN O
o NN NN O
- NN NN O
dihydro NN NN O
- NN NN O
5n NN NN O
- NN NN O
propyl NN NN O
- NN NN O
2H NN NN O
- NN NN O
pyrazo NN NN O
lo NN NN O
- NN NN O
3 NN NN O
- NN NN O
4 NN NN O
- NN NN O
quinoline NN NN O
hydrochloride NN NN O
) NN NN O
were NN NN O
also NN NN O
used NN NN O
for NN NN O
comparison NN NN O
. NN NN O
   
Acute NN NN O
administration NN NN O
of NN NN O
A NN NN O
- NN NN O
86929 NN NN O
was NN NN O
as NN NN O
efficacious NN NN O
in NN NN O
alleviating NN NN O
MPTP NN NN O
- NN NN O
induced NN NN O
parkinsonism NN NN B-Disease
as NN NN O
levodopa NN NN O
and NN NN O
LY NN NN O
- NN NN O
171555 NN NN O
, NN NN O
but NN NN O
was NN NN O
less NN NN O
likely NN NN O
to NN NN O
reproduce NN NN O
the NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
in NN NN O
these NN NN O
animals NN NN O
than NN NN O
with NN NN O
either NN NN O
LY NN NN O
- NN NN O
171555 NN NN O
or NN NN O
subsequent NN NN O
challenge NN NN O
of NN NN O
levodopa NN NN O
. NN NN O
   
Selective NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
DA NN NN O
D1 NN NN O
receptor NN NN O
may NN NN O
provide NN NN O
better NN NN O
integration NN NN O
of NN NN O
neural NN NN O
inputs NN NN O
transmitted NN NN O
to NN NN O
the NN NN O
internal NN NN O
segment NN NN O
of NN NN O
the NN NN O
globus NN NN O
pallidus NN NN O
( NN NN O
referred NN NN O
to NN NN O
as NN NN O
the NN NN O
basal NN NN O
ganglia NN NN O
output NN NN O
) NN NN O
compared NN NN O
with NN NN O
levodopa NN NN O
and NN NN O
selective NN NN O
DA NN NN O
D2 NN NN O
receptor NN NN O
agonist NN NN O
. NN NN O
   
Potent NN NN O
DA NN NN O
D1 NN NN O
receptor NN NN O
agents NN NN O
with NN NN O
an NN NN O
intermediate NN NN O
duration NN NN O
of NN NN O
efficacy NN NN O
such NN NN O
as NN NN O
A NN NN O
- NN NN O
86929 NN NN O
( NN NN O
approximately NN NN O
4 NN NN O
hr NN NN O
at NN NN O
higher NN NN O
doses NN NN O
tested NN NN O
) NN NN O
are NN NN O
potential NN NN O
therapeutic NN NN O
tools NN NN O
in NN NN O
PD NN NN B-Disease
and NN NN O
merit NN NN O
further NN NN O
attention NN NN O
. NN NN O
   
Neuropeptide NN NN O
- NN NN O
Y NN NN O
immunoreactivity NN NN O
in NN NN O
the NN NN O
pilocarpine NN NN O
model NN NN O
of NN NN O
temporal NN NN B-Disease
lobe NN NN I-Disease
epilepsy NN NN I-Disease
. NN NN O
   
Neuropeptide NN NN O
- NN NN O
Y NN NN O
( NN NN O
NPY NN NN O
) NN NN O
is NN NN O
expressed NN NN O
by NN NN O
granule NN NN O
cells NN NN O
and NN NN O
mossy NN NN O
fibres NN NN O
of NN NN O
the NN NN O
hippocampal NN NN O
dentate NN NN O
gyrus NN NN O
during NN NN O
experimental NN NN O
temporal NN NN B-Disease
lobe NN NN I-Disease
epilepsy NN NN I-Disease
( NN NN O
TLE NN NN B-Disease
) NN NN O
. NN NN O
   
This NN NN O
expression NN NN O
may NN NN O
represent NN NN O
an NN NN O
endogenous NN NN O
damping NN NN O
mechanism NN NN O
since NN NN O
NPY NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
block NN NN O
seizure NN NN B-Disease
- NN NN O
like NN NN O
events NN NN O
following NN NN O
high NN NN O
- NN NN O
frequency NN NN O
stimulation NN NN O
in NN NN O
hippocampal NN NN O
slices NN NN O
. NN NN O
   
The NN NN O
pilocarpine NN NN O
( NN NN O
PILO NN NN O
) NN NN O
model NN NN O
of NN NN O
epilepsy NN NN B-Disease
is NN NN O
characterized NN NN O
by NN NN O
an NN NN O
acute NN NN O
period NN NN O
of NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
followed NN NN O
by NN NN O
spontaneous NN NN O
recurrent NN NN O
seizures NN NN B-Disease
and NN NN O
related NN NN O
brain NN NN B-Disease
damage NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
peroxidase NN NN O
- NN NN O
antiperoxidase NN NN O
immunostaining NN NN O
for NN NN O
NPY NN NN O
in NN NN O
several NN NN O
brain NN NN O
regions NN NN O
in NN NN O
this NN NN O
model NN NN O
. NN NN O
   
PILO NN NN O
- NN NN O
injected NN NN O
animals NN NN O
exhibited NN NN O
NPY NN NN O
immunoreactivity NN NN O
in NN NN O
the NN NN O
region NN NN O
of NN NN O
the NN NN O
mossy NN NN O
fibre NN NN O
terminals NN NN O
, NN NN O
in NN NN O
the NN NN O
dentate NN NN O
gyrus NN NN O
inner NN NN O
molecular NN NN O
layer NN NN O
and NN NN O
, NN NN O
in NN NN O
a NN NN O
few NN NN O
cases NN NN O
, NN NN O
within NN NN O
presumed NN NN O
granule NN NN O
cells NN NN O
. NN NN O
   
NPY NN NN O
immunoreactivity NN NN O
was NN NN O
also NN NN O
dramatically NN NN O
changed NN NN O
in NN NN O
the NN NN O
entorhinal NN NN O
cortex NN NN O
, NN NN O
amygdala NN NN O
and NN NN O
sensorimotor NN NN O
areas NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
PILO NN NN O
injected NN NN O
animals NN NN O
exhibited NN NN O
a NN NN O
reduction NN NN O
in NN NN O
the NN NN O
number NN NN O
of NN NN O
NPY NN NN O
- NN NN O
immunoreactive NN NN O
interneurons NN NN O
compared NN NN O
with NN NN O
controls NN NN O
. NN NN O
   
The NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
changes NN NN O
in NN NN O
NPY NN NN O
expression NN NN O
, NN NN O
including NN NN O
expression NN NN O
in NN NN O
the NN NN O
granule NN NN O
cells NN NN O
and NN NN O
mossy NN NN O
fibres NN NN O
and NN NN O
the NN NN O
loss NN NN O
of NN NN O
vulnerable NN NN O
NPY NN NN O
neurons NN NN O
, NN NN O
are NN NN O
present NN NN O
in NN NN O
the NN NN O
PILO NN NN O
model NN NN O
of NN NN O
TLE NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
significance NN NN O
of NN NN O
this NN NN O
changed NN NN O
synthesis NN NN O
of NN NN O
NPY NN NN O
remains NN NN O
to NN NN O
be NN NN O
determined NN NN O
. NN NN O
   
Posteroventral NN NN O
medial NN NN O
pallidotomy NN NN O
in NN NN O
advanced NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Posteroventral NN NN O
medial NN NN O
pallidotomy NN NN O
sometimes NN NN O
produces NN NN O
striking NN NN O
improvement NN NN O
in NN NN O
patients NN NN O
with NN NN O
advanced NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
, NN NN O
but NN NN O
the NN NN O
studies NN NN O
to NN NN O
date NN NN O
have NN NN O
involved NN NN O
small NN NN O
numbers NN NN O
of NN NN O
patients NN NN O
and NN NN O
short NN NN O
- NN NN O
term NN NN O
follow NN NN O
- NN NN O
up NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Forty NN NN O
patients NN NN O
with NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
underwent NN NN O
serial NN NN O
, NN NN O
detailed NN NN O
assessments NN NN O
both NN NN O
after NN NN O
drug NN NN O
withdrawal NN NN O
( NN NN O
"""""""" NN NN O
off NN NN O
"""""""" NN NN O
period NN NN O
) NN NN O
and NN NN O
while NN NN O
taking NN NN O
their NN NN O
optimal NN NN O
medical NN NN O
regimens NN NN O
( NN NN O
"""""""" NN NN O
on NN NN O
"""""""" NN NN O
period NN NN O
) NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
were NN NN O
examined NN NN O
preoperatively NN NN O
and NN NN O
39 NN NN O
were NN NN O
examined NN NN O
at NN NN O
six NN NN O
months NN NN O
; NN NN O
27 NN NN O
of NN NN O
the NN NN O
patients NN NN O
were NN NN O
also NN NN O
examined NN NN O
at NN NN O
one NN NN O
year NN NN O
, NN NN O
and NN NN O
11 NN NN O
at NN NN O
two NN NN O
years NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
percent NN NN O
improvements NN NN O
at NN NN O
six NN NN O
months NN NN O
were NN NN O
as NN NN O
follows NN NN O
: NN NN O
off NN NN O
- NN NN O
period NN NN O
score NN NN O
for NN NN O
overall NN NN O
motor NN NN O
function NN NN O
, NN NN O
28 NN NN O
percent NN NN O
( NN NN O
95 NN NN O
percent NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
19 NN NN O
to NN NN O
38 NN NN O
percent NN NN O
) NN NN O
, NN NN O
with NN NN O
most NN NN O
of NN NN O
the NN NN O
improvement NN NN O
in NN NN O
the NN NN O
contralateral NN NN O
limbs NN NN O
; NN NN O
off NN NN O
- NN NN O
period NN NN O
score NN NN O
for NN NN O
activities NN NN O
of NN NN O
daily NN NN O
living NN NN O
, NN NN O
29 NN NN O
percent NN NN O
( NN NN O
95 NN NN O
percent NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
19 NN NN O
to NN NN O
39 NN NN O
percent NN NN O
) NN NN O
; NN NN O
on NN NN O
- NN NN O
period NN NN O
score NN NN O
for NN NN O
contralateral NN NN O
dyskinesias NN NN B-Disease
, NN NN O
82 NN NN O
percent NN NN O
( NN NN O
95 NN NN O
percent NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
72 NN NN O
to NN NN O
91 NN NN O
percent NN NN O
) NN NN O
; NN NN O
and NN NN O
on NN NN O
- NN NN O
period NN NN O
score NN NN O
for NN NN O
ipsilateral NN NN O
dyskinesias NN NN B-Disease
, NN NN O
44 NN NN O
percent NN NN O
( NN NN O
95 NN NN O
percent NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
29 NN NN O
to NN NN O
59 NN NN O
percent NN NN O
) NN NN O
. NN NN O
   
The NN NN O
improvements NN NN O
in NN NN O
dyskinesias NN NN B-Disease
and NN NN O
the NN NN O
total NN NN O
scores NN NN O
for NN NN O
off NN NN O
- NN NN O
period NN NN O
parkinsonism NN NN B-Disease
, NN NN O
contralateral NN NN O
bradykinesia NN NN B-Disease
, NN NN O
and NN NN O
rigidity NN NN B-Disease
were NN NN O
sustained NN NN O
in NN NN O
the NN NN O
11 NN NN O
patients NN NN O
examined NN NN O
at NN NN O
two NN NN O
years NN NN O
. NN NN O
   
The NN NN O
improvement NN NN O
in NN NN O
ipsilateral NN NN O
dyskinesias NN NN B-Disease
was NN NN O
lost NN NN O
after NN NN O
one NN NN O
year NN NN O
, NN NN O
and NN NN O
the NN NN O
improvements NN NN O
in NN NN O
postural NN NN O
stability NN NN O
and NN NN O
gait NN NN O
lasted NN NN O
only NN NN O
three NN NN O
to NN NN O
six NN NN O
months NN NN O
. NN NN O
   
Approximately NN NN O
half NN NN O
the NN NN O
patients NN NN O
who NN NN O
had NN NN O
been NN NN O
dependent NN NN O
on NN NN O
assistance NN NN O
in NN NN O
activities NN NN O
of NN NN O
daily NN NN O
living NN NN O
in NN NN O
the NN NN O
off NN NN O
period NN NN O
before NN NN O
surgery NN NN O
became NN NN O
independent NN NN O
after NN NN O
surgery NN NN O
. NN NN O
   
The NN NN O
complications NN NN O
of NN NN O
surgery NN NN O
were NN NN O
generally NN NN O
well NN NN O
tolerated NN NN O
, NN NN O
and NN NN O
there NN NN O
were NN NN O
no NN NN O
significant NN NN O
changes NN NN O
in NN NN O
the NN NN O
use NN NN O
of NN NN O
medication NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
In NN NN O
late NN NN O
- NN NN O
stage NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
, NN NN O
pallidotomy NN NN O
significantly NN NN O
reduces NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
and NN NN O
off NN NN O
- NN NN O
period NN NN O
disability NN NN O
. NN NN O
   
Much NN NN O
of NN NN O
the NN NN O
benefit NN NN O
is NN NN O
sustained NN NN O
at NN NN O
two NN NN O
years NN NN O
, NN NN O
although NN NN O
some NN NN O
improvements NN NN O
, NN NN O
such NN NN O
as NN NN O
those NN NN O
on NN NN O
the NN NN O
ipsilateral NN NN O
side NN NN O
and NN NN O
in NN NN O
axial NN NN O
symptoms NN NN O
, NN NN O
wane NN NN O
within NN NN O
the NN NN O
first NN NN O
year NN NN O
. NN NN O
   
The NN NN O
on NN NN O
- NN NN O
period NN NN O
symptoms NN NN O
that NN NN O
are NN NN O
resistant NN NN O
to NN NN O
dopaminergic NN NN O
therapy NN NN O
do NN NN O
not NN NN O
respond NN NN O
to NN NN O
pallidotomy NN NN O
. NN NN O
   
Clarithromycin NN NN O
- NN NN O
induced NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
. NN NN O
   
Clarithromycin NN NN O
is NN NN O
a NN NN O
relatively NN NN O
new NN NN O
macrolide NN NN O
antibiotic NN NN O
that NN NN O
offers NN NN O
twice NN NN O
- NN NN O
daily NN NN O
dosing NN NN O
. NN NN O
   
It NN NN O
differs NN NN O
from NN NN O
erythromycin NN NN O
only NN NN O
in NN NN O
the NN NN O
methylation NN NN O
of NN NN O
the NN NN O
hydroxyl NN NN O
group NN NN O
at NN NN O
position NN NN O
6 NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
side NN NN O
- NN NN O
effect NN NN O
profile NN NN O
of NN NN O
erythromycin NN NN O
is NN NN O
established NN NN O
, NN NN O
including NN NN O
gastroenteritis NN NN B-Disease
and NN NN O
interactions NN NN O
with NN NN O
other NN NN O
drugs NN NN O
subject NN NN O
to NN NN O
hepatic NN NN O
mixed NN NN O
- NN NN O
function NN NN O
oxidase NN NN O
metabolism NN NN O
, NN NN O
experience NN NN O
with NN NN O
the NN NN O
newer NN NN O
macrolides NN NN O
is NN NN O
still NN NN O
being NN NN O
recorded NN NN O
. NN NN O
   
Cardiotoxicity NN NN B-Disease
has NN NN O
been NN NN O
demonstrated NN NN O
after NN NN O
both NN NN O
intravenous NN NN O
and NN NN O
oral NN NN O
administration NN NN O
of NN NN O
erythromycin NN NN O
but NN NN O
has NN NN O
never NN NN O
been NN NN O
reported NN NN O
with NN NN O
the NN NN O
newer NN NN O
macrolides NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
ventricular NN NN B-Disease
dysrhythmias NN NN I-Disease
that NN NN O
occurred NN NN O
after NN NN O
six NN NN O
therapeutic NN NN O
doses NN NN O
of NN NN O
clarithromycin NN NN O
. NN NN O
   
The NN NN O
dysrhythmias NN NN B-Disease
resolved NN NN O
after NN NN O
discontinuation NN NN O
of NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
glyceryl NN NN O
trinitrate NN NN O
on NN NN O
the NN NN O
sphincter NN NN B-Disease
of NN NN I-Disease
Oddi NN NN I-Disease
spasm NN NN I-Disease
evoked NN NN O
by NN NN O
prostigmine NN NN O
- NN NN O
morphine NN NN O
administration NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
In NN NN O
this NN NN O
study NN NN O
the NN NN O
effect NN NN O
of NN NN O
glyceryl NN NN O
trinitrate NN NN O
on NN NN O
the NN NN O
prostigmine NN NN O
- NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
sphincter NN NN B-Disease
of NN NN I-Disease
Oddi NN NN I-Disease
spasm NN NN I-Disease
was NN NN O
evaluated NN NN O
in NN NN O
nine NN NN O
female NN NN O
patients NN NN O
with NN NN O
sphincter NN NN B-Disease
of NN NN I-Disease
Oddi NN NN I-Disease
dyskinesia NN NN I-Disease
. NN NN O
   
METHOD NN NN O
: NN NN O
Sphincter NN NN B-Disease
of NN NN I-Disease
Oddi NN NN I-Disease
spasm NN NN I-Disease
was NN NN O
induced NN NN O
by NN NN O
prostigmine NN NN O
- NN NN O
morphine NN NN O
administration NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
prostigmine NN NN O
intramuscularly NN NN O
and NN NN O
10 NN NN O
mg NN NN O
morphine NN NN O
subcutaneously NN NN O
) NN NN O
and NN NN O
visualized NN NN O
by NN NN O
quantitative NN NN O
hepatobiliary NN NN O
scintigraphy NN NN O
. NN NN O
   
The NN NN O
entire NN NN O
procedure NN NN O
was NN NN O
repeated NN NN O
during NN NN O
glyceryl NN NN O
trinitrate NN NN O
infusion NN NN O
( NN NN O
Nitrolingual NN NN O
1 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
for NN NN O
120 NN NN O
min NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Prostigmine NN NN O
- NN NN O
morphine NN NN O
provocation NN NN O
caused NN NN O
significant NN NN O
increases NN NN O
in NN NN O
the NN NN O
time NN NN O
to NN NN O
peak NN NN O
activity NN NN O
( NN NN O
Tmax NN NN O
) NN NN O
over NN NN O
the NN NN O
hepatic NN NN O
hilum NN NN O
( NN NN O
HH NN NN O
: NN NN O
34 NN NN O
. NN NN O
33 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
. NN NN O
05 NN NN O
vs NN NN O
. NN NN O
22 NN NN O
. NN NN O
77 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
26 NN NN O
) NN NN O
and NN NN O
the NN NN O
common NN NN O
bile NN NN O
duct NN NN O
( NN NN O
CBD NN NN O
: NN NN O
60 NN NN O
. NN NN O
44 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
. NN NN O
99 NN NN O
vs NN NN O
. NN NN O
40 NN NN O
. NN NN O
0 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
88 NN NN O
) NN NN O
and NN NN O
in NN NN O
the NN NN O
half NN NN O
- NN NN O
time NN NN O
of NN NN O
excretion NN NN O
( NN NN O
T1 NN NN O
/ NN NN O
2 NN NN O
) NN NN O
over NN NN O
the NN NN O
liver NN NN O
parenchyma NN NN O
( NN NN O
LP NN NN O
: NN NN O
120 NN NN O
. NN NN O
04 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
16 NN NN O
. NN NN O
01 NN NN O
vs NN NN O
. NN NN O
27 NN NN O
. NN NN O
37 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
19 NN NN O
) NN NN O
, NN NN O
HH NN NN O
( NN NN O
117 NN NN O
. NN NN O
61 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
14 NN NN O
. NN NN O
71 NN NN O
vs NN NN O
. NN NN O
31 NN NN O
. NN NN O
85 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
99 NN NN O
) NN NN O
and NN NN O
CBD NN NN O
( NN NN O
158 NN NN O
. NN NN O
11 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
9 NN NN O
. NN NN O
18 NN NN O
vs NN NN O
. NN NN O
40 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
. NN NN O
24 NN NN O
) NN NN O
, NN NN O
indicating NN NN O
a NN NN O
complete NN NN O
spasm NN NN B-Disease
at NN NN O
the NN NN O
level NN NN O
of NN NN O
the NN NN O
sphincter NN NN O
of NN NN O
Oddi NN NN O
. NN NN O
   
Glyceryl NN NN O
trinitrate NN NN O
infusion NN NN O
completely NN NN O
normalized NN NN O
the NN NN O
prostigmine NN NN O
- NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
alterations NN NN O
in NN NN O
these NN NN O
quantitative NN NN O
parameters NN NN O
( NN NN O
TmaX NN NN O
over NN NN O
the NN NN O
LP NN NN O
: NN NN O
11 NN NN O
. NN NN O
33 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
13 NN NN O
; NN NN O
over NN NN O
the NN NN O
HH NN NN O
: NN NN O
18 NN NN O
. NN NN O
88 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
48 NN NN O
; NN NN O
and NN NN O
over NN NN O
the NN NN O
CBD NN NN O
: NN NN O
36 NN NN O
. NN NN O
22 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
92 NN NN O
; NN NN O
and NN NN O
T1 NN NN O
/ NN NN O
2 NN NN O
over NN NN O
the NN NN O
LP NN NN O
: NN NN O
28 NN NN O
. NN NN O
21 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
83 NN NN O
; NN NN O
over NN NN O
the NN NN O
HH NN NN O
: NN NN O
33 NN NN O
. NN NN O
42 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
10 NN NN O
; NN NN O
and NN NN O
over NN NN O
the NN NN O
CBD NN NN O
: NN NN O
41 NN NN O
. NN NN O
66 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
. NN NN O
33 NN NN O
) NN NN O
, NN NN O
suggesting NN NN O
an NN NN O
effective NN NN O
sphincter NN NN O
- NN NN O
relaxing NN NN O
effect NN NN O
of NN NN O
glyceryl NN NN O
trinitrate NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
These NN NN O
results NN NN O
provide NN NN O
the NN NN O
first NN NN O
evidence NN NN O
of NN NN O
the NN NN O
effectiveness NN NN O
of NN NN O
glyceryl NN NN O
trinitrate NN NN O
on NN NN O
the NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
sphincter NN NN B-Disease
of NN NN I-Disease
Oddi NN NN I-Disease
spasm NN NN I-Disease
in NN NN O
humans NN NN O
. NN NN O
   
Since NN NN O
glyceryl NN NN O
trinitrate NN NN O
is NN NN O
able NN NN O
to NN NN O
overcome NN NN O
even NN NN O
the NN NN O
drastic NN NN O
effect NN NN O
of NN NN O
morphine NN NN O
, NN NN O
it NN NN O
might NN NN O
be NN NN O
of NN NN O
relevance NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
sphincter NN NN B-Disease
of NN NN I-Disease
Oddi NN NN I-Disease
dyskinesia NN NN I-Disease
. NN NN O
   
Immunopathology NN NN O
of NN NN O
penicillamine NN NN O
- NN NN O
induced NN NN O
glomerular NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
Four NN NN O
patients NN NN O
with NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
developed NN NN O
heavy NN NN O
proteinuria NN NN B-Disease
after NN NN O
five NN NN O
to NN NN O
12 NN NN O
months NN NN O
of NN NN O
treatment NN NN O
with NN NN O
D NN NN O
- NN NN O
penicillamine NN NN O
. NN NN O
   
Light NN NN O
microscopy NN NN O
of NN NN O
renal NN NN O
biopsy NN NN O
samples NN NN O
showed NN NN O
minimal NN NN O
glomerular NN NN O
capillary NN NN O
wall NN NN O
thickening NN NN O
and NN NN O
mesangial NN NN O
matrix NN NN O
increase NN NN O
, NN NN O
or NN NN O
no NN NN O
departure NN NN O
from NN NN O
normal NN NN O
. NN NN O
   
Electron NN NN O
microscopy NN NN O
, NN NN O
however NN NN O
, NN NN O
revealed NN NN O
subepithelial NN NN O
electron NN NN O
- NN NN O
dense NN NN O
deposits NN NN O
, NN NN O
fusion NN NN O
of NN NN O
epithelial NN NN O
cell NN NN O
foot NN NN O
processes NN NN O
, NN NN O
and NN NN O
evidence NN NN O
of NN NN O
mesangial NN NN O
cell NN NN O
hyperactivity NN NN O
. NN NN O
   
Immunofluorescence NN NN O
microscopy NN NN O
demonstrated NN NN O
granular NN NN O
capillary NN NN O
wall NN NN O
deposits NN NN O
of NN NN O
IgG NN NN O
and NN NN O
C3 NN NN O
. NN NN O
   
The NN NN O
findings NN NN O
were NN NN O
similar NN NN O
to NN NN O
those NN NN O
in NN NN O
early NN NN O
membranous NN NN B-Disease
glomerulonephritis NN NN I-Disease
, NN NN O
differences NN NN O
being NN NN O
observed NN NN O
however NN NN O
in NN NN O
the NN NN O
results NN NN O
of NN NN O
staining NN NN O
for NN NN O
the NN NN O
early NN NN O
- NN NN O
acting NN NN O
complement NN NN O
components NN NN O
C1q NN NN O
and NN NN O
C4 NN NN O
. NN NN O
   
It NN NN O
is NN NN O
tentatively NN NN O
concluded NN NN O
that NN NN O
complement NN NN O
was NN NN O
activated NN NN O
by NN NN O
the NN NN O
classical NN NN O
pathway NN NN O
. NN NN O
   
Experimental NN NN O
cranial NN NN O
pain NN NN B-Disease
elicited NN NN O
by NN NN O
capsaicin NN NN O
: NN NN O
a NN NN O
PET NN NN O
study NN NN O
. NN NN O
   
Using NN NN O
a NN NN O
positron NN NN O
emission NN NN O
tomography NN NN O
( NN NN O
PET NN NN O
) NN NN O
study NN NN O
it NN NN O
was NN NN O
shown NN NN O
recently NN NN O
that NN NN O
in NN NN O
migraine NN NN B-Disease
without NN NN O
aura NN NN O
certain NN NN O
areas NN NN O
in NN NN O
the NN NN O
brain NN NN O
stem NN NN O
were NN NN O
activated NN NN O
during NN NN O
the NN NN O
headache NN NN B-Disease
state NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
the NN NN O
headache NN NN B-Disease
free NN NN O
interval NN NN O
. NN NN O
   
It NN NN O
was NN NN O
suggested NN NN O
that NN NN O
this NN NN O
brain NN NN O
stem NN NN O
activation NN NN O
is NN NN O
inherent NN NN O
to NN NN O
the NN NN O
migraine NN NN B-Disease
attack NN NN O
itself NN NN O
and NN NN O
represents NN NN O
the NN NN O
so NN NN O
called NN NN O
' NN NN O
migraine NN NN B-Disease
generator NN NN O
' NN NN O
. NN NN O
   
To NN NN O
test NN NN O
this NN NN O
hypothesis NN NN O
we NN NN O
performed NN NN O
an NN NN O
experimental NN NN O
pain NN NN B-Disease
study NN NN O
in NN NN O
seven NN NN O
healthy NN NN O
volunteers NN NN O
, NN NN O
using NN NN O
the NN NN O
same NN NN O
positioning NN NN O
in NN NN O
the NN NN O
PET NN NN O
scanner NN NN O
as NN NN O
in NN NN O
the NN NN O
migraine NN NN B-Disease
patients NN NN O
. NN NN O
   
A NN NN O
small NN NN O
amount NN NN O
of NN NN O
capsaicin NN NN O
was NN NN O
administered NN NN O
subcutaneously NN NN O
in NN NN O
the NN NN O
right NN NN O
forehead NN NN O
to NN NN O
evoke NN NN O
a NN NN O
burning NN NN O
painful NN NN B-Disease
sensation NN NN O
in NN NN O
the NN NN O
first NN NN O
division NN NN O
of NN NN O
the NN NN O
trigeminal NN NN O
nerve NN NN O
. NN NN O
   
Increases NN NN O
of NN NN O
regional NN NN O
cerebral NN NN O
blood NN NN O
flow NN NN O
( NN NN O
rCBF NN NN O
) NN NN O
were NN NN O
found NN NN O
bilaterally NN NN O
in NN NN O
the NN NN O
insula NN NN O
, NN NN O
in NN NN O
the NN NN O
anterior NN NN O
cingulate NN NN O
cortex NN NN O
, NN NN O
the NN NN O
cavernous NN NN O
sinus NN NN O
and NN NN O
the NN NN O
cerebellum NN NN O
. NN NN O
   
Using NN NN O
the NN NN O
same NN NN O
stereotactic NN NN O
space NN NN O
limits NN NN O
as NN NN O
in NN NN O
the NN NN O
above NN NN O
mentioned NN NN O
migraine NN NN B-Disease
study NN NN O
no NN NN O
brain NN NN O
stem NN NN O
activation NN NN O
was NN NN O
found NN NN O
in NN NN O
the NN NN O
acute NN NN O
pain NN NN B-Disease
state NN NN O
compared NN NN O
to NN NN O
the NN NN O
pain NN NN B-Disease
free NN NN O
state NN NN O
. NN NN O
   
The NN NN O
increase NN NN O
of NN NN O
activation NN NN O
in NN NN O
the NN NN O
region NN NN O
of NN NN O
the NN NN O
cavernous NN NN O
sinus NN NN O
however NN NN O
, NN NN O
suggests NN NN O
that NN NN O
this NN NN O
structure NN NN O
is NN NN O
more NN NN O
likely NN NN O
to NN NN O
be NN NN O
involved NN NN O
in NN NN O
trigeminal NN NN O
transmitted NN NN O
pain NN NN B-Disease
as NN NN O
such NN NN O
, NN NN O
rather NN NN O
than NN NN O
in NN NN O
a NN NN O
specific NN NN O
type NN NN O
of NN NN O
headache NN NN B-Disease
as NN NN O
was NN NN O
suggested NN NN O
for NN NN O
cluster NN NN B-Disease
headache NN NN I-Disease
. NN NN O
   
Value NN NN O
of NN NN O
methylprednisolone NN NN O
in NN NN O
prevention NN NN O
of NN NN O
the NN NN O
arthralgia NN NN B-Disease
- NN NN O
myalgia NN NN B-Disease
syndrome NN NN O
associated NN NN O
with NN NN O
the NN NN O
total NN NN O
dose NN NN O
infusion NN NN O
of NN NN O
iron NN NN O
dextran NN NN O
: NN NN O
a NN NN O
double NN NN O
blind NN NN O
randomized NN NN O
trial NN NN O
. NN NN O
   
The NN NN O
safety NN NN O
and NN NN O
efficacy NN NN O
of NN NN O
total NN NN O
dose NN NN O
infusion NN NN O
( NN NN O
TDI NN NN O
) NN NN O
of NN NN O
iron NN NN O
dextran NN NN O
has NN NN O
been NN NN O
well NN NN O
documented NN NN O
. NN NN O
   
In NN NN O
40 NN NN O
% NN NN O
of NN NN O
treated NN NN O
patients NN NN O
, NN NN O
an NN NN O
arthralgia NN NN B-Disease
- NN NN O
myalgia NN NN B-Disease
syndrome NN NN O
develops NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
prospective NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
whether NN NN O
intravenous NN NN O
( NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
administration NN NN O
of NN NN O
methylprednisolone NN NN O
( NN NN O
MP NN NN O
) NN NN O
prevents NN NN O
this NN NN O
complication NN NN O
. NN NN O
   
Sixty NN NN O
- NN NN O
five NN NN O
patients NN NN O
, NN NN O
34 NN NN O
women NN NN O
and NN NN O
31 NN NN O
men NN NN O
, NN NN O
ages NN NN O
36 NN NN O
to NN NN O
80 NN NN O
years NN NN O
, NN NN O
received NN NN O
either NN NN O
normal NN NN O
saline NN NN O
before NN NN O
and NN NN O
after NN NN O
TDI NN NN O
( NN NN O
group NN NN O
1 NN NN O
) NN NN O
, NN NN O
125 NN NN O
mg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
MP NN NN O
before NN NN O
and NN NN O
saline NN NN O
after NN NN O
TDI NN NN O
( NN NN O
group NN NN O
2 NN NN O
) NN NN O
, NN NN O
or NN NN O
125 NN NN O
mg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
MP NN NN O
before NN NN O
and NN NN O
after NN NN O
TDI NN NN O
( NN NN O
group NN NN O
3 NN NN O
) NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
observed NN NN O
for NN NN O
72 NN NN O
hours NN NN O
and NN NN O
reactions NN NN O
were NN NN O
recorded NN NN O
and NN NN O
graded NN NN O
according NN NN O
to NN NN O
severity NN NN O
. NN NN O
   
Fifty NN NN O
- NN NN O
eight NN NN O
percent NN NN O
of NN NN O
group NN NN O
1 NN NN O
patients NN NN O
, NN NN O
33 NN NN O
% NN NN O
of NN NN O
group NN NN O
2 NN NN O
, NN NN O
and NN NN O
26 NN NN O
% NN NN O
of NN NN O
group NN NN O
3 NN NN O
had NN NN O
reactions NN NN O
to NN NN O
TDI NN NN O
. NN NN O
   
The NN NN O
severity NN NN O
of NN NN O
reactions NN NN O
( NN NN O
minimal NN NN O
, NN NN O
mild NN NN O
, NN NN O
and NN NN O
moderate NN NN O
, NN NN O
respectively NN NN O
) NN NN O
was NN NN O
as NN NN O
follows NN NN O
: NN NN O
group NN NN O
1 NN NN O
- NN NN O
- NN NN O
6 NN NN O
, NN NN O
6 NN NN O
, NN NN O
and NN NN O
2 NN NN O
; NN NN O
group NN NN O
2 NN NN O
- NN NN O
- NN NN O
1 NN NN O
, NN NN O
5 NN NN O
, NN NN O
and NN NN O
0 NN NN O
; NN NN O
group NN NN O
3 NN NN O
- NN NN O
- NN NN O
5 NN NN O
, NN NN O
1 NN NN O
, NN NN O
and NN NN O
0 NN NN O
. NN NN O
   
Data NN NN O
were NN NN O
analyzed NN NN O
by NN NN O
the NN NN O
two NN NN O
- NN NN O
sided NN NN O
Fisher NN NN O
' NN NN O
s NN NN O
exact NN NN O
test NN NN O
using NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
intervals NN NN O
with NN NN O
the NN NN O
approximation NN NN O
of NN NN O
Woolf NN NN O
. NN NN O
   
These NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
administration NN NN O
of NN NN O
MP NN NN O
before NN NN O
and NN NN O
after NN NN O
TDI NN NN O
reduces NN NN O
the NN NN O
frequency NN NN O
and NN NN O
severity NN NN O
of NN NN O
the NN NN O
arthralgia NN NN B-Disease
- NN NN O
myalgia NN NN B-Disease
syndrome NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
125 NN NN O
mg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
MP NN NN O
should NN NN O
be NN NN O
given NN NN O
routinely NN NN O
before NN NN O
and NN NN O
after NN NN O
TDI NN NN O
of NN NN O
iron NN NN O
dextran NN NN O
. NN NN O
   
Prolongation NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
QT NN NN I-Disease
interval NN NN I-Disease
related NN NN O
to NN NN O
cisapride NN NN O
- NN NN O
diltiazem NN NN O
interaction NN NN O
. NN NN O
   
Cisapride NN NN O
, NN NN O
a NN NN O
cytochrome NN NN O
P450 NN NN O
3A4 NN NN O
( NN NN O
CYP3A4 NN NN O
) NN NN O
substrate NN NN O
, NN NN O
is NN NN O
widely NN NN O
prescribed NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
gastrointestinal NN NN B-Disease
motility NN NN I-Disease
disorders NN NN I-Disease
. NN NN O
   
Prolongation NN NN B-Disease
of NN NN I-Disease
QT NN NN I-Disease
interval NN NN I-Disease
, NN NN O
torsades NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
, NN NN O
and NN NN O
sudden NN NN B-Disease
cardiac NN NN I-Disease
death NN NN I-Disease
have NN NN O
been NN NN O
reported NN NN O
after NN NN O
concomitant NN NN O
administration NN NN O
with NN NN O
erythromycin NN NN O
or NN NN O
azole NN NN O
antifungal NN NN O
agents NN NN O
, NN NN O
but NN NN O
not NN NN O
with NN NN O
other NN NN O
CYP3A4 NN NN O
inhibitors NN NN O
. NN NN O
   
A NN NN O
possible NN NN O
drug NN NN O
interaction NN NN O
occurred NN NN O
in NN NN O
a NN NN O
45 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
who NN NN O
was NN NN O
taking NN NN O
cisapride NN NN O
for NN NN O
gastroesophageal NN NN B-Disease
reflux NN NN I-Disease
disorder NN NN I-Disease
and NN NN O
diltiazem NN NN O
, NN NN O
an NN NN O
agent NN NN O
that NN NN O
has NN NN O
inhibitory NN NN O
effect NN NN O
on NN NN O
CYP3A4 NN NN O
, NN NN O
for NN NN O
hypertension NN NN B-Disease
. NN NN O
   
The NN NN O
patient NN NN O
was NN NN O
in NN NN O
near NN NN O
syncope NN NN B-Disease
and NN NN O
had NN NN O
QT NN NN B-Disease
- NN NN I-Disease
interval NN NN I-Disease
prolongation NN NN I-Disease
. NN NN O
   
After NN NN O
discontinuing NN NN O
cisapride NN NN O
, NN NN O
the NN NN O
QT NN NN O
interval NN NN O
returned NN NN O
to NN NN O
normal NN NN O
and NN NN O
symptoms NN NN O
did NN NN O
not NN NN O
recur NN NN O
. NN NN O
   
We NN NN O
suggest NN NN O
that NN NN O
caution NN NN O
be NN NN O
taken NN NN O
when NN NN O
cisapride NN NN O
is NN NN O
prescribed NN NN O
with NN NN O
any NN NN O
potent NN NN O
inhibitor NN NN O
of NN NN O
CYP3A4 NN NN O
, NN NN O
including NN NN O
diltiazem NN NN O
. NN NN O
   
Cortical NN NN O
motor NN NN O
overactivation NN NN O
in NN NN O
parkinsonian NN NN B-Disease
patients NN NN O
with NN NN O
L NN NN O
- NN NN O
dopa NN NN O
- NN NN O
induced NN NN O
peak NN NN O
- NN NN O
dose NN NN O
dyskinesia NN NN B-Disease
. NN NN O
   
We NN NN O
have NN NN O
studied NN NN O
the NN NN O
regional NN NN O
cerebral NN NN O
blood NN NN O
flow NN NN O
( NN NN O
rCBF NN NN O
) NN NN O
changes NN NN O
induced NN NN O
by NN NN O
the NN NN O
execution NN NN O
of NN NN O
a NN NN O
finger NN NN O
- NN NN O
to NN NN O
- NN NN O
thumb NN NN O
opposition NN NN O
motor NN NN O
task NN NN O
in NN NN O
the NN NN O
supplementary NN NN O
and NN NN O
primary NN NN O
motor NN NN O
cortex NN NN O
of NN NN O
two NN NN O
groups NN NN O
of NN NN O
parkinsonian NN NN B-Disease
patients NN NN O
on NN NN O
L NN NN O
- NN NN O
dopa NN NN O
medication NN NN O
, NN NN O
the NN NN O
first NN NN O
one NN NN O
without NN NN O
L NN NN O
- NN NN O
dopa NN NN O
induced NN NN O
dyskinesia NN NN B-Disease
( NN NN O
n NN NN O
= NN NN O
23 NN NN O
) NN NN O
and NN NN O
the NN NN O
other NN NN O
with NN NN O
moderate NN NN O
peak NN NN O
- NN NN O
dose NN NN O
dyskinesia NN NN B-Disease
( NN NN O
n NN NN O
= NN NN O
15 NN NN O
) NN NN O
, NN NN O
and NN NN O
of NN NN O
a NN NN O
group NN NN O
of NN NN O
14 NN NN O
normal NN NN O
subjects NN NN O
. NN NN O
   
Single NN NN O
photon NN NN O
emission NN NN O
tomography NN NN O
with NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
133Xe NN NN O
was NN NN O
used NN NN O
to NN NN O
measure NN NN O
the NN NN O
rCBF NN NN O
changes NN NN O
. NN NN O
   
The NN NN O
dyskinetic NN NN B-Disease
parkinsonian NN NN B-Disease
patients NN NN O
exhibited NN NN O
a NN NN O
pattern NN NN O
of NN NN O
response NN NN O
which NN NN O
was NN NN O
markedly NN NN O
different NN NN O
from NN NN O
those NN NN O
of NN NN O
the NN NN O
normal NN NN O
subjects NN NN O
and NN NN O
non NN NN O
- NN NN O
dyskinetic NN NN B-Disease
parkinsonian NN NN B-Disease
patients NN NN O
, NN NN O
with NN NN O
a NN NN O
significant NN NN O
overactivation NN NN O
in NN NN O
the NN NN O
supplementary NN NN O
motor NN NN O
area NN NN O
and NN NN O
the NN NN O
ipsi NN NN O
- NN NN O
and NN NN O
contralateral NN NN O
primary NN NN O
motor NN NN O
areas NN NN O
. NN NN O
   
These NN NN O
results NN NN O
are NN NN O
compatible NN NN O
with NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
an NN NN O
hyperkinetic NN NN B-Disease
abnormal NN NN B-Disease
involuntary NN NN I-Disease
movement NN NN I-Disease
, NN NN O
like NN NN O
L NN NN O
- NN NN O
dopa NN NN O
- NN NN O
induced NN NN O
peak NN NN O
dose NN NN O
dyskinesia NN NN B-Disease
, NN NN O
is NN NN O
due NN NN O
to NN NN O
a NN NN O
disinhibition NN NN O
of NN NN O
the NN NN O
primary NN NN O
and NN NN O
associated NN NN O
motor NN NN O
cortex NN NN O
secondary NN NN O
to NN NN O
an NN NN O
excessive NN NN O
outflow NN NN O
of NN NN O
the NN NN O
pallidothalamocortical NN NN O
motor NN NN O
loop NN NN O
. NN NN O
   
Open NN NN O
- NN NN O
label NN NN O
assessment NN NN O
of NN NN O
levofloxacin NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
acute NN NN O
bacterial NN NN O
sinusitis NN NN B-Disease
in NN NN O
adults NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
To NN NN O
evaluate NN NN O
the NN NN O
efficacy NN NN O
and NN NN O
safety NN NN O
of NN NN O
levofloxacin NN NN O
( NN NN O
500 NN NN O
mg NN NN O
orally NN NN O
once NN NN O
daily NN NN O
for NN NN O
10 NN NN O
to NN NN O
14 NN NN O
days NN NN O
) NN NN O
in NN NN O
treating NN NN O
adult NN NN O
outpatients NN NN O
with NN NN O
acute NN NN O
bacterial NN NN O
sinusitis NN NN B-Disease
. NN NN O
   
PATIENTS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
A NN NN O
total NN NN O
of NN NN O
329 NN NN O
patients NN NN O
enrolled NN NN O
in NN NN O
the NN NN O
study NN NN O
at NN NN O
24 NN NN O
centers NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
had NN NN O
a NN NN O
pre NN NN O
- NN NN O
therapy NN NN O
Gram NN NN O
' NN NN O
s NN NN O
stain NN NN O
and NN NN O
culture NN NN O
of NN NN O
sinus NN NN O
exudate NN NN O
obtained NN NN O
by NN NN O
antral NN NN O
puncture NN NN O
or NN NN O
nasal NN NN O
endoscopy NN NN O
. NN NN O
   
Clinical NN NN O
response NN NN O
was NN NN O
assessed NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
signs NN NN O
and NN NN O
symptoms NN NN O
and NN NN O
sinus NN NN O
radiograph NN NN O
or NN NN O
computed NN NN O
tomography NN NN O
results NN NN O
. NN NN O
   
Microbiologic NN NN O
cure NN NN O
rates NN NN O
were NN NN O
determined NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
presumed NN NN O
plus NN NN O
documented NN NN O
eradication NN NN O
of NN NN O
the NN NN O
pre NN NN O
- NN NN O
therapy NN NN O
pathogen NN NN O
( NN NN O
s NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
most NN NN O
common NN NN O
pathogens NN NN O
were NN NN O
Haemophilus NN NN O
influenzae NN NN O
, NN NN O
Streptococcus NN NN O
pneumoniae NN NN O
, NN NN O
Staphylococcus NN NN O
aureus NN NN O
, NN NN O
and NN NN O
Moraxella NN NN O
catarrhalis NN NN O
. NN NN O
   
Of NN NN O
300 NN NN O
clinically NN NN O
evaluable NN NN O
patients NN NN O
, NN NN O
175 NN NN O
( NN NN O
58 NN NN O
% NN NN O
) NN NN O
were NN NN O
cured NN NN O
and NN NN O
90 NN NN O
( NN NN O
30 NN NN O
% NN NN O
) NN NN O
were NN NN O
improved NN NN O
at NN NN O
the NN NN O
post NN NN O
- NN NN O
therapy NN NN O
evaluation NN NN O
, NN NN O
resulting NN NN O
in NN NN O
a NN NN O
clinical NN NN O
success NN NN O
rate NN NN O
of NN NN O
88 NN NN O
% NN NN O
. NN NN O
   
Thirty NN NN O
- NN NN O
five NN NN O
patients NN NN O
( NN NN O
12 NN NN O
% NN NN O
) NN NN O
clinically NN NN O
failed NN NN O
treatment NN NN O
. NN NN O
   
The NN NN O
microbiologic NN NN O
eradication NN NN O
rate NN NN O
( NN NN O
presumed NN NN O
plus NN NN O
documented NN NN O
) NN NN O
among NN NN O
138 NN NN O
microbiologically NN NN O
evaluable NN NN O
patients NN NN O
was NN NN O
92 NN NN O
% NN NN O
. NN NN O
   
Microbiologic NN NN O
eradication NN NN O
rates NN NN O
( NN NN O
presumed NN NN O
plus NN NN O
documented NN NN O
) NN NN O
of NN NN O
the NN NN O
most NN NN O
common NN NN O
pathogens NN NN O
ranged NN NN O
from NN NN O
93 NN NN O
% NN NN O
( NN NN O
M NN NN O
. NN NN O
catarrhalis NN NN O
) NN NN O
to NN NN O
100 NN NN O
% NN NN O
( NN NN O
S NN NN O
. NN NN O
pneumoniae NN NN O
) NN NN O
at NN NN O
the NN NN O
post NN NN O
- NN NN O
therapy NN NN O
visit NN NN O
. NN NN O
   
All NN NN O
but NN NN O
one NN NN O
of NN NN O
the NN NN O
265 NN NN O
patients NN NN O
who NN NN O
were NN NN O
cured NN NN O
or NN NN O
improved NN NN O
at NN NN O
post NN NN O
- NN NN O
therapy NN NN O
returned NN NN O
for NN NN O
a NN NN O
long NN NN O
- NN NN O
term NN NN O
follow NN NN O
- NN NN O
up NN NN O
visit NN NN O
; NN NN O
243 NN NN O
( NN NN O
92 NN NN O
% NN NN O
) NN NN O
remained NN NN O
well NN NN O
4 NN NN O
to NN NN O
6 NN NN O
weeks NN NN O
after NN NN O
therapy NN NN O
; NN NN O
and NN NN O
21 NN NN O
( NN NN O
8 NN NN O
% NN NN O
) NN NN O
had NN NN O
a NN NN O
relapse NN NN O
of NN NN O
symptoms NN NN O
. NN NN O
   
Adverse NN NN O
events NN NN O
considered NN NN O
to NN NN O
be NN NN O
related NN NN O
to NN NN O
levofloxacin NN NN O
administration NN NN O
were NN NN O
reported NN NN O
by NN NN O
29 NN NN O
patients NN NN O
( NN NN O
9 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
The NN NN O
most NN NN O
common NN NN O
drug NN NN O
- NN NN O
related NN NN O
adverse NN NN O
events NN NN O
were NN NN O
diarrhea NN NN B-Disease
, NN NN O
flatulence NN NN B-Disease
, NN NN O
and NN NN O
nausea NN NN B-Disease
; NN NN O
most NN NN O
adverse NN NN O
events NN NN O
were NN NN O
mild NN NN O
to NN NN O
moderate NN NN O
in NN NN O
severity NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
results NN NN O
of NN NN O
this NN NN O
study NN NN O
indicate NN NN O
that NN NN O
levofloxacin NN NN O
500 NN NN O
mg NN NN O
once NN NN O
daily NN NN O
is NN NN O
an NN NN O
effective NN NN O
and NN NN O
safe NN NN O
treatment NN NN O
for NN NN O
acute NN NN O
bacterial NN NN O
sinusitis NN NN B-Disease
. NN NN O
   
Iatrogenic NN NN O
risks NN NN O
of NN NN O
endometrial NN NN B-Disease
carcinoma NN NN I-Disease
after NN NN O
treatment NN NN O
for NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
in NN NN O
a NN NN O
large NN NN O
French NN NN O
case NN NN O
- NN NN O
control NN NN O
study NN NN O
. NN NN O
   
F NN NN O
d NN NN O
ration NN NN O
Nationale NN NN O
des NN NN O
Centres NN NN O
de NN NN O
Lutte NN NN O
Contre NN NN O
le NN NN O
Cancer NN NN O
( NN NN O
FNCLCC NN NN O
) NN NN O
. NN NN O
   
Since NN NN O
tamoxifen NN NN O
is NN NN O
widely NN NN O
used NN NN O
in NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
treatment NN NN O
and NN NN O
has NN NN O
been NN NN O
proposed NN NN O
for NN NN O
the NN NN O
prevention NN NN O
of NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
its NN NN O
endometrial NN NN O
iatrogenic NN NN O
effects NN NN O
must NN NN O
be NN NN O
carefully NN NN O
examined NN NN O
. NN NN O
   
We NN NN O
have NN NN O
investigated NN NN O
the NN NN O
association NN NN O
between NN NN O
endometrial NN NN B-Disease
cancer NN NN I-Disease
and NN NN O
tamoxifen NN NN O
use NN NN O
or NN NN O
other NN NN O
treatments NN NN O
in NN NN O
women NN NN O
treated NN NN O
for NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
in NN NN O
a NN NN O
case NN NN O
- NN NN O
control NN NN O
study NN NN O
. NN NN O
   
Cases NN NN O
of NN NN O
endometrial NN NN B-Disease
cancer NN NN I-Disease
diagnosed NN NN O
after NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
( NN NN O
n NN NN O
= NN NN O
135 NN NN O
) NN NN O
and NN NN O
467 NN NN O
controls NN NN O
matched NN NN O
for NN NN O
age NN NN O
, NN NN O
year NN NN O
of NN NN O
diagnosis NN NN O
of NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
and NN NN O
hospital NN NN O
and NN NN O
survival NN NN O
time NN NN O
with NN NN O
an NN NN O
intact NN NN O
uterus NN NN O
were NN NN O
included NN NN O
. NN NN O
   
Women NN NN O
who NN NN O
had NN NN O
received NN NN O
tamoxifen NN NN O
were NN NN O
significantly NN NN O
more NN NN O
likely NN NN O
to NN NN O
have NN NN O
endometrial NN NN B-Disease
cancer NN NN I-Disease
diagnosed NN NN O
than NN NN O
those NN NN O
who NN NN O
had NN NN O
not NN NN O
( NN NN O
crude NN NN O
relative NN NN O
risk NN NN O
= NN NN O
4 NN NN O
. NN NN O
9 NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
) NN NN O
. NN NN O
   
Univariate NN NN O
and NN NN O
adjusted NN NN O
analyses NN NN O
showed NN NN O
that NN NN O
the NN NN O
risk NN NN O
increased NN NN O
with NN NN O
the NN NN O
length NN NN O
of NN NN O
treatment NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
) NN NN O
or NN NN O
the NN NN O
cumulative NN NN O
dose NN NN O
of NN NN O
tamoxifen NN NN O
received NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
) NN NN O
, NN NN O
irrespective NN NN O
of NN NN O
the NN NN O
daily NN NN O
dose NN NN O
. NN NN O
   
Women NN NN O
who NN NN O
had NN NN O
undergone NN NN O
pelvic NN NN O
radiotherapy NN NN O
also NN NN O
had NN NN O
a NN NN O
higher NN NN O
risk NN NN O
( NN NN O
crude NN NN O
relative NN NN O
risk NN NN O
= NN NN O
7 NN NN O
. NN NN O
8 NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
) NN NN O
. NN NN O
   
After NN NN O
adjusting NN NN O
for NN NN O
confounding NN NN O
factors NN NN O
, NN NN O
the NN NN O
risk NN NN O
was NN NN O
higher NN NN O
for NN NN O
tamoxifen NN NN O
users NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
0012 NN NN O
) NN NN O
, NN NN O
treatment NN NN O
for NN NN O
more NN NN O
than NN NN O
3 NN NN O
years NN NN O
( NN NN O
all NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
03 NN NN O
) NN NN O
and NN NN O
pelvic NN NN O
radiotherapy NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
012 NN NN O
) NN NN O
. NN NN O
   
Women NN NN O
who NN NN O
had NN NN O
endometrial NN NN B-Disease
cancer NN NN I-Disease
and NN NN O
had NN NN O
received NN NN O
tamoxifen NN NN O
had NN NN O
more NN NN O
advanced NN NN B-Disease
disease NN NN I-Disease
and NN NN O
poorer NN NN O
prognosis NN NN O
than NN NN O
those NN NN O
with NN NN O
endometrial NN NN B-Disease
cancer NN NN I-Disease
who NN NN O
had NN NN O
not NN NN O
received NN NN O
this NN NN O
treatment NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
a NN NN O
causal NN NN O
role NN NN O
of NN NN O
tamoxifen NN NN O
in NN NN O
endometrial NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
particularly NN NN O
when NN NN O
used NN NN O
as NN NN O
currently NN NN O
proposed NN NN O
for NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
prevention NN NN O
. NN NN O
   
Pelvic NN NN O
radiotherapy NN NN O
may NN NN O
be NN NN O
an NN NN O
additional NN NN O
iatrogenic NN NN O
factor NN NN O
for NN NN O
women NN NN O
with NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
Endometrial NN NN B-Disease
cancers NN NN I-Disease
diagnosed NN NN O
in NN NN O
women NN NN O
treated NN NN O
with NN NN O
tamoxifen NN NN O
have NN NN O
poorer NN NN O
prognosis NN NN O
. NN NN O
   
Women NN NN O
who NN NN O
receive NN NN O
tamoxifen NN NN O
for NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
should NN NN O
be NN NN O
offered NN NN O
gynaecological NN NN O
surveillance NN NN O
during NN NN O
and NN NN O
after NN NN O
treatment NN NN O
. NN NN O
   
A NN NN O
long NN NN O
- NN NN O
term NN NN O
evaluation NN NN O
of NN NN O
the NN NN O
risk NN NN O
- NN NN O
benefit NN NN O
ratio NN NN O
of NN NN O
tamoxifen NN NN O
as NN NN O
a NN NN O
preventive NN NN O
treatment NN NN O
for NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
is NN NN O
clearly NN NN O
warranted NN NN O
. NN NN O
   
Contribution NN NN O
of NN NN O
the NN NN O
glycine NN NN O
site NN NN O
of NN NN O
NMDA NN NN O
receptors NN NN O
in NN NN O
rostral NN NN O
and NN NN O
intermediate NN NN O
- NN NN O
caudal NN NN O
parts NN NN O
of NN NN O
the NN NN O
striatum NN NN O
to NN NN O
the NN NN O
regulation NN NN O
of NN NN O
muscle NN NN O
tone NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
assess NN NN O
the NN NN O
contribution NN NN O
of NN NN O
the NN NN O
glycine NN NN O
site NN NN O
of NN NN O
NMDA NN NN O
receptors NN NN O
in NN NN O
the NN NN O
striatum NN NN O
to NN NN O
the NN NN O
regulation NN NN O
of NN NN O
muscle NN NN O
tone NN NN O
. NN NN O
   
Muscle NN NN O
tone NN NN O
was NN NN O
examined NN NN O
using NN NN O
a NN NN O
combined NN NN O
mechanoand NN NN O
electromyographic NN NN O
method NN NN O
, NN NN O
which NN NN O
measured NN NN O
simultaneously NN NN O
the NN NN O
muscle NN NN O
resistance NN NN O
( NN NN O
MMG NN NN O
) NN NN O
of NN NN O
the NN NN O
rat NN NN O
' NN NN O
s NN NN O
hind NN NN O
foot NN NN O
to NN NN O
passive NN NN O
extension NN NN O
and NN NN O
flexion NN NN O
in NN NN O
the NN NN O
ankle NN NN O
joint NN NN O
and NN NN O
the NN NN O
electromyographic NN NN O
activity NN NN O
( NN NN O
EMG NN NN O
) NN NN O
of NN NN O
the NN NN O
antagonistic NN NN O
muscles NN NN O
of NN NN O
that NN NN O
joint NN NN O
: NN NN O
gastrocnemius NN NN O
and NN NN O
tibialis NN NN O
anterior NN NN O
. NN NN O
   
Muscle NN NN B-Disease
rigidity NN NN I-Disease
was NN NN O
induced NN NN O
by NN NN O
haloperidol NN NN O
( NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
. NN NN O
   
5 NN NN O
, NN NN O
7 NN NN O
- NN NN O
dichlorokynurenic NN NN O
acid NN NN O
( NN NN O
5 NN NN O
, NN NN O
7 NN NN O
- NN NN O
DCKA NN NN O
) NN NN O
, NN NN O
a NN NN O
selective NN NN O
glycine NN NN O
site NN NN O
antagonist NN NN O
, NN NN O
injected NN NN O
in NN NN O
doses NN NN O
of NN NN O
2 NN NN O
. NN NN O
5 NN NN O
and NN NN O
4 NN NN O
. NN NN O
5 NN NN O
microg NN NN O
/ NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microl NN NN O
bilaterally NN NN O
, NN NN O
into NN NN O
the NN NN O
rostral NN NN O
region NN NN O
of NN NN O
the NN NN O
striatum NN NN O
, NN NN O
decreased NN NN O
both NN NN O
the NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
muscle NN NN B-Disease
rigidity NN NN I-Disease
( NN NN O
MMG NN NN O
) NN NN O
and NN NN O
the NN NN O
enhanced NN NN O
electromyographic NN NN O
activity NN NN O
( NN NN O
EMG NN NN O
) NN NN O
. NN NN O
   
5 NN NN O
, NN NN O
7 NN NN O
- NN NN O
DCKA NN NN O
injected NN NN O
bilaterally NN NN O
in NN NN O
a NN NN O
dose NN NN O
of NN NN O
4 NN NN O
. NN NN O
5 NN NN O
microg NN NN O
/ NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microl NN NN O
into NN NN O
the NN NN O
intermediate NN NN O
- NN NN O
caudal NN NN O
region NN NN O
of NN NN O
the NN NN O
striatum NN NN O
of NN NN O
rats NN NN O
not NN NN O
pretreated NN NN O
with NN NN O
haloperidol NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
the NN NN O
muscle NN NN O
tone NN NN O
. NN NN O
   
The NN NN O
present NN NN O
results NN NN O
suggest NN NN O
that NN NN O
blockade NN NN O
of NN NN O
the NN NN O
glycine NN NN O
site NN NN O
of NN NN O
NMDA NN NN O
receptors NN NN O
in NN NN O
the NN NN O
rostral NN NN O
part NN NN O
of NN NN O
the NN NN O
striatum NN NN O
may NN NN O
be NN NN O
mainly NN NN O
responsible NN NN O
for NN NN O
the NN NN O
antiparkinsonian NN NN O
action NN NN O
of NN NN O
this NN NN O
drug NN NN O
. NN NN O
   
Carboplatin NN NN O
toxic NN NN O
effects NN NN O
on NN NN O
the NN NN O
peripheral NN NN O
nervous NN NN O
system NN NN O
of NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
most NN NN O
striking NN NN O
of NN NN O
carboplatin NN NN O
' NN NN O
s NN NN O
advantages NN NN O
( NN NN O
CBDCA NN NN O
) NN NN O
over NN NN O
cisplatin NN NN O
( NN NN O
CDDP NN NN O
) NN NN O
is NN NN O
its NN NN O
markedly NN NN O
reduced NN NN O
rate NN NN O
of NN NN O
neurotoxic NN NN B-Disease
effects NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
use NN NN O
of NN NN O
CBDCA NN NN O
higher NN NN O
- NN NN O
intensity NN NN O
schedules NN NN O
and NN NN O
the NN NN O
association NN NN O
with NN NN O
other NN NN O
neurotoxic NN NN B-Disease
drugs NN NN O
in NN NN O
polychemotherapy NN NN O
may NN NN O
cause NN NN O
some NN NN O
concern NN NN O
about NN NN O
its NN NN O
safety NN NN O
with NN NN O
respect NN NN O
to NN NN O
peripheral NN NN B-Disease
nervous NN NN I-Disease
system NN NN I-Disease
damage NN NN I-Disease
. NN NN O
   
MATERIALS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
Two NN NN O
different NN NN O
schedules NN NN O
of NN NN O
CBDCA NN NN O
administration NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
and NN NN O
15 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
twice NN NN O
a NN NN O
week NN NN O
for NN NN O
nine NN NN O
times NN NN O
) NN NN O
were NN NN O
evaluated NN NN O
in NN NN O
Wistar NN NN O
rats NN NN O
. NN NN O
   
Neurotoxicity NN NN B-Disease
was NN NN O
assessed NN NN O
for NN NN O
behavioral NN NN O
( NN NN O
tail NN NN O
- NN NN O
flick NN NN O
test NN NN O
) NN NN O
, NN NN O
neurophysiological NN NN O
( NN NN O
nerve NN NN O
conduction NN NN O
velocity NN NN O
in NN NN O
the NN NN O
tail NN NN O
nerve NN NN O
) NN NN O
, NN NN O
morphological NN NN O
, NN NN O
morphometrical NN NN O
and NN NN O
analytical NN NN O
effects NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
CBDCA NN NN O
administration NN NN O
induced NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
peripheral NN NN B-Disease
neurotoxicity NN NN I-Disease
. NN NN O
   
Pain NN NN B-Disease
perception NN NN O
and NN NN O
nerve NN NN O
conduction NN NN O
velocity NN NN O
in NN NN O
the NN NN O
tail NN NN O
were NN NN O
significantly NN NN O
impaired NN NN O
, NN NN O
particularly NN NN O
after NN NN O
the NN NN O
high NN NN O
- NN NN O
dose NN NN O
treatment NN NN O
. NN NN O
   
The NN NN O
dorsal NN NN O
root NN NN O
ganglia NN NN O
sensory NN NN O
neurons NN NN O
and NN NN O
, NN NN O
to NN NN O
a NN NN O
lesser NN NN O
extent NN NN O
, NN NN O
satellite NN NN O
cells NN NN O
showed NN NN O
the NN NN O
same NN NN O
changes NN NN O
as NN NN O
those NN NN O
induced NN NN O
by NN NN O
CDDP NN NN O
, NN NN O
mainly NN NN O
affecting NN NN O
the NN NN O
nucleus NN NN O
and NN NN O
nucleolus NN NN O
of NN NN O
ganglionic NN NN O
sensory NN NN O
neurons NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
significant NN NN O
amounts NN NN O
of NN NN O
platinum NN NN O
were NN NN O
detected NN NN O
in NN NN O
the NN NN O
dorsal NN NN O
root NN NN O
ganglia NN NN O
and NN NN O
kidney NN NN O
after NN NN O
CBDCA NN NN O
treatment NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
CBDCA NN NN O
is NN NN O
neurotoxic NN NN B-Disease
in NN NN O
our NN NN O
model NN NN O
, NN NN O
and NN NN O
the NN NN O
type NN NN O
of NN NN O
pathological NN NN O
changes NN NN O
it NN NN O
induces NN NN O
are NN NN O
so NN NN O
closely NN NN O
similar NN NN O
to NN NN O
those NN NN O
caused NN NN O
by NN NN O
CDDP NN NN O
that NN NN O
it NN NN O
is NN NN O
probable NN NN O
that NN NN O
neurotoxicity NN NN B-Disease
is NN NN O
induced NN NN O
in NN NN O
the NN NN O
two NN NN O
drugs NN NN O
by NN NN O
the NN NN O
same NN NN O
mechanism NN NN O
. NN NN O
   
This NN NN O
model NN NN O
can NN NN O
be NN NN O
used NN NN O
alone NN NN O
or NN NN O
in NN NN O
combination NN NN O
with NN NN O
other NN NN O
drugs NN NN O
to NN NN O
explore NN NN O
the NN NN O
effect NN NN O
of NN NN O
CBDCA NN NN O
on NN NN O
the NN NN O
peripheral NN NN O
nervous NN NN O
system NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
cisapride NN NN O
on NN NN O
symptoms NN NN O
and NN NN O
postcibal NN NN O
small NN NN O
- NN NN O
bowel NN NN O
motor NN NN O
function NN NN O
in NN NN O
patients NN NN O
with NN NN O
irritable NN NN B-Disease
bowel NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Irritable NN NN B-Disease
bowel NN NN I-Disease
syndrome NN NN I-Disease
is NN NN O
a NN NN O
common NN NN O
cause NN NN O
of NN NN O
abdominal NN NN B-Disease
pain NN NN I-Disease
and NN NN O
discomfort NN NN O
and NN NN O
may NN NN O
be NN NN O
related NN NN O
to NN NN O
disordered NN NN B-Disease
gastrointestinal NN NN I-Disease
motility NN NN I-Disease
. NN NN O
   
Our NN NN O
aim NN NN O
was NN NN O
to NN NN O
assess NN NN O
the NN NN O
effects NN NN O
of NN NN O
long NN NN O
- NN NN O
term NN NN O
treatment NN NN O
with NN NN O
a NN NN O
prokinetic NN NN O
agent NN NN O
, NN NN O
cisapride NN NN O
, NN NN O
on NN NN O
postprandial NN NN O
jejunal NN NN O
motility NN NN O
and NN NN O
symptoms NN NN O
in NN NN O
the NN NN O
irritable NN NN B-Disease
bowel NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
IBS NN NN B-Disease
) NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Thirty NN NN O
- NN NN O
eight NN NN O
patients NN NN O
with NN NN O
IBS NN NN B-Disease
( NN NN O
constipation NN NN B-Disease
- NN NN O
predominant NN NN O
, NN NN O
n NN NN O
= NN NN O
17 NN NN O
; NN NN O
diarrhoea NN NN B-Disease
- NN NN O
predominant NN NN O
, NN NN O
n NN NN O
= NN NN O
21 NN NN O
) NN NN O
underwent NN NN O
24 NN NN O
- NN NN O
h NN NN O
ambulatory NN NN O
jejunal NN NN O
manometry NN NN O
before NN NN O
and NN NN O
after NN NN O
12 NN NN O
week NN NN O
' NN NN O
s NN NN O
treatment NN NN O
[ NN NN O
cisapride NN NN O
, NN NN O
5 NN NN O
mg NN NN O
three NN NN O
times NN NN O
daily NN NN O
( NN NN O
n NN NN O
= NN NN O
19 NN NN O
) NN NN O
or NN NN O
placebo NN NN O
( NN NN O
n NN NN O
= NN NN O
19 NN NN O
) NN NN O
] NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
In NN NN O
diarrhoea NN NN B-Disease
- NN NN O
predominant NN NN O
patients NN NN O
significant NN NN O
differences NN NN O
in NN NN O
contraction NN NN O
characteristics NN NN O
were NN NN O
observed NN NN O
between NN NN O
the NN NN O
cisapride NN NN O
and NN NN O
placebo NN NN O
groups NN NN O
. NN NN O
   
In NN NN O
cisapride NN NN O
- NN NN O
treated NN NN O
diarrhoea NN NN B-Disease
- NN NN O
predominant NN NN O
patients NN NN O
the NN NN O
mean NN NN O
contraction NN NN O
amplitude NN NN O
was NN NN O
higher NN NN O
( NN NN O
29 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
2 NN NN O
versus NN NN O
24 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
6 NN NN O
mm NN NN O
Hg NN NN O
, NN NN O
cisapride NN NN O
versus NN NN O
placebo NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
; NN NN O
pretreatment NN NN O
, NN NN O
25 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
. NN NN O
0 NN NN O
mm NN NN O
Hg NN NN O
) NN NN O
, NN NN O
the NN NN O
mean NN NN O
contraction NN NN O
duration NN NN O
longer NN NN O
( NN NN O
3 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
2 NN NN O
versus NN NN O
3 NN NN O
. NN NN O
0 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
2 NN NN O
sec NN NN O
, NN NN O
cisapride NN NN O
versus NN NN O
placebo NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
; NN NN O
pretreatment NN NN O
, NN NN O
3 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
5 NN NN O
sec NN NN O
) NN NN O
, NN NN O
and NN NN O
the NN NN O
mean NN NN O
contraction NN NN O
frequency NN NN O
lower NN NN O
( NN NN O
2 NN NN O
. NN NN O
0 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
2 NN NN O
versus NN NN O
2 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
4 NN NN O
cont NN NN O
. NN NN O
/ NN NN O
min NN NN O
, NN NN O
cisapride NN NN O
versus NN NN O
placebo NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
; NN NN O
pretreatment NN NN O
, NN NN O
2 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
1 NN NN O
cont NN NN O
. NN NN O
/ NN NN O
min NN NN O
] NN NN O
than NN NN O
patients NN NN O
treated NN NN O
with NN NN O
placebo NN NN O
. NN NN O
   
No NN NN O
significant NN NN O
differences NN NN O
in NN NN O
jejunal NN NN O
motility NN NN O
were NN NN O
found NN NN O
in NN NN O
the NN NN O
constipation NN NN B-Disease
- NN NN O
predominant NN NN O
IBS NN NN B-Disease
group NN NN O
. NN NN O
   
Symptoms NN NN O
were NN NN O
assessed NN NN O
by NN NN O
using NN NN O
a NN NN O
visual NN NN O
analogue NN NN O
scale NN NN O
before NN NN O
and NN NN O
after NN NN O
treatment NN NN O
. NN NN O
   
Symptom NN NN O
scores NN NN O
relating NN NN O
to NN NN O
the NN NN O
severity NN NN O
of NN NN O
constipation NN NN B-Disease
were NN NN O
lower NN NN O
in NN NN O
cisapride NN NN O
- NN NN O
treated NN NN O
constipation NN NN B-Disease
- NN NN O
predominant NN NN O
IBS NN NN B-Disease
patients NN NN O
[ NN NN O
score NN NN O
, NN NN O
54 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
versus NN NN O
67 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
14 NN NN O
mm NN NN O
, NN NN O
cisapride NN NN O
versus NN NN O
placebo NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
; NN NN O
pretreatment NN NN O
, NN NN O
62 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
19 NN NN O
mm NN NN O
] NN NN O
. NN NN O
   
Diarrhoea NN NN B-Disease
- NN NN O
predominant NN NN O
IBS NN NN B-Disease
patients NN NN O
had NN NN O
a NN NN O
higher NN NN O
pain NN NN B-Disease
score NN NN O
after NN NN O
cisapride NN NN O
therapy NN NN O
[ NN NN O
score NN NN O
, NN NN O
55 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
15 NN NN O
versus NN NN O
34 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
12 NN NN O
mm NN NN O
, NN NN O
cisapride NN NN O
versus NN NN O
placebo NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
; NN NN O
pretreatment NN NN O
, NN NN O
67 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
19 NN NN O
mm NN NN O
] NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Cisapride NN NN O
affects NN NN O
jejunal NN NN O
contraction NN NN O
characteristics NN NN O
and NN NN O
some NN NN O
symptoms NN NN O
in NN NN O
IBS NN NN B-Disease
. NN NN O
   
Prevention NN NN O
of NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
with NN NN O
tamoxifen NN NN O
: NN NN O
preliminary NN NN O
findings NN NN O
from NN NN O
the NN NN O
Italian NN NN O
randomised NN NN O
trial NN NN O
among NN NN O
hysterectomised NN NN O
women NN NN O
. NN NN O
   
Italian NN NN O
Tamoxifen NN NN O
Prevention NN NN O
Study NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Tamoxifen NN NN O
is NN NN O
a NN NN O
candidate NN NN O
chemopreventive NN NN O
agent NN NN O
in NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
although NN NN O
the NN NN O
drug NN NN O
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
endometrial NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
Therefore NN NN O
we NN NN O
did NN NN O
a NN NN O
trial NN NN O
in NN NN O
hysterectomised NN NN O
women NN NN O
of NN NN O
tamoxifen NN NN O
as NN NN O
a NN NN O
chemopreventive NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
In NN NN O
October NN NN O
, NN NN O
1992 NN NN O
, NN NN O
we NN NN O
started NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
, NN NN O
randomised NN NN O
trial NN NN O
of NN NN O
tamoxifen NN NN O
in NN NN O
women NN NN O
( NN NN O
mainly NN NN O
in NN NN O
Italy NN NN O
) NN NN O
who NN NN O
did NN NN O
not NN NN O
have NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
and NN NN O
who NN NN O
had NN NN O
had NN NN O
a NN NN O
hysterectomy NN NN O
. NN NN O
   
Women NN NN O
were NN NN O
randomised NN NN O
to NN NN O
receive NN NN O
tamoxifen NN NN O
20 NN NN O
mg NN NN O
per NN NN O
day NN NN O
or NN NN O
placebo NN NN O
, NN NN O
both NN NN O
orally NN NN O
for NN NN O
5 NN NN O
years NN NN O
. NN NN O
   
The NN NN O
original NN NN O
plan NN NN O
was NN NN O
to NN NN O
follow NN NN O
the NN NN O
intervention NN NN O
phase NN NN O
by NN NN O
5 NN NN O
years NN NN O
' NN NN O
follow NN NN O
- NN NN O
up NN NN O
. NN NN O
   
In NN NN O
June NN NN O
, NN NN O
1997 NN NN O
, NN NN O
the NN NN O
trialists NN NN O
and NN NN O
the NN NN O
data NN NN O
- NN NN O
monitoring NN NN O
committee NN NN O
decided NN NN O
to NN NN O
end NN NN O
recruitment NN NN O
primarily NN NN O
because NN NN O
of NN NN O
the NN NN O
number NN NN O
of NN NN O
women NN NN O
dropping NN NN O
out NN NN O
of NN NN O
the NN NN O
study NN NN O
. NN NN O
   
Recruitment NN NN O
ended NN NN O
on NN NN O
July NN NN O
11 NN NN O
, NN NN O
1997 NN NN O
, NN NN O
and NN NN O
the NN NN O
study NN NN O
will NN NN O
continue NN NN O
as NN NN O
planned NN NN O
. NN NN O
   
The NN NN O
primary NN NN O
endpoints NN NN O
are NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
and NN NN O
deaths NN NN O
from NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
This NN NN O
preliminary NN NN O
interim NN NN O
analysis NN NN O
is NN NN O
based NN NN O
on NN NN O
intention NN NN O
- NN NN O
to NN NN O
- NN NN O
treat NN NN O
. NN NN O
   
FINDINGS NN NN O
: NN NN O
5408 NN NN O
women NN NN O
were NN NN O
randomised NN NN O
; NN NN O
participating NN NN O
women NN NN O
have NN NN O
a NN NN O
median NN NN O
follow NN NN O
- NN NN O
up NN NN O
of NN NN O
46 NN NN O
months NN NN O
for NN NN O
major NN NN O
endpoints NN NN O
. NN NN O
   
41 NN NN O
cases NN NN O
of NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
occurred NN NN O
so NN NN O
far NN NN O
; NN NN O
there NN NN O
have NN NN O
been NN NN O
no NN NN O
deaths NN NN O
from NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
There NN NN O
is NN NN O
no NN NN O
difference NN NN O
in NN NN O
breast NN NN B-Disease
- NN NN I-Disease
cancer NN NN I-Disease
frequency NN NN O
between NN NN O
the NN NN O
placebo NN NN O
( NN NN O
22 NN NN O
cases NN NN O
) NN NN O
and NN NN O
tamoxifen NN NN O
( NN NN O
19 NN NN O
) NN NN O
arms NN NN O
. NN NN O
   
There NN NN O
is NN NN O
a NN NN O
statistically NN NN O
significant NN NN O
reduction NN NN O
of NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
among NN NN O
women NN NN O
receiving NN NN O
tamoxifen NN NN O
who NN NN O
also NN NN O
used NN NN O
hormone NN NN O
- NN NN O
replacement NN NN O
therapy NN NN O
during NN NN O
the NN NN O
trial NN NN O
: NN NN O
among NN NN O
390 NN NN O
women NN NN O
on NN NN O
such NN NN O
therapy NN NN O
and NN NN O
allocated NN NN O
to NN NN O
placebo NN NN O
, NN NN O
we NN NN O
found NN NN O
eight NN NN O
cases NN NN O
of NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
compared NN NN O
with NN NN O
one NN NN O
case NN NN O
among NN NN O
362 NN NN O
women NN NN O
allocated NN NN O
to NN NN O
tamoxifen NN NN O
. NN NN O
   
Compared NN NN O
with NN NN O
the NN NN O
placebo NN NN O
group NN NN O
, NN NN O
there NN NN O
was NN NN O
a NN NN O
significantly NN NN O
increased NN NN O
risk NN NN O
of NN NN O
vascular NN NN B-Disease
events NN NN I-Disease
and NN NN O
hypertriglyceridaemia NN NN B-Disease
among NN NN O
women NN NN O
on NN NN O
tamoxifen NN NN O
. NN NN O
   
INTERPRETATION NN NN O
: NN NN O
Although NN NN O
this NN NN O
preliminary NN NN O
analysis NN NN O
has NN NN O
low NN NN O
power NN NN O
, NN NN O
in NN NN O
this NN NN O
cohort NN NN O
of NN NN O
women NN NN O
at NN NN O
low NN NN O
- NN NN O
to NN NN O
- NN NN O
normal NN NN O
risk NN NN O
of NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
the NN NN O
postulated NN NN O
protective NN NN O
effects NN NN O
of NN NN O
tamoxifen NN NN O
are NN NN O
not NN NN O
yet NN NN O
apparent NN NN O
. NN NN O
   
Women NN NN O
using NN NN O
hormone NN NN O
- NN NN O
replacement NN NN O
therapy NN NN O
appear NN NN O
to NN NN O
have NN NN O
benefited NN NN O
from NN NN O
use NN NN O
of NN NN O
tamoxifen NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
deaths NN NN O
from NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
recorded NN NN O
in NN NN O
women NN NN O
in NN NN O
the NN NN O
study NN NN O
. NN NN O
   
It NN NN O
is NN NN O
essential NN NN O
to NN NN O
continue NN NN O
follow NN NN O
- NN NN O
up NN NN O
to NN NN O
quantify NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
risks NN NN O
and NN NN O
benefits NN NN O
of NN NN O
tamoxifen NN NN O
therapy NN NN O
. NN NN O
   
Epileptogenic NN NN O
activity NN NN O
of NN NN O
folic NN NN O
acid NN NN O
after NN NN O
drug NN NN O
induces NN NN O
SLE NN NN B-Disease
( NN NN O
folic NN NN O
acid NN NN O
and NN NN O
epilepsy NN NN B-Disease
) NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
study NN NN O
the NN NN O
effect NN NN O
of NN NN O
folic NN NN O
acid NN NN O
- NN NN O
containing NN NN O
multivitamin NN NN O
supplementation NN NN O
in NN NN O
epileptic NN NN B-Disease
women NN NN O
before NN NN O
and NN NN O
during NN NN O
pregnancy NN NN O
in NN NN O
order NN NN O
to NN NN O
determine NN NN O
the NN NN O
rate NN NN O
of NN NN O
structural NN NN O
birth NN NN B-Disease
defects NN NN I-Disease
and NN NN O
epilepsy NN NN B-Disease
- NN NN O
related NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
STUDY NN NN O
DESIGN NN NN O
: NN NN O
First NN NN O
a NN NN O
randomised NN NN O
trial NN NN O
, NN NN O
later NN NN O
periconception NN NN O
care NN NN O
including NN NN O
in NN NN O
total NN NN O
12225 NN NN O
females NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Of NN NN O
60 NN NN O
epileptic NN NN B-Disease
women NN NN O
with NN NN O
periconceptional NN NN O
folic NN NN O
acid NN NN O
( NN NN O
0 NN NN O
. NN NN O
8 NN NN O
mg NN NN O
) NN NN O
- NN NN O
containing NN NN O
multivitamin NN NN O
supplementation NN NN O
, NN NN O
no NN NN O
one NN NN O
developed NN NN O
epilepsy NN NN B-Disease
- NN NN O
related NN NN O
side NN NN O
effects NN NN O
during NN NN O
the NN NN O
periconception NN NN O
period NN NN O
. NN NN O
   
One NN NN O
epileptic NN NN B-Disease
woman NN NN O
delivered NN NN O
a NN NN O
newborn NN NN O
with NN NN O
cleft NN NN B-Disease
lip NN NN I-Disease
and NN NN I-Disease
palate NN NN I-Disease
. NN NN O
   
Another NN NN O
patient NN NN O
exhibited NN NN O
with NN NN O
a NN NN O
cluster NN NN O
of NN NN O
seizures NN NN B-Disease
after NN NN O
the NN NN O
periconception NN NN O
period NN NN O
using NN NN O
another NN NN O
multivitamin NN NN O
. NN NN O
   
This NN NN O
22 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
epileptic NN NN B-Disease
woman NN NN O
was NN NN O
treated NN NN O
continuously NN NN O
by NN NN O
carbamazepine NN NN O
and NN NN O
a NN NN O
folic NN NN O
acid NN NN O
( NN NN O
1 NN NN O
mg NN NN O
) NN NN O
- NN NN O
containing NN NN O
multivitamin NN NN O
from NN NN O
the NN NN O
20th NN NN O
week NN NN O
of NN NN O
gestation NN NN O
. NN NN O
   
She NN NN O
developed NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
and NN NN O
later NN NN O
symptoms NN NN O
of NN NN O
systemic NN NN B-Disease
lupus NN NN I-Disease
erythematodes NN NN I-Disease
. NN NN O
   
Her NN NN O
pregnancy NN NN O
ended NN NN O
with NN NN O
stillbirth NN NN B-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
epileptic NN NN B-Disease
pregnant NN NN O
patient NN NN O
' NN NN O
s NN NN O
autoimmune NN NN B-Disease
disease NN NN I-Disease
( NN NN O
probably NN NN O
drug NN NN O
- NN NN O
induced NN NN O
lupus NN NN B-Disease
) NN NN O
could NN NN O
damage NN NN O
the NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
, NN NN O
therefore NN NN O
the NN NN O
therapeutic NN NN O
dose NN NN O
( NN NN O
> NN NN O
or NN NN O
= NN NN O
1 NN NN O
mg NN NN O
) NN NN O
of NN NN O
folic NN NN O
acid NN NN O
triggered NN NN O
a NN NN O
cluster NN NN O
of NN NN O
seizures NN NN B-Disease
. NN NN O
   
Physiological NN NN O
dose NN NN O
( NN NN O
< NN NN O
1 NN NN O
mg NN NN O
) NN NN O
of NN NN O
folic NN NN O
acid NN NN O
both NN NN O
in NN NN O
healthy NN NN O
and NN NN O
60 NN NN O
epileptic NN NN B-Disease
women NN NN O
, NN NN O
all NN NN O
without NN NN O
any NN NN O
autoimmune NN NN B-Disease
disease NN NN I-Disease
, NN NN O
did NN NN O
not NN NN O
increase NN NN O
the NN NN O
risk NN NN O
for NN NN O
epileptic NN NN B-Disease
seizures NN NN I-Disease
. NN NN O
   
Stroke NN NN B-Disease
and NN NN O
cocaine NN NN O
or NN NN O
amphetamine NN NN O
use NN NN O
. NN NN O
   
The NN NN O
association NN NN O
of NN NN O
cocaine NN NN O
and NN NN O
amphetamine NN NN O
use NN NN O
with NN NN O
hemorrhagic NN NN O
and NN NN O
ischemic NN NN B-Disease
stroke NN NN B-Disease
is NN NN O
based NN NN O
almost NN NN O
solely NN NN O
on NN NN O
data NN NN O
from NN NN O
case NN NN O
series NN NN O
. NN NN O
   
The NN NN O
limited NN NN O
number NN NN O
of NN NN O
epidemiologic NN NN O
studies NN NN O
of NN NN O
stroke NN NN B-Disease
and NN NN O
use NN NN O
of NN NN O
cocaine NN NN O
and NN NN O
/ NN NN O
or NN NN O
amphetamine NN NN O
have NN NN O
been NN NN O
done NN NN O
in NN NN O
settings NN NN O
that NN NN O
serve NN NN O
mostly NN NN O
the NN NN O
poor NN NN O
and NN NN O
/ NN NN O
or NN NN O
minorities NN NN O
. NN NN O
   
This NN NN O
case NN NN O
- NN NN O
control NN NN O
study NN NN O
was NN NN O
conducted NN NN O
in NN NN O
the NN NN O
defined NN NN O
population NN NN O
comprising NN NN O
members NN NN O
of NN NN O
Kaiser NN NN O
Permanente NN NN O
of NN NN O
Northern NN NN O
and NN NN O
Southern NN NN O
California NN NN O
. NN NN O
   
We NN NN O
attempted NN NN O
to NN NN O
identify NN NN O
all NN NN O
incident NN NN O
strokes NN NN B-Disease
in NN NN O
women NN NN O
ages NN NN O
15 NN NN O
- NN NN O
44 NN NN O
years NN NN O
during NN NN O
a NN NN O
3 NN NN O
- NN NN O
year NN NN O
period NN NN O
using NN NN O
hospital NN NN O
admission NN NN O
and NN NN O
discharge NN NN O
records NN NN O
, NN NN O
emergency NN NN O
department NN NN O
logs NN NN O
, NN NN O
and NN NN O
payment NN NN O
requests NN NN O
for NN NN O
out NN NN O
- NN NN O
of NN NN O
- NN NN O
plan NN NN O
hospitalizations NN NN O
. NN NN O
   
We NN NN O
selected NN NN O
controls NN NN O
, NN NN O
matched NN NN O
on NN NN O
age NN NN O
and NN NN O
facility NN NN O
of NN NN O
usual NN NN O
care NN NN O
, NN NN O
at NN NN O
random NN NN O
from NN NN O
healthy NN NN O
members NN NN O
of NN NN O
the NN NN O
health NN NN O
plan NN NN O
. NN NN O
   
We NN NN O
obtained NN NN O
information NN NN O
in NN NN O
face NN NN O
- NN NN O
to NN NN O
- NN NN O
face NN NN O
interviews NN NN O
. NN NN O
   
There NN NN O
were NN NN O
347 NN NN O
confirmed NN NN O
stroke NN NN B-Disease
cases NN NN O
and NN NN O
1 NN NN O
, NN NN O
021 NN NN O
controls NN NN O
. NN NN O
   
The NN NN O
univariate NN NN O
matched NN NN O
odds NN NN O
ratio NN NN O
for NN NN O
stroke NN NN B-Disease
in NN NN O
women NN NN O
who NN NN O
admitted NN NN O
to NN NN O
using NN NN O
cocaine NN NN O
and NN NN O
/ NN NN O
or NN NN O
amphetamine NN NN O
was NN NN O
8 NN NN O
. NN NN O
5 NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
= NN NN O
3 NN NN O
. NN NN O
6 NN NN O
- NN NN O
20 NN NN O
. NN NN O
0 NN NN O
) NN NN O
. NN NN O
   
After NN NN O
further NN NN O
adjustment NN NN O
for NN NN O
potential NN NN O
confounders NN NN O
, NN NN O
the NN NN O
odds NN NN O
ratio NN NN O
in NN NN O
women NN NN O
who NN NN O
reported NN NN O
using NN NN O
cocaine NN NN O
and NN NN O
/ NN NN O
or NN NN O
amphetamine NN NN O
was NN NN O
7 NN NN O
. NN NN O
0 NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
= NN NN O
2 NN NN O
. NN NN O
8 NN NN O
- NN NN O
17 NN NN O
. NN NN O
9 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
use NN NN O
of NN NN O
cocaine NN NN O
and NN NN O
/ NN NN O
or NN NN O
amphetamine NN NN O
is NN NN O
a NN NN O
strong NN NN O
risk NN NN O
factor NN NN O
for NN NN O
stroke NN NN B-Disease
in NN NN O
this NN NN O
socioeconomically NN NN O
heterogeneous NN NN O
, NN NN O
insured NN NN O
urban NN NN O
population NN NN O
. NN NN O
   
Acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
subsequent NN NN O
to NN NN O
the NN NN O
administration NN NN O
of NN NN O
rifampicin NN NN O
. NN NN O
   
A NN NN O
follow NN NN O
- NN NN O
up NN NN O
study NN NN O
of NN NN O
cases NN NN O
reported NN NN O
earlier NN NN O
. NN NN O
   
A NN NN O
clinical NN NN O
presentation NN NN O
is NN NN O
made NN NN O
of NN NN O
a NN NN O
2 NN NN O
- NN NN O
3 NN NN O
year NN NN O
follow NN NN O
- NN NN O
up NN NN O
of NN NN O
six NN NN O
cases NN NN O
of NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
that NN NN O
have NN NN O
been NN NN O
reported NN NN O
earlier NN NN O
. NN NN O
   
The NN NN O
patients NN NN O
had NN NN O
developed NN NN O
transient NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
after NN NN O
the NN NN O
intermittent NN NN O
administration NN NN O
of NN NN O
rifampicin NN NN O
. NN NN O
   
The NN NN O
stage NN NN O
of NN NN O
olig NN NN O
- NN NN O
anuria NN NN B-Disease
lasted NN NN O
for NN NN O
1 NN NN O
- NN NN O
3 NN NN O
weeks NN NN O
, NN NN O
and NN NN O
five NN NN O
of NN NN O
the NN NN O
patients NN NN O
were NN NN O
treated NN NN O
by NN NN O
hemodialysis NN NN O
. NN NN O
   
Two NN NN O
of NN NN O
the NN NN O
patients NN NN O
died NN NN O
due NN NN O
to NN NN O
unrelated NN NN O
causes NN NN O
during NN NN O
the NN NN O
follow NN NN O
- NN NN O
up NN NN O
period NN NN O
. NN NN O
   
The NN NN O
four NN NN O
patients NN NN O
re NN NN O
- NN NN O
examined NN NN O
were NN NN O
clinically NN NN O
cured NN NN O
. NN NN O
   
Pathologic NN NN O
findings NN NN O
by NN NN O
light NN NN O
microscopy NN NN O
and NN NN O
immunofluorescence NN NN O
at NN NN O
biopsy NN NN O
were NN NN O
scarce NN NN O
. NN NN O
   
Nothing NN NN O
abnormal NN NN O
was NN NN O
seen NN NN O
by NN NN O
electron NN NN O
microscopy NN NN O
in NN NN O
two NN NN O
of NN NN O
the NN NN O
cases NN NN O
studied NN NN O
. NN NN O
   
Renal NN NN O
function NN NN O
was NN NN O
normal NN NN O
. NN NN O
   
In NN NN O
three NN NN O
cases NN NN O
the NN NN O
excretion NN NN O
at NN NN O
131I NN NN O
- NN NN O
hippuran NN NN O
renography NN NN O
was NN NN O
slightly NN NN O
slowed NN NN O
. NN NN O
   
Although NN NN O
in NN NN O
the NN NN O
acute NN NN O
stage NN NN O
the NN NN O
renal NN NN B-Disease
lesions NN NN I-Disease
histologically NN NN O
appeared NN NN O
toxic NN NN O
, NN NN O
evidence NN NN O
suggestive NN NN O
of NN NN O
an NN NN O
immunological NN NN O
mechanism NN NN O
cannot NN NN O
be NN NN O
excluded NN NN O
. NN NN O
   
Chronic NN NN O
effects NN NN O
of NN NN O
a NN NN O
novel NN NN O
synthetic NN NN O
anthracycline NN NN O
derivative NN NN O
( NN NN O
SM NN NN O
- NN NN O
5887 NN NN O
) NN NN O
on NN NN O
normal NN NN O
heart NN NN O
and NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
cardiomyopathy NN NN B-Disease
in NN NN O
beagle NN NN O
dogs NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
investigate NN NN O
the NN NN O
chronic NN NN O
cardiotoxic NN NN B-Disease
potential NN NN O
of NN NN O
SM NN NN O
- NN NN O
5887 NN NN O
and NN NN O
a NN NN O
possible NN NN O
deteriorating NN NN O
effect NN NN O
of NN NN O
SM NN NN O
- NN NN O
5887 NN NN O
on NN NN O
low NN NN O
- NN NN O
grade NN NN O
cardiotoxicity NN NN B-Disease
pre NN NN O
- NN NN O
induced NN NN O
by NN NN O
doxorubicin NN NN O
in NN NN O
beagle NN NN O
dogs NN NN O
. NN NN O
   
In NN NN O
the NN NN O
chronic NN NN O
treatment NN NN O
, NN NN O
beagle NN NN O
dogs NN NN O
of NN NN O
each NN NN O
sex NN NN O
were NN NN O
given NN NN O
intravenously NN NN O
once NN NN O
every NN NN O
3 NN NN O
weeks NN NN O
, NN NN O
either NN NN O
a NN NN O
sublethal NN NN O
dose NN NN O
of NN NN O
doxorubicin NN NN O
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
or NN NN O
SM NN NN O
- NN NN O
5887 NN NN O
( NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
. NN NN O
   
The NN NN O
experiment NN NN O
was NN NN O
terminated NN NN O
3 NN NN O
weeks NN NN O
after NN NN O
the NN NN O
ninth NN NN O
dosing NN NN O
. NN NN O
   
Animals NN NN O
which NN NN O
received NN NN O
over NN NN O
six NN NN O
courses NN NN O
of NN NN O
doxorubicin NN NN O
demonstrated NN NN O
the NN NN O
electrocardiogram NN NN O
( NN NN O
ECG NN NN O
) NN NN O
changes NN NN O
, NN NN O
decrease NN NN O
of NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
high NN NN O
- NN NN O
grade NN NN O
histopathological NN NN O
cardiomyopathy NN NN B-Disease
, NN NN O
while NN NN O
animals NN NN O
which NN NN O
were NN NN O
terminally NN NN O
sacrificed NN NN O
after NN NN O
the NN NN O
SM NN NN O
- NN NN O
5887 NN NN O
administration NN NN O
did NN NN O
not NN NN O
show NN NN O
any NN NN O
changes NN NN O
in NN NN O
ECG NN NN O
, NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
histopathological NN NN O
examinations NN NN O
. NN NN O
   
To NN NN O
examine NN NN O
a NN NN O
possibly NN NN O
deteriorating NN NN O
cardiotoxic NN NN B-Disease
effect NN NN O
of NN NN O
SM NN NN O
- NN NN O
5887 NN NN O
, NN NN O
low NN NN O
- NN NN O
grade NN NN O
cardiomyopathy NN NN B-Disease
was NN NN O
induced NN NN O
in NN NN O
dogs NN NN O
by NN NN O
four NN NN O
courses NN NN O
of NN NN O
doxorubicin NN NN O
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
. NN NN O
   
Nine NN NN O
weeks NN NN O
after NN NN O
pre NN NN O
- NN NN O
treatment NN NN O
, NN NN O
dogs NN NN O
were NN NN O
given NN NN O
four NN NN O
courses NN NN O
of NN NN O
either NN NN O
doxorubicin NN NN O
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
or NN NN O
SM NN NN O
- NN NN O
5887 NN NN O
( NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
once NN NN O
every NN NN O
3 NN NN O
weeks NN NN O
. NN NN O
   
The NN NN O
low NN NN O
- NN NN O
grade NN NN O
cardiotoxic NN NN B-Disease
changes NN NN O
were NN NN O
enhanced NN NN O
by NN NN O
the NN NN O
additional NN NN O
doxorubicin NN NN O
treatment NN NN O
. NN NN O
   
On NN NN O
the NN NN O
contrary NN NN O
, NN NN O
the NN NN O
SM NN NN O
- NN NN O
5887 NN NN O
treatment NN NN O
did NN NN O
not NN NN O
progress NN NN O
the NN NN O
grade NN NN O
of NN NN O
cardiomyopathy NN NN B-Disease
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
SM NN NN O
- NN NN O
5887 NN NN O
does NN NN O
not NN NN O
have NN NN O
any NN NN O
potential NN NN O
of NN NN O
chronic NN NN O
cardiotoxicity NN NN B-Disease
and NN NN O
deteriorating NN NN O
effect NN NN O
on NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
in NN NN O
dogs NN NN O
. NN NN O
   
Risk NN NN O
for NN NN O
valvular NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
among NN NN O
users NN NN O
of NN NN O
fenfluramine NN NN O
and NN NN O
dexfenfluramine NN NN O
who NN NN O
underwent NN NN O
echocardiography NN NN O
before NN NN O
use NN NN O
of NN NN O
medication NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Because NN NN O
uncontrolled NN NN O
echocardiographic NN NN O
surveys NN NN O
suggested NN NN O
that NN NN O
up NN NN O
to NN NN O
30 NN NN O
% NN NN O
to NN NN O
38 NN NN O
% NN NN O
of NN NN O
users NN NN O
of NN NN O
fenfluramine NN NN O
and NN NN O
dexfenfluramine NN NN O
had NN NN O
valvular NN NN B-Disease
disease NN NN I-Disease
, NN NN O
these NN NN O
drugs NN NN O
were NN NN O
withdrawn NN NN O
from NN NN O
the NN NN O
market NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
determine NN NN O
the NN NN O
risk NN NN O
for NN NN O
new NN NN O
or NN NN O
worsening NN NN O
valvular NN NN B-Disease
abnormalities NN NN I-Disease
among NN NN O
users NN NN O
of NN NN O
fenfluramine NN NN O
or NN NN O
dexfenfluramine NN NN O
who NN NN O
underwent NN NN O
echocardiography NN NN O
before NN NN O
they NN NN O
began NN NN O
to NN NN O
take NN NN O
these NN NN O
medications NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
Cohort NN NN O
study NN NN O
. NN NN O
   
SETTING NN NN O
: NN NN O
Academic NN NN O
primary NN NN O
care NN NN O
practices NN NN O
. NN NN O
   
PATIENTS NN NN O
: NN NN O
46 NN NN O
patients NN NN O
who NN NN O
used NN NN O
fenfluramine NN NN O
or NN NN O
dexfenfluramine NN NN O
for NN NN O
14 NN NN O
days NN NN O
or NN NN O
more NN NN O
and NN NN O
had NN NN O
echocardiograms NN NN O
obtained NN NN O
before NN NN O
therapy NN NN O
. NN NN O
   
MEASUREMENTS NN NN O
: NN NN O
Follow NN NN O
- NN NN O
up NN NN O
echocardiography NN NN O
. NN NN O
   
The NN NN O
primary NN NN O
outcome NN NN O
was NN NN O
new NN NN O
or NN NN O
worsening NN NN O
valvulopathy NN NN B-Disease
, NN NN O
defined NN NN O
as NN NN O
progression NN NN O
of NN NN O
either NN NN O
aortic NN NN B-Disease
or NN NN I-Disease
mitral NN NN I-Disease
regurgitation NN NN I-Disease
by NN NN O
at NN NN O
least NN NN O
one NN NN O
degree NN NN O
of NN NN O
severity NN NN O
and NN NN O
disease NN NN O
that NN NN O
met NN NN O
U NN NN O
. NN NN O
S NN NN O
. NN NN O
   
Food NN NN O
and NN NN O
Drug NN NN O
Administration NN NN O
criteria NN NN O
( NN NN O
at NN NN O
least NN NN O
mild NN NN O
aortic NN NN B-Disease
regurgitation NN NN I-Disease
or NN NN O
moderate NN NN O
mitral NN NN B-Disease
regurgitation NN NN I-Disease
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Two NN NN O
patients NN NN O
( NN NN O
4 NN NN O
. NN NN O
3 NN NN O
% NN NN O
[ NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
0 NN NN O
. NN NN O
6 NN NN O
% NN NN O
to NN NN O
14 NN NN O
. NN NN O
8 NN NN O
% NN NN O
] NN NN O
) NN NN O
receiving NN NN O
fenfluramine NN NN O
- NN NN O
phentermine NN NN O
developed NN NN O
valvular NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
One NN NN O
had NN NN O
baseline NN NN O
bicuspid NN NN B-Disease
aortic NN NN I-Disease
valve NN NN I-Disease
and NN NN O
mild NN NN O
aortic NN NN B-Disease
regurgitation NN NN I-Disease
that NN NN O
progressed NN NN O
to NN NN O
moderate NN NN O
regurgitation NN NN O
. NN NN O
   
The NN NN O
second NN NN O
patient NN NN O
developed NN NN O
new NN NN O
moderate NN NN O
aortic NN NN B-Disease
insufficiency NN NN I-Disease
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Users NN NN O
of NN NN O
diet NN NN O
medications NN NN O
are NN NN O
at NN NN O
risk NN NN O
for NN NN O
valvular NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
incidence NN NN O
may NN NN O
be NN NN O
lower NN NN O
than NN NN O
that NN NN O
reported NN NN O
previously NN NN O
. NN NN O
   
Therapeutic NN NN O
drug NN NN O
monitoring NN NN O
of NN NN O
tobramycin NN NN O
: NN NN O
once NN NN O
- NN NN O
daily NN NN O
versus NN NN O
twice NN NN O
- NN NN O
daily NN NN O
dosage NN NN O
schedules NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
evaluate NN NN O
the NN NN O
effect NN NN O
of NN NN O
dosage NN NN O
regimen NN NN O
( NN NN O
once NN NN O
- NN NN O
daily NN NN O
vs NN NN O
. NN NN O
twice NN NN O
- NN NN O
daily NN NN O
) NN NN O
of NN NN O
tobramicyn NN NN O
on NN NN O
steady NN NN O
- NN NN O
state NN NN O
serum NN NN O
concentrations NN NN O
and NN NN O
toxicity NN NN B-Disease
. NN NN O
   
MATERIALS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
Patients NN NN O
undergoing NN NN O
treatment NN NN O
with NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
tobramycin NN NN O
( NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
) NN NN O
were NN NN O
randomised NN NN O
to NN NN O
two NN NN O
groups NN NN O
. NN NN O
   
Group NN NN O
OD NN NN O
( NN NN O
n NN NN O
= NN NN O
22 NN NN O
) NN NN O
received NN NN O
a NN NN O
once NN NN O
- NN NN O
daily NN NN O
dose NN NN O
of NN NN O
tobramycin NN NN O
and NN NN O
group NN NN O
TD NN NN O
( NN NN O
n NN NN O
= NN NN O
21 NN NN O
) NN NN O
received NN NN O
the NN NN O
same NN NN O
dose NN NN O
divided NN NN O
into NN NN O
two NN NN O
doses NN NN O
daily NN NN O
. NN NN O
   
Tobramycin NN NN O
serum NN NN O
concentrations NN NN O
( NN NN O
peak NN NN O
and NN NN O
trough NN NN O
) NN NN O
were NN NN O
measured NN NN O
by NN NN O
enzyme NN NN O
multiplied NN NN O
immunoassay NN NN O
. NN NN O
   
The NN NN O
renal NN NN O
and NN NN O
auditory NN NN O
functions NN NN O
of NN NN O
the NN NN O
patients NN NN O
were NN NN O
monitored NN NN O
before NN NN O
, NN NN O
during NN NN O
and NN NN O
immediately NN NN O
after NN NN O
treatment NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
two NN NN O
groups NN NN O
were NN NN O
comparable NN NN O
with NN NN O
respect NN NN O
to NN NN O
sex NN NN O
, NN NN O
age NN NN O
, NN NN O
body NN NN O
weight NN NN O
and NN NN O
renal NN NN O
function NN NN O
. NN NN O
   
No NN NN O
statistically NN NN O
significant NN NN O
differences NN NN O
were NN NN O
found NN NN O
in NN NN O
mean NN NN O
daily NN NN O
dose NN NN O
, NN NN O
duration NN NN O
of NN NN O
treatment NN NN O
, NN NN O
or NN NN O
cumulative NN NN O
dose NN NN O
. NN NN O
   
Trough NN NN O
concentrations NN NN O
were NN NN O
< NN NN O
2 NN NN O
g NN NN O
/ NN NN O
ml NN NN O
in NN NN O
the NN NN O
two NN NN O
groups NN NN O
( NN NN O
100 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Peak NN NN O
concentrations NN NN O
were NN NN O
> NN NN O
6 NN NN O
microg NN NN O
/ NN NN O
ml NN NN O
in NN NN O
100 NN NN O
% NN NN O
of NN NN O
the NN NN O
OD NN NN O
group NN NN O
and NN NN O
in NN NN O
67 NN NN O
% NN NN O
of NN NN O
the NN NN O
TD NN NN O
group NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Mean NN NN O
peak NN NN O
concentrations NN NN O
were NN NN O
markedly NN NN O
different NN NN O
: NN NN O
11 NN NN O
. NN NN O
00 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
89 NN NN O
microg NN NN O
/ NN NN O
ml NN NN O
in NN NN O
OD NN NN O
vs NN NN O
. NN NN O
6 NN NN O
. NN NN O
53 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
45 NN NN O
microg NN NN O
/ NN NN O
ml NN NN O
in NN NN O
TD NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
pharmacokinetics NN NN O
parameters NN NN O
were NN NN O
: NN NN O
Ke NN NN O
, NN NN O
( NN NN O
0 NN NN O
. NN NN O
15 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
03 NN NN O
/ NN NN O
h NN NN O
in NN NN O
OD NN NN O
vs NN NN O
. NN NN O
0 NN NN O
. NN NN O
24 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
06 NN NN O
/ NN NN O
h NN NN O
in NN NN O
TD NN NN O
) NN NN O
, NN NN O
t1 NN NN O
/ NN NN O
2 NN NN O
, NN NN O
( NN NN O
4 NN NN O
. NN NN O
95 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
41 NN NN O
h NN NN O
in NN NN O
OD NN NN O
vs NN NN O
. NN NN O
3 NN NN O
. NN NN O
07 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
71 NN NN O
h NN NN O
in NN NN O
TD NN NN O
) NN NN O
, NN NN O
Vd NN NN O
( NN NN O
0 NN NN O
. NN NN O
35 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
11 NN NN O
l NN NN O
/ NN NN O
kg NN NN O
in NN NN O
OD NN NN O
vs NN NN O
. NN NN O
0 NN NN O
. NN NN O
33 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
09 NN NN O
l NN NN O
/ NN NN O
kg NN NN O
in NN NN O
TD NN NN O
) NN NN O
, NN NN O
Cl NN NN O
( NN NN O
0 NN NN O
. NN NN O
86 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
29 NN NN O
ml NN NN O
/ NN NN O
min NN NN O
/ NN NN O
kg NN NN O
in NN NN O
OD NN NN O
vs NN NN O
. NN NN O
1 NN NN O
. NN NN O
28 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
33 NN NN O
ml NN NN O
/ NN NN O
min NN NN O
/ NN NN O
kg NN NN O
in NN NN O
TD NN NN O
) NN NN O
. NN NN O
   
Increased NN NN O
serum NN NN O
creatinine NN NN O
was NN NN O
observed NN NN O
in NN NN O
73 NN NN O
% NN NN O
of NN NN O
patients NN NN O
in NN NN O
OD NN NN O
versus NN NN O
57 NN NN O
% NN NN O
of NN NN O
patients NN NN O
in NN NN O
TD NN NN O
, NN NN O
without NN NN O
evidence NN NN O
of NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
In NN NN O
TD NN NN O
group NN NN O
, NN NN O
three NN NN O
patients NN NN O
developed NN NN O
decreased NN NN B-Disease
auditory NN NN I-Disease
function NN NN I-Disease
, NN NN O
of NN NN O
which NN NN O
one NN NN O
presented NN NN O
with NN NN O
an NN NN O
auditory NN NN B-Disease
loss NN NN I-Disease
of NN NN O
- NN NN O
30 NN NN O
dB NN NN O
, NN NN O
whereas NN NN O
in NN NN O
the NN NN O
OD NN NN O
group NN NN O
only NN NN O
one NN NN O
patient NN NN O
presented NN NN O
decreased NN NN B-Disease
auditory NN NN I-Disease
function NN NN I-Disease
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
This NN NN O
small NN NN O
study NN NN O
suggests NN NN O
that NN NN O
a NN NN O
once NN NN O
- NN NN O
daily NN NN O
dosing NN NN O
regimen NN NN O
of NN NN O
tobramycin NN NN O
is NN NN O
at NN NN O
least NN NN O
as NN NN O
effective NN NN O
as NN NN O
and NN NN O
is NN NN O
no NN NN O
more NN NN O
and NN NN O
possibly NN NN O
less NN NN O
toxic NN NN O
than NN NN O
the NN NN O
twice NN NN O
- NN NN O
daily NN NN O
regimen NN NN O
. NN NN O
   
Using NN NN O
a NN NN O
single NN NN O
- NN NN O
dose NN NN O
therapy NN NN O
, NN NN O
peak NN NN O
concentration NN NN O
determination NN NN O
is NN NN O
not NN NN O
necessary NN NN O
, NN NN O
only NN NN O
trough NN NN O
samples NN NN O
should NN NN O
be NN NN O
monitored NN NN O
to NN NN O
ensure NN NN O
levels NN NN O
below NN NN O
2 NN NN O
microg NN NN O
/ NN NN O
ml NN NN O
. NN NN O
   
Enhanced NN NN O
bradycardia NN NN B-Disease
induced NN NN O
by NN NN O
beta NN NN O
- NN NN O
adrenoceptor NN NN O
antagonists NN NN O
in NN NN O
rats NN NN O
pretreated NN NN O
with NN NN O
isoniazid NN NN O
. NN NN O
   
High NN NN O
doses NN NN O
of NN NN O
isoniazid NN NN O
increase NN NN O
hypotension NN NN B-Disease
induced NN NN O
by NN NN O
vasodilators NN NN O
and NN NN O
change NN NN O
the NN NN O
accompanying NN NN O
reflex NN NN O
tachycardia NN NN B-Disease
to NN NN O
bradycardia NN NN B-Disease
, NN NN O
an NN NN O
interaction NN NN O
attributed NN NN O
to NN NN O
decreased NN NN O
synthesis NN NN O
of NN NN O
brain NN NN O
gamma NN NN O
- NN NN O
aminobutyric NN NN O
acid NN NN O
( NN NN O
GABA NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
the NN NN O
possible NN NN O
enhancement NN NN O
by NN NN O
isoniazid NN NN O
of NN NN O
bradycardia NN NN B-Disease
induced NN NN O
by NN NN O
beta NN NN O
- NN NN O
adrenoceptor NN NN O
antagonists NN NN O
was NN NN O
determined NN NN O
in NN NN O
rats NN NN O
anaesthetised NN NN O
with NN NN O
chloralose NN NN O
- NN NN O
urethane NN NN O
. NN NN O
   
Isoniazid NN NN O
significantly NN NN O
increased NN NN O
bradycardia NN NN B-Disease
after NN NN O
propranolol NN NN O
, NN NN O
pindolol NN NN O
, NN NN O
labetalol NN NN O
and NN NN O
atenolol NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
after NN NN O
clonidine NN NN O
, NN NN O
but NN NN O
not NN NN O
after NN NN O
hexamethonium NN NN O
or NN NN O
carbachol NN NN O
. NN NN O
   
Enhancement NN NN O
was NN NN O
not NN NN O
observed NN NN O
in NN NN O
rats NN NN O
pretreated NN NN O
with NN NN O
methylatropine NN NN O
or NN NN O
previously NN NN O
vagotomised NN NN O
. NN NN O
   
These NN NN O
results NN NN O
are NN NN O
compatible NN NN O
with NN NN O
interference NN NN O
by NN NN O
isoniazid NN NN O
with NN NN O
GABAergic NN NN O
inhibition NN NN O
of NN NN O
cardiac NN NN O
parasympathetic NN NN O
tone NN NN O
. NN NN O
   
Such NN NN O
interference NN NN O
could NN NN O
be NN NN O
exerted NN NN O
centrally NN NN O
, NN NN O
possibly NN NN O
at NN NN O
the NN NN O
nucleus NN NN O
ambiguus NN NN O
, NN NN O
or NN NN O
peripherally NN NN O
at NN NN O
the NN NN O
sinus NN NN O
node NN NN O
. NN NN O
   
Structural NN NN B-Disease
and NN NN I-Disease
functional NN NN I-Disease
impairment NN NN I-Disease
of NN NN I-Disease
mitochondria NN NN I-Disease
in NN NN O
adriamycin NN NN O
- NN NN O
induced NN NN O
cardiomyopathy NN NN B-Disease
in NN NN O
mice NN NN O
: NN NN O
suppression NN NN O
of NN NN O
cytochrome NN NN O
c NN NN O
oxidase NN NN O
II NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
The NN NN O
use NN NN O
of NN NN O
adriamycin NN NN O
( NN NN O
ADR NN NN O
) NN NN O
in NN NN O
cancer NN NN B-Disease
chemotherapy NN NN O
has NN NN O
been NN NN O
limited NN NN O
due NN NN O
to NN NN O
its NN NN O
cumulative NN NN O
cardiovascular NN NN B-Disease
toxicity NN NN I-Disease
. NN NN O
   
Earlier NN NN O
observations NN NN O
that NN NN O
ADR NN NN O
interacts NN NN O
with NN NN O
mitochondrial NN NN O
cytochrome NN NN O
c NN NN O
oxidase NN NN O
( NN NN O
COX NN NN O
) NN NN O
and NN NN O
suppresses NN NN O
its NN NN O
enzyme NN NN O
activity NN NN O
led NN NN O
us NN NN O
to NN NN O
investigate NN NN O
ADR NN NN O
' NN NN O
s NN NN O
action NN NN O
on NN NN O
the NN NN O
cardiovascular NN NN O
functions NN NN O
and NN NN O
heart NN NN O
mitochondrial NN NN O
morphology NN NN O
in NN NN O
Balb NN NN O
- NN NN O
c NN NN O
mice NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
treated NN NN O
with NN NN O
ADR NN NN O
for NN NN O
several NN NN O
weeks NN NN O
. NN NN O
   
At NN NN O
various NN NN O
times NN NN O
during NN NN O
treatment NN NN O
, NN NN O
the NN NN O
animals NN NN O
were NN NN O
assessed NN NN O
for NN NN O
cardiovascular NN NN O
functions NN NN O
by NN NN O
electrocardiography NN NN O
and NN NN O
for NN NN O
heart NN NN O
tissue NN NN O
damage NN NN O
by NN NN O
electron NN NN O
microscopy NN NN O
. NN NN O
   
In NN NN O
parallel NN NN O
, NN NN O
total NN NN O
RNA NN NN O
was NN NN O
extracted NN NN O
from NN NN O
samples NN NN O
of NN NN O
dissected NN NN O
heart NN NN O
and NN NN O
analyzed NN NN O
by NN NN O
Northern NN NN O
blot NN NN O
hybridization NN NN O
to NN NN O
determine NN NN O
the NN NN O
steady NN NN O
- NN NN O
state NN NN O
level NN NN O
of NN NN O
three NN NN O
RNA NN NN O
transcripts NN NN O
encoded NN NN O
by NN NN O
the NN NN O
COXII NN NN O
, NN NN O
COXIII NN NN O
, NN NN O
and NN NN O
COXIV NN NN O
genes NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
samples NN NN O
obtained NN NN O
from NN NN O
the NN NN O
liver NN NN O
of NN NN O
the NN NN O
same NN NN O
animals NN NN O
were NN NN O
analyzed NN NN O
for NN NN O
comparative NN NN O
studies NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
indicated NN NN O
that NN NN O
1 NN NN O
) NN NN O
treatment NN NN O
of NN NN O
mice NN NN O
with NN NN O
ADR NN NN O
caused NN NN O
cardiovascular NN NN B-Disease
arrhythmias NN NN I-Disease
characterized NN NN O
by NN NN O
bradycardia NN NN B-Disease
, NN NN O
extension NN NN O
of NN NN O
ventricular NN NN O
depolarization NN NN O
time NN NN O
( NN NN O
tQRS NN NN O
) NN NN O
, NN NN O
and NN NN O
failure NN NN O
of NN NN O
QRS NN NN O
at NN NN O
high NN NN O
concentrations NN NN O
( NN NN O
10 NN NN O
- NN NN O
14 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
cumulative NN NN O
dose NN NN O
) NN NN O
; NN NN O
2 NN NN O
) NN NN O
the NN NN O
heart NN NN O
mitochondria NN NN O
underwent NN NN O
swelling NN NN B-Disease
, NN NN O
fusion NN NN O
, NN NN O
dissolution NN NN O
, NN NN O
and NN NN O
/ NN NN O
or NN NN O
disruption NN NN O
of NN NN O
mitochondrial NN NN O
cristae NN NN O
after NN NN O
several NN NN O
weeks NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
Such NN NN O
abnormalities NN NN O
were NN NN O
not NN NN O
observed NN NN O
in NN NN O
the NN NN O
mitochondria NN NN O
of NN NN O
liver NN NN O
tissue NN NN O
; NN NN O
and NN NN O
3 NN NN O
) NN NN O
among NN NN O
the NN NN O
three NN NN O
genes NN NN O
of NN NN O
COX NN NN O
enzyme NN NN O
examined NN NN O
, NN NN O
only NN NN O
COXII NN NN O
gene NN NN O
expression NN NN O
was NN NN O
suppressed NN NN O
by NN NN O
ADR NN NN O
treatment NN NN O
, NN NN O
mainly NN NN O
after NN NN O
8 NN NN O
weeks NN NN O
in NN NN O
both NN NN O
heart NN NN O
and NN NN O
liver NN NN O
. NN NN O
   
Knowing NN NN O
that NN NN O
heart NN NN O
mitochondria NN NN O
represent NN NN O
almost NN NN O
40 NN NN O
% NN NN O
of NN NN O
heart NN NN O
muscle NN NN O
by NN NN O
weight NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
the NN NN O
deteriorating NN NN O
effects NN NN O
of NN NN O
ADR NN NN O
on NN NN O
cardiovascular NN NN O
function NN NN O
involve NN NN O
mitochondrial NN NN B-Disease
structural NN NN I-Disease
and NN NN I-Disease
functional NN NN I-Disease
impairment NN NN I-Disease
. NN NN O
   
   
